,Broader,N,PUBMEDID,AUTHOR,parentterm,STAGE,DATE,ACCESSION,DiseaseOrTrait
4802,European,146.0,15761122.0,Klein RJ,Neurological disorder,initial,2005-03-10,GCST000001,Age-related macular degeneration
1575,Asian,1.0,16252231.0,Maraganore DM,Neurological disorder,replication,2005-09-09,GCST000002,Parkinson's disease
5487,European,541.0,16252231.0,Maraganore DM,Neurological disorder,replication,2005-09-09,GCST000002,Parkinson's disease
5778,European,744.0,16252231.0,Maraganore DM,Neurological disorder,initial,2005-09-09,GCST000002,Parkinson's disease
13768,Other/Mixed,141.0,16252231.0,Maraganore DM,Neurological disorder,initial,2005-09-09,GCST000002,Parkinson's disease
1574,Asian,1.0,16252231.0,Maraganore DM,Neurological disorder,initial,2005-09-09,GCST000002,Parkinson's disease
13761,Other/Mixed,122.0,16252231.0,Maraganore DM,Neurological disorder,replication,2005-09-09,GCST000002,Parkinson's disease
797,African American or Afro-Caribbean,866.0,16614226.0,Herbert A,"Other measurement, Metabolic disorder",replication,2006-04-14,GCST000003,Obesity
9798,European,10527.0,16614226.0,Herbert A,"Other measurement, Metabolic disorder",replication,2006-04-14,GCST000003,Obesity
8508,European,4851.0,16648850.0,Arking DE,Cardiovascular measurement,replication,2006-04-30,GCST000004,QT interval
4898,European,200.0,16648850.0,Arking DE,Cardiovascular measurement,initial,2006-04-30,GCST000004,QT interval
5482,European,537.0,17052657.0,Fung HC,Neurological disorder,initial,2006-09-28,GCST000005,Parkinson's disease
1898,Asian,226.0,17053108.0,Dewan A,Neurological disorder,initial,2006-10-19,GCST000006,Age-related macular degeneration (wet)
5105,European,341.0,17053149.0,Papassotiropoulos A,Other measurement,initial,2006-10-20,GCST000007,Memory performance
13666,Other/Mixed,18.0,17053149.0,Papassotiropoulos A,Other measurement,replication,2006-10-20,GCST000007,Memory performance
5661,European,662.0,17053149.0,Papassotiropoulos A,Other measurement,replication,2006-10-20,GCST000007,Memory performance
14128,Other/Mixed,1584.0,17068223.0,Duerr RH,"Digestive system disorder, Immune system disorder",replication,2006-10-26,GCST000008,Inflammatory bowel disease
6286,European,1095.0,17068223.0,Duerr RH,"Digestive system disorder, Immune system disorder",initial,2006-10-26,GCST000008,Inflammatory bowel disease
5767,European,740.0,17099884.0,Liu QR,Neurological disorder,initial,2006-12-05,GCST000009,Addiction
809,African American or Afro-Caribbean,920.0,17099884.0,Liu QR,Neurological disorder,initial,2006-12-05,GCST000009,Addiction
6071,European,948.0,17158188.0,Bierut LJ,Neurological disorder,initial,2006-12-07,GCST000010,Nicotine dependence
6130,European,981.0,17158188.0,Bierut LJ,Neurological disorder,replication,2006-12-07,GCST000010,Nicotine dependence
5603,European,621.0,17223258.0,Spinola M,Cancer,replication,2007-01-16,GCST000011,Lung cancer
5683,European,673.0,17223258.0,Spinola M,Cancer,initial,2007-01-16,GCST000011,Lung cancer
8768,European,5511.0,17293876.0,Sladek R,Metabolic disorder,replication,2007-02-11,GCST000012,Type 2 diabetes
6466,European,1275.0,17293876.0,Sladek R,Metabolic disorder,initial,2007-02-11,GCST000012,Type 2 diabetes
5494,European,547.0,17362836.0,Schymick JC,Neurological disorder,initial,2007-02-20,GCST000013,Amyotrophic lateral sclerosis
6627,European,1475.0,17447842.0,Libioulle C,Digestive system disorder,initial,2007-03-05,GCST000014,Crohn's disease
7775,European,3109.0,17447842.0,Libioulle C,Digestive system disorder,replication,2007-03-05,GCST000014,Crohn's disease
5616,European,632.0,17357082.0,Melquist S,Neurological disorder,initial,2007-03-08,GCST000015,Progressive supranuclear palsy
5578,European,604.0,17357082.0,Melquist S,Neurological disorder,replication,2007-03-08,GCST000015,Progressive supranuclear palsy
5074,European,322.0,17522711.0,Lencz T,Neurological disorder,initial,2007-03-20,GCST000016,Schizophrenia
7327,European,2329.0,17401363.0,Yeager M,Cancer,initial,2007-04-01,GCST000017,Prostate cancer
8086,European,3655.0,17401366.0,Gudmundsson J,Cancer,replication,2007-04-01,GCST000019,Prostate cancer
13816,Other/Mixed,207.0,17395743.0,Hanson RL,Other disease,initial,2007-04-01,GCST000020,End-stage renal disease
6272,European,1086.0,17474819.0,Coon KD,Neurological disorder,initial,2007-04-01,GCST000018,Alzheimer's disease (late onset)
765,African American or Afro-Caribbean,745.0,17401366.0,Gudmundsson J,Cancer,replication,2007-04-01,GCST000019,Prostate cancer
8947,European,6266.0,17401363.0,Yeager M,Cancer,replication,2007-04-01,GCST000017,Prostate cancer
8392,European,4517.0,17401366.0,Gudmundsson J,Cancer,initial,2007-04-01,GCST000019,Prostate cancer
5305,European,454.0,17407593.0,Uhl GR,Neurological disorder,initial,2007-04-03,GCST000021,Nicotine dependence
10845,European,29596.0,17434869.0,Frayling TM,"Body measurement, Other measurement",replication,2007-04-12,GCST000022,Body mass index
9824,European,10657.0,17434869.0,Frayling TM,"Body measurement, Other measurement",initial,2007-04-12,GCST000022,Body mass index
9535,European,8686.0,17460697.0,Steinthorsdottir V,Metabolic disorder,initial,2007-04-26,GCST000027,Type 2 diabetes
8672,European,5217.0,17463246.0,Saxena R,Lipid or lipoprotein measurement,replication,2007-04-26,GCST000026,Triglycerides
8511,European,4862.0,17463249.0,Zeggini E,Metabolic disorder,initial,2007-04-26,GCST000025,Type 2 diabetes
9651,European,9461.0,17460697.0,Steinthorsdottir V,Metabolic disorder,replication,2007-04-26,GCST000027,Type 2 diabetes
9854,European,10850.0,17463246.0,Saxena R,Metabolic disorder,replication,2007-04-26,GCST000028,Type 2 diabetes
7698,European,2931.0,17463246.0,Saxena R,Metabolic disorder,initial,2007-04-26,GCST000028,Type 2 diabetes
7536,European,2623.0,17463246.0,Saxena R,Lipid or lipoprotein measurement,initial,2007-04-26,GCST004919,HDL cholesterol levels
7554,European,2659.0,17463246.0,Saxena R,Lipid or lipoprotein measurement,initial,2007-04-26,GCST000026,Triglycerides
7332,European,2335.0,17463248.0,Scott LJ,Metabolic disorder,initial,2007-04-26,GCST000024,Type 2 diabetes
7520,European,2601.0,17463246.0,Saxena R,Lipid or lipoprotein measurement,initial,2007-04-26,GCST004920,LDL cholesterol levels
9590,European,9103.0,17463249.0,Zeggini E,Metabolic disorder,replication,2007-04-26,GCST000025,Type 2 diabetes
7418,European,2473.0,17463248.0,Scott LJ,Metabolic disorder,replication,2007-04-26,GCST000024,Type 2 diabetes
6608,European,1451.0,17463246.0,Saxena R,Lipid or lipoprotein measurement,initial,2007-04-26,GCST004921,Apolipoprotein A1 levels
5106,European,341.0,17470457.0,Huentelman MJ,Biological process,initial,2007-04-30,GCST000029,Episodic memory
5334,European,472.0,17470457.0,Huentelman MJ,Biological process,replication,2007-04-30,GCST000029,Episodic memory
9614,European,9289.0,17478679.0,Helgadottir A,Cardiovascular disease,replication,2007-05-03,GCST000030,Myocardial infarction
10677,European,23791.0,17478681.0,McPherson R,Cardiovascular disease,replication,2007-05-03,GCST000031,Coronary heart disease
9396,European,8335.0,17478679.0,Helgadottir A,Cardiovascular disease,initial,2007-05-03,GCST000030,Myocardial infarction
5620,European,634.0,17478681.0,McPherson R,Cardiovascular disease,initial,2007-05-03,GCST000031,Coronary heart disease
5446,European,517.0,17434096.0,Matarin M,Cardiovascular disease,initial,2007-05-06,GCST000032,Stroke
6783,European,1648.0,17486107.0,Baum AE,Neurological disorder,replication,2007-05-08,GCST000033,Bipolar disorder
6214,European,1024.0,17486107.0,Baum AE,Neurological disorder,initial,2007-05-08,GCST000033,Bipolar disorder
4907,European,204.0,17505501.0,Kindmark A,"Liver enzyme measurement, Response to drug",initial,2007-05-15,GCST000034,Response to ximelagatran treatment (increased serum alanine aminotransferase levels)
4641,European,26.0,17505501.0,Kindmark A,"Liver enzyme measurement, Response to drug",replication,2007-05-15,GCST000034,Response to ximelagatran treatment (increased serum alanine aminotransferase levels)
7290,European,2287.0,17529973.0,Hunter DJ,Cancer,initial,2007-05-27,GCST000036,Breast cancer
11253,European,48565.0,17529967.0,Easton DF,Cancer,replication,2007-05-27,GCST000035,Breast cancer
7339,European,2352.0,17529973.0,Hunter DJ,Cancer,replication,2007-05-27,GCST000036,Breast cancer
14057,Other/Mixed,896.0,17529973.0,Hunter DJ,Cancer,replication,2007-05-27,GCST000036,Breast cancer
2557,Asian,1126.0,17529974.0,Stacey SN,Cancer,replication,2007-05-27,GCST000037,Breast cancer
798,African American or Afro-Caribbean,870.0,17529974.0,Stacey SN,Cancer,replication,2007-05-27,GCST000037,Breast cancer
12990,Hispanic or Latin American,840.0,17529974.0,Stacey SN,Cancer,replication,2007-05-27,GCST000037,Breast cancer
9568,European,8921.0,17529974.0,Stacey SN,Cancer,replication,2007-05-27,GCST000037,Breast cancer
5796,European,754.0,17529967.0,Easton DF,Cancer,initial,2007-05-27,GCST000035,Breast cancer
10039,European,13145.0,17529974.0,Stacey SN,Cancer,initial,2007-05-27,GCST000037,Breast cancer
3939,Asian,7928.0,17529967.0,Easton DF,Cancer,replication,2007-05-27,GCST000035,Breast cancer
13915,Other/Mixed,441.0,17529974.0,Stacey SN,Cancer,replication,2007-05-27,GCST000037,Breast cancer
7816,European,3206.0,17554261.0,Parkes M,Digestive system disorder,replication,2007-06-06,GCST000039,Crohn's disease
10397,European,17991.0,17554260.0,Todd JA,Metabolic disorder,replication,2007-06-06,GCST000038,Type 1 diabetes
8592,European,5000.0,17554260.0,Todd JA,Metabolic disorder,initial,2007-06-06,GCST000038,Type 1 diabetes
8489,European,4806.0,17554300.0,Wellcome Trust Case Control Consortium,Neurological disorder,initial,2007-06-07,GCST000044,Bipolar disorder
8450,European,4686.0,17554300.0,Wellcome Trust Case Control Consortium,Digestive system disorder,initial,2007-06-07,GCST000042,Crohn's disease
8512,European,4862.0,17554300.0,Wellcome Trust Case Control Consortium,Metabolic disorder,initial,2007-06-07,GCST000047,Type 2 diabetes
8525,European,4890.0,17554300.0,Wellcome Trust Case Control Consortium,Cardiovascular disease,initial,2007-06-07,GCST000041,Hypertension
8486,European,4798.0,17554300.0,Wellcome Trust Case Control Consortium,Immune system disorder,initial,2007-06-07,GCST000040,Rheumatoid arthritis
8528,European,4901.0,17554300.0,Wellcome Trust Case Control Consortium,Metabolic disorder,initial,2007-06-07,GCST000043,Type 1 diabetes
8514,European,4864.0,17554300.0,Wellcome Trust Case Control Consortium,Cardiovascular disease,initial,2007-06-07,GCST000045,Coronary heart disease
7237,European,2200.0,17558408.0,van Heel DA,Immune system disorder,initial,2007-06-10,GCST000048,Celiac disease
7424,European,2480.0,17558408.0,van Heel DA,Immune system disorder,replication,2007-06-10,GCST000048,Celiac disease
6160,European,997.0,17668382.0,Salonen JT,Metabolic disorder,initial,2007-06-26,GCST000049,Type 2 diabetes
8721,European,5349.0,17668382.0,Salonen JT,Metabolic disorder,replication,2007-06-26,GCST000049,Type 2 diabetes
8600,European,5026.0,17603472.0,Gudbjartsson DF,Cardiovascular disease,initial,2007-07-01,GCST000051,Atrial fibrillation/atrial flutter
10391,European,17810.0,17603472.0,Gudbjartsson DF,Cardiovascular disease,replication,2007-07-01,GCST000051,Atrial fibrillation/atrial flutter
8610,European,5050.0,17603485.0,Gudmundsson J,Cancer,replication,2007-07-01,GCST000050,Prostate cancer
3330,Asian,3169.0,17603472.0,Gudbjartsson DF,Cardiovascular disease,replication,2007-07-01,GCST000051,Atrial fibrillation/atrial flutter
10023,European,12791.0,17603485.0,Gudmundsson J,Cancer,initial,2007-07-01,GCST000050,Prostate cancer
9793,European,10472.0,17618283.0,Zanke BW,Cancer,replication,2007-07-08,GCST000052,Colorectal cancer
10008,European,12580.0,17618284.0,Tomlinson I,Cancer,replication,2007-07-08,GCST000053,Colorectal cancer
6972,European,1890.0,17618284.0,Tomlinson I,Cancer,initial,2007-07-08,GCST000053,Colorectal cancer
7435,European,2503.0,17632545.0,Hakonarson H,Metabolic disorder,replication,2007-07-15,GCST000054,Type 1 diabetes
12835,Hispanic or Latin American,334.0,17632509.0,Buch S,Digestive system disorder,replication,2007-07-15,GCST000055,Gallstone disease
7771,European,3105.0,17632545.0,Hakonarson H,Metabolic disorder,initial,2007-07-15,GCST000054,Type 1 diabetes
5624,European,640.0,17632509.0,Buch S,Digestive system disorder,initial,2007-07-15,GCST000055,Gallstone disease
7665,European,2868.0,17632509.0,Buch S,Digestive system disorder,replication,2007-07-15,GCST000055,Gallstone disease
8515,European,4864.0,17634449.0,Samani NJ,Cardiovascular disease,initial,2007-07-18,GCST000057,Coronary heart disease
7333,European,2336.0,17637780.0,Winkelmann J,Neurological disorder,replication,2007-07-18,GCST000056,Restless legs syndrome
7078,European,2045.0,17637780.0,Winkelmann J,Neurological disorder,initial,2007-07-18,GCST000056,Restless legs syndrome
7453,European,2519.0,17634449.0,Samani NJ,Cardiovascular disease,replication,2007-07-18,GCST000057,Coronary heart disease
7239,European,2206.0,17634447.0,Stefansson H,Neurological disorder,replication,2007-07-19,GCST000058,Restless legs syndrome
5361,European,486.0,17641165.0,Fellay J,"Biological process, Other measurement, Other disease",initial,2007-07-19,GCST000059,HIV-1 viral setpoint
10247,European,15970.0,17634447.0,Stefansson H,Neurological disorder,initial,2007-07-19,GCST000058,Restless legs syndrome
4795,European,140.0,17641165.0,Fellay J,"Biological process, Other measurement, Other disease",replication,2007-07-19,GCST000059,HIV-1 viral setpoint
8468,European,4741.0,17658951.0,Scuteri A,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",initial,2007-07-20,GCST000060,Obesity-related traits
819,African American or Afro-Caribbean,968.0,17658951.0,Scuteri A,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",replication,2007-07-20,GCST000060,Obesity-related traits
12987,Hispanic or Latin American,824.0,17658951.0,Scuteri A,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",replication,2007-07-20,GCST000060,Obesity-related traits
6623,European,1471.0,17658951.0,Scuteri A,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",replication,2007-07-20,GCST000060,Obesity-related traits
7318,European,2320.0,17611496.0,Moffatt MF,Other disease,replication,2007-07-26,GCST000061,Asthma
7203,European,2187.0,17611496.0,Moffatt MF,Other disease,initial,2007-07-26,GCST000061,Asthma
8675,European,5224.0,17660530.0,Hafler DA,Immune system disorder,initial,2007-07-29,GCST000062,Multiple sclerosis
9153,European,7136.0,17660530.0,Hafler DA,Immune system disorder,replication,2007-07-29,GCST000062,Multiple sclerosis
6670,European,1533.0,17667963.0,Shifman S,"Neurological disorder, Other measurement",replication,2007-07-31,GCST000063,Neuroticism
7100,European,2054.0,17667963.0,Shifman S,"Neurological disorder, Other measurement",initial,2007-07-31,GCST000063,Neuroticism
5279,European,438.0,17671248.0,Dunckley T,Neurological disorder,replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
1602,Asian,8.0,17671248.0,Dunckley T,Neurological disorder,replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
12769,Hispanic or Latin American,87.0,17671248.0,Dunckley T,Neurological disorder,replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
6029,European,928.0,17671248.0,Dunckley T,Neurological disorder,initial,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
1840,Asian,188.0,17653210.0,Maeda S,Metabolic disorder,initial,2007-08-01,GCST000064,Type 2 diabetes nephropathy
13810,Other/Mixed,192.0,17671248.0,Dunckley T,Neurological disorder,replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
17,African,35.0,17671248.0,Dunckley T,Neurological disorder,replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
13615,Other/Mixed,3.0,17671248.0,Dunckley T,"Neurological disorder, Neurological disorder",replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
8960,European,6309.0,17684544.0,Franke A,Digestive system disorder,replication,2007-08-08,GCST000066,Crohn's disease
5840,European,792.0,17684544.0,Franke A,Digestive system disorder,initial,2007-08-08,GCST000066,Crohn's disease
10155,European,14649.0,17690259.0,Thorleifsson G,Neurological disorder,initial,2007-08-09,GCST000067,Glaucoma (exfoliation)
5183,European,397.0,17690259.0,Thorleifsson G,Neurological disorder,replication,2007-08-09,GCST000067,Glaucoma (exfoliation)
8550,European,4921.0,17767157.0,Weedon MN,"Other measurement, Body measurement",initial,2007-09-02,GCST000068,Height
4728,European,90.0,17767159.0,Menzel S,Hematological measurement,replication,2007-09-02,GCST000069,F-cell distribution
4852,European,179.0,17767159.0,Menzel S,Hematological measurement,initial,2007-09-02,GCST000069,F-cell distribution
10833,European,29098.0,17767157.0,Weedon MN,"Other measurement, Body measurement",replication,2007-09-02,GCST000068,Height
7957,European,3380.0,17804836.0,Plenge RM,Immune system disorder,initial,2007-09-05,GCST000070,Rheumatoid arthritis
6327,European,1146.0,17804789.0,Raelson JV,Digestive system disorder,initial,2007-09-05,GCST000071,Crohn's disease
7787,European,3141.0,17804789.0,Raelson JV,Digestive system disorder,replication,2007-09-05,GCST000071,Crohn's disease
7684,European,2911.0,17804836.0,Plenge RM,Immune system disorder,replication,2007-09-05,GCST000070,Rheumatoid arthritis
6895,European,1782.0,17827064.0,van Es MA,Neurological disorder,replication,2007-09-07,GCST000072,Amyotrophic lateral sclerosis
6007,European,911.0,17827064.0,van Es MA,Neurological disorder,initial,2007-09-07,GCST000072,Amyotrophic lateral sclerosis
14183,Other/Mixed,2834.0,17846125.0,Hanson RL,Metabolic disorder,replication,2007-09-10,GCST000074,Type 2 diabetes
8495,European,4815.0,17848626.0,Florez JC,"Metabolic disorder, Other measurement",replication,2007-09-10,GCST000073,Type 2 diabetes and 6 quantitative traits
5227,European,419.0,17846126.0,Rampersaud E,Metabolic disorder,initial,2007-09-10,GCST000076,Type 2 diabetes
6975,European,1892.0,17846125.0,Hanson RL,Metabolic disorder,replication,2007-09-10,GCST000074,Type 2 diabetes
12963,Hispanic or Latin American,760.0,17846125.0,Hanson RL,Metabolic disorder,replication,2007-09-10,GCST000074,Type 2 diabetes
13965,Other/Mixed,634.0,17846126.0,Rampersaud E,Metabolic disorder,replication,2007-09-10,GCST000076,Type 2 diabetes
13966,Other/Mixed,634.0,17848626.0,Florez JC,"Metabolic disorder, Other measurement",replication,2007-09-10,GCST000073,Type 2 diabetes and 6 quantitative traits
7740,European,3022.0,17846126.0,Rampersaud E,Metabolic disorder,replication,2007-09-10,GCST000076,Type 2 diabetes
12905,Hispanic or Latin American,561.0,17846124.0,Hayes MG,Metabolic disorder,initial,2007-09-10,GCST000075,Type 2 diabetes
6273,European,1087.0,17848626.0,Florez JC,"Metabolic disorder, Other measurement",initial,2007-09-10,GCST000073,Type 2 diabetes and 6 quantitative traits
12921,Hispanic or Latin American,603.0,17848626.0,Florez JC,"Metabolic disorder, Other measurement",replication,2007-09-10,GCST000073,Type 2 diabetes and 6 quantitative traits
12920,Hispanic or Latin American,603.0,17846126.0,Rampersaud E,Metabolic disorder,replication,2007-09-10,GCST000076,Type 2 diabetes
14056,Other/Mixed,895.0,17846125.0,Hanson RL,Metabolic disorder,initial,2007-09-10,GCST000074,Type 2 diabetes
6642,European,1506.0,17846124.0,Hayes MG,Metabolic disorder,replication,2007-09-10,GCST000075,Type 2 diabetes
14055,Other/Mixed,895.0,17846124.0,Hayes MG,Metabolic disorder,replication,2007-09-10,GCST000075,Type 2 diabetes
6439,European,1238.0,17903301.0,Vasan RS,Cardiovascular measurement,initial,2007-09-19,GCST000089,Exercise treadmill test traits
5703,European,694.0,17903297.0,Seshadri S,Other measurement,initial,2007-09-19,GCST000098,Cognitive test performance
5789,European,747.0,17903306.0,Newton-Cheh C,Cardiovascular measurement,initial,2007-09-19,GCST000086,Heart rate variability traits
6441,European,1238.0,17903301.0,Vasan RS,"Other trait, Other measurement",initial,2007-09-19,GCST000110,Echocardiographic traits
6511,European,1341.0,17903300.0,Fox CS,"Body measurement, Other measurement",initial,2007-09-19,GCST000090,Body mass index
9357,European,8100.0,17903299.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",replication,2007-09-19,GCST000078,Lipid traits
6440,European,1238.0,17903301.0,Vasan RS,Other measurement,initial,2007-09-19,GCST000102,Endothelial function traits
5716,European,705.0,17903297.0,Seshadri S,Other measurement,initial,2007-09-19,GCST000088,Volumetric brain MRI
6266,European,1079.0,17903300.0,Fox CS,Body measurement,initial,2007-09-19,GCST000084,Waist circumference
6201,European,1012.0,17903293.0,Benjamin EJ,"Other measurement, Liver enzyme measurement, Cardiovascular measurement, Inflammatory measurement",initial,2007-09-19,GCST000083,Select biomarker traits
5981,European,886.0,17903294.0,Yang Q,Other measurement,initial,2007-09-19,GCST000082,Factor VII
6247,European,1062.0,17903294.0,Yang Q,"Hematological measurement, Inflammatory measurement, Other measurement, Cardiovascular measurement, Biological process",initial,2007-09-19,GCST000080,Hemostatic factors and hematological phenotypes
7009,European,1951.0,17903306.0,Newton-Cheh C,Cardiovascular measurement,initial,2007-09-19,GCST000111,Electrocardiographic traits
6274,European,1087.0,17903299.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",initial,2007-09-19,GCST000078,Lipid traits
4824,European,165.0,17911428.0,Cervino AC,Immune system disorder,initial,2007-10-08,GCST000112,Lupus
6973,European,1890.0,17934461.0,Broderick P,Cancer,initial,2007-10-14,GCST000113,Colorectal cancer
10069,European,13475.0,17934461.0,Broderick P,Cancer,replication,2007-10-14,GCST000113,Colorectal cancer
2331,Asian,737.0,17999355.0,Stokowski RP,"Other trait, Other measurement",initial,2007-10-15,GCST000114,Skin pigmentation
1917,Asian,231.0,17999355.0,Stokowski RP,"Other trait, Other measurement",replication,2007-10-15,GCST000114,Skin pigmentation
8189,European,3932.0,17952075.0,Sulem P,Other trait,replication,2007-10-21,GCST000118,Blond vs. brown hair color
7719,European,2986.0,17952075.0,Sulem P,Other trait,initial,2007-10-21,GCST000118,Blond vs. brown hair color
5184,European,397.0,17982456.0,Plenge RM,Immune system disorder,initial,2007-11-04,GCST000122,Rheumatoid arthritis
6822,European,1707.0,17982456.0,Plenge RM,Immune system disorder,replication,2007-11-04,GCST000122,Rheumatoid arthritis
8328,European,4305.0,17997608.0,Li S,"Metabolic disorder, Other measurement",initial,2007-11-09,GCST000123,Urate levels
6485,European,1301.0,17997608.0,Li S,"Metabolic disorder, Other measurement",replication,2007-11-09,GCST000123,Urate levels
5669,European,667.0,17998437.0,Li H,Neurological disorder,replication,2007-11-12,GCST000124,Alzheimer's disease
6632,European,1489.0,17998437.0,Li H,Neurological disorder,initial,2007-11-12,GCST000124,Alzheimer's disease
1993,Asian,311.0,18075462.0,Suzuki S,Cardiovascular disease,replication,2007-11-17,GCST000125,Coronary spasm
1729,Asian,100.0,18075462.0,Suzuki S,Cardiovascular disease,initial,2007-11-17,GCST000125,Coronary spasm
5258,European,432.0,18057069.0,Cronin S,Neurological disorder,initial,2007-12-07,GCST000126,Amyotrophic lateral sclerosis
6613,European,1458.0,18057069.0,Cronin S,Neurological disorder,replication,2007-12-07,GCST000126,Amyotrophic lateral sclerosis
7248,European,2225.0,18084291.0,van Es MA,Neurological disorder,replication,2007-12-16,GCST000127,Amyotrophic lateral sclerosis
6614,European,1458.0,18084291.0,van Es MA,Neurological disorder,initial,2007-12-16,GCST000127,Amyotrophic lateral sclerosis
6741,European,1603.0,18073375.0,Duggan D,Cancer,replication,2007-12-19,GCST000128,Prostate cancer
726,African American or Afro-Caribbean,556.0,18073375.0,Duggan D,Cancer,replication,2007-12-19,GCST000128,Prostate cancer
7654,European,2834.0,18073375.0,Duggan D,Cancer,initial,2007-12-19,GCST000128,Prostate cancer
7271,European,2269.0,18159244.0,Hinney A,Metabolic disorder,replication,2007-12-26,GCST000129,Obesity (early onset extreme)
6034,European,929.0,18159244.0,Hinney A,Metabolic disorder,initial,2007-12-26,GCST000129,Obesity (early onset extreme)
7015,European,1955.0,18179892.0,Wallace C,"Metabolic disorder, Other measurement",initial,2008-01-10,GCST000130,Urate levels
7014,European,1955.0,18179892.0,Wallace C,"Lipid or lipoprotein measurement, Other measurement",initial,2008-01-10,GCST000131,LDL cholesterol
8572,European,4955.0,18179892.0,Wallace C,"Metabolic disorder, Other measurement",replication,2008-01-10,GCST000130,Urate levels
8571,European,4955.0,18179892.0,Wallace C,"Lipid or lipoprotein measurement, Other measurement",replication,2008-01-10,GCST000131,LDL cholesterol
1217,African American or Afro-Caribbean,3860.0,18193045.0,Sanna S,"Other measurement, Body measurement",replication,2008-01-13,GCST000136,Height
10424,European,18544.0,18193044.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",replication,2008-01-13,GCST000134,LDL cholesterol
10425,European,18554.0,18193044.0,Kathiresan S,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000133,HDL cholesterol
6194,European,1005.0,18193046.0,Kooner JS,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000137,Triglycerides
9906,European,11437.0,18193043.0,Willer CJ,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000135,HDL cholesterol
7612,European,2758.0,18193044.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",initial,2008-01-13,GCST000134,LDL cholesterol
7611,European,2758.0,18193044.0,Kathiresan S,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000138,Triglycerides
2505,Asian,1006.0,18193046.0,Kooner JS,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000137,Triglycerides
9033,European,6669.0,18193045.0,Sanna S,"Other measurement, Body measurement",initial,2008-01-13,GCST000136,Height
10426,European,18554.0,18193044.0,Kathiresan S,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000138,Triglycerides
9695,European,9741.0,18193043.0,Willer CJ,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000139,Triglycerides
9534,European,8684.0,18193043.0,Willer CJ,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000139,Triglycerides
14165,Other/Mixed,2528.0,18193046.0,Kooner JS,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000137,Triglycerides
9529,European,8656.0,18193043.0,Willer CJ,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000135,HDL cholesterol
10033,European,12981.0,18193043.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",replication,2008-01-13,GCST000132,LDL cholesterol
9515,European,8589.0,18193043.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",initial,2008-01-13,GCST000132,LDL cholesterol
7610,European,2758.0,18193044.0,Kathiresan S,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000133,HDL cholesterol
9082,European,6827.0,18193046.0,Kooner JS,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000137,Triglycerides
10674,European,23684.0,18193045.0,Sanna S,"Other measurement, Body measurement",replication,2008-01-13,GCST000136,Height
2578,Asian,1181.0,18193046.0,Kooner JS,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000137,Triglycerides
4704,European,81.0,18195134.0,Byun E,Response to drug,replication,2008-01-14,GCST000140,Response to interferon beta therapy
4915,European,206.0,18195134.0,Byun E,Response to drug,initial,2008-01-14,GCST000140,Response to interferon beta therapy
7772,European,3105.0,18198356.0,Hakonarson H,Metabolic disorder,initial,2008-01-15,GCST000141,Type 1 diabetes
7785,European,3136.0,18198356.0,Hakonarson H,Metabolic disorder,replication,2008-01-15,GCST000141,Type 1 diabetes
8434,European,4651.0,18204098.0,Hom G,Immune system disorder,initial,2008-01-20,GCST000144,Systemic lupus erythematosus
7897,European,3297.0,18204447.0,Kozyrev SV,Immune system disorder,replication,2008-01-20,GCST000143,Systemic lupus erythematosus
5842,European,794.0,18204447.0,Kozyrev SV,Immune system disorder,initial,2008-01-20,GCST000143,Systemic lupus erythematosus
6785,European,1650.0,18204098.0,Hom G,Immune system disorder,replication,2008-01-20,GCST000144,Systemic lupus erythematosus
7752,European,3037.0,18204446.0,Harley JB,Immune system disorder,initial,2008-01-20,GCST000142,Systemic lupus erythematosus
8093,European,3671.0,18204446.0,Harley JB,Immune system disorder,replication,2008-01-20,GCST000142,Systemic lupus erythematosus
5946,European,860.0,18067574.0,Butcher LM,Biological process,initial,2008-01-22,GCST000145,General cognitive ability
7810,European,3195.0,18067574.0,Butcher LM,Biological process,replication,2008-01-22,GCST000145,General cognitive ability
6584,European,1406.0,18252221.0,Kayser M,Other trait,initial,2008-01-24,GCST000146,Iris color
9090,European,6867.0,18252221.0,Kayser M,Other trait,replication,2008-01-24,GCST000146,Iris color
7047,European,2000.0,18227835.0,Berrettini W,Neurological disorder,replication,2008-01-29,GCST000147,Nicotine dependence
9232,European,7481.0,18227835.0,Berrettini W,Neurological disorder,initial,2008-01-29,GCST000147,Nicotine dependence
8329,European,4305.0,18245381.0,Uda M,Hematological measurement,initial,2008-02-05,GCST000150,Fetal hemoglobin levels
5455,European,521.0,18245381.0,Uda M,Hematological measurement,replication,2008-02-05,GCST000150,Fetal hemoglobin levels
8580,European,4979.0,18262040.0,Sandhu MS,"Lipid or lipoprotein measurement, Other measurement",replication,2008-02-09,GCST000151,LDL cholesterol
9931,European,11685.0,18262040.0,Sandhu MS,"Lipid or lipoprotein measurement, Other measurement",initial,2008-02-09,GCST000151,LDL cholesterol
10239,European,15829.0,18264098.0,Gudmundsson J,Cancer,replication,2008-02-10,GCST000153,Prostate cancer
9023,European,6634.0,18264097.0,Eeles RA,Cancer,replication,2008-02-10,GCST000152,Prostate cancer
8120,European,3748.0,18264097.0,Eeles RA,Cancer,initial,2008-02-10,GCST000152,Prostate cancer
7328,European,2329.0,18264096.0,Thomas G,Cancer,initial,2008-02-10,GCST000154,Prostate cancer
10659,European,23226.0,18264098.0,Gudmundsson J,Cancer,initial,2008-02-10,GCST000153,Prostate cancer
9309,European,7905.0,18264096.0,Thomas G,Cancer,replication,2008-02-10,GCST000154,Prostate cancer
14187,Other/Mixed,2931.0,18282107.0,Shifman S,Neurological disorder,initial,2008-02-15,GCST000155,Schizophrenia
8830,European,5802.0,18282107.0,Shifman S,Neurological disorder,replication,2008-02-15,GCST000155,Schizophrenia
14223,Other/Mixed,4148.0,18282107.0,Shifman S,Neurological disorder,replication,2008-02-15,GCST000155,Schizophrenia
2432,Asian,873.0,18282107.0,Shifman S,Neurological disorder,replication,2008-02-15,GCST000155,Schizophrenia
2234,Asian,580.0,18316681.0,Uhl GR,Neurological disorder,initial,2008-03-01,GCST000156,Methamphetamine dependence
8608,European,5049.0,18311140.0,Hunt KA,Immune system disorder,replication,2008-03-02,GCST000157,Celiac disease
7227,European,2189.0,18311140.0,Hunt KA,Immune system disorder,initial,2008-03-02,GCST000157,Celiac disease
8007,European,3469.0,18317468.0,Sklar P,Neurological disorder,initial,2008-03-04,GCST000158,Bipolar disorder
6998,European,1943.0,18317468.0,Sklar P,Neurological disorder,replication,2008-03-04,GCST000158,Bipolar disorder
8141,European,3812.0,18325910.0,Liu YJ,"Other measurement, Metabolic disorder",replication,2008-03-05,GCST000159,Obesity
6163,European,1000.0,18325910.0,Liu YJ,"Other measurement, Metabolic disorder",initial,2008-03-05,GCST000159,Obesity
9750,European,9947.0,18327256.0,Doring A,"Metabolic disorder, Other measurement",replication,2008-03-09,GCST000161,Urate levels
5718,European,706.0,18327257.0,Vitart V,"Metabolic disorder, Other measurement",replication,2008-03-09,GCST000160,Urate levels
6777,European,1644.0,18327256.0,Doring A,"Metabolic disorder, Other measurement",initial,2008-03-09,GCST000161,Urate levels
5843,European,794.0,18327257.0,Vitart V,"Metabolic disorder, Other measurement",initial,2008-03-09,GCST000160,Urate levels
7344,European,2359.0,18326623.0,Gold B,Cancer,replication,2008-03-11,GCST000162,Breast cancer
5497,European,548.0,18326623.0,Gold B,Cancer,initial,2008-03-11,GCST000162,Breast cancer
7326,European,2327.0,18332876.0,Kirov G,Neurological disorder,initial,2008-03-11,GCST000163,Schizophrenia
684,African American or Afro-Caribbean,436.0,18347602.0,Sullivan PF,Neurological disorder,initial,2008-03-18,GCST000164,Schizophrenia
5896,European,828.0,18347602.0,Sullivan PF,Neurological disorder,initial,2008-03-18,GCST000164,Schizophrenia
13817,Other/Mixed,207.0,18347602.0,Sullivan PF,Neurological disorder,initial,2008-03-18,GCST000164,Schizophrenia
8321,European,4288.0,18364390.0,Capon F,Immune system disorder,replication,2008-03-25,GCST000165,Psoriasis
8038,European,3529.0,18360741.0,Butcher LM,Other measurement,replication,2008-03-25,GCST000166,Environmental confusion in the home
5909,European,838.0,18360741.0,Butcher LM,Other measurement,initial,2008-03-25,GCST000166,Environmental confusion in the home
5584,European,606.0,18364390.0,Capon F,Immune system disorder,initial,2008-03-25,GCST000165,Psoriasis
9769,European,10128.0,18372903.0,Zeggini E,Metabolic disorder,initial,2008-03-30,GCST000167,Type 2 diabetes
11579,European,79792.0,18372903.0,Zeggini E,Metabolic disorder,replication,2008-03-30,GCST000167,Type 2 diabetes
6943,European,1849.0,18372905.0,Tomlinson IP,Cancer,initial,2008-03-30,GCST000169,Colorectal cancer
10537,European,20688.0,18372901.0,Tenesa A,Cancer,replication,2008-03-30,GCST000168,Colorectal cancer
10979,European,33951.0,18372905.0,Tomlinson IP,Cancer,replication,2008-03-30,GCST000169,Colorectal cancer
7037,European,1983.0,18372901.0,Tenesa A,Cancer,initial,2008-03-30,GCST000168,Colorectal cancer
3893,Asian,7579.0,18372901.0,Tenesa A,Cancer,replication,2008-03-30,GCST000168,Colorectal cancer
7297,European,2291.0,18385676.0,Amos CI,Cancer,initial,2008-04-03,GCST000172,Lung cancer
5844,European,794.0,18385738.0,Hung RJ,Cancer,replication,2008-04-03,GCST000170,Lung cancer
8506,European,4848.0,18385739.0,Thorgeirsson TE,Neurological disorder,replication,2008-04-03,GCST000171,Nicotine dependence
14235,Other/Mixed,6471.0,18385738.0,Hung RJ,Cancer,replication,2008-04-03,GCST000170,Lung cancer
9864,European,10995.0,18385739.0,Thorgeirsson TE,Neurological disorder,initial,2008-04-03,GCST000171,Nicotine dependence
14228,Other/Mixed,4448.0,18385738.0,Hung RJ,Cancer,initial,2008-04-03,GCST000170,Lung cancer
8979,European,6418.0,18385676.0,Amos CI,Cancer,replication,2008-04-03,GCST000172,Lung cancer
7353,European,2370.0,18369459.0,Liu Y,Immune system disorder,replication,2008-04-04,GCST000173,Psoriasis
5758,European,737.0,18369459.0,Liu Y,Immune system disorder,initial,2008-04-04,GCST000173,Psoriasis
10388,European,17801.0,18391950.0,Lettre G,"Other measurement, Body measurement",replication,2008-04-06,GCST000176,Height
10293,European,16482.0,18391952.0,Weedon MN,"Other measurement, Body measurement",replication,2008-04-06,GCST000174,Height
10879,European,30968.0,18391951.0,Gudbjartsson DF,"Other measurement, Body measurement",initial,2008-04-06,GCST000175,Height
10238,European,15821.0,18391950.0,Lettre G,"Other measurement, Body measurement",initial,2008-04-06,GCST000176,Height
10094,European,13665.0,18391952.0,Weedon MN,"Other measurement, Body measurement",initial,2008-04-06,GCST000174,Height
9507,European,8541.0,18391951.0,Gudbjartsson DF,"Other measurement, Body measurement",replication,2008-04-06,GCST000175,Height
6311,European,1140.0,18403759.0,Ober C,Inflammatory measurement,replication,2008-04-09,GCST000177,YKL-40 levels
5617,European,632.0,18403759.0,Ober C,Inflammatory measurement,initial,2008-04-09,GCST000177,YKL-40 levels
8633,European,5106.0,18439552.0,Reiner AP,Inflammatory measurement,replication,2008-04-24,GCST000179,C-reactive protein
6006,European,909.0,18439552.0,Reiner AP,Inflammatory measurement,initial,2008-04-24,GCST000179,C-reactive protein
8966,European,6345.0,18439548.0,Ridker PM,Inflammatory measurement,initial,2008-04-24,GCST000178,C-reactive protein
7132,European,2094.0,18455228.0,Richards JB,Other measurement,initial,2008-04-29,GCST000182,Bone mineral density
8846,European,5861.0,18445777.0,Styrkarsdottir U,Other measurement,initial,2008-04-29,GCST000181,Bone mineral density (hip)
8845,European,5861.0,18445777.0,Styrkarsdottir U,Other measurement,initial,2008-04-29,GCST000180,Bone mineral density (spine)
9318,European,7925.0,18445777.0,Styrkarsdottir U,Other measurement,replication,2008-04-29,GCST000181,Bone mineral density (hip)
8986,European,6463.0,18455228.0,Richards JB,Other measurement,replication,2008-04-29,GCST000182,Bone mineral density
9317,European,7925.0,18445777.0,Styrkarsdottir U,Other measurement,replication,2008-04-29,GCST000180,Bone mineral density (spine)
5013,European,284.0,18449908.0,Poduslo SE,Neurological disorder,replication,2008-04-30,GCST000183,Alzheimer's disease
4643,European,30.0,18449908.0,Poduslo SE,Neurological disorder,initial,2008-04-30,GCST000183,Alzheimer's disease
8405,European,4561.0,18454146.0,Chambers JC,"Body measurement, Lipid or lipoprotein measurement",replication,2008-05-04,GCST000184,Waist circumference and related phenotypes
11456,European,66340.0,18454148.0,Loos RJ,"Body measurement, Other measurement",replication,2008-05-04,GCST000185,Body mass index
3869,Asian,7394.0,18454146.0,Chambers JC,"Body measurement, Lipid or lipoprotein measurement",replication,2008-05-04,GCST000184,Waist circumference and related phenotypes
3218,Asian,2684.0,18454146.0,Chambers JC,"Body measurement, Lipid or lipoprotein measurement",initial,2008-05-04,GCST000184,Waist circumference and related phenotypes
10326,European,16876.0,18454148.0,Loos RJ,"Body measurement, Other measurement",initial,2008-05-04,GCST000185,Body mass index
5625,European,642.0,18471798.0,Valdes AM,Other disease,initial,2008-05-08,GCST000186,Knee osteoarthritis
12721,Hispanic or Latin American,6.0,18463975.0,Kibriya MG,Cancer,initial,2008-05-08,GCST000187,Breast cancer
4663,European,52.0,18463975.0,Kibriya MG,Cancer,initial,2008-05-08,GCST000187,Breast cancer
402,African American or Afro-Caribbean,2.0,18463975.0,Kibriya MG,Cancer,initial,2008-05-08,GCST000187,Breast cancer
8044,European,3549.0,18471798.0,Valdes AM,Other disease,replication,2008-05-08,GCST000186,Knee osteoarthritis
8412,European,4590.0,18464913.0,Melzer D,"Other measurement, Inflammatory measurement, Liver enzyme measurement, Hematological measurement, Lipid or lipoprotein measurement",replication,2008-05-09,GCST000189,Protein quantitative trait loci
6386,European,1200.0,18464913.0,Melzer D,"Other measurement, Inflammatory measurement, Liver enzyme measurement, Hematological measurement, Lipid or lipoprotein measurement",initial,2008-05-09,GCST000189,Protein quantitative trait loci
7759,European,3075.0,18463370.0,Maris JM,Cancer,initial,2008-05-09,GCST000188,Neuroblastoma
7661,European,2848.0,18463370.0,Maris JM,Cancer,replication,2008-05-09,GCST000188,Neuroblastoma
9491,European,8465.0,18483556.0,Han J,Other trait,replication,2008-05-16,GCST000191,Black vs. red hair color
9490,European,8465.0,18483556.0,Han J,Other trait,replication,2008-05-16,GCST000190,Black vs. blond hair color
7291,European,2287.0,18483556.0,Han J,Other trait,initial,2008-05-16,GCST000190,Black vs. blond hair color
7292,European,2287.0,18483556.0,Han J,Other trait,initial,2008-05-16,GCST000191,Black vs. red hair color
7921,European,3330.0,18488028.0,Sulem P,Other trait,replication,2008-05-18,GCST000197,Freckles
7916,European,3330.0,18488028.0,Sulem P,Immune system disorder,replication,2008-05-18,GCST000195,Skin sensitivity to sun
8643,European,5130.0,18488028.0,Sulem P,"Other disease, Other trait",initial,2008-05-18,GCST000196,Burning and freckling
7917,European,3330.0,18488028.0,Sulem P,"Other disease, Other trait",replication,2008-05-18,GCST000196,Burning and freckling
7919,European,3330.0,18488028.0,Sulem P,Other trait,replication,2008-05-18,GCST000193,Red vs. non-red hair color
7918,European,3330.0,18488028.0,Sulem P,Other trait,replication,2008-05-18,GCST000192,Blue vs. green eyes
7920,European,3330.0,18488028.0,Sulem P,Other trait,replication,2008-05-18,GCST000194,Blond vs. brown hair color
8642,European,5130.0,18488028.0,Sulem P,Immune system disorder,initial,2008-05-18,GCST000195,Skin sensitivity to sun
8644,European,5130.0,18488028.0,Sulem P,Other trait,initial,2008-05-18,GCST000192,Blue vs. green eyes
7425,European,2481.0,18488026.0,Brown KM,Cancer,replication,2008-05-18,GCST000198,Melanoma
6854,European,1728.0,18488026.0,Brown KM,Cancer,initial,2008-05-18,GCST000198,Melanoma
8645,European,5130.0,18488028.0,Sulem P,Other trait,initial,2008-05-18,GCST000193,Red vs. non-red hair color
8646,European,5130.0,18488028.0,Sulem P,Other trait,initial,2008-05-18,GCST000194,Blond vs. brown hair color
8647,European,5130.0,18488028.0,Sulem P,Other trait,initial,2008-05-18,GCST000197,Freckles
8330,European,4305.0,18514160.0,Arnaud-Lopez L,"Other measurement, Other trait",initial,2008-06-01,GCST000199,Thyroid stimulating hormone levels
8275,European,4158.0,18514160.0,Arnaud-Lopez L,"Other measurement, Other trait",replication,2008-06-01,GCST000199,Thyroid stimulating hormone levels
1623,Asian,16.0,18521091.0,Volpi S,Response to drug,initial,2008-06-03,GCST000201,Response to iloperidone treatment (QT prolongation)
13638,Other/Mixed,7.0,18521091.0,Volpi S,Response to drug,initial,2008-06-03,GCST000201,Response to iloperidone treatment (QT prolongation)
4687,European,69.0,18521091.0,Volpi S,Response to drug,initial,2008-06-03,GCST000201,Response to iloperidone treatment (QT prolongation)
13754,Other/Mixed,106.0,18521090.0,Lavedan C,Response to drug,initial,2008-06-03,GCST000200,Response to iloperidone treatment (PANSS-T score)
13753,Other/Mixed,104.0,18521090.0,Lavedan C,Response to drug,replication,2008-06-03,GCST000200,Response to iloperidone treatment (PANSS-T score)
492,African American or Afro-Caribbean,91.0,18521091.0,Volpi S,Response to drug,initial,2008-06-03,GCST000201,Response to iloperidone treatment (QT prolongation)
5505,European,550.0,18519826.0,Uhl GR,Biological process,initial,2008-06-04,GCST000203,Smoking cessation
8630,European,5088.0,18521185.0,Chen WM,Other measurement,initial,2008-06-04,GCST000202,Fasting plasma glucose
10419,European,18436.0,18521185.0,Chen WM,Other measurement,replication,2008-06-04,GCST000202,Fasting plasma glucose
4855,European,181.0,18535201.0,Cooper GM,Response to drug,initial,2008-06-05,GCST000204,Warfarin maintenance dose
5153,European,374.0,18535201.0,Cooper GM,Response to drug,replication,2008-06-05,GCST000204,Warfarin maintenance dose
5647,European,654.0,18451265.0,Bouatia-Naji N,Other measurement,initial,2008-06-19,GCST000205,Fasting plasma glucose
9629,European,9353.0,18451265.0,Bouatia-Naji N,Other measurement,replication,2008-06-19,GCST000205,Fasting plasma glucose
7059,European,2019.0,18576341.0,Behrens EM,Immune system disorder,initial,2008-06-24,GCST000206,Arthritis (juvenile idiopathic)
9362,European,8151.0,18587394.0,Barrett JC,Digestive system disorder,replication,2008-06-29,GCST000207,Crohn's disease
9662,European,9541.0,18587394.0,Barrett JC,Digestive system disorder,initial,2008-06-29,GCST000207,Crohn's disease
4890,European,195.0,18591461.0,Turner ST,Response to drug,initial,2008-06-30,GCST000208,Response to diuretic therapy
561,African American or Afro-Caribbean,194.0,18591461.0,Turner ST,Response to drug,initial,2008-06-30,GCST000208,Response to diuretic therapy
4719,European,87.0,18594024.0,Sarasquete ME,Other disease,initial,2008-07-01,GCST000209,Osteonecrosis of the jaw
8408,European,4570.0,18604267.0,Pare G,Cardiovascular measurement,initial,2008-07-04,GCST000210,Soluble ICAM-1
7053,European,2008.0,18604267.0,Pare G,Cardiovascular measurement,replication,2008-07-04,GCST000210,Soluble ICAM-1
4725,European,89.0,18615156.0,Liu C,Response to drug,initial,2008-07-10,GCST000211,Response to TNF antagonist treatment
6358,European,1174.0,18723019.0,Franke A,"Digestive system disorder, Other disease",initial,2008-07-21,GCST000212,Crohn's disease and sarcoidosis (combined)
7376,European,2408.0,18723019.0,Franke A,"Digestive system disorder, Other disease",replication,2008-07-21,GCST000212,Crohn's disease and sarcoidosis (combined)
10309,European,16664.0,18650507.0,Link E,Response to drug,replication,2008-07-23,GCST000213,Response to statin therapy
4842,European,175.0,18650507.0,Link E,Response to drug,initial,2008-07-23,GCST000213,Response to statin therapy
8566,European,4946.0,18660810.0,Schormair B,Neurological disorder,replication,2008-07-27,GCST000214,Restless legs syndrome
7274,European,2272.0,18660810.0,Schormair B,Neurological disorder,initial,2008-07-27,GCST000214,Restless legs syndrome
3398,Asian,3647.0,18677311.0,O'Donovan MC,Neurological disorder,replication,2008-07-30,GCST000215,Schizophrenia
9825,European,10658.0,18677311.0,O'Donovan MC,Neurological disorder,replication,2008-07-30,GCST000215,Schizophrenia
7981,European,3416.0,18677311.0,O'Donovan MC,Neurological disorder,initial,2008-07-30,GCST000215,Schizophrenia
6512,European,1341.0,19165918.0,Graham RR,Immune system disorder,replication,2008-08-01,GCST000216,Systemic lupus erythematosus
7513,European,2586.0,19165918.0,Graham RR,Immune system disorder,initial,2008-08-01,GCST000216,Systemic lupus erythematosus
5855,European,804.0,18668548.0,Julia A,Immune system disorder,replication,2008-08-01,GCST000217,Rheumatoid arthritis
5852,European,800.0,18668548.0,Julia A,Immune system disorder,initial,2008-08-01,GCST000217,Rheumatoid arthritis
9810,European,10596.0,18711365.0,Ferreira MA,Neurological disorder,initial,2008-08-17,GCST000220,Bipolar disorder
4183,Asian,12361.0,18711366.0,Unoki H,Metabolic disorder,replication,2008-08-17,GCST000221,Type 2 diabetes
2847,Asian,1752.0,18711366.0,Unoki H,Metabolic disorder,initial,2008-08-17,GCST000221,Type 2 diabetes
4234,Asian,13173.0,18711367.0,Yasuda K,Metabolic disorder,replication,2008-08-17,GCST000219,Type 2 diabetes
9012,European,6570.0,18711367.0,Yasuda K,Metabolic disorder,replication,2008-08-17,GCST000219,Type 2 diabetes
9637,European,9387.0,18711366.0,Unoki H,Metabolic disorder,replication,2008-08-17,GCST000221,Type 2 diabetes
2809,Asian,1691.0,18711367.0,Yasuda K,Metabolic disorder,initial,2008-08-17,GCST000219,Type 2 diabetes
9700,European,9769.0,18846228.0,Weidinger S,Other measurement,replication,2008-08-22,GCST000222,IgE levels
6667,European,1530.0,18846228.0,Weidinger S,Other measurement,initial,2008-08-22,GCST000222,IgE levels
6192,European,1004.0,18729187.0,Galvan A,Cancer,initial,2008-08-26,GCST000223,Lung adenocarcinoma
8683,European,5261.0,18758464.0,Kugathasan S,"Digestive system disorder, Immune system disorder",initial,2008-08-31,GCST000225,Inflammatory bowel disease
10249,European,16046.0,18758464.0,Kugathasan S,"Digestive system disorder, Immune system disorder",replication,2008-08-31,GCST000225,Inflammatory bowel disease
7581,European,2701.0,18758461.0,Di Bernardo MC,Cancer,replication,2008-08-31,GCST000224,Chronic lymphocytic leukemia
6999,European,1943.0,18758461.0,Di Bernardo MC,Cancer,initial,2008-08-31,GCST000224,Chronic lymphocytic leukemia
14051,Other/Mixed,868.0,18759275.0,McArdle PF,Cardiovascular measurement,initial,2008-09-01,GCST000227,Uric acid levels
6967,European,1880.0,18762592.0,van den Oord EJ,"Neurological disorder, Other measurement",replication,2008-09-01,GCST000226,Neuroticism
6429,European,1227.0,18762592.0,van den Oord EJ,"Neurological disorder, Other measurement",initial,2008-09-01,GCST000226,Neuroticism
6244,European,1059.0,18776911.0,Hazra A,Other measurement,replication,2008-09-07,GCST000228,Vitamin B12 levels
6791,European,1658.0,18776911.0,Hazra A,Other measurement,initial,2008-09-07,GCST000228,Vitamin B12 levels
6164,European,1000.0,18776929.0,Liu YZ,Body measurement,initial,2008-09-08,GCST000229,Hip bone size
6414,European,1216.0,18776929.0,Liu YZ,Body measurement,replication,2008-09-08,GCST000229,Hip bone size
6268,European,1081.0,18760390.0,Huyghe JR,Neurological disorder,initial,2008-09-12,GCST000230,Hearing impairment
9694,European,9736.0,18794853.0,Raychaudhuri S,Immune system disorder,replication,2008-09-14,GCST000232,Rheumatoid arthritis
11035,European,36139.0,18794855.0,Kiemeney LA,Cancer,initial,2008-09-14,GCST000231,Urinary bladder cancer
10242,European,15853.0,18794853.0,Raychaudhuri S,Immune system disorder,initial,2008-09-14,GCST000232,Rheumatoid arthritis
8879,European,5965.0,18794855.0,Kiemeney LA,Cancer,replication,2008-09-14,GCST000231,Urinary bladder cancer
5221,European,413.0,18780872.0,Liu P,Cancer,initial,2008-09-17,GCST000233,Lung cancer
14160,Other/Mixed,2346.0,18802019.0,Burkhardt R,"Lipid or lipoprotein measurement, Other measurement",initial,2008-09-18,GCST000234,LDL cholesterol
12746,Hispanic or Latin American,34.0,18821564.0,Mick E,Neurological disorder,initial,2008-09-26,GCST000235,Attention deficit hyperactivity disorder
4767,European,105.0,18821564.0,Mick E,Neurological disorder,initial,2008-09-26,GCST000235,Attention deficit hyperactivity disorder
13678,Other/Mixed,22.0,18821564.0,Mick E,Neurological disorder,initial,2008-09-26,GCST000235,Attention deficit hyperactivity disorder
431,African American or Afro-Caribbean,26.0,18821564.0,Mick E,Neurological disorder,initial,2008-09-26,GCST000235,Attention deficit hyperactivity disorder
2241,Asian,611.0,18820697.0,Miyagawa T,Neurological disorder,initial,2008-09-28,GCST000236,Narcolepsy
2362,Asian,773.0,18820697.0,Miyagawa T,Neurological disorder,replication,2008-09-28,GCST000236,Narcolepsy
554,African American or Afro-Caribbean,184.0,18820697.0,Miyagawa T,Neurological disorder,replication,2008-09-28,GCST000236,Narcolepsy
5834,European,785.0,18820697.0,Miyagawa T,Neurological disorder,replication,2008-09-28,GCST000236,Narcolepsy
7319,European,2321.0,18823527.0,Abraham R,Neurological disorder,initial,2008-09-29,GCST000237,Alzheimer's disease
9958,European,11847.0,18834626.0,Dehghan A,"Metabolic disorder, Other measurement",initial,2008-10-01,GCST000242,Urate levels
1215,African American or Afro-Caribbean,3843.0,18834626.0,Dehghan A,"Metabolic disorder, Other measurement",replication,2008-10-01,GCST000242,Urate levels
10002,European,12476.0,18991354.0,Gretarsdottir S,Cardiovascular disease,initial,2008-10-01,GCST000239,Stroke (ischemic)
6109,European,970.0,19802338.0,Chasman DI,"Lipid or lipoprotein measurement, Other measurement",replication,2008-10-01,GCST000241,Lipid traits
8973,European,6382.0,19802338.0,Chasman DI,"Lipid or lipoprotein measurement, Other measurement",initial,2008-10-01,GCST000241,Lipid traits
8317,European,4274.0,20031538.0,Heid IM,Lipid or lipoprotein measurement,initial,2008-10-01,GCST000240,HDL cholesterol
2244,Asian,618.0,18835860.0,Mushiroda T,Cancer,replication,2008-10-01,GCST000238,Idiopathic pulmonary fibrosis
10688,European,23919.0,18991354.0,Gretarsdottir S,Cardiovascular disease,replication,2008-10-01,GCST000239,Stroke (ischemic)
10245,European,15873.0,20031538.0,Heid IM,Lipid or lipoprotein measurement,replication,2008-10-01,GCST000240,HDL cholesterol
2541,Asian,1093.0,18835860.0,Mushiroda T,Cancer,initial,2008-10-01,GCST000238,Idiopathic pulmonary fibrosis
9868,European,11024.0,18834626.0,Dehghan A,"Metabolic disorder, Other measurement",replication,2008-10-01,GCST000242,Urate levels
7001,European,1944.0,18836448.0,Franke A,Immune system disorder,initial,2008-10-05,GCST000243,Ulcerative colitis
8567,European,4946.0,18836448.0,Franke A,Immune system disorder,replication,2008-10-05,GCST000243,Ulcerative colitis
7798,European,3158.0,18840781.0,Grant SF,Metabolic disorder,initial,2008-10-07,GCST000244,Type 1 diabetes
9327,European,7976.0,18840781.0,Grant SF,Metabolic disorder,replication,2008-10-07,GCST000244,Type 1 diabetes
7638,European,2803.0,18846501.0,Sonuga-Barke EJ,"Neurological disorder, Other measurement",initial,2008-10-07,GCST000247,Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction)
7637,European,2803.0,18846501.0,Sonuga-Barke EJ,"Neurological disorder, Other measurement",initial,2008-10-07,GCST000245,Conduct disorder (maternal expressed emotions interaction)
5565,European,593.0,18839057.0,Lesch KP,Neurological disorder,initial,2008-10-07,GCST000246,Attention deficit hyperactivity disorder
3405,Asian,3669.0,18940312.0,Yuan X,"Liver enzyme measurement, Other measurement",replication,2008-10-10,GCST000248,Liver enzyme levels
9286,European,7751.0,18940312.0,Yuan X,"Liver enzyme measurement, Other measurement",initial,2008-10-10,GCST000248,Liver enzyme levels
6195,European,1005.0,18940312.0,Yuan X,"Liver enzyme measurement, Other measurement",replication,2008-10-10,GCST000248,Liver enzyme levels
8152,European,3836.0,18849991.0,Richards JB,"Other measurement, Other disease",replication,2008-10-12,GCST000250,Male-pattern baldness
6303,European,1125.0,18849991.0,Richards JB,"Other measurement, Other disease",initial,2008-10-12,GCST000250,Male-pattern baldness
8243,European,4060.0,18849993.0,Stacey SN,Cancer,replication,2008-10-12,GCST000249,Basal cell carcinoma
10987,European,34047.0,18849993.0,Stacey SN,Cancer,initial,2008-10-12,GCST000249,Basal cell carcinoma
5509,European,553.0,18849994.0,Hillmer AM,"Other measurement, Other disease",replication,2008-10-12,GCST000251,Male-pattern baldness
5861,European,808.0,18849994.0,Hillmer AM,"Other measurement, Other disease",initial,2008-10-12,GCST000251,Male-pattern baldness
5357,European,484.0,18941528.0,Comabella M,Immune system disorder,initial,2008-10-22,GCST000252,Multiple sclerosis
6729,European,1586.0,18941528.0,Comabella M,Immune system disorder,replication,2008-10-22,GCST000252,Multiple sclerosis
11115,European,39859.0,18952825.0,Johansson A,"Other measurement, Body measurement",replication,2008-10-24,GCST000254,Height
7645,European,2814.0,18951430.0,Anney RJ,Neurological disorder,initial,2008-10-24,GCST000253,Attention deficit hyperactivity disorder and conduct disorder
858,African American or Afro-Caribbean,1148.0,18952825.0,Johansson A,"Other measurement, Body measurement",replication,2008-10-24,GCST000254,Height
8182,European,3925.0,18952825.0,Johansson A,"Other measurement, Body measurement",initial,2008-10-24,GCST000254,Height
6515,European,1345.0,18976728.0,Bertram L,Neurological disorder,initial,2008-10-29,GCST000255,Alzheimer's disease
7524,European,2605.0,18976728.0,Bertram L,Neurological disorder,replication,2008-10-29,GCST000255,Alzheimer's disease
9781,European,10295.0,18978787.0,Wang Y,Cancer,initial,2008-11-02,GCST000257,Lung cancer
10270,European,16235.0,18978792.0,Cooper JD,Metabolic disorder,replication,2008-11-02,GCST000258,Type 1 diabetes
9492,European,8472.0,18978790.0,McKay JD,Cancer,replication,2008-11-02,GCST000256,Lung cancer
9372,European,8207.0,18978792.0,Cooper JD,Metabolic disorder,initial,2008-11-02,GCST000258,Type 1 diabetes
8737,European,5431.0,18978787.0,Wang Y,Cancer,replication,2008-11-02,GCST000257,Lung cancer
9052,European,6717.0,18978790.0,McKay JD,Cancer,initial,2008-11-02,GCST000256,Lung cancer
7639,European,2803.0,18980221.0,Neale BM,Neurological disorder,initial,2008-11-03,GCST000259,Attention deficit hyperactivity disorder
6974,European,1890.0,18987618.0,Cronin S,Neurological disorder,initial,2008-11-05,GCST000260,Amyotrophic lateral sclerosis
7261,European,2246.0,18985386.0,Pankratz N,Neurological disorder,initial,2008-11-06,GCST000261,Parkinson's disease (familial)
9301,European,7856.0,18997786.0,Bilguvar K,Cardiovascular disease,initial,2008-11-09,GCST000262,Intracranial aneurysm
7602,European,2739.0,18997785.0,Aulchenko YS,Immune system disorder,replication,2008-11-09,GCST000263,Multiple sclerosis
5346,European,480.0,19009022.0,Drgon T,Neurological disorder,initial,2008-11-09,GCST000264,Nicotine dependence
2571,Asian,1171.0,18997786.0,Bilguvar K,Cardiovascular disease,replication,2008-11-09,GCST000262,Intracranial aneurysm
4965,European,240.0,18997785.0,Aulchenko YS,Immune system disorder,initial,2008-11-09,GCST000263,Multiple sclerosis
6950,European,1861.0,19010793.0,Baranzini SE,"Immune system disorder, Other measurement",initial,2008-11-14,GCST000267,Multiple sclerosis (age of onset)
6949,European,1861.0,19010793.0,Baranzini SE,Immune system disorder,initial,2008-11-14,GCST000269,Multiple sclerosis
6799,European,1674.0,19010793.0,Baranzini SE,Immune system disorder,initial,2008-11-14,GCST000265,Brain lesion load
6769,European,1636.0,19010793.0,Baranzini SE,Immune system disorder,initial,2008-11-14,GCST000268,Normalized brain volume
6800,European,1677.0,19010793.0,Baranzini SE,Immune system disorder,initial,2008-11-14,GCST000266,Multiple sclerosis (severity)
11048,European,37210.0,19011631.0,Houlston RS,Cancer,replication,2008-11-16,GCST000270,Colorectal cancer
8150,European,3831.0,19011631.0,Houlston RS,Cancer,initial,2008-11-16,GCST000270,Colorectal cancer
4769,European,106.0,19023125.0,Potkin SG,"Neurological disorder, Other measurement",initial,2008-11-20,GCST000271,Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction)
2245,Asian,618.0,19030899.0,Lei SF,"Other measurement, Body measurement",initial,2008-11-23,GCST000272,Height
3289,Asian,2953.0,19030899.0,Lei SF,"Other measurement, Body measurement",replication,2008-11-23,GCST000272,Height
8204,European,3972.0,18957941.0,Terracciano A,Other trait,initial,2008-11-24,GCST000273,Personality dimensions
5014,European,284.0,19043545.0,Gieger C,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2008-11-28,GCST000274,Metabolite levels
11024,European,35812.0,19060907.0,Prokopenko I,Other measurement,initial,2008-12-01,GCST000276,Fasting plasma glucose
4785,European,130.0,19047183.0,Friedman RA,Neurological disorder,replication,2008-12-01,GCST000275,Hearing impairment
6807,European,1692.0,19047183.0,Friedman RA,Neurological disorder,initial,2008-12-01,GCST000275,Hearing impairment
9591,European,9103.0,19056611.0,Timpson NJ,Metabolic disorder,replication,2008-12-03,GCST000277,Type 2 diabetes
8513,European,4862.0,19056611.0,Timpson NJ,Metabolic disorder,initial,2008-12-03,GCST000277,Type 2 diabetes
7624,European,2790.0,18821565.0,Lasky-Su J,Biological process,initial,2008-12-05,GCST000278,Hyperactive-impulsive symptoms
7627,European,2790.0,18937294.0,Lasky-Su J,Neurological disorder,initial,2008-12-05,GCST000280,Attention deficit hyperactivity disorder (time to onset)
7626,European,2790.0,18821565.0,Lasky-Su J,Neurological disorder,initial,2008-12-05,GCST000281,Attention deficit hyperactivity disorder
7625,European,2790.0,18821565.0,Lasky-Su J,Biological process,initial,2008-12-05,GCST000279,Inattentive symptoms
10503,European,19840.0,19060906.0,Kathiresan S,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000290,HDL cholesterol
7167,European,2151.0,19060909.0,Bouatia-Naji N,Other measurement,initial,2008-12-07,GCST000291,Fasting plasma glucose
10504,European,19840.0,19060906.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",initial,2008-12-07,GCST000287,LDL cholesterol
10532,European,20623.0,19060906.0,Kathiresan S,Lipid or lipoprotein measurement,replication,2008-12-07,GCST000286,Triglycerides
10533,European,20623.0,19060906.0,Kathiresan S,Lipid or lipoprotein measurement,replication,2008-12-07,GCST000290,HDL cholesterol
10387,European,17797.0,19060911.0,Aulchenko YS,"Lipid or lipoprotein measurement, Other measurement",initial,2008-12-07,GCST000282,LDL cholesterol
10590,European,21412.0,19060911.0,Aulchenko YS,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000288,HDL cholesterol
10534,European,20623.0,19060906.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",replication,2008-12-07,GCST000287,LDL cholesterol
8471,European,4763.0,19060910.0,Sabatti C,"Lipid or lipoprotein measurement, Other measurement",initial,2008-12-07,GCST000283,LDL cholesterol
8470,European,4763.0,19060910.0,Sabatti C,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000284,HDL cholesterol
10637,European,22562.0,19060911.0,Aulchenko YS,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000285,"Cholesterol, total"
10252,European,16094.0,19060909.0,Bouatia-Naji N,Other measurement,replication,2008-12-07,GCST000291,Fasting plasma glucose
10392,European,17815.0,19060911.0,Aulchenko YS,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000289,Triglycerides
10502,European,19840.0,19060906.0,Kathiresan S,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000286,Triglycerides
8472,European,4763.0,19060910.0,Sabatti C,"Other measurement, Biological process, Lipid or lipoprotein measurement",initial,2008-12-07,GCST000292,Metabolic traits
8041,European,3540.0,19065144.0,Sullivan PF,Neurological disorder,initial,2008-12-09,GCST000293,Major depressive disorder
9965,European,11972.0,19065144.0,Sullivan PF,Neurological disorder,replication,2008-12-09,GCST000293,Major depressive disorder
7813,European,3200.0,19081515.0,Mead S,Neurological disorder,initial,2008-12-11,GCST000294,Creutzfeldt-Jakob disease
14041,Other/Mixed,810.0,19081515.0,Mead S,Neurological disorder,replication,2008-12-11,GCST000294,Creutzfeldt-Jakob disease
8070,European,3610.0,19081515.0,Mead S,Neurological disorder,replication,2008-12-11,GCST000294,Creutzfeldt-Jakob disease
9089,European,6865.0,19079262.0,Styrkarsdottir U,Other measurement,initial,2008-12-14,GCST000297,Bone mineral density (hip)
9088,European,6865.0,19079262.0,Styrkarsdottir U,Other measurement,initial,2008-12-14,GCST000295,Bone mineral density (spine)
9499,European,8510.0,19079262.0,Styrkarsdottir U,Other measurement,replication,2008-12-14,GCST000295,Bone mineral density (spine)
9870,European,11036.0,19079260.0,Thorleifsson G,Body measurement,replication,2008-12-14,GCST000299,Weight
9500,European,8510.0,19079262.0,Styrkarsdottir U,Other measurement,replication,2008-12-14,GCST000297,Bone mineral density (hip)
10914,European,32387.0,19079261.0,Willer CJ,"Body measurement, Other measurement",initial,2008-12-14,GCST000298,Body mass index
11521,European,72598.0,19079260.0,Thorleifsson G,Body measurement,initial,2008-12-14,GCST000299,Weight
11522,European,72598.0,19079260.0,Thorleifsson G,"Body measurement, Other measurement",initial,2008-12-14,GCST000296,Body mass index
862,African American or Afro-Caribbean,1160.0,19079260.0,Thorleifsson G,"Body measurement, Other measurement",initial,2008-12-14,GCST000296,Body mass index
11391,European,59082.0,19079261.0,Willer CJ,"Body measurement, Other measurement",replication,2008-12-14,GCST000298,Body mass index
9871,European,11036.0,19079260.0,Thorleifsson G,"Body measurement, Other measurement",replication,2008-12-14,GCST000296,Body mass index
861,African American or Afro-Caribbean,1160.0,19079260.0,Thorleifsson G,Body measurement,initial,2008-12-14,GCST000299,Weight
6015,European,918.0,19084217.0,Benyamin B,Other measurement,initial,2008-12-17,GCST000301,Iron status biomarkers
14008,Other/Mixed,698.0,19074352.0,Pollin TI,Lipid or lipoprotein measurement,replication,2008-12-17,GCST000300,Triglycerides
5217,European,411.0,19084217.0,Benyamin B,Other measurement,initial,2008-12-17,GCST000302,Iron status biomarkers
14040,Other/Mixed,809.0,19074352.0,Pollin TI,Lipid or lipoprotein measurement,initial,2008-12-17,GCST000300,Triglycerides
10153,European,14618.0,19096518.0,Pare G,Other measurement,initial,2008-12-19,GCST000303,Glycated hemoglobin levels
5309,European,455.0,19096518.0,Pare G,Other measurement,replication,2008-12-19,GCST000303,Glycated hemoglobin levels
7788,European,3141.0,19107115.0,Muglia P,Neurological disorder,initial,2008-12-23,GCST000304,Major depressive disorder
6742,European,1606.0,19110211.0,Meisinger C,Hematological measurement,initial,2008-12-24,GCST000305,Mean platelet volume
9519,European,8617.0,19110211.0,Meisinger C,Hematological measurement,replication,2008-12-24,GCST000305,Mean platelet volume
13946,Other/Mixed,575.0,19114657.0,Wang Y,"Other measurement, Cardiovascular measurement",replication,2008-12-29,GCST000306,Blood pressure
8969,European,6361.0,19114657.0,Wang Y,"Other measurement, Cardiovascular measurement",replication,2008-12-29,GCST000306,Blood pressure
5490,European,542.0,19114657.0,Wang Y,"Other measurement, Cardiovascular measurement",initial,2008-12-29,GCST000306,Blood pressure
7564,European,2678.0,19116933.0,Hinks A,Immune system disorder,replication,2009-01-01,GCST000309,Arthritis (juvenile idiopathic)
6760,European,1627.0,19115949.0,Limou S,Immune system disorder,initial,2009-01-01,GCST000308,AIDS progression
7655,European,2834.0,19117981.0,Sun J,Cancer,initial,2009-01-01,GCST000307,Prostate cancer
8431,European,4636.0,19117981.0,Sun J,Cancer,replication,2009-01-01,GCST000307,Prostate cancer
5320,European,463.0,19116933.0,Hinks A,Immune system disorder,initial,2009-01-01,GCST000309,Arthritis (juvenile idiopathic)
5313,European,458.0,19118814.0,Beecham GW,Neurological disorder,replication,2009-01-03,GCST000310,Alzheimer's disease
6147,European,988.0,19118814.0,Beecham GW,Neurological disorder,initial,2009-01-03,GCST000310,Alzheimer's disease
8033,European,3525.0,19122664.0,Silverberg MS,Immune system disorder,initial,2009-01-04,GCST000311,Ulcerative colitis
7434,European,2502.0,19122664.0,Silverberg MS,Immune system disorder,replication,2009-01-04,GCST000311,Ulcerative colitis
6108,European,970.0,19125160.0,Feulner TM,Neurological disorder,initial,2009-01-07,GCST000313,Alzheimer's disease
13888,Other/Mixed,357.0,19124843.0,Ober C,Lipid or lipoprotein measurement,initial,2009-01-07,GCST000312,Lp (a) levels
6240,European,1054.0,19124843.0,Ober C,Lipid or lipoprotein measurement,replication,2009-01-07,GCST000312,Lp (a) levels
4968,European,241.0,19132087.0,Burgner D,Immune system disorder,initial,2009-01-09,GCST000314,Kawasaki disease
6995,European,1940.0,19132087.0,Burgner D,Immune system disorder,replication,2009-01-09,GCST000314,Kawasaki disease
7135,European,2099.0,19136949.0,Carrasquillo MM,Neurological disorder,initial,2009-01-11,GCST000315,Alzheimer's disease
7609,European,2756.0,19136949.0,Carrasquillo MM,Neurological disorder,replication,2009-01-11,GCST000315,Alzheimer's disease
6255,European,1075.0,19148276.0,Tanaka T,Other measurement,initial,2009-01-16,GCST000316,Polyunsaturated fatty acid levels
6258,European,1076.0,19148276.0,Tanaka T,Other measurement,replication,2009-01-16,GCST000316,Polyunsaturated fatty acid levels
10868,European,30395.0,19151717.0,Rafnar T,Cancer,initial,2009-01-18,GCST000318,Basal cell carcinoma
10134,European,14186.0,19151714.0,Meyre D,"Other measurement, Metabolic disorder",replication,2009-01-18,GCST000317,Obesity
6719,European,1575.0,19151717.0,Rafnar T,Cancer,replication,2009-01-18,GCST000318,Basal cell carcinoma
7631,European,2796.0,19151714.0,Meyre D,"Other measurement, Metabolic disorder",initial,2009-01-18,GCST000317,Obesity
7041,European,1986.0,19165155.0,Ling H,Other measurement,initial,2009-01-22,GCST000319,Adiponectin levels
2082,Asian,400.0,19165232.0,Otowa T,Neurological disorder,initial,2009-01-23,GCST000320,Panic disorder
7613,European,2759.0,19169254.0,Nair RP,Immune system disorder,initial,2009-01-25,GCST000322,Psoriasis
3105,Asian,2271.0,19169255.0,Zhang XJ,Immune system disorder,initial,2009-01-25,GCST000321,Psoriasis
9763,European,10089.0,19169254.0,Nair RP,Immune system disorder,replication,2009-01-25,GCST000322,Psoriasis
4217,Asian,13061.0,19169255.0,Zhang XJ,Immune system disorder,replication,2009-01-25,GCST000321,Psoriasis
25,African,53.0,19176441.0,Yang JJ,"Response to drug, Cancer",initial,2009-01-28,GCST000323,Response to treatment for acute lymphoblastic leukemia
5127,European,356.0,19176441.0,Yang JJ,"Response to drug, Cancer",initial,2009-01-28,GCST000323,Response to treatment for acute lymphoblastic leukemia
13736,Other/Mixed,78.0,19176441.0,Yang JJ,"Response to drug, Cancer",initial,2009-01-28,GCST000323,Response to treatment for acute lymphoblastic leukemia
6377,European,1191.0,19185284.0,Ferrucci L,Other measurement,initial,2009-01-29,GCST000324,Carotenoid and tocopherol levels
7483,European,2540.0,19185284.0,Ferrucci L,Other measurement,replication,2009-01-29,GCST000324,Carotenoid and tocopherol levels
6698,European,1552.0,19181680.0,Timpson NJ,Other measurement,initial,2009-01-30,GCST000325,Bone mineral density
8166,European,3875.0,19181680.0,Timpson NJ,Other measurement,replication,2009-01-30,GCST000325,Bone mineral density
10177,European,14830.0,19182806.0,Stefansson H,Other trait,initial,2009-02-01,GCST000329,Essential tremor
6838,European,1720.0,19182806.0,Stefansson H,Other trait,replication,2009-02-01,GCST000329,Essential tremor
5993,European,898.0,19260139.0,Polasek O,"Other measurement, Body measurement",initial,2009-02-01,GCST000327,Anthropometric traits
5994,European,898.0,19260141.0,Zemunik T,"Cardiovascular measurement, Hematological measurement, Lipid or lipoprotein measurement, Other measurement",initial,2009-02-01,GCST000328,Biochemical measures
2023,Asian,347.0,19187332.0,Kim SH,Other disease,initial,2009-02-01,GCST000330,Asthma (toluene diisocyanate-induced)
4774,European,112.0,19207018.0,Kim H,Other trait,initial,2009-02-01,GCST000326,Pain
10408,European,18245.0,20031564.0,Ridker PM,Lipid or lipoprotein measurement,initial,2009-02-01,GCST000331,HDL cholesterol
5912,European,840.0,19188921.0,Liu YZ,Biological process,initial,2009-02-03,GCST000332,Smoking behavior
885,African American or Afro-Caribbean,1251.0,19188921.0,Liu YZ,Biological process,replication,2009-02-03,GCST000332,Smoking behavior
9265,European,7623.0,19188921.0,Liu YZ,Biological process,replication,2009-02-03,GCST000332,Smoking behavior
7455,European,2521.0,19193627.0,Chio A,Neurological disorder,initial,2009-02-04,GCST000333,Amyotrophic lateral sclerosis
8785,European,5616.0,19193627.0,Chio A,Neurological disorder,replication,2009-02-04,GCST000333,Amyotrophic lateral sclerosis
2302,Asian,700.0,19196962.0,Garcia-Barcelo MM,Digestive system disorder,replication,2009-02-05,GCST000334,Hirschsprung disease
2199,Asian,527.0,19196962.0,Garcia-Barcelo MM,Digestive system disorder,initial,2009-02-05,GCST000334,Hirschsprung disease
10148,European,14455.0,19197363.0,Need AC,Neurological disorder,replication,2009-02-06,GCST000336,Schizophrenia
6863,European,1734.0,19197363.0,Need AC,Neurological disorder,initial,2009-02-06,GCST000336,Schizophrenia
7186,European,2159.0,19198613.0,Gudmundsson J,Cancer,replication,2009-02-06,GCST000335,Thyroid cancer
11053,European,37388.0,19198613.0,Gudmundsson J,Cancer,initial,2009-02-06,GCST000335,Thyroid cancer
14185,Other/Mixed,2906.0,19197348.0,Lowe JK,"Other measurement, Body measurement, Lipid or lipoprotein measurement, Inflammatory measurement",initial,2009-02-06,GCST000337,Quantitative traits
10479,European,19492.0,19198609.0,Kathiresan S,Cardiovascular disease,replication,2009-02-08,GCST000340,Myocardial infarction (early onset)
10144,European,14398.0,19198611.0,Tregouet DA,Cardiovascular disease,replication,2009-02-08,GCST000341,Coronary heart disease
9977,European,12118.0,19198610.0,Gudbjartsson DF,Hematological measurement,replication,2009-02-08,GCST000339,Eosinophil counts
3607,Asian,5212.0,19198610.0,Gudbjartsson DF,Hematological measurement,replication,2009-02-08,GCST000339,Eosinophil counts
8898,European,6042.0,19198609.0,Kathiresan S,Cardiovascular disease,initial,2009-02-08,GCST000340,Myocardial infarction (early onset)
9638,European,9392.0,19198610.0,Gudbjartsson DF,Hematological measurement,initial,2009-02-08,GCST000339,Eosinophil counts
11088,European,38253.0,19198612.0,Erdmann J,Cardiovascular disease,replication,2009-02-08,GCST000338,Coronary heart disease
8516,European,4864.0,19198611.0,Tregouet DA,Cardiovascular disease,initial,2009-02-08,GCST000341,Coronary heart disease
7454,European,2520.0,19198612.0,Erdmann J,Cardiovascular disease,initial,2009-02-08,GCST000338,Coronary heart disease
6740,European,1601.0,19221038.0,Soranzo N,Hematological measurement,replication,2009-02-12,GCST000342,Mean platelet volume
7753,European,3057.0,19219042.0,Zheng W,Cancer,replication,2009-02-15,GCST000343,Breast cancer
3879,Asian,7502.0,19219042.0,Zheng W,Cancer,replication,2009-02-15,GCST000343,Breast cancer
3311,Asian,3027.0,19219042.0,Zheng W,Cancer,initial,2009-02-15,GCST000343,Breast cancer
14093,Other/Mixed,1262.0,19389651.0,Smith JG,Cardiovascular measurement,initial,2009-02-15,GCST000344,Electrocardiographic conduction measures
13957,Other/Mixed,604.0,19230858.0,Schrauwen I,Neurological disorder,initial,2009-02-18,GCST000345,Otosclerosis
14131,Other/Mixed,1719.0,19230858.0,Schrauwen I,Neurological disorder,replication,2009-02-18,GCST000345,Otosclerosis
6165,European,1000.0,19249006.0,Xiong DH,Other measurement,initial,2009-02-25,GCST000347,Bone mineral density
8551,European,4925.0,19249006.0,Xiong DH,Other measurement,replication,2009-02-25,GCST000347,Bone mineral density
150,African,908.0,19249006.0,Xiong DH,Other measurement,replication,2009-02-25,GCST000347,Bone mineral density
5359,European,485.0,19242412.0,Gu Y,Other disease,replication,2009-02-25,GCST000346,Cystic fibrosis severity
5071,European,320.0,19242412.0,Gu Y,Other disease,initial,2009-02-25,GCST000346,Cystic fibrosis severity
3404,Asian,3655.0,19249006.0,Xiong DH,Other measurement,replication,2009-02-25,GCST000347,Bone mineral density
8341,European,4342.0,19247474.0,Caporaso N,Biological process,initial,2009-02-27,GCST000349,Smoking behavior
6489,European,1304.0,19252134.0,Pezzolesi MG,Metabolic disorder,replication,2009-02-27,GCST000348,Type 2 diabetes nephropathy
6820,European,1705.0,19252134.0,Pezzolesi MG,Metabolic disorder,initial,2009-02-27,GCST000348,Type 2 diabetes nephropathy
2399,Asian,804.0,19259986.0,Hattori E,Neurological disorder,replication,2009-03-02,GCST000350,Bipolar disorder
1877,Asian,214.0,19259986.0,Hattori E,Neurological disorder,initial,2009-03-02,GCST000350,Bipolar disorder
13839,Other/Mixed,249.0,19268276.0,Vink JM,Biological process,replication,2009-03-04,GCST000351,Smoking behavior
8020,European,3497.0,19268276.0,Vink JM,Biological process,initial,2009-03-04,GCST000351,Smoking behavior
3290,Asian,2955.0,19268274.0,Liu XG,Other measurement,replication,2009-03-04,GCST000352,Body mass (lean)
8000,European,3460.0,19268274.0,Liu XG,Other measurement,replication,2009-03-04,GCST000352,Body mass (lean)
6116,European,973.0,19268274.0,Liu XG,Other measurement,initial,2009-03-04,GCST000352,Body mass (lean)
9261,European,7614.0,19268276.0,Vink JM,Biological process,replication,2009-03-04,GCST000351,Smoking behavior
5588,European,607.0,19270707.0,Birnbaum S,"Other trait, Other measurement, Other disease",initial,2009-03-08,GCST000353,Orofacial clefts
6782,European,1647.0,19278955.0,Tregouet DA,Cardiovascular disease,initial,2009-03-10,GCST000354,Venous thromboembolism
7863,European,3237.0,19278955.0,Tregouet DA,Cardiovascular disease,replication,2009-03-10,GCST000354,Venous thromboembolism
6752,European,1616.0,19282985.0,Liu YZ,Other measurement,replication,2009-03-13,GCST000355,Menarche (age at onset)
5340,European,477.0,19282985.0,Liu YZ,Other measurement,initial,2009-03-13,GCST000355,Menarche (age at onset)
2666,Asian,1387.0,19282985.0,Liu YZ,Other measurement,replication,2009-03-13,GCST000355,Menarche (age at onset)
5931,European,849.0,19287509.0,Cui J,Other measurement,replication,2009-03-14,GCST000356,Anti-cyclic Citrullinated Peptide Antibody
5478,European,531.0,19287509.0,Cui J,Other measurement,initial,2009-03-14,GCST000356,Anti-cyclic Citrullinated Peptide Antibody
7914,European,3323.0,19287384.0,Kilpivaara O,Cancer,initial,2009-03-15,GCST000357,Myeloproliferative neoplasms
7700,European,2934.0,19303062.0,Tanaka T,"Other measurement, Cardiovascular measurement",initial,2009-03-18,GCST000358,Folate pathway vitamin levels
5699,European,686.0,19303062.0,Tanaka T,"Other measurement, Cardiovascular measurement",replication,2009-03-18,GCST000358,Folate pathway vitamin levels
5561,European,588.0,19300499.0,Takeuchi F,Response to drug,replication,2009-03-20,GCST000360,Warfarin maintenance dose
7607,European,2752.0,19300482.0,Pillai SG,Other disease,replication,2009-03-20,GCST000359,Chronic obstructive pulmonary disease
6766,European,1633.0,19300482.0,Pillai SG,Other disease,initial,2009-03-20,GCST000359,Chronic obstructive pulmonary disease
5905,European,835.0,19300500.0,Wilk JB,Other measurement,replication,2009-03-20,GCST000362,Pulmonary function
9279,European,7691.0,19300500.0,Wilk JB,Other measurement,initial,2009-03-20,GCST000362,Pulmonary function
6238,European,1053.0,19300499.0,Takeuchi F,Response to drug,initial,2009-03-20,GCST000360,Warfarin maintenance dose
7644,European,2812.0,19304780.0,Org E,Cardiovascular disease,replication,2009-03-20,GCST000361,Hypertension
6090,European,954.0,19304780.0,Org E,Cardiovascular disease,initial,2009-03-20,GCST000361,Hypertension
10095,European,13685.0,19305408.0,Newton-Cheh C,Cardiovascular measurement,initial,2009-03-22,GCST000363,QT interval
10243,European,15854.0,19305408.0,Newton-Cheh C,Cardiovascular measurement,replication,2009-03-22,GCST000363,QT interval
10240,European,15842.0,19305409.0,Pfeufer A,Cardiovascular measurement,initial,2009-03-22,GCST000364,QT interval
7293,European,2287.0,19330030.0,Thomas G,Cancer,initial,2009-03-29,GCST000365,Breast cancer
10411,European,18282.0,19330030.0,Thomas G,Cancer,replication,2009-03-29,GCST000365,Breast cancer
7039,European,1984.0,20031582.0,Thompson JF,Response to drug,initial,2009-04-01,GCST000369,Response to statin therapy
5913,European,840.0,20031578.0,Pare G,Cardiovascular measurement,replication,2009-04-01,GCST000367,Homocysteine levels
10114,European,13974.0,20031578.0,Pare G,Cardiovascular measurement,initial,2009-04-01,GCST000367,Homocysteine levels
8297,European,4221.0,20031579.0,Tarasov KV,Cardiovascular measurement,initial,2009-04-01,GCST000370,Arterial stiffness
7552,European,2654.0,20031579.0,Tarasov KV,Cardiovascular measurement,replication,2009-04-01,GCST000370,Arterial stiffness
8124,European,3761.0,20031582.0,Thompson JF,Response to drug,replication,2009-04-01,GCST000369,Response to statin therapy
10617,European,22096.0,20031576.0,Dehghan A,Hematological measurement,initial,2009-04-01,GCST000366,Fibrinogen
10375,European,17686.0,20031577.0,Danik JS,Hematological measurement,initial,2009-04-01,GCST000368,Fibrinogen
10374,European,17686.0,20031576.0,Dehghan A,Hematological measurement,replication,2009-04-01,GCST000366,Fibrinogen
7294,European,2287.0,19340012.0,Nan H,Other trait,initial,2009-04-02,GCST000371,Tanning
5958,European,870.0,19340012.0,Nan H,Other trait,replication,2009-04-02,GCST000371,Tanning
9163,European,7187.0,19343178.0,Soranzo N,"Other measurement, Body measurement",replication,2009-04-03,GCST000372,Height
10015,European,12611.0,19343178.0,Soranzo N,"Other measurement, Body measurement",initial,2009-04-03,GCST000372,Height
1946,Asian,266.0,19403135.0,Yamada Y,Cardiovascular disease,initial,2009-04-05,GCST000373,Stroke (ischemic)
3737,Asian,5981.0,19403135.0,Yamada Y,Cardiovascular disease,replication,2009-04-05,GCST000373,Stroke (ischemic)
2428,Asian,854.0,19349983.0,Kamatani Y,"Digestive system disorder, Other measurement",replication,2009-04-06,GCST000375,Hepatitis B
2551,Asian,1113.0,19349983.0,Kamatani Y,"Digestive system disorder, Other measurement",initial,2009-04-06,GCST000375,Hepatitis B
3503,Asian,4420.0,19349983.0,Kamatani Y,"Digestive system disorder, Other measurement",replication,2009-04-06,GCST000375,Hepatitis B
9015,European,6594.0,19349984.0,Esparza-Gordillo J,Immune system disorder,replication,2009-04-06,GCST000374,Atopic dermatitis
7734,European,3011.0,19349984.0,Esparza-Gordillo J,Immune system disorder,initial,2009-04-06,GCST000374,Atopic dermatitis
6347,European,1165.0,19359265.0,Mangino M,Other measurement,replication,2009-04-08,GCST000376,Telomere length
6758,European,1625.0,19359265.0,Mangino M,Other measurement,initial,2009-04-08,GCST000376,Telomere length
2447,Asian,900.0,19359809.0,Hiura Y,Lipid or lipoprotein measurement,initial,2009-04-10,GCST000377,HDL cholesterol
2893,Asian,1810.0,19359809.0,Hiura Y,Lipid or lipoprotein measurement,replication,2009-04-10,GCST000377,HDL cholesterol
5062,European,314.0,19367585.0,Poduslo SE,Biological process,initial,2009-04-14,GCST000378,Aging
403,African American or Afro-Caribbean,2.0,19367585.0,Poduslo SE,Biological process,initial,2009-04-14,GCST000378,Aging
10493,European,19602.0,19369658.0,Ikram MA,Cardiovascular disease,initial,2009-04-15,GCST000379,Stroke
8314,European,4265.0,19369658.0,Ikram MA,Cardiovascular disease,replication,2009-04-15,GCST000379,Stroke
1122,African American or Afro-Caribbean,3004.0,19369658.0,Ikram MA,Cardiovascular disease,replication,2009-04-15,GCST000379,Stroke
4018,Asian,8842.0,19396169.0,Cho YS,"Other measurement, Body measurement",initial,2009-04-26,GCST000380,Height
3934,Asian,7861.0,19396169.0,Cho YS,"Body measurement, Cardiovascular measurement, Other measurement",replication,2009-04-26,GCST000381,Biomedical quantitative traits
3935,Asian,7861.0,19396169.0,Cho YS,"Other measurement, Body measurement",replication,2009-04-26,GCST000380,Height
4017,Asian,8842.0,19396169.0,Cho YS,"Body measurement, Cardiovascular measurement, Other measurement",initial,2009-04-26,GCST000381,Biomedical quantitative traits
9850,European,10796.0,19404256.0,Wang K,Neurological disorder,initial,2009-04-28,GCST000382,Autism
7075,European,2038.0,19404256.0,Wang K,Neurological disorder,replication,2009-04-28,GCST000382,Autism
4179,Asian,11977.0,19401414.0,Takeuchi F,Metabolic disorder,replication,2009-04-29,GCST000383,Type 2 diabetes
2511,Asian,1022.0,19401414.0,Takeuchi F,Metabolic disorder,initial,2009-04-29,GCST000383,Type 2 diabetes
5797,European,754.0,19330027.0,Ahmed S,Cancer,initial,2009-05-01,GCST004948,Breast cancer
11583,European,80356.0,19330027.0,Ahmed S,Cancer,replication,2009-05-01,GCST004948,Breast cancer
10671,European,23660.0,19330027.0,Ahmed S,Cancer,replication,2009-05-01,GCST004949,Breast cancer
3534,Asian,4631.0,19330027.0,Ahmed S,Cancer,replication,2009-05-01,GCST004948,Breast cancer
5798,European,754.0,19330027.0,Ahmed S,Cancer,initial,2009-05-01,GCST004949,Breast cancer
7395,European,2440.0,19412175.0,Capasso M,Cancer,initial,2009-05-03,GCST000384,Neuroblastoma (high-risk)
5733,European,718.0,19412176.0,Hallmayer J,Neurological disorder,replication,2009-05-03,GCST000385,Narcolepsy
7430,European,2490.0,19412175.0,Capasso M,Cancer,replication,2009-05-03,GCST000384,Neuroblastoma (high-risk)
2568,Asian,1166.0,19412176.0,Hallmayer J,Neurological disorder,replication,2009-05-03,GCST000385,Narcolepsy
614,African American or Afro-Caribbean,277.0,19412176.0,Hallmayer J,Neurological disorder,replication,2009-05-03,GCST000385,Narcolepsy
6968,European,1881.0,19412176.0,Hallmayer J,Neurological disorder,initial,2009-05-03,GCST000385,Narcolepsy
14244,Other/Mixed,9464.0,19414484.0,Johnson AD,Other measurement,initial,2009-05-04,GCST000386,Bilirubin levels
10402,European,18190.0,19416921.0,Scott LJ,Neurological disorder,initial,2009-05-05,GCST000387,Bipolar disorder
8327,European,4300.0,19419973.0,Sanna S,Other measurement,initial,2009-05-06,GCST000388,Bilirubin levels
7569,European,2692.0,19419973.0,Sanna S,Other measurement,replication,2009-05-06,GCST000388,Bilirubin levels
14135,Other/Mixed,1776.0,19426955.0,Himes BE,Other disease,replication,2009-05-07,GCST000389,Asthma
1276,African American or Afro-Caribbean,5264.0,19426955.0,Himes BE,Other disease,replication,2009-05-07,GCST000389,Asthma
6398,European,1205.0,19426955.0,Himes BE,Other disease,initial,2009-05-07,GCST000389,Asthma
2026,Asian,350.0,19421330.0,Yang HC,Cardiovascular disease,initial,2009-05-07,GCST000390,Hypertension (young onset)
2799,Asian,1666.0,19421330.0,Yang HC,Cardiovascular disease,replication,2009-05-07,GCST000390,Hypertension (young onset)
10213,European,15339.0,19426955.0,Himes BE,Other disease,replication,2009-05-07,GCST000389,Asthma
13093,Hispanic or Latin American,1776.0,19426955.0,Himes BE,Other disease,replication,2009-05-07,GCST000389,Asthma
13014,Hispanic or Latin American,961.0,19430760.0,Rich SS,Other trait,replication,2009-05-09,GCST000391,Insulin resistance/response
12816,Hispanic or Latin American,229.0,19430760.0,Rich SS,Other trait,initial,2009-05-09,GCST000391,Insulin resistance/response
10834,European,29136.0,19430479.0,Levy D,Cardiovascular disease,initial,2009-05-10,GCST000398,Hypertension
10299,European,16559.0,19430480.0,Barrett JC,Metabolic disorder,initial,2009-05-10,GCST000392,Type 1 diabetes
10836,European,29136.0,19430479.0,Levy D,Other measurement,initial,2009-05-10,GCST000396,Diastolic blood pressure
10835,European,29136.0,19430479.0,Levy D,Other measurement,initial,2009-05-10,GCST000393,Systolic blood pressure
7854,European,3219.0,19430482.0,Kottgen A,"Other measurement, Other disease",replication,2009-05-10,GCST000397,Renal function and chronic kidney disease
4213,Asian,12889.0,19430483.0,Newton-Cheh C,Other measurement,replication,2009-05-10,GCST000395,Systolic blood pressure
10996,European,34433.0,19430479.0,Levy D,Cardiovascular disease,replication,2009-05-10,GCST000398,Hypertension
10999,European,34433.0,19430483.0,Newton-Cheh C,Other measurement,initial,2009-05-10,GCST000394,Diastolic blood pressure
11751,European,100347.0,19430483.0,Newton-Cheh C,Other measurement,replication,2009-05-10,GCST000394,Diastolic blood pressure
11000,European,34433.0,19430483.0,Newton-Cheh C,Other measurement,initial,2009-05-10,GCST000395,Systolic blood pressure
4212,Asian,12889.0,19430483.0,Newton-Cheh C,Other measurement,replication,2009-05-10,GCST000394,Diastolic blood pressure
10997,European,34433.0,19430479.0,Levy D,Other measurement,replication,2009-05-10,GCST000393,Systolic blood pressure
10052,European,13279.0,19430480.0,Barrett JC,Metabolic disorder,replication,2009-05-10,GCST000392,Type 1 diabetes
10506,European,19877.0,19430482.0,Kottgen A,"Other measurement, Other disease",initial,2009-05-10,GCST000397,Renal function and chronic kidney disease
10998,European,34433.0,19430479.0,Levy D,Other measurement,replication,2009-05-10,GCST000396,Diastolic blood pressure
11752,European,100347.0,19430483.0,Newton-Cheh C,Other measurement,replication,2009-05-10,GCST000395,Systolic blood pressure
13863,Other/Mixed,322.0,19442274.0,Fei Y,Cardiovascular disease,initial,2009-05-14,GCST000399,Behcet's disease
10212,European,15297.0,19448622.0,Sulem P,Other measurement,initial,2009-05-15,GCST000400,Menarche (age at onset)
7500,European,2560.0,19448619.0,Stolk L,Other measurement,replication,2009-05-15,GCST000401,Menopause (age at onset)
5136,European,359.0,19448189.0,Perlis RH,"Response to drug, Neurological disorder",replication,2009-05-15,GCST000402,Response to lithium treatment in bipolar disorder
7717,European,2979.0,19448619.0,Stolk L,Other measurement,initial,2009-05-15,GCST000401,Menopause (age at onset)
9757,European,10040.0,19448622.0,Sulem P,Other measurement,replication,2009-05-15,GCST000400,Menarche (age at onset)
14084,Other/Mixed,1177.0,19448189.0,Perlis RH,"Response to drug, Neurological disorder",initial,2009-05-15,GCST000402,Response to lithium treatment in bipolar disorder
10278,European,16373.0,19448623.0,Ong KK,Other measurement,replication,2009-05-17,GCST000405,Menarche (age at onset)
10366,European,17510.0,19448620.0,Perry JR,Other measurement,initial,2009-05-17,GCST000404,Menarche (age at onset)
8459,European,4714.0,19448623.0,Ong KK,Other measurement,initial,2009-05-17,GCST000405,Menarche (age at onset)
10363,European,17438.0,19448621.0,He C,Other measurement,initial,2009-05-17,GCST000403,Menarche and menopause (age at onset)
14073,Other/Mixed,1094.0,19451621.0,Landers JE,Neurological disorder,replication,2009-05-18,GCST000406,Amyotrophic lateral sclerosis
14220,Other/Mixed,4079.0,19451621.0,Landers JE,Neurological disorder,initial,2009-05-18,GCST000406,Amyotrophic lateral sclerosis
5715,European,704.0,19454037.0,Arnett DK,Cardiovascular measurement,replication,2009-05-19,GCST000407,Left ventricular mass
929,African American or Afro-Caribbean,1467.0,19454037.0,Arnett DK,Cardiovascular measurement,replication,2009-05-19,GCST000407,Left ventricular mass
4904,European,202.0,19454037.0,Arnett DK,Cardiovascular measurement,initial,2009-05-19,GCST000407,Left ventricular mass
7056,European,2012.0,19458352.0,Hirschfield GM,Cancer,initial,2009-05-20,GCST000408,Primary biliary cholangitis
6862,European,1732.0,19458352.0,Hirschfield GM,Cancer,replication,2009-05-20,GCST000408,Primary biliary cholangitis
12817,Hispanic or Latin American,229.0,19461586.0,Norris JM,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",initial,2009-05-21,GCST000409,Obesity-related traits
13015,Hispanic or Latin American,961.0,19461586.0,Norris JM,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",replication,2009-05-21,GCST000409,Obesity-related traits
235,African,2040.0,19465909.0,Jallow M,Digestive system disorder,initial,2009-05-24,GCST000410,Malaria
260,African,3463.0,19465909.0,Jallow M,Digestive system disorder,replication,2009-05-24,GCST000410,Malaria
7372,European,2390.0,19456320.0,Ma D,Neurological disorder,replication,2009-05-28,GCST000411,Autism
4832,European,172.0,19478329.0,Aston KI,Other disease,initial,2009-05-28,GCST000412,Male infertility
6567,European,1390.0,19456320.0,Ma D,Neurological disorder,initial,2009-05-28,GCST000411,Autism
2049,Asian,371.0,19478819.0,Ng CC,Cancer,initial,2009-05-29,GCST000413,Nasopharyngeal carcinoma
2101,Asian,420.0,19478819.0,Ng CC,Cancer,replication,2009-05-29,GCST000413,Nasopharyngeal carcinoma
5121,European,350.0,19483685.0,Daly AK,Digestive system disorder,initial,2009-05-31,GCST000415,Drug-induced liver injury (flucloxacillin)
6771,European,1639.0,19483682.0,Kanetsky PA,Cancer,replication,2009-05-31,GCST000416,Testicular cancer
7361,European,2377.0,19483681.0,Rapley EA,Cancer,replication,2009-05-31,GCST000414,Testicular germ cell tumor
6381,European,1196.0,19483682.0,Kanetsky PA,Cancer,initial,2009-05-31,GCST000416,Testicular cancer
7191,European,2165.0,19483681.0,Rapley EA,Cancer,initial,2009-05-31,GCST000414,Testicular germ cell tumor
7069,European,2034.0,19488044.0,Smith EN,Neurological disorder,initial,2009-06-02,GCST000417,Bipolar disorder
826,African American or Afro-Caribbean,1015.0,19488044.0,Smith EN,Neurological disorder,initial,2009-06-02,GCST000417,Bipolar disorder
7869,European,3244.0,19488044.0,Smith EN,Neurological disorder,replication,2009-06-02,GCST000417,Bipolar disorder
10802,European,28141.0,19503597.0,Kolz M,Cardiovascular measurement,initial,2009-06-05,GCST000418,Uric acid levels
14139,Other/Mixed,1861.0,19497516.0,Elmore JR,Cardiovascular disease,replication,2009-06-06,GCST000419,Abdominal aortic aneurysm
9111,European,6922.0,19503088.0,Gregersen PK,Immune system disorder,initial,2009-06-07,GCST000420,Rheumatoid arthritis
14232,Other/Mixed,5486.0,19503088.0,Gregersen PK,Immune system disorder,replication,2009-06-07,GCST000420,Rheumatoid arthritis
7877,European,3266.0,19508968.0,Zhai G,Other disease,replication,2009-06-08,GCST000421,Osteoarthritis
6914,European,1804.0,19508968.0,Zhai G,Other disease,initial,2009-06-08,GCST000421,Osteoarthritis
4804,European,150.0,19508998.0,Knauff EA,Other disease,replication,2009-06-09,GCST000422,Premature ovarian failure
5095,European,334.0,19508998.0,Knauff EA,Other disease,initial,2009-06-09,GCST000422,Premature ovarian failure
5169,European,387.0,19525478.0,Malarstig A,Cardiovascular measurement,initial,2009-06-12,GCST000423,Homocysteine levels
6442,European,1238.0,19525478.0,Malarstig A,Cardiovascular measurement,replication,2009-06-12,GCST000423,Homocysteine levels
8406,European,4566.0,19525955.0,Bahlo M,Immune system disorder,replication,2009-06-14,GCST000425,Multiple sclerosis
8603,European,5031.0,19525955.0,Bahlo M,Immune system disorder,initial,2009-06-14,GCST000425,Multiple sclerosis
8337,European,4331.0,19525953.0,De Jager PL,Immune system disorder,replication,2009-06-14,GCST000424,Multiple sclerosis
9718,European,9844.0,19525953.0,De Jager PL,Immune system disorder,initial,2009-06-14,GCST000424,Multiple sclerosis
8205,European,3972.0,19553259.0,Cotsapas C,"Metabolic disorder, Body measurement",initial,2009-06-24,GCST000426,Obesity (extreme)
11095,European,38580.0,19557161.0,Lindgren CM,Metabolic disorder,initial,2009-06-26,GCST000428,Adiposity
10889,European,31373.0,19557197.0,Heard-Costa NL,Body measurement,initial,2009-06-26,GCST000427,Waist circumference
11758,European,102064.0,19557161.0,Lindgren CM,Metabolic disorder,replication,2009-06-26,GCST000428,Adiposity
9841,European,10743.0,19561606.0,Thorleifsson G,Other disease,replication,2009-06-28,GCST000429,Kidney stones
11022,European,35540.0,19561606.0,Thorleifsson G,Other disease,initial,2009-06-28,GCST000429,Kidney stones
9107,European,6909.0,19571811.0,Purcell SM,Neurological disorder,initial,2009-07-01,GCST000434,Schizophrenia
10598,European,21751.0,19571809.0,Shi J,Neurological disorder,replication,2009-07-01,GCST000433,Schizophrenia
14262,Other/Mixed,17967.0,19567438.0,Elliott P,Inflammatory measurement,initial,2009-07-01,GCST000430,C-reactive protein
10258,European,16161.0,19571808.0,Stefansson H,Neurological disorder,initial,2009-07-01,GCST000435,Schizophrenia
6934,European,1834.0,19581569.0,Treutlein J,"Other measurement, Neurological disorder",initial,2009-07-01,GCST000432,Alcohol dependence
1036,African American or Afro-Caribbean,2259.0,19571809.0,Shi J,Neurological disorder,initial,2009-07-01,GCST000433,Schizophrenia
7062,European,2020.0,19581569.0,Treutlein J,"Other measurement, Neurological disorder",replication,2009-07-01,GCST000432,Alcohol dependence
14251,Other/Mixed,13615.0,19567438.0,Elliott P,Inflammatory measurement,replication,2009-07-01,GCST000430,C-reactive protein
9109,European,6912.0,19570815.0,Estrada K,"Other measurement, Body measurement",replication,2009-07-01,GCST000431,Height
10517,European,20185.0,19571811.0,Purcell SM,Neurological disorder,replication,2009-07-01,GCST000434,Schizophrenia
10890,European,31375.0,19571808.0,Stefansson H,Neurological disorder,replication,2009-07-01,GCST000435,Schizophrenia
8718,European,5334.0,19571809.0,Shi J,Neurological disorder,initial,2009-07-01,GCST000433,Schizophrenia
9759,European,10074.0,19570815.0,Estrada K,"Other measurement, Body measurement",initial,2009-07-01,GCST000431,Height
6609,European,1451.0,19578179.0,Teichert M,Response to drug,initial,2009-07-04,GCST000436,Acenocoumarol maintenance dosage
8772,European,5548.0,19578367.0,Shete S,Cancer,initial,2009-07-05,GCST000439,Glioma
13798,Other/Mixed,174.0,19578366.0,Wrensch M,Cancer,replication,2009-07-05,GCST000440,Glioma (high-grade)
13598,Other/Mixed,2.0,19578366.0,Wrensch M,Cancer,replication,2009-07-05,GCST000440,Glioma (high-grade)
8767,European,5498.0,19578367.0,Shete S,Cancer,replication,2009-07-05,GCST000439,Glioma
6656,European,1524.0,19578365.0,Falchi M,Cancer,initial,2009-07-05,GCST000438,Cutaneous nevi
4836,European,174.0,19578366.0,Wrensch M,Cancer,replication,2009-07-05,GCST000440,Glioma (high-grade)
8286,European,4179.0,19578364.0,Bishop DT,Cancer,replication,2009-07-05,GCST000437,Melanoma
9916,European,11514.0,19578365.0,Falchi M,Cancer,replication,2009-07-05,GCST000438,Cutaneous nevi
8448,European,4684.0,19578366.0,Wrensch M,Cancer,initial,2009-07-05,GCST000440,Glioma (high-grade)
8751,European,5456.0,19578364.0,Bishop DT,Cancer,initial,2009-07-05,GCST000437,Melanoma
8251,European,4094.0,19584346.0,Vasan RS,Other measurement,replication,2009-07-08,GCST000441,Cardiac structure and function
10016,European,12612.0,19584346.0,Vasan RS,Cardiovascular measurement,initial,2009-07-08,GCST000442,Aortic root size
10017,European,12612.0,19584346.0,Vasan RS,Other measurement,initial,2009-07-08,GCST000441,Cardiac structure and function
8250,European,4094.0,19584346.0,Vasan RS,Cardiovascular measurement,replication,2009-07-08,GCST000442,Aortic root size
6072,European,948.0,19584900.0,Tonjes A,"Other measurement, Body measurement",initial,2009-07-08,GCST000443,Body mass index and fat mass
8048,European,3558.0,19587794.0,Nolte IM,Cardiovascular measurement,initial,2009-07-09,GCST000444,QT interval
10842,European,29527.0,19587794.0,Nolte IM,Cardiovascular measurement,replication,2009-07-09,GCST000444,QT interval
11034,European,36137.0,19597491.0,Gudbjartsson DF,Cardiovascular disease,initial,2009-07-13,GCST000446,Atrial fibrillation
11141,European,40518.0,19597492.0,Benjamin EJ,Cardiovascular disease,initial,2009-07-13,GCST000445,Atrial fibrillation
3317,Asian,3049.0,19597491.0,Gudbjartsson DF,Cardiovascular disease,replication,2009-07-13,GCST000446,Atrial fibrillation
8933,European,6218.0,19597492.0,Benjamin EJ,Cardiovascular disease,replication,2009-07-13,GCST000445,Atrial fibrillation
8831,European,5806.0,19597491.0,Gudbjartsson DF,Cardiovascular disease,replication,2009-07-13,GCST000446,Atrial fibrillation
828,African American or Afro-Caribbean,1017.0,19609347.0,Adeyemo A,Cardiovascular disease,initial,2009-07-17,GCST000447,Hypertension
158,African,980.0,19609347.0,Adeyemo A,Cardiovascular disease,replication,2009-07-17,GCST000447,Hypertension
5826,European,781.0,19620980.0,Skibola CF,Cancer,initial,2009-07-20,GCST000448,Follicular lymphoma
7868,European,3241.0,19620980.0,Skibola CF,Cancer,replication,2009-07-20,GCST000448,Follicular lymphoma
2324,Asian,718.0,19625618.0,Nakano M,Neurological disorder,initial,2009-07-22,GCST000449,Glaucoma (primary open-angle)
2429,Asian,857.0,19625618.0,Nakano M,Neurological disorder,replication,2009-07-22,GCST000449,Glaucoma (primary open-angle)
5823,European,778.0,20031604.0,Cheng YC,Other measurement,initial,2009-08-01,GCST000450,Matrix metalloproteinase levels
7325,European,2325.0,20031603.0,Marroni F,Cardiovascular measurement,initial,2009-08-01,GCST000452,QT interval
7324,European,2325.0,20031603.0,Marroni F,Cardiovascular measurement,initial,2009-08-01,GCST000451,RR interval (heart rate)
4770,European,106.0,19667218.0,Comabella M,Response to drug,initial,2009-08-01,GCST000453,Response to interferon beta therapy
4739,European,94.0,19667218.0,Comabella M,Response to drug,replication,2009-08-01,GCST000453,Response to interferon beta therapy
10288,European,16421.0,19648919.0,Song H,Cancer,replication,2009-08-02,GCST000455,Ovarian cancer
6988,European,1926.0,19648920.0,Wu X,Cancer,initial,2009-08-02,GCST000454,Bladder cancer
11194,European,44331.0,19648920.0,Wu X,Cancer,replication,2009-08-02,GCST000454,Bladder cancer
8310,European,4247.0,19648918.0,Amundadottir L,Cancer,replication,2009-08-02,GCST000456,Pancreatic cancer
8056,European,3576.0,19648918.0,Amundadottir L,Cancer,initial,2009-08-02,GCST000456,Pancreatic cancer
8280,European,4170.0,19648919.0,Song H,Cancer,initial,2009-08-02,GCST000455,Ovarian cancer
8372,European,4462.0,19651812.0,Chambers JC,Other measurement,replication,2009-08-03,GCST000457,Fasting plasma glucose
3876,Asian,7474.0,19651812.0,Chambers JC,Other measurement,initial,2009-08-03,GCST000457,Fasting plasma glucose
8900,European,6062.0,19656524.0,Grant SF,"Other trait, Other measurement, Other disease",initial,2009-08-03,GCST000458,Orofacial clefts
7961,European,3390.0,19654303.0,Broderick P,Cancer,initial,2009-08-04,GCST000459,Lung cancer
8756,European,5470.0,19654303.0,Broderick P,Cancer,replication,2009-08-04,GCST000459,Lung cancer
3108,Asian,2275.0,19664746.0,Tse KP,Cancer,replication,2009-08-05,GCST000460,Nasopharyngeal carcinoma
2224,Asian,562.0,19664746.0,Tse KP,Cancer,initial,2009-08-05,GCST000460,Nasopharyngeal carcinoma
1595,Asian,4.0,19668339.0,Potkin SG,Neurological disorder,initial,2009-08-07,GCST000461,Hippocampal atrophy
421,African American or Afro-Caribbean,21.0,19668339.0,Potkin SG,Neurological disorder,initial,2009-08-07,GCST000461,Hippocampal atrophy
13599,Other/Mixed,2.0,19668339.0,Potkin SG,Neurological disorder,initial,2009-08-07,GCST000461,Hippocampal atrophy
5125,European,354.0,19668339.0,Potkin SG,Neurological disorder,initial,2009-08-07,GCST000461,Hippocampal atrophy
13651,Other/Mixed,11.0,19680635.0,Alkelai A,Response to drug,initial,2009-08-13,GCST000462,Response to antipsychotic treatment
4984,European,257.0,19680635.0,Alkelai A,Response to drug,initial,2009-08-13,GCST000462,Response to antipsychotic treatment
515,African American or Afro-Caribbean,129.0,19680635.0,Alkelai A,Response to drug,initial,2009-08-13,GCST000462,Response to antipsychotic treatment
10468,European,19275.0,19684603.0,Trevino LR,Cancer,initial,2009-08-16,GCST000464,Acute lymphoblastic leukemia (childhood)
5959,European,871.0,19684573.0,Ge D,Digestive system disorder,initial,2009-08-16,GCST000465,Response to hepatitis C treatment
12763,Hispanic or Latin American,75.0,19684573.0,Ge D,Digestive system disorder,initial,2009-08-16,GCST000465,Response to hepatitis C treatment
7904,European,3305.0,19684604.0,Papaemmanuil E,Cancer,initial,2009-08-16,GCST000463,Acute lymphoblastic leukemia (childhood)
557,African American or Afro-Caribbean,191.0,19684573.0,Ge D,Digestive system disorder,initial,2009-08-16,GCST000465,Response to hepatitis C treatment
2548,Asian,1109.0,19698717.0,Cui R,Cancer,initial,2009-08-18,GCST000466,Esophageal cancer
3217,Asian,2680.0,19698717.0,Cui R,Cancer,replication,2009-08-18,GCST000466,Esophageal cancer
13619,Other/Mixed,4.0,19706858.0,Shuldiner AR,"Response to drug, Cardiovascular measurement",replication,2009-08-26,GCST000467,Response to clopidogrel therapy
5243,European,429.0,19706858.0,Shuldiner AR,"Response to drug, Cardiovascular measurement",initial,2009-08-26,GCST000467,Response to clopidogrel therapy
484,African American or Afro-Caribbean,83.0,19706858.0,Shuldiner AR,"Response to drug, Cardiovascular measurement",replication,2009-08-26,GCST000467,Response to clopidogrel therapy
4796,European,140.0,19706858.0,Shuldiner AR,"Response to drug, Cardiovascular measurement",replication,2009-08-26,GCST000467,Response to clopidogrel therapy
6166,European,1000.0,19714249.0,Liu YZ,"Other disease, Metabolic disorder",initial,2009-08-28,GCST000469,Obesity and osteoporosis
12897,Hispanic or Latin American,531.0,19714205.0,Hancock DB,"Other disease, Other measurement",replication,2009-08-28,GCST000468,Asthma (childhood onset)
7943,European,3355.0,19714249.0,Liu YZ,"Other disease, Metabolic disorder",replication,2009-08-28,GCST000469,Obesity and osteoporosis
13079,Hispanic or Latin American,1476.0,19714205.0,Hancock DB,"Other disease, Other measurement",initial,2009-08-28,GCST000468,Asthma (childhood onset)
14129,Other/Mixed,1682.0,19724244.0,Laje G,Response to drug,replication,2009-08-31,GCST000470,Response to antidepressant treatment
13805,Other/Mixed,180.0,19724244.0,Laje G,Response to drug,initial,2009-08-31,GCST000470,Response to antidepressant treatment
6383,European,1198.0,19736353.0,Ising M,Response to drug,replication,2009-09-01,GCST000471,Response to antidepressant treatment
5710,European,700.0,19736353.0,Ising M,Response to drug,initial,2009-09-01,GCST000471,Response to antidepressant treatment
5394,European,494.0,19721433.0,McClay JL,Response to drug,initial,2009-09-01,GCST000473,Response to antipsychotic treatment
13838,Other/Mixed,244.0,19721433.0,McClay JL,Response to drug,initial,2009-09-01,GCST000473,Response to antipsychotic treatment
6945,European,1850.0,19723657.0,Spain SL,Cancer,initial,2009-09-01,GCST000472,Colorectal cancer
7549,European,2649.0,19723657.0,Spain SL,Cancer,replication,2009-09-01,GCST000472,Colorectal cancer
7535,European,2622.0,19727025.0,De Moor MH,Biological process,initial,2009-09-02,GCST000474,Leisure-time exercise behaviour
6035,European,929.0,19729412.0,Tonjes A,"Other measurement, Body measurement",initial,2009-09-03,GCST000475,Height
5341,European,477.0,19729612.0,Paterson AD,Inflammatory measurement,replication,2009-09-03,GCST000476,Soluble E-selectin levels
5696,European,685.0,19729612.0,Paterson AD,Inflammatory measurement,initial,2009-09-03,GCST000476,Soluble E-selectin levels
8821,European,5758.0,19729412.0,Tonjes A,"Other measurement, Body measurement",replication,2009-09-03,GCST000475,Height
6093,European,958.0,19734545.0,Need AC,Other measurement,initial,2009-09-04,GCST000477,Cognitive performance
1740,Asian,104.0,19734545.0,Need AC,Other measurement,initial,2009-09-04,GCST000477,Cognitive performance
1868,Asian,207.0,19734545.0,Need AC,Other measurement,initial,2009-09-04,GCST000477,Cognitive performance
9899,European,11336.0,19734901.0,van Es MA,Neurological disorder,initial,2009-09-06,GCST000481,Amyotrophic lateral sclerosis
10021,European,12676.0,19734900.0,Rung J,Metabolic disorder,replication,2009-09-06,GCST000478,Type 2 diabetes
6558,European,1376.0,19734900.0,Rung J,Metabolic disorder,initial,2009-09-06,GCST000478,Type 2 diabetes
9199,European,7360.0,19734903.0,Lambert JC,Neurological disorder,initial,2009-09-06,GCST000480,Alzheimer's disease
8344,European,4363.0,19734902.0,Harold D,Neurological disorder,replication,2009-09-06,GCST000479,Alzheimer's disease
9940,European,11789.0,19734902.0,Harold D,Neurological disorder,initial,2009-09-06,GCST000479,Alzheimer's disease
9176,European,7275.0,19734903.0,Lambert JC,Neurological disorder,replication,2009-09-06,GCST000480,Alzheimer's disease
9493,European,8472.0,19734901.0,van Es MA,Neurological disorder,replication,2009-09-06,GCST000481,Amyotrophic lateral sclerosis
5495,European,547.0,19740415.0,Sha Q,Neurological disorder,initial,2009-09-09,GCST000482,Amyotrophic lateral sclerosis (SNP x SNP interaction)
8473,European,4763.0,19744961.0,Hazra A,"Other measurement, Cardiovascular measurement",initial,2009-09-10,GCST000483,Folate pathway vitamin levels
5708,European,699.0,20061627.0,Heinzen EL,Neurological disorder,initial,2009-09-11,GCST000484,Alzheimer's disease
5510,European,555.0,19749758.0,Suppiah V,Digestive system disorder,replication,2009-09-13,GCST000485,Response to hepatitis C treatment
1795,Asian,142.0,19749757.0,Tanaka Y,Digestive system disorder,initial,2009-09-13,GCST000486,Response to hepatitis C treatment
1823,Asian,172.0,19749757.0,Tanaka Y,Digestive system disorder,replication,2009-09-13,GCST000486,Response to hepatitis C treatment
5035,European,293.0,19749758.0,Suppiah V,Digestive system disorder,initial,2009-09-13,GCST000485,Response to hepatitis C treatment
7151,European,2134.0,19754311.0,Le Clerc S,Immune system disorder,initial,2009-09-15,GCST000487,AIDS
14278,Other/Mixed,38640.0,19767753.0,Eeles RA,Cancer,replication,2009-09-20,GCST000488,Prostate cancer
11051,European,37350.0,19767754.0,Gudmundsson J,Cancer,initial,2009-09-20,GCST000489,Prostate cancer
8121,European,3748.0,19767753.0,Eeles RA,Cancer,initial,2009-09-20,GCST000488,Prostate cancer
10709,European,24193.0,19767754.0,Gudmundsson J,Cancer,replication,2009-09-20,GCST000489,Prostate cancer
5939,European,857.0,19772629.0,Latourelle JC,"Neurological disorder, Other measurement",initial,2009-09-22,GCST000490,Parkinson's disease (age of onset)
5790,European,747.0,19772629.0,Latourelle JC,"Neurological disorder, Other measurement",replication,2009-09-22,GCST000490,Parkinson's disease (age of onset)
2736,Asian,1510.0,19779542.0,Nakanishi H,Other trait,replication,2009-09-25,GCST000491,Myopia (pathological)
2612,Asian,1231.0,19779542.0,Nakanishi H,Other trait,initial,2009-09-25,GCST000491,Myopia (pathological)
4862,European,186.0,19786962.0,Roeske D,Biological process,replication,2009-09-29,GCST000492,Speech perception in dyslexia
4899,European,200.0,19786962.0,Roeske D,Biological process,initial,2009-09-29,GCST000492,Speech perception in dyslexia
8260,European,4110.0,19798445.0,Hicks AA,"Other measurement, Lipid or lipoprotein measurement",initial,2009-10-02,GCST000493,Sphingolipid levels
10462,European,19195.0,19801982.0,Rivadeneira F,Other measurement,initial,2009-10-04,GCST000495,Bone mineral density (hip)
10461,European,19195.0,19801982.0,Rivadeneira F,Other measurement,initial,2009-10-04,GCST000494,Bone mineral density (spine)
14126,Other/Mixed,1553.0,19812673.0,Weiss LA,Neurological disorder,initial,2009-10-08,GCST000496,Autism
14231,Other/Mixed,5265.0,19812673.0,Weiss LA,Neurological disorder,replication,2009-10-08,GCST000496,Autism
9647,European,9456.0,19862010.0,Ganesh SK,Hematological measurement,replication,2009-10-11,GCST000502,Hematocrit
8667,European,5187.0,19820698.0,Chambers JC,Hematological measurement,replication,2009-10-11,GCST000501,Hemoglobin
8962,European,6316.0,19820698.0,Chambers JC,Hematological measurement,initial,2009-10-11,GCST000501,Hemoglobin
10707,European,24167.0,19862010.0,Ganesh SK,Hematological measurement,initial,2009-10-11,GCST000504,Mean corpuscular hemoglobin
10705,European,24167.0,19862010.0,Ganesh SK,Hematological measurement,initial,2009-10-11,GCST000502,Hematocrit
10704,European,24167.0,19862010.0,Ganesh SK,Hematological measurement,initial,2009-10-11,GCST000500,Other erythrocyte phenotypes
10703,European,24167.0,19862010.0,Ganesh SK,Hematological measurement,initial,2009-10-11,GCST000499,Hemoglobin
8008,European,3470.0,19820699.0,Benyamin B,Other measurement,replication,2009-10-11,GCST000505,Iron status biomarkers
9649,European,9456.0,19862010.0,Ganesh SK,Hematological measurement,replication,2009-10-11,GCST000504,Mean corpuscular hemoglobin
4077,Asian,9685.0,19820698.0,Chambers JC,Hematological measurement,initial,2009-10-11,GCST000501,Hemoglobin
9648,European,9456.0,19862010.0,Ganesh SK,Hematological measurement,replication,2009-10-11,GCST000503,Mean corpuscular volume
10706,European,24167.0,19862010.0,Ganesh SK,Hematological measurement,initial,2009-10-11,GCST000503,Mean corpuscular volume
8496,European,4818.0,19820699.0,Benyamin B,Other measurement,initial,2009-10-11,GCST000505,Iron status biomarkers
9646,European,9456.0,19862010.0,Ganesh SK,Hematological measurement,replication,2009-10-11,GCST000500,Other erythrocyte phenotypes
9645,European,9456.0,19862010.0,Ganesh SK,Hematological measurement,replication,2009-10-11,GCST000499,Hemoglobin
3812,Asian,6721.0,19820698.0,Chambers JC,Hematological measurement,replication,2009-10-11,GCST000501,Hemoglobin
8425,European,4627.0,19820697.0,Soranzo N,Hematological measurement,initial,2009-10-11,GCST000498,Hematological parameters
9620,European,9316.0,19820697.0,Soranzo N,Hematological measurement,replication,2009-10-11,GCST000497,Mean platelet volume
9621,European,9316.0,19820697.0,Soranzo N,Hematological measurement,replication,2009-10-11,GCST000498,Hematological parameters
8424,European,4627.0,19820697.0,Soranzo N,Hematological measurement,initial,2009-10-11,GCST000497,Mean platelet volume
9924,European,11587.0,19836008.0,Landi MT,Cancer,initial,2009-10-15,GCST000506,Lung adenocarcinoma
10588,European,21379.0,19836008.0,Landi MT,Cancer,replication,2009-10-15,GCST000506,Lung adenocarcinoma
3099,Asian,2252.0,19838193.0,Han JW,Immune system disorder,initial,2009-10-18,GCST000507,Systemic lupus erythematosus
4107,Asian,10202.0,19838193.0,Han JW,Immune system disorder,replication,2009-10-18,GCST000507,Systemic lupus erythematosus
12802,Hispanic or Latin American,183.0,19846067.0,Garriock HA,Response to drug,initial,2009-10-19,GCST000509,Response to citalopram treatment
594,African American or Afro-Caribbean,241.0,19846067.0,Garriock HA,Response to drug,initial,2009-10-19,GCST000509,Response to citalopram treatment
6248,European,1067.0,19846067.0,Garriock HA,Response to drug,initial,2009-10-19,GCST000509,Response to citalopram treatment
1976,Asian,293.0,19850125.0,Kim HJ,Immune system disorder,initial,2009-10-19,GCST000508,Neuromyelitis optica
1651,Asian,37.0,19850125.0,Kim HJ,Immune system disorder,replication,2009-10-19,GCST000508,Neuromyelitis optica
7468,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008426,Red blood cell count
7469,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008428,Eosinophil counts
7463,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST000510,Platelet count
7465,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008420,Mean corpuscular volume
8183,European,3925.0,19851299.0,Johansson A,Body measurement,initial,2009-10-22,GCST000511,Weight
7466,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008421,Monocyte count
8184,European,3925.0,19851299.0,Johansson A,"Body measurement, Other measurement",initial,2009-10-22,GCST000512,Body mass index
6683,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008428,Eosinophil counts
7464,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008418,Mean corpuscular hemoglobin concentration
7472,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008431,Lymphocyte counts
6688,European,1543.0,19853236.0,Ferreira MA,"Hematological measurement, Inflammatory measurement",replication,2009-10-22,GCST008419,White blood cell count
6682,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008426,Red blood cell count
6681,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008425,Neutrophil count
6680,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008421,Monocyte count
6679,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008420,Mean corpuscular volume
6678,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008418,Mean corpuscular hemoglobin concentration
6677,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST000510,Platelet count
7471,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008430,Hematocrit
6684,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008429,Hemoglobin levels
7475,European,2538.0,19853236.0,Ferreira MA,Inflammatory measurement,initial,2009-10-22,GCST008427,Basophil count
6685,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008430,Hematocrit
7474,European,2538.0,19853236.0,Ferreira MA,"Hematological measurement, Inflammatory measurement",initial,2009-10-22,GCST008419,White blood cell count
6686,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008431,Lymphocyte counts
7473,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008432,Mean corpuscular hemoglobin
6687,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008432,Mean corpuscular hemoglobin
7467,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008425,Neutrophil count
6689,European,1543.0,19853236.0,Ferreira MA,Inflammatory measurement,replication,2009-10-22,GCST008427,Basophil count
7470,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008429,Hemoglobin levels
547,African American or Afro-Caribbean,163.0,20029952.0,Sebastiani P,Neurological disorder,replication,2009-10-23,GCST000513,Sickle cell anemia (severity)
896,African American or Afro-Caribbean,1265.0,20029952.0,Sebastiani P,Neurological disorder,initial,2009-10-23,GCST000513,Sickle cell anemia (severity)
5230,European,421.0,19875103.0,Aberg K,Response to drug,initial,2009-10-27,GCST000514,Response to antipsychotic therapy (extrapyramidal side effects)
13751,Other/Mixed,103.0,19875103.0,Aberg K,Response to drug,initial,2009-10-27,GCST000514,Response to antipsychotic therapy (extrapyramidal side effects)
585,African American or Afro-Caribbean,214.0,19875103.0,Aberg K,Response to drug,initial,2009-10-27,GCST000514,Response to antipsychotic therapy (extrapyramidal side effects)
7498,European,2557.0,19874204.0,Guo Y,Other measurement,replication,2009-10-29,GCST000515,Bone mineral density
6564,European,1382.0,19875614.0,Paterson AD,Other measurement,replication,2009-10-29,GCST000516,Glycemic control in type 1 diabetes (HbA1c)
6132,European,983.0,19874204.0,Guo Y,Other measurement,initial,2009-10-29,GCST000515,Bone mineral density
6490,European,1304.0,19875614.0,Paterson AD,Other measurement,initial,2009-10-29,GCST000516,Glycemic control in type 1 diabetes (HbA1c)
6984,European,1919.0,19880490.0,Tanaka T,Other measurement,initial,2009-10-30,GCST000517,Iron levels
9599,European,9169.0,19838195.0,Gateva V,Immune system disorder,initial,2009-11-01,GCST004867,Systemic lupus erythematosus
8950,European,6292.0,19838195.0,Gateva V,Immune system disorder,replication,2009-11-01,GCST004867,Systemic lupus erythematosus
6287,European,1096.0,19929986.0,Craig DW,Other disease,initial,2009-11-01,GCST000518,End-stage renal disease
10552,European,20985.0,19896111.0,Medland SE,Other trait,initial,2009-11-04,GCST000519,Hair morphology
4693,European,76.0,19890347.0,Birlea SA,Immune system disorder,initial,2009-11-05,GCST000520,Vitiligo
6455,European,1255.0,19897590.0,Schaefer AS,Digestive system disorder,initial,2009-11-06,GCST000521,Periodontitis
4019,Asian,8842.0,19893584.0,Kim JJ,"Other measurement, Body measurement",initial,2009-11-06,GCST000522,Height
5398,European,496.0,19897590.0,Schaefer AS,Digestive system disorder,replication,2009-11-06,GCST000521,Periodontitis
13705,Other/Mixed,41.0,19901119.0,Trevino LR,Response to drug,initial,2009-11-09,GCST000523,Methotrexate phramacokinetics (acute lymphoblastic leukemia)
5067,European,315.0,19901119.0,Trevino LR,Response to drug,initial,2009-11-09,GCST000523,Methotrexate phramacokinetics (acute lymphoblastic leukemia)
472,African American or Afro-Caribbean,73.0,19901119.0,Trevino LR,Response to drug,initial,2009-11-09,GCST000523,Methotrexate phramacokinetics (acute lymphoblastic leukemia)
1598,Asian,5.0,19901119.0,Trevino LR,Response to drug,initial,2009-11-09,GCST000523,Methotrexate phramacokinetics (acute lymphoblastic leukemia)
12983,Hispanic or Latin American,814.0,19902172.0,Palmer ND,"Other measurement, Other trait",replication,2009-11-10,GCST000526,Insulin-related traits
7257,European,2237.0,19910028.0,Mathias RA,Other disease,replication,2009-11-10,GCST000525,Asthma
6387,European,1200.0,20039944.0,Docherty SJ,Biological process,initial,2009-11-10,GCST000524,Mathematical ability
12818,Hispanic or Latin American,229.0,19902172.0,Palmer ND,"Other measurement, Other trait",initial,2009-11-10,GCST000526,Insulin-related traits
973,African American or Afro-Caribbean,1864.0,19910028.0,Mathias RA,Other disease,initial,2009-11-10,GCST000525,Asthma
7012,European,1954.0,20039944.0,Docherty SJ,Biological process,replication,2009-11-10,GCST000524,Mathematical ability
1275,African American or Afro-Caribbean,5205.0,19910028.0,Mathias RA,Other disease,replication,2009-11-10,GCST000525,Asthma
9323,European,7934.0,19915575.0,Simon-Sanchez J,Neurological disorder,replication,2009-11-15,GCST000528,Parkinson's disease
9290,European,7778.0,19915572.0,Barrett JC,Immune system disorder,initial,2009-11-15,GCST000527,Ulcerative colitis
8806,European,5691.0,19915575.0,Simon-Sanchez J,Neurological disorder,initial,2009-11-15,GCST000528,Parkinson's disease
2639,Asian,1310.0,19915573.0,Asano K,Immune system disorder,initial,2009-11-15,GCST000529,Ulcerative colitis
9154,European,7139.0,19915572.0,Barrett JC,Immune system disorder,replication,2009-11-15,GCST000527,Ulcerative colitis
9513,European,8571.0,19915574.0,Imielinski M,Digestive system disorder,initial,2009-11-15,GCST000531,Inflammatory bowel disease (early onset)
4312,Asian,16686.0,19915576.0,Satake W,Neurological disorder,replication,2009-11-15,GCST000530,Parkinson's disease
9077,European,6818.0,19915574.0,Imielinski M,Digestive system disorder,replication,2009-11-15,GCST000531,Inflammatory bowel disease (early onset)
3378,Asian,3509.0,19915576.0,Satake W,Neurological disorder,initial,2009-11-15,GCST000530,Parkinson's disease
2696,Asian,1473.0,19915573.0,Asano K,Immune system disorder,replication,2009-11-15,GCST000529,Ulcerative colitis
1824,Asian,174.0,20183929.0,Nuinoon M,Other disease,replication,2009-11-19,GCST000532,Beta thalassemia/hemoglobin E disease
2246,Asian,618.0,20183929.0,Nuinoon M,Other disease,initial,2009-11-19,GCST000532,Beta thalassemia/hemoglobin E disease
7048,European,2000.0,19936222.0,Chasman DI,Other measurement,replication,2009-11-20,GCST000533,Lipid metabolism phenotypes
10349,European,17296.0,19936222.0,Chasman DI,Other measurement,initial,2009-11-20,GCST000533,Lipid metabolism phenotypes
5554,European,583.0,19944697.0,Karlsen TH,Digestive system disorder,initial,2009-11-25,GCST000534,Primary sclerosing cholangitis
8103,European,3701.0,19944697.0,Karlsen TH,Digestive system disorder,replication,2009-11-25,GCST000534,Primary sclerosing cholangitis
2296,Asian,690.0,19950302.0,Zhou X,Neurological disorder,initial,2009-11-30,GCST000535,Systemic sclerosis
8159,European,3854.0,19950302.0,Zhou X,Neurological disorder,replication,2009-11-30,GCST000535,Systemic sclerosis
1672,Asian,60.0,19954339.0,Yin CS,Other trait,initial,2009-12-01,GCST000536,Sasang constitutional medicine type
8437,European,4659.0,20018283.0,Heid IM,Other measurement,initial,2009-12-02,GCST000537,Adiponectin levels
10099,European,13795.0,20018283.0,Heid IM,Other measurement,replication,2009-12-02,GCST000537,Adiponectin levels
8930,European,6202.0,20011104.0,Richards JB,Other measurement,replication,2009-12-05,GCST000538,Adiponectin levels
9506,European,8531.0,20011104.0,Richards JB,Other measurement,initial,2009-12-05,GCST000538,Adiponectin levels
10051,European,13276.0,19966805.0,Wallace C,Metabolic disorder,replication,2009-12-06,GCST000539,Type 1 diabetes
5640,European,651.0,19961619.0,Castro-Giner F,Immune system disorder,replication,2009-12-06,GCST000540,Atopy
4943,European,225.0,19961619.0,Castro-Giner F,Immune system disorder,initial,2009-12-06,GCST000540,Atopy
10300,European,16559.0,19966805.0,Wallace C,Metabolic disorder,initial,2009-12-06,GCST000539,Type 1 diabetes
6145,European,987.0,20175129.0,Zhao LJ,Other measurement,initial,2009-12-11,GCST000541,Femoral neck bone geometry
6631,European,1488.0,20175129.0,Zhao LJ,Other measurement,replication,2009-12-11,GCST000541,Femoral neck bone geometry
3032,Asian,2118.0,20175129.0,Zhao LJ,Other measurement,replication,2009-12-11,GCST000541,Femoral neck bone geometry
10518,European,20288.0,20010834.0,Repapi E,Other measurement,initial,2009-12-13,GCST000544,Pulmonary function
10263,European,16178.0,20010835.0,Hancock DB,Other measurement,replication,2009-12-13,GCST000542,Pulmonary function
11334,European,54276.0,20010834.0,Repapi E,Other measurement,replication,2009-12-13,GCST000544,Pulmonary function
10548,European,20890.0,20010835.0,Hancock DB,Other measurement,initial,2009-12-13,GCST000542,Pulmonary function
8017,European,3494.0,20012890.0,Ronald A,Other measurement,replication,2009-12-13,GCST000543,Social and non-social autistic-like traits
6617,European,1462.0,20012890.0,Ronald A,Other measurement,initial,2009-12-13,GCST000543,Social and non-social autistic-like traits
146,African,848.0,20018918.0,Solovieff N,Hematological measurement,initial,2009-12-16,GCST000545,Fetal hemoglobin levels
4055,Asian,9209.0,20018961.0,Zhang FR,Neurological disorder,replication,2009-12-16,GCST000546,Leprosy
88,African,305.0,20018918.0,Solovieff N,Hematological measurement,replication,2009-12-16,GCST000545,Fetal hemoglobin levels
2090,Asian,406.0,20018918.0,Solovieff N,Hematological measurement,replication,2009-12-16,GCST000545,Fetal hemoglobin levels
2959,Asian,1931.0,20018961.0,Zhang FR,Neurological disorder,initial,2009-12-16,GCST000546,Leprosy
1749,Asian,113.0,20018918.0,Solovieff N,Hematological measurement,replication,2009-12-16,GCST000545,Fetal hemoglobin levels
5648,European,655.0,20023658.0,Mangold E,"Other trait, Other measurement, Other disease",replication,2009-12-20,GCST000547,Orofacial clefts
6835,European,1717.0,20023658.0,Mangold E,"Other trait, Other measurement, Other disease",initial,2009-12-20,GCST000547,Orofacial clefts
7620,European,2781.0,20032318.0,Sleiman PM,Other disease,initial,2009-12-23,GCST000548,Asthma
7412,European,2463.0,20032318.0,Sleiman PM,Other disease,replication,2009-12-23,GCST000548,Asthma
1199,African American or Afro-Caribbean,3712.0,20032318.0,Sleiman PM,Other disease,replication,2009-12-23,GCST000548,Asthma
7346,European,2362.0,20041166.0,Fellay J,Other disease,initial,2009-12-24,GCST000549,HIV-1 control
6393,European,1202.0,20037589.0,Illig T,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",replication,2009-12-27,GCST000550,Metabolite levels
6219,European,1029.0,20037589.0,Illig T,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2009-12-27,GCST000550,Metabolite levels
9205,European,7385.0,20038947.0,Shyn SI,Neurological disorder,initial,2009-12-29,GCST000551,Major depressive disorder (broad)
5093,European,333.0,20038948.0,Papassotiropoulos A,Biological process,initial,2009-12-29,GCST000552,Memory (short-term)
6814,European,1699.0,20038948.0,Papassotiropoulos A,Biological process,replication,2009-12-29,GCST000552,Memory (short-term)
6149,European,988.0,20045101.0,Ferreira MA,Hematological measurement,replication,2009-12-31,GCST008637,CD4-positive T-lymphocyte count
6152,European,988.0,20045101.0,Ferreira MA,Hematological measurement,replication,2009-12-31,GCST008640,CD56-positive NK-lymphocyte cell count
6153,European,988.0,20045101.0,Ferreira MA,Inflammatory measurement,replication,2009-12-31,GCST000553,CD4:CD8 lymphocyte ratio
6151,European,988.0,20045101.0,Ferreira MA,Hematological measurement,replication,2009-12-31,GCST008639,CD19-positive B-lymphocyte count
6150,European,988.0,20045101.0,Ferreira MA,Hematological measurement,replication,2009-12-31,GCST008638,CD8-positive T-lymphocyte count
9639,European,9401.0,20044523.0,Debette S,Cardiovascular disease,initial,2009-12-31,GCST000554,Subclinical brain infarct
6925,European,1822.0,20044523.0,Debette S,Cardiovascular disease,replication,2009-12-31,GCST000554,Subclinical brain infarct
6148,European,988.0,20045101.0,Ferreira MA,Hematological measurement,replication,2009-12-31,GCST008636,CD3-positive T-lymphocyte count
739,African American or Afro-Caribbean,644.0,20044523.0,Debette S,Cardiovascular disease,replication,2009-12-31,GCST000554,Subclinical brain infarct
7476,European,2538.0,20045101.0,Ferreira MA,Hematological measurement,initial,2009-12-31,GCST008636,CD3-positive T-lymphocyte count
7481,European,2538.0,20045101.0,Ferreira MA,Inflammatory measurement,initial,2009-12-31,GCST000553,CD4:CD8 lymphocyte ratio
7477,European,2538.0,20045101.0,Ferreira MA,Hematological measurement,initial,2009-12-31,GCST008637,CD4-positive T-lymphocyte count
7478,European,2538.0,20045101.0,Ferreira MA,Hematological measurement,initial,2009-12-31,GCST008638,CD8-positive T-lymphocyte count
7479,European,2538.0,20045101.0,Ferreira MA,Hematological measurement,initial,2009-12-31,GCST008639,CD19-positive B-lymphocyte count
7480,European,2538.0,20045101.0,Ferreira MA,Hematological measurement,initial,2009-12-31,GCST008640,CD56-positive NK-lymphocyte cell count
13633,Other/Mixed,5.0,20215924.0,Liu X,Other measurement,initial,2010-01-01,GCST000556,Functional MRI
4671,European,57.0,20215924.0,Liu X,Other measurement,initial,2010-01-01,GCST000556,Functional MRI
407,African American or Afro-Caribbean,6.0,20215924.0,Liu X,Other measurement,initial,2010-01-01,GCST000556,Functional MRI
4850,European,177.0,20009918.0,Shrestha S,"Cardiovascular disease, Cardiovascular measurement, Other disease",initial,2010-01-01,GCST000555,Carotid atherosclerosis in HIV infection
6532,European,1362.0,20060832.0,Rauch A,Digestive system disorder,initial,2010-01-07,GCST000557,Chronic hepatitis C infection
14238,Other/Mixed,7397.0,20112360.0,Kerkhof HJ,Other disease,replication,2010-01-07,GCST000558,Osteoarthritis
8503,European,4837.0,20112360.0,Kerkhof HJ,Other disease,initial,2010-01-07,GCST000558,Osteoarthritis
11154,European,41597.0,20112360.0,Kerkhof HJ,Other disease,replication,2010-01-07,GCST000558,Osteoarthritis
7887,European,3282.0,20066028.0,Igl W,Lipid or lipoprotein measurement,replication,2010-01-08,GCST000559,Cholesterol
5650,European,656.0,20066028.0,Igl W,Lipid or lipoprotein measurement,initial,2010-01-08,GCST000559,Cholesterol
2451,Asian,906.0,20072603.0,Guo Y,Other disease,replication,2010-01-08,GCST000560,Osteoporosis
2303,Asian,700.0,20072603.0,Guo Y,Other disease,initial,2010-01-08,GCST000560,Osteoporosis
7381,European,2416.0,20062062.0,Reveille JD,Immune system disorder,replication,2010-01-10,GCST000563,Ankylosing spondylitis
10020,European,12670.0,20062063.0,Holm H,Cardiovascular measurement,initial,2010-01-10,GCST000561,Electrocardiographic traits
9786,European,10352.0,20062063.0,Holm H,Cardiovascular measurement,replication,2010-01-10,GCST000561,Electrocardiographic traits
8725,European,5370.0,20062061.0,Chambers JC,Cardiovascular measurement,replication,2010-01-10,GCST000564,Electrocardiographic traits
10811,European,28517.0,20062060.0,Pfeufer A,Cardiovascular measurement,initial,2010-01-10,GCST000562,PR interval
3770,Asian,6243.0,20062061.0,Chambers JC,Cardiovascular measurement,replication,2010-01-10,GCST000564,Electrocardiographic traits
9172,European,7193.0,20062062.0,Reveille JD,Immune system disorder,initial,2010-01-10,GCST000563,Ankylosing spondylitis
3805,Asian,6543.0,20062061.0,Chambers JC,Cardiovascular measurement,initial,2010-01-10,GCST000564,Electrocardiographic traits
2253,Asian,623.0,20066004.0,Chung CM,Other measurement,replication,2010-01-12,GCST000565,Angiotensin-converting enzyme activity
2083,Asian,400.0,20066004.0,Chung CM,Other measurement,initial,2010-01-12,GCST000565,Angiotensin-converting enzyme activity
5119,European,347.0,20068591.0,Van Laer L,Neurological disorder,initial,2010-01-13,GCST000566,Hearing impairment
8021,European,3497.0,20070850.0,Edwards TL,Neurological disorder,initial,2010-01-13,GCST000567,Parkinson's disease
8443,European,4677.0,20081856.0,McMahon FJ,Neurological disorder,replication,2010-01-17,GCST000570,Major mood disorders
11544,European,76558.0,20081858.0,Dupuis J,Other measurement,replication,2010-01-17,GCST000568,Fasting blood glucose
11208,European,46186.0,20081858.0,Dupuis J,Other measurement,initial,2010-01-17,GCST000568,Fasting blood glucose
10235,European,15754.0,20081856.0,McMahon FJ,Neurological disorder,initial,2010-01-17,GCST000570,Major mood disorders
11046,European,37037.0,20081858.0,Dupuis J,"Other measurement, Other trait",initial,2010-01-17,GCST005179,Homeostasis model assessment of insulin resistance
10871,European,30620.0,20081857.0,Saxena R,Other measurement,replication,2010-01-17,GCST000569,Two-hour glucose challenge
11039,European,36466.0,20081858.0,Dupuis J,Other measurement,initial,2010-01-17,GCST005180,Homeostasis model assessment of beta-cell function
11419,European,62264.0,20081858.0,Dupuis J,"Other measurement, Other trait",replication,2010-01-17,GCST005179,Homeostasis model assessment of insulin resistance
14252,Other/Mixed,15234.0,20081857.0,Saxena R,Other measurement,initial,2010-01-17,GCST000569,Two-hour glucose challenge
11418,European,62264.0,20081858.0,Dupuis J,Other measurement,replication,2010-01-17,GCST005180,Homeostasis model assessment of beta-cell function
11417,European,62264.0,20081858.0,Dupuis J,Other measurement,replication,2010-01-17,GCST000571,Fasting blood insulin
11087,European,38238.0,20081858.0,Dupuis J,Other measurement,initial,2010-01-17,GCST000571,Fasting blood insulin
3476,Asian,4185.0,20096396.0,Kung AW,Other measurement,replication,2010-01-20,GCST000572,Bone mineral density
10109,European,13913.0,20096396.0,Kung AW,Other measurement,replication,2010-01-20,GCST000572,Bone mineral density
2387,Asian,785.0,20096396.0,Kung AW,Other measurement,initial,2010-01-20,GCST000572,Bone mineral density
5749,European,733.0,20100581.0,Shen L,Other measurement,initial,2010-01-22,GCST000573,Brain imaging
9214,European,7416.0,20101243.0,Petersen GM,Cancer,initial,2010-01-24,GCST000574,Pancreatic cancer
13893,Other/Mixed,369.0,20101243.0,Petersen GM,Cancer,initial,2010-01-24,GCST000574,Pancreatic cancer
1768,Asian,126.0,20101243.0,Petersen GM,Cancer,initial,2010-01-24,GCST000574,Pancreatic cancer
6227,European,1040.0,20117844.0,Brynedal B,Immune system disorder,initial,2010-02-01,GCST000577,Multiple sclerosis (severity)
8176,European,3901.0,20159242.0,Li X,Other disease,initial,2010-02-01,GCST000576,Asthma
5963,European,873.0,20117844.0,Brynedal B,Immune system disorder,replication,2010-02-01,GCST000577,Multiple sclerosis (severity)
7553,European,2656.0,20125088.0,Shi J,Neurological disorder,initial,2010-02-02,GCST000578,Major depressive disorder
12722,Hispanic or Latin American,7.0,20125193.0,Cirulli ET,Other measurement,initial,2010-02-03,GCST000579,Cognitive performance
1819,Asian,167.0,20125193.0,Cirulli ET,Other measurement,initial,2010-02-03,GCST000579,Cognitive performance
5867,European,813.0,20125193.0,Cirulli ET,Other measurement,initial,2010-02-03,GCST000579,Cognitive performance
1689,Asian,74.0,20125193.0,Cirulli ET,Other measurement,initial,2010-02-03,GCST000579,Cognitive performance
7686,European,2917.0,20139977.0,Codd V,Other measurement,initial,2010-02-07,GCST000586,Telomere length
4262,Asian,14364.0,20139978.0,Kamatani Y,Hematological measurement,initial,2010-02-07,GCST000585,Mean corpuscular volume
4263,Asian,14377.0,20139978.0,Kamatani Y,Hematological measurement,initial,2010-02-07,GCST000582,Mean corpuscular hemoglobin concentration
4264,Asian,14392.0,20139978.0,Kamatani Y,Hematological measurement,initial,2010-02-07,GCST000588,Red blood cell count
9657,European,9492.0,20139977.0,Codd V,Other measurement,replication,2010-02-07,GCST000586,Telomere length
4261,Asian,14362.0,20139978.0,Kamatani Y,Hematological measurement,initial,2010-02-07,GCST000587,Mean corpuscular hemoglobin
4268,Asian,14677.0,20139978.0,Kamatani Y,"Hematological measurement, Inflammatory measurement",initial,2010-02-07,GCST000589,White blood cell count
4265,Asian,14402.0,20139978.0,Kamatani Y,"Other measurement, Liver enzyme measurement, Cardiovascular measurement, Hematological measurement, Lipid or lipoprotein measurement",initial,2010-02-07,GCST000583,Hematological and biochemical traits
4040,Asian,8993.0,20139978.0,Kamatani Y,Lipid or lipoprotein measurement,initial,2010-02-07,GCST000584,Triglycerides
4035,Asian,8868.0,20139978.0,Kamatani Y,"Metabolic disorder, Other measurement",initial,2010-02-07,GCST000581,Urate levels
4280,Asian,14806.0,20139978.0,Kamatani Y,Hematological measurement,initial,2010-02-07,GCST000580,Platelet count
941,African American or Afro-Caribbean,1571.0,20152958.0,Xing C,Other measurement,replication,2010-02-11,GCST000591,Fasting plasma glucose
1000,African American or Afro-Caribbean,2029.0,20152958.0,Xing C,Other measurement,initial,2010-02-11,GCST000591,Fasting plasma glucose
6654,European,1523.0,20150558.0,He M,Inflammatory measurement,initial,2010-02-11,GCST000590,Interleukin-18 levels
8148,European,3825.0,20152958.0,Xing C,Other measurement,replication,2010-02-11,GCST000591,Fasting plasma glucose
5273,European,435.0,20150558.0,He M,Inflammatory measurement,replication,2010-02-11,GCST000590,Interleukin-18 levels
9216,European,7428.0,20152958.0,Xing C,Other measurement,initial,2010-02-11,GCST000591,Fasting plasma glucose
2892,Asian,1798.0,20169177.0,Yang W,Immune system disorder,initial,2010-02-12,GCST000592,Systemic lupus erythematosus
9767,European,10112.0,20159113.0,Jakkula E,Immune system disorder,replication,2010-02-12,GCST000593,Multiple sclerosis
3565,Asian,4785.0,20169177.0,Yang W,Immune system disorder,replication,2010-02-12,GCST000592,Systemic lupus erythematosus
2415,Asian,833.0,20169177.0,Yang W,Immune system disorder,replication,2010-02-12,GCST000592,Systemic lupus erythematosus
4908,European,204.0,20159113.0,Jakkula E,Immune system disorder,initial,2010-02-12,GCST000593,Multiple sclerosis
7743,European,3024.0,20154673.0,Van Deerlin VM,Neurological disorder,initial,2010-02-14,GCST000595,Frontotemporal lobar degeneration
5626,European,642.0,20154673.0,Van Deerlin VM,Neurological disorder,replication,2010-02-14,GCST000595,Frontotemporal lobar degeneration
5562,European,590.0,20064070.0,Herbeck JT,Other disease,replication,2010-02-15,GCST000596,HIV-1 progression
4814,European,156.0,20064070.0,Herbeck JT,Other disease,initial,2010-02-15,GCST000596,HIV-1 progression
5768,European,740.0,20171287.0,Stein JL,Other measurement,initial,2010-02-17,GCST000597,Brain structure
5673,European,669.0,20164292.0,Koller DL,Other measurement,replication,2010-02-17,GCST000598,Bone mineral density
6657,European,1524.0,20164292.0,Koller DL,Other measurement,initial,2010-02-17,GCST000598,Bone mineral density
2944,Asian,1894.0,20172861.0,Okada Y,Hematological measurement,replication,2010-02-18,GCST000600,Neutrophil count
9710,European,9813.0,20167578.0,Barbalic M,"Cardiovascular measurement, Other measurement",initial,2010-02-18,GCST000599,Soluble levels of adhesion molecules
3726,Asian,5771.0,20172861.0,Okada Y,Hematological measurement,initial,2010-02-18,GCST000600,Neutrophil count
3342,Asian,3276.0,20174558.0,Tsai FJ,Metabolic disorder,replication,2010-02-19,GCST000601,Type 2 diabetes
2943,Asian,1889.0,20174558.0,Tsai FJ,Metabolic disorder,initial,2010-02-19,GCST000601,Type 2 diabetes
8476,European,4771.0,20173747.0,Ellinor PT,Cardiovascular disease,replication,2010-02-21,GCST000602,Atrial fibrillation
6154,European,988.0,20173735.0,Fellay J,Digestive system disorder,initial,2010-02-21,GCST000604,Chronic hepatitis C infection
8333,European,4320.0,20173748.0,Cho MH,Other disease,initial,2010-02-21,GCST000603,Chronic obstructive pulmonary disease
59,African,198.0,20173735.0,Fellay J,Digestive system disorder,initial,2010-02-21,GCST000604,Chronic hepatitis C infection
10127,European,14179.0,20173747.0,Ellinor PT,Cardiovascular disease,initial,2010-02-21,GCST000602,Atrial fibrillation
6197,European,1006.0,20173748.0,Cho MH,Other disease,replication,2010-02-21,GCST000603,Chronic obstructive pulmonary disease
6639,European,1504.0,20167575.0,Sun Q,Other measurement,initial,2010-02-22,GCST000605,Soluble leptin receptor levels
5448,European,518.0,20147318.0,Qi L,Inflammatory measurement,replication,2010-02-22,GCST000606,E-selectin levels
6196,European,1005.0,20147318.0,Qi L,Inflammatory measurement,initial,2010-02-22,GCST000606,E-selectin levels
5968,European,875.0,20167575.0,Sun Q,Other measurement,replication,2010-02-22,GCST000605,Soluble leptin receptor levels
10290,European,16443.0,20185149.0,Athanasiu L,Neurological disorder,replication,2010-02-23,GCST000607,Schizophrenia
5419,European,506.0,20185149.0,Athanasiu L,Neurological disorder,initial,2010-02-23,GCST000607,Schizophrenia
1712,Asian,93.0,20189245.0,Han S,Cancer,initial,2010-02-25,GCST000608,Acute lymphoblastic leukemia (childhood)
4355,Asian,19633.0,20189936.0,Okada Y,"Other measurement, Body measurement",initial,2010-02-26,GCST000611,Height
8869,European,5919.0,20195514.0,Pillas D,Biological process,initial,2010-02-26,GCST000609,Primary tooth development (time to first tooth eruption)
8818,European,5752.0,20195514.0,Pillas D,Biological process,initial,2010-02-26,GCST000610,Primary tooth development (number of teeth)
9814,European,10602.0,20190752.0,Dubois PC,Immune system disorder,replication,2010-02-28,GCST000612,Celiac disease
10207,European,15283.0,20190752.0,Dubois PC,Immune system disorder,initial,2010-02-28,GCST000612,Celiac disease
5776,European,742.0,20197096.0,Stein JL,Neurological disorder,initial,2010-03-01,GCST000614,Brain structure (temporal lobe volume)
5075,European,324.0,20235792.0,Uhl GR,Biological process,initial,2010-03-01,GCST000616,Smoking cessation
5777,European,742.0,20197096.0,Stein JL,Other measurement,initial,2010-03-01,GCST000615,Brain structure (hippocampal volume)
6580,European,1399.0,20201924.0,Edenberg HJ,"Other measurement, Neurological disorder",initial,2010-03-01,GCST000617,Alcohol dependence
68,African,226.0,20487506.0,Joubert BR,Biological process,initial,2010-03-01,GCST000613,HIV (mother-to-child transmission)
707,African American or Afro-Caribbean,485.0,20201924.0,Edenberg HJ,"Other measurement, Neurological disorder",initial,2010-03-01,GCST000617,Alcohol dependence
13752,Other/Mixed,103.0,20195266.0,Adkins DE,Response to drug,initial,2010-03-02,GCST000618,Response to antipsychotic treatment
586,African American or Afro-Caribbean,214.0,20195266.0,Adkins DE,Response to drug,initial,2010-03-02,GCST000618,Response to antipsychotic treatment
6939,European,1845.0,20202923.0,Bierut LJ,"Other measurement, Neurological disorder",replication,2010-03-02,GCST000619,Alcohol dependence
7559,European,2668.0,20202923.0,Bierut LJ,"Other measurement, Neurological disorder",initial,2010-03-02,GCST000619,Alcohol dependence
863,African American or Afro-Caribbean,1161.0,20202923.0,Bierut LJ,"Other measurement, Neurological disorder",initial,2010-03-02,GCST000619,Alcohol dependence
5231,European,421.0,20195266.0,Adkins DE,Response to drug,initial,2010-03-02,GCST000618,Response to antipsychotic treatment
6482,European,1300.0,20208534.0,Rothenberg ME,Digestive system disorder,replication,2010-03-07,GCST000620,Eosinophilic esophagitis (pediatric)
7171,European,2155.0,20208534.0,Rothenberg ME,Digestive system disorder,initial,2010-03-07,GCST000620,Eosinophilic esophagitis (pediatric)
5124,European,352.0,20212171.0,Buil A,Cardiovascular measurement,initial,2010-03-08,GCST000621,C4b binding protein levels
8219,European,4006.0,20222955.0,Pattaro C,Other measurement,initial,2010-03-11,GCST000622,Creatinine levels
7072,European,2035.0,20222955.0,Pattaro C,Other measurement,replication,2010-03-11,GCST000622,Creatinine levels
9655,European,9484.0,20228799.0,McGovern DP,Immune system disorder,initial,2010-03-14,GCST000624,Ulcerative colitis
7605,European,2746.0,20228798.0,Franke A,Immune system disorder,initial,2010-03-14,GCST000623,Ulcerative colitis
8062,European,3589.0,20228799.0,McGovern DP,Immune system disorder,replication,2010-03-14,GCST000624,Ulcerative colitis
9325,European,7967.0,20228798.0,Franke A,Immune system disorder,replication,2010-03-14,GCST000623,Ulcerative colitis
9258,European,7604.0,20231535.0,Smith NL,Other measurement,replication,2010-03-15,GCST000625,Factor VII levels
9257,European,7604.0,20231535.0,Smith NL,Hematological measurement,replication,2010-03-15,GCST000627,vWF levels
10220,European,15422.0,20231535.0,Smith NL,Other measurement,initial,2010-03-15,GCST000625,Factor VII levels
10668,European,23608.0,20231535.0,Smith NL,Hematological measurement,initial,2010-03-15,GCST000627,vWF levels
9256,European,7604.0,20231535.0,Smith NL,Hematological measurement,replication,2010-03-15,GCST000626,Factor VIII levels
10205,European,15279.0,20231535.0,Smith NL,Hematological measurement,initial,2010-03-15,GCST000626,Factor VIII levels
12994,Hispanic or Latin American,858.0,20237162.0,Bozaoglu K,Cardiovascular measurement,initial,2010-03-17,GCST000628,Chemerin levels
6597,European,1431.0,20303064.0,Houlihan LM,Hematological measurement,initial,2010-03-18,GCST000631,Activated partial thromboplastin time
6969,European,1884.0,20305777.0,Nakajima M,Other disease,replication,2010-03-18,GCST000629,Knee osteoarthritis
8138,European,3791.0,20304771.0,Newman AB,Other measurement,initial,2010-03-18,GCST000632,Longevity
3492,Asian,4295.0,20305777.0,Nakajima M,Other disease,initial,2010-03-18,GCST000629,Knee osteoarthritis
8892,European,6025.0,20304771.0,Newman AB,Other measurement,replication,2010-03-18,GCST000632,Longevity
7674,European,2889.0,20303062.0,Medland SE,Body measurement,initial,2010-03-18,GCST000630,Digit length ratio
2192,Asian,514.0,20305777.0,Nakajima M,Other disease,replication,2010-03-18,GCST000629,Knee osteoarthritis
8087,European,3659.0,20303062.0,Medland SE,Body measurement,replication,2010-03-18,GCST000630,Digit length ratio
13692,Other/Mixed,26.0,20304703.0,Li Y,Cancer,initial,2010-03-19,GCST000633,Lung cancer
6481,European,1299.0,20304703.0,Li Y,Cancer,replication,2010-03-19,GCST000633,Lung cancer
13821,Other/Mixed,219.0,20304703.0,Li Y,Cancer,replication,2010-03-19,GCST000633,Lung cancer
5743,European,728.0,20304703.0,Li Y,Cancer,initial,2010-03-19,GCST000633,Lung cancer
5947,European,860.0,20306291.0,Davis OS,Biological process,initial,2010-03-21,GCST000634,Cognitive ability
7532,European,2619.0,20306291.0,Davis OS,Biological process,replication,2010-03-21,GCST000634,Cognitive ability
8185,European,3928.0,20339536.0,Barber MJ,Response to drug,initial,2010-03-22,GCST000635,Response to statin therapy
4670,European,56.0,20308991.0,Kim S,Other measurement,initial,2010-03-23,GCST000636,Brain cytoarchitecture
8339,European,4335.0,20332263.0,Azzato EM,Cancer,replication,2010-03-23,GCST000637,Breast cancer (prognosis)
14263,Other/Mixed,19611.0,20360844.0,Arking DE,Cardiovascular disease,replication,2010-03-25,GCST000638,Sudden cardiac arrest
5639,European,650.0,20360844.0,Arking DE,Cardiovascular disease,initial,2010-03-25,GCST000638,Sudden cardiac arrest
9584,European,9029.0,20348956.0,Kiemeney LA,Cancer,replication,2010-03-28,GCST000639,Urinary bladder cancer
11148,European,41199.0,20348956.0,Kiemeney LA,Cancer,initial,2010-03-28,GCST000639,Urinary bladder cancer
6211,European,1021.0,20350937.0,Takahashi M,Cancer,initial,2010-03-29,GCST000640,"Thyroid cancer (Papillary, radiation-related)"
9921,European,11536.0,20397748.0,Liu JZ,"Other measurement, Body measurement",initial,2010-04-01,GCST000644,Height
9920,European,11536.0,20397748.0,Liu JZ,"Body measurement, Other measurement",initial,2010-04-01,GCST000642,Body mass index
5719,European,706.0,20360315.0,Uher R,Response to drug,initial,2010-04-01,GCST000643,Response to antidepressants
2268,Asian,660.0,20363506.0,Meguro A,Neurological disorder,initial,2010-04-02,GCST000645,Glaucoma
10210,European,15295.0,20364137.0,Yasuno K,Cardiovascular disease,initial,2010-04-04,GCST000646,Intracranial aneurysm
3564,Asian,4777.0,20364137.0,Yasuno K,Cardiovascular disease,replication,2010-04-04,GCST000646,Intracranial aneurysm
14025,Other/Mixed,746.0,20372150.0,Freathy RM,Body measurement,replication,2010-04-06,GCST000648,Birth weight
6433,European,1231.0,20370913.0,Ma L,Lipid or lipoprotein measurement,replication,2010-04-06,GCST000647,Cholesterol
9818,European,10623.0,20372150.0,Freathy RM,Body measurement,initial,2010-04-06,GCST000648,Birth weight
10793,European,27591.0,20372150.0,Freathy RM,Body measurement,replication,2010-04-06,GCST000648,Birth weight
14132,Other/Mixed,1748.0,20372150.0,Freathy RM,Body measurement,replication,2010-04-06,GCST000648,Birth weight
9223,European,7467.0,20383147.0,Radstake TR,Neurological disorder,initial,2010-04-11,GCST000650,Systemic sclerosis
10680,European,23812.0,20383145.0,Chambers JC,Other measurement,initial,2010-04-11,GCST000651,Creatinine levels
9191,European,7322.0,20383147.0,Radstake TR,Neurological disorder,replication,2010-04-11,GCST000650,Systemic sclerosis
11462,European,67093.0,20383146.0,Kottgen A,"Other disease, Other measurement",initial,2010-04-11,GCST000649,Chronic kidney disease
10653,European,22982.0,20383146.0,Kottgen A,"Other disease, Other measurement",replication,2010-04-11,GCST000649,Chronic kidney disease
10306,European,16626.0,20383145.0,Chambers JC,Other measurement,replication,2010-04-11,GCST000651,Creatinine levels
6468,European,1278.0,20385826.0,Neale BM,Neurological disorder,replication,2010-04-12,GCST000653,Age-related macular degeneration
2510,Asian,1014.0,20385819.0,Chen W,Neurological disorder,replication,2010-04-12,GCST000652,Age-related macular degeneration
7905,European,3307.0,20385819.0,Chen W,Neurological disorder,initial,2010-04-12,GCST000652,Age-related macular degeneration
10107,European,13890.0,20385819.0,Chen W,Neurological disorder,replication,2010-04-12,GCST000652,Age-related macular degeneration
2990,Asian,2000.0,20386566.0,Lee MT,Neurological disorder,initial,2010-04-13,GCST000654,Bipolar I disorder
2674,Asian,1409.0,20386566.0,Lee MT,Neurological disorder,replication,2010-04-13,GCST000654,Bipolar I disorder
713,African American or Afro-Caribbean,515.0,20205591.0,Pelak K,"Biological process, Other measurement, Other disease",initial,2010-04-15,GCST000656,HIV-1 viral setpoint
5930,European,848.0,20395239.0,Macgregor S,Other measurement,replication,2010-04-15,GCST000659,Optic nerve measurement (cup area)
5929,European,848.0,20395239.0,Macgregor S,Other measurement,replication,2010-04-15,GCST000658,Optic nerve measurement (rim area)
5928,European,848.0,20395239.0,Macgregor S,Other measurement,replication,2010-04-15,GCST000657,Optic nerve measurement (disc area)
5927,European,848.0,20395239.0,Macgregor S,Other measurement,replication,2010-04-15,GCST000655,Optic nerve measurement (cup-to-disc ratio)
6545,European,1368.0,20395239.0,Macgregor S,Other measurement,initial,2010-04-15,GCST000657,Optic nerve measurement (disc area)
6544,European,1368.0,20395239.0,Macgregor S,Other measurement,initial,2010-04-15,GCST000655,Optic nerve measurement (cup-to-disc ratio)
6546,European,1368.0,20395239.0,Macgregor S,Other measurement,initial,2010-04-15,GCST000658,Optic nerve measurement (rim area)
6547,European,1368.0,20395239.0,Macgregor S,Other measurement,initial,2010-04-15,GCST000659,Optic nerve measurement (cup area)
172,African,1188.0,20400458.0,Kang SJ,"Other measurement, Body measurement",initial,2010-04-16,GCST000660,Anthropometric traits
1236,African American or Afro-Caribbean,4175.0,20400458.0,Kang SJ,"Other measurement, Body measurement",replication,2010-04-16,GCST000660,Anthropometric traits
763,African American or Afro-Caribbean,743.0,20400458.0,Kang SJ,"Other measurement, Body measurement",initial,2010-04-16,GCST000660,Anthropometric traits
108,African,466.0,20400778.0,Morrison AC,"Other measurement, Cardiovascular disease",initial,2010-04-17,GCST000661,Mortality in heart failure
7501,European,2562.0,20400778.0,Morrison AC,"Other measurement, Cardiovascular disease",initial,2010-04-17,GCST000661,Mortality in heart failure
8225,European,4021.0,20410501.0,Jin Y,Immune system disorder,initial,2010-04-21,GCST000662,Vitiligo
8080,European,3635.0,20410501.0,Jin Y,Immune system disorder,replication,2010-04-21,GCST000662,Vitiligo
8774,European,5552.0,20421936.0,Scherag A,Metabolic disorder,replication,2010-04-22,GCST000663,Obesity (early onset extreme)
7266,European,2258.0,20421936.0,Scherag A,Metabolic disorder,initial,2010-04-22,GCST000663,Obesity (early onset extreme)
11621,European,84605.0,20418489.0,Qi L,Metabolic disorder,replication,2010-04-23,GCST000665,Type 2 diabetes
7247,European,2221.0,20418485.0,Ahn J,Other measurement,replication,2010-04-23,GCST000664,Vitamin D levels
8388,European,4501.0,20418485.0,Ahn J,Other measurement,initial,2010-04-23,GCST000664,Vitamin D levels
8797,European,5643.0,20418489.0,Qi L,Metabolic disorder,initial,2010-04-23,GCST000665,Type 2 diabetes
10887,European,31266.0,20418888.0,Thorgeirsson TE,Biological process,initial,2010-04-25,GCST000667,Smoking behavior
11344,European,54731.0,20418888.0,Thorgeirsson TE,Biological process,replication,2010-04-25,GCST000667,Smoking behavior
11147,European,41150.0,20418889.0,Liu JZ,Biological process,initial,2010-04-25,GCST000668,Smoking behavior
11877,European,120516.0,20418889.0,Liu JZ,Biological process,replication,2010-04-25,GCST000668,Smoking behavior
11530,European,74035.0,20418890.0,Tobacco and Genetics Consortium,Biological process,initial,2010-04-25,GCST000666,Smoking behavior
14143,Other/Mixed,1893.0,20421499.0,Levy D,Other measurement,replication,2010-04-26,GCST000669,Telomere length
4860,European,185.0,20421487.0,Hodgkinson CA,Other measurement,replication,2010-04-26,GCST000670,Electroencephalogram traits
7669,European,2876.0,20421499.0,Levy D,Other measurement,replication,2010-04-26,GCST000669,Telomere length
7982,European,3417.0,20421499.0,Levy D,Other measurement,initial,2010-04-26,GCST000669,Telomere length
13864,Other/Mixed,322.0,20421487.0,Hodgkinson CA,Other measurement,initial,2010-04-26,GCST000670,Electroencephalogram traits
9032,European,6668.0,20442857.0,Suchindran S,Lipid or lipoprotein measurement,initial,2010-04-29,GCST000671,Lipoprotein-associated phospholipase A2 activity and mass
14133,Other/Mixed,1769.0,20436469.0,Beaty TH,Other trait,replication,2010-05-02,GCST000673,Cleft lip
3079,Asian,2194.0,20436469.0,Beaty TH,Other trait,replication,2010-05-02,GCST000673,Cleft lip
6809,European,1693.0,20436471.0,Albagha OM,Other disease,initial,2010-05-02,GCST000672,Paget's disease
5779,European,744.0,20436471.0,Albagha OM,Other disease,replication,2010-05-02,GCST000672,Paget's disease
5892,European,825.0,20436469.0,Beaty TH,Other trait,initial,2010-05-02,GCST000673,Cleft lip
2004,Asian,322.0,20436469.0,Beaty TH,Other trait,replication,2010-05-02,GCST000673,Cleft lip
8149,European,3830.0,20436469.0,Beaty TH,Other trait,replication,2010-05-02,GCST000673,Cleft lip
2520,Asian,1038.0,20436469.0,Beaty TH,Other trait,initial,2010-05-02,GCST000673,Cleft lip
10550,European,20926.0,20445134.0,Smith NL,Cardiovascular disease,initial,2010-05-05,GCST000675,Heart failure
5807,European,760.0,20451256.0,Djurovic S,Neurological disorder,initial,2010-05-05,GCST000674,Bipolar disorder
9830,European,10693.0,20451256.0,Djurovic S,Neurological disorder,replication,2010-05-05,GCST000674,Bipolar disorder
1098,African American or Afro-Caribbean,2895.0,20445134.0,Smith NL,Cardiovascular disease,initial,2010-05-05,GCST000675,Heart failure
5044,European,299.0,20452100.0,Kramer PL,Neurological disorder,initial,2010-05-06,GCST000676,Alzheimer's disease
10749,European,25708.0,20453842.0,Stahl EA,Immune system disorder,initial,2010-05-09,GCST000679,Rheumatoid arthritis
3695,Asian,5683.0,20453841.0,Kochi Y,Immune system disorder,initial,2010-05-09,GCST000677,Rheumatoid arthritis
8131,European,3780.0,20453840.0,Sanna S,Immune system disorder,replication,2010-05-09,GCST000680,Multiple sclerosis
9509,European,8556.0,20453838.0,Turnbull C,Cancer,initial,2010-05-09,GCST000678,Breast cancer
10722,European,24799.0,20453838.0,Turnbull C,Cancer,replication,2010-05-09,GCST000678,Breast cancer
4377,Asian,22127.0,20453841.0,Kochi Y,Immune system disorder,replication,2010-05-09,GCST000677,Rheumatoid arthritis
6880,European,1754.0,20453840.0,Sanna S,Immune system disorder,initial,2010-05-09,GCST000680,Multiple sclerosis
10225,European,15574.0,20453842.0,Stahl EA,Immune system disorder,replication,2010-05-09,GCST000679,Rheumatoid arthritis
1878,Asian,214.0,20460270.0,Garcia-Barcelo MM,Digestive system disorder,replication,2010-05-11,GCST000681,Biliary atresia
2355,Asian,762.0,20460270.0,Garcia-Barcelo MM,Digestive system disorder,initial,2010-05-11,GCST000681,Biliary atresia
10513,European,20037.0,20460622.0,Seshadri S,Neurological disorder,replication,2010-05-12,GCST000682,Alzheimer's disease
14269,Other/Mixed,25610.0,20460622.0,Seshadri S,Neurological disorder,initial,2010-05-12,GCST000682,Alzheimer's disease
8247,European,4075.0,20485516.0,Lu Y,Other measurement,initial,2010-05-13,GCST000683,Central corneal thickness
8878,European,5951.0,20463881.0,Liu F,Other trait,initial,2010-05-16,GCST000685,Eye color traits
8042,European,3543.0,20463881.0,Liu F,Other trait,replication,2010-05-16,GCST000685,Eye color traits
4872,European,190.0,20484958.0,Diergaarde B,Cancer,initial,2010-05-17,GCST000686,Pancreatic cancer
4797,European,142.0,20484958.0,Diergaarde B,Cancer,replication,2010-05-17,GCST000686,Pancreatic cancer
3372,Asian,3477.0,20512145.0,Bei JX,Cancer,initial,2010-05-30,GCST000687,Nasopharyngeal carcinoma
3873,Asian,7407.0,20512145.0,Bei JX,Cancer,replication,2010-05-30,GCST000687,Nasopharyngeal carcinoma
1932,Asian,245.0,20463552.0,Wu C,Response to drug,initial,2010-06-01,GCST000688,Response to platinum-based chemotherapy in small-cell lung cancer
591,African American or Afro-Caribbean,225.0,20520587.0,Nielsen DA,Neurological disorder,initial,2010-06-01,GCST000690,Heroin addiction
7928,European,3336.0,20516156.0,Lewis CM,Neurological disorder,replication,2010-06-01,GCST000689,Major depressive disorder
1837,Asian,183.0,20463552.0,Wu C,Response to drug,replication,2010-06-01,GCST000688,Response to platinum-based chemotherapy in small-cell lung cancer
7859,European,3230.0,20516156.0,Lewis CM,Neurological disorder,initial,2010-06-01,GCST000689,Major depressive disorder
5122,European,350.0,20520587.0,Nielsen DA,Neurological disorder,initial,2010-06-01,GCST000690,Heroin addiction
9787,European,10380.0,20522523.0,Kasperaviciute D,Neurological disorder,initial,2010-06-03,GCST000691,Partial epilepsies
4324,Asian,17363.0,20526339.0,Quan C,Immune system disorder,replication,2010-06-06,GCST000692,Vitiligo
791,African American or Afro-Caribbean,840.0,20526338.0,Johnson AD,Biological process,replication,2010-06-06,GCST000693,Platelet aggregation
8216,European,3991.0,20526338.0,Johnson AD,Biological process,initial,2010-06-06,GCST000693,Platelet aggregation
3192,Asian,2546.0,20526339.0,Quan C,Immune system disorder,initial,2010-06-06,GCST000692,Vitiligo
5799,European,755.0,20528957.0,Oedegaard KJ,"Cardiovascular disease, Neurological disorder",initial,2010-06-07,GCST000695,Migraine in psychiatric disorder
6637,European,1495.0,20529992.0,Teupser D,Other measurement,initial,2010-06-07,GCST000694,Phytosterol levels
7687,European,2917.0,20529992.0,Teupser D,Other measurement,replication,2010-06-07,GCST000694,Phytosterol levels
5310,European,455.0,20528957.0,Oedegaard KJ,"Cardiovascular disease, Neurological disorder",replication,2010-06-07,GCST000695,Migraine in psychiatric disorder
814,African American or Afro-Caribbean,942.0,20532800.0,Bostrom MA,Other disease,initial,2010-06-08,GCST000696,End-stage renal disease (non-diabetic)
750,African American or Afro-Caribbean,699.0,20532800.0,Bostrom MA,Other disease,replication,2010-06-08,GCST000696,End-stage renal disease (non-diabetic)
10254,European,16125.0,20541252.0,Wang TJ,Other trait,initial,2010-06-09,GCST000697,Vitamin D insufficiency
10394,European,17871.0,20541252.0,Wang TJ,Other trait,replication,2010-06-09,GCST000697,Vitamin D insufficiency
8053,European,3569.0,20548944.0,Hsu YH,Other disease,initial,2010-06-10,GCST000698,Osteoporosis-related phenotypes
8369,European,4455.0,20548946.0,Ramdas WD,Other measurement,replication,2010-06-10,GCST000699,Optic disc parameters
9283,European,7721.0,20548944.0,Hsu YH,Other disease,replication,2010-06-10,GCST000698,Osteoporosis-related phenotypes
8370,European,4455.0,20548946.0,Ramdas WD,Other measurement,replication,2010-06-10,GCST000700,Vertical cup-disc ratio
9200,European,7360.0,20548946.0,Ramdas WD,Other measurement,initial,2010-06-10,GCST000699,Optic disc parameters
9201,European,7360.0,20548946.0,Ramdas WD,Other measurement,initial,2010-06-10,GCST000700,Vertical cup-disc ratio
8262,European,4120.0,20543847.0,Turnbull C,Cancer,replication,2010-06-13,GCST000701,Testicular germ cell cancer
8870,European,5926.0,20543847.0,Turnbull C,Cancer,initial,2010-06-13,GCST000701,Testicular germ cell cancer
4649,European,37.0,20558996.0,Ott J,Neurological disorder,initial,2010-06-17,GCST000702,Schizophrenia
10272,European,16264.0,20558539.0,Kestenbaum B,Other measurement,initial,2010-06-17,GCST000703,Phosphorus levels
8746,European,5444.0,20558539.0,Kestenbaum B,Other measurement,replication,2010-06-17,GCST000703,Phosphorus levels
8258,European,4099.0,20570966.0,McGovern DP,Digestive system disorder,initial,2010-06-22,GCST000705,Crohn's disease
1649,Asian,35.0,20534544.0,Beall CM,Hematological measurement,initial,2010-06-22,GCST000704,Hemoglobin levels
6668,European,1531.0,20570966.0,McGovern DP,Digestive system disorder,replication,2010-06-22,GCST000705,Crohn's disease
1812,Asian,161.0,20534544.0,Beall CM,Hematological measurement,replication,2010-06-22,GCST000704,Hemoglobin levels
9596,European,9126.0,20585627.0,Eriksson N,"Other trait, Biological process",initial,2010-06-24,GCST000706,Common traits (Other)
9594,European,9126.0,20585627.0,Eriksson N,"Other measurement, Other trait",initial,2010-06-24,GCST000710,Eye color
9593,European,9126.0,20585627.0,Eriksson N,"Other measurement, Other trait",initial,2010-06-24,GCST000707,Hair color
3473,Asian,4157.0,20585626.0,Long J,Cancer,initial,2010-06-24,GCST000709,Breast cancer
9595,European,9126.0,20585627.0,Eriksson N,Other trait,initial,2010-06-24,GCST000708,Freckling
4415,Asian,28152.0,20585626.0,Long J,Cancer,replication,2010-06-24,GCST000709,Breast cancer
8752,European,5459.0,20585626.0,Long J,Cancer,replication,2010-06-24,GCST000709,Breast cancer
12819,Hispanic or Latin American,229.0,20600896.0,Engelman CD,Other measurement,initial,2010-06-26,GCST000711,Vitamin D levels
13016,Hispanic or Latin American,961.0,20600896.0,Engelman CD,Other measurement,replication,2010-06-26,GCST000711,Vitamin D levels
11231,European,47117.0,20581827.0,Voight BF,Metabolic disorder,initial,2010-06-27,GCST000712,Type 2 diabetes
13646,Other/Mixed,8.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000713,Conduct disorder (symptom count)
13647,Other/Mixed,8.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000714,Conduct disorder
886,African American or Afro-Caribbean,1257.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000713,Conduct disorder (symptom count)
11730,European,94337.0,20581827.0,Voight BF,Metabolic disorder,replication,2010-06-27,GCST000712,Type 2 diabetes
887,African American or Afro-Caribbean,1257.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000714,Conduct disorder
7574,European,2698.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000713,Conduct disorder (symptom count)
7575,European,2698.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000714,Conduct disorder
14,African,33.0,20592726.0,Chen SH,"Cancer, Response to drug",replication,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
1586,Asian,2.0,20592726.0,Chen SH,"Cancer, Response to drug",replication,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
12756,Hispanic or Latin American,46.0,20592726.0,Chen SH,"Cancer, Response to drug",initial,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
13634,Other/Mixed,5.0,20592726.0,Chen SH,"Cancer, Response to drug",replication,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
1596,Asian,4.0,20592726.0,Chen SH,"Cancer, Response to drug",initial,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
4927,European,211.0,20592726.0,Chen SH,"Cancer, Response to drug",initial,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
13674,Other/Mixed,21.0,20592726.0,Chen SH,"Cancer, Response to drug",initial,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
6591,European,1415.0,20598377.0,Nischwitz S,Immune system disorder,initial,2010-06-30,GCST000716,Multiple sclerosis
12741,Hispanic or Latin American,24.0,20592726.0,Chen SH,"Cancer, Response to drug",replication,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
21,African,40.0,20592726.0,Chen SH,"Cancer, Response to drug",initial,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
4760,European,99.0,20592726.0,Chen SH,"Cancer, Response to drug",replication,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
8338,European,4332.0,20596022.0,Petukhova L,Other disease,initial,2010-07-01,GCST000719,Alopecia areata
8733,European,5411.0,20595679.0,Feehally J,Other disease,initial,2010-07-01,GCST000718,Nephropathy
2349,Asian,758.0,20664687.0,Lin HJ,"Neurological disorder, Metabolic disorder",initial,2010-07-01,GCST000717,Cataracts in type 2 diabetes
3097,Asian,2239.0,20610895.0,Koriyama H,Cardiovascular disease,replication,2010-07-02,GCST000720,Peripheral artery disease
2754,Asian,1553.0,20610895.0,Koriyama H,Cardiovascular disease,initial,2010-07-02,GCST000720,Peripheral artery disease
3509,Asian,4458.0,20601957.0,Uno S,Other disease,replication,2010-07-04,GCST000721,Endometriosis
3232,Asian,2741.0,20601957.0,Uno S,Other disease,initial,2010-07-04,GCST000721,Endometriosis
10038,European,13074.0,20610541.0,Lascorz J,Cancer,replication,2010-07-07,GCST000722,Colorectal cancer
6767,European,1634.0,20610541.0,Lascorz J,Cancer,initial,2010-07-07,GCST000722,Colorectal cancer
2169,Asian,482.0,20613766.0,Akiyama K,Cardiovascular disease,initial,2010-07-08,GCST000723,Intracranial aneurysm
2670,Asian,1398.0,20613766.0,Akiyama K,Cardiovascular disease,replication,2010-07-08,GCST000723,Intracranial aneurysm
7254,European,2235.0,20634892.0,Calboli FC,"Neurological disorder, Other measurement",initial,2010-07-09,GCST004569,Neuroticism
7253,European,2235.0,20634892.0,Calboli FC,"Neurological disorder, Other measurement",initial,2010-07-09,GCST000724,Neuroticism (age interaction)
2697,Asian,1479.0,20622878.0,Remmers EF,Cardiovascular disease,replication,2010-07-11,GCST000726,Behcet's disease
13885,Other/Mixed,352.0,20622878.0,Remmers EF,Cardiovascular disease,replication,2010-07-11,GCST000726,Behcet's disease
1942,Asian,259.0,20622879.0,Mizuki N,Cardiovascular disease,replication,2010-07-11,GCST000728,Behcet's disease
14162,Other/Mixed,2493.0,20622878.0,Remmers EF,Cardiovascular disease,initial,2010-07-11,GCST000726,Behcet's disease
5483,European,537.0,20622880.0,Bezzina CR,Cardiovascular disease,replication,2010-07-11,GCST000725,Ventricular fibrillation
10897,European,31795.0,20622881.0,Gretarsdottir S,Cardiovascular disease,initial,2010-07-11,GCST000727,Abdominal aortic aneurysm
6111,European,972.0,20622880.0,Bezzina CR,Cardiovascular disease,initial,2010-07-11,GCST000725,Ventricular fibrillation
14164,Other/Mixed,2494.0,20622879.0,Mizuki N,Cardiovascular disease,replication,2010-07-11,GCST000728,Behcet's disease
13879,Other/Mixed,336.0,20622878.0,Remmers EF,Cardiovascular disease,replication,2010-07-11,GCST000726,Behcet's disease
5244,European,430.0,20622878.0,Remmers EF,Cardiovascular disease,replication,2010-07-11,GCST000726,Behcet's disease
9835,European,10718.0,20622881.0,Gretarsdottir S,Cardiovascular disease,replication,2010-07-11,GCST000727,Abdominal aortic aneurysm
2651,Asian,1348.0,20622879.0,Mizuki N,Cardiovascular disease,initial,2010-07-11,GCST000728,Behcet's disease
2149,Asian,470.0,20637204.0,Ochi H,"Other trait, Response to drug",replication,2010-07-13,GCST000729,Ribavirin-induced anemia
2131,Asian,453.0,20637204.0,Ochi H,"Other trait, Response to drug",initial,2010-07-13,GCST000729,Ribavirin-induced anemia
2542,Asian,1096.0,20639394.0,Kang TW,Other measurement,replication,2010-07-16,GCST000730,Bilirubin levels
4016,Asian,8841.0,20639394.0,Kang TW,Other measurement,initial,2010-07-16,GCST000730,Bilirubin levels
11103,European,38991.0,20639392.0,Eijgelsheim M,Cardiovascular measurement,initial,2010-07-16,GCST000731,Resting heart rate
6916,European,1810.0,20602913.0,Duffy DL,Other measurement,initial,2010-07-17,GCST000732,Nevus count
8640,European,5127.0,20602913.0,Duffy DL,Other measurement,replication,2010-07-17,GCST000732,Nevus count
6578,European,1398.0,20639880.0,Liu X,Cancer,initial,2010-07-18,GCST000733,Primary biliary cholangitis
4650,European,37.0,20639878.0,Singer JB,Digestive system disorder,initial,2010-07-18,GCST000735,Lumiracoxib-related liver injury
4699,European,79.0,20639878.0,Singer JB,Digestive system disorder,replication,2010-07-18,GCST000735,Lumiracoxib-related liver injury
13800,Other/Mixed,176.0,20639878.0,Singer JB,Digestive system disorder,initial,2010-07-18,GCST000735,Lumiracoxib-related liver injury
13590,Other/Mixed,1.0,20639878.0,Singer JB,Digestive system disorder,initial,2010-07-18,GCST000735,Lumiracoxib-related liver injury
9634,European,9372.0,20639881.0,Conde L,Cancer,replication,2010-07-18,GCST000734,Follicular lymphoma
13591,Other/Mixed,1.0,20639878.0,Singer JB,Digestive system disorder,replication,2010-07-18,GCST000735,Lumiracoxib-related liver injury
6598,European,1431.0,20639881.0,Conde L,Cancer,initial,2010-07-18,GCST000734,Follicular lymphoma
8288,European,4187.0,20639880.0,Liu X,Cancer,replication,2010-07-18,GCST000733,Primary biliary cholangitis
12737,Hispanic or Latin American,16.0,20639878.0,Singer JB,Digestive system disorder,replication,2010-07-18,GCST000735,Lumiracoxib-related liver injury
12719,Hispanic or Latin American,3.0,20639878.0,Singer JB,Digestive system disorder,initial,2010-07-18,GCST000735,Lumiracoxib-related liver injury
13904,Other/Mixed,405.0,20639878.0,Singer JB,Digestive system disorder,replication,2010-07-18,GCST000735,Lumiracoxib-related liver injury
9567,European,8919.0,20661308.0,Kapur K,Other measurement,initial,2010-07-22,GCST000736,Calcium levels
8265,European,4126.0,20661308.0,Kapur K,Other measurement,replication,2010-07-22,GCST000736,Calcium levels
3441,Asian,3947.0,20661308.0,Kapur K,Other measurement,initial,2010-07-22,GCST000736,Calcium levels
6793,European,1660.0,20657596.0,Johansen CT,"Metabolic disorder, Lipid or lipoprotein measurement",initial,2010-07-25,GCST000737,Hypertriglyceridemia
12767,Hispanic or Latin American,85.0,20659327.0,Kariuki SN,Immune system disorder,replication,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
615,African American or Afro-Caribbean,280.0,20659327.0,Kariuki SN,Immune system disorder,replication,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
4834,European,173.0,20659327.0,Kariuki SN,Immune system disorder,replication,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
12743,Hispanic or Latin American,32.0,20659327.0,Kariuki SN,Immune system disorder,initial,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
8003,European,3467.0,20662065.0,Clancy RM,Immune system disorder,initial,2010-07-26,GCST000738,Neonatal lupus
1624,Asian,16.0,20659327.0,Kariuki SN,Immune system disorder,initial,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
420,African American or Afro-Caribbean,20.0,20659327.0,Kariuki SN,Immune system disorder,initial,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
4648,European,36.0,20659327.0,Kariuki SN,Immune system disorder,initial,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
6432,European,1230.0,20663923.0,Anney R,Neurological disorder,initial,2010-07-27,GCST000740,Autism
14150,Other/Mixed,1965.0,20663923.0,Anney R,Neurological disorder,replication,2010-07-27,GCST000740,Autism
5832,European,783.0,20663923.0,Anney R,Neurological disorder,replication,2010-07-27,GCST000740,Autism
13770,Other/Mixed,155.0,20663923.0,Anney R,Neurological disorder,initial,2010-07-27,GCST000740,Autism
965,African American or Afro-Caribbean,1815.0,20668430.0,Genovese G,Other disease,initial,2010-07-28,GCST000741,Glomerulosclerosis
5045,European,299.0,20668430.0,Genovese G,Other disease,replication,2010-07-28,GCST000741,Glomerulosclerosis
6733,European,1592.0,20668430.0,Genovese G,Other disease,initial,2010-07-28,GCST000741,Glomerulosclerosis
2193,Asian,518.0,20668459.0,Kim HN,"Other measurement, Body measurement",initial,2010-07-29,GCST000744,Height
3765,Asian,6200.0,20686608.0,Low SK,Cancer,initial,2010-07-29,GCST000745,Pancreatic cancer
6976,European,1892.0,20673876.0,Rietschel M,Neurological disorder,initial,2010-07-29,GCST000743,Major depressive disorder
9356,European,8097.0,20686651.0,Gudbjartsson DF,"Other disease, Other measurement",replication,2010-07-29,GCST000742,Chronic kidney disease and serum creatinine levels
11100,European,38765.0,20686651.0,Gudbjartsson DF,"Other disease, Other measurement",initial,2010-07-29,GCST000742,Chronic kidney disease and serum creatinine levels
6086,European,950.0,20673876.0,Rietschel M,Neurological disorder,replication,2010-07-29,GCST000743,Major depressive disorder
6612,European,1457.0,20675712.0,Reed DR,Biological process,initial,2010-07-31,GCST000746,Bitter taste response
4690,European,73.0,20675712.0,Reed DR,Biological process,replication,2010-07-31,GCST000746,Bitter taste response
3427,Asian,3869.0,20676096.0,Zhang H,Cancer,replication,2010-08-01,GCST000752,Hepatocellular carcinoma
1603,Asian,8.0,20670164.0,Horinouchi M,Cancer,initial,2010-08-01,GCST000749,Acute lymphoblastic leukemia (childhood)
8734,European,5415.0,20732625.0,Neale BM,Neurological disorder,initial,2010-08-01,GCST000751,Attention deficit hyperactivity disorder
3975,Asian,8416.0,20676098.0,Takata R,Cancer,replication,2010-08-01,GCST000750,Prostate cancer
2319,Asian,707.0,20676096.0,Zhang H,Cancer,initial,2010-08-01,GCST000752,Hepatocellular carcinoma
1625,Asian,16.0,20670164.0,Horinouchi M,Cancer,replication,2010-08-01,GCST000749,Acute lymphoblastic leukemia (childhood)
9051,European,6707.0,20707712.0,Mosing MA,Other trait,initial,2010-08-01,GCST000747,Self-rated health
3579,Asian,4969.0,20676098.0,Takata R,Cancer,initial,2010-08-01,GCST000750,Prostate cancer
3193,Asian,2554.0,20694148.0,Zabaneh D,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2010-08-04,GCST000753,Metabolic syndrome
3098,Asian,2240.0,20694148.0,Zabaneh D,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",replication,2010-08-04,GCST000753,Metabolic syndrome
8637,European,5117.0,20691247.0,Verweij KJ,Other trait,initial,2010-08-04,GCST000754,Personality dimensions
3556,Asian,4699.0,20700438.0,Hsiung CA,Cancer,replication,2010-08-05,GCST000761,Lung adenocarcinoma
9488,European,8463.0,20700443.0,Meyer TE,Other measurement,replication,2010-08-05,GCST000756,Magnesium levels
10217,European,15366.0,20700443.0,Meyer TE,Other measurement,initial,2010-08-05,GCST000756,Magnesium levels
11749,European,100184.0,20686565.0,Teslovich TM,Lipid or lipoprotein measurement,initial,2010-08-05,GCST000760,"Cholesterol, total"
7940,European,3351.0,20732627.0,Neale BM,Neurological disorder,initial,2010-08-05,GCST000757,Attention deficit hyperactivity disorder
2570,Asian,1169.0,20700438.0,Hsiung CA,Cancer,initial,2010-08-05,GCST000761,Lung adenocarcinoma
11748,European,99900.0,20686565.0,Teslovich TM,Lipid or lipoprotein measurement,initial,2010-08-05,GCST000755,HDL cholesterol
11739,European,95454.0,20686565.0,Teslovich TM,"Lipid or lipoprotein measurement, Other measurement",initial,2010-08-05,GCST000759,LDL cholesterol
11741,European,96598.0,20686565.0,Teslovich TM,Lipid or lipoprotein measurement,initial,2010-08-05,GCST000758,Triglycerides
296,African,6066.0,20694014.0,Thye T,"Other disease, Other measurement",replication,2010-08-08,GCST000764,Tuberculosis
7276,European,2280.0,20694013.0,Davila S,Other disease,replication,2010-08-08,GCST000762,Meningococcal disease
8662,European,5178.0,20694013.0,Davila S,Other disease,initial,2010-08-08,GCST000762,Meningococcal disease
292,African,5359.0,20694014.0,Thye T,"Other disease, Other measurement",initial,2010-08-08,GCST000764,Tuberculosis
6651,European,1520.0,20694011.0,Ferreira RC,Other measurement,initial,2010-08-08,GCST000763,Immunoglobulin A
6430,European,1228.0,20694011.0,Ferreira RC,Other measurement,replication,2010-08-08,GCST000763,Immunoglobulin A
4962,European,236.0,20708005.0,Chalasani N,"Liver enzyme measurement, Cancer, Digestive system disorder",initial,2010-08-10,GCST000765,Non-alcoholic fatty liver disease histology (other)
4960,European,236.0,20708005.0,Chalasani N,"Cancer, Digestive system disorder",initial,2010-08-10,GCST000766,Non-alcoholic fatty liver disease histology (lobular)
4961,European,236.0,20708005.0,Chalasani N,"Cancer, Digestive system disorder",initial,2010-08-10,GCST000767,Non-alcoholic fatty liver disease histology (AST)
10530,European,20611.0,20705733.0,O'Seaghdha CM,Other measurement,initial,2010-08-12,GCST000769,Calcium levels
7365,European,2383.0,20709820.0,Kong X,Other disease,initial,2010-08-13,GCST000770,Emphysema-related traits
8212,European,3986.0,20711177.0,Hamza TH,Neurological disorder,initial,2010-08-15,GCST000772,Parkinson's disease
3276,Asian,2892.0,20711176.0,Nakashima M,Other disease,replication,2010-08-15,GCST000773,Keloid
5950,European,865.0,20711174.0,Hor H,Neurological disorder,replication,2010-08-15,GCST000771,Narcolepsy
6464,European,1264.0,20711174.0,Hor H,Neurological disorder,initial,2010-08-15,GCST000771,Narcolepsy
2554,Asian,1122.0,20711176.0,Nakashima M,Other disease,initial,2010-08-15,GCST000773,Keloid
8287,European,4186.0,20713499.0,Huang J,Neurological disorder,initial,2010-08-16,GCST000774,"Schizophrenia, bipolar disorder and depression (combined)"
8853,European,5882.0,20719862.0,Vitart V,Other measurement,replication,2010-08-18,GCST000775,Central corneal thickness
6605,European,1445.0,20719862.0,Vitart V,Other measurement,initial,2010-08-18,GCST000775,Central corneal thickness
3256,Asian,2810.0,20729853.0,Wang LD,Cancer,initial,2010-08-22,GCST000776,Esophageal cancer
3684,Asian,5623.0,20729852.0,Abnet CC,Cancer,initial,2010-08-22,GCST000777,Esophageal cancer and gastric cancer
4349,Asian,19526.0,20729853.0,Wang LD,Cancer,replication,2010-08-22,GCST000776,Esophageal cancer
5149,European,369.0,20811658.0,Uhl GR,Biological process,initial,2010-08-24,GCST000778,Smoking cessation
8493,European,4811.0,20800221.0,Terracciano A,Neurological disorder,initial,2010-08-25,GCST000779,Depression (quantitative trait)
5999,European,902.0,20801718.0,Laaksovirta H,Neurological disorder,initial,2010-08-27,GCST000781,Amyotrophic lateral sclerosis
6559,European,1376.0,20802025.0,Tang W,Hematological measurement,replication,2010-08-27,GCST000780,Protein C levels
9349,European,8048.0,20802025.0,Tang W,Hematological measurement,initial,2010-08-27,GCST000780,Protein C levels
11177,European,43264.0,20802479.0,Anttila V,Cardiovascular disease,replication,2010-08-29,GCST000782,Migraine
10070,European,13478.0,20802479.0,Anttila V,Cardiovascular disease,initial,2010-08-29,GCST000782,Migraine
4966,European,240.0,20808326.0,Krumbiegel M,Neurological disorder,initial,2010-09-01,GCST000784,Pseudoexfoliation syndrome
6590,European,1413.0,20808326.0,Krumbiegel M,Neurological disorder,replication,2010-09-01,GCST000784,Pseudoexfoliation syndrome
12828,Hispanic or Latin American,286.0,20871662.0,Fu YP,Metabolic disorder,initial,2010-09-02,GCST000786,Diabetic retinopathy
4364,Asian,20289.0,20818381.0,Yamauchi T,Metabolic disorder,replication,2010-09-05,GCST000787,Type 2 diabetes
10226,European,15595.0,20818381.0,Yamauchi T,Metabolic disorder,replication,2010-09-05,GCST000787,Type 2 diabetes
3886,Asian,7541.0,20818381.0,Yamauchi T,Metabolic disorder,initial,2010-09-05,GCST000787,Type 2 diabetes
2546,Asian,1108.0,20832056.0,Ikeda M,Neurological disorder,initial,2010-09-08,GCST000788,Schizophrenia
7983,European,3417.0,20832056.0,Ikeda M,Neurological disorder,replication,2010-09-08,GCST000788,Schizophrenia
3443,Asian,3962.0,20832056.0,Ikeda M,Neurological disorder,replication,2010-09-08,GCST000788,Schizophrenia
5467,European,525.0,20838585.0,Smith EN,"Body measurement, Other disease, Lipid or lipoprotein measurement",initial,2010-09-09,GCST004704,Cardiovascular risk factors
7397,European,2442.0,20838585.0,Smith EN,"Body measurement, Other disease, Lipid or lipoprotein measurement, Other measurement",replication,2010-09-09,GCST000789,Cardiovascular risk factors (age interaction)
7396,European,2442.0,20838585.0,Smith EN,"Body measurement, Other disease, Lipid or lipoprotein measurement",replication,2010-09-09,GCST004704,Cardiovascular risk factors
5468,European,525.0,20838585.0,Smith EN,"Body measurement, Other disease, Lipid or lipoprotein measurement, Other measurement",initial,2010-09-09,GCST000789,Cardiovascular risk factors (age interaction)
5027,European,290.0,20825314.0,Baratz KH,Neurological disorder,initial,2010-09-09,GCST000790,Fuchs's corneal dystrophy
6283,European,1093.0,20826269.0,Panicker V,Other trait,replication,2010-09-10,GCST000791,Thyroid function
7058,European,2014.0,20826269.0,Panicker V,Other trait,initial,2010-09-10,GCST000791,Thyroid function
2125,Asian,444.0,20833655.0,Cha PC,Response to drug,replication,2010-09-10,GCST000792,Warfarin maintenance dose
2735,Asian,1508.0,20833655.0,Cha PC,Response to drug,initial,2010-09-10,GCST000792,Warfarin maintenance dose
8716,European,5328.0,20835239.0,Solouki AM,Other trait,initial,2010-09-12,GCST000795,Refractive error
10065,European,13414.0,20835236.0,Hysi PG,Other trait,replication,2010-09-12,GCST000794,Refractive error
11036,European,36140.0,20835238.0,Thorleifsson G,Neurological disorder,initial,2010-09-12,GCST000793,Glaucoma (primary open-angle)
9779,European,10280.0,20835239.0,Solouki AM,Other trait,replication,2010-09-12,GCST000795,Refractive error
8304,European,4239.0,20835238.0,Thorleifsson G,Neurological disorder,replication,2010-09-12,GCST000793,Glaucoma (primary open-angle)
8315,European,4270.0,20835236.0,Hysi PG,Other trait,initial,2010-09-12,GCST000794,Refractive error
3221,Asian,2729.0,20862305.0,Shu XO,Metabolic disorder,initial,2010-09-16,GCST000796,Type 2 diabetes
6896,European,1782.0,20849430.0,Franklin CS,Other measurement,initial,2010-09-16,GCST000798,Glycated hemoglobin levels
14266,Other/Mixed,21680.0,20862305.0,Shu XO,Metabolic disorder,replication,2010-09-16,GCST000796,Type 2 diabetes
2739,Asian,1521.0,20844546.0,Adachi S,Other disease,initial,2010-09-16,GCST000797,Endometriosis
3759,Asian,6132.0,20877124.0,Hiura Y,Cardiovascular disease,replication,2010-09-18,GCST000799,Hypertension
2466,Asian,936.0,20877124.0,Hiura Y,Cardiovascular disease,initial,2010-09-18,GCST000799,Hypertension
11404,European,60473.0,20852632.0,Goode EL,Cancer,replication,2010-09-19,GCST000802,Ovarian cancer
10487,European,19570.0,20852633.0,Bolton KL,Cancer,replication,2010-09-19,GCST000800,Ovarian cancer
8264,European,4122.0,20852632.0,Goode EL,Cancer,initial,2010-09-19,GCST000802,Ovarian cancer
8881,European,5986.0,20852631.0,Antoniou AC,Cancer,replication,2010-09-19,GCST000801,Breast cancer
7366,European,2383.0,20852631.0,Antoniou AC,Cancer,initial,2010-09-19,GCST000801,Breast cancer
8263,European,4121.0,20852633.0,Bolton KL,Cancer,initial,2010-09-19,GCST000800,Ovarian cancer
11216,European,46368.0,20858683.0,Soranzo N,Other measurement,initial,2010-09-21,GCST000803,Glycated hemoglobin levels
14151,Other/Mixed,2035.0,20885792.0,Naj AC,Neurological disorder,initial,2010-09-23,GCST000808,Alzheimer's disease (late onset)
4076,Asian,9665.0,20864672.0,Waterworth DM,"Lipid or lipoprotein measurement, Other measurement",replication,2010-09-23,GCST000807,LDL cholesterol
10383,European,17723.0,20864672.0,Waterworth DM,"Lipid or lipoprotein measurement, Other measurement",initial,2010-09-23,GCST000807,LDL cholesterol
4075,Asian,9665.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,replication,2010-09-23,GCST000809,Triglycerides
4074,Asian,9665.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,replication,2010-09-23,GCST000805,HDL cholesterol
11075,European,37774.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,replication,2010-09-23,GCST000809,Triglycerides
11076,European,37774.0,20864672.0,Waterworth DM,"Lipid or lipoprotein measurement, Other measurement",replication,2010-09-23,GCST000807,LDL cholesterol
10382,European,17723.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,initial,2010-09-23,GCST000809,Triglycerides
5961,European,872.0,20861866.0,Kopplin LJ,Neurological disorder,initial,2010-09-23,GCST000806,Age-related macular degeneration
10381,European,17723.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,initial,2010-09-23,GCST000805,HDL cholesterol
11074,European,37774.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,replication,2010-09-23,GCST000805,HDL cholesterol
8125,European,3762.0,20861866.0,Kopplin LJ,Neurological disorder,replication,2010-09-23,GCST000806,Age-related macular degeneration
14270,Other/Mixed,26475.0,20860503.0,Moffatt MF,Other disease,initial,2010-09-23,GCST000804,Asthma
9480,European,8428.0,20872241.0,Li J,Cancer,initial,2010-09-26,GCST000811,Breast cancer
4109,Asian,10242.0,20871597.0,Miki D,Cancer,replication,2010-09-26,GCST000810,Lung adenocarcinoma
3280,Asian,2904.0,20871597.0,Miki D,Cancer,initial,2010-09-26,GCST000810,Lung adenocarcinoma
5971,European,878.0,20876420.0,Ingle JN,Response to drug,initial,2010-09-27,GCST000813,Adverse response to aromatase inhibitors
5720,European,706.0,20877300.0,Perroud N,"Biological process, Other measurement",initial,2010-09-28,GCST000816,Suicidal ideation
3062,Asian,2162.0,20876614.0,Yoon KA,Cancer,initial,2010-09-28,GCST000815,Non-small cell lung cancer
7735,European,3012.0,20927387.0,Kullo IJ,Hematological measurement,initial,2010-09-28,GCST000814,Red blood cell traits
3107,Asian,2274.0,20876614.0,Yoon KA,Cancer,replication,2010-09-28,GCST000815,Non-small cell lung cancer
11270,European,50074.0,20881960.0,Lango Allen H,"Other measurement, Body measurement",replication,2010-09-29,GCST000817,Height
11941,European,133653.0,20881960.0,Lango Allen H,"Other measurement, Body measurement",initial,2010-09-29,GCST000817,Height
10616,European,22054.0,20884846.0,Yang Q,"Metabolic disorder, Other measurement",replication,2010-09-30,GCST000818,Urate levels
10805,European,28283.0,20884846.0,Yang Q,"Metabolic disorder, Other measurement",initial,2010-09-30,GCST000818,Urate levels
8301,European,4234.0,20889312.0,Wang KS,Neurological disorder,initial,2010-10-01,GCST000821,Bipolar disorder and schizophrenia
12744,Hispanic or Latin American,32.0,20920776.0,DeWan AT,Other disease,initial,2010-10-01,GCST000819,Asthma
13657,Other/Mixed,14.0,20920776.0,DeWan AT,Other disease,initial,2010-10-01,GCST000819,Asthma
12747,Hispanic or Latin American,34.0,20920776.0,DeWan AT,Other disease,replication,2010-10-01,GCST000819,Asthma
10103,European,13844.0,20801717.0,Shatunov A,Neurological disorder,initial,2010-10-01,GCST000820,Amyotrophic lateral sclerosis
432,African American or Afro-Caribbean,29.0,20920776.0,DeWan AT,Other disease,replication,2010-10-01,GCST000819,Asthma
417,African American or Afro-Caribbean,15.0,20920776.0,DeWan AT,Other disease,initial,2010-10-01,GCST000819,Asthma
13717,Other/Mixed,51.0,20920776.0,DeWan AT,Other disease,replication,2010-10-01,GCST000819,Asthma
5167,European,385.0,20920776.0,DeWan AT,Other disease,replication,2010-10-01,GCST000819,Asthma
4657,European,47.0,20920776.0,DeWan AT,Other disease,initial,2010-10-01,GCST000819,Asthma
496,African American or Afro-Caribbean,93.0,20923822.0,Niu N,Biological process,initial,2010-10-05,GCST000823,Radiation response
14018,Other/Mixed,738.0,20921969.0,Aberg K,Response to drug,initial,2010-10-05,GCST000822,Antipsychotic drug-induced QTc interval prolongation
1718,Asian,95.0,20923822.0,Niu N,Biological process,initial,2010-10-05,GCST000823,Radiation response
481,African American or Afro-Caribbean,79.0,20932654.0,Kerns SL,"Cancer, Other disease, Biological process",initial,2010-10-05,GCST000824,Erectile dysfunction and prostate cancer treatment
4726,European,89.0,20923822.0,Niu N,Biological process,initial,2010-10-05,GCST000823,Radiation response
5172,European,390.0,20932310.0,Han MR,Other measurement,initial,2010-10-08,GCST000826,Cerebrospinal T-tau levels
5173,European,390.0,20932310.0,Han MR,Other measurement,initial,2010-10-08,GCST000827,Cerebrospinal fluid AB1-42 levels
3449,Asian,4001.0,20887962.0,Jee SH,Other measurement,initial,2010-10-08,GCST000828,Adiponectin levels
3115,Asian,2304.0,20887962.0,Jee SH,Other measurement,replication,2010-10-08,GCST000828,Adiponectin levels
5171,European,390.0,20932310.0,Han MR,Other measurement,initial,2010-10-08,GCST000825,Cerebrospinal P-tau181p levels
11906,European,125931.0,20935630.0,Speliotes EK,"Body measurement, Other measurement",replication,2010-10-10,GCST000830,Body mass index
11898,European,123865.0,20935630.0,Speliotes EK,"Body measurement, Other measurement",initial,2010-10-10,GCST000830,Body mass index
11560,European,77167.0,20935629.0,Heid IM,"Other measurement, Body measurement",initial,2010-10-10,GCST000829,Waist-hip ratio
11828,European,113636.0,20935629.0,Heid IM,"Other measurement, Body measurement",replication,2010-10-10,GCST000829,Waist-hip ratio
4933,European,217.0,20939080.0,Greenbaum L,Neurological disorder,initial,2010-10-11,GCST000831,Tardive dyskinesia in schizophrenia
13648,Other/Mixed,8.0,20939080.0,Greenbaum L,Neurological disorder,initial,2010-10-11,GCST000831,Tardive dyskinesia in schizophrenia
13773,Other/Mixed,170.0,20939080.0,Greenbaum L,Neurological disorder,replication,2010-10-11,GCST000831,Tardive dyskinesia in schizophrenia
504,African American or Afro-Caribbean,102.0,20939080.0,Greenbaum L,Neurological disorder,initial,2010-10-11,GCST000831,Tardive dyskinesia in schizophrenia
2034,Asian,360.0,20947153.0,Ueta M,Other disease,initial,2010-10-12,GCST000832,Stevens-Johnson syndrome
8765,European,5488.0,20953186.0,Huffmeier U,Immune system disorder,replication,2010-10-17,GCST000835,Psoriatic arthritis
9196,European,7353.0,20953190.0,Strange A,Immune system disorder,initial,2010-10-17,GCST000833,Psoriasis
9525,European,8638.0,20953190.0,Strange A,Immune system disorder,replication,2010-10-17,GCST000833,Psoriasis
9310,European,7909.0,20953188.0,Ellinghaus E,Immune system disorder,replication,2010-10-17,GCST000836,Psoriasis
6753,European,1618.0,20953188.0,Ellinghaus E,Immune system disorder,initial,2010-10-17,GCST000836,Psoriasis
6616,European,1460.0,20953186.0,Huffmeier U,Immune system disorder,initial,2010-10-17,GCST000835,Psoriatic arthritis
2874,Asian,1780.0,20966902.0,Croteau-Chonka DC,"Body measurement, Other measurement",initial,2010-10-21,GCST000840,Body mass index
4691,European,73.0,20971583.0,Ojwang JO,Other disease,initial,2010-10-22,GCST000841,Dupuytren's disease
9324,European,7962.0,20972440.0,Houlston RS,Cancer,initial,2010-10-24,GCST000843,Colorectal cancer
11368,European,56656.0,20972438.0,Rothman N,Cancer,replication,2010-10-24,GCST000842,Bladder cancer
10869,European,30420.0,20972440.0,Houlston RS,Cancer,initial,2010-10-24,GCST000843,Colorectal cancer
9528,European,8652.0,20972438.0,Rothman N,Cancer,initial,2010-10-24,GCST000842,Bladder cancer
5649,European,655.0,20978177.0,Penney KL,"Cancer, Other measurement",replication,2010-10-26,GCST000844,Prostate cancer mortality
5522,European,564.0,20978177.0,Penney KL,"Cancer, Other measurement",initial,2010-10-26,GCST000844,Prostate cancer mortality
11037,European,36386.0,21082022.0,Padmanabhan S,Cardiovascular disease,replication,2010-10-28,GCST000849,Hypertension
7429,European,2486.0,21060860.0,Gaudet MM,Cancer,replication,2010-10-28,GCST000846,Breast cancer in BRCA2 mutation carriers
6816,European,1703.0,21060860.0,Gaudet MM,Cancer,initial,2010-10-28,GCST000846,Breast cancer in BRCA2 mutation carriers
8896,European,6041.0,20981099.0,Kong A,Other measurement,initial,2010-10-28,GCST000848,Recombination measurement (females)
7913,European,3320.0,21082022.0,Padmanabhan S,Cardiovascular disease,initial,2010-10-28,GCST000849,Hypertension
9027,European,6652.0,21060863.0,Ikram MK,Other measurement,replication,2010-10-28,GCST000847,Retinal vascular caliber
8348,European,4389.0,20981099.0,Kong A,Other measurement,initial,2010-10-28,GCST000845,Recombination measurement (males)
10216,European,15358.0,21060863.0,Ikram MK,Other measurement,initial,2010-10-28,GCST000847,Retinal vascular caliber
5411,European,502.0,21037115.0,Wan ES,"Other disease, Body measurement",replication,2010-10-29,GCST000850,Body mass in chronic obstructive pulmonary disease
7706,European,2950.0,21037115.0,Wan ES,"Other disease, Body measurement",initial,2010-10-29,GCST000850,Body mass in chronic obstructive pulmonary disease
8828,European,5788.0,21037568.0,Enciso-Mora V,Cancer,initial,2010-10-31,GCST000851,Hodgkin's lymphoma
8759,European,5473.0,21037568.0,Enciso-Mora V,Cancer,replication,2010-10-31,GCST000851,Hodgkin's lymphoma
8349,European,4390.0,21041247.0,Perlis RH,"Biological process, Neurological disorder",initial,2010-11-01,GCST000854,Suicide risk
7576,European,2698.0,21041247.0,Perlis RH,"Biological process, Neurological disorder",replication,2010-11-01,GCST000854,Suicide risk
8001,European,3462.0,20848476.0,Haritunians T,Immune system disorder,initial,2010-11-01,GCST000853,Ulcerative colitis
7331,European,2334.0,21041692.0,Denny JC,Cardiovascular measurement,initial,2010-11-01,GCST000852,Atrioventricular conduction
2675,Asian,1413.0,21044949.0,Yang J,Immune system disorder,replication,2010-11-02,GCST000858,Systemic lupus erythematosus
5948,European,862.0,21184583.0,Zlojutro M,Other measurement,replication,2010-11-02,GCST000857,Event-related brain oscillations
8907,European,6104.0,21042317.0,Wray NR,Neurological disorder,initial,2010-11-02,GCST000856,Major depressive disorder
2858,Asian,1772.0,21044949.0,Yang J,Immune system disorder,initial,2010-11-02,GCST000858,Systemic lupus erythematosus
3457,Asian,4071.0,21044949.0,Yang J,Immune system disorder,replication,2010-11-02,GCST000858,Systemic lupus erythematosus
13740,Other/Mixed,80.0,21184583.0,Zlojutro M,Other measurement,replication,2010-11-02,GCST000857,Event-related brain oscillations
9093,European,6880.0,21044948.0,Spencer CC,Neurological disorder,initial,2010-11-02,GCST000855,Parkinson's disease
623,African American or Afro-Caribbean,293.0,21184583.0,Zlojutro M,Other measurement,initial,2010-11-02,GCST000857,Event-related brain oscillations
9011,European,6560.0,21042317.0,Wray NR,Neurological disorder,replication,2010-11-02,GCST000856,Major depressive disorder
5814,European,771.0,21184583.0,Zlojutro M,Other measurement,initial,2010-11-02,GCST000857,Event-related brain oscillations
537,African American or Afro-Caribbean,153.0,21184583.0,Zlojutro M,Other measurement,replication,2010-11-02,GCST000857,Event-related brain oscillations
7741,European,3023.0,21044948.0,Spencer CC,Neurological disorder,replication,2010-11-02,GCST000855,Parkinson's disease
1831,Asian,180.0,21072201.0,Kim JH,Other trait,initial,2010-11-03,GCST000859,Aspirin intolerance in asthmatics
2236,Asian,592.0,21072201.0,Kim JH,Other trait,replication,2010-11-03,GCST000859,Aspirin intolerance in asthmatics
1754,Asian,117.0,21048783.0,Kamada F,Cardiovascular disease,initial,2010-11-04,GCST000860,Moyamoya disease
12937,Hispanic or Latin American,677.0,21051598.0,Pereyra F,Other disease,initial,2010-11-04,GCST000863,HIV-1 control
6672,European,1534.0,21057379.0,Curtis D,Neurological disorder,initial,2010-11-04,GCST000862,Bipolar disorder and schizophrenia
6827,European,1712.0,21051598.0,Pereyra F,Other disease,initial,2010-11-04,GCST000863,HIV-1 control
835,African American or Afro-Caribbean,1035.0,21668797.0,Agrawal A,Neurological disorder,initial,2010-11-04,GCST000861,Cannabis dependence
882,African American or Afro-Caribbean,1233.0,21051598.0,Pereyra F,Other disease,initial,2010-11-04,GCST000863,HIV-1 control
1744,Asian,108.0,21048783.0,Kamada F,Cardiovascular disease,replication,2010-11-04,GCST000860,Moyamoya disease
7060,European,2019.0,21668797.0,Agrawal A,Neurological disorder,initial,2010-11-04,GCST000861,Cannabis dependence
669,African American or Afro-Caribbean,401.0,21059989.0,Lee JH,Neurological disorder,initial,2010-11-08,GCST000864,Alzheimer's disease
5915,European,841.0,21059979.0,Shen H,"Lipid or lipoprotein measurement, Other measurement",initial,2010-11-08,GCST000866,LDL cholesterol
12748,Hispanic or Latin American,34.0,21059989.0,Lee JH,Neurological disorder,initial,2010-11-08,GCST000864,Alzheimer's disease
5655,European,658.0,21059989.0,Lee JH,Neurological disorder,initial,2010-11-08,GCST000864,Alzheimer's disease
5736,European,720.0,21061259.0,Plant D,"Immune system disorder, Response to drug",replication,2010-11-08,GCST000865,Response to anti-TNF therapy in rheumatoid arthritis
5525,European,566.0,21061259.0,Plant D,"Immune system disorder, Response to drug",initial,2010-11-08,GCST000865,Response to anti-TNF therapy in rheumatoid arthritis
5664,European,663.0,21059979.0,Shen H,"Lipid or lipoprotein measurement, Other measurement",replication,2010-11-08,GCST000866,LDL cholesterol
8154,European,3839.0,21059989.0,Lee JH,Neurological disorder,replication,2010-11-08,GCST000864,Alzheimer's disease
13807,Other/Mixed,186.0,21059989.0,Lee JH,Neurological disorder,replication,2010-11-08,GCST000864,Alzheimer's disease
5529,European,573.0,21051773.0,Scerri TS,"Other trait, Neurological disorder",replication,2010-11-09,GCST000868,Handedness in dyslexia
8668,European,5200.0,21062454.0,Li J,Cancer,initial,2010-11-09,GCST000867,Breast cancer (estrogen-receptor negative)
3155,Asian,2428.0,21068099.0,Evangelou E,Other disease,replication,2010-11-10,GCST000869,Osteoarthritis
10030,European,12868.0,21068099.0,Evangelou E,Other disease,replication,2010-11-10,GCST000869,Osteoarthritis
11089,European,38280.0,21068099.0,Evangelou E,Other disease,initial,2010-11-10,GCST000869,Osteoarthritis
1742,Asian,105.0,21079520.0,Sato Y,"Other measurement, Cancer",initial,2010-11-12,GCST000871,Non-small cell lung cancer (survival)
9160,European,7170.0,21076409.0,Sotoodehnia N,Cardiovascular measurement,replication,2010-11-14,GCST000872,QRS duration
11136,European,40407.0,21076409.0,Sotoodehnia N,Cardiovascular measurement,initial,2010-11-14,GCST000872,QRS duration
8474,European,4766.0,21079607.0,Wang K,Metabolic disorder,initial,2010-11-16,GCST000873,Anorexia nervosa
9782,European,10296.0,21084426.0,Saad M,Neurological disorder,replication,2010-11-17,GCST000874,Parkinson's disease
7742,European,3023.0,21084426.0,Saad M,Neurological disorder,initial,2010-11-17,GCST000874,Parkinson's disease
7152,European,2136.0,21124955.0,Marzi C,Lipid or lipoprotein measurement,replication,2010-11-18,GCST000876,Amyloid A serum levels
8293,European,4212.0,21124955.0,Marzi C,Lipid or lipoprotein measurement,initial,2010-11-18,GCST000876,Amyloid A serum levels
7683,European,2905.0,21088011.0,Erdmann J,Cardiovascular disease,initial,2010-11-18,GCST000875,Coronary heart disease
8151,European,3835.0,21124946.0,Paternoster L,Other measurement,replication,2010-11-18,GCST000877,Bone mineral density
10255,European,16131.0,21088011.0,Erdmann J,Cardiovascular disease,replication,2010-11-18,GCST000875,Coronary heart disease
6992,European,1934.0,21124946.0,Paternoster L,Other measurement,initial,2010-11-18,GCST000877,Bone mineral density
3321,Asian,3087.0,21095009.0,Li YJ,Other trait,replication,2010-11-20,GCST000878,Myopia (pathological)
2493,Asian,980.0,21095009.0,Li YJ,Other trait,initial,2010-11-20,GCST000878,Myopia (pathological)
10878,European,30962.0,21102463.0,Franke A,Digestive system disorder,replication,2010-11-21,GCST000879,Crohn's disease
10589,European,21389.0,21102463.0,Franke A,Digestive system disorder,initial,2010-11-21,GCST000879,Crohn's disease
11664,European,87802.0,21102462.0,Elks CE,Other measurement,initial,2010-11-21,GCST000880,Menarche (age at onset)
10164,European,14731.0,21102462.0,Elks CE,Other measurement,replication,2010-11-21,GCST000880,Menarche (age at onset)
2785,Asian,1628.0,21104366.0,Tan L,Other measurement,replication,2010-11-23,GCST000881,Bone mineral density (wrist)
6167,European,1000.0,21104366.0,Tan L,Other measurement,initial,2010-11-23,GCST000881,Bone mineral density (wrist)
5684,European,673.0,21106707.0,Gu J,"Response to drug, Other measurement",initial,2010-11-24,GCST000882,Response to bleomycin (chromatid breaks)
14019,Other/Mixed,738.0,21107309.0,McClay JL,Biological process,initial,2010-11-24,GCST000883,Response to antipsychotic treatment in schizophrenia (working memory)
14021,Other/Mixed,738.0,21107309.0,McClay JL,Response to drug,initial,2010-11-24,GCST000884,Response to antipsychotic treatment
14020,Other/Mixed,738.0,21107309.0,McClay JL,Biological process,initial,2010-11-24,GCST000885,Response to antipsychotic treatment in schizophrenia (reasoning)
5904,European,834.0,21106707.0,Gu J,"Response to drug, Other measurement",replication,2010-11-24,GCST000882,Response to bleomycin (chromatid breaks)
8690,European,5277.0,21098978.0,Sherva R,Neurological disorder,replication,2010-11-25,GCST000886,Alzheimer's disease
2827,Asian,1733.0,21107343.0,Aoki A,Cardiovascular disease,initial,2010-11-25,GCST000887,Myocardial infarction
13844,Other/Mixed,266.0,21098978.0,Sherva R,Neurological disorder,initial,2010-11-25,GCST000886,Alzheimer's disease
4154,Asian,11397.0,21107343.0,Aoki A,Cardiovascular disease,replication,2010-11-25,GCST000887,Myocardial infarction
6249,European,1067.0,21113153.0,van der Zanden LF,Other disease,replication,2010-11-28,GCST000888,Hypospadias
6037,European,930.0,21113153.0,van der Zanden LF,Other disease,initial,2010-11-28,GCST000888,Hypospadias
1988,Asian,305.0,21118971.0,Wu C,Cancer,replication,2010-11-30,GCST000896,Small-cell lung cancer (survival)
6064,European,939.0,21116278.0,Furney SJ,Other measurement,initial,2010-11-30,GCST000899,Entorhinal cortical volume
6059,European,939.0,21116278.0,Furney SJ,"Neurological disorder, Other measurement",initial,2010-11-30,GCST000893,Entorhinal cortical volume (Alzheimer's disease interaction)
1933,Asian,245.0,21118971.0,Wu C,Cancer,initial,2010-11-30,GCST000896,Small-cell lung cancer (survival)
6099,European,963.0,21116278.0,Furney SJ,Other measurement,initial,2010-11-30,GCST000891,Whole-brain volume
6058,European,939.0,21116278.0,Furney SJ,"Neurological disorder, Other measurement",initial,2010-11-30,GCST000889,Entorhinal cortical thickness (Alzheimer's disease interaction)
6060,European,939.0,21116278.0,Furney SJ,"Neurological disorder, Other measurement",initial,2010-11-30,GCST000897,Hippocampal volume (Alzheimer's disease interaction)
6098,European,963.0,21116278.0,Furney SJ,"Neurological disorder, Other measurement",initial,2010-11-30,GCST000895,Whole-brain volume (Alzheimer's disease interaction)
6061,European,939.0,21116278.0,Furney SJ,Other measurement,initial,2010-11-30,GCST000890,Hippocampal volume
6065,European,939.0,21116278.0,Furney SJ,"Other measurement, Neurological disorder",initial,2010-11-30,GCST000892,Total ventricular volume (Alzheimer's disease interaction)
6062,European,939.0,21116278.0,Furney SJ,Other measurement,initial,2010-11-30,GCST000894,Entorhinal cortical thickness
6063,European,939.0,21116278.0,Furney SJ,Other measurement,initial,2010-11-30,GCST000898,Total ventricular volume
2130,Asian,451.0,21105107.0,Clifford RJ,Cancer,initial,2010-12-01,GCST000902,Hepatocellular carcinoma
2252,Asian,622.0,21105107.0,Clifford RJ,Cancer,replication,2010-12-01,GCST000902,Hepatocellular carcinoma
13767,Other/Mixed,140.0,21130132.0,Mick E,Response to drug,initial,2010-12-01,GCST000903,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)
5154,European,374.0,21123754.0,Kim S,"Other measurement, Neurological disorder",initial,2010-12-01,GCST000900,Alzheimer's disease biomarkers
8521,European,4881.0,21124317.0,Wang K,Cancer,initial,2010-12-01,GCST000901,Neuroblastoma
8004,European,3467.0,21124317.0,Wang K,Cancer,replication,2010-12-01,GCST000901,Neuroblastoma
8234,European,4039.0,21130836.0,Luciano M,Biological process,initial,2010-12-03,GCST000905,Information processing speed
5714,European,703.0,21131588.0,Slager SL,Cancer,initial,2010-12-03,GCST000906,Chronic lymphocytic leukemia
6415,European,1217.0,21131588.0,Slager SL,Cancer,replication,2010-12-03,GCST000906,Chronic lymphocytic leukemia
9150,European,7116.0,21131975.0,Purdue MP,Cancer,replication,2010-12-05,GCST000907,Renal cell carcinoma
9984,European,12277.0,21131975.0,Purdue MP,Cancer,initial,2010-12-05,GCST000907,Renal cell carcinoma
5116,European,346.0,21139019.0,Walsh KM,Cancer,initial,2010-12-07,GCST000908,Ileal carcinoids
5579,European,604.0,21150878.0,Ferreira MA,Other disease,replication,2010-12-08,GCST000910,Asthma
7653,European,2832.0,21150878.0,Ferreira MA,Other disease,initial,2010-12-08,GCST000910,Asthma
982,African American or Afro-Caribbean,1994.0,21150874.0,McDonough CW,Metabolic disorder,initial,2010-12-08,GCST000909,Type 2 diabetes nephropathy
917,African American or Afro-Caribbean,1399.0,21150874.0,McDonough CW,Metabolic disorder,replication,2010-12-08,GCST000909,Type 2 diabetes nephropathy
5449,European,518.0,21087763.0,Carrasquillo MM,Other measurement,initial,2010-12-10,GCST000911,Progranulin levels
5315,European,459.0,21087763.0,Carrasquillo MM,Other measurement,replication,2010-12-10,GCST000911,Progranulin levels
1682,Asian,67.0,21149285.0,Ozeki T,Response to drug,replication,2010-12-10,GCST000912,Adverse response to carbamazepine
2463,Asian,934.0,21149285.0,Ozeki T,Response to drug,initial,2010-12-10,GCST000912,Adverse response to carbamazepine
9020,European,6616.0,21149283.0,Oexle K,Other measurement,initial,2010-12-10,GCST000913,Iron status biomarkers
2788,Asian,1639.0,21151128.0,Chen ZJ,Other disease,initial,2010-12-12,GCST000914,Polycystic ovary syndrome
7812,European,3199.0,21151127.0,Melum E,Digestive system disorder,replication,2010-12-12,GCST000915,Primary sclerosing cholangitis
9776,European,10254.0,21151130.0,Painter JN,Other disease,initial,2010-12-12,GCST000916,Endometriosis
4047,Asian,9130.0,21151128.0,Chen ZJ,Other disease,replication,2010-12-12,GCST000914,Polycystic ovary syndrome
8438,European,4663.0,21151130.0,Painter JN,Other disease,replication,2010-12-12,GCST000916,Endometriosis
8094,European,3677.0,21151127.0,Melum E,Digestive system disorder,initial,2010-12-12,GCST000915,Primary sclerosing cholangitis
185,African,1379.0,21160409.0,Petrovski S,"Immune system disorder, Other disease",initial,2010-12-14,GCST000918,HIV-1 susceptibility
7730,European,3000.0,21156761.0,Padyukov L,Immune system disorder,initial,2010-12-14,GCST000917,Rheumatoid arthritis
7138,European,2105.0,21156761.0,Padyukov L,Immune system disorder,replication,2010-12-14,GCST000917,Rheumatoid arthritis
4319,Asian,17176.0,21211798.0,Yamada Y,Cardiovascular disease,replication,2010-12-15,GCST000920,Myocardial infarction
1962,Asian,271.0,21211798.0,Yamada Y,Cardiovascular disease,initial,2010-12-15,GCST000920,Myocardial infarction
9241,European,7538.0,21160077.0,Gudmundsson J,Other measurement,initial,2010-12-15,GCST000919,Serum prostate-specific antigen levels
7359,European,2373.0,21160077.0,Gudmundsson J,Other measurement,replication,2010-12-15,GCST000919,Serum prostate-specific antigen levels
5532,European,576.0,21197116.0,Ryu E,Neurological disorder,initial,2010-12-17,GCST000921,Age-related macular degeneration
13600,Other/Mixed,2.0,21197116.0,Ryu E,Neurological disorder,initial,2010-12-17,GCST000921,Age-related macular degeneration
9,African,12.0,21197116.0,Ryu E,Neurological disorder,initial,2010-12-17,GCST000921,Age-related macular degeneration
14024,Other/Mixed,744.0,21197116.0,Ryu E,Neurological disorder,replication,2010-12-17,GCST000921,Age-related macular degeneration
7892,European,3294.0,21173776.0,de Moor MH,"Biological process, Other measurement",replication,2010-12-21,GCST006328,Extraversion
7893,European,3294.0,21173776.0,de Moor MH,"Neurological disorder, Other measurement",replication,2010-12-21,GCST006327,Neuroticism
7895,European,3294.0,21173776.0,de Moor MH,Other measurement,replication,2010-12-21,GCST006326,Conscientiousness
7896,European,3294.0,21173776.0,de Moor MH,Other measurement,replication,2010-12-21,GCST006329,Agreeableness
10359,European,17375.0,21173776.0,de Moor MH,Other measurement,initial,2010-12-21,GCST000922,Openness
14180,Other/Mixed,2744.0,21177295.0,Panoutsopoulou K,Other disease,replication,2010-12-21,GCST000923,Osteoarthritis
7894,European,3294.0,21173776.0,de Moor MH,Other measurement,replication,2010-12-21,GCST000922,Openness
11355,European,56173.0,21177295.0,Panoutsopoulou K,Other disease,replication,2010-12-21,GCST000923,Osteoarthritis
10361,European,17375.0,21173776.0,de Moor MH,Other measurement,initial,2010-12-21,GCST006329,Agreeableness
10357,European,17375.0,21173776.0,de Moor MH,"Biological process, Other measurement",initial,2010-12-21,GCST006328,Extraversion
9354,European,8071.0,21177295.0,Panoutsopoulou K,Other disease,initial,2010-12-21,GCST000923,Osteoarthritis
10360,European,17375.0,21173776.0,de Moor MH,Other measurement,initial,2010-12-21,GCST006326,Conscientiousness
10358,European,17375.0,21173776.0,de Moor MH,"Neurological disorder, Other measurement",initial,2010-12-21,GCST006327,Neuroticism
462,African American or Afro-Caribbean,56.0,21177773.0,Moyer AM,Response to drug,initial,2010-12-22,GCST000924,Response to acetaminophen (hepatotoxicity)
1673,Asian,60.0,21177773.0,Moyer AM,Response to drug,initial,2010-12-22,GCST000924,Response to acetaminophen (hepatotoxicity)
4672,European,60.0,21177773.0,Moyer AM,Response to drug,initial,2010-12-22,GCST000924,Response to acetaminophen (hepatotoxicity)
7499,European,2559.0,21203500.0,Lauc G,Other measurement,initial,2010-12-23,GCST000925,N-glycan levels
5331,European,470.0,21183627.0,Bouchard C,Other measurement,initial,2010-12-23,GCST000926,Maximal oxygen uptake response
73,African,247.0,21183627.0,Bouchard C,Other measurement,replication,2010-12-23,GCST000926,Maximal oxygen uptake response
9588,European,9091.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",initial,2010-12-26,GCST000930,Body mass index (sex interaction)
9587,European,9091.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",initial,2010-12-26,GCST000929,Body mass index
6215,European,1024.0,21186350.0,Zhou K,Response to drug,initial,2010-12-26,GCST000927,Response to metformin in type 2 diabetes (glycemic)
7667,European,2872.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",replication,2010-12-26,GCST000930,Body mass index (sex interaction)
7309,European,2314.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",initial,2010-12-26,GCST000928,Waist-to-hip ratio (sex interaction)
7310,European,2314.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",initial,2010-12-26,GCST000931,Waist circumference (sex interaction)
7666,European,2872.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",replication,2010-12-26,GCST000929,Body mass index
7668,European,2872.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",replication,2010-12-26,GCST000931,Waist circumference (sex interaction)
7680,European,2896.0,21186350.0,Zhou K,Response to drug,replication,2010-12-26,GCST000927,Response to metformin in type 2 diabetes (glycemic)
7902,European,3304.0,21302353.0,Perroud N,Neurological disorder,initial,2010-12-28,GCST000932,Hoarding
3234,Asian,2742.0,21196492.0,Okada Y,Inflammatory measurement,replication,2010-12-31,GCST000933,C-reactive protein
4102,Asian,10112.0,21196492.0,Okada Y,Inflammatory measurement,initial,2010-12-31,GCST000933,C-reactive protein
6823,European,1708.0,21211648.0,Ege MJ,"Other disease, Other measurement",initial,2011-01-01,GCST000934,Asthma or atopy (farm exposure interaction)
7998,European,3457.0,21208937.0,Pichler I,Other measurement,replication,2011-01-04,GCST000935,Iron status biomarkers
8791,European,5633.0,21208937.0,Pichler I,Other measurement,initial,2011-01-04,GCST000935,Iron status biomarkers
821,African American or Afro-Caribbean,989.0,21212386.0,Arnett DK,"Other trait, Other measurement",replication,2011-01-06,GCST000936,Cardiac muscle measurement
888,African American or Afro-Caribbean,1258.0,21212386.0,Arnett DK,"Other trait, Other measurement",initial,2011-01-06,GCST000936,Cardiac muscle measurement
6498,European,1316.0,21212386.0,Arnett DK,"Other trait, Other measurement",replication,2011-01-06,GCST000936,Cardiac muscle measurement
14075,Other/Mixed,1113.0,21216876.0,Sharma S,Other disease,initial,2011-01-07,GCST000938,Adolescent idiopathic scoliosis
6431,European,1228.0,21216876.0,Sharma S,Other disease,replication,2011-01-07,GCST000938,Adolescent idiopathic scoliosis
9780,European,10280.0,21216879.0,Kaplan RC,Other measurement,initial,2011-01-07,GCST000937,Insulin-like growth factors
2388,Asian,786.0,21221998.0,Kim JJ,Immune system disorder,initial,2011-01-09,GCST000939,Kawasaki disease
2755,Asian,1556.0,21221998.0,Kim JJ,Immune system disorder,replication,2011-01-09,GCST000939,Kawasaki disease
2468,Asian,940.0,21155030.0,Cheong MY,Cardiovascular disease,replication,2011-01-11,GCST000941,Stroke (ischemic)
2000,Asian,320.0,21155030.0,Cheong MY,Cardiovascular disease,initial,2011-01-11,GCST000941,Stroke (ischemic)
1713,Asian,93.0,22384361.0,Cheng YC,Cardiovascular disease,initial,2011-01-11,GCST000940,Stroke
8625,European,5074.0,21221126.0,Shen Y,Other disease,initial,2011-01-11,GCST000942,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
6155,European,989.0,22384361.0,Cheng YC,Cardiovascular disease,initial,2011-01-11,GCST000940,Stroke
853,African American or Afro-Caribbean,1086.0,21223598.0,Wineinger NE,Cardiovascular measurement,initial,2011-01-11,GCST000943,Aortic root size
761,African American or Afro-Caribbean,734.0,22384361.0,Cheng YC,Cardiovascular disease,initial,2011-01-11,GCST000940,Stroke
8318,European,4276.0,22384361.0,Cheng YC,Cardiovascular disease,replication,2011-01-11,GCST000940,Stroke
3143,Asian,2383.0,21228123.0,Ochi H,Digestive system disorder,initial,2011-01-12,GCST000944,Response to hepatitis C treatment
7596,European,2723.0,21239051.0,Reilly MP,Cardiovascular disease,initial,2011-01-14,GCST000945,Coronary artery disease
7144,European,2116.0,21239051.0,Reilly MP,Cardiovascular disease,replication,2011-01-14,GCST000946,Myocardial infarction in coronary artery disease
9189,European,7311.0,21239051.0,Reilly MP,Cardiovascular disease,initial,2011-01-14,GCST000946,Myocardial infarction in coronary artery disease
10335,European,17053.0,21239051.0,Reilly MP,Cardiovascular disease,replication,2011-01-14,GCST000945,Coronary artery disease
5070,European,317.0,21242121.0,Frullanti E,Cancer,replication,2011-01-17,GCST000947,Lung adenocarcinoma (clinical stage)
5572,European,600.0,21242121.0,Frullanti E,Cancer,initial,2011-01-17,GCST000947,Lung adenocarcinoma (clinical stage)
3374,Asian,3481.0,21242260.0,Cui R,Cancer,initial,2011-01-17,GCST000948,Colorectal cancer
3926,Asian,7782.0,21242260.0,Cui R,Cancer,replication,2011-01-17,GCST000948,Colorectal cancer
7632,European,2796.0,21248740.0,Simon-Sanchez J,Neurological disorder,initial,2011-01-19,GCST000950,Parkinson's disease
5010,European,282.0,21283782.0,Tore S,Other disease,replication,2011-01-20,GCST000951,Nephrolithiasis
4837,European,174.0,21283782.0,Tore S,Other disease,initial,2011-01-20,GCST000951,Nephrolithiasis
4938,European,222.0,21245432.0,Spraggs CF,Response to drug,initial,2011-01-24,GCST000953,Lapatinib-induced hepatotoxicity in breast cancer
13700,Other/Mixed,31.0,21245432.0,Spraggs CF,Response to drug,replication,2011-01-24,GCST000953,Lapatinib-induced hepatotoxicity in breast cancer
13746,Other/Mixed,87.0,21245432.0,Spraggs CF,Response to drug,initial,2011-01-24,GCST000953,Lapatinib-induced hepatotoxicity in breast cancer
8967,European,6346.0,21263130.0,Fletcher O,Cancer,initial,2011-01-24,GCST000952,Breast cancer
4801,European,144.0,21245432.0,Spraggs CF,Response to drug,replication,2011-01-24,GCST000953,Lapatinib-induced hepatotoxicity in breast cancer
10398,European,18021.0,21263130.0,Fletcher O,Cancer,replication,2011-01-24,GCST000952,Breast cancer
2821,Asian,1721.0,21270382.0,Baik I,"Biological process, Other measurement",initial,2011-01-26,GCST000954,Alcohol consumption
2552,Asian,1113.0,21270382.0,Baik I,"Biological process, Other measurement",replication,2011-01-26,GCST000954,Alcohol consumption
9775,European,10249.0,21298027.0,Festen EA,"Digestive system disorder, Immune system disorder",initial,2011-01-27,GCST000955,Crohn's disease and celiac disease
170,African,1103.0,21298047.0,Chen X,Neurological disorder,initial,2011-01-27,GCST000956,Substance dependence
6504,European,1325.0,21273288.0,Del Greco M F,Cardiovascular measurement,initial,2011-01-27,GCST000957,Natriuretic peptide levels
6869,European,1746.0,21273288.0,Del Greco M F,Cardiovascular measurement,replication,2011-01-27,GCST000957,Natriuretic peptide levels
9900,European,11367.0,21298027.0,Festen EA,"Digestive system disorder, Immune system disorder",replication,2011-01-27,GCST000955,Crohn's disease and celiac disease
7457,European,2524.0,21298047.0,Chen X,Neurological disorder,initial,2011-01-27,GCST000956,Substance dependence
6324,European,1145.0,21278746.0,Lindstrom S,"Other measurement, Cancer",replication,2011-01-30,GCST000958,Percent mammographic density
8520,European,4877.0,21278746.0,Lindstrom S,"Other measurement, Cancer",initial,2011-01-30,GCST000958,Percent mammographic density
8490,European,4806.0,21254220.0,Jiang Y,Neurological disorder,initial,2011-02-01,GCST000961,Bipolar disorder
5934,European,851.0,21348951.0,Parsa A,Other trait,initial,2011-02-01,GCST000960,Cardiac hypertrophy
10353,European,17352.0,21292315.0,Nalls MA,Neurological disorder,initial,2011-02-01,GCST000959,Parkinson's disease
2231,Asian,574.0,21326860.0,Tsai FJ,Immune system disorder,replication,2011-02-04,GCST000962,Kawasaki disease
829,African American or Afro-Caribbean,1017.0,21294900.0,Charles BA,Cardiovascular measurement,initial,2011-02-04,GCST000963,Uric acid levels
2297,Asian,696.0,21326860.0,Tsai FJ,Immune system disorder,initial,2011-02-04,GCST000962,Kawasaki disease
10764,European,26405.0,21297633.0,Anderson CA,Immune system disorder,initial,2011-02-06,GCST000964,Ulcerative colitis
10634,European,22545.0,21297633.0,Anderson CA,Immune system disorder,replication,2011-02-06,GCST000964,Ulcerative colitis
11454,European,66185.0,21300955.0,Dehghan A,Inflammatory measurement,initial,2011-02-07,GCST000965,C-reactive protein levels
10295,European,16540.0,21300955.0,Dehghan A,Inflammatory measurement,replication,2011-02-07,GCST000965,C-reactive protein levels
8775,European,5580.0,21305692.0,Belmonte Mahon P,"Other trait, Neurological disorder, Other measurement",initial,2011-02-08,GCST000969,Bipolar disorder (age of onset and psychotic symptoms)
1706,Asian,90.0,21497773.0,Ziliak D,Response to drug,initial,2011-02-08,GCST000968,Response to platinum-based chemotherapy in head and neck cancers
27,African,59.0,21497773.0,Ziliak D,Response to drug,replication,2011-02-08,GCST000968,Response to platinum-based chemotherapy in head and neck cancers
2424,Asian,849.0,21310492.0,Huang YC,Metabolic disorder,initial,2011-02-08,GCST000966,Diabetic retinopathy
4729,European,90.0,21497773.0,Ziliak D,Response to drug,initial,2011-02-08,GCST000967,Response to platinum-based chemotherapy in head and neck cancers
4730,European,90.0,21497773.0,Ziliak D,Response to drug,replication,2011-02-08,GCST000968,Response to platinum-based chemotherapy in head and neck cancers
3120,Asian,2313.0,21307088.0,Khor CC,Other measurement,initial,2011-02-09,GCST000970,Optic disc area
9624,European,9326.0,21307088.0,Khor CC,Other measurement,replication,2011-02-09,GCST000970,Optic disc area
3040,Asian,2132.0,21307088.0,Khor CC,Other measurement,initial,2011-02-09,GCST000970,Optic disc area
1363,African American or Afro-Caribbean,7813.0,21347282.0,Lettre G,Lipid or lipoprotein measurement,initial,2011-02-10,GCST000974,HDL cholesterol
1365,African American or Afro-Caribbean,7917.0,21347282.0,Lettre G,Cardiovascular disease,initial,2011-02-10,GCST000973,Hypertension
1278,African American or Afro-Caribbean,5313.0,21347282.0,Lettre G,Cardiovascular disease,initial,2011-02-10,GCST000972,Coronary heart disease
1308,African American or Afro-Caribbean,6247.0,21347284.0,Smith JG,Cardiovascular measurement,initial,2011-02-10,GCST000971,PR interval
1242,African American or Afro-Caribbean,4323.0,21347282.0,Lettre G,Lipid or lipoprotein measurement,replication,2011-02-10,GCST000974,HDL cholesterol
1091,African American or Afro-Caribbean,2854.0,21347282.0,Lettre G,Cardiovascular disease,replication,2011-02-10,GCST000973,Hypertension
1211,African American or Afro-Caribbean,3789.0,21347282.0,Lettre G,"Lipid or lipoprotein measurement, Other measurement",replication,2011-02-10,GCST000975,LDL cholesterol
1350,African American or Afro-Caribbean,7565.0,21347282.0,Lettre G,"Lipid or lipoprotein measurement, Other measurement",initial,2011-02-10,GCST000975,LDL cholesterol
1336,African American or Afro-Caribbean,6942.0,21347282.0,Lettre G,Metabolic disorder,initial,2011-02-10,GCST000976,Type 2 diabetes
989,African American or Afro-Caribbean,2022.0,21347284.0,Smith JG,Cardiovascular measurement,replication,2011-02-10,GCST000971,PR interval
1033,African American or Afro-Caribbean,2250.0,21347282.0,Lettre G,Cardiovascular disease,replication,2011-02-10,GCST000972,Coronary heart disease
1022,African American or Afro-Caribbean,2159.0,21347282.0,Lettre G,Metabolic disorder,replication,2011-02-10,GCST000976,Type 2 diabetes
7656,European,2836.0,21316860.0,Velders FP,Other measurement,replication,2011-02-11,GCST000978,Cortisol secretion
6825,European,1711.0,21316860.0,Velders FP,Other measurement,initial,2011-02-11,GCST000978,Cortisol secretion
7342,European,2357.0,21314694.0,Kendler KS,"Other measurement, Neurological disorder",initial,2011-02-11,GCST000977,Alcohol dependence
780,African American or Afro-Caribbean,812.0,21314694.0,Kendler KS,"Other measurement, Neurological disorder",initial,2011-02-11,GCST000977,Alcohol dependence
4991,European,269.0,21359210.0,Ricci G,"Other disease, Other measurement",initial,2011-02-16,GCST000979,Asthma (childhood onset)
8155,European,3839.0,21379329.0,Wijsman EM,Neurological disorder,initial,2011-02-17,GCST000980,Alzheimer's disease (late onset)
5686,European,677.0,21326295.0,Jin Y,Immune system disorder,replication,2011-02-17,GCST000981,Vitiligo
5815,European,772.0,21379329.0,Wijsman EM,Neurological disorder,replication,2011-02-17,GCST000980,Alzheimer's disease (late onset)
12860,Hispanic or Latin American,418.0,21379329.0,Wijsman EM,Neurological disorder,replication,2011-02-17,GCST000980,Alzheimer's disease (late onset)
685,African American or Afro-Caribbean,440.0,21326311.0,Bhatnagar P,"Neurological disorder, Hematological measurement",initial,2011-02-17,GCST000982,F-cell distribution in sickle cell anaemia
6510,European,1339.0,21326295.0,Jin Y,Immune system disorder,initial,2011-02-17,GCST000981,Vitiligo
12723,Hispanic or Latin American,7.0,21339755.0,Liu X,Other measurement,initial,2011-02-22,GCST000983,5-HTT brain serotonin transporter levels
7677,European,2894.0,21323541.0,Stanescu HC,Other disease,initial,2011-02-22,GCST000984,Idiopathic membranous nephropathy
4662,European,51.0,21339755.0,Liu X,Other measurement,replication,2011-02-22,GCST000983,5-HTT brain serotonin transporter levels
4636,European,13.0,21339755.0,Liu X,Other measurement,initial,2011-02-22,GCST000983,5-HTT brain serotonin transporter levels
415,African American or Afro-Caribbean,13.0,21339755.0,Liu X,Other measurement,initial,2011-02-22,GCST000983,5-HTT brain serotonin transporter levels
11157,European,41821.0,21353194.0,Cichon S,Neurological disorder,replication,2011-02-23,GCST000985,Bipolar disorder
7036,European,1982.0,21353194.0,Cichon S,Neurological disorder,initial,2011-02-23,GCST000985,Bipolar disorder
9982,European,12213.0,21383967.0,Zhernakova A,Other disease,replication,2011-02-24,GCST000987,Celiac disease or Rheumatoid arthritis
8064,European,3595.0,21390209.0,Hu X,Neurological disorder,initial,2011-02-24,GCST000986,Alzheimer's disease (late onset)
11082,European,38053.0,21383967.0,Zhernakova A,Other disease,initial,2011-02-24,GCST000987,Celiac disease or Rheumatoid arthritis
10893,European,31580.0,21355061.0,Boger CA,Other trait,initial,2011-02-25,GCST000988,Urinary albumin excretion
6804,European,1682.0,21357381.0,Figueiredo JC,Cancer,replication,2011-02-25,GCST000989,Colorectal cancer
10888,European,31277.0,21355061.0,Boger CA,Other trait,replication,2011-02-25,GCST000988,Urinary albumin excretion
4879,European,191.0,21364930.0,Bol SM,Other disease,initial,2011-02-25,GCST000990,HIV-1 replication
7228,European,2190.0,21357381.0,Figueiredo JC,Cancer,initial,2011-02-25,GCST000989,Colorectal cancer
1769,Asian,126.0,21519539.0,Cho SC,Neurological disorder,initial,2011-02-25,GCST000991,Autism spectrum disorders (language delay)
1975,Asian,284.0,23480133.0,Kim Y,Cardiovascular disease,initial,2011-02-28,GCST000993,Vascular dementia
9019,European,6611.0,21357676.0,Sulem P,"Biological process, Other measurement",initial,2011-02-28,GCST000992,Coffee consumption
2046,Asian,368.0,23480133.0,Kim Y,Cardiovascular disease,replication,2011-02-28,GCST000993,Vascular dementia
8239,European,4050.0,21357676.0,Sulem P,"Biological process, Other measurement",replication,2011-02-28,GCST000992,Coffee consumption
3694,Asian,5666.0,21372407.0,Takeuchi F,Biological process,replication,2011-03-01,GCST000994,Drinking behavior
2694,Asian,1462.0,21372407.0,Takeuchi F,Biological process,initial,2011-03-01,GCST000994,Drinking behavior
7010,European,1951.0,21368711.0,Alliey-Rodriguez N,"Neurological disorder, Other trait",initial,2011-03-02,GCST000995,Personality traits in bipolar disorder
8998,European,6530.0,21408207.0,Chung SA,Immune system disorder,initial,2011-03-03,GCST000996,Systemic lupus erythematosus
11503,European,69899.0,21378095.0,Fox ER,"Other measurement, Cardiovascular measurement",replication,2011-03-04,GCST000997,Blood pressure
1345,African American or Afro-Caribbean,7473.0,21378095.0,Fox ER,"Other measurement, Cardiovascular measurement",initial,2011-03-04,GCST000997,Blood pressure
173,African,1188.0,21378095.0,Fox ER,"Other measurement, Cardiovascular measurement",replication,2011-03-04,GCST000997,Blood pressure
1444,African American or Afro-Caribbean,10694.0,21378095.0,Fox ER,"Other measurement, Cardiovascular measurement",replication,2011-03-04,GCST000997,Blood pressure
11369,European,56682.0,21378990.0,Schunkert H,Cardiovascular disease,replication,2011-03-06,GCST000998,Coronary heart disease
4278,Asian,14790.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Cardiovascular disease,initial,2011-03-06,GCST000999,Coronary heart disease
10233,European,15682.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Cardiovascular disease,initial,2011-03-06,GCST000999,Coronary heart disease
10995,European,34406.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Cardiovascular disease,replication,2011-03-06,GCST000999,Coronary heart disease
2139,Asian,460.0,21378986.0,Wang F,Cardiovascular disease,initial,2011-03-06,GCST001000,Coronary heart disease
5856,European,804.0,21386754.0,Marciante KD,"Other disease, Response to drug",initial,2011-03-06,GCST001002,Cerivastatin-induced rhabdomyolysis
3764,Asian,6187.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Cardiovascular disease,replication,2011-03-06,GCST000999,Coronary heart disease
11092,European,38384.0,21378987.0,Holm H,Cardiovascular disease,initial,2011-03-06,GCST001001,Sick sinus syndrome
11656,European,86995.0,21378990.0,Schunkert H,Cardiovascular disease,initial,2011-03-06,GCST000998,Coronary heart disease
3894,Asian,7593.0,21378986.0,Wang F,Cardiovascular disease,replication,2011-03-06,GCST001000,Coronary heart disease
6787,European,1654.0,21378987.0,Holm H,Cardiovascular disease,replication,2011-03-06,GCST001001,Sick sinus syndrome
10621,European,22161.0,21386085.0,Kraja AT,Metabolic disorder,initial,2011-03-08,GCST001007,Metabolic syndrome (bivariate traits)
10623,European,22161.0,21386085.0,Kraja AT,"Other measurement, Lipid or lipoprotein measurement",initial,2011-03-08,GCST001004,Triglycerides-Blood Pressure (TG-BP)
10620,European,22161.0,21386085.0,Kraja AT,Lipid or lipoprotein measurement,initial,2011-03-08,GCST001005,HDL Cholesterol - Triglycerides (HDLC-TG)
10622,European,22161.0,21386085.0,Kraja AT,"Metabolic disorder, Lipid or lipoprotein measurement",initial,2011-03-08,GCST001006,Waist Circumference - Triglycerides (WC-TG)
10619,European,22161.0,21386085.0,Kraja AT,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2011-03-08,GCST001003,Metabolic syndrome
7044,European,1997.0,21423719.0,Speliotes EK,Digestive system disorder,replication,2011-03-10,GCST001008,Nonalcoholic fatty liver disease
9162,European,7176.0,21423719.0,Speliotes EK,Digestive system disorder,initial,2011-03-10,GCST001008,Nonalcoholic fatty liver disease
7377,European,2410.0,21399633.0,Gharavi AG,Other disease,replication,2011-03-13,GCST001009,Nephropathy
2692,Asian,1460.0,21399633.0,Gharavi AG,Other disease,replication,2011-03-13,GCST001009,Nephropathy
3023,Asian,2096.0,21399633.0,Gharavi AG,Other disease,initial,2011-03-13,GCST001009,Nephropathy
7782,European,3134.0,21399635.0,Mells GF,Cancer,replication,2011-03-13,GCST001010,Primary biliary cholangitis
9122,European,7003.0,21399635.0,Mells GF,Cancer,initial,2011-03-13,GCST001010,Primary biliary cholangitis
9792,European,10425.0,21437268.0,McKay JD,Cancer,initial,2011-03-17,GCST001011,Oral cavity and pharyngeal cancer
10542,European,20726.0,21437268.0,McKay JD,Cancer,replication,2011-03-17,GCST001011,Oral cavity and pharyngeal cancer
7351,European,2368.0,21424380.0,Sehrawat B,Cancer,replication,2011-03-19,GCST001012,Breast cancer
5608,European,623.0,21424380.0,Sehrawat B,Cancer,initial,2011-03-19,GCST001012,Breast cancer
7117,European,2073.0,21418511.0,Deelen J,Other measurement,initial,2011-03-21,GCST001013,Longevity
14198,Other/Mixed,3298.0,21418511.0,Deelen J,Other measurement,replication,2011-03-21,GCST001013,Longevity
8055,European,3575.0,21418511.0,Deelen J,Other measurement,replication,2011-03-21,GCST001013,Longevity
5098,European,337.0,21428769.0,McCormack M,Response to drug,replication,2011-03-24,GCST001014,Adverse response to carbamazepine
8240,European,4052.0,21428769.0,McCormack M,Response to drug,initial,2011-03-24,GCST001014,Adverse response to carbamazepine
4684,European,67.0,21396408.0,Miller EK,Response to drug,initial,2011-03-25,GCST001016,Vaccine-related adverse events
7577,European,2698.0,21423239.0,Willour VL,"Biological process, Neurological disorder",initial,2011-03-25,GCST001015,Suicide attempts in bipolar disorder
7650,European,2829.0,21441570.0,Grassi MA,Metabolic disorder,initial,2011-03-26,GCST001017,Diabetic retinopathy
2831,Asian,1741.0,21441931.0,Okamoto K,Other disease,initial,2011-03-27,GCST001018,Nephrotic syndrome (acquired)
3660,Asian,5581.0,21441931.0,Okamoto K,Other disease,replication,2011-03-27,GCST001018,Nephrotic syndrome (acquired)
9863,European,10980.0,21448238.0,Ligthart L,Cardiovascular disease,initial,2011-03-30,GCST001019,Migraine
9540,European,8731.0,21448238.0,Ligthart L,Cardiovascular disease,replication,2011-03-30,GCST001019,Migraine
5691,European,679.0,21483845.0,McLaren CE,Other trait,initial,2011-03-31,GCST001020,Iron deficiency
5690,European,679.0,21483845.0,McLaren CE,Other measurement,initial,2011-03-31,GCST001021,Iron status biomarkers
4954,European,232.0,21483845.0,McLaren CE,Other measurement,replication,2011-03-31,GCST001021,Iron status biomarkers
4955,European,232.0,21483845.0,McLaren CE,Other trait,replication,2011-03-31,GCST001020,Iron deficiency
7295,European,2287.0,21459883.0,Villard E,Cardiovascular disease,initial,2011-04-01,GCST001023,Idiopathic dilated cardiomyopathy
2756,Asian,1558.0,21452313.0,Freudenberg J,Immune system disorder,initial,2011-04-01,GCST001022,Rheumatoid arthritis
7415,European,2467.0,21459883.0,Villard E,Cardiovascular disease,replication,2011-04-01,GCST001023,Idiopathic dilated cardiomyopathy
2684,Asian,1437.0,21452313.0,Freudenberg J,Immune system disorder,replication,2011-04-01,GCST001022,Rheumatoid arthritis
3811,Asian,6683.0,21460842.0,Cha PC,Cancer,replication,2011-04-03,GCST001027,Uterine fibroids
11106,European,39342.0,21460840.0,Hollingworth P,Neurological disorder,replication,2011-04-03,GCST001025,Alzheimer's disease
11098,European,38754.0,21460841.0,Naj AC,Neurological disorder,replication,2011-04-03,GCST001026,Alzheimer's disease (late onset)
10522,European,20373.0,21460840.0,Hollingworth P,Neurological disorder,initial,2011-04-03,GCST001025,Alzheimer's disease
3315,Asian,3035.0,21460842.0,Cha PC,Cancer,initial,2011-04-03,GCST001027,Uterine fibroids
10232,European,15675.0,21460841.0,Naj AC,Neurological disorder,initial,2011-04-03,GCST001026,Alzheimer's disease (late onset)
5047,European,302.0,21467234.0,FitzGerald LM,Cancer,initial,2011-04-05,GCST001028,Prostate cancer
7296,European,2289.0,21467234.0,FitzGerald LM,Cancer,replication,2011-04-05,GCST001028,Prostate cancer
10558,European,21185.0,21471458.0,Schumann G,"Biological process, Other measurement",replication,2011-04-06,GCST001029,Alcohol consumption
10761,European,26316.0,21471458.0,Schumann G,"Biological process, Other measurement",initial,2011-04-06,GCST001029,Alcohol consumption
5040,European,296.0,21473668.0,Fliers EA,Neurological disorder,replication,2011-04-07,GCST001030,Attention deficit hyperactivity disorder motor coordination
2507,Asian,1008.0,21471979.0,Kumar V,Cancer,initial,2011-04-07,GCST001031,Large B-cell lymphoma
11238,European,47431.0,21490707.0,Cornelis MC,Biological process,initial,2011-04-07,GCST001032,Caffeine consumption
5984,European,890.0,21473668.0,Fliers EA,Neurological disorder,initial,2011-04-07,GCST001030,Attention deficit hyperactivity disorder motor coordination
3002,Asian,2034.0,21490949.0,Sim X,Metabolic disorder,initial,2011-04-07,GCST001033,Type 2 diabetes
3442,Asian,3955.0,21490949.0,Sim X,Metabolic disorder,initial,2011-04-07,GCST001033,Type 2 diabetes
3396,Asian,3634.0,21471979.0,Kumar V,Cancer,replication,2011-04-07,GCST001031,Large B-cell lymphoma
3046,Asian,2146.0,21490949.0,Sim X,Metabolic disorder,initial,2011-04-07,GCST001033,Type 2 diabetes
8057,European,3581.0,21478494.0,Nan H,Cancer,replication,2011-04-09,GCST001034,Cutaneous nevi
9598,European,9136.0,21478494.0,Nan H,Cancer,initial,2011-04-09,GCST001034,Cutaneous nevi
5755,European,735.0,21483023.0,Wu X,"Response to drug, Cancer",replication,2011-04-11,GCST001035,Response to platinum-based chemotherapy in non-small-cell lung cancer
5078,European,327.0,21483023.0,Wu X,"Response to drug, Cancer",initial,2011-04-11,GCST001035,Response to platinum-based chemotherapy in non-small-cell lung cancer
12993,Hispanic or Latin American,857.0,21483430.0,Carless MA,Other measurement,initial,2011-04-12,GCST001037,Neuranatomic and neurocognitive phenotypes
5750,European,733.0,21570397.0,Lucena MI,Digestive system disorder,initial,2011-04-12,GCST001036,Drug-induced liver injury (amoxicillin-clavulanate)
10178,European,14846.0,21533175.0,Zhai G,Other measurement,initial,2011-04-14,GCST001038,Dehydroepiandrosterone sulphate levels
7134,European,2096.0,21497890.0,Orange JS,Immune system disorder,initial,2011-04-15,GCST001039,Common variable immunodeficiency
6418,European,1223.0,21497890.0,Orange JS,Immune system disorder,replication,2011-04-15,GCST001039,Common variable immunodeficiency
3341,Asian,3269.0,21499248.0,Kumar V,Cancer,replication,2011-04-17,GCST001041,Hepatocellular carcinoma
8983,European,6455.0,21499250.0,Spurdle AB,Cancer,initial,2011-04-17,GCST001040,Endometrial cancer
9853,European,10843.0,21499250.0,Spurdle AB,Cancer,replication,2011-04-17,GCST001040,Endometrial cancer
3392,Asian,3611.0,21499248.0,Kumar V,Cancer,initial,2011-04-17,GCST001041,Hepatocellular carcinoma
5754,European,734.0,21502949.0,Stein JL,Other measurement,initial,2011-04-19,GCST001045,Caudate nucleus volume
3225,Asian,2733.0,21505073.0,Terao C,Immune system disorder,initial,2011-04-19,GCST001042,Rheumatoid arthritis
3156,Asian,2431.0,21544081.0,Dorajoo R,"Other measurement, Metabolic disorder",initial,2011-04-19,GCST001046,Obesity
3643,Asian,5429.0,21544081.0,Dorajoo R,"Other measurement, Metabolic disorder",initial,2011-04-19,GCST001046,Obesity
3187,Asian,2531.0,21544081.0,Dorajoo R,"Other measurement, Metabolic disorder",initial,2011-04-19,GCST001046,Obesity
5322,European,464.0,21502949.0,Stein JL,Other measurement,replication,2011-04-19,GCST001045,Caudate nucleus volume
5139,European,362.0,21502966.0,Weber F,Response to drug,initial,2011-04-19,GCST001043,Response to interferon beta therapy
2111,Asian,437.0,21505071.0,Li Z,Other trait,initial,2011-04-19,GCST001044,Myopia (pathological)
5872,European,818.0,21502966.0,Weber F,Response to drug,replication,2011-04-19,GCST001043,Response to interferon beta therapy
4216,Asian,12962.0,21505071.0,Li Z,Other trait,replication,2011-04-19,GCST001044,Myopia (pathological)
4053,Asian,9171.0,21505073.0,Terao C,Immune system disorder,replication,2011-04-19,GCST001042,Rheumatoid arthritis
10549,European,20898.0,21533022.0,Duncan EL,Other measurement,replication,2011-04-21,GCST001050,Bone mineral density
8595,European,5001.0,21533074.0,Smedby KE,Cancer,replication,2011-04-21,GCST001051,Follicular lymphoma
6788,European,1654.0,21493818.0,Shaw SY,Other measurement,initial,2011-04-21,GCST001048,Monocyte early outgrowth colony forming units
6352,European,1170.0,21533074.0,Smedby KE,Cancer,initial,2011-04-21,GCST001051,Follicular lymphoma
10628,European,22435.0,21533024.0,Pare G,Cardiovascular measurement,initial,2011-04-21,GCST001047,Soluble ICAM-1
7016,European,1955.0,21533022.0,Duncan EL,Other measurement,initial,2011-04-21,GCST001050,Bone mineral density
10556,European,21052.0,21502573.0,Smith NL,Cardiovascular measurement,initial,2011-04-21,GCST001049,D-dimer levels
7963,European,3393.0,21529783.0,Heath AC,Neurological disorder,replication,2011-04-27,GCST001053,Alcoholism (alcohol use disorder factor score)
7964,European,3393.0,21529783.0,Heath AC,Neurological disorder,replication,2011-04-27,GCST001054,Alcoholism (alcohol dependence factor score)
9548,European,8754.0,21529783.0,Heath AC,Neurological disorder,initial,2011-04-27,GCST001055,Alcoholism (12-month weekly alcohol consumption)
7965,European,3393.0,21529783.0,Heath AC,Neurological disorder,replication,2011-04-27,GCST001055,Alcoholism (12-month weekly alcohol consumption)
9546,European,8754.0,21529783.0,Heath AC,Neurological disorder,initial,2011-04-27,GCST001053,Alcoholism (alcohol use disorder factor score)
9545,European,8754.0,21529783.0,Heath AC,Neurological disorder,initial,2011-04-27,GCST001052,Alcoholism (heaviness of drinking)
7962,European,3393.0,21529783.0,Heath AC,Neurological disorder,replication,2011-04-27,GCST001052,Alcoholism (heaviness of drinking)
9547,European,8754.0,21529783.0,Heath AC,Neurological disorder,initial,2011-04-27,GCST001054,Alcoholism (alcohol dependence factor score)
6245,European,1060.0,21552555.0,Wang K,"Other measurement, Metabolic disorder",initial,2011-04-28,GCST001057,Obesity
5735,European,719.0,21521612.0,Kohli MA,Neurological disorder,initial,2011-04-28,GCST001056,Major depressive disorder
822,African American or Afro-Caribbean,991.0,21521612.0,Kohli MA,Neurological disorder,replication,2011-04-28,GCST001056,Major depressive disorder
10113,European,13969.0,21521612.0,Kohli MA,Neurological disorder,replication,2011-04-28,GCST001056,Major depressive disorder
6382,European,1196.0,21552555.0,Wang K,"Other measurement, Metabolic disorder",replication,2011-04-28,GCST001057,Obesity
9922,European,11582.0,21531791.0,Sanson M,Cancer,initial,2011-04-29,GCST001058,Glioma
8366,European,4446.0,21532571.0,Burdon KP,Neurological disorder,initial,2011-05-01,GCST001062,Glaucoma
47,African,115.0,21507922.0,Ramsuran V,Hematological measurement,initial,2011-05-01,GCST001059,Neutrophil count
5800,European,755.0,21502085.0,Troyer JL,Immune system disorder,initial,2011-05-01,GCST001060,AIDS progression
48,African,115.0,21507922.0,Ramsuran V,Hematological measurement,initial,2011-05-01,GCST001061,Platelet count
8760,European,5474.0,21532571.0,Burdon KP,Neurological disorder,replication,2011-05-01,GCST001062,Glaucoma
5816,European,773.0,21540310.0,Hofmann S,Other disease,initial,2011-05-03,GCST001064,Sarcoidosis
5862,European,808.0,21540461.0,Kim DH,Cancer,replication,2011-05-03,GCST001063,Chronic myeloid leukemia
7949,European,3365.0,21540310.0,Hofmann S,Other disease,replication,2011-05-03,GCST001064,Sarcoidosis
2298,Asian,698.0,21540461.0,Kim DH,Cancer,initial,2011-05-03,GCST001063,Chronic myeloid leukemia
2613,Asian,1237.0,21540461.0,Kim DH,Cancer,replication,2011-05-03,GCST001063,Chronic myeloid leukemia
734,African American or Afro-Caribbean,610.0,21546767.0,Murea M,Other disease,initial,2011-05-05,GCST001066,Dialysis-related mortality
6581,European,1399.0,21551455.0,Kanetsky PA,Cancer,replication,2011-05-06,GCST001067,Testicular cancer
6465,European,1268.0,21551455.0,Kanetsky PA,Cancer,initial,2011-05-06,GCST001067,Testicular cancer
7410,European,2460.0,21573004.0,Prescott J,Other measurement,replication,2011-05-10,GCST001068,Telomere length
8045,European,3554.0,21573004.0,Prescott J,Other measurement,initial,2011-05-10,GCST001068,Telomere length
8074,European,3620.0,21565293.0,Teumer A,Other measurement,initial,2011-05-13,GCST001069,Thyroid volume
6476,European,1290.0,21565293.0,Teumer A,Other measurement,replication,2011-05-13,GCST001069,Thyroid volume
2845,Asian,1747.0,21573128.0,Kou I,Other disease,initial,2011-05-15,GCST001071,Osteoporosis
4354,Asian,19608.0,21572416.0,Kato N,"Other measurement, Cardiovascular measurement",initial,2011-05-15,GCST001074,Blood pressure
6951,European,1862.0,21572414.0,Suhre K,Other measurement,replication,2011-05-15,GCST001073,Urinary metabolites
4353,Asian,19608.0,21572416.0,Kato N,"Other measurement, Cardiovascular measurement",initial,2011-05-15,GCST001072,Blood pressure
4437,Asian,30765.0,21572416.0,Kato N,"Other measurement, Cardiovascular measurement",replication,2011-05-15,GCST001072,Blood pressure
3605,Asian,5203.0,21573128.0,Kou I,Other disease,replication,2011-05-15,GCST001071,Osteoporosis
13153,Hispanic or Latin American,2584.0,21573907.0,Parra EJ,Metabolic disorder,initial,2011-05-15,GCST001070,Type 2 diabetes
4438,Asian,30765.0,21572416.0,Kato N,"Other measurement, Cardiovascular measurement",replication,2011-05-15,GCST001074,Blood pressure
2502,Asian,1001.0,21625490.0,Andiappan AK,Immune system disorder,initial,2011-05-20,GCST001075,Atopy
6136,European,984.0,21703177.0,Thompson AJ,Digestive system disorder,initial,2011-05-20,GCST001076,IFN-related cytopenia
12773,Hispanic or Latin American,99.0,21703177.0,Thompson AJ,Digestive system disorder,initial,2011-05-20,GCST001076,IFN-related cytopenia
3261,Asian,2834.0,21625490.0,Andiappan AK,Immune system disorder,replication,2011-05-20,GCST001075,Atopy
573,African American or Afro-Caribbean,201.0,21703177.0,Thompson AJ,Digestive system disorder,initial,2011-05-20,GCST001076,IFN-related cytopenia
1326,African American or Afro-Caribbean,6715.0,21602798.0,Haiman CA,Cancer,initial,2011-05-22,GCST001078,Prostate cancer
7314,European,2317.0,21602797.0,Wright FA,Other disease,initial,2011-05-22,GCST001077,Cystic fibrosis severity
225,African,1705.0,21602798.0,Haiman CA,Cancer,replication,2011-05-22,GCST001078,Prostate cancer
1179,African American or Afro-Caribbean,3408.0,21602798.0,Haiman CA,Cancer,replication,2011-05-22,GCST001078,Prostate cancer
5995,European,898.0,21602797.0,Wright FA,Other disease,replication,2011-05-22,GCST001077,Cystic fibrosis severity
11345,European,54758.0,21606135.0,Wild PS,Cardiovascular disease,replication,2011-05-23,GCST001079,Coronary heart disease
8604,European,5031.0,21606135.0,Wild PS,Cardiovascular disease,initial,2011-05-23,GCST001079,Coronary heart disease
6100,European,963.0,21612516.0,Malovini A,Other measurement,initial,2011-05-25,GCST001081,Longevity
5005,European,276.0,21612516.0,Malovini A,Other measurement,replication,2011-05-25,GCST001081,Longevity
2381,Asian,777.0,21618603.0,Beaty TH,"Other disease, Other trait, Other measurement",initial,2011-05-26,GCST001082,Orofacial clefts (maternal alcohol consumption interaction)
13720,Other/Mixed,57.0,21618603.0,Beaty TH,"Other disease, Other trait, Other measurement",initial,2011-05-26,GCST001082,Orofacial clefts (maternal alcohol consumption interaction)
5868,European,816.0,21618603.0,Beaty TH,"Other disease, Other trait, Other measurement",initial,2011-05-26,GCST001082,Orofacial clefts (maternal alcohol consumption interaction)
8594,European,5000.0,21626137.0,Slavin TP,Cardiovascular disease,initial,2011-05-28,GCST001085,Hypertension (SNP x SNP interaction)
8593,European,5000.0,21626137.0,Slavin TP,Cardiovascular disease,initial,2011-05-28,GCST001084,Coronary heart disease (SNP X SNP interaction)
7789,European,3145.0,21623375.0,Albagha OM,Other disease,replication,2011-05-29,GCST001086,Paget's disease
7991,European,3440.0,21623375.0,Albagha OM,Other disease,initial,2011-05-29,GCST001086,Paget's disease
6279,European,1088.0,21627779.0,Antunez C,Neurological disorder,initial,2011-05-31,GCST001087,Alzheimer's disease
10032,European,12943.0,21627779.0,Antunez C,Neurological disorder,replication,2011-05-31,GCST001087,Alzheimer's disease
2538,Asian,1088.0,21640322.0,Shi Y,Other trait,initial,2011-06-02,GCST001088,Myopia (pathological)
3976,Asian,8445.0,21640322.0,Shi Y,Other trait,replication,2011-06-02,GCST001088,Myopia (pathological)
3458,Asian,4075.0,21642993.0,Wu C,Cancer,initial,2011-06-05,GCST001089,Esophageal cancer
3950,Asian,8143.0,21642993.0,Wu C,Cancer,replication,2011-06-05,GCST001089,Esophageal cancer
2035,Asian,360.0,21674006.0,Yamada K,Neurological disorder,initial,2011-06-06,GCST001090,Schizophrenia
8958,European,6307.0,21646302.0,Bielinski SJ,Other measurement,initial,2011-06-06,GCST001091,Bilirubin levels
3073,Asian,2175.0,21674006.0,Yamada K,Neurological disorder,replication,2011-06-06,GCST001090,Schizophrenia
13047,Hispanic or Latin American,1310.0,21647700.0,Below JE,Metabolic disorder,replication,2011-06-07,GCST001092,Type 2 diabetes
2814,Asian,1709.0,21647738.0,Wu Y,Inflammatory measurement,initial,2011-06-07,GCST001093,C-reactive protein
13043,Hispanic or Latin American,1273.0,21647700.0,Below JE,Metabolic disorder,initial,2011-06-07,GCST001092,Type 2 diabetes
2077,Asian,391.0,21659334.0,Tanaka Y,Digestive system disorder,replication,2011-06-09,GCST001094,Response to hepatitis C treatment
1985,Asian,303.0,21659334.0,Tanaka Y,Digestive system disorder,initial,2011-06-09,GCST001094,Response to hepatitis C treatment
9661,European,9538.0,21694764.0,Martin NW,Other measurement,initial,2011-06-09,GCST001097,Educational attainment
6619,European,1470.0,21654844.0,Briggs FB,Immune system disorder,initial,2011-06-09,GCST001096,Multiple sclerosis
5128,European,356.0,21659360.0,Wade R,Response to drug,initial,2011-06-09,GCST001095,Response to antineoplastic agents
5158,European,380.0,21659360.0,Wade R,Response to drug,replication,2011-06-09,GCST001095,Response to antineoplastic agents
6107,European,968.0,21694764.0,Martin NW,Other measurement,replication,2011-06-09,GCST001097,Educational attainment
5140,European,362.0,21665988.0,Horne BD,Cardiovascular disease,replication,2011-06-10,GCST001098,Peripartum cardiomyopathy
5582,European,605.0,21658281.0,Aouizerat BE,Cardiovascular disease,initial,2011-06-10,GCST001104,Sudden cardiac arrest
13635,Other/Mixed,5.0,21665988.0,Horne BD,Cardiovascular disease,initial,2011-06-10,GCST001098,Peripartum cardiomyopathy
5581,European,605.0,21658281.0,Aouizerat BE,Cardiovascular disease,initial,2011-06-10,GCST001102,Sudden cardiac arrest
5580,European,605.0,21658281.0,Aouizerat BE,Cardiovascular disease,initial,2011-06-10,GCST001099,Sudden cardiac arrest
8664,European,5181.0,21665994.0,Kutalik Z,Biological process,initial,2011-06-10,GCST001103,Alcohol consumption (transferrin glycosylation)
2994,Asian,2008.0,21665993.0,Han S,Other measurement,initial,2011-06-10,GCST001101,Corneal curvature
3044,Asian,2142.0,21665993.0,Han S,Other measurement,replication,2011-06-10,GCST001101,Corneal curvature
9054,European,6728.0,21665990.0,Yu Y,Neurological disorder,initial,2011-06-10,GCST001100,Age-related macular degeneration
11381,European,57814.0,21665990.0,Yu Y,Neurological disorder,replication,2011-06-10,GCST001100,Age-related macular degeneration
5763,European,739.0,21665988.0,Horne BD,Cardiovascular disease,initial,2011-06-10,GCST001098,Peripartum cardiomyopathy
2461,Asian,929.0,21665993.0,Han S,Other measurement,replication,2011-06-10,GCST001101,Corneal curvature
3112,Asian,2281.0,21665993.0,Han S,Other measurement,initial,2011-06-10,GCST001101,Corneal curvature
10660,European,23230.0,21666692.0,Chasman DI,Cardiovascular disease,initial,2011-06-12,GCST001105,Migraine
10385,European,17777.0,21666692.0,Chasman DI,Cardiovascular disease,replication,2011-06-12,GCST001105,Migraine
8620,European,5062.0,21666691.0,Sun LD,Immune system disorder,replication,2011-06-13,GCST001106,Atopic dermatitis
4297,Asian,15821.0,21666691.0,Sun LD,Immune system disorder,replication,2011-06-13,GCST001106,Atopic dermatitis
3137,Asian,2374.0,21666691.0,Sun LD,Immune system disorder,initial,2011-06-13,GCST001106,Atopic dermatitis
980,African American or Afro-Caribbean,1940.0,21698141.0,Freedman BI,Other disease,initial,2011-06-16,GCST001107,End-stage renal disease
6298,European,1113.0,21685187.0,Siedlinski M,"Other disease, Other measurement",initial,2011-06-16,GCST001111,Current cigarettes per day in chronic obstructive pulmonary disease
904,African American or Afro-Caribbean,1323.0,21698141.0,Freedman BI,Other disease,replication,2011-06-16,GCST001107,End-stage renal disease
1807,Asian,158.0,21679298.0,Ma X,Neurological disorder,initial,2011-06-16,GCST001110,Schizophrenia
7744,European,3024.0,21681796.0,Fornage M,Other measurement,replication,2011-06-16,GCST001109,White matter hyperintensity burden
7967,European,3397.0,21685187.0,Siedlinski M,"Other disease, Biological process",initial,2011-06-16,GCST001113,Age at smoking initiation in chronic obstructive pulmonary disease
9633,European,9361.0,21681796.0,Fornage M,Other measurement,initial,2011-06-16,GCST001109,White matter hyperintensity burden
7758,European,3071.0,21685187.0,Siedlinski M,"Other disease, Biological process",initial,2011-06-16,GCST001108,Smoking cessation in chronic obstructive pulmonary disease
7992,European,3440.0,21685187.0,Siedlinski M,"Other disease, Other measurement",initial,2011-06-16,GCST001112,Lifetime average cigarettes per day in chronic obstructive pulmonary disease
6342,European,1162.0,21688384.0,Wang KS,"Neurological disorder, Other measurement",initial,2011-06-17,GCST001114,Schizophrenia (age at onset) (sex interaction)
6343,European,1162.0,21688384.0,Wang KS,"Neurological disorder, Other measurement",initial,2011-06-17,GCST001115,Schizophrenia (age at onset)
6250,European,1068.0,21688384.0,Wang KS,"Neurological disorder, Other measurement",replication,2011-06-17,GCST001114,Schizophrenia (age at onset) (sex interaction)
6251,European,1068.0,21688384.0,Wang KS,"Neurological disorder, Other measurement",replication,2011-06-17,GCST001115,Schizophrenia (age at onset)
8419,European,4611.0,21685912.0,Hoglinger GU,Neurological disorder,replication,2011-06-19,GCST001116,Progressive supranuclear palsy
8229,European,4027.0,21685912.0,Hoglinger GU,Neurological disorder,initial,2011-06-19,GCST001116,Progressive supranuclear palsy
13866,Other/Mixed,329.0,21685912.0,Hoglinger GU,Neurological disorder,initial,2011-06-19,GCST001116,Progressive supranuclear palsy
538,African American or Afro-Caribbean,156.0,21696813.0,Schauberger EM,"Other disease, Other measurement",replication,2011-06-20,GCST001117,Asthma (childhood onset)
9608,European,9243.0,21696813.0,Schauberger EM,"Other disease, Other measurement",replication,2011-06-20,GCST001117,Asthma (childhood onset)
13766,Other/Mixed,138.0,21696813.0,Schauberger EM,"Other disease, Other measurement",replication,2011-06-20,GCST001117,Asthma (childhood onset)
5087,European,331.0,21682944.0,Alkelai A,Neurological disorder,initial,2011-06-20,GCST001119,Schizophrenia
13210,Hispanic or Latin American,3693.0,21696813.0,Schauberger EM,"Other disease, Other measurement",replication,2011-06-20,GCST001117,Asthma (childhood onset)
2332,Asian,744.0,21699788.0,Okada Y,"Digestive system disorder, Immune system disorder",initial,2011-06-20,GCST001118,Ulcerative colitis or Crohn's disease
5006,European,277.0,21696813.0,Schauberger EM,"Other disease, Other measurement",initial,2011-06-20,GCST001117,Asthma (childhood onset)
13808,Other/Mixed,189.0,21682944.0,Alkelai A,Neurological disorder,replication,2011-06-20,GCST001119,Schizophrenia
2496,Asian,983.0,21699788.0,Okada Y,"Digestive system disorder, Immune system disorder",replication,2011-06-20,GCST001118,Ulcerative colitis or Crohn's disease
7035,European,1979.0,21700265.0,Kullo IJ,Inflammatory measurement,initial,2011-06-22,GCST001120,Erythrocyte sedimentation rate
7580,European,2699.0,21703634.0,Wang KS,"Other measurement, Neurological disorder",initial,2011-06-22,GCST001121,Alcohol dependence
8788,European,5628.0,21700265.0,Kullo IJ,Inflammatory measurement,replication,2011-06-22,GCST001120,Erythrocyte sedimentation rate
7924,European,3334.0,21703634.0,Wang KS,"Other measurement, Neurological disorder",replication,2011-06-22,GCST001121,Alcohol dependence
14076,Other/Mixed,1120.0,21701565.0,Malhotra A,"Body measurement, Other measurement",initial,2011-06-23,GCST001123,Body mass index
6732,European,1591.0,21700879.0,Qi L,Other measurement,initial,2011-06-23,GCST001122,Adiponectin levels
5613,European,626.0,21700879.0,Qi L,Other measurement,replication,2011-06-23,GCST001122,Adiponectin levels
1200,African American or Afro-Caribbean,3724.0,21701570.0,Ng MC,"Body measurement, Other measurement",replication,2011-06-23,GCST001125,Body mass index
10932,European,33050.0,21738487.0,Do CB,Neurological disorder,initial,2011-06-23,GCST001126,Parkinson's disease
14155,Other/Mixed,2133.0,21701565.0,Malhotra A,"Body measurement, Other measurement",replication,2011-06-23,GCST001123,Body mass index
957,African American or Afro-Caribbean,1715.0,21701570.0,Ng MC,"Body measurement, Other measurement",initial,2011-06-23,GCST001125,Body mass index
8949,European,6271.0,21700618.0,Nan H,Cancer,replication,2011-06-23,GCST001124,Basal cell carcinoma
9351,European,8058.0,21700618.0,Nan H,Cancer,initial,2011-06-23,GCST001124,Basal cell carcinoma
4720,European,87.0,21705454.0,Huang RS,Response to drug,initial,2011-06-24,GCST001127,Response to platinum-based agents
4664,European,52.0,21705454.0,Huang RS,Response to drug,replication,2011-06-24,GCST001127,Response to platinum-based agents
3889,Asian,7557.0,21706003.0,Kilpelainen TO,Metabolic disorder,initial,2011-06-26,GCST001128,Adiposity
11113,European,39576.0,21706003.0,Kilpelainen TO,Metabolic disorder,replication,2011-06-26,GCST001128,Adiposity
7304,European,2306.0,21706340.0,Teerlink C,Cancer,initial,2011-06-26,GCST001129,Melanoma
10831,European,29069.0,21706003.0,Kilpelainen TO,Metabolic disorder,initial,2011-06-26,GCST001128,Adiposity
5079,European,327.0,21708048.0,Jiao H,"Other measurement, Metabolic disorder",initial,2011-06-28,GCST001130,Obesity
9785,European,10337.0,21708048.0,Jiao H,"Other measurement, Metabolic disorder",replication,2011-06-28,GCST001130,Obesity
6751,European,1614.0,21740922.0,Nebel A,Other measurement,replication,2011-06-29,GCST001131,Longevity
6923,European,1821.0,21740922.0,Nebel A,Other measurement,initial,2011-06-29,GCST001131,Longevity
4277,Asian,14767.0,21738479.0,Reiner AP,"Hematological measurement, Inflammatory measurement",replication,2011-06-30,GCST001133,White blood cell count
10480,European,19509.0,21738479.0,Reiner AP,"Hematological measurement, Inflammatory measurement",replication,2011-06-30,GCST001133,White blood cell count
4004,Asian,8794.0,21738478.0,Okada Y,"Hematological measurement, Inflammatory measurement",initial,2011-06-30,GCST001134,White blood cell types
3739,Asian,5998.0,21738478.0,Okada Y,"Hematological measurement, Inflammatory measurement",replication,2011-06-30,GCST001134,White blood cell types
10138,European,14265.0,21738491.0,Arking DE,Cardiovascular disease,replication,2011-06-30,GCST001132,Sudden cardiac arrest
13202,Hispanic or Latin American,3551.0,21738479.0,Reiner AP,"Hematological measurement, Inflammatory measurement",replication,2011-06-30,GCST001133,White blood cell count
10560,European,21283.0,21738491.0,Arking DE,Cardiovascular disease,initial,2011-06-30,GCST001132,Sudden cardiac arrest
1488,African American or Afro-Caribbean,16388.0,21738479.0,Reiner AP,"Hematological measurement, Inflammatory measurement",initial,2011-06-30,GCST001133,White blood cell count
1965,Asian,274.0,21787189.0,Nyberg F,Other disease,initial,2011-07-01,GCST001136,Interstitial lung disease
4979,European,251.0,21694509.0,Janicki PK,Other trait,initial,2011-07-01,GCST001138,Postoperative nausea and vomiting
10481,European,19509.0,21738480.0,Nalls MA,"Hematological measurement, Inflammatory measurement",initial,2011-07-01,GCST001137,White blood cell count
4918,European,208.0,21694509.0,Janicki PK,Other trait,replication,2011-07-01,GCST001138,Postoperative nausea and vomiting
9957,European,11823.0,21738480.0,Nalls MA,"Hematological measurement, Inflammatory measurement",replication,2011-07-01,GCST001137,White blood cell count
3637,Asian,5408.0,21725308.0,Hu Z,Cancer,initial,2011-07-03,GCST001140,Lung cancer
3128,Asian,2335.0,21725309.0,Miki D,Digestive system disorder,replication,2011-07-03,GCST001139,Chronic hepatitis C infection
4211,Asian,12722.0,21725308.0,Hu Z,Cancer,replication,2011-07-03,GCST001140,Lung cancer
2491,Asian,977.0,21725309.0,Miki D,Digestive system disorder,initial,2011-07-03,GCST001139,Chronic hepatitis C infection
6156,European,992.0,21729881.0,Major JM,Other measurement,replication,2011-07-05,GCST001142,Vitamin E levels
14182,Other/Mixed,2775.0,21729881.0,Major JM,Other measurement,replication,2011-07-05,GCST001142,Vitamin E levels
5957,European,869.0,22303337.0,Wang K,Lipid or lipoprotein measurement,replication,2011-07-05,GCST001143,HDL cholesterol
8222,European,4014.0,21729881.0,Major JM,Other measurement,initial,2011-07-05,GCST001142,Vitamin E levels
6601,European,1437.0,22303337.0,Wang K,Lipid or lipoprotein measurement,initial,2011-07-05,GCST001143,HDL cholesterol
6669,European,1531.0,21750702.0,Schosser A,"Biological process, Other measurement",replication,2011-07-05,GCST001141,Suicidal ideation
7170,European,2154.0,21750702.0,Schosser A,"Biological process, Other measurement",initial,2011-07-05,GCST001141,Suicidal ideation
485,African American or Afro-Caribbean,83.0,21755009.0,Wheeler HE,Response to drug,initial,2011-07-06,GCST001145,Chemotherapeutic susceptibility
9483,European,8434.0,21732829.0,Dolmans GH,Other disease,replication,2011-07-06,GCST001144,Dupuytren's disease
54,African,176.0,21755009.0,Wheeler HE,Response to drug,initial,2011-07-06,GCST001145,Chemotherapeutic susceptibility
8101,European,3692.0,21732829.0,Dolmans GH,Other disease,initial,2011-07-06,GCST001144,Dupuytren's disease
7335,European,2340.0,21750679.0,Allanore Y,Neurological disorder,initial,2011-07-07,GCST001146,Systemic sclerosis
8782,European,5608.0,21750679.0,Allanore Y,Neurological disorder,replication,2011-07-07,GCST001146,Systemic sclerosis
9175,European,7240.0,21743057.0,Schumacher FR,Cancer,initial,2011-07-08,GCST001147,Prostate cancer
10122,European,14090.0,21743057.0,Schumacher FR,Cancer,replication,2011-07-08,GCST001147,Prostate cancer
14250,Other/Mixed,12595.0,21743467.0,Kote-Jarai Z,Cancer,replication,2011-07-10,GCST001148,Prostate cancer
11210,European,46191.0,21743467.0,Kote-Jarai Z,Cancer,replication,2011-07-10,GCST001148,Prostate cancer
10074,European,13560.0,21743467.0,Kote-Jarai Z,Cancer,initial,2011-07-10,GCST001148,Prostate cancer
674,African American or Afro-Caribbean,410.0,21743467.0,Kote-Jarai Z,Cancer,replication,2011-07-10,GCST001148,Prostate cancer
2426,Asian,853.0,21743467.0,Kote-Jarai Z,Cancer,replication,2011-07-10,GCST001148,Prostate cancer
9016,European,6594.0,21743469.0,Evans DM,Immune system disorder,replication,2011-07-10,GCST001149,Ankylosing spondylitis
9955,European,11802.0,21743469.0,Evans DM,Immune system disorder,initial,2011-07-10,GCST001149,Ankylosing spondylitis
3180,Asian,2514.0,21750111.0,Mbarek H,"Digestive system disorder, Other measurement",initial,2011-07-12,GCST001150,Hepatitis B
3809,Asian,6649.0,21750111.0,Mbarek H,"Digestive system disorder, Other measurement",replication,2011-07-12,GCST001150,Hepatitis B
9991,European,12352.0,21752600.0,Chen J,Neurological disorder,replication,2011-07-12,GCST001151,Schizophrenia
10966,European,33577.0,21747397.0,Rietschel M,Neurological disorder,replication,2011-07-12,GCST001152,Schizophrenia
8522,European,4883.0,21747397.0,Rietschel M,Neurological disorder,initial,2011-07-12,GCST001152,Schizophrenia
1018,African American or Afro-Caribbean,2127.0,21752600.0,Chen J,Neurological disorder,replication,2011-07-12,GCST001151,Schizophrenia
10091,European,13632.0,21750109.0,Rafnar T,Cancer,replication,2011-07-12,GCST001153,Bladder cancer
7909,European,3313.0,21752600.0,Chen J,Neurological disorder,initial,2011-07-12,GCST001151,Schizophrenia
13934,Other/Mixed,515.0,21750109.0,Rafnar T,Cancer,replication,2011-07-12,GCST001153,Bladder cancer
11187,European,43837.0,21750109.0,Rafnar T,Cancer,initial,2011-07-12,GCST001153,Bladder cancer
6853,European,1727.0,21757650.0,Debette S,Cardiovascular measurement,replication,2011-07-14,GCST001155,Vascular endothelial growth factor levels
9686,European,9689.0,21779176.0,Winkelmann J,Neurological disorder,replication,2011-07-14,GCST001159,Restless legs syndrome
9207,European,7385.0,21779181.0,Gorlova O,Neurological disorder,replication,2011-07-14,GCST001160,Systemic sclerosis
9206,European,7385.0,21779181.0,Gorlova O,Neurological disorder,replication,2011-07-14,GCST001156,Systemic sclerosis
9225,European,7468.0,21779181.0,Gorlova O,Neurological disorder,initial,2011-07-14,GCST001160,Systemic sclerosis
7407,European,2448.0,21779176.0,Winkelmann J,Neurological disorder,initial,2011-07-14,GCST001159,Restless legs syndrome
8035,European,3527.0,21757650.0,Debette S,Cardiovascular measurement,initial,2011-07-14,GCST001155,Vascular endothelial growth factor levels
8639,European,5122.0,21779381.0,Schurks M,"Liver enzyme measurement, Cardiovascular measurement, Other measurement, Other disease, Lipid or lipoprotein measurement, Inflammatory measurement",initial,2011-07-14,GCST001157,Cardiovascular disease risk factors
9224,European,7468.0,21779181.0,Gorlova O,Neurological disorder,initial,2011-07-14,GCST001156,Systemic sclerosis
2804,Asian,1683.0,21764829.0,Png E,Response to drug,initial,2011-07-15,GCST001162,Hepatitis B vaccine response
8963,European,6322.0,21761138.0,Peters U,Cancer,initial,2011-07-15,GCST001161,Colorectal cancer
10348,European,17262.0,21761138.0,Peters U,Cancer,replication,2011-07-15,GCST001161,Colorectal cancer
2960,Asian,1931.0,21764829.0,Png E,Response to drug,replication,2011-07-15,GCST001162,Hepatitis B vaccine response
984,African American or Afro-Caribbean,1996.0,21768215.0,Tin A,"Metabolic disorder, Other measurement",replication,2011-07-18,GCST001163,Urate levels
1401,African American or Afro-Caribbean,8651.0,21768215.0,Tin A,"Metabolic disorder, Other measurement",initial,2011-07-18,GCST001163,Urate levels
13917,Other/Mixed,450.0,21771265.0,Yosifova A,Neurological disorder,replication,2011-07-19,GCST001164,Bipolar disorder
2219,Asian,559.0,21771975.0,Chung CM,Other measurement,replication,2011-07-19,GCST001165,Adiponectin levels
13940,Other/Mixed,564.0,21771265.0,Yosifova A,Neurological disorder,initial,2011-07-19,GCST001164,Bipolar disorder
2065,Asian,382.0,21771975.0,Chung CM,Other measurement,initial,2011-07-19,GCST001165,Adiponectin levels
493,African American or Afro-Caribbean,91.0,21775533.0,Tan XL,Response to drug,initial,2011-07-20,GCST001169,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers
1720,Asian,96.0,21775533.0,Tan XL,Response to drug,initial,2011-07-20,GCST001169,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers
10331,European,16995.0,21782286.0,Walter S,Biological process,initial,2011-07-20,GCST001166,Aging (time to event)
6370,European,1183.0,21775533.0,Tan XL,Response to drug,replication,2011-07-20,GCST001169,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers
10733,European,25007.0,21782286.0,Walter S,"Other measurement, Biological process",initial,2011-07-20,GCST001167,Aging (time to death)
4742,European,96.0,21775533.0,Tan XL,Response to drug,initial,2011-07-20,GCST001169,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers
9790,European,10411.0,21782286.0,Walter S,"Other measurement, Biological process",replication,2011-07-20,GCST001167,Aging (time to death)
1559,African American or Afro-Caribbean,30033.0,21775986.0,Hinch AG,Other measurement,initial,2011-07-20,GCST001168,Recombination measurement
3325,Asian,3106.0,21814517.0,Noguchi E,Other disease,replication,2011-07-21,GCST001172,Asthma
6761,European,1627.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",replication,2011-07-21,GCST001170,Lipid traits
199,African,1478.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",replication,2011-07-21,GCST001170,Lipid traits
5011,European,282.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",initial,2011-07-21,GCST001170,Lipid traits
3324,Asian,3106.0,21814517.0,Noguchi E,Other disease,initial,2011-07-21,GCST001172,Asthma
12760,Hispanic or Latin American,63.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",initial,2011-07-21,GCST001170,Lipid traits
13067,Hispanic or Latin American,1443.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",replication,2011-07-21,GCST001170,Lipid traits
466,African American or Afro-Caribbean,66.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",initial,2011-07-21,GCST001170,Lipid traits
4037,Asian,8903.0,21799836.0,Cui B,Metabolic disorder,replication,2011-07-22,GCST001173,Type 2 diabetes
2767,Asian,1599.0,21799836.0,Cui B,Metabolic disorder,initial,2011-07-22,GCST001173,Type 2 diabetes
6790,European,1657.0,21785125.0,Traglia M,Other measurement,initial,2011-07-25,GCST001174,Hepcidin levels
13809,Other/Mixed,189.0,21795503.0,Alkelai A,Neurological disorder,initial,2011-07-27,GCST001176,Schizophrenia
1655,Asian,48.0,21799462.0,Srinivasan Y,Other trait,replication,2011-07-27,GCST001175,Epirubicin-induced leukopenia
6349,European,1168.0,21795503.0,Alkelai A,Neurological disorder,replication,2011-07-27,GCST001176,Schizophrenia
1961,Asian,270.0,21799462.0,Srinivasan Y,Other trait,initial,2011-07-27,GCST001175,Epirubicin-induced leukopenia
9561,European,8866.0,21829377.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2011-07-28,GCST001177,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)
9564,European,8866.0,21829377.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2011-07-28,GCST001180,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)
9563,European,8866.0,21829377.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2011-07-28,GCST001179,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)
9562,European,8866.0,21829377.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2011-07-28,GCST001178,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)
7303,European,2305.0,21801394.0,Genin E,Other disease,initial,2011-07-29,GCST001181,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
13119,Hispanic or Latin American,2299.0,21804549.0,Torgerson DG,Other disease,replication,2011-07-31,GCST001182,Asthma
3573,Asian,4836.0,21804548.0,Hirota T,Other disease,initial,2011-07-31,GCST001183,Asthma
4427,Asian,30247.0,21804548.0,Hirota T,Other disease,replication,2011-07-31,GCST001183,Asthma
13091,Hispanic or Latin American,1688.0,21804549.0,Torgerson DG,Other disease,initial,2011-07-31,GCST001182,Asthma
7482,European,2538.0,21804547.0,Dobbins SE,Cancer,replication,2011-07-31,GCST001184,Meningioma
1019,African American or Afro-Caribbean,2147.0,21804549.0,Torgerson DG,Other disease,replication,2011-07-31,GCST001182,Asthma
6710,European,1563.0,21804547.0,Dobbins SE,Cancer,initial,2011-07-31,GCST001184,Meningioma
7597,European,2727.0,21804549.0,Torgerson DG,Other disease,replication,2011-07-31,GCST001182,Asthma
7129,European,2088.0,21804549.0,Torgerson DG,Other disease,initial,2011-07-31,GCST001182,Asthma
947,African American or Afro-Caribbean,1612.0,21804549.0,Torgerson DG,Other disease,initial,2011-07-31,GCST001182,Asthma
6241,European,1054.0,21810643.0,Bakken TE,Other measurement,initial,2011-08-01,GCST001187,Cortical thickness
9478,European,8424.0,21846871.0,Mehta NN,Cardiovascular disease,initial,2011-08-01,GCST001185,Coronary heart disease
1799,Asian,149.0,21810746.0,Chantarangsu S,Response to drug,initial,2011-08-01,GCST001186,Nevirapine-induced rash
1918,Asian,233.0,21810746.0,Chantarangsu S,Response to drug,replication,2011-08-01,GCST001186,Nevirapine-induced rash
3839,Asian,6996.0,21846871.0,Mehta NN,Cardiovascular disease,initial,2011-08-01,GCST001185,Coronary heart disease
6757,European,1624.0,21810271.0,Antoni G,"Hematological measurement, Other measurement",initial,2011-08-02,GCST001188,vWF and FVIII levels
5294,European,446.0,21812969.0,Liu X,Neurological disorder,initial,2011-08-03,GCST001189,Parkinson's disease
7993,European,3440.0,21812969.0,Liu X,Neurological disorder,replication,2011-08-03,GCST001189,Parkinson's disease
10453,European,19102.0,21829393.0,Plagnol V,Metabolic disorder,initial,2011-08-04,GCST001191,Type 1 diabetes
7437,European,2506.0,21829393.0,Plagnol V,"Other measurement, Metabolic disorder",initial,2011-08-04,GCST004380,Glutamate decarboxylase autoantibody levels in type 1 diabetes
1375,African American or Afro-Caribbean,8155.0,21829389.0,Barbalic M,Cardiovascular disease,replication,2011-08-04,GCST001190,Coronary heart disease
9391,European,8300.0,21829393.0,Plagnol V,"Other measurement, Metabolic disorder",initial,2011-08-04,GCST004383,Thyroid peroxidase autoantibody levels in type 1 diabetes
7432,European,2498.0,21829393.0,Plagnol V,"Other measurement, Metabolic disorder",initial,2011-08-04,GCST004381,Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes
1100,African American or Afro-Caribbean,2905.0,21829389.0,Barbalic M,Cardiovascular disease,initial,2011-08-04,GCST001190,Coronary heart disease
8335,European,4328.0,21829393.0,Plagnol V,"Other measurement, Metabolic disorder",initial,2011-08-04,GCST004382,Gastric parietal cell autoantibody levels in type 1 diabetes
4700,European,79.0,21826682.0,Isackson PJ,Response to drug,initial,2011-08-08,GCST001192,Response to statin therapy
9808,European,10577.0,21824976.0,Garcia-Closas M,Cancer,initial,2011-08-08,GCST001193,Bladder cancer
8059,European,3583.0,21824976.0,Garcia-Closas M,Cancer,replication,2011-08-08,GCST001193,Bladder cancer
4773,European,109.0,21826682.0,Isackson PJ,Response to drug,replication,2011-08-08,GCST001192,Response to statin therapy
5674,European,670.0,21826061.0,Davies G,Biological process,replication,2011-08-09,GCST001195,Intelligence
8024,European,3511.0,21826061.0,Davies G,Biological process,initial,2011-08-09,GCST001195,Intelligence
1762,Asian,122.0,21826085.0,Tanaka S,Neurological disorder,initial,2011-08-09,GCST001196,Tardive dyskinesia
8478,European,4773.0,21827660.0,Yang TH,Cancer,initial,2011-08-09,GCST001194,Glioma
1825,Asian,174.0,21826085.0,Tanaka S,Neurological disorder,replication,2011-08-09,GCST001196,Tardive dyskinesia
5123,European,351.0,21836138.0,Hadchouel A,Other disease,replication,2011-08-11,GCST001197,Bronchopulmonary dysplasia
4749,European,98.0,21836138.0,Hadchouel A,Other disease,initial,2011-08-11,GCST001197,Bronchopulmonary dysplasia
9917,European,11514.0,21833088.0,Sawcer S,Immune system disorder,replication,2011-08-11,GCST001198,Multiple sclerosis
10772,European,26621.0,21833088.0,Sawcer S,Immune system disorder,initial,2011-08-11,GCST001198,Multiple sclerosis
23,African,47.0,21836138.0,Hadchouel A,Other disease,replication,2011-08-11,GCST001197,Bronchopulmonary dysplasia
42,African,107.0,21836138.0,Hadchouel A,Other disease,initial,2011-08-11,GCST001197,Bronchopulmonary dysplasia
5527,European,572.0,21835309.0,Larsson M,Other measurement,replication,2011-08-12,GCST001199,Iris characteristics
7145,European,2121.0,21835309.0,Larsson M,Other measurement,initial,2011-08-12,GCST001199,Iris characteristics
3880,Asian,7504.0,21841780.0,Chu X,Immune system disorder,replication,2011-08-14,GCST001200,Graves' disease
3295,Asian,2958.0,21841780.0,Chu X,Immune system disorder,initial,2011-08-14,GCST001200,Graves' disease
4838,European,174.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001201,Response to platinum-based chemotherapy (cisplatin)
4839,European,174.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001204,Response to platinum-based chemotherapy (carboplatin)
55,African,176.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001201,Response to platinum-based chemotherapy (cisplatin)
2304,Asian,700.0,21844665.0,Hu HJ,Immune system disorder,initial,2011-08-16,GCST001203,Rheumatoid arthritis
2630,Asian,1289.0,21844665.0,Hu HJ,Immune system disorder,replication,2011-08-16,GCST001203,Rheumatoid arthritis
56,African,176.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001204,Response to platinum-based chemotherapy (carboplatin)
34,African,83.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001204,Response to platinum-based chemotherapy (carboplatin)
1826,Asian,175.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001201,Response to platinum-based chemotherapy (cisplatin)
33,African,83.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001201,Response to platinum-based chemotherapy (cisplatin)
1827,Asian,175.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001204,Response to platinum-based chemotherapy (carboplatin)
7371,European,2389.0,21876681.0,Hamza TH,"Neurological disorder, Biological process",initial,2011-08-18,GCST001205,Parkinson's disease (coffee consumption interaction)
7699,European,2931.0,21876681.0,Hamza TH,"Neurological disorder, Biological process",replication,2011-08-18,GCST001205,Parkinson's disease (coffee consumption interaction)
6391,European,1201.0,21886828.0,Wei W,Cardiovascular measurement,initial,2011-08-19,GCST001206,Uric acid levels (SNP x SNP interaction)
8432,European,4641.0,21886828.0,Wei W,Cardiovascular measurement,replication,2011-08-19,GCST001206,Uric acid levels (SNP x SNP interaction)
9091,European,6879.0,21862451.0,Benyamin B,Liver enzyme measurement,initial,2011-08-23,GCST001207,Butyrylcholinesterase levels
6983,European,1912.0,21862451.0,Benyamin B,Liver enzyme measurement,replication,2011-08-23,GCST001207,Butyrylcholinesterase levels
2668,Asian,1394.0,21866343.0,Ahn MJ,Cancer,replication,2011-08-25,GCST001210,Non-small cell lung cancer
11021,European,35474.0,21871595.0,Day-Williams AG,Other disease,replication,2011-08-25,GCST001209,Osteoarthritis
2469,Asian,942.0,21866343.0,Ahn MJ,Cancer,initial,2011-08-25,GCST001210,Non-small cell lung cancer
839,African American or Afro-Caribbean,1040.0,21901158.0,Irvin MR,Other trait,initial,2011-08-25,GCST001208,Insulin resistance/response
9355,European,8071.0,21871595.0,Day-Williams AG,Other disease,initial,2011-08-25,GCST001209,Osteoarthritis
9831,European,10701.0,21873549.0,Strawbridge RJ,Other measurement,initial,2011-08-26,GCST001212,Proinsulin levels
6206,European,1016.0,21876473.0,Lydall GJ,"Other measurement, Neurological disorder",initial,2011-08-26,GCST001211,Alcohol dependence
10287,European,16378.0,21873549.0,Strawbridge RJ,Other measurement,replication,2011-08-26,GCST001212,Proinsulin levels
4485,Asian,38568.0,21874001.0,Kooner JS,Metabolic disorder,replication,2011-08-28,GCST001213,Type 2 diabetes
4360,Asian,20019.0,21874001.0,Kooner JS,Metabolic disorder,initial,2011-08-28,GCST001213,Type 2 diabetes
8598,European,5006.0,21878437.0,Mondul AM,Other measurement,initial,2011-08-30,GCST001216,Retinol levels
9321,European,7929.0,21876539.0,Amin N,"Biological process, Other measurement",replication,2011-08-30,GCST001215,Coffee consumption
5951,European,866.0,21878436.0,Sampietro ML,Cardiovascular disease,initial,2011-08-30,GCST001214,Coronary restenosis
6302,European,1124.0,21878437.0,Mondul AM,Other measurement,replication,2011-08-30,GCST001216,Retinol levels
10432,European,18716.0,21876539.0,Amin N,"Biological process, Other measurement",initial,2011-08-30,GCST001215,Coffee consumption
7925,European,3335.0,21878436.0,Sampietro ML,Cardiovascular disease,replication,2011-08-30,GCST001214,Coronary restenosis
7646,European,2820.0,21886157.0,Suhre K,"Other measurement, Biological process, Lipid or lipoprotein measurement",initial,2011-08-31,GCST001217,Metabolic traits
6607,European,1450.0,21900290.0,Qi Q,Lipid or lipoprotein measurement,initial,2011-09-06,GCST001218,Lp (a) levels
7725,European,2994.0,21931568.0,Geller F,Biological process,replication,2011-09-08,GCST001221,Permanent tooth development
4905,European,202.0,21931564.0,Nicholson G,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",replication,2011-09-08,GCST001220,Metabolite levels
4798,European,142.0,21931564.0,Nicholson G,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2011-09-08,GCST001220,Metabolite levels
8631,European,5088.0,21931568.0,Geller F,Biological process,initial,2011-09-08,GCST001221,Permanent tooth development
3424,Asian,3837.0,21900946.0,Nakabayashi K,Immune system disorder,initial,2011-09-08,GCST001219,Graves' disease
2763,Asian,1589.0,21900946.0,Nakabayashi K,Immune system disorder,replication,2011-09-08,GCST001219,Graves' disease
5952,European,866.0,21900944.0,Shen H,Liver enzyme measurement,initial,2011-09-08,GCST001222,Aspartate aminotransferase levels
4426,Asian,29968.0,21908515.0,Cai Q,Cancer,replication,2011-09-09,GCST001224,Breast cancer
4702,European,80.0,21912186.0,Smith AK,Immune system disorder,initial,2011-09-09,GCST001223,Chronic fatigue syndrome
3466,Asian,4128.0,21908515.0,Cai Q,Cancer,initial,2011-09-09,GCST001224,Breast cancer
10739,European,25358.0,21907864.0,Ferreira MA,Other disease,replication,2011-09-10,GCST001226,Asthma
8494,European,4811.0,21896673.0,Chen D,Other measurement,initial,2011-09-10,GCST001225,HPV seropositivity
10916,European,32442.0,21907864.0,Ferreira MA,Other disease,initial,2011-09-10,GCST001226,Asthma
13125,Hispanic or Latin American,2344.0,21896673.0,Chen D,Other measurement,replication,2011-09-10,GCST001225,HPV seropositivity
11496,European,69395.0,21909115.0,Ehret GB,Other measurement,initial,2011-09-11,GCST001227,Systolic blood pressure
11497,European,69395.0,21909115.0,Ehret GB,Other measurement,initial,2011-09-11,GCST001228,Diastolic blood pressure
4304,Asian,16280.0,21909106.0,Arakawa S,Neurological disorder,replication,2011-09-11,GCST001232,Age-related macular degeneration
3471,Asian,4150.0,21909106.0,Arakawa S,Neurological disorder,initial,2011-09-11,GCST001232,Age-related macular degeneration
11495,European,69395.0,21909115.0,Ehret GB,Cardiovascular disease,initial,2011-09-11,GCST001238,Hypertension
6772,European,1639.0,21909107.0,LeMaire SA,Cardiovascular disease,initial,2011-09-11,GCST001229,Thoracic aortic aneurysms and dissections
11255,European,48607.0,21909110.0,Wain LV,"Other measurement, Cardiovascular measurement",replication,2011-09-11,GCST001236,Blood pressure
4431,Asian,30395.0,21909109.0,Kim YJ,Liver enzyme measurement,replication,2011-09-11,GCST001234,Gamma glutamyl transpeptidase
4202,Asian,12545.0,21909109.0,Kim YJ,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2011-09-11,GCST001233,Metabolite levels
4429,Asian,30395.0,21909109.0,Kim YJ,Lipid or lipoprotein measurement,replication,2011-09-11,GCST001230,Triglycerides
4432,Asian,30395.0,21909109.0,Kim YJ,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",replication,2011-09-11,GCST001233,Metabolite levels
11531,European,74064.0,21909110.0,Wain LV,"Other measurement, Cardiovascular measurement",initial,2011-09-11,GCST001235,Blood pressure
11943,European,133661.0,21909115.0,Ehret GB,Other measurement,replication,2011-09-11,GCST001227,Systolic blood pressure
13985,Other/Mixed,687.0,21909108.0,Bis JC,"Other measurement, Cardiovascular measurement, Cardiovascular disease",replication,2011-09-11,GCST001231,Carotid intima media thickness
6359,European,1174.0,21909107.0,LeMaire SA,Cardiovascular disease,replication,2011-09-11,GCST001229,Thoracic aortic aneurysms and dissections
11532,European,74064.0,21909110.0,Wain LV,"Other measurement, Cardiovascular measurement",initial,2011-09-11,GCST001236,Blood pressure
11254,European,48607.0,21909110.0,Wain LV,"Other measurement, Cardiovascular measurement",replication,2011-09-11,GCST001235,Blood pressure
4199,Asian,12545.0,21909109.0,Kim YJ,Lipid or lipoprotein measurement,initial,2011-09-11,GCST001230,Triglycerides
11942,European,133661.0,21909115.0,Ehret GB,Cardiovascular disease,replication,2011-09-11,GCST001238,Hypertension
10886,European,31211.0,21909108.0,Bis JC,"Other measurement, Cardiovascular measurement, Cardiovascular disease",initial,2011-09-11,GCST001231,Carotid intima media thickness
4200,Asian,12545.0,21909109.0,Kim YJ,Lipid or lipoprotein measurement,initial,2011-09-11,GCST001237,HDL cholesterol
4201,Asian,12545.0,21909109.0,Kim YJ,Liver enzyme measurement,initial,2011-09-11,GCST001234,Gamma glutamyl transpeptidase
4430,Asian,30395.0,21909109.0,Kim YJ,Lipid or lipoprotein measurement,replication,2011-09-11,GCST001237,HDL cholesterol
11944,European,133661.0,21909115.0,Ehret GB,Other measurement,replication,2011-09-11,GCST001228,Diastolic blood pressure
2504,Asian,1005.0,21912425.0,Tohkin M,Other disease,initial,2011-09-13,GCST001239,Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)
10837,European,29181.0,21935397.0,Paternoster L,"Metabolic disorder, Body measurement",replication,2011-09-15,GCST001240,Obesity (extreme)
8726,European,5373.0,21935397.0,Paternoster L,"Metabolic disorder, Body measurement",initial,2011-09-15,GCST001240,Obesity (extreme)
11229,European,46918.0,21926972.0,Sklar P,Neurological disorder,replication,2011-09-18,GCST001241,Bipolar disorder
10612,European,21856.0,21926974.0,Ripke S,Neurological disorder,initial,2011-09-18,GCST001242,Schizophrenia
10849,European,29839.0,21926974.0,Ripke S,Neurological disorder,replication,2011-09-18,GCST001242,Schizophrenia
10312,European,16731.0,21926972.0,Sklar P,Neurological disorder,initial,2011-09-18,GCST001241,Bipolar disorder
6493,European,1305.0,21940522.0,Shaffer JR,Digestive system disorder,initial,2011-09-21,GCST001244,Dental caries
7971,European,3402.0,21957438.0,Meschia JF,Cardiovascular disease,initial,2011-09-21,GCST001243,Stroke
6810,European,1695.0,21940522.0,Shaffer JR,Digestive system disorder,replication,2011-09-21,GCST001244,Dental caries
14271,Other/Mixed,29807.0,21926416.0,Amos CI,Cancer,replication,2011-09-22,GCST001245,Melanoma
7651,European,2830.0,21926416.0,Amos CI,Cancer,initial,2011-09-22,GCST001245,Melanoma
9930,European,11683.0,21943158.0,Middelberg RP,"Liver enzyme measurement, Cardiovascular measurement, Other measurement, Other disease, Lipid or lipoprotein measurement, Inflammatory measurement",initial,2011-09-24,GCST001247,Cardiovascular disease risk factors
11218,European,46411.0,21946350.0,Soler Artigas M,Other measurement,replication,2011-09-25,GCST001251,Pulmonary function
11156,European,41735.0,21946351.0,Stacey SN,Cancer,initial,2011-09-25,GCST001250,Basal cell carcinoma
14261,Other/Mixed,17607.0,21946351.0,Stacey SN,Cancer,replication,2011-09-25,GCST001250,Basal cell carcinoma
2780,Asian,1627.0,21947420.0,Lei SF,Other measurement,initial,2011-09-25,GCST001249,Spine bone size
6855,European,1728.0,21947420.0,Lei SF,Other measurement,replication,2011-09-25,GCST001249,Spine bone size
11217,European,46411.0,21946350.0,Soler Artigas M,Other measurement,replication,2011-09-25,GCST001248,Pulmonary function
11248,European,48201.0,21946350.0,Soler Artigas M,Other measurement,initial,2011-09-25,GCST001251,Pulmonary function
11247,European,48201.0,21946350.0,Soler Artigas M,Other measurement,initial,2011-09-25,GCST001248,Pulmonary function
6351,European,1169.0,21991891.0,Tantisira KG,Response to drug,initial,2011-09-26,GCST001252,Asthma treatment response
6052,European,935.0,21991891.0,Tantisira KG,Response to drug,replication,2011-09-26,GCST001252,Asthma treatment response
7550,European,2652.0,21980494.0,Germain M,Cardiovascular disease,initial,2011-09-27,GCST001253,Venous thromboembolism
7692,European,2927.0,21956439.0,Zuo L,"Other measurement, Neurological disorder",initial,2011-09-28,GCST001254,Alcohol dependence
868,African American or Afro-Caribbean,1189.0,21956439.0,Zuo L,"Other measurement, Neurological disorder",initial,2011-09-28,GCST001254,Alcohol dependence
10783,European,26890.0,21980299.0,Bradfield JP,Metabolic disorder,initial,2011-09-29,GCST001255,Type 1 diabetes
7946,European,3360.0,21980299.0,Bradfield JP,Metabolic disorder,replication,2011-09-29,GCST001255,Type 1 diabetes
6385,European,1199.0,21980348.0,Fox AA,Cardiovascular disease,initial,2011-09-30,GCST001256,Postoperative ventricular dysfunction
6566,European,1388.0,21980348.0,Fox AA,Cardiovascular disease,replication,2011-09-30,GCST001256,Postoperative ventricular dysfunction
3253,Asian,2798.0,22004137.0,Liu L,"Digestive system disorder, Other measurement",initial,2011-10-01,GCST001257,Hepatitis B
11164,European,42247.0,21964575.0,Rafnar T,Cancer,initial,2011-10-02,GCST001258,Ovarian cancer
4807,European,152.0,21961650.0,Squassina A,"Response to drug, Neurological disorder",replication,2011-10-03,GCST001259,Response to lithium treatment in bipolar disorder
4665,European,52.0,21961650.0,Squassina A,"Response to drug, Neurological disorder",initial,2011-10-03,GCST001259,Response to lithium treatment in bipolar disorder
4082,Asian,9928.0,21971053.0,Takeuchi F,Cardiovascular disease,replication,2011-10-05,GCST001260,Coronary heart disease
3400,Asian,3648.0,21971053.0,Takeuchi F,Cardiovascular disease,initial,2011-10-05,GCST001260,Coronary heart disease
9569,European,8938.0,21998597.0,Ohlsson C,Other measurement,initial,2011-10-06,GCST001264,Testosterone levels
6304,European,1129.0,21979947.0,Li X,"Other measurement, Neurological disorder",replication,2011-10-06,GCST001261,Corneal structure
14264,Other/Mixed,20427.0,21998595.0,N'Diaye A,"Other measurement, Body measurement",initial,2011-10-06,GCST001263,Height
8043,European,3546.0,21979947.0,Li X,"Other measurement, Neurological disorder",initial,2011-10-06,GCST001261,Corneal structure
1492,African American or Afro-Caribbean,16436.0,21998595.0,N'Diaye A,"Other measurement, Body measurement",replication,2011-10-06,GCST001263,Height
8677,European,5244.0,21977987.0,Trompet S,"Lipid or lipoprotein measurement, Other measurement",initial,2011-10-06,GCST001262,LDL cholesterol
8766,European,5491.0,21998597.0,Ohlsson C,Other measurement,replication,2011-10-06,GCST001264,Testosterone levels
6966,European,1879.0,21981779.0,Denny JC,Other disease,replication,2011-10-07,GCST001265,Hypothyroidism
8970,European,6370.0,21981779.0,Denny JC,Other disease,initial,2011-10-07,GCST001265,Hypothyroidism
11144,European,40968.0,21983786.0,Sulem P,Metabolic disorder,initial,2011-10-09,GCST001268,Gout
10222,European,15506.0,21983786.0,Sulem P,Cardiovascular measurement,initial,2011-10-09,GCST001269,Serum uric acid levels
10521,European,20337.0,21983785.0,Macgregor S,Cancer,replication,2011-10-09,GCST001266,Melanoma
9009,European,6555.0,21983785.0,Macgregor S,Cancer,initial,2011-10-09,GCST001266,Melanoma
10034,European,13000.0,21983787.0,Barrett JH,Cancer,replication,2011-10-09,GCST001267,Melanoma
9791,European,10422.0,21983787.0,Barrett JH,Cancer,initial,2011-10-09,GCST001267,Melanoma
13906,Other/Mixed,409.0,21990027.0,Drago A,Response to drug,initial,2011-10-11,GCST001271,Response to antipsychotic therapy (extrapyramidal side effects)
6124,European,977.0,21996601.0,Das K,"Other measurement, Cardiovascular measurement",initial,2011-10-11,GCST001270,Blood pressure
7150,European,2133.0,21993531.0,Kuparinen T,Biological process,initial,2011-10-13,GCST001272,Cytomegalovirus antibody response
9978,European,12126.0,22003152.0,Grallert H,Lipid or lipoprotein measurement,initial,2011-10-14,GCST001273,Lipoprotein-associated phospholipase A2 activity and mass
8132,European,3781.0,22003120.0,Burdon KP,"Other measurement, Neurological disorder",initial,2011-10-14,GCST001274,Corneal structure
6499,European,1317.0,22003120.0,Burdon KP,"Other measurement, Neurological disorder",replication,2011-10-14,GCST001274,Corneal structure
3996,Asian,8739.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001275,Liver enzyme levels (alanine transaminase)
11300,European,52350.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001275,Liver enzyme levels (alanine transaminase)
11301,European,52350.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001276,Liver enzyme levels (alkaline phosphatase)
11302,European,52350.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001277,Liver enzyme levels (gamma-glutamyl transferase)
3551,Asian,4671.0,22001756.0,Khor CC,Other disease,replication,2011-10-16,GCST001278,Dengue shock syndrome
3998,Asian,8739.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001277,Liver enzyme levels (gamma-glutamyl transferase)
3997,Asian,8739.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001276,Liver enzyme levels (alkaline phosphatase)
3452,Asian,4026.0,22001756.0,Khor CC,Other disease,initial,2011-10-16,GCST001278,Dengue shock syndrome
2685,Asian,1443.0,22004975.0,Li R,Immune system disorder,replication,2011-10-17,GCST001279,Systemic lupus erythematosus
3255,Asian,2805.0,22004975.0,Li R,Immune system disorder,initial,2011-10-17,GCST001279,Systemic lupus erythematosus
3896,Asian,7674.0,22004975.0,Li R,Immune system disorder,replication,2011-10-17,GCST001279,Systemic lupus erythematosus
13601,Other/Mixed,2.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001282,Psychosis in Alzheimer's disease
13602,Other/Mixed,2.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001285,Psychosis and Alzheimer's disease
8022,European,3501.0,22004471.0,Frank J,"Other measurement, Neurological disorder",initial,2011-10-18,GCST001281,Alcohol dependence
7107,European,2062.0,22833195.0,Terracciano A,Other measurement,replication,2011-10-18,GCST006796,Excitement-seeking behaviour
2587,Asian,1200.0,21989058.0,Qin Y,Other disease,replication,2011-10-18,GCST001284,Premature ovarian failure
7378,European,2410.0,22010048.0,Wu X,Cancer,initial,2011-10-18,GCST001283,Renal cell carcinoma
9302,European,7860.0,22833195.0,Terracciano A,Other measurement,initial,2011-10-18,GCST006796,Excitement-seeking behaviour
6375,European,1190.0,22005931.0,Kamboh MI,"Neurological disorder, Other measurement",initial,2011-10-18,GCST001280,Alzheimer's disease (age of onset)
5675,European,671.0,22006218.0,Yoon D,Biological process,replication,2011-10-18,GCST001286,Smoking behavior
414,African American or Afro-Caribbean,12.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001285,Psychosis and Alzheimer's disease
9985,European,12277.0,22010048.0,Wu X,Cancer,replication,2011-10-18,GCST001283,Renal cell carcinoma
413,African American or Afro-Caribbean,12.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001282,Psychosis in Alzheimer's disease
2628,Asian,1286.0,21989058.0,Qin Y,Other disease,initial,2011-10-18,GCST001284,Premature ovarian failure
7063,European,2020.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001282,Psychosis in Alzheimer's disease
9115,European,6944.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001285,Psychosis and Alzheimer's disease
911,African American or Afro-Caribbean,1366.0,22006218.0,Yoon D,Biological process,replication,2011-10-18,GCST001286,Smoking behavior
4020,Asian,8842.0,22006218.0,Yoon D,Biological process,initial,2011-10-18,GCST001286,Smoking behavior
6911,European,1795.0,22012869.0,Hinney A,Neurological disorder,initial,2011-10-19,GCST001287,Attention deficit hyperactivity disorder
8346,European,4374.0,22012869.0,Hinney A,Neurological disorder,replication,2011-10-19,GCST001287,Attention deficit hyperactivity disorder
5568,European,598.0,22013104.0,Melka MG,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",initial,2011-10-19,GCST001288,Obesity-related traits
14249,Other/Mixed,11163.0,22028671.0,Surakka I,"Lipid or lipoprotein measurement, Other measurement",replication,2011-10-20,GCST001289,Lipid traits
9914,European,11509.0,22028671.0,Surakka I,"Lipid or lipoprotein measurement, Other measurement",replication,2011-10-20,GCST001289,Lipid traits
10907,European,32225.0,22028671.0,Surakka I,"Lipid or lipoprotein measurement, Other measurement",initial,2011-10-20,GCST001289,Lipid traits
1374,African American or Afro-Caribbean,8149.0,22021425.0,Carty CL,"Other measurement, Body measurement",initial,2011-10-21,GCST001290,Height
1514,African American or Afro-Caribbean,20809.0,22021425.0,Carty CL,"Other measurement, Body measurement",replication,2011-10-21,GCST001290,Height
3979,Asian,8600.0,22019778.0,Zhang F,Neurological disorder,replication,2011-10-23,GCST001292,Leprosy
4103,Asian,10149.0,22019779.0,Takahashi Y,Other disease,replication,2011-10-23,GCST001293,Scoliosis
3173,Asian,2506.0,22019779.0,Takahashi Y,Other disease,initial,2011-10-23,GCST001293,Scoliosis
3773,Asian,6287.0,22019778.0,Zhang F,Neurological disorder,initial,2011-10-23,GCST001292,Leprosy
14134,Other/Mixed,1772.0,22029572.0,Simonson MA,"Liver enzyme measurement, Cardiovascular measurement, Other measurement, Other disease, Lipid or lipoprotein measurement, Inflammatory measurement",initial,2011-10-26,GCST001294,Cardiovascular disease risk factors
6565,European,1385.0,22027810.0,Forstbauer LM,Other disease,initial,2011-10-26,GCST001295,Alopecia areata
5409,European,501.0,22030708.0,Menke A,"Biological process, Other measurement",replication,2011-10-26,GCST001296,Suicidal ideation
7736,European,3012.0,22027810.0,Forstbauer LM,Other disease,replication,2011-10-26,GCST001295,Alopecia areata
5185,European,397.0,22030708.0,Menke A,"Biological process, Other measurement",initial,2011-10-26,GCST001296,Suicidal ideation
5597,European,612.0,22032556.0,Brockschmidt FF,"Other measurement, Other disease",replication,2011-10-27,GCST001297,Male-pattern baldness
6384,European,1198.0,22032556.0,Brockschmidt FF,"Other measurement, Other disease",initial,2011-10-27,GCST001297,Male-pattern baldness
3825,Asian,6897.0,22037551.0,Shi Y,Cancer,replication,2011-10-30,GCST001300,Gastric cancer
3343,Asian,3279.0,22037551.0,Shi Y,Cancer,initial,2011-10-30,GCST001300,Gastric cancer
4038,Asian,8922.0,22037555.0,Shi Y,Neurological disorder,replication,2011-10-30,GCST001301,Schizophrenia
3130,Asian,2345.0,22037552.0,Yue WH,Neurological disorder,initial,2011-10-30,GCST001299,Schizophrenia
4073,Asian,9630.0,22037552.0,Yue WH,Neurological disorder,replication,2011-10-30,GCST001299,Schizophrenia
10460,European,19193.0,22037553.0,Haiman CA,Cancer,replication,2011-10-30,GCST001298,Breast cancer
1204,African American or Afro-Caribbean,3749.0,22037553.0,Haiman CA,Cancer,initial,2011-10-30,GCST001298,Breast cancer
200,African,1487.0,22037903.0,Crosslin DR,"Hematological measurement, Inflammatory measurement",initial,2011-10-30,GCST001302,White blood cell count
9974,European,12046.0,22037903.0,Crosslin DR,"Hematological measurement, Inflammatory measurement",initial,2011-10-30,GCST001302,White blood cell count
4108,Asian,10218.0,22037555.0,Shi Y,Neurological disorder,initial,2011-10-30,GCST001301,Schizophrenia
8729,European,5388.0,22037553.0,Haiman CA,Cancer,initial,2011-10-30,GCST001298,Breast cancer
6331,European,1151.0,22041458.0,Clark SL,"Response to drug, Other trait",initial,2011-11-01,GCST001308,Response to anti-depressant treatment in major depressive disorder
9990,European,12347.0,22036096.0,Ramasamy A,Immune system disorder,initial,2011-11-01,GCST001303,IgE grass sensitization
13909,Other/Mixed,418.0,22295569.0,Karunas AS,Other disease,replication,2011-11-01,GCST001306,Asthma
5179,European,395.0,22051697.0,Du R,Other disease,initial,2011-11-01,GCST001309,Asthma
10006,European,12526.0,22010049.0,Middelberg RP,Liver enzyme measurement,initial,2011-11-01,GCST001307,Gamma glutamyl transferase levels
10031,European,12898.0,22036096.0,Ramasamy A,Immune system disorder,initial,2011-11-01,GCST001310,Allergic rhinitis
7640,European,2809.0,22044751.0,Foster MC,Other measurement,initial,2011-11-01,GCST001304,Renal sinus fat
621,African American or Afro-Caribbean,288.0,22041458.0,Clark SL,"Response to drug, Other trait",initial,2011-11-01,GCST001308,Response to anti-depressant treatment in major depressive disorder
12912,Hispanic or Latin American,584.0,22051697.0,Du R,Other disease,replication,2011-11-01,GCST001309,Asthma
13980,Other/Mixed,678.0,22295569.0,Karunas AS,Other disease,initial,2011-11-01,GCST001306,Asthma
6708,European,1562.0,22054870.0,De Jager PL,"Other trait, Biological process",replication,2011-11-03,GCST001311,Cognitive decline
5792,European,749.0,22054870.0,De Jager PL,"Other trait, Biological process",initial,2011-11-03,GCST001311,Cognitive decline
14013,Other/Mixed,717.0,22054870.0,De Jager PL,"Other trait, Biological process",replication,2011-11-03,GCST001311,Cognitive decline
11128,European,40011.0,22055160.0,Bown MJ,Cardiovascular disease,replication,2011-11-04,GCST001312,Abdominal aortic aneurysm
9161,European,7172.0,22055160.0,Bown MJ,Cardiovascular disease,initial,2011-11-04,GCST001312,Abdominal aortic aneurysm
5966,European,874.0,22064162.0,Edwards AC,Neurological disorder,initial,2011-11-05,GCST001313,Depression and alcohol dependence
2250,Asian,620.0,22057235.0,Trynka G,Immune system disorder,initial,2011-11-06,GCST005523,Celiac disease
10669,European,23649.0,22057235.0,Trynka G,Immune system disorder,initial,2011-11-06,GCST005523,Celiac disease
3347,Asian,3310.0,22065538.0,Morisaki H,Other measurement,initial,2011-11-07,GCST001314,Adiponectin levels
7281,European,2286.0,22087292.0,Sun L,Other measurement,replication,2011-11-07,GCST001315,Femoral neck bone geometry
2781,Asian,1627.0,22087292.0,Sun L,Other measurement,initial,2011-11-07,GCST001315,Femoral neck bone geometry
9295,European,7809.0,22075330.0,Granada M,Other measurement,replication,2011-11-08,GCST001316,IgE levels
10536,European,20634.0,22068335.0,Mitchell GF,Cardiovascular measurement,initial,2011-11-08,GCST001317,Aortic stiffness
9081,European,6819.0,22075330.0,Granada M,Other measurement,initial,2011-11-08,GCST001316,IgE levels
8713,European,5306.0,22068335.0,Mitchell GF,Cardiovascular measurement,replication,2011-11-08,GCST001317,Aortic stiffness
7544,European,2647.0,22075249.0,Tang WH,Other measurement,initial,2011-11-10,GCST001318,Serum ceruloplasmin levels
7098,European,2050.0,22075249.0,Tang WH,Other measurement,replication,2011-11-10,GCST001318,Serum ceruloplasmin levels
5992,European,893.0,22076464.0,Ellinghaus E,Cancer,initial,2011-11-11,GCST001320,Acute lymphoblastic leukemia (childhood)
8340,European,4338.0,22076464.0,Ellinghaus E,Cancer,replication,2011-11-11,GCST001320,Acute lymphoblastic leukemia (childhood)
5956,European,869.0,22072270.0,Wang KS,Neurological disorder,initial,2011-11-11,GCST001319,Alcohol withdrawal symptoms
5893,European,825.0,22072270.0,Wang KS,Neurological disorder,replication,2011-11-11,GCST001319,Alcohol withdrawal symptoms
8735,European,5421.0,22080838.0,Cho MH,Other disease,initial,2011-11-11,GCST001321,Chronic obstructive pulmonary disease
9028,European,6657.0,22081228.0,Khor CC,Immune system disorder,initial,2011-11-13,GCST001322,Kawasaki disease
13905,Other/Mixed,405.0,22081228.0,Khor CC,Immune system disorder,replication,2011-11-13,GCST001322,Kawasaki disease
7013,European,1954.0,22081228.0,Khor CC,Immune system disorder,replication,2011-11-13,GCST001322,Kawasaki disease
3189,Asian,2540.0,22081228.0,Khor CC,Immune system disorder,replication,2011-11-13,GCST001322,Kawasaki disease
5879,European,822.0,22833209.0,Hu X,"Other measurement, Other trait",initial,2011-11-15,GCST004371,Rate of cognitive decline in mild cognitive impairment (time interaction)
8104,European,3708.0,22086417.0,Cozen W,Cancer,initial,2011-11-15,GCST001323,Nodular sclerosis Hodgkin lymphoma
5080,European,327.0,22086417.0,Cozen W,Cancer,replication,2011-11-15,GCST001323,Nodular sclerosis Hodgkin lymphoma
5722,European,707.0,22095909.0,Lange CM,Digestive system disorder,initial,2011-11-16,GCST001325,Response to hepatitis C treatment
737,African American or Afro-Caribbean,619.0,22085899.0,Chen G,Other measurement,initial,2011-11-16,GCST001324,Bilirubin levels
955,African American or Afro-Caribbean,1683.0,22101970.0,Kho AN,Metabolic disorder,initial,2011-11-19,GCST001326,Type 2 diabetes
8488,European,4805.0,22101970.0,Kho AN,Metabolic disorder,initial,2011-11-19,GCST001326,Type 2 diabetes
6253,European,1073.0,22105620.0,Papassotiropoulos A,Other measurement,initial,2011-11-22,GCST001327,Memory performance
8906,European,6095.0,22116812.0,Schrijvers EM,Cardiovascular disease,replication,2011-11-23,GCST001328,Vascular dementia
8809,European,5700.0,22116812.0,Schrijvers EM,Cardiovascular disease,initial,2011-11-23,GCST001328,Vascular dementia
3367,Asian,3451.0,22116939.0,Guo Y,Neurological disorder,initial,2011-11-24,GCST001329,Epilepsy
4956,European,232.0,22116950.0,Schuh-Huerta SM,Other measurement,initial,2011-11-24,GCST001330,Ovarian reserve
2532,Asian,1080.0,22116939.0,Guo Y,Neurological disorder,replication,2011-11-24,GCST001329,Epilepsy
572,African American or Afro-Caribbean,200.0,22116950.0,Schuh-Huerta SM,Other measurement,initial,2011-11-24,GCST001330,Ovarian reserve
6288,European,1096.0,22120009.0,Broderick P,Cancer,replication,2011-11-27,GCST001331,Multiple myeloma
9252,European,7578.0,22120009.0,Broderick P,Cancer,initial,2011-11-27,GCST001331,Multiple myeloma
1834,Asian,182.0,22118420.0,Datta S,Other measurement,initial,2011-11-28,GCST001333,Bilirubin levels
5711,European,700.0,22126837.0,LeBlanc M,"Biological process, Other measurement",initial,2011-11-28,GCST001332,Cognitive function
10430,European,18600.0,22139419.0,Gieger C,Hematological measurement,initial,2011-11-30,GCST001335,Mean platelet volume
10444,European,18838.0,22139419.0,Gieger C,Hematological measurement,replication,2011-11-30,GCST001337,Platelet count
6738,European,1597.0,22137330.0,Sanchez-Juan P,Neurological disorder,initial,2011-11-30,GCST001334,Creutzfeldt-Jakob disease (variant)
11257,European,48666.0,22139419.0,Gieger C,Hematological measurement,initial,2011-11-30,GCST001337,Platelet count
13185,Hispanic or Latin American,3468.0,22131368.0,Chen CT,Other measurement,initial,2011-11-30,GCST001336,Menarche and menopause (age at onset)
10443,European,18838.0,22139419.0,Gieger C,Hematological measurement,replication,2011-11-30,GCST001335,Mean platelet volume
4652,European,42.0,22137330.0,Sanchez-Juan P,Neurological disorder,replication,2011-11-30,GCST001334,Creutzfeldt-Jakob disease (variant)
4880,European,192.0,21897333.0,Irvin MR,"Body measurement, Other disease",initial,2011-12-01,GCST001343,Fat distribution (HIV)
825,African American or Afro-Caribbean,1009.0,22159054.0,Logue MW,Neurological disorder,initial,2011-12-01,GCST001342,Alzheimer's disease
7762,European,3091.0,22105264.0,Allen-Brady K,Other disease,initial,2011-12-01,GCST001340,Pelvic organ prolapse
13765,Other/Mixed,129.0,22130093.0,Nam RK,Cancer,replication,2011-12-01,GCST001338,Prostate cancer
90,African,311.0,22130093.0,Nam RK,Cancer,replication,2011-12-01,GCST001338,Prostate cancer
10377,European,17698.0,22190364.0,Patsopoulos NA,Immune system disorder,initial,2011-12-01,GCST001341,Multiple sclerosis
3042,Asian,2139.0,22144915.0,Fan Q,"Neurological disorder, Other trait",replication,2011-12-01,GCST001339,Corneal astigmatism
4694,European,76.0,22105264.0,Allen-Brady K,Other disease,replication,2011-12-01,GCST001340,Pelvic organ prolapse
3035,Asian,2120.0,22144915.0,Fan Q,"Neurological disorder, Other trait",replication,2011-12-01,GCST001339,Corneal astigmatism
1841,Asian,189.0,22130093.0,Nam RK,Cancer,replication,2011-12-01,GCST001338,Prostate cancer
2996,Asian,2016.0,22144915.0,Fan Q,"Neurological disorder, Other trait",initial,2011-12-01,GCST001339,Corneal astigmatism
7641,European,2810.0,22130093.0,Nam RK,Cancer,replication,2011-12-01,GCST001338,Prostate cancer
3095,Asian,2238.0,22144915.0,Fan Q,"Neurological disorder, Other trait",initial,2011-12-01,GCST001339,Corneal astigmatism
5676,European,671.0,22140272.0,Dalgaard MD,Other disease,replication,2011-12-03,GCST001344,Testicular dysgenesis syndrome
6028,European,927.0,22140272.0,Dalgaard MD,Other disease,initial,2011-12-03,GCST001344,Testicular dysgenesis syndrome
3661,Asian,5596.0,22138694.0,Lin Z,Immune system disorder,replication,2011-12-04,GCST001345,Ankylosing spondylitis
3753,Asian,6068.0,22138694.0,Lin Z,Immune system disorder,initial,2011-12-04,GCST001345,Ankylosing spondylitis
8893,European,6032.0,22144573.0,O'Donnell CJ,Other trait,replication,2011-12-05,GCST001347,Coronary artery calcification
5037,European,294.0,22142827.0,Innocenti F,"Response to drug, Cancer",initial,2011-12-05,GCST001346,Response to gemcitabine in pancreatic cancer
9753,European,9961.0,22144573.0,O'Donnell CJ,Other trait,initial,2011-12-05,GCST001347,Coronary artery calcification
2611,Asian,1228.0,22174901.0,Chan KY,Cancer,replication,2011-12-08,GCST001348,Hepatocellular carcinoma
1848,Asian,192.0,22174901.0,Chan KY,Cancer,initial,2011-12-08,GCST001348,Hepatocellular carcinoma
7521,European,2601.0,22156575.0,Paus T,Body measurement,replication,2011-12-09,GCST001349,Brain development
5513,European,557.0,22156575.0,Paus T,Body measurement,initial,2011-12-09,GCST001349,Brain development
3003,Asian,2034.0,22158537.0,Cho YS,Metabolic disorder,initial,2011-12-11,GCST001351,Type 2 diabetes
3647,Asian,5480.0,22158540.0,Wu C,Cancer,replication,2011-12-11,GCST001350,Pancreatic cancer
4464,Asian,35873.0,22158537.0,Cho YS,Metabolic disorder,replication,2011-12-11,GCST001351,Type 2 diabetes
3298,Asian,2972.0,22158540.0,Wu C,Cancer,initial,2011-12-11,GCST001350,Pancreatic cancer
4282,Asian,15000.0,22158537.0,Cho YS,Metabolic disorder,initial,2011-12-11,GCST001351,Type 2 diabetes
2876,Asian,1783.0,22158537.0,Cho YS,Metabolic disorder,initial,2011-12-11,GCST001351,Type 2 diabetes
142,African,798.0,22174851.0,Lingappa JR,"Immune system disorder, Other disease",initial,2011-12-12,GCST001353,HIV-1 susceptibility
112,African,496.0,22174851.0,Lingappa JR,"Biological process, Other measurement, Other disease",initial,2011-12-12,GCST001352,HIV-1 viral setpoint
8198,European,3967.0,22170493.0,Ellinghaus E,Immune system disorder,initial,2011-12-15,GCST001355,Psoriatic arthritis
7950,European,3367.0,21908519.0,Huffman JE,Other measurement,initial,2011-12-15,GCST005046,N-glycan levels
5335,European,472.0,22174390.0,Rankinen T,Cardiovascular measurement,initial,2011-12-15,GCST001354,Heart rate variability traits
9538,European,8716.0,22170493.0,Ellinghaus E,Immune system disorder,replication,2011-12-15,GCST001355,Psoriatic arthritis
1887,Asian,222.0,22180457.0,Kiyotani K,Response to drug,replication,2011-12-16,GCST001357,Response to tamoxifen in breast cancer
1681,Asian,62.0,22179738.0,Lai HM,Metabolic disorder,initial,2011-12-16,GCST001356,Gout
1930,Asian,240.0,22180457.0,Kiyotani K,Response to drug,initial,2011-12-16,GCST001357,Response to tamoxifen in breast cancer
2991,Asian,2000.0,22182935.0,Chen DT,Neurological disorder,initial,2011-12-20,GCST001358,Bipolar disorder
8157,European,3843.0,22182935.0,Chen DT,Neurological disorder,replication,2011-12-20,GCST001358,Bipolar disorder
10022,European,12755.0,22182935.0,Chen DT,Neurological disorder,initial,2011-12-20,GCST001358,Bipolar disorder
2521,Asian,1045.0,22188591.0,Anantharaman R,Other disease,replication,2011-12-21,GCST001360,Asthma
7070,European,2034.0,22205951.0,Kerner B,Neurological disorder,initial,2011-12-21,GCST001359,Bipolar disorder
2494,Asian,980.0,22188591.0,Anantharaman R,Other disease,initial,2011-12-21,GCST001360,Asthma
10311,European,16717.0,22199011.0,Murabito JM,Cardiovascular measurement,replication,2011-12-23,GCST001361,Ankle-brachial index
11155,European,41692.0,22199011.0,Murabito JM,Cardiovascular measurement,initial,2011-12-23,GCST001361,Ankle-brachial index
3208,Asian,2638.0,22197933.0,Hu Z,Other disease,initial,2011-12-25,GCST001362,Non-obstructive azoospermia
3699,Asian,5704.0,22197929.0,Yu XQ,Other disease,initial,2011-12-25,GCST001364,IgA nephropathy
3763,Asian,6167.0,22197929.0,Yu XQ,Other disease,replication,2011-12-25,GCST001364,IgA nephropathy
3747,Asian,6023.0,22197933.0,Hu Z,Other disease,replication,2011-12-25,GCST001362,Non-obstructive azoospermia
10736,European,25252.0,22197932.0,Paternoster L,Immune system disorder,replication,2011-12-25,GCST001363,Atopic dermatitis
10756,European,26171.0,22197932.0,Paternoster L,Immune system disorder,initial,2011-12-25,GCST001363,Atopic dermatitis
5186,European,397.0,22216198.0,Athanasiadis G,"Other measurement, Hematological measurement",initial,2011-12-28,GCST001365,Anticoagulant levels
754,African American or Afro-Caribbean,706.0,22205395.0,Tekola Ayele F,Inflammatory measurement,initial,2011-12-29,GCST006104,Interleukin-1-receptor antagonist levels
753,African American or Afro-Caribbean,704.0,22205395.0,Tekola Ayele F,Inflammatory measurement,initial,2011-12-29,GCST006103,Interleukin-6 levels
752,African American or Afro-Caribbean,704.0,22205395.0,Tekola Ayele F,Inflammatory measurement,initial,2011-12-29,GCST006102,Interleukin-10 levels
101,African,425.0,22205395.0,Tekola Ayele F,Inflammatory measurement,replication,2011-12-29,GCST006102,Interleukin-10 levels
2700,Asian,1496.0,22171074.0,Tan A,Lipid or lipoprotein measurement,replication,2011-12-30,GCST001367,Triglycerides
2977,Asian,1999.0,22171074.0,Tan A,Lipid or lipoprotein measurement,initial,2011-12-30,GCST001367,Triglycerides
9179,European,7296.0,22210626.0,Mead S,Neurological disorder,initial,2011-12-30,GCST001366,Prion diseases
13947,Other/Mixed,576.0,22210626.0,Mead S,Neurological disorder,initial,2011-12-30,GCST001366,Prion diseases
483,African American or Afro-Caribbean,82.0,22864933.0,O'Donnell PH,Response to drug,initial,2012-01-03,GCST001368,Capecitabine sensitivity
1703,Asian,84.0,22864933.0,O'Donnell PH,Response to drug,initial,2012-01-03,GCST001368,Capecitabine sensitivity
4822,European,164.0,22864933.0,O'Donnell PH,Response to drug,initial,2012-01-03,GCST001368,Capecitabine sensitivity
53,African,173.0,22864933.0,O'Donnell PH,Response to drug,initial,2012-01-03,GCST001368,Capecitabine sensitivity
1245,African American or Afro-Caribbean,4455.0,22238593.0,Palmer ND,Metabolic disorder,replication,2012-01-04,GCST001369,Type 2 diabetes
983,African American or Afro-Caribbean,1994.0,22238593.0,Palmer ND,Metabolic disorder,initial,2012-01-04,GCST001369,Type 2 diabetes
9658,European,9515.0,22219177.0,Tao S,"Cancer, Other measurement",initial,2012-01-04,GCST001370,Prostate cancer (SNP x SNP interaction)
6282,European,1092.0,22228203.0,Aslibekyan S,"Other measurement, Inflammatory measurement, Response to drug",initial,2012-01-05,GCST001371,Inflammatory biomarkers
5802,European,757.0,22245343.0,Meda SA,Neurological disorder,initial,2012-01-08,GCST001372,Alzheimer's disease
6483,European,1300.0,22229870.0,Karns R,Cardiovascular measurement,initial,2012-01-09,GCST001374,Uric acid levels
2968,Asian,1950.0,22232737.0,Shu XO,"Other measurement, Cancer",initial,2012-01-09,GCST001373,Breast cancer (survival)
3474,Asian,4160.0,22232737.0,Shu XO,"Other measurement, Cancer",replication,2012-01-09,GCST001373,Breast cancer (survival)
2817,Asian,1714.0,22233651.0,Kwak SH,Metabolic disorder,replication,2012-01-10,GCST001375,Diabetes (gestational)
2815,Asian,1710.0,22233651.0,Kwak SH,Metabolic disorder,initial,2012-01-10,GCST001375,Diabetes (gestational)
6002,European,904.0,22247754.0,Murray SS,Cardiovascular disease,initial,2012-01-11,GCST001376,Life threatening arrhythmia
2562,Asian,1140.0,22239941.0,Png E,"Other disease, Other measurement",replication,2012-01-13,GCST001377,Tuberculosis
1890,Asian,223.0,22239941.0,Png E,"Other disease, Other measurement",initial,2012-01-13,GCST001377,Tuberculosis
8071,European,3616.0,22239941.0,Png E,"Other disease, Other measurement",replication,2012-01-13,GCST001377,Tuberculosis
6087,European,951.0,22443383.0,Oudot-Mellakh T,"Hematological measurement, Inflammatory measurement, Other measurement, Cardiovascular measurement, Biological process",initial,2012-01-16,GCST001378,Hemostatic factors and hematological phenotypes
5033,European,292.0,22279548.0,Sebastiani P,Other measurement,replication,2012-01-18,GCST001379,Longevity
6829,European,1715.0,22279548.0,Sebastiani P,Other measurement,initial,2012-01-18,GCST001379,Longevity
4792,European,139.0,22388998.0,Zhang CK,Metabolic disorder,initial,2012-01-19,GCST001380,Gaucher disease severity
11186,European,43773.0,22267200.0,Gudmundsson J,Cancer,replication,2012-01-22,GCST001382,Thyroid cancer
10146,European,14435.0,22267201.0,Stolk L,Other measurement,replication,2012-01-22,GCST001381,Menopause (age at onset)
10796,European,27758.0,22267200.0,Gudmundsson J,Cancer,initial,2012-01-22,GCST001382,Thyroid cancer
11101,European,38968.0,22267201.0,Stolk L,Other measurement,initial,2012-01-22,GCST001381,Menopause (age at onset)
5396,European,495.0,22295056.0,Christie JD,Other disease,replication,2012-01-25,GCST001383,Acute lung injury
7664,European,2866.0,22295056.0,Christie JD,Other disease,initial,2012-01-25,GCST001383,Acute lung injury
6573,European,1392.0,22291609.0,Naitza S,"Other measurement, Inflammatory measurement, Response to drug",replication,2012-01-26,GCST001385,Inflammatory biomarkers
3491,Asian,4275.0,22291604.0,Okada Y,Immune system disorder,initial,2012-01-26,GCST001384,Systemic lupus erythematosus
4425,Asian,29951.0,22291604.0,Okada Y,Immune system disorder,replication,2012-01-26,GCST001384,Systemic lupus erythematosus
8456,European,4694.0,22291609.0,Naitza S,"Other measurement, Inflammatory measurement, Response to drug",initial,2012-01-26,GCST001385,Inflammatory biomarkers
3956,Asian,8260.0,22286173.0,Low SK,Cardiovascular disease,replication,2012-01-27,GCST001388,Intracranial aneurysm
6360,European,1176.0,22286212.0,Urayama KY,Cancer,replication,2012-01-27,GCST001387,Hodgkin's lymphoma
9262,European,7617.0,22286212.0,Urayama KY,Cancer,initial,2012-01-27,GCST001387,Hodgkin's lymphoma
5318,European,462.0,22286170.0,Cusanovich DA,Hematological measurement,initial,2012-01-27,GCST001389,Lymphocyte counts
3823,Asian,6867.0,22286173.0,Low SK,Cardiovascular disease,initial,2012-01-27,GCST001388,Intracranial aneurysm
1719,Asian,95.0,22293537.0,Kiyotani K,"Response to drug, Cancer",replication,2012-01-29,GCST001390,Response to gemcitabine in pancreatic cancer
1697,Asian,79.0,22293537.0,Kiyotani K,"Response to drug, Cancer",initial,2012-01-29,GCST001390,Response to gemcitabine in pancreatic cancer
9395,European,8330.0,22286219.0,Kettunen J,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2012-01-29,GCST001391,Metabolite levels
9394,European,8330.0,22286219.0,Kettunen J,Other measurement,initial,2012-01-29,GCST001392,Lipid metabolism phenotypes
3418,Asian,3782.0,22290723.0,Ryu J,Other measurement,replication,2012-01-30,GCST001393,Glycated hemoglobin levels
3490,Asian,4275.0,22290723.0,Ryu J,Other measurement,initial,2012-01-30,GCST001393,Glycated hemoglobin levels
6316,European,1142.0,22420046.0,Stergiakouli E,Neurological disorder,replication,2012-02-01,GCST001395,Attention deficit hyperactivity disorder
10264,European,16179.0,22293688.0,Huang J,Digestive system disorder,initial,2012-02-01,GCST001396,Crohn's disease
8832,European,5808.0,22420046.0,Stergiakouli E,Neurological disorder,initial,2012-02-01,GCST001395,Attention deficit hyperactivity disorder
10266,European,16179.0,22293688.0,Huang J,Metabolic disorder,initial,2012-02-01,GCST001397,Type 2 diabetes
10265,European,16179.0,22293688.0,Huang J,Metabolic disorder,initial,2012-02-01,GCST001394,Type 1 diabetes
7972,European,3402.0,22306654.0,Feenstra B,Digestive system disorder,initial,2012-02-05,GCST001399,Infantile hypertrophic pyloric stenosis
11151,European,41458.0,22306652.0,Bellenguez C,Cardiovascular disease,replication,2012-02-05,GCST001400,Stroke
9659,European,9520.0,22306652.0,Bellenguez C,Cardiovascular disease,initial,2012-02-05,GCST001400,Stroke
257,African,3176.0,22306650.0,Thye T,"Other disease, Other measurement",initial,2012-02-05,GCST001398,Tuberculosis
300,African,7178.0,22306650.0,Thye T,"Other disease, Other measurement",replication,2012-02-05,GCST001398,Tuberculosis
9784,European,10315.0,22306650.0,Thye T,"Other disease, Other measurement",replication,2012-02-05,GCST001398,Tuberculosis
6797,European,1672.0,22306654.0,Feenstra B,Digestive system disorder,replication,2012-02-05,GCST001399,Infantile hypertrophic pyloric stenosis
9869,European,11032.0,22319020.0,Davies RW,Cardiovascular disease,replication,2012-02-07,GCST001401,Coronary heart disease
5839,European,791.0,22310351.0,Fernandez-Rozadilla C,Response to drug,replication,2012-02-07,GCST001403,Fluorouracil treatment response in colorectal cancer
10110,European,13949.0,22319020.0,Davies RW,Cardiovascular disease,initial,2012-02-07,GCST001401,Coronary heart disease
4906,European,203.0,22310351.0,Fernandez-Rozadilla C,Response to drug,initial,2012-02-07,GCST001403,Fluorouracil treatment response in colorectal cancer
3578,Asian,4965.0,22322875.0,Kim SJ,"Cardiovascular disease, Other measurement",initial,2012-02-09,GCST001405,Hypertension risk in short sleep duration
2452,Asian,907.0,22318345.0,Cha PC,Cancer,initial,2012-02-09,GCST001404,Gallbladder cancer
2460,Asian,928.0,22318345.0,Cha PC,Cancer,replication,2012-02-09,GCST001404,Gallbladder cancer
8481,European,4779.0,22327514.0,Postel-Vinay S,Cancer,initial,2012-02-12,GCST001407,Ewing sarcoma
7017,European,1960.0,22327514.0,Postel-Vinay S,Cancer,replication,2012-02-12,GCST001407,Ewing sarcoma
9120,European,6989.0,22331829.0,Chasman DI,"Lipid or lipoprotein measurement, Response to drug",initial,2012-02-13,GCST001408,Response to statins (LDL cholesterol change)
8624,European,5071.0,22333899.0,Wei WH,Body measurement,replication,2012-02-15,GCST001409,Body mass index (SNP x SNP interaction)
8117,European,3745.0,22342860.0,Marjamaa A,Cardiovascular measurement,replication,2012-02-15,GCST001410,Early cardiac repolarization
8085,European,3653.0,22333899.0,Wei WH,Body measurement,initial,2012-02-15,GCST001409,Body mass index (SNP x SNP interaction)
6959,European,1870.0,22342860.0,Marjamaa A,Cardiovascular measurement,initial,2012-02-15,GCST001410,Early cardiac repolarization
8232,European,4034.0,22359512.0,Demirkan A,Lipid or lipoprotein measurement,initial,2012-02-16,GCST001414,Phospholipid levels (plasma)
5232,European,421.0,22343285.0,Bakken TE,Other measurement,initial,2012-02-16,GCST001411,Occipital cortical area (total cortical area interaction)
6755,European,1622.0,22341974.0,Paternoster L,"Other trait, Other measurement",replication,2012-02-16,GCST001412,Facial morphology
7202,European,2185.0,22341974.0,Paternoster L,"Other trait, Other measurement",initial,2012-02-16,GCST001412,Facial morphology
5808,European,760.0,22343285.0,Bakken TE,Other measurement,replication,2012-02-16,GCST001411,Occipital cortical area (total cortical area interaction)
8233,European,4034.0,22359512.0,Demirkan A,"Other measurement, Lipid or lipoprotein measurement",initial,2012-02-16,GCST001413,Sphingolipid levels
4387,Asian,22762.0,22344219.0,Wen W,"Body measurement, Other measurement",initial,2012-02-19,GCST001415,Body mass index
3157,Asian,2431.0,22344219.0,Wen W,"Body measurement, Other measurement",initial,2012-02-19,GCST001415,Body mass index
4406,Asian,26620.0,22344221.0,Okada Y,Body measurement,initial,2012-02-19,GCST001416,Body mass index (SNP x SNP interaction)
4463,Asian,35625.0,22344221.0,Okada Y,Body measurement,replication,2012-02-19,GCST001416,Body mass index (SNP x SNP interaction)
3185,Asian,2522.0,22344219.0,Wen W,"Body measurement, Other measurement",initial,2012-02-19,GCST001415,Body mass index
4522,Asian,53215.0,22344219.0,Wen W,"Body measurement, Other measurement",replication,2012-02-19,GCST001415,Body mass index
3033,Asian,2118.0,22344219.0,Wen W,"Body measurement, Other measurement",replication,2012-02-19,GCST001415,Body mass index
6624,European,1472.0,22354554.0,Thompson SD,Immune system disorder,initial,2012-02-21,GCST001417,Arthritis (juvenile idiopathic)
9549,European,8754.0,22354554.0,Thompson SD,Immune system disorder,replication,2012-02-21,GCST001417,Arthritis (juvenile idiopathic)
582,African American or Afro-Caribbean,207.0,22497812.0,Clark PJ,"Lipid or lipoprotein measurement, Digestive system disorder",initial,2012-02-22,GCST001418,Lipid levels in hepatitis C treatment
12771,Hispanic or Latin American,95.0,22497812.0,Clark PJ,"Lipid or lipoprotein measurement, Digestive system disorder",initial,2012-02-22,GCST001418,Lipid levels in hepatitis C treatment
7571,European,2697.0,22365631.0,Greenwood TA,"Other measurement, Neurological disorder, Other trait",initial,2012-02-22,GCST001419,Temperament (bipolar disorder)
6208,European,1017.0,22497812.0,Clark PJ,"Lipid or lipoprotein measurement, Digestive system disorder",initial,2012-02-22,GCST001418,Lipid levels in hepatitis C treatment
3612,Asian,5242.0,22383897.0,Long J,Cancer,initial,2012-02-23,GCST001420,Breast cancer
4460,Asian,34455.0,22383897.0,Long J,Cancer,replication,2012-02-23,GCST001420,Breast cancer
6718,European,1573.0,22362865.0,Knaapila A,Biological process,initial,2012-02-23,GCST001422,Odorant perception
2641,Asian,1313.0,22383894.0,Pierce BL,Other measurement,initial,2012-02-23,GCST001421,Arsenic metabolism
4946,European,226.0,22362865.0,Knaapila A,Biological process,replication,2012-02-23,GCST001422,Odorant perception
2978,Asian,1999.0,22367966.0,Lin X,Other measurement,initial,2012-02-24,GCST001424,Vitamin B12 levels
7494,European,2550.0,22368281.0,Deshmukh HA,Response to drug,replication,2012-02-24,GCST001425,Response to statin therapy
2701,Asian,1496.0,22367966.0,Lin X,Other measurement,replication,2012-02-24,GCST001424,Vitamin B12 levels
7584,European,2702.0,22368281.0,Deshmukh HA,Response to drug,initial,2012-02-24,GCST001425,Response to statin therapy
1995,Asian,315.0,22384028.0,Guo Y,Cardiovascular disease,initial,2012-02-24,GCST001423,Hypertension
8651,European,5136.0,22367438.0,Tao S,"Cancer, Other measurement",replication,2012-02-26,GCST001426,Prostate cancer (SNP x SNP interaction)
7903,European,3304.0,22377092.0,Wang KS,Neurological disorder,replication,2012-02-27,GCST001427,Nicotine dependence
7384,European,2420.0,22377092.0,Wang KS,Neurological disorder,initial,2012-02-27,GCST001427,Nicotine dependence
5651,European,656.0,22449649.0,Loo SK,Biological process,initial,2012-02-28,GCST001428,Intelligence
6003,European,904.0,22613542.0,Chen XD,Biological process,initial,2012-03-01,GCST001429,Drinking behavior
4276,Asian,14765.0,22396660.0,Urabe Y,Other disease,replication,2012-03-01,GCST001432,Nephrolithiasis
6550,European,1372.0,22379998.0,McCormack M,Response to drug,initial,2012-03-01,GCST001431,Adverse response to lamotrigine and phenytoin
3291,Asian,2955.0,22613542.0,Chen XD,Biological process,replication,2012-03-01,GCST001429,Drinking behavior
9495,European,8477.0,22451204.0,Pankratz N,Neurological disorder,initial,2012-03-01,GCST001430,Parkinson's disease
7600,European,2733.0,22613542.0,Chen XD,Biological process,replication,2012-03-01,GCST001429,Drinking behavior
3972,Asian,8375.0,22396660.0,Urabe Y,Other disease,initial,2012-03-01,GCST001432,Nephrolithiasis
8843,European,5849.0,22451204.0,Pankratz N,Neurological disorder,replication,2012-03-01,GCST001430,Parkinson's disease
4072,Asian,9621.0,22387998.0,Tanikawa C,Digestive system disorder,replication,2012-03-04,GCST001433,Duodenal ulcer
4386,Asian,22737.0,22387998.0,Tanikawa C,Digestive system disorder,initial,2012-03-04,GCST001433,Duodenal ulcer
5615,European,631.0,22403646.0,Froguel P,Hematological measurement,initial,2012-03-05,GCST001435,Haptoglobin levels
8350,European,4391.0,22403646.0,Froguel P,Hematological measurement,replication,2012-03-05,GCST001435,Haptoglobin levels
13750,Other/Mixed,100.0,22391508.0,Jiang R,Other measurement,initial,2012-03-05,GCST001434,Naphthyl-keratin adduct levels
9807,European,10564.0,22399527.0,Kristiansson K,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2012-03-07,GCST001436,Metabolic syndrome
7766,European,3095.0,22412388.0,Kenny EE,Digestive system disorder,replication,2012-03-08,GCST001438,Crohn's disease
1803,Asian,152.0,22399142.0,Jongjaroenprasert W,Metabolic disorder,initial,2012-03-08,GCST001437,Thyrotoxic hypokalemic periodic paralysis
1490,African American or Afro-Caribbean,16388.0,22423221.0,Qayyum R,Hematological measurement,initial,2012-03-08,GCST008047,Platelet count
1489,African American or Afro-Caribbean,16388.0,22423221.0,Qayyum R,Hematological measurement,initial,2012-03-08,GCST001439,Mean platelet volume
7726,European,2994.0,22412388.0,Kenny EE,Digestive system disorder,initial,2012-03-08,GCST001438,Crohn's disease
1691,Asian,76.0,22399142.0,Jongjaroenprasert W,Metabolic disorder,replication,2012-03-08,GCST001437,Thyrotoxic hypokalemic periodic paralysis
2305,Asian,700.0,22428042.0,Nakano M,Neurological disorder,replication,2012-03-12,GCST001441,Glaucoma (primary open-angle)
5566,European,594.0,22417934.0,Athanasiu L,"Body measurement, Biological process, Lipid or lipoprotein measurement",initial,2012-03-12,GCST001440,Body mass index and cholesterol (psychopharmacological treatment)
2737,Asian,1519.0,22428042.0,Nakano M,Neurological disorder,initial,2012-03-12,GCST001441,Glaucoma (primary open-angle)
6284,European,1094.0,22419666.0,Shi M,"Other trait, Other measurement, Other disease",initial,2012-03-14,GCST001442,Orofacial clefts
14098,Other/Mixed,1277.0,22419666.0,Shi M,"Other trait, Other measurement, Other disease",initial,2012-03-14,GCST001442,Orofacial clefts
6265,European,1078.0,22432041.0,Johnson MP,Cardiovascular disease,initial,2012-03-14,GCST001443,Preeclampsia
8541,European,4916.0,22432041.0,Johnson MP,Cardiovascular disease,replication,2012-03-14,GCST001443,Preeclampsia
14286,Other/Mixed,98080.0,22438815.0,Lill CM,Neurological disorder,replication,2012-03-15,GCST001445,Parkinson's disease
9968,European,12018.0,22424883.0,Imboden M,Other measurement,replication,2012-03-15,GCST001444,Pulmonary function decline
5480,European,535.0,22425255.0,Lopez LM,Other measurement,initial,2012-03-15,GCST001446,White matter integrity
8261,European,4118.0,22424883.0,Imboden M,Other measurement,initial,2012-03-15,GCST001444,Pulmonary function decline
8673,European,5218.0,22446040.0,Wang KS,"Body measurement, Other measurement",initial,2012-03-16,GCST001448,Body mass index
14027,Other/Mixed,762.0,22446040.0,Wang KS,"Body measurement, Other measurement",replication,2012-03-16,GCST001448,Body mass index
10500,European,19800.0,22426144.0,Long J,Cancer,replication,2012-03-16,GCST001447,Endometrial cancer
2872,Asian,1774.0,22426144.0,Long J,Cancer,replication,2012-03-16,GCST001447,Endometrial cancer
3379,Asian,3514.0,22426144.0,Long J,Cancer,initial,2012-03-16,GCST001447,Endometrial cancer
9197,European,7353.0,22430674.0,Lambert JC,Neurological disorder,initial,2012-03-20,GCST001449,Alzheimer's disease
10414,European,18330.0,22430674.0,Lambert JC,Neurological disorder,replication,2012-03-20,GCST001449,Alzheimer's disease
7142,European,2112.0,22437554.0,Major JM,Biological process,initial,2012-03-21,GCST001450,Response to Vitamin E supplementation
13894,Other/Mixed,372.0,22437316.0,Sarig O,Immune system disorder,replication,2012-03-22,GCST001452,Pemphigus vulgaris
5195,European,399.0,22437316.0,Sarig O,Immune system disorder,replication,2012-03-22,GCST001452,Pemphigus vulgaris
4041,Asian,9014.0,22419738.0,Osman W,Neurological disorder,replication,2012-03-22,GCST001451,Glaucoma (primary open-angle)
3943,Asian,7993.0,22419738.0,Osman W,Neurological disorder,initial,2012-03-22,GCST001451,Glaucoma (primary open-angle)
1860,Asian,201.0,22445761.0,Kurose K,Other trait,initial,2012-03-23,GCST001453,Sexual dysfunction (SSRI/SNRI-related)
2825,Asian,1729.0,22446961.0,Lee YC,Immune system disorder,initial,2012-03-25,GCST001456,Kawasaki disease
3419,Asian,3807.0,22446962.0,Onouchi Y,Immune system disorder,initial,2012-03-25,GCST001455,Kawasaki disease
2405,Asian,811.0,22446961.0,Lee YC,Immune system disorder,replication,2012-03-25,GCST001456,Kawasaki disease
4410,Asian,26961.0,22446963.0,Okada Y,Immune system disorder,replication,2012-03-25,GCST001454,Rheumatoid arthritis
4367,Asian,20965.0,22446963.0,Okada Y,Immune system disorder,initial,2012-03-25,GCST001454,Rheumatoid arthritis
2643,Asian,1328.0,22479419.0,Liou YJ,Neurological disorder,initial,2012-03-27,GCST001458,Schizophrenia (treatment resistant)
3494,Asian,4325.0,22452962.0,Kim HC,Cancer,initial,2012-03-27,GCST001457,Breast cancer
3937,Asian,7894.0,22452962.0,Kim HC,Cancer,replication,2012-03-27,GCST001457,Breast cancer
1964,Asian,273.0,22479419.0,Liou YJ,Neurological disorder,replication,2012-03-27,GCST001458,Schizophrenia (treatment resistant)
5821,European,777.0,22457343.0,Martinelli-Boneschi F,Immune system disorder,replication,2012-03-28,GCST001459,Multiple sclerosis
9100,European,6896.0,22470424.0,Kwee LC,Neurological disorder,initial,2012-03-28,GCST001460,Amyotrophic lateral sclerosis
4140,Asian,11139.0,22456796.0,Imamura M,Metabolic disorder,replication,2012-03-28,GCST001461,Type 2 diabetes
3887,Asian,7541.0,22456796.0,Imamura M,Metabolic disorder,initial,2012-03-28,GCST001461,Type 2 diabetes
6322,European,1144.0,22470424.0,Kwee LC,Neurological disorder,replication,2012-03-28,GCST001460,Amyotrophic lateral sclerosis
5248,European,431.0,22457343.0,Martinelli-Boneschi F,Immune system disorder,initial,2012-03-28,GCST001459,Multiple sclerosis
9799,European,10536.0,22479202.0,Dastani Z,Other measurement,replication,2012-03-29,GCST001465,Adiponectin levels
11534,European,74354.0,22479191.0,Pattaro C,"Other disease, Other measurement",initial,2012-03-29,GCST001466,Chronic kidney disease
8075,European,3623.0,22479309.0,Boraska V,Body measurement,replication,2012-03-29,GCST001462,Brachial circumference
2873,Asian,1776.0,22479202.0,Dastani Z,Other measurement,initial,2012-03-29,GCST001463,Adiponectin levels
128,African,606.0,22455414.0,Tekola Ayele F,Immune system disorder,replication,2012-03-29,GCST001464,Podoconiosis
10840,European,29347.0,22479202.0,Dastani Z,Other measurement,initial,2012-03-29,GCST001463,Adiponectin levels
10436,European,18753.0,22479309.0,Boraska V,Body measurement,initial,2012-03-29,GCST001462,Brachial circumference
96,African,397.0,22455414.0,Tekola Ayele F,Immune system disorder,initial,2012-03-29,GCST001464,Podoconiosis
11356,European,56246.0,22479191.0,Pattaro C,"Other disease, Other measurement",replication,2012-03-29,GCST001466,Chronic kidney disease
2393,Asian,800.0,22479346.0,Yang HC,Cardiovascular disease,initial,2012-03-29,GCST001467,Hypertension
1239,African American or Afro-Caribbean,4232.0,22479202.0,Dastani Z,Other measurement,initial,2012-03-29,GCST001463,Adiponectin levels
8596,European,5003.0,22479346.0,Yang HC,Cardiovascular disease,replication,2012-03-29,GCST001467,Hypertension
10841,European,29347.0,22479202.0,Dastani Z,Other measurement,initial,2012-03-29,GCST001465,Adiponectin levels
1996,Asian,315.0,22479346.0,Yang HC,Cardiovascular disease,replication,2012-03-29,GCST001467,Hypertension
8126,European,3763.0,22466613.0,Sun L,Digestive system disorder,initial,2012-04-01,GCST001468,Cystic fibrosis (meconium ileus)
7357,European,2372.0,22466613.0,Sun L,Digestive system disorder,replication,2012-04-01,GCST001468,Cystic fibrosis (meconium ileus)
11380,European,57478.0,22472876.0,Sullivan PF,Neurological disorder,replication,2012-04-03,GCST001469,Major depressive disorder
10437,European,18759.0,22472876.0,Sullivan PF,Neurological disorder,initial,2012-04-03,GCST001469,Major depressive disorder
5068,European,315.0,22472174.0,Xiao Y,Cancer,initial,2012-04-03,GCST001470,Glioblastoma
5270,European,434.0,22472174.0,Xiao Y,Cancer,replication,2012-04-03,GCST001470,Glioblastoma
7245,European,2214.0,22488850.0,Zuo L,Neurological disorder,initial,2012-04-04,GCST001471,Alcohol and nicotine co-dependence
811,African American or Afro-Caribbean,929.0,22488850.0,Zuo L,Neurological disorder,initial,2012-04-04,GCST001471,Alcohol and nicotine co-dependence
111,African,486.0,22492993.0,Doumatey AP,Inflammatory measurement,replication,2012-04-05,GCST001472,C-reactive protein
790,African American or Afro-Caribbean,837.0,22492993.0,Doumatey AP,Inflammatory measurement,initial,2012-04-05,GCST001472,C-reactive protein
10191,European,15131.0,22482804.0,Ellinghaus D,"Digestive system disorder, Immune system disorder",initial,2012-04-06,GCST001473,Crohn's disease and psoriasis
10356,European,17360.0,22482804.0,Ellinghaus D,"Digestive system disorder, Immune system disorder",replication,2012-04-06,GCST001473,Crohn's disease and psoriasis
11105,European,39282.0,22493691.0,Eriksson N,Other disease,initial,2012-04-06,GCST001474,Hypothyroidism
10104,European,13848.0,22484627.0,Bradfield JP,"Other measurement, Metabolic disorder",initial,2012-04-08,GCST001475,Obesity
8524,European,4888.0,22484627.0,Bradfield JP,"Other measurement, Metabolic disorder",replication,2012-04-08,GCST001475,Obesity
14077,Other/Mixed,1157.0,22491018.0,Wang J,"Immune system disorder, Biological process",initial,2012-04-10,GCST001476,Response to tocilizumab in rheumatoid arthritis
13935,Other/Mixed,526.0,22491018.0,Wang J,"Immune system disorder, Biological process",replication,2012-04-10,GCST001476,Response to tocilizumab in rheumatoid arthritis
6292,European,1104.0,22509378.0,Burri A,Other trait,initial,2012-04-11,GCST001477,Sexual dysfunction (female)
1797,Asian,147.0,22503698.0,Bhatnagar R,"Cancer, Other measurement",initial,2012-04-12,GCST001480,Oral cancers (chewing tobacco related)
7158,European,2142.0,22526605.0,Howson JM,"Other measurement, Metabolic disorder",initial,2012-04-12,GCST001479,Type 1 diabetes autoantibodies
5936,European,855.0,22526605.0,Howson JM,"Other measurement, Metabolic disorder",replication,2012-04-12,GCST001479,Type 1 diabetes autoantibodies
14273,Other/Mixed,32961.0,22504420.0,Estrada K,Other measurement,initial,2012-04-15,GCST001482,Lumbar spine bone mineral density
9846,European,10768.0,22504419.0,Taal HR,Body measurement,initial,2012-04-15,GCST001484,Head circumference (infant)
14243,Other/Mixed,8175.0,22504418.0,Ikram MA,Other measurement,initial,2012-04-15,GCST001483,Intracranial volume
14274,Other/Mixed,32961.0,22504420.0,Estrada K,Other measurement,initial,2012-04-15,GCST007691,Femoral neck bone mineral density
10003,European,12514.0,22504417.0,Stein JL,Other measurement,replication,2012-04-15,GCST001481,Brain structure
9393,European,8321.0,22504419.0,Taal HR,Body measurement,replication,2012-04-15,GCST001484,Head circumference (infant)
9606,European,9232.0,22504421.0,Bis JC,Other measurement,initial,2012-04-15,GCST001485,Hippocampal volume
7316,European,2318.0,22504421.0,Bis JC,Other measurement,replication,2012-04-15,GCST001485,Hippocampal volume
11277,European,50933.0,22504420.0,Estrada K,Other measurement,replication,2012-04-15,GCST001482,Lumbar spine bone mineral density
11278,European,50933.0,22504420.0,Estrada K,Other measurement,replication,2012-04-15,GCST007691,Femoral neck bone mineral density
12922,Hispanic or Latin American,605.0,22504417.0,Stein JL,Other measurement,replication,2012-04-15,GCST001481,Brain structure
9294,European,7795.0,22504417.0,Stein JL,Other measurement,initial,2012-04-15,GCST001481,Brain structure
6879,European,1752.0,22504418.0,Ikram MA,Other measurement,replication,2012-04-15,GCST001483,Intracranial volume
13835,Other/Mixed,237.0,22504417.0,Stein JL,Other measurement,replication,2012-04-15,GCST001481,Brain structure
13034,Hispanic or Latin American,1171.0,22508271.0,Rasmussen-Torvik LJ,Other measurement,initial,2012-04-16,GCST001486,Fasting plasma glucose
912,African American or Afro-Caribbean,1366.0,22508271.0,Rasmussen-Torvik LJ,Other measurement,initial,2012-04-16,GCST001486,Fasting plasma glucose
8113,European,3736.0,22494929.0,Rawal R,Other trait,initial,2012-04-16,GCST001487,Thyroid function
7338,European,2349.0,22508271.0,Rasmussen-Torvik LJ,Other measurement,initial,2012-04-16,GCST001486,Fasting plasma glucose
2279,Asian,664.0,22508271.0,Rasmussen-Torvik LJ,Other measurement,initial,2012-04-16,GCST001486,Fasting plasma glucose
8109,European,3727.0,22494929.0,Rawal R,Other trait,replication,2012-04-16,GCST001487,Thyroid function
4011,Asian,8834.0,22513714.0,Shin J,Metabolic disorder,initial,2012-04-19,GCST001488,Gout
12774,Hispanic or Latin American,99.0,22524403.0,Rice JP,Neurological disorder,initial,2012-04-24,GCST001490,Nicotine dependence
7267,European,2267.0,22524403.0,Rice JP,Neurological disorder,initial,2012-04-24,GCST001490,Nicotine dependence
6444,European,1241.0,22532574.0,Stevens KN,"Other measurement, Cancer",initial,2012-04-24,GCST001489,Percent mammographic density
824,African American or Afro-Caribbean,999.0,22524403.0,Rice JP,Neurological disorder,initial,2012-04-24,GCST001490,Nicotine dependence
9597,European,9126.0,22532574.0,Stevens KN,"Other measurement, Cancer",replication,2012-04-24,GCST001489,Percent mammographic density
589,African American or Afro-Caribbean,217.0,22542470.0,Ovsyannikova IG,"Response to drug, Other measurement",initial,2012-04-25,GCST001491,Immune response to smallpox vaccine (IL-6)
5538,European,580.0,22542470.0,Ovsyannikova IG,"Response to drug, Other measurement",initial,2012-04-25,GCST001491,Immune response to smallpox vaccine (IL-6)
12815,Hispanic or Latin American,217.0,22542470.0,Ovsyannikova IG,"Response to drug, Other measurement",initial,2012-04-25,GCST001491,Immune response to smallpox vaccine (IL-6)
3215,Asian,2665.0,22541561.0,Zhao H,Other disease,initial,2012-04-26,GCST001494,Non-obstructive azoospermia
9022,European,6633.0,22570617.0,Wiggs JL,Neurological disorder,initial,2012-04-26,GCST001493,Glaucoma (primary open-angle)
5202,European,407.0,22538805.0,Tantisira KG,Other disease,replication,2012-04-26,GCST001495,Asthma
5225,European,418.0,22538805.0,Tantisira KG,Other disease,initial,2012-04-26,GCST001495,Asthma
3470,Asian,4137.0,22541561.0,Zhao H,Other disease,replication,2012-04-26,GCST001494,Non-obstructive azoospermia
807,African American or Afro-Caribbean,905.0,22558097.0,Milton JN,"Digestive system disorder, Neurological disorder, Other measurement",initial,2012-04-27,GCST001497,Cholelithiasis-related traits in sickle cell anemia
2786,Asian,1629.0,22558069.0,Osman W,Other measurement,replication,2012-04-27,GCST001496,Non-albumin protein levels
4043,Asian,9103.0,22558069.0,Osman W,Other measurement,initial,2012-04-27,GCST001496,Non-albumin protein levels
1020,African American or Afro-Caribbean,2152.0,22558097.0,Milton JN,"Digestive system disorder, Neurological disorder, Other measurement",replication,2012-04-27,GCST001497,Cholelithiasis-related traits in sickle cell anemia
5115,European,344.0,22605921.0,Gibson J,Neurological disorder,replication,2012-04-28,GCST001498,Glaucoma (primary open-angle)
8825,European,5767.0,22605921.0,Gibson J,Neurological disorder,initial,2012-04-28,GCST001498,Glaucoma (primary open-angle)
11393,European,59133.0,22544366.0,Ellinor PT,Cardiovascular disease,initial,2012-04-29,GCST001499,Atrial fibrillation
10219,European,15411.0,22544366.0,Ellinor PT,Cardiovascular disease,replication,2012-04-29,GCST001499,Atrial fibrillation
8719,European,5339.0,22544364.0,Turnbull C,Cancer,replication,2012-04-29,GCST001500,Wilms tumor
7542,European,2636.0,22544364.0,Turnbull C,Cancer,initial,2012-04-29,GCST001500,Wilms tumor
509,African American or Afro-Caribbean,116.0,22550155.0,Edelstein LC,"Cardiovascular measurement, Hematological measurement",initial,2012-05-01,GCST001501,Platelet thrombus formation
4781,European,125.0,22550155.0,Edelstein LC,"Cardiovascular measurement, Hematological measurement",initial,2012-05-01,GCST001501,Platelet thrombus formation
4771,European,107.0,22560479.0,Forno E,"Other disease, Other measurement",replication,2012-05-02,GCST001502,Asthma (childhood onset)
5530,European,573.0,22560479.0,Forno E,"Other disease, Other measurement",initial,2012-05-02,GCST001502,Asthma (childhood onset)
12916,Hispanic or Latin American,591.0,22560479.0,Forno E,"Other disease, Other measurement",replication,2012-05-02,GCST001502,Asthma (childhood onset)
9966,European,11972.0,22570627.0,van Koolwijk LM,Other measurement,initial,2012-05-03,GCST001506,Intraocular pressure
2401,Asian,808.0,22551897.0,Mahasirimongkol S,"Other disease, Other measurement",replication,2012-05-03,GCST001504,Tuberculosis
2328,Asian,728.0,22551897.0,Mahasirimongkol S,"Other disease, Other measurement",initial,2012-05-03,GCST001504,Tuberculosis
9034,European,6685.0,22570697.0,Matesanz F,Immune system disorder,initial,2012-05-03,GCST001505,Multiple sclerosis
9233,European,7482.0,22570627.0,van Koolwijk LM,Other measurement,replication,2012-05-03,GCST001506,Intraocular pressure
2588,Asian,1201.0,22551897.0,Mahasirimongkol S,"Other disease, Other measurement",replication,2012-05-03,GCST001504,Tuberculosis
8811,European,5725.0,22570697.0,Matesanz F,Immune system disorder,replication,2012-05-03,GCST001505,Multiple sclerosis
6706,European,1560.0,22554406.0,Kang SJ,"Neurological disorder, Other measurement",initial,2012-05-03,GCST001503,Electroencephalographic traits in alcoholism
2555,Asian,1122.0,22551897.0,Mahasirimongkol S,"Other disease, Other measurement",initial,2012-05-03,GCST001504,Tuberculosis
13745,Other/Mixed,85.0,22556244.0,Kenny EE,"Other measurement, Other trait",initial,2012-05-04,GCST001507,Hair color
6720,European,1576.0,22561531.0,Wan YI,Other disease,replication,2012-05-05,GCST001508,Asthma
8319,European,4279.0,22561531.0,Wan YI,Other disease,initial,2012-05-05,GCST001508,Asthma
7556,European,2661.0,22561518.0,Jin Y,Immune system disorder,replication,2012-05-06,GCST001509,Vitiligo
4893,European,196.0,22569225.0,Krintel SB,"Immune system disorder, Response to drug",initial,2012-05-06,GCST001510,Response to TNF-alpha inhibitors in rheumatoid arthritis
7858,European,3228.0,22561518.0,Jin Y,Immune system disorder,initial,2012-05-06,GCST001509,Vitiligo
8364,European,4442.0,22566624.0,Castano Betancourt MC,Other disease,replication,2012-05-07,GCST001516,Osteoarthritis
4695,European,77.0,22566560.0,Malhotra AK,Other trait,initial,2012-05-07,GCST001517,Antipsychotic drug-induced weight gain
8992,European,6523.0,22566624.0,Castano Betancourt MC,Other disease,initial,2012-05-07,GCST001516,Osteoarthritis
427,African American or Afro-Caribbean,22.0,22566560.0,Malhotra AK,Other trait,replication,2012-05-07,GCST001517,Antipsychotic drug-induced weight gain
559,African American or Afro-Caribbean,193.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",initial,2012-05-07,GCST001518,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
9670,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001515,Economic and political preferences (immigration/crime)
9671,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001519,Economic and political preferences
562,African American or Afro-Caribbean,194.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",replication,2012-05-07,GCST001518,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
9669,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001514,Economic and political preferences (feminism/equality)
9667,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001512,Economic and political preferences (environmentalism)
9668,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001513,Economic and political preferences (fairness)
9666,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001511,Economic and political preferences (time)
560,African American or Afro-Caribbean,193.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",initial,2012-05-07,GCST001520,Response to angiotensin II receptor blocker therapy
439,African American or Afro-Caribbean,32.0,22566560.0,Malhotra AK,Other trait,initial,2012-05-07,GCST001517,Antipsychotic drug-induced weight gain
4858,European,183.0,22566560.0,Malhotra AK,Other trait,replication,2012-05-07,GCST001517,Antipsychotic drug-induced weight gain
5178,European,394.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",initial,2012-05-07,GCST001518,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
4894,European,198.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",initial,2012-05-07,GCST001520,Response to angiotensin II receptor blocker therapy
4892,European,196.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",replication,2012-05-07,GCST001518,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
9804,European,10557.0,22589738.0,Fox CS,Other measurement,initial,2012-05-10,GCST001524,Visceral adipose tissue/subcutaneous adipose tissue ratio
8764,European,5487.0,22589742.0,Fox CS,Other measurement,initial,2012-05-10,GCST001522,Pericardial fat
2354,Asian,761.0,22589742.0,Fox CS,Other measurement,replication,2012-05-10,GCST001522,Pericardial fat
13056,Hispanic or Latin American,1399.0,22589742.0,Fox CS,Other measurement,replication,2012-05-10,GCST001522,Pericardial fat
923,African American or Afro-Caribbean,1442.0,22589742.0,Fox CS,Other measurement,replication,2012-05-10,GCST001522,Pericardial fat
9803,European,10557.0,22589738.0,Fox CS,Other measurement,initial,2012-05-10,GCST001521,Subcutaneous adipose tissue
9806,European,10557.0,22589738.0,Fox CS,"Other measurement, Body measurement",initial,2012-05-10,GCST001523,Visceral adipose tissue adjusted for BMI
9805,European,10557.0,22589738.0,Fox CS,Other measurement,initial,2012-05-10,GCST001525,Visceral fat
11093,European,38422.0,22581228.0,Manning AK,"Body measurement, Other measurement",replication,2012-05-13,GCST001527,Fasting blood glucose (BMI interaction)
11383,European,58074.0,22581228.0,Manning AK,"Body measurement, Other measurement",initial,2012-05-13,GCST001527,Fasting blood glucose (BMI interaction)
11293,European,51750.0,22581228.0,Manning AK,Other measurement,initial,2012-05-13,GCST005185,Fasting blood insulin
11292,European,51750.0,22581228.0,Manning AK,"Body measurement, Other measurement",initial,2012-05-13,GCST001526,Fasting blood insulin (BMI interaction)
10974,European,33823.0,22581228.0,Manning AK,Other measurement,replication,2012-05-13,GCST005185,Fasting blood insulin
11094,European,38422.0,22581228.0,Manning AK,Other measurement,replication,2012-05-13,GCST005186,Fasting blood glucose
11384,European,58074.0,22581228.0,Manning AK,Other measurement,initial,2012-05-13,GCST005186,Fasting blood glucose
10973,European,33823.0,22581228.0,Manning AK,"Body measurement, Other measurement",replication,2012-05-13,GCST001526,Fasting blood insulin (BMI interaction)
6798,European,1673.0,22745009.0,Melville SA,Neurological disorder,initial,2012-05-15,GCST001530,Hippocampal atrophy
9997,European,12433.0,22832960.0,Service SK,Other measurement,initial,2012-05-15,GCST001531,Temperament
1789,Asian,136.0,22584459.0,Sasayama D,Response to drug,replication,2012-05-15,GCST001528,Response to antidepressants
6462,European,1262.0,22832961.0,Kamboh MI,Neurological disorder,replication,2012-05-15,GCST001529,Alzheimer's disease
677,African American or Afro-Caribbean,419.0,22745009.0,Melville SA,Neurological disorder,replication,2012-05-15,GCST001530,Hippocampal atrophy
7249,European,2229.0,22832961.0,Kamboh MI,Neurological disorder,initial,2012-05-15,GCST001529,Alzheimer's disease
1710,Asian,92.0,22584459.0,Sasayama D,Response to drug,initial,2012-05-15,GCST001528,Response to antidepressants
568,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001535,Immune reponse to smallpox (secreted IL-2)
567,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001534,Immune reponse to smallpox (secreted IL-10)
565,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001532,Immune response to smallpox vaccine (IL-6)
5433,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001532,Immune response to smallpox vaccine (IL-6)
569,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001536,Immune reponse to smallpox (secreted TNF-alpha)
5435,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001534,Immune reponse to smallpox (secreted IL-10)
5436,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001535,Immune reponse to smallpox (secreted IL-2)
5437,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001536,Immune reponse to smallpox (secreted TNF-alpha)
5438,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001537,Immune reponse to smallpox (secreted IL-12p40)
5439,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001538,Immune reponse to smallpox (secreted IFN-alpha)
5434,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001533,Immune reponse to smallpox (secreted IL-1beta)
570,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001537,Immune reponse to smallpox (secreted IL-12p40)
566,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001533,Immune reponse to smallpox (secreted IL-1beta)
571,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001538,Immune reponse to smallpox (secreted IFN-alpha)
1560,African American or Afro-Caribbean,32389.0,22832964.0,David SP,Biological process,initial,2012-05-22,GCST001539,Smoking behavior
4992,European,269.0,22633400.0,Kosova G,"Other measurement, Other trait",initial,2012-05-23,GCST001540,Male fertility
6473,European,1287.0,22628157.0,Levine AJ,Neurological disorder,initial,2012-05-24,GCST001542,HIV-associated dementia
9609,European,9244.0,22628180.0,Luciano M,Other trait,replication,2012-05-24,GCST001541,Personality dimensions
8948,European,6268.0,22628180.0,Luciano M,Other trait,initial,2012-05-24,GCST001541,Personality dimensions
7298,European,2291.0,22637743.0,Wei S,"Cancer, Other measurement",initial,2012-05-27,GCST001543,Lung cancer (asbestos exposure interaction)
10386,European,17780.0,22634755.0,Dunlop MG,Cancer,initial,2012-05-27,GCST001544,Colorectal cancer
3375,Asian,3481.0,22634755.0,Dunlop MG,Cancer,replication,2012-05-27,GCST001544,Colorectal cancer
11047,European,37170.0,22634755.0,Dunlop MG,Cancer,replication,2012-05-27,GCST001544,Colorectal cancer
5741,European,726.0,22658931.0,Pajewski NM,Response to drug,initial,2012-05-30,GCST001547,Immune response to anthrax vaccine
14161,Other/Mixed,2427.0,22666496.0,Shiffman D,"Cardiovascular disease, Response to drug",replication,2012-05-30,GCST001545,Coronary heart disease event reduction (statin therapy interaction)
5287,European,443.0,22658654.0,Chung SJ,Neurological disorder,initial,2012-05-30,GCST001546,Parkinson's disease (motor and cognition)
13981,Other/Mixed,682.0,22666496.0,Shiffman D,"Cardiovascular disease, Response to drug",initial,2012-05-30,GCST001545,Coronary heart disease event reduction (statin therapy interaction)
10024,European,12806.0,22693459.0,Li R,"Other measurement, Other disease",initial,2012-05-31,GCST001548,Male-pattern baldness
8039,European,3529.0,22648509.0,Wang KS,Other trait,initial,2012-05-31,GCST001549,Formal thought disorder in schizophrenia
13639,Other/Mixed,7.0,22856363.0,Ousdal OT,Other measurement,replication,2012-06-01,GCST001551,Amygdala reactivity
4942,European,224.0,22856363.0,Ousdal OT,Other measurement,initial,2012-06-01,GCST001551,Amygdala reactivity
1643,Asian,29.0,22856363.0,Ousdal OT,Other measurement,replication,2012-06-01,GCST001551,Amygdala reactivity
416,African American or Afro-Caribbean,13.0,22856363.0,Ousdal OT,Other measurement,replication,2012-06-01,GCST001551,Amygdala reactivity
6300,European,1117.0,22661486.0,Ulmer M,Other measurement,initial,2012-06-01,GCST001552,Central corneal thickness
4661,European,50.0,22856363.0,Ousdal OT,Other measurement,replication,2012-06-01,GCST001551,Amygdala reactivity
4981,European,252.0,22665904.0,Willis JA,Cancer,initial,2012-06-04,GCST001556,Pancreatic cancer
6739,European,1598.0,22675492.0,Prescott J,Other measurement,initial,2012-06-04,GCST001554,Sex hormone-binding globulin levels
5846,European,798.0,22665904.0,Willis JA,Cancer,replication,2012-06-04,GCST001556,Pancreatic cancer
1610,Asian,10.0,22665904.0,Willis JA,Cancer,replication,2012-06-04,GCST001556,Pancreatic cancer
422,African American or Afro-Caribbean,21.0,22665904.0,Willis JA,Cancer,replication,2012-06-04,GCST001556,Pancreatic cancer
6725,European,1583.0,22675492.0,Prescott J,Other measurement,initial,2012-06-04,GCST001553,Estradiol levels
6730,European,1589.0,22675492.0,Prescott J,Other measurement,initial,2012-06-04,GCST001555,Testosterone levels
1597,Asian,4.0,22665904.0,Willis JA,Cancer,replication,2012-06-04,GCST001556,Pancreatic cancer
14189,Other/Mixed,2962.0,22672568.0,Heit JA,Cardiovascular disease,initial,2012-06-05,GCST001557,Venous thromboembolism
9155,European,7151.0,22683750.0,Sinner MF,Cardiovascular measurement,replication,2012-06-06,GCST001559,Early cardiac repolarization
9234,European,7482.0,22683750.0,Sinner MF,Cardiovascular measurement,initial,2012-06-06,GCST001559,Early cardiac repolarization
3240,Asian,2789.0,22685421.0,Fan Q,Other trait,initial,2012-06-07,GCST001561,Myopia (pathological)
13032,Hispanic or Latin American,1108.0,22673963.0,Lasky-Su J,Other measurement,replication,2012-06-07,GCST001560,Vitamin D levels
6592,European,1416.0,22673963.0,Lasky-Su J,Other measurement,initial,2012-06-07,GCST001560,Vitamin D levels
3059,Asian,2155.0,22685421.0,Fan Q,Other trait,initial,2012-06-07,GCST001561,Myopia (pathological)
13852,Other/Mixed,285.0,22678113.0,Cox HC,Cardiovascular disease,initial,2012-06-08,GCST001562,Migraine
10751,European,25713.0,22678113.0,Cox HC,Cardiovascular disease,replication,2012-06-08,GCST001562,Migraine
8656,European,5160.0,22683712.0,Freilinger T,Cardiovascular disease,replication,2012-06-10,GCST001563,Migraine
6927,European,1824.0,22694930.0,Li X,Other disease,initial,2012-06-11,GCST001564,Asthma
2051,Asian,374.0,22693232.0,Zhou J,Biological process,replication,2012-06-12,GCST001568,Influenza (severity)
8433,European,4646.0,22688191.0,Bergen SE,Neurological disorder,initial,2012-06-12,GCST001565,Schizophrenia
8762,European,5482.0,22688191.0,Bergen SE,Neurological disorder,initial,2012-06-12,GCST001567,Bipolar disorder and schizophrenia
14268,Other/Mixed,24763.0,22692763.0,Liu CT,Other measurement,replication,2012-06-12,GCST001566,Bone mineral density (sex interaction)
7695,European,2929.0,22688191.0,Bergen SE,Neurological disorder,initial,2012-06-12,GCST001569,Bipolar disorder
10738,European,25353.0,22692763.0,Liu CT,Other measurement,initial,2012-06-12,GCST001566,Bone mineral density (sex interaction)
1659,Asian,51.0,22693232.0,Zhou J,Biological process,initial,2012-06-12,GCST001568,Influenza (severity)
7657,European,2842.0,22694956.0,Cipriani V,Neurological disorder,replication,2012-06-13,GCST001571,Age-related macular degeneration
7678,European,2894.0,22700719.0,Slager SL,Cancer,replication,2012-06-13,GCST001570,Chronic lymphocytic leukemia
8518,European,4866.0,22700719.0,Slager SL,Cancer,initial,2012-06-13,GCST001570,Chronic lymphocytic leukemia
7763,European,3092.0,22694956.0,Cipriani V,Neurological disorder,initial,2012-06-13,GCST001571,Age-related macular degeneration
5475,European,528.0,22704111.0,Hotaling JM,"Other disease, Metabolic disorder",initial,2012-06-13,GCST001572,Erectile dysfunction in type 1 diabetes
7526,European,2611.0,22703881.0,Tang W,Hematological measurement,replication,2012-06-14,GCST001574,Activated partial thromboplastin time
6142,European,986.0,22703881.0,Tang W,Hematological measurement,replication,2012-06-14,GCST001573,Prothrombin time
5101,European,339.0,22701019.0,Sabater-Lleal M,Hematological measurement,initial,2012-06-14,GCST001575,Factor XI
2693,Asian,1461.0,22719876.0,Kawaguchi T,Digestive system disorder,initial,2012-06-14,GCST001576,Nonalcoholic fatty liver disease
5656,European,658.0,22701019.0,Sabater-Lleal M,Hematological measurement,replication,2012-06-14,GCST001575,Factor XI
7511,European,2583.0,22703881.0,Tang W,Hematological measurement,initial,2012-06-14,GCST001573,Prothrombin time
9607,European,9240.0,22703881.0,Tang W,Hematological measurement,initial,2012-06-14,GCST001574,Activated partial thromboplastin time
8570,European,4953.0,22705344.0,Sobrin L,Neurological disorder,initial,2012-06-15,GCST001578,Age-related macular degeneration (geographic atrophy)
7518,European,2594.0,22705344.0,Sobrin L,Neurological disorder,initial,2012-06-15,GCST001577,Age-related macular degeneration (CNV vs. GA)
8867,European,5909.0,22705344.0,Sobrin L,Neurological disorder,initial,2012-06-15,GCST001579,Age-related macular degeneration (choroidal neovascularisation)
3815,Asian,6805.0,22726844.0,Kim JW,Cardiovascular measurement,initial,2012-06-20,GCST001580,QT interval
14148,Other/Mixed,1949.0,22745674.0,Hager J,Cardiovascular disease,initial,2012-06-20,GCST001581,Coronary heart disease
14166,Other/Mixed,2547.0,22745674.0,Hager J,Cardiovascular disease,replication,2012-06-20,GCST001581,Coronary heart disease
3868,Asian,7373.0,22726844.0,Kim JW,Cardiovascular measurement,replication,2012-06-20,GCST001580,QT interval
4368,Asian,21043.0,22737229.0,Nishida N,"Biological process, Digestive system disorder",replication,2012-06-21,GCST001582,Hepatitis B (viral clearance)
2215,Asian,550.0,22737229.0,Nishida N,"Biological process, Digestive system disorder",initial,2012-06-21,GCST001582,Hepatitis B (viral clearance)
14067,Other/Mixed,928.0,23505185.0,Plourde M,Metabolic disorder,initial,2012-06-28,GCST001583,Adiposity
2397,Asian,801.0,22744181.0,Hai R,"Other measurement, Body measurement",initial,2012-06-29,GCST001584,Lean body mass and age at menarche (combined)
6808,European,1692.0,22744181.0,Hai R,"Other measurement, Body measurement",replication,2012-06-29,GCST001584,Lean body mass and age at menarche (combined)
10262,European,16175.0,22747683.0,Eriksson N,Body measurement,initial,2012-06-30,GCST001585,Breast size
4409,Asian,26932.0,22751097.0,Lu X,Cardiovascular disease,replication,2012-07-01,GCST001587,Coronary heart disease
9926,European,11617.0,22794196.0,Lu Y,Cancer,replication,2012-07-01,GCST001589,Ovarian cancer
3802,Asian,6534.0,22751097.0,Lu X,Cardiovascular disease,initial,2012-07-01,GCST001587,Coronary heart disease
6210,European,1020.0,22699663.0,Divaris K,Digestive system disorder,initial,2012-07-01,GCST001588,Periodontal microbiota
7374,European,2402.0,22754043.0,Byrne EM,Other measurement,initial,2012-07-01,GCST001586,Insomnia (caffeine-induced)
6140,European,985.0,22794196.0,Lu Y,Cancer,initial,2012-07-01,GCST001589,Ovarian cancer
6574,European,1392.0,22760553.0,Adkins DE,Response to drug,initial,2012-07-03,GCST001591,Response to citalopram treatment
6344,European,1163.0,22764253.0,Thier S,Other trait,replication,2012-07-03,GCST001590,Essential tremor
610,African American or Afro-Caribbean,264.0,22760553.0,Adkins DE,Response to drug,initial,2012-07-03,GCST001591,Response to citalopram treatment
13755,Other/Mixed,106.0,22760553.0,Adkins DE,Response to drug,initial,2012-07-03,GCST001591,Response to citalopram treatment
6536,European,1364.0,22764253.0,Thier S,Other trait,initial,2012-07-03,GCST001590,Essential tremor
10417,European,18419.0,22763110.0,Zeggini E,Other disease,initial,2012-07-03,GCST001592,Osteoarthritis
11272,European,50411.0,22763110.0,Zeggini E,Other disease,replication,2012-07-03,GCST001592,Osteoarthritis
6778,European,1644.0,22792082.0,Himes BE,"Response to drug, Other disease",initial,2012-07-05,GCST001597,Asthma (bronchodilator response)
6935,European,1834.0,22792070.0,Medina-Gomez C,Other measurement,initial,2012-07-05,GCST001594,Bone mineral density
1770,Asian,126.0,22763476.0,Zhang D,"Other measurement, Cardiovascular measurement",initial,2012-07-05,GCST001598,Blood pressure
6236,European,1051.0,22792082.0,Himes BE,"Response to drug, Other disease",replication,2012-07-05,GCST001597,Asthma (bronchodilator response)
2515,Asian,1035.0,22792221.0,Takamoto M,Neurological disorder,replication,2012-07-05,GCST001596,Glaucoma
2421,Asian,843.0,22792221.0,Takamoto M,Neurological disorder,initial,2012-07-05,GCST001596,Glaucoma
8850,European,5878.0,22792071.0,Zheng HF,Other measurement,initial,2012-07-05,GCST001593,Cortical thickness
6222,European,1032.0,22792071.0,Zheng HF,Other measurement,replication,2012-07-05,GCST001593,Cortical thickness
8805,European,5672.0,22792071.0,Zheng HF,Other measurement,initial,2012-07-05,GCST001595,Bone mineral density
9872,European,11052.0,22792070.0,Medina-Gomez C,Other measurement,replication,2012-07-05,GCST001594,Bone mineral density
4987,European,263.0,22773346.0,Edwards DR,Biological process,initial,2012-07-07,GCST001599,Aging
2702,Asian,1496.0,22673310.0,Liao M,Other measurement,replication,2012-07-07,GCST001600,IgG levels
2979,Asian,1999.0,22673310.0,Liao M,Other measurement,initial,2012-07-07,GCST001600,IgG levels
5012,European,282.0,22785395.0,Gaj P,Neurological disorder,initial,2012-07-11,GCST001602,Alzheimer's disease
6496,European,1312.0,22780124.0,Lind PA,Biological process,initial,2012-07-11,GCST001601,Gambling
3309,Asian,3003.0,22807686.0,Li S,Cancer,initial,2012-07-12,GCST001603,Hepatocellular carcinoma
810,African American or Afro-Caribbean,927.0,22791750.0,Chen G,"Other measurement, Other trait",initial,2012-07-12,GCST001604,Insulin-related traits
126,African,570.0,22791750.0,Chen G,"Other measurement, Other trait",replication,2012-07-12,GCST001604,Insulin-related traits
4052,Asian,9156.0,22807686.0,Li S,Cancer,replication,2012-07-12,GCST001603,Hepatocellular carcinoma
4198,Asian,12536.0,22797724.0,Shiraishi K,Cancer,replication,2012-07-15,GCST001609,Lung adenocarcinoma
4494,Asian,42257.0,22797727.0,Okada Y,Other measurement,initial,2012-07-15,GCST001606,Renal function-related traits (sCR)
4489,Asian,39717.0,22797727.0,Okada Y,Other measurement,initial,2012-07-15,GCST001610,Renal function-related traits (BUN)
4372,Asian,21417.0,22797727.0,Okada Y,"Other measurement, Cardiovascular measurement",initial,2012-07-15,GCST001608,Renal function-related traits (urea)
4357,Asian,19662.0,22797727.0,Okada Y,Other measurement,replication,2012-07-15,GCST001606,Renal function-related traits (sCR)
3844,Asian,7028.0,22797724.0,Shiraishi K,Cancer,initial,2012-07-15,GCST001609,Lung adenocarcinoma
4496,Asian,42451.0,22797727.0,Okada Y,Other measurement,initial,2012-07-15,GCST001607,Renal function-related traits (eGRFcrea)
4326,Asian,17461.0,22797727.0,Okada Y,Other measurement,replication,2012-07-15,GCST001610,Renal function-related traits (BUN)
4164,Asian,11657.0,22797727.0,Okada Y,"Other measurement, Cardiovascular measurement",replication,2012-07-15,GCST001608,Renal function-related traits (urea)
4356,Asian,19636.0,22797727.0,Okada Y,Other measurement,replication,2012-07-15,GCST001607,Renal function-related traits (eGRFcrea)
8865,European,5905.0,23055271.0,Gregersen PK,"Neurological disorder, Other disease",initial,2012-07-16,GCST001611,Myasthenia gravis
8089,European,3664.0,23055271.0,Gregersen PK,"Neurological disorder, Other disease",replication,2012-07-16,GCST001611,Myasthenia gravis
9367,European,8175.0,22829776.0,Coviello AD,Other measurement,replication,2012-07-19,GCST001612,Sex hormone-binding globulin levels
10600,European,21791.0,22829776.0,Coviello AD,Other measurement,initial,2012-07-19,GCST001612,Sex hormone-binding globulin levels
8925,European,6173.0,22808956.0,Lyons PA,Immune system disorder,initial,2012-07-19,GCST001613,Antineutrophil cytoplasmic antibody-associated vasculitis
7778,European,3120.0,22808956.0,Lyons PA,Immune system disorder,replication,2012-07-19,GCST001613,Antineutrophil cytoplasmic antibody-associated vasculitis
8188,European,3931.0,22814818.0,Hoehn R,Other measurement,initial,2012-07-20,GCST001614,Central corneal thickness
6593,European,1418.0,22814818.0,Hoehn R,Other measurement,replication,2012-07-20,GCST001614,Central corneal thickness
8343,European,4356.0,22821403.0,Ellinghaus D,"Digestive system disorder, Immune system disorder",initial,2012-07-23,GCST001615,Sclerosing cholangitis and ulcerative colitis (combined)
4978,European,246.0,22828495.0,Brown AA,Other measurement,initial,2012-07-24,GCST001618,Neural processing (facial expression)
5975,European,883.0,22911860.0,Hernandez DG,Neurological disorder,initial,2012-07-24,GCST001617,Parkinson's disease
4715,European,85.0,22828495.0,Brown AA,Other measurement,replication,2012-07-24,GCST001618,Neural processing (facial expression)
9056,European,6739.0,22837380.0,Fischer A,Other disease,replication,2012-07-26,GCST001622,Sarcoidosis
7873,European,3248.0,22843503.0,Qi Q,Other measurement,initial,2012-07-26,GCST001620,Resistin levels
6364,European,1181.0,22841784.0,Patin E,"Cancer, Digestive system disorder",replication,2012-07-26,GCST001623,Hepatitis C induced liver fibrosis
10929,European,32875.0,22837378.0,Wilk JB,Other measurement,initial,2012-07-26,GCST001621,Airflow obstruction
7671,European,2881.0,22837378.0,Wilk JB,Other measurement,replication,2012-07-26,GCST001621,Airflow obstruction
5657,European,659.0,22843503.0,Qi Q,Other measurement,replication,2012-07-26,GCST001620,Resistin levels
14115,Other/Mixed,1419.0,22843504.0,Anney R,Neurological disorder,initial,2012-07-26,GCST001619,Autism
14103,Other/Mixed,1314.0,22843504.0,Anney R,Neurological disorder,replication,2012-07-26,GCST001619,Autism
6341,European,1161.0,22841784.0,Patin E,"Cancer, Digestive system disorder",initial,2012-07-26,GCST001623,Hepatitis C induced liver fibrosis
7157,European,2139.0,22837380.0,Fischer A,Other disease,initial,2012-07-26,GCST001622,Sarcoidosis
511,African American or Afro-Caribbean,117.0,22843789.0,Baldwin RM,"Response to drug, Neurological disorder, Other measurement",replication,2012-07-27,GCST001624,Paclitaxel-induced neuropathy
11831,European,114863.0,22843499.0,Boraska V,Other measurement,initial,2012-07-27,GCST001625,Sex ratio at birth
4812,European,154.0,22843789.0,Baldwin RM,"Response to drug, Neurological disorder, Other measurement",replication,2012-07-27,GCST001624,Paclitaxel-induced neuropathy
5937,European,855.0,22843789.0,Baldwin RM,"Response to drug, Neurological disorder, Other measurement",initial,2012-07-27,GCST001624,Paclitaxel-induced neuropathy
2980,Asian,1999.0,22864923.0,Yang C,Other measurement,initial,2012-08-03,GCST001626,IgA levels
2703,Asian,1496.0,22864923.0,Yang C,Other measurement,replication,2012-08-03,GCST001626,IgA levels
2614,Asian,1239.0,22863731.0,Cheung CL,Metabolic disorder,initial,2012-08-05,GCST001627,Thyrotoxic hypokalemic periodic paralysis
3144,Asian,2385.0,22863734.0,Ludwig KU,"Other trait, Other measurement, Other disease",replication,2012-08-05,GCST001628,Orofacial clefts
8106,European,3715.0,22863734.0,Ludwig KU,"Other trait, Other measurement, Other disease",initial,2012-08-05,GCST001628,Orofacial clefts
2133,Asian,454.0,22863731.0,Cheung CL,Metabolic disorder,replication,2012-08-05,GCST001627,Thyrotoxic hypokalemic periodic paralysis
5211,European,409.0,22872573.0,Hu L,"Response to drug, Cancer",replication,2012-08-07,GCST001629,Response to platinum-based chemotherapy in non-small-cell lung cancer
733,African American or Afro-Caribbean,605.0,22869035.0,Logue MW,Neurological disorder,replication,2012-08-07,GCST001630,Post-traumatic stress disorder
2016,Asian,340.0,22872573.0,Hu L,"Response to drug, Cancer",replication,2012-08-07,GCST001629,Response to platinum-based chemotherapy in non-small-cell lung cancer
11193,European,44216.0,22883433.0,Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2,Neurological disorder,replication,2012-08-07,GCST001631,Schizophrenia
5384,European,491.0,22869035.0,Logue MW,Neurological disorder,initial,2012-08-07,GCST001630,Post-traumatic stress disorder
2200,Asian,528.0,22872573.0,Hu L,"Response to drug, Cancer",initial,2012-08-07,GCST001629,Response to platinum-based chemotherapy in non-small-cell lung cancer
7970,European,3400.0,22883433.0,Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2,Neurological disorder,initial,2012-08-07,GCST001631,Schizophrenia
5870,European,817.0,22890011.0,Frazier-Wood AC,Response to drug,initial,2012-08-09,GCST001632,Response to fenofibrate
10304,European,16616.0,22886559.0,Rajaraman P,Cancer,replication,2012-08-11,GCST001633,Glioma
9073,European,6811.0,22886559.0,Rajaraman P,Cancer,initial,2012-08-11,GCST001633,Glioma
4296,Asian,15804.0,22885925.0,Shi Y,Other disease,replication,2012-08-12,GCST001634,Polycystic ovary syndrome
3613,Asian,5255.0,22885925.0,Shi Y,Other disease,initial,2012-08-12,GCST001634,Polycystic ovary syndrome
9316,European,7919.0,22889921.0,Stewart SE,Neurological disorder,initial,2012-08-14,GCST001636,Obsessive-compulsive disorder
12892,Hispanic or Latin American,496.0,22889924.0,Scharf JM,Neurological disorder,replication,2012-08-14,GCST001635,Tourette syndrome
8945,European,6249.0,22889924.0,Scharf JM,Neurological disorder,initial,2012-08-14,GCST001635,Tourette syndrome
242,African,2153.0,22895189.0,Timmann C,Digestive system disorder,initial,2012-08-15,GCST001637,Malaria
295,African,5755.0,22895189.0,Timmann C,Digestive system disorder,replication,2012-08-15,GCST001637,Malaria
3641,Asian,5415.0,22899653.0,Timofeeva MN,Cancer,replication,2012-08-16,GCST001638,Lung cancer
9018,European,6608.0,22916037.0,Inouye M,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2012-08-16,GCST001639,Metabolite levels
11195,European,44385.0,22899653.0,Timofeeva MN,Cancer,initial,2012-08-16,GCST001638,Lung cancer
6516,European,1345.0,22903471.0,Hibar DP,Other measurement,initial,2012-08-18,GCST001640,Lentiform nucleus volume
5894,European,826.0,22907691.0,Breitfeld J,Other measurement,initial,2012-08-21,GCST001642,Vaspin levels
5407,European,499.0,22907730.0,Ji Y,Response to drug,initial,2012-08-21,GCST001641,Response to antidepressants
6915,European,1806.0,22907691.0,Breitfeld J,Other measurement,replication,2012-08-21,GCST001642,Vaspin levels
6401,European,1207.0,22907730.0,Ji Y,Response to drug,replication,2012-08-21,GCST001641,Response to antidepressants
7506,European,2567.0,22911880.0,Boraska V,"Metabolic disorder, Neurological disorder",initial,2012-08-22,GCST001644,Eating disorders
5810,European,767.0,22911880.0,Boraska V,"Metabolic disorder, Neurological disorder",replication,2012-08-22,GCST001644,Eating disorders
7623,European,2786.0,22915352.0,Power RA,"Neurological disorder, Other measurement",replication,2012-08-22,GCST001643,Depression (age of onset)
8336,European,4330.0,22915352.0,Power RA,"Neurological disorder, Other measurement",initial,2012-08-22,GCST001643,Depression (age of onset)
884,African American or Afro-Caribbean,1249.0,23067351.0,Rasmussen-Torvik LJ,"Lipid or lipoprotein measurement, Other measurement",initial,2012-08-23,GCST001645,LDL cholesterol
3580,Asian,4969.0,22923026.0,Cheng I,Cancer,replication,2012-08-24,GCST001646,Prostate cancer
13111,Hispanic or Latin American,2100.0,22923026.0,Cheng I,Cancer,initial,2012-08-24,GCST001646,Prostate cancer
3016,Asian,2075.0,22923026.0,Cheng I,Cancer,initial,2012-08-24,GCST001646,Prostate cancer
8780,European,5602.0,22923026.0,Cheng I,Cancer,replication,2012-08-24,GCST001646,Prostate cancer
8076,European,3625.0,22925353.0,Lee HJ,Neurological disorder,initial,2012-08-25,GCST001647,Bipolar disorder
1288,African American or Afro-Caribbean,5761.0,22923054.0,Chen F,Cancer,initial,2012-08-25,GCST001648,Breast cancer
1472,African American or Afro-Caribbean,14579.0,22923054.0,Chen F,Cancer,replication,2012-08-25,GCST001648,Breast cancer
3267,Asian,2875.0,22922875.0,Vithana EN,Neurological disorder,initial,2012-08-26,GCST001649,Glaucoma (primary angle closure)
3627,Asian,5319.0,22922875.0,Vithana EN,Neurological disorder,initial,2012-08-26,GCST001649,Glaucoma (primary angle closure)
3340,Asian,3268.0,22922875.0,Vithana EN,Neurological disorder,initial,2012-08-26,GCST001649,Glaucoma (primary angle closure)
13881,Other/Mixed,340.0,22922875.0,Vithana EN,Neurological disorder,replication,2012-08-26,GCST001649,Glaucoma (primary angle closure)
2073,Asian,389.0,22922875.0,Vithana EN,Neurological disorder,replication,2012-08-26,GCST001649,Glaucoma (primary angle closure)
3625,Asian,5301.0,22922875.0,Vithana EN,Neurological disorder,replication,2012-08-26,GCST001649,Glaucoma (primary angle closure)
8499,European,4830.0,22922875.0,Vithana EN,Neurological disorder,replication,2012-08-26,GCST001649,Glaucoma (primary angle closure)
1210,African American or Afro-Caribbean,3787.0,22939635.0,Reiner AP,Inflammatory measurement,replication,2012-08-28,GCST001650,C-reactive protein
5076,European,325.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
13592,Other/Mixed,1.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
418,African American or Afro-Caribbean,18.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
13637,Other/Mixed,6.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
1611,Asian,10.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
8803,European,5656.0,22939635.0,Reiner AP,Inflammatory measurement,replication,2012-08-28,GCST001650,C-reactive protein
1390,African American or Afro-Caribbean,8280.0,22939635.0,Reiner AP,Inflammatory measurement,initial,2012-08-28,GCST001650,C-reactive protein
13200,Hispanic or Latin American,3548.0,22939635.0,Reiner AP,Inflammatory measurement,initial,2012-08-28,GCST001650,C-reactive protein
12738,Hispanic or Latin American,17.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
13201,Hispanic or Latin American,3548.0,22939635.0,Reiner AP,Inflammatory measurement,replication,2012-08-28,GCST001650,C-reactive protein
6960,European,1870.0,22936702.0,Hofmann S,Other disease,initial,2012-08-30,GCST001654,Sarcoidosis
14156,Other/Mixed,2165.0,22935194.0,Connolly JJ,Neurological disorder,initial,2012-08-30,GCST001655,Autism
9209,European,7405.0,22936702.0,Hofmann S,Other disease,replication,2012-08-30,GCST001654,Sarcoidosis
7614,European,2761.0,22936669.0,Julia A,Digestive system disorder,replication,2012-08-30,GCST001652,Crohn's disease
7616,European,2765.0,22936669.0,Julia A,Digestive system disorder,initial,2012-08-30,GCST001652,Crohn's disease
7856,European,3225.0,22936694.0,Jin G,Other measurement,initial,2012-08-30,GCST001653,Androgen levels
7888,European,3286.0,22960237.0,Han Y,Other measurement,replication,2012-08-31,GCST001656,Comprehensive strength and appendicular lean mass
2782,Asian,1627.0,22960237.0,Han Y,Other measurement,initial,2012-08-31,GCST001656,Comprehensive strength and appendicular lean mass
13841,Other/Mixed,253.0,22885689.0,Levinson DF,Neurological disorder,initial,2012-09-01,GCST001657,Schizophrenia
3402,Asian,3650.0,22885922.0,Morris AP,Metabolic disorder,replication,2012-09-01,GCST005047,Type 2 diabetes
7879,European,3267.0,22885689.0,Levinson DF,Neurological disorder,initial,2012-09-01,GCST001657,Schizophrenia
11558,European,77138.0,22885922.0,Morris AP,Metabolic disorder,replication,2012-09-01,GCST005047,Type 2 diabetes
5847,European,798.0,22881374.0,Cummings AC,Neurological disorder,initial,2012-09-01,GCST001658,Alzheimer's disease (late onset)
11487,European,69033.0,22885922.0,Morris AP,Metabolic disorder,initial,2012-09-01,GCST005047,Type 2 diabetes
7375,European,2406.0,22941190.0,Holliday EG,Cardiovascular disease,initial,2012-09-02,GCST001659,Stroke (ischemic)
1092,African American or Afro-Caribbean,2856.0,22941191.0,Diskin SJ,Cancer,replication,2012-09-02,GCST001660,Neuroblastoma
6307,European,1131.0,22941191.0,Diskin SJ,Cancer,replication,2012-09-02,GCST001660,Neuroblastoma
11337,European,54410.0,22941190.0,Holliday EG,Cardiovascular disease,replication,2012-09-02,GCST001659,Stroke (ischemic)
8955,European,6303.0,22941191.0,Diskin SJ,Cancer,initial,2012-09-02,GCST001660,Neuroblastoma
8214,European,3988.0,22949513.0,EPICURE Consortium,Neurological disorder,initial,2012-09-04,GCST001662,Generalized epilepsy
8063,European,3590.0,22949513.0,EPICURE Consortium,Neurological disorder,replication,2012-09-04,GCST001662,Generalized epilepsy
5061,European,310.0,22945461.0,Rahmioglu N,Liver enzyme measurement,initial,2012-09-04,GCST001661,CYP3A4 enzyme activity
8308,European,4243.0,22959728.0,Ahmeti KB,"Neurological disorder, Other measurement",initial,2012-09-05,GCST001663,Amyotrophic lateral sclerosis (age of onset)
9632,European,9355.0,22959728.0,Ahmeti KB,Neurological disorder,initial,2012-09-05,GCST004793,Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals
9630,European,9355.0,22959728.0,Ahmeti KB,Neurological disorder,initial,2012-09-05,GCST001664,Amyotrophic lateral sclerosis
8307,European,4243.0,22959728.0,Ahmeti KB,Neurological disorder,initial,2012-09-05,GCST004791,Amyotrophic lateral sclerosis (C9orf72 mutation interaction)
9631,European,9355.0,22959728.0,Ahmeti KB,Neurological disorder,initial,2012-09-05,GCST004792,Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals
3279,Asian,2902.0,22951594.0,Elgazzar S,Cancer,initial,2012-09-06,GCST001667,Breast cancer
7801,European,3166.0,22961961.0,Foroud T,Cardiovascular disease,initial,2012-09-06,GCST001665,Intracranial aneurysm
3257,Asian,2818.0,22951725.0,Tang XF,Immune system disorder,initial,2012-09-06,GCST001670,Vitiligo
3508,Asian,4450.0,22951594.0,Elgazzar S,Cancer,replication,2012-09-06,GCST001667,Breast cancer
4301,Asian,16064.0,22951725.0,Tang XF,Immune system disorder,replication,2012-09-06,GCST001670,Vitiligo
3004,Asian,2034.0,22961080.0,Li H,Metabolic disorder,replication,2012-09-06,GCST001666,Type 2 diabetes
3078,Asian,2192.0,22951595.0,Hwang JY,Other disease,replication,2012-09-06,GCST001669,Polycystic ovary syndrome
4462,Asian,35339.0,22961080.0,Li H,Metabolic disorder,replication,2012-09-06,GCST001666,Type 2 diabetes
2877,Asian,1783.0,22961080.0,Li H,Metabolic disorder,replication,2012-09-06,GCST001666,Type 2 diabetes
9653,European,9469.0,22956598.0,Peters MJ,Other trait,replication,2012-09-06,GCST001668,Pain
3077,Asian,2192.0,22951595.0,Hwang JY,Other disease,initial,2012-09-06,GCST001669,Polycystic ovary syndrome
3410,Asian,3712.0,22961080.0,Li H,Metabolic disorder,initial,2012-09-06,GCST001666,Type 2 diabetes
9146,European,7099.0,22956598.0,Peters MJ,Other trait,initial,2012-09-06,GCST001668,Pain
4951,European,229.0,23225573.0,Buck D,Other measurement,initial,2012-09-08,GCST001671,IgG levels
5212,European,409.0,23225573.0,Buck D,Other measurement,replication,2012-09-08,GCST001671,IgG levels
3459,Asian,4075.0,22960999.0,Wu C,Cancer,initial,2012-09-09,GCST001672,Esophageal cancer  (alcohol interaction)
8135,European,3784.0,22968431.0,Urban TJ,"Response to drug, Digestive system disorder",initial,2012-09-09,GCST001673,Drug-induced liver injury
10442,European,18811.0,22961001.0,Su Z,Digestive system disorder,replication,2012-09-09,GCST001675,Barrett's esophagus
4314,Asian,16712.0,22960999.0,Wu C,Cancer,replication,2012-09-09,GCST001674,Esophageal cancer (squamous cell)
7679,European,2894.0,22968431.0,Urban TJ,"Response to drug, Digestive system disorder",replication,2012-09-09,GCST001673,Drug-induced liver injury
4313,Asian,16712.0,22960999.0,Wu C,Cancer,replication,2012-09-09,GCST001672,Esophageal cancer  (alcohol interaction)
3460,Asian,4075.0,22960999.0,Wu C,Cancer,initial,2012-09-09,GCST001674,Esophageal cancer (squamous cell)
9128,European,7024.0,22961001.0,Su Z,Digestive system disorder,initial,2012-09-09,GCST001675,Barrett's esophagus
11936,European,133154.0,22982992.0,Yang J,"Body measurement, Other measurement",initial,2012-09-12,GCST001676,Body mass index
11395,European,59325.0,22982992.0,Yang J,"Body measurement, Other measurement",replication,2012-09-12,GCST001676,Body mass index
9117,European,6972.0,22976474.0,Siddiq A,Cancer,replication,2012-09-13,GCST001683,Breast cancer
7153,European,2136.0,22982463.0,Tang WH,Cardiovascular measurement,initial,2012-09-13,GCST001677,Paraoxonase activity
13078,Hispanic or Latin American,1464.0,22976474.0,Siddiq A,Cancer,replication,2012-09-13,GCST001683,Breast cancer
3696,Asian,5683.0,23028356.0,Myouzen K,Immune system disorder,initial,2012-09-13,GCST001681,Rheumatoid arthritis
4480,Asian,37586.0,23028356.0,Myouzen K,Immune system disorder,replication,2012-09-13,GCST001681,Rheumatoid arthritis
1203,African American or Afro-Caribbean,3748.0,22976474.0,Siddiq A,Cancer,initial,2012-09-13,GCST001683,Breast cancer
7636,European,2801.0,22969067.0,Mishra A,Other measurement,initial,2012-09-13,GCST001680,Corneal curvature
8246,European,4071.0,23028347.0,Liu F,"Other trait, Other measurement",replication,2012-09-13,GCST001678,Facial morphology
2704,Asian,1496.0,23028341.0,Yang X,Other measurement,replication,2012-09-13,GCST001679,Complement C3 and C4 levels
6168,European,1000.0,22981920.0,Weissflog L,Neurological disorder,initial,2012-09-13,GCST001682,Personality disorders
2455,Asian,914.0,22976474.0,Siddiq A,Cancer,replication,2012-09-13,GCST001683,Breast cancer
2981,Asian,1999.0,23028341.0,Yang X,Other measurement,initial,2012-09-13,GCST001679,Complement C3 and C4 levels
8730,European,5388.0,23028347.0,Liu F,"Other trait, Other measurement",initial,2012-09-13,GCST001678,Facial morphology
10921,European,32530.0,22976474.0,Siddiq A,Cancer,initial,2012-09-13,GCST001683,Breast cancer
2484,Asian,963.0,23000144.0,Nakamura M,Cancer,initial,2012-09-18,GCST001685,Primary biliary cholangitis
8238,European,4048.0,22986903.0,Hansel NN,Other disease,initial,2012-09-18,GCST001686,Chronic obstructive pulmonary disease
6890,European,1772.0,22986903.0,Hansel NN,Other disease,replication,2012-09-18,GCST001686,Chronic obstructive pulmonary disease
10492,European,19599.0,22990020.0,Huang J,Other measurement,initial,2012-09-18,GCST001684,Plasminogen activator inhibitor type 1 levels (PAI-1)
2672,Asian,1402.0,23000144.0,Nakamura M,Cancer,replication,2012-09-18,GCST001685,Primary biliary cholangitis
9843,European,10764.0,22990020.0,Huang J,Other measurement,replication,2012-09-18,GCST001684,Plasminogen activator inhibitor type 1 levels (PAI-1)
8446,European,4683.0,22993228.0,Williams FM,Other disease,initial,2012-09-19,GCST001687,Disc degeneration (lumbar)
8170,European,3889.0,22997280.0,Ho JE,Hematological measurement,initial,2012-09-20,GCST006519,Growth differentiation factor-15 levels
5863,European,810.0,22990015.0,Arning A,Cardiovascular disease,initial,2012-09-20,GCST001689,Stroke (pediatric)
8937,European,6231.0,23028342.0,Sandholm N,Metabolic disorder,initial,2012-09-20,GCST001688,Type 1 diabetes nephropathy
8449,European,4684.0,23028342.0,Sandholm N,Metabolic disorder,replication,2012-09-20,GCST001688,Type 1 diabetes nephropathy
8072,European,3618.0,23001122.0,Orr N,Cancer,initial,2012-09-23,GCST001690,Breast cancer (male)
6008,European,912.0,23001122.0,Orr N,Cancer,replication,2012-09-23,GCST001690,Breast cancer (male)
4744,European,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001694,Response to taxane treatment (placlitaxel)
12984,Hispanic or Latin American,815.0,23017229.0,Voruganti VS,Other measurement,initial,2012-09-24,GCST001691,Monocyte chemoattractant protein-1 levels
14096,Other/Mixed,1268.0,23007406.0,Yang JJ,Cancer,initial,2012-09-24,GCST001693,Acute lymphoblastic leukemia (childhood)
1721,Asian,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001692,Response to taxane treatment (docetaxel)
1722,Asian,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001694,Response to taxane treatment (placlitaxel)
14095,Other/Mixed,1267.0,23007406.0,Yang JJ,Cancer,replication,2012-09-24,GCST001693,Acute lymphoblastic leukemia (childhood)
501,African American or Afro-Caribbean,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001694,Response to taxane treatment (placlitaxel)
4743,European,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001692,Response to taxane treatment (docetaxel)
500,African American or Afro-Caribbean,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001692,Response to taxane treatment (docetaxel)
4165,Asian,11696.0,23049750.0,Kumasaka N,Biological process,initial,2012-09-25,GCST001696,Smoking behavior
3645,Asian,5462.0,23049750.0,Kumasaka N,Biological process,replication,2012-09-25,GCST001696,Smoking behavior
7566,European,2681.0,23010768.0,Meier S,Neurological disorder,replication,2012-09-25,GCST001695,Bipolar disorder (Negative mood delusions)
9602,European,9190.0,23001564.0,Mangino M,Other measurement,initial,2012-09-25,GCST001697,Telomere length
7767,European,3095.0,23010768.0,Meier S,Neurological disorder,initial,2012-09-25,GCST001695,Bipolar disorder (Negative mood delusions)
11312,European,53190.0,23022100.0,Franceschini N,Other measurement,initial,2012-09-26,GCST001699,Serum albumin level
4106,Asian,10168.0,23022100.0,Franceschini N,"Hematological measurement, Other measurement",initial,2012-09-26,GCST001698,Serum total protein level
13825,Other/Mixed,230.0,23021708.0,Kerns SL,"Cancer, Other disease, Biological process",replication,2012-09-26,GCST001700,Erectile dysfunction and prostate cancer treatment
13834,Other/Mixed,235.0,23021708.0,Kerns SL,"Cancer, Other disease, Biological process",initial,2012-09-26,GCST001700,Erectile dysfunction and prostate cancer treatment
4063,Asian,9380.0,23022100.0,Franceschini N,Other measurement,initial,2012-09-26,GCST001699,Serum albumin level
10748,European,25539.0,23022100.0,Franceschini N,"Hematological measurement, Other measurement",initial,2012-09-26,GCST001698,Serum total protein level
10431,European,18604.0,23028483.0,Ramasamy A,Other disease,initial,2012-09-28,GCST001701,Asthma
10209,European,15286.0,23028483.0,Ramasamy A,Other disease,replication,2012-09-28,GCST001701,Asthma
3153,Asian,2425.0,23023329.0,Xu J,Cancer,initial,2012-09-30,GCST001702,Prostate cancer
4136,Asian,10993.0,23023329.0,Xu J,Cancer,replication,2012-09-30,GCST001702,Prostate cancer
9902,European,11375.0,22961000.0,Liu JZ,Cancer,initial,2012-10-01,GCST005581,Primary biliary cirrhosis
6840,European,1720.0,23031429.0,Surakka I,Other measurement,initial,2012-10-03,GCST001703,Apolipoprotein Levels
6839,European,1720.0,23031429.0,Surakka I,Lipid or lipoprotein measurement,initial,2012-10-03,GCST001704,Cholesterol and Triglycerides
6459,European,1261.0,23031429.0,Surakka I,Lipid or lipoprotein measurement,replication,2012-10-03,GCST001704,Cholesterol and Triglycerides
5023,European,289.0,23054467.0,Postula M,Cardiovascular measurement,initial,2012-10-04,GCST001705,Platelet reactivity
11127,European,39965.0,23041239.0,Traylor M,Cardiovascular disease,replication,2012-10-05,GCST001706,Stroke (ischemic)
3162,Asian,2465.0,23041239.0,Traylor M,Cardiovascular disease,replication,2012-10-05,GCST001706,Stroke (ischemic)
11535,European,74393.0,23041239.0,Traylor M,Cardiovascular disease,initial,2012-10-05,GCST001706,Stroke (ischemic)
2569,Asian,1167.0,23041938.0,Lee YJ,Cardiovascular disease,initial,2012-10-06,GCST001707,Behcet's disease
2258,Asian,635.0,23041938.0,Lee YJ,Cardiovascular disease,replication,2012-10-06,GCST001707,Behcet's disease
4036,Asian,8877.0,23042114.0,Hirota T,Immune system disorder,replication,2012-10-07,GCST001709,Atopic dermatitis
8568,European,4948.0,23053960.0,Lee YH,Immune system disorder,initial,2012-10-07,GCST001708,Systemic lupus erythematosus
4067,Asian,9443.0,23042114.0,Hirota T,Immune system disorder,initial,2012-10-07,GCST001709,Atopic dermatitis
6834,European,1716.0,23043469.0,Menzel S,Hematological measurement,replication,2012-10-09,GCST001710,HbA2 levels
6449,European,1251.0,23049088.0,Meng W,Other trait,initial,2012-10-09,GCST001712,Myopia (pathological)
7320,European,2322.0,23043469.0,Menzel S,Hematological measurement,initial,2012-10-09,GCST001710,HbA2 levels
8130,European,3776.0,23056639.0,de Boer RA,Other measurement,initial,2012-10-09,GCST001711,Protein biomarker
6017,European,920.0,23064961.0,Shaffer JR,Digestive system disorder,initial,2012-10-11,GCST001713,Dental caries
10635,European,22548.0,23065704.0,Amin Al Olama A,Cancer,initial,2012-10-12,GCST001714,Prostate cancer
11263,European,49121.0,23065704.0,Amin Al Olama A,Cancer,replication,2012-10-12,GCST001714,Prostate cancer
6801,European,1678.0,23093944.0,Krumsiek J,Other measurement,initial,2012-10-18,GCST006249,Serum metabolite levels
8173,European,3895.0,23100282.0,Hopewell JC,Response to drug,initial,2012-10-24,GCST001716,Response to statin therapy
6583,European,1402.0,23133572.0,Rye MS,Neurological disorder,initial,2012-10-25,GCST001717,Otitis media (chronic/recurrent)
4062,Asian,9374.0,23103227.0,Jin G,Cancer,initial,2012-10-25,GCST001718,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)"
4366,Asian,20437.0,23103227.0,Jin G,Cancer,replication,2012-10-25,GCST001718,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)"
11399,European,59585.0,23104005.0,Gudmundsson J,Cancer,initial,2012-10-28,GCST001719,Prostate cancer
3590,Asian,5061.0,23104006.0,Nyholt DR,Other disease,replication,2012-10-28,GCST001720,Endometriosis
10036,European,13053.0,23104005.0,Gudmundsson J,Cancer,replication,2012-10-28,GCST001719,Prostate cancer
9894,European,11256.0,23104006.0,Nyholt DR,Other disease,initial,2012-10-28,GCST001720,Endometriosis
3233,Asian,2741.0,23104006.0,Nyholt DR,Other disease,initial,2012-10-28,GCST001720,Endometriosis
6556,European,1374.0,23108145.0,Wang LE,Cancer,replication,2012-10-29,GCST001721,Lung Cancer (DNA repair capacity)
6893,European,1774.0,23108145.0,Wang LE,Cancer,initial,2012-10-29,GCST001721,Lung Cancer (DNA repair capacity)
7282,European,2286.0,23108985.0,Guo YF,Other measurement,replication,2012-10-30,GCST001722,Body mass (lean)
2783,Asian,1627.0,23108985.0,Guo YF,Other measurement,initial,2012-10-30,GCST001722,Body mass (lean)
2982,Asian,1999.0,23118916.0,Yang M,Other measurement,initial,2012-10-31,GCST001724,IgM levels
5036,European,293.0,23118974.0,Candille SI,"Other measurement, Other trait",replication,2012-10-31,GCST001723,Eye color
4843,European,175.0,23118974.0,Candille SI,"Other measurement, Other trait",initial,2012-10-31,GCST001723,Eye color
2705,Asian,1496.0,23118916.0,Yang M,Other measurement,replication,2012-10-31,GCST001724,IgM levels
5443,European,516.0,23047291.0,Brown CC,Response to drug,initial,2012-11-01,GCST001730,Response to temozolomide
10993,European,34366.0,23128233.0,Jostins L,"Digestive system disorder, Immune system disorder",initial,2012-11-01,GCST001725,Inflammatory bowel disease
10994,European,34366.0,23128233.0,Jostins L,Immune system disorder,initial,2012-11-01,GCST001728,Ulcerative colitis
11171,European,42698.0,23128233.0,Jostins L,Digestive system disorder,replication,2012-11-01,GCST001729,Crohn's disease
9086,European,6851.0,23118302.0,Chu AY,Lipid or lipoprotein measurement,initial,2012-11-01,GCST001727,Lipoprotein-associated phospholipase A2 activity and mass
11173,European,42698.0,23128233.0,Jostins L,Immune system disorder,replication,2012-11-01,GCST001728,Ulcerative colitis
10093,European,13664.0,23118302.0,Chu AY,Lipid or lipoprotein measurement,replication,2012-11-01,GCST001727,Lipoprotein-associated phospholipase A2 activity and mass
8717,European,5329.0,23118302.0,Chu AY,Lipid or lipoprotein measurement,initial,2012-11-01,GCST001726,Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
11172,European,42698.0,23128233.0,Jostins L,"Digestive system disorder, Immune system disorder",replication,2012-11-01,GCST001725,Inflammatory bowel disease
10992,European,34366.0,23128233.0,Jostins L,Digestive system disorder,initial,2012-11-01,GCST001729,Crohn's disease
5063,European,314.0,23114982.0,Siegert S,"Other measurement, Body measurement, Cancer",initial,2012-11-02,GCST001731,Colorectal cancer (environment interaction)
6460,European,1261.0,23114982.0,Siegert S,"Other measurement, Body measurement, Cancer",replication,2012-11-02,GCST001731,Colorectal cancer (environment interaction)
2634,Asian,1301.0,23818313.0,Kim HJ,"Other measurement, Metabolic disorder",replication,2012-11-06,GCST001732,Obesity
2346,Asian,756.0,23818313.0,Kim HJ,"Other measurement, Metabolic disorder",initial,2012-11-06,GCST001732,Obesity
5523,European,564.0,23142968.0,Betcheva ET,Neurological disorder,initial,2012-11-07,GCST001733,Schizophrenia
5242,European,427.0,23142968.0,Betcheva ET,Neurological disorder,replication,2012-11-07,GCST001733,Schizophrenia
1467,African American or Afro-Caribbean,13415.0,23139255.0,Butler AM,Cardiovascular measurement,initial,2012-11-08,GCST001735,PR interval
2024,Asian,348.0,23144319.0,Lee Y,Cancer,initial,2012-11-08,GCST001734,Non-small cell lung cancer
7011,European,1951.0,23144326.0,Kim DK,"Other disease, Hematological measurement, Inflammatory measurement, Other measurement",initial,2012-11-09,GCST001737,Chronic obstructive pulmonary disease-related biomarkers
2350,Asian,758.0,23137000.0,Lin HJ,"Neurological disorder, Metabolic disorder",initial,2012-11-09,GCST001736,Cataracts in type 2 diabetes
6712,European,1564.0,23146381.0,Levin AM,Other measurement,initial,2012-11-10,GCST001739,IgE levels
6508,European,1329.0,23146381.0,Levin AM,Other measurement,replication,2012-11-10,GCST001739,IgE levels
5841,European,793.0,23149075.0,Aslibekyan S,Response to drug,initial,2012-11-10,GCST001738,Response to fenofibrate (adiponectin levels)
1121,African American or Afro-Caribbean,2961.0,23146381.0,Levin AM,Other measurement,replication,2012-11-10,GCST001739,IgE levels
13080,Hispanic or Latin American,1477.0,23146381.0,Levin AM,Other measurement,replication,2012-11-10,GCST001739,IgE levels
12822,Hispanic or Latin American,259.0,23146381.0,Levin AM,Other measurement,initial,2012-11-10,GCST001739,IgE levels
1047,African American or Afro-Caribbean,2469.0,23146381.0,Levin AM,Other measurement,initial,2012-11-10,GCST001739,IgE levels
3450,Asian,4012.0,23143601.0,Lan Q,Cancer,replication,2012-11-11,GCST001740,Lung cancer
8665,European,5183.0,23143602.0,Whitcomb DC,Digestive system disorder,initial,2012-11-11,GCST001741,Pancreatitis
4098,Asian,10054.0,23143601.0,Lan Q,Cancer,initial,2012-11-11,GCST001740,Lung cancer
8626,European,5080.0,23143602.0,Whitcomb DC,Digestive system disorder,replication,2012-11-11,GCST001741,Pancreatitis
3158,Asian,2435.0,23149450.0,Otowa T,Neurological disorder,initial,2012-11-13,GCST001742,Panic disorder
2583,Asian,1190.0,23149450.0,Otowa T,Neurological disorder,replication,2012-11-13,GCST001742,Panic disorder
9998,European,12438.0,23150908.0,Jonsson T,Neurological disorder,initial,2012-11-14,GCST001743,Alzheimer's disease
8621,European,5069.0,23150908.0,Jonsson T,Neurological disorder,replication,2012-11-14,GCST001743,Alzheimer's disease
1835,Asian,182.0,23151678.0,Takata R,Response to drug,initial,2012-11-15,GCST001744,Serum tamsulosin hydrochloride concentration
5174,European,390.0,23160099.0,Justice CM,Neurological disorder,initial,2012-11-18,GCST001745,Sagittal craniosynostosis
1457,African American or Afro-Caribbean,13105.0,23166209.0,Smith JG,Cardiovascular measurement,initial,2012-11-19,GCST001746,QT interval
2398,Asian,802.0,23180272.0,Park BL,Other trait,initial,2012-11-21,GCST001747,Aspirin exacerbated respiratory disease in asthmatics
2561,Asian,1138.0,23180272.0,Park BL,Other trait,replication,2012-11-21,GCST001747,Aspirin exacerbated respiratory disease in asthmatics
1466,African American or Afro-Caribbean,13372.0,23183192.0,Deo R,Cardiovascular measurement,initial,2012-11-23,GCST001748,Resting heart rate
5627,European,642.0,23180869.0,Wu C,Cancer,initial,2012-11-24,GCST001749,Pancreatic cancer
2037,Asian,363.0,23180869.0,Wu C,Cancer,replication,2012-11-24,GCST001749,Pancreatic cancer
10005,European,12525.0,23184150.0,Henrion M,Cancer,replication,2012-11-25,GCST001750,Renal cell carcinoma
9849,European,10781.0,23184150.0,Henrion M,Cancer,initial,2012-11-25,GCST001750,Renal cell carcinoma
1757,Asian,118.0,23183491.0,Nishizawa D,Response to drug,initial,2012-11-27,GCST001751,Opioid sensitivity
1922,Asian,235.0,23183491.0,Nishizawa D,Response to drug,replication,2012-11-27,GCST001751,Opioid sensitivity
1381,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004582,Waist-to-hip circumference ratio (dietary energy interaction)
13189,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004581,Body mass index  (smoking years interaction)
1386,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Other measurement, Body measurement",initial,2012-11-29,GCST004584,Waist-to-hip circumference ratio (smoking years interaction)
1383,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004586,Body mass index (ever vs never smoking interaction)
1378,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004579,Waist-to-hip circumference ratio (alcohol intake interaction)
1377,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST001753,Body mass index (alcohol intake interaction)
13190,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004582,Waist-to-hip circumference ratio (dietary energy interaction)
3454,Asian,4055.0,23209447.0,Tang M,Cancer,initial,2012-11-29,GCST001752,Nasopharyngeal carcinoma
13192,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004586,Body mass index (ever vs never smoking interaction)
13193,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004587,Body mass index (dietary energy interaction)
13194,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Other measurement, Body measurement",initial,2012-11-29,GCST001754,Waist-to-hip circumference ratio (ever vs never smoking interaction)
1382,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004583,Waist-to-hip circumference ratio (recreational physical activity interaction)
13195,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Other measurement, Body measurement",initial,2012-11-29,GCST004584,Waist-to-hip circumference ratio (smoking years interaction)
13187,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004579,Waist-to-hip circumference ratio (alcohol intake interaction)
1379,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004580,Body mass index (recreational physical activity interaction)
2498,Asian,985.0,23209447.0,Tang M,Cancer,replication,2012-11-29,GCST001752,Nasopharyngeal carcinoma
13191,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004583,Waist-to-hip circumference ratio (recreational physical activity interaction)
1384,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004587,Body mass index (dietary energy interaction)
13188,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004580,Body mass index (recreational physical activity interaction)
1380,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004581,Body mass index  (smoking years interaction)
13186,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST001753,Body mass index (alcohol intake interaction)
1385,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Other measurement, Body measurement",initial,2012-11-29,GCST001754,Waist-to-hip circumference ratio (ever vs never smoking interaction)
486,African American or Afro-Caribbean,83.0,23204130.0,Wheeler HE,"Response to drug, Neurological disorder, Other measurement",initial,2012-11-30,GCST001755,Paclitaxel-induced neuropathy
2784,Asian,1627.0,23207799.0,Deng FY,Other measurement,replication,2012-11-30,GCST001756,Spine bone size
7283,European,2286.0,23207799.0,Deng FY,Other measurement,initial,2012-11-30,GCST001756,Spine bone size
37,African,87.0,23204130.0,Wheeler HE,"Response to drug, Neurological disorder, Other measurement",initial,2012-11-30,GCST001755,Paclitaxel-induced neuropathy
7436,European,2503.0,23207799.0,Deng FY,Other measurement,replication,2012-11-30,GCST001756,Spine bone size
4696,European,77.0,23204130.0,Wheeler HE,"Response to drug, Neurological disorder, Other measurement",initial,2012-11-30,GCST001755,Paclitaxel-induced neuropathy
11178,European,43327.0,23143596.0,Eyre S,Immune system disorder,initial,2012-12-01,GCST005568,Rheumatoid arthritis (ACPA-positive)
11240,European,47580.0,23143596.0,Eyre S,Immune system disorder,initial,2012-12-01,GCST005569,Rheumatoid arthritis
9717,European,9826.0,22922229.0,Cooper JD,Immune system disorder,initial,2012-12-01,GCST005525,Hashimoto thyroiditis
10942,European,33394.0,23143594.0,Tsoi LC,Immune system disorder,initial,2012-12-01,GCST005527,Psoriasis
7408,European,2454.0,23212062.0,Fanous AH,Neurological disorder,initial,2012-12-01,GCST001757,Schizophrenia
9928,European,11649.0,22922229.0,Cooper JD,Immune system disorder,initial,2012-12-01,GCST005526,Graves' disease
9976,European,12097.0,22922229.0,Cooper JD,Immune system disorder,initial,2012-12-01,GCST005524,Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis)
10458,European,19167.0,23143596.0,Eyre S,Immune system disorder,initial,2012-12-01,GCST005567,Rheumatoid arthritis (ACPA-negative)
11170,European,42519.0,23202124.0,Horikoshi M,Body measurement,replication,2012-12-02,GCST001758,Birth weight
10777,European,26836.0,23202124.0,Horikoshi M,Body measurement,initial,2012-12-02,GCST001758,Birth weight
4003,Asian,8776.0,23209189.0,Tabassum R,Metabolic disorder,replication,2012-12-03,GCST001759,Type 2 diabetes
3037,Asian,2128.0,23209189.0,Tabassum R,Metabolic disorder,initial,2012-12-03,GCST001759,Type 2 diabetes
10638,European,22570.0,23209189.0,Tabassum R,Metabolic disorder,replication,2012-12-03,GCST001759,Type 2 diabetes
13095,Hispanic or Latin American,1809.0,23181788.0,Lasky-Su J,Other disease,replication,2012-12-04,GCST001763,Asthma
7885,European,3280.0,23207651.0,Davies G,"Other trait, Biological process",initial,2012-12-04,GCST001761,Cognitive decline
8160,European,3855.0,23181788.0,Lasky-Su J,Other disease,initial,2012-12-04,GCST001763,Asthma
12985,Hispanic or Latin American,815.0,23251661.0,Comuzzie AG,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",initial,2012-12-04,GCST001762,Obesity-related traits
6538,European,1367.0,23207651.0,Davies G,"Other trait, Biological process",replication,2012-12-04,GCST001761,Cognitive decline
8796,European,5640.0,23181788.0,Lasky-Su J,Other disease,replication,2012-12-04,GCST001763,Asthma
6030,European,928.0,23213074.0,Adams LA,"Liver enzyme measurement, Cancer, Digestive system disorder",initial,2012-12-05,GCST001766,Non-alcoholic fatty liver disease histology (other)
11430,European,62553.0,23222517.0,van der Harst P,Hematological measurement,initial,2012-12-05,GCST001765,Red blood cell traits
11434,European,63506.0,23222517.0,van der Harst P,Hematological measurement,replication,2012-12-05,GCST001765,Red blood cell traits
4060,Asian,9308.0,23222517.0,van der Harst P,Hematological measurement,initial,2012-12-05,GCST001765,Red blood cell traits
5412,European,502.0,23223146.0,Le Clerc S,Biological process,initial,2012-12-06,GCST001767,Aging (facial)
812,African American or Afro-Caribbean,929.0,23216389.0,Zuo L,Neurological disorder,replication,2012-12-06,GCST001769,Alcohol and nicotine co-dependence
2816,Asian,1713.0,23001997.0,Hou S,Cardiovascular disease,replication,2012-12-06,GCST001768,Behcet's disease
8114,European,3737.0,23216389.0,Zuo L,Neurological disorder,replication,2012-12-06,GCST001769,Alcohol and nicotine co-dependence
7246,European,2214.0,23216389.0,Zuo L,Neurological disorder,initial,2012-12-06,GCST001769,Alcohol and nicotine co-dependence
2543,Asian,1098.0,23001997.0,Hou S,Cardiovascular disease,initial,2012-12-06,GCST001768,Behcet's disease
7606,European,2748.0,23229837.0,Aragam N,"Neurological disorder, Other measurement",initial,2012-12-11,GCST001771,Neuroticism
12824,Hispanic or Latin American,266.0,23233662.0,Ramsey LB,Response to drug,initial,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
5974,European,882.0,23233654.0,Umicevic Mirkov M,"Immune system disorder, Response to drug",initial,2012-12-11,GCST001772,Response to TNF-alpha inhibitors in rheumatoid arthritis
5709,European,699.0,23233662.0,Ramsey LB,Response to drug,replication,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
13764,Other/Mixed,127.0,23233662.0,Ramsey LB,Response to drug,initial,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
463,African American or Afro-Caribbean,58.0,23233662.0,Ramsey LB,Response to drug,initial,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
1628,Asian,22.0,23233662.0,Ramsey LB,Response to drug,initial,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
6924,European,1821.0,23233654.0,Umicevic Mirkov M,"Immune system disorder, Response to drug",replication,2012-12-11,GCST001772,Response to TNF-alpha inhibitors in rheumatoid arthritis
5858,European,806.0,23233662.0,Ramsey LB,Response to drug,initial,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
587,African American or Afro-Caribbean,214.0,23241943.0,Clark SL,Response to drug,initial,2012-12-12,GCST001773,Response to antipsychotic treatment
5233,European,421.0,23241943.0,Clark SL,Response to drug,initial,2012-12-12,GCST001773,Response to antipsychotic treatment
7510,European,2578.0,23237013.0,Power RA,"Other trait, Other measurement",initial,2012-12-14,GCST001774,Reporting of stressful life event
6332,European,1151.0,23237013.0,Power RA,"Other trait, Other measurement",replication,2012-12-14,GCST001774,Reporting of stressful life event
3181,Asian,2514.0,23242368.0,Jiang DK,"Digestive system disorder, Cancer",initial,2012-12-16,GCST001775,Hepatocellular carcinoma in hepatitis B infection
1007,African American or Afro-Caribbean,2053.0,23247143.0,Yu B,Cardiovascular measurement,initial,2012-12-16,GCST001776,Cardiac Troponin-T levels
4057,Asian,9285.0,23242368.0,Jiang DK,"Digestive system disorder, Cancer",replication,2012-12-16,GCST001775,Hepatocellular carcinoma in hepatitis B infection
9656,European,9491.0,23247143.0,Yu B,Cardiovascular measurement,initial,2012-12-16,GCST001776,Cardiac Troponin-T levels
8303,European,4238.0,23247145.0,Makela KM,Lipid or lipoprotein measurement,replication,2012-12-17,GCST001777,LDL (oxidized)
7123,European,2080.0,23247145.0,Makela KM,Lipid or lipoprotein measurement,initial,2012-12-17,GCST001777,LDL (oxidized)
7334,European,2338.0,23255317.0,Wooten EC,Cardiovascular disease,replication,2012-12-19,GCST001778,Hypertrophic cardiomyopathy
6161,European,997.0,23255317.0,Wooten EC,Cardiovascular disease,initial,2012-12-19,GCST001778,Hypertrophic cardiomyopathy
1368,African American or Afro-Caribbean,7943.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001781,Mean corpuscular volume
1369,African American or Afro-Caribbean,7943.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001782,Mean corpuscular hemoglobin concentration
1370,African American or Afro-Caribbean,7943.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001783,Platelet count
1371,African American or Afro-Caribbean,7943.0,23263863.0,Li J,"Hematological measurement, Cardiovascular measurement, Other measurement",initial,2012-12-20,GCST001779,Hematology traits
8943,European,6234.0,23263863.0,Li J,"Hematological measurement, Cardiovascular measurement, Other measurement",initial,2012-12-20,GCST001779,Hematology traits
8942,European,6234.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001783,Platelet count
8941,European,6234.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001782,Mean corpuscular hemoglobin concentration
11269,European,50047.0,23284291.0,Hancock DB,Other measurement,initial,2012-12-20,GCST001784,Pulmonary function (smoking interaction)
8939,European,6234.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001780,Mean corpuscular hemoglobin
1367,African American or Afro-Caribbean,7943.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001780,Mean corpuscular hemoglobin
8940,European,6234.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001781,Mean corpuscular volume
3414,Asian,3761.0,23266558.0,Yamazaki K,Digestive system disorder,initial,2012-12-21,GCST001785,Crohn's disease
10797,European,27809.0,23266556.0,Peters U,Cancer,initial,2012-12-21,GCST001787,Colorectal cancer
4317,Asian,16951.0,23266558.0,Yamazaki K,Digestive system disorder,replication,2012-12-21,GCST001785,Crohn's disease
6953,European,1867.0,23266556.0,Peters U,Cancer,replication,2012-12-21,GCST001787,Colorectal cancer
9221,European,7443.0,23259602.0,Wang X,Digestive system disorder,initial,2012-12-21,GCST001786,Dental caries
3933,Asian,7847.0,23266556.0,Peters U,Cancer,replication,2012-12-21,GCST001787,Colorectal cancer
13062,Hispanic or Latin American,1422.0,23263444.0,Frazier-Wood AC,Other disease,replication,2012-12-22,GCST001789,Lipoprotein diameter
5871,European,817.0,23263444.0,Frazier-Wood AC,Other disease,initial,2012-12-22,GCST001789,Lipoprotein diameter
2351,Asian,758.0,23263444.0,Frazier-Wood AC,Other disease,replication,2012-12-22,GCST001789,Lipoprotein diameter
6125,European,979.0,23263445.0,Lawrance-Owen AJ,Body measurement,initial,2012-12-22,GCST001788,Digit length ratio
7389,European,2430.0,23263444.0,Frazier-Wood AC,Other disease,replication,2012-12-22,GCST001789,Lipoprotein diameter
945,African American or Afro-Caribbean,1594.0,23263444.0,Frazier-Wood AC,Other disease,replication,2012-12-22,GCST001789,Lipoprotein diameter
6226,European,1036.0,23263486.0,Kottgen A,Metabolic disorder,replication,2012-12-23,GCST001790,Gout
9374,European,8229.0,23263489.0,Huyghe JR,Other measurement,initial,2012-12-23,GCST008109,Fasting blood proinsulin levels
9377,European,8229.0,23263489.0,Huyghe JR,Other measurement,initial,2012-12-23,GCST008112,Proinsulin levels (early-phase conversion)
9375,European,8229.0,23263489.0,Huyghe JR,Other measurement,initial,2012-12-23,GCST008110,Insulinogenic index
9378,European,8229.0,23263489.0,Huyghe JR,Other measurement,initial,2012-12-23,GCST008113,Proinsulin levels (late-phase conversion)
11800,European,110347.0,23263486.0,Kottgen A,"Metabolic disorder, Other measurement",initial,2012-12-23,GCST001791,Urate levels
11494,European,69374.0,23263486.0,Kottgen A,Metabolic disorder,initial,2012-12-23,GCST001790,Gout
10754,European,26060.0,23263487.0,Jia WH,Cancer,replication,2012-12-23,GCST001792,Colorectal cancer
9376,European,8229.0,23263489.0,Huyghe JR,Other measurement,initial,2012-12-23,GCST008111,Insulin disposition index
3932,Asian,7847.0,23263487.0,Jia WH,Cancer,initial,2012-12-23,GCST001792,Colorectal cancer
4146,Asian,11280.0,23263487.0,Jia WH,Cancer,replication,2012-12-23,GCST001792,Colorectal cancer
10926,European,32813.0,23263486.0,Kottgen A,"Metabolic disorder, Other measurement",replication,2012-12-23,GCST001791,Urate levels
7874,European,3250.0,23267103.0,Desch KC,Other measurement,initial,2012-12-24,GCST001793,Coagulation factor levels
10446,European,18938.0,23300701.0,Jiao S,Cancer,initial,2012-12-26,GCST001794,Colorectal cancer (SNP x SNP interaction)
8666,European,5185.0,23300701.0,Jiao S,Cancer,replication,2012-12-26,GCST001794,Colorectal cancer (SNP x SNP interaction)
4039,Asian,8923.0,23273568.0,Yang W,Immune system disorder,replication,2012-12-27,GCST001795,Systemic lupus erythematosus
2676,Asian,1416.0,23273568.0,Yang W,Immune system disorder,replication,2012-12-27,GCST001795,Systemic lupus erythematosus
2983,Asian,1999.0,23269536.0,Sun J,Other measurement,initial,2012-12-27,GCST001796,Prostate-specific antigen levels
3586,Asian,5050.0,23273568.0,Yang W,Immune system disorder,initial,2012-12-27,GCST001795,Systemic lupus erythematosus
2706,Asian,1496.0,23269536.0,Sun J,Other measurement,replication,2012-12-27,GCST001796,Prostate-specific antigen levels
10018,European,12612.0,23275298.0,Fox ER,Other measurement,replication,2012-12-28,GCST001797,Cardiac structure and function
1046,African American or Afro-Caribbean,2468.0,23275298.0,Fox ER,Other measurement,replication,2012-12-28,GCST001797,Cardiac structure and function
1327,African American or Afro-Caribbean,6765.0,23275298.0,Fox ER,Other measurement,initial,2012-12-28,GCST001797,Cardiac structure and function
6842,European,1722.0,23359319.0,Jin G,Other measurement,replication,2013-01-01,GCST001799,Prostate-specific antigen levels
9987,European,12307.0,23459209.0,Faraco J,Neurological disorder,initial,2013-01-01,GCST005522,Narcolepsy
7809,European,3192.0,23359319.0,Jin G,Other measurement,initial,2013-01-01,GCST001799,Prostate-specific antigen levels
7136,European,2100.0,23381943.0,Williams FM,"Hematological measurement, Other measurement",initial,2013-01-01,GCST001798,End-stage coagulation
5057,European,306.0,23279374.0,Athanasiadis G,Other measurement,initial,2013-01-02,GCST001800,&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
10310,European,16709.0,23290196.0,Hek K,Neurological disorder,replication,2013-01-02,GCST001802,Depression (quantitative trait)
5376,European,487.0,23703922.0,Li WD,Cardiovascular measurement,initial,2013-01-02,GCST001801,Uric acid levels
11002,European,34549.0,23290196.0,Hek K,Neurological disorder,initial,2013-01-02,GCST001802,Depression (quantitative trait)
3113,Asian,2281.0,23401653.0,Guggenheim JA,Other measurement,replication,2013-01-03,GCST001803,Corneal curvature
3285,Asian,2937.0,23401653.0,Guggenheim JA,Other measurement,replication,2013-01-03,GCST001803,Corneal curvature
3045,Asian,2142.0,23401653.0,Guggenheim JA,Other measurement,replication,2013-01-03,GCST001803,Corneal curvature
7065,European,2023.0,23401653.0,Guggenheim JA,Other measurement,initial,2013-01-03,GCST001803,Corneal curvature
2964,Asian,1941.0,23291585.0,Fakiola M,Other disease,replication,2013-01-06,GCST001805,Leishmaniasis (visceral)
10037,European,13057.0,23291589.0,Lu Y,"Other measurement, Neurological disorder",initial,2013-01-06,GCST001806,Corneal structure
14119,Other/Mixed,1468.0,23291587.0,Kirino Y,Cardiovascular disease,replication,2013-01-06,GCST001804,Behcet's disease
3188,Asian,2538.0,23291589.0,Lu Y,"Other measurement, Neurological disorder",initial,2013-01-06,GCST001806,Corneal structure
3018,Asian,2078.0,23291585.0,Fakiola M,Other disease,initial,2013-01-06,GCST001805,Leishmaniasis (visceral)
2939,Asian,1883.0,23291589.0,Lu Y,"Other measurement, Neurological disorder",initial,2013-01-06,GCST001806,Corneal structure
14163,Other/Mixed,2493.0,23291587.0,Kirino Y,Cardiovascular disease,initial,2013-01-06,GCST001804,Behcet's disease
3190,Asian,2542.0,23291589.0,Lu Y,"Other measurement, Neurological disorder",initial,2013-01-06,GCST001806,Corneal structure
2652,Asian,1352.0,23291587.0,Kirino Y,Cardiovascular disease,replication,2013-01-06,GCST001804,Behcet's disease
13103,Hispanic or Latin American,1970.0,23291585.0,Fakiola M,Other disease,initial,2013-01-06,GCST001805,Leishmaniasis (visceral)
8110,European,3729.0,23297363.0,Cordell HJ,Other trait,replication,2013-01-07,GCST001807,Tetralogy of Fallot
4121,Asian,10326.0,23300138.0,He M,Other measurement,replication,2013-01-07,GCST001808,Tumor biomarkers
3368,Asian,3451.0,23300138.0,He M,Other measurement,initial,2013-01-07,GCST001808,Tumor biomarkers
8884,European,5994.0,23297363.0,Cordell HJ,Other trait,initial,2013-01-07,GCST001807,Tetralogy of Fallot
11232,European,47117.0,23300278.0,Saxena R,Metabolic disorder,replication,2013-01-08,GCST001809,Type 2 diabetes
4458,Asian,33707.0,23300278.0,Saxena R,Metabolic disorder,replication,2013-01-08,GCST001809,Type 2 diabetes
2771,Asian,1616.0,23300278.0,Saxena R,Metabolic disorder,initial,2013-01-08,GCST001809,Type 2 diabetes
4506,Asian,45687.0,23300278.0,Saxena R,Metabolic disorder,replication,2013-01-08,GCST001809,Type 2 diabetes
10340,European,17091.0,23307926.0,Perry JR,Other measurement,initial,2013-01-09,GCST001810,Menopause (age at onset)
9397,European,8340.0,23307926.0,Perry JR,Other measurement,replication,2013-01-09,GCST001810,Menopause (age at onset)
7042,European,1993.0,23326512.0,Greenwood TA,Neurological disorder,initial,2013-01-10,GCST001811,Bipolar disorder (mania)
12915,Hispanic or Latin American,589.0,23326239.0,Rubicz R,"Other disease, Other measurement",replication,2013-01-10,GCST001812,Epstein-Barr virus immune response (EBNA-1)
13049,Hispanic or Latin American,1367.0,23326239.0,Rubicz R,"Other disease, Other measurement",initial,2013-01-10,GCST001812,Epstein-Barr virus immune response (EBNA-1)
3478,Asian,4205.0,23303382.0,Hong KW,"Hematological measurement, Cardiovascular measurement, Other measurement",replication,2013-01-10,GCST001813,Hematology traits
6328,European,1147.0,23326512.0,Greenwood TA,Neurological disorder,replication,2013-01-10,GCST001811,Bipolar disorder (mania)
3537,Asian,4637.0,23303382.0,Hong KW,"Hematological measurement, Cardiovascular measurement, Other measurement",initial,2013-01-10,GCST001813,Hematology traits
3477,Asian,4190.0,23326517.0,Holliday EG,Neurological disorder,replication,2013-01-11,GCST001814,Age-related macular degeneration
10501,European,19805.0,23326517.0,Holliday EG,Neurological disorder,initial,2013-01-11,GCST001814,Age-related macular degeneration
3560,Asian,4745.0,23321320.0,Urabe Y,Cancer,replication,2013-01-12,GCST001815,Hepatitis C induced liver cirrhosis
2823,Asian,1727.0,23321320.0,Urabe Y,Cancer,initial,2013-01-12,GCST001815,Hepatitis C induced liver cirrhosis
6646,European,1516.0,23319801.0,Rafiq S,Cancer,replication,2013-01-14,GCST001816,Breast cancer (prognosis)
5481,European,536.0,23319801.0,Rafiq S,Cancer,initial,2013-01-14,GCST001816,Breast cancer (prognosis)
5189,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001818,Metabolite levels (HVA/5-HIAA ratio)
5188,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001817,Metabolite levels (HVA-5-HIAA Factor score)
5194,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001824,Metabolite levels (HVA)
5190,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001820,Metabolite levels (5-HIAA)
5192,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001822,Metabolite levels (MHPG)
5193,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001823,Metabolite levels (HVA/MHPG ratio)
10618,European,22100.0,23322567.0,Lopes MC,"Neurological disorder, Other trait",initial,2013-01-15,GCST001819,Corneal astigmatism
5191,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001821,Metabolite levels (5-HIAA/ MHPG Ratio)
9053,European,6720.0,23328707.0,Tin A,Other measurement,initial,2013-01-16,GCST001825,Beta-trace protein levels
960,African American or Afro-Caribbean,1734.0,23328707.0,Tin A,Other measurement,replication,2013-01-16,GCST001825,Beta-trace protein levels
3439,Asian,3927.0,23341777.0,Dong J,Cancer,initial,2013-01-17,GCST001827,Squamous cell carcinoma
8156,European,3841.0,23349640.0,Vijai J,Cancer,replication,2013-01-17,GCST001826,Lymphoma
3982,Asian,8632.0,23341777.0,Dong J,Cancer,replication,2013-01-17,GCST001827,Squamous cell carcinoma
4679,European,64.0,23337848.0,Posti JP,Other disease,initial,2013-01-18,GCST001828,Vascular constriction
13731,Other/Mixed,68.0,23337848.0,Posti JP,Other disease,replication,2013-01-18,GCST001828,Vascular constriction
5383,European,490.0,23337944.0,Haghighi A,Biological process,replication,2013-01-22,GCST001829,Fat intake
5569,European,598.0,23337944.0,Haghighi A,Biological process,initial,2013-01-22,GCST001829,Fat intake
2682,Asian,1427.0,23349225.0,Hwang JY,Other disease,initial,2013-01-24,GCST001830,Osteoporosis
3327,Asian,3136.0,23349225.0,Hwang JY,Other disease,replication,2013-01-24,GCST001830,Osteoporosis
5325,European,466.0,23354978.0,Rinella ES,Cancer,replication,2013-01-25,GCST001831,Breast cancer
6191,European,1001.0,23354978.0,Rinella ES,Cancer,initial,2013-01-25,GCST001831,Breast cancer
7853,European,3216.0,23350875.0,Fernandez-Rozadilla C,Cancer,replication,2013-01-26,GCST001832,Colorectal cancer
6524,European,1355.0,23350875.0,Fernandez-Rozadilla C,Cancer,initial,2013-01-26,GCST001832,Colorectal cancer
4826,European,168.0,23374588.0,Martinelli-Boneschi F,"Response to drug, Neurological disorder",replication,2013-01-29,GCST001835,Response to cholinesterase inhibitors in Alzheimer's disease
9574,European,8961.0,23362303.0,Wu JH,Lipid or lipoprotein measurement,initial,2013-01-29,GCST001838,Palmitic acid (16:0) levels
9999,European,12441.0,23358156.0,Benyamin B,Biological process,initial,2013-01-29,GCST001837,Intelligence (childhood)
8387,European,4500.0,23382809.0,Xu C,Neurological disorder,initial,2013-01-29,GCST001836,Schizophrenia (negative symptoms)
4827,European,169.0,23374588.0,Martinelli-Boneschi F,"Response to drug, Neurological disorder",initial,2013-01-29,GCST001835,Response to cholinesterase inhibitors in Alzheimer's disease
6888,European,1770.0,23358160.0,Borglum AD,Neurological disorder,initial,2013-01-29,GCST001839,Schizophrenia
9576,European,8961.0,23362303.0,Wu JH,Lipid or lipoprotein measurement,initial,2013-01-29,GCST001841,Palmitoleic acid (16:1n-7) levels
9575,European,8961.0,23362303.0,Wu JH,Lipid or lipoprotein measurement,initial,2013-01-29,GCST001840,Stearic acid (18:0) levels
9345,European,8025.0,23358160.0,Borglum AD,Neurological disorder,replication,2013-01-29,GCST001839,Schizophrenia
6889,European,1770.0,23358160.0,Borglum AD,"Neurological disorder, Other disease",initial,2013-01-29,GCST001833,Schizophrenia (cytomegalovirus infection interaction)
8773,European,5548.0,23358156.0,Benyamin B,Biological process,replication,2013-01-29,GCST001837,Intelligence (childhood)
9573,European,8961.0,23362303.0,Wu JH,Lipid or lipoprotein measurement,initial,2013-01-29,GCST001834,Oleic acid (18:1n-9) levels
9346,European,8025.0,23358160.0,Borglum AD,"Neurological disorder, Other disease",replication,2013-01-29,GCST001833,Schizophrenia (cytomegalovirus infection interaction)
8477,European,4771.0,23386860.0,Pasquale LR,"Metabolic disorder, Other measurement",initial,2013-01-30,GCST001843,Type 2 diabetes (dietary heme iron intake interaction)
4330,Asian,18189.0,23364009.0,Yang X,Biological process,replication,2013-01-30,GCST001842,Drinking behavior
3583,Asian,5010.0,23364009.0,Yang X,Biological process,initial,2013-01-30,GCST001842,Drinking behavior
10963,European,33533.0,23372041.0,Chu AY,Biological process,initial,2013-01-30,GCST001844,Dietary macronutrient intake
11091,European,38360.0,23372041.0,Chu AY,Biological process,replication,2013-01-30,GCST001844,Dietary macronutrient intake
7263,European,2247.0,23382691.0,Lauc G,Other measurement,initial,2013-01-31,GCST001848,IgG glycosylation
4006,Asian,8830.0,23371916.0,Dai X,Other measurement,replication,2013-01-31,GCST001846,Bilirubin levels
2689,Asian,1452.0,23371916.0,Dai X,Other measurement,initial,2013-01-31,GCST001846,Bilirubin levels
13882,Other/Mixed,346.0,23376709.0,Kerns SL,"Cancer, Biological process, Other trait",initial,2013-01-31,GCST001847,Urinary symptoms in response to radiotherapy in prostate cancer
3701,Asian,5714.0,23364394.0,Lee JY,Cardiovascular disease,initial,2013-01-31,GCST001845,Coronary heart disease
3944,Asian,8028.0,23364394.0,Lee JY,Cardiovascular disease,replication,2013-01-31,GCST001845,Coronary heart disease
6942,European,1848.0,23382691.0,Lauc G,Other measurement,initial,2013-01-31,GCST001849,IgG glycosylation
13896,Other/Mixed,377.0,23376709.0,Kerns SL,"Cancer, Biological process, Other trait",replication,2013-01-31,GCST001847,Urinary symptoms in response to radiotherapy in prostate cancer
5102,European,339.0,23378610.0,Xie W,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",replication,2013-02-01,GCST001852,Metabolite levels
7603,European,2740.0,23894747.0,Aberg KA,Neurological disorder,replication,2013-02-01,GCST001851,Schizophrenia
6193,European,1004.0,23378610.0,Xie W,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2013-02-01,GCST001852,Metabolite levels
3114,Asian,2296.0,23894747.0,Aberg KA,Neurological disorder,replication,2013-02-01,GCST001851,Schizophrenia
894,African American or Afro-Caribbean,1262.0,23894747.0,Aberg KA,Neurological disorder,replication,2013-02-01,GCST001851,Schizophrenia
7264,European,2256.0,23377640.0,GENDEP Investigators,Neurological disorder,initial,2013-02-01,GCST001850,Major depressive disorder
10614,European,21953.0,23894747.0,Aberg KA,Neurological disorder,initial,2013-02-01,GCST001851,Schizophrenia
7994,European,3444.0,23381795.0,Verweij N,Cardiovascular measurement,initial,2013-02-04,GCST001853,Circulating vasoactive peptide levels
7860,European,3230.0,23381795.0,Verweij N,Cardiovascular measurement,replication,2013-02-04,GCST001853,Circulating vasoactive peptide levels
10475,European,19411.0,23393555.0,Jensen RA,Neurological disorder,initial,2013-02-05,GCST001854,Retinopathy in non-diabetics
10765,European,26420.0,23408906.0,Porcu E,Other measurement,initial,2013-02-07,GCST001856,Thyroid hormone levels
13620,Other/Mixed,4.0,23392654.0,Lewis JP,Biological process,replication,2013-02-07,GCST001855,Response to antiplatelet therapy
5729,European,710.0,23392654.0,Lewis JP,Biological process,replication,2013-02-07,GCST001855,Response to antiplatelet therapy
5524,European,565.0,23392654.0,Lewis JP,Biological process,initial,2013-02-07,GCST001855,Response to antiplatelet therapy
12826,Hispanic or Latin American,276.0,23392654.0,Lewis JP,Biological process,replication,2013-02-07,GCST001855,Response to antiplatelet therapy
593,African American or Afro-Caribbean,237.0,23392654.0,Lewis JP,Biological process,replication,2013-02-07,GCST001855,Response to antiplatelet therapy
3106,Asian,2273.0,23396134.0,Verhoeven VJ,Other trait,initial,2013-02-10,GCST001858,Refractive error
11052,European,37382.0,23396134.0,Verhoeven VJ,Other trait,initial,2013-02-10,GCST001858,Refractive error
3028,Asian,2108.0,23396134.0,Verhoeven VJ,Other trait,initial,2013-02-10,GCST001858,Refractive error
6380,European,1195.0,23372042.0,Lane J,"Immune system disorder, Other disease",initial,2013-02-10,GCST001857,HIV-1 susceptibility
3447,Asian,3995.0,23396134.0,Verhoeven VJ,Other trait,initial,2013-02-10,GCST001858,Refractive error
647,African American or Afro-Caribbean,342.0,23400010.0,Del-Aguila JL,"Response to drug, Lipid or lipoprotein measurement, Other measurement",initial,2013-02-12,GCST001859,Thiazide-induced adverse metabolic effects in hypertensive patients
5237,European,425.0,23400010.0,Del-Aguila JL,"Response to drug, Lipid or lipoprotein measurement, Other measurement",initial,2013-02-12,GCST001859,Thiazide-induced adverse metabolic effects in hypertensive patients
5015,European,284.0,23412934.0,Gourraud PA,Immune system disorder,initial,2013-02-13,GCST001860,Multiple sclerosis
13820,Other/Mixed,213.0,23406172.0,Milton JN,Neurological disorder,replication,2013-02-14,GCST001862,Sickle cell anemia (haemolysis)
3518,Asian,4491.0,23408455.0,Wakai K,Biological process,replication,2013-02-14,GCST001861,Confectionary intake
2467,Asian,939.0,23408455.0,Wakai K,Biological process,initial,2013-02-14,GCST001861,Confectionary intake
9055,European,6728.0,23417110.0,Tin A,Other measurement,initial,2013-02-16,GCST001863,Beta-2 microglubulin plasma levels
5783,European,745.0,23388002.0,Thanassoulis G,Other trait,replication,2013-02-17,GCST001864,Mitral annular calcification
13106,Hispanic or Latin American,2027.0,23388002.0,Thanassoulis G,Other trait,replication,2013-02-17,GCST001864,Mitral annular calcification
2366,Asian,774.0,23388002.0,Thanassoulis G,Other trait,replication,2013-02-17,GCST001864,Mitral annular calcification
9114,European,6942.0,23388002.0,Thanassoulis G,Cardiovascular disease,initial,2013-02-17,GCST001865,Aortic-valve calcification
1054,African American or Afro-Caribbean,2497.0,23388002.0,Thanassoulis G,Other trait,replication,2013-02-17,GCST001864,Mitral annular calcification
2365,Asian,774.0,23388002.0,Thanassoulis G,Cardiovascular disease,replication,2013-02-17,GCST001865,Aortic-valve calcification
5782,European,745.0,23388002.0,Thanassoulis G,Cardiovascular disease,replication,2013-02-17,GCST001865,Aortic-valve calcification
1053,African American or Afro-Caribbean,2497.0,23388002.0,Thanassoulis G,Cardiovascular disease,replication,2013-02-17,GCST001865,Aortic-valve calcification
13105,Hispanic or Latin American,2027.0,23388002.0,Thanassoulis G,Cardiovascular disease,replication,2013-02-17,GCST001865,Aortic-valve calcification
8139,European,3795.0,23388002.0,Thanassoulis G,Other trait,initial,2013-02-17,GCST001864,Mitral annular calcification
13772,Other/Mixed,169.0,23420232.0,Duggal P,Digestive system disorder,replication,2013-02-19,GCST001867,Chronic hepatitis C infection
4900,European,200.0,23423138.0,Ludwig KU,Biological process,initial,2013-02-19,GCST001866,Mathematical ability in children with dyslexia
5511,European,555.0,23419831.0,Ramanan VK,"Other measurement, Neurological disorder",initial,2013-02-19,GCST001868,Alzheimer's disease biomarkers
5428,European,510.0,23423138.0,Ludwig KU,Biological process,replication,2013-02-19,GCST001866,Mathematical ability in children with dyslexia
13916,Other/Mixed,447.0,23420232.0,Duggal P,Digestive system disorder,initial,2013-02-19,GCST001867,Chronic hepatitis C infection
6724,European,1581.0,23420232.0,Duggal P,Digestive system disorder,initial,2013-02-19,GCST001867,Chronic hepatitis C infection
5034,European,292.0,23420232.0,Duggal P,Digestive system disorder,replication,2013-02-19,GCST001867,Chronic hepatitis C infection
618,African American or Afro-Caribbean,284.0,23420232.0,Duggal P,Digestive system disorder,replication,2013-02-19,GCST001867,Chronic hepatitis C infection
13895,Other/Mixed,373.0,23420232.0,Duggal P,Digestive system disorder,initial,2013-02-19,GCST001867,Chronic hepatitis C infection
14253,Other/Mixed,16093.0,23423446.0,Hein R,"Cancer, Other trait",replication,2013-02-20,GCST001869,Breast cancer (menopausal hormone therapy interaction)
5747,European,731.0,23423446.0,Hein R,"Cancer, Other trait",initial,2013-02-20,GCST001869,Breast cancer (menopausal hormone therapy interaction)
4988,European,263.0,23432519.0,O'Brien RP,Other measurement,initial,2013-02-21,GCST001871,Renal transplant outcome
8851,European,5878.0,23437003.0,Paternoster L,Other measurement,initial,2013-02-21,GCST001870,Bone mineral density
6237,European,1052.0,23437003.0,Paternoster L,Other measurement,replication,2013-02-21,GCST001870,Bone mineral density
6963,European,1874.0,23509613.0,Kamboh MI,Other measurement,initial,2013-02-24,GCST001872,Presence of antiphospholipid antibodies
10553,European,21020.0,23446634.0,Chen Z,Hematological measurement,replication,2013-02-26,GCST001873,Red blood cell traits
1416,African American or Afro-Caribbean,9692.0,23446634.0,Chen Z,Hematological measurement,replication,2013-02-26,GCST001873,Red blood cell traits
4259,Asian,14088.0,23446634.0,Chen Z,Hematological measurement,replication,2013-02-26,GCST001873,Red blood cell traits
1493,African American or Afro-Caribbean,16485.0,23446634.0,Chen Z,Hematological measurement,initial,2013-02-26,GCST001873,Red blood cell traits
9851,European,10799.0,23449627.0,Cousminer DL,"Body measurement, Biological process",initial,2013-02-27,GCST001876,Pubertal anthropometrics
1787,Asian,134.0,23454411.0,Lin MT,"Immune system disorder, Cardiovascular disease",initial,2013-02-27,GCST001878,Coronary arterial lesions in patients with Kawasaki disease
8982,European,6438.0,23455491.0,Zuo L,"Other measurement, Neurological disorder",replication,2013-02-27,GCST001874,Alcohol dependence
10120,European,14040.0,23449627.0,Cousminer DL,"Body measurement, Biological process",initial,2013-02-27,GCST001875,Pubertal anthropometrics
9689,European,9710.0,23449627.0,Cousminer DL,"Body measurement, Biological process",replication,2013-02-27,GCST001875,Pubertal anthropometrics
1934,Asian,245.0,23454411.0,Lin MT,"Immune system disorder, Cardiovascular disease",replication,2013-02-27,GCST001878,Coronary arterial lesions in patients with Kawasaki disease
7693,European,2927.0,23455491.0,Zuo L,"Other measurement, Neurological disorder",initial,2013-02-27,GCST001874,Alcohol dependence
11409,European,61220.0,23453885.0,Smoller JW,Neurological disorder,initial,2013-02-27,GCST001877,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)"
3729,Asian,5811.0,23406873.0,Shi Y,Other trait,replication,2013-02-28,GCST001881,Myopia (pathological)
171,African,1103.0,23533358.0,Liu Z,Neurological disorder,initial,2013-02-28,GCST001880,Addiction
7458,European,2524.0,23533358.0,Liu Z,Neurological disorder,initial,2013-02-28,GCST001880,Addiction
2779,Asian,1625.0,23406873.0,Shi Y,Other trait,initial,2013-02-28,GCST001881,Myopia (pathological)
1289,African American or Afro-Caribbean,5761.0,23468962.0,Song C,Cancer,initial,2013-02-28,GCST001879,Breast cancer
5379,European,489.0,23281178.0,Hong MG,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",replication,2013-03-01,GCST001882,Metabolite levels
2079,Asian,396.0,23456092.0,Park BL,"Other measurement, Neurological disorder",initial,2013-03-01,GCST001883,Alcohol dependence
2488,Asian,975.0,23456092.0,Park BL,"Other measurement, Neurological disorder",replication,2013-03-01,GCST001883,Alcohol dependence
5196,European,402.0,23281178.0,Hong MG,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2013-03-01,GCST001882,Metabolite levels
13845,Other/Mixed,271.0,23314186.0,Crosslin DR,Hematological measurement,initial,2013-03-03,GCST001887,Monocyte count
2935,Asian,1881.0,23456168.0,Hao Y,"Other measurement, Body measurement",replication,2013-03-03,GCST001885,Height
11476,European,67980.0,23455637.0,Iles MM,Cancer,replication,2013-03-03,GCST001886,Melanoma
10314,European,16753.0,23455636.0,Fritsche LG,Neurological disorder,replication,2013-03-03,GCST001884,Age-related macular degeneration
8542,European,4919.0,23455637.0,Iles MM,Cancer,initial,2013-03-03,GCST001886,Melanoma
14054,Other/Mixed,894.0,23314186.0,Crosslin DR,Hematological measurement,initial,2013-03-03,GCST001887,Monocyte count
3472,Asian,4150.0,23455636.0,Fritsche LG,Neurological disorder,initial,2013-03-03,GCST001884,Age-related macular degeneration
2508,Asian,1008.0,23455636.0,Fritsche LG,Neurological disorder,replication,2013-03-03,GCST001884,Age-related macular degeneration
11349,European,55115.0,23455636.0,Fritsche LG,Neurological disorder,initial,2013-03-03,GCST001884,Age-related macular degeneration
9719,European,9849.0,23314186.0,Crosslin DR,Hematological measurement,initial,2013-03-03,GCST001887,Monocyte count
3803,Asian,6534.0,23456168.0,Hao Y,"Other measurement, Body measurement",initial,2013-03-03,GCST001885,Height
1915,Asian,229.0,23455636.0,Fritsche LG,Neurological disorder,initial,2013-03-03,GCST001884,Age-related macular degeneration
8390,European,4504.0,23459936.0,Divaris K,Digestive system disorder,initial,2013-03-04,GCST001888,Periodontitis
13978,Other/Mixed,656.0,23459936.0,Divaris K,Digestive system disorder,replication,2013-03-04,GCST001888,Periodontitis
8687,European,5272.0,23463857.0,Ritchie MD,Cardiovascular measurement,initial,2013-03-05,GCST001893,Electrocardiographic conduction measures
7313,European,2316.0,23472165.0,Albertsen HM,Other disease,replication,2013-03-05,GCST001894,Endometriosis
10126,European,14174.0,23472165.0,Albertsen HM,Other disease,initial,2013-03-05,GCST001894,Endometriosis
11137,European,40407.0,23463857.0,Ritchie MD,Cardiovascular measurement,replication,2013-03-05,GCST001893,Electrocardiographic conduction measures
7973,European,3403.0,23472185.0,Mero IL,"Immune system disorder, Other measurement",replication,2013-03-05,GCST001891,Multiple sclerosis (OCB status)
6659,European,1528.0,23472185.0,Mero IL,"Immune system disorder, Other measurement",initial,2013-03-05,GCST001892,Multiple sclerosis (OCB status)
6658,European,1528.0,23472185.0,Mero IL,"Immune system disorder, Other measurement",initial,2013-03-05,GCST001891,Multiple sclerosis (OCB status)
5088,European,331.0,23471985.0,Jahanshad N,Other measurement,initial,2013-03-05,GCST001889,Brain connectivity
10970,European,33781.0,23459443.0,Avery CL,"Cardiovascular measurement, Response to drug",initial,2013-03-05,GCST001890,QT interval (drug interaction)
1609,Asian,9.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
6635,European,1490.0,23467860.0,Pare G,Response to drug,initial,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
1617,Asian,15.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
4909,European,204.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
6,African,6.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
1634,Asian,25.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
12761,Hispanic or Latin American,66.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
13593,Other/Mixed,1.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
6131,European,982.0,23470693.0,Zeng Z,Digestive system disorder,initial,2013-03-07,GCST001896,Smooth-surface caries
6159,European,996.0,23470693.0,Zeng Z,Digestive system disorder,initial,2013-03-07,GCST001897,Pit-and-Fissure caries
9177,European,7280.0,23474815.0,Stambolian D,Other trait,initial,2013-03-07,GCST001898,Refractive error
10495,European,19763.0,23474815.0,Stambolian D,Other trait,replication,2013-03-07,GCST001898,Refractive error
7235,European,2198.0,23482656.0,Chen D,Cancer,replication,2013-03-12,GCST001900,Cervical cancer
8583,European,4982.0,23482656.0,Chen D,Cancer,initial,2013-03-12,GCST001900,Cervical cancer
7534,European,2620.0,23561647.0,van Setten J,Other trait,initial,2013-03-13,GCST001902,Coronary artery calcification
13090,Hispanic or Latin American,1644.0,23493294.0,Gao X,Other measurement,initial,2013-03-14,GCST001903,Central corneal thickness
12787,Hispanic or Latin American,124.0,23493294.0,Gao X,Other measurement,replication,2013-03-14,GCST001903,Central corneal thickness
13116,Hispanic or Latin American,2240.0,23505323.0,Weissglas-Volkov D,Lipid or lipoprotein measurement,initial,2013-03-15,GCST001904,HDL cholesterol
13114,Hispanic or Latin American,2121.0,23505323.0,Weissglas-Volkov D,"Metabolic disorder, Lipid or lipoprotein measurement",replication,2013-03-15,GCST001905,Hypertriglyceridemia
13113,Hispanic or Latin American,2121.0,23505323.0,Weissglas-Volkov D,Lipid or lipoprotein measurement,replication,2013-03-15,GCST001904,HDL cholesterol
13117,Hispanic or Latin American,2240.0,23505323.0,Weissglas-Volkov D,"Metabolic disorder, Lipid or lipoprotein measurement",initial,2013-03-15,GCST001905,Hypertriglyceridemia
6587,European,1408.0,23502781.0,Germain M,Cardiovascular disease,initial,2013-03-17,GCST001908,Pulmonary arterial hypertension (without BMPR2 mutations)
9578,European,8966.0,23502783.0,Weinhold N,Cancer,initial,2013-03-17,GCST001907,Multiple myeloma (hyperdiploidy)
9577,European,8966.0,23502783.0,Weinhold N,Cancer,initial,2013-03-17,GCST001906,Multiple myeloma (IgH translocation)
5170,European,387.0,23496005.0,Luca G,Neurological disorder,replication,2013-03-18,GCST001909,Narcolepsy with cataplexy
7101,European,2054.0,23508960.0,Zhou G,Other measurement,initial,2013-03-18,GCST001910,Aspirin hydrolysis (plasma)
5556,European,585.0,23496005.0,Luca G,Neurological disorder,initial,2013-03-18,GCST001909,Narcolepsy with cataplexy
928,African American or Afro-Caribbean,1452.0,23512250.0,Xu H,Cancer,initial,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
5197,European,403.0,23508266.0,Duan QL,"Response to drug, Other disease",initial,2013-03-19,GCST001911,Asthma (bronchodilator response)
13048,Hispanic or Latin American,1313.0,23512250.0,Xu H,Cancer,initial,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
7343,European,2358.0,23512250.0,Xu H,Cancer,initial,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
870,African American or Afro-Caribbean,1203.0,23512250.0,Xu H,Cancer,replication,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
12917,Hispanic or Latin American,592.0,23508266.0,Duan QL,"Response to drug, Other disease",replication,2013-03-19,GCST001911,Asthma (bronchodilator response)
6416,European,1220.0,23508266.0,Duan QL,"Response to drug, Other disease",replication,2013-03-19,GCST001911,Asthma (bronchodilator response)
12977,Hispanic or Latin American,783.0,23512250.0,Xu H,Cancer,replication,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
7802,European,3175.0,23512250.0,Xu H,Cancer,replication,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
7551,European,2652.0,23509962.0,Greliche N,Cardiovascular disease,replication,2013-03-20,GCST001913,Venous thromboembolism (SNP x SNP interaction)
6773,European,1639.0,23509962.0,Greliche N,Cardiovascular disease,initial,2013-03-20,GCST001913,Venous thromboembolism (SNP x SNP interaction)
1627,Asian,17.0,23518928.0,Liu M,Other measurement,initial,2013-03-21,GCST001914,Estradiol plasma levels (breast cancer)
13636,Other/Mixed,5.0,23518928.0,Liu M,Other measurement,initial,2013-03-21,GCST001914,Estradiol plasma levels (breast cancer)
5712,European,700.0,23518928.0,Liu M,Other measurement,initial,2013-03-21,GCST001914,Estradiol plasma levels (breast cancer)
24,African,50.0,23518928.0,Liu M,Other measurement,initial,2013-03-21,GCST001914,Estradiol plasma levels (breast cancer)
5050,European,303.0,23535033.0,Sherva R,Neurological disorder,initial,2013-03-24,GCST001915,Alzheimer's disease (cognitive decline)
7599,European,2727.0,23544013.0,Couch FJ,"Other measurement, Cancer",initial,2013-03-27,GCST001917,Ovarian cancer in BRCA1 mutation carriers
3047,Asian,2146.0,23532257.0,Ma RC,Metabolic disorder,replication,2013-03-27,GCST001919,Type 2 diabetes
4488,Asian,38983.0,23532257.0,Ma RC,Metabolic disorder,replication,2013-03-27,GCST001919,Type 2 diabetes
2975,Asian,1998.0,23532257.0,Ma RC,Metabolic disorder,replication,2013-03-27,GCST001919,Type 2 diabetes
11233,European,47117.0,23532257.0,Ma RC,Metabolic disorder,replication,2013-03-27,GCST001919,Type 2 diabetes
9963,European,11964.0,23544013.0,Couch FJ,"Cancer, Other measurement",replication,2013-03-27,GCST001916,Breast Cancer in BRCA1 mutation carriers
9373,European,8211.0,23544012.0,Gaudet MM,Cancer,initial,2013-03-27,GCST007302,Breast cancer in BRCA2 mutation carriers
2789,Asian,1639.0,23532257.0,Ma RC,Metabolic disorder,initial,2013-03-27,GCST001919,Type 2 diabetes
7598,European,2727.0,23544013.0,Couch FJ,"Cancer, Other measurement",initial,2013-03-27,GCST001916,Breast Cancer in BRCA1 mutation carriers
6690,European,1544.0,23541324.0,Li X,"Other measurement, Other disease",initial,2013-03-27,GCST001918,Pulmonary function in asthmatics
9964,European,11964.0,23544013.0,Couch FJ,"Other measurement, Cancer",replication,2013-03-27,GCST001917,Ovarian cancer in BRCA1 mutation carriers
2183,Asian,501.0,23539754.0,Yamada Y,"Other disease, Other measurement",initial,2013-03-28,GCST001924,Chronic kidney disease
9585,European,9049.0,23535967.0,Tin A,Other measurement,initial,2013-03-28,GCST001923,Glomerular filtration rate
698,African American or Afro-Caribbean,455.0,23534349.0,Jeff JM,Cardiovascular measurement,initial,2013-03-28,GCST001922,QT interval
4793,European,139.0,23555300.0,Cui J,"Immune system disorder, Response to drug",replication,2013-03-28,GCST001926,Response to anti-TNF therapy in rheumatoid arthritis
699,African American or Afro-Caribbean,455.0,23534349.0,Jeff JM,Cardiovascular measurement,initial,2013-03-28,GCST001925,PR interval
1802,Asian,151.0,23555300.0,Cui J,"Immune system disorder, Response to drug",replication,2013-03-28,GCST001926,Response to anti-TNF therapy in rheumatoid arthritis
2582,Asian,1184.0,23535911.0,Kitamoto T,"Cancer, Other measurement, Digestive system disorder",replication,2013-03-28,GCST001928,Pediatric non-alcoholic fatty liver disease activity score
7585,European,2706.0,23555300.0,Cui J,"Immune system disorder, Response to drug",initial,2013-03-28,GCST001927,Response to anti-TNF therapy in rheumatoid arthritis
2642,Asian,1326.0,23535911.0,Kitamoto T,"Cancer, Other measurement, Digestive system disorder",initial,2013-03-28,GCST001928,Pediatric non-alcoholic fatty liver disease activity score
696,African American or Afro-Caribbean,455.0,23534349.0,Jeff JM,Cardiovascular measurement,initial,2013-03-28,GCST001920,QRS duration
697,African American or Afro-Caribbean,455.0,23534349.0,Jeff JM,Cardiovascular measurement,initial,2013-03-28,GCST001921,Heart rate
5751,European,733.0,23555300.0,Cui J,"Immune system disorder, Response to drug",initial,2013-03-28,GCST001926,Response to anti-TNF therapy in rheumatoid arthritis
3349,Asian,3350.0,23539754.0,Yamada Y,"Other disease, Other measurement",replication,2013-03-28,GCST001924,Chronic kidney disease
10641,European,22627.0,23535729.0,Michailidou K,Cancer,initial,2013-04-01,GCST001937,Breast cancer
9136,European,7070.0,23548203.0,Zhang M,"Other measurement, Other trait",initial,2013-04-01,GCST001932,Hair color
13007,Hispanic or Latin American,921.0,23517042.0,Melen E,"Body measurement, Other disease",replication,2013-04-01,GCST001945,Body mass index in asthmatics
6126,European,979.0,23517042.0,Melen E,"Body measurement, Other disease",replication,2013-04-01,GCST001945,Body mass index in asthmatics
11658,European,87170.0,23535729.0,Michailidou K,Cancer,replication,2013-04-01,GCST001937,Breast cancer
11072,European,37684.0,23535734.0,Codd V,Other measurement,initial,2013-04-01,GCST001936,Telomere length
2566,Asian,1149.0,23511034.0,Yang SK,Immune system disorder,replication,2013-04-01,GCST001938,Ulcerative colitis
3184,Asian,2519.0,23511034.0,Yang SK,Immune system disorder,replication,2013-04-01,GCST001934,Ulcerative colitis
13774,Other/Mixed,171.0,23517042.0,Melen E,"Body measurement, Other disease",initial,2013-04-01,GCST001945,Body mass index in asthmatics
10636,European,22548.0,23535732.0,Eeles RA,Cancer,initial,2013-04-01,GCST001942,Prostate cancer
8393,European,4524.0,23517042.0,Melen E,"Body measurement, Other disease",initial,2013-04-01,GCST001945,Body mass index in asthmatics
9995,European,12359.0,23517042.0,Melen E,Body measurement,initial,2013-04-01,GCST001935,Body mass index in non-asthmatics
2558,Asian,1127.0,23511034.0,Yang SK,Immune system disorder,initial,2013-04-01,GCST001934,Ulcerative colitis
2579,Asian,1183.0,23535730.0,Pharoah PD,Cancer,replication,2013-04-01,GCST001941,Ovarian cancer
11245,European,47969.0,23535733.0,Garcia-Closas M,Cancer,replication,2013-04-01,GCST001930,Breast cancer
2559,Asian,1127.0,23511034.0,Yang SK,Immune system disorder,initial,2013-04-01,GCST001938,Ulcerative colitis
11107,European,39377.0,23535732.0,Eeles RA,Cancer,replication,2013-04-01,GCST001942,Prostate cancer
11114,European,39674.0,23535730.0,Pharoah PD,Cancer,replication,2013-04-01,GCST001941,Ovarian cancer
1875,Asian,212.0,23535730.0,Pharoah PD,Cancer,replication,2013-04-01,GCST001941,Ovarian cancer
9365,European,8165.0,23535730.0,Pharoah PD,Cancer,initial,2013-04-01,GCST001941,Ovarian cancer
6549,European,1371.0,23555189.0,Chen Z,Other measurement,initial,2013-04-01,GCST001946,PCA3 expression level
7431,European,2496.0,23548203.0,Zhang M,"Other measurement, Other trait",replication,2013-04-01,GCST001929,Eye color
9840,European,10739.0,23535734.0,Codd V,Other measurement,replication,2013-04-01,GCST001936,Telomere length
9061,European,6747.0,23548203.0,Zhang M,"Other trait, Cancer",initial,2013-04-01,GCST001940,Non-melanoma skin cancer
9613,European,9283.0,23548203.0,Zhang M,Other disease,initial,2013-04-01,GCST001933,Sunburns
8302,European,4236.0,23548203.0,Zhang M,Other disease,replication,2013-04-01,GCST001933,Sunburns
13869,Other/Mixed,331.0,23517042.0,Melen E,Body measurement,initial,2013-04-01,GCST001935,Body mass index in non-asthmatics
8274,European,4155.0,23548203.0,Zhang M,"Other measurement, Other trait",replication,2013-04-01,GCST001932,Hair color
8164,European,3871.0,23548203.0,Zhang M,"Other measurement, Other trait",initial,2013-04-01,GCST001929,Eye color
11108,European,39387.0,23535733.0,Garcia-Closas M,Cancer,initial,2013-04-01,GCST001930,Breast cancer
9684,European,9678.0,23548203.0,Zhang M,Other trait,initial,2013-04-01,GCST001939,Tanning
7121,European,2078.0,23548203.0,Zhang M,"Other trait, Cancer",replication,2013-04-01,GCST001940,Non-melanoma skin cancer
6450,European,1252.0,23551011.0,Zhao L,Cardiovascular disease,initial,2013-04-02,GCST001949,Preeclampsia
3348,Asian,3338.0,23565137.0,Miyashita A,Neurological disorder,replication,2013-04-02,GCST001947,Alzheimer's disease (late onset)
7642,European,2810.0,23565138.0,Trzaskowski M,"Other measurement, Other trait",initial,2013-04-02,GCST001948,Anxiety
10648,European,22771.0,23565137.0,Miyashita A,Neurological disorder,replication,2013-04-02,GCST001947,Alzheimer's disease (late onset)
12951,Hispanic or Latin American,720.0,23551011.0,Zhao L,Cardiovascular disease,initial,2013-04-02,GCST001949,Preeclampsia
833,African American or Afro-Caribbean,1031.0,23551011.0,Zhao L,Cardiovascular disease,initial,2013-04-02,GCST001949,Preeclampsia
2828,Asian,1735.0,23565137.0,Miyashita A,Neurological disorder,initial,2013-04-02,GCST001947,Alzheimer's disease (late onset)
8487,European,4804.0,23565138.0,Trzaskowski M,"Other measurement, Other trait",replication,2013-04-02,GCST001948,Anxiety
11274,European,50627.0,23593239.0,van der Loos MJ,Other measurement,initial,2013-04-04,GCST001952,Self-employment
5410,European,501.0,23593202.0,Ran S,Other measurement,replication,2013-04-04,GCST001950,Femoral neck bone geometry and menarche (age at onset)
6469,European,1278.0,23562540.0,Cruchaga C,"Other measurement, Neurological disorder",initial,2013-04-04,GCST001951,Alzheimer's disease biomarkers
2410,Asian,826.0,23593202.0,Ran S,Other measurement,replication,2013-04-04,GCST001950,Femoral neck bone geometry and menarche (age at onset)
6856,European,1728.0,23593202.0,Ran S,Other measurement,initial,2013-04-04,GCST001950,Femoral neck bone geometry and menarche (age at onset)
10251,European,16068.0,23563607.0,Berndt SI,"Body measurement, Other measurement",initial,2013-04-07,GCST001955,Body mass index
9099,European,6889.0,23563609.0,Wheeler E,Metabolic disorder,initial,2013-04-07,GCST001957,Obesity (early onset extreme)
9038,European,6703.0,23563607.0,Berndt SI,"Other measurement, Body measurement",replication,2013-04-07,GCST001954,Waist-hip ratio
9688,European,9703.0,23563607.0,Berndt SI,"Other measurement, Body measurement",replication,2013-04-07,GCST001956,Height
7710,European,2961.0,23563609.0,Wheeler E,Metabolic disorder,replication,2013-04-07,GCST001957,Obesity (early onset extreme)
12207,European,204498.0,23563607.0,Berndt SI,"Other measurement, Metabolic disorder",initial,2013-04-07,GCST001953,Obesity
10267,European,16196.0,23563607.0,Berndt SI,"Other measurement, Body measurement",initial,2013-04-07,GCST001956,Height
11940,European,133637.0,23563607.0,Berndt SI,"Other measurement, Metabolic disorder",replication,2013-04-07,GCST001953,Obesity
9778,European,10255.0,23563607.0,Berndt SI,"Other measurement, Body measurement",initial,2013-04-07,GCST001954,Waist-hip ratio
9703,European,9791.0,23563607.0,Berndt SI,"Body measurement, Other measurement",replication,2013-04-07,GCST001955,Body mass index
7398,European,2442.0,23568457.0,Wade TD,Metabolic disorder,initial,2013-04-09,GCST001958,Bulimia nervosa
8847,European,5866.0,23572186.0,Zheng HF,Other measurement,initial,2013-04-09,GCST001962,Bone mineral density
7459,European,2524.0,23568457.0,Wade TD,Metabolic disorder,initial,2013-04-09,GCST001961,Anorexia nervosa
12949,Hispanic or Latin American,715.0,23572186.0,Zheng HF,Other measurement,replication,2013-04-09,GCST001962,Bone mineral density
7456,European,2521.0,23568457.0,Wade TD,Metabolic disorder,initial,2013-04-09,GCST001959,Eating disorders (purging via substances)
6792,European,1659.0,23568457.0,Wade TD,"Metabolic disorder, Neurological disorder",initial,2013-04-09,GCST001960,Eating disorders
7299,European,2296.0,23575227.0,Urbanek M,"Other measurement, Body measurement, Other trait",replication,2013-04-10,GCST001964,Anthropometric traits in newborns
2590,Asian,1207.0,23575227.0,Urbanek M,"Other measurement, Body measurement, Other trait",initial,2013-04-10,GCST001964,Anthropometric traits in newborns
12927,Hispanic or Latin American,616.0,23575227.0,Urbanek M,"Other measurement, Body measurement, Other trait",initial,2013-04-10,GCST001964,Anthropometric traits in newborns
6534,European,1363.0,23575227.0,Urbanek M,"Other measurement, Body measurement, Other trait",initial,2013-04-10,GCST001964,Anthropometric traits in newborns
855,African American or Afro-Caribbean,1095.0,23575227.0,Urbanek M,"Other measurement, Body measurement, Other trait",initial,2013-04-10,GCST001964,Anthropometric traits in newborns
1294,African American or Afro-Caribbean,5896.0,23571587.0,Reitz C,Neurological disorder,initial,2013-04-10,GCST001963,Alzheimer's disease (late onset)
3804,Asian,6536.0,23575436.0,Go MJ,Metabolic disorder,replication,2013-04-11,GCST001965,Glycemic traits
3905,Asian,7696.0,23575436.0,Go MJ,Metabolic disorder,initial,2013-04-11,GCST001965,Glycemic traits
9307,European,7884.0,23585552.0,Kirin M,Neurological disorder,replication,2013-04-11,GCST001966,Rhegmatogenous retinal detachment
7647,European,2820.0,23585552.0,Kirin M,Neurological disorder,initial,2013-04-11,GCST001966,Rhegmatogenous retinal detachment
277,African,4607.0,23583978.0,Monda KL,"Body measurement, Other measurement",replication,2013-04-14,GCST001967,Body mass index
1563,African American or Afro-Caribbean,37956.0,23583978.0,Monda KL,"Body measurement, Other measurement",initial,2013-04-14,GCST001967,Body mass index
1557,African American or Afro-Caribbean,27661.0,23583978.0,Monda KL,"Body measurement, Other measurement",replication,2013-04-14,GCST001967,Body mass index
174,African,1188.0,23583978.0,Monda KL,"Body measurement, Other measurement",initial,2013-04-14,GCST001967,Body mass index
11896,European,123706.0,23583978.0,Monda KL,"Body measurement, Other measurement",replication,2013-04-14,GCST001967,Body mass index
7617,European,2766.0,23583980.0,Fingerlin TE,Other disease,replication,2013-04-14,GCST001968,Interstitial lung disease
11642,European,85787.0,23583979.0,den Hoed M,Cardiovascular measurement,initial,2013-04-14,GCST001969,Heart rate
3807,Asian,6568.0,23583979.0,den Hoed M,Cardiovascular measurement,initial,2013-04-14,GCST001969,Heart rate
8954,European,6299.0,23583980.0,Fingerlin TE,Other disease,initial,2013-04-14,GCST001968,Interstitial lung disease
11677,European,88823.0,23583979.0,den Hoed M,Cardiovascular measurement,replication,2013-04-14,GCST001969,Heart rate
2293,Asian,687.0,23646285.0,Khor SS,Neurological disorder,initial,2013-04-16,GCST001971,Hypersomnia (HLA-DQB1*06:02 negative)
13886,Other/Mixed,352.0,23592221.0,Rahmani M,Other measurement,initial,2013-04-16,GCST001970,Menopause (age at onset)
11102,European,38968.0,23592221.0,Rahmani M,Other measurement,replication,2013-04-16,GCST001970,Menopause (age at onset)
13943,Other/Mixed,573.0,23592221.0,Rahmani M,Other measurement,replication,2013-04-16,GCST001970,Menopause (age at onset)
1090,African American or Afro-Caribbean,2850.0,23599027.0,Demerath EW,Other measurement,replication,2013-04-17,GCST001973,Menarche (age at onset)
1919,Asian,234.0,23594818.0,Ikeda M,Neurological disorder,initial,2013-04-17,GCST001975,Psychosis (methamphetamine induced)
1499,African American or Afro-Caribbean,18089.0,23599027.0,Demerath EW,Other measurement,initial,2013-04-17,GCST001973,Menarche (age at onset)
6270,European,1084.0,24429156.0,Noth I,Cancer,initial,2013-04-17,GCST001974,Idiopathic pulmonary fibrosis
7265,European,2257.0,24429156.0,Noth I,Cancer,replication,2013-04-17,GCST001974,Idiopathic pulmonary fibrosis
11665,European,87802.0,23599027.0,Demerath EW,Other measurement,replication,2013-04-17,GCST001973,Menarche (age at onset)
2545,Asian,1100.0,23594818.0,Ikeda M,Neurological disorder,initial,2013-04-17,GCST001972,Methamphetamine dependence
6363,European,1180.0,23642732.0,Cox AJ,Other measurement,initial,2013-04-19,GCST001976,Bilirubin levels
2506,Asian,1007.0,23562823.0,Sheu WH,Metabolic disorder,initial,2013-04-19,GCST001977,Diabetic retinopathy
12913,Hispanic or Latin American,585.0,23562823.0,Sheu WH,Metabolic disorder,replication,2013-04-19,GCST001977,Diabetic retinopathy
10244,European,15872.0,23603761.0,Hinks A,Immune system disorder,initial,2013-04-21,GCST005528,Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)
6811,European,1697.0,23626673.0,Matullo G,Cancer,replication,2013-04-23,GCST001978,Malignant pleural mesothelioma
5803,European,759.0,23626673.0,Matullo G,Cancer,initial,2013-04-23,GCST001978,Malignant pleural mesothelioma
9611,European,9260.0,23620142.0,Reiner AP,Cardiovascular measurement,initial,2013-04-24,GCST001980,Circulating myeloperoxidase levels (plasma)
9617,European,9305.0,23620142.0,Reiner AP,Cardiovascular measurement,initial,2013-04-24,GCST001979,Circulating myeloperoxidase levels (serum)
3134,Asian,2365.0,23624525.0,Deng M,Neurological disorder,initial,2013-04-28,GCST001981,Amyotrophic lateral sclerosis
3167,Asian,2483.0,23624525.0,Deng M,Neurological disorder,replication,2013-04-28,GCST001981,Amyotrophic lateral sclerosis
6456,European,1256.0,23620144.0,Sulkava S,Neurological disorder,initial,2013-04-29,GCST001983,Job-related exhaustion
3283,Asian,2910.0,23612905.0,Zhao SX,Immune system disorder,initial,2013-04-29,GCST001984,Graves' disease
4218,Asian,13080.0,23612905.0,Zhao SX,Immune system disorder,replication,2013-04-29,GCST001982,Graves' disease
3282,Asian,2910.0,23612905.0,Zhao SX,Immune system disorder,initial,2013-04-29,GCST001982,Graves' disease
4302,Asian,16242.0,23612905.0,Zhao SX,Immune system disorder,replication,2013-04-29,GCST001984,Graves' disease
10105,European,13864.0,23620144.0,Sulkava S,Neurological disorder,replication,2013-04-29,GCST001983,Job-related exhaustion
5094,European,333.0,23633212.0,Rinella ES,Other trait,replication,2013-04-30,GCST001985,Weight loss (gastric bypass surgery)
4844,European,175.0,23633212.0,Rinella ES,Other trait,initial,2013-04-30,GCST001985,Weight loss (gastric bypass surgery)
6434,European,1233.0,23577725.0,Naj AC,Neurological disorder,initial,2013-05-01,GCST001987,Age-related macular degeneration (extreme sampling)
10964,European,33533.0,23636237.0,Tanaka T,Biological process,replication,2013-05-01,GCST001988,Dietary macronutrient intake
11149,European,41257.0,23636237.0,Tanaka T,Biological process,replication,2013-05-01,GCST001989,Dietary macronutrient intake
4919,European,208.0,23577725.0,Naj AC,Neurological disorder,replication,2013-05-01,GCST001986,Age-related macular degeneration
6594,European,1419.0,23577725.0,Naj AC,"Other measurement, Neurological disorder",initial,2013-05-01,GCST001990,Age-related macular degeneration (smoking status interaction)
11065,European,37537.0,23636237.0,Tanaka T,Biological process,initial,2013-05-01,GCST001988,Dietary macronutrient intake
6978,European,1893.0,23577725.0,Naj AC,Neurological disorder,initial,2013-05-01,GCST001986,Age-related macular degeneration
4799,European,143.0,23577725.0,Naj AC,Neurological disorder,replication,2013-05-01,GCST001987,Age-related macular degeneration (extreme sampling)
11066,European,37537.0,23636237.0,Tanaka T,Biological process,initial,2013-05-01,GCST001989,Dietary macronutrient intake
5081,European,327.0,23643386.0,Hatoum IJ,Other trait,replication,2013-05-02,GCST001991,Weight loss (gastric bypass surgery)
2054,Asian,376.0,23678272.0,Cheong KA,Immune system disorder,replication,2013-05-02,GCST001992,Vitiligo (non-segmental)
5702,European,693.0,23643386.0,Hatoum IJ,Other trait,initial,2013-05-02,GCST001991,Weight loss (gastric bypass surgery)
1876,Asian,212.0,23678272.0,Cheong KA,Immune system disorder,initial,2013-05-02,GCST001992,Vitiligo (non-segmental)
2586,Asian,1196.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002001,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
2560,Asian,1129.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001997,Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)
1879,Asian,214.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001993,Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)
2186,Asian,503.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002002,Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)
3191,Asian,2543.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002005,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)
2197,Asian,523.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002004,Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
2235,Asian,582.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001999,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
2132,Asian,453.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001996,Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)
2063,Asian,380.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001995,Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
1997,Asian,316.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002006,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
2262,Asian,647.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002007,Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
2261,Asian,643.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002008,Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
1977,Asian,293.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001994,Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)
2572,Asian,1171.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001998,Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)
1800,Asian,149.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002009,Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)
1989,Asian,306.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002003,Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)
1714,Asian,93.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002000,Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)
2644,Asian,1331.0,23644492.0,Wu C,"Cancer, Other measurement",initial,2013-05-05,GCST002010,Esophageal squamous cell cancer (length of survival)
2969,Asian,1962.0,23644492.0,Wu C,"Cancer, Other measurement",replication,2013-05-05,GCST002010,Esophageal squamous cell cancer (length of survival)
11196,European,44499.0,23650146.0,Tang W,Cardiovascular disease,initial,2013-05-05,GCST002012,Venous thromboembolism
9062,European,6767.0,23650146.0,Tang W,Cardiovascular disease,replication,2013-05-05,GCST002012,Venous thromboembolism
11529,European,73965.0,23644456.0,Styrkarsdottir U,Other measurement,initial,2013-05-05,GCST002011,Bone mineral density
4294,Asian,15495.0,23667675.0,Tanikawa C,Other measurement,initial,2013-05-07,GCST002013,Menarche (age at onset)
6474,European,1287.0,23658558.0,Bae HT,Other trait,replication,2013-05-08,GCST002015,Personality dimensions
9796,European,10485.0,23652523.0,Mayerle J,Other measurement,initial,2013-05-08,GCST002014,Helicobacter pylori serologic status
8416,European,4595.0,23658558.0,Bae HT,Other trait,initial,2013-05-08,GCST002016,Personality dimensions
7540,European,2631.0,23658558.0,Bae HT,Other trait,initial,2013-05-08,GCST002015,Personality dimensions
6133,European,983.0,23665963.0,Dubinsky MC,Digestive system disorder,initial,2013-05-09,GCST002018,Crohn's disease (time to surgery)
5599,European,614.0,23665963.0,Dubinsky MC,Digestive system disorder,initial,2013-05-09,GCST002017,Crohn's disease (need for surgery)
2984,Asian,1999.0,23661040.0,Liao M,Other measurement,initial,2013-05-10,GCST002019,IgE levels
2707,Asian,1496.0,23661040.0,Liao M,Other measurement,replication,2013-05-10,GCST002019,IgE levels
4411,Asian,27204.0,23666238.0,Kou I,Other disease,replication,2013-05-12,GCST002020,Scoliosis
6371,European,1184.0,23666238.0,Kou I,Other disease,replication,2013-05-12,GCST002020,Scoliosis
8871,European,5932.0,23666240.0,Ruark E,Cancer,initial,2013-05-12,GCST002022,Testicular germ cell tumor
9975,European,12070.0,23666239.0,Chung CC,Cancer,replication,2013-05-12,GCST002023,Testicular germ cell tumor
10090,European,13627.0,23669352.0,Graff M,"Body measurement, Other measurement",initial,2013-05-12,GCST002021,Body mass index
9882,European,11146.0,23666240.0,Ruark E,Cancer,replication,2013-05-12,GCST002022,Testicular germ cell tumor
6770,European,1638.0,23666239.0,Chung CC,Cancer,initial,2013-05-12,GCST002023,Testicular germ cell tumor
10271,European,16253.0,23669352.0,Graff M,"Body measurement, Other measurement",replication,2013-05-12,GCST002021,Body mass index
3174,Asian,2506.0,23666238.0,Kou I,Other disease,initial,2013-05-12,GCST002020,Scoliosis
13914,Other/Mixed,438.0,23668334.0,Shan J,Cancer,replication,2013-05-13,GCST002024,Prostate cancer
13822,Other/Mixed,221.0,23668334.0,Shan J,Cancer,initial,2013-05-13,GCST002024,Prostate cancer
1891,Asian,223.0,23677057.0,Kim JJ,"Immune system disorder, Cardiovascular disease",replication,2013-05-16,GCST002026,Coronary arterial lesions in patients with Kawasaki disease
6407,European,1209.0,23696881.0,Wood AR,Other measurement,initial,2013-05-16,GCST009166,Renal system biomarkers
6406,European,1209.0,23696881.0,Wood AR,Other measurement,initial,2013-05-16,GCST009164,Circulating inorganic ion levels
6405,European,1209.0,23696881.0,Wood AR,Other measurement,initial,2013-05-16,GCST009161,Diabetes biomarker traits
6404,European,1209.0,23696881.0,Wood AR,"Hematological measurement, Cardiovascular measurement, Other measurement",initial,2013-05-16,GCST009162,Hematology traits
6403,European,1208.0,23696881.0,Wood AR,Cardiovascular measurement,initial,2013-05-16,GCST009171,Homocysteine levels
6400,European,1206.0,23696881.0,Wood AR,Other measurement,initial,2013-05-16,GCST009170,Chloride levels
6399,European,1206.0,23696881.0,Wood AR,"Lipid or lipoprotein measurement, Other measurement",initial,2013-05-16,GCST009165,Lipid or lipoprotein levels
6390,European,1200.0,23696881.0,Wood AR,Other measurement,initial,2013-05-16,GCST009167,Vitamin levels
6389,European,1200.0,23696881.0,Wood AR,Other measurement,initial,2013-05-16,GCST009163,Hormone measurements
7124,European,2083.0,23696881.0,Wood AR,Other measurement,initial,2013-05-16,GCST009169,Vitamin B12 levels
1793,Asian,140.0,23677057.0,Kim JJ,"Immune system disorder, Cardiovascular disease",initial,2013-05-16,GCST002026,Coronary arterial lesions in patients with Kawasaki disease
6408,European,1209.0,23696881.0,Wood AR,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",initial,2013-05-16,GCST009159,Blood protein levels
6388,European,1200.0,23696881.0,Wood AR,Other measurement,initial,2013-05-16,GCST009160,Carotenoid levels
6348,European,1167.0,23696881.0,Wood AR,Inflammatory measurement,initial,2013-05-16,GCST009168,Tumor necrosis factor alpha levels
675,African American or Afro-Caribbean,411.0,23696099.0,Ding K,Hematological measurement,replication,2013-05-20,GCST002027,Red blood cell traits
978,African American or Afro-Caribbean,1904.0,23696099.0,Ding K,Hematological measurement,initial,2013-05-20,GCST002027,Red blood cell traits
5604,European,621.0,23698163.0,Gong J,Other measurement,replication,2013-05-21,GCST002028,Serum selenium levels
6395,European,1203.0,23698163.0,Gong J,Other measurement,initial,2013-05-21,GCST002028,Serum selenium levels
2195,Asian,520.0,23746317.0,Yamaguchi T,Other disease,initial,2013-05-23,GCST002029,Temporomandibular joint disorder
342,African,12316.0,23717212.0,Band G,Digestive system disorder,initial,2013-05-23,GCST002033,Malaria
9915,European,11513.0,23704328.0,Fatemifar G,Biological process,initial,2013-05-23,GCST002031,Primary tooth development (number of teeth)
5602,European,620.0,23704207.0,Wu X,"Other measurement, Cancer",initial,2013-05-23,GCST002032,Non-small cell lung cancer (survival)
2621,Asian,1256.0,23704207.0,Wu X,"Other measurement, Cancer",replication,2013-05-23,GCST002032,Non-small cell lung cancer (survival)
9880,European,11118.0,23704328.0,Fatemifar G,Biological process,initial,2013-05-23,GCST002030,Primary tooth development (time to first tooth eruption)
14033,Other/Mixed,778.0,23719583.0,Kerns SL,Biological process,replication,2013-05-26,GCST002034,Adverse response to radiation therapy
7790,European,3146.0,23708191.0,Cordell HJ,Cardiovascular disease,replication,2013-05-26,GCST002035,Congenital heart disease
13862,Other/Mixed,320.0,23719583.0,Kerns SL,Biological process,initial,2013-05-26,GCST002034,Adverse response to radiation therapy
3748,Asian,6026.0,23708190.0,Hu Z,Cardiovascular disease,replication,2013-05-26,GCST002036,Congenital heart malformation
9118,European,6978.0,23708191.0,Cordell HJ,Cardiovascular disease,initial,2013-05-26,GCST002035,Congenital heart disease
3076,Asian,2191.0,23708190.0,Hu Z,Cardiovascular disease,initial,2013-05-26,GCST002036,Congenital heart malformation
1177,African American or Afro-Caribbean,3380.0,23726511.0,Xie P,Neurological disorder,initial,2013-05-28,GCST002038,Post-traumatic stress disorder
1178,African American or Afro-Caribbean,3392.0,23726511.0,Xie P,Neurological disorder,initial,2013-05-28,GCST002037,Post-traumatic stress disorder (asjusted for relatedness)
764,African American or Afro-Caribbean,744.0,23726511.0,Xie P,Neurological disorder,replication,2013-05-28,GCST002038,Post-traumatic stress disorder
6940,European,1846.0,23726511.0,Xie P,Neurological disorder,initial,2013-05-28,GCST002037,Post-traumatic stress disorder (asjusted for relatedness)
6937,European,1838.0,23726511.0,Xie P,Neurological disorder,initial,2013-05-28,GCST002038,Post-traumatic stress disorder
6723,European,1578.0,23726511.0,Xie P,Neurological disorder,replication,2013-05-28,GCST002038,Post-traumatic stress disorder
1338,African American or Afro-Caribbean,7138.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,replication,2013-05-29,GCST002044,Triglycerides
1337,African American or Afro-Caribbean,7138.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,replication,2013-05-29,GCST002043,HDL cholesterol
7523,European,2603.0,23720494.0,Evans DM,Other measurement,initial,2013-05-29,GCST002041,Blood trace element (Cu levels)
1351,African American or Afro-Caribbean,7601.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,initial,2013-05-29,GCST002044,Triglycerides
1364,African American or Afro-Caribbean,7861.0,23726366.0,Coram MA,"Lipid or lipoprotein measurement, Other measurement",initial,2013-05-29,GCST002042,LDL cholesterol
1366,African American or Afro-Caribbean,7917.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,initial,2013-05-29,GCST002043,HDL cholesterol
7522,European,2603.0,23720494.0,Evans DM,Other measurement,initial,2013-05-29,GCST002040,Blood trace element (Zn levels)
1339,African American or Afro-Caribbean,7138.0,23726366.0,Coram MA,"Lipid or lipoprotein measurement, Other measurement",replication,2013-05-29,GCST002042,LDL cholesterol
13199,Hispanic or Latin American,3506.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,initial,2013-05-29,GCST002043,HDL cholesterol
13182,Hispanic or Latin American,3425.0,23726366.0,Coram MA,"Lipid or lipoprotein measurement, Other measurement",initial,2013-05-29,GCST002042,LDL cholesterol
8761,European,5477.0,23720494.0,Evans DM,Other measurement,initial,2013-05-29,GCST002039,Blood trace element (Se levels)
13177,Hispanic or Latin American,3335.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,initial,2013-05-29,GCST002044,Triglycerides
532,African American or Afro-Caribbean,145.0,23726668.0,Hunter AM,Response to drug,initial,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
13703,Other/Mixed,39.0,23726668.0,Hunter AM,Response to drug,initial,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
11755,European,101069.0,23722424.0,Rietveld CA,Other measurement,initial,2013-05-30,GCST002045,Educational attainment
11908,European,126559.0,23722424.0,Rietveld CA,Other measurement,initial,2013-05-30,GCST002047,Educational attainment (college completion)
1626,Asian,16.0,23726668.0,Hunter AM,Response to drug,initial,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
11909,European,126559.0,23722424.0,Rietveld CA,Other measurement,initial,2013-05-30,GCST008396,Educational attainment (years of education)
5557,European,585.0,23726668.0,Hunter AM,Response to drug,replication,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
12788,Hispanic or Latin American,126.0,23726668.0,Hunter AM,Response to drug,initial,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
5818,European,774.0,23726668.0,Hunter AM,Response to drug,initial,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
10744,European,25490.0,23722424.0,Rietveld CA,Other measurement,replication,2013-05-30,GCST002045,Educational attainment
7050,European,2001.0,23728906.0,Byrne EM,Other measurement,replication,2013-05-31,GCST002051,Sleep latency
7312,European,2315.0,23728906.0,Byrne EM,Other measurement,initial,2013-05-31,GCST002049,Sleep quality
2993,Asian,2003.0,23728934.0,Yang L,Neurological disorder,initial,2013-05-31,GCST002048,Attention deficit hyperactivity disorder
7275,European,2278.0,23728906.0,Byrne EM,Other measurement,initial,2013-05-31,GCST002053,Sleep duration
7268,European,2267.0,23728906.0,Byrne EM,"Neurological disorder, Other measurement",initial,2013-05-31,GCST002052,Insomnia
7321,European,2322.0,23728906.0,Byrne EM,Other measurement,initial,2013-05-31,GCST002050,Sleep time
7311,European,2314.0,23728906.0,Byrne EM,Other measurement,initial,2013-05-31,GCST002054,Sleep depth
7277,European,2280.0,23728906.0,Byrne EM,Other measurement,initial,2013-05-31,GCST002051,Sleep latency
2178,Asian,489.0,23732972.0,Hashimoto R,"Other trait, Biological process",initial,2013-06-01,GCST002055,Cognitive decline
11997,European,143849.0,23603763.0,Liu JZ,"Digestive system disorder, Immune system disorder, Other disease, Metabolic disorder",initial,2013-06-01,GCST005563,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)"
10819,European,28868.0,23603763.0,Liu JZ,Digestive system disorder,initial,2013-06-01,GCST006670,Primary sclerosing cholangitis
5845,European,797.0,23727862.0,Savage SA,Cancer,replication,2013-06-02,GCST002056,Osteosarcoma
7968,European,3397.0,23727862.0,Savage SA,Cancer,initial,2013-06-02,GCST002056,Osteosarcoma
4983,European,256.0,23725790.0,Renteria ME,Biological process,initial,2013-06-03,GCST002058,DNA methylation (variation)
5166,European,384.0,23725790.0,Renteria ME,Biological process,replication,2013-06-03,GCST002058,DNA methylation (variation)
6216,European,1024.0,23725790.0,Renteria ME,Biological process,initial,2013-06-03,GCST002057,DNA methylation (parent-of-origin)
9025,European,6649.0,23738518.0,Luciano M,Biological process,initial,2013-06-05,GCST002060,Word reading
9024,European,6649.0,23738518.0,Luciano M,Biological process,initial,2013-06-05,GCST002059,Non-word repetition
683,African American or Afro-Caribbean,432.0,23755828.0,Perera MA,Response to drug,replication,2013-06-05,GCST002061,Warfarin maintenance dose
715,African American or Afro-Caribbean,533.0,23755828.0,Perera MA,Response to drug,initial,2013-06-05,GCST002061,Warfarin maintenance dose
9026,European,6649.0,23738518.0,Luciano M,Biological process,initial,2013-06-05,GCST002062,Reading and spelling
7621,European,2784.0,23761726.0,Yazar S,"Neurological disorder, Other trait",initial,2013-06-06,GCST002064,Corneal astigmatism
11964,European,137052.0,23754948.0,Randall JC,"Other measurement, Body measurement, Other trait",replication,2013-06-06,GCST002063,Sexual dimorphism in anthropometric traits
11946,European,133723.0,23754948.0,Randall JC,"Other measurement, Body measurement, Other trait",initial,2013-06-06,GCST002063,Sexual dimorphism in anthropometric traits
8540,European,4915.0,23743675.0,Kapoor M,"Biological process, Other measurement",initial,2013-06-07,GCST002065,Alcohol consumption
2810,Asian,1691.0,23749188.0,Tan DE,Cancer,initial,2013-06-09,GCST002066,B cell non-Hodgkin lymphoma
3810,Asian,6667.0,23749188.0,Tan DE,Cancer,replication,2013-06-09,GCST002066,B cell non-Hodgkin lymphoma
3281,Asian,2909.0,23760081.0,Kim YJ,Digestive system disorder,replication,2013-06-10,GCST002068,Chronic hepatitis B infection
2671,Asian,1400.0,23760081.0,Kim YJ,Digestive system disorder,initial,2013-06-10,GCST002068,Chronic hepatitis B infection
5916,European,841.0,23753411.0,Turner ST,Response to drug,replication,2013-06-10,GCST002067,Response to diuretic therapy in hypertension
9773,European,10198.0,23740937.0,Martin JE,"Neurological disorder, Immune system disorder",replication,2013-06-10,GCST002069,Systemic lupus erythematosus and Systemic sclerosis
9860,European,10911.0,23740937.0,Martin JE,"Neurological disorder, Immune system disorder",initial,2013-06-10,GCST002069,Systemic lupus erythematosus and Systemic sclerosis
5235,European,424.0,23753411.0,Turner ST,Response to drug,initial,2013-06-10,GCST002067,Response to diuretic therapy in hypertension
6299,European,1114.0,23752247.0,Loukola A,Biological process,initial,2013-06-11,GCST002070,Smoking behavior
8708,European,5294.0,23752247.0,Loukola A,Biological process,replication,2013-06-11,GCST002070,Smoking behavior
8190,European,3939.0,23776548.0,Sim X,Other measurement,replication,2013-06-12,GCST002071,Retinal arteriolar caliber
10433,European,18722.0,23776548.0,Sim X,Other measurement,initial,2013-06-12,GCST002071,Retinal arteriolar caliber
5517,European,562.0,23785401.0,Leone MA,"Immune system disorder, Other measurement",initial,2013-06-13,GCST002072,Multiple sclerosis (OCB status)
6970,European,1884.0,23785401.0,Leone MA,"Immune system disorder, Other measurement",replication,2013-06-13,GCST002072,Multiple sclerosis (OCB status)
9347,European,8027.0,23770605.0,Berndt SI,Cancer,replication,2013-06-16,GCST002073,Chronic lymphocytic leukemia
9477,European,8400.0,23770605.0,Berndt SI,Cancer,initial,2013-06-16,GCST002073,Chronic lymphocytic leukemia
4800,European,143.0,23776197.0,Leandro-Garcia LJ,"Response to drug, Neurological disorder, Other measurement",initial,2013-06-17,GCST002074,Paclitaxel-induced neuropathy
4786,European,130.0,23823136.0,Larsen MH,Other measurement,initial,2013-06-18,GCST002075,Lipopolysaccharide induced cytokine levels
5559,European,586.0,23823136.0,Larsen MH,Other measurement,replication,2013-06-18,GCST002075,Lipopolysaccharide induced cytokine levels
4829,European,170.0,23805179.0,Hass J,"Neurological disorder, Other measurement",initial,2013-06-21,GCST002076,Hippocampal volume in schizophrenia
9650,European,9458.0,23805179.0,Hass J,"Neurological disorder, Other measurement",replication,2013-06-21,GCST002076,Hippocampal volume in schizophrenia
5848,European,798.0,23793441.0,Davis MF,Neurological disorder,initial,2013-06-21,GCST002077,Parkinson's disease
11577,European,79357.0,23793025.0,Anttila V,Cardiovascular disease,initial,2013-06-23,GCST002080,Migraine with aura
11541,European,76534.0,23793025.0,Anttila V,Cardiovascular disease,initial,2013-06-23,GCST002078,Migraine without aura
10457,European,19147.0,23793025.0,Anttila V,Cardiovascular disease,initial,2013-06-23,GCST002079,Migraine - clinic-based
11860,European,118710.0,23793025.0,Anttila V,Cardiovascular disease,initial,2013-06-23,GCST002081,Migraine
11324,European,53862.0,23817569.0,Hinds DA,Immune system disorder,initial,2013-06-30,GCST002083,Self-reported allergy
10248,European,16034.0,23817571.0,Bonnelykke K,Other measurement,replication,2013-06-30,GCST002084,Allergic sensitization
4152,Asian,11363.0,23817570.0,Shi Y,Cancer,replication,2013-06-30,GCST002082,Cervical cancer
3498,Asian,4392.0,23817570.0,Shi Y,Cancer,initial,2013-06-30,GCST002082,Cervical cancer
10241,European,15845.0,23817571.0,Bonnelykke K,Other measurement,initial,2013-06-30,GCST002084,Allergic sensitization
10642,European,22647.0,23749187.0,Cortes A,Immune system disorder,initial,2013-07-01,GCST005529,Ankylosing spondylitis
10643,European,22647.0,23749187.0,Cortes A,Immune system disorder,initial,2013-07-01,GCST005530,Ankylosing spondylitis (SNP x SNP interaction)
5804,European,759.0,23827383.0,Cadby G,Cancer,replication,2013-07-01,GCST002085,Malignant mesothelioma
7419,European,2475.0,23827383.0,Cadby G,Cancer,initial,2013-07-01,GCST002085,Malignant mesothelioma
3326,Asian,3117.0,23749187.0,Cortes A,Immune system disorder,initial,2013-07-01,GCST005529,Ankylosing spondylitis
3109,Asian,2275.0,23844046.0,Dorajoo R,Inflammatory measurement,initial,2013-07-02,GCST002086,C-reactive protein
3096,Asian,2238.0,23844046.0,Dorajoo R,Inflammatory measurement,initial,2013-07-02,GCST002086,C-reactive protein
3074,Asian,2179.0,23844046.0,Dorajoo R,Inflammatory measurement,initial,2013-07-02,GCST002086,C-reactive protein
5658,European,659.0,23830517.0,Saruhan-Direskeneli G,Cardiovascular disease,initial,2013-07-03,GCST006863,Takayasu arteritis
11191,European,44147.0,23824729.0,van Meurs JB,Cardiovascular measurement,initial,2013-07-03,GCST002087,Homocysteine levels
14035,Other/Mixed,788.0,23830517.0,Saruhan-Direskeneli G,Cardiovascular disease,initial,2013-07-03,GCST006863,Takayasu arteritis
12791,Hispanic or Latin American,138.0,23829686.0,Ding L,"Other disease, Other measurement",replication,2013-07-05,GCST002088,Asthma (childhood onset)
539,African American or Afro-Caribbean,156.0,23829686.0,Ding L,"Other disease, Other measurement",replication,2013-07-05,GCST002088,Asthma (childhood onset)
6475,European,1287.0,23829686.0,Ding L,"Other disease, Other measurement",initial,2013-07-05,GCST002088,Asthma (childhood onset)
7200,European,2175.0,23836780.0,Blue Mountains Eye Study (BMES),Other measurement,initial,2013-07-07,GCST002089,Intraocular pressure
8519,European,4866.0,23836780.0,Blue Mountains Eye Study (BMES),Other measurement,replication,2013-07-07,GCST002089,Intraocular pressure
13979,Other/Mixed,664.0,23838604.0,Pare G,"Cardiovascular disease, Response to drug",initial,2013-07-08,GCST002091,Angioedema in response to angiotensin-converting enzyme inhibitor
13735,Other/Mixed,76.0,23838604.0,Pare G,"Cardiovascular disease, Response to drug",replication,2013-07-08,GCST002091,Angioedema in response to angiotensin-converting enzyme inhibitor
7696,European,2930.0,23874384.0,Viding E,Biological process,initial,2013-07-09,GCST002092,Callous-unemotional behaviour
9558,European,8824.0,23853074.0,Meder B,Cardiovascular disease,replication,2013-07-12,GCST002093,Idiopathic dilated cardiomyopathy
7749,European,3029.0,23853074.0,Meder B,Cardiovascular disease,initial,2013-07-12,GCST002093,Idiopathic dilated cardiomyopathy
3376,Asian,3488.0,23850713.0,Yang SK,Digestive system disorder,replication,2013-07-14,GCST002094,Crohn's disease
2622,Asian,1265.0,23850713.0,Yang SK,Digestive system disorder,initial,2013-07-14,GCST002094,Crohn's disease
6746,European,1610.0,23857890.0,Power RA,Neurological disorder,initial,2013-07-15,GCST002095,Major depressive disorder
8501,European,4835.0,23871474.0,Psychosis Endophenotypes International Consortium,Neurological disorder,initial,2013-07-17,GCST002096,Psychosis
1290,African American or Afro-Caribbean,5823.0,23870195.0,Wojczynski MK,Other trait,initial,2013-07-19,GCST002097,Coronary artery calcification
9756,European,9992.0,23870195.0,Wojczynski MK,Other trait,replication,2013-07-19,GCST002097,Coronary artery calcification
2609,Asian,1224.0,23872634.0,Bezzina CR,Cardiovascular disease,replication,2013-07-21,GCST002098,Brugada syndrome
6582,European,1400.0,23872634.0,Bezzina CR,Cardiovascular disease,replication,2013-07-21,GCST002098,Brugada syndrome
6595,European,1427.0,23872634.0,Bezzina CR,Cardiovascular disease,initial,2013-07-21,GCST002098,Brugada syndrome
2062,Asian,379.0,23875689.0,Hong SN,Cancer,replication,2013-07-22,GCST002099,Colorectal cancer
1743,Asian,105.0,23875689.0,Hong SN,Cancer,initial,2013-07-22,GCST002099,Colorectal cancer
10087,European,13581.0,23935489.0,McLaren PJ,"Immune system disorder, Other disease",initial,2013-07-25,GCST002101,HIV-1 susceptibility
8747,European,5446.0,23886662.0,Weidinger S,Immune system disorder,replication,2013-07-25,GCST002100,Atopic dermatitis
8787,European,5617.0,23886662.0,Weidinger S,Immune system disorder,initial,2013-07-25,GCST002100,Atopic dermatitis
6374,European,1187.0,23894154.0,Kohler A,Cancer,initial,2013-07-26,GCST002102,Thyroid cancer
9035,European,6685.0,23894154.0,Kohler A,Cancer,replication,2013-07-26,GCST002102,Thyroid cancer
13004,Hispanic or Latin American,908.0,23897914.0,Wang H,Other disease,initial,2013-07-29,GCST002104,Bronchopulmonary dysplasia
14038,Other/Mixed,795.0,23897914.0,Wang H,Other disease,replication,2013-07-29,GCST002104,Bronchopulmonary dysplasia
5175,European,390.0,23897914.0,Wang H,Other disease,initial,2013-07-29,GCST002104,Bronchopulmonary dysplasia
592,African American or Afro-Caribbean,225.0,23897914.0,Wang H,Other disease,initial,2013-07-29,GCST002104,Bronchopulmonary dysplasia
13771,Other/Mixed,167.0,23897914.0,Wang H,Other disease,initial,2013-07-29,GCST002104,Bronchopulmonary dysplasia
13701,Other/Mixed,36.0,23897914.0,Wang H,Other disease,initial,2013-07-29,GCST002104,Bronchopulmonary dysplasia
7258,European,2240.0,23900074.0,Pooley KA,Other measurement,initial,2013-07-29,GCST002103,Telomere length
1746,Asian,109.0,23910658.0,McRae JF,Biological process,replication,2013-07-31,GCST002107,Odorant perception (&beta;-ionone)
12986,Hispanic or Latin American,817.0,23903356.0,Hayes MG,Other measurement,initial,2013-07-31,GCST002110,Glycemic traits (pregnancy)
846,African American or Afro-Caribbean,1075.0,23903356.0,Hayes MG,Other measurement,initial,2013-07-31,GCST002110,Glycemic traits (pregnancy)
6796,European,1664.0,23935956.0,Pistis G,Hematological measurement,initial,2013-07-31,GCST002109,Red blood cell traits
6539,European,1367.0,23903356.0,Hayes MG,Other measurement,initial,2013-07-31,GCST002110,Glycemic traits (pregnancy)
1745,Asian,109.0,23910658.0,McRae JF,Biological process,replication,2013-07-31,GCST002105,Odorant perception (isobutyraldehyde)
4866,European,187.0,23910658.0,McRae JF,Biological process,initial,2013-07-31,GCST002105,Odorant perception (isobutyraldehyde)
4867,European,187.0,23910658.0,McRae JF,Biological process,initial,2013-07-31,GCST002106,Odorant perception (&beta;-damascenone)
4727,European,89.0,23910658.0,McRae JF,Biological process,replication,2013-07-31,GCST002106,Odorant perception (&beta;-damascenone)
10321,European,16764.0,23935956.0,Pistis G,Hematological measurement,replication,2013-07-31,GCST002109,Red blood cell traits
1692,Asian,76.0,23921680.0,Kim DS,Immune system disorder,initial,2013-07-31,GCST002108,Allergic dermatitis (nickel)
7746,European,3026.0,23903356.0,Hayes MG,Other measurement,replication,2013-07-31,GCST002110,Glycemic traits (pregnancy)
4868,European,187.0,23910658.0,McRae JF,Biological process,initial,2013-07-31,GCST002107,Odorant perception (&beta;-ionone)
2575,Asian,1178.0,23903356.0,Hayes MG,Other measurement,initial,2013-07-31,GCST002110,Glycemic traits (pregnancy)
2540,Asian,1089.0,23903073.0,Kim HN,Other trait,initial,2013-08-01,GCST002111,Personality dimensions
3022,Asian,2090.0,23903073.0,Kim HN,Other trait,replication,2013-08-01,GCST002111,Personality dimensions
5600,European,618.0,23936387.0,Ostensson M,Immune system disorder,initial,2013-08-02,GCST002112,Celiac disease
6323,European,1144.0,23932459.0,Yao TC,Other measurement,initial,2013-08-06,GCST002113,Pulmonary function
5671,European,668.0,23918034.0,Kuhnisch J,Other disease,initial,2013-08-07,GCST002114,Molar-incisor hypomineralization
8175,European,3900.0,23929743.0,Yadav S,Other measurement,replication,2013-08-08,GCST002116,Blood pressure variability
8140,European,3802.0,23929743.0,Yadav S,Other measurement,initial,2013-08-08,GCST002116,Blood pressure variability
3954,Asian,8216.0,24144296.0,Cheng CY,Other measurement,replication,2013-08-08,GCST002115,Axial length
10007,European,12531.0,24144296.0,Cheng CY,Other measurement,initial,2013-08-08,GCST002115,Axial length
3584,Asian,5030.0,23933737.0,Khor CC,Other trait,initial,2013-08-09,GCST002117,Myopia (severe)
3572,Asian,4800.0,23933737.0,Khor CC,Other trait,replication,2013-08-09,GCST002117,Myopia (severe)
891,African American or Afro-Caribbean,1260.0,23934736.0,Yu B,Other measurement,initial,2013-08-11,GCST002120,Metabolite levels (Dihydroxy docosatrienoic acid)
890,African American or Afro-Caribbean,1260.0,23934736.0,Yu B,Other measurement,initial,2013-08-11,GCST002119,Metabolite levels  (X-11787)
889,African American or Afro-Caribbean,1260.0,23934736.0,Yu B,Other measurement,initial,2013-08-11,GCST002118,Metabolite levels (Pyroglutamine)
7786,European,3137.0,23953852.0,Pan Y,"Biological process, Other measurement",replication,2013-08-13,GCST002121,Alcohol consumption
2437,Asian,877.0,23967269.0,Kim JH,"Other disease, Other measurement",initial,2013-08-13,GCST002125,IgE levels in asthmatics (D.f. specific)
2436,Asian,877.0,23967269.0,Kim JH,"Other disease, Other measurement",initial,2013-08-13,GCST002124,IgE levels in asthmatics (D.p. specific)
13861,Other/Mixed,315.0,23937595.0,Al Safar HS,Metabolic disorder,replication,2013-08-13,GCST002123,Type 2 diabetes
2435,Asian,877.0,23967269.0,Kim JH,"Other disease, Other measurement",initial,2013-08-13,GCST002122,IgE levels in asthmatics
13804,Other/Mixed,178.0,23937595.0,Al Safar HS,Metabolic disorder,initial,2013-08-13,GCST002123,Type 2 diabetes
7567,European,2687.0,23953852.0,Pan Y,"Biological process, Other measurement",initial,2013-08-13,GCST002121,Alcohol consumption
8230,European,4032.0,24024966.0,Teumer A,Digestive system disorder,initial,2013-08-14,GCST002127,Periodontitis (Mean PAL)
4408,Asian,26805.0,23945395.0,Hara K,Metabolic disorder,initial,2013-08-14,GCST002128,Type 2 diabetes
7433,European,2501.0,24024966.0,Teumer A,Digestive system disorder,initial,2013-08-14,GCST002129,Periodontitis (DPAL)
4484,Asian,38401.0,23945395.0,Hara K,Metabolic disorder,replication,2013-08-14,GCST002128,Type 2 diabetes
9169,European,7188.0,23942779.0,McGue M,"Other measurement, Neurological disorder",initial,2013-08-14,GCST002134,Alcohol dependence
7713,European,2969.0,24024966.0,Teumer A,Digestive system disorder,initial,2013-08-14,GCST002136,Periodontitis (PAL4Q3)
8178,European,3915.0,24024966.0,Teumer A,Digestive system disorder,initial,2013-08-14,GCST002126,Periodontitis (CDC/AAP)
9168,European,7188.0,23942779.0,McGue M,"Biological process, Other measurement",initial,2013-08-14,GCST002130,Alcohol consumption
9165,European,7188.0,23942779.0,McGue M,Biological process,initial,2013-08-14,GCST002133,Illicit drug use
9164,European,7188.0,23942779.0,McGue M,Biological process,initial,2013-08-14,GCST002132,Non-substance related behavioral disinhibition
9167,European,7188.0,23942779.0,McGue M,"Biological process, Neurological disorder, Other measurement",initial,2013-08-14,GCST002131,Behavioural disinhibition (generation interaction)
9166,European,7188.0,23942779.0,McGue M,Biological process,initial,2013-08-14,GCST002135,Nicotine use
1503,African American or Afro-Caribbean,19744.0,23966867.0,Liu CT,"Other measurement, Body measurement",initial,2013-08-15,GCST002138,Waist-hip ratio
1352,African American or Afro-Caribbean,7606.0,23966867.0,Liu CT,"Other measurement, Body measurement",replication,2013-08-15,GCST002138,Waist-hip ratio
1543,African American or Afro-Caribbean,23564.0,23966867.0,Liu CT,Body measurement,initial,2013-08-15,GCST002137,Waist circumference
1430,African American or Afro-Caribbean,10027.0,23966867.0,Liu CT,Body measurement,replication,2013-08-15,GCST002137,Waist circumference
5046,European,301.0,23956247.0,Knevel R,"Immune system disorder, Other measurement",replication,2013-08-16,GCST002139,Joint damage progression in ACPA-positive rheumatoid arthritis
8897,European,6041.0,23955597.0,Chubb D,Cancer,replication,2013-08-18,GCST002140,Multiple myeloma
9678,European,9641.0,23955597.0,Chubb D,Cancer,initial,2013-08-18,GCST002140,Multiple myeloma
286,African,5108.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",replication,2013-08-20,GCST002143,Blood pressure
1014,African American or Afro-Caribbean,2114.0,23958962.0,Gelernter J,Neurological disorder,replication,2013-08-20,GCST002142,Cocaine dependence
12894,Hispanic or Latin American,503.0,23966204.0,Ledda M,Biological process,initial,2013-08-20,GCST002144,Bitter taste perception
8385,European,4498.0,23958962.0,Gelernter J,Neurological disorder,replication,2013-08-20,GCST002142,Cocaine dependence
4352,Asian,19601.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",replication,2013-08-20,GCST002143,Blood pressure
12781,Hispanic or Latin American,104.0,23966204.0,Ledda M,Biological process,replication,2013-08-20,GCST002144,Bitter taste perception
7362,European,2379.0,23958962.0,Gelernter J,Neurological disorder,initial,2013-08-20,GCST002142,Cocaine dependence
1173,African American or Afro-Caribbean,3318.0,23958962.0,Gelernter J,Neurological disorder,initial,2013-08-20,GCST002142,Cocaine dependence
1277,African American or Afro-Caribbean,5266.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",replication,2013-08-20,GCST002143,Blood pressure
175,African,1188.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",initial,2013-08-20,GCST002143,Blood pressure
186,African,1389.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",replication,2013-08-20,GCST002143,Blood pressure
1558,African American or Afro-Caribbean,28190.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",initial,2013-08-20,GCST002143,Blood pressure
11498,European,69395.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",replication,2013-08-20,GCST002143,Blood pressure
7492,European,2546.0,23989729.0,Feenstra B,Digestive system disorder,replication,2013-08-21,GCST002145,Infantile hypertrophic pyloric stenosis
7951,European,3372.0,23989729.0,Feenstra B,Digestive system disorder,initial,2013-08-21,GCST002145,Infantile hypertrophic pyloric stenosis
14116,Other/Mixed,1435.0,23989729.0,Feenstra B,Digestive system disorder,replication,2013-08-21,GCST002145,Infantile hypertrophic pyloric stenosis
6575,European,1392.0,23990791.0,Thun GA,Other measurement,initial,2013-08-22,GCST002146,Serum alpha1-antitrypsin levels
11715,European,91323.0,23969696.0,Sabater-Lleal M,Hematological measurement,initial,2013-08-22,GCST002147,Fibrinogen
10004,European,12518.0,23990791.0,Thun GA,Other measurement,replication,2013-08-22,GCST002146,Serum alpha1-antitrypsin levels
13070,Hispanic or Latin American,1447.0,23969696.0,Sabater-Lleal M,Hematological measurement,replication,2013-08-22,GCST002147,Fibrinogen
1392,African American or Afro-Caribbean,8423.0,23969696.0,Sabater-Lleal M,Hematological measurement,replication,2013-08-22,GCST002147,Fibrinogen
6726,European,1584.0,23974705.0,Allen EK,Neurological disorder,replication,2013-08-23,GCST002148,Otitis media (chronic/recurrent)
13689,Other/Mixed,25.0,23974705.0,Allen EK,Neurological disorder,initial,2013-08-23,GCST002148,Otitis media (chronic/recurrent)
5534,European,577.0,23974705.0,Allen EK,Neurological disorder,initial,2013-08-23,GCST002148,Otitis media (chronic/recurrent)
9893,European,11244.0,23974872.0,Ripke S,Neurological disorder,initial,2013-08-25,GCST002149,Schizophrenia
9664,European,9542.0,23974872.0,Ripke S,Neurological disorder,replication,2013-08-25,GCST002149,Schizophrenia
8864,European,5902.0,23983088.0,Miller FW,Neurological disorder,initial,2013-08-27,GCST002151,Dermatomyositis
6157,European,994.0,23984888.0,Himes BE,Other trait,initial,2013-08-28,GCST002152,Airway hyperresponsiveness
8217,European,4004.0,23984888.0,Himes BE,Other trait,replication,2013-08-28,GCST002152,Airway hyperresponsiveness
7306,European,2310.0,23982368.0,Qi L,"Other disease, Metabolic disorder",initial,2013-08-28,GCST002153,Cardiovascular heart disease in diabetics
6965,European,1878.0,23982368.0,Qi L,"Other disease, Metabolic disorder",replication,2013-08-28,GCST002153,Cardiovascular heart disease in diabetics
10790,European,27498.0,23989986.0,Evangelou E,Other disease,replication,2013-08-29,GCST002155,Osteoarthritis (hip)
11284,European,51537.0,23989986.0,Evangelou E,Other disease,initial,2013-08-29,GCST002155,Osteoarthritis (hip)
13094,Hispanic or Latin American,1782.0,23992748.0,Drake KA,"Response to drug, Other disease",initial,2013-08-29,GCST002154,Asthma (bronchodilator response)
12896,Hispanic or Latin American,529.0,23992748.0,Drake KA,"Response to drug, Other disease",replication,2013-08-29,GCST002154,Asthma (bronchodilator response)
1715,Asian,94.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002156,Response to mTOR inhibitor (rapamycin)
1716,Asian,94.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002157,Response to mTOR inhibitor (everolimus)
8972,European,6381.0,23996088.0,Migliorini G,Cancer,initial,2013-08-30,GCST002158,Acute lymphoblastic leukemia (B-cell precursor)
494,African American or Afro-Caribbean,91.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002156,Response to mTOR inhibitor (rapamycin)
4722,European,87.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002157,Response to mTOR inhibitor (everolimus)
4721,European,87.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002156,Response to mTOR inhibitor (rapamycin)
7701,European,2937.0,23996088.0,Migliorini G,Cancer,replication,2013-08-30,GCST002158,Acute lymphoblastic leukemia (B-cell precursor)
495,African American or Afro-Caribbean,91.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002157,Response to mTOR inhibitor (everolimus)
7027,European,1962.0,23740775.0,Xie G,Cardiovascular disease,initial,2013-09-01,GCST002159,Wegener's granulomatosis
6881,European,1756.0,23740775.0,Xie G,Cardiovascular disease,replication,2013-09-01,GCST002159,Wegener's granulomatosis
7028,European,1962.0,23740775.0,Xie G,Cardiovascular disease,initial,2013-09-01,GCST002160,Wegener's granulomatosis
5591,European,608.0,23740775.0,Xie G,Cardiovascular disease,replication,2013-09-01,GCST002160,Wegener's granulomatosis
6203,European,1015.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002163,Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity)
719,African American or Afro-Caribbean,541.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002162,Lung function (FVC)
722,African American or Afro-Caribbean,541.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002165,Lung function (FEV1)
720,African American or Afro-Caribbean,541.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002163,Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity)
6204,European,1015.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002164,Lung function (FEV1/FVC)
6205,European,1015.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002165,Lung function (FEV1)
721,African American or Afro-Caribbean,541.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002164,Lung function (FEV1/FVC)
6202,European,1015.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002162,Lung function (FVC)
4379,Asian,22275.0,24001895.0,Kelly TN,"Other measurement, Cardiovascular measurement",initial,2013-09-03,GCST002167,Blood pressure
3495,Asian,4325.0,24001895.0,Kelly TN,"Other measurement, Cardiovascular measurement",initial,2013-09-03,GCST002167,Blood pressure
4418,Asian,28783.0,24001895.0,Kelly TN,"Other measurement, Cardiovascular measurement",replication,2013-09-03,GCST002167,Blood pressure
8944,European,6236.0,24002674.0,Ozel AB,Other measurement,initial,2013-09-04,GCST002168,Intraocular pressure
4135,Asian,10988.0,24023777.0,Miyake A,Other disease,replication,2013-09-04,GCST002169,Adolescent idiopathic scoliosis (severe)
3001,Asian,2028.0,24023777.0,Miyake A,Other disease,initial,2013-09-04,GCST002169,Adolescent idiopathic scoliosis (severe)
8399,European,4550.0,24014518.0,Kasperaviciute D,Neurological disorder,replication,2013-09-06,GCST002170,Mesial temporal lobe epilepsy with hippocampal sclerosis
9512,European,8570.0,24014518.0,Kasperaviciute D,Neurological disorder,initial,2013-09-06,GCST002170,Mesial temporal lobe epilepsy with hippocampal sclerosis
13690,Other/Mixed,25.0,24080187.0,Guffanti G,Neurological disorder,initial,2013-09-08,GCST002171,Post-traumatic stress disorder
4654,European,45.0,24080187.0,Guffanti G,Neurological disorder,initial,2013-09-08,GCST002171,Post-traumatic stress disorder
7484,European,2541.0,24080187.0,Guffanti G,Neurological disorder,replication,2013-09-08,GCST002171,Post-traumatic stress disorder
648,African American or Afro-Caribbean,342.0,24080187.0,Guffanti G,Neurological disorder,initial,2013-09-08,GCST002171,Post-traumatic stress disorder
7545,European,2647.0,24015780.0,Wetherill L,"Other measurement, Neurological disorder",replication,2013-09-09,GCST002172,Alcohol dependence
7322,European,2322.0,24015780.0,Wetherill L,"Other measurement, Neurological disorder",initial,2013-09-09,GCST002172,Alcohol dependence
2875,Asian,1782.0,24023260.0,Wu Y,"Lipid or lipoprotein measurement, Other measurement",initial,2013-09-10,GCST002174,Lipid traits
8679,European,5248.0,24023261.0,Keller M,"Lipid or lipoprotein measurement, Other measurement",replication,2013-09-10,GCST002173,Lipid traits
5911,European,839.0,24023261.0,Keller M,"Lipid or lipoprotein measurement, Other measurement",initial,2013-09-10,GCST002173,Lipid traits
2820,Asian,1719.0,24023260.0,Wu Y,"Lipid or lipoprotein measurement, Other measurement",replication,2013-09-10,GCST002174,Lipid traits
1895,Asian,224.0,24025145.0,Chung S,"Other disease, Response to drug",initial,2013-09-11,GCST002176,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)
5284,European,440.0,24024963.0,Eicher JD,Neurological disorder,replication,2013-09-11,GCST002175,Reading disability and language impairment
1896,Asian,224.0,24025145.0,Chung S,"Other disease, Response to drug",initial,2013-09-11,GCST002177,Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
8322,European,4291.0,24024963.0,Eicher JD,Neurological disorder,initial,2013-09-11,GCST002175,Reading disability and language impairment
1741,Asian,104.0,24025145.0,Chung S,"Other disease, Response to drug",initial,2013-09-11,GCST002180,Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)
2580,Asian,1183.0,24025145.0,Chung S,Other disease,initial,2013-09-11,GCST002181,Adverse response to chemotherapy in breast cancer (alopecia)
1629,Asian,23.0,24025145.0,Chung S,Other disease,replication,2013-09-11,GCST002181,Adverse response to chemotherapy in breast cancer (alopecia)
1709,Asian,91.0,24025145.0,Chung S,"Other disease, Response to drug",initial,2013-09-11,GCST002178,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
1761,Asian,120.0,24025145.0,Chung S,"Response to drug, Other disease",initial,2013-09-11,GCST002179,Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)
5744,European,728.0,24068947.0,Brandler WM,"Other trait, Neurological disorder",initial,2013-09-12,GCST002183,Relative hand skill in reading disability
7255,European,2235.0,24029427.0,Sandholm N,"Other disease, Metabolic disorder",initial,2013-09-12,GCST002182,End-stage renal disease in Type 1 diabetics
10089,European,13582.0,24026423.0,Shameer K,Hematological measurement,initial,2013-09-12,GCST002186,Platelet count
8934,European,6219.0,24026423.0,Shameer K,Hematological measurement,initial,2013-09-12,GCST002184,Mean platelet volume
7558,European,2666.0,24068947.0,Brandler WM,Other trait,initial,2013-09-12,GCST002185,Relative hand skill
6649,European,1517.0,24029427.0,Sandholm N,"Other disease, Metabolic disorder",replication,2013-09-12,GCST002182,End-stage renal disease in Type 1 diabetics
13912,Other/Mixed,428.0,24037343.0,Chang ALS,Biological process,initial,2013-09-13,GCST002189,Skin youthfulness
14039,Other/Mixed,807.0,24037343.0,Chang ALS,Biological process,replication,2013-09-13,GCST002189,Skin youthfulness
950,African American or Afro-Caribbean,1617.0,24058526.0,Bhatnagar P,"Neurological disorder, Other measurement",initial,2013-09-13,GCST002187,Systolic blood pressure in sickle cell anemia
7262,European,2246.0,24039173.0,McGrath LM,"Neurological disorder, Other measurement",initial,2013-09-13,GCST002188,"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia"
3057,Asian,2151.0,24043878.0,Wong EH,Neurological disorder,replication,2013-09-16,GCST002190,Schizophrenia
3365,Asian,3437.0,24045676.0,Pyun JA,Other measurement,initial,2013-09-16,GCST002191,Menarche (age at onset)
2896,Asian,1827.0,24045676.0,Pyun JA,Other measurement,initial,2013-09-16,GCST002192,Menopause (age at onset)
3175,Asian,2506.0,24043878.0,Wong EH,Neurological disorder,initial,2013-09-16,GCST002190,Schizophrenia
10872,European,30620.0,24046328.0,Bradley DT,Cardiovascular disease,replication,2013-09-17,GCST002193,Abdominal aortic aneurysm
9135,European,7069.0,24046328.0,Bradley DT,Cardiovascular disease,initial,2013-09-17,GCST002193,Abdominal aortic aneurysm
8652,European,5143.0,24047826.0,Kleber ME,Other measurement,initial,2013-09-18,GCST002196,Homoarginine levels
8776,European,5584.0,24047820.0,St Pourcain B,Other measurement,initial,2013-09-18,GCST002194,Social communication problems
14017,Other/Mixed,733.0,24057671.0,Chimusa ER,"Other disease, Other measurement",initial,2013-09-18,GCST002198,Tuberculosis
6626,European,1474.0,24047826.0,Kleber ME,Other measurement,replication,2013-09-18,GCST002196,Homoarginine levels
6537,European,1364.0,24047820.0,St Pourcain B,Other measurement,replication,2013-09-18,GCST002194,Social communication problems
2986,Asian,1999.0,24049095.0,Chen Z,Other measurement,initial,2013-09-18,GCST002199,Follicule stimulating hormone
2709,Asian,1496.0,24049095.0,Chen Z,Other measurement,replication,2013-09-18,GCST002199,Follicule stimulating hormone
14016,Other/Mixed,733.0,24057671.0,Chimusa ER,"Other disease, Other measurement",initial,2013-09-18,GCST002197,Tuberculosis
2985,Asian,1999.0,24049095.0,Chen Z,Other measurement,initial,2013-09-18,GCST002195,Hormone measurements
2708,Asian,1496.0,24049095.0,Chen Z,Other measurement,replication,2013-09-18,GCST002195,Hormone measurements
7560,European,2668.0,24047446.0,Schosser A,"Neurological disorder, Other trait",initial,2013-09-19,GCST002200,Anxiety and major depressive disorder
10597,European,21679.0,24068962.0,O'Seaghdha CM,Other measurement,replication,2013-09-19,GCST002201,Calcium levels
11110,European,39400.0,24068962.0,O'Seaghdha CM,Other measurement,initial,2013-09-19,GCST002201,Calcium levels
6653,European,1522.0,24047446.0,Schosser A,"Neurological disorder, Other trait",initial,2013-09-19,GCST002202,Anxiety in major depressive disorder
13823,Other/Mixed,225.0,24065354.0,Al-Qahtani A,Digestive system disorder,replication,2013-09-24,GCST002204,Liver disease in chronic hepatitis B virus infection
1766,Asian,125.0,24086445.0,Wang Q,"Neurological disorder, Other measurement",initial,2013-09-24,GCST002203,Gray matter volume (schizophrenia interaction)
13977,Other/Mixed,648.0,24065354.0,Al-Qahtani A,Digestive system disorder,initial,2013-09-24,GCST002204,Liver disease in chronic hepatitis B virus infection
7341,European,2355.0,24065183.0,Armour JA,Other trait,initial,2013-09-25,GCST002205,Handedness
6727,European,1585.0,24065183.0,Armour JA,Other trait,initial,2013-09-25,GCST002206,Handedness
2170,Asian,484.0,24124411.0,Park TJ,Liver enzyme measurement,initial,2013-09-30,GCST002207,Liver enzyme levels (alanine transaminase)
3796,Asian,6428.0,24124408.0,Hong KW,Cardiovascular disease,initial,2013-09-30,GCST002209,Orthostatic hypotension
2171,Asian,484.0,24124411.0,Park TJ,Liver enzyme measurement,initial,2013-09-30,GCST002208,Liver enzyme levels (aspartate transaminase)
1758,Asian,118.0,24159609.0,Choi H,Cancer,initial,2013-10-01,GCST002210,Acute myeloid leukemia
2462,Asian,929.0,24132900.0,Kanazawa T,Neurological disorder,initial,2013-10-01,GCST002211,Psychosis (atypical)
1780,Asian,129.0,24159609.0,Choi H,Cancer,replication,2013-10-01,GCST002210,Acute myeloid leukemia
9604,European,9211.0,24084763.0,Wang J,Cancer,replication,2013-10-01,GCST002212,Colorectal adenoma (advanced)
6585,European,1406.0,24084763.0,Wang J,Cancer,initial,2013-10-01,GCST002212,Colorectal adenoma (advanced)
6012,European,915.0,24098343.0,Polfus LM,"Other trait, Other measurement",initial,2013-10-03,GCST002213,Coronary artery calcification (smoking interaction)
6217,European,1025.0,24098343.0,Polfus LM,"Other trait, Other measurement",replication,2013-10-03,GCST002213,Coronary artery calcification (smoking interaction)
2690,Asian,1452.0,24094242.0,Li J,Liver enzyme measurement,initial,2013-10-05,GCST002214,Serum alkaline phosphatase levels
4007,Asian,8830.0,24094242.0,Li J,Liver enzyme measurement,replication,2013-10-05,GCST002214,Serum alkaline phosphatase levels
11725,European,93982.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,replication,2013-10-06,GCST002216,Triglycerides
2766,Asian,1592.0,24097066.0,Li Y,Neurological disorder,initial,2013-10-06,GCST002217,Sjgren's syndrome
8316,European,4270.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002215,Endometrial cancer
4000,Asian,8743.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,replication,2013-10-06,GCST002219,Triglycerides
12844,Hispanic or Latin American,382.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002215,Endometrial cancer
12845,Hispanic or Latin American,382.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002218,Endometrial cancer
9901,European,11369.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002218,Endometrial cancer
3453,Asian,4030.0,24097066.0,Li Y,Neurological disorder,replication,2013-10-06,GCST002217,Sjgren's syndrome
3328,Asian,3136.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002218,Endometrial cancer
11727,European,93982.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,replication,2013-10-06,GCST002223,HDL cholesterol
13743,Other/Mixed,81.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002218,Endometrial cancer
2040,Asian,366.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002215,Endometrial cancer
8757,European,5472.0,24096698.0,De Vivo I,Cancer,initial,2013-10-06,GCST002215,Endometrial cancer
8758,European,5472.0,24096698.0,De Vivo I,Cancer,initial,2013-10-06,GCST002218,Endometrial cancer
11736,European,94595.0,24097068.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",initial,2013-10-06,GCST002222,LDL cholesterol
11735,European,94595.0,24097068.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",initial,2013-10-06,GCST002220,LDL cholesterol
11734,European,94595.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,initial,2013-10-06,GCST002223,HDL cholesterol
11733,European,94595.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,initial,2013-10-06,GCST002221,"Cholesterol, total"
11726,European,93982.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,replication,2013-10-06,GCST002221,"Cholesterol, total"
275,African,4420.0,24097068.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",replication,2013-10-06,GCST002220,LDL cholesterol
11732,European,94595.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,initial,2013-10-06,GCST002219,Triglycerides
11731,European,94595.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,initial,2013-10-06,GCST002216,Triglycerides
609,African American or Afro-Caribbean,262.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002218,Endometrial cancer
608,African American or Afro-Caribbean,262.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002215,Endometrial cancer
11728,European,93982.0,24097068.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",replication,2013-10-06,GCST002222,LDL cholesterol
13742,Other/Mixed,81.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002215,Endometrial cancer
14046,Other/Mixed,840.0,24101674.0,Hanson RL,Metabolic disorder,initial,2013-10-07,GCST002224,Type 2 diabetes
14186,Other/Mixed,2908.0,24101674.0,Hanson RL,Metabolic disorder,replication,2013-10-07,GCST002224,Type 2 diabetes
14213,Other/Mixed,3926.0,24101674.0,Hanson RL,Metabolic disorder,replication,2013-10-07,GCST002224,Type 2 diabetes
2774,Asian,1622.0,24064335.0,Pei YF,Other measurement,initial,2013-10-08,GCST002226,Fat body mass
3408,Asian,3697.0,24216480.0,Song YQ,Other disease,initial,2013-10-08,GCST002225,Disc degeneration (lumbar)
2778,Asian,1624.0,24064335.0,Pei YF,"Body measurement, Other measurement",initial,2013-10-08,GCST002227,Body mass index
755,African American or Afro-Caribbean,709.0,24064335.0,Pei YF,Other measurement,initial,2013-10-08,GCST002226,Fat body mass
1346,African American or Afro-Caribbean,7478.0,24064335.0,Pei YF,"Body measurement, Other measurement",initial,2013-10-08,GCST002227,Body mass index
8980,European,6433.0,24064335.0,Pei YF,Other measurement,initial,2013-10-08,GCST002226,Fat body mass
8739,European,5434.0,24216480.0,Song YQ,Other disease,replication,2013-10-08,GCST002225,Disc degeneration (lumbar)
4343,Asian,19097.0,24216480.0,Song YQ,Other disease,replication,2013-10-08,GCST002225,Disc degeneration (lumbar)
9489,European,8463.0,24064335.0,Pei YF,"Body measurement, Other measurement",initial,2013-10-08,GCST002227,Body mass index
12852,Hispanic or Latin American,408.0,24064335.0,Pei YF,Other measurement,initial,2013-10-08,GCST002226,Fat body mass
3231,Asian,2740.0,24064335.0,Pei YF,Other measurement,replication,2013-10-08,GCST002226,Fat body mass
8581,European,4979.0,24064335.0,Pei YF,"Body measurement, Other measurement",replication,2013-10-08,GCST002227,Body mass index
3230,Asian,2740.0,24064335.0,Pei YF,"Body measurement, Other measurement",replication,2013-10-08,GCST002227,Body mass index
13178,Hispanic or Latin American,3348.0,24064335.0,Pei YF,"Body measurement, Other measurement",initial,2013-10-08,GCST002227,Body mass index
8576,European,4967.0,24064335.0,Pei YF,Other measurement,replication,2013-10-08,GCST002226,Fat body mass
6103,European,965.0,24133439.0,Jones RM,Other measurement,initial,2013-10-11,GCST002228,Social autistic-like traits
6031,European,928.0,24114350.0,Zhang M,Other disease,initial,2013-10-11,GCST002229,Acne (severe teenage)
6576,European,1392.0,24114350.0,Zhang M,Other disease,replication,2013-10-11,GCST002229,Acne (severe teenage)
9508,European,8547.0,24121790.0,Levine DM,"Digestive system disorder, Cancer, Other disease",replication,2013-10-13,GCST002231,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
9293,European,7785.0,24121790.0,Levine DM,Digestive system disorder,replication,2013-10-13,GCST002230,Barrett's esophagus
9292,European,7785.0,24121790.0,Levine DM,Cancer,replication,2013-10-13,GCST002232,Esophageal adenocarcinoma
8744,European,5442.0,24121790.0,Levine DM,Cancer,initial,2013-10-13,GCST002232,Esophageal adenocarcinoma
8745,European,5442.0,24121790.0,Levine DM,Digestive system disorder,initial,2013-10-13,GCST002230,Barrett's esophagus
9152,European,7135.0,24121790.0,Levine DM,"Digestive system disorder, Cancer, Other disease",initial,2013-10-13,GCST002231,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
3928,Asian,7827.0,24105470.0,Wu Y,Other measurement,initial,2013-10-14,GCST002233,Adiponectin levels
4110,Asian,10250.0,24105470.0,Wu Y,Other measurement,replication,2013-10-14,GCST002233,Adiponectin levels
3772,Asian,6280.0,24143190.0,Low SK,Cancer,replication,2013-10-15,GCST002234,Breast cancer
3559,Asian,4741.0,24143190.0,Low SK,Cancer,initial,2013-10-15,GCST002234,Breast cancer
7363,European,2379.0,24143882.0,Gelernter J,Response to drug,initial,2013-10-19,GCST002235,Opioid sensitivity
1015,African American or Afro-Caribbean,2116.0,24143882.0,Gelernter J,Response to drug,replication,2013-10-19,GCST002235,Opioid sensitivity
1174,African American or Afro-Caribbean,3318.0,24143882.0,Gelernter J,Response to drug,initial,2013-10-19,GCST002235,Opioid sensitivity
8384,European,4496.0,24143882.0,Gelernter J,Response to drug,replication,2013-10-19,GCST002235,Opioid sensitivity
14224,Other/Mixed,4344.0,24141364.0,Perez-Andreu V,Cancer,initial,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
6675,European,1541.0,24141364.0,Perez-Andreu V,Cancer,initial,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
877,African American or Afro-Caribbean,1228.0,24141364.0,Perez-Andreu V,Cancer,replication,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
13691,Other/Mixed,25.0,24141364.0,Perez-Andreu V,Cancer,replication,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
13775,Other/Mixed,171.0,24141364.0,Perez-Andreu V,Cancer,replication,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
13006,Hispanic or Latin American,920.0,24141364.0,Perez-Andreu V,Cancer,replication,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
8083,European,3647.0,24141364.0,Perez-Andreu V,Cancer,replication,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
13046,Hispanic or Latin American,1287.0,24141364.0,Perez-Andreu V,Cancer,initial,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
9306,European,7882.0,24149102.0,Frampton M,Cancer,initial,2013-10-22,GCST002237,Hodgkin's lymphoma
6252,European,1071.0,24149102.0,Frampton M,Cancer,replication,2013-10-22,GCST002237,Hodgkin's lymphoma
6141,European,985.0,24152035.0,Goodbourn PT,Other measurement,initial,2013-10-23,GCST002238,Contrast sensitivity
8635,European,5110.0,24159190.0,Seppala I,"Cardiovascular measurement, Other measurement",initial,2013-10-24,GCST002241,Asymmetrical dimethylarginine levels
10435,European,18729.0,24163127.0,Figueroa JD,Cancer,initial,2013-10-24,GCST002243,Bladder cancer
8636,European,5110.0,24159190.0,Seppala I,Other measurement,initial,2013-10-24,GCST002242,Serum dimethylarginine levels (asymmetric/symetric ratio)
8931,European,6206.0,24163127.0,Figueroa JD,Cancer,initial,2013-10-24,GCST002240,Bladder cancer
8634,European,5110.0,24159190.0,Seppala I,"Cardiovascular measurement, Other measurement",initial,2013-10-24,GCST002239,Symmetrical dimethylarginine levels
2631,Asian,1294.0,24513584.0,Oei L,Other disease,replication,2013-10-25,GCST002244,Fractures (vertebral)
10757,European,26217.0,24513584.0,Oei L,Other disease,replication,2013-10-25,GCST002244,Fractures (vertebral)
7727,European,2995.0,24513584.0,Oei L,Other disease,initial,2013-10-25,GCST002244,Fractures (vertebral)
4081,Asian,9903.0,24162738.0,Hu Z,"Digestive system disorder, Other measurement",replication,2013-10-27,GCST002246,Hepatitis B
2942,Asian,1888.0,24162738.0,Hu Z,"Digestive system disorder, Other measurement",initial,2013-10-27,GCST002246,Hepatitis B
11350,European,55134.0,24162737.0,Lambert JC,Neurological disorder,initial,2013-10-27,GCST002245,Alzheimer's disease (late onset)
10507,European,19884.0,24162737.0,Lambert JC,Neurological disorder,replication,2013-10-27,GCST002245,Alzheimer's disease (late onset)
2936,Asian,1881.0,24165912.0,He J,"Other measurement, Biological process",initial,2013-10-28,GCST002247,Blood pressure measurement (cold pressor test)
2915,Asian,1850.0,24165912.0,He J,"Other measurement, Biological process",initial,2013-10-28,GCST002250,Blood pressure measurement (low sodium intervention)
2269,Asian,660.0,24165912.0,He J,"Other measurement, Biological process",replication,2013-10-28,GCST002250,Blood pressure measurement (low sodium intervention)
5873,European,820.0,24204828.0,Zheng JS,Other measurement,initial,2013-10-28,GCST002248,Fasting insulin (dietary factor interaction)
2267,Asian,659.0,24165912.0,He J,"Other measurement, Biological process",replication,2013-10-28,GCST002249,Blood pressure measurement (high sodium intervention)
2299,Asian,698.0,24165912.0,He J,"Other measurement, Biological process",replication,2013-10-28,GCST002247,Blood pressure measurement (cold pressor test)
2266,Asian,654.0,24165912.0,He J,"Other measurement, Biological process",replication,2013-10-28,GCST002252,Blood pressure measurement (high sodium and potassium intervention)
2907,Asian,1836.0,24165912.0,He J,"Other measurement, Biological process",initial,2013-10-28,GCST002252,Blood pressure measurement (high sodium and potassium intervention)
5874,European,820.0,24204828.0,Zheng JS,Other measurement,initial,2013-10-28,GCST002251,Homeostasis model assessment of beta-cell function (dietary factor interaction)
5875,European,820.0,24204828.0,Zheng JS,Other measurement,initial,2013-10-28,GCST002253,Homeostasis model assessment of insulin resistance (dietary factor interaction)
2908,Asian,1840.0,24165912.0,He J,"Other measurement, Biological process",initial,2013-10-28,GCST002249,Blood pressure measurement (high sodium intervention)
8365,European,4443.0,24182552.0,Matteini AM,"Other measurement, Inflammatory measurement, Response to drug",initial,2013-10-29,GCST002255,Inflammatory biomarkers
2623,Asian,1266.0,24204295.0,Han F,Neurological disorder,initial,2013-10-31,GCST002259,Narcolepsy (onset before 2009 H1N1 influenza pandemic)
2501,Asian,1000.0,24204295.0,Han F,"Neurological disorder, Other measurement",initial,2013-10-31,GCST002261,Narcolepsy (age of onset)
2175,Asian,487.0,24172245.0,Haga S,Digestive system disorder,initial,2013-10-31,GCST002256,Tooth agenesis (third molar)
3335,Asian,3186.0,24204295.0,Han F,Neurological disorder,initial,2013-10-31,GCST002260,Narcolepsy
2176,Asian,487.0,24172245.0,Haga S,Digestive system disorder,initial,2013-10-31,GCST002257,Tooth agenesis (maxillary third molar)
2177,Asian,487.0,24172245.0,Haga S,Digestive system disorder,initial,2013-10-31,GCST002258,Tooth agenesis (mandibular third molar)
10135,European,14188.0,24204295.0,Han F,Neurological disorder,replication,2013-10-31,GCST002260,Narcolepsy
11152,European,41505.0,24076602.0,Beecham AH,Immune system disorder,replication,2013-11-01,GCST005531,Multiple sclerosis
11096,European,38582.0,24076602.0,Beecham AH,Immune system disorder,initial,2013-11-01,GCST005531,Multiple sclerosis
4963,European,236.0,24236485.0,Cornejo-Garcia JA,"Other disease, Cardiovascular disease, Response to drug",initial,2013-11-01,GCST002263,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)
7354,European,2370.0,24097067.0,Lessard CJ,Neurological disorder,initial,2013-11-01,GCST004878,Sjgren's syndrome
8299,European,4229.0,24097067.0,Lessard CJ,Neurological disorder,replication,2013-11-01,GCST004879,Sjgren's syndrome
8281,European,4175.0,24097067.0,Lessard CJ,Neurological disorder,initial,2013-11-01,GCST005532,Sjgren's syndrome
7355,European,2370.0,24097067.0,Lessard CJ,Neurological disorder,initial,2013-11-01,GCST004879,Sjgren's syndrome
1698,Asian,79.0,24192120.0,Kamide K,"Other measurement, Response to drug",replication,2013-11-01,GCST002262,Blood pressure (response to antihypertensive medication)
1945,Asian,265.0,24192120.0,Kamide K,"Other measurement, Response to drug",initial,2013-11-01,GCST002262,Blood pressure (response to antihypertensive medication)
1886,Asian,221.0,24236485.0,Cornejo-Garcia JA,"Other disease, Cardiovascular disease, Response to drug",initial,2013-11-01,GCST002263,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)
8890,European,6022.0,24097067.0,Lessard CJ,Neurological disorder,replication,2013-11-01,GCST004878,Sjgren's syndrome
1431,African American or Afro-Caribbean,10068.0,24185611.0,Cook MB,Cancer,replication,2013-11-02,GCST002264,Prostate cancer
154,African,932.0,24185611.0,Cook MB,Cancer,initial,2013-11-02,GCST002264,Prostate cancer
7688,European,2920.0,24080446.0,Rudolph A,"Cancer, Other trait",initial,2013-11-04,GCST002265,Breast cancer (menopausal hormone therapy interaction)
5488,European,541.0,24080446.0,Rudolph A,"Cancer, Other trait",initial,2013-11-04,GCST002266,Lobular breast cancer (menopausal hormone therapy interaction)
10328,European,16955.0,24080446.0,Rudolph A,"Cancer, Other trait",replication,2013-11-04,GCST002265,Breast cancer (menopausal hormone therapy interaction)
9749,European,9942.0,24080446.0,Rudolph A,"Cancer, Other trait",replication,2013-11-04,GCST002266,Lobular breast cancer (menopausal hormone therapy interaction)
6067,European,943.0,24190013.0,Earp MA,Cancer,initial,2013-11-05,GCST002267,Epithelial ovarian cancer
10967,European,33689.0,24190013.0,Earp MA,Cancer,replication,2013-11-05,GCST002267,Epithelial ovarian cancer
2966,Asian,1945.0,24189344.0,Xia K,Neurological disorder,initial,2013-11-05,GCST002268,Autism
8174,European,3897.0,24189344.0,Xia K,Neurological disorder,replication,2013-11-05,GCST002268,Autism
6146,European,987.0,24223155.0,Behr ER,"Biological process, Cardiovascular disease",initial,2013-11-06,GCST002269,Drug-induced torsades de pointes
3364,Asian,3427.0,24244560.0,Chen P,Other measurement,initial,2013-11-07,GCST002270,Glycated hemoglobin levels
2744,Asian,1529.0,24244560.0,Chen P,Other measurement,initial,2013-11-07,GCST002270,Glycated hemoglobin levels
2829,Asian,1735.0,24244560.0,Chen P,Other measurement,initial,2013-11-07,GCST002270,Glycated hemoglobin levels
2189,Asian,505.0,24265751.0,Li W,Neurological disorder,replication,2013-11-12,GCST002271,Delayed encephalopathy in acute carbon monoxide poisoning
738,African American or Afro-Caribbean,630.0,24220910.0,Purdue MP,Cancer,initial,2013-11-12,GCST002272,Renal cell carcinoma
2099,Asian,419.0,24265751.0,Li W,Neurological disorder,initial,2013-11-12,GCST002271,Delayed encephalopathy in acute carbon monoxide poisoning
745,African American or Afro-Caribbean,683.0,24220910.0,Purdue MP,Cancer,replication,2013-11-12,GCST002272,Renal cell carcinoma
8445,European,4678.0,24220699.0,Gudmundsson J,Cancer,replication,2013-11-13,GCST002273,Renal cell carcinoma
11491,European,69230.0,24220699.0,Gudmundsson J,Cancer,initial,2013-11-13,GCST002273,Renal cell carcinoma
8097,European,3684.0,24241537.0,Bonnelykke K,"Other disease, Other measurement",initial,2013-11-17,GCST002275,Asthma (childhood onset)
3598,Asian,5139.0,24249740.0,Zhang L,Other measurement,replication,2013-11-17,GCST002276,Bone mineral density
9837,European,10732.0,24249740.0,Zhang L,Other measurement,replication,2013-11-17,GCST002276,Bone mineral density
759,African American or Afro-Caribbean,712.0,24249740.0,Zhang L,Other measurement,initial,2013-11-17,GCST002276,Bone mineral density
2749,Asian,1547.0,24249740.0,Zhang L,Other measurement,initial,2013-11-17,GCST002276,Bone mineral density
12856,Hispanic or Latin American,409.0,24249740.0,Zhang L,Other measurement,initial,2013-11-17,GCST002276,Bone mineral density
7754,European,3058.0,24241537.0,Bonnelykke K,"Other disease, Other measurement",replication,2013-11-17,GCST002275,Asthma (childhood onset)
9494,European,8472.0,24249740.0,Zhang L,Other measurement,initial,2013-11-17,GCST002276,Bone mineral density
975,African American or Afro-Caribbean,1875.0,24253340.0,Lencz T,Neurological disorder,replication,2013-11-19,GCST002277,Schizophrenia
2533,Asian,1080.0,24253340.0,Lencz T,Neurological disorder,replication,2013-11-19,GCST002277,Schizophrenia
7486,European,2544.0,24253340.0,Lencz T,Neurological disorder,initial,2013-11-19,GCST002277,Schizophrenia
9121,European,6993.0,24253340.0,Lencz T,Neurological disorder,replication,2013-11-19,GCST002277,Schizophrenia
8427,European,4630.0,24256812.0,Fogh I,Neurological disorder,replication,2013-11-20,GCST002283,Amyotrophic lateral sclerosis (sporadic)
10044,European,13225.0,24256812.0,Fogh I,Neurological disorder,initial,2013-11-20,GCST002283,Amyotrophic lateral sclerosis (sporadic)
12911,Hispanic or Latin American,580.0,24324551.0,Deng X,"Other measurement, Cardiovascular measurement",initial,2013-11-20,GCST002284,QRS duration in Tripanosoma cruzi seropositivity
12910,Hispanic or Latin American,580.0,24324551.0,Deng X,"Other measurement, Cardiovascular measurement",initial,2013-11-20,GCST002279,PR interval in Tripanosoma cruzi seropositivity
12906,Hispanic or Latin American,580.0,24324551.0,Deng X,"Cardiovascular measurement, Other measurement",initial,2013-11-20,GCST002278,QT interval in Tripanosoma cruzi seropositivity
12909,Hispanic or Latin American,580.0,24324551.0,Deng X,Other measurement,initial,2013-11-20,GCST002282,Parasitemia in Tripanosoma cruzi seropositivity
12908,Hispanic or Latin American,580.0,24324551.0,Deng X,Other measurement,initial,2013-11-20,GCST002280,Antibody status in Tripanosoma cruzi seropositivity
12907,Hispanic or Latin American,580.0,24324551.0,Deng X,"Cardiovascular measurement, Other measurement",initial,2013-11-20,GCST002281,Ejection fraction in Tripanosoma cruzi seropositivity
12895,Hispanic or Latin American,513.0,24324551.0,Deng X,"Cardiovascular disease, Other measurement",initial,2013-11-20,GCST002285,Chagas cardiomyopathy in Tripanosoma cruzi seropositivity
4948,European,227.0,24280104.0,Wu AC,"Response to drug, Other disease",replication,2013-11-23,GCST002291,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)
5539,European,581.0,24280104.0,Wu AC,"Response to drug, Other disease",initial,2013-11-23,GCST002291,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)
1994,Asian,314.0,24277619.0,Quillen EE,"Other measurement, Neurological disorder",initial,2013-11-26,GCST002293,Alcohol dependence
1963,Asian,272.0,24277619.0,Quillen EE,"Biological process, Other measurement",initial,2013-11-26,GCST002294,Alcohol consumption (max-drinks)
10666,European,23527.0,24280982.0,Ruderfer DM,Neurological disorder,initial,2013-11-26,GCST002295,Schizophrenia or bipolar disorder
1982,Asian,298.0,24277619.0,Quillen EE,Biological process,initial,2013-11-26,GCST002292,Response to alcohol consumption (flushing response)
1838,Asian,185.0,24282030.0,Pan L,Response to drug,initial,2013-11-28,GCST002297,Hepatitis B vaccine response
2849,Asian,1756.0,24282030.0,Pan L,Response to drug,replication,2013-11-28,GCST002297,Hepatitis B vaccine response
2695,Asian,1467.0,23918589.0,Negi S,Immune system disorder,initial,2013-12-01,GCST002300,Rheumatoid arthritis
8324,European,4295.0,24292274.0,Speedy HE,Cancer,replication,2013-12-01,GCST002299,Chronic lymphocytic leukemia
3017,Asian,2075.0,23918589.0,Negi S,Immune system disorder,replication,2013-12-01,GCST002300,Rheumatoid arthritis
9113,European,6938.0,24292274.0,Speedy HE,Cancer,initial,2013-12-01,GCST002299,Chronic lymphocytic leukemia
4740,European,94.0,24778558.0,Domarkiene I,Cardiovascular disease,initial,2013-12-01,GCST002298,Coronary heart disease
7663,European,2860.0,24348519.0,Namjou B,"Body measurement, Other measurement",initial,2013-12-03,GCST002301,Body mass index
8249,European,4088.0,24405752.0,An P,Other measurement,initial,2013-12-04,GCST002303,Glycated hemoglobin levels
3163,Asian,2474.0,24324648.0,Yatagai Y,Other measurement,replication,2013-12-04,GCST002302,IgE levels
2576,Asian,1180.0,24324648.0,Yatagai Y,Other measurement,initial,2013-12-04,GCST002302,IgE levels
11243,European,47822.0,24405752.0,An P,Other measurement,replication,2013-12-04,GCST002303,Glycated hemoglobin levels
8650,European,5131.0,24315451.0,van der Valk RJ,Other measurement,initial,2013-12-05,GCST002304,Fractional exhaled nitric oxide (childhood)
13033,Hispanic or Latin American,1155.0,24315451.0,van der Valk RJ,Other measurement,initial,2013-12-05,GCST002304,Fractional exhaled nitric oxide (childhood)
14171,Other/Mixed,2572.0,24315451.0,van der Valk RJ,Other measurement,initial,2013-12-05,GCST002304,Fractional exhaled nitric oxide (childhood)
8552,European,4928.0,24325915.0,Purrington KS,Cancer,initial,2013-12-09,GCST002305,"Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)"
7999,European,3457.0,24325915.0,Purrington KS,Cancer,replication,2013-12-09,GCST002305,"Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)"
3638,Asian,5408.0,24325914.0,Chu M,Cancer,initial,2013-12-09,GCST006866,Lung cancer (SNP x SNP interaction)
3942,Asian,7984.0,24325914.0,Chu M,Cancer,replication,2013-12-09,GCST006866,Lung cancer (SNP x SNP interaction)
6588,European,1408.0,24322204.0,Winham SJ,"Body measurement, Neurological disorder",initial,2013-12-10,GCST002306,Bipolar disorder (body mass index interaction)
9096,European,6882.0,24376456.0,Simino J,"Biological process, Other measurement",initial,2013-12-12,GCST002307,Systolic blood pressure (alcohol consumption interaction)
9095,European,6882.0,24376456.0,Simino J,"Biological process, Cardiovascular measurement",initial,2013-12-12,GCST002310,Pulse pressure (alcohol consumption interaction)
9098,European,6882.0,24376456.0,Simino J,"Biological process, Other measurement",initial,2013-12-12,GCST002309,Diastolic blood pressure (alcohol consumption interaction)
9097,European,6882.0,24376456.0,Simino J,"Biological process, Other measurement",initial,2013-12-12,GCST002308,Mean arterial pressure (alcohol consumption interaction)
12930,Hispanic or Latin American,632.0,24379826.0,Voruganti VS,Cardiovascular measurement,initial,2013-12-16,GCST002311,Serum uric acid levels
5685,European,673.0,24347629.0,Shaffer JR,"Other measurement, Digestive system disorder",initial,2013-12-17,GCST002312,Periodontal disease-related phenotype (Socransky)
2232,Asian,577.0,24351856.0,Nanayakkara S,"Other disease, Other measurement",initial,2013-12-18,GCST002313,Chronic kidney disease
2233,Asian,577.0,24351856.0,Nanayakkara S,Other measurement,initial,2013-12-18,GCST002314,Glomerular filtration rate
7033,European,1967.0,24357727.0,Rocanin-Arjo A,Other measurement,initial,2013-12-19,GCST002315,Thrombin generation potential phenotypes
6457,European,1257.0,24357727.0,Rocanin-Arjo A,Other measurement,replication,2013-12-19,GCST002315,Thrombin generation potential phenotypes
3366,Asian,3444.0,24376798.0,Miki D,Digestive system disorder,initial,2013-12-20,GCST002316,Chronic hepatitis C infection
4448,Asian,32668.0,24376798.0,Miki D,Digestive system disorder,replication,2013-12-20,GCST002316,Chronic hepatitis C infection
2225,Asian,562.0,24376627.0,Su WH,Cancer,initial,2013-12-23,GCST006524,Nasopharyngeal carcinoma (SNP x SNP interaction)
2047,Asian,368.0,24376627.0,Su WH,Cancer,replication,2013-12-23,GCST006524,Nasopharyngeal carcinoma (SNP x SNP interaction)
4236,Asian,13263.0,24390342.0,Okada Y,Immune system disorder,replication,2013-12-25,GCST002318,Rheumatoid arthritis
7817,European,3207.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
13092,Hispanic or Latin American,1728.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
11385,European,58284.0,24390342.0,Okada Y,Immune system disorder,initial,2013-12-25,GCST002318,Rheumatoid arthritis
4383,Asian,22515.0,24390342.0,Okada Y,Immune system disorder,initial,2013-12-25,GCST002318,Rheumatoid arthritis
3445,Asian,3968.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
13392,Hispanic or Latin American,8214.0,24390345.0,Williams AL,Metabolic disorder,initial,2013-12-25,GCST002317,Type 2 diabetes
3693,Asian,5648.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
1238,African American or Afro-Caribbean,4230.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
9665,European,9576.0,24390342.0,Okada Y,Immune system disorder,replication,2013-12-25,GCST002318,Rheumatoid arthritis
3075,Asian,2187.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
14099,Other/Mixed,1277.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
6295,European,1111.0,24375517.0,Lohmann K,Neurological disorder,initial,2013-12-26,GCST002319,Musician's dystonia
805,African American or Afro-Caribbean,890.0,24468470.0,Zhang C,Other trait,initial,2013-12-26,GCST002320,Cognitive decline (age-related)
4969,European,241.0,24375517.0,Lohmann K,Neurological disorder,replication,2013-12-26,GCST002319,Musician's dystonia
8823,European,5765.0,24468470.0,Zhang C,Other trait,initial,2013-12-26,GCST002320,Cognitive decline (age-related)
3369,Asian,3451.0,24386095.0,Zhou L,"Lipid or lipoprotein measurement, Other measurement",initial,2013-12-30,GCST002321,Lipid traits
4008,Asian,8830.0,24386095.0,Zhou L,"Lipid or lipoprotein measurement, Other measurement",replication,2013-12-30,GCST002321,Lipid traits
10544,European,20776.0,24388013.0,Ferreira MA,"Other disease, Immune system disorder",initial,2013-12-30,GCST002322,Asthma and hay fever
7923,European,3333.0,24388013.0,Ferreira MA,"Other disease, Immune system disorder",replication,2013-12-30,GCST002322,Asthma and hay fever
777,African American or Afro-Caribbean,801.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",replication,2014-01-01,GCST004711,Alcohol dependence
8649,European,5131.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",initial,2014-01-01,GCST004711,Alcohol dependence
9392,European,8305.0,24449572.0,Orozco G,Immune system disorder,initial,2014-01-01,GCST002323,Rheumatoid arthritis
740,African American or Afro-Caribbean,651.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",replication,2014-01-01,GCST004712,Alcohol dependence
9195,European,7351.0,24449572.0,Orozco G,Immune system disorder,replication,2014-01-01,GCST002323,Rheumatoid arthritis
8678,European,5244.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",replication,2014-01-01,GCST004712,Alcohol dependence
1258,African American or Afro-Caribbean,4629.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",initial,2014-01-01,GCST004711,Alcohol dependence
8442,European,4671.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",initial,2014-01-01,GCST004712,Alcohol dependence
6870,European,1746.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",replication,2014-01-01,GCST004711,Alcohol dependence
9543,European,8747.0,24489884.0,Mick E,Biological process,initial,2014-01-01,GCST002324,Anger
1237,African American or Afro-Caribbean,4213.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",initial,2014-01-01,GCST004712,Alcohol dependence
8891,European,6023.0,24383474.0,Manichaikul A,Other disease,replication,2014-01-02,GCST002326,Pulmonary emphysema
2315,Asian,704.0,24383474.0,Manichaikul A,Other disease,initial,2014-01-02,GCST002326,Pulmonary emphysema
1056,African American or Afro-Caribbean,2510.0,24383474.0,Manichaikul A,Other disease,initial,2014-01-02,GCST002326,Pulmonary emphysema
7514,European,2587.0,24383474.0,Manichaikul A,Other disease,initial,2014-01-02,GCST002326,Pulmonary emphysema
8235,European,4040.0,24387989.0,Mayes MD,Neurological disorder,initial,2014-01-02,GCST005535,Diffuse cutaneous systemic sclerosis
9485,European,8442.0,24387989.0,Mayes MD,Neurological disorder,replication,2014-01-02,GCST005533,Limited cutaneous systemic scleroderma
8709,European,5299.0,24387989.0,Mayes MD,Neurological disorder,initial,2014-01-02,GCST005534,Systemic sclerosis
6445,European,1241.0,24392092.0,Luksys G,Other measurement,initial,2014-01-02,GCST002325,Memory performance
8414,European,4593.0,24387989.0,Mayes MD,Neurological disorder,initial,2014-01-02,GCST005533,Limited cutaneous systemic scleroderma
13112,Hispanic or Latin American,2113.0,24383474.0,Manichaikul A,Other disease,initial,2014-01-02,GCST002326,Pulmonary emphysema
9751,European,9952.0,24387989.0,Mayes MD,Neurological disorder,replication,2014-01-02,GCST005534,Systemic sclerosis
9156,European,7152.0,24387989.0,Mayes MD,Neurological disorder,replication,2014-01-02,GCST005535,Diffuse cutaneous systemic sclerosis
6920,European,1815.0,24387768.0,Xu W,Neurological disorder,initial,2014-01-04,GCST002327,Bipolar disorder
3767,Asian,6223.0,24387323.0,Kim WJ,Other measurement,initial,2014-01-06,GCST002328,Lung function
3220,Asian,2720.0,24387323.0,Kim WJ,Other measurement,replication,2014-01-06,GCST002328,Lung function
13214,Hispanic or Latin American,3774.0,24406073.0,Galanter JM,Other disease,initial,2014-01-07,GCST002330,Asthma
3013,Asian,2062.0,24399259.0,He L,Other disease,initial,2014-01-07,GCST002329,Acne (severe)
3654,Asian,5520.0,24399259.0,He L,Other disease,replication,2014-01-07,GCST002329,Acne (severe)
11827,European,113616.0,24403052.0,Stacey SN,Cancer,initial,2014-01-08,GCST002331,Basal cell carcinoma
8904,European,6090.0,24403052.0,Stacey SN,Cancer,replication,2014-01-08,GCST002331,Basal cell carcinoma
2394,Asian,800.0,24413707.0,Chiang KM,Cardiovascular disease,initial,2014-01-11,GCST002332,Hypertension (young onset)
2711,Asian,1499.0,24413707.0,Chiang KM,Cardiovascular disease,replication,2014-01-11,GCST002332,Hypertension (young onset)
8597,European,5003.0,24413707.0,Chiang KM,Cardiovascular disease,replication,2014-01-11,GCST002332,Hypertension (young onset)
7364,European,2380.0,24430505.0,Moayyeri A,Other measurement,initial,2014-01-14,GCST002335,Bone properties (heel)
9760,European,10074.0,24430505.0,Moayyeri A,Other measurement,replication,2014-01-14,GCST002333,Bone properties (heel)
2329,Asian,730.0,24430505.0,Moayyeri A,Other measurement,initial,2014-01-14,GCST002335,Bone properties (heel)
8404,European,4556.0,24430505.0,Moayyeri A,Other measurement,initial,2014-01-14,GCST002334,Bone properties (heel)
6971,European,1885.0,24430505.0,Moayyeri A,Other measurement,initial,2014-01-14,GCST002333,Bone properties (heel)
3168,Asian,2483.0,24430505.0,Moayyeri A,Other measurement,initial,2014-01-14,GCST002333,Bone properties (heel)
9873,European,11058.0,24430505.0,Moayyeri A,Other measurement,replication,2014-01-14,GCST002335,Bone properties (heel)
7256,European,2236.0,24430505.0,Moayyeri A,Other measurement,replication,2014-01-14,GCST002334,Bone properties (heel)
2181,Asian,500.0,24529757.0,Xie T,Neurological disorder,initial,2014-01-17,GCST002337,Amyotrophic lateral sclerosis (sporadic)
8498,European,4829.0,24478790.0,Lee JH,Other measurement,initial,2014-01-17,GCST002336,Telomere length
2361,Asian,772.0,24444492.0,Kuo PH,Neurological disorder,replication,2014-01-18,GCST002338,Bipolar I disorder
2084,Asian,400.0,24444492.0,Kuo PH,Neurological disorder,initial,2014-01-18,GCST002338,Bipolar I disorder
1858,Asian,200.0,24465431.0,Ma RC,Metabolic disorder,initial,2014-01-20,GCST002339,Type 2 diabetes (young onset) and obesity
3438,Asian,3917.0,24465473.0,Liu Y,Other measurement,replication,2014-01-21,GCST002341,Telomere length
3502,Asian,4415.0,24448986.0,Zhang B,Cancer,initial,2014-01-21,GCST002340,Colorectal cancer
4275,Asian,14764.0,24448986.0,Zhang B,Cancer,replication,2014-01-21,GCST002340,Colorectal cancer
3207,Asian,2632.0,24465473.0,Liu Y,Other measurement,initial,2014-01-21,GCST002341,Telomere length
5705,European,696.0,24465473.0,Liu Y,Other measurement,replication,2014-01-21,GCST002341,Telomere length
4779,European,124.0,24486069.0,Park HW,"Response to drug, Other disease",initial,2014-01-31,GCST002342,Asthma (corticosteroid response)
5041,European,297.0,24486069.0,Park HW,"Response to drug, Other disease",replication,2014-01-31,GCST002342,Asthma (corticosteroid response)
4674,European,60.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002345,Response to cytadine analogues (cytosine arabinoside)
4673,European,60.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002343,Response to cytidine analogues (gemcitabine)
11161,European,42208.0,24507774.0,Peloso GM,Lipid or lipoprotein measurement,initial,2014-02-01,GCST007849,Triglycerides
459,African American or Afro-Caribbean,54.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002343,Response to cytidine analogues (gemcitabine)
460,African American or Afro-Caribbean,54.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002345,Response to cytadine analogues (cytosine arabinoside)
11162,European,42208.0,24507774.0,Peloso GM,Lipid or lipoprotein measurement,initial,2014-02-01,GCST007850,HDL cholesterol
1674,Asian,60.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002343,Response to cytidine analogues (gemcitabine)
359,African,14330.0,24507774.0,Peloso GM,Lipid or lipoprotein measurement,initial,2014-02-01,GCST007849,Triglycerides
11163,European,42208.0,24507774.0,Peloso GM,"Lipid or lipoprotein measurement, Other measurement",initial,2014-02-01,GCST007848,LDL cholesterol
7329,European,2329.0,24687471.0,Harlaar N,Biological process,initial,2014-02-01,GCST002344,Receptive language ability
1675,Asian,60.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002345,Response to cytadine analogues (cytosine arabinoside)
8526,European,4896.0,24342994.0,Lencz T,Biological process,initial,2014-02-01,GCST006523,General cognitive ability
7543,European,2639.0,24687471.0,Harlaar N,Biological process,replication,2014-02-01,GCST002344,Receptive language ability
360,African,14330.0,24507774.0,Peloso GM,Lipid or lipoprotein measurement,initial,2014-02-01,GCST007850,HDL cholesterol
361,African,14330.0,24507774.0,Peloso GM,"Lipid or lipoprotein measurement, Other measurement",initial,2014-02-01,GCST007848,LDL cholesterol
8935,European,6225.0,24493630.0,Ahsan H,Cancer,initial,2014-02-03,GCST002346,Breast cancer (early onset)
9572,European,8945.0,24493630.0,Ahsan H,Cancer,replication,2014-02-03,GCST002346,Breast cancer (early onset)
13721,Other/Mixed,57.0,24516586.0,Wu T,"Other trait, Other measurement",initial,2014-02-06,GCST002348,Cleft plate (environmental tobacco smoke interaction)
2382,Asian,777.0,24516586.0,Wu T,"Other trait, Other measurement",initial,2014-02-06,GCST002348,Cleft plate (environmental tobacco smoke interaction)
5869,European,816.0,24516586.0,Wu T,"Other trait, Other measurement",initial,2014-02-06,GCST002348,Cleft plate (environmental tobacco smoke interaction)
4848,European,176.0,24503447.0,Nelson D,"Response to drug, Other measurement, Digestive system disorder",initial,2014-02-06,GCST002349,Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels)
4847,European,176.0,24503447.0,Nelson D,"Response to drug, Other measurement, Digestive system disorder",initial,2014-02-06,GCST002347,Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity)
1059,African American or Afro-Caribbean,2570.0,24621683.0,Cho MH,Other disease,initial,2014-02-07,GCST002351,Chronic obstructive pulmonary disease (moderate to severe)
9147,European,7100.0,24621683.0,Cho MH,Other disease,initial,2014-02-07,GCST002350,Chronic obstructive pulmonary disease (severe)
9699,European,9767.0,24621683.0,Cho MH,Other disease,initial,2014-02-07,GCST002351,Chronic obstructive pulmonary disease (moderate to severe)
1058,African American or Afro-Caribbean,2570.0,24621683.0,Cho MH,Other disease,initial,2014-02-07,GCST002350,Chronic obstructive pulmonary disease (severe)
4361,Asian,20019.0,24509480.0,Mahajan A,Metabolic disorder,initial,2014-02-09,GCST002352,Type 2 diabetes
11559,European,77138.0,24509480.0,Mahajan A,Metabolic disorder,replication,2014-02-09,GCST002352,Type 2 diabetes
13151,Hispanic or Latin American,2583.0,24509480.0,Mahajan A,Metabolic disorder,initial,2014-02-09,GCST002352,Type 2 diabetes
4339,Asian,18817.0,24509480.0,Mahajan A,Metabolic disorder,initial,2014-02-09,GCST002352,Type 2 diabetes
11488,European,69033.0,24509480.0,Mahajan A,Metabolic disorder,initial,2014-02-09,GCST002352,Type 2 diabetes
7750,European,3031.0,24511991.0,Hill-Burns EM,Neurological disorder,replication,2014-02-10,GCST002353,Parkinson's disease
8213,European,3986.0,24511991.0,Hill-Burns EM,Neurological disorder,initial,2014-02-10,GCST002353,Parkinson's disease
2439,Asian,879.0,24514567.0,Boraska V,Metabolic disorder,replication,2014-02-11,GCST002354,Anorexia nervosa
10384,European,17767.0,24514567.0,Boraska V,Metabolic disorder,initial,2014-02-11,GCST002354,Anorexia nervosa
3370,Asian,3451.0,24513273.0,Yang B,Cardiovascular measurement,initial,2014-02-11,GCST002355,Serum uric acid levels
4009,Asian,8830.0,24513273.0,Yang B,Cardiovascular measurement,replication,2014-02-11,GCST002355,Serum uric acid levels
7618,European,2774.0,24518671.0,Nag A,Other measurement,initial,2014-02-11,GCST002356,Intraocular pressure
9897,European,11306.0,24514567.0,Boraska V,Metabolic disorder,replication,2014-02-11,GCST002354,Anorexia nervosa
10650,European,22789.0,24518671.0,Nag A,Other measurement,replication,2014-02-11,GCST002356,Intraocular pressure
4059,Asian,9299.0,24532676.0,Kim K,Immune system disorder,initial,2014-02-14,GCST006048,Rheumatoid arthritis (ACPA-positive)
6946,European,1853.0,24532677.0,Bossini-Castillo L,Immune system disorder,replication,2014-02-14,GCST002357,Rheumatoid arthritis (ACPA-negative)
9159,European,7156.0,24532677.0,Bossini-Castillo L,Immune system disorder,initial,2014-02-14,GCST002357,Rheumatoid arthritis (ACPA-negative)
11205,European,45790.0,24532676.0,Kim K,Immune system disorder,initial,2014-02-14,GCST006048,Rheumatoid arthritis (ACPA-positive)
8037,European,3528.0,24535457.0,Chouraki V,Other measurement,initial,2014-02-18,GCST002360,Plasma amyloid beta peptide concentrations (ABx-40)
6127,European,979.0,24556642.0,Zeng Z,Digestive system disorder,initial,2014-02-18,GCST002358,Pit-and-Fissure caries
6198,European,1006.0,24556642.0,Zeng Z,Digestive system disorder,initial,2014-02-18,GCST002361,Smooth-surface caries
8036,European,3528.0,24535457.0,Chouraki V,Other measurement,initial,2014-02-18,GCST002359,Plasma amyloid beta peptide concentrations (ABx-42)
7779,European,3121.0,24839885.0,Benke KS,Other measurement,initial,2014-02-19,GCST002362,Preschool internalizing problems
12751,Hispanic or Latin American,39.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002365,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)
465,African American or Afro-Caribbean,61.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002363,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)
488,African American or Afro-Caribbean,86.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002366,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)
13953,Other/Mixed,601.0,24586186.0,Rueedi R,Other measurement,replication,2014-02-20,GCST002364,Urinary metabolites (H-NMR features)
482,African American or Afro-Caribbean,79.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002365,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)
12754,Hispanic or Latin American,43.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002366,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)
12745,Hispanic or Latin American,33.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002363,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)
4766,European,104.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002365,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)
4782,European,125.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002366,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)
4737,European,93.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002363,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)
5906,European,835.0,24586186.0,Rueedi R,Other measurement,initial,2014-02-20,GCST002364,Urinary metabolites (H-NMR features)
8789,European,5628.0,24564958.0,St Pourcain B,Other measurement,initial,2014-02-24,GCST002367,Social communication problems
5426,European,508.0,24574247.0,Yuan H,"Neurological disorder, Other measurement",initial,2014-02-25,GCST002368,Maternal genotype effects in autism spectrum disorder families
5592,European,609.0,24571439.0,Nudel R,Neurological disorder,initial,2014-02-26,GCST002369,Parent of origin effect on language impairment (maternal)
6676,European,1541.0,24582949.0,Docampo E,Immune system disorder,replication,2014-02-26,GCST002370,Fibromyalgia
5420,European,506.0,24571439.0,Nudel R,Neurological disorder,replication,2014-02-26,GCST002369,Parent of origin effect on language impairment (maternal)
5415,European,503.0,24582949.0,Docampo E,Immune system disorder,initial,2014-02-26,GCST002370,Fibromyalgia
9903,European,11388.0,24569950.0,Hatemi PK,Other trait,initial,2014-02-26,GCST002372,Political ideology
5593,European,609.0,24571439.0,Nudel R,Neurological disorder,initial,2014-02-26,GCST002371,Parent of origin effect on language impairment (paternal)
10412,European,18297.0,24586183.0,Medici M,Other measurement,initial,2014-02-27,GCST002378,Thyroid peroxidase antibody positivity
9580,European,8990.0,24586183.0,Medici M,Other measurement,replication,2014-02-27,GCST002378,Thyroid peroxidase antibody positivity
8383,European,4487.0,24578379.0,Huang J,Cardiovascular measurement,replication,2014-02-27,GCST002374,Plasma plasminogen activator levels
2112,Asian,438.0,24583629.0,Senapati S,"Immune system disorder, Response to drug",initial,2014-02-27,GCST002375,Response to methotrexate in rheumatoid arthritis
10784,European,26929.0,24578379.0,Huang J,Cardiovascular measurement,initial,2014-02-27,GCST002374,Plasma plasminogen activator levels
9364,European,8159.0,24586183.0,Medici M,Other measurement,replication,2014-02-27,GCST002373,Thyroid peroxidase antibody levels
9858,European,10884.0,24578125.0,Olden M,Other measurement,initial,2014-02-27,GCST002376,Urinary uromodulin levels
5326,European,466.0,24578207.0,Opherk C,"Cardiovascular disease, Other measurement",initial,2014-02-27,GCST002377,White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy
9992,European,12353.0,24586183.0,Medici M,Other measurement,initial,2014-02-27,GCST002373,Thyroid peroxidase antibody levels
8819,European,5756.0,24487271.0,Weizman A,"Digestive system disorder, Other trait",initial,2014-03-01,GCST002379,Pyoderma gangrenosum in inflammatory bowel disease
8820,European,5756.0,24487271.0,Weizman A,"Digestive system disorder, Other trait",initial,2014-03-01,GCST002380,Erythema nodosum in inflammatory bowel disease
2220,Asian,559.0,24123702.0,Chung CM,Other measurement,replication,2014-03-03,GCST002381,Resistin levels
2066,Asian,382.0,24123702.0,Chung CM,Other measurement,initial,2014-03-03,GCST002381,Resistin levels
6987,European,1925.0,24595857.0,Sandholm N,"Other measurement, Metabolic disorder",initial,2014-03-05,GCST002382,Urinary albumin excretion rate in type 1 diabetes
8122,European,3750.0,24595857.0,Sandholm N,"Other measurement, Metabolic disorder",replication,2014-03-05,GCST002382,Urinary albumin excretion rate in type 1 diabetes
2919,Asian,1860.0,24603532.0,Nongpiur ME,Other measurement,initial,2014-03-06,GCST002383,Anterior chamber depth
2431,Asian,872.0,24603532.0,Nongpiur ME,Other measurement,initial,2014-03-06,GCST002383,Anterior chamber depth
2408,Asian,824.0,24603532.0,Nongpiur ME,Other measurement,replication,2014-03-06,GCST002383,Anterior chamber depth
2848,Asian,1752.0,24603532.0,Nongpiur ME,Other measurement,initial,2014-03-06,GCST002383,Anterior chamber depth
7910,European,3313.0,24604477.0,An P,Lipid or lipoprotein measurement,replication,2014-03-07,GCST002384,NHDL cholesterol
6032,European,928.0,24604477.0,An P,Lipid or lipoprotein measurement,initial,2014-03-07,GCST002384,NHDL cholesterol
5811,European,767.0,24614497.0,Oikkonen J,Biological process,initial,2014-03-11,GCST002387,Musical aptitude
10697,European,24025.0,24618891.0,Muhleisen TW,Neurological disorder,initial,2014-03-11,GCST002385,Bipolar disorder
892,African American or Afro-Caribbean,1260.0,24625756.0,Yu B,Other measurement,initial,2014-03-13,GCST002388,Serum metabolite levels
7113,European,2065.0,24656865.0,Woo D,Cardiovascular disease,replication,2014-03-18,GCST002389,Intracerebral hemorrhage
12981,Hispanic or Latin American,794.0,24656865.0,Woo D,Cardiovascular disease,replication,2014-03-18,GCST002389,Intracerebral hemorrhage
7747,European,3026.0,24656865.0,Woo D,Cardiovascular disease,initial,2014-03-18,GCST002389,Intracerebral hemorrhage
848,African American or Afro-Caribbean,1083.0,24656865.0,Woo D,Cardiovascular disease,replication,2014-03-18,GCST002389,Intracerebral hemorrhage
4245,Asian,13585.0,24647736.0,Chen P,Other measurement,replication,2014-03-19,GCST002390,Glycated hemoglobin levels
4321,Asian,17290.0,24647736.0,Chen P,Other measurement,initial,2014-03-19,GCST002390,Glycated hemoglobin levels
2824,Asian,1727.0,24647736.0,Chen P,Other measurement,initial,2014-03-19,GCST002390,Glycated hemoglobin levels
74,African,258.0,24651765.0,Williams SR,Cardiovascular measurement,initial,2014-03-20,GCST002391,Plasma homocysteine levels (post-methionine load test)
6845,European,1725.0,24651765.0,Williams SR,Cardiovascular measurement,initial,2014-03-20,GCST002391,Plasma homocysteine levels (post-methionine load test)
13759,Other/Mixed,117.0,24651765.0,Williams SR,Cardiovascular measurement,initial,2014-03-20,GCST002391,Plasma homocysteine levels (post-methionine load test)
3639,Asian,5408.0,24658283.0,Zhang R,"Other measurement, Cancer",initial,2014-03-22,GCST002392,Lung cancer (smoking interaction)
3310,Asian,3023.0,24658283.0,Zhang R,"Other measurement, Cancer",replication,2014-03-22,GCST002392,Lung cancer (smoking interaction)
9213,European,7413.0,24662972.0,Figueroa JD,Cancer,initial,2014-03-24,GCST002397,Bladder cancer (smoking interaction)
3007,Asian,2035.0,24665060.0,Argos M,Other measurement,initial,2014-03-24,GCST002393,Smoking quantity
9366,European,8168.0,24662972.0,Figueroa JD,Cancer,replication,2014-03-24,GCST002397,Bladder cancer (smoking interaction)
3006,Asian,2035.0,24665060.0,Argos M,"Biological process, Other measurement",initial,2014-03-24,GCST002394,Age of smoking initiation
3005,Asian,2035.0,24665060.0,Argos M,Biological process,initial,2014-03-24,GCST002395,Smoking cessation
3629,Asian,5354.0,24665060.0,Argos M,Biological process,initial,2014-03-24,GCST002396,Smoking initiation
5938,European,855.0,24680774.0,Mezzavilla M,Cardiovascular measurement,initial,2014-03-25,GCST002398,Resting heart rate
5752,European,733.0,24667120.0,Zhang TX,Other disease,replication,2014-03-25,GCST002399,Clubfoot
6577,European,1396.0,24667120.0,Zhang TX,Other disease,initial,2014-03-25,GCST002399,Clubfoot
7034,European,1973.0,24675659.0,Hartiala J,Other measurement,initial,2014-03-27,GCST002400,Plasma trimethylamine N-oxide levels
6977,European,1892.0,24675659.0,Hartiala J,Other measurement,replication,2014-03-27,GCST002400,Plasma trimethylamine N-oxide levels
9672,European,9617.0,24676358.0,Viktorin A,Other measurement,initial,2014-03-27,GCST002402,Serum IgA levels
5358,European,484.0,24677629.0,Wolf EJ,Neurological disorder,initial,2014-03-27,GCST002401,Post-traumatic stress disorder
7622,European,2785.0,24676358.0,Viktorin A,Other measurement,replication,2014-03-27,GCST002402,Serum IgA levels
11485,European,68486.0,24688116.0,Deelen J,Other measurement,replication,2014-03-31,GCST002404,Longevity (90 years and older)
10682,European,23850.0,24688116.0,Deelen J,Other measurement,initial,2014-03-31,GCST002403,Longevity (85 years and older)
10529,European,20518.0,24688116.0,Deelen J,Other measurement,initial,2014-03-31,GCST002404,Longevity (90 years and older)
11533,European,74216.0,24688116.0,Deelen J,Other measurement,replication,2014-03-31,GCST002403,Longevity (85 years and older)
10423,European,18535.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005217,Insulin levels adjusted for BMI
10525,European,20461.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005216,Corrected insulin response adjusted for insulin sensitivity index
8355,European,4409.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005217,Insulin levels adjusted for BMI
10545,European,20792.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005220,Insulin levels
10526,European,20461.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005222,Insulin disposition index
10541,European,20722.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005215,Corrected insulin response
8714,European,5318.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005215,Corrected insulin response
8483,European,4789.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005216,Corrected insulin response adjusted for insulin sensitivity index
8334,European,4324.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005218,Area under the curve of insulin levels
8300,European,4231.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005223,Ratio of the area under the curve for insulin and the area under the curve for glucose
10528,European,20514.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005221,Insulin sensitivity index
8367,European,4447.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005219,Incremental insulin
8382,European,4483.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005220,Insulin levels
10539,European,20706.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005219,Incremental insulin
10531,European,20620.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005218,Area under the curve of insulin levels
8475,European,4768.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005221,Insulin sensitivity index
8648,European,5130.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005222,Insulin disposition index
10527,European,20513.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005223,Ratio of the area under the curve for insulin and the area under the curve for glucose
26,African,57.0,24952865.0,Akerblom A,"Cardiovascular disease, Other measurement",initial,2014-04-04,GCST002406,Plasma cystastin c levels in acute coronary syndrome
1707,Asian,90.0,24952865.0,Akerblom A,"Cardiovascular disease, Other measurement",initial,2014-04-04,GCST002406,Plasma cystastin c levels in acute coronary syndrome
2094,Asian,412.0,24700089.0,Miura K,Cancer,initial,2014-04-04,GCST002405,Cervical cancer
9707,European,9801.0,24952865.0,Akerblom A,"Cardiovascular disease, Other measurement",initial,2014-04-04,GCST002406,Plasma cystastin c levels in acute coronary syndrome
5704,European,694.0,24709693.0,Cobb J,"Response to drug, Immune system disorder",initial,2014-04-08,GCST002408,Response to methotrexate in juvenile idiopathic arthritis
9296,European,7816.0,24714607.0,Dijkstra AE,Other trait,replication,2014-04-08,GCST002407,Chronic mucus hypersecretion
5990,European,890.0,24629169.0,Ising M,"Other measurement, Biological process",initial,2014-04-08,GCST007698,perceptual and visual search speed and executive function (trail making test BA) (age interaction)
5989,European,890.0,24629169.0,Ising M,"Other measurement, Biological process",initial,2014-04-08,GCST007695,perceptual and visual search speed and executive function (trail making test BA)
5985,European,890.0,24629169.0,Ising M,Biological process,initial,2014-04-08,GCST007693,perceptual and visual search speed (trail making test A)
5987,European,890.0,24629169.0,Ising M,Other measurement,initial,2014-04-08,GCST007694,executive function (trail making test B)
5986,European,890.0,24629169.0,Ising M,Biological process,initial,2014-04-08,GCST007696,perceptual and visual search speed (trail making test A) (age interaction)
5988,European,890.0,24629169.0,Ising M,Other measurement,initial,2014-04-08,GCST007697,executive function (trail making test B) (age interaction)
7769,European,3102.0,24714607.0,Dijkstra AE,Other trait,initial,2014-04-08,GCST002407,Chronic mucus hypersecretion
12975,Hispanic or Latin American,776.0,24736177.0,Sprooten E,Other measurement,initial,2014-04-13,GCST002409,White matter microstructure (global fractional anisotropy)
11502,European,69776.0,24728293.0,Styrkarsdottir U,Other disease,initial,2014-04-13,GCST002410,"Osteoarthritis (hand, severe)"
9474,European,8386.0,24728293.0,Styrkarsdottir U,Other disease,replication,2014-04-13,GCST002410,"Osteoarthritis (hand, severe)"
10853,European,29974.0,24737748.0,Whiffin N,Cancer,replication,2014-04-15,GCST002411,Colorectal cancer
1992,Asian,308.0,24737549.0,Yoon KA,"Other measurement, Cancer",replication,2014-04-15,GCST002412,Non-small cell lung cancer (recurrence rate)
10066,European,13443.0,24737748.0,Whiffin N,Cancer,initial,2014-04-15,GCST002411,Colorectal cancer
1936,Asian,250.0,24737549.0,Yoon KA,"Other measurement, Cancer",initial,2014-04-15,GCST002412,Non-small cell lung cancer (recurrence rate)
8612,European,5051.0,24740154.0,Lange EM,Cancer,initial,2014-04-16,GCST002413,Prostate cancer (early onset)
6562,European,1380.0,24740207.0,Moy KA,Other measurement,initial,2014-04-16,GCST002414,Serum vitamin D-binding protein levels
8016,European,3492.0,24740154.0,Lange EM,Cancer,replication,2014-04-16,GCST002413,Prostate cancer (early onset)
3241,Asian,2789.0,24722205.0,Kwak SH,Other measurement,initial,2014-04-17,GCST002417,Plasma thyroid-stimulating hormone levels
3242,Asian,2789.0,24722205.0,Kwak SH,Other measurement,initial,2014-04-17,GCST002418,Free thyroxine concentration
2414,Asian,829.0,24722205.0,Kwak SH,Other measurement,replication,2014-04-17,GCST002418,Free thyroxine concentration
2413,Asian,829.0,24722205.0,Kwak SH,Other measurement,replication,2014-04-17,GCST002417,Plasma thyroid-stimulating hormone levels
3358,Asian,3396.0,24722205.0,Kwak SH,Other measurement,initial,2014-04-17,GCST002416,Thyroid peroxidase antibody positivity
10415,European,18404.0,24743840.0,Figueiredo JC,"Other measurement, Cancer",initial,2014-04-17,GCST002415,Colorectal cancer (diet interaction)
2420,Asian,842.0,24722205.0,Kwak SH,Other measurement,replication,2014-04-17,GCST002416,Thyroid peroxidase antibody positivity
6036,European,929.0,24882193.0,Winham SJ,"Metabolic disorder, Neurological disorder",initial,2014-04-19,GCST002420,Binge eating behaviour in bipolar disorder
5897,European,828.0,24882193.0,Winham SJ,"Metabolic disorder, Neurological disorder",replication,2014-04-19,GCST002420,Binge eating behaviour in bipolar disorder
6794,European,1660.0,24882193.0,Winham SJ,"Metabolic disorder, Neurological disorder",replication,2014-04-19,GCST002419,Binge eating behaviour and bipolar disorder
7030,European,1963.0,24882193.0,Winham SJ,"Metabolic disorder, Neurological disorder",initial,2014-04-19,GCST002419,Binge eating behaviour and bipolar disorder
7707,European,2950.0,24753544.0,Knipe DW,Cancer,initial,2014-04-21,GCST002421,Prostate cancer
7891,European,3291.0,24753544.0,Knipe DW,Cancer,replication,2014-04-21,GCST002421,Prostate cancer
8407,European,4569.0,24755620.0,Perez-Palma E,Neurological disorder,initial,2014-04-22,GCST002422,Alzheimer's disease
8402,European,4554.0,24768677.0,de Boer YS,Immune system disorder,replication,2014-04-23,GCST002423,Autoimmune hepatitis type-1
10121,European,14085.0,24768677.0,de Boer YS,Immune system disorder,initial,2014-04-23,GCST002423,Autoimmune hepatitis type-1
2450,Asian,903.0,24763700.0,Vinayagamoorthy N,Inflammatory measurement,replication,2014-04-24,GCST002424,C-reactive protein levels
3895,Asian,7626.0,24763700.0,Vinayagamoorthy N,Inflammatory measurement,initial,2014-04-24,GCST002424,C-reactive protein levels
8920,European,6147.0,24770850.0,Cousminer DL,Other measurement,initial,2014-04-25,GCST002427,Puberty onset (breast development)
8129,European,3769.0,24770850.0,Cousminer DL,Other measurement,initial,2014-04-25,GCST002426,Puberty onset (genital enlargement)
4920,European,208.0,24770850.0,Cousminer DL,Other measurement,replication,2014-04-25,GCST002426,Puberty onset (genital enlargement)
6560,European,1376.0,24770850.0,Cousminer DL,Other measurement,replication,2014-04-25,GCST002425,Puberty onset
9748,European,9916.0,24770850.0,Cousminer DL,Other measurement,initial,2014-04-25,GCST002425,Puberty onset
14230,Other/Mixed,5244.0,24816038.0,Postmus I,Response to drug,initial,2014-04-26,GCST002428,Cardiovascular event reduction in the elderly at risk for vascular disease (statin therapy interaction)
6892,European,1773.0,24785509.0,Barnett GC,"Cancer, Biological process",initial,2014-04-28,GCST002431,Response to radiotherapy in cancer (late toxicity)
5444,European,516.0,24785509.0,Barnett GC,"Cancer, Biological process",replication,2014-04-28,GCST002431,Response to radiotherapy in cancer (late toxicity)
1842,Asian,189.0,24792382.0,Park TJ,"Response to drug, Other measurement, Other disease",initial,2014-04-30,GCST002432,Response to inhaled corticosteroid treatment in asthma (change in FEV1)
3554,Asian,4685.0,24782177.0,Jiang L,Immune system disorder,replication,2014-05-01,GCST002433,Rheumatoid arthritis
6392,European,1201.0,24797007.0,Holliday EG,Digestive system disorder,replication,2014-05-01,GCST002436,Irritable bowel syndrome
3292,Asian,2955.0,24827717.0,Yang F,"Body measurement, Other measurement",replication,2014-05-01,GCST002435,Body mass index
2945,Asian,1895.0,24782177.0,Jiang L,Immune system disorder,initial,2014-05-01,GCST002433,Rheumatoid arthritis
2237,Asian,597.0,24827717.0,Yang F,"Body measurement, Other measurement",initial,2014-05-01,GCST002435,Body mass index
10750,European,25708.0,24782177.0,Jiang L,Immune system disorder,replication,2014-05-01,GCST002434,Rheumatoid arthritis
6715,European,1570.0,24797007.0,Holliday EG,Digestive system disorder,initial,2014-05-01,GCST002436,Irritable bowel syndrome
2946,Asian,1895.0,24782177.0,Jiang L,Immune system disorder,initial,2014-05-01,GCST002434,Rheumatoid arthritis
10053,European,13285.0,24795349.0,Saxena R,Other measurement,replication,2014-05-03,GCST002437,Telomere length
3148,Asian,2397.0,24795349.0,Saxena R,Other measurement,replication,2014-05-03,GCST002437,Telomere length
2772,Asian,1616.0,24795349.0,Saxena R,Other measurement,initial,2014-05-03,GCST002437,Telomere length
6232,European,1044.0,24800985.0,Agopian AJ,"Cardiovascular disease, Other measurement",replication,2014-05-06,GCST002438,Conotruncal heart defects
14141,Other/Mixed,1868.0,24800985.0,Agopian AJ,"Cardiovascular disease, Other measurement",initial,2014-05-06,GCST002438,Conotruncal heart defects
13696,Other/Mixed,30.0,24800985.0,Agopian AJ,"Cardiovascular disease, Other measurement",replication,2014-05-06,GCST002438,Conotruncal heart defects
5574,European,602.0,24801482.0,Baron-Cohen S,Biological process,initial,2014-05-06,GCST002439,Mathematical ability
7861,European,3234.0,24847357.0,Ye Z,Other disease,initial,2014-05-09,GCST002440,Staphylococcus aureus infection
5976,European,883.0,24811271.0,Kennedy RB,Response to drug,initial,2014-05-09,GCST002441,Immune response to measles-mumps-rubella vaccine
9297,European,7824.0,24816252.0,Shin SY,Other measurement,initial,2014-05-11,GCST002443,Blood metabolite levels
6887,European,1767.0,24816252.0,Shin SY,Other measurement,replication,2014-05-11,GCST002442,Blood metabolite ratios
8778,European,5591.0,24816252.0,Shin SY,Other measurement,initial,2014-05-11,GCST002442,Blood metabolite ratios
9524,European,8631.0,24823311.0,Guan W,Lipid or lipoprotein measurement,initial,2014-05-13,GCST002450,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)
9523,European,8631.0,24823311.0,Guan W,Lipid or lipoprotein measurement,initial,2014-05-13,GCST002449,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)
9522,European,8631.0,24823311.0,Guan W,Lipid or lipoprotein measurement,initial,2014-05-13,GCST002448,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)
13134,Hispanic or Latin American,2428.0,24824216.0,Myers RA,"Other disease, Other measurement",initial,2014-05-13,GCST002445,Asthma (sex interaction)
8436,European,4658.0,24825563.0,McDonald ML,"Other disease, Other measurement",replication,2014-05-13,GCST002447,Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry)
9520,European,8631.0,24823311.0,Guan W,Lipid or lipoprotein measurement,initial,2014-05-13,GCST002444,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)
1123,African American or Afro-Caribbean,3015.0,24824216.0,Myers RA,"Other disease, Other measurement",initial,2014-05-13,GCST002445,Asthma (sex interaction)
8069,European,3606.0,24824216.0,Myers RA,"Other disease, Other measurement",initial,2014-05-13,GCST002445,Asthma (sex interaction)
785,African American or Afro-Caribbean,820.0,24825563.0,McDonald ML,"Other disease, Other measurement",initial,2014-05-13,GCST002447,Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry)
9521,European,8631.0,24823311.0,Guan W,Lipid or lipoprotein measurement,initial,2014-05-13,GCST002446,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)
7323,European,2322.0,24832863.0,Wetherill L,Neurological disorder,initial,2014-05-16,GCST002452,Substance dependence phenotypes
2937,Asian,1881.0,24837172.0,Juyal G,Immune system disorder,replication,2014-05-16,GCST002453,Ulcerative colitis
2610,Asian,1225.0,24837172.0,Juyal G,Immune system disorder,initial,2014-05-16,GCST002453,Ulcerative colitis
7546,European,2647.0,24832863.0,Wetherill L,Neurological disorder,replication,2014-05-16,GCST002452,Substance dependence phenotypes
3957,Asian,8270.0,24836286.0,Zhang B,Cancer,initial,2014-05-18,GCST002454,Colorectal cancer
11011,European,35246.0,24836286.0,Zhang B,Cancer,replication,2014-05-18,GCST002454,Colorectal cancer
4486,Asian,38638.0,24836286.0,Zhang B,Cancer,replication,2014-05-18,GCST002454,Colorectal cancer
14211,Other/Mixed,3741.0,24842889.0,Vacic V,Neurological disorder,initial,2014-05-19,GCST002455,Parkinson's disease
14184,Other/Mixed,2889.0,24842889.0,Vacic V,Neurological disorder,replication,2014-05-19,GCST002455,Parkinson's disease
10291,European,16468.0,24850809.0,Verweij N,Cardiovascular measurement,initial,2014-05-21,GCST002456,PR segment
10292,European,16468.0,24850809.0,Verweij N,Cardiovascular measurement,initial,2014-05-21,GCST002457,P wave duration
3337,Asian,3235.0,24852370.0,Zhan M,Other measurement,replication,2014-05-22,GCST002458,Serum thyroid-stimulating hormone levels
2650,Asian,1346.0,24852370.0,Zhan M,Other measurement,initial,2014-05-22,GCST002458,Serum thyroid-stimulating hormone levels
1960,Asian,269.0,24863034.0,Urano T,Other measurement,initial,2014-05-23,GCST002459,Lean body mass
2534,Asian,1081.0,24863034.0,Urano T,Other measurement,replication,2014-05-23,GCST002459,Lean body mass
11718,European,91850.0,24861552.0,Rafnar T,Cancer,initial,2014-05-26,GCST002460,Urinary bladder cancer
10234,European,15697.0,24861552.0,Rafnar T,Cancer,replication,2014-05-26,GCST002460,Urinary bladder cancer
4508,Asian,47352.0,24861553.0,Wen W,"Body measurement, Other measurement",replication,2014-05-26,GCST002461,Body mass index
3493,Asian,4301.0,24861553.0,Wen W,"Body measurement, Other measurement",initial,2014-05-26,GCST002461,Body mass index
4550,Asian,82438.0,24861553.0,Wen W,"Body measurement, Other measurement",initial,2014-05-26,GCST002461,Body mass index
9384,European,8276.0,24958192.0,Gusareva ES,Neurological disorder,initial,2014-05-28,GCST002462,Alzheimer's disease (SNP x SNP interaction)
9139,European,7076.0,24958192.0,Gusareva ES,Neurological disorder,replication,2014-05-28,GCST002462,Alzheimer's disease (SNP x SNP interaction)
7800,European,3163.0,24871463.0,Armstrong DL,Immune system disorder,initial,2014-05-29,GCST002463,Systemic lupus erythematosus
8002,European,3464.0,24871321.0,Sambo F,"Other disease, Metabolic disorder",initial,2014-05-29,GCST002464,End-stage renal disease or diabetic nephropathy in type 1 diabetes
10786,European,27209.0,24880342.0,Wang Y,Cancer,initial,2014-06-01,GCST002466,Lung cancer
11252,European,48541.0,24880342.0,Wang Y,Cancer,replication,2014-06-01,GCST002466,Lung cancer
4745,European,96.0,24751813.0,Drago A,"Response to drug, Neurological disorder",initial,2014-06-01,GCST002465,Response to haloperidol in psychosis
13323,Hispanic or Latin American,6017.0,24886709.0,Ko A,Lipid or lipoprotein measurement,replication,2014-06-02,GCST002469,HDL cholesterol
13322,Hispanic or Latin American,6017.0,24886709.0,Ko A,Lipid or lipoprotein measurement,replication,2014-06-02,GCST002468,Triglycerides
13321,Hispanic or Latin American,6017.0,24886709.0,Ko A,Lipid or lipoprotein measurement,replication,2014-06-02,GCST002467,"Cholesterol, total"
13212,Hispanic or Latin American,3701.0,24886709.0,Ko A,Lipid or lipoprotein measurement,initial,2014-06-02,GCST002467,"Cholesterol, total"
13175,Hispanic or Latin American,3323.0,24886709.0,Ko A,Lipid or lipoprotein measurement,initial,2014-06-02,GCST002468,Triglycerides
13213,Hispanic or Latin American,3701.0,24886709.0,Ko A,Lipid or lipoprotein measurement,initial,2014-06-02,GCST002469,HDL cholesterol
3523,Asian,4544.0,24903457.0,Kim YK,"Other measurement, Cardiovascular measurement",replication,2014-06-05,GCST004705,Blood pressure
3878,Asian,7486.0,24903457.0,Kim YK,"Other measurement, Cardiovascular measurement",initial,2014-06-05,GCST004705,Blood pressure
595,African American or Afro-Caribbean,241.0,24909733.0,Cook-Sather SD,Response to drug,initial,2014-06-05,GCST002472,Morphine dose requirement in tonsillectomy and adenoidectomy surgery
3522,Asian,4544.0,24903457.0,Kim YK,"Other measurement, Body measurement",replication,2014-06-05,GCST002471,Blood pressure (anthropometric measures interaction)
5007,European,277.0,24909733.0,Cook-Sather SD,Response to drug,initial,2014-06-05,GCST002472,Morphine dose requirement in tonsillectomy and adenoidectomy surgery
3877,Asian,7486.0,24903457.0,Kim YK,"Other measurement, Body measurement",initial,2014-06-05,GCST002471,Blood pressure (anthropometric measures interaction)
469,African American or Afro-Caribbean,70.0,24909733.0,Cook-Sather SD,Response to drug,replication,2014-06-05,GCST002472,Morphine dose requirement in tonsillectomy and adenoidectomy surgery
4692,European,75.0,24909733.0,Cook-Sather SD,Response to drug,replication,2014-06-05,GCST002472,Morphine dose requirement in tonsillectomy and adenoidectomy surgery
9259,European,7608.0,24908248.0,Walsh KM,Cancer,initial,2014-06-08,GCST002474,Glioma (high-grade)
6891,European,1772.0,24908248.0,Walsh KM,Cancer,replication,2014-06-08,GCST002474,Glioma (high-grade)
2535,Asian,1086.0,24919509.0,Terao C,Other measurement,initial,2014-06-11,GCST002476,Prostate-specific antigen levels
3575,Asian,4864.0,24916648.0,Hirokawa M,Cardiovascular disease,initial,2014-06-11,GCST002475,Myocardial infarction
4490,Asian,39809.0,24916648.0,Hirokawa M,Cardiovascular disease,replication,2014-06-11,GCST002475,Myocardial infarction
7393,European,2435.0,24916650.0,Versmissen J,"Cardiovascular disease, Metabolic disorder",replication,2014-06-11,GCST002478,Coronary heart disease in familial hypercholesterolemia
6902,European,1788.0,24962325.0,Kapoor M,"Neurological disorder, Other measurement",initial,2014-06-11,GCST002477,Alcohol dependence (age at onset)
2635,Asian,1302.0,24919509.0,Terao C,Other measurement,replication,2014-06-11,GCST002476,Prostate-specific antigen levels
5327,European,466.0,24916650.0,Versmissen J,"Cardiovascular disease, Metabolic disorder",initial,2014-06-11,GCST002478,Coronary heart disease in familial hypercholesterolemia
7049,European,2000.0,24925725.0,Chung SA,Immune system disorder,initial,2014-06-12,GCST002479,Lupus nephritis in systemic lupus erythematosus
8386,European,4499.0,24920014.0,Cozen W,Cancer,replication,2014-06-12,GCST002480,Hodgkin's lymphoma
9687,European,9693.0,24920014.0,Cozen W,Cancer,initial,2014-06-12,GCST002480,Hodgkin's lymphoma
8231,European,4033.0,24927181.0,Navarini AA,Other disease,replication,2014-06-13,GCST002481,Acne (severe)
9129,European,7025.0,24927181.0,Navarini AA,Other disease,initial,2014-06-13,GCST002481,Acne (severe)
12823,Hispanic or Latin American,264.0,24954085.0,Della-Morte D,"Other measurement, Cardiovascular measurement",replication,2014-06-14,GCST002482,Carotid plaque burden (smoking interaction)
12935,Hispanic or Latin American,665.0,24954085.0,Della-Morte D,"Other measurement, Cardiovascular measurement",initial,2014-06-14,GCST002482,Carotid plaque burden (smoking interaction)
11299,European,52253.0,24929828.0,Loth DW,Other measurement,initial,2014-06-15,GCST002483,Lung function (forced vital capacity)
10930,European,32917.0,24929828.0,Loth DW,Other measurement,replication,2014-06-15,GCST002483,Lung function (forced vital capacity)
3983,Asian,8637.0,24929828.0,Loth DW,Other measurement,replication,2014-06-15,GCST002483,Lung function (forced vital capacity)
1298,African American or Afro-Caribbean,6070.0,24929828.0,Loth DW,Other measurement,replication,2014-06-15,GCST002483,Lung function (forced vital capacity)
12991,Hispanic or Latin American,849.0,24929828.0,Loth DW,Other measurement,replication,2014-06-15,GCST002483,Lung function (forced vital capacity)
6225,European,1035.0,24934506.0,Eny KM,Other measurement,replication,2014-06-17,GCST002484,Skin fluorescence
9708,European,9803.0,24934506.0,Eny KM,Other measurement,initial,2014-06-17,GCST002484,Skin fluorescence
2068,Asian,384.0,24938310.0,Nakano M,Neurological disorder,replication,2014-06-18,GCST002486,Exfoliation glaucoma or exfoliation syndrome
3331,Asian,3170.0,24942650.0,Terao C,Other measurement,initial,2014-06-18,GCST002488,Anti-citrullinated peptide antibody
6633,European,1489.0,24939585.0,Fransen E,Neurological disorder,initial,2014-06-18,GCST002487,Age-related hearing impairment (SNP x SNP interaction)
6634,European,1489.0,24939585.0,Fransen E,Neurological disorder,initial,2014-06-18,GCST002491,Age-related hearing impairment
2987,Asian,1999.0,24941225.0,Liang Y,Other measurement,initial,2014-06-18,GCST002485,Elevated serum carcinoembryonic antigen levels
2446,Asian,898.0,24938310.0,Nakano M,Neurological disorder,initial,2014-06-18,GCST002486,Exfoliation glaucoma or exfoliation syndrome
2254,Asian,625.0,24940741.0,Chang SW,Digestive system disorder,initial,2014-06-18,GCST002490,Chronic hepatitis B infection
3014,Asian,2063.0,24940741.0,Chang SW,Digestive system disorder,replication,2014-06-18,GCST002490,Chronic hepatitis B infection
3332,Asian,3170.0,24942650.0,Terao C,Other measurement,initial,2014-06-18,GCST002489,Rheumatoid factor
2917,Asian,1855.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002495,Blood pressure (age interaction)
2913,Asian,1849.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002495,Blood pressure (age interaction)
2914,Asian,1849.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002497,Blood pressure
2918,Asian,1855.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002497,Blood pressure
9328,European,7976.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002493,"Bone mineral density (paediatric, skull)"
13832,Other/Mixed,232.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002494,"Bone mineral density (paediatric, total body less head)"
3172,Asian,2502.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002497,Blood pressure
3171,Asian,2502.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002495,Blood pressure (age interaction)
13830,Other/Mixed,232.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002492,"Bone mineral density (paediatric, lower limb)"
9341,European,8007.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002496,"Bone mineral density (paediatric, upper limb)"
13831,Other/Mixed,232.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002493,"Bone mineral density (paediatric, skull)"
3165,Asian,2476.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002497,Blood pressure
3164,Asian,2476.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002495,Blood pressure (age interaction)
11179,European,43445.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002495,Blood pressure (age interaction)
13833,Other/Mixed,232.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002496,"Bone mineral density (paediatric, upper limb)"
11180,European,43445.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002497,Blood pressure
9340,European,8007.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002494,"Bone mineral density (paediatric, total body less head)"
9339,European,8007.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002492,"Bone mineral density (paediatric, lower limb)"
14086,Other/Mixed,1177.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002493,"Bone mineral density (paediatric, skull)"
11353,European,55796.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",initial,2014-06-19,GCST002497,Blood pressure
11352,European,55796.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",initial,2014-06-19,GCST002495,Blood pressure (age interaction)
14087,Other/Mixed,1177.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002494,"Bone mineral density (paediatric, total body less head)"
14088,Other/Mixed,1177.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002496,"Bone mineral density (paediatric, upper limb)"
14085,Other/Mixed,1177.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002492,"Bone mineral density (paediatric, lower limb)"
8415,European,4593.0,24950379.0,Metrustry SJ,Body measurement,initial,2014-06-20,GCST002499,Birth weight
3081,Asian,2200.0,24951543.0,Liao J,Other trait,initial,2014-06-20,GCST002498,Age-related nuclear cataracts
3199,Asian,2571.0,24951543.0,Liao J,Other trait,initial,2014-06-20,GCST002498,Age-related nuclear cataracts
3136,Asian,2369.0,24951543.0,Liao J,Other trait,initial,2014-06-20,GCST002498,Age-related nuclear cataracts
10939,European,33316.0,24952745.0,Arking DE,Cardiovascular measurement,replication,2014-06-22,GCST002500,QT interval
11510,European,71061.0,24952745.0,Arking DE,Cardiovascular measurement,initial,2014-06-22,GCST002500,QT interval
5864,European,810.0,24957906.0,Kuiper JJ,Cardiovascular disease,initial,2014-06-22,GCST002501,Birdshot chorioretinopathy
7648,European,2823.0,24957906.0,Kuiper JJ,Cardiovascular disease,replication,2014-06-22,GCST002501,Birdshot chorioretinopathy
3611,Asian,5220.0,24963161.0,Chen P,Other measurement,replication,2014-06-24,GCST002502,Corneal curvature
3041,Asian,2138.0,24963161.0,Chen P,Other measurement,initial,2014-06-24,GCST002502,Corneal curvature
3036,Asian,2124.0,24963161.0,Chen P,Other measurement,initial,2014-06-24,GCST002502,Corneal curvature
3333,Asian,3178.0,24963161.0,Chen P,Other measurement,initial,2014-06-24,GCST002502,Corneal curvature
7871,European,3245.0,25009551.0,Kullo IJ,Cardiovascular disease,initial,2014-06-25,GCST002504,Peripheral artery disease
7882,European,3270.0,24964207.0,Mullins N,"Biological process, Neurological disorder",initial,2014-06-25,GCST002503,Suicide attempts in depression or bipolar disorder
6904,European,1791.0,25009551.0,Kullo IJ,Cardiovascular disease,replication,2014-06-25,GCST002504,Peripheral artery disease
5791,European,747.0,24964207.0,Mullins N,"Biological process, Neurological disorder",initial,2014-06-25,GCST002505,Suicidal ideation in depression or bipolar disorder
11220,European,46553.0,24975945.0,Ganesh SK,"Other measurement, Cardiovascular measurement",initial,2014-06-26,GCST002506,Blood pressure
3662,Asian,5605.0,24975945.0,Ganesh SK,"Other measurement, Cardiovascular measurement",replication,2014-06-26,GCST002506,Blood pressure
7756,European,3063.0,24974787.0,Meng W,"Metabolic disorder, Other trait",initial,2014-06-26,GCST002507,Neuropathic pain in type 2 diabetes
11001,European,34433.0,24975945.0,Ganesh SK,"Other measurement, Cardiovascular measurement",replication,2014-06-26,GCST002506,Blood pressure
10465,European,19243.0,24931836.0,Diekstra FP,Neurological disorder,initial,2014-06-27,GCST002510,Amyotrophic lateral sclerosis or frontotemporal dementia
9344,European,8014.0,24931836.0,Diekstra FP,Neurological disorder,replication,2014-06-27,GCST002510,Amyotrophic lateral sclerosis or frontotemporal dementia
6944,European,1849.0,24931836.0,Diekstra FP,Neurological disorder,initial,2014-06-27,GCST002508,Frontotemporal dementia
10362,European,17394.0,24931836.0,Diekstra FP,Neurological disorder,initial,2014-06-27,GCST002509,Amyotrophic lateral sclerosis
5793,European,749.0,24974847.0,Fachal L,"Cancer, Biological process",replication,2014-06-29,GCST002511,Response to radiotherapy in prostate cancer (toxicity)
5641,European,652.0,24974847.0,Fachal L,"Cancer, Biological process",initial,2014-06-29,GCST002511,Response to radiotherapy in prostate cancer (toxicity)
6471,European,1281.0,24978480.0,Real LM,Cancer,initial,2014-06-30,GCST002513,Colorectal cancer (SNP x SNP interaction)
6470,European,1281.0,24978480.0,Real LM,Cancer,initial,2014-06-30,GCST002512,Colorectal cancer
8910,European,6122.0,24980573.0,Song F,Cancer,initial,2014-06-30,GCST002514,Melanoma
10416,European,18416.0,24980573.0,Song F,Cancer,replication,2014-06-30,GCST002514,Melanoma
7942,European,3354.0,24978480.0,Real LM,Cancer,replication,2014-06-30,GCST002513,Colorectal cancer (SNP x SNP interaction)
7941,European,3354.0,24978480.0,Real LM,Cancer,replication,2014-06-30,GCST002512,Colorectal cancer
8985,European,6462.0,24943344.0,Ferrari R,Neurological disorder,initial,2014-07-01,GCST002516,Frontotemporal dementia
2085,Asian,400.0,24986923.0,Chu M,"Other disease, Biological process",initial,2014-07-01,GCST002515,Pneumoconiosis in silica exposure
8987,European,6466.0,24943344.0,Ferrari R,Neurological disorder,replication,2014-07-01,GCST002516,Frontotemporal dementia
13050,Hispanic or Latin American,1367.0,24962563.0,Rubicz R,"Biological process, Other measurement",initial,2014-07-01,GCST002518,Food antigen IgG levels
2514,Asian,1031.0,24986923.0,Chu M,"Other disease, Biological process",replication,2014-07-01,GCST002515,Pneumoconiosis in silica exposure
10787,European,27249.0,24983941.0,Tang W,Other measurement,initial,2014-07-01,GCST002517,Rate of change of FEV1 (time interaction)
8999,European,6535.0,24993907.0,Smolonska J,Other disease,initial,2014-07-03,GCST002519,Asthma or chronic obstructive pulmonary disease
14265,Other/Mixed,20912.0,24993907.0,Smolonska J,Other disease,replication,2014-07-03,GCST002519,Asthma or chronic obstructive pulmonary disease
6435,European,1235.0,24993907.0,Smolonska J,Other disease,replication,2014-07-03,GCST002519,Asthma or chronic obstructive pulmonary disease
8430,European,4634.0,24999842.0,Garner C,Immune system disorder,initial,2014-07-07,GCST002520,Celiac disease
10445,European,18901.0,25043464.0,Jun G,Neurological disorder,replication,2014-07-08,GCST002523,Alzheimer's disease
1263,African American or Afro-Caribbean,4896.0,25043464.0,Jun G,Neurological disorder,replication,2014-07-08,GCST002523,Alzheimer's disease
7169,European,2153.0,25003214.0,Davis OS,Biological process,replication,2014-07-08,GCST002522,Reading or mathematical ability
7629,European,2794.0,25003214.0,Davis OS,Biological process,initial,2014-07-08,GCST002522,Reading or mathematical ability
2910,Asian,1845.0,25043464.0,Jun G,Neurological disorder,replication,2014-07-08,GCST002523,Alzheimer's disease
7578,European,2698.0,25044411.0,Liao SY,Other measurement,initial,2014-07-08,GCST002521,Lung function (forced expiratory volume in 1 second)
13732,Other/Mixed,70.0,25008200.0,Feng P,Digestive system disorder,initial,2014-07-09,GCST002524,Chronic periodontitis
556,African American or Afro-Caribbean,190.0,25008200.0,Feng P,Digestive system disorder,initial,2014-07-09,GCST002524,Chronic periodontitis
6628,European,1476.0,25008200.0,Feng P,Digestive system disorder,replication,2014-07-09,GCST002524,Chronic periodontitis
93,African,343.0,25008200.0,Feng P,Digestive system disorder,replication,2014-07-09,GCST002524,Chronic periodontitis
1147,African American or Afro-Caribbean,3158.0,25006744.0,Castaldi PJ,Other measurement,initial,2014-07-09,GCST002525,Local histogram emphysema pattern
8984,European,6456.0,25006744.0,Castaldi PJ,Other measurement,initial,2014-07-09,GCST002525,Local histogram emphysema pattern
5585,European,606.0,25008200.0,Feng P,Digestive system disorder,initial,2014-07-09,GCST002524,Chronic periodontitis
7630,European,2795.0,25010111.0,Bolton JL,Other measurement,replication,2014-07-10,GCST002526,Cortisol levels (plasma)
10012,European,12597.0,25010111.0,Bolton JL,Other measurement,initial,2014-07-10,GCST002526,Cortisol levels (plasma)
9752,European,9953.0,25017104.0,Kottyan LC,Digestive system disorder,initial,2014-07-13,GCST002527,Eosinophilic esophagitis
14071,Other/Mixed,983.0,25023989.0,Schmit SL,Cancer,initial,2014-07-14,GCST002528,Colorectal cancer
14149,Other/Mixed,1962.0,25023989.0,Schmit SL,Cancer,replication,2014-07-14,GCST002528,Colorectal cancer
7716,European,2976.0,25023989.0,Schmit SL,Cancer,initial,2014-07-14,GCST002528,Colorectal cancer
13173,Hispanic or Latin American,3174.0,25027321.0,Hoffmann TJ,Neurological disorder,initial,2014-07-15,GCST002529,Glaucoma
8197,European,3966.0,25028398.0,Weiss FU,Other measurement,initial,2014-07-15,GCST002532,High serum lipase activity
5141,European,363.0,25027320.0,Ramirez A,"Neurological disorder, Other measurement",initial,2014-07-15,GCST002531,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia
8196,European,3966.0,25028398.0,Weiss FU,Other measurement,initial,2014-07-15,GCST002530,Serum lipase activity
1362,African American or Afro-Caribbean,7787.0,25027321.0,Hoffmann TJ,Neurological disorder,initial,2014-07-15,GCST002529,Glaucoma
6604,European,1444.0,25028398.0,Weiss FU,Other measurement,replication,2014-07-15,GCST002532,High serum lipase activity
6603,European,1444.0,25028398.0,Weiss FU,Other measurement,replication,2014-07-15,GCST002530,Serum lipase activity
3860,Asian,7295.0,25035420.0,Hong KW,Cardiovascular measurement,replication,2014-07-17,GCST002533,QRS duration
3755,Asian,6085.0,25035420.0,Hong KW,Cardiovascular measurement,initial,2014-07-17,GCST002533,QRS duration
3756,Asian,6085.0,25035420.0,Hong KW,Cardiovascular measurement,initial,2014-07-17,GCST002535,PR interval
6134,European,983.0,25030430.0,Zignego AL,"Digestive system disorder, Immune system disorder",initial,2014-07-17,GCST002534,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection
5000,European,271.0,25030430.0,Zignego AL,"Digestive system disorder, Immune system disorder",replication,2014-07-17,GCST002534,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection
3861,Asian,7295.0,25035420.0,Hong KW,Cardiovascular measurement,replication,2014-07-17,GCST002535,PR interval
2081,Asian,398.0,25042611.0,Griffin PJ,"Neurological disorder, Hematological measurement",replication,2014-07-19,GCST002536,Hemoglobin A2 levels in sickle cell anemia
736,African American or Afro-Caribbean,618.0,25042611.0,Griffin PJ,"Neurological disorder, Hematological measurement",initial,2014-07-19,GCST002536,Hemoglobin A2 levels in sickle cell anemia
553,African American or Afro-Caribbean,173.0,25042611.0,Griffin PJ,"Neurological disorder, Hematological measurement",replication,2014-07-19,GCST002536,Hemoglobin A2 levels in sickle cell anemia
11379,European,57338.0,25038754.0,Cai Q,Cancer,replication,2014-07-20,GCST002537,Breast cancer
4479,Asian,37511.0,25038754.0,Cai Q,Cancer,replication,2014-07-20,GCST002537,Breast cancer
4068,Asian,9450.0,25038754.0,Cai Q,Cancer,initial,2014-07-20,GCST002537,Breast cancer
7131,European,2089.0,25044758.0,Stergiakouli E,Body measurement,replication,2014-07-21,GCST002538,Height adjusted BMI
3610,Asian,5219.0,25056061.0,Ripke S,Neurological disorder,initial,2014-07-22,GCST002539,Schizophrenia
11605,European,82315.0,25056061.0,Ripke S,Neurological disorder,initial,2014-07-22,GCST002539,Schizophrenia
11473,European,67749.0,25056061.0,Ripke S,Neurological disorder,replication,2014-07-22,GCST002539,Schizophrenia
6101,European,964.0,25057126.0,Ramos YF,Other measurement,replication,2014-07-23,GCST002540,Osteoarthritis biomarkers
3302,Asian,2994.0,25055868.0,Sano M,Cardiovascular measurement,initial,2014-07-23,GCST002542,Electrocardiographic traits
3816,Asian,6805.0,25055868.0,Sano M,Cardiovascular measurement,replication,2014-07-23,GCST002542,Electrocardiographic traits
12163,European,182413.0,25231870.0,Perry JR,Other measurement,initial,2014-07-23,GCST002541,Menarche (age at onset)
8435,European,4654.0,25057126.0,Ramos YF,Other measurement,initial,2014-07-23,GCST002540,Osteoarthritis biomarkers
8413,European,4591.0,25060954.0,Wolber LE,Biological process,initial,2014-07-24,GCST002543,Hearing function
13884,Other/Mixed,348.0,25060954.0,Wolber LE,Biological process,initial,2014-07-24,GCST002543,Hearing function
3841,Asian,7017.0,25064007.0,Nakajima M,Other disease,replication,2014-07-27,GCST002545,Ossification of the posterior longitudinal ligament of the spine
11794,European,108990.0,25064009.0,Nalls MA,Neurological disorder,initial,2014-07-27,GCST002544,Parkinson's disease
9859,European,10904.0,25064009.0,Nalls MA,Neurological disorder,replication,2014-07-27,GCST002544,Parkinson's disease
3938,Asian,7922.0,25064007.0,Nakajima M,Other disease,initial,2014-07-27,GCST002545,Ossification of the posterior longitudinal ligament of the spine
3350,Asian,3362.0,25087078.0,Anney RJ,Neurological disorder,initial,2014-07-30,GCST002547,Epilepsy
2308,Asian,702.0,25080503.0,Kwan JS,Cardiovascular measurement,initial,2014-07-30,GCST002546,Osteoprotegerin levels
1168,African American or Afro-Caribbean,3273.0,25087078.0,Anney RJ,Neurological disorder,initial,2014-07-30,GCST002547,Epilepsy
14094,Other/Mixed,1264.0,25087078.0,Anney RJ,Neurological disorder,initial,2014-07-30,GCST002547,Epilepsy
10664,European,23453.0,25087078.0,Anney RJ,Neurological disorder,initial,2014-07-30,GCST002547,Epilepsy
9676,European,9634.0,25080503.0,Kwan JS,Cardiovascular measurement,initial,2014-07-30,GCST002546,Osteoprotegerin levels
10816,European,28694.0,25082827.0,Julia A,Immune system disorder,initial,2014-07-31,GCST002548,Ulcerative colitis
7340,European,2352.0,25082827.0,Julia A,Immune system disorder,replication,2014-07-31,GCST002548,Ulcerative colitis
5245,European,430.0,24528284.0,Ji Y,"Response to drug, Neurological disorder",initial,2014-08-01,GCST002549,Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)
9021,European,6631.0,24869959.0,Jacobs LC,Other measurement,initial,2014-08-01,GCST006522,Upper eyelid sagging severity
760,African American or Afro-Caribbean,712.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002551,Allergic rhinitis in non-asthmatics
13121,Hispanic or Latin American,2326.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002550,Allergic rhinitis
13939,Other/Mixed,561.0,25085501.0,Bunyavanich S,"Other disease, Immune system disorder",initial,2014-08-02,GCST002552,Allergic rhinitis in asthma
6021,European,923.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002551,Allergic rhinitis in non-asthmatics
12961,Hispanic or Latin American,752.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002551,Allergic rhinitis in non-asthmatics
13085,Hispanic or Latin American,1574.0,25085501.0,Bunyavanich S,"Other disease, Immune system disorder",initial,2014-08-02,GCST002552,Allergic rhinitis in asthma
898,African American or Afro-Caribbean,1273.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002550,Allergic rhinitis
7071,European,2034.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002550,Allergic rhinitis
6296,European,1111.0,25085501.0,Bunyavanich S,"Other disease, Immune system disorder",initial,2014-08-02,GCST002552,Allergic rhinitis in asthma
10211,European,15295.0,25086665.0,Wolpin BM,Cancer,replication,2014-08-03,GCST002553,Pancreatic cancer
9065,European,6785.0,25086665.0,Wolpin BM,Cancer,initial,2014-08-03,GCST002553,Pancreatic cancer
5701,European,690.0,25140149.0,Hohman TJ,Other measurement,initial,2014-08-04,GCST002554,Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction)
4079,Asian,9802.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002557,Neutrophil count
10482,European,19509.0,25096241.0,Keller MF,"Hematological measurement, Inflammatory measurement",initial,2014-08-05,GCST002556,White blood cell count
1491,African American or Afro-Caribbean,16388.0,25096241.0,Keller MF,"Hematological measurement, Inflammatory measurement",initial,2014-08-05,GCST002556,White blood cell count
10297,European,16550.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002555,Monocyte count
10298,European,16550.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002557,Neutrophil count
4080,Asian,9810.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002555,Monocyte count
4316,Asian,16843.0,25096241.0,Keller MF,"Hematological measurement, Inflammatory measurement",initial,2014-08-05,GCST002556,White blood cell count
1343,African American or Afro-Caribbean,7391.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002557,Neutrophil count
1342,African American or Afro-Caribbean,7369.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002555,Monocyte count
2153,Asian,472.0,25096692.0,Chung WH,"Response to drug, Other disease",initial,2014-08-06,GCST002558,Phenytoin-induced severe cutaneous adverse reactions
6846,European,1725.0,25147783.0,Keene KL,"Other measurement, Cardiovascular disease",initial,2014-08-06,GCST002559,Vitamin B levels in ischemic stroke
3316,Asian,3038.0,25096692.0,Chung WH,"Response to drug, Other disease",replication,2014-08-06,GCST002558,Phenytoin-induced severe cutaneous adverse reactions
2064,Asian,380.0,25096692.0,Chung WH,"Response to drug, Other disease",replication,2014-08-06,GCST002558,Phenytoin-induced severe cutaneous adverse reactions
75,African,258.0,25147783.0,Keene KL,"Other measurement, Cardiovascular disease",initial,2014-08-06,GCST002559,Vitamin B levels in ischemic stroke
13760,Other/Mixed,117.0,25147783.0,Keene KL,"Other measurement, Cardiovascular disease",initial,2014-08-06,GCST002559,Vitamin B levels in ischemic stroke
1449,African American or Afro-Caribbean,11544.0,25102180.0,Ng MC,Metabolic disorder,replication,2014-08-07,GCST002560,Type 2 diabetes
1544,African American or Afro-Caribbean,23827.0,25102180.0,Ng MC,Metabolic disorder,initial,2014-08-07,GCST002560,Type 2 diabetes
11234,European,47117.0,25102180.0,Ng MC,Metabolic disorder,replication,2014-08-07,GCST002560,Type 2 diabetes
1322,African American or Afro-Caribbean,6596.0,25105248.0,Wang H,Cancer,initial,2014-08-08,GCST002561,Colorectal cancer
3795,Asian,6424.0,25105248.0,Wang H,Cancer,initial,2014-08-08,GCST002561,Colorectal cancer
11010,European,35034.0,25105248.0,Wang H,Cancer,replication,2014-08-08,GCST002561,Colorectal cancer
8136,European,3784.0,25108383.0,Geller F,Other disease,replication,2014-08-10,GCST002563,Hypospadias
3237,Asian,2783.0,25108386.0,Hou S,Neurological disorder,initial,2014-08-10,GCST002562,Vogt-Koyanagi-Harada syndrome
8989,European,6492.0,25108383.0,Geller F,Other disease,initial,2014-08-10,GCST002563,Hypospadias
2032,Asian,358.0,25108385.0,Yang SK,"Digestive system disorder, Other trait, Response to drug",replication,2014-08-10,GCST007229,Thiopurine-induced early leukopenia in Crohn's disease
3496,Asian,4358.0,25108386.0,Hou S,Neurological disorder,replication,2014-08-10,GCST002562,Vogt-Koyanagi-Harada syndrome
2017,Asian,340.0,25108385.0,Yang SK,"Digestive system disorder, Other trait, Response to drug",initial,2014-08-10,GCST007229,Thiopurine-induced early leukopenia in Crohn's disease
6339,European,1157.0,25111785.0,Jamain S,Neurological disorder,replication,2014-08-11,GCST002564,Bipolar disorder (early onset)
6989,European,1930.0,25111785.0,Jamain S,Neurological disorder,initial,2014-08-11,GCST002564,Bipolar disorder (early onset)
6996,European,1941.0,25109461.0,Ollila HM,Other measurement,initial,2014-08-11,GCST002565,Sleep duration
9083,European,6834.0,25109461.0,Ollila HM,Other measurement,replication,2014-08-11,GCST002565,Sleep duration
5628,European,642.0,25117820.0,Schneider BP,"Cancer, Cardiovascular disease, Response to drug",initial,2014-08-12,GCST002566,Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)
5629,European,642.0,25117820.0,Schneider BP,"Cancer, Cardiovascular disease, Response to drug",initial,2014-08-12,GCST002567,Response to chemotherapy in breast cancer (hypertension) (bevacizumab)
132,African,637.0,25014791.0,Govind N,Immune system disorder,initial,2014-08-14,GCST005562,Rheumatoid arthritis
4139,Asian,11124.0,25129146.0,Wu C,Cancer,initial,2014-08-17,GCST002568,Esophageal squamous cell carcinoma
4359,Asian,19712.0,25129146.0,Wu C,Cancer,replication,2014-08-17,GCST002568,Esophageal squamous cell carcinoma
5731,European,716.0,25138779.0,Mitchell LE,Cardiovascular disease,initial,2014-08-18,GCST002572,Congenital left-sided heart lesions
3630,Asian,5354.0,25133637.0,Scannell Bryan M,"Body measurement, Other measurement",initial,2014-08-18,GCST002571,Body mass index
5637,European,648.0,25138779.0,Mitchell LE,Cardiovascular disease,replication,2014-08-18,GCST002572,Congenital left-sided heart lesions
5638,European,648.0,25138779.0,Mitchell LE,"Cardiovascular disease, Other measurement",replication,2014-08-18,GCST002574,Congenital left-sided heart lesions (maternal effect)
3628,Asian,5344.0,25133637.0,Scannell Bryan M,"Other measurement, Body measurement",initial,2014-08-18,GCST002573,Height
3581,Asian,4983.0,25133637.0,Scannell Bryan M,Body measurement,initial,2014-08-18,GCST002575,Body mass index (change over time)
13687,Other/Mixed,24.0,25138779.0,Mitchell LE,"Cardiovascular disease, Other measurement",replication,2014-08-18,GCST002574,Congenital left-sided heart lesions (maternal effect)
5732,European,716.0,25138779.0,Mitchell LE,"Cardiovascular disease, Other measurement",initial,2014-08-18,GCST002574,Congenital left-sided heart lesions (maternal effect)
13686,Other/Mixed,24.0,25138779.0,Mitchell LE,Cardiovascular disease,replication,2014-08-18,GCST002572,Congenital left-sided heart lesions
3338,Asian,3244.0,25133637.0,Scannell Bryan M,Body measurement,initial,2014-08-18,GCST002570,Overweight status
13818,Other/Mixed,207.0,25138779.0,Mitchell LE,Cardiovascular disease,initial,2014-08-18,GCST002572,Congenital left-sided heart lesions
13819,Other/Mixed,207.0,25138779.0,Mitchell LE,"Cardiovascular disease, Other measurement",initial,2014-08-18,GCST002574,Congenital left-sided heart lesions (maternal effect)
3510,Asian,4474.0,25133637.0,Scannell Bryan M,Body measurement,initial,2014-08-18,GCST002569,Underweight status
3487,Asian,4255.0,25134534.0,Chen K,Cancer,replication,2014-08-19,GCST002576,Epithelial ovarian cancer
3082,Asian,2216.0,25134534.0,Chen K,Cancer,initial,2014-08-19,GCST002576,Epithelial ovarian cancer
2030,Asian,354.0,25145502.0,Tang S,"Other measurement, Cancer",initial,2014-08-22,GCST002577,Non-small cell lung cancer (survival)
2006,Asian,327.0,25145502.0,Tang S,"Other measurement, Cancer",replication,2014-08-22,GCST002577,Non-small cell lung cancer (survival)
2988,Asian,1999.0,25162662.0,Liao M,Other measurement,initial,2014-08-27,GCST002578,Ferritin levels
2710,Asian,1496.0,25162662.0,Liao M,Other measurement,replication,2014-08-27,GCST002578,Ferritin levels
6894,European,1778.0,25130324.0,Cai DC,Other measurement,initial,2014-08-29,GCST002579,Heschl's gyrus morphology
10791,European,27558.0,25173106.0,Hysi PG,Other measurement,initial,2014-08-31,GCST002580,Intraocular pressure
10035,European,13044.0,25173105.0,Gharahkhani P,Neurological disorder,replication,2014-08-31,GCST002582,Glaucoma (primary open-angle)
2972,Asian,1971.0,25173107.0,Chen Y,Neurological disorder,initial,2014-08-31,GCST002581,Glaucoma (high intraocular pressure)
3353,Asian,3377.0,25173107.0,Chen Y,Neurological disorder,replication,2014-08-31,GCST002581,Glaucoma (high intraocular pressure)
7793,European,3147.0,25173105.0,Gharahkhani P,Neurological disorder,initial,2014-08-31,GCST002582,Glaucoma (primary open-angle)
3923,Asian,7738.0,25173106.0,Hysi PG,Other measurement,initial,2014-08-31,GCST002580,Intraocular pressure
6652,European,1521.0,25072098.0,Bloom AJ,"Biological process, Other measurement",initial,2014-09-01,GCST002584,Exhaled carbon monoxide levels
5152,European,372.0,25410890.0,Frau F,"Other measurement, Response to drug",initial,2014-09-01,GCST002583,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels)
599,African American or Afro-Caribbean,247.0,25072098.0,Bloom AJ,"Biological process, Other measurement",initial,2014-09-01,GCST002584,Exhaled carbon monoxide levels
4932,European,216.0,25410890.0,Frau F,"Other measurement, Response to drug",replication,2014-09-01,GCST002583,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels)
4393,Asian,24740.0,25187374.0,Hwang JY,Other measurement,initial,2014-09-03,GCST002586,Fasting plasma glucose
3444,Asian,3963.0,25186300.0,Terao C,Other measurement,replication,2014-09-03,GCST002585,Antinuclear antibody levels
4371,Asian,21345.0,25187374.0,Hwang JY,Other measurement,replication,2014-09-03,GCST002586,Fasting plasma glucose
3334,Asian,3185.0,25186300.0,Terao C,Other measurement,initial,2014-09-03,GCST002585,Antinuclear antibody levels
6527,European,1357.0,25187353.0,Goldstein JI,"Response to drug, Other trait",initial,2014-09-04,GCST002595,Clozapine-induced agranulocytosis
10421,European,18509.0,25192705.0,Du M,"Other measurement, Cancer",initial,2014-09-05,GCST002596,Colorectal cancer (calcium intake interaction)
6898,European,1784.0,25442119.0,McLaughlin RL,"Neurological disorder, Other measurement",initial,2014-09-06,GCST007145,Amyotrophic lateral sclerosis (age of onset)
6897,European,1784.0,25442119.0,McLaughlin RL,Neurological disorder,initial,2014-09-06,GCST007144,Amyotrophic lateral sclerosis
6397,European,1204.0,25442119.0,McLaughlin RL,Neurological disorder,initial,2014-09-06,GCST007146,Amyotrophic lateral sclerosis
3300,Asian,2988.0,25194280.0,Wei Q,Cancer,initial,2014-09-07,GCST002597,Laryngeal squamous cell carcinoma
3604,Asian,5202.0,25194280.0,Wei Q,Cancer,replication,2014-09-07,GCST002597,Laryngeal squamous cell carcinoma
11772,European,106736.0,25201988.0,Rietveld CA,Other measurement,initial,2014-09-08,GCST002598,Educational attainment
9866,European,11001.0,25200001.0,Robinson PC,Neurological disorder,initial,2014-09-08,GCST007362,Acute anterior uveitis (with or without ankylosing spondylitis)
9704,European,9793.0,25199915.0,Broer L,Other measurement,initial,2014-09-08,GCST002599,Longevity (90 years and older)
7697,European,2930.0,25200001.0,Robinson PC,"Immune system disorder, Neurological disorder",initial,2014-09-08,GCST007361,Acute anterior uveitis in ankylosing spondylitis
5238,European,425.0,25201287.0,Del-Aguila JL,"Response to drug, Other trait",initial,2014-09-09,GCST002600,Response to thiazide diuretic treatment (hypokalemia)
649,African American or Afro-Caribbean,342.0,25201287.0,Del-Aguila JL,"Response to drug, Other trait",initial,2014-09-09,GCST002600,Response to thiazide diuretic treatment (hypokalemia)
7870,European,3244.0,25208887.0,Ma Q,Other measurement,initial,2014-09-10,GCST002601,Plasma plasminogen levels
7960,European,3389.0,25214527.0,Dube MP,"Cardiovascular measurement, Response to drug",replication,2014-09-11,GCST002603,Creatine kinase in statin users
7980,European,3412.0,25214527.0,Dube MP,"Cardiovascular measurement, Response to drug",initial,2014-09-11,GCST002603,Creatine kinase in statin users
6836,European,1718.0,25208829.0,Anderson D,Other measurement,initial,2014-09-11,GCST002602,Vitamin D levels
6748,European,1611.0,25224099.0,Gueant JL,Other measurement,initial,2014-09-12,GCST007161,beta-lactam allergy measurement
5660,European,661.0,25224099.0,Gueant JL,Other measurement,replication,2014-09-12,GCST007161,beta-lactam allergy measurement
4891,European,195.0,25223841.0,Li J,Neurological disorder,replication,2014-09-13,GCST002604,Schizophrenia (treatment resistant)
4840,European,174.0,25223841.0,Li J,Neurological disorder,initial,2014-09-13,GCST002604,Schizophrenia (treatment resistant)
335,African,10463.0,25217961.0,Al Olama AA,Cancer,initial,2014-09-14,GCST002606,Prostate cancer
13110,Hispanic or Latin American,2080.0,25217961.0,Al Olama AA,Cancer,initial,2014-09-14,GCST002606,Prostate cancer
7241,European,2207.0,25217962.0,Heap GA,"Digestive system disorder, Response to drug",initial,2014-09-14,GCST002607,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)
4698,European,78.0,25217962.0,Heap GA,"Digestive system disorder, Response to drug",replication,2014-09-14,GCST002607,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)
11471,European,67543.0,25217961.0,Al Olama AA,Cancer,initial,2014-09-14,GCST002606,Prostate cancer
6112,European,972.0,25218607.0,Coleman EA,"Digestive system disorder, Response to drug, Cancer",initial,2014-09-14,GCST002605,Response to chemotherapy in multiple myeloma (oral mucositis) (high-dose melphalan)
3837,Asian,6954.0,25217961.0,Al Olama AA,Cancer,initial,2014-09-14,GCST002606,Prostate cancer
1039,African American or Afro-Caribbean,2347.0,25224454.0,Li J,Other measurement,initial,2014-09-15,GCST002609,Iron status biomarkers
5429,European,510.0,25221879.0,Wu K,"Other measurement, Other disease",initial,2014-09-15,GCST002608,Pulmonary function in asthmatics
637,African American or Afro-Caribbean,329.0,25224454.0,Li J,Other measurement,replication,2014-09-15,GCST002609,Iron status biomarkers
2172,Asian,484.0,25223902.0,Go MJ,Other measurement,initial,2014-09-16,GCST002610,Fasting plasma glucose (childhood)
10040,European,13150.0,25226531.0,St Pourcain B,Biological process,initial,2014-09-16,GCST002611,Expressive vocabulary in infants
9010,European,6558.0,25226531.0,St Pourcain B,Biological process,replication,2014-09-16,GCST002611,Expressive vocabulary in infants
2379,Asian,776.0,25223902.0,Go MJ,Other measurement,replication,2014-09-16,GCST002610,Fasting plasma glucose (childhood)
7073,European,2036.0,25237182.0,Erickson SW,Cancer,initial,2014-09-18,GCST002614,Multiple myeloma
10108,European,13912.0,25233373.0,Simpson CL,"Other trait, Neurological disorder",initial,2014-09-18,GCST002617,Hyperopia
5932,European,849.0,25234806.0,Dijkstra AE,"Other disease, Other trait",initial,2014-09-18,GCST002612,Chronic mucus hypersecretion in chronic obstructive pulmonary disease
6519,European,1348.0,25234806.0,Dijkstra AE,Other trait,initial,2014-09-18,GCST002613,Chronic mucus hypersecretion
7399,European,2443.0,25234806.0,Dijkstra AE,Other trait,replication,2014-09-18,GCST002613,Chronic mucus hypersecretion
7774,European,3106.0,25234806.0,Dijkstra AE,"Other disease, Other trait",replication,2014-09-18,GCST002612,Chronic mucus hypersecretion in chronic obstructive pulmonary disease
7818,European,3208.0,25233373.0,Simpson CL,"Other trait, Neurological disorder",replication,2014-09-18,GCST002617,Hyperopia
5168,European,386.0,25240745.0,Lopez S,Other measurement,initial,2014-09-18,GCST002616,Mitochondrial DNA levels
8410,European,4581.0,25233373.0,Simpson CL,Other trait,replication,2014-09-18,GCST002615,Myopia
10228,European,15619.0,25233373.0,Simpson CL,Other trait,initial,2014-09-18,GCST002615,Myopia
14233,Other/Mixed,5503.0,25352737.0,Ritchie MD,"Other measurement, Other trait",initial,2014-09-19,GCST002618,Age-related cataracts (age at onset)
44,African,114.0,25352737.0,Ritchie MD,Other trait,initial,2014-09-19,GCST002619,Age-related cataracts
13799,Other/Mixed,174.0,25352737.0,Ritchie MD,Other trait,initial,2014-09-19,GCST002619,Age-related cataracts
9149,European,7109.0,25352737.0,Ritchie MD,Other trait,initial,2014-09-19,GCST002619,Age-related cataracts
6333,European,1151.0,25245031.0,Luneburg N,"Cardiovascular measurement, Other measurement",replication,2014-09-21,GCST002620,Asymmetrical dimethylarginine levels
6334,European,1152.0,25245031.0,Luneburg N,"Cardiovascular measurement, Other measurement",replication,2014-09-21,GCST002622,Symmetrical dimethylarginine levels
8740,European,5439.0,25241909.0,Lee JH,Other disease,initial,2014-09-21,GCST002621,Chronic bronchitis in chronic obstructive pulmonary disease
8119,European,3747.0,25245031.0,Luneburg N,Other measurement,initial,2014-09-21,GCST002623,L-arginine levels
9180,European,7297.0,25241909.0,Lee JH,Other disease,initial,2014-09-21,GCST002624,Chronic obstructive pulmonary disease
8741,European,5439.0,25241909.0,Lee JH,Other disease,initial,2014-09-21,GCST002625,Chronic bronchitis and chronic obstructive pulmonary disease
6340,European,1159.0,25245031.0,Luneburg N,Other measurement,replication,2014-09-21,GCST002623,L-arginine levels
8116,European,3742.0,25245031.0,Luneburg N,"Cardiovascular measurement, Other measurement",initial,2014-09-21,GCST002620,Asymmetrical dimethylarginine levels
8118,European,3745.0,25245031.0,Luneburg N,"Cardiovascular measurement, Other measurement",initial,2014-09-21,GCST002622,Symmetrical dimethylarginine levels
979,African American or Afro-Caribbean,1931.0,25241909.0,Lee JH,Other disease,initial,2014-09-21,GCST002625,Chronic bronchitis and chronic obstructive pulmonary disease
3000,Asian,2026.0,25241763.0,Springelkamp H,Other measurement,replication,2014-09-22,GCST002626,Vertical cup-disc ratio
10557,European,21094.0,25241763.0,Springelkamp H,Other measurement,initial,2014-09-22,GCST002626,Vertical cup-disc ratio
3160,Asian,2453.0,25241763.0,Springelkamp H,Other measurement,replication,2014-09-22,GCST002626,Vertical cup-disc ratio
3116,Asian,2305.0,25241763.0,Springelkamp H,Other measurement,replication,2014-09-22,GCST002626,Vertical cup-disc ratio
8755,European,5466.0,25248455.0,Ek WE,Digestive system disorder,initial,2014-09-23,GCST002629,Irritable bowel syndrome
4538,Asian,69146.0,25249183.0,Lu X,Other measurement,replication,2014-09-23,GCST002631,Diastolic blood pressure
4536,Asian,69146.0,25249183.0,Lu X,Cardiovascular disease,replication,2014-09-23,GCST002627,Hypertension
6954,European,1868.0,25246029.0,DiStefano JK,"Lipid or lipoprotein measurement, Metabolic disorder",initial,2014-09-23,GCST002632,Hepatic lipid content in extreme obesity
8025,European,3511.0,25248455.0,Ek WE,Digestive system disorder,replication,2014-09-23,GCST002629,Irritable bowel syndrome
4537,Asian,69146.0,25249183.0,Lu X,Other measurement,replication,2014-09-23,GCST002630,Systolic blood pressure
6955,European,1868.0,25246029.0,DiStefano JK,"Metabolic disorder, Other measurement",initial,2014-09-23,GCST002628,Bilirubin levels in extreme obesity
4069,Asian,9469.0,25249183.0,Lu X,Cardiovascular disease,initial,2014-09-23,GCST002627,Hypertension
4177,Asian,11816.0,25249183.0,Lu X,Other measurement,initial,2014-09-23,GCST002630,Systolic blood pressure
4178,Asian,11816.0,25249183.0,Lu X,Other measurement,initial,2014-09-23,GCST002631,Diastolic blood pressure
8659,European,5165.0,25256182.0,Foroud T,Cardiovascular disease,initial,2014-09-25,GCST002633,Intracranial aneurysm
2512,Asian,1026.0,25303641.0,Zhang F,Other disease,replication,2014-09-25,GCST002634,Kashin-Beck disease
6497,European,1312.0,25256105.0,Freitag-Wolf S,"Digestive system disorder, Other measurement",initial,2014-09-25,GCST002635,Aggressive periodontitis (sex interaction)
9084,European,6837.0,25256182.0,Foroud T,Cardiovascular disease,replication,2014-09-25,GCST002633,Intracranial aneurysm
2818,Asian,1717.0,25303641.0,Zhang F,Other disease,initial,2014-09-25,GCST002634,Kashin-Beck disease
5960,European,871.0,25256105.0,Freitag-Wolf S,"Digestive system disorder, Other measurement",replication,2014-09-25,GCST002635,Aggressive periodontitis (sex interaction)
8868,European,5916.0,25261932.0,Cerhan JR,Cancer,replication,2014-09-28,GCST002636,Diffuse large B cell lymphoma
9919,European,11523.0,25261932.0,Cerhan JR,Cancer,initial,2014-09-28,GCST002636,Diffuse large B cell lymphoma
1830,Asian,178.0,25266886.0,Kim JJ,"Immune system disorder, Other measurement, Inflammatory measurement",initial,2014-09-30,GCST002640,Inflammatory biomarkers in Kawasaki disease
2636,Asian,1302.0,25317111.0,Seo I,"Biological process, Cardiovascular disease, Metabolic disorder",initial,2014-09-30,GCST002637,Medication adherence in chronic diseases
2154,Asian,473.0,25266886.0,Kim JJ,"Immune system disorder, Other measurement, Inflammatory measurement",replication,2014-09-30,GCST002640,Inflammatory biomarkers in Kawasaki disease
8527,European,4899.0,25534755.0,Chaste P,"Neurological disorder, Other measurement",initial,2014-09-30,GCST002639,Autism spectrum disorder-related traits
3995,Asian,8738.0,25317112.0,Oh S,Digestive system disorder,initial,2014-09-30,GCST002638,Gastritis
2213,Asian,548.0,25271088.0,Singh A,"Other measurement, Body measurement",initial,2014-10-01,GCST002641,Hip circumference (psychosocial stress interaction)
7411,European,2460.0,25271088.0,Singh A,"Other measurement, Body measurement",initial,2014-10-01,GCST002641,Hip circumference (psychosocial stress interaction)
5518,European,562.0,25089948.0,Theusch E,"Other measurement, Response to drug",initial,2014-10-01,GCST002642,Response to simvastatin treatment (PCSK9 protein level change)
13041,Hispanic or Latin American,1250.0,25271088.0,Singh A,"Other measurement, Body measurement",initial,2014-10-01,GCST002641,Hip circumference (psychosocial stress interaction)
939,African American or Afro-Caribbean,1547.0,25271088.0,Singh A,"Other measurement, Body measurement",initial,2014-10-01,GCST002641,Hip circumference (psychosocial stress interaction)
7797,European,3157.0,25271088.0,Singh A,"Other measurement, Body measurement",replication,2014-10-01,GCST002641,Hip circumference (psychosocial stress interaction)
620,African American or Afro-Caribbean,287.0,25089948.0,Theusch E,"Other measurement, Response to drug",replication,2014-10-01,GCST002642,Response to simvastatin treatment (PCSK9 protein level change)
9203,European,7381.0,25279986.0,Skibola CF,Cancer,replication,2014-10-02,GCST002643,Follicular lymphoma
9797,European,10486.0,25279986.0,Skibola CF,Cancer,initial,2014-10-02,GCST002643,Follicular lymphoma
3758,Asian,6112.0,25281661.0,Matsuda K,Cancer,initial,2014-10-03,GCST002645,Bladder cancer
10803,European,28238.0,25281659.0,van der Valk RJ,Body measurement,initial,2014-10-03,GCST002646,Infant length
13955,Other/Mixed,603.0,25281659.0,van der Valk RJ,Body measurement,replication,2014-10-03,GCST002644,Birth length
9517,European,8609.0,25281661.0,Matsuda K,Cancer,replication,2014-10-03,GCST002645,Bladder cancer
10807,European,28439.0,25281659.0,van der Valk RJ,Body measurement,initial,2014-10-03,GCST002644,Birth length
10257,European,16145.0,25281659.0,van der Valk RJ,Body measurement,replication,2014-10-03,GCST002644,Birth length
2263,Asian,651.0,25281659.0,van der Valk RJ,Body measurement,replication,2014-10-03,GCST002644,Birth length
3888,Asian,7556.0,25281661.0,Matsuda K,Cancer,replication,2014-10-03,GCST002645,Bladder cancer
13849,Other/Mixed,280.0,25281659.0,van der Valk RJ,Body measurement,replication,2014-10-03,GCST002644,Birth length
11582,European,80067.0,25282103.0,Wood AR,"Other measurement, Body measurement",replication,2014-10-05,GCST002647,Height
12309,European,253288.0,25282103.0,Wood AR,"Other measurement, Body measurement",initial,2014-10-05,GCST002647,Height
6378,European,1191.0,25284319.0,Sanchez-Mora C,Neurological disorder,initial,2014-10-06,GCST002648,Persistent attention-deficit hyperactivity disorder
8218,European,4005.0,25284319.0,Sanchez-Mora C,Neurological disorder,replication,2014-10-06,GCST002648,Persistent attention-deficit hyperactivity disorder
13856,Other/Mixed,311.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002649,Nicotine glucouronidation
1372,African American or Afro-Caribbean,7964.0,25288136.0,Cornelis MC,"Biological process, Other measurement",replication,2014-10-07,GCST002650,Coffee consumption (cups per day)
657,African American or Afro-Caribbean,364.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002652,Cotinine glucuronidation
1216,African American or Afro-Caribbean,3845.0,25288136.0,Cornelis MC,"Biological process, Other measurement",replication,2014-10-07,GCST002651,Coffee consumption
2285,Asian,674.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002652,Cotinine glucuronidation
10854,European,30062.0,25288136.0,Cornelis MC,"Biological process, Other measurement",replication,2014-10-07,GCST002650,Coffee consumption (cups per day)
11251,European,48528.0,25288136.0,Cornelis MC,"Biological process, Other measurement",initial,2014-10-07,GCST002651,Coffee consumption
11717,European,91462.0,25288136.0,Cornelis MC,"Biological process, Other measurement",initial,2014-10-07,GCST002650,Coffee consumption (cups per day)
12876,Hispanic or Latin American,453.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002649,Nicotine glucouronidation
656,African American or Afro-Caribbean,364.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002649,Nicotine glucouronidation
2284,Asian,674.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002649,Nicotine glucouronidation
12877,Hispanic or Latin American,453.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002652,Cotinine glucuronidation
10068,European,13469.0,25288136.0,Cornelis MC,"Biological process, Other measurement",replication,2014-10-07,GCST002651,Coffee consumption
5275,European,437.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002649,Nicotine glucouronidation
13857,Other/Mixed,311.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002652,Cotinine glucuronidation
5276,European,437.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002652,Cotinine glucuronidation
7155,European,2138.0,25411281.0,Dashti HS,Other measurement,initial,2014-10-08,GCST002653,Circulating phylloquinone levels
261,African,3485.0,25297839.0,Crosslin DR,"Other disease, Other measurement",initial,2014-10-09,GCST002654,Shingles
10418,European,18423.0,25297839.0,Crosslin DR,"Other disease, Other measurement",initial,2014-10-09,GCST002654,Shingles
12928,Hispanic or Latin American,621.0,25297839.0,Crosslin DR,"Other disease, Other measurement",initial,2014-10-09,GCST002654,Shingles
8417,European,4603.0,25305756.0,Kiryluk K,Other disease,initial,2014-10-12,GCST002655,IgA nephropathy
3489,Asian,4271.0,25305756.0,Kiryluk K,Other disease,replication,2014-10-12,GCST002655,IgA nephropathy
3024,Asian,2096.0,25305756.0,Kiryluk K,Other disease,initial,2014-10-12,GCST002655,IgA nephropathy
6143,European,986.0,25451450.0,Jacobsen KK,"Cardiovascular disease, Neurological disorder",replication,2014-10-12,GCST002656,Migraine in bipolar disorder
9679,European,9642.0,25305756.0,Kiryluk K,Other disease,replication,2014-10-12,GCST002655,IgA nephropathy
6557,European,1374.0,25451450.0,Jacobsen KK,"Cardiovascular disease, Neurological disorder",initial,2014-10-12,GCST002656,Migraine in bipolar disorder
7038,European,1983.0,25310577.0,Evans TJ,Cancer,replication,2014-10-13,GCST002657,Acute lymphoblastic leukemia (childhood)
2217,Asian,555.0,25310821.0,Kim JH,Digestive system disorder,initial,2014-10-13,GCST002658,Hirschsprung disease
6695,European,1550.0,25310577.0,Evans TJ,Cancer,initial,2014-10-13,GCST002657,Acute lymphoblastic leukemia (childhood)
2282,Asian,667.0,25328121.0,Lee JY,"Cardiovascular measurement, Cardiovascular disease",initial,2014-10-17,GCST002659,Coronary artery disease-related phenotypes
2427,Asian,853.0,25328121.0,Lee JY,"Cardiovascular measurement, Cardiovascular disease",replication,2014-10-17,GCST002659,Coronary artery disease-related phenotypes
5337,European,474.0,25457201.0,de Tayrac M,"Metabolic disorder, Other measurement",initial,2014-10-18,GCST002660,Hereditary hemochromatosis-related traits (HFE mutation homozygotes)
5786,European,746.0,25457201.0,de Tayrac M,"Metabolic disorder, Other measurement",replication,2014-10-18,GCST002660,Hereditary hemochromatosis-related traits (HFE mutation homozygotes)
10188,European,15031.0,25329471.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2014-10-20,GCST002661,HDL cholesterol (SNP x SNP interaction)
13337,Hispanic or Latin American,6614.0,25327703.0,Fejerman L,Cancer,replication,2014-10-20,GCST002662,Breast cancer
13264,Hispanic or Latin American,4710.0,25327703.0,Fejerman L,Cancer,initial,2014-10-20,GCST002662,Breast cancer
7728,European,2996.0,25329471.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2014-10-20,GCST002661,HDL cholesterol (SNP x SNP interaction)
13741,Other/Mixed,80.0,25729143.0,Ahmetov I,Other measurement,initial,2014-10-21,GCST002664,Maximal oxygen uptake response
2203,Asian,536.0,25335168.0,Hashimoto R,Other measurement,initial,2014-10-21,GCST002663,Superior frontal gyrus grey matter volume
5215,European,410.0,25338677.0,Kariuki SN,"Other measurement, Immune system disorder",initial,2014-10-23,GCST002666,Interferon alpha levels in systemic lupus erythematosus
694,African American or Afro-Caribbean,450.0,25338677.0,Kariuki SN,"Other measurement, Immune system disorder",replication,2014-10-23,GCST002666,Interferon alpha levels in systemic lupus erythematosus
5730,European,715.0,25338677.0,Kariuki SN,"Other measurement, Immune system disorder",replication,2014-10-23,GCST002666,Interferon alpha levels in systemic lupus erythematosus
8277,European,4162.0,25343990.0,Cornelis MC,Other measurement,initial,2014-10-24,GCST002671,Toenail selenium levels
14122,Other/Mixed,1472.0,25342443.0,Lindstrom S,Other measurement,replication,2014-10-24,GCST002668,Mammographic density (non-dense area)
5112,European,343.0,25342443.0,Lindstrom S,"Other measurement, Cancer",replication,2014-10-24,GCST002669,Percent mammographic density
9255,European,7600.0,25342443.0,Lindstrom S,Other measurement,initial,2014-10-24,GCST002668,Mammographic density (non-dense area)
14123,Other/Mixed,1472.0,25342443.0,Lindstrom S,"Other measurement, Cancer",replication,2014-10-24,GCST002669,Percent mammographic density
14121,Other/Mixed,1472.0,25342443.0,Lindstrom S,Other measurement,replication,2014-10-24,GCST002667,Mammographic density (dense area)
9314,European,7916.0,25342443.0,Lindstrom S,"Other measurement, Cancer",initial,2014-10-24,GCST002669,Percent mammographic density
5110,European,343.0,25342443.0,Lindstrom S,Other measurement,replication,2014-10-24,GCST002667,Mammographic density (dense area)
9677,European,9639.0,25343990.0,Cornelis MC,Other measurement,initial,2014-10-24,GCST002670,Blood and toenail selenium levels
5111,European,343.0,25342443.0,Lindstrom S,Other measurement,replication,2014-10-24,GCST002668,Mammographic density (non-dense area)
9254,European,7600.0,25342443.0,Lindstrom S,Other measurement,initial,2014-10-24,GCST002667,Mammographic density (dense area)
8607,European,5047.0,25344690.0,Feenstra B,Other trait,initial,2014-10-26,GCST002674,Febrile seizures (MMR vaccine-related)
7565,European,2679.0,25344690.0,Feenstra B,Other trait,replication,2014-10-26,GCST002673,Febrile seizures (MMR vaccine-unrelated)
7761,European,3087.0,25344690.0,Feenstra B,Other trait,replication,2014-10-26,GCST002674,Febrile seizures (MMR vaccine-related)
7760,European,3087.0,25344690.0,Feenstra B,Other trait,replication,2014-10-26,GCST002672,Febrile seizures
8909,European,6117.0,25344690.0,Feenstra B,Other trait,initial,2014-10-26,GCST002672,Febrile seizures
8638,European,5118.0,25344690.0,Feenstra B,Other trait,initial,2014-10-26,GCST002673,Febrile seizures (MMR vaccine-unrelated)
10429,European,18596.0,25350695.0,Postmus I,"Lipid or lipoprotein measurement, Response to drug",initial,2014-10-28,GCST002675,Response to statins (LDL cholesterol change)
10661,European,23279.0,25350695.0,Postmus I,"Lipid or lipoprotein measurement, Response to drug",replication,2014-10-28,GCST002675,Response to statins (LDL cholesterol change)
10690,European,23986.0,25352340.0,Benyamin B,Other measurement,initial,2014-10-29,GCST002678,Iron status biomarkers (transferrin levels)
10731,European,24986.0,25352340.0,Benyamin B,Other measurement,replication,2014-10-29,GCST002680,Iron status biomarkers (transferrin saturation)
10689,European,23986.0,25352340.0,Benyamin B,Other measurement,initial,2014-10-29,GCST002677,Iron status biomarkers (ferritin levels)
10691,European,23986.0,25352340.0,Benyamin B,Other measurement,initial,2014-10-29,GCST002679,Iron status biomarkers (iron levels)
10730,European,24986.0,25352340.0,Benyamin B,Other measurement,replication,2014-10-29,GCST002679,Iron status biomarkers (iron levels)
10729,European,24986.0,25352340.0,Benyamin B,Other measurement,replication,2014-10-29,GCST002678,Iron status biomarkers (transferrin levels)
10728,European,24986.0,25352340.0,Benyamin B,Other measurement,replication,2014-10-29,GCST002677,Iron status biomarkers (ferritin levels)
10692,European,23986.0,25352340.0,Benyamin B,Other measurement,initial,2014-10-29,GCST002680,Iron status biomarkers (transferrin saturation)
5343,European,478.0,25353672.0,Fernandez-Navarro P,Other measurement,initial,2014-10-29,GCST002676,Mammographic density
577,African American or Afro-Caribbean,205.0,25456346.0,Nievergelt CM,Neurological disorder,initial,2014-10-30,GCST002681,Post-traumatic stress disorder
2151,Asian,470.0,25456346.0,Nievergelt CM,Neurological disorder,initial,2014-10-30,GCST002681,Post-traumatic stress disorder
7201,European,2179.0,25456346.0,Nievergelt CM,Neurological disorder,initial,2014-10-30,GCST002681,Post-traumatic stress disorder
13973,Other/Mixed,640.0,25456346.0,Nievergelt CM,Neurological disorder,initial,2014-10-30,GCST002681,Post-traumatic stress disorder
5385,European,491.0,25456346.0,Nievergelt CM,Neurological disorder,replication,2014-10-30,GCST002681,Post-traumatic stress disorder
9612,European,9260.0,25158072.0,Yu D,Neurological disorder,initial,2014-10-31,GCST002682,Tourette's syndrome or obsessive-compulsive disorder
8171,European,3889.0,25409777.0,Thyagarajan B,Other measurement,initial,2014-11-01,GCST002683,Pulmonary function
2747,Asian,1540.0,25364816.0,Awata T,Metabolic disorder,replication,2014-11-03,GCST002684,Diabetic retinopathy in type 2 diabetes
2127,Asian,446.0,25364816.0,Awata T,Metabolic disorder,initial,2014-11-03,GCST002684,Diabetic retinopathy in type 2 diabetes
2976,Asian,1998.0,25367360.0,Li Q,Other trait,initial,2014-11-04,GCST002685,Refractive astigmatism
11068,European,37608.0,25367360.0,Li Q,Other trait,initial,2014-11-04,GCST002685,Refractive astigmatism
3751,Asian,6049.0,25367360.0,Li Q,Other trait,initial,2014-11-04,GCST002685,Refractive astigmatism
3063,Asian,2165.0,25367360.0,Li Q,Other trait,initial,2014-11-04,GCST002685,Refractive astigmatism
91,African,321.0,25372704.0,Mtatiro SN,"Neurological disorder, Hematological measurement",replication,2014-11-05,GCST002687,Fetal hemoglobin levels in sickle cell anemia
1074,African American or Afro-Caribbean,2701.0,25376901.0,Munir MS,Hematological measurement,initial,2014-11-05,GCST002686,Protein C levels
176,African,1213.0,25372704.0,Mtatiro SN,"Neurological disorder, Hematological measurement",initial,2014-11-05,GCST002687,Fetal hemoglobin levels in sickle cell anemia
9770,European,10129.0,25378659.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2014-11-06,GCST002688,Very long-chain saturated fatty acid levels (fatty acid 22:0)
9771,European,10129.0,25378659.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2014-11-06,GCST002690,Very long-chain saturated fatty acid levels (fatty acid 20:0)
9313,European,7915.0,25378659.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2014-11-06,GCST002689,Very long-chain saturated fatty acid levels (fatty acid 24:0)
13649,Other/Mixed,8.0,25378290.0,McQueen MB,Body measurement,initial,2014-11-07,GCST002692,Body mass index (change over time)
498,African American or Afro-Caribbean,94.0,25670933.0,Hanchard NA,"Neurological disorder, Biological process",initial,2014-11-07,GCST002691,Alloimmunization response to red blood cell transfusion in sickle cell anemia
6013,European,917.0,25378290.0,McQueen MB,Body measurement,initial,2014-11-07,GCST002692,Body mass index (change over time)
1686,Asian,73.0,25378290.0,McQueen MB,Body measurement,initial,2014-11-07,GCST002692,Body mass index (change over time)
742,African American or Afro-Caribbean,677.0,25378290.0,McQueen MB,Body measurement,initial,2014-11-07,GCST002692,Body mass index (change over time)
12814,Hispanic or Latin American,209.0,25378290.0,McQueen MB,Body measurement,initial,2014-11-07,GCST002692,Body mass index (change over time)
3159,Asian,2443.0,25383971.0,Dunstan SJ,Other disease,initial,2014-11-10,GCST002693,Enteric fever
9148,European,7100.0,25383866.0,Kirkpatrick RM,Biological process,initial,2014-11-10,GCST002694,General cognitive ability
2495,Asian,981.0,25383971.0,Dunstan SJ,Other disease,replication,2014-11-10,GCST002693,Enteric fever
2407,Asian,819.0,25383971.0,Dunstan SJ,Other disease,replication,2014-11-10,GCST002693,Enteric fever
13890,Other/Mixed,363.0,25385369.0,Ramanan VK,Biological process,replication,2014-11-11,GCST002695,Episodic memory
9036,European,6687.0,25385369.0,Ramanan VK,Biological process,replication,2014-11-11,GCST002695,Episodic memory
8693,European,5283.0,25385369.0,Ramanan VK,Biological process,initial,2014-11-11,GCST002695,Episodic memory
758,African American or Afro-Caribbean,711.0,25385369.0,Ramanan VK,Biological process,replication,2014-11-11,GCST002695,Episodic memory
784,African American or Afro-Caribbean,817.0,25385369.0,Ramanan VK,Biological process,initial,2014-11-11,GCST002695,Episodic memory
13961,Other/Mixed,605.0,25385369.0,Ramanan VK,Biological process,initial,2014-11-11,GCST002695,Episodic memory
732,African American or Afro-Caribbean,597.0,25390645.0,Otowa T,Neurological disorder,initial,2014-11-12,GCST002696,Anxiety disorder
6812,European,1697.0,25390645.0,Otowa T,Neurological disorder,initial,2014-11-12,GCST002696,Anxiety disorder
6199,European,1008.0,25407941.0,Sleiman PM,Digestive system disorder,replication,2014-11-19,GCST002697,Eosinophilic esophagitis
8305,European,4240.0,25407941.0,Sleiman PM,Digestive system disorder,initial,2014-11-19,GCST002697,Eosinophilic esophagitis
5757,European,736.0,25411163.0,Maitland ML,Other measurement,initial,2014-11-19,GCST002698,Serum VEGFR2 concentration
6096,European,959.0,25917933.0,Zai CC,"Biological process, Neurological disorder, Other measurement",initial,2014-11-20,GCST002699,Suicide in bipolar disorder
10237,European,15809.0,25420145.0,Debette S,Cardiovascular disease,initial,2014-11-24,GCST002700,Cervical artery dissection
7906,European,3307.0,25420145.0,Debette S,Cardiovascular disease,replication,2014-11-24,GCST002700,Cervical artery dissection
1213,African American or Afro-Caribbean,3811.0,25648963.0,Debette S,Other measurement,replication,2014-11-25,GCST002701,Verbal declarative memory
10832,European,29076.0,25648963.0,Debette S,Other measurement,initial,2014-11-25,GCST002701,Verbal declarative memory
9817,European,10617.0,25648963.0,Debette S,Other measurement,replication,2014-11-25,GCST002701,Verbal declarative memory
4524,Asian,57699.0,25429064.0,He M,"Other measurement, Body measurement",replication,2014-11-26,GCST002702,Height
4465,Asian,36227.0,25429064.0,He M,"Other measurement, Body measurement",initial,2014-11-26,GCST002702,Height
2198,Asian,523.0,25429627.0,Oryoji D,Immune system disorder,initial,2014-11-27,GCST002705,Hashimoto thyroiditis versus Graves' disease
6410,European,1211.0,25431337.0,Bouzigon E,Other measurement,initial,2014-11-27,GCST002704,Fractional exhaled nitric oxide levels
2216,Asian,554.0,25434496.0,Kim S,Other measurement,initial,2014-11-27,GCST002703,Prostate-specific antigen levels
9618,European,9308.0,25431337.0,Bouzigon E,Other measurement,replication,2014-11-27,GCST002704,Fractional exhaled nitric oxide levels
2146,Asian,467.0,25429627.0,Oryoji D,Immune system disorder,replication,2014-11-27,GCST002705,Hashimoto thyroiditis versus Graves' disease
2758,Asian,1575.0,25434496.0,Kim S,Other measurement,replication,2014-11-27,GCST002703,Prostate-specific antigen levels
8378,European,4469.0,25387707.0,Vaidyanathan U,Other measurement,initial,2014-12-01,GCST002710,Anti-saccade response
8361,European,4424.0,25387706.0,Vaidyanathan U,Other measurement,initial,2014-12-01,GCST002706,Electrodermal activity
652,African American or Afro-Caribbean,351.0,25436638.0,Malinowski JR,Other measurement,initial,2014-12-01,GCST002707,Serum thyroid-stimulating hormone levels
8228,European,4026.0,25387704.0,Malone SM,Other measurement,initial,2014-12-01,GCST002709,Electroencephalogram traits
7915,European,3323.0,25387708.0,Vaidyanathan U,Other measurement,initial,2014-12-01,GCST002708,Acoustic startle blink response
8389,European,4501.0,25436638.0,Malinowski JR,Other measurement,initial,2014-12-01,GCST002707,Serum thyroid-stimulating hormone levels
6629,European,1480.0,25468567.0,Perez-Andreu V,Cancer,initial,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
852,African American or Afro-Caribbean,1085.0,25468567.0,Perez-Andreu V,Cancer,replication,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
14192,Other/Mixed,3027.0,25468567.0,Perez-Andreu V,Cancer,initial,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
8115,European,3739.0,25468567.0,Perez-Andreu V,Cancer,replication,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
1261,African American or Afro-Caribbean,4771.0,25469926.0,Gottlieb DJ,Other measurement,replication,2014-12-02,GCST002711,Sleep duration
916,African American or Afro-Caribbean,1378.0,25468567.0,Perez-Andreu V,Cancer,initial,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
11235,European,47180.0,25469926.0,Gottlieb DJ,Other measurement,initial,2014-12-02,GCST002711,Sleep duration
13030,Hispanic or Latin American,1084.0,25468567.0,Perez-Andreu V,Cancer,initial,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
12898,Hispanic or Latin American,535.0,25468567.0,Perez-Andreu V,Cancer,replication,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
13937,Other/Mixed,558.0,25468567.0,Perez-Andreu V,Cancer,replication,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
8689,European,5275.0,25477429.0,Lieb W,Cardiovascular measurement,initial,2014-12-04,GCST002714,Plasma renin activity levels
6618,European,1462.0,25476525.0,Germain M,Metabolic disorder,initial,2014-12-06,GCST002716,Diabetic nephropathy in type 1 diabetes
8964,European,6341.0,25476525.0,Germain M,Metabolic disorder,replication,2014-12-06,GCST002716,Diabetic nephropathy in type 1 diabetes
12880,Hispanic or Latin American,454.0,25488688.0,Pino-Yanes M,Other measurement,replication,2014-12-06,GCST002717,Serum IgE levels
13176,Hispanic or Latin American,3334.0,25488688.0,Pino-Yanes M,Other measurement,initial,2014-12-06,GCST002717,Serum IgE levels
14197,Other/Mixed,3286.0,25483131.0,Ghassibe-Sabbagh M,Metabolic disorder,initial,2014-12-08,GCST002718,Type 2 diabetes
7881,European,3269.0,25562672.0,Byrne EM,Other measurement,initial,2014-12-09,GCST002719,Seasonality
5982,European,887.0,25562672.0,Byrne EM,Other measurement,replication,2014-12-09,GCST002719,Seasonality
9342,European,8013.0,25646338.0,Mozaffarian D,Lipid or lipoprotein measurement,initial,2014-12-10,GCST002721,Trans fatty acid levels
11202,European,45530.0,25493955.0,Gorski M,"Other disease, Other measurement, Other trait",initial,2014-12-10,GCST002720,Kidney function decline traits
2283,Asian,669.0,25646338.0,Mozaffarian D,Lipid or lipoprotein measurement,replication,2014-12-10,GCST002721,Trans fatty acid levels
847,African American or Afro-Caribbean,1082.0,25646338.0,Mozaffarian D,Lipid or lipoprotein measurement,replication,2014-12-10,GCST002721,Trans fatty acid levels
10399,European,18028.0,25493955.0,Gorski M,"Other disease, Other measurement, Other trait",replication,2014-12-10,GCST002720,Kidney function decline traits
12934,Hispanic or Latin American,657.0,25646338.0,Mozaffarian D,Lipid or lipoprotein measurement,replication,2014-12-10,GCST002721,Trans fatty acid levels
12728,Hispanic or Latin American,8.0,25503805.0,Karnes JH,"Response to drug, Other trait",initial,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
13640,Other/Mixed,7.0,25503805.0,Karnes JH,"Response to drug, Other trait",initial,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
5240,European,426.0,25503805.0,Karnes JH,"Response to drug, Other trait",replication,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
5865,European,811.0,25503805.0,Karnes JH,"Response to drug, Other trait",initial,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
1576,Asian,1.0,25503805.0,Karnes JH,"Response to drug, Other trait",initial,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
510,African American or Afro-Caribbean,116.0,25503805.0,Karnes JH,"Response to drug, Other trait",initial,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
6643,European,1507.0,25524241.0,Richter HE,Other trait,initial,2014-12-15,GCST002723,Urgency urinary incontinence
6640,European,1504.0,25524241.0,Richter HE,Other trait,replication,2014-12-15,GCST002723,Urgency urinary incontinence
8259,European,4108.0,25514360.0,Hansel NN,"Other disease, Other measurement",initial,2014-12-16,GCST002724,Airway responsiveness in chronic obstructive pulmonary disease
13239,Hispanic or Latin American,4176.0,25524916.0,Palmer ND,Other measurement,initial,2014-12-18,GCST002726,Glucose homeostasis traits
6702,European,1553.0,25533491.0,Rautanen A,"Other measurement, Other trait, Other disease",initial,2014-12-18,GCST002725,Sepsis from pneumonia (survival)
5484,European,538.0,25533491.0,Rautanen A,"Other measurement, Other trait, Other disease",replication,2014-12-18,GCST002725,Sepsis from pneumonia (survival)
7628,European,2791.0,25521368.0,Tonjes A,Cardiovascular measurement,initial,2014-12-18,GCST004389,Circulating chemerin levels
6513,European,1341.0,25526632.0,Rafiq S,"Other measurement, Cancer",initial,2014-12-19,GCST002727,Breast cancer (survival)
6655,European,1523.0,25526632.0,Rafiq S,"Other measurement, Cancer",replication,2014-12-19,GCST002727,Breast cancer (survival)
8054,European,3574.0,25552591.0,Lieb W,Cardiovascular measurement,initial,2014-12-31,GCST002731,Endothelial growth factor levels
3936,Asian,7861.0,25705162.0,Oh JH,Hematological measurement,replication,2014-12-31,GCST002733,Platelet count
4022,Asian,8842.0,25705162.0,Oh JH,Hematological measurement,initial,2014-12-31,GCST002733,Platelet count
3308,Asian,3000.0,25705159.0,Hong Y,Other trait,initial,2014-12-31,GCST002730,Hepatitis
4021,Asian,8842.0,25705158.0,Shim U,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2014-12-31,GCST002732,Metabolic syndrome
7804,European,3184.0,25552591.0,Lieb W,Cardiovascular measurement,replication,2014-12-31,GCST002731,Endothelial growth factor levels
6280,European,1090.0,25557950.0,Alonso A,"Digestive system disorder, Immune system disorder, Other trait, Biological process",initial,2014-12-31,GCST002729,Crohn's disease-related phenotypes
11595,European,80607.0,25551457.0,Baumert J,"Other measurement, Body measurement, Biological process, Hematological measurement",initial,2014-12-31,GCST002734,"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)"
6478,European,1296.0,25557950.0,Alonso A,"Digestive system disorder, Immune system disorder, Other trait, Biological process",replication,2014-12-31,GCST002729,Crohn's disease-related phenotypes
2953,Asian,1925.0,25489960.0,Yang SK,Digestive system disorder,replication,2015-01-01,GCST008485,Crohn's disease
2581,Asian,1183.0,25489960.0,Yang SK,Digestive system disorder,initial,2015-01-01,GCST008485,Crohn's disease
1788,Asian,135.0,25824743.0,Haryono SJ,Cancer,initial,2015-01-01,GCST002735,Breast cancer
250,African,2790.0,25561047.0,Musani SK,Cardiovascular measurement,initial,2015-01-05,GCST002736,B-type natriuretic peptide levels
3320,Asian,3080.0,25566987.0,Hosgood HD 3rd,"Other measurement, Cancer",initial,2015-01-08,GCST002739,Lung cancer (household air pollution interaction)
9983,European,12244.0,25574825.0,Baurecht H,Immune system disorder,initial,2015-01-08,GCST002738,Psoriasis
2951,Asian,1922.0,25574032.0,Lee H,Other disease,initial,2015-01-08,GCST002741,Polycystic ovary syndrome
10403,European,18190.0,25574825.0,Baurecht H,"Immune system disorder, Other disease",initial,2015-01-08,GCST002740,Inflammatory skin disease
8875,European,5946.0,25574825.0,Baurecht H,Immune system disorder,initial,2015-01-08,GCST002737,Atopic dermatitis
2513,Asian,1027.0,25574032.0,Lee H,Other disease,replication,2015-01-08,GCST002741,Polycystic ovary syndrome
9131,European,7046.0,25569183.0,Vijai J,Cancer,initial,2015-01-08,GCST002742,Marginal zone lymphoma
6533,European,1362.0,25569183.0,Vijai J,Cancer,replication,2015-01-08,GCST002742,Marginal zone lymphoma
14167,Other/Mixed,2547.0,25884002.0,Moore CB,"Lipid or lipoprotein measurement, Other disease",initial,2015-01-09,GCST002744,HDL Cholesterol in HIV-infection
14110,Other/Mixed,1376.0,25575512.0,Lu W,Lipid or lipoprotein measurement,initial,2015-01-09,GCST002746,Lipoprotein (a) - cholesterol levels
14168,Other/Mixed,2547.0,25884002.0,Moore CB,"Other disease, Hematological measurement",initial,2015-01-09,GCST002743,Neutrophil count in HIV-infection
14169,Other/Mixed,2547.0,25884002.0,Moore CB,"Other disease, Other measurement",initial,2015-01-09,GCST002745,Total bilirubin levels in HIV-1 infection
7660,European,2845.0,25583994.0,Tardif JC,"Response to drug, Cardiovascular measurement, Cardiovascular disease",initial,2015-01-11,GCST002747,Response to Dalcetrapib treatment in acute coronary syndrome
10072,European,13491.0,25581431.0,Kuchenbaecker KB,Cancer,initial,2015-01-12,GCST002748,Epithelial ovarian cancer
11357,European,56254.0,25581431.0,Kuchenbaecker KB,Cancer,replication,2015-01-12,GCST002748,Epithelial ovarian cancer
12836,Hispanic or Latin American,337.0,25584925.0,Chen W,Other disease,replication,2015-01-13,GCST002750,Chronic obstructive pulmonary disease
1717,Asian,94.0,25628645.0,Tong Y,"Other measurement, Response to drug",initial,2015-01-13,GCST002749,Response to Homoharringtonine (cytotoxicity)
497,African American or Afro-Caribbean,93.0,25628645.0,Tong Y,"Other measurement, Response to drug",initial,2015-01-13,GCST002749,Response to Homoharringtonine (cytotoxicity)
13036,Hispanic or Latin American,1188.0,25584925.0,Chen W,Other disease,initial,2015-01-13,GCST002750,Chronic obstructive pulmonary disease
4734,European,91.0,25628645.0,Tong Y,"Other measurement, Response to drug",initial,2015-01-13,GCST002749,Response to Homoharringtonine (cytotoxicity)
9533,European,8683.0,25644374.0,Poirier JG,"Other measurement, Cancer",initial,2015-01-19,GCST002753,Lung cancer and family history of lung cancer
13656,Other/Mixed,12.0,25599974.0,Zhang H,"Other measurement, Other trait",replication,2015-01-19,GCST002752,Spontaneous preterm birth (preterm delivery)
563,African American or Afro-Caribbean,194.0,25599974.0,Zhang H,"Other measurement, Other trait",replication,2015-01-19,GCST002752,Spontaneous preterm birth (preterm delivery)
14138,Other/Mixed,1851.0,25599974.0,Zhang H,"Other measurement, Other trait",initial,2015-01-19,GCST002751,Spontaneous preterm birth (preterm birth)
13898,Other/Mixed,392.0,25599974.0,Zhang H,"Other measurement, Other trait",replication,2015-01-19,GCST002751,Spontaneous preterm birth (preterm birth)
12803,Hispanic or Latin American,184.0,25599974.0,Zhang H,"Other measurement, Other trait",replication,2015-01-19,GCST002752,Spontaneous preterm birth (preterm delivery)
14142,Other/Mixed,1881.0,25599974.0,Zhang H,"Other measurement, Other trait",initial,2015-01-19,GCST002752,Spontaneous preterm birth (preterm delivery)
4765,European,103.0,25599974.0,Zhang H,"Other measurement, Other trait",replication,2015-01-19,GCST002752,Spontaneous preterm birth (preterm delivery)
6297,European,1112.0,25604533.0,Renauer PA,Cardiovascular disease,initial,2015-01-20,GCST006575,Takayasu arteritis
14070,Other/Mixed,978.0,25604533.0,Renauer PA,Cardiovascular disease,initial,2015-01-20,GCST006575,Takayasu arteritis
10042,European,13171.0,25607358.0,Hibar DP,Other measurement,initial,2015-01-21,GCST002756,Subcortical brain region volumes
10190,European,15130.0,25607358.0,Hibar DP,Other measurement,replication,2015-01-21,GCST002756,Subcortical brain region volumes
2209,Asian,545.0,25607358.0,Hibar DP,Other measurement,replication,2015-01-21,GCST002756,Subcortical brain region volumes
12954,Hispanic or Latin American,736.0,25607358.0,Hibar DP,Other measurement,replication,2015-01-21,GCST002756,Subcortical brain region volumes
7739,European,3020.0,25608926.0,Betz RC,Other disease,replication,2015-01-22,GCST004866,Alopecia areata
7438,European,2507.0,25616667.0,Goris A,"Immune system disorder, Other measurement",initial,2015-01-22,GCST002758,Oligoclonal band status in multiple sclerosis
9246,European,7565.0,25608926.0,Betz RC,Other disease,initial,2015-01-22,GCST004866,Alopecia areata
5817,European,773.0,25616667.0,Goris A,"Other measurement, Immune system disorder",initial,2015-01-22,GCST002757,Immunoglobulin G index levels in multiple sclerosis
11584,European,80494.0,25628336.0,Hromatka BS,Other trait,initial,2015-01-26,GCST002759,Motion sickness
5077,European,325.0,25625606.0,Mather KA,Neurological disorder,initial,2015-01-27,GCST002760,Hippocampal atrophy
10935,European,33231.0,25625282.0,Mahajan A,Other measurement,initial,2015-01-27,GCST007858,Fasting blood glucose adjusted for BMI
10877,European,30825.0,25625282.0,Mahajan A,Other measurement,initial,2015-01-27,GCST007857,Fasting blood insulin adjusted for BMI
5405,European,498.0,25625606.0,Mather KA,Other measurement,initial,2015-01-27,GCST002761,Hippocampal volume
3150,Asian,2405.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002765,Optic disc area
3117,Asian,2305.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002763,Optic disc area
3093,Asian,2225.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002762,Optic cup area
4266,Asian,14515.0,25629512.0,Cheng CY,Neurological disorder,replication,2015-01-28,GCST002766,Exudative age-related macular degeneration
10345,European,17248.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002763,Optic disc area
3118,Asian,2305.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002765,Optic disc area
2998,Asian,2025.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002762,Optic cup area
10343,European,17218.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002762,Optic cup area
3039,Asian,2131.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002765,Optic disc area
3038,Asian,2131.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002763,Optic disc area
10344,European,17218.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002764,Optic cup area
3092,Asian,2225.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002764,Optic cup area
3132,Asian,2363.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002764,Optic cup area
2997,Asian,2025.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002764,Optic cup area
3149,Asian,2405.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002763,Optic disc area
3927,Asian,7810.0,25629512.0,Cheng CY,Neurological disorder,initial,2015-01-28,GCST002766,Exudative age-related macular degeneration
3133,Asian,2363.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002762,Optic cup area
10346,European,17248.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002765,Optic disc area
11018,European,35380.0,25631608.0,Wessel J,Other measurement,initial,2015-01-29,GCST007898,Fasting blood insulin
11276,European,50900.0,25631608.0,Wessel J,Other measurement,initial,2015-01-29,GCST007899,Fasting blood glucose
1415,African American or Afro-Caribbean,9664.0,25631608.0,Wessel J,Other measurement,initial,2015-01-29,GCST007899,Fasting blood glucose
1455,African American or Afro-Caribbean,12738.0,25631608.0,Wessel J,Other measurement,initial,2015-01-29,GCST007898,Fasting blood insulin
7955,European,3378.0,25637581.0,Derringer J,Other measurement,replication,2015-01-31,GCST002768,Behavioral disinhibition
6305,European,1129.0,25637581.0,Derringer J,Other measurement,initial,2015-01-31,GCST002768,Behavioral disinhibition
45,African,114.0,25637581.0,Derringer J,Other measurement,initial,2015-01-31,GCST002768,Behavioral disinhibition
13704,Other/Mixed,40.0,25637581.0,Derringer J,Other measurement,initial,2015-01-31,GCST002768,Behavioral disinhibition
13706,Other/Mixed,42.0,25637581.0,Derringer J,Other measurement,initial,2015-01-31,GCST002768,Behavioral disinhibition
12887,Hispanic or Latin American,477.0,25637581.0,Derringer J,Other measurement,initial,2015-01-31,GCST002768,Behavioral disinhibition
12801,Hispanic or Latin American,175.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002769,Response to abacavir-containing treatment in HIV-1 infection (virologic failure)
5489,European,541.0,25637336.0,Chan JP,Other measurement,replication,2015-02-01,GCST002770,Hand grip strength
82,African,265.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002769,Response to abacavir-containing treatment in HIV-1 infection (virologic failure)
5117,European,346.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002769,Response to abacavir-containing treatment in HIV-1 infection (virologic failure)
119,African,545.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002771,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)
7130,European,2088.0,25637336.0,Chan JP,Other measurement,initial,2015-02-01,GCST002770,Hand grip strength
5759,European,737.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002771,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)
12829,Hispanic or Latin American,314.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002771,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)
3946,Asian,8060.0,25642632.0,Liu H,Neurological disorder,initial,2015-02-02,GCST002772,Leprosy
4303,Asian,16270.0,25642632.0,Liu H,Neurological disorder,replication,2015-02-02,GCST002772,Leprosy
3060,Asian,2158.0,25646370.0,Matsuo H,Metabolic disorder,initial,2015-02-02,GCST002773,Gout
3142,Asian,2382.0,25646370.0,Matsuo H,Metabolic disorder,replication,2015-02-02,GCST002773,Gout
11325,European,53949.0,25644384.0,Davies G,"Biological process, Other measurement",initial,2015-02-03,GCST002774,Cognitive function
5496,European,547.0,25722978.0,Borghese B,Other disease,replication,2015-02-04,GCST002776,Endometriosis
4703,European,80.0,25722978.0,Borghese B,Other disease,initial,2015-02-04,GCST002776,Endometriosis
4731,European,90.0,25656473.0,de With SA,"Response to drug, Other measurement",initial,2015-02-05,GCST002777,Clozapine-induced cytotoxicity
6762,European,1629.0,25663231.0,Beecham GW,"Neurological disorder, Other measurement",initial,2015-02-06,GCST002778,Parkinson disease and lewy body pathology
1693,Asian,76.0,25672763.0,Ueta M,"Other disease, Response to drug",replication,2015-02-08,GCST002779,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement
2402,Asian,808.0,25672763.0,Ueta M,"Other disease, Response to drug",initial,2015-02-08,GCST002779,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement
12800,Hispanic or Latin American,174.0,25672763.0,Ueta M,"Other disease, Response to drug",replication,2015-02-08,GCST002779,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement
2003,Asian,321.0,25672763.0,Ueta M,"Other disease, Response to drug",replication,2015-02-08,GCST002779,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement
4815,European,156.0,25665007.0,Xu H,"Other trait, Neurological disorder, Response to drug",initial,2015-02-09,GCST002780,Cisplatin-induced hearing loss in brain tumor patients
4070,Asian,9573.0,25672891.0,Shimizu S,Digestive system disorder,initial,2015-02-11,GCST002781,Periodontitis
3967,Asian,8345.0,25672891.0,Shimizu S,Digestive system disorder,replication,2015-02-11,GCST002781,Periodontitis
103,African,461.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004066,Hip circumference
3245,Asian,2791.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004065,Waist circumference
104,African,461.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004067,Hip circumference adjusted for BMI
3250,Asian,2791.0,25673412.0,Shungin D,"Other measurement, Body measurement",replication,2015-02-12,GCST004064,Waist-hip ratio
3247,Asian,2791.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004067,Hip circumference adjusted for BMI
803,African American or Afro-Caribbean,887.0,25673413.0,Locke AE,"Body measurement, Other measurement",initial,2015-02-12,GCST002783,Body mass index
13044,Hispanic or Latin American,1276.0,25673413.0,Locke AE,"Body measurement, Other measurement",initial,2015-02-12,GCST002783,Body mass index
3246,Asian,2791.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004066,Hip circumference
3249,Asian,2791.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
3248,Asian,2791.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
11470,European,67326.0,25673412.0,Shungin D,"Other measurement, Body measurement",replication,2015-02-12,GCST004064,Waist-hip ratio
2792,Asian,1650.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004065,Waist circumference
2793,Asian,1650.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004066,Hip circumference
11993,European,142762.0,25673412.0,Shungin D,"Body measurement, Other measurement",initial,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
1395,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004065,Waist circumference
11670,European,88138.0,25673413.0,Locke AE,"Body measurement, Other measurement",replication,2015-02-12,GCST002783,Body mass index
1396,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004066,Hip circumference
1397,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004067,Hip circumference adjusted for BMI
1398,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
1399,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
2794,Asian,1650.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004067,Hip circumference adjusted for BMI
11992,European,142762.0,25673412.0,Shungin D,Body measurement,initial,2015-02-12,GCST004067,Hip circumference adjusted for BMI
11991,European,142762.0,25673412.0,Shungin D,Body measurement,initial,2015-02-12,GCST004066,Hip circumference
1400,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,"Other measurement, Body measurement",replication,2015-02-12,GCST004064,Waist-hip ratio
11990,European,142762.0,25673412.0,Shungin D,Body measurement,initial,2015-02-12,GCST004065,Waist circumference
105,African,461.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
1402,African American or Afro-Caribbean,8755.0,25673413.0,Locke AE,"Body measurement, Other measurement",replication,2015-02-12,GCST002783,Body mass index
12270,European,236781.0,25673413.0,Locke AE,"Body measurement, Other measurement",initial,2015-02-12,GCST002783,Body mass index
106,African,461.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
107,African,461.0,25673412.0,Shungin D,"Other measurement, Body measurement",replication,2015-02-12,GCST004064,Waist-hip ratio
3395,Asian,3622.0,25673413.0,Locke AE,"Body measurement, Other measurement",replication,2015-02-12,GCST002783,Body mass index
2795,Asian,1650.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
102,African,461.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004065,Waist circumference
2797,Asian,1650.0,25673412.0,Shungin D,"Other measurement, Body measurement",replication,2015-02-12,GCST004064,Waist-hip ratio
2846,Asian,1747.0,25673413.0,Locke AE,"Body measurement, Other measurement",replication,2015-02-12,GCST002783,Body mass index
11995,European,142762.0,25673412.0,Shungin D,"Other measurement, Body measurement",initial,2015-02-12,GCST004064,Waist-hip ratio
11469,European,67326.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
11468,European,67326.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
11467,European,67326.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004067,Hip circumference adjusted for BMI
2796,Asian,1650.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
11465,European,67326.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004065,Waist circumference
11466,European,67326.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004066,Hip circumference
11994,European,142762.0,25673412.0,Shungin D,"Body measurement, Other measurement",initial,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
5360,European,485.0,25695618.0,Chittani M,"Other measurement, Response to drug, Cardiovascular disease",initial,2015-02-18,GCST002784,Blood pressure response to hydrochlorothiazide in hypertension
6691,European,1545.0,25695618.0,Chittani M,"Other measurement, Response to drug, Cardiovascular disease",replication,2015-02-18,GCST002784,Blood pressure response to hydrochlorothiazide in hypertension
3925,Asian,7760.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
110,African,481.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
3528,Asian,4600.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
3216,Asian,2672.0,25706626.0,Aung T,Neurological disorder,initial,2015-02-23,GCST002787,Exfoliation syndrome
10013,European,12600.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
5734,European,718.0,25713168.0,Leng S,Other measurement,replication,2015-02-23,GCST002786,Gene methylation in lung tissue
7659,European,2844.0,25705849.0,Jacobs LC,Other measurement,initial,2015-02-23,GCST002785,Facial pigmentation
13749,Other/Mixed,99.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
12842,Hispanic or Latin American,373.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
14118,Other/Mixed,1455.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
6345,European,1163.0,25713168.0,Leng S,Other measurement,initial,2015-02-23,GCST002786,Gene methylation in lung tissue
1587,Asian,2.0,25710658.0,Diouf B,"Response to drug, Cancer, Neurological disorder",initial,2015-02-24,GCST002792,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
12755,Hispanic or Latin American,44.0,25710658.0,Diouf B,"Response to drug, Cancer, Neurological disorder",initial,2015-02-24,GCST002792,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
7232,European,2197.0,25710614.0,Hong X,Other measurement,initial,2015-02-24,GCST002789,Egg allergy
4922,European,209.0,25710658.0,Diouf B,"Response to drug, Cancer, Neurological disorder",initial,2015-02-24,GCST002792,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
7231,European,2197.0,25710614.0,Hong X,Other measurement,initial,2015-02-24,GCST002788,Milk allergy
22,African,43.0,25710658.0,Diouf B,"Response to drug, Cancer, Neurological disorder",initial,2015-02-24,GCST002792,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
4787,European,131.0,25710614.0,Hong X,Other measurement,replication,2015-02-24,GCST002791,Peanut allergy
7233,European,2197.0,25710614.0,Hong X,Other measurement,initial,2015-02-24,GCST002790,Food allergy
7234,European,2197.0,25710614.0,Hong X,Other measurement,initial,2015-02-24,GCST002791,Peanut allergy
12749,Hispanic or Latin American,36.0,25771307.0,Watson AL,Metabolic disorder,initial,2015-02-26,GCST008434,Type 2 diabetes
5456,European,521.0,25881214.0,Shah AA,Other trait,initial,2015-02-27,GCST002793,Vein graft stenosis in coronary artery bypass grafting
5740,European,724.0,25562107.0,Israel E,"Response to drug, Other disease",initial,2015-03-01,GCST002796,Bronchodilator response in asthma
7260,European,2242.0,25337690.0,Redler S,Other disease,initial,2015-03-01,GCST005539,Alopecia areata
766,African American or Afro-Caribbean,754.0,25101718.0,Lee JH,"Other disease, Other trait",initial,2015-03-01,GCST002797,Pulmonary artery enlargement in chronic obstructive pulmonary disease
5282,European,439.0,25562107.0,Israel E,"Response to drug, Other disease",replication,2015-03-01,GCST002796,Bronchodilator response in asthma
8883,European,5993.0,25101718.0,Lee JH,Other disease,initial,2015-03-01,GCST002795,Chronic obstructive pulmonary disease
987,African American or Afro-Caribbean,2009.0,25101718.0,Lee JH,"Other disease, Other trait",initial,2015-03-01,GCST002798,Pulmonary artery enlargement and chronic obstructive pulmonary disease
1032,African American or Afro-Caribbean,2243.0,25101718.0,Lee JH,Other disease,initial,2015-03-01,GCST002795,Chronic obstructive pulmonary disease
8320,European,4287.0,25101718.0,Lee JH,"Other disease, Other trait",initial,2015-03-01,GCST002797,Pulmonary artery enlargement in chronic obstructive pulmonary disease
7118,European,2076.0,25337690.0,Redler S,Other disease,replication,2015-03-01,GCST005539,Alopecia areata
8108,European,3718.0,25101718.0,Lee JH,"Other disease, Other trait",initial,2015-03-01,GCST002798,Pulmonary artery enlargement and chronic obstructive pulmonary disease
2805,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,"Other measurement, Other trait",initial,2015-03-05,GCST002799,Number of pregnancies
2807,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,"Other measurement, Other trait",initial,2015-03-05,GCST002801,Number of children
2806,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,"Other measurement, Other trait",initial,2015-03-05,GCST002800,Number of children (6+ vs. 0 or 1)
10092,European,13651.0,25743335.0,Taylor PN,Other measurement,initial,2015-03-06,GCST008164,Free thyroxine concentration
10276,European,16335.0,25743335.0,Taylor PN,"Other measurement, Other trait",initial,2015-03-06,GCST008165,Thyroid stimulating hormone levels
6447,European,1246.0,25758996.0,Pirastu N,Other measurement,replication,2015-03-11,GCST002803,Red wine liking
6461,European,1261.0,25758996.0,Pirastu N,Other measurement,replication,2015-03-11,GCST002802,White wine liking
13099,Hispanic or Latin American,1932.0,25758998.0,Rubicz R,Other measurement,initial,2015-03-11,GCST002804,Antibody level in response to infection
7273,European,2271.0,25758996.0,Pirastu N,Other measurement,initial,2015-03-11,GCST002803,Red wine liking
7259,European,2240.0,25758996.0,Pirastu N,Other measurement,initial,2015-03-11,GCST002802,White wine liking
13897,Other/Mixed,391.0,25760438.0,Anderson D,Metabolic disorder,initial,2015-03-11,GCST002806,Type 2 diabetes
13889,Other/Mixed,361.0,25760438.0,Anderson D,"Body measurement, Other measurement",initial,2015-03-11,GCST002805,Body mass index
13887,Other/Mixed,353.0,25758996.0,Pirastu N,Other measurement,replication,2015-03-11,GCST002803,Red wine liking
13878,Other/Mixed,335.0,25758996.0,Pirastu N,Other measurement,replication,2015-03-11,GCST002802,White wine liking
8779,European,5595.0,25772935.0,Germain M,Cardiovascular disease,replication,2015-03-12,GCST002808,Venous thromboembolism
6982,European,1911.0,25763902.0,Draaken M,Other disease,initial,2015-03-12,GCST002807,Classic bladder exstrophy
11402,European,60139.0,25772935.0,Germain M,Cardiovascular disease,initial,2015-03-12,GCST002808,Venous thromboembolism
6088,European,951.0,25827505.0,Swaminathan S,Neurological disorder,initial,2015-03-14,GCST002809,Bipolar disorder
631,African American or Afro-Caribbean,317.0,25827505.0,Swaminathan S,Neurological disorder,initial,2015-03-14,GCST002809,Bipolar disorder
6438,European,1237.0,25827505.0,Swaminathan S,Neurological disorder,replication,2015-03-14,GCST002809,Bipolar disorder
9881,European,11137.0,25774636.0,Curtis J,"Other disease, Other measurement",initial,2015-03-16,GCST002810,Tuberculosis
3386,Asian,3537.0,25775280.0,Sun Y,Other trait,replication,2015-03-16,GCST002811,Nonsyndromic cleft lip with or without cleft palate
14218,Other/Mixed,3950.0,25774636.0,Curtis J,"Other disease, Other measurement",replication,2015-03-16,GCST002810,Tuberculosis
3027,Asian,2106.0,25775280.0,Sun Y,Other trait,initial,2015-03-16,GCST002811,Nonsyndromic cleft lip with or without cleft palate
278,African,4637.0,25774636.0,Curtis J,"Other disease, Other measurement",replication,2015-03-16,GCST002810,Tuberculosis
13971,Other/Mixed,638.0,25781172.0,Avramopoulos D,"Neurological disorder, Other measurement",initial,2015-03-17,GCST002815,Bipolar disorder (inflammation and infection response interaction)
8292,European,4203.0,25778476.0,Jun G,"Neurological disorder, Other measurement",replication,2015-03-17,GCST002814,Alzheimer's disease (APOE e4 interaction)
6901,European,1786.0,25778476.0,Jun G,Neurological disorder,replication,2015-03-17,GCST002813,Alzheimer's disease in APOE e4+ carriers
10341,European,17187.0,25781442.0,Nan H,"Cancer, Other measurement",initial,2015-03-17,GCST002816,Colorectal cancer (aspirin and/or NSAID use interaction)
7382,European,2417.0,25778476.0,Jun G,Neurological disorder,replication,2015-03-17,GCST002817,Alzheimer's disease in APOE e4- carriers
14009,Other/Mixed,701.0,25781172.0,Avramopoulos D,"Neurological disorder, Other measurement",initial,2015-03-17,GCST002812,Schizophrenia (inflammation and infection response interaction)
5506,European,552.0,25784220.0,Sharma S,Other disease,replication,2015-03-18,GCST002819,Adolescent idiopathic scoliosis
986,African American or Afro-Caribbean,2004.0,25786224.0,Johnson EO,"Immune system disorder, Other disease",initial,2015-03-18,GCST002818,HIV-1 susceptibility
6372,European,1184.0,25784220.0,Sharma S,Other disease,initial,2015-03-18,GCST002819,Adolescent idiopathic scoliosis
6309,European,1132.0,25786224.0,Johnson EO,"Immune system disorder, Other disease",initial,2015-03-18,GCST002818,HIV-1 susceptibility
971,African American or Afro-Caribbean,1852.0,25786224.0,Johnson EO,"Immune system disorder, Other disease",replication,2015-03-18,GCST002818,HIV-1 susceptibility
3186,Asian,2524.0,25784220.0,Sharma S,Other disease,replication,2015-03-18,GCST002819,Adolescent idiopathic scoliosis
5693,European,681.0,25786224.0,Johnson EO,"Immune system disorder, Other disease",replication,2015-03-18,GCST002818,HIV-1 susceptibility
5096,European,334.0,25866641.0,Xu W,"Cancer, Other measurement",initial,2015-03-19,GCST002822,Survival in colon cancer
4831,European,171.0,25866641.0,Xu W,"Other measurement, Cancer",initial,2015-03-19,GCST002821,Survival in rectal cancer
5249,European,431.0,25866641.0,Xu W,"Other measurement, Cancer",initial,2015-03-19,GCST002820,Survival in microsatellite instability low/stable colorectal cancer
1578,Asian,1.0,25799145.0,Kappen JH,"Cardiovascular disease, Cardiovascular disease, Cardiovascular disease",initial,2015-03-23,GCST002824,Behcet's disease
12714,Hispanic or Latin American,1.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002823,Behcet's disease
1577,Asian,1.0,25799145.0,Kappen JH,"Cardiovascular disease, Cardiovascular disease, Cardiovascular disease",initial,2015-03-23,GCST002823,Behcet's disease
12715,Hispanic or Latin American,1.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002824,Behcet's disease
14214,Other/Mixed,3934.0,25799145.0,Kappen JH,Cardiovascular disease,replication,2015-03-23,GCST002824,Behcet's disease
13594,Other/Mixed,1.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002823,Behcet's disease
13087,Hispanic or Latin American,1601.0,25798622.0,Knowles JW,Other trait,replication,2015-03-23,GCST002825,Insulin resistance/response
4853,European,180.0,25799145.0,Kappen JH,Cardiovascular disease,replication,2015-03-23,GCST002823,Behcet's disease
13595,Other/Mixed,1.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002824,Behcet's disease
7615,European,2764.0,25798622.0,Knowles JW,Other trait,initial,2015-03-23,GCST002825,Insulin resistance/response
13837,Other/Mixed,241.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002824,Behcet's disease
6458,European,1259.0,25798622.0,Knowles JW,Other trait,replication,2015-03-23,GCST002825,Insulin resistance/response
13836,Other/Mixed,241.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002823,Behcet's disease
4668,European,54.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002824,Behcet's disease
4667,European,54.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002823,Behcet's disease
9644,European,9445.0,25811787.0,Huffman JE,"Other measurement, Body measurement",initial,2015-03-26,GCST002828,Urate levels in obese individuals
10329,European,16957.0,25817017.0,Carmona FD,Cardiovascular disease,initial,2015-03-26,GCST006198,Giant cell arteritis
10813,European,28610.0,25811787.0,Huffman JE,"Body measurement, Other measurement",initial,2015-03-26,GCST002827,Urate levels (BMI interaction)
10339,European,17078.0,25811787.0,Huffman JE,"Body measurement, Other measurement",initial,2015-03-26,GCST002829,Urate levels in overweight individuals
10206,European,15282.0,25811787.0,Huffman JE,"Body measurement, Other measurement",initial,2015-03-26,GCST002830,Urate levels in lean individuals
10901,European,31950.0,25811787.0,Huffman JE,"Body measurement, Other measurement",initial,2015-03-26,GCST002826,Urate levels (BMI interaction)
10112,European,13959.0,25811787.0,Huffman JE,"Body measurement, Other measurement",replication,2015-03-26,GCST002827,Urate levels (BMI interaction)
3371,Asian,3460.0,25823570.0,Miyake M,Other measurement,replication,2015-03-31,GCST002836,Axial length
9768,European,10114.0,25826619.0,Henrion MY,Cancer,replication,2015-03-31,GCST002835,Renal cell carcinoma
2433,Asian,876.0,25823687.0,Cao S,"Response to drug, Cancer, Other trait",replication,2015-03-31,GCST002833,Platinum-induced myelosuppression in non-small cell lung cancer
3769,Asian,6234.0,25823570.0,Miyake M,Other measurement,replication,2015-03-31,GCST002834,Corneal curvature
2007,Asian,328.0,25823687.0,Cao S,"Response to drug, Cancer, Other trait",initial,2015-03-31,GCST002833,Platinum-induced myelosuppression in non-small cell lung cancer
9856,European,10871.0,25826619.0,Henrion MY,Cancer,initial,2015-03-31,GCST002835,Renal cell carcinoma
3339,Asian,3248.0,25823570.0,Miyake M,Other measurement,initial,2015-03-31,GCST002836,Axial length
7052,European,2007.0,25823570.0,Miyake M,Other measurement,replication,2015-03-31,GCST002834,Corneal curvature
10975,European,33864.0,25751625.0,Michailidou K,Cancer,initial,2015-04-01,GCST004950,Breast cancer
4680,European,64.0,25813999.0,Jeong S,"Response to drug, Other measurement",initial,2015-04-01,GCST002837,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)
4658,European,49.0,25813999.0,Jeong S,"Response to drug, Other measurement",replication,2015-04-01,GCST002837,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)
11682,European,89677.0,25751625.0,Michailidou K,Cancer,initial,2015-04-01,GCST007236,Breast cancer
11683,European,89677.0,25751625.0,Michailidou K,Cancer,replication,2015-04-01,GCST004950,Breast cancer
7704,European,2949.0,25643325.0,Renton AE,"Neurological disorder, Other disease",initial,2015-04-01,GCST002838,Myasthenia gravis
5991,European,890.0,25643325.0,Renton AE,"Neurological disorder, Other disease",replication,2015-04-01,GCST002838,Myasthenia gravis
10847,European,29652.0,25751624.0,Onengut-Gumuscu S,Metabolic disorder,initial,2015-04-01,GCST005536,Type 1 diabetes
6020,European,922.0,25839716.0,Ng E,Other measurement,initial,2015-04-02,GCST002839,Polychlorinated biphenyl levels
7811,European,3198.0,25849990.0,Tapper W,Cancer,initial,2015-04-07,GCST002840,Myeloproliferative neoplasms
2812,Asian,1699.0,25848760.0,Sun Y,Other disease,replication,2015-04-07,GCST002841,Developmental dysplasia of the hip
2470,Asian,944.0,25848760.0,Sun Y,Other disease,initial,2015-04-07,GCST002841,Developmental dysplasia of the hip
8882,European,5992.0,25849990.0,Tapper W,Cancer,replication,2015-04-07,GCST002840,Myeloproliferative neoplasms
4365,Asian,20338.0,25854761.0,Zuo X,Immune system disorder,replication,2015-04-09,GCST008479,Psoriasis
1190,African American or Afro-Caribbean,3545.0,25865494.0,Chan Y,Body measurement,initial,2015-04-09,GCST002843,Sitting height ratio
8661,European,5170.0,25855136.0,Stacey SN,Cancer,replication,2015-04-09,GCST002842,Basal cell carcinoma
12332,European,270930.0,25855136.0,Stacey SN,Cancer,initial,2015-04-09,GCST002842,Basal cell carcinoma
10595,European,21590.0,25865494.0,Chan Y,Body measurement,initial,2015-04-09,GCST002843,Sitting height ratio
4380,Asian,22422.0,25854761.0,Zuo X,Immune system disorder,initial,2015-04-09,GCST008479,Psoriasis
10301,European,16559.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
4050,Asian,9145.0,25861811.0,Li Z,Neurological disorder,initial,2015-04-10,GCST008391,Glaucoma (primary open-angle)
8923,European,6163.0,25865352.0,Schaarschmidt H,Immune system disorder,initial,2015-04-10,GCST002844,Atopic dermatitis
778,African American or Afro-Caribbean,801.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
3301,Asian,2993.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
3533,Asian,4628.0,25862617.0,Zhang Y,Immune system disorder,replication,2015-04-10,GCST002845,Systemic lupus erythematosus
2679,Asian,1425.0,25862617.0,Zhang Y,Immune system disorder,replication,2015-04-10,GCST002845,Systemic lupus erythematosus
3287,Asian,2949.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
14053,Other/Mixed,891.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
4176,Asian,11760.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
7776,European,3111.0,25865352.0,Schaarschmidt H,Immune system disorder,replication,2015-04-10,GCST002844,Atopic dermatitis
3010,Asian,2042.0,25861811.0,Li Z,Neurological disorder,initial,2015-04-10,GCST008391,Glaucoma (primary open-angle)
3587,Asian,5050.0,25862617.0,Zhang Y,Immune system disorder,initial,2015-04-10,GCST002845,Systemic lupus erythematosus
2417,Asian,837.0,25861811.0,Li Z,Neurological disorder,initial,2015-04-10,GCST008391,Glaucoma (primary open-angle)
875,African American or Afro-Caribbean,1226.0,25861811.0,Li Z,Neurological disorder,initial,2015-04-10,GCST008391,Glaucoma (primary open-angle)
6529,European,1358.0,25875332.0,Zayats T,Neurological disorder,initial,2015-04-13,GCST002848,Attention deficit hyperactivity disorder
2698,Asian,1494.0,25867717.0,Song N,"Cancer, Other measurement",replication,2015-04-13,GCST002847,Disease-free survival in breast cancer
2826,Asian,1732.0,25867717.0,Song N,"Cancer, Other measurement",initial,2015-04-13,GCST002847,Disease-free survival in breast cancer
10067,European,13462.0,25869804.0,Ibrahim-Verbaas CA,Biological process,initial,2015-04-14,GCST002849,Executive function
1146,African American or Afro-Caribbean,3146.0,25869804.0,Ibrahim-Verbaas CA,Biological process,replication,2015-04-14,GCST002849,Executive function
10940,European,33337.0,25869804.0,Ibrahim-Verbaas CA,Biological process,initial,2015-04-14,GCST002850,Information processing speed
10540,European,20720.0,25869804.0,Ibrahim-Verbaas CA,Biological process,replication,2015-04-14,GCST002849,Executive function
9484,European,8436.0,25869804.0,Ibrahim-Verbaas CA,Biological process,replication,2015-04-14,GCST002850,Information processing speed
924,African American or Afro-Caribbean,1444.0,25869804.0,Ibrahim-Verbaas CA,Biological process,replication,2015-04-14,GCST002850,Information processing speed
9343,European,8013.0,25877299.0,Kristiansen W,Cancer,initial,2015-04-15,GCST002855,Testicular germ cell tumor
3420,Asian,3810.0,25888059.0,Cha S,Other trait,initial,2015-04-15,GCST002851,Sasang constitutional medicine type (Tae-Yang)
7588,European,2709.0,25877299.0,Kristiansen W,Cancer,replication,2015-04-15,GCST002855,Testicular germ cell tumor
2801,Asian,1680.0,25888059.0,Cha S,Other trait,replication,2015-04-15,GCST002852,Sasang constitutional medicine type (So-Yang)
3422,Asian,3810.0,25888059.0,Cha S,Other trait,initial,2015-04-15,GCST002853,Sasang constitutional medicine type (Tae-Eum)
3423,Asian,3810.0,25888059.0,Cha S,Other trait,initial,2015-04-15,GCST002854,Sasang constitutional medicine type (So-Eum)
2803,Asian,1680.0,25888059.0,Cha S,Other trait,replication,2015-04-15,GCST002854,Sasang constitutional medicine type (So-Eum)
2802,Asian,1680.0,25888059.0,Cha S,Other trait,replication,2015-04-15,GCST002853,Sasang constitutional medicine type (Tae-Eum)
3421,Asian,3810.0,25888059.0,Cha S,Other trait,initial,2015-04-15,GCST002852,Sasang constitutional medicine type (So-Yang)
2800,Asian,1680.0,25888059.0,Cha S,Other trait,replication,2015-04-15,GCST002851,Sasang constitutional medicine type (Tae-Yang)
13011,Hispanic or Latin American,931.0,25898001.0,Dong C,Other measurement,initial,2015-04-16,GCST002856,Carotid artery intima media thickness (sex interaction)
607,African American or Afro-Caribbean,257.0,25898001.0,Dong C,Other measurement,replication,2015-04-16,GCST002856,Carotid artery intima media thickness (sex interaction)
4811,European,153.0,25898001.0,Dong C,Other measurement,replication,2015-04-16,GCST002856,Carotid artery intima media thickness (sex interaction)
4676,European,60.0,25896417.0,Nakada TA,"Response to drug, Inflammatory measurement",initial,2015-04-17,GCST002858,Cytokine and corticosteroid-stimulated IL-6 production
1214,African American or Afro-Caribbean,3817.0,25886283.0,Chang X,Other measurement,initial,2015-04-17,GCST002857,Calcium levels
8684,European,5261.0,25886283.0,Chang X,Other measurement,initial,2015-04-17,GCST002857,Calcium levels
7315,European,2317.0,25886283.0,Chang X,Other measurement,initial,2015-04-17,GCST002860,Magnesium levels
4675,European,60.0,25896417.0,Nakada TA,"Inflammatory measurement, Response to drug",initial,2015-04-17,GCST002859,Cytokine-stimulated IL-6 production
899,African American or Afro-Caribbean,1283.0,25886283.0,Chang X,Other measurement,initial,2015-04-17,GCST002860,Magnesium levels
11080,European,37954.0,25890600.0,Guo Q,"Other measurement, Cancer",initial,2015-04-18,GCST002861,Breast cancer (survival)
9060,European,6745.0,25898129.0,Shim H,"Lipid or lipoprotein measurement, Response to drug",replication,2015-04-21,GCST002865,Response to statin therapy (LDL cholesterol subfractions)
5138,European,361.0,25896534.0,Julia A,"Immune system disorder, Response to drug",initial,2015-04-21,GCST002869,"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis"
2226,Asian,567.0,25897834.0,Biernacka JM,"Response to drug, Neurological disorder",initial,2015-04-21,GCST002868,Response to serotonin reuptake inhibitors in major depressive disorder
6957,European,1868.0,25898129.0,Shim H,"Lipid or lipoprotein measurement, Response to drug",initial,2015-04-21,GCST002865,Response to statin therapy (LDL cholesterol subfractions)
6956,European,1868.0,25898129.0,Shim H,Lipid or lipoprotein measurement,initial,2015-04-21,GCST002870,LDL cholesterol subfractions
4976,European,245.0,25896534.0,Julia A,"Immune system disorder, Response to drug",replication,2015-04-21,GCST002869,"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis"
9059,European,6745.0,25898129.0,Shim H,Lipid or lipoprotein measurement,replication,2015-04-21,GCST002870,LDL cholesterol subfractions
5043,European,298.0,25897834.0,Biernacka JM,"Response to drug, Neurological disorder",initial,2015-04-21,GCST002868,Response to serotonin reuptake inhibitors in major depressive disorder
7922,European,3330.0,25855579.0,Mancikova V,Cancer,replication,2015-04-22,GCST002873,Thyroid cancer
5997,European,900.0,25855579.0,Mancikova V,Cancer,initial,2015-04-22,GCST002873,Thyroid cancer
8193,European,3953.0,25898920.0,Korostishevsky M,Other measurement,initial,2015-04-22,GCST002872,Blood metabolite levels
9532,European,8682.0,25903422.0,Yin X,Immune system disorder,initial,2015-04-23,GCST002874,Psoriasis
4119,Asian,10303.0,25903422.0,Yin X,Immune system disorder,replication,2015-04-23,GCST002874,Psoriasis
3597,Asian,5134.0,25903422.0,Yin X,Immune system disorder,initial,2015-04-23,GCST002874,Psoriasis
9844,European,10767.0,25903422.0,Yin X,Immune system disorder,replication,2015-04-23,GCST002874,Psoriasis
5996,European,898.0,25918132.0,Yucesoy B,"Biological process, Other disease",initial,2015-04-26,GCST002875,Diisocyanate-induced asthma
6254,European,1073.0,25936594.0,Tomer Y,"Immune system disorder, Metabolic disorder",initial,2015-04-27,GCST002876,Type 1 diabetes and autoimmune thyroid diseases
5469,European,525.0,25936594.0,Tomer Y,"Immune system disorder, Metabolic disorder",replication,2015-04-27,GCST002876,Type 1 diabetes and autoimmune thyroid diseases
5406,European,498.0,25918995.0,Salvatore JE,Other measurement,replication,2015-04-28,GCST002877,Adult antisocial behavior
7953,European,3373.0,25918841.0,Sanchez-Juan P,Neurological disorder,replication,2015-04-28,GCST002878,Creutzfeldt-Jakob disease (sporadic)
7360,European,2373.0,25918841.0,Sanchez-Juan P,Neurological disorder,initial,2015-04-28,GCST002878,Creutzfeldt-Jakob disease (sporadic)
5605,European,621.0,25918995.0,Salvatore JE,Other measurement,initial,2015-04-28,GCST002877,Adult antisocial behavior
3397,Asian,3644.0,25802187.0,Jiang DK,Digestive system disorder,initial,2015-04-28,GCST002879,Chronic hepatitis B infection
4270,Asian,14727.0,25802187.0,Jiang DK,Digestive system disorder,replication,2015-04-28,GCST002879,Chronic hepatitis B infection
2251,Asian,620.0,25920553.0,Coleman C,Immune system disorder,replication,2015-04-29,GCST008489,Celiac disease
10670,European,23649.0,25920553.0,Coleman C,Immune system disorder,replication,2015-04-29,GCST008489,Celiac disease
5972,European,878.0,25920553.0,Coleman C,Immune system disorder,initial,2015-04-29,GCST008489,Celiac disease
2392,Asian,797.0,25935106.0,Kim KW,Immune system disorder,initial,2015-04-30,GCST002880,Recalcitrant atopic dermatitis
1928,Asian,238.0,25676789.0,Wen CC,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2015-05-01,GCST004751,Serum uric acid levels in response to allopurinol in gout
487,African American or Afro-Caribbean,84.0,25676789.0,Wen CC,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2015-05-01,GCST004751,Serum uric acid levels in response to allopurinol in gout
12768,Hispanic or Latin American,85.0,25676789.0,Wen CC,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2015-05-01,GCST004751,Serum uric acid levels in response to allopurinol in gout
7066,European,2025.0,25934476.0,de Vries PS,Other measurement,replication,2015-05-01,GCST002881,ADAMTS13 activity
6744,European,1607.0,25676789.0,Wen CC,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2015-05-01,GCST004751,Serum uric acid levels in response to allopurinol in gout
7986,European,3423.0,25934476.0,de Vries PS,Other measurement,initial,2015-05-01,GCST002881,ADAMTS13 activity
6986,European,1922.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",replication,2015-05-02,GCST002883,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
6909,European,1794.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",initial,2015-05-02,GCST002882,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
6985,European,1922.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",replication,2015-05-02,GCST002882,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
6910,European,1794.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",initial,2015-05-02,GCST002883,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
13672,Other/Mixed,19.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",replication,2015-05-02,GCST002883,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
13667,Other/Mixed,18.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",initial,2015-05-02,GCST002882,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
13671,Other/Mixed,19.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",replication,2015-05-02,GCST002882,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
13668,Other/Mixed,18.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",initial,2015-05-02,GCST002883,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
5348,European,481.0,25827949.0,Kunz M,Immune system disorder,replication,2015-05-04,GCST002884,Cutaneous lupus erythematosus
6602,European,1439.0,25827949.0,Kunz M,Immune system disorder,initial,2015-05-04,GCST002884,Cutaneous lupus erythematosus
5028,European,290.0,25944848.0,Athanasiu L,"Response to drug, Neurological disorder, Other measurement",initial,2015-05-05,GCST002885,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)
9932,European,11693.0,25939698.0,Tsoi LC,Immune system disorder,initial,2015-05-05,GCST002889,Psoriasis
10524,European,20440.0,25939698.0,Tsoi LC,Immune system disorder,replication,2015-05-05,GCST002889,Psoriasis
4861,European,185.0,25944848.0,Athanasiu L,"Neurological disorder, Other measurement, Response to drug",initial,2015-05-05,GCST002887,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)
5899,European,829.0,25944848.0,Athanasiu L,"Response to drug, Neurological disorder, Other measurement",initial,2015-05-05,GCST002888,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)
8397,European,4545.0,25939597.0,Berndt SI,"Cancer, Other measurement",initial,2015-05-05,GCST002886,Prostate cancer aggressiveness
9326,European,7973.0,25939597.0,Berndt SI,"Cancer, Other measurement",replication,2015-05-05,GCST002886,Prostate cancer aggressiveness
10218,European,15402.0,25939597.0,Berndt SI,Cancer,replication,2015-05-05,GCST002890,Prostate cancer
5072,European,320.0,25944848.0,Athanasiu L,"Neurological disorder, Other measurement, Response to drug",initial,2015-05-05,GCST002891,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio)
9243,European,7541.0,25939597.0,Berndt SI,Cancer,initial,2015-05-05,GCST002890,Prostate cancer
5606,European,622.0,25948407.0,Kertai MD,"Other trait, Cardiovascular disease",replication,2015-05-06,GCST002892,Perioperative myocardial infarction in coronary artery bypass surgery
8179,European,3918.0,25953783.0,Warrington NM,Body measurement,replication,2015-05-07,GCST002893,Body mass index (age interaction)
8180,European,3918.0,25953783.0,Warrington NM,"Body measurement, Other measurement",replication,2015-05-07,GCST002894,Body mass index
7745,European,3025.0,25956309.0,Palomba G,Cancer,initial,2015-05-10,GCST002895,Breast cancer
11899,European,124013.0,25956309.0,Palomba G,Cancer,replication,2015-05-10,GCST002895,Breast cancer
6521,European,1351.0,25964295.0,Khan S,"Other measurement, Cancer",replication,2015-05-11,GCST002902,Survival in breast cancer (estrogen-receptor negative)
8460,European,4723.0,25964295.0,Khan S,"Other measurement, Cancer, Response to drug",replication,2015-05-11,GCST002901,Survival in endocrine treated breast cancer (estrogen-receptor positive)
11416,European,62166.0,25961943.0,Surakka I,Lipid or lipoprotein measurement,initial,2015-05-11,GCST002899,HDL cholesterol
5567,European,597.0,25964295.0,Khan S,"Other measurement, Cancer",initial,2015-05-11,GCST002902,Survival in breast cancer (estrogen-receptor negative)
11415,European,62166.0,25961943.0,Surakka I,Lipid or lipoprotein measurement,initial,2015-05-11,GCST002897,Triglycerides
7952,European,3372.0,25964295.0,Khan S,"Other measurement, Cancer",replication,2015-05-11,GCST002903,Survival in breast cancer (estrogen-receptor positive)
5623,European,639.0,25964295.0,Khan S,"Other measurement, Cancer",initial,2015-05-11,GCST002903,Survival in breast cancer (estrogen-receptor positive)
6437,European,1236.0,25964295.0,Khan S,"Other measurement, Cancer, Response to drug",initial,2015-05-11,GCST002901,Survival in endocrine treated breast cancer (estrogen-receptor positive)
11414,European,62166.0,25961943.0,Surakka I,Lipid or lipoprotein measurement,initial,2015-05-11,GCST002896,"Cholesterol, total"
11386,European,58358.0,25961943.0,Surakka I,"Lipid or lipoprotein measurement, Other measurement",initial,2015-05-11,GCST002898,LDL cholesterol
7561,European,2668.0,25963972.0,Liu F,Immune system disorder,initial,2015-05-12,GCST002908,Skin sensitivity to sun
8844,European,5857.0,25963972.0,Liu F,Other trait,initial,2015-05-12,GCST002906,Skin colour saturation
6711,European,1563.0,25963331.0,Hatzimanolis A,Other trait,replication,2015-05-12,GCST002905,Endophenotypes for schizophrenia in healthy individuals
6267,European,1079.0,25963331.0,Hatzimanolis A,Other trait,initial,2015-05-12,GCST002905,Endophenotypes for schizophrenia in healthy individuals
9622,European,9316.0,25963972.0,Liu F,Other trait,initial,2015-05-12,GCST002907,Perceived skin darkness
8692,European,5278.0,25963972.0,Liu F,Other trait,replication,2015-05-12,GCST002907,Perceived skin darkness
3874,Asian,7444.0,25967671.0,Li C,Metabolic disorder,replication,2015-05-13,GCST002909,Gout
7182,European,2158.0,25972531.0,Carter TC,Other measurement,initial,2015-05-13,GCST006797,Pyridoxal levels
7183,European,2158.0,25972531.0,Carter TC,Other measurement,initial,2015-05-13,GCST006798,4-pyridoxic acid levels
7184,European,2158.0,25972531.0,Carter TC,Other measurement,initial,2015-05-13,GCST006799,Pyridoxal 5'-phosphate levels
3323,Asian,3103.0,25967671.0,Li C,Metabolic disorder,initial,2015-05-13,GCST002909,Gout
3463,Asian,4093.0,25972035.0,Vinayagamoorthy N,Other measurement,replication,2015-05-14,GCST002911,Calcium levels
5573,European,600.0,25914168.0,Esposito F,"Immune system disorder, Response to drug",replication,2015-05-14,GCST002910,Response to interferon beta in multiple sclerosis
3524,Asian,4558.0,25972035.0,Vinayagamoorthy N,Other measurement,initial,2015-05-14,GCST002911,Calcium levels
4776,European,116.0,25914168.0,Esposito F,"Immune system disorder, Response to drug",initial,2015-05-14,GCST002910,Response to interferon beta in multiple sclerosis
2549,Asian,1109.0,25986216.0,Toyoda H,Neurological disorder,replication,2015-05-15,GCST002912,Narcolepsy with cataplexy
2973,Asian,1971.0,25986216.0,Toyoda H,Neurological disorder,initial,2015-05-15,GCST002912,Narcolepsy with cataplexy
1599,Asian,6.0,25988933.0,Almli LM,Neurological disorder,initial,2015-05-18,GCST002914,Post-traumatic stress disorder
1094,African American or Afro-Caribbean,2868.0,25988933.0,Almli LM,Neurological disorder,replication,2015-05-18,GCST002914,Post-traumatic stress disorder
13621,Other/Mixed,4.0,25988933.0,Almli LM,Neurological disorder,initial,2015-05-18,GCST002914,Post-traumatic stress disorder
4655,European,45.0,25988933.0,Almli LM,Neurological disorder,initial,2015-05-18,GCST002914,Post-traumatic stress disorder
18,African,35.0,25988933.0,Almli LM,Neurological disorder,initial,2015-05-18,GCST002914,Post-traumatic stress disorder
14195,Other/Mixed,3126.0,25987655.0,Fernandez CA,"Cancer, Response to drug",initial,2015-05-18,GCST002915,Asparaginase hypersensitivity in acute lymphoblastic leukemia
1737,Asian,103.0,25985088.0,Oguchi T,"Immune system disorder, Other trait",initial,2015-05-18,GCST002913,Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis
12758,Hispanic or Latin American,57.0,25988933.0,Almli LM,Neurological disorder,initial,2015-05-18,GCST002914,Post-traumatic stress disorder
13806,Other/Mixed,182.0,25987655.0,Fernandez CA,"Cancer, Response to drug",replication,2015-05-18,GCST002915,Asparaginase hypersensitivity in acute lymphoblastic leukemia
9058,European,6744.0,25987507.0,Minica CC,"Neurological disorder, Biological process",initial,2015-05-19,GCST002916,Cannabis use (initiation)
8654,European,5148.0,25987507.0,Minica CC,"Biological process, Other measurement",initial,2015-05-19,GCST002917,Cannabis use (age at onset)
1923,Asian,236.0,25987243.0,Parham LR,"Digestive system disorder, Response to drug",initial,2015-05-19,GCST002918,Lapatinib-induced hepatotoxicity
5819,European,775.0,25987243.0,Parham LR,"Digestive system disorder, Response to drug",initial,2015-05-19,GCST002918,Lapatinib-induced hepatotoxicity
10368,European,17556.0,25990418.0,Al-Tassan NA,Cancer,initial,2015-05-20,GCST002919,Colorectal cancer
9702,European,9786.0,25993607.0,de Moor MH,"Neurological disorder, Other measurement",replication,2015-05-20,GCST002920,Neuroticism
11437,European,63661.0,25993607.0,de Moor MH,"Neurological disorder, Other measurement",initial,2015-05-20,GCST002920,Neuroticism
1752,Asian,116.0,26015512.0,Komatsu M,"Other measurement, Response to drug",initial,2015-05-26,GCST002924,Paclitaxel-induced cytotoxicity
7572,European,2697.0,26007630.0,Swaminathan B,Cancer,replication,2015-05-26,GCST002921,Multiple myeloma
12262,European,224749.0,26007630.0,Swaminathan B,Cancer,initial,2015-05-26,GCST002921,Multiple myeloma
1796,Asian,145.0,26015512.0,Komatsu M,"Response to drug, Neurological disorder, Other measurement",initial,2015-05-26,GCST002923,Paclitaxel-induced neuropathy
7573,European,2697.0,26007630.0,Swaminathan B,"Other disease, Cancer",replication,2015-05-26,GCST002922,Multiple myeloma and monoclonal gammopathy
12375,European,296835.0,26007630.0,Swaminathan B,"Other disease, Cancer",initial,2015-05-26,GCST002922,Multiple myeloma and monoclonal gammopathy
35,African,83.0,26015512.0,Komatsu M,"Other measurement, Response to drug",replication,2015-05-26,GCST002924,Paclitaxel-induced cytotoxicity
4697,European,77.0,26015512.0,Komatsu M,"Other measurement, Response to drug",replication,2015-05-26,GCST002924,Paclitaxel-induced cytotoxicity
38,African,87.0,26015512.0,Komatsu M,"Other measurement, Response to drug",replication,2015-05-26,GCST002924,Paclitaxel-induced cytotoxicity
7685,European,2913.0,26014426.0,Ruth KS,Other measurement,initial,2015-05-27,GCST002925,Sex hormone levels
5380,European,489.0,26025128.0,Park HW,"Response to drug, Other disease, Other measurement",initial,2015-05-27,GCST002926,Bone mineral accretion in asthma (oral corticosteroid dose interaction)
1087,African American or Afro-Caribbean,2737.0,26058915.0,Tin A,Other measurement,initial,2015-05-29,GCST002933,Magnesium levels
6074,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002928,Nickel levels
815,African American or Afro-Caribbean,942.0,26058915.0,Tin A,Other measurement,replication,2015-05-29,GCST002933,Magnesium levels
6076,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002930,Cobalt levels
6077,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002931,Aluminium levels
6078,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002932,Manganese levels
6083,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002938,Copper levels
6079,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002934,Zinc levels
6080,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002935,Lead levels
6081,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002936,Cadmium levels
6082,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002937,Molybdenum levels
6075,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002929,Chromium levels
6073,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002927,Mercury levels
6417,European,1221.0,26024889.0,Qayyum R,Biological process,replication,2015-05-30,GCST002939,Platelet aggregation
788,African American or Afro-Caribbean,825.0,26024889.0,Qayyum R,Biological process,initial,2015-05-30,GCST002939,Platelet aggregation
513,African American or Afro-Caribbean,119.0,26024889.0,Qayyum R,Biological process,replication,2015-05-30,GCST002939,Platelet aggregation
4180,Asian,12095.0,26028593.0,Li M,Other disease,initial,2015-06-01,GCST002943,IgA nephropathy
9242,European,7539.0,26034056.0,Hoffmann TJ,Cancer,replication,2015-06-01,GCST002944,Prostate cancer
11049,European,37272.0,26034056.0,Hoffmann TJ,Cancer,initial,2015-06-01,GCST002944,Prostate cancer
13207,Hispanic or Latin American,3629.0,26034056.0,Hoffmann TJ,Cancer,initial,2015-06-01,GCST002944,Prostate cancer
1034,African American or Afro-Caribbean,2251.0,26034056.0,Hoffmann TJ,Cancer,initial,2015-06-01,GCST002944,Prostate cancer
1124,African American or Afro-Caribbean,3033.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002941,Airway imaging phenotypes
5283,European,439.0,26030142.0,Van Driest SL,"Response to drug, Other measurement",replication,2015-06-01,GCST002948,Peak creatinine levels in vancomycin therapy
1125,African American or Afro-Caribbean,3033.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002942,Percentage gas trapping
1126,African American or Afro-Caribbean,3033.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002945,Emphysema imaging phenotypes
9583,European,8998.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002945,Emphysema imaging phenotypes
5381,European,489.0,26030142.0,Van Driest SL,"Response to drug, Other measurement",initial,2015-06-01,GCST002948,Peak creatinine levels in vancomycin therapy
5785,European,745.0,26030142.0,Van Driest SL,"Response to drug, Other measurement",initial,2015-06-01,GCST002947,Renal elimination rate in vancomycin therapy
5784,European,745.0,26030142.0,Van Driest SL,"Other measurement, Response to drug",initial,2015-06-01,GCST002946,Vancomycin trough in vancomycin therapy
8957,European,6305.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002942,Percentage gas trapping
3762,Asian,6162.0,26029870.0,Ye Z,Cancer,replication,2015-06-01,GCST002940,Sporadic pituitary adenoma
9582,European,8998.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002941,Airway imaging phenotypes
3387,Asian,3559.0,26029870.0,Ye Z,Cancer,initial,2015-06-01,GCST002940,Sporadic pituitary adenoma
3336,Asian,3226.0,26034056.0,Hoffmann TJ,Cancer,initial,2015-06-01,GCST002944,Prostate cancer
1259,African American or Afro-Caribbean,4679.0,26034056.0,Hoffmann TJ,Cancer,replication,2015-06-01,GCST002944,Prostate cancer
4298,Asian,15898.0,26028593.0,Li M,Other disease,replication,2015-06-01,GCST002943,IgA nephropathy
5113,European,343.0,26030142.0,Van Driest SL,"Other measurement, Response to drug",replication,2015-06-01,GCST002946,Vancomycin trough in vancomycin therapy
5114,European,343.0,26030142.0,Van Driest SL,"Response to drug, Other measurement",replication,2015-06-01,GCST002947,Renal elimination rate in vancomycin therapy
4985,European,259.0,26031901.0,Dahlin A,"Other measurement, Other disease, Response to drug",initial,2015-06-02,GCST002951,Response to zileuton treatment in asthma (FEV1 change interaction)
4869,European,187.0,26031901.0,Dahlin A,"Other measurement, Other disease, Response to drug",replication,2015-06-02,GCST002951,Response to zileuton treatment in asthma (FEV1 change interaction)
2591,Asian,1211.0,26220383.0,Jang HW,Neurological disorder,initial,2015-06-02,GCST002950,Epilepsy
2553,Asian,1114.0,26220383.0,Jang HW,"Response to drug, Other disease, Neurological disorder",initial,2015-06-02,GCST002949,Epilepsy and lamotrigine-induced maculopapular eruptions
642,African American or Afro-Caribbean,337.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002953,Pediatric areal bone mineral density (radius)
5349,European,481.0,26041818.0,Chesi A,Other measurement,replication,2015-06-03,GCST002952,Pediatric bone mineral content (radius)
6005,European,908.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002953,Pediatric areal bone mineral density (radius)
13763,Other/Mixed,126.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002953,Pediatric areal bone mineral density (radius)
6004,European,908.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002952,Pediatric bone mineral content (radius)
641,African American or Afro-Caribbean,337.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002952,Pediatric bone mineral content (radius)
5350,European,481.0,26041818.0,Chesi A,Other measurement,replication,2015-06-03,GCST002953,Pediatric areal bone mineral density (radius)
13762,Other/Mixed,126.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002952,Pediatric bone mineral content (radius)
4005,Asian,8808.0,26049409.0,Hirano A,Neurological disorder,initial,2015-06-05,GCST002954,Alzheimer's disease (late onset)
3955,Asian,8223.0,26049409.0,Hirano A,Neurological disorder,replication,2015-06-05,GCST002954,Alzheimer's disease (late onset)
12874,Hispanic or Latin American,449.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002956,3-hydroxypropylmercapturic acid levels in smokers
2316,Asian,704.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002956,3-hydroxypropylmercapturic acid levels in smokers
654,African American or Afro-Caribbean,362.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002956,3-hydroxypropylmercapturic acid levels in smokers
13867,Other/Mixed,329.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002956,3-hydroxypropylmercapturic acid levels in smokers
12875,Hispanic or Latin American,452.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002957,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
13868,Other/Mixed,329.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002957,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
2309,Asian,702.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002957,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
653,African American or Afro-Caribbean,361.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002957,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
5280,European,438.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002956,3-hydroxypropylmercapturic acid levels in smokers
5285,European,440.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002957,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
13603,Other/Mixed,2.0,26067905.0,Bari R,"Immune system disorder, Biological process",initial,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
13665,Other/Mixed,17.0,26067905.0,Bari R,"Immune system disorder, Biological process",replication,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
10,African,13.0,26067905.0,Bari R,"Immune system disorder, Biological process",initial,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
1579,Asian,1.0,26067905.0,Bari R,"Immune system disorder, Biological process",initial,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
4666,European,52.0,26067905.0,Bari R,"Immune system disorder, Biological process",initial,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
12,African,17.0,26067905.0,Bari R,"Immune system disorder, Biological process",replication,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
4681,European,64.0,26067905.0,Bari R,"Immune system disorder, Biological process",replication,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
1588,Asian,2.0,26067905.0,Bari R,"Immune system disorder, Biological process",replication,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
6365,European,1182.0,26068415.0,Draisma HHM,Other measurement,replication,2015-06-12,GCST002959,Hexose levels
156,African,949.0,26114229.0,Ashley-Koch AE,Neurological disorder,initial,2015-06-12,GCST002963,Post-traumatic stress disorder
5805,European,759.0,26114229.0,Ashley-Koch AE,Neurological disorder,initial,2015-06-12,GCST002963,Post-traumatic stress disorder
6367,European,1182.0,26068415.0,Draisma HHM,Other measurement,replication,2015-06-12,GCST002966,Amino acid levels
9227,European,7478.0,26068415.0,Draisma HHM,Other measurement,initial,2015-06-12,GCST002959,Hexose levels
9228,European,7478.0,26068415.0,Draisma HHM,Other measurement,initial,2015-06-12,GCST002961,Acylcarnitine levels
9229,European,7478.0,26068415.0,Draisma HHM,Other measurement,initial,2015-06-12,GCST002966,Amino acid levels
9231,European,7478.0,26068415.0,Draisma HHM,"Other measurement, Lipid or lipoprotein measurement",initial,2015-06-12,GCST002965,Glycerophospholipid levels
5540,European,581.0,26073756.0,McGeachie MJ,Other measurement,initial,2015-06-12,GCST002962,Asthma exacerbations
6366,European,1182.0,26068415.0,Draisma HHM,Other measurement,replication,2015-06-12,GCST002961,Acylcarnitine levels
5642,European,652.0,26073756.0,McGeachie MJ,Other measurement,replication,2015-06-12,GCST002962,Asthma exacerbations
6368,European,1182.0,26068415.0,Draisma HHM,"Other measurement, Lipid or lipoprotein measurement",replication,2015-06-12,GCST002964,Sphingolipid levels
6611,European,1456.0,26154020.0,Ferrari R,Neurological disorder,initial,2015-06-12,GCST002960,Frontotemporal dementia
583,African American or Afro-Caribbean,212.0,26073756.0,McGeachie MJ,Other measurement,replication,2015-06-12,GCST002962,Asthma exacerbations
9230,European,7478.0,26068415.0,Draisma HHM,"Other measurement, Lipid or lipoprotein measurement",initial,2015-06-12,GCST002964,Sphingolipid levels
6369,European,1182.0,26068415.0,Draisma HHM,"Other measurement, Lipid or lipoprotein measurement",replication,2015-06-12,GCST002965,Glycerophospholipid levels
1845,Asian,190.0,25950743.0,Uttayamakul S,"Response to drug, Other disease, Other trait",replication,2015-06-15,GCST002968,Response to stavudine in HIV (lipoatrophy)
1794,Asian,141.0,25950743.0,Uttayamakul S,"Response to drug, Other disease, Other trait",initial,2015-06-15,GCST002968,Response to stavudine in HIV (lipoatrophy)
4982,European,253.0,26077402.0,de Rooy DP,"Immune system disorder, Other measurement",replication,2015-06-15,GCST003256,Joint damage progression in ACPA-negative rheumatoid arthritis
4986,European,262.0,26077402.0,de Rooy DP,"Immune system disorder, Other measurement",initial,2015-06-15,GCST003256,Joint damage progression in ACPA-negative rheumatoid arthritis
10663,European,23337.0,26075790.0,Kelemen LE,Cancer,initial,2015-06-15,GCST002967,Mucinous ovarian carcinoma
5135,European,358.0,26079190.0,Galfalvy H,"Neurological disorder, Other measurement",initial,2015-06-16,GCST002974,Suicide ideation score in major depressive disorder
6917,European,1810.0,26079190.0,Galfalvy H,Biological process,initial,2015-06-16,GCST002969,Suicide behavior
6696,European,1550.0,26079190.0,Galfalvy H,Biological process,initial,2015-06-16,GCST002973,Suicide
5514,European,557.0,26079190.0,Galfalvy H,"Biological process, Neurological disorder",initial,2015-06-16,GCST002972,Suicide attempts in major depressive disorder
1650,Asian,35.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",initial,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
12782,Hispanic or Latin American,107.0,26084801.0,Mirabello L,"Other measurement, Cancer",replication,2015-06-17,GCST002978,Metastasis at diagnosis in osteosarcoma
227,African,1737.0,26083729.0,Maruthur NM,"Other measurement, Metabolic disorder",initial,2015-06-17,GCST002977,Advanced glycation end-product levels
5969,European,877.0,26385043.0,Kertai MD,"Other trait, Cardiovascular disease",initial,2015-06-17,GCST002975,Postoperative atrial fibrillation in coronary artery bypass grafting surgery
5159,European,380.0,26083657.0,Stafford-Smith M,"Other trait, Other measurement",replication,2015-06-17,GCST002982,Acute kidney injury in coronary artery bypass surgery (creatinine rise)
2087,Asian,402.0,26083723.0,Park S,Cardiovascular measurement,initial,2015-06-17,GCST002980,Arterial stiffness (pulse-wave velocity)
2589,Asian,1206.0,26083723.0,Park S,Cardiovascular measurement,replication,2015-06-17,GCST002980,Arterial stiffness (pulse-wave velocity)
5541,European,581.0,26083729.0,Maruthur NM,"Other measurement, Metabolic disorder",initial,2015-06-17,GCST002977,Advanced glycation end-product levels
4947,European,226.0,26084801.0,Mirabello L,"Other measurement, Cancer",replication,2015-06-17,GCST002978,Metastasis at diagnosis in osteosarcoma
28,African,61.0,26084801.0,Mirabello L,"Other measurement, Cancer",replication,2015-06-17,GCST002978,Metastasis at diagnosis in osteosarcoma
5964,European,873.0,26083657.0,Stafford-Smith M,"Other trait, Other measurement",initial,2015-06-17,GCST002982,Acute kidney injury in coronary artery bypass surgery (creatinine rise)
4763,European,101.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",replication,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
1658,Asian,50.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",replication,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
2204,Asian,538.0,26039976.0,Wei Z,"Biological process, Other measurement, Other disease",initial,2015-06-17,GCST002976,HIV-1 viral setpoint
4723,European,88.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",initial,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
8,African,10.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",initial,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
15,African,33.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",replication,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
1471,African American or Afro-Caribbean,14519.0,26089329.0,Carty CL,"Cardiovascular disease, Other trait",initial,2015-06-18,GCST002988,Ischemic stroke
12979,Hispanic or Latin American,786.0,26339675.0,Tosto G,Neurological disorder,replication,2015-06-18,GCST002983,Alzheimer's disease (late onset)
10231,European,15668.0,26087016.0,Pappa I,Other measurement,initial,2015-06-18,GCST002984,Early childhood aggressive behavior
13245,Hispanic or Latin American,4514.0,26339675.0,Tosto G,Neurological disorder,initial,2015-06-18,GCST002983,Alzheimer's disease (late onset)
10447,European,18988.0,26087016.0,Pappa I,Other measurement,initial,2015-06-18,GCST002986,Childhood and early adolescence aggressive behavior
10275,European,16311.0,26087016.0,Pappa I,Other measurement,initial,2015-06-18,GCST002985,Middle childhood and early adolescence aggressive behavior
1473,African American or Afro-Caribbean,14746.0,26089329.0,Carty CL,Cardiovascular disease,initial,2015-06-18,GCST002987,Stroke
5486,European,540.0,26112879.0,Rudkowska I,"Lipid or lipoprotein measurement, Other measurement",initial,2015-06-20,GCST002989,LDL peak particle diameter (total fat intake interaction)
12208,European,204576.0,26098866.0,Helgason H,Cancer,initial,2015-06-22,GCST002990,Gastric adenocarcinoma (histologically verified)
12224,European,208152.0,26098866.0,Helgason H,Cancer,initial,2015-06-22,GCST002992,Gastric cancer
9190,European,7320.0,26098869.0,Childs EJ,Cancer,initial,2015-06-22,GCST002991,Pancreatic cancer
2053,Asian,375.0,26100964.0,Cao S,"Response to drug, Digestive system disorder, Cancer",replication,2015-06-23,GCST002993,Platinum-induced hepatotoxicity in non-small cell lung cancer
2008,Asian,329.0,26100964.0,Cao S,"Response to drug, Digestive system disorder, Cancer",initial,2015-06-23,GCST002993,Platinum-induced hepatotoxicity in non-small cell lung cancer
13278,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST002997,Helix rolling
13279,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST002998,Lobe attachment
13280,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST002999,Lobe size
13281,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003000,Darwin's tubercle
13282,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003001,Ear morphology
13277,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST002996,Folding of antihelix
13283,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003002,Tragus size
13276,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST002994,Ear protrusion
5512,European,555.0,26116289.0,Raginis-Zborowska A,Other trait,initial,2015-06-24,GCST002995,Dysphagia
13286,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003005,Superior crus of antihelix expression
13285,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003004,Crus helix expression
13284,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003003,Antitragus size
4644,European,31.0,26121033.0,Grondin Y,Neurological disorder,initial,2015-06-29,GCST003006,Noise-induced hearing loss
12729,Hispanic or Latin American,10.0,26121033.0,Grondin Y,Neurological disorder,initial,2015-06-29,GCST003006,Noise-induced hearing loss
3428,Asian,3897.0,26129866.0,Hu N,Cancer,initial,2015-06-30,GCST003009,Cardia gastric cancer
3413,Asian,3735.0,26129866.0,Hu N,Cancer,initial,2015-06-30,GCST003007,Non-cardia gastric cancer
4142,Asian,11211.0,26129866.0,Hu N,Cancer,replication,2015-06-30,GCST003007,Non-cardia gastric cancer
3589,Asian,5058.0,26129866.0,Hu N,Cancer,initial,2015-06-30,GCST003010,Gastric cancer
4150,Asian,11286.0,26129866.0,Hu N,Cancer,replication,2015-06-30,GCST003009,Cardia gastric cancer
4669,European,55.0,26121980.0,Chauhan L,"Other measurement, Response to drug, Other trait",initial,2015-06-30,GCST003008,Triptolide cytotoxicity
4281,Asian,14956.0,26129866.0,Hu N,Cancer,replication,2015-06-30,GCST003010,Gastric cancer
13738,Other/Mixed,78.0,27186693.0,Aydin-Son Y,Immune system disorder,initial,2015-07-01,GCST003011,Arthritis (juvenile idiopathic)
2150,Asian,470.0,25325441.0,Baik I,Neurological disorder,initial,2015-07-01,GCST003012,Obstructive sleep apnea
12982,Hispanic or Latin American,795.0,25663218.0,Verhaaren BF,Other measurement,initial,2015-07-02,GCST003013,White matter hyperintensity burden
491,African American or Afro-Caribbean,90.0,26138065.0,Schneider BP,"Cancer, Response to drug, Neurological disorder",replication,2015-07-02,GCST003627,Neuropathy in taxane-treated breast cancer
6528,European,1357.0,26138065.0,Schneider BP,"Cancer, Response to drug, Neurological disorder",initial,2015-07-02,GCST003627,Neuropathy in taxane-treated breast cancer
584,African American or Afro-Caribbean,213.0,26138065.0,Schneider BP,"Cancer, Response to drug, Neurological disorder",initial,2015-07-02,GCST003627,Neuropathy in taxane-treated breast cancer
1861,Asian,201.0,25663218.0,Verhaaren BF,Other measurement,initial,2015-07-02,GCST003013,White matter hyperintensity burden
5836,European,789.0,26138065.0,Schneider BP,"Cancer, Response to drug, Neurological disorder",replication,2015-07-02,GCST003627,Neuropathy in taxane-treated breast cancer
1863,Asian,204.0,25663218.0,Verhaaren BF,Other measurement,initial,2015-07-02,GCST003013,White matter hyperintensity burden
981,African American or Afro-Caribbean,1943.0,25663218.0,Verhaaren BF,Other measurement,initial,2015-07-02,GCST003013,White matter hyperintensity burden
10395,European,17936.0,25663218.0,Verhaaren BF,Other measurement,initial,2015-07-02,GCST003013,White matter hyperintensity burden
5917,European,843.0,26256467.0,Wojczynski MK,"Lipid or lipoprotein measurement, Biological process",replication,2015-07-03,GCST003014,Postprandial triglyceride response to high fat diet meal
5962,European,872.0,26256467.0,Wojczynski MK,"Lipid or lipoprotein measurement, Biological process",initial,2015-07-03,GCST003014,Postprandial triglyceride response to high fat diet meal
5601,European,619.0,26146898.0,Clark SL,"Biological process, Other measurement",initial,2015-07-04,GCST003015,Alcohol consumption
5746,European,730.0,26146898.0,Clark SL,"Biological process, Other measurement",replication,2015-07-04,GCST003015,Alcohol consumption
5156,European,375.0,26207136.0,Cho CH,"Neurological disorder, Other trait",initial,2015-07-06,GCST003016,Hypersomnia during a major depressive episode in bipolar disorder
11081,European,37955.0,26151821.0,Schumacher FR,Cancer,initial,2015-07-07,GCST003017,Colorectal cancer
2291,Asian,683.0,26151496.0,Chen PL,"Immune system disorder, Response to drug, Other trait",initial,2015-07-07,GCST003018,Thionamide-induced agranulocytosis in Graves' disease
4269,Asian,14694.0,26151821.0,Schumacher FR,Cancer,replication,2015-07-07,GCST003017,Colorectal cancer
2227,Asian,567.0,26151496.0,Chen PL,"Immune system disorder, Response to drug, Other trait",replication,2015-07-07,GCST003018,Thionamide-induced agranulocytosis in Graves' disease
9142,European,7091.0,26184321.0,Lin BD,Other trait,initial,2015-07-13,GCST003020,Red vs non-red hair color
9143,European,7091.0,26184321.0,Lin BD,Other trait,initial,2015-07-13,GCST003021,Brown vs. non-brown hair color
9144,European,7091.0,26184321.0,Lin BD,Other trait,initial,2015-07-13,GCST003022,Light vs. dark hair color
9145,European,7091.0,26184321.0,Lin BD,Other trait,initial,2015-07-13,GCST003023,Blond vs non-blond hair color
9141,European,7091.0,26184321.0,Lin BD,Other trait,initial,2015-07-13,GCST003019,Black vs. non-black hair color
148,African,879.0,26169577.0,Mosley JD,"Other trait, Response to drug",initial,2015-07-14,GCST003027,Cough in response to angiotensin-converting enzyme inhibitor drugs
1748,Asian,112.0,26174610.0,Kwak TJ,Other measurement,replication,2015-07-14,GCST003024,Ultraviolet-induced skin pigmentation (minimal erythema dose)
1726,Asian,99.0,26174610.0,Kwak TJ,Other measurement,initial,2015-07-14,GCST003024,Ultraviolet-induced skin pigmentation (minimal erythema dose)
5345,European,479.0,26174813.0,Alemany S,"Neurological disorder, Other measurement",initial,2015-07-14,GCST003025,Attention function in attention deficit hyperactive disorder
2472,Asian,947.0,26169365.0,Huang KC,"Other trait, Metabolic disorder",initial,2015-07-14,GCST003026,Yu-Zhi constitution type in type 2 diabetes
8887,European,6007.0,26169577.0,Mosley JD,"Other trait, Response to drug",initial,2015-07-14,GCST003027,Cough in response to angiotensin-converting enzyme inhibitor drugs
13811,Other/Mixed,194.0,26169577.0,Mosley JD,"Other trait, Response to drug",initial,2015-07-14,GCST003027,Cough in response to angiotensin-converting enzyme inhibitor drugs
8676,European,5231.0,26169577.0,Mosley JD,"Other trait, Response to drug",replication,2015-07-14,GCST003027,Cough in response to angiotensin-converting enzyme inhibitor drugs
5598,European,612.0,26176695.0,Warrier V,Neurological disorder,initial,2015-07-15,GCST003029,Asperger syndrome
3752,Asian,6065.0,26174136.0,Setoh K,Other measurement,replication,2015-07-15,GCST003028,Serum alpha1-antitrypsin levels
3345,Asian,3294.0,26174136.0,Setoh K,Other measurement,initial,2015-07-15,GCST003028,Serum alpha1-antitrypsin levels
5024,European,289.0,26183928.0,Leng S,"Biological process, Other measurement",replication,2015-07-16,GCST003031,MGMT methylation in smokers
12795,Hispanic or Latin American,141.0,26183928.0,Leng S,"Biological process, Other measurement",replication,2015-07-16,GCST003031,MGMT methylation in smokers
6346,European,1163.0,26183928.0,Leng S,"Biological process, Other measurement",initial,2015-07-16,GCST003031,MGMT methylation in smokers
5794,European,750.0,26184070.0,Aebi M,"Neurological disorder, Other measurement",initial,2015-07-16,GCST003030,Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder
4993,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003032,Hearing function (2 kHz)
2162,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003035,Hearing function (4 kHz)
7172,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003032,Hearing function (2 kHz)
7173,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003033,Hearing function (medium tone)
8922,European,6162.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003041,Hearing function (1 kHz)
8921,European,6162.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003035,Hearing function (4 kHz)
7174,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003034,Hearing function (8 kHz)
2163,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003036,Hearing function (low tone)
2161,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003034,Hearing function (8 kHz)
2164,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003037,Hearing function (0.5 kHz)
2165,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003039,Hearing function (0.25 kHz)
7178,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003039,Hearing function (0.25 kHz)
7177,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003037,Hearing function (0.5 kHz)
4881,European,192.0,26186006.0,Abrantes P,Cardiovascular disease,initial,2015-07-17,GCST003038,Intracranial aneurysm
2166,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003040,Hearing function (high tone)
7176,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003036,Hearing function (low tone)
5425,European,507.0,26186006.0,Abrantes P,Cardiovascular disease,replication,2015-07-17,GCST003038,Intracranial aneurysm
2167,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003041,Hearing function (1 kHz)
7179,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003040,Hearing function (high tone)
2160,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003033,Hearing function (medium tone)
7175,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003035,Hearing function (4 kHz)
4996,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003036,Hearing function (low tone)
4994,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003033,Hearing function (medium tone)
4995,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003034,Hearing function (8 kHz)
2159,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003032,Hearing function (2 kHz)
4997,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003037,Hearing function (0.5 kHz)
4998,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003039,Hearing function (0.25 kHz)
4999,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003040,Hearing function (high tone)
7180,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003041,Hearing function (1 kHz)
5922,European,844.0,26188370.0,Burdon KP,Metabolic disorder,initial,2015-07-19,GCST003042,Sight-threatening diabetic retinopathy in type 2 diabetes
5555,European,583.0,26188370.0,Burdon KP,Metabolic disorder,replication,2015-07-19,GCST003042,Sight-threatening diabetic retinopathy in type 2 diabetes
2301,Asian,699.0,26188370.0,Burdon KP,Metabolic disorder,replication,2015-07-19,GCST003042,Sight-threatening diabetic retinopathy in type 2 diabetes
10788,European,27432.0,26192919.0,Liu JZ,Immune system disorder,initial,2015-07-20,GCST003045,Ulcerative colitis
11297,European,51988.0,26192919.0,Liu JZ,"Digestive system disorder, Immune system disorder",replication,2015-07-20,GCST003043,Inflammatory bowel disease
11150,European,41309.0,26192919.0,Liu JZ,Digestive system disorder,replication,2015-07-20,GCST003044,Crohn's disease
14052,Other/Mixed,890.0,26192919.0,Liu JZ,"Digestive system disorder, Immune system disorder",replication,2015-07-20,GCST003043,Inflammatory bowel disease
10547,European,20883.0,26192919.0,Liu JZ,Digestive system disorder,initial,2015-07-20,GCST003044,Crohn's disease
14022,Other/Mixed,739.0,26192919.0,Liu JZ,Immune system disorder,replication,2015-07-20,GCST003045,Ulcerative colitis
11054,European,37394.0,26192919.0,Liu JZ,Immune system disorder,replication,2015-07-20,GCST003045,Ulcerative colitis
3151,Asian,2413.0,26192919.0,Liu JZ,"Digestive system disorder, Immune system disorder",replication,2015-07-20,GCST003043,Inflammatory bowel disease
11003,European,34652.0,26192919.0,Liu JZ,"Digestive system disorder, Immune system disorder",initial,2015-07-20,GCST003043,Inflammatory bowel disease
2574,Asian,1174.0,26192919.0,Liu JZ,Digestive system disorder,replication,2015-07-20,GCST003044,Crohn's disease
3574,Asian,4853.0,26192919.0,Liu JZ,Immune system disorder,replication,2015-07-20,GCST003045,Ulcerative colitis
5303,European,452.0,26194203.0,Ramachandran D,"Cardiovascular disease, Other trait",initial,2015-07-20,GCST003047,Atrioventricular septal defects in Down syndrome
3094,Asian,2229.0,26192919.0,Liu JZ,Immune system disorder,replication,2015-07-20,GCST003045,Ulcerative colitis
1856,Asian,196.0,26190474.0,Dai Y,Biological process,initial,2015-07-20,GCST003046,Trichloroethylene-induced hypersensitivity syndrome
2830,Asian,1735.0,26190474.0,Dai Y,Biological process,replication,2015-07-20,GCST003046,Trichloroethylene-induced hypersensitivity syndrome
3806,Asian,6543.0,26192919.0,Liu JZ,"Digestive system disorder, Immune system disorder",replication,2015-07-20,GCST003043,Inflammatory bowel disease
3640,Asian,5409.0,26192919.0,Liu JZ,Digestive system disorder,replication,2015-07-20,GCST003044,Crohn's disease
13928,Other/Mixed,493.0,26192919.0,Liu JZ,Digestive system disorder,replication,2015-07-20,GCST003044,Crohn's disease
8781,European,5606.0,26199339.0,Liu CY,"Cancer, Other measurement",replication,2015-07-21,GCST003049,Lung cancer (asbestos exposure interaction)
14074,Other/Mixed,1097.0,26198764.0,Goes FS,Neurological disorder,initial,2015-07-21,GCST003048,Schizophrenia
14219,Other/Mixed,4058.0,26198764.0,Goes FS,Neurological disorder,initial,2015-07-21,GCST003050,Schizophrenia
6716,European,1572.0,26199339.0,Liu CY,"Cancer, Other measurement",initial,2015-07-21,GCST003049,Lung cancer (asbestos exposure interaction)
12742,Hispanic or Latin American,27.0,26198393.0,Ziv E,"Other measurement, Cancer",initial,2015-07-22,GCST003051,Multiple myeloma (survival)
13688,Other/Mixed,24.0,26198393.0,Ziv E,"Other measurement, Cancer",initial,2015-07-22,GCST003051,Multiple myeloma (survival)
5329,European,469.0,26198393.0,Ziv E,"Other measurement, Cancer",initial,2015-07-22,GCST003051,Multiple myeloma (survival)
430,African American or Afro-Caribbean,25.0,26198393.0,Ziv E,"Other measurement, Cancer",initial,2015-07-22,GCST003051,Multiple myeloma (survival)
6281,European,1090.0,26198393.0,Ziv E,"Other measurement, Cancer",replication,2015-07-22,GCST003051,Multiple myeloma (survival)
4235,Asian,13249.0,26211971.0,Ogura Y,Other disease,initial,2015-07-23,GCST003052,Adolescent idiopathic scoliosis
3830,Asian,6947.0,26211971.0,Ogura Y,Other disease,replication,2015-07-23,GCST003052,Adolescent idiopathic scoliosis
5607,European,622.0,26209787.0,Barthold JS,Other disease,replication,2015-07-24,GCST003053,Cryptorchidism
8050,European,3562.0,26209787.0,Barthold JS,Other disease,initial,2015-07-24,GCST003053,Cryptorchidism
5451,European,520.0,26222057.0,Pander J,"Cancer, Response to drug, Other measurement",initial,2015-07-29,GCST003058,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)
5450,European,520.0,26222057.0,Pander J,"Cancer, Response to drug, Other measurement",initial,2015-07-29,GCST003057,Progression free survival in metastatic colorectal cancer (chemotherapy interaction)
2182,Asian,500.0,26227905.0,Hu Y,Neurological disorder,initial,2015-07-31,GCST003059,Parkinson's disease
13739,Other/Mixed,79.0,26233692.0,Gan-Or Z,"Neurological disorder, Other measurement",initial,2015-08-02,GCST003060,Parkinson's disease in GBA mutation carriers (age at onset)
13734,Other/Mixed,75.0,26233692.0,Gan-Or Z,"Neurological disorder, Other measurement",replication,2015-08-02,GCST003060,Parkinson's disease in GBA mutation carriers (age at onset)
13658,Other/Mixed,15.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",replication,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
11032,European,36077.0,26237428.0,Law MH,Cancer,initial,2015-08-03,GCST003061,Cutaneous malignant melanoma
411,African American or Afro-Caribbean,11.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",replication,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
5009,European,280.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",initial,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
6721,European,1576.0,26237428.0,Law MH,Cancer,replication,2015-08-03,GCST003061,Cutaneous malignant melanoma
12740,Hispanic or Latin American,23.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",replication,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
1645,Asian,31.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",replication,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
4746,European,96.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",replication,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
6495,European,1309.0,26239289.0,Nelson EC,Neurological disorder,replication,2015-08-04,GCST003614,Opioid dependence
6506,European,1328.0,26239289.0,Nelson EC,Neurological disorder,initial,2015-08-04,GCST003614,Opioid dependence
1775,Asian,128.0,26242244.0,Ma Y,Other measurement,initial,2015-08-05,GCST003066,Exploratory eye movement dysfunction in schizophrenia (total eye scanning length)
1776,Asian,128.0,26242244.0,Ma Y,Other measurement,initial,2015-08-05,GCST003067,Exploratory eye movement dysfunction in schizophrenia (mean eye scanning length)
1774,Asian,128.0,26242244.0,Ma Y,Other measurement,initial,2015-08-05,GCST003065,Exploratory eye movement dysfunction in schizophrenia (responsive search score)
1777,Asian,128.0,26242244.0,Ma Y,Other measurement,initial,2015-08-05,GCST003068,Exploratory eye movement dysfunction in schizophrenia (number of eye fixations)
1773,Asian,128.0,26242244.0,Ma Y,Other measurement,initial,2015-08-05,GCST003064,Exploratory eye movement dysfunction in schizophrenia (cognitive search score)
5336,European,472.0,26252872.0,Li QS,"Other measurement, Other trait",initial,2015-08-07,GCST003075,Cognitive decline rate in late mild cognitive impairment
600,African American or Afro-Caribbean,248.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003084,Glucocorticoid-induced osteonecrosis
5397,European,495.0,26268530.0,Ramanan VK,Other measurement,initial,2015-08-11,GCST003082,Longitudinal change in brain amyloid plaque burden
1656,Asian,48.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003083,Glucocorticoid-induced osteonecrosis (time dependent analysis)
1661,Asian,54.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003084,Glucocorticoid-induced osteonecrosis
1600,Asian,6.0,26265699.0,Karol SE,"Other disease, Response to drug",replication,2015-08-11,GCST003080,Glucocorticoid-induced osteonecrosis (time independent analysis)
5339,European,476.0,26265699.0,Karol SE,"Other disease, Response to drug",replication,2015-08-11,GCST003080,Glucocorticoid-induced osteonecrosis (time independent analysis)
505,African American or Afro-Caribbean,109.0,26265699.0,Karol SE,"Other disease, Response to drug",replication,2015-08-11,GCST003080,Glucocorticoid-induced osteonecrosis (time independent analysis)
12919,Hispanic or Latin American,601.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003083,Glucocorticoid-induced osteonecrosis (time dependent analysis)
12932,Hispanic or Latin American,640.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003084,Glucocorticoid-induced osteonecrosis
6467,European,1275.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003083,Glucocorticoid-induced osteonecrosis (time dependent analysis)
528,African American or Afro-Caribbean,139.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003083,Glucocorticoid-induced osteonecrosis (time dependent analysis)
6872,European,1751.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003084,Glucocorticoid-induced osteonecrosis
12752,Hispanic or Latin American,39.0,26265699.0,Karol SE,"Other disease, Response to drug",replication,2015-08-11,GCST003080,Glucocorticoid-induced osteonecrosis (time independent analysis)
2769,Asian,1611.0,26265036.0,Parra EJ,Response to drug,replication,2015-08-12,GCST003085,Warfarin maintenance dose
5849,European,798.0,26265036.0,Parra EJ,Response to drug,replication,2015-08-12,GCST003085,Warfarin maintenance dose
12841,Hispanic or Latin American,367.0,26265036.0,Parra EJ,Response to drug,initial,2015-08-12,GCST003085,Warfarin maintenance dose
558,African American or Afro-Caribbean,191.0,26265036.0,Parra EJ,Response to drug,replication,2015-08-12,GCST003085,Warfarin maintenance dose
6647,European,1516.0,26272072.0,Jiang X,"Other measurement, Immune system disorder",replication,2015-08-13,GCST006410,ACPA-positive rheumatoid arthritis (smoking interaction)
7508,European,2573.0,26272072.0,Jiang X,"Other measurement, Immune system disorder",initial,2015-08-13,GCST006410,ACPA-positive rheumatoid arthritis (smoking interaction)
7509,European,2573.0,26272072.0,Jiang X,"Other measurement, Immune system disorder",initial,2015-08-13,GCST006807,ACPA-negative rheumatoid arthritis (smoking interaction)
5560,European,587.0,26268663.0,Nalls MA,Neurological disorder,initial,2015-08-13,GCST005548,Parkinson's disease
12348,European,285019.0,26272126.0,Oddsson A,Other disease,initial,2015-08-14,GCST003086,Kidney stones
4260,Asian,14131.0,26278006.0,Ahmad S,Body measurement,initial,2015-08-17,GCST003087,Body mass index variance
5589,European,607.0,26284813.0,Hayes MG,"Other disease, Other measurement",replication,2015-08-18,GCST005269,Luteinizing hormone levels in polycystic ovary syndrome
5586,European,606.0,26284813.0,Hayes MG,"Other measurement, Other disease",replication,2015-08-18,GCST005270,Follicule stimulating hormone levels in polycystic ovary syndrome
8192,European,3948.0,26284813.0,Hayes MG,Other disease,initial,2015-08-18,GCST005273,Polycystic ovary syndrome
8411,European,4582.0,26284813.0,Hayes MG,Other disease,replication,2015-08-18,GCST005273,Polycystic ovary syndrome
6137,European,984.0,26284813.0,Hayes MG,"Other disease, Other measurement",initial,2015-08-18,GCST005274,DHEAS levels in polycystic ovary syndrome
5631,European,645.0,26284813.0,Hayes MG,"Other disease, Other measurement",initial,2015-08-18,GCST005269,Luteinizing hormone levels in polycystic ovary syndrome
6092,European,957.0,26284813.0,Hayes MG,"Other disease, Other measurement",initial,2015-08-18,GCST005272,Testosterone levels in polycystic ovary syndrome
6001,European,903.0,26284813.0,Hayes MG,"Other measurement, Other disease",initial,2015-08-18,GCST005271,Sex hormone-binding globulin levels in polycystic ovary syndrome
7064,European,2021.0,26284813.0,Hayes MG,"Other disease, Other measurement",replication,2015-08-18,GCST005274,DHEAS levels in polycystic ovary syndrome
6335,European,1156.0,26284813.0,Hayes MG,"Other measurement, Other disease",replication,2015-08-18,GCST005271,Sex hormone-binding globulin levels in polycystic ovary syndrome
5636,European,647.0,26284813.0,Hayes MG,"Other measurement, Other disease",initial,2015-08-18,GCST005270,Follicule stimulating hormone levels in polycystic ovary syndrome
6648,European,1516.0,26284813.0,Hayes MG,"Other disease, Other measurement",replication,2015-08-18,GCST005272,Testosterone levels in polycystic ovary syndrome
746,African American or Afro-Caribbean,683.0,26293465.0,Durda P,Other measurement,initial,2015-08-20,GCST003088,Soluble interleukin-2 receptor subunit alpha
7711,European,2964.0,26293465.0,Durda P,Other measurement,initial,2015-08-20,GCST003088,Soluble interleukin-2 receptor subunit alpha
2052,Asian,374.0,26289589.0,Nishizawa D,Neurological disorder,replication,2015-08-20,GCST003093,Nicotine dependence
1798,Asian,148.0,26289589.0,Nishizawa D,Neurological disorder,initial,2015-08-20,GCST003093,Nicotine dependence
5739,European,723.0,26297903.0,Fabbri C,"Other measurement, Neurological disorder",initial,2015-08-20,GCST003091,Depressive episodes in bipolar disorder
8373,European,4464.0,26293465.0,Durda P,Other measurement,replication,2015-08-20,GCST003088,Soluble interleukin-2 receptor subunit alpha
5721,European,706.0,26297903.0,Fabbri C,"Other trait, Neurological disorder",initial,2015-08-20,GCST003089,Manic episodes in bipolar disorder
5738,European,723.0,26297903.0,Fabbri C,"Other measurement, Neurological disorder",initial,2015-08-20,GCST003090,Depressive and manic episodes in bipolar disorder
8981,European,6434.0,26291516.0,Miller FW,Immune system disorder,initial,2015-08-20,GCST003092,Myositis
5760,European,737.0,26299439.0,Li WD,Other measurement,initial,2015-08-24,GCST003095,Adiponectin levels (BMI-adjusted)
5761,European,737.0,26299439.0,Li WD,Other measurement,initial,2015-08-24,GCST003096,Adiponectin levels
10315,European,16753.0,26301688.0,Li YR,"Immune system disorder, Digestive system disorder, Metabolic disorder",initial,2015-08-24,GCST003097,Pediatric autoimmune diseases
9371,European,8201.0,26301497.0,Dina C,Cardiovascular disease,replication,2015-08-24,GCST003094,Mitral valve prolapse
8167,European,3881.0,26301497.0,Dina C,Cardiovascular disease,initial,2015-08-24,GCST003094,Mitral valve prolapse
10404,European,18197.0,26307654.0,Szulkin R,"Cancer, Other measurement",replication,2015-08-25,GCST003100,Prostate cancer (survival)
14048,Other/Mixed,857.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003098,Diabetic kidney disease
13052,Hispanic or Latin American,1373.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003099,Diabetic kidney disease
1164,African American or Afro-Caribbean,3221.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003099,Diabetic kidney disease
14101,Other/Mixed,1297.0,26305897.0,Iyengar SK,Metabolic disorder,replication,2015-08-25,GCST003098,Diabetic kidney disease
13051,Hispanic or Latin American,1373.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003098,Diabetic kidney disease
1163,African American or Afro-Caribbean,3221.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003098,Diabetic kidney disease
7944,European,3355.0,26305897.0,Iyengar SK,Metabolic disorder,replication,2015-08-25,GCST003098,Diabetic kidney disease
5788,European,746.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003099,Diabetic kidney disease
5787,European,746.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003098,Diabetic kidney disease
1097,African American or Afro-Caribbean,2887.0,26305897.0,Iyengar SK,Metabolic disorder,replication,2015-08-25,GCST003098,Diabetic kidney disease
14049,Other/Mixed,857.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003099,Diabetic kidney disease
12936,Hispanic or Latin American,666.0,26498133.0,Arya R,"Immune system disorder, Other measurement",initial,2015-08-26,GCST008643,Joint damage in rheumatoid arthritis
5203,European,407.0,26498133.0,Arya R,"Immune system disorder, Other measurement",initial,2015-08-26,GCST008643,Joint damage in rheumatoid arthritis
6857,European,1728.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003101,Bone mineral density (spine) and age at menarche
12853,Hispanic or Latin American,408.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003101,Bone mineral density (spine) and age at menarche
6858,European,1728.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003102,Bone mineral density (hip) and age at menarche
12854,Hispanic or Latin American,408.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003102,Bone mineral density (hip) and age at menarche
757,African American or Afro-Caribbean,709.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003102,Bone mineral density (hip) and age at menarche
2411,Asian,826.0,26312577.0,Tan LJ,Other measurement,initial,2015-08-27,GCST003101,Bone mineral density (spine) and age at menarche
2412,Asian,826.0,26312577.0,Tan LJ,Other measurement,initial,2015-08-27,GCST003102,Bone mineral density (hip) and age at menarche
756,African American or Afro-Caribbean,709.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003101,Bone mineral density (spine) and age at menarche
2790,Asian,1643.0,26314684.0,Liu X,Neurological disorder,replication,2015-08-28,GCST003104,Autism spectrum disorder
6330,European,1148.0,26316170.0,Demirci FY,Immune system disorder,initial,2015-08-28,GCST003103,Systemic lupus erythematosus
10088,European,13581.0,26316170.0,Demirci FY,Immune system disorder,replication,2015-08-28,GCST003103,Systemic lupus erythematosus
2380,Asian,776.0,26314684.0,Liu X,Neurological disorder,initial,2015-08-28,GCST003104,Autism spectrum disorder
12228,European,209379.0,26235824.0,Styrkarsdottir U,Other measurement,initial,2015-08-29,GCST003106,Low bone mineral density (spine)
12227,European,209379.0,26235824.0,Styrkarsdottir U,Other measurement,initial,2015-08-29,GCST003105,Low bone mineral density (hip)
5362,European,486.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006069,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)
12808,Hispanic or Latin American,202.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006069,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)
643,African American or Afro-Caribbean,338.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006069,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)
4871,European,189.0,26323598.0,Brandl EJ,Other trait,initial,2015-09-01,GCST003109,Antipsychotic drug-induced weight gain
12780,Hispanic or Latin American,100.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006073,Tenofovir clearance in HIV infection
5363,European,486.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006070,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction)
4870,European,189.0,26323598.0,Brandl EJ,"Body measurement, Other trait",initial,2015-09-01,GCST003108,Antipsychotic drug-induced weight gain (time interaction)
12809,Hispanic or Latin American,202.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006070,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction)
536,African American or Afro-Caribbean,149.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006073,Tenofovir clearance in HIV infection
13941,Other/Mixed,568.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",replication,2015-09-01,GCST003107,Post-bronchodilator lung function in asthma (FEV1/FVC)
535,African American or Afro-Caribbean,149.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006071,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction)
13942,Other/Mixed,568.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",replication,2015-09-01,GCST003110,Post-bronchodilator lung function in asthma (FEV1)
644,African American or Afro-Caribbean,338.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006070,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction)
534,African American or Afro-Caribbean,149.0,26148204.0,Wanga V,"Other disease, Other measurement, Response to drug",initial,2015-09-01,GCST006074,Bilirubin levels in tenofovir-treated HIV infection
5424,European,507.0,26177304.0,Waterman M,Immune system disorder,initial,2015-09-01,GCST006583,Ulcerative colitis
12718,Hispanic or Latin American,2.0,26177304.0,Waterman M,Immune system disorder,initial,2015-09-01,GCST006583,Ulcerative colitis
12779,Hispanic or Latin American,100.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006071,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction)
12778,Hispanic or Latin American,100.0,26148204.0,Wanga V,"Other disease, Other measurement, Response to drug",initial,2015-09-01,GCST006074,Bilirubin levels in tenofovir-treated HIV infection
7,African,7.0,26177304.0,Waterman M,Immune system disorder,initial,2015-09-01,GCST006583,Ulcerative colitis
5364,European,486.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006072,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)
4973,European,243.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006073,Tenofovir clearance in HIV infection
12872,Hispanic or Latin American,447.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",initial,2015-09-01,GCST003107,Post-bronchodilator lung function in asthma (FEV1/FVC)
4972,European,243.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006071,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction)
13131,Hispanic or Latin American,2414.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",replication,2015-09-01,GCST003107,Post-bronchodilator lung function in asthma (FEV1/FVC)
4971,European,243.0,26148204.0,Wanga V,"Other disease, Other measurement, Response to drug",initial,2015-09-01,GCST006074,Bilirubin levels in tenofovir-treated HIV infection
12810,Hispanic or Latin American,202.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006072,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)
12873,Hispanic or Latin American,447.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",initial,2015-09-01,GCST003110,Post-bronchodilator lung function in asthma (FEV1)
13132,Hispanic or Latin American,2414.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",replication,2015-09-01,GCST003110,Post-bronchodilator lung function in asthma (FEV1)
1680,Asian,61.0,26177304.0,Waterman M,Immune system disorder,initial,2015-09-01,GCST006583,Ulcerative colitis
645,African American or Afro-Caribbean,338.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006072,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)
4717,European,86.0,26323598.0,Brandl EJ,Other trait,replication,2015-09-01,GCST003109,Antipsychotic drug-induced weight gain
13708,Other/Mixed,44.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
6223,European,1032.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
13642,Other/Mixed,7.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
13643,Other/Mixed,7.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
13622,Other/Mixed,4.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
7427,European,2484.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
13737,Other/Mixed,78.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
13707,Other/Mixed,44.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
1704,Asian,85.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
1654,Asian,43.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
13604,Other/Mixed,2.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
13605,Other/Mixed,2.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
503,African American or Afro-Caribbean,98.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
1705,Asian,85.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
13641,Other/Mixed,7.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
471,African American or Afro-Caribbean,70.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
5575,European,602.0,26421299.0,Li J,Other measurement,initial,2015-09-03,GCST003113,Cingulate cortical amyloid beta load
470,African American or Afro-Caribbean,70.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
7428,European,2484.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
7708,European,2952.0,26350878.0,Tashjian RZ,Other disease,initial,2015-09-05,GCST003115,Rotator cuff tears
2404,Asian,810.0,26343869.0,Xie G,"Other measurement, Cardiovascular measurement, Cardiovascular disease",initial,2015-09-05,GCST003114,Carotid intima media thickness
14159,Other/Mixed,2268.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
4399,Asian,25557.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
4065,Asian,9396.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
13206,Hispanic or Latin American,3615.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
4151,Asian,11323.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
4390,Asian,23156.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
1101,African American or Afro-Caribbean,2908.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
11910,European,126630.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
13234,Hispanic or Latin American,4095.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
14026,Other/Mixed,754.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
1144,African American or Afro-Caribbean,3139.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
11982,European,141217.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
2168,Asian,481.0,26348319.0,Myung W,"Response to drug, Neurological disorder",initial,2015-09-08,GCST003118,Response to serotonin reuptake inhibitors in non-psychotic unipolar depression
1916,Asian,230.0,26348319.0,Myung W,"Response to drug, Neurological disorder",replication,2015-09-08,GCST003118,Response to serotonin reuptake inhibitors in non-psychotic unipolar depression
8161,European,3861.0,26352407.0,Raffler J,Other measurement,initial,2015-09-09,GCST003119,Urinary metabolites
6806,European,1691.0,26352407.0,Raffler J,Other measurement,replication,2015-09-09,GCST003119,Urinary metabolites
10294,European,16530.0,26362759.0,Rothwell S,Neurological disorder,initial,2015-09-11,GCST006053,Dermatomyositis or juvenile dermatomyositis
10303,European,16582.0,26362759.0,Rothwell S,Neurological disorder,initial,2015-09-11,GCST006052,Polymyositis
10405,European,18207.0,26362759.0,Rothwell S,Immune system disorder,initial,2015-09-11,GCST006051,Idiopathic inflammatory myopathy
9701,European,9783.0,26362575.0,van den Berg SM,"Biological process, Other measurement",replication,2015-09-11,GCST003120,Extraversion
11431,European,63030.0,26362575.0,van den Berg SM,"Biological process, Other measurement",initial,2015-09-11,GCST003120,Extraversion
9299,European,7842.0,26365420.0,Mbarek H,"Other measurement, Neurological disorder",initial,2015-09-14,GCST003121,Alcohol dependence
9017,European,6602.0,26366553.0,Danjou F,Hematological measurement,initial,2015-09-14,GCST003122,Hemoglobin levels
8266,European,4131.0,26366553.0,Danjou F,Hematological measurement,replication,2015-09-14,GCST003122,Hemoglobin levels
9300,European,7850.0,26051272.0,Fischer A,Other disease,replication,2015-09-15,GCST005538,Sarcoidosis
9173,European,7208.0,26051272.0,Fischer A,Other disease,initial,2015-09-15,GCST005538,Sarcoidosis
951,African American or Afro-Caribbean,1657.0,26051272.0,Fischer A,Other disease,replication,2015-09-15,GCST005538,Sarcoidosis
5498,European,549.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003123,Severe influenza A (H1N1) infection
5499,European,549.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003124,Mild influenza (H1N1) infection
4817,European,156.0,26379185.0,Garcia-Etxebarria K,Other measurement,initial,2015-09-17,GCST003126,Influenza A (H1N1) severity
4659,European,49.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003123,Severe influenza A (H1N1) infection
1099,African American or Afro-Caribbean,2895.0,26377243.0,Li J,Lipid or lipoprotein measurement,initial,2015-09-17,GCST003127,Lipoprotein (a) levels
5500,European,549.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003125,Influenza A (H1N1) infection
4772,European,107.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003124,Mild influenza (H1N1) infection
4816,European,156.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003125,Influenza A (H1N1) infection
11480,European,68456.0,26390057.0,Kato N,Cardiovascular measurement,replication,2015-09-21,GCST003274,Pulse pressure
11013,European,35352.0,26390057.0,Kato N,Cardiovascular disease,initial,2015-09-21,GCST003276,Hypertension
11481,European,68456.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003272,Systolic blood pressure
4454,Asian,33126.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003275,Mean arterial pressure
11014,European,35352.0,26390057.0,Kato N,Cardiovascular measurement,initial,2015-09-21,GCST003274,Pulse pressure
4513,Asian,48268.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003275,Mean arterial pressure
11017,European,35352.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003275,Mean arterial pressure
4512,Asian,48268.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003273,Diastolic blood pressure
4509,Asian,48268.0,26390057.0,Kato N,Cardiovascular disease,replication,2015-09-21,GCST003276,Hypertension
11016,European,35352.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003273,Diastolic blood pressure
4511,Asian,48268.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003272,Systolic blood pressure
11015,European,35352.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003272,Systolic blood pressure
11479,European,68456.0,26390057.0,Kato N,Cardiovascular disease,replication,2015-09-21,GCST003276,Hypertension
4510,Asian,48268.0,26390057.0,Kato N,Cardiovascular measurement,replication,2015-09-21,GCST003274,Pulse pressure
4305,Asian,16328.0,26390057.0,Kato N,Cardiovascular disease,replication,2015-09-21,GCST003276,Hypertension
11483,European,68456.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003275,Mean arterial pressure
4441,Asian,31516.0,26390057.0,Kato N,Cardiovascular measurement,initial,2015-09-21,GCST003274,Pulse pressure
4442,Asian,31516.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003272,Systolic blood pressure
4443,Asian,31516.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003273,Diastolic blood pressure
4444,Asian,31516.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003275,Mean arterial pressure
4309,Asian,16328.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003275,Mean arterial pressure
4440,Asian,31516.0,26390057.0,Kato N,Cardiovascular disease,initial,2015-09-21,GCST003276,Hypertension
4450,Asian,33126.0,26390057.0,Kato N,Cardiovascular disease,initial,2015-09-21,GCST003276,Hypertension
4451,Asian,33126.0,26390057.0,Kato N,Cardiovascular measurement,initial,2015-09-21,GCST003274,Pulse pressure
11482,European,68456.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003273,Diastolic blood pressure
4452,Asian,33126.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003272,Systolic blood pressure
4307,Asian,16328.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003272,Systolic blood pressure
4453,Asian,33126.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003273,Diastolic blood pressure
4306,Asian,16328.0,26390057.0,Kato N,Cardiovascular measurement,replication,2015-09-21,GCST003274,Pulse pressure
4308,Asian,16328.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003273,Diastolic blood pressure
10046,European,13239.0,26394269.0,Cordell HJ,Cancer,initial,2015-09-22,GCST003129,Primary biliary cholangitis
3161,Asian,2459.0,26394188.0,Zhu Z,Other disease,initial,2015-09-22,GCST003128,Adolescent idiopathic scoliosis
9337,European,7977.0,26394269.0,Cordell HJ,Cancer,replication,2015-09-22,GCST003129,Primary biliary cholangitis
3930,Asian,7832.0,26394188.0,Zhu Z,Other disease,replication,2015-09-22,GCST003128,Adolescent idiopathic scoliosis
2356,Asian,762.0,26398136.0,Kuo PH,Neurological disorder,replication,2015-09-23,GCST003130,Autism spectrum disorder
2683,Asian,1430.0,26398136.0,Kuo PH,Neurological disorder,initial,2015-09-23,GCST003130,Autism spectrum disorder
6022,European,923.0,26401656.0,Burkhardt R,Other measurement,replication,2015-09-24,GCST006879,Blood metabolite levels
7139,European,2107.0,26401656.0,Burkhardt R,Other measurement,initial,2015-09-24,GCST006879,Blood metabolite levels
6703,European,1554.0,26433762.0,Liu X,"Metabolic disorder, Neurological disorder",initial,2015-09-25,GCST003135,Bipolar disorder and eating disorder
7229,European,2190.0,26433762.0,Liu X,"Metabolic disorder, Neurological disorder",initial,2015-09-25,GCST003132,Eating disorder in bipolar disorder
7954,European,3376.0,26433762.0,Liu X,Neurological disorder,initial,2015-09-25,GCST003136,Bipolar disorder
10154,European,14647.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008662,Lung function in never smokers (low FEV1 vs high FEV1)
11258,European,48931.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008667,Smoking status (heavy vs never)
10160,European,14709.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008661,Lung function in heavy smokers (high FEV1 vs average FEV1)
10488,European,19572.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008663,Lung function in never smokers (low FEV1 vs average FEV1)
10838,European,29301.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008664,Lung function (low FEV1 vs high FEV1)
10839,European,29301.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008666,Lung function (low FEV1 vs high FEV1) x smoking interaction
10156,European,14654.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008659,Lung function in heavy smokers (low FEV1 vs high FEV1)
10486,European,19551.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008665,Lung function in heavy smokers (low FEV1 vs average FEV1)
10163,European,14729.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008660,Lung function in never smokers (high FEV1 vs average FEV1)
7051,European,2005.0,26420894.0,Wuttke M,"Other disease, Other measurement",initial,2015-09-28,GCST003140,Chronic kidney disease
6774,European,1641.0,26420894.0,Wuttke M,"Other disease, Other trait",initial,2015-09-28,GCST003141,Proteinuria and chronic kidney disease
13902,Other/Mixed,397.0,26420894.0,Wuttke M,"Other disease, Other trait",initial,2015-09-28,GCST003142,Proteinuria in chronic kidney disease
7111,European,2064.0,26422391.0,Yellin JL,Other trait,initial,2015-09-28,GCST003138,Juvenile osteochondritis dissecans
13901,Other/Mixed,397.0,26420894.0,Wuttke M,"Other disease, Other measurement",initial,2015-09-28,GCST003139,Glomerular filtration rate in chronic kidney disease
5781,European,744.0,26420894.0,Wuttke M,"Other disease, Other trait",initial,2015-09-28,GCST003142,Proteinuria in chronic kidney disease
5780,European,744.0,26420894.0,Wuttke M,"Other disease, Other measurement",initial,2015-09-28,GCST003139,Glomerular filtration rate in chronic kidney disease
11724,European,93055.0,26416764.0,Day FR,Other disease,replication,2015-09-29,GCST003144,Polycystic ovary syndrome
8903,European,6079.0,26417704.0,Corvol H,"Other disease, Other measurement",initial,2015-09-29,GCST003143,Lung disease severity in cystic fibrosis
11667,European,87943.0,26416764.0,Day FR,Other disease,initial,2015-09-29,GCST003144,Polycystic ovary syndrome
334,African,10421.0,26416757.0,Band G,Digestive system disorder,initial,2015-09-30,GCST003145,Severe malaria
362,African,15483.0,26416757.0,Band G,Digestive system disorder,replication,2015-09-30,GCST003145,Severe malaria
7820,European,3213.0,26424050.0,Kinnersley B,Cancer,replication,2015-10-01,GCST003227,Non-glioblastoma glioma
12409,European,309889.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005954,Body mass index x age interaction
12407,European,309889.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005950,Body mass index x sex x age interaction (4df test)
12406,European,309889.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005949,Body mass index x sex interaction
12304,European,252375.0,26426971.0,Winkler TW,Body measurement,initial,2015-10-01,GCST005956,Waist-to-hip ratio adjusted for BMI
12408,European,309889.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005951,Body mass index
13722,Other/Mixed,57.0,26366535.0,Sood RF,Other measurement,initial,2015-10-01,GCST003146,Postburn hypertrophic scarring severity
12075,European,158073.0,26426971.0,Winkler TW,Body measurement,initial,2015-10-01,GCST005958,Waist-to-hip ratio adjusted for BMI (age >50)
9923,European,11582.0,26424050.0,Kinnersley B,Cancer,initial,2015-10-01,GCST003228,Glioma
9706,European,9799.0,26424050.0,Kinnersley B,Cancer,initial,2015-10-01,GCST003227,Non-glioblastoma glioma
12410,European,309889.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005955,Body mass index x sex x age interaction
12193,European,197610.0,26426971.0,Winkler TW,Body measurement,initial,2015-10-01,GCST005952,Body mass index (age>50)
10924,European,32735.0,26367794.0,Zheng HF,Other measurement,initial,2015-10-01,GCST005544,Femoral neck bone mineral density
12305,European,252375.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005959,Waist-to-hip ratio adjusted for BMI x sex interaction
7819,European,3213.0,26424050.0,Kinnersley B,Cancer,replication,2015-10-01,GCST003220,Glioblastoma
12306,European,252375.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005960,Waist-to-hip ratio adjusted for BMI x sex x age interaction
10937,European,33297.0,26367794.0,Zheng HF,Other measurement,initial,2015-10-01,GCST005545,Lumbar spine bone mineral density
7557,European,2662.0,26367794.0,Zheng HF,Other measurement,replication,2015-10-01,GCST005546,Forearm bone mineral density
10269,European,16233.0,26367794.0,Zheng HF,Other measurement,replication,2015-10-01,GCST005545,Lumbar spine bone mineral density
7821,European,3213.0,26424050.0,Kinnersley B,Cancer,replication,2015-10-01,GCST003228,Glioma
11817,European,112279.0,26426971.0,Winkler TW,Body measurement,initial,2015-10-01,GCST005953,Body mass index (age <50)
9605,European,9218.0,26424050.0,Kinnersley B,Cancer,initial,2015-10-01,GCST003220,Glioblastoma
12307,European,252375.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005961,Waist-to-hip ratio adjusted for BMI x age interaction
12308,European,252375.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005962,Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)
1635,Asian,26.0,26366535.0,Sood RF,Other measurement,initial,2015-10-01,GCST003146,Postburn hypertrophic scarring severity
5210,European,408.0,26366535.0,Sood RF,Other measurement,initial,2015-10-01,GCST003146,Postburn hypertrophic scarring severity
11729,European,94302.0,26426971.0,Winkler TW,Body measurement,initial,2015-10-01,GCST005957,Waist-to-hip ratio adjusted for BMI (age <50)
10347,European,17253.0,26367794.0,Zheng HF,Other measurement,replication,2015-10-01,GCST005544,Femoral neck bone mineral density
9360,European,8143.0,26367794.0,Zheng HF,Other measurement,initial,2015-10-01,GCST005546,Forearm bone mineral density
419,African American or Afro-Caribbean,19.0,26366535.0,Sood RF,Other measurement,initial,2015-10-01,GCST003146,Postburn hypertrophic scarring severity
13652,Other/Mixed,11.0,26366535.0,Sood RF,Other measurement,initial,2015-10-01,GCST003146,Postburn hypertrophic scarring severity
9106,European,6901.0,26433129.0,Tin A,Other measurement,initial,2015-10-03,GCST003147,Plasma lactate levels
954,African American or Afro-Caribbean,1671.0,26433129.0,Tin A,Other measurement,replication,2015-10-03,GCST003147,Plasma lactate levels
9226,European,7469.0,26440539.0,Hancock DB,Neurological disorder,replication,2015-10-06,GCST003185,Nicotine dependence
10338,European,17074.0,26440539.0,Hancock DB,Neurological disorder,initial,2015-10-06,GCST003185,Nicotine dependence
3870,Asian,7394.0,26443449.0,Wang M,Cancer,initial,2015-10-07,GCST003148,Prostate cancer
3885,Asian,7524.0,26443449.0,Wang M,Cancer,replication,2015-10-07,GCST003148,Prostate cancer
9288,European,7773.0,26451028.0,Hofer E,Other measurement,initial,2015-10-08,GCST003151,White matter lesion progression
11268,European,50045.0,26450422.0,DeLorenze GN,Other disease,initial,2015-10-08,GCST003150,Staphylococcus aureus infection
9289,European,7773.0,26451028.0,Hofer E,Other measurement,initial,2015-10-08,GCST003152,White matter lesion progression (adjusted for white matter lesion burden at baseline)
11239,European,47564.0,26450422.0,DeLorenze GN,Other disease,initial,2015-10-08,GCST003149,Skin and soft tissue Staphylococcus aureus infection
7555,European,2660.0,26562150.0,Seldin MF,Neurological disorder,initial,2015-10-10,GCST003251,Late-onset myasthenia gravis
5697,European,685.0,26460308.0,Ghesquieres H,"Response to drug, Other measurement, Cancer",replication,2015-10-12,GCST003178,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy
5935,European,852.0,26460308.0,Ghesquieres H,"Response to drug, Other measurement, Cancer",initial,2015-10-12,GCST003178,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy
10848,European,29838.0,26490195.0,Cleynen I,"Digestive system disorder, Immune system disorder",initial,2015-10-18,GCST006960,Inflammatory bowel disease
8926,European,6182.0,26490195.0,Cleynen I,"Digestive system disorder, Immune system disorder",replication,2015-10-18,GCST006960,Inflammatory bowel disease
3138,Asian,2374.0,26482879.0,Paternoster L,Immune system disorder,replication,2015-10-19,GCST003184,Atopic dermatitis
13098,Hispanic or Latin American,1892.0,26482879.0,Paternoster L,Immune system disorder,initial,2015-10-19,GCST003184,Atopic dermatitis
12314,European,257125.0,26482879.0,Paternoster L,Immune system disorder,replication,2015-10-19,GCST003184,Atopic dermatitis
11761,European,103066.0,26482879.0,Paternoster L,Immune system disorder,initial,2015-10-19,GCST003184,Atopic dermatitis
7156,European,2138.0,26482880.0,Buch S,Cancer,initial,2015-10-19,GCST003153,Cirrhosis (alcohol related)
4066,Asian,9438.0,26482879.0,Paternoster L,Immune system disorder,initial,2015-10-19,GCST003184,Atopic dermatitis
7114,European,2070.0,26482880.0,Buch S,Cancer,replication,2015-10-19,GCST003153,Cirrhosis (alcohol related)
902,African American or Afro-Caribbean,1288.0,26482879.0,Paternoster L,Immune system disorder,replication,2015-10-19,GCST003184,Atopic dermatitis
897,African American or Afro-Caribbean,1266.0,26482879.0,Paternoster L,Immune system disorder,initial,2015-10-19,GCST003184,Atopic dermatitis
7196,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003168,Total adipose tissue
7195,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003166,Visceral adipose tissue
7198,European,2171.0,26480920.0,Sung YJ,"Other measurement, Body measurement",replication,2015-10-20,GCST003163,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
7199,European,2171.0,26480920.0,Sung YJ,"Other measurement, Body measurement",replication,2015-10-20,GCST003167,Visceral adipose tissue adjusted for BMI
7194,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003165,Subcutaneous adipose tissue adjusted for BMI
7193,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003164,Subcutaneous adipose tissue
7192,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003162,Visceral adipose tissue/subcutaneous adipose tissue ratio
7197,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003169,Total adipose tissue adjusted for BMI
772,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003168,Total adipose tissue
7450,European,2513.0,26480920.0,Sung YJ,"Other measurement, Body measurement",initial,2015-10-20,GCST003167,Visceral adipose tissue adjusted for BMI
773,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003169,Total adipose tissue adjusted for BMI
774,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,"Other measurement, Body measurement",replication,2015-10-20,GCST003163,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
775,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,"Other measurement, Body measurement",replication,2015-10-20,GCST003167,Visceral adipose tissue adjusted for BMI
771,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003166,Visceral adipose tissue
770,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003165,Subcutaneous adipose tissue adjusted for BMI
769,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003164,Subcutaneous adipose tissue
768,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003162,Visceral adipose tissue/subcutaneous adipose tissue ratio
7441,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003164,Subcutaneous adipose tissue
7442,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003165,Subcutaneous adipose tissue adjusted for BMI
7443,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003166,Visceral adipose tissue
7444,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003168,Total adipose tissue
7445,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003169,Total adipose tissue adjusted for BMI
7446,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003170,Subcutaneous adipose tissue
7447,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003171,Visceral adipose tissue
7448,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003173,Visceral adipose tissue/subcutaneous adipose tissue ratio
7451,European,2513.0,26480920.0,Sung YJ,"Other measurement, Body measurement",initial,2015-10-20,GCST003172,Visceral adipose tissue adjusted for BMI
7449,European,2513.0,26480920.0,Sung YJ,"Other measurement, Body measurement",initial,2015-10-20,GCST003163,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
7440,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003162,Visceral adipose tissue/subcutaneous adipose tissue ratio
4344,Asian,19131.0,26488411.0,Matsukura M,Cardiovascular disease,replication,2015-10-21,GCST003154,Peripheral artery disease
3475,Asian,4168.0,26488411.0,Matsukura M,Cardiovascular disease,initial,2015-10-21,GCST003154,Peripheral artery disease
5344,European,478.0,26491034.0,Sarzynski MA,"Biological process, Lipid or lipoprotein measurement",initial,2015-10-21,GCST003207,Response to exercise (triglyceride level interaction)
10883,European,31149.0,26486471.0,van Loon J,Hematological measurement,initial,2015-10-21,GCST003210,Low vWF levels
10140,European,14267.0,26502338.0,Bentham J,Immune system disorder,initial,2015-10-26,GCST003156,Systemic lupus erythematosus
10139,European,14267.0,26502338.0,Bentham J,Immune system disorder,initial,2015-10-26,GCST003155,Systemic lupus erythematosus
9571,European,8943.0,26502338.0,Bentham J,Immune system disorder,replication,2015-10-26,GCST003155,Systemic lupus erythematosus
8872,European,5932.0,26503584.0,Litchfield K,Cancer,initial,2015-10-27,GCST003246,Testicular germ cell tumor
8873,European,5932.0,26503584.0,Litchfield K,Cancer,initial,2015-10-27,GCST003247,Testicular germ cell tumor
9123,European,7007.0,26503763.0,Song J,"Response to drug, Neurological disorder",initial,2015-10-27,GCST003159,Objective response to lithium treatment
7579,European,2698.0,26503763.0,Song J,"Response to drug, Neurological disorder",initial,2015-10-27,GCST003160,Subjective response to lithium treatment in bipolar disorder
9800,European,10538.0,26503763.0,Song J,"Response to drug, Neurological disorder",initial,2015-10-27,GCST003158,Subjective response to lithium treatment
6361,European,1176.0,26503763.0,Song J,"Response to drug, Neurological disorder",initial,2015-10-27,GCST003161,Objective response to lithium treatment in bipolar disorder
9883,European,11146.0,26503584.0,Litchfield K,Cancer,replication,2015-10-27,GCST003246,Testicular germ cell tumor
10284,European,16375.0,26516778.0,Bis JC,"Response to drug, Cardiovascular disease",initial,2015-10-30,GCST003206,Myocardial infarction in hypertension (calcium channel blocker interaction)
10282,European,16375.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",initial,2015-10-30,GCST003204,Cardiovascular disease in hypertension (diuretic interaction)
10283,European,16375.0,26516778.0,Bis JC,"Response to drug, Cardiovascular disease",initial,2015-10-30,GCST003201,Myocardial infarction in hypertension (beta blocker interaction)
10285,European,16375.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",initial,2015-10-30,GCST003203,Cardiovascular disease in hypertension (beta blocker interaction)
10286,European,16375.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",initial,2015-10-30,GCST003205,Cardiovascular disease in hypertension (calcium channel blocker interaction)
6875,European,1751.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",replication,2015-10-30,GCST003203,Cardiovascular disease in hypertension (beta blocker interaction)
10281,European,16375.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",initial,2015-10-30,GCST003186,Cardiovascular disease in hypertension (ACE inhibitor interaction)
6874,European,1751.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003204,Cardiovascular disease in hypertension (diuretic interaction)
6873,European,1751.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003186,Cardiovascular disease in hypertension (ACE inhibitor interaction)
6356,European,1171.0,26516778.0,Bis JC,"Response to drug, Cardiovascular disease",replication,2015-10-30,GCST003206,Myocardial infarction in hypertension (calcium channel blocker interaction)
6355,European,1171.0,26516778.0,Bis JC,"Response to drug, Cardiovascular disease",replication,2015-10-30,GCST003201,Myocardial infarction in hypertension (beta blocker interaction)
6354,European,1171.0,26516778.0,Bis JC,"Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003202,Myocardial infarction in hypertension (diuretic interaction)
6353,European,1171.0,26516778.0,Bis JC,"Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003187,Myocardial infarction in hypertension (ACE inhibitor interaction)
6876,European,1751.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",replication,2015-10-30,GCST003205,Cardiovascular disease in hypertension (calcium channel blocker interaction)
10280,European,16375.0,26516778.0,Bis JC,"Cardiovascular disease, Response to drug",initial,2015-10-30,GCST003202,Myocardial infarction in hypertension (diuretic interaction)
806,African American or Afro-Caribbean,898.0,26519441.0,Kim S,Cardiovascular measurement,initial,2015-10-30,GCST003157,Plasma homocysteine levels
1234,African American or Afro-Caribbean,4141.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",replication,2015-10-30,GCST003203,Cardiovascular disease in hypertension (beta blocker interaction)
1233,African American or Afro-Caribbean,4141.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003204,Cardiovascular disease in hypertension (diuretic interaction)
1232,African American or Afro-Caribbean,4141.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003186,Cardiovascular disease in hypertension (ACE inhibitor interaction)
10279,European,16375.0,26516778.0,Bis JC,"Cardiovascular disease, Response to drug",initial,2015-10-30,GCST003187,Myocardial infarction in hypertension (ACE inhibitor interaction)
1235,African American or Afro-Caribbean,4141.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",replication,2015-10-30,GCST003205,Cardiovascular disease in hypertension (calcium channel blocker interaction)
157,African,960.0,26519441.0,Kim S,Cardiovascular measurement,initial,2015-10-30,GCST003157,Plasma homocysteine levels
1944,Asian,262.0,26434682.0,Lin YJ,"Immune system disorder, Cardiovascular disease",initial,2015-11-01,GCST003192,Coronary artery aneurysm in Kawasaki disease
10713,European,24367.0,26366551.0,Zoledziewska M,"Other measurement, Body measurement",replication,2015-11-01,GCST005354,Height
1172,African American or Afro-Caribbean,3308.0,26278503.0,Huang C,"Digestive system disorder, Immune system disorder",initial,2015-11-01,GCST008731,Inflammatory bowel disease
8946,European,6252.0,26632684.0,Dong J,Biological process,initial,2015-11-01,GCST003174,Sense of smell
8959,European,6307.0,26366551.0,Zoledziewska M,"Other measurement, Body measurement",initial,2015-11-01,GCST005354,Height
7487,European,2545.0,26414677.0,Day FR,Other measurement,initial,2015-11-01,GCST005560,Menopause (age at onset)
11501,European,69626.0,26414677.0,Day FR,Other measurement,initial,2015-11-01,GCST005312,Menopause (age at onset)
1096,African American or Afro-Caribbean,2885.0,26278503.0,Huang C,Digestive system disorder,initial,2015-11-01,GCST008730,Crohn's disease
1021,African American or Afro-Caribbean,2158.0,26278503.0,Huang C,Immune system disorder,initial,2015-11-01,GCST008732,Ulcerative colitis
11227,European,46638.0,26414677.0,Day FR,Other measurement,replication,2015-11-01,GCST005560,Menopause (age at onset)
5187,European,397.0,26525574.0,Westerlind H,Immune system disorder,replication,2015-11-02,GCST005879,Collagenous colitis
8295,European,4216.0,26525574.0,Westerlind H,Immune system disorder,initial,2015-11-02,GCST005879,Collagenous colitis
6509,European,1335.0,26534935.0,Weng L,Cardiovascular disease,initial,2015-11-03,GCST008436,Nonobstructive coronary artery disease
4738,European,93.0,26528553.0,Davenport ER,Other measurement,initial,2015-11-03,GCST003223,Gut microbiome composition (winter)
4735,European,91.0,26528553.0,Davenport ER,Other measurement,initial,2015-11-03,GCST003221,Gut microbiome composition (summer)
4783,European,127.0,26528553.0,Davenport ER,Other measurement,initial,2015-11-03,GCST003222,Gut microbiome composition (summer and winter)
8479,European,4773.0,26589003.0,Federoff M,Neurological disorder,initial,2015-11-05,GCST003179,Multiple system atrophy
9889,European,11181.0,26542096.0,Marenholz I,"Biological process, Immune system disorder, Other disease",initial,2015-11-06,GCST003180,Atopic march
5866,European,811.0,26546620.0,Xu CF,"Liver enzyme measurement, Response to drug, Cancer",replication,2015-11-06,GCST003232,Response to Pazopanib in cancer (hepatotoxicity)
856,African American or Afro-Caribbean,1102.0,26545240.0,Giri A,Other disease,initial,2015-11-06,GCST003225,Pelvic organ prolapse (moderate/severe)
961,African American or Afro-Caribbean,1741.0,26545240.0,Giri A,Other disease,initial,2015-11-06,GCST003226,Pelvic organ prolapse
13005,Hispanic or Latin American,911.0,26545240.0,Giri A,Other disease,initial,2015-11-06,GCST003226,Pelvic organ prolapse
1750,Asian,114.0,26546620.0,Xu CF,"Liver enzyme measurement, Response to drug, Cancer",replication,2015-11-06,GCST003232,Response to Pazopanib in cancer (hepatotoxicity)
5923,European,844.0,26546620.0,Xu CF,"Liver enzyme measurement, Response to drug, Cancer",initial,2015-11-06,GCST003232,Response to Pazopanib in cancer (hepatotoxicity)
12884,Hispanic or Latin American,468.0,26545240.0,Giri A,Other disease,initial,2015-11-06,GCST003225,Pelvic organ prolapse (moderate/severe)
9385,European,8281.0,26542096.0,Marenholz I,"Biological process, Immune system disorder, Other disease",replication,2015-11-06,GCST003180,Atopic march
2005,Asian,325.0,26546620.0,Xu CF,"Liver enzyme measurement, Response to drug, Cancer",initial,2015-11-06,GCST003232,Response to Pazopanib in cancer (hepatotoxicity)
8961,European,6315.0,26553974.0,McLaren PJ,"Other measurement, Other disease",initial,2015-11-09,GCST003183,Setpoint viral load in HIV-1 infection
11869,European,120246.0,26561523.0,de Vries PS,Hematological measurement,initial,2015-11-10,GCST003194,Fibrinogen levels
1753,Asian,116.0,26566055.0,Mieda T,Other measurement,initial,2015-11-13,GCST003200,Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours)
1920,Asian,234.0,26566055.0,Mieda T,Other measurement,replication,2015-11-13,GCST003200,Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours)
2527,Asian,1050.0,26531332.0,Kim LH,Neurological disorder,initial,2015-11-14,GCST003190,Schizophrenia
2456,Asian,914.0,26531332.0,Kim LH,Neurological disorder,replication,2015-11-14,GCST003190,Schizophrenia
12965,Hispanic or Latin American,761.0,26569114.0,Brown EL,Other measurement,initial,2015-11-16,GCST003182,Staphylococcus aureus nasal carriage (persistent)
12950,Hispanic or Latin American,717.0,26569114.0,Brown EL,Other measurement,initial,2015-11-16,GCST003181,Staphylococcus aureus nasal carriage (intermittent)
2152,Asian,470.0,26580837.0,Chen CJ,Neurological disorder,initial,2015-11-18,GCST003175,Amyotrophic lateral sclerosis
3965,Asian,8344.0,26582766.0,Lu X,Lipid or lipoprotein measurement,initial,2015-11-18,GCST003217,Triglycerides
3963,Asian,8344.0,26582766.0,Lu X,Lipid or lipoprotein measurement,initial,2015-11-18,GCST003214,"Cholesterol, total"
3964,Asian,8344.0,26582766.0,Lu X,Lipid or lipoprotein measurement,initial,2015-11-18,GCST003215,HDL cholesterol
4271,Asian,14739.0,26582766.0,Lu X,Lipid or lipoprotein measurement,replication,2015-11-18,GCST003214,"Cholesterol, total"
3966,Asian,8344.0,26582766.0,Lu X,"Lipid or lipoprotein measurement, Other measurement",initial,2015-11-18,GCST003216,LDL cholesterol
4272,Asian,14739.0,26582766.0,Lu X,Lipid or lipoprotein measurement,replication,2015-11-18,GCST003215,HDL cholesterol
4274,Asian,14739.0,26582766.0,Lu X,"Lipid or lipoprotein measurement, Other measurement",replication,2015-11-18,GCST003216,LDL cholesterol
4273,Asian,14739.0,26582766.0,Lu X,Lipid or lipoprotein measurement,replication,2015-11-18,GCST003217,Triglycerides
8018,European,3494.0,26586795.0,Phipps AI,"Other measurement, Cancer",initial,2015-11-19,GCST003229,Survival in colorectal cancer
2662,Asian,1361.0,26584805.0,Dorajoo R,Other measurement,initial,2015-11-19,GCST003244,Delta-6 desaturase activity
2656,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003238,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)
2654,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003236,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)
8127,European,3764.0,26586795.0,Phipps AI,"Other measurement, Cancer",replication,2015-11-19,GCST003229,Survival in colorectal cancer
2661,Asian,1361.0,26584805.0,Dorajoo R,Other measurement,initial,2015-11-19,GCST003243,Delta-5 desaturase activity
2655,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003237,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)
2658,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003240,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)
2657,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003239,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)
2659,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003241,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)
2660,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003242,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)
7658,European,2843.0,26586795.0,Phipps AI,"Other measurement, Cancer",initial,2015-11-19,GCST003231,Survival in colorectal cancer (non-distant metastatic)
5319,European,462.0,26586795.0,Phipps AI,"Other measurement, Cancer",initial,2015-11-19,GCST003230,Survival in colorectal cancer (distant metastatic)
5274,European,435.0,26586795.0,Phipps AI,"Other measurement, Cancer",replication,2015-11-19,GCST003230,Survival in colorectal cancer (distant metastatic)
7815,European,3205.0,26586795.0,Phipps AI,"Other measurement, Cancer",replication,2015-11-19,GCST003231,Survival in colorectal cancer (non-distant metastatic)
1730,Asian,100.0,26870257.0,Qu LS,"Digestive system disorder, Cancer",initial,2015-11-23,GCST003189,Hepatocellular carcinoma in hepatitis B infection
2222,Asian,560.0,26870257.0,Qu LS,"Digestive system disorder, Cancer",replication,2015-11-23,GCST003189,Hepatocellular carcinoma in hepatitis B infection
11004,European,34744.0,26604143.0,Felix JF,Body measurement,initial,2015-11-24,GCST003177,Childhood body mass index
5983,European,889.0,26620591.0,Barreto-Luis A,Other disease,initial,2015-11-24,GCST003176,Asthma
7240,European,2206.0,26620591.0,Barreto-Luis A,Other disease,replication,2015-11-24,GCST003176,Asthma
1862,Asian,202.0,26600424.0,MacInnis MJ,Cardiovascular disease,replication,2015-11-24,GCST003188,Acute mountain sickness
9898,European,11313.0,26604143.0,Felix JF,Body measurement,replication,2015-11-24,GCST003177,Childhood body mass index
1727,Asian,99.0,26600424.0,MacInnis MJ,Cardiovascular disease,initial,2015-11-24,GCST003188,Acute mountain sickness
14209,Other/Mixed,3710.0,26606652.0,Alarcon-Riquelme ME,Immune system disorder,initial,2015-11-25,GCST003252,Systemic lupus erythematosus
10601,European,21801.0,26626624.0,Stuart PE,Immune system disorder,replication,2015-11-28,GCST003268,Psoriasis vulgaris
10336,European,17062.0,26626624.0,Stuart PE,Immune system disorder,replication,2015-11-28,GCST003270,Psoriatic arthritis
10354,European,17353.0,26626624.0,Stuart PE,"Other measurement, Immune system disorder",replication,2015-11-28,GCST003269,Cutaneous psoriasis
8927,European,6184.0,26626624.0,Stuart PE,"Other measurement, Immune system disorder",replication,2015-11-28,GCST003271,Psoriatic arthritis vs Cutaneous psoriasis
8952,European,6297.0,26626624.0,Stuart PE,"Other measurement, Immune system disorder",initial,2015-11-28,GCST003269,Cutaneous psoriasis
9570,European,8941.0,26626624.0,Stuart PE,Immune system disorder,initial,2015-11-28,GCST003268,Psoriasis vulgaris
9094,European,6880.0,26626624.0,Stuart PE,Immune system disorder,initial,2015-11-28,GCST003270,Psoriatic arthritis
7907,European,3309.0,26626624.0,Stuart PE,"Other measurement, Immune system disorder",initial,2015-11-28,GCST003271,Psoriatic arthritis vs Cutaneous psoriasis
10884,European,31179.0,26621817.0,Cheng TH,Cancer,replication,2015-12-01,GCST003208,Colorectal or endometrial cancer
10586,European,21333.0,26621817.0,Cheng TH,Cancer,initial,2015-12-01,GCST003208,Colorectal or endometrial cancer
10587,European,21333.0,26621817.0,Cheng TH,Cancer,initial,2015-12-01,GCST003209,Colorectal or endometrial cancer
11327,European,54116.0,26631737.0,Teumer A,Other trait,initial,2015-12-02,GCST003253,Microalbuminuria
11207,European,46051.0,26631737.0,Teumer A,Other measurement,initial,2015-12-02,GCST003254,Urinary albumin-to-creatinine ratio in non-diabetics
7029,European,1962.0,26631737.0,Teumer A,"Other measurement, Metabolic disorder",replication,2015-12-02,GCST003250,Urinary albumin-to-creatinine ratio in diabetes
11338,European,54450.0,26631737.0,Teumer A,Other measurement,initial,2015-12-02,GCST003255,Urinary albumin-to-creatinine ratio
8839,European,5825.0,26631737.0,Teumer A,"Other measurement, Metabolic disorder",initial,2015-12-02,GCST003250,Urinary albumin-to-creatinine ratio in diabetes
9764,European,10094.0,26634245.0,Lutz SM,"Other measurement, Response to drug",initial,2015-12-03,GCST003264,Post bronchodilator FEV1/FVC ratio
8742,European,5439.0,26634245.0,Lutz SM,"Other disease, Other measurement, Response to drug",initial,2015-12-03,GCST003265,Post bronchodilator FEV1/FVC ratio in COPD
9030,European,6659.0,26634245.0,Lutz SM,Other measurement,initial,2015-12-03,GCST003266,Pre bronchodilator FEV1
9031,European,6659.0,26634245.0,Lutz SM,Other measurement,initial,2015-12-03,GCST003267,Pre bronchodilator FEV1/FVC ratio
1165,African American or Afro-Caribbean,3260.0,26634245.0,Lutz SM,"Other measurement, Response to drug",initial,2015-12-03,GCST003264,Post bronchodilator FEV1/FVC ratio
1166,African American or Afro-Caribbean,3260.0,26634245.0,Lutz SM,"Response to drug, Other measurement",initial,2015-12-03,GCST003262,Post bronchodilator FEV1
8743,European,5439.0,26634245.0,Lutz SM,"Other disease, Response to drug, Other measurement",initial,2015-12-03,GCST003263,Post bronchodilator FEV1 in COPD
787,African American or Afro-Caribbean,821.0,26634245.0,Lutz SM,"Other disease, Response to drug, Other measurement",initial,2015-12-03,GCST003263,Post bronchodilator FEV1 in COPD
786,African American or Afro-Caribbean,821.0,26634245.0,Lutz SM,"Other disease, Other measurement, Response to drug",initial,2015-12-03,GCST003265,Post bronchodilator FEV1/FVC ratio in COPD
9765,European,10094.0,26634245.0,Lutz SM,"Response to drug, Other measurement",initial,2015-12-03,GCST003262,Post bronchodilator FEV1
11341,European,54550.0,26635082.0,Soler Artigas M,Other measurement,replication,2015-12-04,GCST008481,Lung function (FEV1/FVC)
11342,European,54550.0,26635082.0,Soler Artigas M,Other measurement,replication,2015-12-04,GCST008482,Lung function (FVC)
11340,European,54550.0,26635082.0,Soler Artigas M,Other measurement,replication,2015-12-04,GCST008480,Lung function (FEV1)
11084,European,38199.0,26635082.0,Soler Artigas M,Other measurement,initial,2015-12-04,GCST008481,Lung function (FEV1/FVC)
11083,European,38199.0,26635082.0,Soler Artigas M,Other measurement,initial,2015-12-04,GCST008480,Lung function (FEV1)
11085,European,38199.0,26635082.0,Soler Artigas M,Other measurement,initial,2015-12-04,GCST008482,Lung function (FVC)
5099,European,337.0,26644207.0,Clarelli F,"Immune system disorder, Response to drug",initial,2015-12-08,GCST003193,Response to interferon beta in multiple sclerosis
2201,Asian,534.0,26656879.0,Yu H,"Neurological disorder, Other trait",initial,2015-12-09,GCST003579,Antipsychotic drug-induced weight gain in schizophrenia
2211,Asian,547.0,26656879.0,Yu H,"Neurological disorder, Other trait",replication,2015-12-09,GCST003579,Antipsychotic drug-induced weight gain in schizophrenia
3857,Asian,7263.0,26686025.0,Hwang JY,Other measurement,replication,2015-12-12,GCST003196,Calcaneal bone ultrasound measurement (speed of sound)
2947,Asian,1895.0,26686025.0,Hwang JY,Other measurement,initial,2015-12-12,GCST003196,Calcaneal bone ultrasound measurement (speed of sound)
3058,Asian,2151.0,26704534.0,Sapkota BR,Other measurement,replication,2015-12-15,GCST003191,Vitamin D levels
2667,Asian,1387.0,26704534.0,Sapkota BR,Other measurement,initial,2015-12-15,GCST003191,Vitamin D levels
8092,European,3670.0,26674333.0,Traylor M,"Other measurement, Other trait",initial,2015-12-16,GCST003245,White matter hyperintensities in ischemic stroke
3100,Asian,2252.0,26675016.0,Cha S,Body measurement,replication,2015-12-16,GCST003197,Thoracic-to-hip circumference ratio
3582,Asian,4988.0,26675016.0,Cha S,Body measurement,initial,2015-12-16,GCST003197,Thoracic-to-hip circumference ratio
14207,Other/Mixed,3574.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
13146,Hispanic or Latin American,2547.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
12973,Hispanic or Latin American,771.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
13135,Hispanic or Latin American,2521.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003258,Ischemic stroke
14236,Other/Mixed,6807.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003258,Ischemic stroke
12252,European,219602.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
12157,European,178569.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
14203,Other/Mixed,3562.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
3683,Asian,5615.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
2214,Asian,548.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003258,Ischemic stroke
13163,Hispanic or Latin American,2791.0,26708676.0,Pulit SL,Other trait,initial,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
14210,Other/Mixed,3735.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
13037,Hispanic or Latin American,1234.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003258,Ischemic stroke
12989,Hispanic or Latin American,835.0,26708676.0,Pulit SL,Other trait,replication,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
12978,Hispanic or Latin American,783.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
14227,Other/Mixed,4440.0,26708676.0,Pulit SL,Other trait,initial,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
14229,Other/Mixed,4963.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003258,Ischemic stroke
3650,Asian,5507.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
3657,Asian,5548.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
10855,European,30090.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
13853,Other/Mixed,286.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
12952,Hispanic or Latin American,726.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
2036,Asian,360.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
2038,Asian,363.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
12339,European,277499.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
12320,European,262805.0,26708676.0,Pulit SL,Other trait,replication,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
12507,European,368279.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003258,Ischemic stroke
2143,Asian,462.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
13171,Hispanic or Latin American,2981.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
2021,Asian,346.0,26708676.0,Pulit SL,Other trait,replication,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
14191,Other/Mixed,3015.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
11145,European,40990.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003258,Ischemic stroke
3892,Asian,7578.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003258,Ischemic stroke
13842,Other/Mixed,256.0,26708676.0,Pulit SL,Other trait,replication,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
13846,Other/Mixed,272.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
13149,Hispanic or Latin American,2575.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
10828,European,29039.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
11005,European,34752.0,26708676.0,Pulit SL,Other trait,initial,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
10823,European,28942.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
11722,European,92444.0,26686553.0,Jorgenson E,Other trait,replication,2015-12-21,GCST003198,Inguinal hernia
1694,Asian,77.0,26782385.0,Zhou TQ,Neurological disorder,initial,2015-12-21,GCST003199,Atrophic age-related macular degeneration
10982,European,33976.0,26691988.0,Fritsche LG,Neurological disorder,initial,2015-12-21,GCST003219,Advanced age-related macular degeneration
1695,Asian,77.0,26865924.0,Lee M,"Body measurement, Other measurement",initial,2015-12-21,GCST003248,Body mass index
2757,Asian,1572.0,26691988.0,Fritsche LG,Neurological disorder,replication,2015-12-21,GCST003219,Advanced age-related macular degeneration
99,African,413.0,26691988.0,Fritsche LG,Neurological disorder,replication,2015-12-21,GCST003219,Advanced age-related macular degeneration
10229,European,15623.0,26685716.0,Chang X,Other measurement,replication,2015-12-21,GCST003195,Magnesium levels
1696,Asian,77.0,26865924.0,Lee M,Other measurement,initial,2015-12-21,GCST003249,Basal metabolic rate
2107,Asian,426.0,26782385.0,Zhou TQ,Neurological disorder,replication,2015-12-21,GCST003199,Atrophic age-related macular degeneration
7269,European,2267.0,26685716.0,Chang X,Other measurement,initial,2015-12-21,GCST003195,Magnesium levels
11523,European,72805.0,26686553.0,Jorgenson E,Other trait,initial,2015-12-21,GCST003198,Inguinal hernia
3840,Asian,7001.0,26701879.0,Wang Z,Cancer,initial,2015-12-23,GCST003218,Non-cardia gastric cancer
3953,Asian,8201.0,26701879.0,Wang Z,Cancer,replication,2015-12-23,GCST003218,Non-cardia gastric cancer
78,African,258.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003233,Thrombin-antithrombin complex levels in ischemic stroke
6850,European,1725.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003234,Thrombomodulin levels in ischemic stroke
80,African,258.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003235,Prothrombin fragments F1+2 levels in ischemic stroke
6849,European,1725.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003233,Thrombin-antithrombin complex levels in ischemic stroke
6848,European,1725.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003213,Creatinine levels in ischemic stroke
81,African,258.0,26718567.0,Williams SR,"Other trait, Inflammatory measurement",initial,2015-12-30,GCST003211,C-reactive protein levels in ischemic stroke
76,African,258.0,26718567.0,Williams SR,"Hematological measurement, Other trait",initial,2015-12-30,GCST003212,Fibrinogen levels in ischemic stroke
6847,European,1725.0,26718567.0,Williams SR,"Hematological measurement, Other trait",initial,2015-12-30,GCST003212,Fibrinogen levels in ischemic stroke
6852,European,1725.0,26718567.0,Williams SR,"Other trait, Inflammatory measurement",initial,2015-12-30,GCST003211,C-reactive protein levels in ischemic stroke
6851,European,1725.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003235,Prothrombin fragments F1+2 levels in ischemic stroke
79,African,258.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003234,Thrombomodulin levels in ischemic stroke
77,African,258.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003213,Creatinine levels in ischemic stroke
4099,Asian,10095.0,26545403.0,Bei JX,Cancer,replication,2016-01-01,GCST005113,Nasopharyngeal carcinoma
2940,Asian,1883.0,26398853.0,Ye BD,Immune system disorder,initial,2016-01-01,GCST008483,Ulcerative colitis
2440,Asian,880.0,26546613.0,Gutierrez-Achury J,Immune system disorder,initial,2016-01-01,GCST008644,Celiac disease and Rheumatoid arthritis
2539,Asian,1088.0,26845276.0,Ikeda M,"Other trait, Other measurement, Neurological disorder",initial,2016-01-01,GCST003319,Major depressive disorder (stressful life events interaction)
10057,European,13329.0,26546613.0,Gutierrez-Achury J,Immune system disorder,initial,2016-01-01,GCST008644,Celiac disease and Rheumatoid arthritis
10351,European,17347.0,27897004.0,Verma SS,"Other measurement, Hematological measurement, Liver enzyme measurement",initial,2016-01-01,GCST003540,Clinical laboratory measurements
10352,European,17348.0,27897004.0,Verma SS,"Other measurement, Hematological measurement, Liver enzyme measurement",replication,2016-01-01,GCST003540,Clinical laboratory measurements
3406,Asian,3674.0,26398853.0,Ye BD,Immune system disorder,replication,2016-01-01,GCST008483,Ulcerative colitis
3732,Asian,5892.0,26545403.0,Bei JX,Cancer,initial,2016-01-01,GCST005113,Nasopharyngeal carcinoma
4215,Asian,12924.0,26732429.0,Wang Z,Cancer,replication,2016-01-04,GCST003326,Adenocarcinoma
4224,Asian,13154.0,26732429.0,Wang Z,Cancer,initial,2016-01-04,GCST003325,Lung cancer
9660,European,9534.0,26732621.0,Ruth KS,Other measurement,initial,2016-01-04,GCST003334,Length of menstrual cycle
4214,Asian,12924.0,26732429.0,Wang Z,Cancer,replication,2016-01-04,GCST003325,Lung cancer
4225,Asian,13154.0,26732429.0,Wang Z,Cancer,initial,2016-01-04,GCST003326,Adenocarcinoma
10369,European,17565.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003322,Ischemic stroke (large artery atherosclerosis)
716,African American or Afro-Caribbean,535.0,26732560.0,Cheng YC,Other trait,initial,2016-01-05,GCST003320,Ischemic stroke (undetermined subtype)
678,African American or Afro-Caribbean,426.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003323,Ischemic stroke (cardioembolic)
10393,European,17831.0,26732560.0,Cheng YC,Cardiovascular disease,initial,2016-01-05,GCST003321,Small vessel stroke
3555,Asian,4685.0,26732560.0,Cheng YC,Cardiovascular disease,initial,2016-01-05,GCST003321,Small vessel stroke
3561,Asian,4746.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003323,Ischemic stroke (cardioembolic)
663,African American or Afro-Caribbean,375.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003322,Ischemic stroke (large artery atherosclerosis)
10379,European,17716.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003323,Ischemic stroke (cardioembolic)
10380,European,17716.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003324,Ischemic stroke
3562,Asian,4746.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003324,Ischemic stroke
679,African American or Afro-Caribbean,426.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003324,Ischemic stroke
680,African American or Afro-Caribbean,429.0,26732560.0,Cheng YC,Cardiovascular disease,initial,2016-01-05,GCST003321,Small vessel stroke
3557,Asian,4710.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003322,Ischemic stroke (large artery atherosclerosis)
10400,European,18186.0,26732560.0,Cheng YC,Other trait,initial,2016-01-05,GCST003320,Ischemic stroke (undetermined subtype)
3606,Asian,5207.0,26732560.0,Cheng YC,Other trait,initial,2016-01-05,GCST003320,Ischemic stroke (undetermined subtype)
9544,European,8748.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",replication,2016-01-05,GCST003324,Ischemic stroke
10515,European,20132.0,26733130.0,Styrkarsdottir U,Other measurement,initial,2016-01-06,GCST003388,Bone mineral density (spine)
14246,Other/Mixed,10092.0,26733130.0,Styrkarsdottir U,Other measurement,replication,2016-01-06,GCST003388,Bone mineral density (spine)
14245,Other/Mixed,10037.0,26733130.0,Styrkarsdottir U,Other measurement,replication,2016-01-06,GCST003389,Bone mineral density (hip)
10516,European,20162.0,26733130.0,Styrkarsdottir U,Other measurement,initial,2016-01-06,GCST003389,Bone mineral density (hip)
116,African,528.0,26741287.0,Milet J,Other measurement,initial,2016-01-07,GCST003462,IgG1 response to Plasmodium falciparum antigen (MSP1)
115,African,528.0,26741287.0,Milet J,Other measurement,initial,2016-01-07,GCST003461,"IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7)"
118,African,528.0,26741287.0,Milet J,Other measurement,initial,2016-01-07,GCST003464,IgG3 response to Plasmodium falciparum antigen (MSP2 FC27)
117,African,528.0,26741287.0,Milet J,Other measurement,initial,2016-01-07,GCST003463,IgG3 response to Plasmodium falciparum antigen (MSP2 3D7)
114,African,528.0,26741287.0,Milet J,Other measurement,initial,2016-01-07,GCST003460,IgG1 response to Plasmodium falciparum antigen (GLURP)
2145,Asian,465.0,26746183.0,Watanabe H,"Other measurement, Neurological disorder",initial,2016-01-08,GCST003333,Moderate functional decline in sporadic amyotrophic lateral sclerosis
2144,Asian,465.0,26746183.0,Watanabe H,"Other measurement, Neurological disorder",initial,2016-01-08,GCST003332,Rapid functional decline in sporadic amyotrophic lateral sclerosis
919,African American or Afro-Caribbean,1427.0,26752167.0,Taylor JY,Other measurement,replication,2016-01-11,GCST003365,Systolic blood pressure (cigarette smoking interaction)
920,African American or Afro-Caribbean,1427.0,26752167.0,Taylor JY,Other measurement,replication,2016-01-11,GCST003366,Diastolic blood pressure (cigarette smoking interaction)
849,African American or Afro-Caribbean,1083.0,26752167.0,Taylor JY,Other measurement,initial,2016-01-11,GCST003365,Systolic blood pressure (cigarette smoking interaction)
3390,Asian,3580.0,26752265.0,Bailey JN,Neurological disorder,replication,2016-01-11,GCST003342,Glaucoma (primary open-angle)
9559,European,8836.0,26752265.0,Bailey JN,Neurological disorder,replication,2016-01-11,GCST003342,Glaucoma (primary open-angle)
850,African American or Afro-Caribbean,1083.0,26752167.0,Taylor JY,Other measurement,initial,2016-01-11,GCST003366,Diastolic blood pressure (cigarette smoking interaction)
5142,European,363.0,26752265.0,Bailey JN,Neurological disorder,replication,2016-01-11,GCST003343,Glaucoma (low intraocular pressure)
11050,European,37333.0,26752265.0,Bailey JN,Neurological disorder,initial,2016-01-11,GCST003342,Glaucoma (primary open-angle)
6961,European,1870.0,26752265.0,Bailey JN,Neurological disorder,initial,2016-01-11,GCST003343,Glaucoma (low intraocular pressure)
10941,European,33365.0,26752265.0,Bailey JN,Neurological disorder,initial,2016-01-11,GCST003344,Glaucoma (high intraocular pressure)
10401,European,18186.0,26754954.0,Otowa T,Other measurement,initial,2016-01-12,GCST003369,Anxiety disorder (factor score)
2390,Asian,795.0,26599303.0,Cheung CL,"Response to drug, Other trait",initial,2016-01-12,GCST003580,Antithyroid drug-induced agranulocytosis
2078,Asian,391.0,26599303.0,Cheung CL,"Response to drug, Other trait",replication,2016-01-12,GCST003580,Antithyroid drug-induced agranulocytosis
10350,European,17310.0,26754954.0,Otowa T,Neurological disorder,initial,2016-01-12,GCST003370,Anxiety disorder
3305,Asian,2994.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,initial,2016-01-14,GCST003363,HDL cholesterol levels
3306,Asian,2994.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,initial,2016-01-14,GCST003364,Triglyceride levels
3820,Asian,6805.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,replication,2016-01-14,GCST003364,Triglyceride levels
3819,Asian,6805.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,replication,2016-01-14,GCST003363,HDL cholesterol levels
3818,Asian,6805.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,replication,2016-01-14,GCST003362,Phospholipid levels
3817,Asian,6805.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,replication,2016-01-14,GCST003361,LDL cholesterol levels
4023,Asian,8842.0,26763874.0,Ryu D,Other measurement,initial,2016-01-14,GCST003331,Sex ratio
2464,Asian,935.0,26763874.0,Ryu D,Other measurement,replication,2016-01-14,GCST003331,Sex ratio
7958,European,3384.0,26766742.0,Garcia-Albeniz X,"Cancer, Other trait",initial,2016-01-14,GCST003385,Colorectal cancer (menopausal hormone therapy interaction)
6472,European,1283.0,26766742.0,Garcia-Albeniz X,"Cancer, Other trait",initial,2016-01-14,GCST003386,Colorectal cancer (oestrogen-progestogen hormone therapy interaction)
6743,European,1606.0,26766742.0,Garcia-Albeniz X,"Cancer, Other trait",initial,2016-01-14,GCST003387,Colorectal cancer (oestrogen hormone therapy interaction)
3304,Asian,2994.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,initial,2016-01-14,GCST003362,Phospholipid levels
3303,Asian,2994.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,initial,2016-01-14,GCST003361,LDL cholesterol levels
14069,Other/Mixed,967.0,26767831.0,Grant AV,"Other disease, Other measurement",replication,2016-01-14,GCST003451,Tuberculosis
13938,Other/Mixed,558.0,26767831.0,Grant AV,"Other disease, Other measurement",initial,2016-01-14,GCST003451,Tuberculosis
2126,Asian,444.0,26776603.0,Honne K,"Immune system disorder, Response to drug",initial,2016-01-18,GCST003329,Response to anti-TNF therapy in rheumatoid arthritis
13387,Hispanic or Latin American,7876.0,26780889.0,Below JE,Lipid or lipoprotein measurement,replication,2016-01-19,GCST003304,HDL cholesterol
13388,Hispanic or Latin American,7876.0,26780889.0,Below JE,"Lipid or lipoprotein measurement, Other measurement",replication,2016-01-19,GCST003303,LDL cholesterol
13242,Hispanic or Latin American,4383.0,26780889.0,Below JE,Lipid or lipoprotein measurement,initial,2016-01-19,GCST003302,"Cholesterol, total"
13244,Hispanic or Latin American,4383.0,26780889.0,Below JE,"Lipid or lipoprotein measurement, Other measurement",initial,2016-01-19,GCST003303,LDL cholesterol
13243,Hispanic or Latin American,4383.0,26780889.0,Below JE,Lipid or lipoprotein measurement,initial,2016-01-19,GCST003304,HDL cholesterol
13385,Hispanic or Latin American,7876.0,26780889.0,Below JE,Lipid or lipoprotein measurement,replication,2016-01-19,GCST003301,Triglycerides
13241,Hispanic or Latin American,4383.0,26780889.0,Below JE,Lipid or lipoprotein measurement,initial,2016-01-19,GCST003301,Triglycerides
13386,Hispanic or Latin American,7876.0,26780889.0,Below JE,Lipid or lipoprotein measurement,replication,2016-01-19,GCST003302,"Cholesterol, total"
4397,Asian,25553.0,26785701.0,Wen W,Body measurement,replication,2016-01-20,GCST003335,Waist circumference
4491,Asian,39869.0,26785701.0,Wen W,"Body measurement, Other measurement",initial,2016-01-20,GCST003338,Waist-to-hip ratio adjusted for body mass index
4363,Asian,20137.0,26785701.0,Wen W,"Body measurement, Other measurement",replication,2016-01-20,GCST003338,Waist-to-hip ratio adjusted for body mass index
4492,Asian,39869.0,26785701.0,Wen W,"Other measurement, Body measurement",initial,2016-01-20,GCST003337,Waist-hip ratio
4398,Asian,25553.0,26785701.0,Wen W,"Other measurement, Body measurement",replication,2016-01-20,GCST003337,Waist-hip ratio
4392,Asian,24146.0,26785701.0,Wen W,"Body measurement, Other measurement",replication,2016-01-20,GCST003336,Waist circumference adjusted for body mass index
4502,Asian,44609.0,26785701.0,Wen W,"Body measurement, Other measurement",initial,2016-01-20,GCST003336,Waist circumference adjusted for body mass index
4501,Asian,44609.0,26785701.0,Wen W,Body measurement,initial,2016-01-20,GCST003335,Waist circumference
13365,Hispanic or Latin American,7170.0,26805783.0,Schick UM,Hematological measurement,replication,2016-01-21,GCST003383,Platelet count
11938,European,133413.0,26831199.0,Pattaro C,Other measurement,initial,2016-01-21,GCST003372,Glomerular filtration rate (creatinine)
11859,European,118448.0,26831199.0,Pattaro C,Other measurement,initial,2016-01-21,GCST003401,Glomerular filtration rate in non diabetics (creatinine)
8732,European,5404.0,26908625.0,Johansson A,Cardiovascular measurement,replication,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
11160,European,42166.0,26831199.0,Pattaro C,Other measurement,replication,2016-01-21,GCST003372,Glomerular filtration rate (creatinine)
11038,European,36433.0,26831199.0,Pattaro C,Other measurement,replication,2016-01-21,GCST003401,Glomerular filtration rate in non diabetics (creatinine)
11937,European,133413.0,26831199.0,Pattaro C,Other measurement,initial,2016-01-21,GCST003371,Glomerular filtration rate (creatinine)
16,African,33.0,26908625.0,Johansson A,Cardiovascular measurement,replication,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
1662,Asian,54.0,26908625.0,Johansson A,Cardiovascular measurement,replication,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
10981,European,33972.0,26831199.0,Pattaro C,"Other disease, Other measurement",replication,2016-01-21,GCST003374,Chronic kidney disease
8100,European,3691.0,26908625.0,Johansson A,Cardiovascular measurement,initial,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
364,African,16840.0,26831199.0,Pattaro C,Other measurement,initial,2016-01-21,GCST003371,Glomerular filtration rate (creatinine)
363,African,16471.0,26831199.0,Pattaro C,Other measurement,replication,2016-01-21,GCST003372,Glomerular filtration rate (creatinine)
8573,European,4955.0,26831199.0,Pattaro C,"Other measurement, Metabolic disorder",replication,2016-01-21,GCST003373,Glomerular filtration rate in diabetics (creatinine)
9918,European,11522.0,26831199.0,Pattaro C,"Other measurement, Metabolic disorder",initial,2016-01-21,GCST003373,Glomerular filtration rate in diabetics (creatinine)
4495,Asian,42296.0,26831199.0,Pattaro C,Other measurement,replication,2016-01-21,GCST003372,Glomerular filtration rate (creatinine)
10927,European,32834.0,26831199.0,Pattaro C,Other measurement,initial,2016-01-21,GCST003375,Glomerular filtration rate (cystatin C)
10183,European,14930.0,26831199.0,Pattaro C,Other measurement,replication,2016-01-21,GCST003375,Glomerular filtration rate (cystatin C)
13,African,20.0,26908625.0,Johansson A,Cardiovascular measurement,initial,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
13483,Hispanic or Latin American,12491.0,26805783.0,Schick UM,Hematological measurement,initial,2016-01-21,GCST003383,Platelet count
1644,Asian,29.0,26908625.0,Johansson A,Cardiovascular measurement,initial,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
11850,European,117165.0,26831199.0,Pattaro C,"Other disease, Other measurement",initial,2016-01-21,GCST003374,Chronic kidney disease
14170,Other/Mixed,2563.0,26806518.0,Hou L,"Response to drug, Neurological disorder",initial,2016-01-22,GCST003378,Response to lithium treatment in bipolar disorder
5459,European,522.0,27179730.0,Allen NB,Other trait,replication,2016-01-23,GCST003279,Ideal cardiovascular health (clinical)
9933,European,11708.0,27179730.0,Allen NB,Other trait,initial,2016-01-23,GCST003278,Ideal cardiovascular health (clinical and behavioural)
9934,European,11708.0,27179730.0,Allen NB,Other trait,initial,2016-01-23,GCST003279,Ideal cardiovascular health (clinical)
5458,European,522.0,27179730.0,Allen NB,Other trait,replication,2016-01-23,GCST003278,Ideal cardiovascular health (clinical and behavioural)
12730,Hispanic or Latin American,12.0,26811534.0,Wang X,"Cardiovascular disease, Cancer",replication,2016-01-25,GCST003299,Cardiomyopathy in childhood cancer survivors
4640,European,21.0,26811534.0,Wang X,"Cardiovascular disease, Cancer, Response to drug",replication,2016-01-25,GCST003300,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction)
12731,Hispanic or Latin American,12.0,26811534.0,Wang X,"Cardiovascular disease, Cancer, Response to drug",replication,2016-01-25,GCST003300,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction)
5090,European,331.0,26811534.0,Wang X,"Cardiovascular disease, Cancer, Response to drug",initial,2016-01-25,GCST003300,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction)
4639,European,21.0,26811534.0,Wang X,"Cardiovascular disease, Cancer",replication,2016-01-25,GCST003299,Cardiomyopathy in childhood cancer survivors
5089,European,331.0,26811534.0,Wang X,"Cardiovascular disease, Cancer",initial,2016-01-25,GCST003299,Cardiomyopathy in childhood cancer survivors
13676,Other/Mixed,21.0,26811534.0,Wang X,"Cardiovascular disease, Cancer, Response to drug",replication,2016-01-25,GCST003300,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction)
13675,Other/Mixed,21.0,26811534.0,Wang X,"Cardiovascular disease, Cancer",replication,2016-01-25,GCST003299,Cardiomyopathy in childhood cancer survivors
6522,European,1352.0,26818729.0,Weinsheimer S,Cancer,replication,2016-01-27,GCST003318,Brain arteriovenous malformations (sporadic)
5662,European,662.0,26815016.0,Julia A,"Other measurement, Immune system disorder",replication,2016-01-27,GCST003330,Rheumatoid factor seropositivity in rheumatoid arthritis
13101,Hispanic or Latin American,1956.0,26819262.0,Zhou Y,"Immune system disorder, Other measurement",initial,2016-01-27,GCST003340,Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis
6362,European,1178.0,26815016.0,Julia A,"Other measurement, Immune system disorder",initial,2016-01-27,GCST003330,Rheumatoid factor seropositivity in rheumatoid arthritis
13102,Hispanic or Latin American,1956.0,26819262.0,Zhou Y,Other measurement,initial,2016-01-27,GCST003339,Epstein Barr virus nuclear antigen 1 IgG levels
10378,European,17698.0,26819262.0,Zhou Y,"Immune system disorder, Other measurement",initial,2016-01-27,GCST003340,Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis
6821,European,1706.0,26818729.0,Weinsheimer S,Cancer,initial,2016-01-27,GCST003318,Brain arteriovenous malformations (sporadic)
4493,Asian,41646.0,26818947.0,Imamura M,Metabolic disorder,initial,2016-01-28,GCST003400,Type 2 diabetes
12078,European,160850.0,26818947.0,Imamura M,Metabolic disorder,replication,2016-01-28,GCST003400,Type 2 diabetes
4701,European,79.0,26821981.0,Koga AT,"Other measurement, Neurological disorder",initial,2016-01-28,GCST003341,antipsychotic drug dosage in schizophrenia or schizoaffective disorder
13393,Hispanic or Latin American,8214.0,26818947.0,Imamura M,Metabolic disorder,replication,2016-01-28,GCST003400,Type 2 diabetes
4499,Asian,43412.0,26818947.0,Imamura M,Metabolic disorder,replication,2016-01-28,GCST003400,Type 2 diabetes
4394,Asian,24965.0,26818947.0,Imamura M,Metabolic disorder,replication,2016-01-28,GCST003400,Type 2 diabetes
11412,European,61457.0,26829030.0,Asgari MM,Cancer,initial,2016-01-29,GCST003327,Squamous cell carcinoma
6921,European,1815.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003458,World class endurance athleticism
100,African,415.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003458,World class endurance athleticism
131,African,618.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003459,Endurance athleticism
2294,Asian,688.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003458,World class endurance athleticism
1828,Asian,176.0,26824906.0,Rankinen T,Other measurement,initial,2016-01-29,GCST003458,World class endurance athleticism
1829,Asian,176.0,26824906.0,Rankinen T,Other measurement,initial,2016-01-29,GCST003459,Endurance athleticism
8978,European,6410.0,26829030.0,Asgari MM,Cancer,replication,2016-01-29,GCST003327,Squamous cell carcinoma
6922,European,1815.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003459,Endurance athleticism
2409,Asian,825.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003459,Endurance athleticism
6104,European,965.0,26840454.0,French JD,"Response to drug, Other measurement, Cancer",replication,2016-01-31,GCST003328,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
5008,European,279.0,26840454.0,French JD,"Response to drug, Other measurement, Cancer",initial,2016-01-31,GCST003328,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
14097,Other/Mixed,1273.0,26708285.0,Wakil SM,Cardiovascular disease,replication,2016-02-01,GCST003470,Coronary artery disease
5801,European,755.0,26833182.0,Ware JJ,Other measurement,replication,2016-02-01,GCST003466,Cotinine levels in current smokers
14091,Other/Mixed,1237.0,26708285.0,Wakil SM,Cardiovascular disease,replication,2016-02-01,GCST003471,Myocardial infarction
14234,Other/Mixed,5668.0,26708285.0,Wakil SM,Cardiovascular disease,initial,2016-02-01,GCST003470,Coronary artery disease
676,African American or Afro-Caribbean,416.0,26833246.0,Lu Y,Body measurement,initial,2016-02-01,GCST003435,Body fat percentage
11453,European,65831.0,26833246.0,Lu Y,Body measurement,initial,2016-02-01,GCST003435,Body fat percentage
10985,European,33987.0,26833098.0,Kilpelainen TO,Other measurement,initial,2016-02-01,GCST003368,circulating leptin levels adjusted for BMI
3124,Asian,2333.0,26833246.0,Lu Y,Body measurement,initial,2016-02-01,GCST003435,Body fat percentage
10984,European,33987.0,26833098.0,Kilpelainen TO,Other measurement,initial,2016-02-01,GCST003367,circulating leptin levels
8398,European,4548.0,26833182.0,Ware JJ,Other measurement,initial,2016-02-01,GCST003466,Cotinine levels in current smokers
4058,Asian,9289.0,26833246.0,Lu Y,Body measurement,initial,2016-02-01,GCST003435,Body fat percentage
10407,European,18226.0,26833098.0,Kilpelainen TO,Other measurement,replication,2016-02-01,GCST003368,circulating leptin levels adjusted for BMI
854,African American or Afro-Caribbean,1089.0,26833246.0,Lu Y,Body measurement,replication,2016-02-01,GCST003435,Body fat percentage
14226,Other/Mixed,4431.0,26708285.0,Wakil SM,Cardiovascular disease,initial,2016-02-01,GCST003471,Myocardial infarction
10665,European,23469.0,26833246.0,Lu Y,Body measurement,replication,2016-02-01,GCST003435,Body fat percentage
10406,European,18226.0,26833098.0,Kilpelainen TO,Other measurement,replication,2016-02-01,GCST003367,circulating leptin levels
11680,European,89283.0,26835600.0,Hu Y,Biological process,initial,2016-02-02,GCST003429,Morning vs. evening chronotype
8032,European,3524.0,26830138.0,Herold C,"Neurological disorder, Other measurement",initial,2016-02-02,GCST003427,Alzheimer disease and age of onset
11887,European,122125.0,26835600.0,Hu Y,"Biological process, Other measurement",initial,2016-02-02,GCST003428,Chronotype
5445,European,516.0,27333618.0,Sekula P,Other disease,replication,2016-02-04,GCST003402,Membranous nephropathy
5672,European,668.0,27333618.0,Sekula P,Other disease,initial,2016-02-04,GCST003402,Membranous nephropathy
5286,European,441.0,26861389.0,D'Adamo CR,Other measurement,initial,2016-02-06,GCST003433,Serum lycopene concentrations
3031,Asian,2112.0,26853712.0,Zhang YB,Other disease,replication,2016-02-08,GCST004412,Craniofacial microsomia
3288,Asian,2951.0,26853712.0,Zhang YB,Other disease,initial,2016-02-08,GCST004412,Craniofacial microsomia
4718,European,86.0,26856250.0,Sacchetti E,Response to drug,initial,2016-02-09,GCST003432,Early response to risperidone in schizophrenia
12316,European,258962.0,26908601.0,Hinds DA,"Other trait, Cardiovascular disease",initial,2016-02-09,GCST003390,Thrombosis
3293,Asian,2955.0,26876947.0,Saito T,"Response to drug, Neurological disorder, Other trait",initial,2016-02-11,GCST003450,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
10073,European,13550.0,26908436.0,Siiskonen SJ,Cancer,initial,2016-02-12,GCST003422,Squamous cell carcinoma
6269,European,1082.0,26908436.0,Siiskonen SJ,Cancer,replication,2016-02-12,GCST003422,Squamous cell carcinoma
14113,Other/Mixed,1413.0,26879886.0,Wakil SM,Lipid or lipoprotein measurement,replication,2016-02-16,GCST003391,Low high density lipoprotein cholesterol levels
14221,Other/Mixed,4082.0,26879886.0,Wakil SM,Lipid or lipoprotein measurement,initial,2016-02-16,GCST003391,Low high density lipoprotein cholesterol levels
542,African American or Afro-Caribbean,159.0,26888256.0,Hernandez W,Cardiovascular disease,replication,2016-02-17,GCST003377,Venous thromboembolism
729,African American or Afro-Caribbean,578.0,26888256.0,Hernandez W,Cardiovascular disease,initial,2016-02-17,GCST003377,Venous thromboembolism
2638,Asian,1308.0,26891255.0,Jung ES,Digestive system disorder,replication,2016-02-18,GCST003360,Crohn's disease
2531,Asian,1067.0,26887379.0,Tang W,Digestive system disorder,initial,2016-02-18,GCST008016,Hirschsprung disease
3213,Asian,2644.0,26891255.0,Jung ES,Digestive system disorder,initial,2016-02-18,GCST003360,Crohn's disease
3412,Asian,3725.0,26902266.0,Giri AK,Cardiovascular measurement,replication,2016-02-23,GCST003359,Serum uric acid levels
2550,Asian,1109.0,26902266.0,Giri AK,Cardiovascular measurement,initial,2016-02-23,GCST003359,Serum uric acid levels
11841,European,116470.0,26913989.0,Traylor M,"Neurological disorder, Cardiovascular disease",initial,2016-02-23,GCST003423,Alzheimer's disease or small vessel stroke
10055,European,13312.0,26910538.0,Choi SH,Cardiovascular measurement,initial,2016-02-24,GCST003403,Vascular endothelial growth factor levels
7635,European,2800.0,26910538.0,Choi SH,Cardiovascular measurement,replication,2016-02-24,GCST003403,Vascular endothelial growth factor levels
8801,European,5654.0,26911590.0,Mullin BH,Other measurement,replication,2016-02-25,GCST003381,Bone mineral density (femoral neck)
6230,European,1042.0,26911590.0,Mullin BH,Other measurement,initial,2016-02-25,GCST003381,Bone mineral density (femoral neck)
8800,European,5654.0,26911590.0,Mullin BH,Other measurement,replication,2016-02-25,GCST003380,Bone mineral density (spine)
6229,European,1042.0,26911590.0,Mullin BH,Other measurement,initial,2016-02-25,GCST003380,Bone mineral density (spine)
3514,Asian,4477.0,26912274.0,Zeng Y,Other measurement,initial,2016-02-25,GCST003425,Longevity
6228,European,1042.0,26911590.0,Mullin BH,Other measurement,initial,2016-02-25,GCST003379,Bone mineral density (hip)
8799,European,5654.0,26911590.0,Mullin BH,Other measurement,replication,2016-02-25,GCST003379,Bone mineral density (hip)
450,African American or Afro-Caribbean,49.0,26921259.0,Baurley JW,Other measurement,initial,2016-02-27,GCST003376,Nicotine metabolite ratio
1660,Asian,51.0,26921259.0,Baurley JW,Other measurement,initial,2016-02-27,GCST003376,Nicotine metabolite ratio
4931,European,215.0,26921259.0,Baurley JW,Other measurement,initial,2016-02-27,GCST003376,Nicotine metabolite ratio
13166,Hispanic or Latin American,2922.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003477,Monobrow thickness
13332,Hispanic or Latin American,6357.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003474,Scalp hair shape
13334,Hispanic or Latin American,6357.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003480,Balding
13333,Hispanic or Latin American,6357.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003478,Hair greying
13164,Hispanic or Latin American,2922.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003475,Beard thickness
13165,Hispanic or Latin American,2922.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003476,Eyebrow thickness
13335,Hispanic or Latin American,6357.0,26926045.0,Adhikari K,"Other measurement, Other trait",initial,2016-03-01,GCST003479,Hair color
10695,European,24024.0,26950853.0,Dehghan A,Cardiovascular disease,initial,2016-03-07,GCST003431,Incident coronary heart disease
11067,European,37561.0,26950853.0,Dehghan A,Cardiovascular disease,replication,2016-03-07,GCST003430,Incident myocardial infarction
1376,African American or Afro-Caribbean,8201.0,26950853.0,Dehghan A,Cardiovascular disease,replication,2016-03-07,GCST003430,Incident myocardial infarction
10882,European,31146.0,26950853.0,Dehghan A,Cardiovascular disease,replication,2016-03-07,GCST003431,Incident coronary heart disease
10657,European,23188.0,26950853.0,Dehghan A,Cardiovascular disease,initial,2016-03-07,GCST003430,Incident myocardial infarction
4369,Asian,21096.0,26965516.0,Zeng C,Cancer,initial,2016-03-08,GCST003799,Colorectal cancer
6122,European,975.0,26962152.0,Offenbacher S,Other measurement,initial,2016-03-08,GCST008443,Periodontal disease related phenotype (PCT6)
6120,European,975.0,26962152.0,Offenbacher S,Other measurement,initial,2016-03-08,GCST008441,Periodontal disease related phenotype (PCT4)
6123,European,975.0,26962152.0,Offenbacher S,"Other measurement, Digestive system disorder",initial,2016-03-08,GCST003484,Periodontal disease-related phenotype (Socransky)
6119,European,975.0,26962152.0,Offenbacher S,Other measurement,initial,2016-03-08,GCST008440,Periodontal disease related phenotype (PCT3)
6118,European,975.0,26962152.0,Offenbacher S,Other measurement,initial,2016-03-08,GCST008439,Periodontal disease related phenotype (PCT2)
6121,European,975.0,26962152.0,Offenbacher S,Other measurement,initial,2016-03-08,GCST008442,Periodontal disease related phenotype (PCT5)
4447,Asian,32599.0,26965516.0,Zeng C,Cancer,replication,2016-03-08,GCST003799,Colorectal cancer
5277,European,437.0,26959369.0,Haiman CA,"Biological process, Other measurement",initial,2016-03-09,GCST003483,S-phenylmercapturic acid levels in smokers
8770,European,5526.0,26965164.0,Hanchard NA,Cardiovascular disease,replication,2016-03-09,GCST003419,Congenital left-sided heart lesions
13858,Other/Mixed,311.0,26959369.0,Haiman CA,"Biological process, Other measurement",initial,2016-03-09,GCST003483,S-phenylmercapturic acid levels in smokers
12878,Hispanic or Latin American,453.0,26959369.0,Haiman CA,"Biological process, Other measurement",initial,2016-03-09,GCST003483,S-phenylmercapturic acid levels in smokers
9890,European,11208.0,26959717.0,Nicoletti P,"Response to drug, Digestive system disorder",initial,2016-03-09,GCST003426,Drug-induced liver injury
7880,European,3268.0,26965164.0,Hanchard NA,Cardiovascular disease,initial,2016-03-09,GCST003419,Congenital left-sided heart lesions
11753,European,100420.0,26955885.0,Lane JM,"Biological process, Other measurement",initial,2016-03-09,GCST003453,Chronotype
11023,European,35672.0,26955885.0,Lane JM,Biological process,initial,2016-03-09,GCST003454,Morning vs. evening chronotype
9845,European,10767.0,26956414.0,Berndt SI,Cancer,initial,2016-03-09,GCST003468,Chronic lymphocytic leukemia
2286,Asian,674.0,26959369.0,Haiman CA,"Biological process, Other measurement",initial,2016-03-09,GCST003483,S-phenylmercapturic acid levels in smokers
658,African American or Afro-Caribbean,364.0,26959369.0,Haiman CA,"Biological process, Other measurement",initial,2016-03-09,GCST003483,S-phenylmercapturic acid levels in smokers
11856,European,117775.0,26961502.0,Wood AR,Metabolic disorder,initial,2016-03-10,GCST006801,Type 2 diabetes
11864,European,119688.0,26961502.0,Wood AR,"Body measurement, Other measurement",initial,2016-03-10,GCST006802,Body mass index
10675,European,23689.0,26969751.0,Parmar PG,Other measurement,initial,2016-03-11,GCST003670,Systolic blood pressure
10676,European,23689.0,26969751.0,Parmar PG,Other measurement,initial,2016-03-11,GCST003671,Diastolic blood pressure
11653,European,86475.0,26974007.0,Ellinghaus D,"Immune system disorder, Digestive system disorder",initial,2016-03-14,GCST005537,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)"
1881,Asian,214.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003674,Obstructive sleep apnea trait (apnea hypopnea index)
8794,European,5638.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003674,Obstructive sleep apnea trait (apnea hypopnea index)
8795,European,5638.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003675,Obstructive sleep apnea trait (average respiratory event duration)
13495,Hispanic or Latin American,12558.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",initial,2016-03-15,GCST003674,Obstructive sleep apnea trait (apnea hypopnea index)
13491,Hispanic or Latin American,12557.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",initial,2016-03-15,GCST003673,Obstructive sleep apnea (average oxygen saturation during sleep)
865,African American or Afro-Caribbean,1183.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003673,Obstructive sleep apnea (average oxygen saturation during sleep)
8793,European,5638.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003673,Obstructive sleep apnea (average oxygen saturation during sleep)
1880,Asian,214.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003673,Obstructive sleep apnea (average oxygen saturation during sleep)
866,African American or Afro-Caribbean,1183.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003674,Obstructive sleep apnea trait (apnea hypopnea index)
1882,Asian,214.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003675,Obstructive sleep apnea trait (average respiratory event duration)
867,African American or Afro-Caribbean,1183.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003675,Obstructive sleep apnea trait (average respiratory event duration)
13428,Hispanic or Latin American,10238.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",initial,2016-03-15,GCST003675,Obstructive sleep apnea trait (average respiratory event duration)
1747,Asian,109.0,26980576.0,Kim K,"Immune system disorder, Response to drug",initial,2016-03-15,GCST003445,Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis
6000,European,902.0,26989097.0,Coleman JR,"Other trait, Neurological disorder",initial,2016-03-17,GCST003469,Response to cognitive-behavioural therapy in anxiety disorder
10919,European,32528.0,26997408.0,Demirkan A,Other measurement,initial,2016-03-21,GCST003668,Depressive symptoms measurement (lack of positive affect domain)
1700,Asian,79.0,27001664.0,Yoo J,Other measurement,initial,2016-03-21,GCST003608,Maximal oxygen uptake response
9074,European,6813.0,26997408.0,Demirkan A,Other measurement,replication,2016-03-21,GCST003667,Depressive symptoms measurement (somatic complaints domain)
9075,European,6813.0,26997408.0,Demirkan A,Other measurement,replication,2016-03-21,GCST003668,Depressive symptoms measurement (lack of positive affect domain)
9076,European,6813.0,26997408.0,Demirkan A,Other measurement,replication,2016-03-21,GCST003669,Depressive symptoms measurement (lack of negative affect domain)
10918,European,32528.0,26997408.0,Demirkan A,Other measurement,initial,2016-03-21,GCST003667,Depressive symptoms measurement (somatic complaints domain)
1699,Asian,79.0,27001664.0,Yoo J,Other measurement,initial,2016-03-21,GCST003607,knee peak torque response
10920,European,32528.0,26997408.0,Demirkan A,Other measurement,initial,2016-03-21,GCST003669,Depressive symptoms measurement (lack of negative affect domain)
7673,European,2888.0,27005825.0,Finkel TH,Immune system disorder,initial,2016-03-22,GCST003424,Arthritis (juvenile idiopathic)
2243,Asian,616.0,27001270.0,Vishal M,Neurological disorder,replication,2016-03-22,GCST003446,Glaucoma (primary open-angle)
9291,European,7778.0,27005825.0,Finkel TH,Immune system disorder,replication,2016-03-22,GCST003424,Arthritis (juvenile idiopathic)
2307,Asian,701.0,27001270.0,Vishal M,Neurological disorder,initial,2016-03-22,GCST003446,Glaucoma (primary open-angle)
11439,European,63775.0,27015805.0,Pilling LC,Other measurement,initial,2016-03-23,GCST003392,Parental longevity (father's age at death)
10325,European,16852.0,27008869.0,Chen MM,Cancer,initial,2016-03-23,GCST003436,Endometrial cancer
10723,European,24925.0,27005778.0,Kettunen J,Other measurement,initial,2016-03-23,GCST003664,Metabolite levels (lipid measures)
10724,European,24925.0,27005778.0,Kettunen J,Other measurement,initial,2016-03-23,GCST003665,Metabolite levels (lipoprotein measures)
11203,European,45627.0,27015805.0,Pilling LC,Other measurement,initial,2016-03-23,GCST003394,Parental longevity (combined parental age at death)
11165,European,42273.0,27015805.0,Pilling LC,Other measurement,initial,2016-03-23,GCST003395,Parental extreme longevity (95 years and older)
11305,European,52776.0,27015805.0,Pilling LC,Other measurement,initial,2016-03-23,GCST003393,Parental longevity (mother's age at death)
10725,European,24925.0,27005778.0,Kettunen J,Other measurement,initial,2016-03-23,GCST003666,Metabolite levels (small molecules and protein measures)
762,African American or Afro-Caribbean,736.0,27022141.0,Liu L,"Hematological measurement, Other disease",initial,2016-03-27,GCST006251,High fetal hemoglobin in sickle cell disease
5687,European,678.0,27021820.0,Roostaei T,"Other measurement, Other trait",initial,2016-03-29,GCST003399,Cognitive impairment (brain beta-amyloid deposition interaction)
7712,European,2967.0,27023175.0,Stringer S,Biological process,replication,2016-03-29,GCST003382,Cannabis use
2761,Asian,1584.0,27206850.0,Wang M,Cancer,initial,2016-03-29,GCST003384,Bladder cancer
1068,African American or Afro-Caribbean,2660.0,27023175.0,Stringer S,Biological process,replication,2016-03-29,GCST003382,Cannabis use
3735,Asian,5971.0,27020472.0,Fan Q,Other measurement,initial,2016-03-29,GCST003455,Spherical equivalent (joint analysis main effects and education interaction)
5536,European,579.0,27023328.0,Kulkarni D,"Other trait, Response to drug, Cancer",initial,2016-03-29,GCST003456,Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia)
10911,European,32330.0,27023175.0,Stringer S,Biological process,initial,2016-03-29,GCST003382,Cannabis use
6084,European,949.0,27021820.0,Roostaei T,"Other measurement, Other trait",replication,2016-03-29,GCST003399,Cognitive impairment (brain beta-amyloid deposition interaction)
3103,Asian,2256.0,27020472.0,Fan Q,Other measurement,initial,2016-03-29,GCST003455,Spherical equivalent (joint analysis main effects and education interaction)
3797,Asian,6467.0,27206850.0,Wang M,Cancer,replication,2016-03-29,GCST003384,Bladder cancer
11129,European,40036.0,27020472.0,Fan Q,Other measurement,initial,2016-03-29,GCST003455,Spherical equivalent (joint analysis main effects and education interaction)
6246,European,1060.0,27021288.0,Brevik EJ,"Neurological disorder, Other measurement",initial,2016-03-29,GCST003473,Aggressiveness in attention deficit hyperactivity disorder
3021,Asian,2088.0,27020472.0,Fan Q,Other measurement,initial,2016-03-29,GCST003455,Spherical equivalent (joint analysis main effects and education interaction)
6979,European,1893.0,27028160.0,Sherva R,Other measurement,replication,2016-03-30,GCST003465,Cannabis dependence symptom count
1297,African American or Afro-Caribbean,6000.0,27028160.0,Sherva R,Other measurement,initial,2016-03-30,GCST003465,Cannabis dependence symptom count
9550,European,8754.0,27028160.0,Sherva R,Other measurement,initial,2016-03-30,GCST003465,Cannabis dependence symptom count
10708,European,24168.0,27029810.0,Joshi PK,Other measurement,replication,2016-03-31,GCST005078,Mortality
12333,European,272081.0,27029810.0,Joshi PK,Other measurement,initial,2016-03-31,GCST005078,Mortality
2770,Asian,1613.0,27029810.0,Joshi PK,Other measurement,replication,2016-03-31,GCST005078,Mortality
2015,Asian,338.0,27029810.0,Joshi PK,Other measurement,replication,2016-03-31,GCST005078,Mortality
818,African American or Afro-Caribbean,962.0,27029810.0,Joshi PK,Other measurement,replication,2016-03-31,GCST005078,Mortality
134,African,681.0,27029810.0,Joshi PK,Other measurement,replication,2016-03-31,GCST005078,Mortality
4086,Asian,9982.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003661,Triglycerides
4097,Asian,10000.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003663,"Cholesterol, total"
2314,Asian,703.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003660,HDL cholesterol
1080,African American or Afro-Caribbean,2710.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003661,Triglycerides
4078,Asian,9729.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",replication,2016-04-01,GCST003662,LDL cholesterol
11146,European,41142.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003661,Triglycerides
11139,European,40473.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",initial,2016-04-01,GCST003662,LDL cholesterol
1309,African American or Afro-Caribbean,6287.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003661,Triglycerides
2317,Asian,705.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003661,Triglycerides
11401,European,60078.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",replication,2016-04-01,GCST003662,LDL cholesterol
1307,African American or Afro-Caribbean,6237.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",initial,2016-04-01,GCST003662,LDL cholesterol
1076,African American or Afro-Caribbean,2707.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003663,"Cholesterol, total"
1312,African American or Afro-Caribbean,6480.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003663,"Cholesterol, total"
2295,Asian,689.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",initial,2016-04-01,GCST003662,LDL cholesterol
14282,Other/Mixed,71032.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003663,"Cholesterol, total"
13061,Hispanic or Latin American,1415.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003661,Triglycerides
11408,European,60827.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003661,Triglycerides
1071,African American or Afro-Caribbean,2679.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",replication,2016-04-01,GCST003662,LDL cholesterol
11283,European,51430.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003663,"Cholesterol, total"
1073,African American or Afro-Caribbean,2685.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003660,HDL cholesterol
11275,European,50823.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003660,HDL cholesterol
4096,Asian,9992.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003660,HDL cholesterol
13053,Hispanic or Latin American,1381.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",initial,2016-04-01,GCST003662,LDL cholesterol
13057,Hispanic or Latin American,1407.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003660,HDL cholesterol
2310,Asian,702.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003663,"Cholesterol, total"
13059,Hispanic or Latin American,1412.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003663,"Cholesterol, total"
11516,European,71921.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003660,HDL cholesterol
1311,African American or Afro-Caribbean,6476.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003660,HDL cholesterol
3766,Asian,6205.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
4328,Asian,18063.0,27064256.0,Khor CC,Neurological disorder,initial,2016-04-04,GCST003467,Glaucoma (primary angle closure)
3268,Asian,2875.0,27064256.0,Khor CC,Neurological disorder,initial,2016-04-04,GCST003467,Glaucoma (primary angle closure)
1978,Asian,295.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
8052,European,3563.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
8769,European,5516.0,27064256.0,Khor CC,Neurological disorder,initial,2016-04-04,GCST003467,Glaucoma (primary angle closure)
12831,Hispanic or Latin American,323.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
2577,Asian,1180.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
14152,Other/Mixed,2050.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
11814,European,112067.0,27046643.0,Davies G,Other measurement,initial,2016-04-05,GCST003497,Memory performance
11027,European,36035.0,27046643.0,Davies G,Biological process,initial,2016-04-05,GCST003498,Verbal-numerical reasoning
11805,European,111483.0,27046643.0,Davies G,Other measurement,initial,2016-04-05,GCST003499,Reaction time
11803,European,111114.0,27046643.0,Davies G,Other measurement,initial,2016-04-05,GCST003496,Educational attainment
10106,European,13886.0,27130862.0,Sarnowski C,"Other disease, Other measurement",initial,2016-04-06,GCST008838,Asthma (time to onset)
14275,Other/Mixed,35900.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",replication,2016-04-07,GCST003490,Ischemic stroke (cardioembolic)
41,African,98.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
14280,Other/Mixed,49324.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",replication,2016-04-07,GCST003492,Ischemic stroke
36,African,83.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
7057,European,2012.0,27068588.0,Chauhan G,Cardiovascular disease,replication,2016-04-07,GCST003491,Stroke
7748,European,3028.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",initial,2016-04-07,GCST003492,Ischemic stroke
14277,Other/Mixed,37969.0,27068588.0,Chauhan G,Other trait,replication,2016-04-07,GCST003493,Ischemic stroke (non-cardioembolic)
409,African American or Afro-Caribbean,7.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
408,African American or Afro-Caribbean,7.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
11,African,15.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005948,Cleft palate
1,African,1.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
6991,European,1931.0,27018472.0,Leslie EJ,Other trait,replication,2016-04-07,GCST005947,Cleft palate
8342,European,4348.0,27068588.0,Chauhan G,Cardiovascular disease,initial,2016-04-07,GCST003491,Stroke
6990,European,1931.0,27018472.0,Leslie EJ,Other trait,replication,2016-04-07,GCST005946,Cleft palate
0,African,1.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
12770,Hispanic or Latin American,90.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005948,Cleft palate
11607,European,82383.0,27068588.0,Chauhan G,Other trait,initial,2016-04-07,GCST003493,Ischemic stroke (non-cardioembolic)
1767,Asian,125.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
12933,Hispanic or Latin American,647.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
1755,Asian,117.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005948,Cleft palate
1931,Asian,242.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
5576,European,602.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",initial,2016-04-07,GCST003490,Ischemic stroke (cardioembolic)
12955,Hispanic or Latin American,737.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
5965,European,873.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
1591,Asian,3.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005948,Cleft palate
10463,European,19215.0,27068588.0,Chauhan G,Other trait,replication,2016-04-07,GCST003493,Ischemic stroke (non-cardioembolic)
1653,Asian,41.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
10477,European,19468.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",replication,2016-04-07,GCST003492,Ischemic stroke
1652,Asian,38.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
5107,European,342.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005948,Cleft palate
6413,European,1215.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
10450,European,19094.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",replication,2016-04-07,GCST003490,Ischemic stroke (cardioembolic)
4775,European,114.0,27060151.0,Magrangeas F,"Response to drug, Neurological disorder, Cancer",replication,2016-04-08,GCST003438,Bortezomib-induced peripheral neuropathy in multiple myeloma
5330,European,469.0,27060151.0,Magrangeas F,"Response to drug, Neurological disorder, Cancer",initial,2016-04-08,GCST003438,Bortezomib-induced peripheral neuropathy in multiple myeloma
9937,European,11749.0,27064253.0,Zhou W,Other measurement,initial,2016-04-11,GCST003421,Mosaic loss of chromosome Y
84,African,296.0,27064253.0,Zhou W,Other measurement,initial,2016-04-11,GCST003421,Mosaic loss of chromosome Y
6530,European,1359.0,27207532.0,Roshandel D,"Metabolic disorder, Other measurement",initial,2016-04-12,GCST003418,Skin fluorescence in type 1 diabetes
11716,European,91370.0,27067015.0,Smith DJ,"Neurological disorder, Other measurement",initial,2016-04-12,GCST003447,Neuroticism
725,African American or Afro-Caribbean,554.0,27082954.0,Ward-Caviness CK,"Cardiovascular disease, Other measurement",initial,2016-04-15,GCST004482,Peripheral arterial disease (traffic-related air pollution interaction)
6756,European,1623.0,27082954.0,Ward-Caviness CK,"Cardiovascular disease, Other measurement",initial,2016-04-15,GCST004482,Peripheral arterial disease (traffic-related air pollution interaction)
11493,European,69286.0,27094239.0,Joshi AD,Digestive system disorder,replication,2016-04-16,GCST003725,Gallstone disease
11440,European,63872.0,27094239.0,Joshi AD,Digestive system disorder,initial,2016-04-16,GCST003725,Gallstone disease
13184,Hispanic or Latin American,3459.0,27094239.0,Joshi AD,Digestive system disorder,replication,2016-04-16,GCST003725,Gallstone disease
1443,African American or Afro-Caribbean,10644.0,27094239.0,Joshi AD,Digestive system disorder,replication,2016-04-16,GCST003725,Gallstone disease
12508,European,368890.0,27089181.0,Okbay A,"Neurological disorder, Other measurement",replication,2016-04-18,GCST003769,Depression
12378,European,298420.0,27089181.0,Okbay A,Other measurement,initial,2016-04-18,GCST003766,Subjective well-being
13313,Hispanic or Latin American,5941.0,27207650.0,Schmit SL,Cancer,initial,2016-04-18,GCST003420,Colorectal cancer
12103,European,166205.0,27089181.0,Okbay A,Other measurement,initial,2016-04-18,GCST003767,Life satisfaction
12319,European,262097.0,27089180.0,Day FR,Other measurement,replication,2016-04-18,GCST007336,Age at first birth
11455,European,66310.0,27089180.0,Day FR,Other measurement,initial,2016-04-18,GCST007336,Age at first birth
12162,European,180866.0,27089181.0,Okbay A,"Neurological disorder, Other measurement",initial,2016-04-18,GCST003769,Depression
12129,European,170911.0,27089181.0,Okbay A,"Neurological disorder, Other measurement",initial,2016-04-18,GCST003770,Neuroticism
11901,European,125667.0,27089180.0,Day FR,Other measurement,initial,2016-04-18,GCST007335,Age at first sexual intercourse
12160,European,180281.0,27089181.0,Okbay A,Other measurement,initial,2016-04-18,GCST003768,Positive affect
8248,European,4077.0,28459102.0,Zhang S,Other trait,initial,2016-04-20,GCST004198,Severe gingival inflammation
11895,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003588,Cancer (pleiotropy)
11894,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer
8278,European,4163.0,27098658.0,Muller-Calleja N,Other measurement,initial,2016-04-21,GCST003563,Presence of antiphospholipid antibodies
9619,European,9314.0,27106561.0,Cornelis MC,"Biological process, Other measurement",initial,2016-04-23,GCST003489,Food addiction
94,African,350.0,27114598.0,Liu C,"Cancer, Digestive system disorder",initial,2016-04-25,GCST003501,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
1728,Asian,99.0,27114598.0,Liu C,"Cancer, Digestive system disorder",initial,2016-04-25,GCST003501,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
7757,European,3069.0,27114598.0,Liu C,"Cancer, Digestive system disorder",initial,2016-04-25,GCST003501,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
13035,Hispanic or Latin American,1177.0,27114598.0,Liu C,"Cancer, Digestive system disorder",initial,2016-04-25,GCST003501,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
10469,European,19291.0,27117709.0,Couch FJ,Cancer,initial,2016-04-27,GCST003842,Breast cancer (estrogen-receptor negative)
10470,European,19291.0,27117709.0,Couch FJ,Cancer,initial,2016-04-27,GCST003845,Breast cancer
11266,European,49801.0,27117709.0,Couch FJ,Cancer,replication,2016-04-27,GCST003842,Breast cancer (estrogen-receptor negative)
11449,European,65053.0,27117709.0,Couch FJ,Cancer,replication,2016-04-27,GCST003845,Breast cancer
5967,European,874.0,27126917.0,Spada J,Other measurement,initial,2016-04-29,GCST003518,Daytime sleep phenotypes
6066,European,941.0,27126917.0,Spada J,Other measurement,initial,2016-04-29,GCST003542,Night sleep phenotypes
8655,European,5152.0,26651848.0,Rivera NV,Other disease,replication,2016-05-01,GCST005540,Sarcoidosis (Lofgren's syndrome)
7517,European,2593.0,26651848.0,Rivera NV,Other disease,initial,2016-05-01,GCST005543,Sarcoidosis (non-Lofgren's syndrome)
952,African American or Afro-Caribbean,1657.0,26651848.0,Rivera NV,Other disease,replication,2016-05-01,GCST005543,Sarcoidosis (non-Lofgren's syndrome)
8804,European,5664.0,26651848.0,Rivera NV,Other disease,replication,2016-05-01,GCST005543,Sarcoidosis (non-Lofgren's syndrome)
5342,European,477.0,26651848.0,Rivera NV,Other disease,replication,2016-05-01,GCST005541,Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)
3194,Asian,2561.0,26663301.0,Lessard CJ,Immune system disorder,replication,2016-05-01,GCST003599,Systemic lupus erythematosus
7462,European,2537.0,26651848.0,Rivera NV,Other disease,initial,2016-05-01,GCST005542,Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations)
6233,European,1048.0,26651848.0,Rivera NV,Other disease,initial,2016-05-01,GCST005541,Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)
3642,Asian,5420.0,26663301.0,Lessard CJ,Immune system disorder,initial,2016-05-01,GCST003599,Systemic lupus erythematosus
7356,European,2370.0,26651848.0,Rivera NV,Other disease,initial,2016-05-01,GCST005540,Sarcoidosis (Lofgren's syndrome)
9939,European,11756.0,27135401.0,Cheng TH,Cancer,initial,2016-05-02,GCST003524,Endometrial cancer
10933,European,33125.0,27135401.0,Cheng TH,Cancer,replication,2016-05-02,GCST003524,Endometrial cancer
9927,European,11626.0,27135401.0,Cheng TH,Cancer,initial,2016-05-02,GCST003525,Endometrial endometrioid carcinoma
10906,European,32153.0,27135401.0,Cheng TH,Cancer,replication,2016-05-02,GCST003525,Endometrial endometrioid carcinoma
8670,European,5208.0,27157822.0,Hallberg P,"Response to drug, Other trait",initial,2016-05-03,GCST003527,Anti-thyroid drug induced agranulocytosis
5609,European,623.0,27143689.0,Hertz DL,"Cancer, Neurological disorder, Response to drug",initial,2016-05-03,GCST003672,Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer
8731,European,5392.0,27157822.0,Hallberg P,"Other trait, Biological process",initial,2016-05-03,GCST003526,Non-chemotherapy drug induced agranulocytosis
876,African American or Afro-Caribbean,1227.0,27142222.0,White MJ,"Other disease, Other measurement",initial,2016-05-03,GCST003482,Asthma (childhood onset)
8306,European,4242.0,27142678.0,Amin N,Other measurement,initial,2016-05-04,GCST003481,Sleep latency
6094,European,958.0,27445529.0,Berube JC,Other disease,replication,2016-05-04,GCST003521,Asthma
10867,European,30377.0,27142678.0,Amin N,Other measurement,replication,2016-05-04,GCST003481,Sleep latency
5137,European,360.0,27445529.0,Berube JC,Other disease,initial,2016-05-04,GCST003521,Asthma
883,African American or Afro-Caribbean,1233.0,27151647.0,Chen G,Other measurement,initial,2016-05-05,GCST003538,Alcohol dependence symptom count
7649,European,2828.0,27149122.0,Smith JG,"Other measurement, Cardiovascular disease",initial,2016-05-05,GCST003539,Mortality in heart failure
12393,European,300945.0,27132594.0,Mbarek H,Biological process,replication,2016-05-05,GCST004413,Spontaneous dizygotic twinning
4181,Asian,12204.0,27145994.0,Wang M,Cancer,replication,2016-05-05,GCST003494,Colorectal cancer
10185,European,14933.0,27132594.0,Mbarek H,Biological process,initial,2016-05-05,GCST004413,Spontaneous dizygotic twinning
3122,Asian,2329.0,27145994.0,Wang M,Cancer,initial,2016-05-05,GCST003494,Colorectal cancer
6484,European,1300.0,27149984.0,Degenhardt F,Other measurement,initial,2016-05-05,GCST003523,Coenzyme Q10 levels
7146,European,2122.0,27145994.0,Wang M,Cancer,replication,2016-05-05,GCST003494,Colorectal cancer
7525,European,2605.0,27151647.0,Chen G,Other measurement,initial,2016-05-05,GCST003538,Alcohol dependence symptom count
6962,European,1870.0,27149122.0,Smith JG,"Other measurement, Cardiovascular disease",replication,2016-05-05,GCST003539,Mortality in heart failure
2811,Asian,1693.0,27153935.0,Zhang CE,Neurological disorder,initial,2016-05-06,GCST003522,Dermatomyositis
13693,Other/Mixed,26.0,27173062.0,Azad AK,"Other measurement, Cancer",initial,2016-05-09,GCST003541,Survival in head and neck cancer
13695,Other/Mixed,28.0,27173062.0,Azad AK,"Other measurement, Cancer",replication,2016-05-09,GCST003541,Survival in head and neck cancer
5332,European,470.0,27173062.0,Azad AK,"Other measurement, Cancer",replication,2016-05-09,GCST003541,Survival in head and neck cancer
13480,Hispanic or Latin American,12282.0,27159506.0,Dunn EC,"Other measurement, Other trait",initial,2016-05-09,GCST003562,Anxiety
412,African American or Afro-Caribbean,11.0,27173062.0,Azad AK,"Other measurement, Cancer",replication,2016-05-09,GCST003541,Survival in head and neck cancer
13391,Hispanic or Latin American,8195.0,27159506.0,Dunn EC,"Other measurement, Other trait",replication,2016-05-09,GCST003562,Anxiety
1664,Asian,57.0,27173062.0,Azad AK,"Other measurement, Cancer",replication,2016-05-09,GCST003541,Survival in head and neck cancer
5382,European,489.0,27173062.0,Azad AK,"Other measurement, Cancer",initial,2016-05-09,GCST003541,Survival in head and neck cancer
741,African American or Afro-Caribbean,667.0,27167565.0,Stein MB,Neurological disorder,replication,2016-05-11,GCST003495,Post-traumatic stress disorder
8609,European,5049.0,27167565.0,Stein MB,Neurological disorder,initial,2016-05-11,GCST003495,Post-traumatic stress disorder
13039,Hispanic or Latin American,1242.0,27167565.0,Stein MB,Neurological disorder,replication,2016-05-11,GCST003495,Post-traumatic stress disorder
903,African American or Afro-Caribbean,1312.0,27167565.0,Stein MB,Neurological disorder,initial,2016-05-11,GCST003495,Post-traumatic stress disorder
8220,European,4007.0,27167565.0,Stein MB,Neurological disorder,replication,2016-05-11,GCST003495,Post-traumatic stress disorder
13060,Hispanic or Latin American,1413.0,27167565.0,Stein MB,Neurological disorder,initial,2016-05-11,GCST003495,Post-traumatic stress disorder
1805,Asian,157.0,27171184.0,Kuo HC,"Immune system disorder, Cardiovascular disease",initial,2016-05-12,GCST003560,Coronary artery aneurysm in Kawasaki disease
2389,Asian,786.0,27191271.0,Hu Q,Cardiovascular disease,initial,2016-05-13,GCST003561,Coronary artery disease
953,African American or Afro-Caribbean,1662.0,27393504.0,Zanetti KA,Cancer,replication,2016-05-13,GCST003775,Lung cancer
927,African American or Afro-Caribbean,1448.0,27393504.0,Zanetti KA,Cancer,replication,2016-05-13,GCST003776,Lung adenocarcinoma
1244,African American or Afro-Caribbean,4340.0,27393504.0,Zanetti KA,Cancer,initial,2016-05-13,GCST003776,Lung adenocarcinoma
1260,African American or Afro-Caribbean,4737.0,27393504.0,Zanetti KA,Other measurement,initial,2016-05-13,GCST003779,Smoking behaviour (cigarettes smoked per day)
1230,African American or Afro-Caribbean,4001.0,27393504.0,Zanetti KA,Cancer,initial,2016-05-13,GCST003777,Squamous cell lung carcinoma
4046,Asian,9127.0,27191271.0,Hu Q,Cardiovascular disease,replication,2016-05-13,GCST003561,Coronary artery disease
1280,African American or Afro-Caribbean,5339.0,27393504.0,Zanetti KA,Cancer,initial,2016-05-13,GCST003775,Lung cancer
1207,African American or Afro-Caribbean,3777.0,27393504.0,Zanetti KA,Other measurement,initial,2016-05-13,GCST003778,Smoking status (current vs former)
907,African American or Afro-Caribbean,1329.0,27393504.0,Zanetti KA,Cancer,replication,2016-05-13,GCST003777,Squamous cell lung carcinoma
11514,European,71489.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003989,Chin dimples
12069,European,157242.0,27182965.0,Pickrell JK,Other disease,initial,2016-05-16,GCST003987,Asthma
11442,European,64143.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003998,Joint mobility (Beighton score)
11551,European,76831.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003993,Menarche (age at onset)
11747,European,99695.0,27182965.0,Pickrell JK,Other trait,initial,2016-05-16,GCST003992,Photic sneeze reflex
12449,European,334141.0,27182965.0,Pickrell JK,Neurological disorder,initial,2016-05-16,GCST003984,Parkinson's disease
12148,European,173421.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003995,Tonsillectomy
11354,European,55871.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003994,Age at voice drop
11492,European,69284.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003996,Monobrow
10971,European,33790.0,27182965.0,Pickrell JK,Body measurement,initial,2016-05-16,GCST003985,Breast size
12347,European,283985.0,27182965.0,Pickrell JK,Cardiovascular disease,initial,2016-05-16,GCST003986,Migraine
10365,European,17500.0,27182965.0,Pickrell JK,"Other measurement, Other disease",initial,2016-05-16,GCST003983,Male-pattern baldness
12161,European,180741.0,27182965.0,Pickrell JK,Immune system disorder,initial,2016-05-16,GCST003990,Allergy
11884,European,121810.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003991,Childhood ear infection
12180,European,191843.0,27182965.0,Pickrell JK,Other trait,initial,2016-05-16,GCST003997,Myopia
11950,European,134641.0,27182965.0,Pickrell JK,Other disease,initial,2016-05-16,GCST003988,Hypothyroidism
11459,European,67023.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003999,Nose size
11374,European,56799.0,27189021.0,Cook JP,Metabolic disorder,initial,2016-05-18,GCST003619,Type 2 diabetes
1191,African American or Afro-Caribbean,3571.0,27189021.0,Cook JP,Metabolic disorder,initial,2016-05-18,GCST003619,Type 2 diabetes
10296,European,16546.0,27193031.0,Marquez A,Immune system disorder,initial,2016-05-18,GCST003620,Systemic lupus erythematosus or rheumatoid arthritis
11298,European,52107.0,27193031.0,Marquez A,Immune system disorder,replication,2016-05-18,GCST003620,Systemic lupus erythematosus or rheumatoid arthritis
3558,Asian,4735.0,27189021.0,Cook JP,Metabolic disorder,initial,2016-05-18,GCST003619,Type 2 diabetes
13336,Hispanic or Latin American,6499.0,27189021.0,Cook JP,Metabolic disorder,initial,2016-05-18,GCST003619,Type 2 diabetes
11489,European,69033.0,27189021.0,Cook JP,Metabolic disorder,replication,2016-05-18,GCST003619,Type 2 diabetes
13317,Hispanic or Latin American,5958.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003633,middle facial morphology traits (ordinal measurement)
13319,Hispanic or Latin American,5958.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003637,facial morphology traits (multivariate analysis)
13318,Hispanic or Latin American,5958.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003634,lower facial morphology traits (ordinal measurement)
2952,Asian,1922.0,27195708.0,Scott WR,"Body measurement, Other measurement",replication,2016-05-19,GCST003564,Waist-to-hip ratio adjusted for body mass index
13167,Hispanic or Latin American,2955.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003635,middle facial morphology traits (quantitative measurement)
13168,Hispanic or Latin American,2955.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003636,lower facial morphology traits (quantitative measurement)
3286,Asian,2941.0,27195777.0,Sano M,Cardiovascular measurement,replication,2016-05-19,GCST003630,Left ventricular QRS voltage
13320,Hispanic or Latin American,5958.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003638,upper facial morphology traits (ordinal measurement)
3307,Asian,2994.0,27195777.0,Sano M,Cardiovascular measurement,initial,2016-05-19,GCST003630,Left ventricular QRS voltage
4120,Asian,10318.0,27195708.0,Scott WR,"Body measurement, Other measurement",initial,2016-05-19,GCST003564,Waist-to-hip ratio adjusted for body mass index
12893,Hispanic or Latin American,501.0,27193062.0,Adhikari K,Other measurement,replication,2016-05-19,GCST003633,middle facial morphology traits (ordinal measurement)
4934,European,221.0,27203581.0,Sousa I,Other trait,initial,2016-05-20,GCST003618,Primary spontaneous pneumothorax
5470,European,525.0,27203581.0,Sousa I,Other trait,replication,2016-05-20,GCST003618,Primary spontaneous pneumothorax
3655,Asian,5537.0,27519822.0,Power RA,Neurological disorder,replication,2016-05-24,GCST003558,Major depressive disorder
11765,European,104402.0,27519822.0,Power RA,Neurological disorder,replication,2016-05-24,GCST003558,Major depressive disorder
9925,European,11611.0,27519822.0,Power RA,Neurological disorder,initial,2016-05-24,GCST003558,Major depressive disorder
12340,European,280007.0,27225129.0,Okbay A,Other measurement,initial,2016-05-26,GCST003677,Educational attainment (college completion)
12561,European,405072.0,27225129.0,Okbay A,Other measurement,initial,2016-05-26,GCST003676,Educational attainment (years of education)
4820,European,161.0,28090565.0,Tsai EA,"Neurological disorder, Digestive system disorder",initial,2016-05-26,GCST003616,Liver disease severity in Alagille syndrome
3119,Asian,2308.0,27244555.0,Li Y,"Digestive system disorder, Immune system disorder",initial,2016-05-31,GCST003615,Susceptibility to persistent hepatitis B virus infection
8311,European,4256.0,27244217.0,Fogh I,"Other measurement, Neurological disorder",initial,2016-05-31,GCST003632,Survival in sporadic amyotrophic lateral sclerosis
3856,Asian,7261.0,27244555.0,Li Y,"Digestive system disorder, Immune system disorder",replication,2016-05-31,GCST003615,Susceptibility to persistent hepatitis B virus infection
5485,European,539.0,27304844.0,Khong JJ,"Neurological disorder, Immune system disorder",replication,2016-06-01,GCST003640,Thyroid-associated orbitopathy in graves' disease
5219,European,412.0,27304844.0,Khong JJ,"Neurological disorder, Immune system disorder",initial,2016-06-01,GCST003640,Thyroid-associated orbitopathy in graves' disease
256,African,3106.0,27236921.0,Rautanen A,Other disease,initial,2016-06-02,GCST003649,Pneumococcal bacteremia
195,African,1449.0,27236921.0,Rautanen A,Other disease,replication,2016-06-02,GCST003649,Pneumococcal bacteremia
228,African,1770.0,27236921.0,Rautanen A,Other disease,replication,2016-06-02,GCST003650,Bacteremia
272,African,4213.0,27236921.0,Rautanen A,Other disease,initial,2016-06-02,GCST003650,Bacteremia
7439,European,2511.0,27262462.0,Teerlink CC,"Cancer, Other measurement",initial,2016-06-04,GCST003585,Aggressive prostate cancer
8172,European,3893.0,27262462.0,Teerlink CC,Cancer,initial,2016-06-04,GCST003586,Prostate cancer
7562,European,2671.0,27285765.0,Chen D,Cancer,replication,2016-06-07,GCST003565,Cervical cancer
8902,European,6076.0,27285765.0,Chen D,Cancer,initial,2016-06-07,GCST003565,Cervical cancer
13827,Other/Mixed,230.0,28025368.0,Janicki PK,Neurological disorder,replication,2016-06-10,GCST003930,Complex regional pain syndrome
13826,Other/Mixed,230.0,28025368.0,Janicki PK,Neurological disorder,initial,2016-06-10,GCST003930,Complex regional pain syndrome
2318,Asian,706.0,27296613.0,Salinas YD,"Body measurement, Other measurement",initial,2016-06-13,GCST003647,Body mass index
13038,Hispanic or Latin American,1235.0,27296613.0,Salinas YD,"Body measurement, Other measurement",initial,2016-06-13,GCST003647,Body mass index
940,African American or Afro-Caribbean,1549.0,27296613.0,Salinas YD,"Body measurement, Other measurement",initial,2016-06-13,GCST003647,Body mass index
7373,European,2395.0,27296613.0,Salinas YD,"Body measurement, Other measurement",initial,2016-06-13,GCST003647,Body mass index
1333,African American or Afro-Caribbean,6871.0,27296613.0,Salinas YD,"Body measurement, Other measurement",replication,2016-06-13,GCST003647,Body mass index
13181,Hispanic or Latin American,3379.0,27296613.0,Salinas YD,"Body measurement, Other measurement",replication,2016-06-13,GCST003647,Body mass index
6599,European,1431.0,27315593.0,Lang M,Neurological disorder,initial,2016-06-14,GCST003648,Pathological gambling
12868,Hispanic or Latin American,446.0,27311723.0,Pei YF,Other measurement,replication,2016-06-16,GCST003559,Bone mineral density (hip)
9110,European,6912.0,27311723.0,Pei YF,Other measurement,initial,2016-06-16,GCST003559,Bone mineral density (hip)
792,African American or Afro-Caribbean,845.0,27311723.0,Pei YF,Other measurement,replication,2016-06-16,GCST003559,Bone mineral density (hip)
6110,European,971.0,27311723.0,Pei YF,Other measurement,replication,2016-06-16,GCST003559,Bone mineral density (hip)
8936,European,6226.0,27386562.0,Andlauer TF,Immune system disorder,replication,2016-06-17,GCST003566,Multiple sclerosis
10208,European,15283.0,27386562.0,Andlauer TF,Immune system disorder,initial,2016-06-17,GCST003566,Multiple sclerosis
12016,European,147790.0,27322543.0,Gormley P,Cardiovascular disease,initial,2016-06-20,GCST003721,Migraine without aura
12525,European,375752.0,27322543.0,Gormley P,Cardiovascular disease,initial,2016-06-20,GCST003720,Migraine
12048,European,151215.0,27322543.0,Gormley P,Cardiovascular disease,initial,2016-06-20,GCST003722,Migraine with aura
11008,European,34950.0,27329760.0,Hou L,Neurological disorder,initial,2016-06-21,GCST003724,Bipolar disorder
8712,European,5305.0,27329760.0,Hou L,Neurological disorder,replication,2016-06-21,GCST003724,Bipolar disorder
10792,European,27581.0,27325353.0,Matteini AM,Other measurement,initial,2016-06-21,GCST004494,Hand grip strength
5413,European,502.0,27327535.0,Laville V,Other measurement,initial,2016-06-21,GCST003591,Severity of facial solar lentigines
9715,European,9822.0,27325353.0,Matteini AM,Other measurement,initial,2016-06-21,GCST004493,Lower body strength
6692,European,1546.0,27347659.0,Vaysse A,"Cancer, Other measurement",replication,2016-06-27,GCST003639,Breslow thickness in cutaneous melanoma
4289,Asian,15148.0,27354352.0,Han MR,Cancer,replication,2016-06-27,GCST003520,Breast cancer
4248,Asian,13905.0,27354352.0,Han MR,Cancer,initial,2016-06-27,GCST003520,Breast cancer
6105,European,966.0,27347659.0,Vaysse A,"Cancer, Other measurement",initial,2016-06-27,GCST003639,Breslow thickness in cutaneous melanoma
11929,European,130990.0,27362418.0,Zhang H,Metabolic disorder,initial,2016-06-30,GCST005716,Type 2 diabetes
4340,Asian,18817.0,27362418.0,Zhang H,Metabolic disorder,replication,2016-06-30,GCST005716,Type 2 diabetes
9193,European,7350.0,27363682.0,Mitchell JS,Cancer,replication,2016-07-01,GCST004483,Multiple myeloma
6736,European,1594.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",initial,2016-07-01,GCST003487,Response to fenofibrate (total cholesterol levels)
12283,European,241704.0,27363682.0,Mitchell JS,Cancer,initial,2016-07-01,GCST004483,Multiple myeloma
523,African American or Afro-Caribbean,138.0,27002377.0,Irvin MR,"Response to drug, Lipid or lipoprotein measurement",replication,2016-07-01,GCST003488,Response to fenofibrate (triglyceride levels)
6737,European,1594.0,27002377.0,Irvin MR,"Response to drug, Lipid or lipoprotein measurement",initial,2016-07-01,GCST003488,Response to fenofibrate (triglyceride levels)
6734,European,1594.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",initial,2016-07-01,GCST003485,Response to fenofibrate (HDL cholesterol levels)
521,African American or Afro-Caribbean,138.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003486,Response to fenofibrate (LDL cholesterol levels)
12837,Hispanic or Latin American,350.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003485,Response to fenofibrate (HDL cholesterol levels)
522,African American or Afro-Caribbean,138.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003487,Response to fenofibrate (total cholesterol levels)
12838,Hispanic or Latin American,350.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003486,Response to fenofibrate (LDL cholesterol levels)
6735,European,1594.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",initial,2016-07-01,GCST003486,Response to fenofibrate (LDL cholesterol levels)
12839,Hispanic or Latin American,350.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003487,Response to fenofibrate (total cholesterol levels)
12840,Hispanic or Latin American,350.0,27002377.0,Irvin MR,"Response to drug, Lipid or lipoprotein measurement",replication,2016-07-01,GCST003488,Response to fenofibrate (triglyceride levels)
520,African American or Afro-Caribbean,138.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003485,Response to fenofibrate (HDL cholesterol levels)
14172,Other/Mixed,2672.0,27523435.0,Mosteller M,"Response to drug, Other measurement, Other disease",initial,2016-07-05,GCST003567,Response to inhaled corticosteroid treatment in asthma (change in FEV1)
6768,European,1634.0,27387956.0,Murk W,Other disease,replication,2016-07-07,GCST003682,Asthma (SNP x SNP interaction)
8331,European,4305.0,27397699.0,Pei YF,Other measurement,initial,2016-07-07,GCST003654,Bone mineral density (Ward's triangle area)
12869,Hispanic or Latin American,446.0,27397699.0,Pei YF,Other measurement,initial,2016-07-07,GCST003654,Bone mineral density (Ward's triangle area)
2760,Asian,1579.0,27397699.0,Pei YF,Other measurement,initial,2016-07-07,GCST003654,Bone mineral density (Ward's triangle area)
6759,European,1625.0,27387956.0,Murk W,Other disease,initial,2016-07-07,GCST003682,Asthma (SNP x SNP interaction)
793,African American or Afro-Caribbean,845.0,27397699.0,Pei YF,Other measurement,initial,2016-07-07,GCST003654,Bone mineral density (Ward's triangle area)
7040,European,1985.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",initial,2016-07-11,GCST003653,Parkinson's disease (age of onset)
5762,European,737.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",replication,2016-07-11,GCST003652,"Parkinson's disease (familial, age at onset)"
9929,European,11675.0,27399966.0,Morris DL,Immune system disorder,replication,2016-07-11,GCST003622,Systemic lupus erythematosus
9865,European,10995.0,27399966.0,Morris DL,Immune system disorder,initial,2016-07-11,GCST003622,Systemic lupus erythematosus
3949,Asian,8117.0,27399966.0,Morris DL,Immune system disorder,replication,2016-07-11,GCST003622,Systemic lupus erythematosus
7768,European,3100.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",replication,2016-07-11,GCST003653,Parkinson's disease (age of onset)
6704,European,1554.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",initial,2016-07-11,GCST003651,"Parkinson's disease (non-familial, age at onset)"
5250,European,431.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",initial,2016-07-11,GCST003652,"Parkinson's disease (familial, age at onset)"
3588,Asian,5057.0,27399966.0,Morris DL,Immune system disorder,initial,2016-07-11,GCST003622,Systemic lupus erythematosus
7348,European,2363.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",replication,2016-07-11,GCST003651,"Parkinson's disease (non-familial, age at onset)"
8798,European,5649.0,27400856.0,Legge SE,"Response to drug, Neurological disorder, Other trait",initial,2016-07-12,GCST003628,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
7270,European,2267.0,27412012.0,Lamina C,Lipid or lipoprotein measurement,replication,2016-07-12,GCST003590,Apolipoprotein A-IV levels
10102,European,13813.0,27412012.0,Lamina C,Lipid or lipoprotein measurement,initial,2016-07-12,GCST003590,Apolipoprotein A-IV levels
6014,European,917.0,27412988.0,Tise CG,Other measurement,initial,2016-07-13,GCST003723,Serum sulfate level
10061,European,13354.0,27416945.0,Walford GA,"Body measurement, Other measurement",replication,2016-07-14,GCST003659,Modified Stumvoll Insulin Sensitivity Index (BMI interaction)
10062,European,13354.0,27416945.0,Walford GA,Other measurement,replication,2016-07-14,GCST005178,Modified Stumvoll Insulin Sensitivity Index
10014,European,12601.0,27418160.0,van 't Hof FN,Cardiovascular disease,initial,2016-07-14,GCST003683,"Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)"
10060,European,13354.0,27416945.0,Walford GA,"Body measurement, Other measurement",replication,2016-07-14,GCST003658,Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI)
10318,European,16753.0,27416945.0,Walford GA,Other measurement,initial,2016-07-14,GCST005178,Modified Stumvoll Insulin Sensitivity Index
10317,European,16753.0,27416945.0,Walford GA,"Body measurement, Other measurement",initial,2016-07-14,GCST003659,Modified Stumvoll Insulin Sensitivity Index (BMI interaction)
10316,European,16753.0,27416945.0,Walford GA,"Body measurement, Other measurement",initial,2016-07-14,GCST003658,Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI)
3224,Asian,2729.0,27424934.0,Choi HJ,Other measurement,initial,2016-07-15,GCST003612,Bone mineral density (femoral neck)
2752,Asian,1547.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003612,Bone mineral density (femoral neck)
7864,European,3237.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003610,Bone mineral density (spine)
7865,European,3237.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003611,Bone mineral density (total hip)
2751,Asian,1547.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003611,Bone mineral density (total hip)
3223,Asian,2729.0,27424934.0,Choi HJ,Other measurement,initial,2016-07-15,GCST003611,Bone mineral density (total hip)
2750,Asian,1547.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003610,Bone mineral density (spine)
7866,European,3237.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003612,Bone mineral density (femoral neck)
3222,Asian,2729.0,27424934.0,Choi HJ,Other measurement,initial,2016-07-15,GCST003610,Bone mineral density (spine)
9989,European,12343.0,27424798.0,Chahal HS,Cancer,replication,2016-07-18,GCST003655,Cutaneous squamous cell carcinoma
12353,European,287137.0,27424798.0,Chahal HS,Cancer,initial,2016-07-18,GCST003655,Cutaneous squamous cell carcinoma
3525,Asian,4562.0,27436580.0,Cui Q,Cancer,initial,2016-07-19,GCST003578,Nasopharyngeal carcinoma
4138,Asian,11054.0,27436580.0,Cui Q,Cancer,replication,2016-07-19,GCST003578,Nasopharyngeal carcinoma
6589,European,1409.0,27515689.0,Kerns SL,"Cancer, Biological process",initial,2016-07-20,GCST003582,"Response to radiotherapy in prostate cancer (toxicity, urinary frequency)"
6446,European,1245.0,27515689.0,Kerns SL,"Cancer, Biological process, Other trait",initial,2016-07-20,GCST003581,Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event)
9615,European,9291.0,27439200.0,Nieuwenhuis MA,Other disease,replication,2016-07-20,GCST003589,Bronchial hyperresponsiveness in asthma
6518,European,1346.0,27515689.0,Kerns SL,"Cancer, Biological process, Other disease",initial,2016-07-20,GCST003583,Response to radiotherapy in prostate cancer (overall toxicity)
6630,European,1487.0,27515689.0,Kerns SL,"Cancer, Biological process",initial,2016-07-20,GCST003584,"Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)"
9085,European,6845.0,26202629.0,Johnson EO,Neurological disorder,initial,2016-07-23,GCST003601,Drug abuse
767,African American or Afro-Caribbean,755.0,26202629.0,Johnson EO,Neurological disorder,replication,2016-07-23,GCST003601,Drug abuse
6308,European,1131.0,26202629.0,Johnson EO,Neurological disorder,replication,2016-07-23,GCST003601,Drug abuse
1202,African American or Afro-Caribbean,3742.0,26202629.0,Johnson EO,Neurological disorder,initial,2016-07-23,GCST003601,Drug abuse
6660,European,1528.0,27453504.0,Rhee EP,Other measurement,replication,2016-07-25,GCST009018,Blood metabolite levels
14153,Other/Mixed,2102.0,27455349.0,Minster RL,"Body measurement, Other measurement",replication,2016-07-25,GCST005181,Body mass index
14194,Other/Mixed,3072.0,27455349.0,Minster RL,"Body measurement, Other measurement",initial,2016-07-25,GCST005181,Body mass index
7119,European,2076.0,27453504.0,Rhee EP,Other measurement,initial,2016-07-25,GCST009018,Blood metabolite levels
11028,European,36052.0,27455348.0,van Rheenen W,Neurological disorder,initial,2016-07-25,GCST004692,Amyotrophic lateral sclerosis
8720,European,5346.0,27455348.0,van Rheenen W,Neurological disorder,replication,2016-07-25,GCST004692,Amyotrophic lateral sclerosis
5025,European,289.0,27339598.0,Ulveling D,"Other disease, Digestive system disorder, Other trait",initial,2016-07-29,GCST003606,Liver fibrosis severity in HIV/hepatitis C co-infection
2368,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006112,Diastolic blood pressure x sodium interaction (1df test)
2370,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006114,Mean arterial pressure x sodium interaction (2df test)
8502,European,4835.0,27492634.0,Du Y,Cancer,initial,2016-08-01,GCST003786,Small intestine neuroendocrine tumor
2367,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006111,Diastolic blood pressure x sodium interaction (2df test)
2371,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006115,Systolic blood pressure x sodium interaction (1df test)
2373,Asian,775.0,27271309.0,Li C,"Other measurement, Cardiovascular measurement",replication,2016-08-01,GCST006117,Pulse pressure x sodium interaction (1df test)
2374,Asian,775.0,27271309.0,Li C,"Other measurement, Cardiovascular measurement",replication,2016-08-01,GCST006118,Pulse pressure x sodium interaction (2df test)
12050,European,152127.0,27479909.0,Hyde CL,Neurological disorder,replication,2016-08-01,GCST006041,Major depressive disorder
8457,European,4698.0,27492634.0,Du Y,Cancer,initial,2016-08-01,GCST003788,Pancreatic neuroendocrine tumor
2369,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006113,Systolic blood pressure x sodium interaction (2df test)
2372,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006116,Mean arterial pressure x sodium interaction (1df test)
2923,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006113,Systolic blood pressure x sodium interaction (2df test)
10111,European,13952.0,27579533.0,Zhang M,Cancer,initial,2016-08-01,GCST003758,Pancreatic cancer
8727,European,5374.0,27492634.0,Du Y,Cancer,initial,2016-08-01,GCST003785,Neuroendocrine tumor
12436,European,326113.0,27479909.0,Hyde CL,Neurological disorder,initial,2016-08-01,GCST006041,Major depressive disorder
2928,Asian,1876.0,27271309.0,Li C,"Other measurement, Cardiovascular measurement",initial,2016-08-01,GCST006118,Pulse pressure x sodium interaction (2df test)
2927,Asian,1876.0,27271309.0,Li C,"Other measurement, Cardiovascular measurement",initial,2016-08-01,GCST006117,Pulse pressure x sodium interaction (1df test)
2926,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006116,Mean arterial pressure x sodium interaction (1df test)
2925,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006115,Systolic blood pressure x sodium interaction (1df test)
2924,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006114,Mean arterial pressure x sodium interaction (2df test)
2922,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006112,Diastolic blood pressure x sodium interaction (1df test)
2921,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006111,Diastolic blood pressure x sodium interaction (2df test)
8441,European,4670.0,27492634.0,Du Y,Cancer,initial,2016-08-01,GCST003787,Bronchial neuroendocrine tumor
4373,Asian,21472.0,27480026.0,Liu X,Cardiovascular disease,replication,2016-08-02,GCST003613,Hypertension
2194,Asian,518.0,27480026.0,Liu X,Cardiovascular disease,initial,2016-08-02,GCST003613,Hypertension
5278,European,437.0,27488534.0,Patel YM,"Biological process, Other measurement",initial,2016-08-03,GCST003629,nicotine metabolite ratio in current smokers
13859,Other/Mixed,311.0,27488534.0,Patel YM,"Biological process, Other measurement",initial,2016-08-03,GCST003629,nicotine metabolite ratio in current smokers
12879,Hispanic or Latin American,453.0,27488534.0,Patel YM,"Biological process, Other measurement",initial,2016-08-03,GCST003629,nicotine metabolite ratio in current smokers
659,African American or Afro-Caribbean,364.0,27488534.0,Patel YM,"Biological process, Other measurement",initial,2016-08-03,GCST003629,nicotine metabolite ratio in current smokers
2287,Asian,674.0,27488534.0,Patel YM,"Biological process, Other measurement",initial,2016-08-03,GCST003629,nicotine metabolite ratio in current smokers
6586,European,1407.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003684,Gestational age at birth in labor-initiated deliveries (maternal effect)
6293,European,1109.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003686,Gestational age at birth (child effect)
6868,European,1743.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003688,Gestational age at birth (maternal effect)
4944,European,225.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003689,Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)
5978,European,884.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003687,Gestational age at birth in labor-initiated deliveries (child effect)
5097,European,336.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003685,Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect)
11714,European,91306.0,27494321.0,Jones SE,Other measurement,initial,2016-08-05,GCST006685,Sleep duration (oversleepers)
11104,European,39082.0,27494321.0,Jones SE,Other measurement,initial,2016-08-05,GCST003840,Sleep duration (oversleepers vs undersleepers)
11799,European,110188.0,27494321.0,Jones SE,Other measurement,initial,2016-08-05,GCST006686,Sleep duration (undersleepers)
11830,European,114765.0,27494321.0,Jones SE,Biological process,initial,2016-08-05,GCST003838,Morning vs. evening chronotype
11918,European,127898.0,27494321.0,Jones SE,"Biological process, Other measurement",initial,2016-08-05,GCST003837,Chronotype
11915,European,127573.0,27494321.0,Jones SE,Other measurement,initial,2016-08-05,GCST003839,Sleep duration
2808,Asian,1686.0,27503288.0,Song IW,Neurological disorder,initial,2016-08-08,GCST003604,Sjgren's syndrome
4267,Asian,14610.0,27503288.0,Song IW,Neurological disorder,replication,2016-08-08,GCST003604,Sjgren's syndrome
3585,Asian,5030.0,27501781.0,Shiraishi K,Cancer,initial,2016-08-09,GCST003605,EGFR mutation-positive lung adenocarcinoma
4237,Asian,13301.0,27501781.0,Shiraishi K,Cancer,replication,2016-08-09,GCST003605,EGFR mutation-positive lung adenocarcinoma
3270,Asian,2876.0,27506219.0,Wang W,Other disease,replication,2016-08-09,GCST003819,Endometriosis
1731,Asian,100.0,27506219.0,Wang W,Other disease,initial,2016-08-09,GCST003819,Endometriosis
10559,European,21271.0,27527254.0,Gharahkhani P,Cancer,initial,2016-08-12,GCST003739,Esophageal adenocarcinoma
10662,European,23326.0,27527254.0,Gharahkhani P,Digestive system disorder,initial,2016-08-12,GCST003738,Barrett's esophagus
10789,European,27438.0,27527254.0,Gharahkhani P,"Digestive system disorder, Cancer",initial,2016-08-12,GCST003740,Barrett's esophagus  or Esophageal adenocarcinoma
2002,Asian,320.0,27529621.0,Otowa T,Other measurement,initial,2016-08-16,GCST003835,Depressive symptoms (stressful life events interaction)
2001,Asian,320.0,27529621.0,Otowa T,"Neurological disorder, Other measurement",initial,2016-08-16,GCST003836,Depressive symptoms
2113,Asian,439.0,27529621.0,Otowa T,"Neurological disorder, Other measurement",replication,2016-08-16,GCST003836,Depressive symptoms
2114,Asian,439.0,27529621.0,Otowa T,Other measurement,replication,2016-08-16,GCST003835,Depressive symptoms (stressful life events interaction)
6877,European,1751.0,27531626.0,Polimanti R,"Other measurement, Neurological disorder",initial,2016-08-17,GCST003860,Risky sexual behaviors (alcohol dependence interaction)
1027,African American or Afro-Caribbean,2173.0,27531626.0,Polimanti R,"Other measurement, Neurological disorder",initial,2016-08-17,GCST003860,Risky sexual behaviors (alcohol dependence interaction)
9801,European,10554.0,27568811.0,Marinelli M,Other measurement,initial,2016-08-19,GCST003741,Sleep duration
10333,European,17044.0,27539887.0,Chahal HS,Cancer,replication,2016-08-19,GCST003726,Basal cell carcinoma
6448,European,1250.0,27568811.0,Marinelli M,Other measurement,replication,2016-08-19,GCST003741,Sleep duration
12354,European,287197.0,27539887.0,Chahal HS,Cancer,initial,2016-08-19,GCST003726,Basal cell carcinoma
6912,European,1795.0,27548383.0,Ortiz-Fernandez L,Cardiovascular disease,initial,2016-08-22,GCST007551,Behcet's disease
5756,European,735.0,27548383.0,Ortiz-Fernandez L,Cardiovascular disease,replication,2016-08-22,GCST007551,Behcet's disease
2819,Asian,1717.0,27545300.0,Hao J,"Body measurement, Other disease, Other measurement",initial,2016-08-22,GCST003727,Joint destruction and growth retardation
2306,Asian,700.0,27545300.0,Hao J,"Body measurement, Other disease, Other measurement",replication,2016-08-22,GCST003727,Joint destruction and growth retardation
8028,European,3516.0,27559109.0,Bustamante M,Other trait,replication,2016-08-23,GCST003623,diarrhoeal disease at age 2
8938,European,6233.0,27559109.0,Bustamante M,Other trait,initial,2016-08-23,GCST003624,diarrhoeal disease at age 2 with doctor diagnosis
8128,European,3768.0,27559109.0,Bustamante M,Other trait,replication,2016-08-23,GCST003626,diarrhoeal disease at age 1
8977,European,6403.0,27559109.0,Bustamante M,Other trait,initial,2016-08-23,GCST003625,diarrhoeal disease at age 1 with doctor diagnosis
9222,European,7465.0,27559109.0,Bustamante M,Other trait,replication,2016-08-23,GCST003625,diarrhoeal disease at age 1 with doctor diagnosis
8783,European,5608.0,27559109.0,Bustamante M,Other trait,initial,2016-08-23,GCST003623,diarrhoeal disease at age 2
8822,European,5758.0,27559109.0,Bustamante M,Other trait,initial,2016-08-23,GCST003626,diarrhoeal disease at age 1
9285,European,7722.0,27559109.0,Bustamante M,Other trait,replication,2016-08-23,GCST003624,diarrhoeal disease at age 2 with doctor diagnosis
1947,Asian,267.0,27558924.0,Kim HS,"Digestive system disorder, Other trait, Response to drug",initial,2016-08-24,GCST003603,Thiopurine-induced leukopenia in inflammatory bowel disease
2357,Asian,767.0,27558924.0,Kim HS,"Digestive system disorder, Other trait, Response to drug",replication,2016-08-24,GCST003603,Thiopurine-induced leukopenia in inflammatory bowel disease
7404,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003645,Lower facial height
5678,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003642,Eye morphology
3656,Asian,5546.0,27569725.0,Yang SK,"Digestive system disorder, Immune system disorder",initial,2016-08-25,GCST003602,Inflammatory bowel disease
5679,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003643,Nose morphology
7402,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003643,Nose morphology
5680,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003644,Lip morphology
3648,Asian,5480.0,27569725.0,Yang SK,"Digestive system disorder, Immune system disorder",replication,2016-08-25,GCST003602,Inflammatory bowel disease
5682,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003646,Facial depth
6412,European,1213.0,27561104.0,Pirastu N,"Biological process, Other measurement",initial,2016-08-25,GCST003621,Coffee consumption
7401,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003642,Eye morphology
7400,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003641,Cranial base width
7405,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003646,Facial depth
6828,European,1713.0,27561104.0,Pirastu N,"Biological process, Other measurement",replication,2016-08-25,GCST003621,Coffee consumption
5677,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003641,Cranial base width
7403,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003644,Lip morphology
5681,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003645,Lower facial height
12820,Hispanic or Latin American,251.0,27564568.0,Liu C,"Response to drug, Other measurement, Cancer",initial,2016-08-26,GCST003609,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
1665,Asian,57.0,27564568.0,Liu C,"Response to drug, Other measurement, Cancer",initial,2016-08-26,GCST003609,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
51,African,138.0,27564568.0,Liu C,"Response to drug, Other measurement, Cancer",initial,2016-08-26,GCST003609,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
5204,European,407.0,27564568.0,Liu C,"Response to drug, Other measurement, Cancer",initial,2016-08-26,GCST003609,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
1437,African American or Afro-Caribbean,10305.0,28580392.0,Taylor KC,Other disease,initial,2016-08-27,GCST004403,Bone fracture in osteoporosis
11138,European,40407.0,27577874.0,Evans DS,Cardiovascular measurement,initial,2016-08-29,GCST003598,QRS duration
1456,African American or Afro-Caribbean,13031.0,27577874.0,Evans DS,Cardiovascular measurement,initial,2016-08-29,GCST003598,QRS duration
6507,European,1328.0,27576016.0,Zhao B,"Other measurement, Other trait",initial,2016-08-30,GCST003656,Acute kidney injury in critical illness
6749,European,1612.0,27576016.0,Zhao B,"Other measurement, Other trait",replication,2016-08-30,GCST003656,Acute kidney injury in critical illness
1387,African American or Afro-Caribbean,8224.0,27588450.0,Mahajan A,Other measurement,initial,2016-09-01,GCST003790,Glomerular filtration rate
13527,Hispanic or Latin American,16325.0,27588450.0,Mahajan A,Other measurement,initial,2016-09-01,GCST003790,Glomerular filtration rate
12957,Hispanic or Latin American,743.0,27500523.0,Zhou K,"Response to drug, Other measurement, Metabolic disorder",replication,2016-09-01,GCST004522,Response to metformin in type 2 diabetes (HbA1c reduction)
9601,European,9184.0,27500523.0,Zhou K,"Response to drug, Other measurement, Metabolic disorder",replication,2016-09-01,GCST004522,Response to metformin in type 2 diabetes (HbA1c reduction)
10667,European,23553.0,27588450.0,Mahajan A,Other measurement,initial,2016-09-01,GCST003790,Glomerular filtration rate
10322,European,16769.0,27587472.0,Postmus I,"Lipid or lipoprotein measurement, Response to drug",initial,2016-09-01,GCST003617,Response to statins (HDL cholesterol change)
4391,Asian,23536.0,27588450.0,Mahajan A,Other measurement,initial,2016-09-01,GCST003790,Glomerular filtration rate
869,African American or Afro-Caribbean,1196.0,27500523.0,Zhou K,"Response to drug, Other measurement, Metabolic disorder",replication,2016-09-01,GCST004522,Response to metformin in type 2 diabetes (HbA1c reduction)
9862,European,10951.0,27587472.0,Postmus I,"Lipid or lipoprotein measurement, Response to drug",replication,2016-09-01,GCST003617,Response to statins (HDL cholesterol change)
6551,European,1373.0,27500523.0,Zhou K,"Response to drug, Other measurement, Metabolic disorder",initial,2016-09-01,GCST004522,Response to metformin in type 2 diabetes (HbA1c reduction)
2255,Asian,627.0,27500523.0,Zhou K,"Response to drug, Other measurement, Metabolic disorder",replication,2016-09-01,GCST004522,Response to metformin in type 2 diabetes (HbA1c reduction)
135,African,723.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003781,Breast cancer (estrogen-receptor positive)
184,African,1335.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003782,Breast cancer
1373,African American or Afro-Caribbean,8112.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003782,Breast cancer
1264,African American or Afro-Caribbean,4923.0,28171663.0,Huo D,Cancer,replication,2016-09-04,GCST003782,Breast cancer
1185,African American or Afro-Caribbean,3512.0,28171663.0,Huo D,Cancer,replication,2016-09-04,GCST003780,Breast cancer (estrogen-receptor negative)
1295,African American or Afro-Caribbean,5945.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003781,Breast cancer (estrogen-receptor positive)
1231,African American or Afro-Caribbean,4032.0,28171663.0,Huo D,Cancer,replication,2016-09-04,GCST003781,Breast cancer (estrogen-receptor positive)
1284,African American or Afro-Caribbean,5499.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003780,Breast cancer (estrogen-receptor negative)
133,African,666.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003780,Breast cancer (estrogen-receptor negative)
5652,European,656.0,27595289.0,Goyal RK,"Immune system disorder, Other measurement",initial,2016-09-05,GCST003942,Acute graft versus host disease in bone marrow transplantation (donor effect)
5537,European,579.0,27595289.0,Goyal RK,Immune system disorder,initial,2016-09-05,GCST003941,Acute graft versus host disease in bone marrow transplantation (recipient effect)
8354,European,4402.0,27601451.0,Sanders AE,Other measurement,replication,2016-09-06,GCST003744,Chronic periodontitis (mean interproximal clinical attachment level)
9986,European,12287.0,27476799.0,Nielson CM,Other measurement,initial,2016-09-06,GCST007014,Lumbar spine bone mineral density (trabecular)
808,African American or Afro-Caribbean,908.0,27601451.0,Sanders AE,Other measurement,replication,2016-09-06,GCST003744,Chronic periodontitis (mean interproximal clinical attachment level)
13434,Hispanic or Latin American,10935.0,27601451.0,Sanders AE,Other measurement,initial,2016-09-06,GCST003744,Chronic periodontitis (mean interproximal clinical attachment level)
9876,European,11080.0,27476799.0,Nielson CM,Other measurement,initial,2016-09-06,GCST007015,Lumbar spine bone mineral density (integral)
14222,Other/Mixed,4086.0,27599772.0,Ram R,"Metabolic disorder, Lipid or lipoprotein measurement",initial,2016-09-07,GCST003743,Hypertriglyceridemia
14114,Other/Mixed,1415.0,27599772.0,Ram R,"Metabolic disorder, Lipid or lipoprotein measurement",replication,2016-09-07,GCST003743,Hypertriglyceridemia
9579,European,8970.0,27611488.0,Almoguera B,Other disease,initial,2016-09-09,GCST003833,Adult asthma
10136,European,14247.0,27611488.0,Almoguera B,Other disease,initial,2016-09-09,GCST003831,Asthma
1281,African American or Afro-Caribbean,5372.0,27611488.0,Almoguera B,"Other disease, Other measurement",initial,2016-09-09,GCST003832,Asthma (childhood onset)
1344,African American or Afro-Caribbean,7397.0,27611488.0,Almoguera B,Other disease,initial,2016-09-09,GCST003831,Asthma
8691,European,5277.0,27611488.0,Almoguera B,"Other disease, Other measurement",initial,2016-09-09,GCST003832,Asthma (childhood onset)
990,African American or Afro-Caribbean,2025.0,27611488.0,Almoguera B,Other disease,initial,2016-09-09,GCST003833,Adult asthma
1061,African American or Afro-Caribbean,2600.0,27643478.0,Powers A,Other measurement,initial,2016-09-09,GCST003765,Emotional dysregulation
502,African American or Afro-Caribbean,96.0,28173075.0,Niu N,"Other measurement, Response to drug",initial,2016-09-11,GCST003791,Response to metformin (IC50)
1723,Asian,96.0,28173075.0,Niu N,"Other measurement, Response to drug",initial,2016-09-11,GCST003791,Response to metformin (IC50)
4748,European,96.0,28173075.0,Niu N,"Other measurement, Response to drug",initial,2016-09-11,GCST003791,Response to metformin (IC50)
11978,European,140886.0,27618452.0,Ehret GB,Other measurement,replication,2016-09-12,GCST006258,Diastolic blood pressure
11979,European,140886.0,27618452.0,Ehret GB,Other measurement,replication,2016-09-12,GCST006259,Systolic blood pressure
12202,European,201529.0,27618452.0,Ehret GB,Other measurement,initial,2016-09-12,GCST006259,Systolic blood pressure
12201,European,201529.0,27618452.0,Ehret GB,Other measurement,initial,2016-09-12,GCST006258,Diastolic blood pressure
8458,European,4698.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003802,Response to citalopram or escitalopram in depression
12183,European,193489.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003812,Non-response to antidepressants and depression
40,African,96.0,27623284.0,Verma SS,Neurological disorder,initial,2016-09-13,GCST003745,Glaucoma (primary open-angle)
9685,European,9688.0,27622933.0,Li QS,"Response to drug, Neurological disorder",initial,2016-09-13,GCST003801,Response to selective serotonin reuptake inhibitors in depression
12199,European,198990.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003813,Response to antidepressants and depression
8395,European,4536.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003800,Response to bupropion in depression
12188,European,194909.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003811,Response to citalopram or escitalopram and depression
13769,Other/Mixed,154.0,27623284.0,Verma SS,Neurological disorder,initial,2016-09-13,GCST003745,Glaucoma (primary open-angle)
12186,European,194088.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003810,Non-response to citalopram or escitalopram and depression
12189,European,195222.0,27622933.0,Li QS,"Response to drug, Neurological disorder",initial,2016-09-13,GCST003808,Non-response to selective serotonin reuptake inhibitors and depression
12185,European,193931.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003804,Non-response to bupropion and depression
9592,European,9106.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003803,Response to antidepressants in depression
12187,European,194673.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003806,Response to bupropion and depression
8504,European,4840.0,27623284.0,Verma SS,Neurological disorder,initial,2016-09-13,GCST003745,Glaucoma (primary open-angle)
12194,European,197744.0,27622933.0,Li QS,"Response to drug, Neurological disorder",initial,2016-09-13,GCST003809,Response to selective serotonin reuptake inhibitors and depression
8276,European,4159.0,27629089.0,Sailer A,Neurological disorder,initial,2016-09-14,GCST003783,Multiple system atrophy (pathologically confirmed)
8482,European,4782.0,27629089.0,Sailer A,Neurological disorder,initial,2016-09-14,GCST003784,Multiple system atrophy
4123,Asian,10390.0,27623749.0,Hwang JY,"Body measurement, Other measurement",replication,2016-09-14,GCST003789,Body mass index
2173,Asian,484.0,27623749.0,Hwang JY,"Body measurement, Other measurement",initial,2016-09-14,GCST003789,Body mass index
878,African American or Afro-Caribbean,1228.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003772,Loneliness (linear analysis)
879,African American or Afro-Caribbean,1228.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003773,Loneliness (multivariate analysis)
12929,Hispanic or Latin American,621.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003771,Loneliness
9496,European,8490.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003772,Loneliness (linear analysis)
8877,European,5950.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003771,Loneliness
5769,European,740.0,27639821.0,Scherag A,"Other measurement, Other trait",initial,2016-09-15,GCST003817,Mortality in sepsis
12996,Hispanic or Latin American,867.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003772,Loneliness (linear analysis)
12997,Hispanic or Latin American,867.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003773,Loneliness (multivariate analysis)
789,African American or Afro-Caribbean,825.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003771,Loneliness
9497,European,8490.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003773,Loneliness (multivariate analysis)
7619,European,2775.0,27632927.0,Einarsdottir E,Neurological disorder,initial,2016-09-16,GCST003829,Otitis media (recurrent)
7512,European,2585.0,27632927.0,Einarsdottir E,Neurological disorder,initial,2016-09-16,GCST003828,Otitis media (chronic)
7670,European,2876.0,27632927.0,Einarsdottir E,Neurological disorder,initial,2016-09-16,GCST003827,Otitis media
7541,European,2632.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003861,Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes
5737,European,721.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",replication,2016-09-19,GCST003861,Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes
7979,European,3410.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003866,Kidney disease (late stage) in type 1 diabetes
8203,European,3971.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003864,Kidney disease (early and late stages) in type 1 diabetes
5977,European,883.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",replication,2016-09-19,GCST003864,Kidney disease (early and late stages) in type 1 diabetes
6275,European,1087.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",replication,2016-09-19,GCST003862,Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes
7409,European,2458.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003865,Kidney disease (early stage) in type 1 diabetes
7507,European,2568.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003863,Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes
8224,European,4019.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003862,Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes
8061,European,3584.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003867,Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes
13470,Hispanic or Latin American,12226.0,27650483.0,Kramer HJ,Other measurement,initial,2016-09-20,GCST003774,Urinary albumin-to-creatinine ratio
6169,European,1000.0,27656708.0,Zhang W,Other measurement,replication,2016-09-22,GCST003793,L-arginine levels
6789,European,1655.0,27656889.0,Alemany S,Other measurement,initial,2016-09-22,GCST003719,Attention function
5998,European,901.0,27656708.0,Zhang W,Other measurement,initial,2016-09-22,GCST003793,L-arginine levels
5492,European,546.0,27656889.0,Alemany S,Other measurement,replication,2016-09-22,GCST003719,Attention function
2669,Asian,1394.0,27656708.0,Zhang W,Other measurement,initial,2016-09-22,GCST003793,L-arginine levels
3455,Asian,4059.0,27664181.0,Kawamura R,Other measurement,replication,2016-09-23,GCST003759,Resistin levels
2129,Asian,448.0,27664181.0,Kawamura R,Other measurement,initial,2016-09-23,GCST003759,Resistin levels
5692,European,679.0,27671502.0,Blokland GAM,"Other measurement, Biological process",initial,2016-09-23,GCST003698,Brain activation in response to working memory task
1683,Asian,70.0,27669169.0,Chang IS,"Response to drug, Other measurement, Cancer",replication,2016-09-26,GCST003794,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib
1666,Asian,57.0,27665939.0,Liang KH,"Biological process, Digestive system disorder",initial,2016-09-26,GCST003718,Hepatitis B (viral clearance)
1984,Asian,302.0,27665939.0,Liang KH,"Biological process, Digestive system disorder",replication,2016-09-26,GCST003718,Hepatitis B (viral clearance)
1778,Asian,128.0,27669169.0,Chang IS,"Response to drug, Other measurement, Cancer",initial,2016-09-26,GCST003794,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib
5889,European,824.0,27669027.0,Boueiz A,"Biological process, Other measurement",initial,2016-09-26,GCST003761,Emphysema distribution in smoking
8932,European,6215.0,27669027.0,Boueiz A,"Biological process, Other measurement",initial,2016-09-26,GCST003761,Emphysema distribution in smoking
98,African,402.0,27671213.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",initial,2016-09-26,GCST003792,Liver injury in anti-tuberculosis drug treatment
1112,African American or Afro-Caribbean,2955.0,27669027.0,Boueiz A,"Biological process, Other measurement",initial,2016-09-26,GCST003761,Emphysema distribution in smoking
72,African,244.0,27671213.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",replication,2016-09-26,GCST003792,Liver injury in anti-tuberculosis drug treatment
12885,Hispanic or Latin American,471.0,27670767.0,Chang SW,"Response to drug, Cardiovascular disease, Metabolic disorder",replication,2016-09-27,GCST003797,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)
3532,Asian,4619.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003872,QRS complex (12-leadsum)
6095,European,958.0,27670397.0,Reyes-Gibby CC,"Other trait, Cancer",initial,2016-09-27,GCST003760,Pre-treatment pain in head and neck squamous cell carcinoma
11403,European,60255.0,27659466.0,van der Harst P,Cardiovascular measurement,initial,2016-09-27,GCST003844,QRS duration
10049,European,13263.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003871,QRS complex (Cornell)
10050,European,13263.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003872,QRS complex (12-leadsum)
512,African American or Afro-Caribbean,117.0,27670767.0,Chang SW,"Response to drug, Cardiovascular disease, Metabolic disorder",replication,2016-09-27,GCST003797,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)
10047,European,13263.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003844,QRS duration
3531,Asian,4619.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003871,QRS complex (Cornell)
11256,European,48632.0,27659466.0,van der Harst P,Cardiovascular measurement,initial,2016-09-27,GCST003872,QRS complex (12-leadsum)
11348,European,54993.0,27659466.0,van der Harst P,Cardiovascular measurement,initial,2016-09-27,GCST003870,QRS complex (Sokolow-Lyon)
1192,African American or Afro-Caribbean,3603.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003844,QRS duration
10048,European,13263.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003870,QRS complex (Sokolow-Lyon)
1194,African American or Afro-Caribbean,3603.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003871,QRS complex (Cornell)
3530,Asian,4619.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003870,QRS complex (Sokolow-Lyon)
5216,European,410.0,27670397.0,Reyes-Gibby CC,"Other trait, Cancer",replication,2016-09-27,GCST003760,Pre-treatment pain in head and neck squamous cell carcinoma
1195,African American or Afro-Caribbean,3603.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003872,QRS complex (12-leadsum)
3529,Asian,4619.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003844,QRS duration
11390,European,58862.0,27659466.0,van der Harst P,Cardiovascular measurement,initial,2016-09-27,GCST003871,QRS complex (Cornell)
5507,European,552.0,27670767.0,Chang SW,"Response to drug, Cardiovascular disease, Metabolic disorder",initial,2016-09-27,GCST003797,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)
1193,African American or Afro-Caribbean,3603.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003870,QRS complex (Sokolow-Lyon)
7379,European,2411.0,27769005.0,Nassan M,Neurological disorder,initial,2016-09-30,GCST003742,Bipolar disorder (early onset)
6941,European,1846.0,27769005.0,Nassan M,Neurological disorder,replication,2016-09-30,GCST003742,Bipolar disorder (early onset)
4405,Asian,26183.0,27618448.0,Liu C,Other measurement,replication,2016-10-01,GCST006228,Systolic blood pressure
4414,Asian,27487.0,27618447.0,Surendran P,Other measurement,initial,2016-10-01,GCST006021,Systolic blood pressure
8368,European,4448.0,27696742.0,Yau MS,Other disease,initial,2016-10-01,GCST003820,Knee osteoarthritis
4403,Asian,26183.0,27618448.0,Liu C,Cardiovascular measurement,replication,2016-10-01,GCST006230,Pulse pressure
11874,European,120473.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006227,Diastolic blood pressure
11875,European,120473.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006228,Systolic blood pressure
4404,Asian,26183.0,27618448.0,Liu C,Other measurement,replication,2016-10-01,GCST006227,Diastolic blood pressure
11873,European,120473.0,27618448.0,Liu C,Cardiovascular measurement,initial,2016-10-01,GCST006230,Pulse pressure
11872,European,120473.0,27618448.0,Liu C,Cardiovascular disease,initial,2016-10-01,GCST006229,Hypertension
3212,Asian,2641.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006021,Systolic blood pressure
4412,Asian,27487.0,27618447.0,Surendran P,Cardiovascular measurement,initial,2016-10-01,GCST006022,Pulse pressure
7530,European,2618.0,27696742.0,Yau MS,Other disease,replication,2016-10-01,GCST003820,Knee osteoarthritis
4401,Asian,26183.0,27618447.0,Surendran P,Cardiovascular disease,initial,2016-10-01,GCST006023,Hypertension
4402,Asian,26183.0,27618448.0,Liu C,Cardiovascular disease,replication,2016-10-01,GCST006229,Hypertension
3209,Asian,2641.0,27618447.0,Surendran P,Cardiovascular disease,replication,2016-10-01,GCST006023,Hypertension
3210,Asian,2641.0,27618447.0,Surendran P,Cardiovascular measurement,replication,2016-10-01,GCST006022,Pulse pressure
3211,Asian,2641.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006020,Diastolic blood pressure
11876,European,120473.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006231,Mean arterial pressure
4413,Asian,27487.0,27618447.0,Surendran P,Other measurement,initial,2016-10-01,GCST006020,Diastolic blood pressure
12100,European,165276.0,27618447.0,Surendran P,Other measurement,initial,2016-10-01,GCST006020,Diastolic blood pressure
11902,European,125713.0,27618447.0,Surendran P,Cardiovascular disease,replication,2016-10-01,GCST006023,Hypertension
13247,Hispanic or Latin American,4586.0,27618448.0,Liu C,Cardiovascular measurement,initial,2016-10-01,GCST006230,Pulse pressure
13248,Hispanic or Latin American,4586.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006227,Diastolic blood pressure
13249,Hispanic or Latin American,4586.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006228,Systolic blood pressure
13251,Hispanic or Latin American,4632.0,27618447.0,Surendran P,Cardiovascular disease,replication,2016-10-01,GCST006023,Hypertension
13252,Hispanic or Latin American,4632.0,27618447.0,Surendran P,Cardiovascular measurement,replication,2016-10-01,GCST006022,Pulse pressure
13253,Hispanic or Latin American,4632.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006020,Diastolic blood pressure
13246,Hispanic or Latin American,4586.0,27618448.0,Liu C,Cardiovascular disease,initial,2016-10-01,GCST006229,Hypertension
13254,Hispanic or Latin American,4632.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006021,Systolic blood pressure
12099,European,165276.0,27618447.0,Surendran P,Cardiovascular measurement,initial,2016-10-01,GCST006022,Pulse pressure
12068,European,157090.0,27618447.0,Surendran P,Cardiovascular disease,initial,2016-10-01,GCST006023,Hypertension
12058,European,154543.0,27618448.0,Liu C,Other measurement,replication,2016-10-01,GCST006228,Systolic blood pressure
12057,European,154543.0,27618448.0,Liu C,Other measurement,replication,2016-10-01,GCST006227,Diastolic blood pressure
12056,European,154543.0,27618448.0,Liu C,Cardiovascular measurement,replication,2016-10-01,GCST006230,Pulse pressure
12055,European,154543.0,27618448.0,Liu C,Cardiovascular disease,replication,2016-10-01,GCST006229,Hypertension
12101,European,165276.0,27618447.0,Surendran P,Other measurement,initial,2016-10-01,GCST006021,Systolic blood pressure
1542,African American or Afro-Caribbean,22077.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006021,Systolic blood pressure
13250,Hispanic or Latin American,4586.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006231,Mean arterial pressure
1540,African American or Afro-Caribbean,22077.0,27618447.0,Surendran P,Cardiovascular measurement,replication,2016-10-01,GCST006022,Pulse pressure
1541,African American or Afro-Caribbean,22077.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006020,Diastolic blood pressure
1539,African American or Afro-Caribbean,22077.0,27618447.0,Surendran P,Cardiovascular disease,replication,2016-10-01,GCST006023,Hypertension
1533,African American or Afro-Caribbean,21503.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006231,Mean arterial pressure
1532,African American or Afro-Caribbean,21503.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006228,Systolic blood pressure
1531,African American or Afro-Caribbean,21503.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006227,Diastolic blood pressure
1530,African American or Afro-Caribbean,21503.0,27618448.0,Liu C,Cardiovascular measurement,initial,2016-10-01,GCST006230,Pulse pressure
1529,African American or Afro-Caribbean,21503.0,27618448.0,Liu C,Cardiovascular disease,initial,2016-10-01,GCST006229,Hypertension
11903,European,125713.0,27618447.0,Surendran P,Cardiovascular measurement,replication,2016-10-01,GCST006022,Pulse pressure
11904,European,125713.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006020,Diastolic blood pressure
11905,European,125713.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006021,Systolic blood pressure
8715,European,5323.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003851,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)"
8722,European,5353.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003847,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)"
8051,European,3562.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003850,"Caffeine metabolism (plasma 1,3,7-trimethyluric acid level)"
5903,European,833.0,27702941.0,Cornelis MC,Other measurement,replication,2016-10-03,GCST003847,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)"
5895,European,826.0,27702941.0,Cornelis MC,Other measurement,replication,2016-10-03,GCST003848,"Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level)"
8685,European,5261.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003848,"Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level)"
5477,European,530.0,27694959.0,Bonder MJ,Other measurement,replication,2016-10-03,GCST003855,Gut microbiota (bacterial taxa)
6139,European,984.0,27694959.0,Bonder MJ,Other measurement,initial,2016-10-03,GCST003855,Gut microbiota (bacterial taxa)
2482,Asian,955.0,27694991.0,Adams HH,Other measurement,replication,2016-10-03,GCST003834,Intracranial volume
6138,European,984.0,27694959.0,Bonder MJ,Other measurement,initial,2016-10-03,GCST003854,Gut microbiota (functional units)
9565,European,8882.0,27694927.0,Vijayakrishnan J,Cancer,initial,2016-10-03,GCST003798,Acute lymphoblastic leukemia in childhood (B cell precursor)
9566,European,8911.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003849,"Caffeine metabolism (plasma 3,7-dimethylxanthine (theobromine) level)"
2632,Asian,1294.0,27702942.0,Tang CS,Digestive system disorder,initial,2016-10-03,GCST003764,Hirschsprung disease
10771,European,26577.0,27694991.0,Adams HH,Other measurement,initial,2016-10-03,GCST003834,Intracranial volume
13088,Hispanic or Latin American,1605.0,27694991.0,Adams HH,Other measurement,replication,2016-10-03,GCST003834,Intracranial volume
9586,European,9054.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003846,"Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)"
7347,European,2362.0,27694991.0,Adams HH,Other measurement,replication,2016-10-03,GCST003834,Intracranial volume
7675,European,2891.0,27694927.0,Vijayakrishnan J,Cancer,replication,2016-10-03,GCST003798,Acute lymphoblastic leukemia in childhood (B cell precursor)
5223,European,414.0,27702942.0,Tang CS,Digestive system disorder,initial,2016-10-03,GCST003764,Hirschsprung disease
5891,European,824.0,27702941.0,Cornelis MC,Other measurement,replication,2016-10-03,GCST003851,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)"
5476,European,530.0,27694959.0,Bonder MJ,Other measurement,replication,2016-10-03,GCST003854,Gut microbiota (functional units)
5890,European,824.0,27702941.0,Cornelis MC,Other measurement,replication,2016-10-03,GCST003849,"Caffeine metabolism (plasma 3,7-dimethylxanthine (theobromine) level)"
5880,European,822.0,27702941.0,Cornelis MC,Other measurement,replication,2016-10-03,GCST003846,"Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)"
813,African American or Afro-Caribbean,938.0,27694991.0,Adams HH,Other measurement,replication,2016-10-03,GCST003834,Intracranial volume
12739,Hispanic or Latin American,18.0,27704462.0,Moura Rodrigues R,"Other disease, Response to drug",initial,2016-10-04,GCST003852,Response to dendritic cell-based immunotherapy in HIV infection
6717,European,1572.0,27701424.0,Castano-Betancourt MC,Other measurement,replication,2016-10-04,GCST003853,Hip minimal joint space width
4637,European,15.0,27704462.0,Moura Rodrigues R,"Other disease, Response to drug",initial,2016-10-04,GCST003852,Response to dendritic cell-based immunotherapy in HIV infection
8993,European,6523.0,27701424.0,Castano-Betancourt MC,Other measurement,initial,2016-10-04,GCST003853,Hip minimal joint space width
8988,European,6487.0,27723758.0,Bronson PG,Immune system disorder,initial,2016-10-10,GCST003814,Selective IgA deficiency
10324,European,16823.0,27723779.0,Gong J,"Cancer, Other measurement",initial,2016-10-10,GCST003873,Colorectal cancer (alcohol consumption interaction)
8371,European,4459.0,27758888.0,Ingle JN,"Cancer, Response to drug, Other measurement",initial,2016-10-10,GCST003816,Breast cancer-free interval (treatment with aromatase inhibitor)
1811,Asian,160.0,27723809.0,Matsunami K,"Response to drug, Digestive system disorder, Other measurement",replication,2016-10-10,GCST003824,Depression in response to interferon-based therapy in chronic hepatitis C
10640,European,22601.0,27723779.0,Gong J,"Other measurement, Cancer",initial,2016-10-10,GCST003874,Colorectal cancer (smoking interaction)
5151,European,371.0,27723756.0,Wang J,Other measurement,replication,2016-10-10,GCST003876,Gut microbiota (beta diversity)
1897,Asian,224.0,27723809.0,Matsunami K,"Response to drug, Digestive system disorder, Other measurement",initial,2016-10-10,GCST003824,Depression in response to interferon-based therapy in chronic hepatitis C
530,African American or Afro-Caribbean,140.0,27758888.0,Ingle JN,"Cancer, Response to drug, Other measurement",initial,2016-10-10,GCST003816,Breast cancer-free interval (treatment with aromatase inhibitor)
5535,European,577.0,28364478.0,Sulkava S,Other measurement,replication,2016-10-10,GCST003868,Job-related exhaustion in shift workers
1670,Asian,59.0,27758888.0,Ingle JN,"Cancer, Response to drug, Other measurement",initial,2016-10-10,GCST003816,Breast cancer-free interval (treatment with aromatase inhibitor)
6919,European,1812.0,27723756.0,Wang J,Other measurement,initial,2016-10-10,GCST003876,Gut microbiota (beta diversity)
4849,European,176.0,28364478.0,Sulkava S,Other measurement,initial,2016-10-10,GCST003868,Job-related exhaustion in shift workers
6918,European,1812.0,27723756.0,Wang J,Other measurement,initial,2016-10-10,GCST003875,Gut microbiota (bacterial taxa)
2418,Asian,840.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
1500,African American or Afro-Caribbean,18744.0,27736895.0,Franceschini N,Other measurement,initial,2016-10-13,GCST007237,Systolic blood pressure
10273,European,16288.0,27680694.0,Horikoshi M,Body measurement,replication,2016-10-13,GCST005146,Birth weight
10274,European,16288.0,27680694.0,Horikoshi M,Body measurement,replication,2016-10-13,GCST007557,Birth weight
1501,African American or Afro-Caribbean,18744.0,27736895.0,Franceschini N,Other measurement,initial,2016-10-13,GCST007238,Diastolic blood pressure
13899,Other/Mixed,395.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
13911,Other/Mixed,420.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
2686,Asian,1449.0,27680694.0,Horikoshi M,Body measurement,replication,2016-10-13,GCST005146,Birth weight
11948,European,133903.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST007557,Birth weight
13564,Hispanic or Latin American,19706.0,27736895.0,Franceschini N,Other measurement,initial,2016-10-13,GCST007237,Systolic blood pressure
11947,European,133903.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
13565,Hispanic or Latin American,19706.0,27736895.0,Franceschini N,Other measurement,initial,2016-10-13,GCST007238,Diastolic blood pressure
13891,Other/Mixed,365.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
1325,African American or Afro-Caribbean,6635.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
14014,Other/Mixed,721.0,27964859.0,Zhang M,Other trait,initial,2016-10-14,GCST003843,Petaloid toenail
7883,European,3275.0,27764800.0,Cox DG,"Cancer, Other measurement",initial,2016-10-14,GCST003822,Estrogen receptor status in HER2 positive breast cancer
8748,European,5452.0,27764800.0,Cox DG,"Cancer, Other measurement",initial,2016-10-14,GCST003823,Estrogen receptor status in HER2 negative breast cancer
9539,European,8727.0,27764800.0,Cox DG,"Cancer, Other measurement",initial,2016-10-14,GCST003821,Estrogen receptor status in breast cancer
3296,Asian,2961.0,27964859.0,Zhang M,Other trait,initial,2016-10-14,GCST003843,Petaloid toenail
9498,European,8490.0,27749845.0,Lesseur C,Cancer,initial,2016-10-17,GCST003859,Oropharynx cancer
9536,European,8701.0,27749845.0,Lesseur C,Cancer,initial,2016-10-17,GCST003858,Oral cavity cancer
12938,Hispanic or Latin American,683.0,27980656.0,Justice AE,Other measurement,initial,2016-10-18,GCST003825,Systolic blood pressure change trajectories
10715,European,24442.0,27890468.0,van Hulzen KJE,Neurological disorder,initial,2016-10-18,GCST004002,Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder
10821,European,28925.0,27890468.0,van Hulzen KJE,Neurological disorder,initial,2016-10-18,GCST004001,Bipolar disorder or attention deficit hyperactivity disorder
8195,European,3962.0,27764105.0,Lemmela S,Other trait,initial,2016-10-20,GCST003869,Sciatica
13309,Hispanic or Latin American,5696.0,27764096.0,Hoffmann TJ,Neurological disorder,replication,2016-10-20,GCST003763,Age-related hearing impairment
3644,Asian,5438.0,27764096.0,Hoffmann TJ,Neurological disorder,replication,2016-10-20,GCST003763,Age-related hearing impairment
11303,European,52409.0,27764096.0,Hoffmann TJ,Neurological disorder,initial,2016-10-20,GCST003763,Age-related hearing impairment
1286,African American or Afro-Caribbean,5609.0,27770636.0,Mez J,Neurological disorder,initial,2016-10-20,GCST003815,Late-onset Alzheimer's disease
7133,European,2094.0,27797806.0,Muller SH,Other trait,replication,2016-10-20,GCST003762,Essential tremor
1037,African American or Afro-Caribbean,2279.0,27764096.0,Hoffmann TJ,Neurological disorder,replication,2016-10-20,GCST003763,Age-related hearing impairment
10467,European,19265.0,27764105.0,Lemmela S,Other trait,replication,2016-10-20,GCST003869,Sciatica
9157,European,7154.0,27797806.0,Muller SH,Other trait,initial,2016-10-20,GCST003762,Essential tremor
6411,European,1212.0,27770449.0,Tamm R,Other measurement,initial,2016-10-22,GCST003841,Thiopurine S-methyltransferase activity
12849,Hispanic or Latin American,399.0,27777418.0,Wong ML,Neurological disorder,initial,2016-10-25,GCST005547,Major depressive disorder
779,African American or Afro-Caribbean,811.0,26503814.0,Hardin M,"Other disease, Response to drug, Other measurement",initial,2016-10-27,GCST003830,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)
8824,European,5766.0,26503814.0,Hardin M,"Other disease, Response to drug, Other measurement",initial,2016-10-27,GCST003830,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)
11924,European,130795.0,27798624.0,Eppinga RN,Cardiovascular measurement,replication,2016-10-31,GCST003818,Resting heart rate
13982,Other/Mixed,684.0,27798624.0,Eppinga RN,Cardiovascular measurement,initial,2016-10-31,GCST003818,Resting heart rate
3166,Asian,2478.0,27798624.0,Eppinga RN,Cardiovascular measurement,initial,2016-10-31,GCST003818,Resting heart rate
681,African American or Afro-Caribbean,430.0,27802415.0,Salvi E,"Other measurement, Response to drug, Cardiovascular disease",replication,2016-10-31,GCST003805,Diastolic blood pressure response to hydrochlorothiazide in hypertension
682,African American or Afro-Caribbean,430.0,27802415.0,Salvi E,"Other measurement, Response to drug, Cardiovascular disease",replication,2016-10-31,GCST003807,Systolic blood pressure response to hydrochlorothiazide in hypertension
12266,European,225230.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST006047,Number of children ever born
11919,European,127919.0,27798624.0,Eppinga RN,Cardiovascular measurement,initial,2016-10-31,GCST003818,Resting heart rate
12281,European,238064.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST003795,Age at first birth
11249,European,48408.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST006044,Age at first birth
11762,European,103909.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST006046,Number of children ever born
12176,European,189656.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST006045,Age at first birth
12442,European,329139.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST003796,Number of children ever born
6867,European,1739.0,27802415.0,Salvi E,"Other measurement, Response to drug, Cardiovascular disease",initial,2016-10-31,GCST003807,Systolic blood pressure response to hydrochlorothiazide in hypertension
226,African,1734.0,27798624.0,Eppinga RN,Cardiovascular measurement,initial,2016-10-31,GCST003818,Resting heart rate
6866,European,1739.0,27802415.0,Salvi E,"Other measurement, Response to drug, Cardiovascular disease",initial,2016-10-31,GCST003805,Diastolic blood pressure response to hydrochlorothiazide in hypertension
11026,European,35981.0,27668658.0,Iotchkova V,"Hematological measurement, Cardiovascular measurement, Lipid or lipoprotein measurement, Other measurement",initial,2016-11-01,GCST006101,Cardiometabolic and hematological traits
11760,European,102505.0,27668658.0,Iotchkova V,"Hematological measurement, Cardiovascular measurement, Lipid or lipoprotein measurement, Other measurement",replication,2016-11-01,GCST006101,Cardiometabolic and hematological traits
3277,Asian,2899.0,27487801.0,Wu S,"Other measurement, Other trait",initial,2016-11-01,GCST006468,Straight vs curly hair
14010,Other/Mixed,709.0,27487801.0,Wu S,"Other measurement, Other trait",replication,2016-11-01,GCST006468,Straight vs curly hair
9959,European,11891.0,27454463.0,Jones AV,Other measurement,initial,2016-11-01,GCST003927,Dysmenorrheic pain
8221,European,4008.0,27723757.0,Jin Y,Immune system disorder,replication,2016-11-01,GCST004785,Vitiligo
11131,European,40258.0,27723757.0,Jin Y,Immune system disorder,initial,2016-11-01,GCST004785,Vitiligo
10497,European,19796.0,27790247.0,He L,"Hematological measurement, Body measurement, Lipid or lipoprotein measurement, Other measurement, Cardiovascular measurement",replication,2016-11-03,GCST004046,Age-related disease endophenotypes
10498,European,19796.0,27790247.0,He L,"Hematological measurement, Body measurement, Other measurement, Cardiovascular disease, Cancer, Lipid or lipoprotein measurement, Cardiovascular measurement, Metabolic disorder",replication,2016-11-03,GCST004045,"Age-related diseases, mortality and associated endophenotypes"
9673,European,9618.0,27790247.0,He L,"Hematological measurement, Body measurement, Lipid or lipoprotein measurement, Other measurement, Cardiovascular measurement",initial,2016-11-03,GCST004046,Age-related disease endophenotypes
9674,European,9618.0,27790247.0,He L,"Hematological measurement, Body measurement, Other measurement, Cardiovascular disease, Cancer, Lipid or lipoprotein measurement, Cardiovascular measurement, Metabolic disorder",initial,2016-11-03,GCST004045,"Age-related diseases, mortality and associated endophenotypes"
11811,European,112005.0,27818178.0,Hill WD,Other trait,initial,2016-11-03,GCST007156,Social deprivation
9675,European,9618.0,27790247.0,He L,"Other measurement, Cardiovascular disease, Cancer, Metabolic disorder",initial,2016-11-03,GCST004044,Age-related diseases and mortality
11743,European,96900.0,27818178.0,Hill WD,Other trait,initial,2016-11-03,GCST007155,Household income
10499,European,19796.0,27790247.0,He L,"Other measurement, Cardiovascular disease, Cancer, Metabolic disorder",replication,2016-11-03,GCST004044,Age-related diseases and mortality
8606,European,5034.0,27816938.0,Tanaka T,Other measurement,initial,2016-11-05,GCST003882,Parental longevity (at least one long-lived parent)
743,African American or Afro-Caribbean,682.0,27816938.0,Tanaka T,Other measurement,initial,2016-11-05,GCST003882,Parental longevity (at least one long-lived parent)
11849,European,117109.0,27824142.0,Lin H,Cardiovascular disease,replication,2016-11-08,GCST004018,Atrial fibrillation (SNPxSNP interaction)
11527,European,73410.0,27824142.0,Lin H,Cardiovascular disease,initial,2016-11-08,GCST004018,Atrial fibrillation (SNPxSNP interaction)
6572,European,1390.0,27846195.0,Li Q,"Neurological disorder, Other measurement, Response to drug",initial,2016-11-11,GCST004043,Response to paliperidone in schizophrenia (Multivariate)
6568,European,1390.0,27846195.0,Li Q,"Neurological disorder, Other measurement, Response to drug",initial,2016-11-11,GCST004039,Response to paliperidone in schizophrenia (CGI-S score)
6569,European,1390.0,27846195.0,Li Q,"Neurological disorder, Other measurement, Response to drug",initial,2016-11-11,GCST004040,Response to paliperidone in schizophrenia (positive Marder score)
6571,European,1390.0,27846195.0,Li Q,"Neurological disorder, Other measurement, Response to drug",initial,2016-11-11,GCST004042,Response to paliperidone in schizophrenia (PANSS score)
6570,European,1390.0,27846195.0,Li Q,"Neurological disorder, Other measurement, Response to drug",initial,2016-11-11,GCST004041,Response to paliperidone in schizophrenia (negative Marder score)
6207,European,1016.0,27839851.0,Lind L,Other measurement,initial,2016-11-11,GCST003923,"DDT metabolite (p,p'-DDE levels)"
234,African,2029.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
2140,Asian,461.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007097,Pulse pressure
1129,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007097,Pulse pressure
3853,Asian,7243.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007097,Pulse pressure
1130,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
1131,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007095,Systolic blood pressure
1132,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007098,Diastolic blood pressure
13396,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
232,African,2029.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
3855,Asian,7243.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007098,Diastolic blood pressure
3854,Asian,7243.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007095,Systolic blood pressure
233,African,2029.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
12371,European,295529.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
1133,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
13395,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007097,Pulse pressure
12372,European,295529.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
3906,Asian,7701.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
13398,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007098,Diastolic blood pressure
13394,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
3907,Asian,7701.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
13399,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
3226,Asian,2735.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
3227,Asian,2735.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
3228,Asian,2735.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
2141,Asian,461.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007095,Systolic blood pressure
12373,European,295529.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
11599,European,80792.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007098,Diastolic blood pressure
11597,European,80792.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007097,Pulse pressure
11598,European,80792.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007095,Systolic blood pressure
2142,Asian,461.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007098,Diastolic blood pressure
1128,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
13397,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007095,Systolic blood pressure
3908,Asian,7701.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
13203,Hispanic or Latin American,3584.0,28171582.0,Gao X,Other measurement,initial,2016-11-15,GCST003856,Central corneal thickness
7900,European,3299.0,27846281.0,Galesloot TE,Other measurement,initial,2016-11-15,GCST003945,Hepcidin/transferrin saturation ratio
6209,European,1018.0,27846281.0,Galesloot TE,Other measurement,replication,2016-11-15,GCST003943,Hepcidin levels
13012,Hispanic or Latin American,931.0,28171582.0,Gao X,Other measurement,replication,2016-11-15,GCST003856,Central corneal thickness
7898,European,3299.0,27846281.0,Galesloot TE,Other measurement,initial,2016-11-15,GCST003943,Hepcidin levels
7899,European,3299.0,27846281.0,Galesloot TE,Other measurement,initial,2016-11-15,GCST003944,Hepcidin/ferritin ratio
12142,European,172435.0,27863252.0,Astle WJ,"Hematological measurement, Inflammatory measurement",initial,2016-11-17,GCST004610,White blood cell count
12136,European,171846.0,27863252.0,Astle WJ,Inflammatory measurement,initial,2016-11-17,GCST004618,White blood cell count (basophil)
12137,European,171996.0,27863252.0,Astle WJ,Inflammatory measurement,initial,2016-11-17,GCST004631,Basophil percentage of white cells
12135,European,171771.0,27863252.0,Astle WJ,"Inflammatory measurement, Hematological measurement",initial,2016-11-17,GCST004624,Sum eosinophil basophil counts
12146,European,173039.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004604,Hematocrit
12145,European,172952.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004601,Red blood cell count
12140,European,172378.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004600,Eosinophil percentage of white cells
12139,European,172332.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004630,Mean corpuscular hemoglobin
12143,European,172851.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004605,Mean corpuscular hemoglobin concentration
12138,European,172275.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004606,Eosinophil counts
12141,European,172433.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004602,Mean corpuscular volume
12144,European,172925.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004615,Hemoglobin concentration
12134,European,171748.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004632,Lymphocyte percentage of white cells
12125,European,170702.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004629,Neutrophil count
12124,European,170690.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004619,Reticulocyte fraction of red cells
12126,European,170721.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004625,Monocyte count
12127,European,170761.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004611,High light scatter reticulocyte count
12123,European,170672.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004623,Neutrophil percentage of granulocytes
12122,European,170641.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004622,Reticulocyte count
12121,European,170548.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004628,Immature fraction of reticulocytes
12120,European,170536.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004617,Eosinophil percentage of granulocytes
12128,European,170763.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004612,High light scatter reticulocyte percentage of red cells
12131,European,171529.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004621,Red cell distribution width
12119,European,170494.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004609,Monocyte percentage of white cells
12117,European,170223.0,27863252.0,Astle WJ,Inflammatory measurement,initial,2016-11-17,GCST004634,Basophil percentage of granulocytes
12118,European,170384.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004613,Sum neutrophil eosinophil counts
12132,European,171542.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004633,Neutrophil percentage of white cells
12115,European,169822.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004614,Granulocyte count
12133,European,171643.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004627,Lymphocyte counts
12114,European,169545.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004608,Granulocyte percentage of myeloid white cells
12113,European,169219.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004626,Myeloid white cell count
12102,European,166066.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004603,Platelet count
12088,European,164454.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004599,Mean platelet volume
12087,European,164433.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004616,Platelet distribution width
12086,European,164339.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004607,Plateletcrit
12116,European,170143.0,27863252.0,Astle WJ,"Inflammatory measurement, Hematological measurement",initial,2016-11-17,GCST004620,Sum basophil neutrophil counts
7369,European,2388.0,27894865.0,Gago-Diaz M,Other trait,replication,2016-11-25,GCST009005,Bicuspid aortic valve
6235,European,1049.0,27894865.0,Gago-Diaz M,Other trait,initial,2016-11-25,GCST009006,Bicuspid aortic valve without aortic dilation
7370,European,2388.0,27894865.0,Gago-Diaz M,Other trait,replication,2016-11-25,GCST009006,Bicuspid aortic valve without aortic dilation
6234,European,1049.0,27894865.0,Gago-Diaz M,Other trait,initial,2016-11-25,GCST009005,Bicuspid aortic valve
1786,Asian,133.0,28031287.0,Sasayama D,Other measurement,initial,2016-11-26,GCST004000,Cerebrospinal fluid biomarker levels
11019,European,35438.0,27911795.0,Schumann G,"Biological process, Other measurement",replication,2016-11-28,GCST004026,Alcohol consumption
10880,European,31021.0,27911795.0,Schumann G,Other measurement,replication,2016-11-28,GCST004027,Alcohol consumption (heavy vs. light/non-drinkers)
11537,European,74711.0,27911795.0,Schumann G,Other measurement,initial,2016-11-28,GCST004027,Alcohol consumption (heavy vs. light/non-drinkers)
11508,European,70460.0,27911795.0,Schumann G,"Biological process, Other measurement",initial,2016-11-28,GCST004026,Alcohol consumption
2970,Asian,1964.0,27899376.0,Nakayama A,Metabolic disorder,replication,2016-11-29,GCST003926,Renal underexcretion gout
11766,European,104830.0,27899403.0,Jones GT,Cardiovascular disease,initial,2016-11-29,GCST003877,Abdominal aortic aneurysm
3061,Asian,2158.0,27899376.0,Nakayama A,Metabolic disorder,initial,2016-11-29,GCST003925,Gout
14125,Other/Mixed,1536.0,27899376.0,Nakayama A,Metabolic disorder,replication,2016-11-29,GCST003925,Gout
8641,European,5127.0,27899403.0,Jones GT,Cardiovascular disease,replication,2016-11-29,GCST003877,Abdominal aortic aneurysm
2859,Asian,1773.0,27899376.0,Nakayama A,Metabolic disorder,initial,2016-11-29,GCST003924,Renal overload gout
2898,Asian,1832.0,27899376.0,Nakayama A,Metabolic disorder,initial,2016-11-29,GCST003926,Renal underexcretion gout
3214,Asian,2664.0,27899376.0,Nakayama A,Metabolic disorder,replication,2016-11-29,GCST003925,Gout
10491,European,19596.0,27898682.0,Lotta LA,Other measurement,initial,2016-11-29,GCST006078,Branched-chain amino acid levels (Valine)
2941,Asian,1886.0,27899376.0,Nakayama A,Metabolic disorder,replication,2016-11-29,GCST003924,Renal overload gout
10489,European,19596.0,27898682.0,Lotta LA,Other measurement,initial,2016-11-29,GCST006076,Branched-chain amino acid levels (Leucine)
6932,European,1833.0,27899376.0,Nakayama A,Metabolic disorder,replication,2016-11-29,GCST003925,Gout
10490,European,19596.0,27898682.0,Lotta LA,Other measurement,initial,2016-11-29,GCST006077,Branched-chain amino acid levels (Isoleucine)
6673,European,1534.0,27901618.0,Gref A,"Other disease, Other measurement",initial,2016-11-30,GCST003975,Childhood onset asthma (traffic air pollution exposure interaction)
6903,European,1788.0,27901618.0,Gref A,"Other disease, Other measurement",replication,2016-11-30,GCST003975,Childhood onset asthma (traffic air pollution exposure interaction)
9623,European,9320.0,27915449.0,Corre T,Other measurement,initial,2016-12-03,GCST003929,Urinary electrolytes (magnesium/calcium ratio)
9133,European,7050.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006554,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
1025,African American or Afro-Caribbean,2163.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006542,Visceral adipose tissue
834,African American or Afro-Caribbean,1034.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006538,Subcutaneous adipose tissue
8169,European,3888.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006545,Pericardial fat
900,African American or Afro-Caribbean,1284.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006544,Pericardial adipose tissue adjusted for height and weight
1023,African American or Afro-Caribbean,2161.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003971,Pericardial fat
10158,European,14668.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST003973,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
840,African American or Afro-Caribbean,1041.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003969,Visceral adipose tissue attenuation (Hounslow unit scale)
10166,European,14780.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003965,Subcutaneous adipose tissue
10179,European,14863.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003966,Visceral adipose tissue
8168,European,3888.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006543,Pericardial adipose tissue adjusted for height and weight
8206,European,3978.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006544,Pericardial adipose tissue adjusted for height and weight
1031,African American or Afro-Caribbean,2205.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006551,Visceral adipose tissue/subcutaneous adipose tissue ratio
9132,European,7050.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006552,Visceral adipose tissue/subcutaneous adipose tissue ratio
11966,European,137994.0,27918536.0,Lo MT,"Neurological disorder, Other measurement",replication,2016-12-05,GCST004017,Neuroticism
8815,European,5729.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006548,Visceral adipose tissue attenuation (Hounslow unit scale)
11222,European,46621.0,27918536.0,Lo MT,"Biological process, Other measurement",replication,2016-12-05,GCST004015,Extraversion
1024,African American or Afro-Caribbean,2163.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006537,Subcutaneous adipose tissue
11221,European,46581.0,27918536.0,Lo MT,Other measurement,replication,2016-12-05,GCST004014,Conscientiousness
8808,European,5699.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006550,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
8807,European,5699.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006549,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
801,African American or Afro-Caribbean,877.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006543,Pericardial adipose tissue adjusted for height and weight
837,African American or Afro-Caribbean,1036.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006534,Visceral adipose tissue adjusted for BMI
2075,Asian,390.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006544,Pericardial adipose tissue adjusted for height and weight
11889,European,122867.0,27918536.0,Lo MT,"Neurological disorder, Other measurement",initial,2016-12-05,GCST004017,Neuroticism
8207,European,3978.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006546,Pericardial fat
10180,European,14863.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST003967,Visceral adipose tissue adjusted for BMI
8817,European,5749.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006547,Visceral adipose tissue attenuation (Hounslow unit scale)
836,African American or Afro-Caribbean,1036.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006540,Visceral adipose tissue
1026,African American or Afro-Caribbean,2163.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006533,Visceral adipose tissue adjusted for BMI
2061,Asian,378.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006545,Pericardial fat
2060,Asian,378.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006543,Pericardial adipose tissue adjusted for height and weight
802,African American or Afro-Caribbean,877.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006545,Pericardial fat
10157,European,14668.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003972,Visceral adipose tissue/subcutaneous adipose tissue ratio
11891,European,122886.0,27918536.0,Lo MT,"Biological process, Other measurement",initial,2016-12-05,GCST004015,Extraversion
2076,Asian,390.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006546,Pericardial fat
12939,Hispanic or Latin American,699.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006543,Pericardial adipose tissue adjusted for height and weight
2358,Asian,768.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST003968,Pericardial adipose tissue adjusted for height and weight
12940,Hispanic or Latin American,699.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006545,Pericardial fat
1189,African American or Afro-Caribbean,3529.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006553,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
2359,Asian,768.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003971,Pericardial fat
12958,Hispanic or Latin American,746.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006544,Pericardial adipose tissue adjusted for height and weight
693,African American or Afro-Caribbean,449.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006549,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
12959,Hispanic or Latin American,746.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006546,Pericardial fat
692,African American or Afro-Caribbean,449.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006547,Visceral adipose tissue attenuation (Hounslow unit scale)
9305,European,7866.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003971,Pericardial fat
11545,European,76581.0,27918536.0,Lo MT,Other measurement,initial,2016-12-05,GCST004016,Openness
9263,European,7618.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006551,Visceral adipose tissue/subcutaneous adipose tissue ratio
9264,European,7618.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006553,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
11543,European,76551.0,27918536.0,Lo MT,Other measurement,initial,2016-12-05,GCST004014,Conscientiousness
11542,European,76551.0,27918536.0,Lo MT,Other measurement,initial,2016-12-05,GCST004013,Agreeableness
9912,European,11478.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003969,Visceral adipose tissue attenuation (Hounslow unit scale)
9304,European,7866.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST003968,Pericardial adipose tissue adjusted for height and weight
9219,European,7432.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006540,Visceral adipose tissue
9220,European,7432.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006534,Visceral adipose tissue adjusted for BMI
905,African American or Afro-Caribbean,1324.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006552,Visceral adipose tissue/subcutaneous adipose tissue ratio
9904,European,11398.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003970,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
1183,African American or Afro-Caribbean,3469.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003966,Visceral adipose tissue
1182,African American or Afro-Caribbean,3467.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003965,Subcutaneous adipose tissue
893,African American or Afro-Caribbean,1261.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST003968,Pericardial adipose tissue adjusted for height and weight
901,African American or Afro-Caribbean,1284.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006546,Pericardial fat
13069,Hispanic or Latin American,1445.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003971,Pericardial fat
13068,Hispanic or Latin American,1445.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST003968,Pericardial adipose tissue adjusted for height and weight
1184,African American or Afro-Caribbean,3469.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST003967,Visceral adipose tissue adjusted for BMI
9218,European,7431.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006533,Visceral adipose tissue adjusted for BMI
906,African American or Afro-Caribbean,1324.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006554,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
841,African American or Afro-Caribbean,1041.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003970,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
730,African American or Afro-Caribbean,592.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006548,Visceral adipose tissue attenuation (Hounslow unit scale)
1187,African American or Afro-Caribbean,3529.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003972,Visceral adipose tissue/subcutaneous adipose tissue ratio
9204,European,7381.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006538,Subcutaneous adipose tissue
9208,European,7399.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006537,Subcutaneous adipose tissue
9217,European,7431.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006542,Visceral adipose tissue
1188,African American or Afro-Caribbean,3529.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST003973,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
731,African American or Afro-Caribbean,592.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006550,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
4153,Asian,11382.0,27922604.0,Yu H,Neurological disorder,replication,2016-12-06,GCST003880,Schizophrenia
4104,Asian,10154.0,27922604.0,Yu H,Neurological disorder,initial,2016-12-06,GCST003880,Schizophrenia
10644,European,22653.0,27927781.0,Robinson-Cohen C,Other measurement,initial,2016-12-07,GCST003879,Serum parathyroid hormone levels
8990,European,6502.0,27927781.0,Robinson-Cohen C,Other measurement,replication,2016-12-07,GCST003879,Serum parathyroid hormone levels
10808,European,28489.0,28049566.0,Direk N,"Neurological disorder, Other measurement",replication,2016-12-08,GCST004024,Depressive symptom measurement or major depressive disorder
11504,European,70017.0,28049566.0,Direk N,"Neurological disorder, Other measurement",initial,2016-12-08,GCST004024,Depressive symptom measurement or major depressive disorder
4125,Asian,10640.0,28049566.0,Direk N,"Neurological disorder, Other measurement",replication,2016-12-08,GCST004024,Depressive symptom measurement or major depressive disorder
10071,European,13483.0,27941131.0,Feenstra B,Other measurement,initial,2016-12-09,GCST003974,Tonsillectomy
2188,Asian,504.0,27936112.0,Kalsi G,Neurological disorder,initial,2016-12-09,GCST003878,Heroin dependence
7702,European,2942.0,27941131.0,Feenstra B,Other measurement,replication,2016-12-09,GCST003974,Tonsillectomy
1451,African American or Afro-Caribbean,11731.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004033,QRS interval (sulfonylurea treatment interaction)
1452,African American or Afro-Caribbean,11731.0,27958378.0,Floyd JS,"Response to drug, Cardiovascular measurement",initial,2016-12-13,GCST004032,JT interval (sulfonylurea treatment interaction)
13520,Hispanic or Latin American,15124.0,27958378.0,Floyd JS,"Response to drug, Cardiovascular measurement",initial,2016-12-13,GCST004032,JT interval (sulfonylurea treatment interaction)
13519,Hispanic or Latin American,15124.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004033,QRS interval (sulfonylurea treatment interaction)
13518,Hispanic or Latin American,15124.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004031,QT interval (sulfonylurea treatment interaction)
8011,European,3475.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004455,Interleukin-2 levels
8013,European,3483.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004430,Interleukin-16 levels
8046,European,3557.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004443,Interleukin-13 levels
8099,European,3685.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004440,Interferon gamma-induced protein 10 levels
8040,European,3531.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004421,beta-nerve growth factor levels
8019,European,3494.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004423,Macrophage Migration Inhibitory Factor levels
8096,European,3682.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004428,Stem cell growth factor beta levels
9308,European,7904.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004458,Granulocyte-colony stimulating factor levels
8023,European,3505.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004457,Growth-regulated protein alpha levels
8098,European,3685.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004435,Monokine induced by gamma interferon levels
8034,European,3526.0,27989323.0,Ahola-Olli AV,"Other measurement, Inflammatory measurement",initial,2016-12-13,GCST004445,Interleukin-8 levels
11198,European,45002.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004031,QT interval (sulfonylurea treatment interaction)
9247,European,7565.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004459,Fibroblast growth factor basic levels
9276,European,7681.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004444,Interleukin-10 levels
9280,European,7701.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004456,Interferon gamma levels
6705,European,1559.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004425,Tumor necrosis factor beta levels
8095,European,3677.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004454,Interleukin-2 receptor antagonist levels
9287,European,7760.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004442,Interleukin-17 levels
8031,European,3522.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004434,Macrophage inflammatory protein 1a levels
11199,European,45002.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004033,QRS interval (sulfonylurea treatment interaction)
9390,European,8293.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004438,Monocyte chemoattractant protein-1 levels
9151,European,7118.0,27989323.0,Ahola-Olli AV,Cardiovascular measurement,initial,2016-12-13,GCST004422,Vascular endothelial growth factor levels
7948,European,3364.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004452,Interleukin-5 levels
8081,European,3636.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004441,Interleukin-18 levels
9368,European,8186.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004424,TRAIL levels
8885,European,5998.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004427,Stromal-cell-derived factor 1 alpha levels
5918,European,843.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004437,Monocyte chemoattractant protein-3 levels
7976,European,3409.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004451,Interleukin-7 levels
11200,European,45002.0,27958378.0,Floyd JS,"Response to drug, Cardiovascular measurement",initial,2016-12-13,GCST004032,JT interval (sulfonylurea treatment interaction)
9363,European,8153.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004460,Eotaxin levels
8082,European,3638.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004447,Interleukin-1-receptor antagonist levels
1450,African American or Afro-Caribbean,11731.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004031,QT interval (sulfonylurea treatment interaction)
7984,European,3421.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004431,RANTES levels
7908,European,3309.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004448,Interleukin-1-beta levels
9359,European,8124.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004453,Interleukin-4 levels
9382,European,8243.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004433,Macrophage inflammatory protein 1b levels
5914,European,840.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004436,Macrophage colony stimulating factor levels
8079,European,3634.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004450,Interleukin-9 levels
9389,European,8293.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004432,Platelet-derived growth factor BB levels
9388,European,8292.0,27989323.0,Ahola-Olli AV,Cardiovascular measurement,initial,2016-12-13,GCST004449,Hepatocyte growth factor levels
8077,European,3631.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004420,CTACK levels
5314,European,458.0,27957625.0,Bacchelli E,"Other measurement, Other trait",initial,2016-12-13,GCST003900,Cluster headache
9369,European,8189.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004446,Interleukin-6 levels
9383,European,8270.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004439,Interleukin-12p70 levels
7997,European,3454.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004426,Tumor necrosis factor alpha levels
9387,European,8290.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004429,Stem cell factor levels
2109,Asian,434.0,28000841.0,Baek SH,Other disease,initial,2016-12-14,GCST003918,Idiopathic osteonecrosis of the femoral head
3778,Asian,6316.0,27976721.0,Wang Z,Neurological disorder,initial,2016-12-15,GCST004009,Leprosy
4325,Asian,17450.0,27976721.0,Wang Z,Neurological disorder,replication,2016-12-15,GCST004009,Leprosy
1751,Asian,115.0,27981573.0,Zhong WP,"Cardiovascular disease, Cardiovascular measurement, Response to drug",initial,2016-12-16,GCST003899,Response to clopidogrel therapy in coronary heart disease
10182,European,14890.0,27992413.0,Ji SG,Digestive system disorder,initial,2016-12-19,GCST004030,Primary sclerosing cholangitis
11819,European,112586.0,27992416.0,Lane JM,"Biological process, Other measurement",initial,2016-12-19,GCST003982,Sleep traits (multi-trait analysis)
11392,European,59128.0,27992416.0,Lane JM,"Neurological disorder, Other measurement",initial,2016-12-19,GCST003981,Insomnia
11807,European,111648.0,27992416.0,Lane JM,Other measurement,initial,2016-12-19,GCST003979,Excessive daytime sleepiness
9723,European,9861.0,27992413.0,Ji SG,Digestive system disorder,replication,2016-12-19,GCST004030,Primary sclerosing cholangitis
5820,European,775.0,27993963.0,Schneider BP,"Cardiovascular disease, Cancer, Response to drug",replication,2016-12-19,GCST003939,Adverse response to chemotherapy (congestive heart failure) in breast cancer
5924,European,845.0,27993963.0,Schneider BP,"Cardiovascular disease, Cancer, Response to drug",initial,2016-12-19,GCST003939,Adverse response to chemotherapy (congestive heart failure) in breast cancer
11810,European,111975.0,27992416.0,Lane JM,Other measurement,initial,2016-12-19,GCST003980,Sleep duration
11135,European,40371.0,27997041.0,Traylor M,Cardiovascular disease,replication,2016-12-20,GCST004020,Small vessel stroke
10115,European,14000.0,27997041.0,Traylor M,"Cardiovascular disease, Other trait",initial,2016-12-20,GCST004021,Ischemic stroke (cardioembolic)
10125,European,14162.0,27997041.0,Traylor M,Cardiovascular disease,initial,2016-12-20,GCST004022,Large artery stroke
10752,European,25713.0,27997041.0,Traylor M,"Cardiovascular disease, Other trait",replication,2016-12-20,GCST004023,Ischemic stroke
10150,European,14560.0,27997041.0,Traylor M,Cardiovascular disease,initial,2016-12-20,GCST004020,Small vessel stroke
10452,European,19100.0,27997041.0,Traylor M,Cardiovascular disease,replication,2016-12-20,GCST004022,Large artery stroke
11153,European,41544.0,27997041.0,Traylor M,"Cardiovascular disease, Other trait",replication,2016-12-20,GCST004021,Ischemic stroke (cardioembolic)
10630,European,22495.0,27997041.0,Traylor M,"Cardiovascular disease, Other trait",initial,2016-12-20,GCST004023,Ischemic stroke
2041,Asian,366.0,28011148.0,Zhang M,Other measurement,replication,2016-12-21,GCST003940,Trans-epidermal water loss
1219,African American or Afro-Caribbean,3964.0,28078323.0,Raj T,Other trait,initial,2016-12-21,GCST003901,Cognitive decline (age-related)
2242,Asian,611.0,28011148.0,Zhang M,Other measurement,initial,2016-12-21,GCST003940,Trans-epidermal water loss
10846,European,29646.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004004,Mean corpuscular volume
13936,Other/Mixed,540.0,28011710.0,Benyamin B,Other measurement,initial,2016-12-22,GCST004038,Circulating chromogranin peptide levels
2134,Asian,455.0,28011712.0,Foo JN,Neurological disorder,replication,2016-12-22,GCST003922,Parkinson's disease
1485,African American or Afro-Caribbean,16128.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004005,Hemoglobin levels
14259,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004008,Red blood cell count
1486,African American or Afro-Caribbean,16128.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004008,Red blood cell count
1484,African American or Afro-Caribbean,16128.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004003,Hematocrit
14255,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004004,Mean corpuscular volume
5261,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003931,Carotenoid levels (beta-carotene)
14254,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004003,Hematocrit
14256,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004005,Hemoglobin levels
10555,European,21020.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004007,Mean corpuscular hemoglobin concentration
1299,African American or Afro-Caribbean,6150.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004004,Mean corpuscular volume
10554,European,21020.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004006,Mean corpuscular hemoglobin
14258,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004007,Mean corpuscular hemoglobin concentration
4378,Asian,22274.0,28011712.0,Foo JN,Neurological disorder,replication,2016-12-22,GCST003922,Parkinson's disease
1196,African American or Afro-Caribbean,3621.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004006,Mean corpuscular hemoglobin
5268,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003938,Carotenoid levels (alpha-carotene)
11134,European,40258.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004008,Red blood cell count
11133,European,40258.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004005,Hemoglobin levels
11132,European,40258.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004003,Hematocrit
4253,Asian,14006.0,28011712.0,Foo JN,Neurological disorder,initial,2016-12-22,GCST003922,Parkinson's disease
1197,African American or Afro-Caribbean,3621.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004007,Mean corpuscular hemoglobin concentration
5267,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003937,Retinol levels
14257,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004006,Mean corpuscular hemoglobin
5266,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003936,Vitamin E levels (gamma-tocopherol)
5265,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003935,Vitamin E levels (alpha-tocopherol)
4285,Asian,15062.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004006,Mean corpuscular hemoglobin
4292,Asian,15252.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004008,Red blood cell count
5264,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003934,Carotenoid levels (cryptoxanthin)
4291,Asian,15252.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004005,Hemoglobin levels
5262,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003932,Carotenoid levels (lutein)
5263,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003933,Carotenoid levels (zeaxanthin)
4290,Asian,15252.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004003,Hematocrit
4287,Asian,15074.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004004,Mean corpuscular volume
4286,Asian,15062.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004007,Mean corpuscular hemoglobin concentration
5463,European,523.0,28008999.0,Ostrowski J,Digestive system disorder,replication,2016-12-23,GCST003959,Crohn's disease
6294,European,1110.0,28008999.0,Ostrowski J,Immune system disorder,initial,2016-12-23,GCST003960,Ulcerative colitis
5745,European,729.0,28008999.0,Ostrowski J,"Digestive system disorder, Immune system disorder",replication,2016-12-23,GCST003958,Inflammatory bowel disease
7103,European,2059.0,28012008.0,Lu S,Other measurement,initial,2016-12-23,GCST003920,Hip bone mineral density and alcohol drinking
7104,European,2059.0,28012008.0,Lu S,Other measurement,initial,2016-12-23,GCST003921,Whole body bone mineral density and alcohol drinking
6357,European,1172.0,28008999.0,Ostrowski J,Digestive system disorder,initial,2016-12-23,GCST003959,Crohn's disease
5515,European,558.0,28008999.0,Ostrowski J,Immune system disorder,replication,2016-12-23,GCST003960,Ulcerative colitis
5622,European,636.0,28011674.0,Ruhle F,Cardiovascular disease,initial,2016-12-23,GCST004012,Venous thromboembolism
7102,European,2059.0,28012008.0,Lu S,Other measurement,initial,2016-12-23,GCST003919,Spine bone mineral density and alcohol drinking
6815,European,1700.0,28008999.0,Ostrowski J,"Digestive system disorder, Immune system disorder",initial,2016-12-23,GCST003958,Inflammatory bowel disease
8058,European,3582.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003977,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase
8272,European,4140.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003978,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to proteinase-3
6713,European,1564.0,28040410.0,Meyers JL,Other measurement,initial,2016-12-28,GCST003902,Fast beta electroencephalogram
8381,European,4479.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003976,Antineutrophil cytoplasmic antibody-associated vasculitis
6650,European,1519.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003977,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase
7002,European,1944.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003978,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to proteinase-3
7074,European,2036.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003976,Antineutrophil cytoplasmic antibody-associated vasculitis
9895,European,11259.0,28041642.0,Carmona FD,Cardiovascular disease,initial,2016-12-29,GCST003928,Giant cell arteritis
5432,European,511.0,28039263.0,Wheeler HE,"Other trait, Response to drug",initial,2016-12-30,GCST003898,Cisplatin-induced ototoxicity
9907,European,11450.0,28043905.0,Nicoletti P,"Response to drug, Digestive system disorder",initial,2016-12-30,GCST004086,Drug-induced liver injury
9875,European,11062.0,28043905.0,Nicoletti P,Digestive system disorder,initial,2016-12-30,GCST004079,Drug-induced hepatocellular liver injury
1434,African American or Afro-Caribbean,10235.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004010,QT interval (tricyclic/tetracyclic antidepressant use interaction)
1435,African American or Afro-Caribbean,10235.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004011,RR interval (tricyclic/tetracyclic antidepressant use interaction)
9821,European,10652.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004082,Drug-induced liver injury (nitrofurantoin)
9861,European,10911.0,28043905.0,Nicoletti P,Digestive system disorder,initial,2016-12-30,GCST004081,Drug-induced cholestatic/mixed liver injury
13589,Hispanic or Latin American,69749.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004010,QT interval (tricyclic/tetracyclic antidepressant use interaction)
11158,European,41951.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004010,QT interval (tricyclic/tetracyclic antidepressant use interaction)
13512,Hispanic or Latin American,13808.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004011,RR interval (tricyclic/tetracyclic antidepressant use interaction)
9815,European,10602.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004078,Drug-induced liver injury (terbinafine)
9819,European,10631.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004085,Drug-induced liver injury (fluoroquinolones)
9838,European,10732.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004087,Drug-induced liver injury (nonsteroidal anti-inflammatory drugs)
9823,European,10655.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004084,Drug-induced liver injury (anti-tuberculosis drugs)
9820,European,10647.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004080,Drug-induced liver injury (statins)
9822,European,10655.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004083,Drug-induced liver injury (diclofenac)
11204,European,45706.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004011,RR interval (tricyclic/tetracyclic antidepressant use interaction)
14100,Other/Mixed,1279.0,28222112.0,Dumitrescu L,Cardiovascular disease,initial,2017-01-01,GCST004163,Resistance to antihypertensive treatment in hypertension
3012,Asian,2058.0,28952330.0,Chen SP,Cardiovascular disease,initial,2017-01-01,GCST004900,Migraine without aura
7388,European,2427.0,28222112.0,Dumitrescu L,Cardiovascular disease,initial,2017-01-01,GCST004163,Resistance to antihypertensive treatment in hypertension
13205,Hispanic or Latin American,3596.0,28061514.0,Nannini DR,Other measurement,initial,2017-01-01,GCST004047,Optic nerve measurement (cup-to-disc ratio)
5633,European,646.0,28317148.0,Campo C,"Response to drug, Neurological disorder, Cancer",initial,2017-01-01,GCST003964,Bortezomib-induced peripheral neuropathy in multiple myeloma
13013,Hispanic or Latin American,941.0,28061514.0,Nannini DR,Other measurement,replication,2017-01-01,GCST004047,Optic nerve measurement (cup-to-disc ratio)
2822,Asian,1724.0,28952330.0,Chen SP,Cardiovascular disease,replication,2017-01-01,GCST004900,Migraine without aura
3196,Asian,2567.0,28046027.0,Kim T,Lipid or lipoprotein measurement,replication,2017-01-03,GCST004036,LDL cholesterol to HDL cholesterol ratio
3195,Asian,2567.0,28046027.0,Kim T,Lipid or lipoprotein measurement,replication,2017-01-03,GCST004035,NHDL cholesterol to HDL cholesterol ratio
2391,Asian,796.0,28045058.0,Kim SW,Cardiovascular disease,initial,2017-01-03,GCST004019,Behcet's disease
3621,Asian,5292.0,28046027.0,Kim T,Lipid or lipoprotein measurement,initial,2017-01-03,GCST004035,NHDL cholesterol to HDL cholesterol ratio
3197,Asian,2567.0,28046027.0,Kim T,Lipid or lipoprotein measurement,replication,2017-01-03,GCST004037,Triglyceride to HDL cholesterol ratio
2327,Asian,725.0,28045058.0,Kim SW,Cardiovascular disease,replication,2017-01-03,GCST004019,Behcet's disease
3622,Asian,5292.0,28046027.0,Kim T,Lipid or lipoprotein measurement,initial,2017-01-03,GCST004036,LDL cholesterol to HDL cholesterol ratio
3623,Asian,5292.0,28046027.0,Kim T,Lipid or lipoprotein measurement,initial,2017-01-03,GCST004037,Triglyceride to HDL cholesterol ratio
14047,Other/Mixed,846.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004052,Cleft palate
14196,Other/Mixed,3161.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004050,Cleft lip with or without cleft palate
14199,Other/Mixed,3303.0,28054174.0,Leslie EJ,"Other trait, Other measurement, Other disease",initial,2017-01-04,GCST004051,Orofacial clefts
3527,Asian,4579.0,28054174.0,Leslie EJ,"Other trait, Other measurement, Other disease",initial,2017-01-04,GCST004051,Orofacial clefts
2492,Asian,977.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004052,Cleft palate
8517,European,4865.0,28054174.0,Leslie EJ,"Other trait, Other measurement, Other disease",initial,2017-01-04,GCST004051,Orofacial clefts
3415,Asian,3763.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004050,Cleft lip with or without cleft palate
8202,European,3969.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004050,Cleft lip with or without cleft palate
6886,European,1761.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004052,Cleft palate
20,African,35.0,28062682.0,Carr DF,"Other disease, Response to drug",replication,2017-01-05,GCST004115,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)
61,African,203.0,28062682.0,Carr DF,"Other disease, Digestive system disorder, Response to drug",initial,2017-01-05,GCST004114,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury)
50,African,122.0,28062682.0,Carr DF,"Other disease, Immune system disorder, Response to drug",replication,2017-01-05,GCST004118,Nevirapine-induced hypersensitivity in HIV
62,African,205.0,28062682.0,Carr DF,"Other disease, Immune system disorder, Response to drug",initial,2017-01-05,GCST004116,Nevirapine-induced hypersensitivity in HIV (hypersensitivity syndrome)
31,African,76.0,28062682.0,Carr DF,"Other disease, Digestive system disorder, Response to drug",replication,2017-01-05,GCST004114,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury)
29,African,71.0,28062682.0,Carr DF,"Other disease, Response to drug",replication,2017-01-05,GCST004115,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)
4656,European,45.0,28065765.0,Nagao Y,"Other disease, Digestive system disorder",replication,2017-01-05,GCST004090,Lichen planus in hepatitis C
39,African,87.0,28062682.0,Carr DF,"Other disease, Response to drug",replication,2017-01-05,GCST004117,Nevirapine-induced hypersensitivity in HIV (rash)
19,African,35.0,28062682.0,Carr DF,"Other disease, Digestive system disorder, Response to drug",replication,2017-01-05,GCST004114,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury)
3843,Asian,7024.0,28062665.0,Kawashima M,Cancer,replication,2017-01-05,GCST004145,Primary biliary cholangitis
92,African,333.0,28062682.0,Carr DF,"Other disease, Immune system disorder, Response to drug",initial,2017-01-05,GCST004118,Nevirapine-induced hypersensitivity in HIV
97,African,398.0,28062682.0,Carr DF,"Other disease, Response to drug",initial,2017-01-05,GCST004117,Nevirapine-induced hypersensitivity in HIV (rash)
69,African,233.0,28062682.0,Carr DF,"Other disease, Response to drug",initial,2017-01-05,GCST004115,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)
1943,Asian,261.0,28065765.0,Nagao Y,"Other disease, Digestive system disorder",initial,2017-01-05,GCST004090,Lichen planus in hepatitis C
3274,Asian,2886.0,28062665.0,Kawashima M,Cancer,initial,2017-01-05,GCST004145,Primary biliary cholangitis
6561,European,1377.0,28056976.0,Paziewska A,Cancer,initial,2017-01-06,GCST004120,Primary biliary cholangitis
1708,Asian,90.0,28059113.0,Hao J,Other disease,initial,2017-01-06,GCST004091,Palmar length-width ratio in Kashin-Beck disease
6242,European,1054.0,28056976.0,Paziewska A,Digestive system disorder,initial,2017-01-06,GCST004119,Primary sclerosing cholangitis
2088,Asian,403.0,28059113.0,Hao J,Other disease,replication,2017-01-06,GCST004091,Palmar length-width ratio in Kashin-Beck disease
12104,European,167078.0,28067910.0,Luo Y,Immune system disorder,replication,2017-01-09,GCST008658,Ulcerative colitis
7601,European,2734.0,28067912.0,Lee JC,"Digestive system disorder, Other measurement",initial,2017-01-09,GCST004053,Poor prognosis in Crohn's disease
10681,European,23825.0,28067910.0,Luo Y,Immune system disorder,initial,2017-01-09,GCST008658,Ulcerative colitis
9068,European,6789.0,28073367.0,Zeng X,Other measurement,replication,2017-01-10,GCST004112,Dyspnea
1044,African American or Afro-Caribbean,2382.0,28070124.0,Meyers JL,Other measurement,initial,2017-01-10,GCST004048,Fast beta electroencephalogram
10844,European,29578.0,28073927.0,Springelkamp H,Other measurement,initial,2017-01-10,GCST004074,Intraocular pressure
9331,European,7976.0,28073367.0,Zeng X,Other measurement,initial,2017-01-10,GCST004112,Dyspnea
3968,Asian,8352.0,28073927.0,Springelkamp H,Other measurement,replication,2017-01-10,GCST004074,Intraocular pressure
10631,European,22504.0,28073927.0,Springelkamp H,Other measurement,initial,2017-01-10,GCST004076,Optic disc area
9330,European,7976.0,28073367.0,Zeng X,Other measurement,initial,2017-01-10,GCST004111,Phlegm
10629,European,22484.0,28073927.0,Springelkamp H,Other measurement,initial,2017-01-10,GCST004137,Optic cup area
9067,European,6789.0,28073367.0,Zeng X,Other measurement,replication,2017-01-10,GCST004111,Phlegm
3951,Asian,8168.0,28073927.0,Springelkamp H,Other measurement,replication,2017-01-10,GCST004075,Vertical cup-disc ratio
9329,European,7976.0,28073367.0,Zeng X,Other measurement,initial,2017-01-10,GCST004073,Cough
9066,European,6789.0,28073367.0,Zeng X,Other measurement,replication,2017-01-10,GCST004073,Cough
3866,Asian,7333.0,28073927.0,Springelkamp H,Other measurement,replication,2017-01-10,GCST004137,Optic cup area
10683,European,23899.0,28073927.0,Springelkamp H,Other measurement,initial,2017-01-10,GCST004075,Vertical cup-disc ratio
3862,Asian,7302.0,28073927.0,Springelkamp H,Other measurement,replication,2017-01-10,GCST004076,Optic disc area
10892,European,31478.0,28077804.0,Ben-Avraham D,Other measurement,initial,2017-01-10,GCST004110,Gait speed in old age
7515,European,2588.0,28077804.0,Ben-Avraham D,Other measurement,replication,2017-01-10,GCST004110,Gait speed in old age
10934,European,33181.0,28072414.0,Charney AW,Neurological disorder,initial,2017-01-10,GCST003962,Bipolar disorder
13903,Other/Mixed,401.0,28076899.0,Taylor KE,Neurological disorder,initial,2017-01-11,GCST004061,Sjgren's syndrome
4830,European,170.0,27883235.0,Martino DJ,Other measurement,initial,2017-01-11,GCST003881,Peanut allergy
13694,Other/Mixed,27.0,27883235.0,Martino DJ,Other measurement,initial,2017-01-11,GCST003881,Peanut allergy
8671,European,5212.0,27883235.0,Martino DJ,Other measurement,replication,2017-01-11,GCST003881,Peanut allergy
13733,Other/Mixed,74.0,27883235.0,Martino DJ,Other measurement,replication,2017-01-11,GCST003881,Peanut allergy
2762,Asian,1585.0,28076899.0,Taylor KE,Neurological disorder,initial,2017-01-11,GCST004062,Sjgren's syndrome
2434,Asian,876.0,28076899.0,Taylor KE,Neurological disorder,initial,2017-01-11,GCST004061,Sjgren's syndrome
8267,European,4131.0,28076899.0,Taylor KE,Neurological disorder,initial,2017-01-11,GCST004061,Sjgren's syndrome
1633,Asian,24.0,27883235.0,Martino DJ,Other measurement,initial,2017-01-11,GCST003881,Peanut allergy
120,African,546.0,28076899.0,Taylor KE,Neurological disorder,initial,2017-01-11,GCST004061,Sjgren's syndrome
1075,African American or Afro-Caribbean,2706.0,28082259.0,Pankow JS,Hematological measurement,initial,2017-01-12,GCST006119,Protein C levels
13427,Hispanic or Latin American,10153.0,28081371.0,Sanders AE,Other disease,initial,2017-01-12,GCST004034,Temporomandibular joint disorder
12931,Hispanic or Latin American,636.0,28081371.0,Sanders AE,Other disease,replication,2017-01-12,GCST004034,Temporomandibular joint disorder
8279,European,4167.0,28081215.0,Pardo LM,"Cancer, Other measurement",initial,2017-01-12,GCST004134,Multiple keratinocyte cancers
9848,European,10778.0,28082259.0,Pankow JS,Hematological measurement,initial,2017-01-12,GCST006119,Protein C levels
8784,European,5613.0,28081371.0,Sanders AE,Other disease,replication,2017-01-12,GCST004034,Temporomandibular joint disorder
8107,European,3715.0,28087736.0,Ludwig KU,Other trait,initial,2017-01-13,GCST004088,Nonsyndromic cleft lip with or without cleft palate
3145,Asian,2385.0,28087736.0,Ludwig KU,Other trait,initial,2017-01-13,GCST004088,Nonsyndromic cleft lip with or without cleft palate
13596,Other/Mixed,1.0,28084903.0,Hallberg P,"Other trait, Response to drug",initial,2017-01-13,GCST004049,Cough in response to angiotensin-converting enzyme inhibitor drugs
13951,Other/Mixed,589.0,28087736.0,Ludwig KU,Other trait,replication,2017-01-13,GCST004088,Nonsyndromic cleft lip with or without cleft palate
6325,European,1145.0,28087736.0,Ludwig KU,Other trait,replication,2017-01-13,GCST004088,Nonsyndromic cleft lip with or without cleft palate
12886,Hispanic or Latin American,475.0,28087736.0,Ludwig KU,Other trait,replication,2017-01-13,GCST004088,Nonsyndromic cleft lip with or without cleft palate
4778,European,123.0,28084903.0,Hallberg P,"Other trait, Response to drug",initial,2017-01-13,GCST004049,Cough in response to angiotensin-converting enzyme inhibitor drugs
4747,European,96.0,28108127.0,Eitel I,Cardiovascular disease,initial,2017-01-15,GCST004095,Takotsubo syndrome
506,African American or Afro-Caribbean,111.0,28090653.0,Liu Y,"Liver enzyme measurement, Cancer, Response to drug",initial,2017-01-16,GCST004250,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
13719,Other/Mixed,56.0,28090653.0,Liu Y,"Liver enzyme measurement, Cancer, Response to drug",initial,2017-01-16,GCST004250,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
12759,Hispanic or Latin American,60.0,28090653.0,Liu Y,"Liver enzyme measurement, Cancer, Response to drug",initial,2017-01-16,GCST004250,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
7977,European,3409.0,28060188.0,Hamet P,Metabolic disorder,initial,2017-01-16,GCST004125,Type 2 diabetes (age of onset)
5378,European,488.0,28090653.0,Liu Y,"Liver enzyme measurement, Cancer, Response to drug",initial,2017-01-16,GCST004250,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
12970,Hispanic or Latin American,768.0,28095793.0,Chittoor G,Cardiovascular measurement,initial,2017-01-17,GCST004058,Uric acid clearance
11012,European,35298.0,28093568.0,Trampush JW,"Biological process, Other measurement",initial,2017-01-17,GCST004077,Cognitive function
12971,Hispanic or Latin American,768.0,28095793.0,Chittoor G,Other measurement,initial,2017-01-17,GCST004056,Urinary uric acid to urinary creatinine ratio
12969,Hispanic or Latin American,768.0,28095793.0,Chittoor G,Cardiovascular measurement,initial,2017-01-17,GCST004055,Fractional excretion of uric acid
12968,Hispanic or Latin American,768.0,28095793.0,Chittoor G,Cardiovascular measurement,initial,2017-01-17,GCST004054,Glomerular load of uric acid
12972,Hispanic or Latin American,768.0,28095793.0,Chittoor G,Other measurement,initial,2017-01-17,GCST004057,Creatinine clearance
5321,European,463.0,28100725.0,Chen J,Other measurement,initial,2017-01-18,GCST004092,Plasma t-tau levels
13058,Hispanic or Latin American,1411.0,28098162.0,Hibar DP,Other measurement,replication,2017-01-18,GCST003961,Hippocampal volume
4953,European,229.0,28109725.0,Fuchs O,Other measurement,initial,2017-01-18,GCST004060,Exhaled nitric oxide output
8162,European,3863.0,28098162.0,Hibar DP,Other measurement,replication,2017-01-18,GCST003961,Hippocampal volume
4952,European,229.0,28109725.0,Fuchs O,Other measurement,initial,2017-01-18,GCST004059,Exhaled nitric oxide levels
10776,European,26814.0,28098162.0,Hibar DP,Other measurement,initial,2017-01-18,GCST003961,Hippocampal volume
2442,Asian,886.0,28098162.0,Hibar DP,Other measurement,replication,2017-01-18,GCST003961,Hippocampal volume
728,African American or Afro-Caribbean,562.0,28098162.0,Hibar DP,Other measurement,replication,2017-01-18,GCST003961,Hippocampal volume
2400,Asian,805.0,28100913.0,Ueta M,"Other disease, Response to drug",initial,2017-01-19,GCST004072,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications
2031,Asian,354.0,28100913.0,Ueta M,"Other disease, Response to drug",replication,2017-01-19,GCST004072,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications
11720,European,91953.0,28107422.0,de Vries PS,Hematological measurement,initial,2017-01-20,GCST004122,Fibrinogen levels
11719,European,91953.0,28107422.0,de Vries PS,Hematological measurement,initial,2017-01-20,GCST004121,Fibrinogen levels
5218,European,411.0,28128768.0,Ferrari R,"Neurological disorder, Other measurement",initial,2017-01-23,GCST004096,Frontotemporal dementia (age at onset)
10145,European,14421.0,28112199.0,Law PJ,Cancer,initial,2017-01-23,GCST004099,"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)"
10313,European,16731.0,28115744.0,Ikeda M,Neurological disorder,initial,2017-01-24,GCST004139,Bipolar disorder
14050,Other/Mixed,863.0,28118524.0,Saxena R,Immune system disorder,initial,2017-01-24,GCST004172,Rheumatoid arthritis
13932,Other/Mixed,506.0,28118524.0,Saxena R,Immune system disorder,initial,2017-01-24,GCST004173,Rheumatoid arthritis (rheumatoid factor and anti-cyclic citrullinated peptide seronegative)
13848,Other/Mixed,279.0,28118524.0,Saxena R,Immune system disorder,replication,2017-01-24,GCST004173,Rheumatoid arthritis (rheumatoid factor and anti-cyclic citrullinated peptide seronegative)
6218,European,1027.0,28115739.0,Smith AH,"Neurological disorder, Other measurement",initial,2017-01-24,GCST004136,Methadone dose in opioid dependence
13931,Other/Mixed,504.0,28118524.0,Saxena R,Immune system disorder,replication,2017-01-24,GCST004172,Rheumatoid arthritis
666,African American or Afro-Caribbean,383.0,28115739.0,Smith AH,"Neurological disorder, Other measurement",initial,2017-01-24,GCST004136,Methadone dose in opioid dependence
13918,Other/Mixed,459.0,28118524.0,Saxena R,"Other measurement, Immune system disorder",replication,2017-01-24,GCST004174,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)
4534,Asian,64851.0,28115744.0,Ikeda M,Neurological disorder,initial,2017-01-24,GCST004139,Bipolar disorder
14011,Other/Mixed,709.0,28118524.0,Saxena R,"Other measurement, Immune system disorder",initial,2017-01-24,GCST004174,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)
1899,Asian,226.0,28120872.0,Li X,"Cancer, Response to drug",initial,2017-01-25,GCST004097,Response to platinum-based neoadjuvant chemotherapy in cervical cancer
2048,Asian,370.0,28120872.0,Li X,"Cancer, Response to drug",replication,2017-01-25,GCST004097,Response to platinum-based neoadjuvant chemotherapy in cervical cancer
2384,Asian,780.0,28130311.0,Tan W,Digestive system disorder,initial,2017-01-27,GCST004165,Acute-on-chronic liver failure in hepatitis B
3202,Asian,2587.0,28130311.0,Tan W,Digestive system disorder,replication,2017-01-27,GCST004165,Acute-on-chronic liver failure in hepatitis B
11981,European,140886.0,28135244.0,Warren HR,Other measurement,initial,2017-01-30,GCST004280,Diastolic blood pressure
11980,European,140886.0,28135244.0,Warren HR,Cardiovascular measurement,initial,2017-01-30,GCST004278,Pulse pressure
11977,European,140882.0,28135244.0,Warren HR,Other measurement,initial,2017-01-30,GCST004279,Systolic blood pressure
12178,European,190318.0,28135244.0,Warren HR,Other measurement,replication,2017-01-30,GCST004279,Systolic blood pressure
12177,European,190318.0,28135244.0,Warren HR,Cardiovascular measurement,replication,2017-01-30,GCST004278,Pulse pressure
12179,European,190318.0,28135244.0,Warren HR,Other measurement,replication,2017-01-30,GCST004280,Diastolic blood pressure
943,African American or Afro-Caribbean,1585.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004094,Prostate-specific antigen levels (conditioned on lead SNPs)
13157,Hispanic or Latin American,2716.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004094,Prostate-specific antigen levels (conditioned on lead SNPs)
13156,Hispanic or Latin American,2716.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004093,Prostate-specific antigen levels
3183,Asian,2518.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004094,Prostate-specific antigen levels (conditioned on lead SNPs)
3182,Asian,2518.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004093,Prostate-specific antigen levels
9953,European,11796.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004093,Prostate-specific antigen levels
6993,European,1936.0,28139761.0,Pasanen A,Other trait,replication,2017-01-31,GCST004140,Bronchiolitis
8928,European,6193.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004094,Prostate-specific antigen levels (conditioned on lead SNPs)
5177,European,393.0,27903959.0,Lv H,Cancer,initial,2017-01-31,GCST008413,Core binding factor acute myeloid leukemia
942,African American or Afro-Caribbean,1585.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004093,Prostate-specific antigen levels
10810,European,28503.0,28139693.0,Hoffmann TJ,Other measurement,initial,2017-01-31,GCST004094,Prostate-specific antigen levels (conditioned on lead SNPs)
6158,European,995.0,28139761.0,Pasanen A,Other trait,initial,2017-01-31,GCST004140,Bronchiolitis
10809,European,28503.0,28139693.0,Hoffmann TJ,Other measurement,initial,2017-01-31,GCST004093,Prostate-specific antigen levels
13460,Hispanic or Latin American,11809.0,28158719.0,Jain D,"Hematological measurement, Inflammatory measurement",initial,2017-02-01,GCST004126,White blood cell count
7079,European,2045.0,28053049.0,Sennblad B,Hematological measurement,replication,2017-02-01,GCST004124,Factor XI
13368,Hispanic or Latin American,7200.0,28158719.0,Jain D,Hematological measurement,replication,2017-02-01,GCST004130,White blood cell count (lymphocyte)
13457,Hispanic or Latin American,11809.0,28158719.0,Jain D,Hematological measurement,initial,2017-02-01,GCST004129,White blood cell count (monocyte)
13369,Hispanic or Latin American,7200.0,28158719.0,Jain D,Hematological measurement,replication,2017-02-01,GCST004135,White blood cell count (eosinophil)
13371,Hispanic or Latin American,7200.0,28158719.0,Jain D,Inflammatory measurement,replication,2017-02-01,GCST004127,White blood cell count (basophil)
13370,Hispanic or Latin American,7200.0,28158719.0,Jain D,"Hematological measurement, Inflammatory measurement",replication,2017-02-01,GCST004126,White blood cell count
13367,Hispanic or Latin American,7200.0,28158719.0,Jain D,Hematological measurement,replication,2017-02-01,GCST004129,White blood cell count (monocyte)
13456,Hispanic or Latin American,11809.0,28158719.0,Jain D,Hematological measurement,initial,2017-02-01,GCST004128,White blood cell count (neutrophil)
13458,Hispanic or Latin American,11809.0,28158719.0,Jain D,Hematological measurement,initial,2017-02-01,GCST004130,White blood cell count (lymphocyte)
13366,Hispanic or Latin American,7200.0,28158719.0,Jain D,Hematological measurement,replication,2017-02-01,GCST004128,White blood cell count (neutrophil)
13459,Hispanic or Latin American,11809.0,28158719.0,Jain D,Hematological measurement,initial,2017-02-01,GCST004135,White blood cell count (eosinophil)
10259,European,16169.0,28053049.0,Sennblad B,Hematological measurement,initial,2017-02-01,GCST004124,Factor XI
13461,Hispanic or Latin American,11809.0,28158719.0,Jain D,Inflammatory measurement,initial,2017-02-01,GCST004127,White blood cell count (basophil)
2136,Asian,457.0,28163062.0,Matsuura K,"Other measurement, Response to drug, Cancer",initial,2017-02-02,GCST004160,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy
7099,European,2053.0,28256260.0,Siitonen A,Neurological disorder,initial,2017-02-02,GCST004138,Early-onset Parkinson's disease
2018,Asian,340.0,28163062.0,Matsuura K,"Other measurement, Response to drug, Cancer",replication,2017-02-02,GCST004160,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy
2500,Asian,998.0,28155865.0,Chen H,Biological process,initial,2017-02-03,GCST004123,Mathematical ability
2238,Asian,599.0,28155865.0,Chen H,Biological process,replication,2017-02-03,GCST004123,Mathematical ability
12865,Hispanic or Latin American,440.0,28167095.0,Forno E,"Other measurement, Other disease",initial,2017-02-04,GCST004107,Lung function (FEV1) in asthma (dust mite allergen exposure interaction)
12866,Hispanic or Latin American,440.0,28167095.0,Forno E,"Other measurement, Other disease",initial,2017-02-04,GCST004108,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)
5400,European,497.0,28167095.0,Forno E,"Other measurement, Other disease",replication,2017-02-04,GCST004108,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)
12923,Hispanic or Latin American,605.0,28167095.0,Forno E,"Other measurement, Other disease",replication,2017-02-04,GCST004107,Lung function (FEV1) in asthma (dust mite allergen exposure interaction)
12924,Hispanic or Latin American,605.0,28167095.0,Forno E,"Other measurement, Other disease",replication,2017-02-04,GCST004108,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)
5399,European,497.0,28167095.0,Forno E,"Other measurement, Other disease",replication,2017-02-04,GCST004107,Lung function (FEV1) in asthma (dust mite allergen exposure interaction)
10376,European,17691.0,28165464.0,Law PJ,Cancer,initial,2017-02-06,GCST004146,Chronic lymphocytic leukemia
1265,African American or Afro-Caribbean,4983.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004246,Alzheimer's disease
10656,European,23162.0,28166215.0,Hobbs BD,Other disease,replication,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
3827,Asian,6940.0,28166215.0,Hobbs BD,Other disease,initial,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
1186,African American or Afro-Caribbean,3522.0,28166215.0,Hobbs BD,Other disease,initial,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
2292,Asian,686.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004248,Alzheimer's disease in APOE e4+ carriers
12918,Hispanic or Latin American,600.0,28166215.0,Hobbs BD,Other disease,initial,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
1266,African American or Afro-Caribbean,4983.0,28183528.0,Jun GR,"Neurological disorder, Other measurement",initial,2017-02-06,GCST004247,Alzheimer's disease (APOE e4 interaction)
10151,European,14569.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004249,Alzheimer's disease in APOE e4- carriers
2033,Asian,358.0,28166215.0,Hobbs BD,Other disease,replication,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
11377,European,57176.0,28166213.0,Wain LV,Other measurement,replication,2017-02-06,GCST004184,Lung function (FVC)
11378,European,57176.0,28166213.0,Wain LV,Other measurement,replication,2017-02-06,GCST004185,Lung function (FEV1/FVC)
11244,European,47856.0,28166215.0,Hobbs BD,Other disease,initial,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
10763,European,26320.0,28183528.0,Jun GR,"Neurological disorder, Other measurement",initial,2017-02-06,GCST004247,Alzheimer's disease (APOE e4 interaction)
11259,European,48943.0,28166213.0,Wain LV,Other measurement,initial,2017-02-06,GCST004183,Lung function (FEV1)
10762,European,26320.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004246,Alzheimer's disease
10760,European,26287.0,28183528.0,Jun GR,"Neurological disorder, Other measurement",replication,2017-02-06,GCST004247,Alzheimer's disease (APOE e4 interaction)
11260,European,48943.0,28166213.0,Wain LV,Other measurement,initial,2017-02-06,GCST004184,Lung function (FVC)
11261,European,48943.0,28166213.0,Wain LV,Other measurement,initial,2017-02-06,GCST004185,Lung function (FEV1/FVC)
2911,Asian,1845.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004246,Alzheimer's disease
2912,Asian,1845.0,28183528.0,Jun GR,"Neurological disorder, Other measurement",initial,2017-02-06,GCST004247,Alzheimer's disease (APOE e4 interaction)
8908,European,6107.0,28165464.0,Law PJ,Cancer,replication,2017-02-06,GCST004146,Chronic lymphocytic leukemia
9973,European,12039.0,28183528.0,Jun GR,Neurological disorder,replication,2017-02-06,GCST004248,Alzheimer's disease in APOE e4+ carriers
10137,European,14248.0,28183528.0,Jun GR,Neurological disorder,replication,2017-02-06,GCST004249,Alzheimer's disease in APOE e4- carriers
2567,Asian,1159.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004249,Alzheimer's disease in APOE e4- carriers
10759,European,26287.0,28183528.0,Jun GR,Neurological disorder,replication,2017-02-06,GCST004246,Alzheimer's disease
13758,Other/Mixed,115.0,28183528.0,Jun GR,"Neurological disorder, Other measurement",initial,2017-02-06,GCST004247,Alzheimer's disease (APOE e4 interaction)
13757,Other/Mixed,115.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004249,Alzheimer's disease in APOE e4- carriers
9938,European,11751.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004248,Alzheimer's disease in APOE e4+ carriers
13756,Other/Mixed,115.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004246,Alzheimer's disease
1095,African American or Afro-Caribbean,2877.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004249,Alzheimer's disease in APOE e4- carriers
11376,European,57176.0,28166213.0,Wain LV,Other measurement,replication,2017-02-06,GCST004183,Lung function (FEV1)
1013,African American or Afro-Caribbean,2106.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004248,Alzheimer's disease in APOE e4+ carriers
8974,European,6392.0,28167838.0,Deckert J,Other measurement,replication,2017-02-07,GCST004109,Agoraphobic traits
6548,European,1370.0,28167838.0,Deckert J,Other measurement,initial,2017-02-07,GCST004109,Agoraphobic traits
5366,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004176,Pediatric areal bone mineral density (radius)
5365,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004175,Pediatric bone mineral content (radius)
5368,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004178,Pediatric bone mineral density (hip)
7652,European,2830.0,28212542.0,Ransohoff KJ,Cancer,replication,2017-02-09,GCST004142,Melanoma
5371,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004181,Pediatric bone mineral density (spine)
5372,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004182,Pediatric bone mineral content (spine)
12369,European,291407.0,28212542.0,Ransohoff KJ,Cancer,initial,2017-02-09,GCST004142,Melanoma
5367,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004177,Pediatric bone mineral density (femoral neck)
5369,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004179,Pediatric bone mineral content (femoral neck)
5370,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004180,Pediatric bone mineral content (hip)
6043,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004178,Pediatric bone mineral density (hip)
6042,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004177,Pediatric bone mineral density (femoral neck)
6044,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004179,Pediatric bone mineral content (femoral neck)
6041,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004176,Pediatric areal bone mineral density (radius)
6045,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004180,Pediatric bone mineral content (hip)
6046,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004181,Pediatric bone mineral density (spine)
6047,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004182,Pediatric bone mineral content (spine)
6040,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004175,Pediatric bone mineral content (radius)
2473,Asian,950.0,28187132.0,Kiryluk K,Other measurement,initial,2017-02-10,GCST004159,Serum galactose-deficient IgA1 levels
4977,European,245.0,28187132.0,Kiryluk K,Other measurement,initial,2017-02-10,GCST004159,Serum galactose-deficient IgA1 levels
5835,European,785.0,28187132.0,Kiryluk K,Other measurement,replication,2017-02-10,GCST004159,Serum galactose-deficient IgA1 levels
2265,Asian,653.0,28187132.0,Kiryluk K,Other measurement,replication,2017-02-10,GCST004159,Serum galactose-deficient IgA1 levels
11306,European,52874.0,28196072.0,Hagenaars SP,"Other measurement, Other disease",initial,2017-02-14,GCST006661,Male-pattern baldness
8855,European,5892.0,28193307.0,Lin BD,Hematological measurement,initial,2017-02-14,GCST004170,Monocyte-lymphocyte ratio
11793,European,108976.0,28194004.0,Deary V,Other measurement,initial,2017-02-14,GCST004158,Self-reported tiredness
8854,European,5892.0,28193307.0,Lin BD,Hematological measurement,initial,2017-02-14,GCST004164,Monocyte count
12367,European,290551.0,28195142.0,Gudmundsson J,Cancer,initial,2017-02-14,GCST004144,Thyroid cancer
1279,African American or Afro-Caribbean,5334.0,28203683.0,Heit JA,Cardiovascular disease,initial,2017-02-16,GCST004068,Venous thromboembolism adjusted for sickle cell variant rs77121243-T
4131,Asian,10857.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004237,Triglyceride levels
4483,Asian,38060.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004238,Triglyceride levels
4416,Asian,28183.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004237,Triglyceride levels
4446,Asian,32576.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004235,Total cholesterol levels
4461,Asian,34930.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004232,HDL cholesterol levels
3977,Asian,8478.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004233,LDL cholesterol levels
4130,Asian,10855.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004235,Total cholesterol levels
4332,Asian,18421.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004238,Triglyceride levels
4389,Asian,22814.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004231,Total cholesterol levels
4395,Asian,25169.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004234,HDL cholesterol levels
4482,Asian,37842.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004236,LDL cholesterol levels
4384,Asian,22526.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004236,LDL cholesterol levels
4445,Asian,32285.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004233,LDL cholesterol levels
12156,European,177861.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004237,Triglyceride levels
4523,Asian,57490.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004231,Total cholesterol levels
12147,European,173082.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004233,LDL cholesterol levels
12168,European,187365.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004235,Total cholesterol levels
3999,Asian,8741.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004232,HDL cholesterol levels
4507,Asian,45953.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004234,HDL cholesterol levels
12165,European,187167.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004232,HDL cholesterol levels
12399,European,304241.0,28177523.0,Lin Y,Cancer,initial,2017-02-22,GCST004113,Basal cell carcinoma
12357,European,287338.0,28223688.0,Bjornsdottir G,"Other trait, Other disease, Other measurement",initial,2017-02-22,GCST004098,Sciatica caused by lumbar disc herniation (treated with microdiscectomy)
9600,European,9179.0,28224759.0,Pei YF,Other measurement,initial,2017-02-22,GCST004141,Body fat mass
9537,European,8703.0,28649644.0,Pivot X,"Cancer, Other measurement",initial,2017-02-23,GCST004528,HER2 status in breast cancer
9170,European,7189.0,28282560.0,Pott J,Cardiovascular measurement,initial,2017-02-24,GCST004162,Carotid plaque burden
3754,Asian,6084.0,28232668.0,Yu Y,Other trait,initial,2017-02-24,GCST004166,Nonsyndromic cleft lip with cleft palate
3731,Asian,5888.0,28232668.0,Yu Y,Other trait,replication,2017-02-24,GCST004166,Nonsyndromic cleft lip with cleft palate
6162,European,997.0,28240269.0,Suhre K,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",initial,2017-02-27,GCST004365,Blood protein levels
3362,Asian,3418.0,28334792.0,Nongmaithem SS,Other measurement,replication,2017-02-27,GCST004161,Vitamin B12 levels
7242,European,2209.0,28250457.0,Scerri TS,Neurological disorder,initial,2017-02-27,GCST004171,Macular telangiectasia type 2
13880,Other/Mixed,338.0,28240269.0,Suhre K,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",replication,2017-02-27,GCST004365,Blood protein levels
2503,Asian,1001.0,28334792.0,Nongmaithem SS,Other measurement,initial,2017-02-27,GCST004161,Vitamin B12 levels
6494,European,1306.0,28250457.0,Scerri TS,Neurological disorder,replication,2017-02-27,GCST004171,Macular telangiectasia type 2
3388,Asian,3560.0,28334814.0,Zhu Z,Other disease,initial,2017-02-28,GCST004288,Adolescent idiopathic scoliosis
4124,Asian,10464.0,28334814.0,Zhu Z,Other disease,replication,2017-02-28,GCST004288,Adolescent idiopathic scoliosis
8241,European,4057.0,28253294.0,Vonk JM,"Biological process, Other disease",initial,2017-03-02,GCST004220,Adult onset asthma (smoking interaction)
9240,European,7496.0,28253294.0,Vonk JM,"Biological process, Other disease",replication,2017-03-02,GCST004222,Adult onset asthma in ever-smokers
7007,European,1950.0,28253294.0,Vonk JM,Other disease,initial,2017-03-02,GCST004221,Adult onset asthma in non-smokers
10001,European,12475.0,28253294.0,Vonk JM,"Biological process, Other disease",replication,2017-03-02,GCST004220,Adult onset asthma (smoking interaction)
13375,Hispanic or Latin American,7746.0,28254843.0,Qi Q,Metabolic disorder,initial,2017-03-02,GCST004758,Type 2 diabetes
7140,European,2107.0,28253294.0,Vonk JM,"Biological process, Other disease",initial,2017-03-02,GCST004222,Adult onset asthma in ever-smokers
8582,European,4979.0,28253294.0,Vonk JM,Other disease,replication,2017-03-02,GCST004221,Adult onset asthma in non-smokers
3235,Asian,2751.0,28274756.0,Mhatre S,Cancer,initial,2017-03-03,GCST004201,Gallbladder cancer
2423,Asian,848.0,28274756.0,Mhatre S,Cancer,replication,2017-03-03,GCST004201,Gallbladder cancer
4012,Asian,8839.0,28273873.0,Park YM,Cardiovascular disease,initial,2017-03-05,GCST004143,Hypertension
9888,European,11170.0,28265093.0,Malik R,Cardiovascular disease,initial,2017-03-06,GCST007991,Large artery stroke
2653,Asian,1354.0,28265093.0,Malik R,Cardiovascular disease,initial,2017-03-06,GCST007991,Large artery stroke
13843,Other/Mixed,258.0,28262088.0,Melroy-Greif WE,"Other measurement, Biological process",initial,2017-03-06,GCST005550,Post traumatic stress disorder symptom count in trauma-exposed individuals
12821,Hispanic or Latin American,254.0,28262088.0,Melroy-Greif WE,"Other measurement, Biological process",initial,2017-03-06,GCST005550,Post traumatic stress disorder symptom count in trauma-exposed individuals
13174,Hispanic or Latin American,3238.0,28265120.0,Polimanti R,Other measurement,initial,2017-03-07,GCST004225,Alcohol misuse (trauma interaction)
9839,European,10732.0,28265120.0,Polimanti R,Other measurement,initial,2017-03-07,GCST004225,Alcohol misuse (trauma interaction)
10494,European,19695.0,28270201.0,Nagy R,"Body measurement, Other measurement",initial,2017-03-07,GCST004216,Waist-to-hip ratio adjusted for body mass index
1243,African American or Afro-Caribbean,4329.0,28265120.0,Polimanti R,Other measurement,replication,2017-03-07,GCST004225,Alcohol misuse (trauma interaction)
10484,European,19546.0,28270201.0,Nagy R,Other measurement,initial,2017-03-07,GCST004203,Diastolic blood pressure
7120,European,2077.0,28270201.0,Nagy R,"Metabolic disorder, Other measurement",initial,2017-03-07,GCST004211,Urate levels
10485,European,19547.0,28270201.0,Nagy R,Other measurement,initial,2017-03-07,GCST004204,Systolic blood pressure
10472,European,19293.0,28270201.0,Nagy R,Other measurement,initial,2017-03-07,GCST004215,Urea levels
10466,European,19259.0,28270201.0,Nagy R,Lipid or lipoprotein measurement,initial,2017-03-07,GCST004209,"Cholesterol, total"
10478,European,19480.0,28270201.0,Nagy R,Body measurement,initial,2017-03-07,GCST004210,Body fat percentage
10464,European,19223.0,28270201.0,Nagy R,Lipid or lipoprotein measurement,initial,2017-03-07,GCST004207,HDL cholesterol
10483,European,19546.0,28270201.0,Nagy R,Cardiovascular measurement,initial,2017-03-07,GCST004205,Pulse pressure
10510,European,19920.0,28270201.0,Nagy R,Cardiovascular measurement,initial,2017-03-07,GCST004213,Resting heart rate
10261,European,16174.0,28270201.0,Nagy R,Other measurement,initial,2017-03-07,GCST004206,Fasting plasma glucose
1045,African American or Afro-Caribbean,2391.0,28265120.0,Polimanti R,Other measurement,initial,2017-03-07,GCST004225,Alcohol misuse (trauma interaction)
8123,European,3755.0,28265120.0,Polimanti R,Other measurement,replication,2017-03-07,GCST004225,Alcohol misuse (trauma interaction)
10277,European,16347.0,28270201.0,Nagy R,Other measurement,initial,2017-03-07,GCST004214,Creatinine levels
10509,European,19900.0,28270201.0,Nagy R,"Body measurement, Other measurement",initial,2017-03-07,GCST004208,Body mass index
10511,European,19965.0,28270201.0,Nagy R,"Other measurement, Body measurement",initial,2017-03-07,GCST004212,Height
10633,European,22518.0,28272467.0,Heilmann-Heimbach S,"Other measurement, Other disease",initial,2017-03-08,GCST007815,Male-pattern baldness
5614,European,626.0,28439531.0,Aslibekyan S,Other measurement,initial,2017-03-08,GCST004484,Plasma trimethylamine N-oxide levels
5659,European,660.0,28781888.0,Mobuchon L,Cancer,initial,2017-03-10,GCST004661,Uveal melanoma
5316,European,460.0,28781888.0,Mobuchon L,Cancer,replication,2017-03-10,GCST004661,Uveal melanoma
5103,European,339.0,28283553.0,Srinivasan L,Other trait,initial,2017-03-10,GCST004230,Sepsis in extremely premature infants
1003,African American or Afro-Caribbean,2041.0,28295283.0,Wang H,Cancer,replication,2017-03-13,GCST004168,Colorectal cancer
1323,African American or Afro-Caribbean,6597.0,28295283.0,Wang H,Cancer,initial,2017-03-13,GCST004168,Colorectal cancer
1300,African American or Afro-Caribbean,6154.0,28295283.0,Wang H,Cancer,initial,2017-03-13,GCST004167,Colon cancer
187,African,1411.0,28296344.0,Chen G,"Body measurement, Other measurement",replication,2017-03-13,GCST004255,Body mass index
208,African,1570.0,28296344.0,Chen G,"Body measurement, Other measurement",initial,2017-03-13,GCST004255,Body mass index
1274,African American or Afro-Caribbean,5146.0,28295283.0,Wang H,Cancer,initial,2017-03-13,GCST004169,Rectal cancer
13314,Hispanic or Latin American,5941.0,28295283.0,Wang H,Cancer,replication,2017-03-13,GCST004168,Colorectal cancer
1409,African American or Afro-Caribbean,9020.0,28296344.0,Chen G,"Body measurement, Other measurement",replication,2017-03-13,GCST004255,Body mass index
922,African American or Afro-Caribbean,1434.0,28295283.0,Wang H,Cancer,replication,2017-03-13,GCST004169,Rectal cancer
962,African American or Afro-Caribbean,1753.0,28295283.0,Wang H,Cancer,replication,2017-03-13,GCST004167,Colon cancer
8418,European,4610.0,28179588.0,Fagerholm R,"Cancer, Other measurement",replication,2017-03-14,GCST004229,Survival in breast cancer (TP53 expression interaction)
5182,European,396.0,28292921.0,Boldry EJ,Other measurement,initial,2017-03-14,GCST004254,"Urinary 1,3-butadiene metabolite levels in smokers"
634,African American or Afro-Caribbean,327.0,28292921.0,Boldry EJ,Other measurement,initial,2017-03-14,GCST004254,"Urinary 1,3-butadiene metabolite levels in smokers"
5528,European,572.0,28179588.0,Fagerholm R,"Cancer, Other measurement",initial,2017-03-14,GCST004229,Survival in breast cancer (TP53 expression interaction)
2025,Asian,349.0,28292921.0,Boldry EJ,Other measurement,initial,2017-03-14,GCST004254,"Urinary 1,3-butadiene metabolite levels in smokers"
4818,European,157.0,28179588.0,Fagerholm R,"Cancer, Other measurement",initial,2017-03-14,GCST004228,Survival in TP53 positive breast cancer
9972,European,12020.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004342,Vaccenic acid (18:1n-7) levels
3384,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004341,Nervonic acid (24:1n-9) levels
3382,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004339,Palmitoleic acid (16:1n-7) levels
3385,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004342,Vaccenic acid (18:1n-7) levels
3383,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004340,Erucic acid (22:1n-9) levels
9969,European,12020.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004337,Gondoic acid (20:1n-9) levels
9970,European,12020.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004340,Erucic acid (22:1n-9) levels
9971,European,12020.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004341,Nervonic acid (24:1n-9) levels
3381,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004338,Oleic acid (18:1n-9) levels
3380,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004337,Gondoic acid (20:1n-9) levels
660,African American or Afro-Caribbean,373.0,28300201.0,Hernandez-Pacheco N,"Other trait, Other measurement",replication,2017-03-16,GCST004219,Skin pigmentation
12827,Hispanic or Latin American,285.0,28300201.0,Hernandez-Pacheco N,"Other trait, Other measurement",initial,2017-03-16,GCST004219,Skin pigmentation
3170,Asian,2497.0,28314753.0,Terao C,Neurological disorder,initial,2017-03-17,GCST004202,Systemic sclerosis
9960,European,11907.0,28314753.0,Terao C,Neurological disorder,replication,2017-03-17,GCST004202,Systemic sclerosis
7336,European,2340.0,28314753.0,Terao C,Neurological disorder,initial,2017-03-17,GCST004202,Systemic sclerosis
3154,Asian,2427.0,28314753.0,Terao C,Neurological disorder,replication,2017-03-17,GCST004202,Systemic sclerosis
2187,Asian,503.0,28415562.0,Li X,Other disease,replication,2017-03-18,GCST004200,High-altitude pulmonary edema
1804,Asian,152.0,28415562.0,Li X,Other disease,initial,2017-03-18,GCST004200,High-altitude pulmonary edema
5706,European,696.0,28317342.0,Hivert MF,Other measurement,replication,2017-03-20,GCST004289,Adiponectin levels in pregnancy
6502,European,1322.0,28317342.0,Hivert MF,Other measurement,initial,2017-03-20,GCST004289,Adiponectin levels in pregnancy
12234,European,212171.0,28319091.0,Styrkarsdottir U,"Other disease, Other measurement",initial,2017-03-20,GCST004199,Osteoarthritis (with total hip replacement)
7278,European,2283.0,28322352.0,Ran S,Other measurement,replication,2017-03-21,GCST004218,Lean body mass
14284,Other/Mixed,79845.0,28322246.0,McLaughlin RL,Neurological disorder,initial,2017-03-21,GCST004252,Amyotrophic lateral sclerosis or schizophrenia (pleiotropy)
6170,European,1000.0,28322352.0,Ran S,Other measurement,initial,2017-03-21,GCST004218,Lean body mass
10908,European,32241.0,28322246.0,McLaughlin RL,Neurological disorder,initial,2017-03-21,GCST004252,Amyotrophic lateral sclerosis or schizophrenia (pleiotropy)
7149,European,2129.0,28333968.0,Nielsen TR,Other measurement,replication,2017-03-23,GCST004277,Free thyroxine concentration
1725,Asian,98.0,28352666.0,Liu TC,"Digestive system disorder, Other measurement",initial,2017-03-23,GCST004251,Paneth cell defects in Crohn's disease
7729,European,2998.0,28386217.0,Ritter ML,Neurological disorder,initial,2017-03-23,GCST004223,Attention deficit hyperactivity disorder and obsessive compulsive disorder
7148,European,2129.0,28333968.0,Nielsen TR,Other measurement,replication,2017-03-23,GCST004276,Plasma thyroid-stimulating hormone levels
6802,European,1680.0,28333968.0,Nielsen TR,Other measurement,initial,2017-03-23,GCST004276,Plasma thyroid-stimulating hormone levels
6803,European,1680.0,28333968.0,Nielsen TR,Other measurement,initial,2017-03-23,GCST004277,Free thyroxine concentration
11181,European,43507.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004419,Mucinous ovarian carcinoma
11188,European,43907.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004481,Low-grade serous and serous borderline ovarian cancer
11174,European,42895.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004479,Serous borderline ovarian cancer
10873,European,30659.0,28346443.0,Melin BS,Cancer,initial,2017-03-27,GCST004347,Glioma
10714,European,24381.0,28346443.0,Melin BS,Cancer,initial,2017-03-27,GCST004349,Glioblastoma
11166,European,42307.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004417,Ovarian clear cell cancer
10448,European,19036.0,28346442.0,Phelan CM,"Other measurement, Cancer",initial,2017-03-27,GCST004414,Ovarian cancer in BRCA1 mutation carriers
11433,European,63347.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004415,Invasive epithelial ovarian cancer
11159,European,41953.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004461,Low-grade serous ovarian cancer
11347,European,54990.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004478,Serous invasive ovarian cancer
11185,European,43751.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004418,Endometrioid ovarian cancer
8657,European,5161.0,28030426.0,Mahmoudpour SH,Response to drug,initial,2017-03-27,GCST004029,Angiotensin-converting enzyme inhibitor intolerance
10694,European,24009.0,28346443.0,Melin BS,Cancer,initial,2017-03-27,GCST004348,Non-glioblastoma glioma
9996,European,12412.0,28346442.0,Phelan CM,"Other measurement, Cancer",initial,2017-03-27,GCST004416,Ovarian cancer in BRCA2 mutation carriers
11326,European,53978.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004480,High-grade serous ovarian cancer
11637,European,85426.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004462,Epithelial ovarian cancer
2948,Asian,1908.0,28346466.0,Chen G,Metabolic disorder,initial,2017-03-27,GCST007620,Type 2 diabetes
333,African,10401.0,28346466.0,Chen G,Metabolic disorder,replication,2017-03-27,GCST007620,Type 2 diabetes
6709,European,1562.0,28355232.0,Ward-Caviness CK,Other measurement,initial,2017-03-29,GCST004224,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction)
717,African American or Afro-Caribbean,538.0,28355232.0,Ward-Caviness CK,Other measurement,initial,2017-03-29,GCST004224,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction)
2882,Asian,1790.0,28355295.0,Hong EP,"Other disease, Other measurement",initial,2017-03-29,GCST004226,Tuberculosis
2289,Asian,679.0,28355295.0,Hong EP,"Other disease, Other measurement",replication,2017-03-29,GCST004226,Tuberculosis
11206,European,45889.0,28360221.0,Boger CA,Other measurement,initial,2017-03-30,GCST004267,Blood osmolality (transformed sodium)
4132,Asian,10978.0,28371326.0,Zhu Y,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",replication,2017-03-30,GCST004239,Metabolic syndrome
3881,Asian,7518.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004263,Achilles tendinopathy
3882,Asian,7518.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004265,Anterior cruciate ligament rupture
4133,Asian,10978.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,replication,2017-03-30,GCST004241,Triglyceride levels
11615,European,83264.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004265,Anterior cruciate ligament rupture
10371,European,17637.0,28360221.0,Boger CA,Other measurement,replication,2017-03-30,GCST004267,Blood osmolality (transformed sodium)
8200,European,3968.0,28358029.0,Afshari NA,Neurological disorder,initial,2017-03-30,GCST004217,Fuchs's corneal dystrophy
13405,Hispanic or Latin American,8560.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004263,Achilles tendinopathy
13406,Hispanic or Latin American,8560.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004265,Anterior cruciate ligament rupture
2156,Asian,476.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004263,Achilles tendinopathy
3479,Asian,4219.0,28371326.0,Zhu Y,"Body measurement, Other measurement",replication,2017-03-30,GCST004245,Body mass index
1148,African American or Afro-Caribbean,3161.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004263,Achilles tendinopathy
3480,Asian,4219.0,28371326.0,Zhu Y,"Other measurement, Body measurement",replication,2017-03-30,GCST004244,Waist-hip ratio
11614,European,83264.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004263,Achilles tendinopathy
4134,Asian,10978.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,replication,2017-03-30,GCST004242,HDL cholesterol
1341,African American or Afro-Caribbean,7215.0,28360221.0,Boger CA,Other measurement,initial,2017-03-30,GCST004267,Blood osmolality (transformed sodium)
2834,Asian,1742.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,initial,2017-03-30,GCST004241,Triglyceride levels
2764,Asian,1589.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,replication,2017-03-30,GCST004243,LDL cholesterol levels
2832,Asian,1742.0,28371326.0,Zhu Y,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2017-03-30,GCST004239,Metabolic syndrome
2835,Asian,1742.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,initial,2017-03-30,GCST004242,HDL cholesterol
2833,Asian,1742.0,28371326.0,Zhu Y,"Body measurement, Other measurement",initial,2017-03-30,GCST004245,Body mass index
4002,Asian,8765.0,28360221.0,Boger CA,Other measurement,initial,2017-03-30,GCST004267,Blood osmolality (transformed sodium)
2836,Asian,1742.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,initial,2017-03-30,GCST004243,LDL cholesterol levels
2838,Asian,1742.0,28371326.0,Zhu Y,"Other measurement, Body measurement",initial,2017-03-30,GCST004244,Waist-hip ratio
6606,European,1449.0,28358029.0,Afshari NA,Neurological disorder,replication,2017-03-30,GCST004217,Fuchs's corneal dystrophy
2837,Asian,1742.0,28371326.0,Zhu Y,Other measurement,initial,2017-03-30,GCST004240,Fasting blood glucose
2765,Asian,1589.0,28371326.0,Zhu Y,Other measurement,replication,2017-03-30,GCST004240,Fasting blood glucose
633,African American or Afro-Caribbean,317.0,28289848.0,Haralambieva IH,Response to drug,initial,2017-04-01,GCST004269,Immune response to measles vaccine (measles-specific neutralising antibody titre)
11490,European,69057.0,28199695.0,Jones AV,Other measurement,initial,2017-04-01,GCST004865,Itch intensity from mosquito bite adjusted by bite size
7496,European,2555.0,28289848.0,Haralambieva IH,Response to drug,initial,2017-04-01,GCST004269,Immune response to measles vaccine (measles-specific neutralising antibody titre)
4336,Asian,18422.0,28348047.0,Li C,Other measurement,initial,2017-04-01,GCST004259,Mean arterial pressure (long-term average)
11866,European,120158.0,28373160.0,Klarin D,Cardiovascular disease,initial,2017-04-01,GCST004256,Venous thromboembolism
4333,Asian,18422.0,28348047.0,Li C,Cardiovascular measurement,initial,2017-04-01,GCST004260,Pulse pressure (long-term average)
4335,Asian,18422.0,28348047.0,Li C,Other measurement,initial,2017-04-01,GCST004258,Diastolic blood pressure (long-term average)
9542,European,8746.0,28333195.0,Uimari O,Other disease,initial,2017-04-01,GCST004369,Ovarian disease with few adhesions
4334,Asian,18422.0,28348047.0,Li C,Other measurement,initial,2017-04-01,GCST004257,Systolic blood pressure (long-term average)
5441,European,513.0,28207573.0,Backman JD,Other measurement,initial,2017-04-01,GCST004264,Clopidogrel active metabolite levels
5442,European,513.0,28207573.0,Backman JD,"Response to drug, Cardiovascular measurement",initial,2017-04-01,GCST004266,Response to clopidogrel therapy
632,African American or Afro-Caribbean,317.0,28289848.0,Haralambieva IH,Response to drug,initial,2017-04-01,GCST004268,Immune response to measles vaccine (measles-induced IFN gamma)
11625,European,84724.0,28199695.0,Jones AV,Other measurement,initial,2017-04-01,GCST004861,Itch intensity from mosquito bite
7495,European,2555.0,28289848.0,Haralambieva IH,Response to drug,initial,2017-04-01,GCST004268,Immune response to measles vaccine (measles-induced IFN gamma)
89,African,307.0,28388302.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",initial,2017-04-01,GCST004261,Liver injury in anti-retroviral drug treated HIV
9479,European,8424.0,28333195.0,Uimari O,Other disease,initial,2017-04-01,GCST004370,Deep ovarian and/or rectovaginal disease with dense adhesions
11223,European,46629.0,28348047.0,Li C,Cardiovascular measurement,replication,2017-04-01,GCST004260,Pulse pressure (long-term average)
57,African,186.0,28388302.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",initial,2017-04-01,GCST004262,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis
11224,European,46629.0,28348047.0,Li C,Other measurement,replication,2017-04-01,GCST004257,Systolic blood pressure (long-term average)
49,African,116.0,28388302.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",replication,2017-04-01,GCST004262,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis
11225,European,46629.0,28348047.0,Li C,Other measurement,replication,2017-04-01,GCST004258,Diastolic blood pressure (long-term average)
11226,European,46629.0,28348047.0,Li C,Other measurement,replication,2017-04-01,GCST004259,Mean arterial pressure (long-term average)
9777,European,10254.0,28333195.0,Uimari O,Other disease,initial,2017-04-01,GCST004368,Endometriosis
10302,European,16576.0,28199695.0,Jones AV,Other measurement,initial,2017-04-01,GCST004864,Perceived unattractiveness to mosquitoes
30,African,73.0,28388302.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",replication,2017-04-01,GCST004261,Liver injury in anti-retroviral drug treated HIV
11626,European,84724.0,28199695.0,Jones AV,Other measurement,initial,2017-04-01,GCST004862,Itch intensity from mosquito bite adjusted by bite size
11627,European,84724.0,28199695.0,Jones AV,Other measurement,initial,2017-04-01,GCST004863,Mosquito bite size
14030,Other/Mixed,764.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004286,Midgestational circulating levels of PBDEs (fetal genetic effect)
1630,Asian,23.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
13681,Other/Mixed,22.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
13680,Other/Mixed,22.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
13679,Other/Mixed,22.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
1632,Asian,23.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
424,African American or Afro-Caribbean,21.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
4111,Asian,10295.0,28373541.0,Yang J,Biological process,initial,2017-04-03,GCST006054,High altitude adaptation
14028,Other/Mixed,764.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004282,Midgestational circulating levels of organochlorine pesticides (fetal genetic effect)
5001,European,273.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
1764,Asian,122.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
1631,Asian,23.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
1765,Asian,122.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
425,African American or Afro-Caribbean,21.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
423,African American or Afro-Caribbean,21.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
1763,Asian,122.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
12832,Hispanic or Latin American,329.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
5003,European,273.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
5002,European,273.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
12833,Hispanic or Latin American,329.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
12834,Hispanic or Latin American,329.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
14029,Other/Mixed,764.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004284,Midgestational circulating levels of PCBs (fetal genetic effect)
6661,European,1528.0,28375557.0,Thomsen H,Other disease,initial,2017-04-04,GCST004287,Monoclonal gammopathy of undetermined significance
8564,European,4942.0,28374850.0,Ellinghaus E,Other trait,initial,2017-04-04,GCST004343,Chronic venous disease
8632,European,5092.0,28374850.0,Ellinghaus E,Other trait,replication,2017-04-04,GCST004343,Chronic venous disease
10606,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004653,Peak velocity of the mitral E-wave
10605,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004652,Peak velocity of the mitral A-wave
10861,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004651,Aortic root size
10604,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004650,Diastolic dysfunction with preserved ejection pressure
10860,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004648,Left  ventricle systolic dysfunction
10603,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004649,Isovolumetric relaxation time
10607,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004654,Deceleration time of the mitral E-wave
10168,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004650,Diastolic dysfunction with preserved ejection pressure
10608,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004656,Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.
10863,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004659,Left ventricular mass
10609,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004657,Ratio of the peak velocity of the excursion of the lateral mitral annulus in the early diastolic phase and the peak velocity of the mitral E-wave
10610,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004658,Peak velocity of excursion of lateral mitral annulus in early diastolic phase
10611,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004660,Heart failure with preserved ejection fraction
10175,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004660,Heart failure with preserved ejection fraction
10857,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004645,Left ventricular fractional shortening
10174,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004658,Peak velocity of excursion of lateral mitral annulus in early diastolic phase
10167,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004649,Isovolumetric relaxation time
10173,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004657,Ratio of the peak velocity of the excursion of the lateral mitral annulus in the early diastolic phase and the peak velocity of the mitral E-wave
10172,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004656,Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.
10858,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004646,Left ventricle wall thickness
10171,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004654,Deceleration time of the mitral E-wave
10170,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004653,Peak velocity of the mitral E-wave
10862,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004655,Left ventricle diastolic internal dimension
10169,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004652,Peak velocity of the mitral A-wave
10859,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004647,Left atrial antero-posterior diameter
10117,European,14002.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004651,Aortic root size
10116,European,14002.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004645,Left ventricular fractional shortening
10118,European,14002.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004655,Left ventricle diastolic internal dimension
10119,European,14002.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004659,Left ventricular mass
3940,Asian,7935.0,28406950.0,Kim J,Metabolic disorder,initial,2017-04-13,GCST004304,Prevalent type 2 diabetes
3941,Asian,7935.0,28406950.0,Kim J,Metabolic disorder,initial,2017-04-13,GCST004305,Type 2 diabetes
4753,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004273,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)
4752,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004272,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 12 weeks)
4751,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004271,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks)
4750,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004270,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)
4755,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004275,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)
4754,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004274,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)
13180,Hispanic or Latin American,3358.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004296,Atrial fibrillation
804,African American or Afro-Caribbean,889.0,28416818.0,Christophersen IE,Cardiovascular disease,replication,2017-04-17,GCST004299,Atrial fibrillation
4476,Asian,36792.0,28416818.0,Christophersen IE,Cardiovascular disease,replication,2017-04-17,GCST004298,Atrial fibrillation
11798,European,110099.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004300,Incident atrial fibrillation
3469,Asian,4133.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004298,Atrial fibrillation
11861,European,118755.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004295,Atrial fibrillation
11862,European,118755.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004296,Atrial fibrillation
1293,African American or Afro-Caribbean,5875.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004299,Atrial fibrillation
3468,Asian,4130.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004296,Atrial fibrillation
11863,European,118755.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004297,Atrial fibrillation
11804,European,111432.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004301,Prevalent atrial fibrillation
4477,Asian,36792.0,28416822.0,Low SK,Cardiovascular disease,initial,2017-04-17,GCST004373,Atrial fibrillation
11922,European,129712.0,28416822.0,Low SK,Cardiovascular disease,replication,2017-04-17,GCST004373,Atrial fibrillation
4475,Asian,36792.0,28416818.0,Christophersen IE,Cardiovascular disease,replication,2017-04-17,GCST004295,Atrial fibrillation
1291,African American or Afro-Caribbean,5875.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004295,Atrial fibrillation
13179,Hispanic or Latin American,3358.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004295,Atrial fibrillation
1292,African American or Afro-Caribbean,5875.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004296,Atrial fibrillation
4590,Asian,128184.0,28416822.0,Low SK,Cardiovascular disease,replication,2017-04-17,GCST004373,Atrial fibrillation
3467,Asian,4130.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004295,Atrial fibrillation
2457,Asian,922.0,28416812.0,Yang L,"Neurological disorder, Other measurement",replication,2017-04-18,GCST004336,Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder
6224,European,1033.0,28421636.0,Dennis J,Other measurement,replication,2017-04-18,GCST004344,Tissue factor pathway inhibitor levels
4980,European,251.0,28421636.0,Dennis J,Other measurement,initial,2017-04-18,GCST004344,Tissue factor pathway inhibitor levels
2385,Asian,780.0,28416812.0,Yang L,"Neurological disorder, Other measurement",initial,2017-04-18,GCST004336,Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder
3603,Asian,5158.0,28425483.0,Qiu F,Cancer,initial,2017-04-20,GCST004302,Primary biliary cholangitis
5724,European,707.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004360,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer
5726,European,707.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004362,Plasma estrone levels in resected estrogen-receptor positive breast cancer
5723,European,707.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004359,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer
1619,Asian,15.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004360,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer
451,African American or Afro-Caribbean,52.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004359,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer
454,African American or Afro-Caribbean,52.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004362,Plasma estrone levels in resected estrogen-receptor positive breast cancer
5727,European,707.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004363,Plasma androstenedione levels in resected early stage-receptor positive breast cancer
5725,European,707.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004361,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer
452,African American or Afro-Caribbean,52.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004360,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer
455,African American or Afro-Caribbean,52.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004363,Plasma androstenedione levels in resected early stage-receptor positive breast cancer
1622,Asian,15.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004363,Plasma androstenedione levels in resected early stage-receptor positive breast cancer
1621,Asian,15.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004362,Plasma estrone levels in resected estrogen-receptor positive breast cancer
2202,Asian,534.0,28424481.0,Sugiura-Ogasawara M,Immune system disorder,initial,2017-04-20,GCST004227,Obstetric antiphospholipid syndrome
453,African American or Afro-Caribbean,52.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004361,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer
1620,Asian,15.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004361,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer
3314,Asian,3034.0,28425483.0,Qiu F,Cancer,replication,2017-04-20,GCST004302,Primary biliary cholangitis
1618,Asian,15.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004359,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer
1081,African American or Afro-Caribbean,2711.0,28430825.0,Ng MCY,"Body measurement, Other measurement",replication,2017-04-21,GCST004518,Waist-to-hip ratio adjusted for body mass index
1509,African American or Afro-Caribbean,20384.0,28430825.0,Ng MCY,"Body measurement, Other measurement",initial,2017-04-21,GCST004518,Waist-to-hip ratio adjusted for body mass index
169,African,1056.0,28430825.0,Ng MCY,Body measurement,initial,2017-04-21,GCST004519,Body mass index (adult)
12430,European,322154.0,28430825.0,Ng MCY,Body measurement,replication,2017-04-21,GCST004519,Body mass index (adult)
1564,African American or Afro-Caribbean,46696.0,28430825.0,Ng MCY,Body measurement,initial,2017-04-21,GCST004519,Body mass index (adult)
332,African,10143.0,28430825.0,Ng MCY,Body measurement,replication,2017-04-21,GCST004519,Body mass index (adult)
12230,European,210086.0,28430825.0,Ng MCY,"Body measurement, Other measurement",replication,2017-04-21,GCST004518,Waist-to-hip ratio adjusted for body mass index
4970,European,242.0,28560309.0,Lee E,"Neurological disorder, Other measurement, Other trait",initial,2017-04-23,GCST004253,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction)
7206,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004308,"Facial morphology (factor 4, facial height related to vertical position of gnathion)"
7207,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004309,"Facial morphology (factor 5, width of mouth relative to central midface)"
7222,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004324,Facial morphology (factor 20)
7214,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004316,"Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface)"
7217,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004319,"Facial morphology (factor 15, philtrum width)"
7210,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004312,"Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion)"
7215,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004317,"Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)"
7205,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004307,"Facial morphology (factor 3, length of philtrum)"
7216,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004318,"Facial morphology (factor 14, intercanthal width)"
7221,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004323,Facial morphology (factor 19)
7212,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004314,"Facial morphology (factor 10, width of nasal floor)"
7220,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004322,Facial morphology (factor 18)
7204,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004306,"Facial morphology (factor 2, vertical position of orbits relative to midface)"
7211,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004313,"Facial morphology (factor 9, facial height related to vertical position of nasion)"
7218,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004320,Facial morphology (factor 16)
7213,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004315,"Facial morphology (factor 11, projection of the nose)"
7219,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004321,"Facial morphology (factor 17, height of vermillion upper lip)"
7209,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004311,"Facial morphology (factor 7, width of cartilaginous portion of nose)"
7226,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004328,"Facial morphology (factor 1, breadth of lateral portion of upper face)"
7223,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004325,"Facial morphology (factor 21, depth of nasal alae)"
10161,European,14713.0,28440896.0,Yin X,Neurological disorder,initial,2017-04-25,GCST004294,Nicotine dependence
9278,European,7687.0,28449029.0,Munz M,Digestive system disorder,initial,2017-04-25,GCST004303,Aggressive periodontitis
14034,Other/Mixed,787.0,28449029.0,Munz M,Digestive system disorder,initial,2017-04-25,GCST004303,Aggressive periodontitis
7208,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004310,"Facial morphology (factor 6, height of vermillion lower lip)"
7224,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004326,Facial morphology (factor 22)
7225,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004327,Facial morphology (factor 23)
1176,African American or Afro-Caribbean,3369.0,28440896.0,Yin X,Neurological disorder,initial,2017-04-25,GCST004294,Nicotine dependence
6128,European,979.0,28441426.0,White CC,Biological process,initial,2017-04-25,GCST004291,Residual cognition
12082,European,163276.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
702,African American or Afro-Caribbean,461.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
695,African American or Afro-Caribbean,452.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004410,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)
2741,Asian,1526.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004499,BMI in non-smokers
5004,European,275.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004408,HIV-associated neurocognitive disorder (mild neurocognitive disorder)
700,African American or Afro-Caribbean,461.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004498,BMI in smokers
701,African American or Afro-Caribbean,461.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
12105,European,167121.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
12083,European,163276.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
2743,Asian,1526.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
1441,African American or Afro-Caribbean,10602.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
13215,Hispanic or Latin American,3787.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004499,BMI in non-smokers
13217,Hispanic or Latin American,3787.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
1440,African American or Afro-Caribbean,10602.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004499,BMI in non-smokers
1439,African American or Afro-Caribbean,10602.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
3992,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
3991,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
3989,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
13216,Hispanic or Latin American,3787.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
2742,Asian,1526.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
3987,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
1442,African American or Afro-Caribbean,10602.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
3988,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
11921,European,129415.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004499,BMI in non-smokers
12084,European,163276.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
2885,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
2886,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
2887,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
12092,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
12093,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
11907,European,126046.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
2888,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
2889,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
12094,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
2485,Asian,967.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004498,BMI in smokers
2486,Asian,967.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
2884,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004496,BMI (smoking interaction)
2890,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
11078,European,37784.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004498,BMI in smokers
1083,African American or Afro-Caribbean,2720.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
11031,European,36054.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
2487,Asian,967.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
2891,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
1082,African American or Afro-Caribbean,2720.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004499,BMI in non-smokers
11040,European,36657.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
13010,Hispanic or Latin American,921.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
13009,Hispanic or Latin American,921.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
5160,European,380.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004410,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)
13008,Hispanic or Latin American,921.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004498,BMI in smokers
12106,European,167121.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
2883,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
12091,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
635,African American or Afro-Caribbean,327.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004408,HIV-associated neurocognitive disorder (mild neurocognitive disorder)
3985,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004496,BMI (smoking interaction)
706,African American or Afro-Caribbean,482.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004411,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)
708,African American or Afro-Caribbean,489.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004409,HIV-associated neurocognitive disorder
3984,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
1948,Asian,267.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004498,BMI in smokers
709,African American or Afro-Caribbean,490.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004406,Neurocognitive impairment in HIV-1 infection (continuous)
710,African American or Afro-Caribbean,490.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004407,Neurocognitive impairment in HIV-1 infection (dichotomous)
12097,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
1949,Asian,267.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
12089,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
1062,African American or Afro-Caribbean,2602.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
12096,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
12095,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
11920,European,129288.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
1950,Asian,267.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
1063,African American or Afro-Caribbean,2604.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004498,BMI in smokers
12090,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004496,BMI (smoking interaction)
1064,African American or Afro-Caribbean,2604.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
5290,European,443.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004409,HIV-associated neurocognitive disorder
5289,European,443.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004407,Neurocognitive impairment in HIV-1 infection (dichotomous)
5288,European,443.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004406,Neurocognitive impairment in HIV-1 infection (continuous)
5239,European,425.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004411,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)
3910,Asian,7711.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004499,BMI in non-smokers
3911,Asian,7711.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
3912,Asian,7711.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
3986,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
1084,African American or Afro-Caribbean,2720.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
3990,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
11968,European,139141.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
1461,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
1159,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
13255,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
1465,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
1464,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
13256,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004496,BMI (smoking interaction)
13257,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
13263,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
13258,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
12777,Hispanic or Latin American,99.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004409,HIV-associated neurocognitive disorder
13262,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
13260,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
13259,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
1463,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
1462,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
1162,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
1161,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
1458,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
1160,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
1459,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004496,BMI (smoking interaction)
13261,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
11969,European,139141.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
12112,European,168375.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
12775,Hispanic or Latin American,99.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004406,Neurocognitive impairment in HIV-1 infection (continuous)
1158,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
12107,European,167121.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
12757,Hispanic or Latin American,46.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004408,HIV-associated neurocognitive disorder (mild neurocognitive disorder)
10740,European,25372.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004498,BMI in smokers
10741,European,25372.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
10742,European,25372.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
1156,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
1157,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
12776,Hispanic or Latin American,99.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004407,Neurocognitive impairment in HIV-1 infection (dichotomous)
1155,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004496,BMI (smoking interaction)
11967,European,139141.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004499,BMI in non-smokers
1460,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
12765,Hispanic or Latin American,78.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004410,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)
12772,Hispanic or Latin American,95.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004411,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)
12111,European,168375.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004496,BMI (smoking interaction)
1154,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
12110,European,168375.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
11059,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
11063,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",replication,2017-04-27,GCST004568,Body mass index (physical activity interaction)
11062,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
10899,European,31928.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
1221,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004557,Body mass index
3127,Asian,2334.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
1223,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
11836,European,115827.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004559,Body mass index in physically active individuals
3126,Asian,2334.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
10902,European,32052.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004560,Body mass index in physically inactive individuals
3125,Asian,2334.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004559,Body mass index in physically active individuals
1222,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
11061,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
1224,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
3634,Asian,5379.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
11060,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
1229,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",initial,2017-04-27,GCST004568,Body mass index (physical activity interaction)
2027,Asian,352.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004560,Body mass index in physically inactive individuals
935,African American or Afro-Caribbean,1501.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
12009,European,146942.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
3497,Asian,4372.0,28460022.0,Lee JY,Cardiovascular disease,initial,2017-04-27,GCST004352,Early onset atrial fibrillation
2995,Asian,2012.0,28460022.0,Lee JY,Cardiovascular disease,replication,2017-04-27,GCST004352,Early onset atrial fibrillation
12010,European,146942.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",initial,2017-04-27,GCST004568,Body mass index (physical activity interaction)
933,African American or Afro-Caribbean,1501.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004560,Body mass index in physically inactive individuals
11834,European,115058.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
10782,European,26887.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
10781,European,26887.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
10780,European,26887.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004559,Body mass index in physically active individuals
781,African American or Afro-Caribbean,812.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004560,Body mass index in physically inactive individuals
782,African American or Afro-Caribbean,812.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
1151,African American or Afro-Caribbean,3163.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
783,African American or Afro-Caribbean,812.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
1150,African American or Afro-Caribbean,3163.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
11986,European,142227.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
11987,European,142227.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
3632,Asian,5379.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004560,Body mass index in physically inactive individuals
11055,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004557,Body mass index
11988,European,142227.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
11056,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
10176,European,14789.0,28445677.0,Steri M,Immune system disorder,replication,2017-04-27,GCST004290,Multiple sclerosis
11057,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
1149,African American or Afro-Caribbean,3163.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004559,Body mass index in physically active individuals
1228,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
1227,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
1226,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
1225,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
11058,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
3633,Asian,5379.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
3921,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",initial,2017-04-27,GCST004568,Body mass index (physical activity interaction)
3915,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
3919,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
1319,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
1318,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
2028,Asian,352.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
10881,European,31133.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
2029,Asian,352.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
1317,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
12008,European,146942.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004557,Body mass index
3920,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
12004,European,146049.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
12003,European,146049.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
1320,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
1271,African American or Afro-Caribbean,5072.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004559,Body mass index in physically active individuals
1272,African American or Afro-Caribbean,5072.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
1316,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
1315,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
1273,African American or Afro-Caribbean,5072.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
1314,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
1313,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004557,Body mass index
12002,European,146049.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
9811,European,10600.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004560,Body mass index in physically inactive individuals
9812,European,10600.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
9813,European,10600.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
11813,European,112031.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
1321,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",replication,2017-04-27,GCST004568,Body mass index (physical activity interaction)
934,African American or Afro-Caribbean,1501.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
2861,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
2860,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004557,Body mass index
2869,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
3918,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
3917,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
3916,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
2868,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
2871,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",initial,2017-04-27,GCST004568,Body mass index (physical activity interaction)
2867,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
2866,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
2870,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
2862,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004559,Body mass index in physically active individuals
2865,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
8360,European,4421.0,28445677.0,Steri M,Immune system disorder,initial,2017-04-27,GCST004290,Multiple sclerosis
3913,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004557,Body mass index
2863,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
3914,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
2864,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
13487,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004332,Red blood cell count
13485,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004330,Hematocrit
13488,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004333,Red cell distribution width
10698,European,24063.0,28452372.0,Gorski M,Other measurement,initial,2017-04-28,GCST004293,Glomerular filtration rate (cystatin C)
13269,Hispanic or Latin American,4772.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004335,Mean corpuscular volume
13267,Hispanic or Latin American,4772.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004333,Red cell distribution width
13266,Hispanic or Latin American,4772.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004332,Red blood cell count
13486,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004331,Hemoglobin
13490,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004335,Mean corpuscular volume
13268,Hispanic or Latin American,4772.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004334,Mean corpuscular hemoglobin
11801,European,110517.0,28452372.0,Gorski M,Other measurement,initial,2017-04-28,GCST004292,Glomerular filtration rate (creatinine)
13363,Hispanic or Latin American,7106.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004330,Hematocrit
13265,Hispanic or Latin American,4772.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004329,Mean corpuscular hemoglobin concentration
13489,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004334,Mean corpuscular hemoglobin
13364,Hispanic or Latin American,7106.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004331,Hemoglobin
4713,European,84.0,28453389.0,Koga A,"Response to drug, Neurological disorder",initial,2017-04-28,GCST004375,Resistance to antipsychotic treatment in schizophrenia
13484,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004329,Mean corpuscular hemoglobin concentration
4714,European,84.0,28453389.0,Koga A,"Response to drug, Neurological disorder, Other measurement",initial,2017-04-28,GCST004374,Resistance to antipsychotic treatment in schizophrenia (childhood trauma interaction)
13290,Hispanic or Latin American,5037.0,28461288.0,Yan Q,Other disease,initial,2017-05-01,GCST004390,Asthma
5955,European,868.0,28470677.0,Tang H,"Other measurement, Cancer",initial,2017-05-03,GCST004485,Survival in pancreatic cancer
5876,European,820.0,28470677.0,Tang H,"Other measurement, Cancer",replication,2017-05-03,GCST004485,Survival in pancreatic cancer
3263,Asian,2841.0,28471803.0,Choe EK,Other measurement,initial,2017-05-03,GCST004345,Elevated serum prostate-specific antigen levels in healthy men
2627,Asian,1283.0,28471803.0,Choe EK,Other measurement,replication,2017-05-03,GCST004345,Elevated serum prostate-specific antigen levels in healthy men
10308,European,16627.0,28472463.0,Mullin BH,Other measurement,initial,2017-05-04,GCST004351,Bone ultrasound measurement (broadband ultrasound attenuation)
10307,European,16627.0,28472463.0,Mullin BH,Other measurement,initial,2017-05-04,GCST004350,Bone ultrasound measurement (velocity of sound)
13910,Other/Mixed,419.0,28476931.0,Piaggi P,Other measurement,initial,2017-05-05,GCST004524,Energy expenditure (24h)
13933,Other/Mixed,509.0,28476931.0,Piaggi P,Other measurement,initial,2017-05-05,GCST004523,Resting metabolic rate
13362,Hispanic or Latin American,7047.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004405,Alcohol consumption (drinks per week)
1052,African American or Afro-Caribbean,2475.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004405,Alcohol consumption (drinks per week)
3750,Asian,6034.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004405,Alcohol consumption (drinks per week)
13361,Hispanic or Latin American,7047.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004404,Alcohol consumption (drinkers vs non-drinkers)
1051,African American or Afro-Caribbean,2475.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004404,Alcohol consumption (drinkers vs non-drinkers)
3749,Asian,6034.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004404,Alcohol consumption (drinkers vs non-drinkers)
11512,European,71071.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004405,Alcohol consumption (drinks per week)
11511,European,71071.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004404,Alcohol consumption (drinkers vs non-drinkers)
7187,European,2159.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004487,Peak insulin response
5766,European,739.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST006676,Peak insulin response (insulin secretion adjusted)
13874,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006676,Peak insulin response (insulin secretion adjusted)
7077,European,2042.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006681,Insulin disposition index (BMI adjusted)
13126,Hispanic or Latin American,2345.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004489,Insulin disposition index
7076,European,2042.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004489,Insulin disposition index
13124,Hispanic or Latin American,2337.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006676,Peak insulin response (insulin secretion adjusted)
7127,European,2087.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006677,Acute insulin response (insulin secretion adjusted)
13128,Hispanic or Latin American,2346.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004575,Acute insulin response
13122,Hispanic or Latin American,2337.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004487,Peak insulin response
7126,European,2087.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004575,Acute insulin response
5771,European,741.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST004489,Insulin disposition index
13877,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006681,Insulin disposition index (BMI adjusted)
5775,European,741.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST006681,Insulin disposition index (BMI adjusted)
13876,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006678,Acute insulin response (insulin secretion and BMI adjusted)
5774,European,741.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST006678,Acute insulin response (insulin secretion and BMI adjusted)
5773,European,741.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST006677,Acute insulin response (insulin secretion adjusted)
13129,Hispanic or Latin American,2346.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006677,Acute insulin response (insulin secretion adjusted)
5772,European,741.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST004575,Acute insulin response
7189,European,2159.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006676,Peak insulin response (insulin secretion adjusted)
13123,Hispanic or Latin American,2337.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006675,Peak insulin response (BMI and insulin secretion adjusted)
5472,European,527.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004488,Insulin secretion rate
13875,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006677,Acute insulin response (insulin secretion adjusted)
13127,Hispanic or Latin American,2345.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006681,Insulin disposition index (BMI adjusted)
13871,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004489,Insulin disposition index
5473,European,527.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006679,insulin secretion rate (BMI adjusted)
5764,European,739.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST004487,Peak insulin response
13870,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004487,Peak insulin response
13872,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004575,Acute insulin response
7128,European,2087.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006678,Acute insulin response (insulin secretion and BMI adjusted)
13130,Hispanic or Latin American,2346.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006678,Acute insulin response (insulin secretion and BMI adjusted)
13873,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006675,Peak insulin response (BMI and insulin secretion adjusted)
7188,European,2159.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006675,Peak insulin response (BMI and insulin secretion adjusted)
5765,European,739.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST006675,Peak insulin response (BMI and insulin secretion adjusted)
13855,Other/Mixed,307.0,28492228.0,Parks T,Cardiovascular disease,initial,2017-05-11,GCST004366,Rheumatic heart disease
1999,Asian,319.0,28492228.0,Parks T,Cardiovascular disease,initial,2017-05-11,GCST004366,Rheumatic heart disease
14158,Other/Mixed,2229.0,28492228.0,Parks T,Cardiovascular disease,initial,2017-05-11,GCST004366,Rheumatic heart disease
10686,European,23914.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004386,Diastolic blood pressure
392,African,31155.0,28498854.0,Liang J,Other measurement,initial,2017-05-12,GCST004386,Diastolic blood pressure
10685,European,23914.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004385,Systolic blood pressure
268,African,4187.0,28498854.0,Liang J,Cardiovascular measurement,replication,2017-05-12,GCST004387,Pulse pressure
270,African,4187.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004386,Diastolic blood pressure
4964,European,237.0,28500057.0,Bluett J,"Other disease, Immune system disorder, Response to drug",initial,2017-05-12,GCST004358,Methotrexate-induced interstitial lung disease in rheumatoid arthritis
245,African,2375.0,28498854.0,Liang J,Cardiovascular disease,replication,2017-05-12,GCST004384,Hypertension
370,African,18440.0,28498854.0,Liang J,Cardiovascular disease,initial,2017-05-12,GCST004384,Hypertension
4257,Asian,14016.0,28498854.0,Liang J,"Other measurement, Cardiovascular disease, Cardiovascular measurement",replication,2017-05-12,GCST004388,Blood pressure traits (multi-trait analysis)
9628,European,9348.0,28498854.0,Liang J,Cardiovascular disease,replication,2017-05-12,GCST004384,Hypertension
4256,Asian,14016.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004386,Diastolic blood pressure
10684,European,23914.0,28498854.0,Liang J,Cardiovascular measurement,replication,2017-05-12,GCST004387,Pulse pressure
4255,Asian,14016.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004385,Systolic blood pressure
393,African,31155.0,28498854.0,Liang J,"Other measurement, Cardiovascular disease, Cardiovascular measurement",initial,2017-05-12,GCST004388,Blood pressure traits (multi-trait analysis)
13472,Hispanic or Latin American,12278.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004385,Systolic blood pressure
13473,Hispanic or Latin American,12278.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004386,Diastolic blood pressure
13471,Hispanic or Latin American,12278.0,28498854.0,Liang J,Cardiovascular measurement,replication,2017-05-12,GCST004387,Pulse pressure
391,African,31155.0,28498854.0,Liang J,Other measurement,initial,2017-05-12,GCST004385,Systolic blood pressure
271,African,4187.0,28498854.0,Liang J,"Other measurement, Cardiovascular disease, Cardiovascular measurement",replication,2017-05-12,GCST004388,Blood pressure traits (multi-trait analysis)
4254,Asian,14016.0,28498854.0,Liang J,Cardiovascular measurement,replication,2017-05-12,GCST004387,Pulse pressure
13474,Hispanic or Latin American,12278.0,28498854.0,Liang J,"Other measurement, Cardiovascular disease, Cardiovascular measurement",replication,2017-05-12,GCST004388,Blood pressure traits (multi-trait analysis)
13183,Hispanic or Latin American,3445.0,28498854.0,Liang J,Cardiovascular disease,replication,2017-05-12,GCST004384,Hypertension
10149,European,14477.0,28494655.0,Duncan L,Metabolic disorder,initial,2017-05-12,GCST004367,Anorexia nervosa
3411,Asian,3718.0,28498854.0,Liang J,Cardiovascular disease,replication,2017-05-12,GCST004384,Hypertension
269,African,4187.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004385,Systolic blood pressure
10687,European,23914.0,28498854.0,Liang J,"Other measurement, Cardiovascular disease, Cardiovascular measurement",replication,2017-05-12,GCST004388,Blood pressure traits (multi-trait analysis)
390,African,31155.0,28498854.0,Liang J,Cardiovascular measurement,initial,2017-05-12,GCST004387,Pulse pressure
5919,European,843.0,28641921.0,Li J,Other measurement,initial,2017-05-15,GCST004490,Cerebrospinal fluid t-tau:AB1-42 ratio
13482,Hispanic or Latin American,12375.0,28334935.0,Raffield LM,Other measurement,initial,2017-05-15,GCST004573,Iron status biomarkers (ferritin levels)
13498,Hispanic or Latin American,12589.0,28334935.0,Raffield LM,Other measurement,initial,2017-05-15,GCST004572,Iron status biomarkers (transferrin saturation)
5921,European,843.0,28641921.0,Li J,Other measurement,initial,2017-05-15,GCST004492,Cerebrospinal fluid AB1-42 levels
13497,Hispanic or Latin American,12586.0,28334935.0,Raffield LM,Other measurement,initial,2017-05-15,GCST004571,Iron status biomarkers (total iron binding capacity)
5920,European,843.0,28641921.0,Li J,Other measurement,initial,2017-05-15,GCST004491,Cerebrospinal fluid t-tau levels
13496,Hispanic or Latin American,12580.0,28334935.0,Raffield LM,Other measurement,initial,2017-05-15,GCST004570,Iron status biomarkers (iron levels)
2321,Asian,711.0,28512992.0,Joo YB,Other measurement,initial,2017-05-16,GCST004400,Bone erosion in rheumatoid arthritis
10098,European,13781.0,28512139.0,Mack S,Lipid or lipoprotein measurement,initial,2017-05-16,GCST004399,Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms
10097,European,13781.0,28512139.0,Mack S,Lipid or lipoprotein measurement,initial,2017-05-16,GCST004398,Lipoprotein (a) levels
6693,European,1548.0,28520984.0,Saccone NL,Other measurement,replication,2017-05-17,GCST004511,Smoking status (daily vs non-daily)
895,African American or Afro-Caribbean,1264.0,28520984.0,Saccone NL,Other measurement,replication,2017-05-17,GCST004511,Smoking status (daily vs non-daily)
13148,Hispanic or Latin American,2564.0,28520984.0,Saccone NL,Other measurement,initial,2017-05-17,GCST004511,Smoking status (daily vs non-daily)
13297,Hispanic or Latin American,5085.0,28520984.0,Saccone NL,Other measurement,initial,2017-05-17,GCST004512,Smoking status (heavy vs light)
13500,Hispanic or Latin American,12735.0,28520984.0,Saccone NL,"Biological process, Other measurement",initial,2017-05-17,GCST004514,Smoking status (ever vs never smokers)
12864,Hispanic or Latin American,428.0,28520984.0,Saccone NL,Other measurement,replication,2017-05-17,GCST004511,Smoking status (daily vs non-daily)
13298,Hispanic or Latin American,5119.0,28520984.0,Saccone NL,Other measurement,initial,2017-05-17,GCST004513,Smoking status (current vs former)
13108,Hispanic or Latin American,2065.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004526,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
2312,Asian,702.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004526,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
1093,African American or Afro-Caribbean,2856.0,28545128.0,McDaniel LD,Cancer,replication,2017-05-18,GCST004510,Sporadic neuroblastoma
2313,Asian,702.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004527,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)
2311,Asian,702.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004525,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)
6409,European,1210.0,28545128.0,McDaniel LD,Cancer,replication,2017-05-18,GCST004510,Sporadic neuroblastoma
13107,Hispanic or Latin American,2065.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004525,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)
13109,Hispanic or Latin American,2065.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004527,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)
7392,European,2434.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004527,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)
7391,European,2434.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004526,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
7390,European,2434.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004525,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)
8956,European,6303.0,28545128.0,McDaniel LD,Cancer,initial,2017-05-18,GCST004510,Sporadic neuroblastoma
7737,European,3013.0,28521775.0,Manichaikul A,Other measurement,replication,2017-05-18,GCST004526,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
1048,African American or Afro-Caribbean,2470.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004525,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)
7738,European,3013.0,28521775.0,Manichaikul A,Other measurement,replication,2017-05-18,GCST004527,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)
1049,African American or Afro-Caribbean,2470.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004526,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
1050,African American or Afro-Caribbean,2470.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004527,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)
8163,European,3868.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004683,Psychosis proneness (perceptual aberration scale and revised social anhedonia scale)
8199,European,3967.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004678,Psychosis proneness (hypomanic personality scale)
8242,European,4057.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004685,Psychosis proneness (perceptual aberration scale)
8153,European,3837.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004682,Psychosis proneness (hypomanic personality scale and revised social anhedonia scale)
8227,European,4025.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004686,Psychosis proneness (revised social anhedonia scale)
8137,European,3787.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004681,Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale)
8142,European,3812.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004688,Psychosis proneness (perceptual aberration scale and revised physical anhedonia scale)
8291,European,4191.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004687,Psychosis proneness (schizoidia scale)
8147,European,3824.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004679,Psychosis proneness (hypomanic personality scale and perceptual aberration scale)
8215,European,3988.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004680,Psychosis proneness (revised physical anhedonia scale)
8146,European,3820.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004684,Psychosis proneness (revised physical anhedonia scale and revised social anhedonia scale)
10076,European,13574.0,28540026.0,Anney RJL,Neurological disorder,initial,2017-05-22,GCST004521,Autism spectrum disorder or schizophrenia
10075,European,13574.0,28540026.0,Anney RJL,Neurological disorder,initial,2017-05-22,GCST004520,Autism spectrum disorder
11568,European,78308.0,28530673.0,Sniekers S,Biological process,initial,2017-05-22,GCST004364,Intelligence
12064,European,155828.0,28540026.0,Anney RJL,Neurological disorder,replication,2017-05-22,GCST004520,Autism spectrum disorder
8439,European,4664.0,28533516.0,Cantor RM,"Other measurement, Neurological disorder",initial,2017-05-23,GCST004377,Restricted and repetitive behaviours in autism spectrum disorder
1592,Asian,3.0,28542097.0,Wells QS,"Other trait, Response to drug",replication,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
4808,European,152.0,28542097.0,Wells QS,"Other trait, Response to drug",replication,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
3488,Asian,4262.0,28537267.0,Sapkota Y,Other disease,initial,2017-05-24,GCST004549,Endometriosis
428,African American or Afro-Caribbean,23.0,28542097.0,Wells QS,"Other trait, Response to drug",replication,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
12209,European,204641.0,28537267.0,Sapkota Y,Other disease,initial,2017-05-24,GCST004549,Endometriosis
433,African American or Afro-Caribbean,30.0,28542097.0,Wells QS,"Other trait, Response to drug",initial,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
1580,Asian,1.0,28542097.0,Wells QS,"Other trait, Response to drug",initial,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
10420,European,18478.0,28537254.0,Tsoi LC,Immune system disorder,replication,2017-05-24,GCST004346,Psoriasis
12720,Hispanic or Latin American,4.0,28542097.0,Wells QS,"Other trait, Response to drug",initial,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
5100,European,337.0,28542097.0,Wells QS,"Other trait, Response to drug",initial,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
12356,European,287323.0,28537254.0,Tsoi LC,Immune system disorder,initial,2017-05-24,GCST004346,Psoriasis
8991,European,6507.0,28540843.0,Mbarek H,Neurological disorder,initial,2017-05-25,GCST004486,Major depressive disorder
7827,European,3213.0,28548082.0,Southam L,"Body measurement, Other measurement",initial,2017-05-26,GCST004552,Waist circumference adjusted for body mass index
7828,European,3213.0,28548082.0,Southam L,"Body measurement, Other measurement",initial,2017-05-26,GCST004556,Waist-to-hip ratio adjusted for body mass index
7832,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004543,Mean corpuscular hemoglobin concentration
7838,European,3213.0,28548082.0,Southam L,Lipid or lipoprotein measurement,initial,2017-05-26,GCST004537,High density lipoprotein cholesterol levels
7847,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004547,Systolic blood pressure
7846,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004540,Homeostasis model assessment of insulin resistance adjusted for BMI
7839,European,3213.0,28548082.0,Southam L,Lipid or lipoprotein measurement,initial,2017-05-26,GCST004541,Low density lipoprotein cholesterol levels
7825,European,3213.0,28548082.0,Southam L,Body measurement,initial,2017-05-26,GCST004760,Hip bone size adjusted for BMI
7840,European,3213.0,28548082.0,Southam L,Lipid or lipoprotein measurement,initial,2017-05-26,GCST004548,Total cholesterol levels
7837,European,3213.0,28548082.0,Southam L,Inflammatory measurement,initial,2017-05-26,GCST004530,C-reactive protein levels
7841,European,3213.0,28548082.0,Southam L,Lipid or lipoprotein measurement,initial,2017-05-26,GCST004550,Triglyceride levels
7842,European,3213.0,28548082.0,Southam L,Lipid or lipoprotein measurement,initial,2017-05-26,GCST004759,Very low density lipoprotein cholesterol levels
7824,European,3213.0,28548082.0,Southam L,Body measurement,initial,2017-05-26,GCST004554,Weight
7844,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004532,Fasting blood glucose
7843,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004531,Diastolic blood pressure
7823,European,3213.0,28548082.0,Southam L,Body measurement,initial,2017-05-26,GCST004551,Waist circumference
7822,European,3213.0,28548082.0,Southam L,Body measurement,initial,2017-05-26,GCST004538,Hip bone size
7845,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004533,Fasting blood insulin
7848,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004761,Fasting blood glucose adjusted for BMI
7833,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004544,Mean corpuscular volume
7836,European,3213.0,28548082.0,Southam L,"Hematological measurement, Inflammatory measurement",initial,2017-05-26,GCST004553,White blood cell count
7851,European,3213.0,28548082.0,Southam L,"Other measurement, Body measurement",initial,2017-05-26,GCST004555,Waist-hip ratio
7829,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004535,Hematocrit
7834,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004545,Platelet count
7831,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004542,Mean corpuscular hemoglobin
7850,European,3213.0,28548082.0,Southam L,"Other measurement, Body measurement",initial,2017-05-26,GCST004534,Height
7849,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004762,Fasting blood insulin adjusted for BMI
7852,European,3213.0,28548082.0,Southam L,"Other measurement, Other trait",initial,2017-05-26,GCST004539,Homeostasis model assessment of insulin resistance
7826,European,3213.0,28548082.0,Southam L,"Body measurement, Other measurement",initial,2017-05-26,GCST004529,Body mass index
7830,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004536,Hemoglobin
7835,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004546,Red blood cell count
12077,European,159208.0,28566273.0,Scott RA,Metabolic disorder,initial,2017-05-31,GCST004774,Type 2 diabetes
6707,European,1560.0,28577822.0,Deters KD,Other measurement,initial,2017-05-31,GCST004372,Language performance in older adults (adjusted for episodic memory)
11319,European,53539.0,28566273.0,Scott RA,Metabolic disorder,replication,2017-05-31,GCST004773,Type 2 diabetes
11572,European,79001.0,28566273.0,Scott RA,Metabolic disorder,replication,2017-05-31,GCST004774,Type 2 diabetes
12076,European,159208.0,28566273.0,Scott RA,Metabolic disorder,initial,2017-05-31,GCST004773,Type 2 diabetes
12226,European,209191.0,28552196.0,Tachmazidou I,"Body measurement, Other measurement",replication,2017-06-01,GCST008158,Body mass index
8500,European,4831.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004720,Conotruncal heart defects (inherited effects)
11320,European,53588.0,28552196.0,Tachmazidou I,"Other measurement, Body measurement",initial,2017-06-01,GCST008163,Height
12214,European,205905.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008156,Hip circumference adjusted for BMI
12158,European,179022.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008152,Weight
9826,European,10667.0,28552196.0,Tachmazidou I,Other measurement,replication,2017-06-01,GCST008154,Trunk fat mass
12216,European,206045.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008159,Waist-to-hip ratio adjusted for BMI
9829,European,10676.0,28552196.0,Tachmazidou I,Other measurement,replication,2017-06-01,GCST008153,Lean body mass
12215,European,205909.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008162,Hip circumference
11313,European,53255.0,28552196.0,Tachmazidou I,"Body measurement, Other measurement",initial,2017-06-01,GCST008158,Body mass index
11318,European,53484.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008152,Weight
12210,European,205003.0,28552196.0,Tachmazidou I,"Other measurement, Body measurement",replication,2017-06-01,GCST008163,Height
5770,European,741.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004719,Left ventricular obstructive tract defect (inherited effect)
9057,European,6739.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004718,Congenital heart disease (inherited effect)
10972,European,33811.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008159,Waist-to-hip ratio adjusted for BMI
10976,European,33865.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008156,Hip circumference adjusted for BMI
10029,European,12838.0,28552196.0,Tachmazidou I,Other measurement,initial,2017-06-01,GCST008154,Trunk fat mass
11242,European,47593.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008160,Waist circumference
11241,European,47593.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008151,Waist circumference
7452,European,2514.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004723,Conotruncal heart defects (maternal effects)
6500,European,1317.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004722,Left ventricular obstructive tract defect (maternal effect)
12220,European,206737.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008160,Waist circumference
7945,European,3357.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004721,Congenital heart disease (maternal effect)
9827,European,10670.0,28552196.0,Tachmazidou I,Other measurement,replication,2017-06-01,GCST008157,Body fat mass
12218,European,206723.0,28552196.0,Tachmazidou I,"Body measurement, Other measurement",replication,2017-06-01,GCST008161,Waist circumference adjusted for body mass index
12219,European,206737.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008151,Waist circumference
11230,European,47095.0,28552196.0,Tachmazidou I,"Body measurement, Other measurement",initial,2017-06-01,GCST008161,Waist circumference adjusted for body mass index
9954,European,11801.0,28552196.0,Tachmazidou I,Other measurement,initial,2017-06-01,GCST008153,Lean body mass
9956,European,11802.0,28552196.0,Tachmazidou I,Other measurement,initial,2017-06-01,GCST008157,Body fat mass
10988,European,34088.0,28552196.0,Tachmazidou I,"Other measurement, Body measurement",initial,2017-06-01,GCST008155,Waist-hip ratio
10986,European,34004.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008162,Hip circumference
12217,European,206053.0,28552196.0,Tachmazidou I,"Other measurement, Body measurement",replication,2017-06-01,GCST008155,Waist-hip ratio
11808,European,111749.0,27864402.0,Harris SE,Other trait,initial,2017-06-01,GCST006620,Self-rated health
183,African,1293.0,28584135.0,Chaturvedi S,"Neurological disorder, Other measurement",initial,2017-06-05,GCST004644,Vaso-occlusive pain in sickle-cell anemia
12303,European,251377.0,28585551.0,Sigurdsson S,Digestive system disorder,initial,2017-06-06,GCST008257,Diverticular disease
9245,European,7550.0,28588231.0,Li M,Other measurement,initial,2017-06-06,GCST004643,"1,5-anhydroglucitol levels"
9556,European,8790.0,28588231.0,Li M,Other measurement,replication,2017-06-06,GCST004643,"1,5-anhydroglucitol levels"
12296,European,248715.0,28585551.0,Sigurdsson S,Digestive system disorder,initial,2017-06-06,GCST008256,Diverticulitis
9581,European,8990.0,28585551.0,Sigurdsson S,Digestive system disorder,replication,2017-06-06,GCST008257,Diverticular disease
1001,African American or Afro-Caribbean,2030.0,28588231.0,Li M,Other measurement,replication,2017-06-06,GCST004643,"1,5-anhydroglucitol levels"
11681,European,89553.0,28584286.0,Warrier V,Other measurement,initial,2017-06-06,GCST005755,Cognitive empathy
10181,European,14889.0,28749367.0,Gondalia R,"Other measurement, Cardiovascular measurement",initial,2017-06-08,GCST004642,QT interval (ambient particulate matter interaction)
13084,Hispanic or Latin American,1562.0,28749367.0,Gondalia R,"Other measurement, Cardiovascular measurement",initial,2017-06-08,GCST004642,QT interval (ambient particulate matter interaction)
1287,African American or Afro-Caribbean,5707.0,28749367.0,Gondalia R,"Other measurement, Cardiovascular measurement",initial,2017-06-08,GCST004642,QT interval (ambient particulate matter interaction)
626,African American or Afro-Caribbean,300.0,28598419.0,Hong X,"Body measurement, Other measurement, Other trait",replication,2017-06-09,GCST004843,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
959,African American or Afro-Caribbean,1733.0,28598419.0,Hong X,"Other measurement, Other trait",initial,2017-06-09,GCST004841,Preterm birth (maternal effect)
5695,European,683.0,28598419.0,Hong X,"Other measurement, Other trait",replication,2017-06-09,GCST004841,Preterm birth (maternal effect)
944,African American or Afro-Caribbean,1586.0,28598419.0,Hong X,"Body measurement, Other measurement, Other trait",initial,2017-06-09,GCST004843,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
958,African American or Afro-Caribbean,1733.0,28598419.0,Hong X,Other measurement,initial,2017-06-09,GCST004844,Gestational age at birth (maternal effect)
9654,European,9483.0,28598434.0,Scelo G,Cancer,replication,2017-06-09,GCST004710,Renal cell carcinoma
10885,European,31190.0,28598434.0,Scelo G,Cancer,initial,2017-06-09,GCST004710,Renal cell carcinoma
932,African American or Afro-Caribbean,1496.0,28598419.0,Hong X,"Other trait, Other measurement",initial,2017-06-09,GCST004845,Spontaneous preterm birth (maternal effect)
976,African American or Afro-Caribbean,1886.0,28598419.0,Hong X,"Body measurement, Other measurement, Other trait",initial,2017-06-09,GCST004842,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
776,African American or Afro-Caribbean,782.0,28598419.0,Hong X,"Other measurement, Other trait",replication,2017-06-09,GCST004841,Preterm birth (maternal effect)
5694,European,683.0,28598419.0,Hong X,"Body measurement, Other measurement, Other trait",replication,2017-06-09,GCST004843,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
13511,Hispanic or Latin American,13767.0,28610988.0,Kerr KF,Cardiovascular measurement,initial,2017-06-10,GCST004716,Heart rate variability traits (RMSSD)
9138,European,7073.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004715,Heart rate
9137,European,7073.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004714,Heart rate variability traits (SDNN)
1102,African American or Afro-Caribbean,2908.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004714,Heart rate variability traits (SDNN)
13502,Hispanic or Latin American,13184.0,28610988.0,Kerr KF,Cardiovascular measurement,initial,2017-06-10,GCST004715,Heart rate
1103,African American or Afro-Caribbean,2908.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004716,Heart rate variability traits (RMSSD)
1262,African American or Afro-Caribbean,4771.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004715,Heart rate
13501,Hispanic or Latin American,13184.0,28610988.0,Kerr KF,Cardiovascular measurement,initial,2017-06-10,GCST004714,Heart rate variability traits (SDNN)
8463,European,4730.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004716,Heart rate variability traits (RMSSD)
9250,European,7565.0,28604731.0,Hammerschlag AR,Neurological disorder,replication,2017-06-12,GCST006488,Insomnia complaints
10701,European,24108.0,28604730.0,McKay JD,Cancer,initial,2017-06-12,GCST004746,Small cell lung carcinoma
10718,European,24573.0,28604728.0,Litchfield K,Cancer,initial,2017-06-12,GCST004635,Testicular germ cell tumor
9249,European,7565.0,28604731.0,Hammerschlag AR,Neurological disorder,replication,2017-06-12,GCST006487,Insomnia complaints
11130,European,40187.0,28604730.0,McKay JD,"Other measurement, Cancer",initial,2017-06-12,GCST004749,Lung cancer in ever smokers
8840,European,5828.0,28604728.0,Litchfield K,Cancer,replication,2017-06-12,GCST004635,Testicular germ cell tumor
9248,European,7565.0,28604731.0,Hammerschlag AR,Neurological disorder,replication,2017-06-12,GCST004695,Insomnia complaints
11321,European,53639.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST006488,Insomnia complaints
11823,European,113006.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST004700,Insomnia complaints (sex interaction)
11641,European,85716.0,28604730.0,McKay JD,Cancer,initial,2017-06-12,GCST004748,Lung cancer
11824,European,113006.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST004701,Insomnia complaints (continuous)
11825,European,113054.0,28604731.0,Hammerschlag AR,Other measurement,initial,2017-06-12,GCST004693,Daytime nap
11432,European,63053.0,28604730.0,McKay JD,Cancer,initial,2017-06-12,GCST004750,Squamous cell lung carcinoma
11822,European,113006.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST004695,Insomnia complaints
10367,European,17528.0,28604732.0,Wang Z,Cancer,initial,2017-06-12,GCST004713,Testicular germ cell tumor
11821,European,112866.0,28604731.0,Hammerschlag AR,Other measurement,initial,2017-06-12,GCST004697,Ease of getting up in the morning
11756,European,101185.0,28604731.0,Hammerschlag AR,"Biological process, Other measurement",initial,2017-06-12,GCST004696,Chronotype
11820,European,112717.0,28604731.0,Hammerschlag AR,Other measurement,initial,2017-06-12,GCST004699,Daytime sleepiness
11770,European,105377.0,28604731.0,Hammerschlag AR,Other measurement,initial,2017-06-12,GCST004698,Snoring
11397,European,59512.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST004702,Insomnia complaints (dichotomous)
11396,European,59367.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST006487,Insomnia complaints
11458,European,66756.0,28604730.0,McKay JD,Cancer,initial,2017-06-12,GCST004744,Lung adenocarcinoma
11818,European,112411.0,28604731.0,Hammerschlag AR,Other measurement,initial,2017-06-12,GCST004694,Sleep duration
9722,European,9859.0,28604730.0,McKay JD,"Other measurement, Cancer",initial,2017-06-12,GCST004747,Lung cancer in never smokers
8256,European,4097.0,28608620.0,Coleman JRI,Other measurement,initial,2017-06-13,GCST004731,Facial emotion recognition (fearful faces)
8255,European,4097.0,28608620.0,Coleman JRI,Other measurement,initial,2017-06-13,GCST004730,Facial emotion recognition (sad faces)
8254,European,4097.0,28608620.0,Coleman JRI,Other measurement,initial,2017-06-13,GCST004729,Facial emotion recognition (happy faces)
8253,European,4097.0,28608620.0,Coleman JRI,Other measurement,initial,2017-06-13,GCST004728,Facial emotion recognition (angry faces)
8252,European,4097.0,28608620.0,Coleman JRI,Other measurement,initial,2017-06-13,GCST004727,Facial emotion recognition
12851,Hispanic or Latin American,404.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004732,Heart rate variability traits (pvRSA/HF)
1334,African American or Afro-Caribbean,6895.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004733,Heart rate variability traits (RMSSD)
1335,African American or Afro-Caribbean,6899.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004734,Heart rate variability traits (SDNN)
977,African American or Afro-Caribbean,1901.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004732,Heart rate variability traits (pvRSA/HF)
13444,Hispanic or Latin American,11234.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004733,Heart rate variability traits (RMSSD)
10799,European,27850.0,28613276.0,Nolte IM,Cardiovascular measurement,initial,2017-06-14,GCST004734,Heart rate variability traits (SDNN)
10523,European,20429.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004733,Heart rate variability traits (RMSSD)
9635,European,9377.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004732,Heart rate variability traits (pvRSA/HF)
10770,European,26523.0,28613276.0,Nolte IM,Cardiovascular measurement,initial,2017-06-14,GCST004733,Heart rate variability traits (RMSSD)
10702,European,24125.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004734,Heart rate variability traits (SDNN)
10700,European,24088.0,28613276.0,Nolte IM,Cardiovascular measurement,initial,2017-06-14,GCST004732,Heart rate variability traits (pvRSA/HF)
13445,Hispanic or Latin American,11234.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004734,Heart rate variability traits (SDNN)
546,African American or Afro-Caribbean,159.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004709,Fear of severe pain
13683,Other/Mixed,23.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004707,Fear of medical pain (dental)
13682,Other/Mixed,23.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004706,Fear of pain
13685,Other/Mixed,23.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004709,Fear of severe pain
13684,Other/Mixed,23.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004708,Fear of minor pain
6540,European,1367.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004706,Fear of pain
545,African American or Afro-Caribbean,159.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004708,Fear of minor pain
12736,Hispanic or Latin American,13.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004709,Fear of severe pain
544,African American or Afro-Caribbean,159.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004707,Fear of medical pain (dental)
12734,Hispanic or Latin American,13.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004707,Fear of medical pain (dental)
12733,Hispanic or Latin American,13.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004706,Fear of pain
12735,Hispanic or Latin American,13.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004708,Fear of minor pain
543,African American or Afro-Caribbean,159.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004706,Fear of pain
6542,European,1367.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004708,Fear of minor pain
6541,European,1367.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004707,Fear of medical pain (dental)
6543,European,1367.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004709,Fear of severe pain
7867,European,3238.0,29296746.0,Ma Q,Other measurement,initial,2017-06-19,GCST005945,ADAMTS13 levels
10327,European,16883.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008568,IgA levels
10128,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008569,Composite immunoglobulin trait (IgA x IgG x IgM)
10129,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008570,Composite immunoglobulin trait (IgA x IgG/IgM)
10130,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008571,Composite immunoglobulin trait (IgA x IgG)
6520,European,1350.0,28627999.0,Ikram MA,Other measurement,replication,2017-06-19,GCST004376,Cerebral blood flow
10131,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008572,Composite immunoglobulin trait (IgA/IgG)
7161,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008569,Composite immunoglobulin trait (IgA x IgG x IgM)
7162,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008570,Composite immunoglobulin trait (IgA x IgG/IgM)
10132,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008573,Composite immunoglobulin trait (IgA/IgM)
10147,European,14442.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008575,IgM levels
10133,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008574,Composite immunoglobulin trait (IgG/IgM)
8379,European,4472.0,28627999.0,Ikram MA,Other measurement,initial,2017-06-19,GCST004376,Cerebral blood flow
10223,European,15536.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008576,IgG levels
7163,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008571,Composite immunoglobulin trait (IgA x IgG)
7185,European,2158.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008576,IgG levels
7181,European,2157.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008575,IgM levels
8313,European,4262.0,28630421.0,Li D,Metabolic disorder,initial,2017-06-19,GCST004585,Anorexia nervosa (excluding migration to or from binge-eating disorder or bulimia nervosa)
7166,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008574,Composite immunoglobulin trait (IgG/IgM)
7165,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008573,Composite immunoglobulin trait (IgA/IgM)
7164,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008572,Composite immunoglobulin trait (IgA/IgG)
7168,European,2151.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008568,IgA levels
7485,European,2543.0,28632202.0,Witt SH,Other trait,initial,2017-06-20,GCST004641,Borderline personality disorder
2074,Asian,389.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
1843,Asian,189.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
12798,Hispanic or Latin American,157.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
109,African,467.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
5387,European,492.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
464,African American or Afro-Caribbean,59.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
7770,European,3103.0,28656603.0,Na R,"Other disease, Other trait",initial,2017-06-28,GCST004638,Benign prostatic hyperplasia and/or lower urinary tract symptoms
6097,European,960.0,28656603.0,Na R,"Other disease, Other trait",replication,2017-06-28,GCST004638,Benign prostatic hyperplasia and/or lower urinary tract symptoms
11500,European,69603.0,28658209.0,Huang H,"Digestive system disorder, Immune system disorder",initial,2017-06-28,GCST005837,Inflammatory bowel disease
1967,Asian,278.0,28662289.0,Lin YY,"Digestive system disorder, Cancer",initial,2017-06-29,GCST004736,Familial hepatitis B virus-related hepatocellular carcinoma
279,African,4758.0,28234671.0,Nandakumar P,Other measurement,initial,2017-07-01,GCST007828,Diastolic blood pressure
280,African,4758.0,28234671.0,Nandakumar P,Other measurement,initial,2017-07-01,GCST007829,Systolic blood pressure
1446,African American or Afro-Caribbean,11156.0,28234671.0,Nandakumar P,Other measurement,initial,2017-07-01,GCST007829,Systolic blood pressure
1445,African American or Afro-Caribbean,11156.0,28234671.0,Nandakumar P,Other measurement,initial,2017-07-01,GCST007828,Diastolic blood pressure
9747,European,9896.0,28641744.0,Guo W,Neurological disorder,initial,2017-07-01,GCST004703,Obsessive-compulsive disorder or autism spectrum disorder
7966,European,3394.0,28672053.0,Meng W,"Cancer, Neurological disorder, Metabolic disorder",initial,2017-07-03,GCST004724,Foot ulcer in diabetes and neuropathy
8569,European,4949.0,28672053.0,Meng W,"Cancer, Neurological disorder, Metabolic disorder",initial,2017-07-03,GCST004725,Foot ulcer and neuropathy in diabetes
9640,European,9410.0,29731509.0,Zabaneh D,Biological process,initial,2017-07-04,GCST005626,Extremely high intelligence
3346,Asian,3302.0,28680059.0,Song X,"Cancer, Other trait",initial,2017-07-05,GCST004799,Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma
3733,Asian,5937.0,28680059.0,Song X,"Cancer, Other trait",replication,2017-07-05,GCST004799,Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma
4790,European,137.0,28686080.0,Liu N,Response to drug,replication,2017-07-07,GCST008374,Warfarin maintenance dose (adjusted for clinical factors)
640,African American or Afro-Caribbean,330.0,28686080.0,Liu N,Response to drug,replication,2017-07-07,GCST008374,Warfarin maintenance dose (adjusted for clinical factors)
5713,European,701.0,28686080.0,Liu N,Response to drug,initial,2017-07-07,GCST008374,Warfarin maintenance dose (adjusted for clinical factors)
718,African American or Afro-Caribbean,539.0,28686080.0,Liu N,Response to drug,initial,2017-07-07,GCST008374,Warfarin maintenance dose (adjusted for clinical factors)
4864,European,186.0,28696415.0,Maciukiewicz M,"Neurological disorder, Response to drug",initial,2017-07-11,GCST004740,Duloxetine response in major depressive disorder (remitter/non-remitter status)
4863,European,186.0,28696415.0,Maciukiewicz M,"Neurological disorder, Response to drug",initial,2017-07-11,GCST004738,Duloxetine response in major depressive disorder (% change in symptom score)
4913,European,205.0,28696415.0,Maciukiewicz M,"Neurological disorder, Biological process",initial,2017-07-11,GCST004742,Placebo response in major depressive disorder (remitter/non-remitter status)
4914,European,205.0,28696415.0,Maciukiewicz M,"Neurological disorder, Biological process",initial,2017-07-11,GCST004743,Placebo response in major depressive disorder (responder/non-responder status)
4912,European,205.0,28696415.0,Maciukiewicz M,"Neurological disorder, Biological process",initial,2017-07-11,GCST004739,Placebo response in major depressive disorder (% change in symptom score)
4865,European,186.0,28696415.0,Maciukiewicz M,"Neurological disorder, Response to drug",initial,2017-07-11,GCST004741,Duloxetine response in major depressive disorder (responder/non-responder status)
6477,European,1291.0,28698626.0,Lopez-Mejias R,Immune system disorder,initial,2017-07-11,GCST004745,Immunoglobulin A vasculitis
11311,European,53145.0,29313844.0,Willems SM,Other measurement,replication,2017-07-12,GCST005235,Hand grip strength
11985,European,142035.0,29313844.0,Willems SM,Other measurement,initial,2017-07-12,GCST005235,Hand grip strength
3962,Asian,8339.0,28703219.0,Son HY,Cancer,initial,2017-07-13,GCST004754,Follicular thyroid cancer
2584,Asian,1192.0,28703219.0,Son HY,Cancer,replication,2017-07-13,GCST004753,Papillary thyroid cancer
2594,Asian,1220.0,28703219.0,Son HY,Cancer,replication,2017-07-13,GCST004798,Differentiated thyroid cancer
1724,Asian,97.0,28700999.0,Yang CK,"Digestive system disorder, Cancer",replication,2017-07-13,GCST007514,Hepatitis B virus-related hepatocellular carcinoma
3993,Asian,8689.0,28703219.0,Son HY,Cancer,initial,2017-07-13,GCST004753,Papillary thyroid cancer
4001,Asian,8749.0,28703219.0,Son HY,Cancer,initial,2017-07-13,GCST004798,Differentiated thyroid cancer
2257,Asian,633.0,28703219.0,Son HY,Cancer,replication,2017-07-13,GCST004754,Follicular thyroid cancer
1853,Asian,195.0,28700999.0,Yang CK,"Digestive system disorder, Cancer",initial,2017-07-13,GCST007514,Hepatitis B virus-related hepatocellular carcinoma
2422,Asian,845.0,28703135.0,Ruamviboonsuk P,Neurological disorder,replication,2017-07-13,GCST004737,Neovascular age-related macular degeneration
10454,European,19108.0,28706201.0,Wei WH,Immune system disorder,initial,2017-07-13,GCST005826,Sero-negative rheumatoid arthritis
2687,Asian,1451.0,28703135.0,Ruamviboonsuk P,Neurological disorder,initial,2017-07-13,GCST004737,Neovascular age-related macular degeneration
7875,European,3260.0,28714907.0,Treutlein J,"Digestive system disorder, Cancer",initial,2017-07-17,GCST004755,Chronic alcoholic pancreatitis or alcohol-related cirrhosis
8480,European,4775.0,28714907.0,Treutlein J,"Neurological disorder, Digestive system disorder, Cancer",initial,2017-07-17,GCST004757,Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis
13218,Hispanic or Latin American,3888.0,28714469.0,Langefeld CD,Immune system disorder,initial,2017-07-17,GCST005752,Systemic lupus erythematosus
10410,European,18264.0,28714469.0,Langefeld CD,Immune system disorder,initial,2017-07-17,GCST007400,Systemic lupus erythematosus
10409,European,18264.0,28714469.0,Langefeld CD,Immune system disorder,initial,2017-07-17,GCST005752,Systemic lupus erythematosus
7876,European,3265.0,28714907.0,Treutlein J,"Other measurement, Neurological disorder",initial,2017-07-17,GCST004756,Alcohol dependence
1283,African American or Afro-Caribbean,5422.0,28714469.0,Langefeld CD,Immune system disorder,initial,2017-07-17,GCST005752,Systemic lupus erythematosus
11870,European,120286.0,28714974.0,Klarin D,Cardiovascular disease,initial,2017-07-17,GCST007990,Coronary artery disease
11090,European,38292.0,28724990.0,Zillikens MC,Other measurement,initial,2017-07-19,GCST005036,Lean body mass
11167,European,42360.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005037,Appendicular lean mass
665,African American or Afro-Caribbean,380.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005037,Appendicular lean mass
3931,Asian,7834.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005036,Lean body mass
11236,European,47227.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005036,Lean body mass
3945,Asian,8034.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005036,Lean body mass
3131,Asian,2350.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005037,Appendicular lean mass
664,African American or Afro-Caribbean,380.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005036,Lean body mass
10806,European,28330.0,28724990.0,Zillikens MC,Other measurement,initial,2017-07-19,GCST005037,Appendicular lean mass
11143,European,40832.0,28757204.0,Manousaki D,Other measurement,initial,2017-07-21,GCST004726,Vitamin D levels
5829,European,781.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004765,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
12043,European,150134.0,28739976.0,Wain LV,Other measurement,initial,2017-07-24,GCST004777,Diastolic blood pressure
12041,European,150134.0,28739976.0,Wain LV,Cardiovascular measurement,initial,2017-07-24,GCST004775,Pulse pressure
524,African American or Afro-Caribbean,138.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004763,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
5830,European,781.0,28736931.0,Rotroff DM,"Response to drug, Lipid or lipoprotein measurement, Metabolic disorder",initial,2017-07-24,GCST004766,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes
5828,European,781.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004764,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
525,African American or Afro-Caribbean,138.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004764,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
5827,European,781.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004763,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
6336,European,1156.0,28738859.0,de Jong K,Other measurement,replication,2017-07-24,GCST004800,Forced expiratory volume in 1 second (environmental tobacco smoke interaction)
526,African American or Afro-Caribbean,138.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004765,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
11661,European,87359.0,28739976.0,Wain LV,Other measurement,replication,2017-07-24,GCST004777,Diastolic blood pressure
12042,European,150134.0,28739976.0,Wain LV,Other measurement,initial,2017-07-24,GCST004776,Systolic blood pressure
11660,European,87359.0,28739976.0,Wain LV,Other measurement,replication,2017-07-24,GCST004776,Systolic blood pressure
11659,European,87359.0,28739976.0,Wain LV,Cardiovascular measurement,replication,2017-07-24,GCST004775,Pulse pressure
9852,European,10817.0,28738859.0,de Jong K,Other measurement,initial,2017-07-24,GCST004800,Forced expiratory volume in 1 second (environmental tobacco smoke interaction)
527,African American or Afro-Caribbean,138.0,28736931.0,Rotroff DM,"Response to drug, Lipid or lipoprotein measurement, Metabolic disorder",initial,2017-07-24,GCST004766,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes
11788,European,108309.0,28937693.0,Clarke TK,Other measurement,initial,2017-07-25,GCST004887,Alcohol consumption in current drinkers
11815,European,112117.0,28937693.0,Clarke TK,"Biological process, Other measurement",initial,2017-07-25,GCST004886,Alcohol consumption
1839,Asian,185.0,28744025.0,Woolston AL,"Neurological disorder, Other measurement",initial,2017-07-25,GCST004767,Schizophrenia (age at onset)
14045,Other/Mixed,833.0,28753643.0,Yeo A,"Cardiovascular disease, Biological process",initial,2017-07-28,GCST004965,Myocardial infarction in placebo-treated cardiovascular disease (time to event)
14247,Other/Mixed,10874.0,28753643.0,Yeo A,"Cardiovascular disease, Cardiovascular measurement, Response to drug",initial,2017-07-28,GCST004966,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease
14248,Other/Mixed,10874.0,28753643.0,Yeo A,"Cardiovascular disease, Cardiovascular measurement, Response to drug",initial,2017-07-28,GCST004968,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline)
9338,European,7999.0,28754779.0,Rosendahl J,Digestive system disorder,initial,2017-07-28,GCST004860,Alcoholic chronic pancreatitis
14104,Other/Mixed,1318.0,28753643.0,Yeo A,"Cardiovascular measurement, Cardiovascular disease, Response to drug",initial,2017-07-28,GCST004957,Major coronary event in darapladib-treated cardiovascular disease (time to event)
14117,Other/Mixed,1440.0,28753643.0,Yeo A,"Cardiovascular measurement, Cardiovascular disease, Biological process",initial,2017-07-28,GCST004961,Major coronary event in placebo-treated cardiovascular disease (time to event)
14127,Other/Mixed,1573.0,28753643.0,Yeo A,"Cardiovascular disease, Response to drug",initial,2017-07-28,GCST004959,Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction)
14181,Other/Mixed,2758.0,28753643.0,Yeo A,"Cardiovascular measurement, Cardiovascular disease, Response to drug",initial,2017-07-28,GCST004958,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)
12846,Hispanic or Latin American,390.0,28754176.0,Wang Z,Other measurement,initial,2017-07-28,GCST004768,Motor development (prenatal lead exposure interaction)
12847,Hispanic or Latin American,390.0,28754176.0,Wang Z,Other measurement,initial,2017-07-28,GCST004769,Mental development (prenatal lead exposure interaction)
4928,European,212.0,28753643.0,Yeo A,"Cardiovascular disease, Other trait, Response to drug",initial,2017-07-28,GCST004967,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)
14023,Other/Mixed,740.0,28753643.0,Yeo A,"Cardiovascular disease, Response to drug",initial,2017-07-28,GCST004964,Myocardial infarction in darapladib-treated cardiovascular disease (time to event)
14267,Other/Mixed,22156.0,28753643.0,Yeo A,"Lipid or lipoprotein measurement, Cardiovascular disease",initial,2017-07-28,GCST004963,Lipoprotein phospholipase A2 activity in cardiovascular disease
5351,European,481.0,28753643.0,Yeo A,"Cardiovascular disease, Other trait, Response to drug",initial,2017-07-28,GCST004962,Diarrhoea in darapladib-treated cardiovascular disease (time to event)
2180,Asian,490.0,28754176.0,Wang Z,Other measurement,initial,2017-07-28,GCST004769,Mental development (prenatal lead exposure interaction)
2179,Asian,490.0,28754176.0,Wang Z,Other measurement,initial,2017-07-28,GCST004768,Motor development (prenatal lead exposure interaction)
14140,Other/Mixed,1867.0,28753643.0,Yeo A,"Cardiovascular disease, Response to drug, Other measurement",initial,2017-07-28,GCST004960,Odor events in darapladib-treated cardiovascular disease (time to event)
5853,European,800.0,28763429.0,Serie DJ,"Cardiovascular measurement, Response to drug",initial,2017-07-31,GCST004790,Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer
3600,Asian,5152.0,28761973.0,Peng C,"Cancer, Other measurement",initial,2017-07-31,GCST004837,Lumbar spine bone mineral density or breast cancer (pleiotropy)
5176,European,391.0,28763429.0,Serie DJ,"Cardiovascular measurement, Response to drug",initial,2017-07-31,GCST004789,Change in LVEF in response to paclitaxel in HER2+ breast cancer
6379,European,1191.0,28763429.0,Serie DJ,"Cardiovascular measurement, Response to drug",initial,2017-07-31,GCST004788,Change in LVEF in response to paclitaxel and in response to paclitaxel and trastuzumab in HER+ breast cancer
3601,Asian,5152.0,28761973.0,Peng C,"Other measurement, Cancer",initial,2017-07-31,GCST004836,Femoral neck bone mineral density or breast cancer (pleiotropy)
8669,European,5206.0,28762467.0,Wadelius M,"Other trait, Response to drug",initial,2017-08-01,GCST004781,Sulfasalazine-induced agranulocytosis
13812,Other/Mixed,205.0,28763065.0,Xia K,"Other measurement, Other measurement, Other measurement, Other measurement",initial,2017-08-01,GCST004794,Brain volume in infants (intracranial brain volume)
13813,Other/Mixed,205.0,28763065.0,Xia K,"Other measurement, Other measurement, Other measurement, Other measurement",initial,2017-08-01,GCST004795,Brain volume in infants (white matter)
5131,European,356.0,28763065.0,Xia K,Other measurement,initial,2017-08-01,GCST004796,Brain volume in infants (cerebrospinal fluid)
1328,African American or Afro-Caribbean,6778.0,28794112.0,Christophersen IE,Cardiovascular measurement,initial,2017-08-01,GCST004824,P wave terminal force
5129,European,356.0,28763065.0,Xia K,Other measurement,initial,2017-08-01,GCST004794,Brain volume in infants (intracranial brain volume)
13814,Other/Mixed,205.0,28763065.0,Xia K,"Other measurement, Other measurement, Other measurement, Other measurement",initial,2017-08-01,GCST004796,Brain volume in infants (cerebrospinal fluid)
10896,European,31764.0,28813576.0,Persad PJ,Neurological disorder,initial,2017-08-01,GCST004871,Age-related macular degeneration (SNP x mitochondrial G12771A interaction)
1329,African American or Afro-Caribbean,6778.0,28794112.0,Christophersen IE,Cardiovascular measurement,initial,2017-08-01,GCST004826,P wave duration
13815,Other/Mixed,205.0,28763065.0,Xia K,"Other measurement, Other measurement, Other measurement, Other measurement",initial,2017-08-01,GCST004797,Brain volume in infants (grey matter)
10978,European,33932.0,28813576.0,Persad PJ,Neurological disorder,initial,2017-08-01,GCST004870,Age-related macular degeneration (SNP x mitochondrial A4917G interaction)
1453,African American or Afro-Caribbean,11782.0,29117387.0,Conti DV,Cancer,initial,2017-08-01,GCST004982,Prostate cancer
11077,European,37776.0,28813576.0,Persad PJ,Neurological disorder,initial,2017-08-01,GCST004872,Age-related macular degeneration (SNP x mitochondrial C16069T interaction)
10980,European,33955.0,28794112.0,Christophersen IE,Cardiovascular measurement,initial,2017-08-01,GCST004824,P wave terminal force
11071,European,37678.0,28794112.0,Christophersen IE,Cardiovascular measurement,initial,2017-08-01,GCST004826,P wave duration
155,African,932.0,29117387.0,Conti DV,Cancer,initial,2017-08-01,GCST004982,Prostate cancer
10895,European,31757.0,28813576.0,Persad PJ,Neurological disorder,initial,2017-08-01,GCST004869,Age-related macular degeneration (SNP x mitochondrial T5004C interaction)
11892,European,123195.0,28870582.0,Wang XF,"Neurological disorder, Metabolic disorder",initial,2017-08-01,GCST004880,Alzheimer's disease or type 2 diabetes (pleiotropy)
5132,European,356.0,28763065.0,Xia K,Other measurement,initial,2017-08-01,GCST004797,Brain volume in infants (grey matter)
10983,European,33976.0,28813576.0,Persad PJ,Neurological disorder,initial,2017-08-01,GCST004868,Advanced age-related macular degeneration
5130,European,356.0,28763065.0,Xia K,Other measurement,initial,2017-08-01,GCST004795,Brain volume in infants (white matter)
1736,Asian,102.0,28775256.0,Kawashima-Kumagai K,"Neurological disorder, Other measurement",replication,2017-08-03,GCST004813,Laterality in neovascular age-related macular degeneration
12862,Hispanic or Latin American,420.0,28840121.0,Villalobos-Comparan M,Other measurement,replication,2017-08-03,GCST004834,Lumbar spine bone mineral density
2556,Asian,1124.0,28775256.0,Kawashima-Kumagai K,"Neurological disorder, Other measurement",initial,2017-08-03,GCST004813,Laterality in neovascular age-related macular degeneration
12863,Hispanic or Latin American,420.0,28840121.0,Villalobos-Comparan M,Other measurement,replication,2017-08-03,GCST004835,Femoral neck bone geometry
12858,Hispanic or Latin American,411.0,28840121.0,Villalobos-Comparan M,Other measurement,initial,2017-08-03,GCST004835,Femoral neck bone geometry
12857,Hispanic or Latin American,411.0,28840121.0,Villalobos-Comparan M,Other measurement,initial,2017-08-03,GCST004834,Lumbar spine bone mineral density
1820,Asian,168.0,28775256.0,Kawashima-Kumagai K,"Neurological disorder, Other measurement",replication,2017-08-03,GCST004813,Laterality in neovascular age-related macular degeneration
7912,European,3318.0,28779025.0,Alberts R,"Digestive system disorder, Other measurement",initial,2017-08-04,GCST005859,Liver transplant-free survival in primary sclerosing cholangitis (time to event)
7732,European,3006.0,28779025.0,Alberts R,"Digestive system disorder, Cancer",initial,2017-08-04,GCST005858,Hepatocellular carcinoma in primary sclerosing cholangitis
7862,European,3234.0,28779025.0,Alberts R,Digestive system disorder,initial,2017-08-04,GCST005854,Primary sclerosing cholangitis (small duct vs large duct)
7927,European,3335.0,28779025.0,Alberts R,"Digestive system disorder, Other measurement, Cancer",initial,2017-08-04,GCST005860,Cholangiocarcinoma in primary sclerosing cholangitis (time to event)
7878,European,3266.0,28779025.0,Alberts R,"Immune system disorder, Digestive system disorder",initial,2017-08-04,GCST005853,Autoimmune hepatitis in primary sclerosing cholangitis
7926,European,3335.0,28779025.0,Alberts R,"Digestive system disorder, Cancer",initial,2017-08-04,GCST005855,Cholangiocarcinoma in primary sclerosing cholangitis
4859,European,183.0,28776448.0,Beaudoin JJ,Digestive system disorder,initial,2017-08-04,GCST004784,Alcoholic hepatitis
7705,European,2949.0,28779025.0,Alberts R,"Digestive system disorder, Cancer",initial,2017-08-04,GCST005856,Colorectal carcinoma in primary sclerosing cholangitis
7911,European,3316.0,28779025.0,Alberts R,Digestive system disorder,initial,2017-08-04,GCST005852,Colectomy in primary sclerosing cholangitis
7733,European,3007.0,28779025.0,Alberts R,"Digestive system disorder, Cancer",initial,2017-08-04,GCST005857,Gallbladder carcinoma in primary sclerosing cholangitis
7709,European,2953.0,28783044.0,Ware JS,Other trait,initial,2017-08-07,GCST004786,Thiazide-induced hyponatremia
4901,European,200.0,28783044.0,Ware JS,Other trait,replication,2017-08-07,GCST004786,Thiazide-induced hyponatremia
10814,European,28676.0,28989979.0,Howard DM,Biological process,replication,2017-08-10,GCST008861,General cognitive ability
10474,European,19326.0,28989979.0,Howard DM,Biological process,initial,2017-08-10,GCST008861,General cognitive ability
9104,European,6898.0,28800603.0,Arpawong TE,Other measurement,replication,2017-08-11,GCST004830,Verbal memory performance (residualized delayed recall change)
9103,European,6898.0,28800603.0,Arpawong TE,Other measurement,replication,2017-08-11,GCST004829,Verbal memory performance (residualized delayed recall level)
9102,European,6898.0,28800603.0,Arpawong TE,Other measurement,replication,2017-08-11,GCST004828,Verbal memory performance (immediate recall level)
5300,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005138,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
9101,European,6898.0,28800603.0,Arpawong TE,Other measurement,replication,2017-08-11,GCST004827,Verbal memory performance (immediate recall change)
5299,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005137,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching)
10143,European,14384.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004830,Verbal memory performance (residualized delayed recall change)
5302,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005140,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change)
13712,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005137,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching)
5301,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005139,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
13711,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005136,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
5252,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005135,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change)
13730,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005140,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change)
13729,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005139,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
13728,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005138,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
13727,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005137,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching)
9236,European,7486.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004828,Verbal memory performance (immediate recall level)
5251,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005134,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change)
9237,European,7486.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004829,Verbal memory performance (residualized delayed recall level)
5256,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005139,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
5255,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005138,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
13726,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005136,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
13725,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005135,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change)
5254,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005137,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching)
9238,European,7486.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004831,Verbal memory performance (delayed recall level)
5257,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005140,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change)
9239,European,7486.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004832,Verbal memory performance (delayed recall change)
5253,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005136,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
13713,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005138,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
5298,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005136,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
13714,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005139,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
13715,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005140,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change)
13709,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005134,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change)
13724,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005134,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change)
5297,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005135,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change)
5296,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005134,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change)
13710,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005135,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change)
9235,European,7486.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004827,Verbal memory performance (immediate recall change)
9281,European,7703.0,28843169.0,Neumann A,Other measurement,initial,2017-08-12,GCST004780,Cortisol levels (saliva)
1968,Asian,278.0,28808816.0,Xu C,"Biological process, Other measurement",initial,2017-08-14,GCST004823,Cognitive function
9627,European,9347.0,28806749.0,Leo PJ,Cancer,initial,2017-08-14,GCST004833,Cervical cancer
2974,Asian,1983.0,28809852.0,Liu L,Neurological disorder,initial,2017-08-15,GCST004778,Attention deficit hyperactivity disorder
3275,Asian,2888.0,28809852.0,Liu L,Neurological disorder,replication,2017-08-15,GCST004778,Attention deficit hyperactivity disorder
13850,Other/Mixed,281.0,28828242.0,Dajani R,Metabolic disorder,initial,2017-08-17,GCST004782,Type 2 diabetes
12811,Hispanic or Latin American,203.0,28817678.0,Archer NP,Cancer,initial,2017-08-17,GCST007727,Acute lymphoblastic leukemia (childhood)
13748,Other/Mixed,96.0,28817678.0,Archer NP,Cancer,initial,2017-08-17,GCST007727,Acute lymphoblastic leukemia (childhood)
8539,European,4912.0,28828242.0,Dajani R,Metabolic disorder,replication,2017-08-17,GCST004782,Type 2 diabetes
1865,Asian,205.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",replication,2017-08-23,GCST004801,Response to ranibizumab in age-related macular degeneration (visual acuity)
1866,Asian,205.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",replication,2017-08-23,GCST004802,Response to ranibizumab in age-related macular degeneration (dry maculae)
11657,European,86995.0,28843344.0,Lv WQ,"Cardiovascular disease, Body measurement",replication,2017-08-23,GCST004838,Coronary artery disease and/or body mass index (pleiotropy)
1867,Asian,205.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",replication,2017-08-23,GCST004803,Response to ranibizumab in age-related macular degeneration (additional treatment requirement)
12301,European,249796.0,28843344.0,Lv WQ,"Cardiovascular disease, Body measurement",initial,2017-08-23,GCST004838,Coronary artery disease and/or body mass index (pleiotropy)
1941,Asian,256.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",initial,2017-08-23,GCST004803,Response to ranibizumab in age-related macular degeneration (additional treatment requirement)
14272,Other/Mixed,30482.0,28843344.0,Lv WQ,"Cardiovascular disease, Body measurement",initial,2017-08-23,GCST004838,Coronary artery disease and/or body mass index (pleiotropy)
1403,African American or Afro-Caribbean,8763.0,28836065.0,Hellwege JN,Cancer,initial,2017-08-23,GCST004779,Uterine fibroids
1939,Asian,256.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",initial,2017-08-23,GCST004801,Response to ranibizumab in age-related macular degeneration (visual acuity)
1940,Asian,256.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",initial,2017-08-23,GCST004802,Response to ranibizumab in age-related macular degeneration (dry maculae)
13412,Hispanic or Latin American,8658.0,28838971.0,Mercader JM,Metabolic disorder,initial,2017-08-24,GCST006145,Type 2 diabetes
2999,Asian,2025.0,29088834.0,Kimura M,Cardiovascular disease,initial,2017-08-24,GCST004947,Pulmonary arterial hypertension
32,African,76.0,28839172.0,Mahlman M,"Other disease, Other trait",replication,2017-08-24,GCST004783,Bronchopulmonary dysplasia in preterm infants
13384,Hispanic or Latin American,7820.0,28838971.0,Mercader JM,Metabolic disorder,replication,2017-08-24,GCST006145,Type 2 diabetes
14225,Other/Mixed,4377.0,28838971.0,Mercader JM,Metabolic disorder,replication,2017-08-24,GCST006145,Type 2 diabetes
2509,Asian,1012.0,29088834.0,Kimura M,Cardiovascular disease,replication,2017-08-24,GCST004947,Pulmonary arterial hypertension
5954,European,867.0,28839172.0,Mahlman M,"Other disease, Other trait",replication,2017-08-24,GCST004783,Bronchopulmonary dysplasia in preterm infants
4841,European,174.0,28839172.0,Mahlman M,"Other disease, Other trait",initial,2017-08-24,GCST004783,Bronchopulmonary dysplasia in preterm infants
11279,European,50959.0,28714976.0,Sims R,Neurological disorder,replication,2017-09-01,GCST005549,Alzheimer's disease (late onset)
7773,European,3105.0,28881265.0,Sobalska-Kwapis M,Other disease,initial,2017-09-01,GCST004873,Endometriosis
10990,European,34174.0,28714976.0,Sims R,Neurological disorder,initial,2017-09-01,GCST005549,Alzheimer's disease (late onset)
3399,Asian,3647.0,28776340.0,Son CN,"Cardiovascular measurement, Metabolic disorder",initial,2017-09-01,GCST004825,Hyperuricemia
3352,Asian,3373.0,28869801.0,Takahashi Y,Cancer,replication,2017-09-04,GCST004839,Colorectal cancer
1538,African American or Afro-Caribbean,22000.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004891,Mean arterial pressure
11989,European,142487.0,28869591.0,Kemp JP,Other measurement,initial,2017-09-04,GCST006288,Heel bone mineral density
4244,Asian,13532.0,28869590.0,Zhao W,Metabolic disorder,initial,2017-09-04,GCST004894,Type 2 diabetes
1536,African American or Afro-Caribbean,22000.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004888,Systolic blood pressure
13478,Hispanic or Latin American,12278.0,28871152.0,Sofer T,Other measurement,initial,2017-09-04,GCST004890,Diastolic blood pressure
10519,European,20298.0,28869590.0,Zhao W,Metabolic disorder,initial,2017-09-04,GCST004894,Type 2 diabetes
13479,Hispanic or Latin American,12278.0,28871152.0,Sofer T,Other measurement,initial,2017-09-04,GCST004891,Mean arterial pressure
13477,Hispanic or Latin American,12278.0,28871152.0,Sofer T,Other measurement,initial,2017-09-04,GCST004888,Systolic blood pressure
7423,European,2479.0,28869590.0,Zhao W,Metabolic disorder,replication,2017-09-04,GCST004894,Type 2 diabetes
12063,European,155786.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004891,Mean arterial pressure
13159,Hispanic or Latin American,2764.0,28871152.0,Sofer T,Cardiovascular measurement,replication,2017-09-04,GCST004892,Pulse pressure
13158,Hispanic or Latin American,2764.0,28871152.0,Sofer T,Cardiovascular disease,replication,2017-09-04,GCST004889,Hypertension
13476,Hispanic or Latin American,12278.0,28871152.0,Sofer T,Cardiovascular measurement,initial,2017-09-04,GCST004892,Pulse pressure
13161,Hispanic or Latin American,2764.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004890,Diastolic blood pressure
13162,Hispanic or Latin American,2764.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004891,Mean arterial pressure
1534,African American or Afro-Caribbean,22000.0,28871152.0,Sofer T,Cardiovascular disease,replication,2017-09-04,GCST004889,Hypertension
1537,African American or Afro-Caribbean,22000.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004890,Diastolic blood pressure
2528,Asian,1050.0,28869801.0,Takahashi Y,Cancer,initial,2017-09-04,GCST004839,Colorectal cancer
2529,Asian,1050.0,28869801.0,Takahashi Y,Cancer,initial,2017-09-04,GCST004840,Colorectal cancer
13160,Hispanic or Latin American,2764.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004888,Systolic blood pressure
3254,Asian,2798.0,28869801.0,Takahashi Y,Cancer,replication,2017-09-04,GCST004840,Colorectal cancer
1535,African American or Afro-Caribbean,22000.0,28871152.0,Sofer T,Cardiovascular measurement,replication,2017-09-04,GCST004892,Pulse pressure
12062,European,155786.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004890,Diastolic blood pressure
4417,Asian,28567.0,28869590.0,Zhao W,Metabolic disorder,replication,2017-09-04,GCST004894,Type 2 diabetes
13475,Hispanic or Latin American,12278.0,28871152.0,Sofer T,Cardiovascular disease,initial,2017-09-04,GCST004889,Hypertension
12061,European,155786.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004888,Systolic blood pressure
12060,European,155786.0,28871152.0,Sofer T,Cardiovascular measurement,replication,2017-09-04,GCST004892,Pulse pressure
12059,European,155786.0,28871152.0,Sofer T,Cardiovascular disease,replication,2017-09-04,GCST004889,Hypertension
4519,Asian,50981.0,28869590.0,Zhao W,Metabolic disorder,replication,2017-09-04,GCST004894,Type 2 diabetes
7021,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004927,IgG galactosylation phenotypes (multivariate analysis)
7020,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004926,IgG digalactosylation phenotypes (multivariate analysis)
7018,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004924,IgG monogalactosylation phenotypes (multivariate analysis)
7026,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004932,IgG monosialylation phenotypes (multivariate analysis)
7019,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004925,IgG N-glycosylation phenotypes (multivariate analysis)
7024,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004930,IgG sialylation phenotypes (multivariate analysis)
7023,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004929,IgG fucosylation phenotypes (multivariate analysis)
7022,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004928,IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis)
7025,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004931,IgG disialylation phenotypes (multivariate analysis)
9510,European,8557.0,28886342.0,Ng M,Other disease,initial,2017-09-07,GCST004858,Dupuytren's disease
9527,European,8643.0,28877031.0,Zhang G,Other measurement,replication,2017-09-07,GCST004899,Gestational age at birth (maternal effect)
11183,European,43568.0,28877031.0,Zhang G,Other measurement,initial,2017-09-07,GCST004899,Gestational age at birth (maternal effect)
9516,European,8599.0,28877031.0,Zhang G,"Other measurement, Other trait",replication,2017-09-07,GCST004898,Preterm birth (maternal effect)
11182,European,43567.0,28877031.0,Zhang G,"Other measurement, Other trait",initial,2017-09-07,GCST004898,Preterm birth (maternal effect)
7886,European,3280.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005968,B cell acute lymphoblastic leukaemia (abnormal cytogenetics)
7808,European,3187.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005970,B cell acute lymphoblastic leukaemia in young adulthood
9641,European,9436.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST004939,Glycated hemoglobin levels
7855,European,3220.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005965,B cell acute lymphoblastic leukaemia (normal cytogenetics)
7803,European,3179.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005971,B cell acute lymphoblastic leukaemia in adulthood
7799,European,3161.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005969,Acute lymphoblastic leukemia in childhood (B cell precursor)
9754,European,9961.0,28887542.0,Prins BP,"Lipid or lipoprotein measurement, Other measurement",initial,2017-09-08,GCST005068,LDL cholesterol
8312,European,4259.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005074,Testosterone levels
9732,European,9888.0,28887542.0,Prins BP,"Lipid or lipoprotein measurement, Other measurement",replication,2017-09-08,GCST005068,LDL cholesterol
9731,European,9888.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,replication,2017-09-08,GCST005073,Triglyceride levels
9730,European,9888.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,replication,2017-09-08,GCST005065,"Cholesterol, total"
9729,European,9888.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,replication,2017-09-08,GCST005058,HDL cholesterol
9728,European,9888.0,28887542.0,Prins BP,Inflammatory measurement,replication,2017-09-08,GCST005067,C-reactive protein levels
9727,European,9888.0,28887542.0,Prins BP,Hematological measurement,replication,2017-09-08,GCST005062,Fibrinogen levels
9726,European,9888.0,28887542.0,Prins BP,Hematological measurement,replication,2017-09-08,GCST005060,Hemoglobin levels
9663,European,9541.0,28887542.0,Prins BP,Inflammatory measurement,initial,2017-09-08,GCST005067,C-reactive protein levels
9716,European,9824.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005059,Serum albumin level
9713,European,9818.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005072,Ferritin levels
9712,European,9818.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005070,Urea levels
9711,European,9817.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,initial,2017-09-08,GCST005065,"Cholesterol, total"
9709,European,9803.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005066,Creatinine levels
9705,European,9796.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,initial,2017-09-08,GCST005058,HDL cholesterol
9698,European,9762.0,28887542.0,Prins BP,Hematological measurement,initial,2017-09-08,GCST005062,Fibrinogen levels
9697,European,9747.0,28887542.0,Prins BP,Liver enzyme measurement,initial,2017-09-08,GCST005069,Gamma glutamyl transferase levels
9696,European,9745.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,initial,2017-09-08,GCST005073,Triglyceride levels
9693,European,9733.0,28887542.0,Prins BP,Liver enzyme measurement,initial,2017-09-08,GCST005061,Serum alkaline phosphatase levels
9692,European,9732.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005071,Insulin-like growth factor 1 levels
9691,European,9731.0,28887542.0,Prins BP,Liver enzyme measurement,initial,2017-09-08,GCST004940,Alanine transaminase levels
9690,European,9722.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST004941,Dehydroepiandrosterone sulphate levels
3653,Asian,5514.0,28886140.0,Kwon YC,Immune system disorder,replication,2017-09-08,GCST004859,Kawasaki disease
9681,European,9667.0,28887542.0,Prins BP,Hematological measurement,initial,2017-09-08,GCST005060,Hemoglobin levels
9734,European,9888.0,28887542.0,Prins BP,Liver enzyme measurement,replication,2017-09-08,GCST005061,Serum alkaline phosphatase levels
9735,European,9888.0,28887542.0,Prins BP,Liver enzyme measurement,replication,2017-09-08,GCST005064,Aspartate aminotransferase levels
9733,European,9888.0,28887542.0,Prins BP,Liver enzyme measurement,replication,2017-09-08,GCST004940,Alanine transaminase levels
9737,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST004939,Glycated hemoglobin levels
8010,European,3473.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005972,Acute lymphoblastic leukemia (B-cell precursor)
9652,European,9463.0,28887542.0,Prins BP,Liver enzyme measurement,initial,2017-09-08,GCST005064,Aspartate aminotransferase levels
9755,European,9961.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005063,Glomerular filtration rate
9745,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005074,Testosterone levels
9744,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005072,Ferritin levels
2617,Asian,1249.0,28886140.0,Kwon YC,Immune system disorder,initial,2017-09-08,GCST004859,Kawasaki disease
9743,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005071,Insulin-like growth factor 1 levels
9741,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005066,Creatinine levels
7990,European,3437.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005966,B cell acute lymphoblastic leukaemia (hyperdiploid negative)
9740,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005063,Glomerular filtration rate
9739,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005059,Serum albumin level
7947,European,3360.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005967,B cell acute lymphoblastic leukaemia (Philadelphia chromosome negative)
9738,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST004941,Dehydroepiandrosterone sulphate levels
9742,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005070,Urea levels
9736,European,9888.0,28887542.0,Prins BP,Liver enzyme measurement,replication,2017-09-08,GCST005069,Gamma glutamyl transferase levels
4288,Asian,15146.0,28892062.0,Akiyama M,"Body measurement, Other measurement",replication,2017-09-11,GCST004904,Body mass index
12431,European,322154.0,28892062.0,Akiyama M,"Body measurement, Other measurement",replication,2017-09-11,GCST004904,Body mass index
12573,European,417508.0,28892059.0,Chang D,Neurological disorder,initial,2017-09-11,GCST004902,Parkinson's disease
9935,European,11717.0,28892059.0,Chang D,Neurological disorder,replication,2017-09-11,GCST004902,Parkinson's disease
4625,Asian,158284.0,28892062.0,Akiyama M,"Body measurement, Other measurement",initial,2017-09-11,GCST004904,Body mass index
4337,Asian,18472.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST004903,Glycated hemoglobin levels
2637,Asian,1302.0,28898252.0,Wheeler E,Other measurement,replication,2017-09-12,GCST004903,Glycated hemoglobin levels
1349,African American or Afro-Caribbean,7564.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST007952,Glycated hemoglobin levels
1348,African American or Afro-Caribbean,7564.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST004903,Glycated hemoglobin levels
3135,Asian,2366.0,28898252.0,Wheeler E,Other measurement,replication,2017-09-12,GCST004903,Glycated hemoglobin levels
11671,European,88355.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST004903,Glycated hemoglobin levels
10936,European,33238.0,28898252.0,Wheeler E,Other measurement,replication,2017-09-12,GCST004903,Glycated hemoglobin levels
11672,European,88355.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST007954,Glycated hemoglobin levels
3890,Asian,7572.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST004903,Glycated hemoglobin levels
4338,Asian,18472.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST007953,Glycated hemoglobin levels
3891,Asian,7572.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST007951,Glycated hemoglobin levels
13100,Hispanic or Latin American,1940.0,28902444.0,Stein MB,Biological process,initial,2017-09-13,GCST004893,Suicide attempts
8447,European,4683.0,28902444.0,Stein MB,Biological process,replication,2017-09-13,GCST004893,Suicide attempts
229,African,1772.0,28902444.0,Stein MB,Biological process,initial,2017-09-13,GCST004893,Suicide attempts
145,African,840.0,28902444.0,Stein MB,Biological process,replication,2017-09-13,GCST004893,Suicide attempts
12796,Hispanic or Latin American,149.0,28902444.0,Stein MB,Biological process,replication,2017-09-13,GCST004893,Suicide attempts
9000,European,6539.0,28902444.0,Stein MB,Biological process,initial,2017-09-13,GCST004893,Suicide attempts
12797,Hispanic or Latin American,156.0,28918882.0,Wattacheril J,Digestive system disorder,initial,2017-09-14,GCST004943,Pediatric nonalcoholic steatohepatitis
12812,Hispanic or Latin American,208.0,28918882.0,Wattacheril J,"Cancer, Other measurement, Digestive system disorder",initial,2017-09-14,GCST004942,Pediatric non-alcoholic fatty liver disease activity score
12813,Hispanic or Latin American,208.0,28918882.0,Wattacheril J,"Other trait, Digestive system disorder",initial,2017-09-14,GCST004938,Liver fibrosis in pediatric non-alcoholic fatty acid liver disease
871,African American or Afro-Caribbean,1217.0,28916551.0,Liu Y,Other disease,initial,2017-09-15,GCST004881,Knee osteoarthritis
4112,Asian,10300.0,29212154.0,Lin E,Body measurement,initial,2017-09-16,GCST005872,Waist circumference
2618,Asian,1251.0,28921602.0,Lee MH,"Cancer, Digestive system disorder",initial,2017-09-16,GCST006037,Hepatocellular carcinoma in hepatitis C infection
4113,Asian,10300.0,29212154.0,Lin E,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2017-09-16,GCST005871,Metabolic syndrome
4115,Asian,10300.0,29212154.0,Lin E,Lipid or lipoprotein measurement,initial,2017-09-16,GCST005874,HDL cholesterol
4116,Asian,10300.0,29212154.0,Lin E,Other measurement,initial,2017-09-16,GCST005875,Diastolic blood pressure
4117,Asian,10300.0,29212154.0,Lin E,Other measurement,initial,2017-09-16,GCST005876,Systolic blood pressure
4118,Asian,10300.0,29212154.0,Lin E,Other measurement,initial,2017-09-16,GCST005877,Fasting blood glucose
4114,Asian,10300.0,29212154.0,Lin E,Lipid or lipoprotein measurement,initial,2017-09-16,GCST005873,Triglyceride levels
6795,European,1660.0,28927820.0,Sugier PE,Immune system disorder,initial,2017-09-16,GCST006040,Atopy
705,African American or Afro-Caribbean,480.0,28921760.0,Chenoweth MJ,"Biological process, Other measurement",replication,2017-09-16,GCST004976,nicotine metabolite ratio in current smokers
2544,Asian,1098.0,28921602.0,Lee MH,"Cancer, Digestive system disorder",replication,2017-09-16,GCST006037,Hepatocellular carcinoma in hepatitis C infection
6310,European,1138.0,28927820.0,Sugier PE,Immune system disorder,replication,2017-09-16,GCST006040,Atopy
5295,European,446.0,28927820.0,Sugier PE,Immune system disorder,replication,2017-09-16,GCST006040,Atopy
817,African American or Afro-Caribbean,954.0,28921760.0,Chenoweth MJ,"Biological process, Other measurement",initial,2017-09-16,GCST004976,nicotine metabolite ratio in current smokers
5180,European,395.0,28924153.0,Chang X,Cancer,initial,2017-09-18,GCST004882,Neuroblastoma (11q deletion vs 11q undeleted and MYCN amplification)
8674,European,5222.0,28924153.0,Chang X,Cancer,initial,2017-09-18,GCST004883,Neuroblastoma (11q deletion)
7005,European,1946.0,28924153.0,Chang X,Cancer,replication,2017-09-18,GCST004883,Neuroblastoma (11q deletion)
4803,European,147.0,28935272.0,Moore KN,"Response to drug, Other measurement, Cancer",initial,2017-09-18,GCST004897,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
1906,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004992,White matter microstructure in first episode schizophrenia (right posterior cingulate cortex)
1905,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004991,White matter microstructure in first episode schizophrenia (left inferior parietal cortex)
8724,European,5369.0,28924153.0,Chang X,Cancer,initial,2017-09-18,GCST004885,Neuroblastoma (MYCN amplification)
5026,European,289.0,28935272.0,Moore KN,"Response to drug, Other measurement, Cancer",initial,2017-09-18,GCST004896,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin
1911,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004997,Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis)
1910,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004996,Total mean fractional anisotropy measurement in first episode schizophrenia
1909,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004995,White matter microstructure in first episode schizophrenia (left posterior cingulate cortex)
1908,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004994,White matter microstructure in first episode schizophrenia (left anterior cingulate cortex)
1907,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004993,White matter microstructure in first episode schizophrenia (right anterior cingulate cortex)
8663,European,5178.0,28924153.0,Chang X,Cancer,initial,2017-09-18,GCST004884,Neuroblastoma (1p deletion)
12251,European,219579.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005017,Hepatitis A
12253,European,219605.0,28928442.0,Tian C,"Digestive system disorder, Other measurement",initial,2017-09-19,GCST005004,Hepatitis B
5069,European,315.0,28922980.0,Konte B,"Neurological disorder, Other measurement",initial,2017-09-19,GCST004953,Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia
12149,European,173421.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005014,Tonsillectomy
11425,European,62453.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005011,Yeast infection
11619,European,83620.0,28928442.0,Tian C,"Other measurement, Neurological disorder",initial,2017-09-19,GCST005010,Bacterial meningitis
11398,European,59546.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005019,Number of common colds
11634,European,84913.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005021,Chronic sinus infection
11636,European,85380.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005003,Mumps
11879,European,120649.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005008,Scarlet fever
11639,European,85498.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005016,Measles
11650,European,85903.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005002,Mononucleosis
11536,European,74504.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005007,Strep throat
11951,European,134863.0,28928442.0,Tian C,"Other disease, Other measurement",initial,2017-09-19,GCST005001,Shingles
11673,European,88440.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005000,Cold sores
11424,European,62445.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005005,Plantar warts
11897,European,123751.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST004999,Chickenpox
11618,European,83597.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005020,Rubella
11676,European,88716.0,28928442.0,Tian C,"Other disease, Other measurement",initial,2017-09-19,GCST005006,Tuberculosis
11678,European,89191.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005018,Rheumatic fever
11885,European,121810.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005013,Childhood ear infection
11923,European,130639.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005009,Pneumonia
11484,European,68478.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005012,Urinary tract infection frequency
11679,European,89227.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005015,Myringotomy
11029,European,36052.0,28931804.0,Benyamin B,Neurological disorder,initial,2017-09-20,GCST004901,Amyotrophic lateral sclerosis (sporadic)
8554,European,4931.0,28979897.0,Zeller T,Cardiovascular disease,initial,2017-09-20,GCST004918,Coronary artery disease severity measurement
3462,Asian,4084.0,28931804.0,Benyamin B,Neurological disorder,initial,2017-09-20,GCST008472,Amyotrophic lateral sclerosis (sporadic)
3461,Asian,4084.0,28931804.0,Benyamin B,Neurological disorder,initial,2017-09-20,GCST004901,Amyotrophic lateral sclerosis (sporadic)
7279,European,2283.0,28979897.0,Zeller T,Cardiovascular disease,replication,2017-09-20,GCST004918,Coronary artery disease severity measurement
11030,European,36052.0,28931804.0,Benyamin B,Neurological disorder,initial,2017-09-20,GCST008472,Amyotrophic lateral sclerosis (sporadic)
10373,European,17675.0,28941034.0,Smith CE,"Body measurement, Biological process",replication,2017-09-21,GCST006173,BMI x dairy intake interaction (1df interaction test)
10747,European,25513.0,28941034.0,Smith CE,"Body measurement, Biological process",initial,2017-09-21,GCST006173,BMI x dairy intake interaction (1df interaction test)
3179,Asian,2509.0,29036319.0,Qi H,"Other disease, Other measurement",initial,2017-09-26,GCST004923,Tuberculosis
3178,Asian,2509.0,29036319.0,Qi H,"Other disease, Other measurement",initial,2017-09-26,GCST004922,Tuberculosis
248,African,2698.0,29036319.0,Qi H,"Other disease, Other measurement",initial,2017-09-26,GCST004922,Tuberculosis
3952,Asian,8187.0,29036319.0,Qi H,"Other disease, Other measurement",replication,2017-09-26,GCST004923,Tuberculosis
10693,European,24003.0,28960316.0,Tanskanen T,Cancer,replication,2017-09-28,GCST004895,Colorectal cancer
11843,European,116666.0,28957414.0,Pilling LC,Hematological measurement,initial,2017-09-28,GCST006804,Red cell distribution width
3883,Asian,7518.0,28957384.0,Kim SK,Other disease,initial,2017-09-28,GCST004952,Ankle injury
11616,European,83264.0,28957384.0,Kim SK,Other disease,initial,2017-09-28,GCST004952,Ankle injury
13407,Hispanic or Latin American,8560.0,28957384.0,Kim SK,Other disease,initial,2017-09-28,GCST004952,Ankle injury
10236,European,15783.0,28960316.0,Tanskanen T,Cancer,initial,2017-09-28,GCST004895,Colorectal cancer
10815,European,28677.0,28972577.0,Hancock DB,Neurological disorder,initial,2017-10-03,GCST008496,Nicotine dependence
1428,African American or Afro-Caribbean,9925.0,28972577.0,Hancock DB,Neurological disorder,initial,2017-10-03,GCST008496,Nicotine dependence
10187,European,14980.0,28979981.0,Tielbeek JJ,Other measurement,initial,2017-10-04,GCST004954,Antisocial behavior
9319,European,7926.0,28979981.0,Tielbeek JJ,Other measurement,initial,2017-10-04,GCST006490,Antisocial behavior
9134,European,7054.0,28979981.0,Tielbeek JJ,Other measurement,initial,2017-10-04,GCST006489,Antisocial behavior
2148,Asian,469.0,28983962.0,Cheung JPY,Other disease,initial,2017-10-06,GCST004945,Lumbar spinal stenosis
11606,European,82315.0,28991256.0,Li Z,Neurological disorder,initial,2017-10-09,GCST004946,Schizophrenia
5824,European,779.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005030,Late gestational weight gain (fetal effect)
6947,European,1854.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005029,Early gestation weight gain (maternal effect)
10289,European,16434.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005031,Gestational weight gain (fetal effect)
6636,European,1491.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005153,Colorectal adenoma (advanced)
6600,European,1436.0,28990359.0,Polimanti R,"Neurological disorder, Other measurement",initial,2017-10-09,GCST004955,Risky sexual behaviors in alcohol dependence
8323,European,4294.0,29228715.0,Hofer P,Other trait,initial,2017-10-09,GCST005147,Colonoscopy-negative controls vs population controls
8688,European,5272.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005149,Colorectal cancer
8553,European,4930.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005151,Colorectal adenoma (advanced)
7417,European,2469.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005148,Colorectal cancer
6878,European,1751.0,28990359.0,Polimanti R,"Other measurement, Neurological disorder",initial,2017-10-09,GCST004956,Risky sexual behaviors (alcohol dependence interaction)
8866,European,5908.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005150,Colorectal cancer
9298,European,7827.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005031,Gestational weight gain (fetal effect)
4105,Asian,10154.0,28991256.0,Li Z,Neurological disorder,replication,2017-10-09,GCST004946,Schizophrenia
9282,European,7704.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005029,Early gestation weight gain (maternal effect)
6781,European,1646.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005034,Late gestational weight gain (maternal effect)
6933,European,1833.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005152,Colorectal cancer
7889,European,3289.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005032,Early gestational weight gain (fetal effect)
1028,African American or Afro-Caribbean,2173.0,28990359.0,Polimanti R,"Other measurement, Neurological disorder",initial,2017-10-09,GCST004956,Risky sexual behaviors (alcohol dependence interaction)
9511,European,8559.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005032,Early gestational weight gain (fetal effect)
9526,European,8641.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005030,Late gestational weight gain (fetal effect)
9277,European,7681.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005034,Late gestational weight gain (maternal effect)
938,African American or Afro-Caribbean,1541.0,28990359.0,Polimanti R,"Neurological disorder, Other measurement",initial,2017-10-09,GCST004955,Risky sexual behaviors in alcohol dependence
9896,European,11280.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005033,Gestational weight gain (maternal effect)
9802,European,10555.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005033,Gestational weight gain (maternal effect)
4400,Asian,26026.0,28991256.0,Li Z,Neurological disorder,initial,2017-10-09,GCST004946,Schizophrenia
8485,European,4792.0,29018042.0,Schierding W,Other measurement,initial,2017-10-10,GCST004951,Post-term birth
8351,European,4395.0,29030101.0,Asai Y,Other measurement,initial,2017-10-10,GCST006039,Peanut allergy
8391,European,4506.0,29030101.0,Asai Y,Other measurement,initial,2017-10-10,GCST006038,Food allergy
2965,Asian,1942.0,29031612.0,Hirata J,Immune system disorder,replication,2017-10-12,GCST006036,Psoriasis vulgaris
2320,Asian,708.0,29031612.0,Hirata J,Immune system disorder,initial,2017-10-12,GCST006036,Psoriasis vulgaris
1502,African American or Afro-Caribbean,19433.0,29030599.0,Joshi PK,Other measurement,initial,2017-10-13,GCST004983,Parental lifespan
12668,European,586626.0,29030599.0,Joshi PK,Other measurement,initial,2017-10-13,GCST004983,Parental lifespan
2239,Asian,606.0,29016859.0,Ogura Y,"Other disease, Other measurement",replication,2017-10-15,GCST004981,Curve progression in adolescent idiopathic scoliosis
2961,Asian,1937.0,29016859.0,Ogura Y,"Other disease, Other measurement",initial,2017-10-15,GCST004981,Curve progression in adolescent idiopathic scoliosis
14078,Other/Mixed,1158.0,29045471.0,Robiou-du-Pont S,Other measurement,initial,2017-10-18,GCST007577,Blood pressure (parental or offspring effect)
7703,European,2948.0,29051540.0,Marenholz I,Other measurement,replication,2017-10-20,GCST004980,Peanut allergy
8394,European,4529.0,29059373.0,Li Y,"Biological process, Cancer",initial,2017-10-20,GCST005911,Smoking interaction in squamous cell lung cancer (1df test)
7529,European,2617.0,29051540.0,Marenholz I,Other measurement,initial,2017-10-20,GCST004980,Peanut allergy
7497,European,2556.0,29051540.0,Marenholz I,Other measurement,initial,2017-10-20,GCST004978,Cow's milk allergy
10058,European,13336.0,29059373.0,Li Y,"Biological process, Cancer",initial,2017-10-20,GCST005910,Smoking interaction in non-small cell lung cancer (1df test)
7691,European,2926.0,29051540.0,Marenholz I,Other measurement,replication,2017-10-20,GCST004977,Hen's egg allergy
7681,European,2900.0,29051540.0,Marenholz I,Other measurement,replication,2017-10-20,GCST004978,Cow's milk allergy
9127,European,7015.0,29059373.0,Li Y,"Biological process, Cancer",initial,2017-10-20,GCST005909,Smoking interaction in lung adenocarcinoma (1df test)
9198,European,7353.0,29066090.0,Allen RJ,Cancer,replication,2017-10-20,GCST004986,Idiopathic pulmonary fibrosis
7672,European,2884.0,29051540.0,Marenholz I,Other measurement,initial,2017-10-20,GCST004979,Food allergy
7563,European,2675.0,29051540.0,Marenholz I,Other measurement,initial,2017-10-20,GCST004977,Hen's egg allergy
8049,European,3560.0,29051540.0,Marenholz I,Other measurement,replication,2017-10-20,GCST004979,Food allergy
8201,European,3968.0,29066090.0,Allen RJ,Cancer,initial,2017-10-20,GCST004986,Idiopathic pulmonary fibrosis
10224,European,15566.0,29058716.0,Milne RL,"Cancer, Other measurement",initial,2017-10-23,GCST005075,Breast Cancer in BRCA1 mutation carriers
11666,European,87827.0,29058716.0,Milne RL,Cancer,initial,2017-10-23,GCST005077,Breast cancer
467,African American or Afro-Caribbean,67.0,29057527.0,Ballantine JL,Digestive system disorder,initial,2017-10-23,GCST004989,Early childhood caries
5271,European,434.0,29064910.0,Kure Fischer E,"Response to drug, Neurological disorder, Cardiovascular measurement",initial,2017-10-23,GCST004987,Antipsychotic drug-induced QTc interval change in schizophrenia
10520,European,20328.0,29058377.0,Sanchez-Roige S,Other measurement,initial,2017-10-23,GCST004990,Alcohol consumption over the past year
11519,European,72261.0,29058716.0,Milne RL,Cancer,initial,2017-10-23,GCST005076,Breast cancer (estrogen-receptor negative)
4660,European,49.0,29057527.0,Ballantine JL,Digestive system disorder,initial,2017-10-23,GCST004989,Early childhood caries
11267,European,49801.0,29058716.0,Milne RL,Cancer,replication,2017-10-23,GCST005076,Breast cancer (estrogen-receptor negative)
60,African,202.0,29064910.0,Kure Fischer E,"Response to drug, Neurological disorder, Cardiovascular measurement",initial,2017-10-23,GCST004987,Antipsychotic drug-induced QTc interval change in schizophrenia
1924,Asian,236.0,29058489.0,Ogata S,"Other measurement, Biological process",replication,2017-10-23,GCST004984,White coat effect (clinic systolic blood pressure minus home systolic blood pressure)
4258,Asian,14068.0,29059683.0,Michailidou K,Cancer,replication,2017-10-23,GCST004988,Breast cancer
1925,Asian,236.0,29058489.0,Ogata S,"Other measurement, Biological process",replication,2017-10-23,GCST004985,White coat effect (clinic diastolic blood pressure minus home diastolic blood pressure)
11684,European,89677.0,29059683.0,Michailidou K,Cancer,replication,2017-10-23,GCST004988,Breast cancer
7929,European,3342.0,29058716.0,Milne RL,"Cancer, Other measurement",replication,2017-10-23,GCST005075,Breast Cancer in BRCA1 mutation carriers
13677,Other/Mixed,21.0,29057527.0,Ballantine JL,Digestive system disorder,initial,2017-10-23,GCST004989,Early childhood caries
1980,Asian,295.0,29058489.0,Ogata S,"Other measurement, Biological process",initial,2017-10-23,GCST004985,White coat effect (clinic diastolic blood pressure minus home diastolic blood pressure)
12762,Hispanic or Latin American,74.0,29057527.0,Ballantine JL,Digestive system disorder,initial,2017-10-23,GCST004989,Early childhood caries
11310,European,53143.0,29058716.0,Milne RL,Cancer,replication,2017-10-23,GCST005077,Breast cancer
11970,European,139274.0,29059683.0,Michailidou K,Cancer,initial,2017-10-23,GCST004988,Breast cancer
1979,Asian,295.0,29058489.0,Ogata S,"Other measurement, Biological process",initial,2017-10-23,GCST004984,White coat effect (clinic systolic blood pressure minus home systolic blood pressure)
5144,European,367.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005026,Initial pursuit acceleration in psychotic disorders
66,African,224.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005027,Anti-saccade error rate in psychotic disorders
5502,European,549.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005024,Pursuit maintenance gain
8268,European,4134.0,29065852.0,Hallengren E,Other measurement,initial,2017-10-24,GCST005035,Fasting growth hormone levels
5501,European,549.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005023,Initial pursuit acceleration
5145,European,367.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005027,Anti-saccade error rate in psychotic disorders
65,African,224.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005026,Initial pursuit acceleration in psychotic disorders
85,African,300.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005023,Initial pursuit acceleration
5146,European,367.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005028,Pursuit maintenance gain in psychotic disorders
86,African,300.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005024,Pursuit maintenance gain
8686,European,5262.0,29065852.0,Hallengren E,Other measurement,replication,2017-10-24,GCST005035,Fasting growth hormone levels
87,African,300.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005025,Anti-saccade response
5503,European,549.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005025,Anti-saccade response
67,African,224.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005028,Pursuit maintenance gain in psychotic disorders
6697,European,1551.0,29071344.0,Zhou H,Neurological disorder,replication,2017-10-25,GCST005022,Major depression and alcohol dependence
1929,Asian,238.0,29065906.0,Joo YB,"Immune system disorder, Other measurement",initial,2017-10-25,GCST004998,Severe progression in rheumatoid arthritis
6754,European,1618.0,29071344.0,Zhou H,Neurological disorder,initial,2017-10-25,GCST005022,Major depression and alcohol dependence
1127,African American or Afro-Caribbean,3041.0,29071344.0,Zhou H,Neurological disorder,initial,2017-10-25,GCST005022,Major depression and alcohol dependence
948,African American or Afro-Caribbean,1612.0,29071344.0,Zhou H,Neurological disorder,replication,2017-10-25,GCST005022,Major depression and alcohol dependence
236,African,2078.0,29107063.0,Yashin AI,"Neurological disorder, Other measurement",initial,2017-10-26,GCST006120,Alzheimer's disease (age of onset)
9980,European,12169.0,29107063.0,Yashin AI,"Neurological disorder, Other measurement",initial,2017-10-26,GCST006120,Alzheimer's disease (age of onset)
243,African,2329.0,29107063.0,Yashin AI,Neurological disorder,initial,2017-10-26,GCST006121,Alzheimer's disease
10250,European,16063.0,29107063.0,Yashin AI,Neurological disorder,initial,2017-10-26,GCST006121,Alzheimer's disease
5877,European,820.0,29229094.0,Condreay L,"Other disease, Response to drug",initial,2017-10-26,GCST005115,Response to mepolizumab in severe asthma
874,African American or Afro-Caribbean,1221.0,29077507.0,Chen H,"Other measurement, Neurological disorder",initial,2017-10-27,GCST005051,Obstructive sleep apnea trait (apnea hypopnea index)
13492,Hispanic or Latin American,12557.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
13493,Hispanic or Latin American,12557.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005050,Obstructive sleep apnea during REM sleep (apnea hypopnea index)
581,African American or Afro-Caribbean,206.0,29077507.0,Chen H,Other measurement,replication,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
8814,European,5727.0,29077507.0,Chen H,"Other measurement, Neurological disorder",initial,2017-10-27,GCST005051,Obstructive sleep apnea trait (apnea hypopnea index)
13494,Hispanic or Latin American,12557.0,29077507.0,Chen H,"Other measurement, Neurological disorder",initial,2017-10-27,GCST005051,Obstructive sleep apnea trait (apnea hypopnea index)
8813,European,5727.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005050,Obstructive sleep apnea during REM sleep (apnea hypopnea index)
8812,European,5727.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
872,African American or Afro-Caribbean,1221.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
3251,Asian,2792.0,29077507.0,Chen H,Other measurement,replication,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
8728,European,5382.0,29077507.0,Chen H,Other measurement,replication,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
1914,Asian,228.0,29077507.0,Chen H,"Other measurement, Neurological disorder",initial,2017-10-27,GCST005051,Obstructive sleep apnea trait (apnea hypopnea index)
1912,Asian,228.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
1913,Asian,228.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005050,Obstructive sleep apnea during REM sleep (apnea hypopnea index)
873,African American or Afro-Caribbean,1221.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005050,Obstructive sleep apnea during REM sleep (apnea hypopnea index)
9457,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005498,Triglyceride levels in very large HDL
9455,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005496,Free cholesterol levels in very large HDL
9453,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005494,Total cholesterol levels in very large HDL
9454,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005495,Cholesterol ester levels in very large HDL
9458,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005499,Phospholipid levels in large HDL
9456,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005497,Large HDL particle concentration
9452,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005493,Phospholipid levels in very large HDL
9459,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005500,Total cholesterol levels in large HDL
9449,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005490,Small LDL particle concentration
9450,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005491,Total cholesterol levels in small LDL
9443,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005484,Cholesterol ester levels in large LDL
9444,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005485,Free cholesterol levels in large LDL
9445,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005486,Medium LDL particle concentration
9446,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005487,Phospholipid levels in medium LDL
9447,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005488,Total cholesterol levels in medium LDL
9448,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005489,Cholesterol ester levels in medium LDL
9460,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005501,Cholesterol ester levels in very large HDL
9451,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005492,Very large HDL particle concentration
9462,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005503,Medium HDL particle concentration
367,African,16935.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009151,High density lipoprotein cholesterol levels
9464,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005505,Total cholesterol levels in medium HDL
3958,Asian,8287.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009145,Total cholesterol levels
3959,Asian,8287.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009150,Low density lipoprotein cholesterol levels
3960,Asian,8287.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009151,High density lipoprotein cholesterol levels
3961,Asian,8287.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009152,Triglyceride levels
1601,Asian,6.0,29082582.0,Almli LM,"Other measurement, Biological process",replication,2017-10-30,GCST005236,Problematic alcohol use in trauma-exposed individuals
43,African,108.0,29082582.0,Almli LM,"Other measurement, Biological process",replication,2017-10-30,GCST005236,Problematic alcohol use in trauma-exposed individuals
9442,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005483,Total cholesterol levels in large LDL
12499,European,360838.0,29083406.0,Ferreira MA,"Other disease, Immune system disorder",initial,2017-10-30,GCST005038,"Allergic disease (asthma, hay fever or eczema)"
13851,Other/Mixed,282.0,29082582.0,Almli LM,"Other measurement, Biological process",replication,2017-10-30,GCST005236,Problematic alcohol use in trauma-exposed individuals
9472,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005513,Apolipoprotein A1 levels
9471,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005512,Triglyceride levels in chylomicrons and largest VLDL
9470,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005511,Phospholipid levels in chylomicrons and largest VLDL
9469,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005510,Chylomicron and largest VLDL particle concentration
9468,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005509,Triglyceride levels in small HDL
9467,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005508,Small HDL particle concentration
9466,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005507,Free cholesterol levels in medium HDL
9465,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005506,Cholesterol ester levels in medium HDL
9463,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005504,Phospholipid levels in medium HDL
9441,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005482,Phospholipid levels in large LDL
9461,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005502,Free cholesterol levels in large HDL
9439,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005480,Triglyceride levels in IDL
9407,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005448,Serum total cholesterol levels
9406,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005447,Total cholesterol levels in LDL
9405,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005446,Total cholesterol levels in HDL
9404,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005445,Free cholesterol levels
9403,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005444,Esterified cholesterol levels
9402,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005443,Ratio of apolipoprotein A1 to apolipoprotein B
9401,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005442,Apolipoprotein B levels
13294,Hispanic or Latin American,5084.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009150,Low density lipoprotein cholesterol levels
368,African,16935.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009152,Triglyceride levels
4433,Asian,30468.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009145,Total cholesterol levels
4434,Asian,30468.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009150,Low density lipoprotein cholesterol levels
12278,European,237050.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009152,Triglyceride levels
838,African American or Afro-Caribbean,1036.0,29082582.0,Almli LM,"Other measurement, Biological process",initial,2017-10-30,GCST005236,Problematic alcohol use in trauma-exposed individuals
9408,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005449,Total triglycerides levels
4435,Asian,30468.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009151,High density lipoprotein cholesterol levels
4436,Asian,30468.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009152,Triglyceride levels
13295,Hispanic or Latin American,5084.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009151,High density lipoprotein cholesterol levels
13293,Hispanic or Latin American,5084.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009145,Total cholesterol levels
12272,European,237050.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009146,Total cholesterol levels
12273,European,237050.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009147,Low density lipoprotein cholesterol levels
12274,European,237050.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009148,High density lipoprotein cholesterol levels
12277,European,237050.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009151,High density lipoprotein cholesterol levels
13296,Hispanic or Latin American,5084.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009152,Triglyceride levels
12276,European,237050.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009150,Low density lipoprotein cholesterol levels
12275,European,237050.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009149,Triglyceride levels
9440,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005481,Large LDL particle concentration
365,African,16935.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009145,Total cholesterol levels
5898,European,828.0,29082582.0,Almli LM,"Other measurement, Biological process",replication,2017-10-30,GCST005236,Problematic alcohol use in trauma-exposed individuals
12271,European,237050.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009145,Total cholesterol levels
9409,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005450,Very large VLDL particle concentration
366,African,16935.0,29083408.0,Liu DJ,Lipid or lipoprotein measurement,initial,2017-10-30,GCST009150,Low density lipoprotein cholesterol levels
9422,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005463,Phospholipid levels in medium VLDL
9424,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005465,Cholesterol ester levels in medium VLDL
9410,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005451,Phospholipid levels in very large VLDL
9437,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005478,IDL particle concentration
9423,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005464,Total cholesterol levels in medium VLDL
9438,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005479,Free cholesterol levels in IDL
9427,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005468,Small VLDL particle concentration
9434,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005475,Triglyceride levels in very small VLDL
9436,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005477,Phospholipid levels in IDL
9421,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005462,Medium VLDL particle concentration
9428,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005469,Phospholipid levels in small VLDL
9429,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005470,Total cholesterol levels in small VLDL
9420,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005461,Cholesterol ester levels in large VLDL
9430,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005471,Free cholesterol levels in small VLDL
9419,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005460,Triglyceride levels in large VLDL
9425,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005466,Free cholesterol levels in medium VLDL
9431,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005472,Triglyceride levels in small VLDL
9416,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005457,Mean diameter of VLDL particles
9433,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005474,Phospholipid levels in very small VLDL
9411,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005452,Triglyceride levels in very large VLDL
9412,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005453,Very large VLDL particle concentration
9413,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005454,Phospholipid levels in large VLDL
9414,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005455,Mean diameter of HDL particles
9415,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005456,Mean diameter of LDL particles
9426,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005467,Triglyceride levels in medium VLDL
9417,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005458,Total cholesterol levels in large VLDL
9435,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005476,IDL particle concentration
9418,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005459,Free cholesterol levels in large VLDL
9432,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005473,Very small VLDL particle concentration
9332,European,7976.0,29093028.0,Corre T,Other measurement,initial,2017-11-01,GCST005125,Serum magnesium levels
5612,European,624.0,29059430.0,Morton LM,"Cancer, Biological process",initial,2017-11-01,GCST005112,Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy
2108,Asian,428.0,29104669.0,Chen L,Other disease,initial,2017-11-01,GCST005043,Polycystic ovary syndrome
2768,Asian,1600.0,29104669.0,Chen L,Other disease,replication,2017-11-01,GCST005043,Polycystic ovary syndrome
9333,European,7976.0,29093028.0,Corre T,Other measurement,initial,2017-11-01,GCST005126,Fractional excretion of magnesium
7718,European,2981.0,29059430.0,Morton LM,Cancer,initial,2017-11-01,GCST005111,Breast cancer in childhood cancer survivors
4024,Asian,8842.0,29095316.0,Suh Y,Other measurement,initial,2017-11-01,GCST005127,Lung function (maximal voluntary ventilation)
8863,European,5901.0,29066854.0,Lin BD,Hematological measurement,initial,2017-11-01,GCST005056,Neutrophil count
4025,Asian,8842.0,29095316.0,Suh Y,Other measurement,initial,2017-11-01,GCST005129,Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity)
9589,European,9099.0,29093028.0,Corre T,Other measurement,initial,2017-11-01,GCST005124,Urinary magnesium-to-creatinine ratio
4028,Asian,8842.0,29095316.0,Suh Y,Other measurement,initial,2017-11-01,GCST005132,Lung function (forced expiratory volume in 1 second)
8862,European,5901.0,29066854.0,Lin BD,Hematological measurement,initial,2017-11-01,GCST005055,Lymphocyte counts
8861,European,5901.0,29066854.0,Lin BD,Hematological measurement,initial,2017-11-01,GCST005054,Platelet count
4026,Asian,8842.0,29095316.0,Suh Y,Other measurement,initial,2017-11-01,GCST005130,Lung function (FEV1/FVC)
8860,European,5901.0,29066854.0,Lin BD,Hematological measurement,initial,2017-11-01,GCST005053,Neutrophil-to-lymphocyte ratio
12425,European,317683.0,29029846.0,Schormair B,Neurological disorder,replication,2017-11-01,GCST005042,Restless legs syndrome
8859,European,5901.0,29066854.0,Lin BD,Hematological measurement,initial,2017-11-01,GCST005052,Platelet-to-lymphocyte ratio
4027,Asian,8842.0,29095316.0,Suh Y,Other measurement,initial,2017-11-01,GCST005131,Lung function (forced vital capacity)
11802,European,110851.0,29029846.0,Schormair B,Neurological disorder,initial,2017-11-01,GCST005042,Restless legs syndrome
7244,European,2213.0,29059430.0,Morton LM,Cancer,initial,2017-11-01,GCST005110,Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy
2059,Asian,377.0,29109912.0,Rawofi L,"Other trait, Other measurement",initial,2017-11-02,GCST005084,Skin pigmentation
7930,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005159,Insulin levels in response to oral glucose tolerance test (fasting)
4937,European,221.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",replication,2017-11-02,GCST005041,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
7937,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005166,GIP levels in response to oral glucose tolerance test (120 minutes)
8532,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005162,Glucagon levels in response to oral glucose tolerance test (fasting)
8530,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005159,Insulin levels in response to oral glucose tolerance test (fasting)
7933,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005162,Glucagon levels in response to oral glucose tolerance test (fasting)
7932,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005161,Insulin levels in response to oral glucose tolerance test (120 minutes)
8529,European,4905.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005161,Insulin levels in response to oral glucose tolerance test (120 minutes)
7931,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005160,Insulin levels in response to oral glucose tolerance test (30 minutes)
7938,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005167,GIP levels in response to oral glucose tolerance test (fasting)
8533,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005163,Glucagon levels in response to oral glucose tolerance test (120 minutes)
4936,European,221.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",replication,2017-11-02,GCST005040,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
8536,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005166,GIP levels in response to oral glucose tolerance test (120 minutes)
8537,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005167,GIP levels in response to oral glucose tolerance test (fasting)
7934,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005163,Glucagon levels in response to oral glucose tolerance test (120 minutes)
7935,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005164,GLP-1 levels in response to oral glucose tolerance test (fasting)
7936,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005165,GLP-1 levels in response to oral glucose tolerance test (120 minutes)
8534,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005164,GLP-1 levels in response to oral glucose tolerance test (fasting)
8535,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005165,GLP-1 levels in response to oral glucose tolerance test (120 minutes)
4935,European,221.0,29097388.0,Magvanjav O,"Other measurement, Response to drug",replication,2017-11-02,GCST005039,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)
5064,European,314.0,29097388.0,Magvanjav O,"Other measurement, Response to drug",initial,2017-11-02,GCST005039,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)
12805,Hispanic or Latin American,193.0,29097388.0,Magvanjav O,"Other measurement, Response to drug",replication,2017-11-02,GCST005039,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)
8531,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005160,Insulin levels in response to oral glucose tolerance test (30 minutes)
12806,Hispanic or Latin American,193.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",replication,2017-11-02,GCST005040,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
5065,European,314.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",initial,2017-11-02,GCST005040,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
5066,European,314.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",initial,2017-11-02,GCST005041,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
12807,Hispanic or Latin American,193.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",replication,2017-11-02,GCST005041,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
2057,Asian,377.0,29109912.0,Rawofi L,"Other measurement, Other trait",initial,2017-11-02,GCST005095,Iris heterochromicity
2056,Asian,377.0,29109912.0,Rawofi L,"Other measurement, Other trait",initial,2017-11-02,GCST005094,Iris color (L* coordinate)
2055,Asian,377.0,29109912.0,Rawofi L,"Other measurement, Other trait",initial,2017-11-02,GCST005093,Iris color (a* coordinate)
2058,Asian,377.0,29109912.0,Rawofi L,"Other measurement, Other trait",initial,2017-11-02,GCST005096,Iris color (b* coordinate)
2229,Asian,568.0,29109912.0,Rawofi L,"Other trait, Other measurement",replication,2017-11-02,GCST005084,Skin pigmentation
7230,European,2192.0,29097723.0,Darlow JM,Other disease,initial,2017-11-06,GCST005044,Primary vesicoureteric reflux
8560,European,4936.0,29097723.0,Darlow JM,Other disease,initial,2017-11-06,GCST005045,Primary vesicoureteric reflux
1088,African American or Afro-Caribbean,2801.0,29112194.0,Agrawal A,Neurological disorder,replication,2017-11-07,GCST005133,Cannabis dependence
3284,Asian,2928.0,29209388.0,Cho CH,Neurological disorder,initial,2017-11-07,GCST005107,Restless legs syndrome
9501,European,8515.0,29112194.0,Agrawal A,Neurological disorder,initial,2017-11-07,GCST005133,Cannabis dependence
2135,Asian,456.0,29209388.0,Cho CH,Neurological disorder,replication,2017-11-07,GCST005107,Restless legs syndrome
9350,European,8050.0,29112194.0,Agrawal A,Other measurement,initial,2017-11-07,GCST005128,Cannabis dependence symptom count
7358,European,2372.0,29112194.0,Agrawal A,Neurological disorder,replication,2017-11-07,GCST005133,Cannabis dependence
4528,Asian,60650.0,29118346.0,Sakamoto Y,Other disease,initial,2017-11-08,GCST005048,Idiopathic osteonecrosis of the femoral head
1885,Asian,220.0,29121268.0,Amare AT,"Response to drug, Neurological disorder",initial,2017-11-09,GCST005081,Bipolar disorder lithium response (continuous) or schizophrenia
7349,European,2366.0,29121268.0,Amare AT,"Response to drug, Neurological disorder",initial,2017-11-09,GCST005081,Bipolar disorder lithium response (continuous) or schizophrenia
3649,Asian,5487.0,29124443.0,Yasukochi Y,"Cardiovascular measurement, Metabolic disorder",initial,2017-11-09,GCST007916,Hyperuricemia
1900,Asian,226.0,29121268.0,Amare AT,"Response to drug, Neurological disorder",initial,2017-11-09,GCST005082,Bipolar disorder lithium response (categorical) or schizophrenia
2791,Asian,1646.0,29124443.0,Yasukochi Y,"Other disease, Other measurement",initial,2017-11-09,GCST007920,Chronic kidney disease
3658,Asian,5556.0,29124443.0,Yasukochi Y,"Cardiovascular measurement, Metabolic disorder",replication,2017-11-09,GCST007916,Hyperuricemia
3015,Asian,2073.0,29123153.0,Lee TH,Cardiovascular disease,initial,2017-11-09,GCST005057,Small vessel stroke
3691,Asian,5636.0,29124443.0,Yasukochi Y,Other measurement,initial,2017-11-09,GCST007917,Estimated glomerular filtration rate
7350,European,2366.0,29121268.0,Amare AT,"Response to drug, Neurological disorder",initial,2017-11-09,GCST005082,Bipolar disorder lithium response (categorical) or schizophrenia
3692,Asian,5636.0,29124443.0,Yasukochi Y,Other measurement,initial,2017-11-09,GCST007919,Creatinine levels
3730,Asian,5847.0,29124443.0,Yasukochi Y,Cardiovascular measurement,initial,2017-11-09,GCST007918,Serum uric acid levels
2691,Asian,1453.0,29123153.0,Lee TH,Cardiovascular disease,replication,2017-11-09,GCST005057,Small vessel stroke
3359,Asian,3402.0,29124443.0,Yasukochi Y,"Other disease, Other measurement",replication,2017-11-09,GCST007920,Chronic kidney disease
2207,Asian,542.0,29124805.0,Carlson JC,"Other trait, Other disease",replication,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
1206,African American or Afro-Caribbean,3763.0,29127183.0,Seyerle AA,Cardiovascular measurement,replication,2017-11-10,GCST005080,PR interval
5533,European,576.0,29124805.0,Carlson JC,"Other trait, Other disease",initial,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
52,African,147.0,29124805.0,Carlson JC,"Other trait, Other disease",initial,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
3821,Asian,6805.0,29127183.0,Seyerle AA,Cardiovascular measurement,replication,2017-11-10,GCST005080,PR interval
12883,Hispanic or Latin American,463.0,29124805.0,Carlson JC,"Other trait, Other disease",replication,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
8325,European,4296.0,29127183.0,Seyerle AA,Cardiovascular measurement,replication,2017-11-10,GCST005080,PR interval
13517,Hispanic or Latin American,14756.0,29127183.0,Seyerle AA,Cardiovascular measurement,initial,2017-11-10,GCST005080,PR interval
2459,Asian,927.0,29124805.0,Carlson JC,"Other trait, Other disease",replication,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
5570,European,598.0,29124805.0,Carlson JC,"Other trait, Other disease",replication,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
2042,Asian,367.0,29124805.0,Carlson JC,"Other trait, Other disease",initial,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
13029,Hispanic or Latin American,1050.0,29124805.0,Carlson JC,"Other trait, Other disease",initial,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
5587,European,606.0,29130521.0,Christopher L,Other measurement,initial,2017-11-11,GCST006632,Decline in glucose metabolism in posterior cingulate cortex
12666,European,585478.0,29145611.0,Hu Y,"Other disease, Metabolic disorder",initial,2017-11-14,GCST005114,Osteoporosis or obesity (pleiotropy)
10011,European,12596.0,29147026.0,Chen CH,Other measurement,initial,2017-11-16,GCST005083,Putamen volume
11184,European,43590.0,29146897.0,Pirastu N,"Other measurement, Other disease",initial,2017-11-17,GCST005116,Male-pattern baldness
10735,European,25218.0,29146897.0,Pirastu N,"Other measurement, Other disease",replication,2017-11-17,GCST005116,Male-pattern baldness
3591,Asian,5075.0,29151059.0,Delgado DA,Other measurement,initial,2017-11-18,GCST005143,Telomere length
5020,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005121,Short physical performance battery score
5021,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005122,Hand grip strength
5016,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005117,Activities of daily living score
5017,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005118,Mid-arm muscle circumference
5018,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005119,Calf circumference
5022,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005123,Cognitive performance
6243,European,1055.0,29158487.0,Heckerman D,Other measurement,replication,2017-11-20,GCST005120,Four meter walk test score
5019,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005120,Four meter walk test score
6625,European,1472.0,29160301.0,Fabbri C,Response to drug,replication,2017-11-21,GCST007042,Response to SSRI (symptom improvement)
6929,European,1828.0,29160301.0,Fabbri C,Response to drug,initial,2017-11-21,GCST007060,Response to SSRI (symptom remission)
6517,European,1345.0,29160300.0,Oetting WS,"Other trait, Other measurement",initial,2017-11-21,GCST005144,Tacrolimus trough concentration in kidney transplant patients
7159,European,2145.0,29160301.0,Fabbri C,Response to drug,initial,2017-11-21,GCST007059,Response to antidepressants (symptom improvement)
7160,European,2145.0,29160301.0,Fabbri C,Response to drug,initial,2017-11-21,GCST007061,Response to antidepressants (symptom remission)
6486,European,1301.0,29158497.0,Kadalayil L,"Other measurement, Cancer",replication,2017-11-21,GCST005106,Breast cancer (survival)
8467,European,4739.0,29158497.0,Kadalayil L,"Other measurement, Cancer",initial,2017-11-21,GCST005106,Breast cancer (survival)
6928,European,1828.0,29160301.0,Fabbri C,Response to drug,initial,2017-11-21,GCST007042,Response to SSRI (symptom improvement)
6271,European,1085.0,29168253.0,Seielstad M,Biological process,initial,2017-11-22,GCST005157,Alloimmunization response to pregnancy (HLA class II)
6070,European,946.0,29168253.0,Seielstad M,Biological process,initial,2017-11-22,GCST005154,Alloimmunization response to pregnancy (HLA class I and II)
6641,European,1505.0,29168253.0,Seielstad M,Biological process,initial,2017-11-22,GCST005155,Alloimmunization response to pregnancy
6171,European,1000.0,29168253.0,Seielstad M,Biological process,initial,2017-11-22,GCST005156,Alloimmunization response to pregnancy (HLA class I)
8856,European,5893.0,29170203.0,Alonso N,Other disease,initial,2017-11-23,GCST005097,Fractures (vertebral)
3909,Asian,7704.0,29170429.0,Hachiya T,Other measurement,initial,2017-11-23,GCST005145,Glycated hemoglobin levels
7634,European,2799.0,29170203.0,Alonso N,Other disease,replication,2017-11-23,GCST005097,Fractures (vertebral)
10456,European,19136.0,29299148.0,Liu W,Cancer,initial,2017-11-25,GCST005275,Cancer
12461,European,338460.0,29413154.0,Shadrin AA,"Neurological disorder, Other measurement",initial,2017-11-26,GCST006216,Attention deficit hyperactivity disorder or educational attainment (years of education) (pleiotropy)
7643,European,2811.0,29186428.0,Tonjes A,Other measurement,initial,2017-11-27,GCST005109,Progranulin levels
13018,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005086,Visceral adipose tissue (sex interaction)
13020,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005089,Visceral adipose tissue/subcutaneous adipose tissue ratio
12948,Hispanic or Latin American,707.0,29178545.0,Gao C,"Other measurement, Body measurement",replication,2017-11-27,GCST005087,Visceral adipose tissue adjusted for BMI
13019,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005088,Visceral adipose tissue adjusted for BMI (sex interaction)
198,African,1473.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005963,Epstein Barr virus nuclear antigen 1 IgG levels
13022,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005091,Subcutaneous adipose tissue
12946,Hispanic or Latin American,707.0,29178545.0,Gao C,Other measurement,replication,2017-11-27,GCST005089,Visceral adipose tissue/subcutaneous adipose tissue ratio
12945,Hispanic or Latin American,707.0,29178545.0,Gao C,Other measurement,replication,2017-11-27,GCST005088,Visceral adipose tissue adjusted for BMI (sex interaction)
12944,Hispanic or Latin American,707.0,29178545.0,Gao C,Other measurement,replication,2017-11-27,GCST005086,Visceral adipose tissue (sex interaction)
13017,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005085,Visceral adipose tissue
204,African,1562.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005944,Viral capsid antigen IgG seropositivity
203,African,1562.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005941,Epstein Barr virus nuclear antigen 1 IgG seropositivity
12943,Hispanic or Latin American,707.0,29178545.0,Gao C,Other measurement,replication,2017-11-27,GCST005085,Visceral adipose tissue
6913,European,1800.0,29186428.0,Tonjes A,Other measurement,replication,2017-11-27,GCST005109,Progranulin levels
12947,Hispanic or Latin American,707.0,29178545.0,Gao C,Other measurement,replication,2017-11-27,GCST005090,Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction)
13023,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005092,Subcutaneous adipose tissue (sex interaction)
13021,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005090,Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction)
196,African,1473.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005942,Viral capsid antigen IgG levels
13024,Hispanic or Latin American,983.0,29178545.0,Gao C,"Other measurement, Body measurement",initial,2017-11-27,GCST005087,Visceral adipose tissue adjusted for BMI
7190,European,2162.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005963,Epstein Barr virus nuclear antigen 1 IgG levels
197,African,1473.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005943,Epstein-Barr virus immune response (multivariate analysis)
12585,European,436124.0,29186694.0,Lam M,"Other measurement, Biological process",initial,2017-11-28,GCST005141,Cognitive ability (MTAG)
7537,European,2629.0,29423119.0,Khan S,"Other measurement, Cancer, Response to drug",initial,2017-11-28,GCST005900,Survival in endocrine treated breast cancer (estrogen-receptor positive)
7714,European,2971.0,29423119.0,Khan S,"Other measurement, Cancer",initial,2017-11-28,GCST005901,Survival in breast cancer (estrogen-receptor positive)
11773,European,107207.0,29186694.0,Lam M,Biological process,initial,2017-11-28,GCST005142,Cognitive ability
735,African American or Afro-Caribbean,613.0,29185836.0,Chen MH,Biological process,replication,2017-11-29,GCST008171,Platelet aggregation
6373,European,1184.0,29185836.0,Chen MH,Biological process,replication,2017-11-29,GCST008171,Platelet aggregation
8294,European,4213.0,29185836.0,Chen MH,Biological process,initial,2017-11-29,GCST008171,Platelet aggregation
4706,European,83.0,29187748.0,Morey RA,"Biological process, Other measurement",initial,2017-11-30,GCST005286,Lateral ventricle volume in trauma-exposed individuals
4707,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005239,Amygdala volume in trauma-exposed individuals
4712,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005245,Thalamus volume in trauma-exposed individuals
4705,European,83.0,29187748.0,Morey RA,"Biological process, Other measurement",initial,2017-11-30,GCST005240,Caudate volume in trauma-exposed individuals
4709,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005242,Pallidum volume in trauma-exposed individuals
4710,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005243,Hippocampal volume in trauma-exposed individuals
4711,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005244,Putamen volume in trauma-exposed individuals
473,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Biological process, Other measurement",initial,2017-11-30,GCST005240,Caudate volume in trauma-exposed individuals
474,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Biological process, Other measurement",initial,2017-11-30,GCST005286,Lateral ventricle volume in trauma-exposed individuals
4708,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005241,Nucleus accumbens volume in trauma-exposed individuals
479,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005244,Putamen volume in trauma-exposed individuals
11457,European,66741.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005192,Lobe attachment (rater-scored or self-reported)
13291,Hispanic or Latin American,5062.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005192,Lobe attachment (rater-scored or self-reported)
478,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005243,Hippocampal volume in trauma-exposed individuals
71,African,240.0,29195075.0,Martin AR,"Other trait, Other measurement",replication,2017-11-30,GCST005188,Skin pigmentation
475,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005239,Amygdala volume in trauma-exposed individuals
476,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005241,Nucleus accumbens volume in trauma-exposed individuals
63,African,216.0,29195075.0,Martin AR,Other trait,initial,2017-11-30,GCST005189,Tanning
70,African,240.0,29195075.0,Martin AR,Other trait,replication,2017-11-30,GCST005189,Tanning
64,African,216.0,29195075.0,Martin AR,"Other trait, Other measurement",initial,2017-11-30,GCST005188,Skin pigmentation
11763,European,104103.0,29187730.0,Ward J,Other measurement,initial,2017-11-30,GCST005237,Mood instability
477,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005242,Pallidum volume in trauma-exposed individuals
480,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005245,Thalamus volume in trauma-exposed individuals
11829,European,113968.0,29187730.0,Ward J,Other measurement,initial,2017-11-30,GCST005238,Mood instability
13292,Hispanic or Latin American,5062.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005193,Lobe attachment (rater scored)
10734,European,25035.0,29187746.0,Howard DM,Neurological disorder,replication,2017-11-30,GCST005108,Major depressive disorder
3264,Asian,2857.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005192,Lobe attachment (rater-scored or self-reported)
6905,European,1791.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005193,Lobe attachment (rater scored)
10440,European,18773.0,29187746.0,Howard DM,Neurological disorder,initial,2017-11-30,GCST005108,Major depressive disorder
3265,Asian,2857.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005193,Lobe attachment (rater scored)
10319,European,16757.0,29196614.0,Sud A,Cancer,initial,2017-12-01,GCST005209,Hodgkin's lymphoma
6555,European,1373.0,29237677.0,Salo PP,Cardiovascular measurement,replication,2017-12-01,GCST005208,B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio
12544,European,389166.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006697,"Parental longevity (combined parental attained age, Martingale residuals)"
8558,European,4932.0,29237677.0,Salo PP,Cardiovascular measurement,initial,2017-12-01,GCST005208,B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio
8557,European,4932.0,29237677.0,Salo PP,Cardiovascular measurement,initial,2017-12-01,GCST005207,Midregional pro atrial natriuretic peptide levels
8556,European,4932.0,29237677.0,Salo PP,Cardiovascular measurement,initial,2017-12-01,GCST005206,B-type natriuretic peptide levels
8555,European,4932.0,29237677.0,Salo PP,Cardiovascular measurement,initial,2017-12-01,GCST005205,N-terminal pro B-type natriuretic peptide levels
6554,European,1373.0,29237677.0,Salo PP,Cardiovascular measurement,replication,2017-12-01,GCST005207,Midregional pro atrial natriuretic peptide levels
6553,European,1373.0,29237677.0,Salo PP,Cardiovascular measurement,replication,2017-12-01,GCST005206,B-type natriuretic peptide levels
6552,European,1373.0,29237677.0,Salo PP,Cardiovascular measurement,replication,2017-12-01,GCST005205,N-terminal pro B-type natriuretic peptide levels
12572,European,415311.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006701,Parental longevity (father's attained age)
11655,European,86949.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006698,Parental longevity (both parents in top 10%)
12223,European,208118.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006702,Parental longevity (combined parental age at death)
6051,European,934.0,29251981.0,Weafer J,Other measurement,initial,2017-12-01,GCST005246,Inhibitory control
12570,European,412937.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006696,Parental longevity (mother's attained age)
12424,European,317652.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006700,Parental longevity (father's age at death)
10195,European,15143.0,29196614.0,Sud A,Cancer,initial,2017-12-01,GCST005210,Mixed cellularity Hodgkin lymphoma
10227,European,15603.0,29196614.0,Sud A,Cancer,initial,2017-12-01,GCST005211,Nodular sclerosis Hodgkin lymphoma
8899,European,6049.0,29212897.0,Salminen A,Inflammatory measurement,initial,2017-12-01,GCST005187,Matrix metalloproteinase-8 levels
11871,European,120286.0,29237688.0,Weng LC,Cardiovascular disease,initial,2017-12-01,GCST008486,Atrial fibrillation
12292,European,246941.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006699,Parental longevity (mother's age at death)
10451,European,19099.0,29325848.0,Martin J,"Neurological disorder, Other trait",initial,2017-12-02,GCST005363,Sex difference in attention deficit hyperactivity disorder
11314,European,53293.0,29325848.0,Martin J,Neurological disorder,initial,2017-12-02,GCST005362,Attention deficit hyperactivity disorder
11315,European,53293.0,29325848.0,Martin J,"Neurological disorder, Other measurement",initial,2017-12-02,GCST005361,Attention deficit hyperactivity disorder (sex interaction)
622,African American or Afro-Caribbean,288.0,29206233.0,Shendre A,Cardiovascular measurement,initial,2017-12-04,GCST005182,Common carotid intima-media thickness in HIV negative individuals
820,African American or Afro-Caribbean,970.0,29206233.0,Shendre A,Cardiovascular measurement,initial,2017-12-04,GCST005183,Common carotid intima-media thickness
744,African American or Afro-Caribbean,682.0,29206233.0,Shendre A,"Other disease, Cardiovascular measurement",initial,2017-12-04,GCST005184,Common carotid intima-media thickness in HIV infection
3048,Asian,2146.0,29208002.0,Kim M,Other measurement,initial,2017-12-06,GCST005168,Systolic blood pressure
1756,Asian,117.0,29207912.0,Nishizawa D,"Response to drug, Other measurement",initial,2017-12-06,GCST005364,Opioid requirements during laparoscopic-assisted colectomy
2932,Asian,1876.0,29212900.0,Li C,"Other measurement, Cardiovascular measurement",initial,2017-12-06,GCST005201,Pulse pressure (dietary potassium intake interaction)
14012,Other/Mixed,709.0,29220522.0,Liu F,Other measurement,replication,2017-12-06,GCST005191,Hair shape
10320,European,16763.0,29220522.0,Liu F,Other measurement,initial,2017-12-06,GCST005191,Hair shape
13331,Hispanic or Latin American,6238.0,29220522.0,Liu F,Other measurement,replication,2017-12-06,GCST005191,Hair shape
2931,Asian,1876.0,29212900.0,Li C,Other measurement,initial,2017-12-06,GCST005204,Systolic blood pressure (dietary potassium intake interaction)
2377,Asian,775.0,29212900.0,Li C,Other measurement,replication,2017-12-06,GCST005204,Systolic blood pressure (dietary potassium intake interaction)
13659,Other/Mixed,15.0,29220522.0,Liu F,"Other measurement, Other measurement",replication,2017-12-06,GCST005191,Hair shape
5464,European,523.0,29210060.0,Koster R,"Cancer, Other measurement",initial,2017-12-06,GCST005158,Overall survival in osteosarcoma
12783,Hispanic or Latin American,109.0,29210060.0,Koster R,"Cancer, Other measurement",replication,2017-12-06,GCST005158,Overall survival in osteosarcoma
13525,Hispanic or Latin American,15997.0,29213071.0,Mendez-Giraldez R,Cardiovascular measurement,initial,2017-12-06,GCST005171,QT interval
3049,Asian,2146.0,29208002.0,Kim M,Other measurement,initial,2017-12-06,GCST005169,Diastolic blood pressure
2930,Asian,1876.0,29212900.0,Li C,Other measurement,initial,2017-12-06,GCST005203,Mean arterial pressure (dietary potassium intake interaction)
2376,Asian,775.0,29212900.0,Li C,Other measurement,replication,2017-12-06,GCST005203,Mean arterial pressure (dietary potassium intake interaction)
2375,Asian,775.0,29212900.0,Li C,Other measurement,replication,2017-12-06,GCST005202,Diastolic blood pressure (dietary potassium intake interaction)
3278,Asian,2899.0,29220522.0,Liu F,Other measurement,replication,2017-12-06,GCST005191,Hair shape
2378,Asian,775.0,29212900.0,Li C,"Other measurement, Cardiovascular measurement",replication,2017-12-06,GCST005201,Pulse pressure (dietary potassium intake interaction)
1921,Asian,234.0,29207912.0,Nishizawa D,"Response to drug, Other measurement",replication,2017-12-06,GCST005364,Opioid requirements during laparoscopic-assisted colectomy
2929,Asian,1876.0,29212900.0,Li C,Other measurement,initial,2017-12-06,GCST005202,Diastolic blood pressure (dietary potassium intake interaction)
7337,European,2340.0,29220522.0,Liu F,Other measurement,replication,2017-12-06,GCST005191,Hair shape
7305,European,2308.0,29217827.0,Sanders AR,Other trait,initial,2017-12-07,GCST005247,Male sexual orientation
579,African American or Afro-Caribbean,205.0,29221444.0,Divers J,"Other trait, Metabolic disorder",replication,2017-12-08,GCST005174,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes
580,African American or Afro-Caribbean,205.0,29221444.0,Divers J,"Other trait, Metabolic disorder",replication,2017-12-08,GCST005175,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes
578,African American or Afro-Caribbean,205.0,29221444.0,Divers J,"Other trait, Metabolic disorder",replication,2017-12-08,GCST005173,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes
747,African American or Afro-Caribbean,691.0,29221444.0,Divers J,"Other trait, Metabolic disorder",initial,2017-12-08,GCST005173,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes
748,African American or Afro-Caribbean,691.0,29221444.0,Divers J,"Other trait, Metabolic disorder",initial,2017-12-08,GCST005174,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes
749,African American or Afro-Caribbean,691.0,29221444.0,Divers J,"Other trait, Metabolic disorder",initial,2017-12-08,GCST005175,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes
6033,European,928.0,29230059.0,Sanchez-Roige S,Other measurement,replication,2017-12-11,GCST005248,Delayed reward discounting
10655,European,23127.0,29230059.0,Sanchez-Roige S,Other measurement,initial,2017-12-11,GCST005248,Delayed reward discounting
14276,Other/Mixed,37930.0,29235454.0,Choquet H,Other measurement,replication,2017-12-13,GCST005170,Intraocular pressure
1008,African American or Afro-Caribbean,2070.0,29235454.0,Choquet H,Other measurement,initial,2017-12-13,GCST005170,Intraocular pressure
11375,European,56819.0,29235454.0,Choquet H,Other measurement,initial,2017-12-13,GCST005170,Intraocular pressure
13310,Hispanic or Latin American,5748.0,29235454.0,Choquet H,Other measurement,initial,2017-12-13,GCST005170,Intraocular pressure
3593,Asian,5119.0,29235454.0,Choquet H,Other measurement,initial,2017-12-13,GCST005170,Intraocular pressure
6050,European,933.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006247,Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype)
6048,European,933.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006129,Pediatric areal bone mineral density (spine vs radius & hip discordant skeletal phenotype)
5374,European,486.0,29240982.0,Mitchell JA,Other measurement,replication,2017-12-14,GCST006130,Pediatric areal bone mineral density (concordant skeletal phenotype)
6776,European,1643.0,29253144.0,Voigt EA,"Response to drug, Other measurement",initial,2017-12-14,GCST005177,Rubella-specific interferon-gamma secretion
6049,European,933.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006130,Pediatric areal bone mineral density (concordant skeletal phenotype)
6775,European,1643.0,29253144.0,Voigt EA,"Response to drug, Inflammatory measurement",initial,2017-12-14,GCST005176,Rubella-specific interleukin-6 secretion
574,African American or Afro-Caribbean,202.0,29253144.0,Voigt EA,"Response to drug, Inflammatory measurement",initial,2017-12-14,GCST005176,Rubella-specific interleukin-6 secretion
13921,Other/Mixed,466.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006247,Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype)
575,African American or Afro-Caribbean,202.0,29253144.0,Voigt EA,"Response to drug, Other measurement",initial,2017-12-14,GCST005177,Rubella-specific interferon-gamma secretion
13919,Other/Mixed,466.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006129,Pediatric areal bone mineral density (spine vs radius & hip discordant skeletal phenotype)
5375,European,486.0,29240982.0,Mitchell JA,Other measurement,replication,2017-12-14,GCST006247,Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype)
5373,European,486.0,29240982.0,Mitchell JA,Other measurement,replication,2017-12-14,GCST006129,Pediatric areal bone mineral density (spine vs radius & hip discordant skeletal phenotype)
13920,Other/Mixed,466.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006130,Pediatric areal bone mineral density (concordant skeletal phenotype)
13390,Hispanic or Latin American,8048.0,29505938.0,Dunn EC,"Neurological disorder, Other measurement",replication,2017-12-16,GCST006174,Depressive symptoms
13481,Hispanic or Latin American,12310.0,29505938.0,Dunn EC,"Neurological disorder, Other measurement",initial,2017-12-16,GCST006174,Depressive symptoms
5831,European,782.0,29253858.0,Bohman A,Neurological disorder,initial,2017-12-18,GCST005268,Chronic rhinosinusitis with nasal polyps
12444,European,329821.0,29255261.0,Luciano M,"Neurological disorder, Other measurement",initial,2017-12-18,GCST005232,Neuroticism
11890,European,122867.0,29255261.0,Luciano M,"Neurological disorder, Other measurement",replication,2017-12-18,GCST005232,Neuroticism
449,African American or Afro-Caribbean,48.0,29266176.0,Inaba H,"Cancer, Other measurement, Response to drug",initial,2017-12-19,GCST005214,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia
4957,European,235.0,29266176.0,Inaba H,"Cancer, Other measurement, Response to drug",initial,2017-12-19,GCST005214,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia
6264,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007012,Cerebrospinal fluid AB1-42 levels
6262,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007010,Logical memory (delayed recall)
6261,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007009,Hippocampal volume
5053,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007003,Cerebrospinal fluid p-tau levels in normal cognition
5543,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST006997,Cerebrospinal fluid t-tau levels in mild cognitive impairment
6260,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007008,Cerebrospinal fluid p-tau levels
3043,Asian,2139.0,29263402.0,Han Y,Cardiovascular disease,replication,2017-12-20,GCST005172,Coronary artery disease
5051,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007001,Cerebrospinal AB1-42 levels in normal cognition
5052,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007002,Cerebrospinal fluid t-tau levels in normal cognition
5544,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST006998,Cerebrospinal fluid p-tau levels in mild cognitive impairment
5056,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007006,Logical memory (delayed recall) in normal cognition
5054,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007004,Hippocampal volume in normal cognition
5542,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST006996,Cerebrospinal AB1-42 levels in mild cognitive impairment
6259,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007007,Cerebrospinal fluid t-tau levels
5055,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007005,Logical memory (immediate recall) in normal cognition
4875,European,190.0,29274321.0,Chung J,"Neurological disorder, Other measurement",initial,2017-12-20,GCST006994,Logical memory (immediate recall) in Alzheimer's disease dementia
6263,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007011,Logical memory (immediate recall)
4874,European,190.0,29274321.0,Chung J,"Neurological disorder, Other measurement",initial,2017-12-20,GCST006993,Hippocampal volume in Alzheimer's disease dementia
5545,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST006999,Logical memory (immediate recall) in mild cognitive impairment
4876,European,190.0,29274321.0,Chung J,"Neurological disorder, Other measurement",initial,2017-12-20,GCST006995,Logical memory (delayed recall) in Alzheimer's disease dementia
4877,European,190.0,29274321.0,Chung J,"Other measurement, Neurological disorder",initial,2017-12-20,GCST006991,Cerebrospinal fluid t-tau levels in Alzheimer's disease dementia
3828,Asian,6942.0,29263402.0,Han Y,Cardiovascular disease,initial,2017-12-20,GCST005172,Coronary artery disease
3203,Asian,2603.0,29263402.0,Han Y,Cardiovascular disease,initial,2017-12-20,GCST005172,Coronary artery disease
4873,European,190.0,29274321.0,Chung J,"Neurological disorder, Other measurement",initial,2017-12-20,GCST006990,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia
4878,European,190.0,29274321.0,Chung J,"Other measurement, Neurological disorder",initial,2017-12-20,GCST006992,Cerebrospinal fluid p-tau levels in Alzheimer's disease dementia
5547,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007013,Hippocampal volume in mild cognitive impairment
5546,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007000,Logical memory (delayed recall) in mild cognitive impairment
12182,European,192226.0,29273807.0,Turcot V,"Body measurement, Other measurement",replication,2017-12-22,GCST008128,Body mass index
12181,European,192226.0,29273807.0,Turcot V,"Body measurement, Other measurement",replication,2017-12-22,GCST008124,Body mass index
13054,Hispanic or Latin American,1398.0,29273806.0,Demenais F,Other disease,initial,2017-12-22,GCST005212,Asthma
3417,Asian,3767.0,29273593.0,Duan L,Cardiovascular disease,replication,2017-12-22,GCST005575,Moyamoya disease
3238,Asian,2786.0,29273593.0,Duan L,Cardiovascular disease,initial,2017-12-22,GCST005575,Moyamoya disease
13432,Hispanic or Latin American,10772.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008125,Body mass index
1556,African American or Afro-Caribbean,27610.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008129,Body mass index
13433,Hispanic or Latin American,10772.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008129,Body mass index
12608,European,449886.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008128,Body mass index
13055,Hispanic or Latin American,1398.0,29273806.0,Demenais F,"Other disease, Other measurement",initial,2017-12-22,GCST005213,Asthma (childhood onset)
11917,European,127669.0,29273806.0,Demenais F,Other disease,initial,2017-12-22,GCST006862,Asthma
4423,Asian,29398.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008129,Body mass index
10543,European,20762.0,29273806.0,Demenais F,"Other disease, Other measurement",initial,2017-12-22,GCST005213,Asthma (childhood onset)
4014,Asian,8839.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008129,Body mass index
4013,Asian,8839.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008126,Body mass index
11916,European,127669.0,29273806.0,Demenais F,Other disease,initial,2017-12-22,GCST005212,Asthma
12609,European,449889.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008129,Body mass index
12190,European,196766.0,29273807.0,Turcot V,"Body measurement, Other measurement",replication,2017-12-22,GCST008129,Body mass index
3609,Asian,5215.0,29273806.0,Demenais F,"Other disease, Other measurement",initial,2017-12-22,GCST005213,Asthma (childhood onset)
4422,Asian,29398.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008127,Body mass index
3608,Asian,5215.0,29273806.0,Demenais F,Other disease,initial,2017-12-22,GCST005212,Asthma
1555,African American or Afro-Caribbean,27610.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008124,Body mass index
4923,European,209.0,29278698.0,Zagajewska K,Neurological disorder,initial,2017-12-23,GCST005347,Pseudoexfoliation syndrome
3501,Asian,4409.0,29271184.0,Chung GE,Digestive system disorder,initial,2017-12-26,GCST005190,Nonalcoholic fatty liver disease
2938,Asian,1881.0,29271184.0,Chung GE,Digestive system disorder,replication,2017-12-26,GCST005190,Nonalcoholic fatty liver disease
1701,Asian,80.0,29288229.0,McCormack M,"Response to drug, Other disease",initial,2017-12-29,GCST005200,Phenytoin-induced maculopapular exanthema
4764,European,101.0,29288229.0,McCormack M,"Response to drug, Other disease",replication,2017-12-29,GCST005200,Phenytoin-induced maculopapular exanthema
1974,Asian,282.0,29288229.0,McCormack M,"Other disease, Response to drug",initial,2017-12-29,GCST005198,Carbamazepine-induced maculopapular exanthema
5466,European,524.0,29288229.0,McCormack M,"Response to drug, Other disease",initial,2017-12-29,GCST005200,Phenytoin-induced maculopapular exanthema
2137,Asian,458.0,29288229.0,McCormack M,"Other disease, Response to drug",initial,2017-12-29,GCST005197,Antiepileptic drug-induced maculopapular exanthema
6038,European,930.0,29288229.0,McCormack M,"Response to drug, Other disease",initial,2017-12-29,GCST005199,Lamotrigine-induced maculopapular exanthema
6443,European,1238.0,29288229.0,McCormack M,"Other disease, Response to drug",initial,2017-12-29,GCST005197,Antiepileptic drug-induced maculopapular exanthema
6102,European,964.0,29288229.0,McCormack M,"Other disease, Response to drug",initial,2017-12-29,GCST005198,Carbamazepine-induced maculopapular exanthema
1657,Asian,48.0,29288229.0,McCormack M,"Response to drug, Other disease",initial,2017-12-29,GCST005199,Lamotrigine-induced maculopapular exanthema
8599,European,5007.0,29263008.0,Guerreiro R,Other trait,initial,2018-01-01,GCST005276,Dementia with Lewy bodies
8464,European,4733.0,29364747.0,Jonsson L,Digestive system disorder,replication,2018-01-01,GCST005390,Tooth agenesis (mandibular second premolars)
12493,European,354862.0,29292387.0,Turley P,"Neurological disorder, Other measurement",initial,2018-01-01,GCST005324,Depressive symptoms
12542,European,388538.0,29292387.0,Turley P,Other measurement,initial,2018-01-01,GCST005325,Subjective well-being (MTAG)
2678,Asian,1424.0,29354237.0,Kim HA,Other disease,initial,2018-01-01,GCST005277,Lumbar spondylosis (Kellgren-Lawrence grade)
12462,European,339154.0,29364747.0,Jonsson L,Digestive system disorder,initial,2018-01-01,GCST005391,Tooth agenesis (maxillary lateral incisors)
12494,European,354862.0,29292387.0,Turley P,Other measurement,initial,2018-01-01,GCST005323,Depressive symptoms (MTAG)
12109,European,168105.0,29292387.0,Turley P,Other measurement,initial,2018-01-01,GCST005326,Neuroticism (MTAG)
12463,European,339154.0,29364747.0,Jonsson L,Digestive system disorder,initial,2018-01-01,GCST005392,Tooth agenesis (maxillary second premolars)
2680,Asian,1425.0,29354237.0,Kim HA,Other disease,initial,2018-01-01,GCST005279,Lumbar spondylosis (disc space narrowing)
6376,European,1190.0,29263008.0,Guerreiro R,Other trait,replication,2018-01-01,GCST005276,Dementia with Lewy bodies
2681,Asian,1426.0,29354237.0,Kim HA,Other disease,initial,2018-01-01,GCST005278,Lumbar spondylosis (presence and severity of osteophytes)
12467,European,340498.0,29364747.0,Jonsson L,Digestive system disorder,initial,2018-01-01,GCST005389,Tooth agenesis
12543,European,388538.0,29292387.0,Turley P,Other measurement,initial,2018-01-01,GCST005328,Subjective well-being
5058,European,306.0,29364747.0,Jonsson L,Digestive system disorder,replication,2018-01-01,GCST005391,Tooth agenesis (maxillary lateral incisors)
8924,European,6170.0,29364747.0,Jonsson L,Digestive system disorder,replication,2018-01-01,GCST005389,Tooth agenesis
12108,European,168105.0,29292387.0,Turley P,"Neurological disorder, Other measurement",initial,2018-01-01,GCST005327,Neuroticism
12464,European,339750.0,29364747.0,Jonsson L,Digestive system disorder,initial,2018-01-01,GCST005390,Tooth agenesis (mandibular second premolars)
8144,European,3813.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005551,Systemic sclerosis (anti-topoisomerase-positive)
8236,European,4040.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005335,Diffuse cutaneous systemic sclerosis
8237,European,4040.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005553,Diffuse cutaneous systemic sclerosis
8143,European,3813.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005332,Systemic sclerosis (anti-topoisomerase-positive)
8271,European,4137.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005552,Systemic sclerosis (anti-centromere-positive)
724,African American or Afro-Caribbean,551.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005554,Systemic sclerosis
8270,European,4137.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005333,Systemic sclerosis (anti-centromere-positive)
723,African American or Afro-Caribbean,551.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005336,Systemic sclerosis
8710,European,5299.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005336,Systemic sclerosis
639,African American or Afro-Caribbean,329.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005551,Systemic sclerosis (anti-topoisomerase-positive)
650,African American or Afro-Caribbean,342.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005334,Limited cutaneous systemic scleroderma
8400,European,4553.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005334,Limited cutaneous systemic scleroderma
703,African American or Afro-Caribbean,461.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005335,Diffuse cutaneous systemic sclerosis
617,African American or Afro-Caribbean,281.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005552,Systemic sclerosis (anti-centromere-positive)
4762,European,100.0,29293525.0,Gudmundsdottir V,Other measurement,replication,2018-01-02,GCST005353,GLP-1-stimulated insulin secretion
8401,European,4553.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005555,Limited cutaneous systemic scleroderma
8711,European,5299.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005554,Systemic sclerosis
704,African American or Afro-Caribbean,461.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005553,Diffuse cutaneous systemic sclerosis
616,African American or Afro-Caribbean,281.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005333,Systemic sclerosis (anti-centromere-positive)
638,African American or Afro-Caribbean,329.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005332,Systemic sclerosis (anti-topoisomerase-positive)
651,African American or Afro-Caribbean,342.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005555,Limited cutaneous systemic scleroderma
10413,European,18319.0,29309628.0,Beaumont RN,"Body measurement, Other measurement",replication,2018-01-03,GCST005314,Offspring birth weight
11478,European,68258.0,29309628.0,Beaumont RN,"Body measurement, Other measurement",initial,2018-01-03,GCST005314,Offspring birth weight
908,African American or Afro-Caribbean,1333.0,29304378.0,Medina-Gomez C,Other measurement,initial,2018-01-04,GCST005348,Total body bone mineral density
11475,European,67944.0,29290336.0,Nielsen JB,Cardiovascular disease,initial,2018-01-04,GCST005306,Atrial fibrillation
11358,European,56284.0,29304378.0,Medina-Gomez C,Other measurement,initial,2018-01-04,GCST005348,Total body bone mineral density
10441,European,18805.0,29304378.0,Medina-Gomez C,Other measurement,initial,2018-01-04,GCST005350,Total body bone mineral density (age 45-60)
12405,European,309574.0,29290336.0,Nielsen JB,Cardiovascular disease,replication,2018-01-04,GCST005306,Atrial fibrillation
8627,European,5086.0,29310926.0,Sharma A,"Other measurement, Metabolic disorder",initial,2018-01-05,GCST006196,Type 1 diabetes in high risk HLA genotype individuals (time to event)
8628,European,5086.0,29310926.0,Sharma A,"Other measurement, Metabolic disorder",initial,2018-01-05,GCST006197,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)
9251,European,7570.0,29325096.0,Eriksson AL,Other measurement,initial,2018-01-09,GCST005827,Estrone levels
1612,Asian,10.0,29315502.0,Tamraz B,Other measurement,initial,2018-01-09,GCST006203,Atazanavir levels
1671,Asian,59.0,29317701.0,Rappoport N,"Other measurement, Other trait",initial,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
13196,Hispanic or Latin American,3485.0,29325163.0,Hong J,Other measurement,initial,2018-01-09,GCST005782,Serum 25-Hydroxyvitamin D levels
9746,European,9890.0,29317701.0,Rappoport N,"Other measurement, Other trait",initial,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
10253,European,16124.0,29325163.0,Hong J,Other measurement,initial,2018-01-09,GCST005782,Serum 25-Hydroxyvitamin D levels
918,African American or Afro-Caribbean,1419.0,29317701.0,Rappoport N,"Other measurement, Other trait",replication,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
564,African American or Afro-Caribbean,194.0,29315502.0,Tamraz B,Other measurement,initial,2018-01-09,GCST006203,Atazanavir levels
974,African American or Afro-Caribbean,1874.0,29317701.0,Rappoport N,"Other measurement, Other trait",initial,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
13172,Hispanic or Latin American,3133.0,29317701.0,Rappoport N,"Other measurement, Other trait",replication,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
5091,European,331.0,29317701.0,Rappoport N,"Other measurement, Other trait",replication,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
13097,Hispanic or Latin American,1847.0,29317701.0,Rappoport N,"Other measurement, Other trait",initial,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
4682,European,64.0,29315502.0,Tamraz B,Other measurement,initial,2018-01-09,GCST006203,Atazanavir levels
12789,Hispanic or Latin American,130.0,29315502.0,Tamraz B,Other measurement,initial,2018-01-09,GCST006203,Atazanavir levels
1393,African American or Afro-Caribbean,8541.0,29325163.0,Hong J,Other measurement,initial,2018-01-09,GCST005782,Serum 25-Hydroxyvitamin D levels
9878,European,11097.0,29325096.0,Eriksson AL,Other measurement,initial,2018-01-09,GCST005828,Estradiol levels
1935,Asian,249.0,29317701.0,Rappoport N,"Other measurement, Other trait",initial,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
5029,European,290.0,29317604.0,Liu D,"Neurological disorder, Other measurement",initial,2018-01-10,GCST005342,Plasma kynurenine levels in major depressive disorder
11176,European,43055.0,29317602.0,Hall LS,Neurological disorder,initial,2018-01-10,GCST005231,Major depressive disorder
5030,European,290.0,29317604.0,Liu D,"Neurological disorder, Other measurement",initial,2018-01-10,GCST005343,Plasma kynurenine to tryptophan ratio in major depressive disorder
11112,European,39556.0,29317602.0,Hall LS,Neurological disorder,initial,2018-01-10,GCST005230,Recurrent major depressive disorder
7755,European,3058.0,29478698.0,Cheng Z,Neurological disorder,initial,2018-01-11,GCST005368,Opioid dependence
11880,European,120934.0,29326435.0,Hill WD,Biological process,initial,2018-01-11,GCST005316,Intelligence (MTAG)
988,African American or Afro-Caribbean,2014.0,29478698.0,Cheng Z,Neurological disorder,replication,2018-01-11,GCST005368,Opioid dependence
3798,Asian,6506.0,29331962.0,Kochi Y,Neurological disorder,initial,2018-01-13,GCST005340,Polymyositis
3808,Asian,6610.0,29331962.0,Kochi Y,Neurological disorder,initial,2018-01-13,GCST005339,Dermatomyositis
3776,Asian,6303.0,29331962.0,Kochi Y,Neurological disorder,initial,2018-01-13,GCST005338,Clinically amyopathic dermatomyositis
4768,European,105.0,29331962.0,Kochi Y,Neurological disorder,replication,2018-01-13,GCST005338,Clinically amyopathic dermatomyositis
3822,Asian,6846.0,29331962.0,Kochi Y,Immune system disorder,initial,2018-01-13,GCST005341,Idiopathic inflammatory myopathy
7591,European,2721.0,29346644.0,Yan Q,"Neurological disorder, Other measurement",initial,2018-01-15,GCST005358,Disease progression to choroidal neovascularization form in age-related macular degeneration
7592,European,2721.0,29346644.0,Yan Q,"Neurological disorder, Other measurement",initial,2018-01-15,GCST005359,Disease progression in age-related macular degeneration
7594,European,2721.0,29346644.0,Yan Q,"Neurological disorder, Other measurement",initial,2018-01-15,GCST009144,Disease progression in age-related macular degeneration (adjusted for baseline)
7593,European,2721.0,29346644.0,Yan Q,"Neurological disorder, Other measurement",initial,2018-01-15,GCST005360,Disease progression to geographic atrophy form in age-related macular degeneration
7143,European,2113.0,29343764.0,Jiang X,Other measurement,replication,2018-01-17,GCST005366,Vitamin D levels (dietary vitamin D intake interaction)
11578,European,79366.0,29343764.0,Jiang X,Other measurement,initial,2018-01-17,GCST005367,Vitamin D levels
11116,European,39868.0,29343764.0,Jiang X,Other measurement,initial,2018-01-17,GCST005366,Vitamin D levels (dietary vitamin D intake interaction)
1220,African American or Afro-Caribbean,3972.0,29348612.0,Wiemels JL,Cancer,initial,2018-01-18,GCST005315,Acute lymphoblastic leukemia (childhood)
8060,European,3583.0,29348612.0,Wiemels JL,Cancer,replication,2018-01-18,GCST005315,Acute lymphoblastic leukemia (childhood)
8465,European,4735.0,29348612.0,Wiemels JL,Cancer,initial,2018-01-18,GCST005315,Acute lymphoblastic leukemia (childhood)
13026,Hispanic or Latin American,1041.0,29348612.0,Wiemels JL,Cancer,replication,2018-01-18,GCST005315,Acute lymphoblastic leukemia (childhood)
13431,Hispanic or Latin American,10533.0,29348612.0,Wiemels JL,Cancer,initial,2018-01-18,GCST005315,Acute lymphoblastic leukemia (childhood)
7000,European,1943.0,29360470.0,Miron J,Neurological disorder,initial,2018-01-19,GCST006806,Late-onset Alzheimer's disease
167,African,1040.0,29356057.0,Du Z,Cancer,initial,2018-01-21,GCST005786,Prostate cancer
9610,European,9253.0,29358691.0,Bonas-Guarch S,Metabolic disorder,replication,2018-01-22,GCST005898,Type 2 diabetes
4362,Asian,20019.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005414,Type 2 diabetes
13152,Hispanic or Latin American,2583.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005414,Type 2 diabetes
11540,European,75670.0,29358691.0,Bonas-Guarch S,Metabolic disorder,replication,2018-01-22,GCST005899,Type 2 diabetes
10551,European,20979.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005898,Type 2 diabetes
14260,Other/Mixed,16857.0,29358691.0,Bonas-Guarch S,Metabolic disorder,replication,2018-01-22,GCST005899,Type 2 diabetes
11382,European,57968.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005899,Type 2 diabetes
13197,Hispanic or Latin American,3490.0,29358691.0,Bonas-Guarch S,Metabolic disorder,replication,2018-01-22,GCST005898,Type 2 diabetes
11507,European,70127.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005413,Type 2 diabetes
11912,European,127001.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005414,Type 2 diabetes
4341,Asian,18817.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005414,Type 2 diabetes
3777,Asian,6312.0,29367735.0,Nakagawa-Senda H,"Biological process, Other measurement",initial,2018-01-24,GCST005329,Coffee consumption
1616,Asian,14.0,29367611.0,Gao B,"Cancer, Response to drug",initial,2018-01-24,GCST005352,Paclitaxel disposition in epithelial ovarian cancer
4653,European,42.0,29367611.0,Gao B,"Cancer, Response to drug",initial,2018-01-24,GCST005351,Carboplatin disposition in epthelial ovarian cancer
4683,European,66.0,29367611.0,Gao B,"Cancer, Response to drug",initial,2018-01-24,GCST005352,Paclitaxel disposition in epithelial ovarian cancer
3577,Asian,4949.0,29367735.0,Nakagawa-Senda H,"Biological process, Other measurement",replication,2018-01-24,GCST005329,Coffee consumption
1615,Asian,14.0,29367611.0,Gao B,"Cancer, Response to drug",initial,2018-01-24,GCST005351,Carboplatin disposition in epthelial ovarian cancer
4145,Asian,11261.0,29367735.0,Nakagawa-Senda H,"Biological process, Other measurement",initial,2018-01-24,GCST005330,Coffee consumption
831,African American or Afro-Caribbean,1023.0,29374233.0,Lu AT,Biological process,replication,2018-01-26,GCST005287,Intrinsic epigenetic age acceleration
9476,European,8393.0,29374233.0,Lu AT,Biological process,initial,2018-01-26,GCST005288,Extrinsic epigenetic age acceleration
12890,Hispanic or Latin American,491.0,29374233.0,Lu AT,Biological process,replication,2018-01-26,GCST005287,Intrinsic epigenetic age acceleration
9475,European,8393.0,29374233.0,Lu AT,Biological process,initial,2018-01-26,GCST005287,Intrinsic epigenetic age acceleration
12891,Hispanic or Latin American,491.0,29374233.0,Lu AT,Biological process,replication,2018-01-26,GCST005288,Extrinsic epigenetic age acceleration
832,African American or Afro-Caribbean,1023.0,29374233.0,Lu AT,Biological process,replication,2018-01-26,GCST005288,Extrinsic epigenetic age acceleration
160,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006306,HDL cholesterol
6501,European,1319.0,29379196.0,Fadista J,Digestive system disorder,replication,2018-01-29,GCST005289,Hirschsprung disease
8523,European,4887.0,29379196.0,Fadista J,Digestive system disorder,initial,2018-01-29,GCST005289,Hirschsprung disease
2854,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006470,HDL cholesterol
164,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006472,Triglyceride levels
162,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006469,"Cholesterol, total"
165,African,1017.0,29404214.0,Andaleon A,"Lipid or lipoprotein measurement, Other measurement",initial,2018-01-29,GCST006307,LDL cholesterol
2857,Asian,1765.0,29404214.0,Andaleon A,"Lipid or lipoprotein measurement, Other measurement",initial,2018-01-29,GCST006471,LDL cholesterol
2853,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006469,"Cholesterol, total"
159,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006305,"Cholesterol, total"
163,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006470,HDL cholesterol
161,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006308,Triglycerides
2850,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006305,"Cholesterol, total"
166,African,1017.0,29404214.0,Andaleon A,"Lipid or lipoprotein measurement, Other measurement",initial,2018-01-29,GCST006471,LDL cholesterol
2856,Asian,1765.0,29404214.0,Andaleon A,"Lipid or lipoprotein measurement, Other measurement",initial,2018-01-29,GCST006307,LDL cholesterol
2852,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006308,Triglycerides
2855,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006472,Triglyceride levels
2851,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006306,HDL cholesterol
12804,Hispanic or Latin American,189.0,29382897.0,Pagerols M,"Neurological disorder, Response to drug",replication,2018-01-30,GCST005318,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder
151,African,914.0,29381699.0,Ravenhall M,Digestive system disorder,initial,2018-01-30,GCST005356,Severe malaria
152,African,914.0,29381699.0,Ravenhall M,Digestive system disorder,initial,2018-01-30,GCST005357,Severe malaria (adjusted for sickle cell variant rs334)
4835,European,173.0,29382897.0,Pagerols M,"Neurological disorder, Response to drug",initial,2018-01-30,GCST005318,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder
2416,Asian,834.0,29385134.0,Kawaguchi T,Other measurement,initial,2018-01-31,GCST005311,Hepatocyte fat droplet content in nonalcoholic fatty liver disease
3922,Asian,7730.0,29385134.0,Kawaguchi T,"Cancer, Digestive system disorder",initial,2018-01-31,GCST005309,Nonalcoholic steatohepatitis-derived hepatocellular carcinoma
2228,Asian,567.0,29385134.0,Kawaguchi T,Other measurement,initial,2018-01-31,GCST005310,Brunt grade in nonalcoholic fatty liver disease
12259,European,223782.0,29397368.0,Meng W,Other trait,initial,2018-01-31,GCST005337,Headache
3978,Asian,8574.0,29385134.0,Kawaguchi T,Digestive system disorder,initial,2018-01-31,GCST005308,Nonalcoholic fatty liver disease
2155,Asian,474.0,29385134.0,Kawaguchi T,Other measurement,initial,2018-01-31,GCST005307,Brunt stage in nonalcoholic fatty liver disease
9891,European,11218.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005430,Graft survival time in renal transplantation (donor-recipient interaction)
8290,European,4188.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005430,Graft survival time in renal transplantation (donor-recipient interaction)
2330,Asian,731.0,29581620.0,Fujii R,Immune system disorder,initial,2018-02-01,GCST005556,Pollinosis
8849,European,5866.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005428,Graft survival time in renal transplantation (recipient effect)
8602,European,5027.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005429,Graft survival time in renal transplantation (donor effect)
8601,European,5027.0,29392897.0,Hernandez-Fuentes MP,Cardiovascular disease,replication,2018-02-01,GCST005426,Intracranial haemorrhage in renal transplantation (donors)
7777,European,3116.0,29378355.0,Stanne TM,Other measurement,initial,2018-02-01,GCST005412,Thrombin-activatable fibrinolysis inhibitor levels
7780,European,3124.0,29378355.0,Stanne TM,Hematological measurement,initial,2018-02-01,GCST005411,Thrombin-activatable fibrinolysis inhibitor activation peptide
7794,European,3148.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005431,Acute graft rejection in renal transplantation (recipient effect)
7795,European,3148.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005432,Acute graft rejection in renal transplantation (donor effect)
7317,European,2318.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005432,Acute graft rejection in renal transplantation (donor effect)
7796,European,3148.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005433,Acute graft rejection in renal transplantation (donor-recipient interaction)
7238,European,2204.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005429,Graft survival time in renal transplantation (donor effect)
8848,European,5866.0,29392897.0,Hernandez-Fuentes MP,"Other disease, Other measurement",replication,2018-02-01,GCST005427,End stage renal failure in renal transplantation (recipient effect)
9761,European,10088.0,29392897.0,Hernandez-Fuentes MP,Cardiovascular disease,initial,2018-02-01,GCST005426,Intracranial haemorrhage in renal transplantation (donors)
6694,European,1548.0,29398083.0,Lores-Motta L,Hematological measurement,initial,2018-02-01,GCST005365,Serum C3d:C3 ratio (systemic complement activation)
7570,European,2695.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005431,Acute graft rejection in renal transplantation (recipient effect)
7568,European,2689.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005428,Graft survival time in renal transplantation (recipient effect)
529,African American or Afro-Caribbean,139.0,29278617.0,Sucheston-Campbell LE,"Cancer, Response to drug, Neurological disorder",initial,2018-02-01,GCST005804,Taxane-induced peripheral neuropathy in breast cancer
7147,European,2123.0,29278617.0,Sucheston-Campbell LE,"Cancer, Response to drug, Neurological disorder",initial,2018-02-01,GCST005804,Taxane-induced peripheral neuropathy in breast cancer
6290,European,1098.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005433,Acute graft rejection in renal transplantation (donor-recipient interaction)
2223,Asian,560.0,29581620.0,Fujii R,Immune system disorder,replication,2018-02-01,GCST005556,Pollinosis
5707,European,697.0,29398083.0,Lores-Motta L,Hematological measurement,replication,2018-02-01,GCST005365,Serum C3d:C3 ratio (systemic complement activation)
9762,European,10088.0,29392897.0,Hernandez-Fuentes MP,"Other disease, Other measurement",initial,2018-02-01,GCST005427,End stage renal failure in renal transplantation (recipient effect)
11840,European,116255.0,29391395.0,Strawbridge RJ,Biological process,initial,2018-02-02,GCST005415,Self-reported risk-taking behaviour
13237,Hispanic or Latin American,4162.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005418,FEV1
13238,Hispanic or Latin American,4162.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005419,Lung function (FEV1/FVC)
2787,Asian,1634.0,29408531.0,Zhang D,Cardiovascular measurement,initial,2018-02-02,GCST005369,Serum uric acid levels
11738,European,94612.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005419,Lung function (FEV1/FVC)
13467,Hispanic or Latin American,11822.0,29394082.0,Burkart KM,Other measurement,initial,2018-02-02,GCST005419,Lung function (FEV1/FVC)
13466,Hispanic or Latin American,11822.0,29394082.0,Burkart KM,Other measurement,initial,2018-02-02,GCST005418,FEV1
13304,Hispanic or Latin American,5616.0,29394082.0,Burkart KM,Other disease,initial,2018-02-02,GCST005417,Chronic obstructive pulmonary disease
13429,Hispanic or Latin American,10403.0,29394082.0,Burkart KM,Other measurement,initial,2018-02-02,GCST005416,Airflow obstruction
800,African American or Afro-Caribbean,876.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005419,Lung function (FEV1/FVC)
7243,European,2209.0,29391396.0,McElroy SL,"Metabolic disorder, Neurological disorder",initial,2018-02-02,GCST005386,Binge eating behaviour and bipolar disorder
799,African American or Afro-Caribbean,876.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005418,FEV1
6747,European,1610.0,29391396.0,McElroy SL,"Metabolic disorder, Neurological disorder",initial,2018-02-02,GCST005387,Binge eating behaviour in bipolar disorder
3258,Asian,2818.0,29408531.0,Zhang D,Cardiovascular measurement,replication,2018-02-02,GCST005369,Serum uric acid levels
11971,European,139473.0,29391395.0,Strawbridge RJ,Biological process,replication,2018-02-02,GCST005415,Self-reported risk-taking behaviour
11737,European,94612.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005418,FEV1
4345,Asian,19311.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006033,Relative wall thickness
4182,Asian,12303.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006000,Immunoglobulin measurement (zinc sulfate turbidity test)
4358,Asian,19676.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006008,Left ventricular internal dimension in diastole
4351,Asian,19586.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006007,Left ventricular internal dimension in systole
3980,Asian,8600.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006024,E/A ratio
4331,Asian,18348.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST006015,Fibrinogen levels
4350,Asian,19580.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006029,Fractional shortening
4348,Asian,19516.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006006,Ejection fraction
4347,Asian,19373.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006027,Posterior wall thickness
4327,Asian,17837.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006025,Left ventricular mass index
10624,European,22250.0,29422769.0,Shah RL,"Neurological disorder, Other trait",initial,2018-02-05,GCST005803,Corneal astigmatism
4045,Asian,9120.0,29422769.0,Shah RL,"Neurological disorder, Other trait",initial,2018-02-05,GCST005803,Corneal astigmatism
4342,Asian,19076.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006026,Left ventricular mass
4346,Asian,19318.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006028,Interventricular septum thickness
4530,Asian,62076.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005975,Eosinophil counts
4598,Asian,134182.0,29403010.0,Kanai M,Liver enzyme measurement,initial,2018-02-05,GCST005998,Alanine transaminase levels
4577,Asian,108794.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005996,Red blood cell count
6638,European,1497.0,29404672.0,Roshandel D,"Other measurement, Metabolic disorder",initial,2018-02-05,GCST005437,Random C-peptide levels in type I diabetes
4543,Asian,75391.0,29403010.0,Kanai M,Inflammatory measurement,initial,2018-02-05,GCST006012,C-reactive protein levels
4613,Asian,139818.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005986,Blood urea nitrogen levels
4611,Asian,136597.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005979,Systolic blood pressure
4542,Asian,72866.0,29403010.0,Kanai M,Lipid or lipoprotein measurement,initial,2018-02-05,GCST006004,Low density lipoprotein cholesterol levels
4541,Asian,71701.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005982,Calcium levels
4610,Asian,136482.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006010,Mean arterial pressure
4540,Asian,70657.0,29403010.0,Kanai M,Lipid or lipoprotein measurement,initial,2018-02-05,GCST006005,High density lipoprotein cholesterol levels
4578,Asian,109029.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST005983,Serum uric acid levels
4481,Asian,37767.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST006018,Activated partial thromboplastin time
4497,Asian,42790.0,29403010.0,Kanai M,"Other measurement, Hematological measurement",initial,2018-02-05,GCST006001,Hemoglobin A1c levels
4579,Asian,110207.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005980,Total bilirubin levels
4607,Asian,136249.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006009,Pulse pressure
4576,Asian,108769.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005995,Hemoglobin
6487,European,1303.0,29404672.0,Roshandel D,"Other measurement, Metabolic disorder",initial,2018-02-05,GCST005435,Stimulated C-peptide levels in type I diabetes
4533,Asian,62076.0,29403010.0,Kanai M,Inflammatory measurement,initial,2018-02-05,GCST005976,White blood cell count (basophil)
4532,Asian,62076.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005997,Lymphocyte counts
4562,Asian,98538.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005990,Non-albumin protein levels
4597,Asian,134154.0,29403010.0,Kanai M,Liver enzyme measurement,initial,2018-02-05,GCST005999,Aspartate aminotransferase levels
4596,Asian,132938.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006031,Potassium levels
4531,Asian,62076.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005977,Monocyte count
4591,Asian,128305.0,29403010.0,Kanai M,Lipid or lipoprotein measurement,initial,2018-02-05,GCST006034,Total cholesterol levels
4589,Asian,127304.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006032,Sodium levels
4588,Asian,126402.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006030,Chloride levels
4587,Asian,126319.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST006013,Lactate dehydrogenase levels
4529,Asian,62076.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005974,Neutrophil count
4583,Asian,118309.0,29403010.0,Kanai M,Liver enzyme measurement,initial,2018-02-05,GCST006019,Gamma glutamyl transferase levels
4582,Asian,113509.0,29403010.0,Kanai M,"Hematological measurement, Other measurement",initial,2018-02-05,GCST005989,Serum total protein level
4525,Asian,58110.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST006017,Prothrombin time
4498,Asian,42793.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005981,Phosphorus levels
4575,Asian,108757.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005994,Hematocrit
4612,Asian,136615.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005978,Diastolic blood pressure
4619,Asian,143658.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005984,Glomerular filtration rate
4568,Asian,105597.0,29403010.0,Kanai M,Lipid or lipoprotein measurement,initial,2018-02-05,GCST006003,Triglyceride levels
4563,Asian,98626.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST005987,Albumin-globulin ratio
7061,European,2019.0,29404672.0,Roshandel D,"Other measurement, Metabolic disorder",initial,2018-02-05,GCST005438,Fasting C-peptide levels in type I diabetes
8012,European,3479.0,29404672.0,Roshandel D,"Other measurement, Metabolic disorder",initial,2018-02-05,GCST005436,C-peptide levels in type I diabetes
4618,Asian,142097.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005985,Creatinine levels
4574,Asian,108728.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005992,Mean corpuscular hemoglobin concentration
4565,Asian,105030.0,29403010.0,Kanai M,Liver enzyme measurement,initial,2018-02-05,GCST006016,Serum alkaline phosphatase levels
4569,Asian,106080.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006014,Creatine kinase levels
4570,Asian,107964.0,29403010.0,Kanai M,"Hematological measurement, Inflammatory measurement",initial,2018-02-05,GCST005973,White blood cell count
4551,Asian,93146.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006002,Blood sugar levels
4573,Asian,108256.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST006011,Mean corpuscular volume
4571,Asian,108054.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005993,Mean corpuscular hemoglobin
4564,Asian,102223.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005988,Serum albumin level
4572,Asian,108208.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005991,Platelet count
10000,European,12456.0,29436472.0,Casalone E,Other disease,initial,2018-02-07,GCST005572,Osteoarthritis of the hip (with total joint replacement)
11435,European,63556.0,29436472.0,Casalone E,Other disease,replication,2018-02-07,GCST005573,Osteoarthritis of the hip or knee
9910,European,11475.0,29436472.0,Casalone E,Other disease,replication,2018-02-07,GCST005572,Osteoarthritis of the hip (with total joint replacement)
9911,European,11475.0,29436472.0,Casalone E,Other disease,replication,2018-02-07,GCST005574,Osteoarthritis of the knee (with total joint replacement)
10215,European,15353.0,29436472.0,Casalone E,Other disease,initial,2018-02-07,GCST005573,Osteoarthritis of the hip or knee
9979,European,12127.0,29436472.0,Casalone E,Other disease,initial,2018-02-07,GCST005574,Osteoarthritis of the knee (with total joint replacement)
11774,European,107364.0,29436472.0,Casalone E,Other disease,replication,2018-02-07,GCST005571,Osteoarthritis of the hip or knee (with total joint replacement)
10214,European,15353.0,29436472.0,Casalone E,Other disease,initial,2018-02-07,GCST005571,Osteoarthritis of the hip or knee (with total joint replacement)
46,African,114.0,29432556.0,Brooke RJ,Other disease,initial,2018-02-08,GCST005518,Premature menopause in childhood cancer survivors
10593,European,21536.0,29422604.0,Klein AP,Cancer,initial,2018-02-08,GCST005434,Pancreatic cancer
5698,European,685.0,29432556.0,Brooke RJ,Other disease,initial,2018-02-08,GCST005518,Premature menopause in childhood cancer survivors
668,African American or Afro-Caribbean,394.0,29425463.0,Bime C,Other disease,initial,2018-02-09,GCST005805,Acute respiratory distress syndrome
655,African American or Afro-Caribbean,362.0,29425463.0,Bime C,Other disease,replication,2018-02-09,GCST005805,Acute respiratory distress syndrome
5590,European,607.0,29425463.0,Bime C,Other disease,replication,2018-02-09,GCST005805,Acute respiratory distress syndrome
252,African,2946.0,29452408.0,Shiga Y,Neurological disorder,replication,2018-02-14,GCST005388,Glaucoma (primary open-angle)
11140,European,40480.0,29452408.0,Shiga Y,Neurological disorder,replication,2018-02-14,GCST005388,Glaucoma (primary open-angle)
921,African American or Afro-Caribbean,1432.0,29452408.0,Shiga Y,Neurological disorder,replication,2018-02-14,GCST005388,Glaucoma (primary open-angle)
4385,Asian,22567.0,29452408.0,Shiga Y,Neurological disorder,replication,2018-02-14,GCST005388,Glaucoma (primary open-angle)
4388,Asian,22795.0,29452408.0,Shiga Y,Neurological disorder,initial,2018-02-14,GCST005388,Glaucoma (primary open-angle)
13421,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
4160,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
4159,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
4161,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2900,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
13419,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
2906,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2905,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4162,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
12350,European,285041.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
2899,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
2901,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
2902,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
12349,European,285041.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
2904,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2903,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
4158,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
4163,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
3781,Asian,6340.0,29246937.0,Li Y,"Digestive system disorder, Cancer",replication,2018-02-15,GCST005570,Hepatitis B virus-related hepatocellular carcinoma
13420,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
4157,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
1546,African American or Afro-Caribbean,25814.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
12351,European,285041.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
2476,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
2477,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
2478,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
2479,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2480,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
2481,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
12401,European,305832.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
1358,African American or Afro-Caribbean,7785.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
1357,African American or Afro-Caribbean,7785.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
1356,African American or Afro-Caribbean,7785.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
1301,African American or Afro-Caribbean,6180.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
1302,African American or Afro-Caribbean,6180.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
1303,African American or Afro-Caribbean,6180.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
1304,African American or Afro-Caribbean,6180.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
12387,European,300070.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
2625,Asian,1274.0,29246937.0,Li Y,"Digestive system disorder, Cancer",initial,2018-02-15,GCST005570,Hepatitis B virus-related hepatocellular carcinoma
12388,European,300070.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
3970,Asian,8373.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005409,Open-angle glaucoma and vertical cup-disc ratio
3969,Asian,8352.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005408,Open-angle glaucoma and intra-ocular pressure
12389,European,300070.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
12390,European,300070.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2475,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
4156,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
2474,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
1360,African American or Afro-Caribbean,7786.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
12352,European,285041.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
13418,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
11109,European,39399.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005408,Open-angle glaucoma and intra-ocular pressure
13417,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
13416,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
13415,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
4599,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4600,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
4601,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
4602,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
4603,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
4604,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
4605,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4606,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
13414,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4608,Asian,136451.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
3863,Asian,7307.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005410,Open-angle glaucoma and optic disc area
4609,Asian,136451.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
12402,European,305832.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
3867,Asian,7339.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005406,Open-angle glaucoma and optic cup area
1361,African American or Afro-Caribbean,7786.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
1359,African American or Afro-Caribbean,7785.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
10968,European,33720.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005409,Open-angle glaucoma and vertical cup-disc ratio
9714,European,9821.0,29449654.0,Gharahkhani P,Neurological disorder,initial,2018-02-15,GCST005407,Glaucoma (primary open-angle)
11590,European,80551.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
11585,European,80542.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
11586,European,80542.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
11587,European,80542.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
11588,European,80542.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
11589,European,80551.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
13553,Hispanic or Latin American,17936.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
11591,European,80551.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
11592,European,80551.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
11593,European,80552.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
11594,European,80552.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
1547,African American or Afro-Caribbean,25814.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
1548,African American or Afro-Caribbean,25814.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
1549,African American or Afro-Caribbean,25887.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4242,Asian,13438.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
177,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4243,Asian,13438.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
10910,European,32325.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005410,Open-angle glaucoma and optic disc area
1551,African American or Afro-Caribbean,25887.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
10909,European,32310.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005406,Open-angle glaucoma and optic cup area
1552,African American or Afro-Caribbean,25887.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
1553,African American or Afro-Caribbean,25889.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
13560,Hispanic or Latin American,17947.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
1554,African American or Afro-Caribbean,25889.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
13559,Hispanic or Latin American,17947.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
13558,Hispanic or Latin American,17943.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
13557,Hispanic or Latin American,17943.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
13556,Hispanic or Latin American,17943.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
13555,Hispanic or Latin American,17943.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
13551,Hispanic or Latin American,17936.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
13554,Hispanic or Latin American,17936.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
1550,African American or Afro-Caribbean,25887.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
178,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
13552,Hispanic or Latin American,17936.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
179,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
4189,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
4190,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
4191,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
4188,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4192,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
4193,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
4194,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4195,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
1545,African American or Afro-Caribbean,25814.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
4196,Asian,12481.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
4197,Asian,12481.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
13422,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
181,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
13423,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
182,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
180,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2383,Asian,779.0,29453196.0,Sato Y,Other measurement,replication,2018-02-16,GCST005798,Sperm motility
2406,Asian,811.0,29453196.0,Sato Y,Other measurement,initial,2018-02-16,GCST005798,Sperm motility
3259,Asian,2818.0,29453348.0,Chen CJ,"Cardiovascular measurement, Metabolic disorder",initial,2018-02-16,GCST005802,Hyperuricemia
3260,Asian,2818.0,29453348.0,Chen CJ,Metabolic disorder,initial,2018-02-16,GCST005799,Gout
2699,Asian,1494.0,29453348.0,Chen CJ,Metabolic disorder,initial,2018-02-16,GCST005801,Gout vs. Hyperuricemia
4137,Asian,11046.0,29471430.0,Tanikawa C,Cancer,replication,2018-02-17,GCST005591,Colorectal cancer
4459,Asian,33870.0,29471430.0,Tanikawa C,Cancer,initial,2018-02-17,GCST005591,Colorectal cancer
6837,European,1719.0,29459680.0,Claes P,Other measurement,replication,2018-02-19,GCST007989,Facial morphology traits (63 three-dimensional facial segments)
7330,European,2329.0,29459680.0,Claes P,Other measurement,initial,2018-02-19,GCST007989,Facial morphology traits (63 three-dimensional facial segments)
8452,European,4687.0,29496196.0,McCoy TH Jr.,Other measurement,initial,2018-02-20,GCST005757,Dimensional psychopathology (Positive)
8453,European,4687.0,29496196.0,McCoy TH Jr.,Other measurement,initial,2018-02-20,GCST005758,Dimensional psychopathology (Arousal)
8454,European,4687.0,29496196.0,McCoy TH Jr.,Other measurement,initial,2018-02-20,GCST005759,Dimensional psychopathology (Social)
8068,European,3598.0,29458411.0,Chung J,Other measurement,initial,2018-02-20,GCST005516,Neuritic plaques or neurofibrillary tangles (pleiotropy)
8451,European,4687.0,29496196.0,McCoy TH Jr.,Other measurement,initial,2018-02-20,GCST005756,Dimensional psychopathology (Negative)
8067,European,3598.0,29458411.0,Chung J,"Metabolic disorder, Other measurement",initial,2018-02-20,GCST005517,Neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)
8066,European,3598.0,29458411.0,Chung J,"Metabolic disorder, Other measurement",initial,2018-02-20,GCST005515,Neuritic plaques or cerebral amyloid angiopathy (pleiotropy)
8455,European,4687.0,29496196.0,McCoy TH Jr.,Other measurement,initial,2018-02-20,GCST005760,Dimensional psychopathology (Cognitive)
8065,European,3598.0,29458411.0,Chung J,"Metabolic disorder, Other measurement",initial,2018-02-20,GCST005514,Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)
2524,Asian,1045.0,29460428.0,Gelernter J,Other measurement,initial,2018-02-20,GCST005440,Alcohol dependence symptom count
2523,Asian,1045.0,29460428.0,Gelernter J,"Biological process, Other measurement",initial,2018-02-20,GCST005441,Alcohol consumption (max-drinks)
2522,Asian,1045.0,29460428.0,Gelernter J,Biological process,initial,2018-02-20,GCST005439,Response to alcohol consumption (flushing response)
8409,European,4577.0,29472613.0,Warrier V,Other measurement,initial,2018-02-22,GCST005797,Theory of mind score in adolescence (Emotional Triangles Task)
2256,Asian,630.0,29472232.0,Li Y,Cardiovascular disease,initial,2018-02-22,GCST005582,Coronary artery disease
4370,Asian,21198.0,29472232.0,Li Y,Cardiovascular disease,replication,2018-02-22,GCST005582,Coronary artery disease
5241,European,426.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005519,Heart rate response to beta blockers
548,African American or Afro-Caribbean,168.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",replication,2018-02-24,GCST005519,Heart rate response to beta blockers
4902,European,200.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",replication,2018-02-24,GCST005519,Heart rate response to beta blockers
613,African American or Afro-Caribbean,273.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005519,Heart rate response to beta blockers
514,African American or Afro-Caribbean,127.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005520,Heart rate response to beta blockers (atenolol add-on therapy)
4949,European,228.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005521,Heart rate response to beta blockers (atenolol monotherapy)
533,African American or Afro-Caribbean,146.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005521,Heart rate response to beta blockers (atenolol monotherapy)
4895,European,198.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005520,Heart rate response to beta blockers (atenolol add-on therapy)
11998,European,144368.0,29483656.0,Pardinas AF,Neurological disorder,replication,2018-02-26,GCST006803,Schizophrenia
3319,Asian,3072.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005652,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)
3312,Asian,3027.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005653,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction)
13801,Other/Mixed,177.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005652,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)
13802,Other/Mixed,177.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005653,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction)
11769,European,105318.0,29483656.0,Pardinas AF,Neurological disorder,initial,2018-02-26,GCST006803,Schizophrenia
6926,European,1823.0,29535710.0,Wahl A,Other measurement,initial,2018-02-26,GCST005656,IgG glycosylation patterns
13803,Other/Mixed,177.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005654,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction)
963,African American or Afro-Caribbean,1800.0,29495422.0,Xu H,Cardiovascular disease,initial,2018-02-26,GCST005588,Idiopathic dilated cardiomyopathy
3313,Asian,3027.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005654,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction)
7421,European,2475.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005653,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction)
7422,European,2475.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005654,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction)
6936,European,1836.0,29535710.0,Wahl A,Other measurement,replication,2018-02-26,GCST005656,IgG glycosylation patterns
7420,European,2475.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005652,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)
796,African American or Afro-Caribbean,849.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005796,Lumbar spine bone mineral density
795,African American or Afro-Caribbean,849.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005795,Femoral neck bone mineral density
12871,Hispanic or Latin American,446.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005796,Lumbar spine bone mineral density
11069,European,37657.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005795,Femoral neck bone mineral density
11070,European,37657.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005796,Lumbar spine bone mineral density
12870,Hispanic or Latin American,446.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005795,Femoral neck bone mineral density
2745,Asian,1539.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005795,Femoral neck bone mineral density
2746,Asian,1539.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005796,Lumbar spine bone mineral density
4941,European,223.0,29535370.0,Kleinstein SE,Other measurement,initial,2018-02-28,GCST005559,Virologic severity in Herpes simplex virus type 2 infection
10960,European,33431.0,29615537.0,Kulminski AM,Other measurement,initial,2018-03-01,GCST005773,Lung function (forced vital capacity)
10959,European,33431.0,29615537.0,Kulminski AM,Other measurement,initial,2018-03-01,GCST005772,Diastolic blood pressure
10958,European,33431.0,29615537.0,Kulminski AM,Other measurement,initial,2018-03-01,GCST005771,Creatinine levels
5812,European,770.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005722,Milk allergy (maternal genetic effects)
189,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005845,Heart rate increase in response to exercise
13922,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005845,Heart rate increase in response to exercise
10956,European,33431.0,29615537.0,Kulminski AM,Neurological disorder,initial,2018-03-01,GCST005779,Alzheimer's disease
10955,European,33431.0,29615537.0,Kulminski AM,Metabolic disorder,initial,2018-03-01,GCST005766,Diabetes mellitus
10954,European,33431.0,29615537.0,Kulminski AM,Lipid or lipoprotein measurement,initial,2018-03-01,GCST005781,Total cholesterol levels
10957,European,33431.0,29615537.0,Kulminski AM,Other measurement,initial,2018-03-01,GCST005763,Blood glucose levels
13923,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005846,Heart rate response to recovery post exercise (10 sec)
6722,European,1576.0,29545823.0,O'Brien KM,Other measurement,initial,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
10953,European,33431.0,29615537.0,Kulminski AM,Lipid or lipoprotein measurement,initial,2018-03-01,GCST005780,Triglyceride levels
190,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005846,Heart rate response to recovery post exercise (10 sec)
6763,European,1630.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005721,Food allergy (parent-of-origin effect)
6764,European,1630.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005724,Food allergy (maternal genetic effects)
2665,Asian,1379.0,29503163.0,Yu H,"Response to drug, Neurological disorder",replication,2018-03-01,GCST006292,Response to antipsychotic treatment in schizophrenia
10962,European,33431.0,29615537.0,Kulminski AM,Other trait,initial,2018-03-01,GCST005762,Death
4856,European,181.0,30207284.0,Galvan-Femenia I,"Response to drug, Cancer, Other measurement",initial,2018-03-01,GCST007358,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression)
6023,European,926.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005706,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
6024,European,926.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005707,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
1582,Asian,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005707,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
191,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005847,Heart rate response to recovery post exercise (20 sec)
10961,European,33431.0,29615537.0,Kulminski AM,Other measurement,initial,2018-03-01,GCST005777,Systolic blood pressure
13924,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005847,Heart rate response to recovery post exercise (20 sec)
5519,European,563.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005725,Egg allergy (parent-of-origin effect)
10951,European,33431.0,29615537.0,Kulminski AM,Inflammatory measurement,initial,2018-03-01,GCST005770,C-reactive protein levels
2839,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005845,Heart rate increase in response to exercise
1583,Asian,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005708,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
2840,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005846,Heart rate response to recovery post exercise (10 sec)
6026,European,926.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005709,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
5133,European,356.0,30207284.0,Galvan-Femenia I,"Response to drug, Cancer, Other measurement",replication,2018-03-01,GCST007358,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression)
2841,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005847,Heart rate response to recovery post exercise (20 sec)
3152,Asian,2413.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006292,Response to antipsychotic treatment in schizophrenia
2842,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005848,Heart rate response to recovery post exercise (50 sec)
5907,European,835.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005723,Peanut allergy (maternal genetic effects)
2843,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005849,Heart rate response to recovery post exercise (40 sec)
5908,European,835.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005727,Peanut allergy (parent-of-origin effect)
2844,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005850,Heart rate response to recovery post exercise (30 sec)
3101,Asian,2252.0,29494758.0,Liu L,Immune system disorder,initial,2018-03-01,GCST005754,Systemic lupus erythematosus
194,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005850,Heart rate response to recovery post exercise (30 sec)
10943,European,33431.0,29615537.0,Kulminski AM,"Body measurement, Other measurement",initial,2018-03-01,GCST005769,Body mass index
10944,European,33431.0,29615537.0,Kulminski AM,Cancer,initial,2018-03-01,GCST005768,Cancer
10945,European,33431.0,29615537.0,Kulminski AM,Cardiovascular disease,initial,2018-03-01,GCST005764,Stroke
10946,European,33431.0,29615537.0,Kulminski AM,Cardiovascular disease,initial,2018-03-01,GCST005765,Heart failure
10947,European,33431.0,29615537.0,Kulminski AM,Cardiovascular disease,initial,2018-03-01,GCST005767,Coronary heart disease
10948,European,33431.0,29615537.0,Kulminski AM,Cardiovascular disease,initial,2018-03-01,GCST005778,Atrial fibrillation
193,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005849,Heart rate response to recovery post exercise (40 sec)
10949,European,33431.0,29615537.0,Kulminski AM,Cardiovascular measurement,initial,2018-03-01,GCST005774,Heart rate
192,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005848,Heart rate response to recovery post exercise (50 sec)
13925,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005848,Heart rate response to recovery post exercise (50 sec)
5520,European,563.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005728,Egg allergy (maternal genetic effects)
5813,European,770.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005726,Milk allergy (parent-of-origin effect)
10950,European,33431.0,29615537.0,Kulminski AM,Hematological measurement,initial,2018-03-01,GCST005775,Hematocrit
10952,European,33431.0,29615537.0,Kulminski AM,Lipid or lipoprotein measurement,initial,2018-03-01,GCST005776,High density lipoprotein cholesterol levels
6025,European,926.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005708,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
11330,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005847,Heart rate response to recovery post exercise (20 sec)
12784,Hispanic or Latin American,113.0,29545823.0,O'Brien KM,Other measurement,replication,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
11328,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005845,Heart rate increase in response to exercise
11329,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005846,Heart rate response to recovery post exercise (10 sec)
13744,Other/Mixed,84.0,29545823.0,O'Brien KM,Other measurement,replication,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
12724,Hispanic or Latin American,7.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005706,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
13702,Other/Mixed,38.0,29545823.0,O'Brien KM,Other measurement,initial,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
3,African,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005707,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
576,African American or Afro-Caribbean,204.0,29545823.0,O'Brien KM,Other measurement,replication,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
2106,Asian,425.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006294,Response to risperidone in schizophrenia
4175,Asian,11755.0,29494758.0,Liu L,Immune system disorder,replication,2018-03-01,GCST005754,Systemic lupus erythematosus
4,African,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005708,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
518,African American or Afro-Caribbean,134.0,29545823.0,O'Brien KM,Other measurement,initial,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
12766,Hispanic or Latin American,81.0,29545823.0,O'Brien KM,Other measurement,initial,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
13926,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005849,Heart rate response to recovery post exercise (40 sec)
11331,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005848,Heart rate response to recovery post exercise (50 sec)
11332,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005849,Heart rate response to recovery post exercise (40 sec)
11333,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005850,Heart rate response to recovery post exercise (30 sec)
2,African,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005706,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
1581,Asian,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005706,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
1850,Asian,193.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006297,Response to perphenazine in schizophrenia
1849,Asian,192.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006298,Response to haloperidol in schizophrenia
12726,Hispanic or Latin American,7.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005708,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
12727,Hispanic or Latin American,7.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005709,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
2080,Asian,397.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006285,Response to aripiprazole in schizophrenia
2089,Asian,405.0,29503163.0,Yu H,"Response to drug, Neurological disorder",replication,2018-03-01,GCST006285,Response to aripiprazole in schizophrenia
2091,Asian,408.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006296,Response to ziprazidone in schizophrenia
12725,Hispanic or Latin American,7.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005707,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
2095,Asian,412.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006293,Response to olanzapine in schizophrenia
7595,European,2722.0,29545823.0,O'Brien KM,Other measurement,replication,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
1584,Asian,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005709,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
2221,Asian,559.0,29503163.0,Yu H,"Response to drug, Neurological disorder",replication,2018-03-01,GCST006294,Response to risperidone in schizophrenia
7505,European,2565.0,29562276.0,Venkateswaran S,Immune system disorder,initial,2018-03-01,GCST005815,Childhood onset ulcerative colitis
2072,Asian,386.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006295,Response to quetiapine in schizophrenia
13927,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005850,Heart rate response to recovery post exercise (30 sec)
2096,Asian,415.0,29503163.0,Yu H,"Response to drug, Neurological disorder",replication,2018-03-01,GCST006293,Response to olanzapine in schizophrenia
5,African,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005709,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
12505,European,366726.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006941,Irritable mood
12506,European,367725.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006946,Worry too long after an embarrassing experience
12519,European,372869.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006950,Feeling worry
12521,European,373380.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006945,Feeling guilty
12520,European,373121.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006948,Feeling nervous
12518,European,372047.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006951,Feeling hurt
12526,European,376097.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006943,Feeling miserable
12509,European,369499.0,29500382.0,Nagel M,Neurological disorder,initial,2018-03-02,GCST006949,Suffering from nerves
12533,European,380506.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006940,Neurociticism
12522,European,373733.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006944,Experiencing mood swings
12528,European,376352.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006942,Feeling lonely
12513,European,371318.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006952,Feeling tense
3205,Asian,2628.0,29495898.0,Peterson RE,Neurological disorder,initial,2018-03-02,GCST005690,Major depressive disorder (exposed to adversity)
12524,European,374971.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006947,Feeling fed-up
4071,Asian,9599.0,29495898.0,Peterson RE,Neurological disorder,initial,2018-03-02,GCST005691,Major depressive disorder
3838,Asian,6971.0,29495898.0,Peterson RE,Neurological disorder,initial,2018-03-02,GCST005689,Major depressive disorder (unexposed to adversity)
2122,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007143,Total cholesterol levels
13380,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007140,High density lipoprotein cholesterol levels
1120,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007143,Total cholesterol levels
13382,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007142,Triglycerides
1119,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007142,Triglycerides
2120,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007141,Low density lipoprotein cholesterol levels
2121,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007142,Triglycerides
12324,European,265204.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007131,Low density lipoprotein cholesterol levels
2119,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007140,High density lipoprotein cholesterol levels
13383,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007143,Total cholesterol levels
13381,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007141,Low density lipoprotein cholesterol levels
13378,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007133,Triglycerides
1113,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007131,Low density lipoprotein cholesterol levels
1114,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007132,High density lipoprotein cholesterol levels
1115,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007133,Triglycerides
11550,European,76627.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007143,Total cholesterol levels
11549,European,76627.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007142,Triglycerides
11548,European,76627.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007141,Low density lipoprotein cholesterol levels
11547,European,76627.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007140,High density lipoprotein cholesterol levels
13379,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007134,Total cholesterol levels
13376,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007131,Low density lipoprotein cholesterol levels
12327,European,265204.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007134,Total cholesterol levels
2115,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007131,Low density lipoprotein cholesterol levels
2116,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007132,High density lipoprotein cholesterol levels
1117,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007140,High density lipoprotein cholesterol levels
2117,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007133,Triglycerides
12325,European,265204.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007132,High density lipoprotein cholesterol levels
1118,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007141,Low density lipoprotein cholesterol levels
2118,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007134,Total cholesterol levels
13377,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007132,High density lipoprotein cholesterol levels
1116,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007134,Total cholesterol levels
12326,European,265204.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007133,Triglycerides
1969,Asian,278.0,29559957.0,Wang W,Cardiovascular measurement,initial,2018-03-06,GCST005557,Serum uric acid levels
12491,European,351799.0,29511194.0,Helgadottir A,Cardiovascular disease,initial,2018-03-07,GCST005561,Aortic valve stenosis
12492,European,353586.0,29511167.0,Theriault S,Cardiovascular disease,replication,2018-03-07,GCST005785,Calcific aortic valve stenosis
6018,European,920.0,29513936.0,Haasnoot AJW,Immune system disorder,initial,2018-03-07,GCST006128,Arthritis (juvenile idiopathic)
2563,Asian,1142.0,29514873.0,Mychaleckyj JC,"Lipid or lipoprotein measurement, Other measurement",initial,2018-03-07,GCST005586,Breast milk fatty acid composition (maternal genotype effect)
2564,Asian,1142.0,29514873.0,Mychaleckyj JC,"Lipid or lipoprotein measurement, Other measurement",initial,2018-03-07,GCST005587,Breast milk fatty acid composition (infant genotype effect)
5460,European,522.0,29513936.0,Haasnoot AJW,"Neurological disorder, Immune system disorder",initial,2018-03-07,GCST006126,Uveitis in juvenile idiopathic arthritis
7067,European,2026.0,29511167.0,Theriault S,Cardiovascular disease,initial,2018-03-07,GCST005785,Calcific aortic valve stenosis
5563,European,590.0,29513936.0,Haasnoot AJW,"Neurological disorder, Immune system disorder",initial,2018-03-07,GCST006127,Uveitis (juvenile idiopathic arthritis-associated)
12624,European,456581.0,29511194.0,Helgadottir A,Cardiovascular disease,replication,2018-03-07,GCST005561,Aortic valve stenosis
9908,European,11473.0,29520036.0,Stein MB,"Neurological disorder, Other measurement",initial,2018-03-08,GCST005566,Insomnia
1760,Asian,119.0,29518117.0,Lee HS,"Biological process, Other measurement",initial,2018-03-08,GCST006133,Bone mineral density x blood lead interaction in current smokers (2df test)
11662,European,87740.0,29520040.0,Coleman JRI,Biological process,initial,2018-03-08,GCST007044,Extremely high intelligence
1759,Asian,119.0,29518117.0,Lee HS,"Biological process, Other measurement",initial,2018-03-08,GCST006132,Bone mineral density x blood lead interaction in current smokers (1df test)
13198,Hispanic or Latin American,3499.0,29520036.0,Stein MB,"Neurological disorder, Other measurement",initial,2018-03-08,GCST005566,Insomnia
1072,African American or Afro-Caribbean,2679.0,29520036.0,Stein MB,"Neurological disorder, Other measurement",initial,2018-03-08,GCST005566,Insomnia
519,African American or Afro-Caribbean,135.0,29523524.0,Singh S,"Cardiovascular disease, Other measurement, Response to drug",initial,2018-03-09,GCST005577,Change in glucose in response to thiazide diuretic treatment in hypertension
251,African,2857.0,29523850.0,Gilchrist JJ,Other disease,initial,2018-03-09,GCST005590,Nontyphoidal Salmonella bacteraemia
136,African,734.0,29523850.0,Gilchrist JJ,Other disease,replication,2018-03-09,GCST005590,Nontyphoidal Salmonella bacteraemia
4845,European,175.0,29523524.0,Singh S,"Cardiovascular disease, Other measurement, Response to drug",initial,2018-03-09,GCST005577,Change in glucose in response to thiazide diuretic treatment in hypertension
4939,European,222.0,29523524.0,Singh S,"Cardiovascular disease, Other measurement, Response to drug",replication,2018-03-09,GCST005577,Change in glucose in response to thiazide diuretic treatment in hypertension
531,African American or Afro-Caribbean,140.0,29523524.0,Singh S,"Cardiovascular disease, Other measurement, Response to drug",replication,2018-03-09,GCST005577,Change in glucose in response to thiazide diuretic treatment in hypertension
8894,European,6035.0,29631748.0,McCoy TH Jr.,Neurological disorder,initial,2018-03-10,GCST005851,Delirium
4424,Asian,29821.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
11228,European,46861.0,29527006.0,Warrier V,Other measurement,initial,2018-03-12,GCST005751,Empathy quotient
4505,Asian,45564.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
12197,European,198048.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
2039,Asian,364.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
12233,European,211763.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST006910,Ischemic stroke (cardioembolic)
12232,European,211763.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
4419,Asian,29042.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
1477,African American or Afro-Caribbean,15405.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
12045,European,150765.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
12046,European,150765.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST006907,Ischemic stroke (large artery atherosclerosis)
12602,European,446696.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
2218,Asian,555.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
1479,African American or Afro-Caribbean,15560.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
1483,African American or Afro-Caribbean,15840.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
12589,European,440328.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST006908,Ischemic stroke
12953,Hispanic or Latin American,733.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
7004,European,1945.0,29531279.0,Zhou S,Cardiovascular disease,initial,2018-03-12,GCST005576,Intracranial aneurysm
12588,European,440328.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
3842,Asian,7021.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
3846,Asian,7062.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
2300,Asian,698.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
4455,Asian,33291.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
1513,African American or Afro-Caribbean,20695.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
2043,Asian,367.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
3851,Asian,7129.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
12980,Hispanic or Latin American,791.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
4049,Asian,9144.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
1512,African American or Afro-Caribbean,20687.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
4504,Asian,45564.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
2147,Asian,467.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
4048,Asian,9144.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
12198,European,198048.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST006909,Ischemic stroke (small-vessel)
12976,Hispanic or Latin American,778.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
13083,Hispanic or Latin American,1557.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
13040,Hispanic or Latin American,1247.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
12603,European,446696.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST006906,Stroke
13408,Hispanic or Latin American,8560.0,29534260.0,Kim SK,"Other trait, Cancer",initial,2018-03-13,GCST005558,Plantar fascial disorders
9126,European,7012.0,29531327.0,Meijsen JJ,"Other measurement, Neurological disorder",initial,2018-03-13,GCST008584,Cognitive performance (language ability) x major depressive disorder status interaction
2585,Asian,1193.0,29534301.0,Nishida N,"Response to drug, Other measurement",initial,2018-03-13,GCST005606,Response to hepatitis B vaccine
9125,European,7012.0,29531327.0,Meijsen JJ,Other measurement,initial,2018-03-13,GCST008587,Cognitive performance (language ability)
9192,European,7344.0,29532581.0,Hallfors J,Other measurement,replication,2018-03-13,GCST006299,Smoking behaviour (cigarettes smoked per day)
1152,African American or Afro-Caribbean,3166.0,29534260.0,Kim SK,"Other trait, Cancer",initial,2018-03-13,GCST005558,Plantar fascial disorders
8994,European,6524.0,29531327.0,Meijsen JJ,"Biological process, Other measurement",initial,2018-03-13,GCST008590,Cognitive performance (processing speed)
8997,European,6524.0,29531327.0,Meijsen JJ,"Other measurement, Neurological disorder",initial,2018-03-13,GCST008585,Cognitive performance (language ability) x major depressive disorder status interaction
3884,Asian,7518.0,29534260.0,Kim SK,"Other trait, Cancer",initial,2018-03-13,GCST005558,Plantar fascial disorders
6213,European,1021.0,29531327.0,Meijsen JJ,"Neurological disorder, Biological process, Other measurement",initial,2018-03-13,GCST008589,Cognitive performance (processing speed) in major depressive disorder
6212,European,1021.0,29531327.0,Meijsen JJ,"Neurological disorder, Biological process, Other measurement",initial,2018-03-13,GCST008586,Cognitive performance (processing speed) x major depressive disorder type interaction
6832,European,1715.0,29532581.0,Hallfors J,Other measurement,initial,2018-03-13,GCST006301,Nicotine dependence symptom count
6831,European,1715.0,29532581.0,Hallfors J,Other measurement,initial,2018-03-13,GCST006299,Smoking behaviour (cigarettes smoked per day)
6830,European,1715.0,29532581.0,Hallfors J,Neurological disorder,initial,2018-03-13,GCST006302,Nicotine dependence
6826,European,1711.0,29532581.0,Hallfors J,Other measurement,initial,2018-03-13,GCST006300,Smoking behaviour (maximum cigarettes in a 24 hour period)
6818,European,1703.0,29532581.0,Hallfors J,Other measurement,initial,2018-03-13,GCST006869,Nicotine withdrawal
11617,European,83264.0,29534260.0,Kim SK,"Other trait, Cancer",initial,2018-03-13,GCST005558,Plantar fascial disorders
6817,European,1703.0,29532581.0,Hallfors J,Other measurement,initial,2018-03-13,GCST006303,Nicotine withdrawal symptom count
8995,European,6524.0,29531327.0,Meijsen JJ,"Neurological disorder, Biological process, Other measurement",initial,2018-03-13,GCST008583,Cognitive performance (processing speed) x major depressive disorder status interaction
8996,European,6524.0,29531327.0,Meijsen JJ,Other measurement,initial,2018-03-13,GCST008588,Cognitive performance (language ability)
4791,European,137.0,29538362.0,Jilling T,"Other trait, Digestive system disorder",initial,2018-03-14,GCST005800,Surgical necrotising enterocolitis in extremely premature birth
5634,European,646.0,29547969.0,Chen X,Other measurement,replication,2018-03-14,GCST005761,Immunoglobulin M against phosphorylcholine (IgM anti-PC) levels
12790,Hispanic or Latin American,136.0,29538362.0,Jilling T,"Other trait, Digestive system disorder",initial,2018-03-14,GCST005800,Surgical necrotising enterocolitis in extremely premature birth
7731,European,3002.0,29547969.0,Chen X,Other measurement,initial,2018-03-14,GCST005761,Immunoglobulin M against phosphorylcholine (IgM anti-PC) levels
627,African American or Afro-Caribbean,303.0,29538362.0,Jilling T,"Other trait, Digestive system disorder",initial,2018-03-14,GCST005800,Surgical necrotising enterocolitis in extremely premature birth
5208,European,407.0,29551627.0,Hawcutt DB,"Response to drug, Other measurement, Other disease",initial,2018-03-15,GCST005926,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma
5207,European,407.0,29551627.0,Hawcutt DB,"Response to drug, Other measurement, Other disease",initial,2018-03-15,GCST005925,Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma
8377,European,4466.0,29551738.0,Dong J,"Other measurement, Cancer",initial,2018-03-15,GCST006532,Esophageal adenocarcinoma x pack-years of smoking exposure interaction
5205,European,407.0,29551627.0,Hawcutt DB,"Other measurement, Response to drug",initial,2018-03-15,GCST005924,Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L)
6321,European,1143.0,29545352.0,Li Y,"Other disease, Other measurement",initial,2018-03-15,GCST005666,Fractional excretion of metabolites in chronic kidney disease
6320,European,1143.0,29545352.0,Li Y,"Other disease, Other measurement",initial,2018-03-15,GCST005651,Urinary metabolite concentrations in chronic kidney disease
6319,European,1143.0,29545352.0,Li Y,"Other disease, Other measurement",initial,2018-03-15,GCST005650,Serum metabolite ratios in chronic kidney disease
5206,European,407.0,29551627.0,Hawcutt DB,"Other measurement, Response to drug",initial,2018-03-15,GCST005927,Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L)
6318,European,1143.0,29545352.0,Li Y,"Other disease, Other measurement",initial,2018-03-15,GCST005649,Urinary metabolite ratios in chronic kidney disease
8703,European,5286.0,29551738.0,Dong J,"Other measurement, Digestive system disorder",initial,2018-03-15,GCST006528,Barrett's esophagus x pack-years of smoking exposure interaction
8702,European,5286.0,29551738.0,Dong J,"Other measurement, Digestive system disorder",initial,2018-03-15,GCST006527,Barrett's esophagus x smoking interaction
8376,European,4466.0,29551738.0,Dong J,"Other measurement, Cancer",initial,2018-03-15,GCST006530,Esophageal adenocarcinoma x smoking interaction
8375,European,4466.0,29551738.0,Dong J,"Cancer, Digestive system disorder",initial,2018-03-15,GCST006531,Esophageal adenocarcinoma x gastroesophageal reflux disease interaction
8374,European,4466.0,29551738.0,Dong J,"Body measurement, Cancer",initial,2018-03-15,GCST006525,Esophageal adenocarcinoma x BMI interaction
6317,European,1143.0,29545352.0,Li Y,"Other disease, Other measurement",initial,2018-03-15,GCST005648,Serum metabolite concentrations in chronic kidney disease
8701,European,5286.0,29551738.0,Dong J,Digestive system disorder,initial,2018-03-15,GCST006526,Barrett's esophagus x gastroesophageal reflux disease interaction
8700,European,5286.0,29551738.0,Dong J,"Body measurement, Digestive system disorder",initial,2018-03-15,GCST006529,Barrett's esophagus x BMI interaction
5571,European,599.0,29555444.0,Hamer MA,Other trait,replication,2018-03-16,GCST006981,Facial wrinkles
8026,European,3513.0,29555444.0,Hamer MA,Other trait,initial,2018-03-16,GCST006981,Facial wrinkles
8876,European,5947.0,29743933.0,Wu B,Other measurement,initial,2018-03-18,GCST006404,Glycemic traits (multi-trait analysis)
11273,European,50508.0,29559693.0,Zengini E,Other disease,initial,2018-03-20,GCST005814,Osteoarthritis (hospital diagnosed)
9967,European,11989.0,29559693.0,Zengini E,Other disease,initial,2018-03-20,GCST005810,Osteoarthritis of the hip (hospital diagnosed)
12225,European,208850.0,29559693.0,Zengini E,Other disease,replication,2018-03-20,GCST005812,Osteoarthritis of the hip or knee (hospital diagnosed)
3799,Asian,6509.0,29558500.0,Lee J,Other measurement,replication,2018-03-20,GCST005791,Creatinine levels
3800,Asian,6509.0,29558500.0,Lee J,Other measurement,replication,2018-03-20,GCST005792,Glomerular filtration rate
14237,Other/Mixed,7064.0,29558500.0,Lee J,Other measurement,initial,2018-03-20,GCST005794,Blood urea nitrogen levels
12155,European,177463.0,29559693.0,Zengini E,Other disease,replication,2018-03-20,GCST005813,Osteoarthritis of the knee (hospital diagnosed)
10931,European,32970.0,29559693.0,Zengini E,Other disease,initial,2018-03-20,GCST005812,Osteoarthritis of the hip or knee (hospital diagnosed)
11436,European,63556.0,29559693.0,Zengini E,Other disease,initial,2018-03-20,GCST005811,Osteoarthritis (self-reported)
3849,Asian,7064.0,29558500.0,Lee J,Other measurement,initial,2018-03-20,GCST005792,Glomerular filtration rate
3409,Asian,3703.0,29558500.0,Lee J,Cardiovascular measurement,replication,2018-03-20,GCST005793,Uric acid levels
3847,Asian,7064.0,29558500.0,Lee J,Cardiovascular measurement,initial,2018-03-20,GCST005793,Uric acid levels
3801,Asian,6509.0,29558500.0,Lee J,Other measurement,replication,2018-03-20,GCST005794,Blood urea nitrogen levels
3848,Asian,7064.0,29558500.0,Lee J,Other measurement,initial,2018-03-20,GCST005791,Creatinine levels
12211,European,205135.0,29559693.0,Zengini E,Other disease,replication,2018-03-20,GCST005810,Osteoarthritis of the hip (hospital diagnosed)
4155,Asian,11409.0,29559738.0,Sasayama D,Other trait,initial,2018-03-20,GCST005809,Photic sneeze reflex
12323,European,264362.0,29559693.0,Zengini E,Other disease,replication,2018-03-20,GCST005814,Osteoarthritis (hospital diagnosed)
10625,European,22347.0,29559693.0,Zengini E,Other disease,initial,2018-03-20,GCST005813,Osteoarthritis of the knee (hospital diagnosed)
11596,European,80610.0,29566793.0,Nicolas A,Neurological disorder,initial,2018-03-21,GCST005647,Amyotrophic lateral sclerosis
10337,European,17062.0,29563502.0,Fejzo MS,Other disease,initial,2018-03-21,GCST005930,Hyperemesis gravidarum
11322,European,53731.0,29563502.0,Fejzo MS,Other measurement,initial,2018-03-21,GCST005929,Severity of nausea and vomiting of pregnancy
6784,European,1648.0,29563502.0,Fejzo MS,Other disease,replication,2018-03-21,GCST005930,Hyperemesis gravidarum
6479,European,1297.0,29563342.0,Li XS,Hematological measurement,initial,2018-03-22,GCST005670,Plasma trimethyllysine levels
8429,European,4633.0,29628937.0,Jiang J,Hematological measurement,initial,2018-03-23,GCST005712,Growth differentiation factor-15 levels (conditioned on rs888663)
1668,Asian,57.0,29572449.0,Gurung RL,"Hematological measurement, Metabolic disorder",replication,2018-03-23,GCST005808,Plasma haptoglobin levels in type 2 diabetes
1667,Asian,57.0,29572449.0,Gurung RL,"Hematological measurement, Metabolic disorder",replication,2018-03-23,GCST005807,Urinary haptoglobin levels in type 2 diabetes
1927,Asian,236.0,29572449.0,Gurung RL,"Hematological measurement, Metabolic disorder",initial,2018-03-23,GCST005808,Plasma haptoglobin levels in type 2 diabetes
8428,European,4633.0,29628937.0,Jiang J,Hematological measurement,initial,2018-03-23,GCST005711,Growth differentiation factor-15 levels
1926,Asian,236.0,29572449.0,Gurung RL,"Hematological measurement, Metabolic disorder",initial,2018-03-23,GCST005807,Urinary haptoglobin levels in type 2 diabetes
5859,European,807.0,29628937.0,Jiang J,Hematological measurement,replication,2018-03-23,GCST005711,Growth differentiation factor-15 levels
5860,European,807.0,29628937.0,Jiang J,Hematological measurement,replication,2018-03-23,GCST005712,Growth differentiation factor-15 levels (conditioned on rs888663)
2191,Asian,512.0,29572449.0,Gurung RL,"Hematological measurement, Metabolic disorder",replication,2018-03-23,GCST005807,Urinary haptoglobin levels in type 2 diabetes
12237,European,214493.0,29590334.0,Bjornsson T,Cardiovascular disease,replication,2018-03-24,GCST005687,Aortic coarctation
11976,European,140700.0,29590334.0,Bjornsson T,Cardiovascular disease,initial,2018-03-24,GCST005687,Aortic coarctation
4930,European,214.0,29580174.0,Ala-Mutka EM,"Cardiovascular measurement, Response to drug, Cardiovascular disease",initial,2018-03-27,GCST005646,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension
5323,European,465.0,29580174.0,Ala-Mutka EM,"Cardiovascular measurement, Response to drug, Cardiovascular disease",replication,2018-03-27,GCST005646,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension
5635,European,646.0,29594489.0,Apewokin S,"Other disease, Cancer",initial,2018-03-28,GCST005686,Clostridium difficile infection in multiple myeloma
11835,European,115486.0,29617998.0,Gao XR,Other measurement,initial,2018-03-28,GCST005580,Intraocular pressure
864,African American or Afro-Caribbean,1178.0,29596498.0,Charles BA,Hematological measurement,initial,2018-03-29,GCST005578,Low white blood cell count (conditioned on rs2814778)
985,African American or Afro-Caribbean,1997.0,29596498.0,Charles BA,Hematological measurement,initial,2018-03-29,GCST005579,Low white blood cell count
1937,Asian,254.0,29603369.0,Naito T,"Digestive system disorder, Other measurement",initial,2018-03-30,GCST005783,Bone mineral density (lumbar spine) in inflammatory bowel disease
1938,Asian,254.0,29603369.0,Naito T,"Other measurement, Digestive system disorder",initial,2018-03-30,GCST005784,Bone mineral density (femoral neck) in inflammatory bowel disease
4780,European,124.0,29608535.0,Kuehn MH,Cardiovascular disease,initial,2018-03-30,GCST005688,Idiopathic intracranial hypertension
1589,Asian,2.0,29608535.0,Kuehn MH,Cardiovascular disease,initial,2018-03-30,GCST005688,Idiopathic intracranial hypertension
13644,Other/Mixed,7.0,29608535.0,Kuehn MH,Cardiovascular disease,initial,2018-03-30,GCST005688,Idiopathic intracranial hypertension
448,African American or Afro-Caribbean,42.0,29608535.0,Kuehn MH,Cardiovascular disease,initial,2018-03-30,GCST005688,Idiopathic intracranial hypertension
9766,European,10098.0,29603866.0,Pain O,Other measurement,initial,2018-03-31,GCST005720,Parent-rated negative symptoms
9014,European,6579.0,29603866.0,Pain O,Other measurement,initial,2018-03-31,GCST005718,Anhedonia
9530,European,8665.0,29603866.0,Pain O,Other measurement,initial,2018-03-31,GCST005717,Paranoia and hallucinations
8953,European,6297.0,29603866.0,Pain O,Other measurement,initial,2018-03-31,GCST005719,Cognitive disorganisation
7345,European,2359.0,29603866.0,Pain O,Other measurement,replication,2018-03-31,GCST005718,Anhedonia
624,African American or Afro-Caribbean,297.0,29650764.0,McDonough CW,Cardiovascular measurement,initial,2018-04-01,GCST006043,Plasma renin activity levels
5317,European,461.0,29650764.0,McDonough CW,Cardiovascular measurement,initial,2018-04-01,GCST006043,Plasma renin activity levels
4805,European,150.0,29650764.0,McDonough CW,Cardiovascular measurement,replication,2018-04-01,GCST006043,Plasma renin activity levels
4794,European,139.0,29670602.0,Moreau K,"Other disease, Cardiovascular disease",initial,2018-04-04,GCST006805,Infective endocarditis in Staphylococcus aureus infection
13442,Hispanic or Latin American,11185.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005936,Supraventricular ectopy
13441,Hispanic or Latin American,11185.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005935,Ventricular ectopy or supraventricular ectopy (pleiotropy)
13443,Hispanic or Latin American,11185.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005937,Ventricular ectopy
10632,European,22517.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005936,Supraventricular ectopy
330,African,9274.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005937,Ventricular ectopy
10672,European,23672.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005935,Ventricular ectopy or supraventricular ectopy (pleiotropy)
10673,European,23672.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005937,Ventricular ectopy
329,African,9274.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005936,Supraventricular ectopy
4854,European,180.0,29670602.0,Moreau K,"Other disease, Cardiovascular disease",replication,2018-04-04,GCST006805,Infective endocarditis in Staphylococcus aureus infection
328,African,9274.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005935,Ventricular ectopy or supraventricular ectopy (pleiotropy)
9847,European,10769.0,29622589.0,Tereshchenko LG,Cardiovascular measurement,initial,2018-04-05,GCST005905,Global electrical heterogeneity phenotypes
3829,Asian,6943.0,29621232.0,Spracklen CN,Other measurement,initial,2018-04-05,GCST005914,Glycated hemoglobin levels
3727,Asian,5786.0,29621232.0,Spracklen CN,Other measurement,initial,2018-04-05,GCST005913,Fasting blood glucose
3728,Asian,5786.0,29621232.0,Spracklen CN,Other measurement,initial,2018-04-05,GCST005915,Fasting blood insulin
253,African,3057.0,29622589.0,Tereshchenko LG,Cardiovascular measurement,initial,2018-04-05,GCST005905,Global electrical heterogeneity phenotypes
3702,Asian,5731.0,29621232.0,Spracklen CN,Metabolic disorder,initial,2018-04-05,GCST005912,Type 2 diabetes
14292,Other/Mixed,153287.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007516,Type 2 diabetes (adjusted for BMI)
14291,Other/Mixed,153287.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007515,Type 2 diabetes
3971,Asian,8373.0,29632305.0,Lee HS,Metabolic disorder,initial,2018-04-09,GCST005878,Metabolic syndrome (multivariate analysis)
12379,European,298957.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007515,Type 2 diabetes
10334,European,17051.0,29632299.0,Vijayakrishnan J,Cancer,initial,2018-04-09,GCST005832,Acute lymphoblastic leukemia in childhood (B cell precursor)
3407,Asian,3694.0,29632305.0,Lee HS,Metabolic disorder,replication,2018-04-09,GCST005878,Metabolic syndrome (multivariate analysis)
12380,European,298957.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007516,Type 2 diabetes (adjusted for BMI)
12381,European,298957.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007517,Type 2 diabetes
12382,European,298957.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007518,Type 2 diabetes (adjusted for BMI)
7662,European,2854.0,29631575.0,Obeidat M,"Other disease, Other measurement",initial,2018-04-10,GCST005917,Current cigarettes per day in chronic obstructive pulmonary disease
7586,European,2706.0,29631575.0,Obeidat M,"Other disease, Other measurement",initial,2018-04-10,GCST005919,Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease
8226,European,4024.0,29631575.0,Obeidat M,"Other disease, Other measurement",initial,2018-04-10,GCST005916,Cotinine levels in smokers with chronic obstructive pulmonary disease
7676,European,2892.0,29631575.0,Obeidat M,"Other disease, Biological process",initial,2018-04-10,GCST005918,Smoking cessation in chronic obstructive pulmonary disease
7519,European,2596.0,30134803.0,Matana A,Other measurement,initial,2018-04-11,GCST006431,Plasma parathyroid hormone levels
5925,European,845.0,29650774.0,Rotroff DM,"Response to drug, Other measurement, Metabolic disorder",initial,2018-04-12,GCST005753,Change in HbA1c levels in response to metformin treatment in type 2 diabetes
2240,Asian,607.0,29674289.0,Cheon EJ,Lipid or lipoprotein measurement,initial,2018-04-12,GCST005671,Cholesterol efflux capacity
590,African American or Afro-Caribbean,222.0,29650774.0,Rotroff DM,"Response to drug, Other measurement, Metabolic disorder",initial,2018-04-12,GCST005753,Change in HbA1c levels in response to metformin treatment in type 2 diabetes
9116,European,6963.0,29650774.0,Rotroff DM,"Response to drug, Other measurement, Metabolic disorder",replication,2018-04-12,GCST005753,Change in HbA1c levels in response to metformin treatment in type 2 diabetes
827,African American or Afro-Caribbean,1015.0,29650774.0,Rotroff DM,"Response to drug, Other measurement, Metabolic disorder",replication,2018-04-12,GCST005753,Change in HbA1c levels in response to metformin treatment in type 2 diabetes
10019,European,12636.0,29659830.0,Warrington NM,Body measurement,initial,2018-04-12,GCST005748,Digit length ratio (right hand)
1808,Asian,158.0,29674289.0,Cheon EJ,Lipid or lipoprotein measurement,replication,2018-04-12,GCST005671,Cholesterol efflux capacity
10009,European,12586.0,29659830.0,Warrington NM,Body measurement,initial,2018-04-12,GCST005750,Digit length ratio
10142,European,14382.0,29659830.0,Warrington NM,Body measurement,initial,2018-04-12,GCST005749,Digit length ratio (left hand)
5414,European,502.0,29654602.0,Laville V,Other measurement,initial,2018-04-13,GCST006365,Upper eyelid sagging severity
10800,European,27865.0,29662168.0,Hysi PG,"Other measurement, Other trait",replication,2018-04-16,GCST006075,Hair color
12245,European,217584.0,29662059.0,Howard DM,Neurological disorder,initial,2018-04-16,GCST005903,Major depressive disorder (ICD-10 coded)
12432,European,322580.0,29662059.0,Howard DM,Neurological disorder,initial,2018-04-16,GCST005902,Depression (broad)
12368,European,290891.0,29662168.0,Hysi PG,"Other measurement, Other trait",initial,2018-04-16,GCST006075,Hair color
12151,European,174519.0,29662059.0,Howard DM,Neurological disorder,initial,2018-04-16,GCST005904,Major depressive disorder (probable)
3898,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006820,Positive reappraisal
3792,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006826,Emotional expression
3899,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006821,Problem solving
3900,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006822,Disengagement
3901,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006823,Emotional coping (emotional expression/emotional support seeking)
3903,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006825,Perceived stress
3904,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006826,Emotional expression
3897,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006819,Emotional support seeking
3791,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006825,Perceived stress
3902,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006824,Approach coping (positive reappraisal/problem solving)
3789,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006823,Emotional coping (emotional expression/emotional support seeking)
3785,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006819,Emotional support seeking
3790,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006824,Approach coping (positive reappraisal/problem solving)
3788,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006822,Disengagement
3786,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006820,Positive reappraisal
3787,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006821,Problem solving
7531,European,2618.0,29678681.0,Matana A,Other measurement,initial,2018-04-18,GCST008368,Plasma anti-thyroid peroxidase levels
12500,European,360838.0,29679657.0,Ferreira MA,"Other disease, Immune system disorder",initial,2018-04-18,GCST007732,"Allergic disease (asthma, hay fever or eczema)"
7538,European,2629.0,29678681.0,Matana A,Other measurement,initial,2018-04-18,GCST008367,Plasma anti-thyroglobulin and anti-thyroid peroxidase levels (bivariate analysis)
7539,European,2629.0,29678681.0,Matana A,Other measurement,initial,2018-04-18,GCST008369,Plasma anti-thyroglobulin levels
9879,European,11103.0,29673008.0,Bonfiglio F,Digestive system disorder,initial,2018-04-19,GCST006535,Irritable bowel syndrome
13661,Other/Mixed,15.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006221,White matter growth
13662,Other/Mixed,15.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006222,Cerebellum growth
13663,Other/Mixed,15.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006223,Cerebral cortical growth
1604,Asian,8.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006220,Basal ganglia growth
1605,Asian,8.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006221,White matter growth
13664,Other/Mixed,15.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006224,Right lateral prefrontal cortical growth
1606,Asian,8.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006222,Cerebellum growth
13660,Other/Mixed,15.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006220,Basal ganglia growth
438,African American or Afro-Caribbean,31.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006224,Right lateral prefrontal cortical growth
1608,Asian,8.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006224,Right lateral prefrontal cortical growth
435,African American or Afro-Caribbean,31.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006221,White matter growth
437,African American or Afro-Caribbean,31.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006223,Cerebral cortical growth
5552,European,581.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006224,Right lateral prefrontal cortical growth
1607,Asian,8.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006223,Cerebral cortical growth
436,African American or Afro-Caribbean,31.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006222,Cerebellum growth
5551,European,581.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006223,Cerebral cortical growth
5550,European,581.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006222,Cerebellum growth
5548,European,581.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006220,Basal ganglia growth
434,African American or Afro-Caribbean,31.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006220,Basal ganglia growth
5549,European,581.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006221,White matter growth
1305,African American or Afro-Caribbean,6224.0,29691896.0,Keaton JM,Metabolic disorder,initial,2018-04-24,GCST006494,"Type 2 diabetes (SNP x SNP interaction, 1df)"
12257,European,223215.0,29691431.0,Tikkanen E,Other measurement,initial,2018-04-24,GCST005829,Hand grip strength
11806,European,111610.0,29691431.0,Tikkanen E,Other measurement,replication,2018-04-24,GCST005829,Hand grip strength
12450,European,334825.0,29691431.0,Tikkanen E,Other measurement,initial,2018-04-24,GCST005830,Hand grip strength
1306,African American or Afro-Caribbean,6224.0,29691896.0,Keaton JM,Metabolic disorder,initial,2018-04-24,GCST006495,"Type 2 diabetes (SNP x SNP interaction, 2df)"
8047,European,3557.0,29695241.0,Charmet R,"Cardiovascular disease, Metabolic disorder",initial,2018-04-25,GCST006281,Coronary artery disease in type 1 diabetes
8359,European,4419.0,29698431.0,Roosenboom J,Other measurement,initial,2018-04-26,GCST005940,Maximum cranial width
12647,European,480359.0,29700475.0,Wray NR,"Neurological disorder, Other measurement",initial,2018-04-26,GCST005839,Depression
8358,European,4419.0,29698431.0,Roosenboom J,Other measurement,initial,2018-04-26,GCST005939,Cephalic index
8357,European,4419.0,29698431.0,Roosenboom J,Other measurement,initial,2018-04-26,GCST005938,Maximum cranial length
7608,European,2754.0,29698419.0,Pande M,Cancer,initial,2018-04-26,GCST006035,Breast cancer and/or colorectal cancer
3872,Asian,7405.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
8681,European,5248.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005884,Chronic kidney disease and diabetic kidney disease in diabetes
2013,Asian,332.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005887,Late diabetic kidney disease in type 2 diabetes
9626,European,9333.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
3652,Asian,5508.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
12437,European,326113.0,29728651.0,Li X,Neurological disorder,initial,2018-04-27,GCST005907,Major depressive disorder
8680,European,5248.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005883,Chronic kidney disease and diabetic kidney disease in type 2 diabetes
3651,Asian,5508.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
3636,Asian,5387.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005893,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)
9625,European,9333.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
6306,European,1129.0,29703846.0,Wei WQ,"Cardiovascular measurement, Response to drug",replication,2018-04-27,GCST006217,Coronary heart disease events during statin therapy
1738,Asian,103.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005887,Late diabetic kidney disease in type 2 diabetes
3724,Asian,5738.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005885,End-stage renal disease in type 2 diabetes
1739,Asian,103.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005888,Late diabetic kidney disease in diabetes
9720,European,9853.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005887,Late diabetic kidney disease in type 2 diabetes
4249,Asian,13915.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005887,Late diabetic kidney disease in type 2 diabetes
9603,European,9197.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",initial,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
3635,Asian,5387.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005894,Diabetic kidney disease in diabetes (ESRD vs. no ESRD)
9721,European,9853.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005888,Late diabetic kidney disease in diabetes
6964,European,1877.0,29703947.0,Jawinski P,Other measurement,initial,2018-04-27,GCST006138,Resting-state electroencephalogram vigilance
2014,Asian,332.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005888,Late diabetic kidney disease in diabetes
8886,European,6000.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
2069,Asian,384.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
9772,European,10164.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005880,Chronic kidney disease in diabetes
3725,Asian,5738.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005886,End-stage renal disease in diabetes
1888,Asian,222.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
9680,European,9650.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005894,Diabetic kidney disease in diabetes (ESRD vs. no ESRD)
1814,Asian,165.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
1832,Asian,180.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
2158,Asian,480.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
1809,Asian,159.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005880,Chronic kidney disease in diabetes
3871,Asian,7405.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
10508,European,19896.0,29728651.0,Li X,Neurological disorder,replication,2018-04-27,GCST005907,Major depressive disorder
2157,Asian,480.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005880,Chronic kidney disease in diabetes
10124,European,14150.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
9643,European,9443.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005893,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)
10123,European,14150.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005880,Chronic kidney disease in diabetes
1821,Asian,169.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005885,End-stage renal disease in type 2 diabetes
8738,European,5433.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005884,Chronic kidney disease and diabetic kidney disease in diabetes
8802,European,5655.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005886,End-stage renal disease in diabetes
8976,European,6400.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005886,End-stage renal disease in diabetes
1810,Asian,159.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
8810,European,5717.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
4299,Asian,16047.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
8975,European,6400.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005885,End-stage renal disease in type 2 diabetes
4250,Asian,13915.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005888,Late diabetic kidney disease in diabetes
1990,Asian,307.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
1991,Asian,307.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
3775,Asian,6287.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
4300,Asian,16047.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
3774,Asian,6287.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005880,Chronic kidney disease in diabetes
8298,European,4227.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
1813,Asian,165.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005880,Chronic kidney disease in diabetes
1822,Asian,169.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005886,End-stage renal disease in diabetes
9642,European,9443.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005894,Diabetic kidney disease in diabetes (ESRD vs. no ESRD)
7406,European,2447.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005885,End-stage renal disease in type 2 diabetes
2489,Asian,975.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
2490,Asian,975.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
9352,European,8063.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005888,Late diabetic kidney disease in diabetes
2070,Asian,384.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
1893,Asian,223.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
8105,European,3711.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005887,Late diabetic kidney disease in type 2 diabetes
1889,Asian,222.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
1791,Asian,137.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
8014,European,3485.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
2124,Asian,440.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
2123,Asian,440.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
1892,Asian,223.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
9857,European,10875.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
1833,Asian,180.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
1852,Asian,194.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005884,Chronic kidney disease and diabetic kidney disease in diabetes
2449,Asian,900.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005884,Chronic kidney disease and diabetic kidney disease in diabetes
10041,European,13158.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",initial,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
2098,Asian,418.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005893,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)
4126,Asian,10640.0,29728651.0,Li X,Neurological disorder,initial,2018-04-27,GCST005907,Major depressive disorder
2097,Asian,418.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005894,Diabetic kidney disease in diabetes (ESRD vs. no ESRD)
2448,Asian,900.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005883,Chronic kidney disease and diabetic kidney disease in type 2 diabetes
1851,Asian,194.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005883,Chronic kidney disease and diabetic kidney disease in type 2 diabetes
2248,Asian,619.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
1790,Asian,137.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
7300,European,2298.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005883,Chronic kidney disease and diabetic kidney disease in type 2 diabetes
2247,Asian,619.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
9266,European,7626.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
9993,European,12356.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
8015,European,3485.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
9828,European,10674.0,29703846.0,Wei WQ,"Cardiovascular measurement, Response to drug",initial,2018-04-27,GCST006217,Coronary heart disease events during statin therapy
9994,European,12356.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
8505,European,4842.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005893,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)
7054,European,2008.0,29724592.0,Pottier C,Neurological disorder,replication,2018-04-30,GCST006154,Frontotemporal dementia
5161,European,382.0,29724592.0,Pottier C,Neurological disorder,initial,2018-04-30,GCST006152,Language impairment in frontotemporal lobe dementia
6952,European,1865.0,29724592.0,Pottier C,Neurological disorder,replication,2018-04-30,GCST006148,Frontotemporal dementia with GRN mutation
4685,European,67.0,29724592.0,Pottier C,"Neurological disorder, Other measurement",replication,2018-04-30,GCST006149,Frontotemporal dementia with GRN mutation (age at onset)
5162,European,382.0,29724592.0,Pottier C,Neurological disorder,initial,2018-04-30,GCST006153,Parkinsonism in frontotemporal lobe dementia
4925,European,210.0,29724592.0,Pottier C,"Neurological disorder, Other measurement",replication,2018-04-30,GCST006147,Frontotemporal dementia (age at onset)
5163,European,382.0,29724592.0,Pottier C,"Neurological disorder, Biological process",initial,2018-04-30,GCST006146,Behavioural changes in frontotemporal lobe dementia
6665,European,1528.0,29724592.0,Pottier C,"Neurological disorder, Other measurement",initial,2018-04-30,GCST006147,Frontotemporal dementia (age at onset)
6664,European,1528.0,29724592.0,Pottier C,Neurological disorder,initial,2018-04-30,GCST006154,Frontotemporal dementia
5165,European,382.0,29724592.0,Pottier C,"Neurological disorder, Other trait",initial,2018-04-30,GCST006151,Memory dysfunction in frontotemporal lobe dementia
6663,European,1528.0,29724592.0,Pottier C,Neurological disorder,initial,2018-04-30,GCST006150,Frontotemporal dementia
6662,European,1528.0,29724592.0,Pottier C,Neurological disorder,initial,2018-04-30,GCST006148,Frontotemporal dementia with GRN mutation
5164,European,382.0,29724592.0,Pottier C,"Neurological disorder, Other measurement",initial,2018-04-30,GCST006149,Frontotemporal dementia with GRN mutation (age at onset)
6997,European,1941.0,29724592.0,Pottier C,Neurological disorder,replication,2018-04-30,GCST006150,Frontotemporal dementia
1855,Asian,195.0,29847655.0,Fan BJ,Other measurement,initial,2018-05-01,GCST006050,Central corneal thickness
13229,Hispanic or Latin American,4038.0,29847655.0,Fan BJ,Other measurement,replication,2018-05-01,GCST006049,Central corneal thickness
1854,Asian,195.0,29847655.0,Fan BJ,Other measurement,initial,2018-05-01,GCST006049,Central corneal thickness
13230,Hispanic or Latin American,4038.0,29847655.0,Fan BJ,Other measurement,replication,2018-05-01,GCST006050,Central corneal thickness
7890,European,3290.0,29748315.0,Pott J,Other measurement,initial,2018-05-01,GCST006284,Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease
9108,European,6911.0,29847655.0,Fan BJ,Other measurement,replication,2018-05-01,GCST006050,Central corneal thickness
8491,European,4806.0,29847655.0,Fan BJ,Other measurement,replication,2018-05-01,GCST006049,Central corneal thickness
2738,Asian,1520.0,29847655.0,Fan BJ,Other measurement,replication,2018-05-01,GCST006050,Central corneal thickness
4990,European,264.0,29730043.0,Li J,"Response to drug, Neurological disorder",initial,2018-05-02,GCST006248,Response to lurasidone in schizophrenia
541,African American or Afro-Caribbean,158.0,29730043.0,Li J,"Response to drug, Neurological disorder",initial,2018-05-02,GCST006248,Response to lurasidone in schizophrenia
4777,European,119.0,29998114.0,Gadad BS,"Neurological disorder, Response to drug",initial,2018-05-03,GCST006818,Remission after antidepressant treatment in major depression
12586,European,436236.0,30271922.0,Clifton EAD,Biological process,initial,2018-05-03,GCST006810,Self-reported risk-taking behaviour
12610,European,450406.0,30271922.0,Clifton EAD,"Biological process, Other measurement",initial,2018-05-03,GCST006812,Smoking status (ever vs never smokers)
4926,European,210.0,29998114.0,Gadad BS,"Neurological disorder, Response to drug",initial,2018-05-03,GCST006817,Response to antidepressants in depression
3513,Asian,4476.0,29725004.0,Hosoda Y,Other measurement,initial,2018-05-03,GCST005715,Myopic maculopathy
3344,Asian,3279.0,29725004.0,Hosoda Y,Other measurement,replication,2018-05-03,GCST005715,Myopic maculopathy
9913,European,11494.0,29738550.0,de Oliveira Otto MC,Lipid or lipoprotein measurement,initial,2018-05-08,GCST005869,Circulating odd-numbered chain saturated fatty acid levels (C15:0)
11881,European,121296.0,29739929.0,Visconti A,Other trait,initial,2018-05-08,GCST005897,Low tan response
5717,European,705.0,29739359.0,Graham PS,Metabolic disorder,initial,2018-05-08,GCST006282,Diabetic macular edema in type 2 diabetes
11351,European,55382.0,29739929.0,Visconti A,Other trait,replication,2018-05-08,GCST005897,Low tan response
5596,European,611.0,29739359.0,Graham PS,Metabolic disorder,initial,2018-05-08,GCST006283,Proliferative diabetic retinopathy in type 2 diabetes
8888,European,6016.0,29738550.0,de Oliveira Otto MC,Lipid or lipoprotein measurement,initial,2018-05-08,GCST005866,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0)
6981,European,1910.0,29738550.0,de Oliveira Otto MC,Lipid or lipoprotein measurement,initial,2018-05-08,GCST005862,Circulating odd-numbered chain saturated fatty acid levels (C19:0)
8889,European,6016.0,29738550.0,de Oliveira Otto MC,Lipid or lipoprotein measurement,initial,2018-05-08,GCST005868,Circulating odd-numbered chain saturated fatty acid levels (C17:0)
9253,European,7582.0,29738550.0,de Oliveira Otto MC,Lipid or lipoprotein measurement,initial,2018-05-08,GCST005861,Circulating odd-numbered chain saturated fatty acid levels (C23:0)
10434,European,18723.0,29743610.0,Ostrom QT,Cancer,initial,2018-05-09,GCST005931,Glioma
10096,European,13722.0,29743610.0,Ostrom QT,Cancer,initial,2018-05-09,GCST005933,Non-glioblastoma glioma
10196,European,15203.0,29743610.0,Ostrom QT,Cancer,initial,2018-05-09,GCST005932,Glioblastoma
5474,European,527.0,29747637.0,Li JQ,Other measurement,initial,2018-05-10,GCST005713,Plasma neurofilament light levels
9482,European,8429.0,29752348.0,Rutten-Jacobs LCA,Other measurement,initial,2018-05-11,GCST006062,White matter hyperintensity volume
5104,European,340.0,29751835.0,Hu H,Other measurement,initial,2018-05-11,GCST005714,Cerebrospinal fluid beta-site APP cleaving enzyme levels
9381,European,8239.0,29752348.0,Rutten-Jacobs LCA,Other measurement,initial,2018-05-11,GCST006064,White matter integrity (mean diffusivity)
9380,European,8239.0,29752348.0,Rutten-Jacobs LCA,Other measurement,initial,2018-05-11,GCST006063,White matter integrity (fractional anisotropy)
12843,Hispanic or Latin American,374.0,29750799.0,Chao MJ,"Neurological disorder, Other measurement",initial,2018-05-11,GCST007113,Huntington's disease (age at onset)
8244,European,4061.0,29750799.0,Chao MJ,"Neurological disorder, Other measurement",initial,2018-05-11,GCST007113,Huntington's disease (age at onset)
9905,European,11429.0,29762745.0,Claus EB,Cancer,initial,2018-05-12,GCST005870,Meningioma
5452,European,520.0,29762745.0,Claus EB,Cancer,replication,2018-05-12,GCST005870,Meningioma
3947,Asian,8107.0,29760442.0,Iglesias AI,Other measurement,initial,2018-05-14,GCST005667,Central corneal thickness
3948,Asian,8107.0,29760442.0,Iglesias AI,Other measurement,initial,2018-05-14,GCST006367,Central corneal thickness
10389,European,17803.0,29760442.0,Iglesias AI,Other measurement,initial,2018-05-14,GCST005667,Central corneal thickness
10390,European,17803.0,29760442.0,Iglesias AI,Other measurement,initial,2018-05-14,GCST006366,Central corneal thickness
1170,African American or Afro-Caribbean,3280.0,29767774.0,Lutz SM,"Other disease, Other measurement",initial,2018-05-15,GCST006042,Current cigarettes per day in chronic obstructive pulmonary disease
4741,European,95.0,29766673.0,Fusco JP,"Biological process, Cancer",initial,2018-05-15,GCST005747,Non-small cell lung cancer in heavy smokers
4788,European,133.0,29766673.0,Fusco JP,"Biological process, Cancer",replication,2018-05-15,GCST005747,Non-small cell lung cancer in heavy smokers
9029,European,6658.0,29767774.0,Lutz SM,"Other disease, Other measurement",initial,2018-05-15,GCST006042,Current cigarettes per day in chronic obstructive pulmonary disease
5493,European,546.0,29769526.0,Estrada K,Immune system disorder,replication,2018-05-16,GCST005964,Neuromyelitis optica
11464,European,67257.0,29769521.0,Ramirez J,Cardiovascular measurement,initial,2018-05-16,GCST005788,Heart rate response to recovery post exercise
11524,European,73265.0,29771307.0,Aponte JL,Other measurement,initial,2018-05-16,GCST005790,Rosacea symptom severity
1970,Asian,278.0,29868124.0,Wu Y,Body measurement,initial,2018-05-16,GCST006430,Body mass index and waist-hip ratio (pleiotropy)
5926,European,847.0,29769526.0,Estrada K,Immune system disorder,initial,2018-05-16,GCST006938,Neuromyelitis optica (AQP4-IgG-negative)
11460,European,67062.0,29769521.0,Ramirez J,Cardiovascular measurement,initial,2018-05-16,GCST005789,Resting heart rate
11463,European,67257.0,29769521.0,Ramirez J,Cardiovascular measurement,initial,2018-05-16,GCST005787,Heart rate response to exercise
2212,Asian,547.0,29769613.0,Sun X,"Neurological disorder, Other measurement",initial,2018-05-16,GCST006219,Executive function in ADHD
5471,European,526.0,29769526.0,Estrada K,Immune system disorder,replication,2018-05-16,GCST006937,Neuromyelitis optica (AQP4-IgG-positive)
5347,European,480.0,29769526.0,Estrada K,Immune system disorder,replication,2018-05-16,GCST006938,Neuromyelitis optica (AQP4-IgG-negative)
6010,European,913.0,29769526.0,Estrada K,Immune system disorder,initial,2018-05-16,GCST005964,Neuromyelitis optica
5933,European,850.0,29769526.0,Estrada K,Immune system disorder,initial,2018-05-16,GCST006937,Neuromyelitis optica (AQP4-IgG-positive)
10922,European,32545.0,29773799.0,Horikoshi M,Other measurement,replication,2018-05-17,GCST005863,Menopause (age at onset)
4428,Asian,30266.0,29773799.0,Horikoshi M,Other measurement,initial,2018-05-17,GCST005865,Early age at menarche
4500,Asian,43861.0,29773799.0,Horikoshi M,Other measurement,initial,2018-05-17,GCST005863,Menopause (age at onset)
11526,European,73397.0,29773799.0,Horikoshi M,Other measurement,replication,2018-05-17,GCST005867,Menarche (age at onset)
4535,Asian,67029.0,29773799.0,Horikoshi M,Other measurement,initial,2018-05-17,GCST005867,Menarche (age at onset)
4396,Asian,25432.0,29773799.0,Horikoshi M,Other measurement,initial,2018-05-17,GCST005864,Late age at menarche
8289,European,4187.0,30271932.0,Oskarsson GR,Other measurement,initial,2018-05-17,GCST006536,Serum erythropoietin levels
4686,European,68.0,30271932.0,Oskarsson GR,Other measurement,replication,2018-05-17,GCST006536,Serum erythropoietin levels
4147,Asian,11283.0,29779033.0,Hishida A,"Other disease, Other measurement",initial,2018-05-18,GCST006391,Chronic kidney disease
4624,Asian,148829.0,29779033.0,Hishida A,Other measurement,initial,2018-05-18,GCST006393,Serum creatinine levels
12317,European,260279.0,29777097.0,Marioni RE,Other measurement,initial,2018-05-18,GCST005920,Paternal history of Alzheimer's disease
12364,European,288676.0,29777097.0,Marioni RE,Other measurement,initial,2018-05-18,GCST005923,Maternal history of Alzheimer's disease
4148,Asian,11283.0,29779033.0,Hishida A,Other measurement,initial,2018-05-18,GCST006392,Estimated glomerular filtration rate
4623,Asian,148829.0,29779033.0,Hishida A,Other measurement,initial,2018-05-18,GCST006392,Estimated glomerular filtration rate
12411,European,314278.0,29777097.0,Marioni RE,"Neurological disorder, Other measurement",initial,2018-05-18,GCST005922,Alzheimer's disease or family history of Alzheimer's disease
4149,Asian,11283.0,29779033.0,Hishida A,Other measurement,initial,2018-05-18,GCST006393,Serum creatinine levels
4622,Asian,148829.0,29779033.0,Hishida A,"Other disease, Other measurement",initial,2018-05-18,GCST006391,Chronic kidney disease
12412,European,314278.0,29777097.0,Marioni RE,Other measurement,initial,2018-05-18,GCST005921,Family history of Alzheimer's disease
2067,Asian,383.0,29784950.0,Sawai H,"Digestive system disorder, Cancer",replication,2018-05-21,GCST005746,Hepatocellular carcinoma in hepatitis B infection
12310,European,253288.0,29782485.0,Rueger S,"Other measurement, Body measurement",initial,2018-05-21,GCST005908,Height
12455,European,336474.0,29782485.0,Rueger S,"Other measurement, Body measurement",replication,2018-05-21,GCST005908,Height
11842,European,116538.0,29785011.0,Zhu Z,"Other disease, Immune system disorder",initial,2018-05-21,GCST007564,Asthma or allergic disease (pleiotropy)
11759,European,102453.0,29785011.0,Zhu Z,"Other disease, Immune system disorder",initial,2018-05-21,GCST007563,"Allergic disease (asthma, hay fever or eczema)"
11972,European,139555.0,29785010.0,Khawaja AP,Other measurement,initial,2018-05-21,GCST006412,Intraocular pressure
11702,European,90853.0,29785011.0,Zhu Z,Other disease,initial,2018-05-21,GCST007562,Asthma
6514,European,1341.0,29787419.0,Hrdlickova B,Digestive system disorder,replication,2018-05-21,GCST005928,Refractory celiac disease type II
2499,Asian,989.0,29784950.0,Sawai H,"Digestive system disorder, Cancer",initial,2018-05-21,GCST005746,Hepatocellular carcinoma in hepatitis B infection
2526,Asian,1048.0,29784950.0,Sawai H,"Digestive system disorder, Cancer",replication,2018-05-21,GCST005746,Hepatocellular carcinoma in hepatitis B infection
5979,European,884.0,29787419.0,Hrdlickova B,Digestive system disorder,initial,2018-05-21,GCST005928,Refractory celiac disease type II
5837,European,790.0,29786918.0,Vonk JM,"Other disease, Other trait",initial,2018-05-22,GCST007423,Clinical remission in asthma
5670,European,667.0,29786918.0,Vonk JM,"Other disease, Other trait",initial,2018-05-22,GCST007424,Complete remission in asthma
5108,European,342.0,29786918.0,Vonk JM,"Other disease, Other trait",replication,2018-05-22,GCST007424,Complete remission in asthma
5312,European,456.0,29786918.0,Vonk JM,"Other disease, Other trait",replication,2018-05-22,GCST007423,Clinical remission in asthma
3029,Asian,2110.0,29808027.0,Tedja MS,Other measurement,initial,2018-05-28,GCST006289,Spherical equivalent
3030,Asian,2110.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
11740,European,95505.0,29808027.0,Tedja MS,"Other measurement, Other trait",replication,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
3177,Asian,2506.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
11764,European,104293.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006290,Myopia (age of diagnosis)
4284,Asian,15044.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
11192,European,44192.0,29808027.0,Tedja MS,Other measurement,initial,2018-05-28,GCST006289,Spherical equivalent
12019,European,148485.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
3110,Asian,2275.0,29808027.0,Tedja MS,Other measurement,initial,2018-05-28,GCST006289,Spherical equivalent
4283,Asian,15044.0,29808027.0,Tedja MS,Other measurement,initial,2018-05-28,GCST006289,Spherical equivalent
3176,Asian,2506.0,29808027.0,Tedja MS,Other measurement,initial,2018-05-28,GCST006289,Spherical equivalent
3111,Asian,2275.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
6885,European,1760.0,30680360.0,McCoy TH Jr,Other disease,initial,2018-05-29,GCST007250,Nonunion in individuals with fractures
3363,Asian,3418.0,29844195.0,Hosoda Y,Other measurement,initial,2018-05-29,GCST006068,Sub-foveal choroidal thickness
12392,European,300486.0,29844566.0,Davies G,Biological process,initial,2018-05-29,GCST006269,General cognitive ability
129,African,608.0,29844224.0,Loomis SJ,Other measurement,replication,2018-05-29,GCST006056,Fructosamine levels
2624,Asian,1271.0,29857070.0,Gao J,Immune system disorder,initial,2018-05-29,GCST006584,Pemphigus vulgaris
130,African,608.0,29844224.0,Loomis SJ,Other measurement,replication,2018-05-29,GCST006057,Percent glycated albumin
6492,European,1304.0,29844224.0,Loomis SJ,Other measurement,replication,2018-05-29,GCST006057,Percent glycated albumin
9269,European,7647.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006057,Percent glycated albumin
240,African,2104.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006059,Fasting blood glucose
241,African,2104.0,29844224.0,Loomis SJ,"Other measurement, Hematological measurement",initial,2018-05-29,GCST006060,Hemoglobin A1c levels
239,African,2104.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006058,Total glycated albumin levels
9270,European,7647.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006058,Total glycated albumin levels
9271,European,7647.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006059,Fasting blood glucose
9272,European,7647.0,29844224.0,Loomis SJ,"Other measurement, Hematological measurement",initial,2018-05-29,GCST006060,Hemoglobin A1c levels
237,African,2104.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006056,Fructosamine levels
238,African,2104.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006057,Percent glycated albumin
12445,European,330069.0,29844566.0,Davies G,Other measurement,initial,2018-05-29,GCST006268,Reaction time
6491,European,1304.0,29844224.0,Loomis SJ,Other measurement,replication,2018-05-29,GCST006056,Fructosamine levels
3219,Asian,2692.0,29844195.0,Hosoda Y,Other measurement,replication,2018-05-29,GCST006068,Sub-foveal choroidal thickness
3026,Asian,2104.0,29857070.0,Gao J,Immune system disorder,replication,2018-05-29,GCST006584,Pemphigus vulgaris
9268,European,7647.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006056,Fructosamine levels
6068,European,944.0,29860282.0,Scelsi MA,Other measurement,initial,2018-05-30,GCST006136,Alzheimer's disease progression score
10330,European,16966.0,29848360.0,Julia A,Immune system disorder,initial,2018-05-30,GCST005831,Systemic lupus erythematosus
6027,European,926.0,29860282.0,Scelsi MA,Other measurement,initial,2018-05-30,GCST006134,Hippocampal volume
6057,European,936.0,29860282.0,Scelsi MA,Other measurement,initial,2018-05-30,GCST006135,Cortical amyloid beta load
3712,Asian,5734.0,29855537.0,Hirata T,Other measurement,initial,2018-05-31,GCST006637,Pain medicine use during menstruation
8826,European,5781.0,30273415.0,Hatzikotoulas K,Other disease,replication,2018-05-31,GCST006566,Developmental dysplasia of the hip
3676,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006638,Menstruation quality of life impact (fever)
3711,Asian,5734.0,29855537.0,Hirata T,Other measurement,initial,2018-05-31,GCST006636,Menstruation quality of life impact (dysmenorrhea)
3720,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006643,Menstruation quality of life impact (bowel movement)
3719,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006639,Heavy vaginal discharge
3714,Asian,5734.0,29855537.0,Hirata T,"Other measurement, Other disease",initial,2018-05-31,GCST006645,Menstruation quality of life impact (edema)
8269,European,4134.0,30273415.0,Hatzikotoulas K,Other disease,initial,2018-05-31,GCST006566,Developmental dysplasia of the hip
12750,Hispanic or Latin American,36.0,29855589.0,Chernus J,Other trait,initial,2018-05-31,GCST006280,Velopharyngeal dysfunction
3715,Asian,5734.0,29855537.0,Hirata T,Other trait,initial,2018-05-31,GCST006653,Vaginal discharge (itching)
3716,Asian,5734.0,29855537.0,Hirata T,Other trait,initial,2018-05-31,GCST006654,Vaginal discharge (smell)
3717,Asian,5734.0,29855537.0,Hirata T,Other trait,initial,2018-05-31,GCST006657,Vaginal discharge (metrorrhagia)
3722,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006647,Menstruation quality of life impact (joint pain)
3718,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006638,Menstruation quality of life impact (fever)
3721,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006646,Menstruation quality of life impact (headache)
3713,Asian,5734.0,29855537.0,Hirata T,Other measurement,initial,2018-05-31,GCST006656,Dysmenorrheic pain severity
3723,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006652,Menstruation quality of life impact (stiff neck)
3675,Asian,5614.0,29855537.0,Hirata T,Other trait,replication,2018-05-31,GCST006654,Vaginal discharge (smell)
3705,Asian,5734.0,29855537.0,Hirata T,"Body measurement, Other measurement",initial,2018-05-31,GCST006650,Menstruation quality of life impact (pressure in breast)
3707,Asian,5734.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",initial,2018-05-31,GCST006648,Menstruation quality of life impact (loss of concentration)
3706,Asian,5734.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",initial,2018-05-31,GCST006644,Menstruation quality of life impact (depression)
3678,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006643,Menstruation quality of life impact (bowel movement)
3671,Asian,5614.0,29855537.0,Hirata T,Other measurement,replication,2018-05-31,GCST006637,Pain medicine use during menstruation
3704,Asian,5734.0,29855537.0,Hirata T,"Biological process, Other measurement",initial,2018-05-31,GCST006642,Menstruation quality of life impact (increased appetite)
3703,Asian,5734.0,29855537.0,Hirata T,"Biological process, Other measurement",initial,2018-05-31,GCST006641,Menstruation quality of life impact (aggressiveness)
3668,Asian,5614.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",replication,2018-05-31,GCST006651,Menstruation quality of life impact (sleepiness)
3679,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006646,Menstruation quality of life impact (headache)
3681,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006652,Menstruation quality of life impact (stiff neck)
3672,Asian,5614.0,29855537.0,Hirata T,Other measurement,replication,2018-05-31,GCST006656,Dysmenorrheic pain severity
5688,European,678.0,29852030.0,Lores-Motta L,"Neurological disorder, Response to drug, Other measurement",initial,2018-05-31,GCST006808,Response to anti-VEGF treatment in neovascular age-related macular degeneration (visual acuity)
3673,Asian,5614.0,29855537.0,Hirata T,"Other measurement, Other disease",replication,2018-05-31,GCST006645,Menstruation quality of life impact (edema)
3670,Asian,5614.0,29855537.0,Hirata T,Other measurement,replication,2018-05-31,GCST006636,Menstruation quality of life impact (dysmenorrhea)
3667,Asian,5614.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",replication,2018-05-31,GCST006644,Menstruation quality of life impact (depression)
3680,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006647,Menstruation quality of life impact (joint pain)
3708,Asian,5734.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",initial,2018-05-31,GCST006649,Menstruation quality of life impact (nervousness)
3669,Asian,5614.0,29855537.0,Hirata T,"Other disease, Other measurement",replication,2018-05-31,GCST006640,Menstruation quality of life impact (acne)
3665,Asian,5614.0,29855537.0,Hirata T,"Biological process, Other measurement",replication,2018-05-31,GCST006642,Menstruation quality of life impact (increased appetite)
3710,Asian,5734.0,29855537.0,Hirata T,"Other disease, Other measurement",initial,2018-05-31,GCST006640,Menstruation quality of life impact (acne)
3674,Asian,5614.0,29855537.0,Hirata T,Other trait,replication,2018-05-31,GCST006653,Vaginal discharge (itching)
3677,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006639,Heavy vaginal discharge
3709,Asian,5734.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",initial,2018-05-31,GCST006651,Menstruation quality of life impact (sleepiness)
3663,Asian,5609.0,29855537.0,Hirata T,Body measurement,initial,2018-05-31,GCST006655,Breast size
3664,Asian,5614.0,29855537.0,Hirata T,"Biological process, Other measurement",replication,2018-05-31,GCST006641,Menstruation quality of life impact (aggressiveness)
3666,Asian,5614.0,29855537.0,Hirata T,"Body measurement, Other measurement",replication,2018-05-31,GCST006650,Menstruation quality of life impact (pressure in breast)
4967,European,240.0,29967566.0,Roberts CH,Other measurement,initial,2018-06-03,GCST006225,Chlamydia trachomatis seropositivity
7141,European,2110.0,29883787.0,Gregson CL,Other measurement,initial,2018-06-05,GCST006143,Bone mineral density (total hip)
8857,European,5899.0,29883787.0,Gregson CL,Other measurement,initial,2018-06-05,GCST006141,High bone mineral density
6563,European,1380.0,29883787.0,Gregson CL,Other measurement,initial,2018-06-05,GCST006142,Lumbar spine bone mineral density
1241,African American or Afro-Caribbean,4306.0,29885931.0,Langefeld CD,Other disease,initial,2018-06-06,GCST006814,End-stage renal disease
880,African American or Afro-Caribbean,1229.0,29885931.0,Langefeld CD,"Other disease, Other measurement",initial,2018-06-06,GCST006816,End stage renal disease in APOL1 risk genotype-positive individuals
1067,African American or Afro-Caribbean,2649.0,29885931.0,Langefeld CD,"Other disease, Other measurement",initial,2018-06-06,GCST006813,End stage renal disease x APOL1 genotype interaction
1167,African American or Afro-Caribbean,3269.0,29875475.0,Montalvo-Ortiz JL,Biological process,initial,2018-06-06,GCST006175,Cannabis-related aggression
7901,European,3301.0,29875488.0,Sun BB,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",initial,2018-06-06,GCST005806,Blood protein levels
1135,African American or Afro-Caribbean,3076.0,29885931.0,Langefeld CD,"Other disease, Other measurement",initial,2018-06-06,GCST006815,End stage renal disease in APOL1 risk genotype-negative individuals
490,African American or Afro-Caribbean,89.0,29875475.0,Montalvo-Ortiz JL,Biological process,replication,2018-06-06,GCST006175,Cannabis-related aggression
7493,European,2546.0,29875475.0,Montalvo-Ortiz JL,Biological process,initial,2018-06-06,GCST006175,Cannabis-related aggression
6231,European,1043.0,29884837.0,Reyes-Gibby CC,"Cancer, Other trait",initial,2018-06-08,GCST005934,Neuropathic pain in head and neck cancer
8565,European,4944.0,29904099.0,Kottyan LC,Digestive system disorder,initial,2018-06-08,GCST009070,Eosinophilic esophagitis
13301,Hispanic or Latin American,5189.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006066,Glaucoma (primary open-angle)
14204,Other/Mixed,3571.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
284,African,5103.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006067,Glaucoma (primary open-angle)
283,African,5103.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
10737,European,25300.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006080,Prostate cancer aggressiveness (high vs low)
13300,Hispanic or Latin American,5189.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
3512,Asian,4475.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006067,Glaucoma (primary open-angle)
12654,European,537409.0,29892015.0,Roselli C,Cardiovascular disease,initial,2018-06-11,GCST006061,Atrial fibrillation
14205,Other/Mixed,3571.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006067,Glaucoma (primary open-angle)
11528,European,73475.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006083,Prostate cancer (advanced)
968,African American or Afro-Caribbean,1847.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
14206,Other/Mixed,3571.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006066,Glaucoma (primary open-angle)
3511,Asian,4475.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006066,Glaucoma (primary open-angle)
3596,Asian,5120.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006066,Glaucoma (primary open-angle)
12236,European,214102.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
3594,Asian,5120.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
969,African American or Afro-Caribbean,1847.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006066,Glaucoma (primary open-angle)
3595,Asian,5120.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006067,Glaucoma (primary open-angle)
12080,European,162201.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006067,Glaucoma (primary open-angle)
13289,Hispanic or Latin American,5022.0,29892015.0,Roselli C,Cardiovascular disease,initial,2018-06-11,GCST006061,Atrial fibrillation
11388,European,58751.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006082,Prostate cancer aggressiveness (high vs low/intermediate)
2445,Asian,895.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006066,Glaucoma (primary open-angle)
3631,Asian,5370.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
4478,Asian,36792.0,29892015.0,Roselli C,Cardiovascular disease,initial,2018-06-11,GCST006061,Atrial fibrillation
11974,European,140254.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006085,Prostate cancer
11296,European,51901.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006067,Glaucoma (primary open-angle)
11280,European,51244.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006089,Prostate cancer (early onset)
2444,Asian,895.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006067,Glaucoma (primary open-angle)
11413,European,61978.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006084,Prostate cancer (Gleason score)
12081,European,162201.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006066,Glaucoma (primary open-angle)
11295,European,51901.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006066,Glaucoma (primary open-angle)
285,African,5103.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006066,Glaucoma (primary open-angle)
1407,African American or Afro-Caribbean,8967.0,29892015.0,Roselli C,Cardiovascular disease,initial,2018-06-11,GCST006061,Atrial fibrillation
11546,European,76581.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006081,Prostate cancer (advanced vs non-advanced)
6666,European,1528.0,30134812.0,Chattopadhyay S,Other disease,initial,2018-06-11,GCST006917,Monoclonal gammopathy of undetermined significance
13302,Hispanic or Latin American,5189.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006067,Glaucoma (primary open-angle)
970,African American or Afro-Caribbean,1847.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006067,Glaucoma (primary open-angle)
13611,Other/Mixed,2.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006929,Attention function
13612,Other/Mixed,2.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006931,Verbal memory
13609,Other/Mixed,2.0,29907492.0,Nakahara S,"Biological process, Other measurement",initial,2018-06-12,GCST006933,Cognitive function
4883,European,192.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006932,Reasoning
13623,Other/Mixed,4.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006930,Working memory
13610,Other/Mixed,2.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006928,Visual memory
4884,European,192.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006934,Information processing speed
4141,Asian,11182.0,29895819.0,Endo C,Other trait,initial,2018-06-12,GCST006091,Freckles
4144,Asian,11253.0,29895819.0,Endo C,Other measurement,initial,2018-06-12,GCST006096,Age spots
443,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,"Biological process, Other measurement",initial,2018-06-12,GCST006933,Cognitive function
4888,European,192.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006931,Verbal memory
4887,European,192.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006929,Attention function
13629,Other/Mixed,4.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006931,Verbal memory
4886,European,192.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006928,Visual memory
13625,Other/Mixed,4.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006934,Information processing speed
445,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006929,Attention function
446,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006931,Verbal memory
4882,European,192.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006930,Working memory
4885,European,192.0,29907492.0,Nakahara S,"Biological process, Other measurement",initial,2018-06-12,GCST006933,Cognitive function
4143,Asian,11244.0,29895819.0,Endo C,Other trait,initial,2018-06-12,GCST006095,Excessive hairiness
13627,Other/Mixed,4.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006928,Visual memory
13626,Other/Mixed,4.0,29907492.0,Nakahara S,"Biological process, Other measurement",initial,2018-06-12,GCST006933,Cognitive function
13628,Other/Mixed,4.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006929,Attention function
444,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006928,Visual memory
13624,Other/Mixed,4.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006932,Reasoning
1639,Asian,28.0,29907492.0,Nakahara S,"Biological process, Other measurement",initial,2018-06-12,GCST006933,Cognitive function
3576,Asian,4878.0,29895819.0,Endo C,"Other measurement, Other trait",initial,2018-06-12,GCST006094,Straight vs curly hair
3521,Asian,4538.0,29895819.0,Endo C,Other trait,initial,2018-06-12,GCST006090,Excessive sweating
442,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006934,Information processing speed
1641,Asian,28.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006929,Attention function
13608,Other/Mixed,2.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006934,Information processing speed
1636,Asian,28.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006930,Working memory
1642,Asian,28.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006931,Verbal memory
3440,Asian,3941.0,29895819.0,Endo C,Other measurement,initial,2018-06-12,GCST006093,Thick vs thin eyebrows
1637,Asian,28.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006932,Reasoning
441,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006932,Reasoning
1640,Asian,28.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006928,Visual memory
13606,Other/Mixed,2.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006930,Working memory
440,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006930,Working memory
1638,Asian,28.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006934,Information processing speed
13607,Other/Mixed,2.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006932,Reasoning
3682,Asian,5614.0,29895819.0,Endo C,Other measurement,initial,2018-06-12,GCST006092,Double-edged eyelids
5418,European,505.0,29942513.0,Penney ME,Cancer,initial,2018-06-13,GCST006411,Mucinous adenocarcinoma in colorectal cancer
11703,European,91084.0,29899525.0,Klimentidis YC,Other measurement,initial,2018-06-13,GCST006099,Accelerometer-based physical activity measurement (average acceleration)
6329,European,1147.0,29898447.0,Alaraudanjoki VK,Other measurement,initial,2018-06-13,GCST006226,Erosive tooth wear (severe vs none or mild)
12529,European,377234.0,29899525.0,Klimentidis YC,Other measurement,initial,2018-06-13,GCST006097,Moderate to vigorous physical activity levels
12490,European,350492.0,29899525.0,Klimentidis YC,Other measurement,initial,2018-06-13,GCST006100,Strenuous sports or other exercises
11701,European,90667.0,29899525.0,Klimentidis YC,Other measurement,initial,2018-06-13,GCST006079,Accelerometer-based physical activity measurement (fraction of time with accelerations >425 milli-gravities)
7003,European,1944.0,29898447.0,Alaraudanjoki VK,Other measurement,initial,2018-06-13,GCST006218,Erosive tooth wear (severe vs non-severe)
12318,European,261055.0,29899525.0,Klimentidis YC,Other measurement,initial,2018-06-13,GCST006098,Vigorous physical activity
113,African,510.0,29903748.0,Debiec H,Other disease,initial,2018-06-14,GCST006252,Childhood steroid-sensitive nephrotic syndrome
13883,Other/Mixed,346.0,29903748.0,Debiec H,Other disease,initial,2018-06-14,GCST006252,Childhood steroid-sensitive nephrotic syndrome
7633,European,2796.0,29903748.0,Debiec H,Other disease,initial,2018-06-14,GCST006252,Childhood steroid-sensitive nephrotic syndrome
13315,Hispanic or Latin American,5941.0,29917119.0,Schmit SL,Cancer,replication,2018-06-16,GCST006131,Colorectal cancer
4374,Asian,21630.0,29917119.0,Schmit SL,Cancer,replication,2018-06-16,GCST006131,Colorectal cancer
11411,European,61335.0,29917119.0,Schmit SL,Cancer,replication,2018-06-16,GCST006131,Colorectal cancer
11474,European,67812.0,29917119.0,Schmit SL,Cancer,initial,2018-06-16,GCST006131,Colorectal cancer
1324,African American or Afro-Caribbean,6597.0,29917119.0,Schmit SL,Cancer,initial,2018-06-16,GCST006131,Colorectal cancer
13273,Hispanic or Latin American,4812.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
1270,African American or Afro-Caribbean,5041.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
2881,Asian,1789.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
4617,Asian,141026.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
13271,Hispanic or Latin American,4812.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",initial,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
844,African American or Afro-Caribbean,1062.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
13506,Hispanic or Latin American,13377.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
4632,Asian,306423.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",replication,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
4616,Asian,141024.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
11706,European,91102.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
11373,European,56705.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
11704,European,91099.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",initial,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
2879,Asian,1789.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
2878,Asian,1789.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",initial,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
13504,Hispanic or Latin American,13371.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
13505,Hispanic or Latin American,13371.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
13274,Hispanic or Latin American,4812.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
11712,European,91110.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
4635,Asian,306423.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
4634,Asian,306423.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
4615,Asian,141023.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
2880,Asian,1789.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
1267,African American or Afro-Caribbean,5041.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",replication,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
1268,African American or Afro-Caribbean,5041.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
843,African American or Afro-Caribbean,1062.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
11370,European,56705.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",initial,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
1269,African American or Afro-Caribbean,5041.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
11371,European,56705.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
11372,European,56705.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
13503,Hispanic or Latin American,13370.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",replication,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
4633,Asian,306423.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
842,African American or Afro-Caribbean,1062.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",replication,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
4950,European,228.0,29915124.0,Marini S,Cardiovascular disease,initial,2018-06-18,GCST006139,Hematoma volume in lobar spontaneous intracerebral hemorrhage
12344,European,281376.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
1418,African American or Afro-Caribbean,9725.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
11844,European,116778.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
1528,African American or Afro-Caribbean,21417.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
1525,African American or Afro-Caribbean,21416.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",initial,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
845,African American or Afro-Caribbean,1062.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
4187,Asian,12365.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
4614,Asian,141023.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",replication,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
4186,Asian,12365.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
4825,European,166.0,29915124.0,Marini S,Cardiovascular disease,initial,2018-06-18,GCST006140,Hematoma volume in non-lobar spontaneous intracerebral hemorrhage
4828,European,169.0,29915124.0,Marini S,Cardiovascular disease,replication,2018-06-18,GCST006140,Hematoma volume in non-lobar spontaneous intracerebral hemorrhage
4184,Asian,12365.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",initial,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
4689,European,71.0,29915124.0,Marini S,Cardiovascular disease,replication,2018-06-18,GCST006139,Hematoma volume in lobar spontaneous intracerebral hemorrhage
13404,Hispanic or Latin American,8471.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
331,African,9725.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",initial,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
4185,Asian,12365.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
1414,African American or Afro-Caribbean,9565.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
11845,European,116784.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
1413,African American or Afro-Caribbean,9565.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
13272,Hispanic or Latin American,4812.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
1526,African American or Afro-Caribbean,21416.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
1527,African American or Afro-Caribbean,21416.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
13401,Hispanic or Latin American,8470.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",initial,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
13402,Hispanic or Latin American,8470.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
12342,European,281318.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
13403,Hispanic or Latin American,8471.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
12341,European,281311.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
12902,Hispanic or Latin American,535.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
11847,European,116836.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
12901,Hispanic or Latin American,535.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
12900,Hispanic or Latin American,535.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
11846,European,116835.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",replication,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
12899,Hispanic or Latin American,535.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",replication,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
11705,European,91099.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
12343,European,281371.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",replication,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
10913,European,32338.0,29924316.0,Byun J,"Other measurement, Cancer",initial,2018-06-19,GCST006087,Familial lung adenocarcinoma
10900,European,31930.0,29924316.0,Byun J,"Other measurement, Cancer",initial,2018-06-19,GCST006088,Familial squamous cell lung carcinoma
3688,Asian,5634.0,29921221.0,Cha S,Other measurement,initial,2018-06-19,GCST006109,Lip morphology
3689,Asian,5634.0,29921221.0,Cha S,Other measurement,initial,2018-06-19,GCST006110,Nose morphology
2963,Asian,1940.0,29921221.0,Cha S,Other measurement,replication,2018-06-19,GCST006110,Nose morphology
2958,Asian,1926.0,29921221.0,Cha S,"Other trait, Other measurement",replication,2018-06-19,GCST006108,Facial morphology
2957,Asian,1926.0,29921221.0,Cha S,Other measurement,replication,2018-06-19,GCST006109,Lip morphology
2956,Asian,1926.0,29921221.0,Cha S,Other measurement,replication,2018-06-19,GCST006107,Upper eyelid morphology
11025,European,35953.0,29924316.0,Byun J,"Other measurement, Cancer",initial,2018-06-19,GCST006086,Familial lung cancer
2955,Asian,1926.0,29921221.0,Cha S,Other measurement,replication,2018-06-19,GCST006106,Forehead morphology
2954,Asian,1926.0,29921221.0,Cha S,Other measurement,replication,2018-06-19,GCST006105,Eye morphology
2608,Asian,1220.0,29923122.0,Kakuta Y,"Other trait, Digestive system disorder, Response to drug",initial,2018-06-19,GCST006209,Thiopurine-induced fever in inflammatory bowel disease
3685,Asian,5634.0,29921221.0,Cha S,Other measurement,initial,2018-06-19,GCST006105,Eye morphology
2607,Asian,1220.0,29923122.0,Kakuta Y,"Other disease, Digestive system disorder, Response to drug",initial,2018-06-19,GCST006213,Thiopurine-induced skin symptoms in inflammatory bowel disease
2606,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Response to drug, Other measurement",initial,2018-06-19,GCST006211,Thiopurine-induced infection in inflammatory bowel disease
3690,Asian,5634.0,29921221.0,Cha S,"Other trait, Other measurement",initial,2018-06-19,GCST006108,Facial morphology
2604,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Response to drug",initial,2018-06-19,GCST006212,Thiopurine-induced liver dysfunction in inflammatory bowel disease
2603,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Response to drug",initial,2018-06-19,GCST006208,Thiopurine-induced pancreatitis in inflammatory bowel disease
2605,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Response to drug, Other disease",initial,2018-06-19,GCST006210,Thiopurine-induced digestive symptoms in inflammatory bowel disease
2602,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006204,Thiopurine-induced severe leukopenia in inflammatory bowel disease
2592,Asian,1215.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006205,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease
2593,Asian,1215.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006215,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease (conditioned on rs116855232)
2595,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other disease, Response to drug",initial,2018-06-19,GCST006199,Thiopurine-induced severe alopecia in inflammatory bowel disease (conditioned on rs116855232)
3687,Asian,5634.0,29921221.0,Cha S,Other measurement,initial,2018-06-19,GCST006107,Upper eyelid morphology
2596,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other disease, Response to drug",initial,2018-06-19,GCST006206,Thiopurine-induced alopecia in inflammatory bowel disease
2597,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other disease, Response to drug",initial,2018-06-19,GCST006207,Thiopurine-induced severe alopecia in inflammatory bowel disease
2599,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006200,Thiopurine-induced severe leukopenia in inflammatory bowel disease (conditioned on rs116855232)
2598,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other disease, Response to drug",initial,2018-06-19,GCST006214,Thiopurine-induced alopecia in inflammatory bowel disease (conditioned on rs116855232)
2600,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006201,Thiopurine-induced leukopenia in inflammatory bowel disease
2601,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006202,Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232)
3686,Asian,5634.0,29921221.0,Cha S,Other measurement,initial,2018-06-19,GCST006106,Forehead morphology
10332,European,17037.0,29931343.0,Haworth S,Digestive system disorder,initial,2018-06-20,GCST006312,Childhood dental caries in primary teeth
10059,European,13353.0,29931343.0,Haworth S,Digestive system disorder,initial,2018-06-20,GCST006311,Childhood dental caries in permanent teeth
4833,European,172.0,29934777.0,Witten A,"Response to drug, Other trait",initial,2018-06-22,GCST006144,Heparin-induced thrombocytopenia
4889,European,192.0,29934777.0,Witten A,"Response to drug, Other trait",initial,2018-06-22,GCST006144,Heparin-induced thrombocytopenia
12621,European,456426.0,29936532.0,Colodro-Conde L,Other measurement,initial,2018-06-23,GCST007422,Socioeconomic status of place of residence
12651,European,504130.0,29936532.0,Colodro-Conde L,Other measurement,initial,2018-06-23,GCST007421,Population density of place of residence
2989,Asian,1999.0,29953918.0,Deng C,Other measurement,initial,2018-06-25,GCST006137,Serum folate levels
12328,European,269867.0,29942086.0,Savage JE,Biological process,initial,2018-06-25,GCST006250,Intelligence
12489,European,348219.0,29942085.0,Nagel M,"Other measurement, Other trait",initial,2018-06-25,GCST006478,Worry
12497,European,357957.0,29942085.0,Nagel M,Neurological disorder,initial,2018-06-25,GCST006475,Depressed affect
12606,European,449484.0,29942085.0,Nagel M,"Neurological disorder, Other measurement",initial,2018-06-25,GCST006476,Neuroticism
12679,European,688809.0,29942085.0,Nagel M,"Neurological disorder, Other measurement",initial,2018-06-25,GCST006477,Depression
1732,Asian,100.0,30065583.0,Choi MR,Other measurement,initial,2018-06-28,GCST006939,Skin hydration
4924,European,209.0,29959729.0,Zhong XL,Other measurement,initial,2018-06-29,GCST006279,Cerebrospinal fluid -synuclein levels
4219,Asian,13112.0,30304924.0,Kim HJ,Immune system disorder,replication,2018-06-30,GCST006809,Kawasaki disease
2633,Asian,1296.0,30304924.0,Kim HJ,Immune system disorder,initial,2018-06-30,GCST006809,Kawasaki disease
7280,European,2284.0,30134085.0,Zhang H,Other measurement,initial,2018-07-01,GCST006406,Cognitive flexibility
2190,Asian,511.0,30004843.0,Ge S,Other measurement,initial,2018-07-01,GCST006257,Elevated fasting plasma glucose
4010,Asian,8832.0,30045251.0,Lee MR,"Body measurement, Other measurement",initial,2018-07-01,GCST006369,Body mass index
1060,African American or Afro-Caribbean,2589.0,30134085.0,Zhang H,Other measurement,initial,2018-07-01,GCST006406,Cognitive flexibility
2386,Asian,781.0,29967481.0,Joo YB,"Immune system disorder, Other measurement",initial,2018-07-02,GCST006260,Childhood onset systemic lupus erythematosus
2773,Asian,1621.0,29970928.0,Zhu Z,"Biological process, Other measurement",initial,2018-07-03,GCST006253,Short-term memory (digit-span task)
12614,European,452302.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006921,Regular attendance at a pub or social club
3244,Asian,2790.0,29970928.0,Zhu Z,Other measurement,replication,2018-07-03,GCST006255,Short-term memory (shared component of digit-span and visuospatial tasks)
3239,Asian,2788.0,29970928.0,Zhu Z,"Biological process, Other measurement",replication,2018-07-03,GCST006253,Short-term memory (digit-span task)
12613,European,452302.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006920,Regular attendance at a gym or sports club
10812,European,28599.0,29971594.0,Rosenberger A,"Cancer, Other measurement",initial,2018-07-03,GCST006413,Lung cancer x radon exposure interaction (1df)
2920,Asian,1862.0,29970928.0,Zhu Z,Other measurement,replication,2018-07-03,GCST006256,Long-term memory (delayed word recall task)
3243,Asian,2790.0,29970928.0,Zhu Z,Other measurement,replication,2018-07-03,GCST006254,Short-term memory (visuospatial task)
12594,European,445024.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006923,Loneliness
12395,European,302567.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006919,Ability to confide in someone
2740,Asian,1522.0,29970928.0,Zhu Z,Other measurement,initial,2018-07-03,GCST006256,Long-term memory (delayed word recall task)
12365,European,288950.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006918,Social isolation
12615,European,452302.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006922,Regular attendance at a religious group
2777,Asian,1623.0,29970928.0,Zhu Z,Other measurement,initial,2018-07-03,GCST006255,Short-term memory (shared component of digit-span and visuospatial tasks)
2776,Asian,1623.0,29970928.0,Zhu Z,Other measurement,initial,2018-07-03,GCST006254,Short-term memory (visuospatial task)
12649,European,487647.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006924,Loneliness (MTAG)
4911,European,204.0,29973135.0,Rimpela JM,"Other measurement, Cardiovascular disease",initial,2018-07-04,GCST006274,Systolic blood pressure night-to-day ratio in hypertension
4910,European,204.0,29973135.0,Rimpela JM,"Other measurement, Cardiovascular disease",initial,2018-07-04,GCST006273,Diastolic blood pressure night-to-day ratio in hypertension
5272,European,434.0,29981864.0,Mohammadnejad A,"Immune system disorder, Other measurement",initial,2018-07-05,GCST008138,Allergic rhinitis x sex interaction
1859,Asian,200.0,29975729.0,Kim TH,"Digestive system disorder, Other measurement",initial,2018-07-05,GCST006364,Hepatitis B surface antigen seroclearance in chronic hepatitis B infection
2102,Asian,421.0,30034349.0,Lin E,"Response to drug, Neurological disorder",initial,2018-07-06,GCST006266,Remission after SSRI treatment in major depression
2103,Asian,421.0,30034349.0,Lin E,"Response to drug, Neurological disorder",initial,2018-07-06,GCST006267,Response to selective serotonin reuptake inhibitors in depression
6239,European,1053.0,30289108.0,Li W,"Cancer, Other measurement",initial,2018-07-07,GCST008493,Prostate cancer mortality
6699,European,1552.0,30289108.0,Li W,"Cancer, Other measurement",replication,2018-07-07,GCST008493,Prostate cancer mortality
11713,European,91114.0,29988085.0,Merino J,Biological process,initial,2018-07-09,GCST006388,Dietary macronutrient intake
12154,European,177315.0,29988085.0,Merino J,Biological process,replication,2018-07-09,GCST006388,Dietary macronutrient intake
10230,European,15666.0,30003307.0,Fall T,"Cardiovascular disease, Metabolic disorder",initial,2018-07-12,GCST006405,Coronary artery disease in diabetes
10727,European,24953.0,30003630.0,Minica CC,"Biological process, Other measurement",initial,2018-07-13,GCST006386,Cannabis use (age at onset)
8112,European,3735.0,30003630.0,Minica CC,"Biological process, Other measurement",replication,2018-07-13,GCST006386,Cannabis use (age at onset)
2259,Asian,636.0,30012571.0,Jia X,Other disease,initial,2018-07-16,GCST006246,Childhood steroid-sensitive nephrotic syndrome
4645,European,31.0,30013178.0,Kowalec K,"Immune system disorder, Response to drug, Digestive system disorder",replication,2018-07-16,GCST006270,Drug-induced liver injury in interferon-beta-treated multiple sclerosis
2465,Asian,935.0,30012571.0,Jia X,Other disease,initial,2018-07-16,GCST006246,Childhood steroid-sensitive nephrotic syndrome
4806,European,151.0,30013178.0,Kowalec K,"Immune system disorder, Response to drug, Digestive system disorder",initial,2018-07-16,GCST006270,Drug-induced liver injury in interferon-beta-treated multiple sclerosis
4974,European,243.0,30014611.0,Weiss RB,"Neurological disorder, Other measurement",initial,2018-07-16,GCST006286,Age at loss of ambulation in Duchenne muscular dystrophy
5753,European,733.0,30145303.0,Kimbrel NA,"Biological process, Other measurement",initial,2018-07-17,GCST006429,Suicidal ideation
11566,European,77898.0,30012220.0,Prins BP,Cardiovascular measurement,initial,2018-07-17,GCST007104,QRS duration
11565,European,77898.0,30012220.0,Prins BP,Cardiovascular measurement,initial,2018-07-17,GCST007103,QRS duration
11809,European,111874.0,30012220.0,Prins BP,Cardiovascular measurement,replication,2018-07-17,GCST007104,QRS duration
5748,European,732.0,30145303.0,Kimbrel NA,Biological process,initial,2018-07-17,GCST006428,Suicide attempts
1355,African American or Afro-Caribbean,7695.0,30012220.0,Prins BP,Cardiovascular measurement,initial,2018-07-17,GCST007105,QRS duration
1354,African American or Afro-Caribbean,7695.0,30012220.0,Prins BP,Cardiovascular measurement,initial,2018-07-17,GCST007104,QRS duration
5092,European,331.0,30031151.0,Virtanen VB,Digestive system disorder,replication,2018-07-18,GCST006272,Hirschsprung disease
5306,European,454.0,30031151.0,Virtanen VB,Digestive system disorder,initial,2018-07-18,GCST006271,Hirschsprung disease
5386,European,491.0,30031151.0,Virtanen VB,Digestive system disorder,initial,2018-07-18,GCST006272,Hirschsprung disease
7604,European,2740.0,30079052.0,Rujescu D,Neurological disorder,initial,2018-07-20,GCST006275,Vestibular neuritis
12695,European,811539.0,30038396.0,Lee JJ,Biological process,initial,2018-07-23,GCST006568,Highest math class taken (MTAG)
12315,European,257841.0,30038396.0,Lee JJ,Other measurement,initial,2018-07-23,GCST006572,Cognitive performance
12660,European,564698.0,30038396.0,Lee JJ,Biological process,initial,2018-07-23,GCST006573,Self-reported math ability
12707,European,1131881.0,30038396.0,Lee JJ,Other measurement,initial,2018-07-23,GCST006442,Educational attainment (years of education)
12556,European,402382.0,30038396.0,Lee JJ,Other measurement,initial,2018-07-23,GCST006570,Cognitive performance (MTAG)
12678,European,670471.0,30038396.0,Lee JJ,Biological process,initial,2018-07-23,GCST006569,Self-reported math ability (MTAG)
12706,European,1131438.0,30038396.0,Lee JJ,Other measurement,initial,2018-07-23,GCST006571,Educational attainment (MTAG)
12580,European,430445.0,30038396.0,Lee JJ,Biological process,initial,2018-07-23,GCST006574,Highest math class taken
11721,European,92340.0,30046033.0,van Setten J,Cardiovascular measurement,initial,2018-07-25,GCST007045,PR interval
12551,European,394929.0,30048462.0,Kim SK,Other measurement,initial,2018-07-26,GCST006433,Heel bone mineral density
9473,European,8372.0,30049742.0,Terzikhan N,Other measurement,initial,2018-07-26,GCST006473,Diffusing capacity of the lung for carbon monoxide traits
11965,European,137086.0,30054594.0,MacGregor S,Neurological disorder,initial,2018-07-27,GCST006395,Glaucoma
5516,European,559.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006349,Anti-Toxoplasma gondii IgG levels
4736,European,91.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006345,Anti-Epstein-Barr virus early antigen (EA) IgG levels
3403,Asian,3650.0,30054458.0,Xue A,Metabolic disorder,initial,2018-07-27,GCST006867,Type 2 diabetes
2110,Asian,434.0,30054556.0,Akiyama M,"Neurological disorder, Response to drug",initial,2018-07-27,GCST006277,Response to ranibizumab in age-related macular degeneration (exudative)
4638,European,15.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006355,Anti-hepatitis B virus core antigen (HBc) IgG levels
5632,European,645.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006346,Anti-herpes simplex virus 1 IgG levels
2020,Asian,344.0,30060048.0,Wang SC,"Neurological disorder, Other measurement",initial,2018-07-27,GCST006856,Methadone dose in opioid dependence
4846,European,175.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006363,Anti-Helicobacter pylori IgG levels
5427,European,508.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006354,Anti-hepatitis B virus surface antigen (HBs) IgG levels
12620,European,455607.0,30054458.0,Xue A,Metabolic disorder,initial,2018-07-27,GCST006868,Type 2 diabetes
6174,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006332,Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG seropositivity
5822,European,777.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006350,Anti-influenza A virus IgG levels
6172,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006330,Anti-Epstein-Barr virus early antigen (EA) IgG seropositivity
4921,European,208.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006347,Anti-herpes simplex virus 2 IgG levels
6184,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006342,Anti-rubella virus IgG seropositivity
6185,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006343,Anti-hepatitis B virus core antigen (HBc) IgG seropositivity
5980,European,885.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006351,Anti-measles virus IgG levels
6186,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006356,Anti-hepatitis B virus surface antigen (HBs) IgG seropositivity
6009,European,912.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006352,Anti-mumps virus IgG levels
6053,European,935.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006353,Anti-rubella virus IgG levels
6187,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006357,IgG levels
6188,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006358,IgE levels
6189,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006359,IgM levels
6190,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006360,IgA levels
6011,European,914.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006361,Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG levels
5120,European,347.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006344,Anti-cytomegalovirus IgG levels
6091,European,956.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006362,Anti-Epstein-Barr virus viral capsid antigen (VCA) IgG levels
2174,Asian,485.0,30054556.0,Akiyama M,"Neurological disorder, Response to drug",replication,2018-07-27,GCST006277,Response to ranibizumab in age-related macular degeneration (exudative)
11939,European,133492.0,30054594.0,MacGregor S,Other measurement,initial,2018-07-27,GCST006394,Intraocular pressure
6183,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006341,Anti-mumps virus IgG seropositivity
6182,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006340,Anti-measles virus IgG seropositivity
6039,European,931.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006348,Anti-varicella zoster virus IgG levels
6175,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006333,Anti-Epstein-Barr virus viral capsid antigen (VCA) IgG seropositivity
6173,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006331,Anti-cytomegalovirus IgG seropositivity
6176,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006334,Anti-herpes simplex virus 1 IgG seropositivity
6177,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006335,Anti-herpes simplex virus 2 IgG seropositivity
6181,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006339,Anti-influenza A virus IgG seropositivity
6180,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006338,Anti-Toxoplasma gondii IgG seropositivity
12675,European,655666.0,30054458.0,Xue A,Metabolic disorder,initial,2018-07-27,GCST006867,Type 2 diabetes
6179,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006337,Anti-Helicobacter pylori IgG seropositivity
6178,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006336,Anti-varicella zoster virus IgG seropositivity
322,African,8429.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006481,Lung function (FEV1)
12703,European,1030836.0,30061737.0,Nielsen JB,Cardiovascular disease,initial,2018-07-30,GCST006414,Atrial fibrillation
4083,Asian,9959.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006481,Lung function (FEV1)
13453,Hispanic or Latin American,11775.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006481,Lung function (FEV1)
4085,Asian,9959.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006483,Lung function (FVC)
13454,Hispanic or Latin American,11775.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006482,Lung function (FEV1/FVC)
13455,Hispanic or Latin American,11775.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006483,Lung function (FVC)
324,African,8429.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006483,Lung function (FVC)
11407,European,60552.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006483,Lung function (FVC)
11406,European,60552.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006482,Lung function (FEV1/FVC)
11405,European,60552.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006481,Lung function (FEV1)
323,African,8429.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006482,Lung function (FEV1/FVC)
4084,Asian,9959.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006482,Lung function (FEV1/FVC)
5401,European,497.0,30066433.0,Jabbari E,Neurological disorder,initial,2018-07-31,GCST006276,Non-Richardson's syndrome vs Richardson's syndrome in progressive supranuclear palsy
6779,European,1645.0,30068317.0,Li X,"Other measurement, Biological process",initial,2018-08-01,GCST006309,Post bronchodilator percent predicted FEV1 in smoking
6780,European,1645.0,30068317.0,Li X,"Other measurement, Biological process",initial,2018-08-01,GCST006310,Post bronchodilator FEV1/FVC ratio in smoking
4945,European,225.0,30098192.0,Shaaban S,Neurological disorder,replication,2018-08-01,GCST008739,Amblyopia
7416,European,2467.0,30098192.0,Shaaban S,Other trait,replication,2018-08-01,GCST008737,Esotropia
7106,European,2061.0,30098192.0,Shaaban S,"Other trait, Neurological disorder",initial,2018-08-01,GCST008740,Hyperopia
6117,European,973.0,30098192.0,Shaaban S,Neurological disorder,initial,2018-08-01,GCST008738,Accommodative esotropia
2128,Asian,447.0,30067105.0,Chang LC,"Response to drug, Immune system disorder",initial,2018-08-01,GCST006278,Adverse response to antithyroid drugs in Graves disease
8707,European,5293.0,30369316.0,Low-Kam C,Lipid or lipoprotein measurement,initial,2018-08-01,GCST007117,Cholesterol efflux capacity (BHK stimulated assay)
5084,European,330.0,30098192.0,Shaaban S,Neurological disorder,replication,2018-08-01,GCST008738,Accommodative esotropia
8706,European,5293.0,30369316.0,Low-Kam C,Lipid or lipoprotein measurement,initial,2018-08-01,GCST007116,Cholesterol efflux capacity (ABCA-1 dependent assay)
8705,European,5293.0,30369316.0,Low-Kam C,Lipid or lipoprotein measurement,initial,2018-08-01,GCST007115,Cholesterol efflux capacity (cAMP stimulated assay)
8704,European,5293.0,30369316.0,Low-Kam C,Lipid or lipoprotein measurement,initial,2018-08-01,GCST007114,Cholesterol efflux capacity
7272,European,2270.0,30067744.0,Howe LJ,Other trait,initial,2018-08-01,GCST006415,Nonsyndromic cleft lip with or without cleft palate
5949,European,862.0,30098192.0,Shaaban S,"Other trait, Neurological disorder",replication,2018-08-01,GCST008740,Hyperopia
8919,European,6136.0,30067744.0,Howe LJ,Other measurement,initial,2018-08-01,GCST006407,Philtrum width
1836,Asian,182.0,30067105.0,Chang LC,"Response to drug, Immune system disorder",replication,2018-08-01,GCST006278,Adverse response to antithyroid drugs in Graves disease
8484,European,4790.0,30098192.0,Shaaban S,Other trait,initial,2018-08-01,GCST008737,Esotropia
7154,European,2137.0,30098192.0,Shaaban S,Neurological disorder,replication,2018-08-01,GCST008741,Non-accommodative esotropia
7125,European,2086.0,30098192.0,Shaaban S,Neurological disorder,initial,2018-08-01,GCST008739,Amblyopia
8145,European,3817.0,30098192.0,Shaaban S,Neurological disorder,initial,2018-08-01,GCST008741,Non-accommodative esotropia
7781,European,3126.0,30070759.0,Olsson M,Other measurement,initial,2018-08-02,GCST006417,Plasma factor VII activating protease levels
10438,European,18770.0,30071075.0,Jiang L,Other measurement,initial,2018-08-02,GCST006402,Energy intake
7814,European,3200.0,30072576.0,Emilsson V,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",initial,2018-08-02,GCST006585,Blood protein levels
10439,European,18770.0,30071075.0,Jiang L,Other measurement,initial,2018-08-02,GCST006403,Energy expenditure
8257,European,4098.0,30073298.0,Schellevis RL,Neurological disorder,initial,2018-08-02,GCST006416,Chronic central serous retinopathy
5900,European,830.0,30196823.0,Blum S,Immune system disorder,initial,2018-08-02,GCST006836,Guillain-Barr syndrome
12764,Hispanic or Latin American,77.0,30092369.0,Mainali B,Other disease,initial,2018-08-06,GCST008308,Infection persistence (>18 months) in genital human papillomavirus 16 infection
4732,European,90.0,30092369.0,Mainali B,Other disease,initial,2018-08-06,GCST008308,Infection persistence (>18 months) in genital human papillomavirus 16 infection
429,African American or Afro-Caribbean,24.0,30092369.0,Mainali B,Other disease,initial,2018-08-06,GCST008308,Infection persistence (>18 months) in genital human papillomavirus 16 infection
3592,Asian,5081.0,30099483.0,Hwangbo Y,Other disease,replication,2018-08-06,GCST006387,Thyroid nodules
2712,Asian,1502.0,30099483.0,Hwangbo Y,Other disease,initial,2018-08-06,GCST006387,Thyroid nodules
4756,European,98.0,30087447.0,Aubart M,"Neurological disorder, Cardiovascular disease",initial,2018-08-07,GCST006957,Severe aortic features in Marfan syndrome
10710,European,24196.0,30087453.0,Yilmaz Z,"Neurological disorder, Metabolic disorder",initial,2018-08-07,GCST006576,Anorexia nervosa or obsessive-compulsive disorder
9988,European,12308.0,30089514.0,Chen JA,Neurological disorder,initial,2018-08-08,GCST006418,Progressive supranuclear palsy
11886,European,121885.0,30093612.0,O'Mara TA,Cancer,initial,2018-08-09,GCST006464,Endometrial cancer
11346,European,54884.0,30093612.0,O'Mara TA,Cancer,initial,2018-08-09,GCST006465,Endometrial cancer (endometrioid histology)
11041,European,36677.0,30093612.0,O'Mara TA,Cancer,initial,2018-08-09,GCST006466,Endometrial cancer (Non-endometrioid histology)
7122,European,2079.0,30093639.0,Machiela MJ,Cancer,initial,2018-08-09,GCST006467,Ewing sarcoma
8466,European,4735.0,30093639.0,Machiela MJ,Cancer,replication,2018-08-09,GCST006467,Ewing sarcoma
4252,Asian,13980.0,30102679.0,Hara M,Biological process,initial,2018-08-10,GCST006858,Leisure-time exercise behaviour (age-stratified)
3009,Asian,2036.0,30102679.0,Hara M,Biological process,initial,2018-08-10,GCST006858,Leisure-time exercise behaviour (age-stratified)
3008,Asian,2036.0,30102679.0,Hara M,Biological process,initial,2018-08-10,GCST006857,Leisure-time exercise behaviour
4251,Asian,13980.0,30102679.0,Hara M,Biological process,initial,2018-08-10,GCST006857,Leisure-time exercise behaviour
12564,European,408458.0,30104761.0,Zhou W,Cardiovascular disease,initial,2018-08-13,GCST008370,Coronary artery disease
5293,European,444.0,30103242.0,Karhausen JA,Other trait,initial,2018-08-13,GCST006435,Thrombocytopenia in coronary artery bypass surgery
12555,European,402223.0,30104761.0,Zhou W,Neurological disorder,initial,2018-08-13,GCST008373,Glaucoma
5806,European,759.0,30104601.0,Ren H,"Other measurement, Neurological disorder",initial,2018-08-13,GCST006927,Anhedonia in major depressive disorder
9795,European,10473.0,30104567.0,Ji X,Cancer,initial,2018-08-13,GCST006399,Lung cancer
10917,European,32465.0,30104567.0,Ji X,Cancer,replication,2018-08-13,GCST006399,Lung cancer
12562,European,407757.0,30104761.0,Zhou W,Cancer,initial,2018-08-13,GCST008371,Thyroid cancer
7105,European,2059.0,30102696.0,Chen Y,Digestive system disorder,initial,2018-08-13,GCST006390,Biliary atresia
9794,European,10473.0,30104567.0,Ji X,Cancer,initial,2018-08-13,GCST006398,Lung cancer (SNP x SNP interaction)
10758,European,26271.0,30104567.0,Ji X,"Other measurement, Cancer",replication,2018-08-13,GCST006400,Lung cancer in ever smokers
5148,European,368.0,30102696.0,Chen Y,Digestive system disorder,replication,2018-08-13,GCST006390,Biliary atresia
4823,European,164.0,30103242.0,Karhausen JA,Other trait,initial,2018-08-13,GCST006435,Thrombocytopenia in coronary artery bypass surgery
9531,European,8669.0,30104567.0,Ji X,"Other measurement, Cancer",initial,2018-08-13,GCST006400,Lung cancer in ever smokers
12540,European,387318.0,30104761.0,Zhou W,Cancer,initial,2018-08-13,GCST008372,Colorectal cancer
3859,Asian,7290.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",initial,2018-08-14,GCST006368,Body mass index
14060,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Body measurement,initial,2018-08-14,GCST007058,Hip circumference
14106,Other/Mixed,1353.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,initial,2018-08-14,GCST006436,Triglyceride levels
14107,Other/Mixed,1353.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,initial,2018-08-14,GCST006437,Low density lipoprotein cholesterol levels
2895,Asian,1822.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",replication,2018-08-14,GCST006368,Body mass index
12415,European,315347.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",initial,2018-08-14,GCST006368,Body mass index
14079,Other/Mixed,1176.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,replication,2018-08-14,GCST006436,Triglyceride levels
5085,European,330.0,30108209.0,Ganjgahi H,Other measurement,initial,2018-08-14,GCST006389,Brain imaging measurements
14108,Other/Mixed,1353.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,initial,2018-08-14,GCST006438,High density lipoprotein cholesterol levels
14082,Other/Mixed,1176.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,replication,2018-08-14,GCST006439,Total cholesterol levels
14081,Other/Mixed,1176.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,replication,2018-08-14,GCST006438,High density lipoprotein cholesterol levels
14064,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,"Other measurement, Body measurement",initial,2018-08-14,GCST007056,Waist-hip ratio
14061,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,"Body measurement, Other measurement",initial,2018-08-14,GCST007053,Body mass index
321,African,8261.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",replication,2018-08-14,GCST006368,Body mass index
14062,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Cardiovascular measurement,initial,2018-08-14,GCST007051,Pulse rate
4056,Asian,9275.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",replication,2018-08-14,GCST006368,Body mass index
12581,European,431743.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",replication,2018-08-14,GCST006368,Body mass index
11515,European,71500.0,30120083.0,Ferguson A,Biological process,initial,2018-08-14,GCST006396,Disrupted circadian rhythm (low relative amplitude of rest-activity cycles)
14109,Other/Mixed,1353.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,initial,2018-08-14,GCST006439,Total cholesterol levels
14063,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Lipid or lipoprotein measurement,initial,2018-08-14,GCST007052,Lipoprotein (a) levels
14059,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Body measurement,initial,2018-08-14,GCST007055,Waist circumference
2138,Asian,459.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",initial,2018-08-14,GCST006368,Body mass index
14058,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Body measurement,initial,2018-08-14,GCST007054,Weight
13400,Hispanic or Latin American,8322.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",initial,2018-08-14,GCST006368,Body mass index
1134,African American or Afro-Caribbean,3069.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",initial,2018-08-14,GCST006368,Body mass index
14080,Other/Mixed,1176.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,replication,2018-08-14,GCST006437,Low density lipoprotein cholesterol levels
11562,European,77440.0,30120083.0,Ferguson A,Biological process,initial,2018-08-14,GCST006397,Relative amplitude of rest-activity cycles
14065,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,"Other measurement, Body measurement",initial,2018-08-14,GCST007057,Height
9087,European,6861.0,30111768.0,Yao C,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",initial,2018-08-15,GCST007128,Blood protein levels
8326,European,4298.0,30111768.0,Yao C,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",replication,2018-08-15,GCST007128,Blood protein levels
13780,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006501,Nasal root breadth
2725,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006509,Side of face morphology (principal component model)
13789,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006510,Cheek morphology (principal component model)
13776,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006497,Nose wing breadth
13777,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006498,Brow ridge morphology (principal component model)
2726,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006510,Cheek morphology (principal component model)
2724,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006508,Eye morphology (principal component model)
13792,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006513,Brow ridge morphology (partial least square model)
13778,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006499,Nose length
2727,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006511,Nose morphology (principal component model)
2730,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006514,Eye morphology (partial least square model)
13796,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006517,Nose morphology (partial least square model)
13794,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006515,Side of face morphology (partial least square model)
2728,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006512,Mouth morphology (principal component model)
13793,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006514,Eye morphology (partial least square model)
13779,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006500,Nosetip height
2729,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006513,Brow ridge morphology (partial least square model)
13992,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006503,Eye length
11271,European,50264.0,30116032.0,Erlangsen A,Biological process,initial,2018-08-16,GCST006419,Suicide attempts
13995,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006506,Lip thickness
14006,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006517,Nose morphology (partial least square model)
13986,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006497,Nose wing breadth
10370,European,17596.0,30116032.0,Erlangsen A,"Biological process, Neurological disorder",initial,2018-08-16,GCST006420,Affective disorder and suicide attempts
13989,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006500,Nosetip height
13987,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006498,Brow ridge morphology (principal component model)
13991,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006502,Nasal root height
12753,Hispanic or Latin American,42.0,30113228.0,Torgerson DG,"Other disease, Other trait",initial,2018-08-16,GCST006460,Bronchopulmonary dysplasia in preterm infants
13996,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006507,Lower face length
13997,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006508,Eye morphology (principal component model)
13791,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006512,Mouth morphology (principal component model)
13790,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006511,Nose morphology (principal component model)
4851,European,177.0,30113228.0,Torgerson DG,"Other disease, Other trait",initial,2018-08-16,GCST006460,Bronchopulmonary dysplasia in preterm infants
2723,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006507,Lower face length
2713,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006497,Nose wing breadth
2714,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006498,Brow ridge morphology (principal component model)
2715,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006499,Nose length
2716,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006500,Nosetip height
14007,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006518,Mouth morphology (partial least square model)
13988,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006499,Nose length
2717,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006501,Nasal root breadth
2718,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006502,Nasal root height
2719,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006503,Eye length
13797,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006518,Mouth morphology (partial least square model)
13994,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006505,Labial fissure length
2720,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006504,Interorbital distance
2721,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006505,Labial fissure length
2722,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006506,Lip thickness
13999,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006510,Cheek morphology (principal component model)
14003,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006514,Eye morphology (partial least square model)
13795,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006516,Cheek morphology (partial least square model)
12622,European,456426.0,30124842.0,Yengo L,"Body measurement, Other measurement",initial,2018-08-16,GCST006900,Body mass index
13998,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006509,Side of face morphology (principal component model)
14001,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006512,Mouth morphology (principal component model)
13787,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006508,Eye morphology (principal component model)
14002,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006513,Brow ridge morphology (partial least square model)
13786,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006507,Lower face length
13788,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006509,Side of face morphology (principal component model)
13990,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006501,Nasal root breadth
14004,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006515,Side of face morphology (partial least square model)
14000,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006511,Nose morphology (principal component model)
13784,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006505,Labial fissure length
13783,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006504,Interorbital distance
13782,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006503,Eye length
517,African American or Afro-Caribbean,133.0,30113228.0,Torgerson DG,"Other disease, Other trait",initial,2018-08-16,GCST006460,Bronchopulmonary dysplasia in preterm infants
13993,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006504,Interorbital distance
13785,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006506,Lip thickness
2731,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006515,Side of face morphology (partial least square model)
2732,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006516,Cheek morphology (partial least square model)
12623,European,456426.0,30124842.0,Yengo L,"Other measurement, Body measurement",initial,2018-08-16,GCST006901,Height
13781,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006502,Nasal root height
2734,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006518,Mouth morphology (partial least square model)
2733,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006517,Nose morphology (partial least square model)
14005,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006516,Cheek morphology (partial least square model)
1901,Asian,226.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006449,Eye movement (integrated eye movement score)
1679,Asian,60.0,30120336.0,Kikuchi M,"Neurological disorder, Other measurement",initial,2018-08-17,GCST006459,Eye movement in schizophrenia (scanpath length)
1903,Asian,226.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006455,Eye movement (scanpath length)
1816,Asian,166.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006453,Eye movement (duration of fixations)
1678,Asian,60.0,30120336.0,Kikuchi M,"Neurological disorder, Other measurement",initial,2018-08-17,GCST006454,Eye movement in schizophrenia (duration of fixations)
1677,Asian,60.0,30120336.0,Kikuchi M,"Neurological disorder, Other measurement",initial,2018-08-17,GCST006451,Eye movement in schizophrenia (integrated eye movement score)
1676,Asian,60.0,30120336.0,Kikuchi M,"Neurological disorder, Other measurement",initial,2018-08-17,GCST006448,Eye movement in schizophrenia (horizontal position gain)
4688,European,70.0,30120429.0,Schlauch KA,Metabolic disorder,initial,2018-08-17,GCST006492,Obesity without metabolic disease
1815,Asian,166.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006450,Eye movement (integrated eye movement score)
1902,Asian,226.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006452,Eye movement (duration of fixations)
2185,Asian,502.0,30120420.0,Sun R,Other measurement,initial,2018-08-17,GCST006441,Mental composite score
2184,Asian,502.0,30120420.0,Sun R,Other measurement,initial,2018-08-17,GCST006440,Motor composite score
12882,Hispanic or Latin American,462.0,30120420.0,Sun R,Other measurement,initial,2018-08-17,GCST006441,Mental composite score
12881,Hispanic or Latin American,462.0,30120420.0,Sun R,Other measurement,initial,2018-08-17,GCST006440,Motor composite score
1817,Asian,166.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006456,Eye movement (scanpath length)
1818,Asian,166.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006458,Eye movement (horizontal position gain)
1904,Asian,226.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006457,Eye movement (horizontal position gain)
13747,Other/Mixed,92.0,30130595.0,Dominguez-Cruz MG,Metabolic disorder,initial,2018-08-18,GCST006484,Type 2 diabetes
14036,Other/Mixed,790.0,30134952.0,Traglia M,Other measurement,initial,2018-08-22,GCST006625,Neonatal cytokine/chemokine levels (maternal genetic effect)
14037,Other/Mixed,790.0,30134952.0,Traglia M,"Other measurement, Inflammatory measurement",initial,2018-08-22,GCST006621,Midgestational cytokine/chemokine levels (maternal genetic effect)
14032,Other/Mixed,764.0,30134952.0,Traglia M,"Other measurement, Inflammatory measurement",initial,2018-08-22,GCST006622,Neonatal cytokine/chemokine levels (fetal genetic effect)
14031,Other/Mixed,764.0,30134952.0,Traglia M,Other measurement,initial,2018-08-22,GCST006623,Midgestational cytokine/chemokine levels (fetal genetic effect)
3050,Asian,2148.0,30132804.0,Kim M,Lipid or lipoprotein measurement,initial,2018-08-22,GCST006860,Low HDL-cholesterol levels
3515,Asian,4477.0,30294719.0,Zeng Y,Other measurement,initial,2018-08-24,GCST006658,Longevity
12164,European,184756.0,30150663.0,Pasman JA,Biological process,initial,2018-08-27,GCST006421,Cannabis use
2105,Asian,424.0,30169657.0,Ashar FN,Cardiovascular disease,replication,2018-08-28,GCST006401,Sudden cardiac arrest
10851,European,29928.0,30169657.0,Ashar FN,Cardiovascular disease,initial,2018-08-28,GCST006401,Sudden cardiac arrest
7792,European,3146.0,30153862.0,Maxwell TJ,Other measurement,initial,2018-08-28,GCST007130,Cerebrospinal fluid t-tau:AB1-42 ratio
7791,European,3146.0,30153862.0,Maxwell TJ,Other measurement,initial,2018-08-28,GCST007129,Cerebrospinal fluid t-tau:AB1-42 ratio
636,African American or Afro-Caribbean,328.0,30169657.0,Ashar FN,Cardiovascular disease,replication,2018-08-28,GCST006401,Sudden cardiac arrest
14279,Other/Mixed,40333.0,30169657.0,Ashar FN,Cardiovascular disease,replication,2018-08-28,GCST006401,Sudden cardiac arrest
3620,Asian,5281.0,30158200.0,Trajanoska K,Other disease,replication,2018-08-29,GCST006422,Fractures
2395,Asian,800.0,30158200.0,Trajanoska K,Other disease,initial,2018-08-29,GCST006422,Fractures
12321,European,264173.0,30158200.0,Trajanoska K,Other disease,initial,2018-08-29,GCST006422,Fractures
2396,Asian,800.0,30158200.0,Trajanoska K,Other disease,initial,2018-08-29,GCST006423,Fractures
12376,European,297285.0,30158200.0,Trajanoska K,Other disease,replication,2018-08-29,GCST006423,Fractures
14120,Other/Mixed,1468.0,30158200.0,Trajanoska K,Other disease,replication,2018-08-29,GCST006422,Fractures
11190,European,44108.0,30158200.0,Trajanoska K,Other disease,replication,2018-08-29,GCST006422,Fractures
12322,European,264173.0,30158200.0,Trajanoska K,Other disease,initial,2018-08-29,GCST006423,Fractures
1966,Asian,275.0,30161160.0,Onishi H,"Other measurement, Cancer, Response to drug",initial,2018-08-30,GCST006615,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer
7285,European,2286.0,30172743.0,Liang X,Other measurement,initial,2018-08-30,GCST006444,Bone mineral density (hip)
7284,European,2286.0,30172743.0,Liang X,Other measurement,initial,2018-08-30,GCST006443,Total body bone mineral density
7287,European,2286.0,30172743.0,Liang X,Other measurement,initial,2018-08-30,GCST006446,Ulna and radius bone mineral density
12452,European,336107.0,30166351.0,Galvan-Femenia I,Other measurement,replication,2018-08-30,GCST007490,Anthropometric traits (multi-trait analysis)
7286,European,2286.0,30172743.0,Liang X,Other measurement,initial,2018-08-30,GCST006445,Femoral neck bone mineral density
7288,European,2286.0,30172743.0,Liang X,Other measurement,initial,2018-08-30,GCST006447,Bone mineral density (spine)
4975,European,243.0,30160337.0,Asleh R,"Other measurement, Biological process",initial,2018-08-30,GCST006496,Glomerular filtration rate change in heart transplantation
12453,European,336107.0,30166351.0,Galvan-Femenia I,"Other measurement, Body measurement",replication,2018-08-30,GCST007485,Anthropometric traits
8585,European,4988.0,30166351.0,Galvan-Femenia I,Other measurement,initial,2018-08-30,GCST007486,Hair morphology traits
8586,European,4988.0,30166351.0,Galvan-Femenia I,Other measurement,initial,2018-08-30,GCST007490,Anthropometric traits (multi-trait analysis)
8591,European,4988.0,30166351.0,Galvan-Femenia I,Other trait,initial,2018-08-30,GCST007489,Eye color traits
13597,Other/Mixed,1.0,30160337.0,Asleh R,"Other measurement, Biological process",initial,2018-08-30,GCST006496,Glomerular filtration rate change in heart transplantation
12235,European,212444.0,30172742.0,Hu Y,"Other measurement, Metabolic disorder",initial,2018-08-30,GCST006861,Femoral neck bone mineral density or type 2 diabetes (pleiotropy)
8590,European,4988.0,30166351.0,Galvan-Femenia I,Other trait,initial,2018-08-30,GCST007488,Skin pigmentation traits
8589,European,4988.0,30166351.0,Galvan-Femenia I,Other trait,initial,2018-08-30,GCST007482,Handedness
8588,European,4988.0,30166351.0,Galvan-Femenia I,Other trait,initial,2018-08-30,GCST007480,Disorders of lipid metabolism
1685,Asian,72.0,30161160.0,Onishi H,"Other measurement, Cancer, Response to drug",replication,2018-08-30,GCST006615,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer
8584,European,4988.0,30166351.0,Galvan-Femenia I,Cardiovascular measurement,initial,2018-08-30,GCST007481,Heart rate
8587,European,4988.0,30166351.0,Galvan-Femenia I,"Other measurement, Body measurement",initial,2018-08-30,GCST007485,Anthropometric traits
6714,European,1569.0,30166627.0,Massey J,"Immune system disorder, Response to drug, Other measurement",initial,2018-08-31,GCST006610,Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score)
2471,Asian,945.0,30169916.0,Sun Y,Immune system disorder,initial,2018-08-31,GCST006521,Pemphigus vulgaris
2530,Asian,1052.0,30169916.0,Sun Y,Immune system disorder,replication,2018-08-31,GCST006521,Pemphigus vulgaris
2525,Asian,1045.0,30169916.0,Sun Y,Immune system disorder,replication,2018-08-31,GCST006520,Pemphigus foliaceus
2453,Asian,909.0,30169916.0,Sun Y,Immune system disorder,initial,2018-08-31,GCST006520,Pemphigus foliaceus
6824,European,1709.0,30166627.0,Massey J,"Other trait, Immune system disorder, Response to drug",initial,2018-08-31,GCST006608,Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score)
6844,European,1723.0,30166627.0,Massey J,"Immune system disorder, Response to drug, Other measurement",initial,2018-08-31,GCST006609,Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)
6645,European,1514.0,30166627.0,Massey J,"Inflammatory measurement, Immune system disorder, Response to drug",initial,2018-08-31,GCST006607,Response to TNF inhibitor in rheumatoid arthritis (erythrocyte sedimentation rate)
6843,European,1723.0,30166627.0,Massey J,"Immune system disorder, Response to drug, Other measurement",initial,2018-08-31,GCST006606,Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)
14102,Other/Mixed,1301.0,30196971.0,Bray MJ,Other measurement,initial,2018-09-01,GCST006618,Uterine fibroid size (maximum dimension)
1846,Asian,190.0,30088374.0,Park HW,Other disease,replication,2018-09-01,GCST008492,Severe cutaneous adverse drug reactions
2019,Asian,340.0,30088374.0,Park HW,Other disease,initial,2018-09-01,GCST008492,Severe cutaneous adverse drug reactions
6291,European,1102.0,29593015.0,Montasser ME,Lipid or lipoprotein measurement,initial,2018-09-01,GCST008990,Low density lipoprotein cholesterol levels
5850,European,798.0,29593015.0,Montasser ME,Lipid or lipoprotein measurement,replication,2018-09-01,GCST008990,Low density lipoprotein cholesterol levels
12566,European,409728.0,30177863.0,Maguire LH,Digestive system disorder,initial,2018-09-03,GCST006479,Diverticular disease
8440,European,4666.0,30178632.0,Meng W,Metabolic disorder,initial,2018-09-04,GCST006424,Severe diabetic retinopathy in type 2 diabetes
8562,European,4941.0,30181573.0,Jing J,"Other disease, Other measurement",initial,2018-09-04,GCST006426,Serum urate levels in chronic kidney disease
11246,European,47983.0,30181555.0,Strawbridge RJ,Biological process,replication,2018-09-04,GCST006461,Self-reported risk-taking behaviour
8561,European,4941.0,30181573.0,Jing J,"Other disease, Metabolic disorder",initial,2018-09-04,GCST006425,Gout in chronic kidney disease
12441,European,328339.0,30181555.0,Strawbridge RJ,Biological process,initial,2018-09-04,GCST006461,Self-reported risk-taking behaviour
3845,Asian,7031.0,30181555.0,Strawbridge RJ,Biological process,replication,2018-09-04,GCST006461,Self-reported risk-taking behaviour
1347,African American or Afro-Caribbean,7480.0,30181555.0,Strawbridge RJ,Biological process,replication,2018-09-04,GCST006461,Self-reported risk-taking behaviour
711,African American or Afro-Caribbean,492.0,30185882.0,Zeiger AM,Other measurement,initial,2018-09-05,GCST006485,Telomere length
12535,European,382500.0,30220432.0,Haas ME,Other trait,initial,2018-09-06,GCST006586,Urinary albumin excretion
12396,European,302687.0,30220432.0,Haas ME,Other trait,initial,2018-09-06,GCST006463,Urinary albumin excretion (no hypertensive medication)
11197,European,44871.0,30202859.0,Laisk T,Other measurement,initial,2018-09-07,GCST006958,Length of menstrual cycle
9013,European,6576.0,30219690.0,Heinzman JT,"Biological process, Neurological disorder",initial,2018-09-07,GCST006427,Depression in smokers
12655,European,539925.0,30194396.0,Rafnar T,Cancer,initial,2018-09-07,GCST006462,Uterine fibroids
10795,European,27750.0,30194254.0,Sud A,Cancer,initial,2018-09-07,GCST007062,Hodgkin's lymphoma
1145,African American or Afro-Caribbean,3140.0,30219690.0,Heinzman JT,"Biological process, Neurological disorder",initial,2018-09-07,GCST006427,Depression in smokers
12067,European,156028.0,30270018.0,Zhang Q,"Cardiovascular disease, Metabolic disorder",initial,2018-09-09,GCST007359,Type 2 diabetes or coronary artery disease (pleiotropy)
5307,European,454.0,30201983.0,Tulstrup M,"Response to drug, Cancer, Other measurement",initial,2018-09-10,GCST007149,Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
4789,European,136.0,30201983.0,Tulstrup M,"Response to drug, Cancer, Other measurement",replication,2018-09-10,GCST007151,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia
122,African,546.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008100,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
123,African,546.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008101,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
124,African,546.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008102,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
9887,European,11165.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008102,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
6671,European,1533.0,30202041.0,Otani T,"Cardiovascular disease, Biological process, Cardiovascular measurement",initial,2018-09-10,GCST007366,Homocysteine level response to multivitamin in cerebral infarction
138,African,797.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008099,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
139,African,797.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008100,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
140,African,797.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008101,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
141,African,797.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008102,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
5304,European,452.0,30201983.0,Tulstrup M,"Response to drug, Cancer, Other measurement",initial,2018-09-10,GCST007148,Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
6315,European,1141.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008102,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
6313,European,1141.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008100,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
121,African,546.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008099,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
9885,European,11165.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008100,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
9886,European,11165.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008101,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
9884,European,11165.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008099,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
5291,European,443.0,30201983.0,Tulstrup M,"Response to drug, Cancer, Other measurement",initial,2018-09-10,GCST007150,DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia
5292,European,443.0,30201983.0,Tulstrup M,"Response to drug, Cancer, Other measurement",initial,2018-09-10,GCST007151,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia
6314,European,1141.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008101,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
6312,European,1141.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008099,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
8538,European,4910.0,30206230.0,Offenbacher S,Inflammatory measurement,initial,2018-09-11,GCST007542,High IL-1beta levels in gingival crevicular fluid
816,African American or Afro-Caribbean,949.0,30206298.0,Spear ML,"Response to drug, Other disease",initial,2018-09-12,GCST007360,Bronchodilator response in asthma
13096,Hispanic or Latin American,1830.0,30206298.0,Spear ML,"Response to drug, Other disease",initial,2018-09-12,GCST007360,Bronchodilator response in asthma
949,African American or Afro-Caribbean,1615.0,30206298.0,Spear ML,"Response to drug, Other disease",replication,2018-09-12,GCST007360,Bronchodilator response in asthma
12859,Hispanic or Latin American,416.0,30206298.0,Spear ML,"Response to drug, Other disease",replication,2018-09-12,GCST007360,Bronchodilator response in asthma
12300,European,249665.0,30213928.0,Went M,Cancer,initial,2018-09-13,GCST006432,Multiple myeloma
4311,Asian,16543.0,30219835.0,Lin WY,Other measurement,initial,2018-09-13,GCST007617,Blood pressure x alcohol consumption interaction
4310,Asian,16533.0,30219835.0,Lin WY,"Biological process, Other measurement",initial,2018-09-13,GCST007618,Blood pressure (smoking interaction)
9303,European,7865.0,30213928.0,Went M,Cancer,replication,2018-09-13,GCST006432,Multiple myeloma
12583,European,434794.0,30239722.0,Pulit SL,"Body measurement, Other measurement",initial,2018-09-14,GCST009003,Body mass index
8158,European,3844.0,30217971.0,Ho KWD,"Neurological disorder, Other measurement",initial,2018-09-14,GCST007101,Seasonality in depression
12682,European,697734.0,30239722.0,Pulit SL,"Other measurement, Body measurement",initial,2018-09-14,GCST008996,Waist-hip ratio
9284,European,7721.0,30239722.0,Pulit SL,Body measurement,replication,2018-09-14,GCST008999,Waist-to-hip ratio adjusted for BMI
12680,European,694649.0,30239722.0,Pulit SL,Body measurement,initial,2018-09-14,GCST008999,Waist-to-hip ratio adjusted for BMI
10010,European,12591.0,30218097.0,Munz M,Digestive system disorder,initial,2018-09-14,GCST006486,Periodontitis
12694,European,806834.0,30239722.0,Pulit SL,"Body measurement, Other measurement",initial,2018-09-14,GCST009004,Body mass index
7380,European,2412.0,30218097.0,Munz M,Digestive system disorder,replication,2018-09-14,GCST006486,Periodontitis
8332,European,4317.0,30217971.0,Ho KWD,"Neurological disorder, Other measurement",initial,2018-09-14,GCST007102,Seasonality and depression
12523,European,374756.0,30239722.0,Pulit SL,"Body measurement, Other measurement",initial,2018-09-14,GCST009001,Body mass index
12414,European,315284.0,30239722.0,Pulit SL,Body measurement,initial,2018-09-14,GCST008995,Waist-to-hip ratio adjusted for BMI
12419,European,316772.0,30239722.0,Pulit SL,"Other measurement, Body measurement",initial,2018-09-14,GCST008998,Waist-hip ratio
12532,European,379501.0,30239722.0,Pulit SL,Body measurement,initial,2018-09-14,GCST008994,Waist-to-hip ratio adjusted for BMI
10305,European,16624.0,30217807.0,Robinson-Cohen C,Other measurement,initial,2018-09-14,GCST006491,Circulating fibroblast growth factor 23 levels
12534,European,381152.0,30239722.0,Pulit SL,"Other measurement, Body measurement",initial,2018-09-14,GCST008997,Waist-hip ratio
276,African,4443.0,30217807.0,Robinson-Cohen C,Other measurement,replication,2018-09-14,GCST006491,Circulating fibroblast growth factor 23 levels
1684,Asian,71.0,30277654.0,Yokoshima Y,"Cancer, Response to drug",initial,2018-09-14,GCST007106,Response to opioid analgesics in cancer (pain decrease)
5644,European,653.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008218,Non-muscle-invasive bladder cancer age at diagnosis (< 70 years vs  70 years)
6503,European,1323.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008221,Non-muscle-invasive bladder cancer tumour grade (G3 vs G2/G1)
6620,European,1470.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008217,Non-muscle-invasive bladder cancer age at diagnosis
6621,European,1470.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008218,Non-muscle-invasive bladder cancer age at diagnosis (< 70 years vs  70 years)
6622,European,1470.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008220,Non-muscle-invasive bladder cancer tumour stage (Tis/T1 vs Ta)
5618,European,633.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008216,Non-muscle-invasive bladder cancer tumour size
5048,European,302.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008216,Non-muscle-invasive bladder cancer tumour size
5049,European,302.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008219,Non-muscle-invasive bladder cancer tumour size (< 3 cm vs  3 cm)
5619,European,633.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008219,Non-muscle-invasive bladder cancer tumour size (< 3 cm vs  3 cm)
5646,European,653.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008222,Non-muscle-invasive bladder cancer EORTC risk category
5643,European,653.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008217,Non-muscle-invasive bladder cancer age at diagnosis
5645,European,653.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008220,Non-muscle-invasive bladder cancer tumour stage (Tis/T1 vs Ta)
5630,European,643.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008221,Non-muscle-invasive bladder cancer tumour grade (G3 vs G2/G1)
12687,European,757601.0,30224653.0,Evangelou E,Cardiovascular measurement,initial,2018-09-17,GCST006629,Pulse pressure
12688,European,757601.0,30224653.0,Evangelou E,Other measurement,initial,2018-09-17,GCST006624,Systolic blood pressure
12689,European,757601.0,30224653.0,Evangelou E,Other measurement,initial,2018-09-17,GCST006627,Diastolic blood pressure
12690,European,757601.0,30224653.0,Evangelou E,Other measurement,initial,2018-09-17,GCST006628,Systolic blood pressure
12686,European,757601.0,30224653.0,Evangelou E,Cardiovascular measurement,initial,2018-09-17,GCST006626,Pulse pressure
5884,European,823.0,30255771.0,Sarnowski C,"Response to drug, Lipid or lipoprotein measurement",initial,2018-09-17,GCST007663,Triglyceride change in response to fenofibrate treatment
12299,European,249262.0,30224653.0,Evangelou E,Other measurement,replication,2018-09-17,GCST006630,Diastolic blood pressure
12297,European,249262.0,30224653.0,Evangelou E,Cardiovascular measurement,replication,2018-09-17,GCST006629,Pulse pressure
7045,European,1999.0,30223776.0,Hwang LD,Biological process,initial,2018-09-17,GCST006703,Bitter taste perception (multivariate analysis)
7046,European,1999.0,30223776.0,Hwang LD,Biological process,initial,2018-09-17,GCST006704,Bitter taste perception
5881,European,823.0,30255771.0,Sarnowski C,Lipid or lipoprotein measurement,initial,2018-09-17,GCST007661,Triglyceride levels
5882,European,823.0,30255771.0,Sarnowski C,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-17,GCST007658,Triglyceride levels (parental genotype effect)
5886,European,823.0,30255771.0,Sarnowski C,"Response to drug, Other measurement, Lipid or lipoprotein measurement",initial,2018-09-17,GCST007660,Triglyceride levels in response to fenofibrate treatment (parental genotype effect)
5885,European,823.0,30255771.0,Sarnowski C,"Response to drug, Other measurement, Lipid or lipoprotein measurement",initial,2018-09-17,GCST007659,Triglyceride change in response to fenofibrate (parental genotype effect)
5883,European,823.0,30255771.0,Sarnowski C,"Response to drug, Lipid or lipoprotein measurement",initial,2018-09-17,GCST007662,Triglyceride levels in response to fenofibrate
12298,European,249262.0,30224653.0,Evangelou E,Other measurement,replication,2018-09-17,GCST006624,Systolic blood pressure
12691,European,757601.0,30224653.0,Evangelou E,Other measurement,initial,2018-09-17,GCST006630,Diastolic blood pressure
2333,Asian,744.0,30228239.0,Wojcik GL,Other disease,initial,2018-09-18,GCST007109,Diarrhoea-associated Entamoeba histolytica infection
5423,European,506.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007186,Timing of glucose curve peak in pregnancy (gestational week 30-32)
5402,European,497.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007183,General glucose level in pregnancy (gestational week 14-16)
10596,European,21637.0,30226466.0,Valimaki N,Cancer,replication,2018-09-18,GCST007548,Uterine fibroids
5440,European,512.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007182,Two-hour glucose in pregnancy (gestational week 30-32)
1079,African American or Afro-Caribbean,2709.0,30226466.0,Valimaki N,Cancer,replication,2018-09-18,GCST007548,Uterine fibroids
5447,European,517.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007179,Fasting glucose in pregnancy (gestational week 14-16)
5422,European,506.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007184,General glucose level in pregnancy (gestational week 30-32)
3236,Asian,2770.0,30226466.0,Valimaki N,Cancer,replication,2018-09-18,GCST007548,Uterine fibroids
5403,European,497.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007185,Timing of glucose curve peak in pregnancy (gestational week 14-16)
12577,European,424481.0,30226466.0,Valimaki N,Cancer,initial,2018-09-18,GCST007548,Uterine fibroids
201,African,1552.0,30226466.0,Valimaki N,Cancer,replication,2018-09-18,GCST007548,Uterine fibroids
5457,European,521.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007180,Fasting glucose in pregnancy (gestational week 30-32)
5421,European,506.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007181,Two-hour glucose in pregnancy (gestational week 14-16)
2322,Asian,715.0,30230522.0,Zhang S,Immune system disorder,replication,2018-09-19,GCST008068,Pemphigus vulgaris
2260,Asian,636.0,30230522.0,Zhang S,Immune system disorder,replication,2018-09-19,GCST008067,Pemphigus foliaceus
2230,Asian,573.0,30230522.0,Zhang S,Immune system disorder,initial,2018-09-19,GCST008067,Pemphigus foliaceus
2425,Asian,851.0,30230522.0,Zhang S,Immune system disorder,initial,2018-09-19,GCST008069,Pemphigus
2347,Asian,756.0,30230522.0,Zhang S,Immune system disorder,initial,2018-09-19,GCST008068,Pemphigus vulgaris
2345,Asian,750.0,30230522.0,Zhang S,Immune system disorder,replication,2018-09-19,GCST008069,Pemphigus
6019,European,920.0,30237584.0,El Rouby N,Cardiovascular disease,initial,2018-09-20,GCST007135,Resistant hypertension
4989,European,263.0,30237584.0,El Rouby N,Cardiovascular disease,replication,2018-09-20,GCST007136,Resistant hypertension
5653,European,657.0,30237584.0,El Rouby N,Cardiovascular disease,initial,2018-09-20,GCST007136,Resistant hypertension
12830,Hispanic or Latin American,322.0,30237584.0,El Rouby N,Cardiovascular disease,replication,2018-09-20,GCST007136,Resistant hypertension
12903,Hispanic or Latin American,537.0,30237584.0,El Rouby N,Cardiovascular disease,initial,2018-09-20,GCST007136,Resistant hypertension
12995,Hispanic or Latin American,859.0,30237584.0,El Rouby N,Cardiovascular disease,initial,2018-09-20,GCST007135,Resistant hypertension
7383,European,2417.0,30237584.0,El Rouby N,Cardiovascular disease,replication,2018-09-20,GCST007135,Resistant hypertension
2334,Asian,744.0,30242048.0,Chen B,Other measurement,replication,2018-09-21,GCST007178,Perceptual rivalry (voluntary modulation strength)
14154,Other/Mixed,2107.0,30247649.0,Gonzalez-Serna D,Neurological disorder,initial,2018-09-21,GCST006493,Systemic sclerosis
2430,Asian,870.0,30242048.0,Chen B,Other measurement,replication,2018-09-21,GCST007177,Perceptual rivalry (binocular rivalry task)
3519,Asian,4527.0,30242241.0,Hachiya T,Other measurement,initial,2018-09-21,GCST007107,Diastolic blood pressure x sodium interaction (1df test)
2344,Asian,748.0,30242048.0,Chen B,Other measurement,replication,2018-09-21,GCST007176,Perceptual rivalry (Necker cube stimulus)
3486,Asian,4241.0,30242241.0,Hachiya T,Other measurement,replication,2018-09-21,GCST007108,Systolic blood pressure x sodium interaction (1df test)
3485,Asian,4241.0,30242241.0,Hachiya T,Other measurement,replication,2018-09-21,GCST007107,Diastolic blood pressure x sodium interaction (1df test)
3025,Asian,2097.0,30242048.0,Chen B,Other measurement,initial,2018-09-21,GCST007177,Perceptual rivalry (binocular rivalry task)
2934,Asian,1880.0,30242048.0,Chen B,Other measurement,initial,2018-09-21,GCST007176,Perceptual rivalry (Necker cube stimulus)
2933,Asian,1876.0,30242048.0,Chen B,Other measurement,initial,2018-09-21,GCST007178,Perceptual rivalry (voluntary modulation strength)
3520,Asian,4527.0,30242241.0,Hachiya T,Other measurement,initial,2018-09-21,GCST007108,Systolic blood pressure x sodium interaction (1df test)
7721,European,2989.0,30251476.0,Lopez-Mejias R,"Other disease, Immune system disorder",initial,2018-09-24,GCST007041,Cardiovascular event in rheumatoid arthritis
14015,Other/Mixed,721.0,30248107.0,Wu S,Other measurement,initial,2018-09-24,GCST006706,Eyebrow thickness
3297,Asian,2961.0,30248107.0,Wu S,Other measurement,initial,2018-09-24,GCST006706,Eyebrow thickness
8356,European,4411.0,30248107.0,Wu S,Other measurement,replication,2018-09-24,GCST006706,Eyebrow thickness
6525,European,1355.0,30251476.0,Lopez-Mejias R,"Immune system disorder, Cardiovascular disease",initial,2018-09-24,GCST007425,Carotid plaques in rheumatoid arthritis
6526,European,1355.0,30251476.0,Lopez-Mejias R,"Immune system disorder, Other measurement",initial,2018-09-24,GCST007040,Carotid intima media thickness in rheumatoid arthritis
7720,European,2989.0,30251476.0,Lopez-Mejias R,"Immune system disorder, Cardiovascular disease",initial,2018-09-24,GCST007088,Ischemic heart disease in rheumatoid arthritis
13120,Hispanic or Latin American,2301.0,30248107.0,Wu S,Other measurement,initial,2018-09-24,GCST006706,Eyebrow thickness
10043,European,13175.0,30254083.0,Cousminer DL,Metabolic disorder,initial,2018-09-25,GCST007246,Latent autoimmune diabetes vs. type 2 diabetes
6480,European,1297.0,30252935.0,Smith AH,Neurological disorder,initial,2018-09-25,GCST008137,Alcohol withdrawal symptoms
9514,European,8581.0,30254083.0,Cousminer DL,Metabolic disorder,initial,2018-09-25,GCST007245,Latent autoimmune diabetes
4857,European,181.0,30252935.0,Smith AH,Neurological disorder,replication,2018-09-25,GCST008137,Alcohol withdrawal symptoms
7055,European,2009.0,30254083.0,Cousminer DL,Metabolic disorder,replication,2018-09-25,GCST007245,Latent autoimmune diabetes
881,African American or Afro-Caribbean,1231.0,30252935.0,Smith AH,Neurological disorder,initial,2018-09-25,GCST008136,Alcohol withdrawal symptoms
7985,European,3422.0,30254083.0,Cousminer DL,Metabolic disorder,initial,2018-09-25,GCST007247,Latent autoimmune diabetes vs. type 1 diabetes
10615,European,22045.0,30258056.0,Vojinovic D,Other measurement,initial,2018-09-26,GCST007147,Lateral ventricular volume in normal aging
930,African American or Afro-Caribbean,1488.0,30258056.0,Vojinovic D,Other measurement,initial,2018-09-26,GCST007147,Lateral ventricular volume in normal aging
7491,European,2545.0,30363675.0,Cha EDK,Other measurement,initial,2018-09-27,GCST007190,Subcutaneous adipose tissue
7490,European,2545.0,30363675.0,Cha EDK,Other measurement,initial,2018-09-27,GCST007189,visceral adipose tissue/total adipose tissue ratio
6144,European,986.0,30265060.0,MacKillop J,Other measurement,initial,2018-09-27,GCST007153,Delayed reward discounting
12074,European,158025.0,30261039.0,Suri P,Other trait,initial,2018-09-27,GCST007152,Chronic back pain
7488,European,2545.0,30363675.0,Cha EDK,Other measurement,initial,2018-09-27,GCST007187,Visceral adipose tissue
7489,European,2545.0,30363675.0,Cha EDK,Other measurement,initial,2018-09-27,GCST007188,Visceral adipose tissue/subcutaneous adipose tissue ratio
12345,European,283752.0,30261039.0,Suri P,Other trait,replication,2018-09-27,GCST007152,Chronic back pain
1055,African American or Afro-Caribbean,2509.0,30266756.0,Chang X,Cardiovascular disease,initial,2018-09-28,GCST007154,Paediatric migraine
9320,European,7926.0,30266756.0,Chang X,Cardiovascular disease,initial,2018-09-28,GCST007154,Paediatric migraine
2323,Asian,716.0,30266950.0,Miyagawa T,Neurological disorder,replication,2018-09-28,GCST007191,Hypersomnia (HLA-DQB1*06:02 negative)
2813,Asian,1701.0,30266950.0,Miyagawa T,Neurological disorder,initial,2018-09-28,GCST007191,Hypersomnia (HLA-DQB1*06:02 negative)
4029,Asian,8842.0,30454882.0,Daily JW,Other trait,initial,2018-09-28,GCST008975,Insulin resistance/response
1240,African American or Afro-Caribbean,4271.0,30266756.0,Chang X,Cardiovascular disease,replication,2018-09-28,GCST007154,Paediatric migraine
149,African,892.0,30276832.0,Edwards AC,Biological process,initial,2018-10-01,GCST006633,Initial alcohol sensitivity
12855,Hispanic or Latin American,408.0,30276832.0,Edwards AC,Biological process,initial,2018-10-01,GCST006633,Initial alcohol sensitivity
1568,African American or Afro-Caribbean,57332.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006611,HDL cholesterol
8895,European,6039.0,30276832.0,Edwards AC,Biological process,initial,2018-10-01,GCST006633,Initial alcohol sensitivity
1571,African American or Afro-Caribbean,57332.0,30275531.0,Klarin D,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-01,GCST006612,LDL cholesterol
588,African American or Afro-Caribbean,215.0,30357299.0,De T,Response to drug,initial,2018-10-01,GCST007137,Warfarin-associated bleeding
555,African American or Afro-Caribbean,188.0,30357299.0,De T,Response to drug,replication,2018-10-01,GCST007137,Warfarin-associated bleeding
12239,European,215551.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006613,Triglycerides
1570,African American or Afro-Caribbean,57332.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006614,Total cholesterol levels
13115,Hispanic or Latin American,2153.0,30305239.0,Macias-Kauffer LR,Cardiovascular measurement,initial,2018-10-01,GCST006905,Serum uric acid levels
12240,European,215551.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006614,Total cholesterol levels
12241,European,215551.0,30275531.0,Klarin D,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-01,GCST006612,LDL cholesterol
1569,African American or Afro-Caribbean,57332.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006613,Triglycerides
13586,Hispanic or Latin American,24743.0,30275531.0,Klarin D,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-01,GCST006612,LDL cholesterol
13585,Hispanic or Latin American,24743.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006614,Total cholesterol levels
13584,Hispanic or Latin American,24743.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006613,Triglycerides
13583,Hispanic or Latin American,24743.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006611,HDL cholesterol
12238,European,215551.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006611,HDL cholesterol
8090,European,3669.0,30281099.0,Fadista J,Digestive system disorder,replication,2018-10-02,GCST006705,Infantile hypertrophic pyloric stenosis
10571,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006881,Hippocampal tail volume (corrected for total hippocampal volume)
10583,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006893,Fimbria volume
10585,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006895,Parasubiculum volume
10573,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006883,HATA volume (corrected for total hippocampal volume)
10574,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006884,Parasubiculum volume (corrected for total hippocampal volume)
10584,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006894,HATA volume
10577,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006887,Hippocampal subfield CA1 volume
10575,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006885,Presubiculum volume
10581,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006891,Dentate gyrus molecular layer volume
10580,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006890,Dentate gyrus granule cell layer volume
10579,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006889,Hippocampal subfield CA4 volume
10576,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006886,Subiculum volume
10578,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006888,Hippocampal subfield CA3 volume
10572,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006882,Fimbria volume (corrected for total hippocampal volume)
10582,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006892,Hippocampal fissure volume
12256,European,221575.0,30279531.0,Baselmans BML,Other measurement,initial,2018-10-02,GCST006634,Hedonic well-being
10569,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006878,Dentate gyrus molecular layer volume (corrected for total hippocampal volume)
10568,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006877,Dentate gyrus granule cell layer volume (corrected for total hippocampal volume)
10567,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006876,Hippocampal subfield CA4 volume (corrected for total hippocampal volume)
13042,Hispanic or Latin American,1266.0,30281099.0,Fadista J,Digestive system disorder,replication,2018-10-02,GCST006705,Infantile hypertrophic pyloric stenosis
10566,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006875,Hippocampal subfield CA3 volume (corrected for total hippocampal volume)
10565,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006874,Hippocampal subfield CA1 volume (corrected for total hippocampal volume)
10564,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006873,Subiculum volume (corrected for total hippocampal volume)
10563,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006872,Presubiculum volume (corrected for total hippocampal volume)
10562,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006871,Total hippocampal volume
10561,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006870,Hippocampal tail volume
11787,European,108154.0,30279531.0,Baselmans BML,Other measurement,initial,2018-10-02,GCST006635,Eudaimonic well-being
10570,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006880,Hippocampal fissure volume (corrected for total hippocampal volume)
8841,European,5833.0,30281099.0,Fadista J,Digestive system disorder,initial,2018-10-02,GCST006705,Infantile hypertrophic pyloric stenosis
5910,European,838.0,30284222.0,Brcic L,Immune system disorder,initial,2018-10-03,GCST007138,Hashimoto thyroiditis
4503,Asian,45528.0,30285260.0,Ikeda M,Neurological disorder,initial,2018-10-03,GCST007201,Schizophrenia
4526,Asian,58541.0,30285260.0,Ikeda M,Neurological disorder,replication,2018-10-03,GCST007205,Schizophrenia
4456,Asian,33349.0,30281874.0,Tanikawa C,Cancer,initial,2018-10-03,GCST006707,Gastric cancer
5583,European,605.0,30284222.0,Brcic L,Immune system disorder,replication,2018-10-03,GCST007138,Hashimoto thyroiditis
4061,Asian,9348.0,30285260.0,Ikeda M,Neurological disorder,initial,2018-10-03,GCST007205,Schizophrenia
4318,Asian,17062.0,30281874.0,Tanikawa C,Cancer,replication,2018-10-03,GCST006707,Gastric cancer
11557,European,77096.0,30285260.0,Ikeda M,Neurological disorder,replication,2018-10-03,GCST007201,Schizophrenia
5181,European,395.0,30284742.0,Bevilacqua L,Digestive system disorder,initial,2018-10-04,GCST007193,Chronic periodontitis (generalised)
3011,Asian,2053.0,30287856.0,Zheng R,"Other disease, Other measurement",initial,2018-10-04,GCST006619,Tuberculosis
5269,European,433.0,30284742.0,Bevilacqua L,Digestive system disorder,initial,2018-10-04,GCST007195,Chronic periodontitis (slight)
3738,Asian,5986.0,30287856.0,Zheng R,"Other disease, Other measurement",replication,2018-10-04,GCST006619,Tuberculosis
5940,European,857.0,30287865.0,Pinar A,Other measurement,initial,2018-10-04,GCST007243,Intra-individual response time variability (selective attention)
5941,European,857.0,30287865.0,Pinar A,Other measurement,initial,2018-10-04,GCST007244,Intra-individual response time variability (response selection)
5577,European,602.0,30284742.0,Bevilacqua L,Digestive system disorder,initial,2018-10-04,GCST007196,Chronic periodontitis
5147,European,367.0,30284742.0,Bevilacqua L,Digestive system disorder,initial,2018-10-04,GCST007197,Chronic periodontitis (localised)
5083,European,329.0,30284742.0,Bevilacqua L,Digestive system disorder,initial,2018-10-04,GCST007194,Chronic periodontitis (severe)
1201,African American or Afro-Caribbean,3724.0,30287806.0,Zhou H,Other measurement,initial,2018-10-04,GCST006631,Nicotine dependence and major depression (severity of comorbidity)
12170,European,188577.0,30289880.0,Qi G,Lipid or lipoprotein measurement,initial,2018-10-05,GCST006667,Lipid traits (pleiotropy) (HIPO component 2)
12672,European,630791.0,30289880.0,Qi G,Other measurement,initial,2018-10-05,GCST006665,Social science traits (pleiotropy) (HIPO component 1)
12169,European,188577.0,30289880.0,Qi G,Lipid or lipoprotein measurement,initial,2018-10-05,GCST006666,Lipid traits (pleiotropy) (HIPO component 1)
7008,European,1950.0,30338293.0,Wallen ZD,"Neurological disorder, Other measurement",initial,2018-10-05,GCST007198,Parkinson's disease (age at diagnosis)
5742,European,726.0,30338293.0,Wallen ZD,"Neurological disorder, Other measurement",replication,2018-10-05,GCST007198,Parkinson's disease (age at diagnosis)
851,African American or Afro-Caribbean,1083.0,30297428.0,Jorgenson E,Other disease,initial,2018-10-08,GCST007118,Erectile dysfunction
10850,European,29859.0,30297428.0,Jorgenson E,Other disease,initial,2018-10-08,GCST007118,Erectile dysfunction
12229,European,209758.0,30297428.0,Jorgenson E,Other disease,replication,2018-10-08,GCST007118,Erectile dysfunction
3626,Asian,5304.0,30297428.0,Jorgenson E,Other disease,replication,2018-10-08,GCST007118,Erectile dysfunction
2348,Asian,756.0,30298529.0,Stanaway IB,"Other disease, Other measurement",initial,2018-10-08,GCST007139,Shingles
3229,Asian,2737.0,30297428.0,Jorgenson E,Other disease,initial,2018-10-08,GCST007118,Erectile dysfunction
1332,African American or Afro-Caribbean,6831.0,30298529.0,Stanaway IB,"Other disease, Other measurement",initial,2018-10-08,GCST007139,Shingles
11099,European,38763.0,30298529.0,Stanaway IB,"Other disease, Other measurement",initial,2018-10-08,GCST007139,Shingles
2290,Asian,680.0,30297428.0,Jorgenson E,Other disease,replication,2018-10-08,GCST007118,Erectile dysfunction
262,African,3634.0,30297428.0,Jorgenson E,Other disease,replication,2018-10-08,GCST007118,Erectile dysfunction
13170,Hispanic or Latin American,2970.0,30297428.0,Jorgenson E,Other disease,initial,2018-10-08,GCST007118,Erectile dysfunction
12311,European,253288.0,30305743.0,Bycroft C,"Other measurement, Body measurement",replication,2018-10-10,GCST008974,Height
12475,European,343321.0,30305743.0,Bycroft C,"Other measurement, Body measurement",initial,2018-10-10,GCST008974,Height
9481,European,8428.0,30305740.0,Elliott LT,Other measurement,initial,2018-10-10,GCST006777,Brain imaging measurements
11651,European,86335.0,30306274.0,Shah RL,"Neurological disorder, Other trait",initial,2018-10-10,GCST007157,Corneal astigmatism
11652,European,86335.0,30306274.0,Shah RL,"Neurological disorder, Other trait",initial,2018-10-10,GCST007159,Corneal astigmatism
11668,European,88005.0,30306274.0,Shah RL,Other trait,initial,2018-10-10,GCST007158,Refractive astigmatism
11669,European,88005.0,30306274.0,Shah RL,Other trait,initial,2018-10-10,GCST007160,Refractive astigmatism
8223,European,4015.0,30305637.0,McMaster ML,Cancer,initial,2018-10-10,GCST006982,Waldenstrm macroglobulinemia / lymphoplasmacytic lymphoma
8347,European,4386.0,30305740.0,Elliott LT,Other measurement,replication,2018-10-10,GCST006777,Brain imaging measurements
5970,European,877.0,30305637.0,McMaster ML,Cancer,replication,2018-10-10,GCST006982,Waldenstrm macroglobulinemia / lymphoplasmacytic lymphoma
13847,Other/Mixed,275.0,30317457.0,Bonnemaijer PWM,Neurological disorder,initial,2018-10-13,GCST007199,Glaucoma (primary open-angle)
1282,African American or Afro-Caribbean,5408.0,30317457.0,Bonnemaijer PWM,Neurological disorder,replication,2018-10-13,GCST007199,Glaucoma (primary open-angle)
964,African American or Afro-Caribbean,1800.0,30317457.0,Bonnemaijer PWM,Neurological disorder,initial,2018-10-13,GCST007199,Glaucoma (primary open-angle)
147,African,864.0,30317457.0,Bonnemaijer PWM,Neurological disorder,initial,2018-10-13,GCST007199,Glaucoma (primary open-angle)
265,African,3723.0,30317457.0,Bonnemaijer PWM,Neurological disorder,replication,2018-10-13,GCST007199,Glaucoma (primary open-angle)
3875,Asian,7448.0,30323354.0,Lee JY,Cancer,initial,2018-10-15,GCST006719,BRCA1/2-negative high-risk breast cancer
9774,European,10217.0,30320955.0,Baird DA,Body measurement,initial,2018-10-15,GCST006903,Hip shape (DXA scan)
6277,European,1087.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007773,Hyperinsulinemia in less-fat diet
9834,European,10707.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other trait",initial,2018-10-16,GCST007755,Homeostasis model assessment of insulin resistance in more-fat diet
9079,European,6818.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007771,Hyperinsulinemia in lower physical activity
9080,European,6818.0,30327367.0,Jung SY,"Other measurement, Other trait",initial,2018-10-16,GCST007754,Homeostasis model assessment of insulin resistance in lower physical activity
9399,European,8363.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007769,Hyperinsulinemia in non-obese individuals
9398,European,8363.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007746,Hyperglycemia in non-obese individuals
8577,European,4976.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007748,Hyperglycemia in higher physical activity
8578,European,4976.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007770,Hyperinsulinemia in higher physical activity
8579,European,4976.0,30327367.0,Jung SY,"Other measurement, Other trait",initial,2018-10-16,GCST007753,Homeostasis model assessment of insulin resistance in higher physical activity
1983,Asian,301.0,30326835.0,Li Z,Other measurement,initial,2018-10-16,GCST006936,Mitochondrial DNA levels
9832,European,10707.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007749,Hyperglycemia in more-fat diet
9833,European,10707.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007772,Hyperinsulinemia in more-fat diet
9941,European,11794.0,30327367.0,Jung SY,"Body measurement, Other measurement",initial,2018-10-16,GCST007757,Hyperglycemia x BMI interaction
6278,European,1087.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other trait",initial,2018-10-16,GCST007756,Homeostasis model assessment of insulin resistance in less-fat diet
9078,European,6818.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007747,Hyperglycemia in lower physical activity
6276,European,1087.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007750,Hyperglycemia in less-fat diet
7989,European,3431.0,30327367.0,Jung SY,"Metabolic disorder, Other trait",initial,2018-10-16,GCST007751,Homeostasis model assessment of insulin resistance in obesity
7988,European,3431.0,30327367.0,Jung SY,"Metabolic disorder, Other measurement",initial,2018-10-16,GCST007768,Hyperinsulinemia in obesity
7987,European,3431.0,30327367.0,Jung SY,"Metabolic disorder, Other measurement",initial,2018-10-16,GCST007745,Hyperglycemia in obesity
10496,European,19788.0,30325047.0,Gellert-Kristensen H,Digestive system disorder,replication,2018-10-16,GCST007364,Gallstone disease
12458,European,337208.0,30325047.0,Gellert-Kristensen H,Digestive system disorder,initial,2018-10-16,GCST007364,Gallstone disease
9952,European,11794.0,30327367.0,Jung SY,"Other measurement, Other trait",initial,2018-10-16,GCST007765,Homeostasis model assessment of insulin resistance x physical activity interaction
9942,European,11794.0,30327367.0,Jung SY,"Body measurement, Other measurement",initial,2018-10-16,GCST007762,Hyperinsulinemia x BMI interaction
9951,European,11794.0,30327367.0,Jung SY,"Other measurement, Other trait",initial,2018-10-16,GCST007761,Homeostasis model assessment of insulin resistance
9949,European,11794.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007760,Hyperinsulinemia
9948,European,11794.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007758,Hyperglycemia x physical activity interaction
9947,European,11794.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007744,Hyperglycemia
9400,European,8363.0,30327367.0,Jung SY,Other trait,initial,2018-10-16,GCST007752,Homeostasis model assessment of insulin resistance in non-obese individuals
9945,European,11794.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007766,Hyperinsulinemia x saturated fatty acids interaction
9944,European,11794.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007759,Hyperglycemia x saturated fatty acids interaction
9943,European,11794.0,30327367.0,Jung SY,"Body measurement, Other trait",initial,2018-10-16,GCST007763,Homeostasis model assessment of insulin resistance x BMI interaction
9950,European,11794.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007764,Hyperinsulinemia x physical activity interaction
9946,European,11794.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other trait",initial,2018-10-16,GCST007767,Homeostasis model assessment of insulin resistance x saturated fatty acids interaction
2104,Asian,422.0,30343302.0,Kim SH,Other disease,initial,2018-10-19,GCST006659,Polycystic ovary syndrome
11882,European,121604.0,30336701.0,Sanchez-Roige S,Other measurement,initial,2018-10-19,GCST006717,Alcohol use disorder (dependence and problematic use scores)
11883,European,121604.0,30336701.0,Sanchez-Roige S,Other measurement,initial,2018-10-19,GCST006718,Alcohol use disorder (consumption score)
7251,European,2232.0,30339177.0,Shane B,Other measurement,initial,2018-10-19,GCST007579,Serum folate levels
7252,European,2232.0,30339177.0,Shane B,Other measurement,initial,2018-10-19,GCST007580,Red blood cell folate levels
11984,European,141932.0,30336701.0,Sanchez-Roige S,Other measurement,initial,2018-10-19,GCST006716,Alcohol use disorder (total score)
7250,European,2232.0,30339177.0,Shane B,Cardiovascular measurement,initial,2018-10-19,GCST007578,Plasma homocysteine levels
5031,European,290.0,30353303.0,Seo M,"Other disease, Response to drug",initial,2018-10-23,GCST007558,Response to long-term oxygen therapy in chronic obstructive pulmonary disease
13076,Hispanic or Latin American,1461.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008229,Asthma control x inhaled corticosteroid treatment interaction (1df)
4758,European,98.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008229,Asthma control x inhaled corticosteroid treatment interaction (1df)
4757,European,98.0,30367910.0,Levin AM,Other measurement,replication,2018-10-24,GCST008228,Asthma control
913,African American or Afro-Caribbean,1366.0,30367910.0,Levin AM,Other measurement,replication,2018-10-24,GCST008228,Asthma control
914,African American or Afro-Caribbean,1366.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008229,Asthma control x inhaled corticosteroid treatment interaction (1df)
915,African American or Afro-Caribbean,1366.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008230,Asthma control x inhaled corticosteroid treatment interaction (2df)
13077,Hispanic or Latin American,1461.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008230,Asthma control x inhaled corticosteroid treatment interaction (2df)
4759,European,98.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008230,Asthma control x inhaled corticosteroid treatment interaction (2df)
13075,Hispanic or Latin American,1461.0,30367910.0,Levin AM,Other measurement,replication,2018-10-24,GCST008228,Asthma control
596,African American or Afro-Caribbean,244.0,30367910.0,Levin AM,Other measurement,initial,2018-10-24,GCST008228,Asthma control
598,African American or Afro-Caribbean,244.0,30367910.0,Levin AM,"Response to drug, Other measurement",initial,2018-10-24,GCST008230,Asthma control x inhaled corticosteroid treatment interaction (2df)
597,African American or Afro-Caribbean,244.0,30367910.0,Levin AM,"Response to drug, Other measurement",initial,2018-10-24,GCST008229,Asthma control x inhaled corticosteroid treatment interaction (1df)
6135,European,983.0,30361487.0,Yan Q,Other measurement,initial,2018-10-25,GCST006904,Cerebral amyloid deposition (PET imaging)
10626,European,22383.0,30367059.0,Teumer A,Other measurement,replication,2018-10-26,GCST006896,Free thyroxine concentration
10627,European,22383.0,30367059.0,Teumer A,"Other measurement, Other trait",replication,2018-10-26,GCST006899,Thyroid stimulating hormone levels
11264,European,49269.0,30367059.0,Teumer A,Other measurement,initial,2018-10-26,GCST006896,Free thyroxine concentration
11294,European,51823.0,30367059.0,Teumer A,Other disease,initial,2018-10-26,GCST006897,Hyperthyroidism
11317,European,53323.0,30367059.0,Teumer A,Other disease,initial,2018-10-26,GCST006898,Hypothyroidism
11335,European,54288.0,30367059.0,Teumer A,"Other measurement, Other trait",initial,2018-10-26,GCST006899,Thyroid stimulating hormone levels
1069,African American or Afro-Caribbean,2667.0,30373671.0,Hayden LP,"Other measurement, Other disease",initial,2018-10-29,GCST007508,Self-reported childhood asthma in adult smokers
8723,European,5364.0,30373671.0,Hayden LP,"Other measurement, Other disease",initial,2018-10-29,GCST007508,Self-reported childhood asthma in adult smokers
12667,European,586030.0,30374069.0,Styrkarsdottir U,Other disease,initial,2018-10-29,GCST006925,Knee osteoarthritis
12669,European,613790.0,30374069.0,Styrkarsdottir U,Other disease,initial,2018-10-29,GCST006926,Osteoarthritis (hip)
6069,European,944.0,30397551.0,Dorani F,Cancer,initial,2018-10-29,GCST008977,Colorectal cancer
1792,Asian,139.0,30377885.0,Fujimori S,"Response to drug, Digestive system disorder",initial,2018-10-30,GCST007258,Non-steroidal anti-inflammatory drug-induced enteropathy
7386,European,2421.0,30378284.0,Smajlagic D,"Biological process, Other trait",initial,2018-10-31,GCST007404,Performance intelligence quotient (cesarean section interaction)
7387,European,2421.0,30378284.0,Smajlagic D,"Biological process, Other trait",initial,2018-10-31,GCST007405,Full scale intelligence quotient (cesarean section interaction)
7385,European,2421.0,30378284.0,Smajlagic D,"Biological process, Other trait",initial,2018-10-31,GCST007403,Verbal intelligence quotient (cesarean section interaction)
12670,European,620021.0,30459114.0,Jia X,"Cardiovascular disease, Metabolic disorder",initial,2018-10-31,GCST008976,Type 2 diabetes or obesity or coronary artery disease (pleiotropy)
3852,Asian,7198.0,30382898.0,Moon S,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2018-11-01,GCST007738,Metabolic syndrome
12206,European,204402.0,30388399.0,Ligthart S,Inflammatory measurement,initial,2018-11-01,GCST007614,C-reactive protein levels
10514,European,20097.0,30395268.0,Khanshour AM,Other disease,initial,2018-11-01,GCST006902,Adolescent idiopathic scoliosis
12696,European,813375.0,30383316.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-11-01,GCST007249,Ischemic stroke
14283,Other/Mixed,74463.0,30383316.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-11-01,GCST007249,Ischemic stroke
4940,European,222.0,30596066.0,Kong LL,Other measurement,initial,2018-11-01,GCST007206,Brain glucose metabolism (fluorodeoxyglucose uptake)
2640,Asian,1311.0,30480742.0,Miki A,Neurological disorder,initial,2018-11-01,GCST007296,Chronic central serous retinopathy
7959,European,3387.0,30395268.0,Khanshour AM,Other disease,replication,2018-11-01,GCST006902,Adolescent idiopathic scoliosis
12017,European,148164.0,30388399.0,Ligthart S,Inflammatory measurement,initial,2018-11-01,GCST007615,C-reactive protein levels
3262,Asian,2838.0,30382898.0,Moon S,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",replication,2018-11-01,GCST007738,Metabolic syndrome
12698,European,821100.0,30383316.0,Malik R,Cardiovascular disease,initial,2018-11-01,GCST007248,Stroke
4527,Asian,59552.0,30395268.0,Khanshour AM,Other disease,replication,2018-11-01,GCST006902,Adolescent idiopathic scoliosis
4241,Asian,13379.0,30395268.0,Khanshour AM,Other disease,initial,2018-11-01,GCST006902,Adolescent idiopathic scoliosis
3102,Asian,2254.0,30480742.0,Miki A,Neurological disorder,replication,2018-11-01,GCST007296,Chronic central serous retinopathy
14287,Other/Mixed,101040.0,30383316.0,Malik R,Cardiovascular disease,initial,2018-11-01,GCST007248,Stroke
12468,European,340793.0,30392061.0,Orlova E,Immune system disorder,replication,2018-11-03,GCST007595,Appendicitis
11945,European,133680.0,30392061.0,Orlova E,Immune system disorder,initial,2018-11-03,GCST007595,Appendicitis
12374,European,295892.0,30410027.0,Gudmundsson J,Cancer,initial,2018-11-08,GCST007506,Prostate cancer
10965,European,33572.0,30410027.0,Gudmundsson J,Other measurement,initial,2018-11-08,GCST007513,Prostate-specific antigen levels
12370,European,295351.0,30410027.0,Gudmundsson J,"Other disease, Other trait",initial,2018-11-08,GCST007512,Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded)
12394,European,301162.0,30410027.0,Gudmundsson J,"Other disease, Other trait",initial,2018-11-08,GCST007507,Benign prostatic hyperplasia and lower urinary tract symptoms
3864,Asian,7321.0,30412241.0,Takeuchi F,Cancer,initial,2018-11-09,GCST007119,Cervical cancer
12712,European,1432180.0,30413934.0,Broce IJ,"Cardiovascular disease, Body measurement, Neurological disorder, Lipid or lipoprotein measurement, Metabolic disorder",initial,2018-11-09,GCST007303,Alzheimer's disease or cardiovascular risk factors (pleiotropy)
3563,Asian,4756.0,30412241.0,Takeuchi F,Cancer,replication,2018-11-09,GCST007119,Cervical cancer
12547,European,394156.0,30586722.0,Aragam KG,Cardiovascular disease,initial,2018-11-11,GCST007715,Heart failure
10342,European,17195.0,30586722.0,Aragam KG,Cardiovascular disease,replication,2018-11-11,GCST007714,Nonischemic cardiomyopathy
12545,European,390142.0,30586722.0,Aragam KG,Cardiovascular disease,initial,2018-11-11,GCST007714,Nonischemic cardiomyopathy
10025,European,12819.0,30586722.0,Aragam KG,Cardiovascular disease,replication,2018-11-11,GCST007715,Heart failure
10268,European,16226.0,30420678.0,Tasa T,"Biological process, Other disease",initial,2018-11-12,GCST009028,Adverse response to drug
6948,European,1859.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
10645,European,22708.0,30699873.0,van der Merwe C,"Other measurement, Neurological disorder",initial,2018-11-13,GCST007776,Post-traumatic stress disorder or brain volume (pleiotropy)
12000,European,144750.0,30431558.0,Smith SB,Other disease,replication,2018-11-13,GCST007619,Temporomandibular joint disorder
11007,European,34932.0,30699873.0,van der Merwe C,"Other measurement, Neurological disorder",initial,2018-11-13,GCST007775,Anxiety disorder or brain volume (pleiotropy)
13468,Hispanic or Latin American,11975.0,30431558.0,Smith SB,Other disease,replication,2018-11-13,GCST007619,Temporomandibular joint disorder
751,African American or Afro-Caribbean,701.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
11601,European,80888.0,30423114.0,Laufer VA,Immune system disorder,replication,2018-11-13,GCST006959,Rheumatoid arthritis
4382,Asian,22514.0,30423114.0,Laufer VA,Immune system disorder,replication,2018-11-13,GCST006959,Rheumatoid arthritis
12799,Hispanic or Latin American,159.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
1038,African American or Afro-Caribbean,2308.0,30423114.0,Laufer VA,Immune system disorder,initial,2018-11-13,GCST006959,Rheumatoid arthritis
13650,Other/Mixed,8.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
1894,Asian,223.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
13630,Other/Mixed,4.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
11675,European,88583.0,30429480.0,Duffy DL,"Cancer, Other measurement",initial,2018-11-14,GCST007505,Nevus count or cutaneous melanoma
11304,European,52506.0,30429480.0,Duffy DL,Other measurement,initial,2018-11-14,GCST007504,Nevus count
1971,Asian,278.0,30498476.0,Liu H,Lipid or lipoprotein measurement,initial,2018-11-15,GCST007202,High density lipoprotein cholesterol levels
9069,European,6789.0,30449631.0,Zeng X,Other measurement,replication,2018-11-15,GCST008669,"Cough x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
1973,Asian,278.0,30498476.0,Liu H,Lipid or lipoprotein measurement,initial,2018-11-15,GCST007204,Low density lipoprotein cholesterol levels
9070,European,6789.0,30449631.0,Zeng X,Other measurement,replication,2018-11-15,GCST008670,"Dyspnea x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
1972,Asian,278.0,30498476.0,Liu H,Lipid or lipoprotein measurement,initial,2018-11-15,GCST007203,Total cholesterol levels
9336,European,7976.0,30449631.0,Zeng X,Other measurement,initial,2018-11-15,GCST008671,"Phlegm x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
9335,European,7976.0,30449631.0,Zeng X,Other measurement,initial,2018-11-15,GCST008670,"Dyspnea x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
9334,European,7976.0,30449631.0,Zeng X,Other measurement,initial,2018-11-15,GCST008669,"Cough x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
9071,European,6789.0,30449631.0,Zeng X,Other measurement,replication,2018-11-15,GCST008671,"Phlegm x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
6610,European,1453.0,30453627.0,Marklund M,Other measurement,initial,2018-11-17,GCST007635,Fatty acid desaturase activity (serum)
5833,European,783.0,30453627.0,Marklund M,Other measurement,initial,2018-11-17,GCST007636,Fatty acid desaturase activity (adipose tissue)
5973,European,878.0,30450575.0,Hojfeldt SG,"Cancer, Response to drug",initial,2018-11-18,GCST007541,PEG-asparaginase hypersensitivity in childhood acute lymphoblastic leukaemia (allergic reaction grade 2 or more)
5901,European,831.0,30450575.0,Hojfeldt SG,"Cancer, Response to drug",initial,2018-11-18,GCST007540,PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia
5854,European,803.0,30450575.0,Hojfeldt SG,"Cancer, Other measurement",initial,2018-11-18,GCST007539,Silent asparaginase inactivation in childhood acute lymphoblastic leukaemia
137,African,748.0,30452639.0,Butali A,Other trait,replication,2018-11-19,GCST007509,Cleft palate
254,African,3073.0,30452639.0,Butali A,Other trait,initial,2018-11-19,GCST007510,Cleft lip with or without cleft palate
611,African American or Afro-Caribbean,265.0,30452639.0,Butali A,Other trait,replication,2018-11-19,GCST007509,Cleft palate
5479,European,534.0,30453346.0,Tunjungputri RN,"Hematological measurement, Cardiovascular measurement",initial,2018-11-19,GCST007652,Platelet count and reactivity phenotypes
244,African,2364.0,30452639.0,Butali A,Other trait,initial,2018-11-19,GCST007509,Cleft palate
628,African American or Afro-Caribbean,307.0,30452639.0,Butali A,Other trait,replication,2018-11-19,GCST007510,Cleft lip with or without cleft palate
168,African,1049.0,30452639.0,Butali A,Other trait,replication,2018-11-19,GCST007510,Cleft lip with or without cleft palate
10753,European,25897.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007445,Factor VIII levels
13064,Hispanic or Latin American,1440.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007445,Factor VIII levels
1198,African American or Afro-Caribbean,3700.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007446,vWF levels
13065,Hispanic or Latin American,1440.0,30586737.0,Sabater-Lleal M,"Hematological measurement, Other measurement",initial,2018-11-20,GCST007447,vWF and FVIII levels
2364,Asian,773.0,30586737.0,Sabater-Lleal M,"Hematological measurement, Other measurement",initial,2018-11-20,GCST007447,vWF and FVIII levels
11169,European,42379.0,30586737.0,Sabater-Lleal M,"Hematological measurement, Other measurement",initial,2018-11-20,GCST007447,vWF and FVIII levels
12825,Hispanic or Latin American,275.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007446,vWF levels
2363,Asian,773.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007445,Factor VIII levels
11168,European,42379.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007446,vWF levels
9725,European,9870.0,30456828.0,Khramtsova EA,"Neurological disorder, Other measurement",initial,2018-11-20,GCST007207,Obsessive-compulsive disorder x sex interaction
9724,European,9870.0,30456828.0,Khramtsova EA,Neurological disorder,initial,2018-11-20,GCST007208,Obsessive-compulsive disorder
1256,African American or Afro-Caribbean,4500.0,30586737.0,Sabater-Lleal M,"Hematological measurement, Other measurement",initial,2018-11-20,GCST007447,vWF and FVIII levels
1255,African American or Afro-Caribbean,4500.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007445,Factor VIII levels
95,African,371.0,30467376.0,Wilker S,Neurological disorder,replication,2018-11-22,GCST007651,Post-traumatic stress disorder
153,African,924.0,30467376.0,Wilker S,Neurological disorder,initial,2018-11-22,GCST007651,Post-traumatic stress disorder
6765,European,1630.0,30470734.0,Hackinger S,"Neurological disorder, Metabolic disorder",initial,2018-11-23,GCST007220,Schizophrenia and type 2 diabetes
6505,European,1327.0,30470734.0,Hackinger S,"Neurological disorder, Metabolic disorder",initial,2018-11-23,GCST007224,Type 2 diabetes vs schizophrenia and type 2 diabetes
6596,European,1429.0,30470734.0,Hackinger S,"Neurological disorder, Metabolic disorder",initial,2018-11-23,GCST007222,Schizophrenia vs schizophrenia and type 2 diabetes
7006,European,1947.0,30470734.0,Hackinger S,Metabolic disorder,initial,2018-11-23,GCST007221,Type 2 diabetes
7097,European,2049.0,30470734.0,Hackinger S,Neurological disorder,initial,2018-11-23,GCST007219,Schizophrenia
7308,European,2312.0,30468137.0,Fabbri C,"Other measurement, Response to drug",initial,2018-11-23,GCST007666,Depressive symptom improvement
6871,European,1746.0,30470734.0,Hackinger S,"Neurological disorder, Metabolic disorder",initial,2018-11-23,GCST007223,Schizophrenia vs type 2 diabetes
7857,European,3226.0,30468137.0,Fabbri C,"Neurological disorder, Response to drug",initial,2018-11-23,GCST007665,Treatment resistant depression
7307,European,2312.0,30468137.0,Fabbri C,"Neurological disorder, Response to drug",initial,2018-11-23,GCST007667,Treatment resistant depression
11316,European,53293.0,30478444.0,Demontis D,Neurological disorder,initial,2018-11-26,GCST007543,Attention deficit hyperactivity disorder
9379,European,8232.0,30475886.0,Mekli K,Other measurement,initial,2018-11-26,GCST007716,Frailty index
11952,European,136207.0,30478444.0,Demontis D,Neurological disorder,replication,2018-11-26,GCST007543,Attention deficit hyperactivity disorder
2962,Asian,1937.0,30478444.0,Demontis D,Neurological disorder,initial,2018-11-26,GCST007543,Attention deficit hyperactivity disorder
8682,European,5248.0,30475886.0,Mekli K,Other measurement,replication,2018-11-26,GCST007716,Frailty index
8111,European,3731.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007291,Proliferative diabetic retinopathy (vs no DR)
13118,Hispanic or Latin American,2254.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007290,Diabetic retinopathy (moderate NPDR and PDR)
13155,Hispanic or Latin American,2710.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
13133,Hispanic or Latin American,2426.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007289,Proliferative diabetic retinopathy (vs NPDR and no DR)
5689,European,678.0,30488612.0,Xiang B,Neurological disorder,replication,2018-11-28,GCST007657,Alcohol and nicotine co-dependence
6402,European,1207.0,30488612.0,Xiang B,Neurological disorder,initial,2018-11-28,GCST007657,Alcohol and nicotine co-dependence
7352,European,2368.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007291,Proliferative diabetic retinopathy (vs no DR)
1065,African American or Afro-Caribbean,2611.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007289,Proliferative diabetic retinopathy (vs NPDR and no DR)
4518,Asian,50792.0,30487518.0,Takeuchi F,Cardiovascular disease,initial,2018-11-28,GCST007707,Hypertension
956,African American or Afro-Caribbean,1709.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007290,Diabetic retinopathy (moderate NPDR and PDR)
4381,Asian,22472.0,30487518.0,Takeuchi F,Cardiovascular disease,replication,2018-11-28,GCST007707,Hypertension
8444,European,4677.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007290,Diabetic retinopathy (moderate NPDR and PDR)
7765,European,3094.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
4520,Asian,53008.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007703,Systolic blood pressure
972,African American or Afro-Caribbean,1852.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
4246,Asian,13703.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
4521,Asian,53008.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007704,Diastolic blood pressure
1002,African American or Afro-Caribbean,2038.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007291,Proliferative diabetic retinopathy (vs no DR)
4566,Asian,105253.0,30487518.0,Takeuchi F,Cardiovascular measurement,replication,2018-11-28,GCST007705,Pulse pressure
1012,African American or Afro-Caribbean,2094.0,30488612.0,Xiang B,Neurological disorder,initial,2018-11-28,GCST007657,Alcohol and nicotine co-dependence
4567,Asian,105253.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007706,Mean arterial pressure
4592,Asian,130777.0,30487518.0,Takeuchi F,Cardiovascular measurement,initial,2018-11-28,GCST007705,Pulse pressure
3981,Asian,8607.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007290,Diabetic retinopathy (moderate NPDR and PDR)
4593,Asian,130777.0,30487518.0,Takeuchi F,Other measurement,initial,2018-11-28,GCST007703,Systolic blood pressure
4594,Asian,130777.0,30487518.0,Takeuchi F,Other measurement,initial,2018-11-28,GCST007704,Diastolic blood pressure
4595,Asian,130777.0,30487518.0,Takeuchi F,Other measurement,initial,2018-11-28,GCST007706,Mean arterial pressure
7527,European,2614.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007290,Diabetic retinopathy (moderate NPDR and PDR)
7872,European,3246.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007289,Proliferative diabetic retinopathy (vs NPDR and no DR)
9557,European,8821.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007289,Proliferative diabetic retinopathy (vs NPDR and no DR)
10246,European,15918.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
2360,Asian,771.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
11309,European,53008.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007706,Mean arterial pressure
3020,Asian,2085.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007289,Proliferative diabetic retinopathy (vs NPDR and no DR)
3169,Asian,2484.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007291,Proliferative diabetic retinopathy (vs no DR)
2497,Asian,984.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
11767,European,105253.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007703,Systolic blood pressure
11307,European,53008.0,30487518.0,Takeuchi F,Cardiovascular disease,replication,2018-11-28,GCST007707,Hypertension
11308,European,53008.0,30487518.0,Takeuchi F,Cardiovascular measurement,replication,2018-11-28,GCST007705,Pulse pressure
13045,Hispanic or Latin American,1280.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007291,Proliferative diabetic retinopathy (vs no DR)
11768,European,105253.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007704,Diastolic blood pressure
3446,Asian,3989.0,30498034.0,Terao C,Cardiovascular disease,replication,2018-11-29,GCST006984,Takayasu arteritis
2775,Asian,1622.0,30500874.0,Kakuta Y,Digestive system disorder,replication,2018-11-29,GCST007216,Crohn's disease
3198,Asian,2569.0,30498034.0,Terao C,Cardiovascular disease,initial,2018-11-29,GCST006984,Takayasu arteritis
3252,Asian,2796.0,30500874.0,Kakuta Y,Digestive system disorder,initial,2018-11-29,GCST007216,Crohn's disease
12692,European,764012.0,30504769.0,Ferkingstad E,Digestive system disorder,initial,2018-11-30,GCST007209,Gallstone disease
612,African American or Afro-Caribbean,267.0,30578281.0,Williams LM,"Neurological disorder, Biological process",initial,2018-12-01,GCST007210,Alloimmunization response to red blood cell transfusion in sickle cell anemia
516,African American or Afro-Caribbean,130.0,30578281.0,Williams LM,"Neurological disorder, Biological process",replication,2018-12-01,GCST007210,Alloimmunization response to red blood cell transfusion in sickle cell anemia
12676,European,660648.0,30575882.0,Lotta LA,Body measurement,initial,2018-12-01,GCST008733,Waist-to-hip ratio adjusted for BMI
12677,European,663598.0,30575882.0,Lotta LA,"Other measurement, Body measurement",initial,2018-12-01,GCST008734,Waist-hip ratio
12459,European,337536.0,30566020.0,Fukaya E,Other trait,initial,2018-12-01,GCST007225,Varicose veins
11250,European,48434.0,30510157.0,Franceschini N,Cardiovascular disease,initial,2018-12-03,GCST007435,Carotid plaque
3624,Asian,5294.0,30510241.0,Huyghe JR,Cancer,initial,2018-12-03,GCST007856,Colorectal cancer or advanced adenoma
11867,European,120184.0,30510241.0,Huyghe JR,Cancer,initial,2018-12-03,GCST007856,Colorectal cancer or advanced adenoma
12914,Hispanic or Latin American,585.0,30510082.0,Qian M,Cancer,replication,2018-12-03,GCST007276,Acute lymphoblastic leukemia (B-cell precursor)
2565,Asian,1143.0,30511388.0,Yan W,Other disease,replication,2018-12-03,GCST007699,Developmental dysplasia of the hip
2443,Asian,886.0,30511388.0,Yan W,Other disease,initial,2018-12-03,GCST007699,Developmental dysplasia of the hip
946,African American or Afro-Caribbean,1607.0,30510082.0,Qian M,Cancer,replication,2018-12-03,GCST007276,Acute lymphoblastic leukemia (B-cell precursor)
8345,European,4367.0,30510082.0,Qian M,Cancer,replication,2018-12-03,GCST007276,Acute lymphoblastic leukemia (B-cell precursor)
11513,European,71128.0,30510157.0,Franceschini N,"Other measurement, Cardiovascular measurement, Cardiovascular disease",initial,2018-12-03,GCST007436,Carotid intima media thickness
13082,Hispanic or Latin American,1521.0,30510082.0,Qian M,Cancer,initial,2018-12-03,GCST007276,Acute lymphoblastic leukemia (B-cell precursor)
8605,European,5031.0,30514930.0,Mukherjee S,Neurological disorder,initial,2018-12-04,GCST007333,Alzheimer's disease with no specific cognitive domain impairment
8194,European,3957.0,30514930.0,Mukherjee S,Neurological disorder,initial,2018-12-04,GCST007334,Alzheimer's disease with language domain impairment
8852,European,5878.0,30514930.0,Mukherjee S,Neurological disorder,initial,2018-12-04,GCST007331,Alzheimer's disease
8191,European,3944.0,30514930.0,Mukherjee S,Neurological disorder,initial,2018-12-04,GCST007318,Alzheimer's disease with visuospatial domain impairment
8403,European,4554.0,30514930.0,Mukherjee S,"Neurological disorder, Other trait",initial,2018-12-04,GCST007330,Alzheimer's disease with memory domain impairment
8102,European,3695.0,30514930.0,Mukherjee S,"Neurological disorder, Other trait",initial,2018-12-04,GCST007332,Alzheimer's disease with multiple cognitive domain impairments
5109,European,342.0,30563176.0,Westermair AL,"Cardiovascular disease, Neurological disorder",initial,2018-12-05,GCST007230,Severe depressive disorders in coronary artery disease
9936,European,11744.0,30527956.0,Rhodes CJ,Cardiovascular disease,initial,2018-12-05,GCST007228,Pulmonary arterial hypertension
4539,Asian,70506.0,30529582.0,Lu Y,Cancer,initial,2018-12-06,GCST007552,Colorectal cancer
318,African,7594.0,30679032.0,Brazel DM,"Biological process, Other measurement",initial,2018-12-06,GCST008805,Alcohol consumption (drinks per week)
247,African,2685.0,30679032.0,Brazel DM,Other measurement,initial,2018-12-06,GCST008804,Smoking behaviour (cigarettes smoked per day)
12054,European,153918.0,30679032.0,Brazel DM,Other measurement,initial,2018-12-06,GCST008809,Smoking behaviour (cigarettes smoked per day)
249,African,2705.0,30679032.0,Brazel DM,"Other measurement, Biological process",initial,2018-12-06,GCST008807,Smoking behaviour (age at first cigarette)
325,African,8974.0,30679032.0,Brazel DM,"Other measurement, Biological process",initial,2018-12-06,GCST008806,Smoking initiation (ever regular vs never regular)
12496,European,357857.0,30679032.0,Brazel DM,"Biological process, Other measurement",initial,2018-12-06,GCST008811,Alcohol consumption (drinks per week)
12047,European,150993.0,30679032.0,Brazel DM,Other measurement,initial,2018-12-06,GCST008803,Smoking behaviour (cigarette pack-years)
12582,European,433216.0,30679032.0,Brazel DM,"Other measurement, Biological process",initial,2018-12-06,GCST008810,Smoking initiation (ever regular vs never regular)
12005,European,146117.0,30679032.0,Brazel DM,"Other measurement, Biological process",initial,2018-12-06,GCST008802,Smoking behaviour (age at first cigarette)
5118,European,346.0,30531935.0,Crowley JJ,Metabolic disorder,initial,2018-12-07,GCST007233,Fragile X syndrome
9518,European,8609.0,30535121.0,Gao XR,Other measurement,replication,2018-12-07,GCST006976,Macular thickness
11400,European,59814.0,30535121.0,Gao XR,Other measurement,initial,2018-12-07,GCST006976,Macular thickness
11710,European,91105.0,30531941.0,Doherty A,Other measurement,initial,2018-12-10,GCST006915,Physical activity (moderate intensity activity duration)
3360,Asian,3406.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007343,Epilepsy
10726,European,24927.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007350,Focal epilepsy (with hippocampal sclerosis)
11709,European,91105.0,30531941.0,Doherty A,Other measurement,initial,2018-12-10,GCST006914,Sleep duration
10785,European,26969.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007351,Focal epilepsy (with lesion other than hippocampal sclerosis)
10732,European,24996.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007345,Childhood absence epilepsy
10719,European,24633.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007346,Juvenile absence epilepsy
10716,European,24443.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007348,"Epilepsy (generalized, with tonic-clonic seizures alone)"
3351,Asian,3365.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007352,Focal epilepsy
10778,European,26878.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007349,Focal epilepsy (lesion negative)
11711,European,91105.0,30531941.0,Doherty A,Other measurement,initial,2018-12-10,GCST007110,Physical activity (walking duration)
1086,African American or Afro-Caribbean,2731.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007343,Epilepsy
11097,European,38752.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007343,Epilepsy
11708,European,91105.0,30531941.0,Doherty A,Other measurement,initial,2018-12-10,GCST006913,Sedentary behaviour duration
11707,European,91105.0,30531941.0,Doherty A,Other measurement,initial,2018-12-10,GCST006912,Physical activity (overall physical activity time)
3269,Asian,2875.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007353,Generalized epilepsy
10938,European,33313.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007352,Focal epilepsy
12433,European,323317.0,30531825.0,Morgan MD,Other trait,initial,2018-12-10,GCST006988,Blond vs. brown/black hair color
1066,African American or Afro-Caribbean,2645.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007353,Generalized epilepsy
12346,European,283920.0,30531825.0,Morgan MD,Other trait,initial,2018-12-10,GCST006989,Brown vs. black hair color
1070,African American or Afro-Caribbean,2670.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007352,Focal epilepsy
10801,European,27926.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007353,Generalized epilepsy
12386,European,299651.0,30531825.0,Morgan MD,Other trait,initial,2018-12-10,GCST006986,Red vs. brown/black hair color
10743,European,25395.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007347,Juvenile myoclonic epilepsy
10876,European,30810.0,30552067.0,Shrine N,Other disease,initial,2018-12-11,GCST006911,Asthma (moderate or severe)
10779,European,26885.0,30552067.0,Shrine N,Other disease,replication,2018-12-11,GCST006911,Asthma (moderate or severe)
5728,European,708.0,30584014.0,Huang M,Other measurement,initial,2018-12-12,GCST008491,Whole-brain volume
10774,European,26722.0,30542056.0,Petridis C,Other disease,initial,2018-12-12,GCST007234,Acne (severe)
10594,European,21536.0,30541042.0,Walsh N,Cancer,initial,2018-12-12,GCST007235,Pancreatic ductal adenocarcinoma
4733,European,90.0,30552317.0,Guo W,"Neurological disorder, Response to drug, Other measurement",initial,2018-12-14,GCST007317,Response to ketamine in bipolar disorder or major depression (dissociation effects)
2288,Asian,676.0,30552108.0,Kawabata Y,Metabolic disorder,initial,2018-12-14,GCST007433,Fulminant type 1 diabetes
4819,European,157.0,30552317.0,Guo W,"Neurological disorder, Response to drug, Other measurement",initial,2018-12-14,GCST007316,Response to ketamine in bipolar disorder or major depression (antidepressant effects)
7236,European,2198.0,30552173.0,Aterido A,Immune system disorder,initial,2018-12-14,GCST007043,Psoriatic arthritis
13930,Other/Mixed,502.0,30556296.0,Alblooshi H,Neurological disorder,initial,2018-12-16,GCST007700,Substance use disorder
5453,European,520.0,30556296.0,Alblooshi H,Neurological disorder,replication,2018-12-16,GCST007700,Substance use disorder
4329,Asian,18173.0,30557369.0,Yodsurang V,Cancer,initial,2018-12-17,GCST007239,Ovarian cancer
6805,European,1688.0,30563984.0,Hawi Z,Neurological disorder,initial,2018-12-18,GCST006916,Attention deficit hyperactivity disorder
2092,Asian,408.0,30662464.0,Yang C,"Other measurement, Cancer",initial,2018-12-18,GCST008104,Nucleoside diphosphate kinase A levels in hepatocellular carcinoma
7806,European,3186.0,30631343.0,Rolfe S,Other measurement,initial,2018-12-18,GCST007449,Normal facial asymmetry (angle of deformation score)
7805,European,3186.0,30631343.0,Rolfe S,Other measurement,initial,2018-12-18,GCST007448,Normal facial asymmetry (angle of surface orientation score)
7807,European,3186.0,30631343.0,Rolfe S,Other measurement,initial,2018-12-18,GCST007450,Normal facial asymmetry (deformation magnitude)
3973,Asian,8401.0,30566433.0,Taira M,Metabolic disorder,initial,2018-12-19,GCST007021,Type 2 diabetes nephropathy
3974,Asian,8401.0,30566433.0,Taira M,"Other trait, Metabolic disorder",initial,2018-12-19,GCST007022,Type 2 diabetes nephropathy including microalbuminuria
11826,European,113238.0,30566500.0,Day F,Other disease,initial,2018-12-19,GCST007089,Polycystic ovary syndrome
3536,Asian,4634.0,30566433.0,Taira M,"Other trait, Metabolic disorder",replication,2018-12-19,GCST007022,Type 2 diabetes nephropathy including microalbuminuria
3768,Asian,6227.0,30578877.0,Dahlin A,Other disease,initial,2018-12-19,GCST007598,Adult asthma
3535,Asian,4634.0,30566433.0,Taira M,Metabolic disorder,replication,2018-12-19,GCST007021,Type 2 diabetes nephropathy
10769,European,26475.0,30578877.0,Dahlin A,Other disease,replication,2018-12-19,GCST007599,Adult asthma
10768,European,26475.0,30578877.0,Dahlin A,Other disease,replication,2018-12-19,GCST007598,Adult asthma
10767,European,26475.0,30578877.0,Dahlin A,Other disease,replication,2018-12-19,GCST007597,Adult asthma
1057,African American or Afro-Caribbean,2526.0,30578877.0,Dahlin A,Other disease,initial,2018-12-19,GCST007599,Adult asthma
13303,Hispanic or Latin American,5327.0,30578877.0,Dahlin A,Other disease,initial,2018-12-19,GCST007597,Adult asthma
10766,European,26475.0,30578877.0,Dahlin A,Other disease,replication,2018-12-19,GCST007596,Adult asthma
11339,European,54543.0,30578877.0,Dahlin A,Other disease,initial,2018-12-19,GCST007596,Adult asthma
10891,European,31382.0,30573655.0,Acosta-Herrera M,"Neurological disorder, Immune system disorder",initial,2018-12-20,GCST007278,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies)
12212,European,205327.0,30573740.0,Yap CX,"Other measurement, Other disease",initial,2018-12-20,GCST007020,Male-pattern baldness
9158,European,7155.0,30571770.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2018-12-20,GCST008506,Stress sensitivity (neuroticism score x major depressive disorder status interaction)
10654,European,23092.0,30571770.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2018-12-20,GCST008507,Stress sensitivity (neuroticism score x major depressive disorder status interaction)
10864,European,30247.0,30571770.0,Arnau-Soler A,Neurological disorder,initial,2018-12-20,GCST008509,Major depressive disorder
10865,European,30247.0,30571770.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2018-12-20,GCST008508,Stress sensitivity (neuroticism score x major depressive disorder status interaction)
10866,European,30247.0,30571770.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2018-12-20,GCST008510,Neuroticism
12263,European,225112.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007272,Pulse pressure
398,African,63490.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007268,Diastolic blood pressure
12502,European,365998.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007269,Pulse pressure
12503,European,365998.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007267,Systolic blood pressure
12260,European,223805.0,30583798.0,Bovijn J,Other disease,initial,2018-12-21,GCST006956,Erectile dysfunction
12504,European,365998.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007268,Diastolic blood pressure
12264,European,225112.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007270,Systolic blood pressure
3566,Asian,4792.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007269,Pulse pressure
12265,European,225112.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007271,Diastolic blood pressure
13581,Hispanic or Latin American,22802.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007270,Systolic blood pressure
13580,Hispanic or Latin American,22802.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007268,Diastolic blood pressure
397,African,63490.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007267,Systolic blood pressure
13579,Hispanic or Latin American,22802.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007267,Systolic blood pressure
396,African,63490.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007272,Pulse pressure
13578,Hispanic or Latin American,22802.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007272,Pulse pressure
13577,Hispanic or Latin American,22802.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007269,Pulse pressure
399,African,63490.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007270,Systolic blood pressure
395,African,63490.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007269,Pulse pressure
400,African,63490.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007271,Diastolic blood pressure
13582,Hispanic or Latin American,22802.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007271,Diastolic blood pressure
3567,Asian,4792.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007272,Pulse pressure
14177,Other/Mixed,2695.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007270,Systolic blood pressure
3570,Asian,4792.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007270,Systolic blood pressure
14174,Other/Mixed,2695.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007272,Pulse pressure
14173,Other/Mixed,2695.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007269,Pulse pressure
3569,Asian,4792.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007268,Diastolic blood pressure
12384,European,299024.0,30578418.0,Giri A,Other measurement,replication,2018-12-21,GCST007267,Systolic blood pressure
3568,Asian,4792.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007267,Systolic blood pressure
3571,Asian,4792.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007271,Diastolic blood pressure
14178,Other/Mixed,2695.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007271,Diastolic blood pressure
14176,Other/Mixed,2695.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007268,Diastolic blood pressure
12383,European,299024.0,30578418.0,Giri A,Cardiovascular measurement,replication,2018-12-21,GCST007269,Pulse pressure
14175,Other/Mixed,2695.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007267,Systolic blood pressure
12385,European,299024.0,30578418.0,Giri A,Other measurement,replication,2018-12-21,GCST007268,Diastolic blood pressure
5393,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007265,Plasma pyridoxic acid to pyridoxal phosphate ratio
5388,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007260,B6 vitamer levels (multivariate analysis)
5391,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007263,Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio
5389,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007261,Cerebrospinal fluid pyridoxal phosphate levels
5392,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007264,Plasma pyridoxal phosphate to pyridoxal ratio
5390,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007262,Plasma pyridoxal phosphate levels
3299,Asian,2981.0,30591961.0,Huang L,Other measurement,initial,2018-12-24,GCST007998,Intraocular pressure
3659,Asian,5571.0,30591961.0,Huang L,Other measurement,initial,2018-12-24,GCST007998,Intraocular pressure
1030,African American or Afro-Caribbean,2201.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007632,Hepatitis C (spontaneous viral clearance)
6865,European,1736.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007633,Hepatitis C (spontaneous viral clearance)
12889,Hispanic or Latin American,486.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007634,Hepatitis C (spontaneous viral clearance)
12888,Hispanic or Latin American,486.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007631,Hepatitis C (spontaneous viral clearance)
1029,African American or Afro-Caribbean,2201.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007631,Hepatitis C (spontaneous viral clearance)
6864,European,1736.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007631,Hepatitis C (spontaneous viral clearance)
12628,European,458000.0,30595370.0,Kichaev G,"Other measurement, Body measurement",initial,2018-12-27,GCST007841,Height
11996,European,143000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007079,Age at menopause
12511,European,370000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007080,Lung function (FEV1/FVC)
12626,European,458000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007085,Smoking status
12625,European,458000.0,30595370.0,Kichaev G,"Body measurement, Other measurement",initial,2018-12-27,GCST007039,Body mass index
12592,European,445000.0,30595370.0,Kichaev G,Hematological measurement,initial,2018-12-27,GCST007069,Red blood cell count
12633,European,459000.0,30595370.0,Kichaev G,Immune system disorder,initial,2018-12-27,GCST007071,Autoimmune traits
12591,European,444000.0,30595370.0,Kichaev G,"Hematological measurement, Inflammatory measurement",initial,2018-12-27,GCST007070,White blood cell count
12612,European,452000.0,30595370.0,Kichaev G,"Other measurement, Other trait",initial,2018-12-27,GCST007082,Hair color
12593,European,445000.0,30595370.0,Kichaev G,Hematological measurement,initial,2018-12-27,GCST007074,Red cell distribution width
12627,European,458000.0,30595370.0,Kichaev G,"Other measurement, Body measurement",initial,2018-12-27,GCST007067,Waist-hip ratio
12617,European,455000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007037,Educational attainment (years of education)
12596,European,446000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007066,Heel bone mineral density
12567,European,410000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007083,Morning person
12516,European,372000.0,30595370.0,Kichaev G,"Neurological disorder, Other measurement",initial,2018-12-27,GCST007084,Neuroticism
12517,European,372000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007081,Lung function (FVC)
5665,European,665.0,30595539.0,Wallace HJ,Other measurement,initial,2018-12-27,GCST007251,Postburn scar height
5666,European,665.0,30595539.0,Wallace HJ,Other measurement,initial,2018-12-27,GCST007252,Postburn scar pliability
12476,European,344000.0,30595370.0,Kichaev G,Other disease,initial,2018-12-27,GCST007086,Sunburns
12636,European,459000.0,30595370.0,Kichaev G,Other disease,initial,2018-12-27,GCST007073,Hypothyroidism
12222,European,208000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007038,Balding type 1
12635,European,459000.0,30595370.0,Kichaev G,Other disease,initial,2018-12-27,GCST007072,Cardiovascular disease
12637,European,459000.0,30595370.0,Kichaev G,Other disease,initial,2018-12-27,GCST007076,Respiratory diseases
12587,European,440000.0,30595370.0,Kichaev G,Hematological measurement,initial,2018-12-27,GCST007065,Eosinophil counts
12576,European,422000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007087,Systolic blood pressure
12284,European,242000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007078,Menarche (age at onset)
12638,European,459000.0,30595370.0,Kichaev G,Other trait,initial,2018-12-27,GCST007075,Eczema
12590,European,443000.0,30595370.0,Kichaev G,Hematological measurement,initial,2018-12-27,GCST007068,Mean corpuscular hemoglobin
12634,European,459000.0,30595370.0,Kichaev G,Metabolic disorder,initial,2018-12-27,GCST007077,Type 2 diabetes
7682,European,2900.0,30685440.0,Silbernagel G,Lipid or lipoprotein measurement,initial,2018-12-28,GCST007955,Low density lipoprotein triglyceride levels
12066,European,155961.0,30593698.0,Hubel C,Other measurement,initial,2018-12-28,GCST007063,Fat-free mass
12065,European,155961.0,30593698.0,Hubel C,Body measurement,initial,2018-12-28,GCST007064,Body fat percentage
12579,European,426824.0,30598549.0,Morris JA,Other measurement,initial,2018-12-31,GCST006979,Heel bone mineral density
12578,European,426795.0,30598549.0,Morris JA,Other disease,initial,2018-12-31,GCST006980,Fractures
12684,European,731819.0,30598549.0,Morris JA,Other disease,replication,2018-12-31,GCST006980,Fractures
6906,European,1791.0,30582445.0,Mola-Caminal M,"Other trait, Other measurement",replication,2019-01-01,GCST006935,3-month functional outcome in ischaemic stroke (modified Rankin score)
6428,European,1225.0,30582445.0,Mola-Caminal M,"Other trait, Other measurement",initial,2019-01-01,GCST006935,3-month functional outcome in ischaemic stroke (modified Rankin score)
5838,European,790.0,30610941.0,Wang AW,Other measurement,initial,2019-01-02,GCST007726,Anti-Toxoplasma gondii IgG seropositivity
619,African American or Afro-Caribbean,285.0,30610941.0,Wang AW,Other measurement,initial,2019-01-02,GCST007726,Anti-Toxoplasma gondii IgG seropositivity
4620,Asian,143658.0,30604766.0,Morris AP,Other measurement,initial,2019-01-03,GCST007344,Estimated glomerular filtration rate
11949,European,134070.0,30604766.0,Morris AP,Other measurement,initial,2019-01-03,GCST007344,Estimated glomerular filtration rate
1388,African American or Afro-Caribbean,8224.0,30604766.0,Morris AP,Other measurement,initial,2019-01-03,GCST007344,Estimated glomerular filtration rate
13588,Hispanic or Latin American,26344.0,30604766.0,Morris AP,Other measurement,initial,2019-01-03,GCST007344,Estimated glomerular filtration rate
11613,European,83129.0,30610198.0,Soler Artigas M,"Neurological disorder, Biological process",initial,2019-01-04,GCST006983,Attention deficit hyperactivity disorder or cannabis use
5246,European,430.0,30621171.0,Coltell O,"Metabolic disorder, Other measurement",initial,2019-01-04,GCST007016,Serum bilirubin levels x sex interaction in metabolic syndrome
12457,European,337199.0,30610202.0,Ruderfer DM,Biological process,initial,2019-01-04,GCST006978,Suicide attempts
14285,Other/Mixed,82315.0,30610197.0,Smeland OB,"Biological process, Neurological disorder",initial,2019-01-04,GCST007782,Schizophrenia or intelligence (pleiotropy)
10717,European,24546.0,30610202.0,Ruderfer DM,Other measurement,initial,2019-01-04,GCST006977,Predicted suicide risk
11290,European,51710.0,30610197.0,Smeland OB,"Biological process, Neurological disorder",initial,2019-01-04,GCST007781,Bipolar disorder or intelligence (pleiotropy)
5226,European,418.0,30621171.0,Coltell O,"Other measurement, Metabolic disorder",initial,2019-01-04,GCST007017,Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome
5247,European,430.0,30621171.0,Coltell O,"Metabolic disorder, Other measurement",initial,2019-01-04,GCST007018,Serum bilirubin levels in metabolic syndrome
12338,European,275596.0,30617275.0,Erzurumluoglu AM,Other measurement,replication,2019-01-07,GCST007602,Smoking behaviour (cigarettes smoked per day)
12337,European,275596.0,30617275.0,Erzurumluoglu AM,Other measurement,replication,2019-01-07,GCST007601,Smoking behaviour (cigarette pack-years)
12336,European,275596.0,30617275.0,Erzurumluoglu AM,Biological process,replication,2019-01-07,GCST007604,Smoking cessation
12335,European,275596.0,30617275.0,Erzurumluoglu AM,Biological process,replication,2019-01-07,GCST007603,Smoking initiation
12619,European,455258.0,30617256.0,Jansen IE,"Neurological disorder, Other measurement",initial,2019-01-07,GCST007320,Alzheimer's disease or family history of Alzheimer's disease
14288,Other/Mixed,121543.0,30617275.0,Erzurumluoglu AM,Biological process,initial,2019-01-07,GCST007604,Smoking cessation
14289,Other/Mixed,128746.0,30617275.0,Erzurumluoglu AM,Other measurement,initial,2019-01-07,GCST007602,Smoking behaviour (cigarettes smoked per day)
4375,Asian,21962.0,30617275.0,Erzurumluoglu AM,Biological process,initial,2019-01-07,GCST007603,Smoking initiation
12527,European,376113.0,30617256.0,Jansen IE,Other measurement,initial,2019-01-07,GCST007321,Family history of Alzheimer's disease
14290,Other/Mixed,131892.0,30617275.0,Erzurumluoglu AM,Other measurement,initial,2019-01-07,GCST007601,Smoking behaviour (cigarette pack-years)
11576,European,79145.0,30617256.0,Jansen IE,Neurological disorder,initial,2019-01-07,GCST007319,Alzheimer's disease (late onset)
12434,European,324851.0,30617275.0,Erzurumluoglu AM,Biological process,initial,2019-01-07,GCST007603,Smoking initiation
11505,European,70017.0,30626913.0,Amare AT,Neurological disorder,initial,2019-01-09,GCST007256,Broad depression or major depressive disorder (recurrent)
11654,European,86748.0,30626913.0,Amare AT,Neurological disorder,initial,2019-01-09,GCST007255,Broad depression or bipolar disorder
4127,Asian,10640.0,30626913.0,Amare AT,Neurological disorder,initial,2019-01-09,GCST007256,Broad depression or major depressive disorder (recurrent)
11506,European,70017.0,30626913.0,Amare AT,Neurological disorder,initial,2019-01-09,GCST007257,Broad depression or schizophrenia
12531,European,377371.0,30626913.0,Amare AT,Neurological disorder,initial,2019-01-09,GCST007254,Broad depression or major depressive disorder (self-reported)
10364,European,17480.0,30636644.0,Nazarian A,Neurological disorder,initial,2019-01-12,GCST007600,Alzheimer's disease
12560,European,404291.0,30643258.0,Karlsson Linner R,Biological process,initial,2019-01-14,GCST007329,Automobile speeding propensity
12267,European,228033.0,30643256.0,Baselmans BML,"Neurological disorder, Other measurement",replication,2019-01-14,GCST007340,Depressive symptoms
12705,European,1067913.0,30643256.0,Baselmans BML,"Neurological disorder, Other measurement",initial,2019-01-14,GCST007340,Depressive symptoms
12708,European,1232091.0,30643251.0,Liu M,"Other measurement, Biological process",initial,2019-01-14,GCST007474,Smoking initiation (ever regular vs never regular)
12711,European,1359002.0,30643251.0,Liu M,Other measurement,initial,2019-01-14,GCST007468,Smoking initiation (ever regular vs never regular) (MTAG)
12702,European,975353.0,30643258.0,Karlsson Linner R,Biological process,initial,2019-01-14,GCST007325,General risk tolerance (MTAG)
12697,European,820192.0,30643251.0,Liu M,Biological process,initial,2019-01-14,GCST007464,Smoking cessation (MTAG)
1296,African American or Afro-Caribbean,5984.0,30642363.0,Hoffman J,Cancer,replication,2019-01-14,GCST006985,Breast cancer
12568,European,410603.0,30643256.0,Baselmans BML,Other measurement,initial,2019-01-14,GCST007338,Positive affect
12571,European,414343.0,30643258.0,Karlsson Linner R,"Biological process, Other measurement",initial,2019-01-14,GCST007328,Alcohol consumption (drinks per week)
12699,European,931815.0,30643251.0,Liu M,Biological process,initial,2019-01-14,GCST007462,Age of smoking initiation (MTAG)
13413,Hispanic or Latin American,8801.0,30642363.0,Hoffman J,Cancer,initial,2019-01-14,GCST006985,Breast cancer
11600,European,80852.0,30643256.0,Baselmans BML,Other measurement,initial,2019-01-14,GCST007337,Life satisfaction
12701,European,941280.0,30643251.0,Liu M,"Biological process, Other measurement",initial,2019-01-14,GCST007461,Alcohol consumption (drinks per week)
12700,European,939908.0,30643258.0,Karlsson Linner R,Biological process,initial,2019-01-14,GCST007322,General risk tolerance
12704,European,1039210.0,30643251.0,Liu M,Other measurement,initial,2019-01-14,GCST007472,Alcohol consumption (drinks per week) (MTAG)
12713,European,2083151.0,30643256.0,Baselmans BML,Other measurement,initial,2019-01-14,GCST007341,Well-being spectrum (multivariate analysis)
12693,European,765694.0,30643255.0,Kristjansson RP,Neurological disorder,initial,2019-01-14,GCST007444,Chronic rhinosinusitis
12355,European,287239.0,30643256.0,Baselmans BML,Other measurement,replication,2019-01-14,GCST007341,Well-being spectrum (multivariate analysis)
12530,European,377334.0,30643251.0,Liu M,Other measurement,initial,2019-01-14,GCST007459,Smoking behaviour (cigarettes smoked per day)
1181,African American or Afro-Caribbean,3420.0,30642921.0,de Vries PS,Other measurement,initial,2019-01-14,GCST007402,Factor VII activity or levels
1180,African American or Afro-Caribbean,3420.0,30642921.0,de Vries PS,Other measurement,initial,2019-01-14,GCST007401,Factor VII activity
10512,European,20014.0,30642921.0,de Vries PS,Other measurement,initial,2019-01-14,GCST007401,Factor VII activity
3994,Asian,8719.0,30642363.0,Hoffman J,Cancer,replication,2019-01-14,GCST006985,Breast cancer
7939,European,3344.0,30649302.0,Ruth KS,Other measurement,initial,2019-01-14,GCST007363,Anti-Mullerian hormone levels in pre-menopausal women of late reproductive age
12656,European,547219.0,30643251.0,Liu M,Biological process,initial,2019-01-14,GCST007460,Smoking cessation
12653,European,523783.0,30643256.0,Baselmans BML,"Neurological disorder, Other measurement",initial,2019-01-14,GCST007339,Neuroticism
10699,European,24075.0,30642921.0,de Vries PS,Other measurement,initial,2019-01-14,GCST007402,Factor VII activity or levels
12652,European,518633.0,30643258.0,Karlsson Linner R,"Biological process, Other measurement",initial,2019-01-14,GCST007327,Smoking status (ever vs never smokers)
3389,Asian,3574.0,30643196.0,Hitomi Y,Cancer,initial,2019-01-14,GCST007036,Primary biliary cholangitis
12470,European,341427.0,30643251.0,Liu M,"Biological process, Other measurement",initial,2019-01-14,GCST007458,Age of smoking initiation
12659,European,557923.0,30643258.0,Karlsson Linner R,Biological process,initial,2019-01-14,GCST007324,Adventurousness
12559,European,403928.0,30643251.0,Liu M,Other measurement,initial,2019-01-14,GCST007463,Cigarettes smoked per day (MTAG)
13219,Hispanic or Latin American,3992.0,30642363.0,Hoffman J,Cancer,replication,2019-01-14,GCST006985,Breast cancer
12416,European,315894.0,30643258.0,Karlsson Linner R,Biological process,initial,2019-01-14,GCST007323,Risk-taking tendency (4-domain principal component model)
11020,European,35445.0,30643258.0,Karlsson Linner R,Biological process,replication,2019-01-14,GCST007322,General risk tolerance
12512,European,370711.0,30643258.0,Karlsson Linner R,Other measurement,initial,2019-01-14,GCST007326,Number of sexual partners
12683,European,719047.0,30643255.0,Kristjansson RP,Cancer,initial,2019-01-14,GCST007443,Nasal polyps
11394,European,59206.0,30643256.0,Baselmans BML,"Neurological disorder, Other measurement",replication,2019-01-14,GCST007339,Neuroticism
125,African,552.0,30647433.0,Legge SE,"Response to drug, Neurological disorder, Hematological measurement",initial,2019-01-15,GCST006987,Neutrophil level response to clozapine in treatment-resistant schizophrenia
9112,European,6932.0,30649180.0,Luo Q,Other measurement,initial,2019-01-16,GCST007357,Voxel-wise structural brain imaging measurements
12941,Hispanic or Latin American,699.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007729,Small subcortical brain infarct
8965,European,6341.0,30651383.0,Chauhan G,Cardiovascular disease,replication,2019-01-16,GCST007730,Brain infarct
1883,Asian,215.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007730,Brain infarct
447,African American or Afro-Caribbean,40.0,30648747.0,Dudenkov TM,"Response to drug, Cancer",initial,2019-01-16,GCST007664,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer
8816,European,5748.0,30651383.0,Chauhan G,Cardiovascular disease,replication,2019-01-16,GCST007729,Small subcortical brain infarct
2196,Asian,521.0,30651383.0,Chauhan G,Cardiovascular disease,replication,2019-01-16,GCST007730,Brain infarct
10221,European,15464.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007729,Small subcortical brain infarct
1870,Asian,208.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007729,Small subcortical brain infarct
1869,Asian,207.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007730,Brain infarct
12956,Hispanic or Latin American,737.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007730,Brain infarct
1613,Asian,13.0,30648747.0,Dudenkov TM,"Response to drug, Cancer",initial,2019-01-16,GCST007664,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer
6841,European,1721.0,30649180.0,Luo Q,Other measurement,initial,2019-01-16,GCST007357,Voxel-wise structural brain imaging measurements
1857,Asian,196.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007729,Small subcortical brain infarct
5621,European,634.0,30648747.0,Dudenkov TM,"Response to drug, Cancer",initial,2019-01-16,GCST007664,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer
823,African American or Afro-Caribbean,994.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007729,Small subcortical brain infarct
967,African American or Afro-Caribbean,1834.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007730,Brain infarct
10396,European,17956.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007730,Brain infarct
931,African American or Afro-Caribbean,1488.0,30655502.0,Levey DF,Other measurement,replication,2019-01-17,GCST007019,Suicide attempt severity
6452,European,1252.0,30868120.0,Berghuis B,"Response to drug, Other trait, Neurological disorder",initial,2019-01-17,GCST007809,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
6451,European,1252.0,30868120.0,Berghuis B,"Other measurement, Neurological disorder",initial,2019-01-17,GCST007814,Sodium levels in epilepsy
5857,European,804.0,30868120.0,Berghuis B,"Response to drug, Other trait, Neurological disorder",initial,2019-01-17,GCST007810,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
13169,Hispanic or Latin American,2963.0,30655502.0,Levey DF,Other measurement,replication,2019-01-17,GCST007019,Suicide attempt severity
5328,European,468.0,30868120.0,Berghuis B,"Other measurement, Neurological disorder",initial,2019-01-17,GCST007813,"Carbamazepine metabolism (carbamazepine-10,11-diol to carbamazepine ratio) in epilepsy"
5042,European,297.0,30868120.0,Berghuis B,"Response to drug, Other trait, Neurological disorder",initial,2019-01-17,GCST007812,Oxcarbazepine-induced hyponatremia in epilepsy
1218,African American or Afro-Caribbean,3881.0,30655502.0,Levey DF,Other measurement,initial,2019-01-17,GCST007019,Suicide attempt severity
9636,European,9382.0,30655502.0,Levey DF,Other measurement,replication,2019-01-17,GCST007019,Suicide attempt severity
6221,European,1031.0,30868120.0,Berghuis B,"Other trait, Response to drug, Neurological disorder",initial,2019-01-17,GCST007811,Carbamazepine-induced hyponatremia in epilepsy
7394,European,2439.0,30655502.0,Levey DF,Other measurement,initial,2019-01-17,GCST007019,Suicide attempt severity
2280,Asian,665.0,30659259.0,Imaizumi A,Other measurement,replication,2019-01-18,GCST007384,Plasma free proline levels
2483,Asian,959.0,30657218.0,Park SY,Other disease,initial,2019-01-18,GCST007520,Asthma-chronic obstructive pulmonary disease overlap syndrome in asthma
6394,European,1202.0,30659137.0,Traylor M,Other measurement,replication,2019-01-18,GCST007305,White matter hyperintensity volume
6326,European,1145.0,30654714.0,Hurst Z,"Biological process, Cancer",initial,2019-01-18,GCST008107,Radioiodine-refractory disease in thyroid cancer
2281,Asian,665.0,30659259.0,Imaizumi A,Other measurement,replication,2019-01-18,GCST007386,Plasma free asparagine levels
12282,European,239417.0,30664875.0,Cirulli ET,"Response to drug, Digestive system disorder",replication,2019-01-18,GCST007774,Drug-induced liver injury
2649,Asian,1338.0,30659259.0,Imaizumi A,Other measurement,initial,2019-01-18,GCST007386,Plasma free asparagine levels
9892,European,11226.0,30659137.0,Traylor M,Other measurement,initial,2019-01-18,GCST007305,White matter hyperintensity volume
3858,Asian,7271.0,30657218.0,Park SY,Other disease,initial,2019-01-18,GCST007519,Adult asthma
7108,European,2062.0,30891314.0,Saad MN,Immune system disorder,initial,2019-01-18,GCST007843,Rheumatoid arthritis
12988,Hispanic or Latin American,827.0,30664875.0,Cirulli ET,"Response to drug, Digestive system disorder",initial,2019-01-18,GCST007774,Drug-induced liver injury
926,African American or Afro-Caribbean,1447.0,30664875.0,Cirulli ET,"Response to drug, Digestive system disorder",initial,2019-01-18,GCST007774,Drug-induced liver injury
3760,Asian,6143.0,30657218.0,Park SY,Other disease,initial,2019-01-18,GCST007521,Asthma-chronic obstructive  pulmonary disease overlap syndrome
461,African American or Afro-Caribbean,55.0,30654714.0,Hurst Z,"Biological process, Cancer",initial,2019-01-18,GCST008107,Radioiodine-refractory disease in thyroid cancer
10159,European,14689.0,30659475.0,Arias-Vasquez A,Other measurement,initial,2019-01-18,GCST007279,Attention deficit hyperactivity disorder symptom score
2647,Asian,1338.0,30659259.0,Imaizumi A,Other measurement,initial,2019-01-18,GCST007384,Plasma free proline levels
2646,Asian,1338.0,30659259.0,Imaizumi A,Other measurement,initial,2019-01-18,GCST007383,Plasma free amino acid levels (adjusted for one other PFAA)
2645,Asian,1338.0,30659259.0,Imaizumi A,Other measurement,initial,2019-01-18,GCST007382,Plasma free amino acid levels (adjusted for twenty other PFAAs)
2648,Asian,1338.0,30659259.0,Imaizumi A,Other measurement,initial,2019-01-18,GCST007385,Plasma free amino acid levels
14042,Other/Mixed,815.0,30713548.0,Schurz H,Other disease,initial,2019-01-18,GCST007232,Tuberculosis (SNP x SNP interaction)
14043,Other/Mixed,815.0,30713548.0,Schurz H,"Other disease, Other measurement",initial,2019-01-18,GCST007231,Tuberculosis
9981,European,12203.0,30664875.0,Cirulli ET,"Response to drug, Digestive system disorder",initial,2019-01-18,GCST007774,Drug-induced liver injury
12611,European,451099.0,30661054.0,Schafmayer C,Digestive system disorder,initial,2019-01-19,GCST008105,Diverticular disease
11033,European,36089.0,30661054.0,Schafmayer C,Digestive system disorder,replication,2019-01-19,GCST008105,Diverticular disease
9809,European,10594.0,30661239.0,Nicoletti P,Digestive system disorder,initial,2019-01-19,GCST007608,Drug-induced liver injury (isoxazolyl penicillins)
9816,European,10603.0,30661239.0,Nicoletti P,Digestive system disorder,initial,2019-01-19,GCST007607,Drug-induced liver injury (amoxicillin)
9130,European,7032.0,30661239.0,Nicoletti P,Digestive system disorder,initial,2019-01-19,GCST007606,Drug-induced liver injury (flucloxacillin)
11838,European,116138.0,30664634.0,Rask-Andersen M,Body measurement,initial,2019-01-21,GCST007294,Body fat distribution (trunk fat ratio)
11839,European,116138.0,30664634.0,Rask-Andersen M,Body measurement,initial,2019-01-21,GCST007295,Body fat distribution (leg fat ratio)
13329,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,"Other measurement, Other trait",initial,2019-01-21,GCST007454,Hair color
13328,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,"Other measurement, Other trait",initial,2019-01-21,GCST007453,Eye color
12546,European,393873.0,30664745.0,Tachmazidou I,Other disease,initial,2019-01-21,GCST007091,Osteoarthritis (hip)
13327,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,Other measurement,initial,2019-01-21,GCST007457,Eye color (saturation)
13326,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,Other measurement,initial,2019-01-21,GCST007456,Eye color (hue)
13330,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,"Other trait, Other measurement",initial,2019-01-21,GCST007452,Skin pigmentation
13325,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,Other measurement,initial,2019-01-21,GCST007455,Eye color (brightness)
11837,European,116138.0,30664634.0,Rask-Andersen M,Body measurement,initial,2019-01-21,GCST007293,Body fat distribution (arm fat ratio)
13324,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,Other measurement,initial,2019-01-21,GCST007451,"Skin, hair and eye pigmentation (multivariate analysis)"
12288,European,246360.0,30664634.0,Rask-Andersen M,Body measurement,replication,2019-01-21,GCST007293,Body fat distribution (arm fat ratio)
12289,European,246360.0,30664634.0,Rask-Andersen M,Body measurement,replication,2019-01-21,GCST007294,Body fat distribution (trunk fat ratio)
12290,European,246360.0,30664634.0,Rask-Andersen M,Body measurement,replication,2019-01-21,GCST007295,Body fat distribution (leg fat ratio)
12557,European,403124.0,30664745.0,Tachmazidou I,Other disease,initial,2019-01-21,GCST007090,Knee osteoarthritis
12574,European,417596.0,30664745.0,Tachmazidou I,Other disease,initial,2019-01-21,GCST007092,Osteoarthritis of the hip or knee
12618,European,455221.0,30664745.0,Tachmazidou I,Other disease,initial,2019-01-21,GCST007093,Osteoarthritis
11785,European,107617.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
3505,Asian,4441.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
3507,Asian,4442.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
13307,Hispanic or Latin American,5652.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
13306,Hispanic or Latin American,5624.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
3504,Asian,4441.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
3500,Asian,4401.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
3499,Asian,4401.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
13305,Hispanic or Latin American,5624.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
3506,Asian,4442.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
13308,Hispanic or Latin American,5652.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
3794,Asian,6403.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
3793,Asian,6403.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
1511,African American or Afro-Caribbean,20487.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
1010,African American or Afro-Caribbean,2092.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
1011,African American or Afro-Caribbean,2092.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
1016,African American or Afro-Caribbean,2120.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
1017,African American or Afro-Caribbean,2120.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
1209,African American or Afro-Caribbean,3778.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
1208,African American or Afro-Caribbean,3778.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
3201,Asian,2579.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
3783,Asian,6355.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
3200,Asian,2579.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
3784,Asian,6355.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
11784,European,107617.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
1510,African American or Afro-Caribbean,20487.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
13450,Hispanic or Latin American,11422.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
11518,European,72102.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
1506,African American or Afro-Caribbean,20021.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
11563,European,77688.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
11564,European,77688.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
210,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
1505,African American or Afro-Caribbean,20021.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
209,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
214,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
11604,European,81966.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
13424,Hispanic or Latin American,9187.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
13425,Hispanic or Latin American,9187.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
13446,Hispanic or Latin American,11239.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
13447,Hispanic or Latin American,11239.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
13448,Hispanic or Latin American,11421.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
13449,Hispanic or Latin American,11421.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
11603,European,81966.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
211,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
3055,Asian,2149.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
212,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
1507,African American or Afro-Caribbean,20126.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
11622,European,84608.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
3056,Asian,2149.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
11517,European,72102.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
11623,European,84608.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
3051,Asian,2148.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
3052,Asian,2148.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
3053,Asian,2149.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
213,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
13451,Hispanic or Latin American,11422.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
11633,European,84902.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
3054,Asian,2149.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
1508,African American or Afro-Caribbean,20126.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
11632,European,84902.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
10535,European,20623.0,30674883.0,Jin Y,Immune system disorder,initial,2019-01-23,GCST007112,Vitiligo (late onset)
6819,European,1704.0,30674883.0,Jin Y,Immune system disorder,replication,2019-01-23,GCST007112,Vitiligo (late onset)
10505,European,19860.0,30674883.0,Jin Y,Immune system disorder,initial,2019-01-23,GCST007111,Vitiligo (early onset)
6931,European,1830.0,30674883.0,Jin Y,Immune system disorder,replication,2019-01-23,GCST007111,Vitiligo (early onset)
14066,Other/Mixed,920.0,30674050.0,Spiegel AM,Other disease,initial,2019-01-23,GCST007956,Maternal chorioamnionitis
8423,European,4622.0,30674623.0,Syreeni A,"Other measurement, Metabolic disorder",initial,2019-01-23,GCST007605,Glycated hemoglobin levels in type 1 diabetes
7694,European,2927.0,30677029.0,Riveros-McKay F,Body measurement,initial,2019-01-24,GCST007240,Obese vs. thin
10817,European,28698.0,30679814.0,van Setten J,Cardiovascular measurement,initial,2019-01-24,GCST007217,RR interval (heart rate)
9874,European,11058.0,30677029.0,Riveros-McKay F,Body measurement,replication,2019-01-24,GCST007240,Obese vs. thin
1005,African American or Afro-Caribbean,2048.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007218,QT interval
10904,European,32132.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007227,QRS duration
10894,European,31695.0,30679814.0,van Setten J,Cardiovascular measurement,initial,2019-01-24,GCST007226,PR interval
1006,African American or Afro-Caribbean,2048.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007227,QRS duration
10923,European,32597.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007218,QT interval
9322,European,7931.0,30677029.0,Riveros-McKay F,Body measurement,initial,2019-01-24,GCST007242,Normal body mass index vs. thin
1009,African American or Afro-Caribbean,2070.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007226,PR interval
10915,European,32405.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007226,PR interval
10712,European,24252.0,30677029.0,Riveros-McKay F,Body measurement,replication,2019-01-24,GCST007242,Normal body mass index vs. thin
10746,European,25509.0,30679814.0,van Setten J,Cardiovascular measurement,initial,2019-01-24,GCST007227,QRS duration
10775,European,26794.0,30679814.0,van Setten J,Cardiovascular measurement,initial,2019-01-24,GCST007218,QT interval
10804,European,28246.0,30677029.0,Riveros-McKay F,"Metabolic disorder, Body measurement",replication,2019-01-24,GCST007241,Obesity (extreme)
9315,European,7916.0,30677029.0,Riveros-McKay F,"Metabolic disorder, Body measurement",initial,2019-01-24,GCST007241,Obesity (extreme)
11451,European,65534.0,30692689.0,Schork AJ,"Neurological disorder, Metabolic disorder",initial,2019-01-28,GCST007777,Psychiatric disorder
13031,Hispanic or Latin American,1095.0,30692554.0,Bustos BI,Digestive system disorder,initial,2019-01-28,GCST007050,Gallstone disease
13089,Hispanic or Latin American,1643.0,30692554.0,Bustos BI,Digestive system disorder,replication,2019-01-28,GCST007050,Gallstone disease
8905,European,6092.0,30692554.0,Bustos BI,Digestive system disorder,replication,2019-01-28,GCST007050,Gallstone disease
13228,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008077,LDL cholesterol levels
1520,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
1519,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
1426,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
12607,European,449734.0,30696823.0,Jones SE,"Biological process, Other measurement",initial,2019-01-29,GCST007576,Chronotype
999,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
13227,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008076,Triglyceride levels
997,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1517,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
996,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1518,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
998,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
13222,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
13225,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
13136,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
13137,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
1524,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008077,LDL cholesterol levels
13138,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008087,Triglyceride levels in current drinkers
1523,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008076,Triglyceride levels
13139,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
13140,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
13141,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
13142,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
13143,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
13144,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
13220,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
1522,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008070,HDL cholesterol levels
13221,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
995,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1521,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
13223,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
13226,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008070,HDL cholesterol levels
994,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
991,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
1516,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
12558,European,403195.0,30696823.0,Jones SE,Other measurement,initial,2019-01-29,GCST007565,Morning person
13534,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
13535,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
13536,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
13537,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
13538,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
13539,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
13540,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
13411,Hispanic or Latin American,8606.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
13541,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
1419,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
1420,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
1421,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008087,Triglyceride levels in current drinkers
712,African American or Afro-Caribbean,493.0,30697902.0,Hernandez-Pacheco N,"Response to drug, Other measurement",initial,2019-01-29,GCST007100,Asthma exacerbations in inhaled corticosteroid treatment
1422,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1423,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1424,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1425,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
13542,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
993,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
13410,Hispanic or Latin American,8606.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
910,African American or Afro-Caribbean,1349.0,30694715.0,Sakornsakolpat P,Other measurement,initial,2019-01-29,GCST007637,Diffusing capacity of carbon monoxide
992,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
1427,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
13345,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
13346,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
13347,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
13348,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
13349,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
13350,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
13409,Hispanic or Latin American,8606.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
1246,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
1248,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
1249,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
1250,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
1251,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
1252,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
1253,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
1254,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
12992,Hispanic or Latin American,854.0,30697902.0,Hernandez-Pacheco N,"Response to drug, Other measurement",initial,2019-01-29,GCST007100,Asthma exacerbations in inhaled corticosteroid treatment
1247,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
13224,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
3072,Asian,2169.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
11778,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
11776,European,107548.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
11775,European,107548.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
4474,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
4473,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
4472,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
4471,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
4470,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
4469,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
11693,European,89893.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008077,LDL cholesterol levels
11692,European,89893.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008076,Triglyceride levels
11691,European,89893.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008070,HDL cholesterol levels
11690,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
11689,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
11688,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11687,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11686,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11685,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4468,Asian,36673.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
4467,Asian,36673.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
4466,Asian,36673.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
4174,Asian,11706.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008077,LDL cholesterol levels
4173,Asian,11706.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008076,Triglyceride levels
4172,Asian,11706.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008070,HDL cholesterol levels
4171,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4170,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4169,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4168,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11777,European,107548.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
4167,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11779,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
11781,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
11961,European,136986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
11960,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
11959,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
11958,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11957,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11956,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11955,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
1951,Asian,267.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
1952,Asian,267.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
1953,Asian,267.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008087,Triglyceride levels in current drinkers
1954,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1955,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1956,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1957,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1958,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1959,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
4561,Asian,96276.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
4560,Asian,96276.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
4559,Asian,96276.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
4558,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4557,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4556,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4555,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4554,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4553,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
11783,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
11782,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
11780,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
4166,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4095,Asian,9986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
4094,Asian,9986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
11360,European,56505.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
11359,European,56505.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
3437,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3436,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3435,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3434,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3433,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3432,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3431,Asian,3905.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
3430,Asian,3905.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
3429,Asian,3905.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
3091,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3090,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3089,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3088,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3087,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3086,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3085,Asian,2224.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008087,Triglyceride levels in current drinkers
3084,Asian,2224.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
3083,Asian,2224.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
3071,Asian,2169.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
3070,Asian,2169.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
3069,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
3068,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
3067,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
3066,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
3065,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11361,European,56505.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008087,Triglyceride levels in current drinkers
11362,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
11363,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
11364,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
4093,Asian,9986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
4092,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4091,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4090,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4089,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4088,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4087,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
2270,Asian,662.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
2271,Asian,662.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
2272,Asian,662.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
2273,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
2274,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
2275,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
11962,European,136986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
2276,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
2278,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
2335,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
2336,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
2337,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
2338,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
2339,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
2340,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
2341,Asian,744.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008070,HDL cholesterol levels
2342,Asian,744.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008076,Triglyceride levels
2343,Asian,744.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008077,LDL cholesterol levels
11367,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
11366,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
11365,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
2277,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
11963,European,136986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
3064,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
8777,European,5586.0,30694715.0,Sakornsakolpat P,Other measurement,initial,2019-01-29,GCST007637,Diffusing capacity of carbon monoxide
12294,European,248100.0,30696823.0,Jones SE,Other measurement,replication,2019-01-29,GCST007565,Morning person
12293,European,248098.0,30696823.0,Jones SE,"Biological process, Other measurement",replication,2019-01-29,GCST007576,Chronotype
6813,European,1697.0,30697902.0,Hernandez-Pacheco N,"Response to drug, Other measurement",replication,2019-01-29,GCST007100,Asthma exacerbations in inhaled corticosteroid treatment
12391,European,300447.0,30729179.0,Zenin A,Other measurement,initial,2019-01-30,GCST007406,Healthspan
3826,Asian,6921.0,30729179.0,Zenin A,Other measurement,replication,2019-01-30,GCST007406,Healthspan
11602,European,81099.0,30729179.0,Zenin A,Other measurement,replication,2019-01-30,GCST007406,Healthspan
8559,European,4932.0,30711515.0,Hallberg P,"Neurological disorder, Response to drug",initial,2019-01-30,GCST007779,Pandemrix-induced narcolepsy
1212,African American or Afro-Caribbean,3799.0,30729179.0,Zenin A,Other measurement,replication,2019-01-30,GCST007406,Healthspan
255,African,3073.0,30729179.0,Zenin A,Other measurement,replication,2019-01-30,GCST007406,Healthspan
2677,Asian,1422.0,30729179.0,Zenin A,Other measurement,replication,2019-01-30,GCST007406,Healthspan
4646,European,31.0,30711515.0,Hallberg P,"Neurological disorder, Response to drug",replication,2019-01-30,GCST007779,Pandemrix-induced narcolepsy
4122,Asian,10330.0,30705256.0,Koshimizu H,Other measurement,initial,2019-01-31,GCST007297,Psychological distress
7137,European,2102.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007394,Mitochondrial DNA copy number
5086,European,330.0,30706531.0,Tao F,"Neurological disorder, Other measurement",initial,2019-01-31,GCST007304,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A
8754,European,5461.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007399,Mitochondrial DNA copy number
1702,Asian,80.0,30706531.0,Tao F,"Neurological disorder, Other measurement",replication,2019-01-31,GCST007304,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A
7974,European,3405.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007396,Mitochondrial DNA copy number (white blood cells)
7975,European,3405.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007398,Mitochondrial DNA copy number (white blood cells)
7995,European,3452.0,30700811.0,Wigmore EM,Response to drug,initial,2019-01-31,GCST007355,Antidepressant treatment resistance (> 2 drugs prescribed)
7996,European,3452.0,30700811.0,Wigmore EM,Response to drug,initial,2019-01-31,GCST007356,Antidepressant treatment resistance (number of drugs prescribed)
8753,European,5461.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007395,Mitochondrial DNA copy number
8084,European,3647.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007393,Mitochondrial DNA copy number
6016,European,919.0,30806694.0,Walker GJ,"Digestive system disorder, Response to drug, Other trait",initial,2019-02-01,GCST008801,Thiopurine-induced myelosuppression in inflammatory bowel disease
6289,European,1096.0,30794219.0,MacInnes SJ,"Other trait, Other disease, Other measurement",initial,2019-02-01,GCST007550,Osteolysis in total hip arthroplasty (time to prosthesis revision)
8027,European,3514.0,30794219.0,MacInnes SJ,"Other trait, Other disease",initial,2019-02-01,GCST007549,Osteolysis in total hip arthroplasty
4630,Asian,191764.0,30718926.0,Suzuki K,Metabolic disorder,initial,2019-02-04,GCST007847,Type 2 diabetes
8543,European,4919.0,30718454.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2019-02-04,GCST007407,Depressive symptoms
8544,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007408,Depressive symptoms x stressful life events interaction (1df test)
8545,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007409,Depressive symptoms x stressful life events interaction (2df test)
8548,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007412,Depressive symptoms x independent stressful life events interaction (1df test)
8549,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007413,Depressive symptoms x independent stressful life events interaction (2df test)
11744,European,99057.0,30718454.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2019-02-04,GCST007407,Depressive symptoms
11746,European,99057.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007409,Depressive symptoms x stressful life events interaction (2df test)
12709,European,1306354.0,30718901.0,Howard DM,"Neurological disorder, Other measurement",replication,2019-02-04,GCST007342,Depression
8547,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007411,Depressive symptoms x dependent stressful life events interaction (2df test)
11745,European,99057.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007408,Depressive symptoms x stressful life events interaction (1df test)
8546,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007410,Depressive symptoms x dependent stressful life events interaction (1df test)
3835,Asian,6949.0,30718733.0,Moon S,Liver enzyme measurement,initial,2019-02-04,GCST007439,Aspartate aminotransferase levels
2992,Asian,2000.0,30714141.0,Chen H,Cancer,initial,2019-02-04,GCST007842,Glioma
10652,European,22861.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007626,Lack of perseverance
10649,European,22774.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007623,Lack of premeditation
10647,European,22745.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007621,Sensation seeking
10646,European,22738.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007624,Positive urgency
10639,European,22572.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007630,Drug experimentation measurement
10613,European,21876.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007627,Impulsivity (attentional)
10602,European,21806.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007628,Impulsivity (motor)
10599,European,21786.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007629,Impulsivity (non-planning)
3836,Asian,6949.0,30718733.0,Moon S,Liver enzyme measurement,initial,2019-02-04,GCST007440,Alanine aminotransferase levels
10592,European,21495.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007622,Impulsivity
3740,Asian,6000.0,30718733.0,Moon S,Lipid or lipoprotein measurement,replication,2019-02-04,GCST007437,Triglyceride levels
3741,Asian,6000.0,30718733.0,Moon S,Lipid or lipoprotein measurement,replication,2019-02-04,GCST007438,High density lipoprotein cholesterol levels
3742,Asian,6000.0,30718733.0,Moon S,Lipid or lipoprotein measurement,replication,2019-02-04,GCST007441,Total cholesterol levels
3743,Asian,6000.0,30718733.0,Moon S,Lipid or lipoprotein measurement,replication,2019-02-04,GCST007442,Low density lipoprotein cholesterol levels
3744,Asian,6000.0,30718733.0,Moon S,Liver enzyme measurement,replication,2019-02-04,GCST007439,Aspartate aminotransferase levels
3745,Asian,6000.0,30718733.0,Moon S,Liver enzyme measurement,replication,2019-02-04,GCST007440,Alanine aminotransferase levels
3832,Asian,6949.0,30718733.0,Moon S,Lipid or lipoprotein measurement,initial,2019-02-04,GCST007438,High density lipoprotein cholesterol levels
3833,Asian,6949.0,30718733.0,Moon S,Lipid or lipoprotein measurement,initial,2019-02-04,GCST007441,Total cholesterol levels
3834,Asian,6949.0,30718733.0,Moon S,Lipid or lipoprotein measurement,initial,2019-02-04,GCST007442,Low density lipoprotein cholesterol levels
3646,Asian,5479.0,30714141.0,Chen H,Cancer,replication,2019-02-04,GCST007842,Glioma
3831,Asian,6949.0,30718733.0,Moon S,Lipid or lipoprotein measurement,initial,2019-02-04,GCST007437,Triglyceride levels
10651,European,22795.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007625,Negative urgency
12601,European,446238.0,30718901.0,Howard DM,"Neurological disorder, Other measurement",initial,2019-02-04,GCST007342,Depression
11786,European,108090.0,30745170.0,Strawbridge RJ,Other measurement,initial,2019-02-07,GCST007390,Suicidality (suicidal ideation/attempts)
11888,European,122808.0,30745170.0,Strawbridge RJ,Other measurement,initial,2019-02-07,GCST007389,Suicidality
11750,European,100234.0,30745170.0,Strawbridge RJ,Other measurement,initial,2019-02-07,GCST007391,Deliberate self-harm
2249,Asian,619.0,30753327.0,Hishida A,Digestive system disorder,replication,2019-02-08,GCST008713,Severe gastric atrophy
2441,Asian,880.0,30753327.0,Hishida A,Digestive system disorder,initial,2019-02-08,GCST008713,Severe gastric atrophy
2615,Asian,1239.0,30753327.0,Hishida A,Digestive system disorder,initial,2019-02-08,GCST008714,Gastric atrophy
8177,European,3902.0,30737484.0,Thomsen H,Other disease,initial,2019-02-08,GCST007824,Monoclonal gammopathy of undetermined significance
3357,Asian,3385.0,30753327.0,Hishida A,Other measurement,initial,2019-02-08,GCST008716,Anti-Helicobacter pylori IgG seropositivity
3356,Asian,3385.0,30753327.0,Hishida A,Other measurement,initial,2019-02-08,GCST008712,Pepsinogen I/II ratio
2626,Asian,1275.0,30753327.0,Hishida A,Digestive system disorder,replication,2019-02-08,GCST008714,Gastric atrophy
3273,Asian,2885.0,30753327.0,Hishida A,Other measurement,replication,2019-02-08,GCST008716,Anti-Helicobacter pylori IgG seropositivity
3272,Asian,2885.0,30753327.0,Hishida A,Other measurement,replication,2019-02-08,GCST008712,Pepsinogen I/II ratio
3355,Asian,3385.0,30753327.0,Hishida A,Other measurement,initial,2019-02-08,GCST008709,Pepsinogen-I levels
3271,Asian,2885.0,30753327.0,Hishida A,Other measurement,replication,2019-02-08,GCST008709,Pepsinogen-I levels
5157,European,379.0,30738427.0,Penney ME,"Cancer, Other measurement",initial,2019-02-09,GCST007434,Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event)
7503,European,2563.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007469,Rapid automised naming of digits
8006,European,3468.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007479,Reading ability (multivariate)
7504,European,2563.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007470,Rapid automised naming of letters
7764,European,3093.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007465,Phoneme awareness
8005,European,3468.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007466,Word reading
7516,European,2591.0,30741946.0,Gialluisi A,"Biological process, Other measurement",initial,2019-02-11,GCST007471,Short-term memory (digit-span task)
7969,European,3399.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007467,Word spelling
7978,European,3409.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007478,Non-word reading
7502,European,2562.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007473,Rapid automised naming of pictures
12575,European,418553.0,30760885.0,Mbarek H,Other measurement,initial,2019-02-13,GCST007280,Number of twin births
1690,Asian,74.0,30767168.0,Shin JH,Other measurement,initial,2019-02-14,GCST007538,Cellular nuclear factor (erythroid-derived 2)-like 2 levels
4421,Asian,29315.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
4420,Asian,29315.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
12359,European,288492.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
1482,African American or Afro-Caribbean,15687.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
13232,Hispanic or Latin American,4075.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
12360,European,288492.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007487,Waist-to-hip ratio adjusted for BMI (additive genetic model)
12358,European,288492.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
1481,African American or Afro-Caribbean,15687.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
13231,Hispanic or Latin American,4075.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
3814,Asian,6800.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11934,European,132177.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007491,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11429,European,62500.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007496,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
14296,Other/Mixed,180131.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007501,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
14295,Other/Mixed,180131.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007500,Waist-to-hip ratio adjusted for BMI (additive genetic model)
14294,Other/Mixed,164238.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007493,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
14293,Other/Mixed,164238.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007492,Waist-to-hip ratio adjusted for BMI (additive genetic model)
12073,European,157516.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007503,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
12072,European,157516.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007502,Waist-to-hip ratio adjusted for BMI (additive genetic model)
3813,Asian,6800.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
12071,European,157516.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007501,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11420,European,62368.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007500,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11422,European,62368.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007502,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11423,European,62368.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007503,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11426,European,62500.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007492,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11427,European,62500.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007493,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11428,European,62500.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007494,Waist-to-hip ratio adjusted for BMI (additive genetic model)
12070,European,157516.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007500,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11421,European,62368.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007501,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
12361,European,288492.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007491,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11925,European,130976.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007492,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11926,European,130976.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007493,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11927,European,130976.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007494,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11931,European,132177.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11928,European,130976.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007496,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11932,European,132177.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11933,European,132177.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007487,Waist-to-hip ratio adjusted for BMI (additive genetic model)
6436,European,1235.0,30801552.0,Oetting WS,"Other trait, Response to drug, Metabolic disorder",initial,2019-02-19,GCST008578,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event)
6899,European,1785.0,30801552.0,Oetting WS,"Other trait, Response to drug",initial,2019-02-19,GCST008579,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event)
6900,European,1785.0,30801552.0,Oetting WS,"Other trait, Response to drug",initial,2019-02-19,GCST008580,Anemia in mycophenolic acid treated kidney transplant patients (time to event)
5654,European,657.0,30801552.0,Oetting WS,"Other trait, Response to drug",replication,2019-02-19,GCST008579,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event)
3294,Asian,2955.0,30779856.0,Lu HF,Other measurement,replication,2019-02-19,GCST007616,Calcaneus stiffness index
625,African American or Afro-Caribbean,299.0,30801552.0,Oetting WS,"Other trait, Other measurement",initial,2019-02-19,GCST008577,Tacrolimus trough concentration in kidney transplant patients
499,African American or Afro-Caribbean,94.0,30801552.0,Oetting WS,"Other trait, Response to drug, Metabolic disorder",replication,2019-02-19,GCST008578,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event)
3924,Asian,7742.0,30779856.0,Lu HF,Other measurement,initial,2019-02-19,GCST007616,Calcaneus stiffness index
6523,European,1352.0,30801552.0,Oetting WS,"Other trait, Other measurement, Response to drug",initial,2019-02-19,GCST008582,Nephrotoxicity in tacrolimus-treated kidney transplant patients (time to event)
5595,European,609.0,30801552.0,Oetting WS,"Other trait, Other measurement, Response to drug",replication,2019-02-19,GCST008582,Nephrotoxicity in tacrolimus-treated kidney transplant patients (time to event)
606,African American or Afro-Caribbean,256.0,30801552.0,Oetting WS,"Other trait, Response to drug, Metabolic disorder",initial,2019-02-19,GCST008578,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event)
5377,European,487.0,30801552.0,Oetting WS,"Other trait, Response to drug, Metabolic disorder",replication,2019-02-19,GCST008578,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event)
6535,European,1363.0,30801552.0,Oetting WS,"Other trait, Other measurement",initial,2019-02-19,GCST008577,Tacrolimus trough concentration in kidney transplant patients
552,African American or Afro-Caribbean,171.0,30801552.0,Oetting WS,"Other trait, Response to drug",replication,2019-02-19,GCST008579,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event)
646,African American or Afro-Caribbean,338.0,30801552.0,Oetting WS,"Other trait, Response to drug",initial,2019-02-19,GCST008579,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event)
551,African American or Afro-Caribbean,171.0,30801552.0,Oetting WS,"Other trait, Other measurement",replication,2019-02-19,GCST008577,Tacrolimus trough concentration in kidney transplant patients
5594,European,609.0,30801552.0,Oetting WS,"Other trait, Other measurement",replication,2019-02-19,GCST008577,Tacrolimus trough concentration in kidney transplant patients
5281,European,438.0,30801552.0,Oetting WS,"Other trait, Response to drug",replication,2019-02-19,GCST008580,Anemia in mycophenolic acid treated kidney transplant patients (time to event)
4678,European,63.0,30801552.0,Oetting WS,"Other trait, Other measurement, Response to drug",replication,2019-02-19,GCST008581,Nephrotoxicity in cyclosporine-treated kidney transplant patients (time to event)
5338,European,475.0,30801552.0,Oetting WS,"Other trait, Other measurement, Response to drug",initial,2019-02-19,GCST008581,Nephrotoxicity in cyclosporine-treated kidney transplant patients (time to event)
13299,Hispanic or Latin American,5136.0,30787307.0,Daya M,Other disease,initial,2019-02-20,GCST007266,Adult asthma
1412,African American or Afro-Caribbean,9518.0,30787307.0,Daya M,Other disease,initial,2019-02-20,GCST007266,Adult asthma
11443,European,64171.0,30787463.0,Escala-Garcia M,"Other measurement, Cancer",initial,2019-02-21,GCST007475,Breast cancer specific mortality in estrogen receptor positive breast cancer
10260,European,16172.0,30787463.0,Escala-Garcia M,"Other measurement, Cancer",initial,2019-02-21,GCST007476,Breast cancer specific mortality in estrogen receptor negative breast cancer
11742,European,96661.0,30787463.0,Escala-Garcia M,"Other measurement, Cancer",initial,2019-02-21,GCST007477,Breast cancer specific mortality in breast cancer
3599,Asian,5140.0,30810208.0,Nishiyama T,Other measurement,replication,2019-02-22,GCST008770,Sleep duration
4439,Asian,31230.0,30810208.0,Nishiyama T,Other measurement,initial,2019-02-22,GCST008770,Sleep duration
12498,European,359916.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007985,Snoring
10711,European,24218.0,30804560.0,Shrine N,Other measurement,replication,2019-02-25,GCST007430,Peak expiratory flow
5663,European,662.0,30801121.0,O'Donnell S,"Digestive system disorder, Other measurement",initial,2019-02-25,GCST007497,Crohn's disease (time to progression)
6463,European,1263.0,30801121.0,O'Donnell S,"Digestive system disorder, Other measurement",initial,2019-02-25,GCST007499,Crohn's disease (indolent vs progressive)
12584,European,434835.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007983,Morningness
11816,European,112209.0,30805717.0,Zhu Z,"Neurological disorder, Other measurement",initial,2019-02-25,GCST007825,Alzheimer's disease or fasting glucose levels (pleiotropy)
11575,European,79005.0,30804560.0,Shrine N,Other measurement,replication,2019-02-25,GCST007432,FEV1
11574,European,79005.0,30804560.0,Shrine N,Other measurement,replication,2019-02-25,GCST007431,Lung function (FEV1/FVC)
12539,European,386577.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007987,Daytime nap
11570,European,78990.0,30804566.0,Lane JM,Other measurement,replication,2019-02-25,GCST007387,Insomnia symptoms (never/rarely vs. sometimes/usually)
11571,European,78990.0,30804566.0,Lane JM,Other measurement,replication,2019-02-25,GCST007388,Insomnia symptoms (never/rarely vs. usually)
11212,European,46350.0,30804558.0,Grove J,Neurological disorder,initial,2019-02-25,GCST007553,Autism and major depressive disorder (MTAG)
11213,European,46350.0,30804558.0,Grove J,Neurological disorder,initial,2019-02-25,GCST007555,Autism and schizophrenia (MTAG)
11214,European,46350.0,30804558.0,Grove J,Neurological disorder,initial,2019-02-25,GCST007556,Autism spectrum disorder
11215,European,46350.0,30804558.0,Grove J,"Other measurement, Neurological disorder",initial,2019-02-25,GCST007554,Autism and educational attainment (MTAG)
11573,European,79005.0,30804560.0,Shrine N,Other measurement,replication,2019-02-25,GCST007429,Lung function (FVC)
12616,European,453379.0,30804566.0,Lane JM,Other measurement,initial,2019-02-25,GCST007387,Insomnia symptoms (never/rarely vs. sometimes/usually)
12538,European,386548.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007984,Daytime sleepiness
12537,European,385949.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007986,Ease of getting up in the morning
11999,European,144498.0,30804558.0,Grove J,Neurological disorder,replication,2019-02-25,GCST007556,Autism spectrum disorder
12428,European,321047.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007431,Lung function (FEV1/FVC)
12429,European,321047.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007432,FEV1
11833,European,114974.0,30805717.0,Zhu Z,"Neurological disorder, Lipid or lipoprotein measurement",initial,2019-02-25,GCST007827,Alzheimer's disease or HDL levels (pleiotropy)
12710,European,1331010.0,30804565.0,Jansen PR,"Neurological disorder, Other measurement",initial,2019-02-25,GCST007988,Insomnia
12280,European,237627.0,30804566.0,Lane JM,Other measurement,initial,2019-02-25,GCST007388,Insomnia symptoms (never/rarely vs. usually)
6531,European,1360.0,30801121.0,O'Donnell S,"Digestive system disorder, Other measurement",initial,2019-02-25,GCST007498,Crohn's disease (time to first abdominal surgery)
11771,European,105912.0,30805717.0,Zhu Z,"Neurological disorder, Other measurement",initial,2019-02-25,GCST007826,Alzheimer's disease or fasting insulin levels (pleiotropy)
12426,European,321047.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007429,Lung function (FVC)
2210,Asian,546.0,30823506.0,Hong EP,Cardiovascular disease,initial,2019-02-25,GCST007354,Intracranial aneurysm
12536,European,384317.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007982,Sleep duration
12427,European,321047.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007430,Peak expiratory flow
10056,European,13312.0,30808845.0,Thio CHL,Other measurement,initial,2019-02-26,GCST007536,Serum urea levels
5531,European,574.0,30809046.0,Schmitz B,"Cardiovascular disease, Other disease, Other measurement",replication,2019-02-26,GCST007495,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function
6930,European,1829.0,30808802.0,Freidin M,Other trait,initial,2019-02-26,GCST007537,Modic changes
9063,European,6770.0,30807572.0,Gong J,Digestive system disorder,initial,2019-02-26,GCST007367,Meconium ileus in cystic fibrosis
9202,European,7379.0,30808845.0,Thio CHL,Other measurement,replication,2019-02-26,GCST007536,Serum urea levels
5408,European,499.0,30809046.0,Schmitz B,"Cardiovascular disease, Other disease, Other measurement",initial,2019-02-26,GCST007495,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function
7690,European,2921.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007649,Estimated glomerular filtration rate after 5 years in renal transplantation (recipient effect)
7689,European,2921.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007648,Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect)
8874,European,5935.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007645,Estimated glomerular filtration rate after 1 year in renal transplantation (recipient effect)
8380,European,4475.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007644,Estimated glomerular filtration rate after 1 year in renal transplantation (donor effect)
7301,European,2298.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007646,Estimated glomerular filtration rate change in renal transplantation (donor effect)
7302,European,2298.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007647,Estimated glomerular filtration rate change in renal transplantation (recipient effect)
10870,European,30511.0,30820047.0,Kunkle BW,Neurological disorder,replication,2019-02-28,GCST007511,Alzheimer's disease (late onset)
11441,European,63926.0,30820047.0,Kunkle BW,Neurological disorder,initial,2019-02-28,GCST007511,Alzheimer's disease (late onset)
11448,European,65050.0,30818988.0,Klein M,"Other measurement, Neurological disorder",initial,2019-03-01,GCST007588,Attention deficit hyperactivity disorder or amygdala volume (pleiotropy)
11561,European,77317.0,30818988.0,Klein M,"Neurological disorder, Other measurement",initial,2019-03-01,GCST007586,Attention deficit hyperactivity disorder or intracranial volume (pleiotropy)
2438,Asian,877.0,30945665.0,Bandesh K,Other measurement,initial,2019-03-01,GCST008641,C-peptide levels
11447,European,64987.0,30818988.0,Klein M,"Other measurement, Neurological disorder",initial,2019-03-01,GCST007584,Attention deficit hyperactivity disorder or thalamus volume (pleiotropy)
10696,European,24024.0,30818988.0,Klein M,Other measurement,initial,2019-03-01,GCST007589,Intracranial volume
9064,European,6774.0,30818990.0,Yu D,Neurological disorder,replication,2019-03-01,GCST007277,Tourette syndrome
11445,European,64933.0,30818988.0,Klein M,"Other measurement, Neurological disorder",initial,2019-03-01,GCST007585,Attention deficit hyperactivity disorder or pallidum volume (pleiotropy)
2352,Asian,758.0,30945673.0,Prasad G,"Other measurement, Cancer",replication,2019-03-01,GCST007650,Postoperative survival time in hepatocellular carcinoma
11461,European,67083.0,30818988.0,Klein M,"Other measurement, Neurological disorder",initial,2019-03-01,GCST007583,Attention deficit hyperactivity disorder or nucleus accumbens volume (pleiotropy)
11450,European,65065.0,30818988.0,Klein M,"Neurological disorder, Other measurement",initial,2019-03-01,GCST007591,Attention deficit hyperactivity disorder or caudate nucleus volume (pleiotropy)
11446,European,64939.0,30818988.0,Klein M,"Other measurement, Neurological disorder",initial,2019-03-01,GCST007582,Attention deficit hyperactivity disorder or putamen volume (pleiotropy)
11567,European,77997.0,30818988.0,Klein M,"Neurological disorder, Other measurement",initial,2019-03-01,GCST007587,Attention deficit hyperactivity disorder or hippocampal volume (pleiotropy)
5611,European,623.0,30824882.0,Gunjaca I,Other measurement,initial,2019-03-01,GCST007427,Triiodothyronine/thyroxine ratio
10720,European,24704.0,30818988.0,Klein M,Other measurement,initial,2019-03-01,GCST007590,Hippocampal volume
5610,European,623.0,30824882.0,Gunjaca I,Other measurement,initial,2019-03-01,GCST007426,Triiodothyronine levels
12974,Hispanic or Latin American,773.0,30945665.0,Bandesh K,Other measurement,replication,2019-03-01,GCST008641,C-peptide levels
10141,European,14307.0,30818990.0,Yu D,Neurological disorder,initial,2019-03-01,GCST007277,Tourette syndrome
2044,Asian,367.0,30945673.0,Prasad G,"Other measurement, Cancer",initial,2019-03-01,GCST007650,Postoperative survival time in hepatocellular carcinoma
2897,Asian,1829.0,30945665.0,Bandesh K,Other measurement,replication,2019-03-01,GCST008641,C-peptide levels
6301,European,1121.0,30824882.0,Gunjaca I,Other measurement,initial,2019-03-01,GCST007428,Thyroxine levels
12554,European,401656.0,30833571.0,Wiberg A,Neurological disorder,initial,2019-03-04,GCST007581,Carpal tunnel syndrome
11581,European,80003.0,30837465.0,Wittemans LBL,Other measurement,initial,2019-03-05,GCST007638,Glycine levels
9007,European,6545.0,31201950.0,Lutz MW,Other trait,initial,2019-03-06,GCST008235,Cognitive impairment
9006,European,6545.0,31201950.0,Lutz MW,"Lipid or lipoprotein measurement, Other trait",initial,2019-03-06,GCST008233,Cognitive impairment and LDL levels (pleiotropy)
9005,European,6545.0,31201950.0,Lutz MW,"Lipid or lipoprotein measurement, Other trait",initial,2019-03-06,GCST008232,Cognitive impairment and total cholesterol levels (pleiotropy)
9004,European,6545.0,31201950.0,Lutz MW,Lipid or lipoprotein measurement,initial,2019-03-06,GCST008239,Serum total cholesterol levels
9003,European,6545.0,31201950.0,Lutz MW,Lipid or lipoprotein measurement,initial,2019-03-06,GCST008238,Low density lipoprotein cholesterol levels
9008,European,6545.0,31201950.0,Lutz MW,"Other trait, Inflammatory measurement",initial,2019-03-06,GCST008234,Cognitive impairment and C-reactive protein levels (pleiotropy)
9002,European,6545.0,31201950.0,Lutz MW,Lipid or lipoprotein measurement,initial,2019-03-06,GCST008237,High density lipoprotein cholesterol levels
9001,European,6545.0,31201950.0,Lutz MW,Inflammatory measurement,initial,2019-03-06,GCST008236,C-reactive protein levels
7031,European,1966.0,30845926.0,van der Plaat DA,Other measurement,replication,2019-03-07,GCST008246,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers
6833,European,1715.0,30843173.0,Popovic M,Other measurement,initial,2019-03-07,GCST007682,Thyroxine levels
6859,European,1729.0,30843173.0,Popovic M,Other measurement,initial,2019-03-07,GCST007680,Triiodothyronine levels and thyroxine levels
7032,European,1966.0,30845926.0,van der Plaat DA,Other measurement,replication,2019-03-07,GCST008247,Airway obstruction (FEV1/FVC<70%) in never smokers
12598,European,446118.0,30846698.0,Dashti HS,Other measurement,initial,2019-03-07,GCST007561,Sleep duration
5887,European,823.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008242,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers
8622,European,5070.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008246,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers
8509,European,4855.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008244,Airway obstruction (FEV1/FVC<70%) in ever smokers
5888,European,823.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008243,Airway obstruction (FEV1/FVC<70%) in ever smokers
12466,European,339926.0,30846698.0,Dashti HS,Other measurement,initial,2019-03-07,GCST007560,Sleep duration (long sleep)
8623,European,5070.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008247,Airway obstruction (FEV1/FVC<70%) in never smokers
6860,European,1729.0,30843173.0,Popovic M,Other measurement,initial,2019-03-07,GCST007683,Triiodothyronine levels
6861,European,1731.0,30843173.0,Popovic M,"Other measurement, Other trait",initial,2019-03-07,GCST007681,Thyroid stimulating hormone levels
8510,European,4855.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008245,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers
12597,European,446118.0,30846698.0,Dashti HS,Other measurement,initial,2019-03-07,GCST007559,Sleep duration (short sleep)
3080,Asian,2197.0,30866520.0,Er LK,Cardiovascular measurement,initial,2019-03-07,GCST007900,Chemerin levels
7784,European,3134.0,30845926.0,van der Plaat DA,Other measurement,replication,2019-03-07,GCST008245,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers
7783,European,3134.0,30845926.0,van der Plaat DA,Other measurement,replication,2019-03-07,GCST008244,Airway obstruction (FEV1/FVC<70%) in ever smokers
5259,European,432.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008240,Airway obstruction (FEV1/FVC<70%) in never smokers
5260,European,432.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008241,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers
8658,European,5161.0,30850646.0,Tziotzios C,Other disease,initial,2019-03-08,GCST007713,Frontal fibrosing alopecia
5150,European,369.0,30852652.0,Schlicht K,Other measurement,initial,2019-03-09,GCST007690,Metabolic coherence (transcriptomic)
8134,European,3783.0,30852652.0,Schlicht K,Other measurement,replication,2019-03-09,GCST007690,Metabolic coherence (transcriptomic)
2458,Asian,922.0,30854688.0,Wang C,"Cancer, Other measurement",initial,2019-03-10,GCST007737,Anti-sp100 seropositivity in primary biliary cholangitis
2619,Asian,1252.0,30854688.0,Wang C,"Cancer, Other measurement",replication,2019-03-10,GCST007736,Anti-gp210 seropositivity in primary biliary cholangitis
2454,Asian,912.0,30854688.0,Wang C,"Cancer, Other measurement",initial,2019-03-10,GCST007736,Anti-gp210 seropositivity in primary biliary cholangitis
2620,Asian,1252.0,30854688.0,Wang C,"Cancer, Other measurement",replication,2019-03-10,GCST007737,Anti-sp100 seropositivity in primary biliary cholangitis
11796,European,109178.0,30910378.0,Zanetti D,Other measurement,replication,2019-03-12,GCST007721,Urinary potassium to creatinine ratio
11791,European,108800.0,30910378.0,Zanetti D,Other trait,replication,2019-03-12,GCST007719,Albuminuria
11792,European,108942.0,30910378.0,Zanetti D,Other measurement,replication,2019-03-12,GCST007717,Urinary sodium to potassium ratio
12246,European,217634.0,30910378.0,Zanetti D,Other trait,initial,2019-03-12,GCST007719,Albuminuria
12247,European,217996.0,30910378.0,Zanetti D,Other measurement,initial,2019-03-12,GCST007717,Urinary sodium to potassium ratio
12248,European,218435.0,30910378.0,Zanetti D,Other measurement,initial,2019-03-12,GCST007721,Urinary potassium to creatinine ratio
12249,European,218450.0,30910378.0,Zanetti D,Other measurement,initial,2019-03-12,GCST007778,Urinary sodium to creatinine ratio
12250,European,218759.0,30910378.0,Zanetti D,Other measurement,initial,2019-03-12,GCST007718,Urinary albumin-to-creatinine ratio
11795,European,109166.0,30910378.0,Zanetti D,Other measurement,replication,2019-03-12,GCST007778,Urinary sodium to creatinine ratio
11797,European,109530.0,30910378.0,Zanetti D,Other measurement,replication,2019-03-12,GCST007718,Urinary albumin-to-creatinine ratio
12330,European,270059.0,30867560.0,Hill WD,Other measurement,initial,2019-03-13,GCST007709,General factor of neuroticism
12331,European,270059.0,30867560.0,Hill WD,Other measurement,initial,2019-03-13,GCST007710,Anxiety/tension (special factor of neuroticism)
12329,European,270059.0,30867560.0,Hill WD,Other measurement,initial,2019-03-13,GCST007708,Worry/vulnerability (special factor of neuroticism)
6884,European,1758.0,30886212.0,Eszlari N,Biological process,initial,2019-03-18,GCST007679,Reflection (response to stress)
6883,European,1758.0,30886212.0,Eszlari N,Biological process,initial,2019-03-18,GCST007678,Brooding (response to stress)
5038,European,294.0,30889042.0,Innocenti F,"Immune system disorder, Response to drug, Cancer",initial,2019-03-18,GCST007643,Gemcitabine-induced early high-grade neutropenia in pancreatic cancer
6882,European,1758.0,30886212.0,Eszlari N,Biological process,initial,2019-03-18,GCST007677,Rumination (response to stress)
3865,Asian,7321.0,30898391.0,Lawrenson K,Cancer,initial,2019-03-19,GCST007728,Epithelial ovarian cancer
8912,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008316,Corneal endothelial cell size variation coefficient
8915,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008319,Intraocular pressure (corneal compensated)
8911,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008315,Corneal hysteresis
8917,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008321,Corneal endothelial cell shape (percentage of hexagonally shaped cells)
8913,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008317,Central corneal thickness
8918,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008339,Corneal endothelial cell density
8914,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008318,Corneal resistance factor
8916,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008320,Intraocular pressure (Goldman correlated)
6615,European,1459.0,30894546.0,Ivarsdottir EV,Other measurement,replication,2019-03-20,GCST008317,Central corneal thickness
2326,Asian,720.0,30895295.0,Jonnalagadda M,Other measurement,initial,2019-03-21,GCST007739,Skin reflectance (Melanin index)
3850,Asian,7094.0,30899057.0,Lee MG,Metabolic disorder,initial,2019-03-21,GCST008139,Gout
2010,Asian,329.0,30895295.0,Jonnalagadda M,"Other measurement, Other trait",initial,2019-03-21,GCST007741,Iris color (b* coordinate)
2009,Asian,329.0,30895295.0,Jonnalagadda M,"Other measurement, Other trait",initial,2019-03-21,GCST007740,Iris color (a* coordinate)
3929,Asian,7830.0,30899057.0,Lee MG,Metabolic disorder,replication,2019-03-21,GCST008139,Gout
2012,Asian,329.0,30895295.0,Jonnalagadda M,"Other measurement, Other trait",initial,2019-03-21,GCST007743,Iris color (L* coordinate)
3361,Asian,3417.0,30899065.0,Wang M,Other trait,initial,2019-03-21,GCST007687,Photic sneeze reflex
2011,Asian,329.0,30895295.0,Jonnalagadda M,"Other measurement, Other trait",initial,2019-03-21,GCST007742,Iris heterochromicity
10905,European,32136.0,30902966.0,Mufford M,"Other measurement, Neurological disorder",initial,2019-03-22,GCST008909,Symmetry behaviour in Tourette syndrome or subcortical volume measurements (pleiotropy)
11189,European,44056.0,30902966.0,Mufford M,"Other measurement, Neurological disorder",initial,2019-03-22,GCST008907,Tourette syndrome or brain region volumes (pleiotropy)
10903,European,32131.0,30902966.0,Mufford M,"Other measurement, Neurological disorder",initial,2019-03-22,GCST008908,Social disinhibition in Tourette syndrome or subcortical volume measurements (pleiotropy)
14242,Other/Mixed,7898.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007702,Triglyceride levels
12171,European,188577.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007688,Total cholesterol levels
12172,European,188577.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007689,Low density lipoprotein cholesterol levels
12174,European,188577.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007702,Triglyceride levels
14239,Other/Mixed,7898.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007688,Total cholesterol levels
14240,Other/Mixed,7898.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007689,Low density lipoprotein cholesterol levels
3484,Asian,4235.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007702,Triglyceride levels
14241,Other/Mixed,7898.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007701,High density lipoprotein cholesterol levels
3481,Asian,4235.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007688,Total cholesterol levels
2519,Asian,1036.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,initial,2019-03-25,GCST007702,Triglyceride levels
3482,Asian,4235.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007689,Low density lipoprotein cholesterol levels
3483,Asian,4235.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007701,High density lipoprotein cholesterol levels
12173,European,188577.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007701,High density lipoprotein cholesterol levels
2516,Asian,1036.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,initial,2019-03-25,GCST007688,Total cholesterol levels
2517,Asian,1036.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,initial,2019-03-25,GCST007689,Low density lipoprotein cholesterol levels
2518,Asian,1036.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,initial,2019-03-25,GCST007701,High density lipoprotein cholesterol levels
11323,European,53842.0,30920090.0,Trochet H,"Neurological disorder, Immune system disorder, Response to drug, Cardiovascular disease, Digestive system disorder, Other disease, Biological process",initial,2019-03-28,GCST008910,Multiple traits (pleiotropy)
2629,Asian,1288.0,30921371.0,Choi SY,Other trait,replication,2019-03-28,GCST007711,Severe coronary artery calcification
5126,European,355.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",replication,2019-03-28,GCST008148,Response to allopurinol in gout (change in serum uric acid levels)
273,African,4213.0,30920090.0,Trochet H,"Neurological disorder, Immune system disorder, Response to drug, Cardiovascular disease, Digestive system disorder, Other disease, Biological process",initial,2019-03-28,GCST008910,Multiple traits (pleiotropy)
13104,Hispanic or Latin American,1970.0,30920090.0,Trochet H,"Neurological disorder, Immune system disorder, Response to drug, Cardiovascular disease, Digestive system disorder, Other disease, Biological process",initial,2019-03-28,GCST008910,Multiple traits (pleiotropy)
11237,European,47299.0,30929738.0,Ferreira MAR,"Other disease, Other measurement",replication,2019-03-28,GCST007797,Asthma onset (childhood vs adult)
508,African American or Afro-Caribbean,115.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008148,Response to allopurinol in gout (change in serum uric acid levels)
13964,Other/Mixed,631.0,30921485.0,Bejaoui Y,Immune system disorder,initial,2019-03-28,GCST008096,Psoriasis
507,African American or Afro-Caribbean,115.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008147,Response to allopurinol in gout (change in serum uric acid levels)
12469,European,341215.0,30929738.0,Ferreira MAR,Other disease,initial,2019-03-28,GCST007798,Asthma
13944,Other/Mixed,574.0,30921485.0,Bejaoui Y,Immune system disorder,replication,2019-03-28,GCST008096,Psoriasis
12438,European,327253.0,30929738.0,Ferreira MAR,Other disease,initial,2019-03-28,GCST007799,Asthma (adult onset)
10818,European,28835.0,30929738.0,Ferreira MAR,"Other disease, Other measurement",initial,2019-03-28,GCST007797,Asthma onset (childhood vs adult)
5878,European,820.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",replication,2019-03-28,GCST008147,Response to allopurinol in gout (change in serum uric acid levels)
12785,Hispanic or Latin American,114.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008147,Response to allopurinol in gout (change in serum uric acid levels)
1986,Asian,303.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008147,Response to allopurinol in gout (change in serum uric acid levels)
12786,Hispanic or Latin American,114.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008148,Response to allopurinol in gout (change in serum uric acid levels)
2086,Asian,400.0,30921371.0,Choi SY,Other trait,initial,2019-03-28,GCST007711,Severe coronary artery calcification
7548,European,2647.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008148,Response to allopurinol in gout (change in serum uric acid levels)
7547,European,2647.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008147,Response to allopurinol in gout (change in serum uric acid levels)
1987,Asian,303.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008148,Response to allopurinol in gout (change in serum uric acid levels)
3019,Asian,2078.0,30920090.0,Trochet H,"Neurological disorder, Immune system disorder, Response to drug, Cardiovascular disease, Digestive system disorder, Other disease, Biological process",initial,2019-03-28,GCST008910,Multiple traits (pleiotropy)
12413,European,314633.0,30929738.0,Ferreira MAR,"Other disease, Other measurement",initial,2019-03-28,GCST007800,Asthma (childhood onset)
12269,European,234008.0,30929738.0,Ferreira MAR,Other disease,replication,2019-03-28,GCST007799,Asthma (adult onset)
12291,European,246649.0,30929738.0,Ferreira MAR,"Other disease, Other measurement",replication,2019-03-28,GCST007800,Asthma (childhood onset)
13147,Hispanic or Latin American,2554.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008692,LDL cholesterol levels in ever smokers
13340,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
13339,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
5200,European,405.0,30926877.0,Brcic L,"Other measurement, Immune system disorder",initial,2019-03-29,GCST007851,Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis
13338,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008685,HDL cholesterol levels
13531,Hispanic or Latin American,16996.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
13530,Hispanic or Latin American,16996.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
5198,European,405.0,30926877.0,Brcic L,"Immune system disorder, Other measurement",initial,2019-03-29,GCST007831,Anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis
13341,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
3373,Asian,3477.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008701,Triglyceride levels in never smokers
267,African,3750.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
3425,Asian,3841.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008697,Triglyceride levels in non smokers
266,African,3750.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
4549,Asian,81517.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
10054,European,13303.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008696,Triglyceride levels in current smokers
5199,European,405.0,30926877.0,Brcic L,"Other measurement, Immune system disorder",initial,2019-03-29,GCST007830,Anti-thyroid peroxidase (TPOAb) levels in Hashimoto's thyroiditis
3147,Asian,2394.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008679,HDL cholesterol levels in current smokers
13343,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
13516,Hispanic or Latin American,14710.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
4517,Asian,48349.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
4516,Asian,48349.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
13360,Hispanic or Latin American,6705.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
13359,Hispanic or Latin American,6705.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
13358,Hispanic or Latin American,6705.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
13357,Hispanic or Latin American,6705.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
13356,Hispanic or Latin American,6705.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008702,Triglyceride levels
13355,Hispanic or Latin American,6646.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
13342,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
13354,Hispanic or Latin American,6646.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
13352,Hispanic or Latin American,6646.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
13351,Hispanic or Latin American,6646.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008676,LDL cholesterol levels
4548,Asian,81517.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
4515,Asian,48349.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
4514,Asian,48349.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
13344,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
3139,Asian,2375.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008688,LDL cholesterol levels in current smokers
13515,Hispanic or Latin American,14710.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
13353,Hispanic or Latin American,6646.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
13316,Hispanic or Latin American,5941.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008697,Triglyceride levels in non smokers
10100,European,13799.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008688,LDL cholesterol levels in current smokers
13311,Hispanic or Latin American,5873.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008680,HDL cholesterol levels in non smokers
13233,Hispanic or Latin American,4076.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008684,HDL cholesterol levels in never smokers
4051,Asian,9146.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008684,HDL cholesterol levels in never smokers
4044,Asian,9118.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008693,LDL cholesterol levels in never smokers
13544,Hispanic or Latin American,17522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
3539,Asian,4649.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008702,Triglyceride levels
3540,Asian,4649.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
3541,Asian,4649.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
13545,Hispanic or Latin American,17522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
13546,Hispanic or Latin American,17522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
13547,Hispanic or Latin American,17522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
4547,Asian,81517.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
3542,Asian,4649.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
7724,European,2989.0,30922102.0,Pardinas AF,"Response to drug, Neurological disorder",initial,2019-03-29,GCST007686,Plasma norclozapine levels in treatment-resistant schizophrenia
4580,Asian,111921.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
3543,Asian,4649.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
7722,European,2989.0,30922102.0,Pardinas AF,"Response to drug, Neurological disorder",initial,2019-03-29,GCST007684,Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia
13145,Hispanic or Latin American,2544.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008683,HDL cholesterol levels in ever smokers
7723,European,2989.0,30922102.0,Pardinas AF,"Response to drug, Neurological disorder",initial,2019-03-29,GCST007685,Plasma clozapine levels in treatment-resistant schizophrenia
4581,Asian,111921.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
13235,Hispanic or Latin American,4095.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008693,LDL cholesterol levels in never smokers
13236,Hispanic or Latin American,4123.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008701,Triglyceride levels in never smokers
4128,Asian,10742.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008689,LDL cholesterol levels in non smokers
4129,Asian,10777.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008680,HDL cholesterol levels in non smokers
13150,Hispanic or Latin American,2582.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008700,Triglyceride levels in ever smokers
4233,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
4232,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
4231,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
4230,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
4229,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
4228,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
4227,Asian,13171.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008685,HDL cholesterol levels
264,African,3718.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
13312,Hispanic or Latin American,5894.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008689,LDL cholesterol levels in non smokers
4226,Asian,13171.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008676,LDL cholesterol levels
4222,Asian,13117.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
4221,Asian,13117.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
4220,Asian,13117.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
13532,Hispanic or Latin American,16996.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
13533,Hispanic or Latin American,16996.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
3448,Asian,3999.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008692,LDL cholesterol levels in ever smokers
10189,European,15129.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008679,HDL cholesterol levels in current smokers
3451,Asian,4025.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008683,HDL cholesterol levels in ever smokers
263,African,3718.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
4223,Asian,13117.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
4546,Asian,81517.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
11201,European,45506.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008692,LDL cholesterol levels in ever smokers
371,African,18489.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008697,Triglyceride levels in non smokers
382,African,23508.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
2573,Asian,1172.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008700,Triglyceride levels in ever smokers
287,African,5120.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008679,HDL cholesterol levels in current smokers
11694,European,90266.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
11695,European,90266.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
11696,European,90266.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
11697,European,90266.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
11265,European,49475.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008683,HDL cholesterol levels in ever smokers
11698,European,90272.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008685,HDL cholesterol levels
11699,European,90272.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
12960,Hispanic or Latin American,747.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008679,HDL cholesterol levels in current smokers
12962,Hispanic or Latin American,755.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008688,LDL cholesterol levels in current smokers
12015,European,147211.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
11700,European,90272.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
11789,European,108591.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
11790,European,108591.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
380,African,23508.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008702,Triglyceride levels
379,African,23503.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
293,African,5612.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
294,African,5612.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
11175,European,42899.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008700,Triglyceride levels in ever smokers
378,African,23503.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
377,African,23353.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
11851,European,117167.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
11852,European,117167.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
11142,European,40797.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008684,HDL cholesterol levels in never smokers
381,African,23508.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
12014,European,147211.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
12012,European,147060.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
336,African,11649.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008692,LDL cholesterol levels in ever smokers
11486,European,68719.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008689,LDL cholesterol levels in non smokers
290,African,5324.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
11538,European,75138.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008680,HDL cholesterol levels in non smokers
11552,European,77043.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
2403,Asian,808.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008696,Triglyceride levels in current smokers
388,African,23761.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
11553,European,77043.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
11554,European,77047.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008702,Triglyceride levels
11555,European,77047.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
11556,European,77047.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
387,African,23761.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
337,African,11700.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008693,LDL cholesterol levels in never smokers
338,African,11735.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008700,Triglyceride levels in ever smokers
386,African,23761.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
385,African,23761.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008685,HDL cholesterol levels
384,African,23753.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
383,African,23753.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
11608,European,82518.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
11609,European,82518.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
11610,European,82522.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008676,LDL cholesterol levels
11611,European,82522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
11612,European,82522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
339,African,11777.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008701,Triglyceride levels in never smokers
291,African,5324.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
389,African,23761.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
12011,European,147060.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
340,African,11866.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008684,HDL cholesterol levels in never smokers
11854,European,117440.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
11855,European,117440.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
12967,Hispanic or Latin American,764.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008696,Triglyceride levels in current smokers
11438,European,63740.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008697,Triglyceride levels in non smokers
10989,European,34148.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008701,Triglyceride levels in never smokers
376,African,23353.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
375,African,23353.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008676,LDL cholesterol levels
374,African,23348.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
373,African,23348.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
302,African,7217.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
369,African,18384.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008689,LDL cholesterol levels in non smokers
282,African,5022.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008696,Triglyceride levels in current smokers
372,African,18641.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008680,HDL cholesterol levels in non smokers
341,African,11893.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008683,HDL cholesterol levels in ever smokers
11045,European,37016.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008693,LDL cholesterol levels in never smokers
301,African,7217.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
281,African,4973.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008688,LDL cholesterol levels in current smokers
6285,European,1094.0,30929638.0,Matana A,Other measurement,initial,2019-03-30,GCST008170,Thyroglobulin plasma levels
11954,European,136954.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008613,Hematuria
11663,European,87742.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008618,Hematuria (mild)
11983,European,141621.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008605,Glucosuria (moderate to severe)
11858,European,118115.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008617,Hematuria (moderate to severe)
12006,European,146369.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008614,Glucosuria
12001,European,145547.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008610,Proteinuria
11953,European,136698.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008607,Ketonuria
12018,European,148199.0,30476138.0,Benonisdottir S,Other measurement,initial,2019-04-01,GCST008615,Low urine pH
11580,European,79850.0,30476138.0,Benonisdottir S,Other measurement,initial,2019-04-01,GCST008619,Signs of urinary tract infection (nitrites and leukocyte esterase)
11973,European,139555.0,30476138.0,Benonisdottir S,Other measurement,initial,2019-04-01,GCST008604,Urine specific gravity measurement
12040,European,149899.0,30476138.0,Benonisdottir S,Other measurement,initial,2019-04-01,GCST008616,Urine pH measurement
11868,European,120230.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008612,Proteinuria (mild)
11975,European,140260.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008606,Glucosuria (mild)
11853,European,117371.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008608,Ketonuria (moderate to severe)
11832,European,114895.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008609,Ketonuria (mild)
11848,European,116855.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008611,Proteinuria (moderate to severe)
1567,African American or Afro-Caribbean,56648.0,30940813.0,Kranzler HR,"Neurological disorder, Other measurement",initial,2019-04-02,GCST008259,Alcohol use disorder
1847,Asian,190.0,30940813.0,Kranzler HR,"Neurological disorder, Other measurement",initial,2019-04-02,GCST008259,Alcohol use disorder
12629,European,458554.0,30940143.0,Zhu Z,Cardiovascular disease,initial,2019-04-02,GCST007610,Hypertension
1844,Asian,189.0,30940813.0,Kranzler HR,Other measurement,initial,2019-04-02,GCST008258,Alcohol use disorder (consumption score)
12632,European,458969.0,30940143.0,Zhu Z,"Other disease, Cardiovascular measurement",initial,2019-04-02,GCST007656,Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)
12604,European,446696.0,30940143.0,Zhu Z,"Other disease, Cardiovascular disease",initial,2019-04-02,GCST007613,Chronic obstructive pulmonary disease or stroke (pleiotropy)
12630,European,458554.0,30940143.0,Zhu Z,"Other disease, Other measurement, Cardiovascular disease",initial,2019-04-02,GCST007611,Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)
12203,European,202004.0,30940813.0,Kranzler HR,"Neurological disorder, Other measurement",initial,2019-04-02,GCST008259,Alcohol use disorder
2663,Asian,1366.0,30940813.0,Kranzler HR,Other measurement,initial,2019-04-02,GCST008258,Alcohol use disorder (consumption score)
12631,European,458969.0,30940143.0,Zhu Z,Cardiovascular measurement,initial,2019-04-02,GCST007609,Resting heart rate
2664,Asian,1374.0,30940813.0,Kranzler HR,"Neurological disorder, Other measurement",initial,2019-04-02,GCST008259,Alcohol use disorder
12200,European,200680.0,30940813.0,Kranzler HR,Other measurement,initial,2019-04-02,GCST008258,Alcohol use disorder (consumption score)
13514,Hispanic or Latin American,14175.0,30940813.0,Kranzler HR,"Neurological disorder, Other measurement",initial,2019-04-02,GCST008259,Alcohol use disorder
13513,Hispanic or Latin American,14112.0,30940813.0,Kranzler HR,Other measurement,initial,2019-04-02,GCST008258,Alcohol use disorder (consumption score)
1566,African American or Afro-Caribbean,56495.0,30940813.0,Kranzler HR,Other measurement,initial,2019-04-02,GCST008258,Alcohol use disorder (consumption score)
4903,European,200.0,30958311.0,Tao F,"Neurological disorder, Other measurement",initial,2019-04-03,GCST008542,First dorsal interosseous strength in Charcot-Marie-Tooth disease 1A
6731,European,1589.0,30942860.0,Shin J,Other measurement,initial,2019-04-03,GCST008473,Visceral fat
5333,European,471.0,30958311.0,Tao F,Neurological disorder,initial,2019-04-03,GCST008530,Neuropathy in Charcot-Marie-Tooth disease type 1A
5032,European,291.0,30958311.0,Tao F,"Neurological disorder, Other measurement",initial,2019-04-03,GCST008544,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A
794,African American or Afro-Caribbean,847.0,30944420.0,Liu L,Other measurement,initial,2019-04-03,GCST007816,Trunk fat mass adjusted for trunk lean mass
12867,Hispanic or Latin American,445.0,30944420.0,Liu L,Other measurement,initial,2019-04-03,GCST007816,Trunk fat mass adjusted for trunk lean mass
2748,Asian,1541.0,30944420.0,Liu L,Other measurement,initial,2019-04-03,GCST007816,Trunk fat mass adjusted for trunk lean mass
5236,European,424.0,30958311.0,Tao F,"Other trait, Neurological disorder",initial,2019-04-03,GCST008543,Walking difficulty in Charcot-Marie-Tooth disease 1A
5228,European,420.0,30958311.0,Tao F,"Neurological disorder, Other trait",initial,2019-04-03,GCST008537,Decreased sensory function in Charcot-Marie-Tooth disease type 1A
5220,European,412.0,30958311.0,Tao F,"Neurological disorder, Other measurement",initial,2019-04-03,GCST008539,Foot plantar flexion strength in Charcot-Marie-Tooth disease 1A
5214,European,409.0,30958311.0,Tao F,"Other trait, Neurological disorder",initial,2019-04-03,GCST008535,Arthritic-like pain in Charcot-Marie-Tooth type 1A
9541,European,8736.0,30944420.0,Liu L,Other measurement,initial,2019-04-03,GCST007816,Trunk fat mass adjusted for trunk lean mass
5213,European,409.0,30958311.0,Tao F,"Other disease, Neurological disorder",initial,2019-04-03,GCST008536,Scoliosis in Charcot-Marie-Tooth disease 1A
5224,European,417.0,30958311.0,Tao F,"Neurological disorder, Other trait",initial,2019-04-03,GCST008541,Foot deformity in Charcot-Marie-Tooth disease 1A
5143,European,364.0,30958311.0,Tao F,Neurological disorder,initial,2019-04-03,GCST008534,Hearing loss in Charcot-Marie-Tooth disease 1A
5201,European,406.0,30958311.0,Tao F,Neurological disorder,initial,2019-04-03,GCST008532,Burning or tingling in extremities in Charcot-Marie-Tooth disease type 1A
5234,European,423.0,30958311.0,Tao F,"Other trait, Neurological disorder",initial,2019-04-03,GCST008540,"Decreased fine motor function in Charcot-Marie-Tooth disease 1A (buttons, zippers, fasteners, bottles)"
5229,European,420.0,30958311.0,Tao F,"Other trait, Neurological disorder",initial,2019-04-03,GCST008533,Decreased fine motor function in Charcot-Marie-Tooth disease 1A (eating with utensils)
5222,European,413.0,30958311.0,Tao F,"Neurological disorder, Other trait",initial,2019-04-03,GCST008538,Balance difficulty in Charcot-Marie-Tooth disease type 1A
7110,European,2062.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007822,Facial attractiveness (male raters)
8187,European,3928.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007818,Facial attractiveness (female raters)
2353,Asian,758.0,30945699.0,Wei J,"Other measurement, Cancer",replication,2019-04-04,GCST007731,Postoperative survival time in hepatocellular carcinoma
7109,European,2062.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007820,Facial attractiveness (female raters)
14137,Other/Mixed,1828.0,30946743.0,Li Z,Immune system disorder,initial,2019-04-04,GCST007844,Ankylosing spondylitis
8186,European,3928.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007817,Facial attractiveness (male raters)
8181,European,3921.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007819,Facial attractiveness (male raters)
4015,Asian,8839.0,31006500.0,Liu M,Lipid or lipoprotein measurement,initial,2019-04-04,GCST007840,Low HDL-cholesterol levels
14083,Other/Mixed,1176.0,30946743.0,Li Z,Immune system disorder,initial,2019-04-04,GCST007844,Ankylosing spondylitis
2045,Asian,367.0,30945699.0,Wei J,"Other measurement, Cancer",initial,2019-04-04,GCST007731,Postoperative survival time in hepatocellular carcinoma
6907,European,1792.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007821,Facial attractiveness (female raters)
5311,European,455.0,30946739.0,Hu B,Other measurement,replication,2019-04-04,GCST007818,Facial attractiveness (female raters)
6908,European,1792.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007823,Facial attractiveness (male raters)
4929,European,213.0,30946739.0,Hu B,Other measurement,replication,2019-04-04,GCST007822,Facial attractiveness (male raters)
8833,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007801,Sleep duration
8834,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007802,Sleep duration (variability)
11635,European,85205.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007805,Sleep (time to least active 5 hours)
11620,European,84441.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007802,Sleep duration (variability)
11631,European,84810.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007807,Sleep (time to midpoint)
11630,European,84810.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007804,Sleep (number of episodes)
11629,European,84810.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007803,Sleep efficiency
11628,European,84757.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007808,Diurnal inactivity
8353,European,4401.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007808,Diurnal inactivity
8352,European,4401.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007804,Sleep (number of episodes)
11640,European,85670.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007806,Time to most active 10 hours
8836,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007805,Sleep (time to least active 5 hours)
8837,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007806,Time to most active 10 hours
5809,European,762.0,30952644.0,El Charif O,"Cancer, Response to drug, Other trait",initial,2019-04-05,GCST007796,Tinnitus in cisplatin-treated testicular cancer
8838,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007807,Sleep (time to midpoint)
11638,European,85449.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007801,Sleep duration
8835,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007803,Sleep efficiency
3393,Asian,3617.0,30955190.0,Yun S,Other disease,initial,2019-04-06,GCST007734,Incident chronic kidney disease
3394,Asian,3617.0,30955190.0,Yun S,Other measurement,initial,2019-04-06,GCST008837,Estimated glomerular filtration rate reduction (30%)
4585,Asian,121745.0,30993211.0,Nakatochi M,Cardiovascular measurement,initial,2019-04-08,GCST007733,Serum uric acid levels
4584,Asian,121745.0,30993211.0,Nakatochi M,Cardiovascular measurement,initial,2019-04-08,GCST007725,Serum uric acid levels
4210,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008267,Psychological wellbeing index (total score)
1494,African American or Afro-Caribbean,17029.0,31151762.0,Gelernter J,Other measurement,initial,2019-04-08,GCST008675,Maximum habitual alcohol consumption
11674,European,88461.0,30993211.0,Nakatochi M,Cardiovascular measurement,initial,2019-04-08,GCST007733,Serum uric acid levels
4204,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008261,Psychological wellbeing (depressiveness)
4205,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008262,Psychological wellbeing index 1 (lack of subjective wellbeing and health)
4206,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008263,Psychological wellbeing index 3 (fatigue and loss of appetite)
4207,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008264,Psychological wellbeing index 12 (lack of enjoying daily life)
4209,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008266,Psychological wellbeing (health and vitality)
11757,European,101293.0,30993211.0,Nakatochi M,Cardiovascular measurement,replication,2019-04-08,GCST007725,Serum uric acid levels
11911,European,126936.0,31151762.0,Gelernter J,Other measurement,initial,2019-04-08,GCST008675,Maximum habitual alcohol consumption
4208,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008265,Psychological wellbeing (social role performance and self-confidence)
7426,European,2481.0,30999091.0,Wang Y,"Other measurement, Biological process",initial,2019-04-09,GCST008270,Post-traumatic stress disorder symptoms in trauma-exposed soldiers
5324,European,465.0,30972912.0,Wei L,"Response to drug, Digestive system disorder",initial,2019-04-10,GCST008514,Peginterferon alfa-2a treatment response in chronic hepatitis B infection
2547,Asian,1108.0,30972912.0,Wei L,"Response to drug, Digestive system disorder",initial,2019-04-10,GCST008514,Peginterferon alfa-2a treatment response in chronic hepatitis B infection
4631,Asian,198769.0,30975718.0,Tanikawa C,Other disease,initial,2019-04-11,GCST007833,Urolithiasis
2616,Asian,1242.0,30971808.0,Kim JJ,"Immune system disorder, Other trait",replication,2019-04-11,GCST008314,Response to intravenous immunoglobulin treatment in Kawasaki disease
11930,European,131686.0,31070453.0,Zekavat SM,Cardiovascular measurement,initial,2019-04-11,GCST007846,Arterial stiffness
4651,European,37.0,30971809.0,Wendt FR,Response to drug,initial,2019-04-11,GCST008967,Tramadol metabolism (O-desmethyltramadol to tramadol ratio)
9037,European,6692.0,31070471.0,Akinkuolie AO,"Other measurement, Inflammatory measurement",initial,2019-04-11,GCST008260,group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP
9194,European,7350.0,30976013.0,Dekker AM,Neurological disorder,initial,2019-04-11,GCST008978,Amyotrophic lateral sclerosis
3757,Asian,6106.0,30975718.0,Tanikawa C,Other disease,replication,2019-04-11,GCST007833,Urolithiasis
4761,European,99.0,30971809.0,Wendt FR,Response to drug,replication,2019-04-11,GCST008967,Tramadol metabolism (O-desmethyltramadol to tramadol ratio)
1981,Asian,296.0,30971808.0,Kim JJ,"Immune system disorder, Other trait",initial,2019-04-11,GCST008314,Response to intravenous immunoglobulin treatment in Kawasaki disease
12446,European,331037.0,30980028.0,de Kovel CGF,Other trait,initial,2019-04-12,GCST007592,Handedness (Left-handed vs. non-left-handed)
12447,European,331037.0,30980028.0,de Kovel CGF,Other trait,initial,2019-04-12,GCST007593,Ambidextrousness
12448,European,331037.0,30980028.0,de Kovel CGF,Other trait,initial,2019-04-12,GCST007594,Handedness (Right-handed vs. non-right-handed)
9560,European,8857.0,30988330.0,Hellwege JN,Other disease,initial,2019-04-15,GCST008169,Benign prostatic hyperplasia
13929,Other/Mixed,497.0,31040861.0,Thomson RJ,Other measurement,replication,2019-04-16,GCST007832,Urinary albumin-to-creatinine ratio
13840,Other/Mixed,249.0,31040861.0,Thomson RJ,Other measurement,initial,2019-04-16,GCST007832,Urinary albumin-to-creatinine ratio
9092,European,6879.0,30992453.0,Bjornsdottir G,Other measurement,initial,2019-04-16,GCST008312,Sural nerve amplitude potential
9119,European,6979.0,30992453.0,Bjornsdottir G,Other measurement,initial,2019-04-16,GCST008313,Sural nerve conduction velocity
686,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007859,Rapid automised naming and rapid alternating stimulus test performance
689,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007863,Rapid alternating stimulus test for letters/numbers
12999,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007860,Latent naming speed
688,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007862,Latent naming speed
690,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007864,Rapid automised naming of letters
12998,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007859,Rapid automised naming and rapid alternating stimulus test performance
691,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007865,Rapid automised naming of objects
687,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007860,Latent naming speed
13000,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007861,Latent naming speed
13001,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007863,Rapid alternating stimulus test for letters/numbers
13002,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007864,Rapid automised naming of letters
13003,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007865,Rapid automised naming of objects
12563,European,408455.0,30998689.0,Shadrina AS,Other trait,initial,2019-04-18,GCST008057,Varicose veins
9348,European,8031.0,31009812.0,Hung RJ,"Other measurement, Cancer",initial,2019-04-19,GCST008376,Lung cancer in never smokers
9171,European,7192.0,31009812.0,Hung RJ,"Other measurement, Cancer",initial,2019-04-19,GCST008375,Adenocarcinoma in never smokers
6980,European,1900.0,31009812.0,Hung RJ,"Other measurement, Cancer",replication,2019-04-19,GCST008376,Lung cancer in never smokers
6750,European,1612.0,31009812.0,Hung RJ,"Other measurement, Cancer",replication,2019-04-19,GCST008375,Adenocarcinoma in never smokers
12717,Hispanic or Latin American,1.0,31006051.0,Kharazmi M,"Response to drug, Other disease",initial,2019-04-20,GCST008098,Atypical femoral fracture in phosphonate treatment
12716,Hispanic or Latin American,1.0,31006051.0,Kharazmi M,"Response to drug, Other disease",initial,2019-04-20,GCST008097,Bisphosphonate-associated atypical femoral fracture
5155,European,374.0,31006051.0,Kharazmi M,"Response to drug, Other disease",initial,2019-04-20,GCST008098,Atypical femoral fracture in phosphonate treatment
8563,European,4941.0,31006051.0,Kharazmi M,"Response to drug, Other disease",initial,2019-04-20,GCST008097,Bisphosphonate-associated atypical femoral fracture
10591,European,21447.0,31005972.0,Hwang LD,Other measurement,initial,2019-04-21,GCST008762,Intake of sweets
5700,European,686.0,31005972.0,Hwang LD,Other measurement,initial,2019-04-21,GCST008761,Sucrose liking
12150,European,174424.0,31005972.0,Hwang LD,Other measurement,initial,2019-04-21,GCST008759,Intake of total sugars
5851,European,799.0,31009096.0,Meda SA,"Neurological disorder, Other measurement",initial,2019-04-22,GCST008911,Alcohol use disorder
12285,European,242659.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007925,Medication use (vasodilators used in cardiac diseases)
12153,European,176445.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007941,"Medication use (adrenergics, inhalants)"
12279,European,237530.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007930,Medication use (agents acting on the renin-angiotensin system)
12049,European,151636.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007943,Medication use (antihistamines for systemic use)
12268,European,229086.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007928,Medication use (diuretics)
12159,European,179810.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007938,Medication use (anilides)
11754,European,100868.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007944,Medication use (antiglaucoma preparations and miotics)
12053,European,153639.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007924,Medication use (antithrombotic agents)
12261,European,224024.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007927,Medication use (beta blocking agents)
11935,European,132367.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007922,Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease)
12098,European,164520.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007934,"Medication use (anti-inflammatory and antirheumatic products, non-steroids)"
12205,European,204378.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007929,Medication use (calcium channel blockers)
11865,European,119844.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007939,Medication use (antimigraine preparations)
12213,European,205700.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007942,Medication use (glucocorticoids)
4621,Asian,143658.0,31015462.0,Graham SE,Other measurement,initial,2019-04-23,GCST007876,Estimated glomerular filtration rate
12242,European,215668.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007935,Medication use (drugs affecting bone structure and mineralization)
12221,European,206856.0,31015462.0,Graham SE,Other measurement,initial,2019-04-23,GCST007876,Estimated glomerular filtration rate
11472,European,67619.0,31015462.0,Graham SE,"Other disease, Other measurement",initial,2019-04-23,GCST007879,Chronic kidney disease
11812,European,112010.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007937,Medication use (salicylic acid and derivatives)
12400,European,305582.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007932,Medication use (thyroid preparations)
12398,European,304162.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007940,Medication use (antidepressants)
12403,European,305913.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007923,Medication use (drugs used in diabetes)
12334,European,272602.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007933,Medication use (immunosuppressants)
10538,European,20700.0,31015462.0,Graham SE,Other measurement,initial,2019-04-23,GCST007878,Urea levels
12051,European,152380.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007926,Medication use (antihypertensives)
11499,European,69591.0,31015462.0,Graham SE,Other measurement,initial,2019-04-23,GCST007877,Creatinine levels
11569,European,78808.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007936,Medication use (opioids)
12366,European,290385.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007931,Medication use (HMG CoA reductase inhibitors)
9788,European,10395.0,31014085.0,Welsh P,Cardiovascular measurement,initial,2019-04-24,GCST008310,Cardiac Troponin-T levels
2100,Asian,419.0,31020675.0,Omae Y,Other measurement,initial,2019-04-24,GCST007948,KANNO antigen negativity
4810,European,152.0,31241743.0,Jaeger M,Other disease,replication,2019-04-24,GCST008106,Candidemia
4821,European,161.0,31241743.0,Jaeger M,Other disease,initial,2019-04-24,GCST008106,Candidemia
10152,European,14579.0,31014085.0,Welsh P,Cardiovascular measurement,initial,2019-04-24,GCST008309,Cardiac troponin-I levels
11209,European,46186.0,31021400.0,Masotti M,Other measurement,initial,2019-04-25,GCST008674,Glycemic traits (pleiotropy)
217,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008324,Hemoglobin
218,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008325,Platelet count
12439,European,327670.0,31036433.0,Pividori M,"Other disease, Other measurement",initial,2019-04-26,GCST007995,Asthma (childhood onset)
12440,European,328113.0,31036433.0,Pividori M,Other disease,initial,2019-04-26,GCST007996,Chronic obstructive pulmonary disease
219,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008329,Red blood cell count
220,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008330,Mean corpuscular volume
223,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008333,Red cell distribution width
222,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008332,Mean corpuscular hemoglobin concentration
216,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008323,Hematocrit
215,African,1624.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008336,Mean platelet volume
207,African,1565.0,31080455.0,Fatumo S,Inflammatory measurement,initial,2019-04-26,GCST008328,Basophil count
298,African,6407.0,31080455.0,Fatumo S,"Hematological measurement, Inflammatory measurement",initial,2019-04-26,GCST008338,Blood cell traits (multivariate analysis)
206,African,1565.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008327,Monocyte count
205,African,1565.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008326,Lymphocyte counts
202,African,1555.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008335,Eosinophil counts
12465,European,339801.0,31036433.0,Pividori M,Other disease,initial,2019-04-26,GCST007993,Asthma (adult onset)
224,African,1625.0,31080455.0,Fatumo S,"Hematological measurement, Inflammatory measurement",initial,2019-04-26,GCST008322,White blood cell count
11079,European,37846.0,31036433.0,Pividori M,Other disease,initial,2019-04-26,GCST007994,Asthma (age of onset)
188,African,1415.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008334,Neutrophil count
489,African American or Afro-Caribbean,88.0,31028280.0,Ierodiakonou D,"Other measurement, Other disease",replication,2019-04-26,GCST008273,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma
5461,European,522.0,31028280.0,Ierodiakonou D,"Other measurement, Other disease",initial,2019-04-26,GCST008272,Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma
5462,European,522.0,31028280.0,Ierodiakonou D,"Other measurement, Other disease",initial,2019-04-26,GCST008273,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma
297,African,6407.0,31080455.0,Fatumo S,"Hematological measurement, Inflammatory measurement",initial,2019-04-26,GCST008337,Blood cell traits (multivariate analysis)
221,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008331,Mean corpuscular hemoglobin
1669,Asian,58.0,31039275.0,Park SH,"Digestive system disorder, Response to drug",initial,2019-04-30,GCST008397,Infliximab-induced mucosal healing in Crohn's disease
8396,European,4543.0,31040135.0,Dahlin AM,Cancer,initial,2019-04-30,GCST008912,Glioma (pediatric/youth onset)
1663,Asian,54.0,31039275.0,Park SH,"Digestive system disorder, Response to drug",replication,2019-04-30,GCST008397,Infliximab-induced mucosal healing in Crohn's disease
2419,Asian,840.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
1864,Asian,204.0,31058715.0,St Jean PL,"Response to drug, Immune system disorder",replication,2019-05-01,GCST008307,Response to belimumab (SLE response index) in systemic lupus erythematosus
13892,Other/Mixed,365.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
6220,European,1030.0,31118946.0,Jiao H,Metabolic disorder,initial,2019-05-01,GCST007997,Obesity (extreme) (SNP x SNP interaction)
1353,African American or Afro-Caribbean,7687.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
12231,European,210267.0,31043758.0,Warrington NM,"Body measurement, Other measurement",initial,2019-05-01,GCST008363,Offspring birth weight
11291,European,51710.0,31043756.0,Stahl EA,Neurological disorder,initial,2019-05-01,GCST008103,Bipolar disorder
12013,European,147172.0,31043756.0,Stahl EA,Neurological disorder,replication,2019-05-01,GCST008103,Bipolar disorder
1806,Asian,157.0,31058715.0,St Jean PL,"Response to drug, Immune system disorder",initial,2019-05-01,GCST008307,Response to belimumab (SLE response index) in systemic lupus erythematosus
12377,European,298142.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
3206,Asian,2629.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
12926,Hispanic or Latin American,612.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
14044,Other/Mixed,815.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
11211,European,46237.0,31043756.0,Stahl EA,Neurological disorder,initial,2019-05-01,GCST008115,Bipolar I disorder
8245,European,4064.0,31250797.0,Brick LA,Neurological disorder,initial,2019-05-01,GCST008424,Opioid dependence
11006,European,34779.0,31043756.0,Stahl EA,Neurological disorder,initial,2019-05-01,GCST008116,Bipolar II disorder
10912,European,32335.0,31043756.0,Stahl EA,Neurological disorder,initial,2019-05-01,GCST008117,Schizoaffective disorder-bipolar type
11119,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008522,Bitter alcoholic beverage consumption
11648,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008528,Sweet beverage consumption
11647,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008527,Sugar-sweetened beverage consumption
11120,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008523,Pure non-grapefruit juice consumption
274,African,4347.0,31049640.0,Chen J,Metabolic disorder,initial,2019-05-02,GCST008114,Type 2 diabetes
11121,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008524,Bitter non-alcoholic beverage consumption
11122,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008525,Artificially sweetened beverage consumption
11649,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008531,Grapefruit juice consumption
11646,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008525,Artificially sweetened beverage consumption
11126,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008531,Grapefruit juice consumption
4677,European,62.0,31043678.0,Aterido A,"Digestive system disorder, Response to drug",initial,2019-05-02,GCST008271,Anti-adalimumab antibody production in response to treatment in Crohn's disease
4724,European,88.0,31043678.0,Aterido A,"Digestive system disorder, Response to drug",replication,2019-05-02,GCST008271,Anti-adalimumab antibody production in response to treatment in Crohn's disease
11117,European,39924.0,31046077.0,Zhong VW,"Biological process, Other measurement",replication,2019-05-02,GCST008526,Coffee consumption
11125,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008529,Tea consumption
4916,European,206.0,31044621.0,Rimpela JM,"Other measurement, Biological process",initial,2019-05-02,GCST008968,White coat effect (clinic systolic blood pressure minus ambulatory systolic blood pressure)
12454,European,336448.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008522,Bitter alcoholic beverage consumption
4917,European,206.0,31044621.0,Rimpela JM,"Other measurement, Biological process",initial,2019-05-02,GCST008969,White coat effect (clinic diastolic blood pressure minus ambulatory diastolic blood pressure)
11124,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008528,Sweet beverage consumption
11643,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008521,Bitter beverage consumption
11644,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008523,Pure non-grapefruit juice consumption
11645,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008524,Bitter non-alcoholic beverage consumption
11123,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008527,Sugar-sweetened beverage consumption
12451,European,335909.0,31046077.0,Zhong VW,"Biological process, Other measurement",initial,2019-05-02,GCST008526,Coffee consumption
12456,European,336898.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008529,Tea consumption
11118,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008521,Bitter beverage consumption
2688,Asian,1451.0,31050781.0,Zhao SX,"Immune system disorder, Metabolic disorder",replication,2019-05-03,GCST008365,Thyrotoxic hypokalemic periodic paralysis and Graves disease
2759,Asian,1575.0,31050781.0,Zhao SX,"Immune system disorder, Metabolic disorder",initial,2019-05-03,GCST008364,Thyrotoxic hypokalemic periodic paralysis in Graves disease
10830,European,29059.0,31053729.0,Styrkarsdottir U,Other measurement,initial,2019-05-03,GCST008282,Spine bone size
10825,European,28954.0,31053729.0,Styrkarsdottir U,Body measurement,initial,2019-05-03,GCST008278,Femoral neck size
10824,European,28944.0,31053729.0,Styrkarsdottir U,Body measurement,initial,2019-05-03,GCST008279,Trochanter size
4064,Asian,9383.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008278,Femoral neck size
3697,Asian,5696.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008280,Intertrochanteric region size
10822,European,28936.0,31053729.0,Styrkarsdottir U,Body measurement,initial,2019-05-03,GCST008280,Intertrochanteric region size
3698,Asian,5699.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008281,Hip bone size
9353,European,8065.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008279,Trochanter size
8968,European,6351.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008278,Femoral neck size
10820,European,28900.0,31053729.0,Styrkarsdottir U,Body measurement,initial,2019-05-03,GCST008281,Hip bone size
3700,Asian,5711.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008279,Trochanter size
9312,European,7912.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008281,Hip bone size
9311,European,7912.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008280,Intertrochanteric region size
3782,Asian,6345.0,31053729.0,Styrkarsdottir U,Other measurement,replication,2019-05-03,GCST008282,Spine bone size
10184,European,14932.0,31053729.0,Styrkarsdottir U,Other measurement,replication,2019-05-03,GCST008282,Spine bone size
3123,Asian,2331.0,31050781.0,Zhao SX,"Immune system disorder, Metabolic disorder",initial,2019-05-03,GCST008365,Thyrotoxic hypokalemic periodic paralysis and Graves disease
9855,European,10870.0,31055733.0,Nazarian A,"Neurological disorder, Cardiovascular disease",initial,2019-05-05,GCST008438,Alzheimer's disease in hypertension
8492,European,4806.0,31055733.0,Nazarian A,Neurological disorder,initial,2019-05-05,GCST008437,Alzheimer's disease in hypertension-negative individuals
8469,European,4755.0,31059154.0,Chen Z,Neurological disorder,initial,2019-05-06,GCST007845,Progressive supranuclear palsy
9188,European,7310.0,31065058.0,Rongve A,Other trait,initial,2019-05-07,GCST007881,Dementia with Lewy bodies
9842,European,10744.0,31066027.0,Nicoletti P,"Other disease, Response to drug",initial,2019-05-07,GCST008386,Carbamazepine-induced serious cutaneous adverse reaction
9487,European,8454.0,31066027.0,Nicoletti P,"Other disease, Response to drug",initial,2019-05-07,GCST008385,Carbamazepine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
9486,European,8450.0,31066027.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2019-05-07,GCST008383,Carbamazepine-induced liver injury
9836,European,10726.0,31066027.0,Nicoletti P,"Immune system disorder, Response to drug",initial,2019-05-07,GCST008384,Carbamazepine-induced reaction with eosinophilia and systemic symptoms
11539,European,75653.0,31065058.0,Rongve A,Other trait,replication,2019-05-07,GCST007881,Dementia with Lewy bodies
10856,European,30118.0,31070104.0,Jia Q,Other measurement,initial,2019-05-09,GCST007836,Glycine levels
10455,European,19112.0,31070104.0,Jia Q,Other measurement,initial,2019-05-09,GCST007838,Glycine levels
9867,European,11006.0,31070104.0,Jia Q,Other measurement,initial,2019-05-09,GCST007837,Glycine levels
5521,European,563.0,31085060.0,Gisbert L,"Neurological disorder, Other measurement",initial,2019-05-10,GCST007880,Emotional lability in attention deficit hyperactivity disorder
9909,European,11473.0,31081985.0,Stein MB,Other measurement,initial,2019-05-13,GCST007946,Psychological resilience (self-assessed)
5553,European,581.0,31081985.0,Stein MB,Other measurement,initial,2019-05-13,GCST007945,Psychological resilience (outcome-based) in high deployment stress exposure
5404,European,497.0,31135556.0,Wyles CC,Other disease,replication,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
404,African American or Afro-Caribbean,2.0,31135556.0,Wyles CC,Other disease,replication,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
1590,Asian,2.0,31135556.0,Wyles CC,Other disease,initial,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
410,African American or Afro-Caribbean,9.0,31135556.0,Wyles CC,Other disease,initial,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
8296,European,4216.0,31135556.0,Wyles CC,Other disease,initial,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
6994,European,1939.0,31081985.0,Stein MB,Other measurement,initial,2019-05-13,GCST007947,Psychological resilience (outcome-based)
1593,Asian,3.0,31135556.0,Wyles CC,Other disease,replication,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
9183,European,7306.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008287,Alcohol dependence (drinking more than intended)
2971,Asian,1968.0,31089239.0,Choe EK,Other trait,initial,2019-05-14,GCST007921,Right-sided colonic diverticulosis
9182,European,7306.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008285,Alcohol dependence (tolerance)
8611,European,5050.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008287,Alcohol dependence (drinking more than intended)
1106,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008283,Alcohol dependence symptom count
2264,Asian,651.0,31089239.0,Choe EK,Other trait,replication,2019-05-14,GCST007921,Right-sided colonic diverticulosis
9181,European,7305.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008286,Alcohol dependence (withdrawal)
8507,European,4849.0,31090166.0,Lai D,"Other measurement, Neurological disorder",initial,2019-05-14,GCST008284,Alcohol dependence
8616,European,5053.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008286,Alcohol dependence (withdrawal)
8618,European,5053.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008289,Alcohol dependence (giving up activities)
9184,European,7307.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008291,Alcohol dependence (drinking despite problems)
9185,European,7308.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008289,Alcohol dependence (giving up activities)
9186,European,7309.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008288,Alcohol dependence (desire to cut drinking)
8613,European,5052.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008285,Alcohol dependence (tolerance)
9215,European,7418.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008283,Alcohol dependence symptom count
8614,European,5052.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008291,Alcohol dependence (drinking despite problems)
8615,European,5053.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008283,Alcohol dependence symptom count
1104,African American or Afro-Caribbean,2938.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008287,Alcohol dependence (drinking more than intended)
1105,African American or Afro-Caribbean,2939.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008291,Alcohol dependence (drinking despite problems)
9187,European,7309.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008290,Alcohol dependence (time spent drinking)
8619,European,5053.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008290,Alcohol dependence (time spent drinking)
1139,African American or Afro-Caribbean,3134.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008287,Alcohol dependence (drinking more than intended)
966,African American or Afro-Caribbean,1831.0,31090166.0,Lai D,"Other measurement, Neurological disorder",initial,2019-05-14,GCST008284,Alcohol dependence
1141,African American or Afro-Caribbean,3136.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008289,Alcohol dependence (giving up activities)
1142,African American or Afro-Caribbean,3136.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008290,Alcohol dependence (time spent drinking)
1108,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008286,Alcohol dependence (withdrawal)
1143,African American or Afro-Caribbean,3137.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008288,Alcohol dependence (desire to cut drinking)
1138,African American or Afro-Caribbean,3134.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008285,Alcohol dependence (tolerance)
1109,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008288,Alcohol dependence (desire to cut drinking)
1140,African American or Afro-Caribbean,3135.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008291,Alcohol dependence (drinking despite problems)
1110,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008289,Alcohol dependence (giving up activities)
1107,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008285,Alcohol dependence (tolerance)
1111,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008290,Alcohol dependence (time spent drinking)
8309,European,4244.0,31090166.0,Lai D,"Other measurement, Neurological disorder",replication,2019-05-14,GCST008284,Alcohol dependence
1085,African American or Afro-Caribbean,2726.0,31090166.0,Lai D,"Other measurement, Neurological disorder",replication,2019-05-14,GCST008284,Alcohol dependence
11723,European,92967.0,31089142.0,Law PJ,Cancer,initial,2019-05-14,GCST007992,Colorectal cancer
1136,African American or Afro-Caribbean,3130.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008286,Alcohol dependence (withdrawal)
8617,European,5053.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008288,Alcohol dependence (desire to cut drinking)
1153,African American or Afro-Caribbean,3175.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008283,Alcohol dependence symptom count
1405,African American or Afro-Caribbean,8827.0,31092297.0,Guan M,"Metabolic disorder, Other measurement",initial,2019-05-15,GCST007950,Type 2 diabetes and end-stage kidney disease in APOL1 risk genotype negative individuals
1438,African American or Afro-Caribbean,10409.0,31092297.0,Guan M,Metabolic disorder,initial,2019-05-15,GCST007949,Type 2 diabetes and end-stage kidney disease
8273,European,4151.0,31092817.0,Lees JA,Other disease,initial,2019-05-15,GCST009089,Pneumococcal bacteremia
8078,European,3631.0,31092817.0,Lees JA,Neurological disorder,initial,2019-05-15,GCST009087,Pneumococcal meningitis
8133,European,3782.0,31095341.0,Kerns SL,"Cancer, Biological process, Other trait",initial,2019-05-16,GCST008382,Toxicity response to radiotherapy in prostate cancer (increased urinary frequency) (time to event)
2205,Asian,538.0,31095341.0,Kerns SL,"Cancer, Other trait, Biological process",replication,2019-05-16,GCST008380,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event)
7956,European,3379.0,31095341.0,Kerns SL,"Cancer, Biological process, Other trait",initial,2019-05-16,GCST008381,Toxicity response to radiotherapy in prostate cancer (rectal bleeding) (time to event)
8009,European,3470.0,31095341.0,Kerns SL,"Cancer, Biological process, Other trait",initial,2019-05-16,GCST008378,Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event)
8165,European,3871.0,31095341.0,Kerns SL,"Cancer, Biological process, Other disease",initial,2019-05-16,GCST008379,Response to radiotherapy in prostate cancer (overall toxicity)
8073,European,3619.0,31095341.0,Kerns SL,"Cancer, Other trait, Biological process",initial,2019-05-16,GCST008380,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event)
9178,European,7291.0,31099175.0,Wetherill L,Neurological disorder,initial,2019-05-17,GCST008914,Alcohol or illicit drug dependence
1137,African American or Afro-Caribbean,3132.0,31099175.0,Wetherill L,Neurological disorder,initial,2019-05-17,GCST008914,Alcohol or illicit drug dependence
6786,European,1650.0,31099175.0,Wetherill L,Neurological disorder,replication,2019-05-17,GCST008914,Alcohol or illicit drug dependence
6745,European,1609.0,31102405.0,Labreche K,Cancer,initial,2019-05-17,GCST007896,Primary central nervous system lymphoma
1089,African American or Afro-Caribbean,2812.0,31099175.0,Wetherill L,Neurological disorder,replication,2019-05-17,GCST008914,Alcohol or illicit drug dependence
1998,Asian,318.0,31109976.0,Suvichapanich S,"Response to drug, Other disease, Digestive system disorder",initial,2019-05-20,GCST007897,Liver injury in anti-tuberculosis drug treatment
5465,European,523.0,31113495.0,Evans KL,"Other trait, Cardiovascular measurement, Cardiovascular disease",initial,2019-05-21,GCST007999,Heart rate in heart failure with reduced ejection fraction
714,African American or Afro-Caribbean,520.0,31113495.0,Evans KL,"Other trait, Cardiovascular measurement, Cardiovascular disease",initial,2019-05-21,GCST007999,Heart rate in heart failure with reduced ejection fraction
13469,Hispanic or Latin American,12154.0,31118516.0,Flannick J,Metabolic disorder,initial,2019-05-22,GCST008833,Type 2 diabetes
10898,European,31880.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008559,Anxiety and stress-related disorders
10875,European,30785.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008564,Anxiety and stress-related disorders (excluding co-morbid schizophrenia)
1257,African American or Afro-Caribbean,4560.0,31118516.0,Flannick J,Metabolic disorder,initial,2019-05-22,GCST008833,Type 2 diabetes
10843,European,29536.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008562,Anxiety and stress-related disorders (psychiatric co-morbidity weighting design)
10829,European,29056.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008567,Stress-related disorders
11336,European,54311.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008561,Anxiety and stress-related disorders (psychiatric co-morbidity covariate model)
10925,European,32758.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008563,Anxiety and stress-related disorders (including obsessive-compulsive disorder)
3734,Asian,5961.0,31118516.0,Flannick J,Metabolic disorder,initial,2019-05-22,GCST008833,Type 2 diabetes
10794,European,27742.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008565,Anxiety and stress-related disorders (excluding adjustment disorder)
3746,Asian,6019.0,31118516.0,Flannick J,Metabolic disorder,initial,2019-05-22,GCST008833,Type 2 diabetes
10658,European,23198.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008560,Anxiety and stress-related disorders (propensity-score-matching design)
9174,European,7218.0,31118516.0,Flannick J,Metabolic disorder,initial,2019-05-22,GCST008833,Type 2 diabetes
10679,European,23809.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008566,Anxiety disorders
6114,European,972.0,31123309.0,Rayner C,"Other trait, Neurological disorder",initial,2019-05-23,GCST008360,Response to cognitive-behavioural therapy in anxiety disorder
6113,European,972.0,31123309.0,Rayner C,"Other trait, Neurological disorder",initial,2019-05-23,GCST008358,Response to cognitive-behavioural therapy in anxiety and major depressive disorders
6054,European,935.0,31120506.0,Grassmann F,"Other measurement, Neurological disorder",initial,2019-05-23,GCST008356,Geographic atrophy lesion growth rate in age-related macular degeneration
14072,Other/Mixed,993.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
8660,European,5168.0,31127053.0,Tang Y,"Metabolic disorder, Neurological disorder",initial,2019-05-24,GCST008223,Diabetic peripheral neuropathy in type 2 diabetes
3464,Asian,4115.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
12595,European,445655.0,31125052.0,Green HD,Immune system disorder,initial,2019-05-24,GCST009081,Microscopic colitis
1408,African American or Afro-Caribbean,9013.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
1476,African American or Afro-Caribbean,15293.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
14200,Other/Mixed,3500.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
14068,Other/Mixed,966.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
14190,Other/Mixed,2988.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
13970,Other/Mixed,637.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
13526,Hispanic or Latin American,16134.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
6085,European,949.0,31127053.0,Tang Y,"Metabolic disorder, Neurological disorder",replication,2019-05-24,GCST008223,Diabetic peripheral neuropathy in type 2 diabetes
909,African American or Afro-Caribbean,1345.0,31127053.0,Tang Y,"Metabolic disorder, Neurological disorder",replication,2019-05-24,GCST008223,Diabetic peripheral neuropathy in type 2 diabetes
13716,Other/Mixed,50.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
11219,European,46495.0,31125052.0,Green HD,"Immune system disorder, Response to drug",initial,2019-05-24,GCST009080,Microscopic colitis in proton-pump inhibitor treatment
13568,Hispanic or Latin American,20653.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
3401,Asian,3648.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
12243,European,216518.0,31152163.0,Wuttke M,Other measurement,replication,2019-05-31,GCST008058,Estimated glomerular filtration rate
12244,European,216518.0,31152163.0,Wuttke M,Other measurement,replication,2019-05-31,GCST008059,Estimated glomerular filtration rate
4239,Asian,13359.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008061,Estimated glomerular filtration rate
13287,Hispanic or Latin American,4961.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008058,Estimated glomerular filtration rate
401,African,64204.0,31152163.0,Wuttke M,Other measurement,replication,2019-05-31,GCST008058,Estimated glomerular filtration rate
3104,Asian,2262.0,31152121.0,Zhu M,Metabolic disorder,initial,2019-05-31,GCST008377,Type 1 diabetes
1468,African American or Afro-Caribbean,13842.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008058,Estimated glomerular filtration rate
4238,Asian,13359.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008058,Estimated glomerular filtration rate
12671,European,625219.0,31152163.0,Wuttke M,"Other disease, Other measurement",initial,2019-05-31,GCST008065,Chronic kidney disease
1469,African American or Afro-Caribbean,13842.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008066,Estimated glomerular filtration rate
3602,Asian,5152.0,31152121.0,Zhu M,Metabolic disorder,replication,2019-05-31,GCST008377,Type 1 diabetes
12286,European,243029.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008063,Blood urea nitrogen levels
4628,Asian,165726.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008060,Estimated glomerular filtration rate
12663,European,567460.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008058,Estimated glomerular filtration rate
12664,European,567460.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008059,Estimated glomerular filtration rate
4627,Asian,165726.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008058,Estimated glomerular filtration rate
6728,European,1585.0,31189108.0,O'Connor D,"Response to drug, Other measurement",initial,2019-06-01,GCST008499,Meningococcal C functional antibody titers post childhood immunization
6200,European,1011.0,31189108.0,O'Connor D,"Response to drug, Other measurement",replication,2019-06-01,GCST008501,Haemophilus influenza type b polyribosylribitol phosphate IgG concentrations post childhood immunization
6396,European,1203.0,31189108.0,O'Connor D,"Response to drug, Other measurement",initial,2019-06-01,GCST008498,Meningococcal C IgG concentrations post childhood immunization
5504,European,549.0,31189108.0,O'Connor D,"Response to drug, Other measurement",initial,2019-06-01,GCST008500,Tetanus toxoid IgG concentrations post childhood immunization
6129,European,980.0,31189108.0,O'Connor D,"Response to drug, Other measurement",replication,2019-06-01,GCST008498,Meningococcal C IgG concentrations post childhood immunization
6488,European,1303.0,31189108.0,O'Connor D,"Response to drug, Other measurement",replication,2019-06-01,GCST008500,Tetanus toxoid IgG concentrations post childhood immunization
5825,European,779.0,31189108.0,O'Connor D,"Response to drug, Other measurement",replication,2019-06-01,GCST008499,Meningococcal C functional antibody titers post childhood immunization
8827,European,5783.0,31250787.0,Fawns-Ritchie C,Other measurement,initial,2019-06-01,GCST008513,Health literacy
6106,European,967.0,31189108.0,O'Connor D,"Response to drug, Other measurement",initial,2019-06-01,GCST008501,Haemophilus influenza type b polyribosylribitol phosphate IgG concentrations post childhood immunization
1646,Asian,31.0,31155012.0,Nakahara S,"Neurological disorder, Other measurement",initial,2019-06-03,GCST008557,Dentate gyrus volume x schizophrenia interaction
4897,European,199.0,31155012.0,Nakahara S,Other measurement,initial,2019-06-03,GCST008558,Dentate gyrus volume
4896,European,199.0,31155012.0,Nakahara S,"Neurological disorder, Other measurement",initial,2019-06-03,GCST008557,Dentate gyrus volume x schizophrenia interaction
1647,Asian,31.0,31155012.0,Nakahara S,Other measurement,initial,2019-06-03,GCST008558,Dentate gyrus volume
13617,Other/Mixed,3.0,31155012.0,Nakahara S,Other measurement,initial,2019-06-03,GCST008558,Dentate gyrus volume
13616,Other/Mixed,3.0,31155012.0,Nakahara S,"Neurological disorder, Other measurement",initial,2019-06-03,GCST008557,Dentate gyrus volume x schizophrenia interaction
13613,Other/Mixed,2.0,31155012.0,Nakahara S,"Neurological disorder, Other measurement",initial,2019-06-03,GCST008557,Dentate gyrus volume x schizophrenia interaction
13614,Other/Mixed,2.0,31155012.0,Nakahara S,Other measurement,initial,2019-06-03,GCST008558,Dentate gyrus volume
8426,European,4629.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008120,Suicide attempts in schizophrenia
9042,European,6704.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008407,Diastolic blood pressure x physical activity (least active quartile vs others) interaction (1df)
9789,European,10408.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008118,Suicide attempts in major depressive disorder
9045,European,6705.0,31167214.0,Osazuwa-Peters OL,Other measurement,initial,2019-06-05,GCST008392,Systolic blood pressure x physical activity interaction (1df)
9043,European,6704.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008411,Diastolic blood pressure x physical activity (less vs more active half) interaction (2df)
8211,European,3984.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008410,Diastolic blood pressure x physical activity (least vs most active quartile) interaction (2df)
11389,European,58853.0,31164008.0,Mullins N,"Biological process, Neurological disorder",replication,2019-06-05,GCST008121,Suicide attempts in major depressive disorder or bipolar disorder
9046,European,6705.0,31167214.0,Osazuwa-Peters OL,Other measurement,initial,2019-06-05,GCST008393,Systolic blood pressure x physical activity interaction (2df)
9047,European,6705.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008401,Systolic blood pressure x physical activity (less vs more active half) interaction (1df)
8210,European,3984.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008405,Diastolic blood pressure x physical activity (least vs most active quartile) interaction (1df)
10459,European,19172.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008121,Suicide attempts in major depressive disorder or bipolar disorder
9049,European,6705.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008408,Systolic blood pressure x physical activity (less vs more active half) interaction (2df)
9050,European,6705.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008409,Systolic blood pressure x physical activity (least active quartile vs others) interaction (2df)
10064,European,13393.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008122,Suicide attempts in bipolar disorder or schizophrenia
9048,European,6705.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008404,Systolic blood pressure x physical activity (least active quartile vs others) interaction (1df)
9040,European,6704.0,31167214.0,Osazuwa-Peters OL,Other measurement,initial,2019-06-05,GCST008390,DIastolic blood pressure x physical activity interaction (2df)
9039,European,6704.0,31167214.0,Osazuwa-Peters OL,Other measurement,initial,2019-06-05,GCST008389,Diastolic blood pressure x physical activity interaction (1df)
12501,European,363705.0,31168069.0,Ward J,Other measurement,initial,2019-06-05,GCST008357,Mood instability
8209,European,3984.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008402,Systolic blood pressure x physical activity (least vs most active quartile) interaction (2df)
8208,European,3984.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008400,Systolic blood pressure x physical activity (least vs most active quartile) interaction (1df)
10678,European,23801.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008123,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia
9551,European,8764.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008119,Suicide attempts in bipolar disorder
9041,European,6704.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008406,Diastolic blood pressure x physical activity (less vs more active half) interaction (1df)
9044,European,6704.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008412,Diastolic blood pressure x physical activity (least active quartile vs others) interaction (2df)
9072,European,6798.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008881,Estradiol levels
3034,Asian,2118.0,31170924.0,Kong S,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",replication,2019-06-06,GCST008140,Metabolic syndrome
7115,European,2070.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008879,17-hydroxyprogesterone (17-OHP) levels
3549,Asian,4659.0,31170924.0,Kong S,Other measurement,initial,2019-06-06,GCST008144,Fasting plasma glucose
3548,Asian,4659.0,31170924.0,Kong S,Other measurement,initial,2019-06-06,GCST008143,Diastolic blood pressure
7116,European,2070.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008886,Androstenedione levels
3614,Asian,5273.0,31170924.0,Kong S,Body measurement,replication,2019-06-06,GCST008145,Waist circumference
3547,Asian,4659.0,31170924.0,Kong S,Other measurement,initial,2019-06-06,GCST008142,Systolic blood pressure
3546,Asian,4659.0,31170924.0,Kong S,Lipid or lipoprotein measurement,initial,2019-06-06,GCST008150,Triglyceride levels
3545,Asian,4659.0,31170924.0,Kong S,Lipid or lipoprotein measurement,initial,2019-06-06,GCST008141,HDL cholesterol
3544,Asian,4659.0,31170924.0,Kong S,Body measurement,initial,2019-06-06,GCST008145,Waist circumference
7043,European,1993.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008880,Aldosterone levels
3615,Asian,5273.0,31170924.0,Kong S,Lipid or lipoprotein measurement,replication,2019-06-06,GCST008141,HDL cholesterol
3616,Asian,5273.0,31170924.0,Kong S,Lipid or lipoprotein measurement,replication,2019-06-06,GCST008150,Triglyceride levels
3617,Asian,5273.0,31170924.0,Kong S,Other measurement,replication,2019-06-06,GCST008142,Systolic blood pressure
3618,Asian,5273.0,31170924.0,Kong S,Other measurement,replication,2019-06-06,GCST008143,Diastolic blood pressure
3266,Asian,2857.0,31170924.0,Kong S,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2019-06-06,GCST008146,Metabolic syndrome
11064,European,37505.0,31171785.0,Dorajoo R,Other measurement,replication,2019-06-06,GCST008366,Leukocyte telomere length
3619,Asian,5273.0,31170924.0,Kong S,Other measurement,replication,2019-06-06,GCST008144,Fasting plasma glucose
9274,European,7667.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008882,Cortisol levels (plasma)
9273,European,7659.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008883,DHEAS levels
9267,European,7643.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008884,Testosterone levels
3780,Asian,6337.0,31171785.0,Dorajoo R,Other measurement,replication,2019-06-06,GCST008366,Leukocyte telomere length
2916,Asian,1850.0,31170924.0,Kong S,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2019-06-06,GCST008140,Metabolic syndrome
7533,European,2619.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008885,Progesterone levels
4315,Asian,16759.0,31171785.0,Dorajoo R,Other measurement,initial,2019-06-06,GCST008366,Leukocyte telomere length
12674,European,651138.0,31174203.0,Liyanage UE,Cancer,initial,2019-06-07,GCST008871,Basal cell carcinoma
12673,European,635331.0,31174203.0,Liyanage UE,Cancer,initial,2019-06-07,GCST008872,Squamous cell carcinoma
2071,Asian,384.0,31341412.0,Chen QY,Other measurement,replication,2019-06-10,GCST009000,Viral basal core promoter double mutation in hepatitis B virus surface antigen (HBsAg) seropositivity
9260,European,7611.0,31188284.0,Bae H,Other measurement,initial,2019-06-10,GCST008149,Age at menopause
2093,Asian,409.0,31341412.0,Chen QY,Other measurement,initial,2019-06-10,GCST009000,Viral basal core promoter double mutation in hepatitis B virus surface antigen (HBsAg) seropositivity
2673,Asian,1402.0,31186284.0,Liu Y,"Lipid or lipoprotein measurement, Cardiovascular disease",initial,2019-06-11,GCST008433,Lipoprotein (a) levels in coronary artery disease (percutaneous coronary intervention)
258,African,3192.0,31249589.0,Edwards TL,Cancer,replication,2019-06-12,GCST008423,Uterine fibroids
12044,European,150588.0,31249589.0,Edwards TL,Cancer,replication,2019-06-12,GCST008423,Uterine fibroids
11525,European,73302.0,31249589.0,Edwards TL,Cancer,initial,2019-06-12,GCST008423,Uterine fibroids
8284,European,4175.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
8283,European,4175.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
8282,European,4175.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
458,African American or Afro-Caribbean,53.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
457,African American or Afro-Caribbean,53.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
1614,Asian,13.0,31219150.0,Ekenberg C,"Other measurement, Other disease",initial,2019-06-13,GCST008758,Pre-treatment viral load in HIV-1 infection
12861,Hispanic or Latin American,418.0,31219150.0,Ekenberg C,"Other measurement, Other disease",initial,2019-06-13,GCST008758,Pre-treatment viral load in HIV-1 infection
5508,European,552.0,31194736.0,Tiensuu H,"Other trait, Other disease",initial,2019-06-13,GCST008180,Spontaneous preterm birth with premature rupture of membranes
127,African,572.0,31219150.0,Ekenberg C,"Other measurement, Other disease",initial,2019-06-13,GCST008758,Pre-treatment viral load in HIV-1 infection
5454,European,520.0,31194736.0,Tiensuu H,Other trait,initial,2019-06-13,GCST008181,Spontaneous preterm birth without premature rupture of membranes
13653,Other/Mixed,11.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
5395,European,494.0,31194736.0,Tiensuu H,Other trait,initial,2019-06-13,GCST008179,Moderate-to-late spontaneous preterm birth
13654,Other/Mixed,11.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
13655,Other/Mixed,11.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
5667,European,666.0,31194736.0,Tiensuu H,Other measurement,initial,2019-06-13,GCST008176,Gestational age at birth (child effect)
5668,European,666.0,31194736.0,Tiensuu H,"Other measurement, Other trait",initial,2019-06-13,GCST008177,Spontaneous preterm birth (preterm birth)
12184,European,193860.0,31190057.0,Dashti HS,Other measurement,initial,2019-06-13,GCST008555,Breakfast cereal skipping frequency
6579,European,1398.0,31219150.0,Ekenberg C,"Other measurement, Other disease",initial,2019-06-13,GCST008758,Pre-treatment viral load in HIV-1 infection
1735,Asian,100.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
1734,Asian,100.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
1733,Asian,100.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
456,African American or Afro-Caribbean,53.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
13697,Other/Mixed,30.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
9962,European,11963.0,31190057.0,Dashti HS,Other measurement,initial,2019-06-13,GCST008556,Breakfast skipping
13698,Other/Mixed,30.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
13699,Other/Mixed,30.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
12792,Hispanic or Latin American,138.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
12793,Hispanic or Latin American,138.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
12794,Hispanic or Latin American,138.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
13723,Other/Mixed,58.0,31196165.0,Lee E,"Other trait, Cancer, Biological process",initial,2019-06-13,GCST008388,Acute post-radiotherapy pain in breast cancer
12541,European,387649.0,31194737.0,Johnston KJA,Other trait,initial,2019-06-13,GCST008512,Multisite chronic pain
10323,European,16815.0,31194737.0,Johnston KJA,Other trait,initial,2019-06-13,GCST008511,Chronic widespread pain
5564,European,591.0,31194736.0,Tiensuu H,Other trait,initial,2019-06-13,GCST008178,Early spontaneous preterm birth
12850,Hispanic or Latin American,401.0,31196165.0,Lee E,"Other trait, Cancer, Biological process",initial,2019-06-13,GCST008388,Acute post-radiotherapy pain in breast cancer
5134,European,357.0,31196165.0,Lee E,"Other trait, Cancer, Biological process",initial,2019-06-13,GCST008388,Acute post-radiotherapy pain in breast cancer
12848,Hispanic or Latin American,396.0,31207883.0,Rivera-Paredez B,Cardiovascular measurement,initial,2019-06-14,GCST008445,Serum uric acid levels
13211,Hispanic or Latin American,3693.0,31207883.0,Rivera-Paredez B,Cardiovascular measurement,replication,2019-06-14,GCST008445,Serum uric acid levels
8971,European,6378.0,31212010.0,Cabana-Dominguez J,Neurological disorder,initial,2019-06-15,GCST008399,Cocaine dependence
5039,European,294.0,31163085.0,Sharapov SZ,Other measurement,replication,2019-06-15,GCST008108,N-glycan levels
13865,Other/Mixed,327.0,31163085.0,Sharapov SZ,Other measurement,replication,2019-06-15,GCST008108,N-glycan levels
12404,European,306542.0,31209380.0,Demontis D,"Other disease, Neurological disorder",replication,2019-06-17,GCST008414,Cannabis use disorder
8285,European,4176.0,31209380.0,Demontis D,"Neurological disorder, Other disease",initial,2019-06-17,GCST008415,Cannabis use disorder vs schizophrenia
7751,European,3034.0,31206164.0,Richards AL,"Biological process, Neurological disorder",initial,2019-06-17,GCST008387,Cognitive ability in schizophrenia
11282,European,51372.0,31209380.0,Demontis D,"Other disease, Neurological disorder",initial,2019-06-17,GCST008414,Cannabis use disorder
11281,European,51372.0,31209380.0,Demontis D,"Neurological disorder, Metabolic disorder",initial,2019-06-17,GCST008417,Psychiatric disorder
11262,European,48985.0,31209380.0,Demontis D,Neurological disorder,initial,2019-06-17,GCST008416,Psychiatric disorder without cannabis use disorder
5902,European,831.0,31206233.0,Real LM,Other trait,initial,2019-06-17,GCST008502,Low susceptibility to hepatitis C infection
4809,European,152.0,31209788.0,Li HQ,"Other trait, Other measurement",initial,2019-06-18,GCST008274,Cerebral microbleed progression
6644,European,1513.0,31226389.0,Wilman HR,Other measurement,replication,2019-06-18,GCST008172,Liver iron content
9386,European,8289.0,31226389.0,Wilman HR,Other measurement,initial,2019-06-18,GCST008172,Liver iron content
13426,Hispanic or Latin American,9636.0,31213470.0,Moon JY,Other measurement,initial,2019-06-18,GCST008398,Glycated hemoglobin levels
14179,Other/Mixed,2700.0,31211820.0,Deek R,Lipid or lipoprotein measurement,initial,2019-06-18,GCST008444,High density lipoprotein cholesterol levels
5308,European,454.0,31209788.0,Li HQ,Other trait,initial,2019-06-18,GCST008275,Cerebral microbleeds
13270,Hispanic or Latin American,4777.0,31213470.0,Moon JY,Other measurement,replication,2019-06-18,GCST008398,Glycated hemoglobin levels
10086,European,13577.0,31217265.0,Sliz E,"Other measurement, Inflammatory measurement",initial,2019-06-19,GCST008197,Interleukin-8 levels
10084,European,13577.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008204,Monocyte chemoattractant protein-1 levels
1436,African American or Afro-Caribbean,10286.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008052,Waist-hip ratio
12397,European,303288.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008040,Height
13975,Other/Mixed,647.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
13976,Other/Mixed,647.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008053,Height
10083,European,13577.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008201,Interleukin-4 levels
13275,Hispanic or Latin American,4917.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008051,Waist-hip ratio
1497,African American or Afro-Caribbean,17286.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
14111,Other/Mixed,1397.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008033,Fasting blood insulin
1432,African American or Afro-Caribbean,10085.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008035,High density lipoprotein cholesterol levels
1429,African American or Afro-Caribbean,9980.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008046,Triglyceride levels
1417,African American or Afro-Caribbean,9720.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008037,Low density lipoprotein cholesterol levels
14105,Other/Mixed,1346.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008051,Waist-hip ratio
1411,African American or Afro-Caribbean,9140.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008050,Waist-hip ratio
10082,European,13577.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008199,Interferon gamma-induced protein 10 levels
14112,Other/Mixed,1400.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008032,Fasting blood glucose
1433,African American or Afro-Caribbean,10137.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008045,Total cholesterol levels
1447,African American or Afro-Caribbean,11380.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008029,Diastolic blood pressure
1498,African American or Afro-Caribbean,17286.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008053,Height
1496,African American or Afro-Caribbean,17152.0,31217584.0,Wojcik GL,Cardiovascular disease,initial,2019-06-19,GCST008036,Hypertension
1495,African American or Afro-Caribbean,17127.0,31217584.0,Wojcik GL,"Body measurement, Other measurement",initial,2019-06-19,GCST008025,Body mass index
14136,Other/Mixed,1777.0,31217584.0,Wojcik GL,Inflammatory measurement,initial,2019-06-19,GCST008055,C-reactive protein levels
14130,Other/Mixed,1715.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008050,Waist-hip ratio
1480,African American or Afro-Caribbean,15601.0,31217584.0,Wojcik GL,Metabolic disorder,initial,2019-06-19,GCST008048,Type 2 diabetes
12312,European,253288.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
13974,Other/Mixed,645.0,31217584.0,Wojcik GL,"Body measurement, Other measurement",initial,2019-06-19,GCST008025,Body mass index
1478,African American or Afro-Caribbean,15522.0,31217584.0,Wojcik GL,"Other disease, Other measurement",initial,2019-06-19,GCST008026,Chronic kidney disease
13240,Hispanic or Latin American,4198.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008027,Smoking behaviour (cigarettes smoked per day)
1454,African American or Afro-Caribbean,11862.0,31217584.0,Wojcik GL,"Biological process, Other measurement",initial,2019-06-19,GCST008028,Coffee consumption (cups per day)
13829,Other/Mixed,231.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008042,PR interval
1410,African American or Afro-Caribbean,9065.0,31217584.0,Wojcik GL,Other disease,initial,2019-06-19,GCST008031,End-stage renal disease
2206,Asian,541.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008039,Platelet count
13718,Other/Mixed,53.0,31217584.0,Wojcik GL,Other disease,initial,2019-06-19,GCST008031,End-stage renal disease
13828,Other/Mixed,230.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008043,QT interval
1448,African American or Afro-Caribbean,11380.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008044,Systolic blood pressure
13972,Other/Mixed,639.0,31217584.0,Wojcik GL,"Other disease, Other measurement",initial,2019-06-19,GCST008026,Chronic kidney disease
2208,Asian,543.0,31217584.0,Wojcik GL,"Hematological measurement, Inflammatory measurement",initial,2019-06-19,GCST008049,White blood cell count
10085,European,13577.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008205,Interleukin-17 levels
3553,Asian,4680.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008053,Height
1404,African American or Afro-Caribbean,8825.0,31217584.0,Wojcik GL,"Hematological measurement, Inflammatory measurement",initial,2019-06-19,GCST008049,White blood cell count
1175,African American or Afro-Caribbean,3360.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008042,PR interval
1205,African American or Afro-Caribbean,3750.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008038,Mean corpuscular hemoglobin concentration
3146,Asian,2387.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008045,Total cholesterol levels
13962,Other/Mixed,606.0,31217584.0,Wojcik GL,"Hematological measurement, Inflammatory measurement",initial,2019-06-19,GCST008049,White blood cell count
3141,Asian,2381.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008046,Triglyceride levels
3140,Asian,2378.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008035,High density lipoprotein cholesterol levels
3121,Asian,2316.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008037,Low density lipoprotein cholesterol levels
13945,Other/Mixed,574.0,31217584.0,Wojcik GL,Inflammatory measurement,initial,2019-06-19,GCST008055,C-reactive protein levels
13948,Other/Mixed,582.0,31217584.0,Wojcik GL,"Biological process, Other measurement",initial,2019-06-19,GCST008028,Coffee consumption (cups per day)
1171,African American or Afro-Caribbean,3293.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008043,QT interval
13949,Other/Mixed,585.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008050,Waist-hip ratio
2894,Asian,1811.0,31217584.0,Wojcik GL,Inflammatory measurement,initial,2019-06-19,GCST008055,C-reactive protein levels
13952,Other/Mixed,591.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008037,Low density lipoprotein cholesterol levels
13954,Other/Mixed,602.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008030,Estimated glomerular filtration rate
13956,Other/Mixed,603.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008039,Platelet count
2909,Asian,1843.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008050,Waist-hip ratio
2949,Asian,1918.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008027,Smoking behaviour (cigarettes smoked per day)
2950,Asian,1918.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008032,Fasting blood glucose
13960,Other/Mixed,604.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008046,Triglyceride levels
13824,Other/Mixed,226.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008054,QRS duration
13950,Other/Mixed,585.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008052,Waist-hip ratio
1169,African American or Afro-Caribbean,3274.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008054,QRS duration
13963,Other/Mixed,619.0,31217584.0,Wojcik GL,Metabolic disorder,initial,2019-06-19,GCST008048,Type 2 diabetes
1285,African American or Afro-Caribbean,5525.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008033,Fasting blood insulin
10081,European,13577.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008211,Tumor necrosis factor alpha levels
3552,Asian,4680.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
3550,Asian,4663.0,31217584.0,Wojcik GL,Cardiovascular disease,initial,2019-06-19,GCST008036,Hypertension
13969,Other/Mixed,636.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008044,Systolic blood pressure
13968,Other/Mixed,636.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008029,Diastolic blood pressure
1391,African American or Afro-Caribbean,8349.0,31217584.0,Wojcik GL,Inflammatory measurement,initial,2019-06-19,GCST008055,C-reactive protein levels
13967,Other/Mixed,635.0,31217584.0,Wojcik GL,Cardiovascular disease,initial,2019-06-19,GCST008036,Hypertension
1389,African American or Afro-Caribbean,8261.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008030,Estimated glomerular filtration rate
13959,Other/Mixed,604.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008045,Total cholesterol levels
1340,African American or Afro-Caribbean,7171.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008027,Smoking behaviour (cigarettes smoked per day)
2536,Asian,1086.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008029,Diastolic blood pressure
2537,Asian,1086.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008044,Systolic blood pressure
3538,Asian,4647.0,31217584.0,Wojcik GL,"Body measurement, Other measurement",initial,2019-06-19,GCST008025,Body mass index
3526,Asian,4576.0,31217584.0,Wojcik GL,Metabolic disorder,initial,2019-06-19,GCST008048,Type 2 diabetes
3465,Asian,4124.0,31217584.0,Wojcik GL,"Other disease, Other measurement",initial,2019-06-19,GCST008026,Chronic kidney disease
1310,African American or Afro-Caribbean,6457.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008032,Fasting blood glucose
3416,Asian,3764.0,31217584.0,Wojcik GL,"Biological process, Other measurement",initial,2019-06-19,GCST008028,Coffee consumption (cups per day)
2753,Asian,1547.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008033,Fasting blood insulin
3391,Asian,3600.0,31217584.0,Wojcik GL,Other disease,initial,2019-06-19,GCST008031,End-stage renal disease
3377,Asian,3500.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008052,Waist-hip ratio
2798,Asian,1657.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008051,Waist-hip ratio
1406,African American or Afro-Caribbean,8850.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008039,Platelet count
10080,European,13577.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008209,Interleukin-1-beta levels
13958,Other/Mixed,604.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008035,High density lipoprotein cholesterol levels
14193,Other/Mixed,3061.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008052,Waist-hip ratio
13563,Hispanic or Latin American,18949.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008039,Platelet count
13562,Hispanic or Latin American,18548.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008030,Estimated glomerular filtration rate
727,African American or Afro-Caribbean,559.0,31217584.0,Wojcik GL,"Other measurement, Hematological measurement",initial,2019-06-19,GCST008034,Hemoglobin A1c levels
13561,Hispanic or Latin American,18251.0,31217584.0,Wojcik GL,"Hematological measurement, Inflammatory measurement",initial,2019-06-19,GCST008049,White blood cell count
1711,Asian,92.0,31217584.0,Wojcik GL,"Other measurement, Hematological measurement",initial,2019-06-19,GCST008034,Hemoglobin A1c levels
13452,Hispanic or Latin American,11555.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008050,Waist-hip ratio
13550,Hispanic or Latin American,17856.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008046,Triglyceride levels
13549,Hispanic or Latin American,17802.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008045,Total cholesterol levels
13548,Hispanic or Latin American,17751.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008035,High density lipoprotein cholesterol levels
13543,Hispanic or Latin American,17373.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008037,Low density lipoprotein cholesterol levels
13908,Other/Mixed,412.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008032,Fasting blood glucose
1801,Asian,150.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008030,Estimated glomerular filtration rate
13631,Other/Mixed,4.0,31217584.0,Wojcik GL,"Other measurement, Hematological measurement",initial,2019-06-19,GCST008034,Hemoglobin A1c levels
857,African American or Afro-Caribbean,1146.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008051,Waist-hip ratio
13510,Hispanic or Latin American,13702.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008042,PR interval
13529,Hispanic or Latin American,16472.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008052,Waist-hip ratio
13528,Hispanic or Latin American,16405.0,31217584.0,Wojcik GL,Other disease,initial,2019-06-19,GCST008031,End-stage renal disease
13524,Hispanic or Latin American,15912.0,31217584.0,Wojcik GL,Inflammatory measurement,initial,2019-06-19,GCST008055,C-reactive protein levels
13523,Hispanic or Latin American,15837.0,31217584.0,Wojcik GL,"Biological process, Other measurement",initial,2019-06-19,GCST008028,Coffee consumption (cups per day)
14188,Other/Mixed,2946.0,31217584.0,Wojcik GL,Other disease,initial,2019-06-19,GCST008031,End-stage renal disease
10079,European,13577.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008203,Interleukin-1-receptor antagonist levels
14201,Other/Mixed,3500.0,31217584.0,Wojcik GL,"Other disease, Other measurement",initial,2019-06-19,GCST008026,Chronic kidney disease
13499,Hispanic or Latin American,12687.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008033,Fasting blood insulin
1772,Asian,127.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008043,QT interval
1779,Asian,128.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008038,Mean corpuscular hemoglobin concentration
14202,Other/Mixed,3551.0,31217584.0,Wojcik GL,Metabolic disorder,initial,2019-06-19,GCST008048,Type 2 diabetes
13507,Hispanic or Latin American,13420.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008054,QRS duration
13508,Hispanic or Latin American,13556.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008032,Fasting blood glucose
13522,Hispanic or Latin American,15522.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008038,Mean corpuscular hemoglobin concentration
1781,Asian,129.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008042,PR interval
1771,Asian,126.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008054,QRS duration
13673,Other/Mixed,20.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008038,Mean corpuscular hemoglobin concentration
13430,Hispanic or Latin American,10408.0,31217584.0,Wojcik GL,"Other measurement, Hematological measurement",initial,2019-06-19,GCST008034,Hemoglobin A1c levels
13570,Hispanic or Latin American,21549.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008029,Diastolic blood pressure
13571,Hispanic or Latin American,21549.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008044,Systolic blood pressure
13900,Other/Mixed,395.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008033,Fasting blood insulin
14157,Other/Mixed,2176.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008027,Smoking behaviour (cigarettes smoked per day)
13573,Hispanic or Latin American,21936.0,31217584.0,Wojcik GL,Cardiovascular disease,initial,2019-06-19,GCST008036,Hypertension
13574,Hispanic or Latin American,21955.0,31217584.0,Wojcik GL,"Body measurement, Other measurement",initial,2019-06-19,GCST008025,Body mass index
13575,Hispanic or Latin American,22192.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
13576,Hispanic or Latin American,22192.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008053,Height
14147,Other/Mixed,1915.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008046,Triglyceride levels
14208,Other/Mixed,3705.0,31217584.0,Wojcik GL,Cardiovascular disease,initial,2019-06-19,GCST008036,Hypertension
14146,Other/Mixed,1915.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008045,Total cholesterol levels
14145,Other/Mixed,1912.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008035,High density lipoprotein cholesterol levels
14144,Other/Mixed,1900.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008037,Low density lipoprotein cholesterol levels
10077,European,13577.0,31217265.0,Sliz E,Cardiovascular measurement,initial,2019-06-19,GCST008198,Vascular endothelial growth factor levels
10078,European,13577.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008200,Interleukin-6 levels
14212,Other/Mixed,3857.0,31217584.0,Wojcik GL,"Biological process, Other measurement",initial,2019-06-19,GCST008028,Coffee consumption (cups per day)
13854,Other/Mixed,288.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008027,Smoking behaviour (cigarettes smoked per day)
14217,Other/Mixed,3939.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008053,Height
13509,Hispanic or Latin American,13698.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008043,QT interval
14215,Other/Mixed,3936.0,31217584.0,Wojcik GL,"Body measurement, Other measurement",initial,2019-06-19,GCST008025,Body mass index
13567,Hispanic or Latin American,20480.0,31217584.0,Wojcik GL,Metabolic disorder,initial,2019-06-19,GCST008048,Type 2 diabetes
8699,European,5284.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008207,Interleukin-1-alpha levels
13569,Hispanic or Latin American,20920.0,31217584.0,Wojcik GL,"Other disease, Other measurement",initial,2019-06-19,GCST008026,Chronic kidney disease
14216,Other/Mixed,3939.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
8694,European,5284.0,31217265.0,Sliz E,Cardiovascular measurement,initial,2019-06-19,GCST008210,Soluble ICAM-1
8695,European,5284.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008202,Soluble E-selectin levels
8696,European,5284.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008208,Soluble CD40 ligand levels
8697,European,5284.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008196,Soluble VCAM-1 levels
8698,European,5284.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008206,Plasminogen activator inhibitor-1 (PAI-1) levels
13209,Hispanic or Latin American,3644.0,31219225.0,Young KA,Liver enzyme measurement,initial,2019-06-20,GCST008174,Aspartate aminotransferase levels
4642,European,28.0,31220337.0,Carr DF,"Response to drug, Other disease",initial,2019-06-20,GCST008554,Atorvastatin-induced myopathy
4716,European,85.0,31220337.0,Carr DF,"Other disease, Response to drug",initial,2019-06-20,GCST008551,Simvastatin-induced myopathy
13086,Hispanic or Latin American,1577.0,31219225.0,Young KA,Liver enzyme measurement,initial,2019-06-20,GCST008175,Gamma glutamyl transferase levels
4647,European,32.0,31220337.0,Carr DF,"Other disease, Response to drug",initial,2019-06-20,GCST008553,Statin-induced myopathy (severe)
13204,Hispanic or Latin American,3595.0,31219225.0,Young KA,Liver enzyme measurement,initial,2019-06-20,GCST008173,Alanine aminotransferase levels
4784,European,128.0,31220337.0,Carr DF,"Other disease, Response to drug",initial,2019-06-20,GCST008552,Statin-induced myopathy
13389,Hispanic or Latin American,7953.0,31226226.0,Du Z,Cancer,initial,2019-06-21,GCST008231,Prostate cancer
8629,European,5087.0,31231134.0,Laskar RS,Cancer,initial,2019-06-23,GCST008225,Renal cell carcinoma
7715,European,2974.0,31231134.0,Laskar RS,Cancer,replication,2019-06-23,GCST008225,Renal cell carcinoma
9877,European,11087.0,31231134.0,Laskar RS,"Cancer, Other measurement",replication,2019-06-23,GCST008224,Renal cell carcinoma x sex interaction
9361,European,8143.0,31231134.0,Laskar RS,Cancer,initial,2019-06-23,GCST008226,Renal cell carcinoma
9358,European,8113.0,31231134.0,Laskar RS,Cancer,replication,2019-06-23,GCST008226,Renal cell carcinoma
10045,European,13230.0,31231134.0,Laskar RS,"Cancer, Other measurement",initial,2019-06-23,GCST008224,Renal cell carcinoma x sex interaction
13465,Hispanic or Latin American,11816.0,31235808.0,Shungin D,Other measurement,initial,2019-06-24,GCST008298,Number of natural teeth
13435,Hispanic or Latin American,10948.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008300,Periodontitis
11913,European,127121.0,31235810.0,Fung K,Cardiovascular measurement,initial,2019-06-24,GCST008403,Arterial stiffness index
4323,Asian,17350.0,31235808.0,Shungin D,"Other measurement, Digestive system disorder",initial,2019-06-24,GCST008296,Periodontitis or loose teeth
10355,European,17353.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008300,Periodontitis
12650,European,495646.0,31235808.0,Shungin D,"Other measurement, Digestive system disorder",initial,2019-06-24,GCST008296,Periodontitis or loose teeth
12639,European,461031.0,31235808.0,Shungin D,Other measurement,initial,2019-06-24,GCST008297,Loose teeth
12640,European,461031.0,31235808.0,Shungin D,Other measurement,initial,2019-06-24,GCST008303,Painful gums
12641,European,461031.0,31235808.0,Shungin D,Other trait,initial,2019-06-24,GCST008301,Bleeding gums
13436,Hispanic or Latin American,10948.0,31235808.0,Shungin D,"Other measurement, Digestive system disorder",initial,2019-06-24,GCST008296,Periodontitis or loose teeth
10256,European,16133.0,31235808.0,Shungin D,Other measurement,initial,2019-06-24,GCST008298,Number of natural teeth
12646,European,476007.0,31235808.0,Shungin D,"Digestive system disorder, Other trait",initial,2019-06-24,GCST008295,"Number of decayed, missing and filled tooth surfaces or use of dentures"
12643,European,461031.0,31235808.0,Shungin D,Other trait,initial,2019-06-24,GCST008305,Toothache
10162,European,14717.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008299,Number of decayed and filled tooth surfaces per available tooth surface
10186,European,14976.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008302,"Number of decayed, missing and filled tooth surfaces"
12644,European,461031.0,31235808.0,Shungin D,Other trait,initial,2019-06-24,GCST008306,Dentures
13462,Hispanic or Latin American,11816.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008299,Number of decayed and filled tooth surfaces per available tooth surface
13463,Hispanic or Latin American,11816.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008302,"Number of decayed, missing and filled tooth surfaces"
13464,Hispanic or Latin American,11816.0,31235808.0,Shungin D,"Digestive system disorder, Other trait",initial,2019-06-24,GCST008295,"Number of decayed, missing and filled tooth surfaces or use of dentures"
12642,European,461031.0,31235808.0,Shungin D,Other trait,initial,2019-06-24,GCST008304,Mouth ulcers
4322,Asian,17350.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008300,Periodontitis
3824,Asian,6867.0,31243853.0,Chung S,"Response to drug, Other measurement",initial,2019-06-27,GCST008435,Response to hepatitis B vaccine
7367,European,2384.0,31246245.0,Khawaja AP,Other measurement,replication,2019-06-27,GCST008276,Corneal resistance factor
7368,European,2384.0,31246245.0,Khawaja AP,Other measurement,replication,2019-06-27,GCST008277,Corneal hysteresis
3204,Asian,2610.0,31243853.0,Chung S,"Response to drug, Other measurement",replication,2019-06-27,GCST008435,Response to hepatitis B vaccine
13521,Hispanic or Latin American,15124.0,31251759.0,Swenson BR,Cardiovascular measurement,initial,2019-06-28,GCST008422,QRS duration
13618,Other/Mixed,3.0,31299468.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
1585,Asian,1.0,31299468.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
13645,Other/Mixed,7.0,31299468.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
14089,Other/Mixed,1188.0,31299468.0,Condreay LD,"Other disease, Other disease, Response to drug, Response to drug, Other measurement, Other measurement",initial,2019-06-29,GCST008294,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
14090,Other/Mixed,1209.0,31299468.0,Condreay LD,"Other disease, Other disease, Response to drug, Response to drug, Other measurement, Other measurement",initial,2019-06-29,GCST008292,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
1648,Asian,33.0,31299468.0,Condreay LD,"Other disease, Other disease, Response to drug, Response to drug, Other measurement, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
13632,Other/Mixed,4.0,31299468.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
6958,European,1869.0,31299468.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
6056,European,935.0,31262040.0,Pujol-Moix N,Cardiovascular measurement,initial,2019-06-30,GCST008458,Platelet reactivity measurement (collagen-ADP)
8420,European,4611.0,31598132.0,Donati G,Biological process,initial,2019-06-30,GCST008892,Working memory
8422,European,4611.0,31598132.0,Donati G,Other measurement,initial,2019-06-30,GCST008893,Inhibitory control
8421,European,4611.0,31598132.0,Donati G,"Biological process, Other measurement",initial,2019-06-30,GCST008891,Cognitive performance (processing speed)
6055,European,935.0,31262040.0,Pujol-Moix N,Cardiovascular measurement,initial,2019-06-30,GCST008457,Platelet reactivity measurement (collagen-epinephrine)
13907,Other/Mixed,409.0,31260374.0,Pedergnana V,"Response to drug, Digestive system disorder",initial,2019-07-01,GCST008520,Response to direct-acting antiviral treatment in hepatitis C virus genotype 3
14092,Other/Mixed,1258.0,31260374.0,Pedergnana V,"Response to drug, Digestive system disorder",initial,2019-07-01,GCST008517,Response to interferon treatment in hepatitis C virus genotype 3
14124,Other/Mixed,1498.0,31260374.0,Pedergnana V,"Other measurement, Digestive system disorder",initial,2019-07-01,GCST008515,Pre-treatment viral load in hepatitis C virus genotype 3
8091,European,3669.0,31263163.0,Liu CT,Other measurement,initial,2019-07-01,GCST008504,Fasting glucose change (long-term)
8901,European,6064.0,31263063.0,Dufek S,Other disease,initial,2019-07-01,GCST008456,Childhood steroid-sensitive nephrotic syndrome
12514,European,371417.0,31263887.0,Adams MJ,Other trait,initial,2019-07-01,GCST008549,Mental health study participation (provided email address)
12515,European,371428.0,31263887.0,Adams MJ,Other trait,initial,2019-07-01,GCST008550,Mental health study participation (completed survey)
9370,European,8195.0,31263163.0,Liu CT,Other measurement,initial,2019-07-01,GCST008505,Fasting glucose change (short-term)
10101,European,13807.0,31263163.0,Liu CT,Other measurement,initial,2019-07-01,GCST008503,Fasting glucose change
6938,European,1843.0,31264924.0,Meng W,"Metabolic disorder, Other measurement",initial,2019-07-02,GCST008545,Diabetic maculopathy with decreased visual acuity in type 2 diabetes
7528,European,2614.0,31264924.0,Meng W,Metabolic disorder,initial,2019-07-02,GCST008546,Diabetic maculopathy in type 2 diabetes
1884,Asian,218.0,31269844.0,Wu NN,Metabolic disorder,initial,2019-07-03,GCST008448,Diabetes (gestational)
5060,European,306.0,31270906.0,Lai D,Biological process,replication,2019-07-03,GCST008447,Number of alcoholic drinks required to feel an effect (long-term average)
8462,European,4723.0,31270906.0,Lai D,Biological process,initial,2019-07-03,GCST008447,Number of alcoholic drinks required to feel an effect (long-term average)
5059,European,306.0,31270906.0,Lai D,Biological process,replication,2019-07-03,GCST008446,Number of alcoholic drinks required to feel an effect (first five times drinking)
937,African American or Afro-Caribbean,1527.0,31270906.0,Lai D,Biological process,initial,2019-07-03,GCST008447,Number of alcoholic drinks required to feel an effect (long-term average)
936,African American or Afro-Caribbean,1527.0,31270906.0,Lai D,Biological process,initial,2019-07-03,GCST008446,Number of alcoholic drinks required to feel an effect (first five times drinking)
8461,European,4723.0,31270906.0,Lai D,Biological process,initial,2019-07-03,GCST008446,Number of alcoholic drinks required to feel an effect (first five times drinking)
549,African American or Afro-Caribbean,169.0,31270906.0,Lai D,Biological process,replication,2019-07-03,GCST008446,Number of alcoholic drinks required to feel an effect (first five times drinking)
550,African American or Afro-Caribbean,169.0,31270906.0,Lai D,Biological process,replication,2019-07-03,GCST008447,Number of alcoholic drinks required to feel an effect (long-term average)
3322,Asian,3092.0,31268507.0,Periyasamy S,Neurological disorder,initial,2019-07-03,GCST008459,Schizophrenia
6337,European,1156.0,31271701.0,Thibord F,"Cardiovascular disease, Other measurement",replication,2019-07-04,GCST008461,Plasma factor V levels in venous thrombosis
6338,European,1156.0,31271701.0,Thibord F,"Cardiovascular disease, Other measurement",replication,2019-07-04,GCST008462,Plasma factor V levels in venous thrombosis (conditioned on rs6027)
5431,European,510.0,31271701.0,Thibord F,"Cardiovascular disease, Other measurement",initial,2019-07-04,GCST008462,Plasma factor V levels in venous thrombosis (conditioned on rs6027)
5430,European,510.0,31271701.0,Thibord F,"Cardiovascular disease, Other measurement",initial,2019-07-04,GCST008461,Plasma factor V levels in venous thrombosis
13670,Other/Mixed,18.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008269,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease
1687,Asian,73.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008268,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease
1688,Asian,73.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008269,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease
5416,European,504.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008268,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease
4203,Asian,12603.0,31320941.0,Igarashi M,Other measurement,initial,2019-07-05,GCST008597,Fish intake frequency
405,African American or Afro-Caribbean,5.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008268,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease
406,African American or Afro-Caribbean,5.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008269,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease
5417,European,504.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008269,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease
13669,Other/Mixed,18.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008268,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease
3456,Asian,4061.0,31289104.0,Kawamura Y,Metabolic disorder,replication,2019-07-08,GCST008460,Gout vs. Hyperuricemia
13566,Hispanic or Latin American,20210.0,31285632.0,Klarin D,Cardiovascular disease,initial,2019-07-08,GCST008474,Peripheral artery disease
259,African,3284.0,31285632.0,Klarin D,Cardiovascular measurement,initial,2019-07-08,GCST008475,Minimum anklebrachial index
12549,European,394408.0,31285632.0,Klarin D,Cardiovascular disease,replication,2019-07-08,GCST008474,Peripheral artery disease
10063,European,13382.0,31285632.0,Klarin D,Cardiovascular measurement,initial,2019-07-08,GCST008475,Minimum anklebrachial index
2967,Asian,1948.0,31289104.0,Kawamura Y,Metabolic disorder,initial,2019-07-08,GCST008460,Gout vs. Hyperuricemia
12152,European,174992.0,31285632.0,Klarin D,Cardiovascular disease,initial,2019-07-08,GCST008474,Peripheral artery disease
394,African,47858.0,31285632.0,Klarin D,Cardiovascular disease,initial,2019-07-08,GCST008474,Peripheral artery disease
13025,Hispanic or Latin American,998.0,31285632.0,Klarin D,Cardiovascular measurement,initial,2019-07-08,GCST008475,Minimum anklebrachial index
3329,Asian,3152.0,31301374.0,Noguchi E,Immune system disorder,initial,2019-07-10,GCST009143,Hydrolysed wheat protein allergy
2050,Asian,371.0,31301374.0,Noguchi E,Immune system disorder,replication,2019-07-10,GCST009143,Hydrolysed wheat protein allergy
5491,European,545.0,31295725.0,Wang ZT,Other measurement,initial,2019-07-11,GCST008497,Change in neurofilament light levels
5953,European,866.0,31296530.0,Trendowski MR,"Other measurement, Response to drug",initial,2019-07-11,GCST008756,Serum platinum levels after completion of cisplatin chemotherapy
10428,European,18567.0,31294817.0,Chen J,Other measurement,initial,2019-07-11,GCST008547,Time to smoke first cigarette in the morning
9758,European,10061.0,31294817.0,Chen J,Other measurement,replication,2019-07-11,GCST008547,Time to smoke first cigarette in the morning
10476,European,19431.0,31294817.0,Chen J,Other measurement,initial,2019-07-11,GCST008548,Fagerstrm test for nicotine dependence
9124,European,7010.0,31294817.0,Chen J,Other measurement,replication,2019-07-11,GCST008548,Fagerstrm test for nicotine dependence
4247,Asian,13855.0,31319653.0,Jeon C,Cardiovascular disease,initial,2019-07-12,GCST008816,Ischemic heart disease
4457,Asian,33598.0,31319653.0,Jeon C,Other measurement,initial,2019-07-12,GCST008817,Bilirubin levels
11520,European,72517.0,31308545.0,Watson HJ,Metabolic disorder,initial,2019-07-15,GCST008465,Anorexia nervosa
13028,Hispanic or Latin American,1047.0,31315583.0,Lona-Durazo F,"Other trait, Other measurement",initial,2019-07-17,GCST008519,Skin pigmentation
13983,Other/Mixed,684.0,31315583.0,Lona-Durazo F,Other measurement,initial,2019-07-17,GCST008516,Skin pigmentation (conditioned on rs1426654 and rs35397)
661,African American or Afro-Caribbean,373.0,31315583.0,Lona-Durazo F,Other measurement,initial,2019-07-17,GCST008516,Skin pigmentation (conditioned on rs1426654 and rs35397)
662,African American or Afro-Caribbean,373.0,31315583.0,Lona-Durazo F,"Other trait, Other measurement",initial,2019-07-17,GCST008519,Skin pigmentation
10798,European,27820.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008834,Non-small cell lung cancer
13984,Other/Mixed,684.0,31315583.0,Lona-Durazo F,"Other trait, Other measurement",initial,2019-07-17,GCST008519,Skin pigmentation
12966,Hispanic or Latin American,762.0,31315583.0,Lona-Durazo F,"Other trait, Other measurement",initial,2019-07-17,GCST008518,Skin pigmentation
6256,European,1075.0,31311600.0,Namjou B,"Liver enzyme measurement, Digestive system disorder",initial,2019-07-17,GCST008466,Alanine aminotransferase levels in non-alcoholic fatty liver disease
13027,Hispanic or Latin American,1047.0,31315583.0,Lona-Durazo F,Other measurement,initial,2019-07-17,GCST008516,Skin pigmentation (conditioned on rs1426654 and rs35397)
10422,European,18517.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008835,Squamous cell lung carcinoma
4376,Asian,22090.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008836,Lung adenocarcinoma
4959,European,235.0,31311600.0,Namjou B,"Other trait, Digestive system disorder",initial,2019-07-17,GCST008469,Liver fibrosis in non-alcoholic fatty acid liver disease
4958,European,235.0,31311600.0,Namjou B,Other measurement,initial,2019-07-17,GCST008471,Non-alcoholic fatty liver disease activity score
10546,European,20846.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008836,Lung adenocarcinoma
9682,European,9677.0,31311600.0,Namjou B,Digestive system disorder,initial,2019-07-17,GCST008468,Nonalcoholic fatty liver disease
9683,European,9677.0,31311600.0,Namjou B,Digestive system disorder,initial,2019-07-17,GCST008470,Nonalcoholic fatty liver disease (SNP x SNP interaction)
4407,Asian,26655.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008834,Non-small cell lung cancer
4320,Asian,17188.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008835,Squamous cell lung carcinoma
8790,European,5628.0,31346403.0,Massrali A,Other measurement,initial,2019-07-17,GCST008484,Autistic traits score (Social and Communication Disorders Checklist)
6257,European,1075.0,31311600.0,Namjou B,"Liver enzyme measurement, Digestive system disorder",initial,2019-07-17,GCST008467,Aspartate aminotransferase levels in non-alcoholic fatty liver disease
5795,European,750.0,31320639.0,Hillary RF,Other measurement,initial,2019-07-18,GCST008478,Neurological blood protein biomarker levels
859,African American or Afro-Caribbean,1158.0,31324189.0,Kim W,Other measurement,initial,2019-07-19,GCST008476,Emphysema annual change measurement in smokers (percent low attenuation area)
8362,European,4427.0,31324189.0,Kim W,Other measurement,initial,2019-07-19,GCST008476,Emphysema annual change measurement in smokers (percent low attenuation area)
860,African American or Afro-Caribbean,1158.0,31324189.0,Kim W,Other measurement,initial,2019-07-19,GCST008477,Emphysema annual change measurement in smokers (adjusted lung density)
246,African,2578.0,31324766.0,Adeyemo AA,Metabolic disorder,replication,2019-07-19,GCST008463,Type 2 diabetes
1394,African American or Afro-Caribbean,8599.0,31324766.0,Adeyemo AA,Metabolic disorder,initial,2019-07-19,GCST008464,Type 2 diabetes
289,African,5231.0,31324766.0,Adeyemo AA,Metabolic disorder,initial,2019-07-19,GCST008464,Type 2 diabetes
8363,European,4427.0,31324189.0,Kim W,Other measurement,initial,2019-07-19,GCST008477,Emphysema annual change measurement in smokers (adjusted lung density)
288,African,5231.0,31324766.0,Adeyemo AA,Metabolic disorder,initial,2019-07-19,GCST008463,Type 2 diabetes
3736,Asian,5975.0,31345160.0,Jia H,"Biological process, Other measurement",replication,2019-07-26,GCST008487,Coffee consumption
3771,Asian,6264.0,31345160.0,Jia H,"Biological process, Other measurement",initial,2019-07-26,GCST008487,Coffee consumption
1504,African American or Afro-Caribbean,19983.0,31358989.0,Gelernter J,Other measurement,initial,2019-07-29,GCST008490,Post-traumatic stress disorder (re-experiencing symptoms)
6350,European,1168.0,31371054.0,Ruddy KJ,"Response to drug, Cancer",initial,2019-07-29,GCST009153,Adverse response to chemotherapy (amenorrhea) in breast cancer
12648,European,480842.0,31358974.0,Evangelou E,"Biological process, Other measurement",initial,2019-07-29,GCST008757,Alcohol consumption
11857,European,117900.0,31358989.0,Gelernter J,Other measurement,replication,2019-07-29,GCST008490,Post-traumatic stress disorder (re-experiencing symptoms)
12007,European,146660.0,31358989.0,Gelernter J,Other measurement,initial,2019-07-29,GCST008490,Post-traumatic stress disorder (re-experiencing symptoms)
925,African American or Afro-Caribbean,1445.0,31362332.0,Cheng Z,Other measurement,initial,2019-07-30,GCST008596,Opioid overdose severity score
7068,European,2032.0,31362332.0,Cheng Z,Other measurement,initial,2019-07-30,GCST008596,Opioid overdose severity score
6089,European,951.0,31361301.0,Weingarten MFJ,Other measurement,initial,2019-07-30,GCST009027,Serum oxytocin levels
13860,Other/Mixed,312.0,31417607.0,Gazal S,Cardiovascular disease,initial,2019-07-30,GCST008708,Chronic mountain sickness
10721,European,24776.0,31367044.0,Locke AE,"Other measurement, Body measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Inflammatory measurement",replication,2019-07-31,GCST008673,Cardiometabolic traits
10471,European,19292.0,31367044.0,Locke AE,"Other measurement, Body measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Inflammatory measurement",initial,2019-07-31,GCST008673,Cardiometabolic traits
6425,European,1225.0,30576415.0,Gilly A,Other measurement,initial,2019-08-01,GCST008963,Glucose homeostasis traits
6423,European,1225.0,30576415.0,Gilly A,Other measurement,initial,2019-08-01,GCST008957,Hormone measurements
12254,European,220170.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008650,same-sex sexual behaviour
6426,European,1225.0,30576415.0,Gilly A,"Other measurement, Body measurement",initial,2019-08-01,GCST008958,Anthropometric traits
6422,European,1225.0,30576415.0,Gilly A,"Liver enzyme measurement, Other measurement",initial,2019-08-01,GCST008965,Liver disease biomarker
6421,European,1225.0,30576415.0,Gilly A,"Lipid or lipoprotein measurement, Other measurement",initial,2019-08-01,GCST008959,Lipid traits
6419,European,1225.0,30576415.0,Gilly A,"Hematological measurement, Cardiovascular measurement, Other measurement",initial,2019-08-01,GCST008962,Hematology traits
6427,European,1225.0,30576415.0,Gilly A,"Other measurement, Cardiovascular measurement",initial,2019-08-01,GCST008964,Blood pressure
8842,European,5838.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008656,proportion of same-sex sexual behaviour among non-heterosexuals
6424,European,1225.0,30576415.0,Gilly A,Other measurement,initial,2019-08-01,GCST008960,Iron status biomarkers
6420,European,1225.0,30576415.0,Gilly A,Inflammatory measurement,initial,2019-08-01,GCST008961,C-reactive protein levels
12460,European,338218.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008653,same-sex sexual behaviour
12443,European,329546.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008652,same-sex sexual behaviour
12565,European,408995.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008651,same-sex sexual behaviour
11878,European,120552.0,31374203.0,Lam M,"Other measurement, Biological process, Neurological disorder",initial,2019-08-01,GCST008595,"Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)"
10028,European,12834.0,31467194.0,Ganna A,Biological process,replication,2019-08-01,GCST008654,same-sex sexual behaviour
10027,European,12834.0,31467194.0,Ganna A,Biological process,replication,2019-08-01,GCST008653,same-sex sexual behaviour
10026,European,12834.0,31467194.0,Ganna A,Biological process,replication,2019-08-01,GCST008651,same-sex sexual behaviour
10473,European,19325.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008657,proportion of same-sex sexual behaviour among non-heterosexuals
12681,European,695908.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008654,same-sex sexual behaviour
9783,European,10305.0,31467194.0,Ganna A,Biological process,replication,2019-08-01,GCST008652,same-sex sexual behaviour
9275,European,7675.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008655,proportion of same-sex sexual behaviour among non-heterosexuals
5073,European,321.0,31370031.0,Dou KX,Other measurement,initial,2019-08-01,GCST008642,Annualised percent change of cerebrospinal fluid AB1-42 levels
12175,European,188825.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008649,same-sex sexual behaviour
10198,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008704,Parietal lobe volume
9961,European,11936.0,31375628.0,Tengvall K,Other measurement,initial,2019-08-02,GCST009154,Anti-anoctamin 2 antibody levels
9555,European,8789.0,31396565.0,van der Lee SJ,Other measurement,replication,2019-08-02,GCST008715,Frontal lobe volume
9554,European,8789.0,31396565.0,van der Lee SJ,Other measurement,replication,2019-08-02,GCST008705,Temporal lobe volume
1782,Asian,131.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008707,Occipital lobe volume
9552,European,8789.0,31396565.0,van der Lee SJ,Other measurement,replication,2019-08-02,GCST008703,Occipital lobe volume
1873,Asian,211.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008711,Temporal lobe volume
1872,Asian,211.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008710,Parietal lobe volume
1871,Asian,211.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008707,Occipital lobe volume
1785,Asian,131.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008717,Frontal lobe volume
1784,Asian,131.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008711,Temporal lobe volume
10199,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008705,Temporal lobe volume
1783,Asian,131.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008710,Parietal lobe volume
9553,European,8789.0,31396565.0,van der Lee SJ,Other measurement,replication,2019-08-02,GCST008704,Parietal lobe volume
1874,Asian,211.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008717,Frontal lobe volume
10197,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008703,Occipital lobe volume
10203,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008715,Frontal lobe volume
10202,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008711,Temporal lobe volume
10201,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008710,Parietal lobe volume
10204,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008717,Frontal lobe volume
673,African American or Afro-Caribbean,405.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008717,Frontal lobe volume
10200,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008707,Occipital lobe volume
670,African American or Afro-Caribbean,405.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008707,Occipital lobe volume
672,African American or Afro-Caribbean,405.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008711,Temporal lobe volume
671,African American or Afro-Caribbean,405.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008710,Parietal lobe volume
4293,Asian,15358.0,31383772.0,Yan C,Cancer,replication,2019-08-05,GCST008646,Gastric cancer
4054,Asian,9197.0,31383772.0,Yan C,Cancer,initial,2019-08-05,GCST008646,Gastric cancer
13208,Hispanic or Latin American,3637.0,31388106.0,Sofer T,Cardiovascular measurement,initial,2019-08-06,GCST009141,Ankle-brachial index
13374,Hispanic or Latin American,7589.0,31388106.0,Sofer T,Cardiovascular measurement,initial,2019-08-06,GCST009132,Ankle-brachial index
9502,European,8527.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009135,Ankle-brachial index
9503,European,8527.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009136,Ankle-brachial index
9505,European,8527.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009141,Ankle-brachial index
12904,Hispanic or Latin American,553.0,31388106.0,Sofer T,Cardiovascular measurement,initial,2019-08-06,GCST009140,Ankle-brachial index
12942,Hispanic or Latin American,700.0,31388106.0,Sofer T,Cardiovascular measurement,initial,2019-08-06,GCST009135,Ankle-brachial index
12964,Hispanic or Latin American,760.0,31388106.0,Sofer T,Cardiovascular measurement,initial,2019-08-06,GCST009139,Ankle-brachial index
13063,Hispanic or Latin American,1437.0,31388106.0,Sofer T,Cardiovascular measurement,initial,2019-08-06,GCST009136,Ankle-brachial index
1040,African American or Afro-Caribbean,2362.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009135,Ankle-brachial index
13071,Hispanic or Latin American,1447.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009135,Ankle-brachial index
13073,Hispanic or Latin American,1447.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009139,Ankle-brachial index
13373,Hispanic or Latin American,7397.0,31388106.0,Sofer T,Cardiovascular disease,initial,2019-08-06,GCST009134,Peripheral artery disease (borderline)
13081,Hispanic or Latin American,1500.0,31388106.0,Sofer T,Cardiovascular measurement,initial,2019-08-06,GCST009137,Ankle-brachial index
13154,Hispanic or Latin American,2619.0,31388106.0,Sofer T,Cardiovascular measurement,initial,2019-08-06,GCST009138,Ankle-brachial index
13372,Hispanic or Latin American,7397.0,31388106.0,Sofer T,Cardiovascular disease,initial,2019-08-06,GCST009133,Peripheral artery disease
1043,African American or Afro-Caribbean,2362.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009141,Ankle-brachial index
1042,African American or Afro-Caribbean,2362.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009139,Ankle-brachial index
1041,African American or Afro-Caribbean,2362.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009136,Ankle-brachial index
13072,Hispanic or Latin American,1447.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009136,Ankle-brachial index
13074,Hispanic or Latin American,1447.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009141,Ankle-brachial index
9504,European,8527.0,31388106.0,Sofer T,Cardiovascular measurement,replication,2019-08-06,GCST009139,Ankle-brachial index
7289,European,2286.0,31387361.0,Fulmer D,Other trait,initial,2019-08-07,GCST009155,Bicuspid aortic valve
13438,Hispanic or Latin American,11103.0,31393916.0,Andaleon A,Lipid or lipoprotein measurement,initial,2019-08-08,GCST008592,High density lipoprotein cholesterol levels
13439,Hispanic or Latin American,11103.0,31393916.0,Andaleon A,Lipid or lipoprotein measurement,initial,2019-08-08,GCST008593,Low density lipoprotein cholesterol levels
13440,Hispanic or Latin American,11103.0,31393916.0,Andaleon A,Lipid or lipoprotein measurement,initial,2019-08-08,GCST008594,Total cholesterol levels
13437,Hispanic or Latin American,11103.0,31393916.0,Andaleon A,Lipid or lipoprotein measurement,initial,2019-08-08,GCST008591,Triglyceride levels
10449,European,19054.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008725,Diffuse large B-cell lymphoma or rheumatoid arthritis
4101,Asian,10095.0,31409800.0,Pazoki R,Other measurement,replication,2019-08-13,GCST008648,Urinary potassium excretion
319,African,7612.0,31409800.0,Pazoki R,Other measurement,replication,2019-08-13,GCST008647,Urinary sodium excretion
320,African,7612.0,31409800.0,Pazoki R,Other measurement,replication,2019-08-13,GCST008648,Urinary potassium excretion
8574,European,4959.0,31473137.0,Moreno-Grau S,Neurological disorder,replication,2019-08-13,GCST009019,Alzheimer's disease
11086,European,38202.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008722,Diffuse large B-cell lymphoma or multiple sclerosis
11073,European,37714.0,31407831.0,Din L,Immune system disorder,initial,2019-08-13,GCST008718,Follicular lymphoma or multiple sclerosis
8575,European,4959.0,31473137.0,Moreno-Grau S,Neurological disorder,replication,2019-08-13,GCST009021,Alzheimer's disease
9212,European,7409.0,31473137.0,Moreno-Grau S,Neurological disorder,initial,2019-08-13,GCST009021,Alzheimer's disease
9210,European,7409.0,31473137.0,Moreno-Grau S,Neurological disorder,initial,2019-08-13,GCST009019,Alzheimer's disease
9140,European,7089.0,31473137.0,Moreno-Grau S,Neurological disorder,initial,2019-08-13,GCST009022,Alzheimers disease (clinical subgroup AD+)
9211,European,7409.0,31473137.0,Moreno-Grau S,Neurological disorder,initial,2019-08-13,GCST009020,Alzheimer's disease
8858,European,5900.0,31473137.0,Moreno-Grau S,Neurological disorder,initial,2019-08-13,GCST009023,Alzheimers disease (clinical subgroup AD++)
10852,European,29942.0,31407831.0,Din L,"Cancer, Immune system disorder",initial,2019-08-13,GCST008729,Marginal zone lymphoma or systemic lupus erythematosus
10427,European,18566.0,31407831.0,Din L,Immune system disorder,initial,2019-08-13,GCST008719,Follicular lymphoma or rheumatoid arthritis
8088,European,3663.0,31473137.0,Moreno-Grau S,"Cardiovascular disease, Neurological disorder",initial,2019-08-13,GCST009026,Alzheimers disease and/or vascular dementia (clinical subgroup VaD++)
12599,European,446230.0,31409800.0,Pazoki R,Other measurement,initial,2019-08-13,GCST008648,Urinary potassium excretion
12600,European,446237.0,31409800.0,Pazoki R,Other measurement,initial,2019-08-13,GCST008647,Urinary sodium excretion
11044,European,36793.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008721,Chronic lymphocytic leukemia or multiple sclerosis
10928,European,32855.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008727,Chronic lymphocytic leukemia or systemic lupus erythematosus
10977,European,33880.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008723,Marginal zone lymphoma or multiple sclerosis
10991,European,34264.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008728,Diffuse large B-cell lymphoma or systemic lupus erythematosus
10372,European,17645.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008724,Chronic lymphocytic leukemia or rheumatoid arthritis
10165,European,14732.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008726,Marginal zone lymphoma or rheumatoid arthritis
8653,European,5143.0,31473137.0,Moreno-Grau S,Neurological disorder,initial,2019-08-13,GCST009024,Alzheimers disease (clinical subgroup AD+++)
4100,Asian,10095.0,31409800.0,Pazoki R,Other measurement,replication,2019-08-13,GCST008647,Urinary sodium excretion
10969,European,33776.0,31407831.0,Din L,Immune system disorder,initial,2019-08-13,GCST008720,Follicular lymphoma or systemic lupus erythematosus
12420,European,317222.0,31453325.0,Wang H,Other measurement,initial,2019-08-14,GCST009112,Lung function (forced vital capacity) variance
12421,European,317222.0,31453325.0,Wang H,Other measurement,initial,2019-08-14,GCST009117,Lung function (forced vital capacity)
12422,European,317285.0,31453325.0,Wang H,Other measurement,initial,2019-08-14,GCST009113,Lung function (FEV1) variance
12423,European,317285.0,31453325.0,Wang H,Other measurement,initial,2019-08-14,GCST009118,Lung function (FEV1)
12479,European,346535.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009125,Waist-to-hip ratio adjusted for BMI
12418,European,316614.0,31453325.0,Wang H,Other measurement,initial,2019-08-14,GCST009119,Lung function (FEV1/FVC)
12192,European,197261.0,31453325.0,Wang H,Other measurement,initial,2019-08-14,GCST009120,Heel bone mineral density
667,African American or Afro-Caribbean,388.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008600,Longevity (age >90th survival percentile)
12478,European,346393.0,31453325.0,Wang H,"Body measurement, Other measurement",initial,2019-08-14,GCST009121,Body mass index
12471,European,341584.0,31453325.0,Wang H,Other measurement,initial,2019-08-14,GCST009106,Basal metabolic rate variance
12472,European,341584.0,31453325.0,Wang H,Other measurement,initial,2019-08-14,GCST009129,Basal metabolic rate
12473,European,341632.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009105,Body fat percentage variance
12474,European,341632.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009126,Body fat percentage
12417,European,316614.0,31453325.0,Wang H,Other measurement,initial,2019-08-14,GCST009114,Lung function (FEV1/FVC) variance
11043,European,36745.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008600,Longevity (age >90th survival percentile)
11042,European,36745.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008598,Longevity (age >90th survival percentile)
10827,European,28967.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008601,Longevity (age >99th survival percentile)
3516,Asian,4477.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008600,Longevity (age >90th survival percentile)
12480,European,346535.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009127,BMI-adjusted waist-hip ratio variance
12481,European,346781.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009109,Hip circumference variance
10826,European,28967.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008599,Longevity (age >99th survival percentile)
12477,European,346393.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009107,Body mass index variance
12487,European,347158.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009108,Waist circumference variance
12196,European,197758.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009128,Birth weight
12486,European,347134.0,31453325.0,Wang H,"Other measurement, Body measurement",initial,2019-08-14,GCST009124,Waist-hip ratio
12485,European,347134.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009110,Waist-hip ratio variance
12484,European,347086.0,31453325.0,Wang H,"Other measurement, Body measurement",initial,2019-08-14,GCST009142,Height
9244,European,7544.0,31413261.0,Deelen J,Other measurement,replication,2019-08-14,GCST008598,Longevity (age >90th survival percentile)
12488,European,347158.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009122,Waist circumference
12195,European,197758.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009116,Birth weight variance
12483,European,347086.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009111,Height variance
3517,Asian,4477.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008601,Longevity (age >99th survival percentile)
12482,European,346781.0,31453325.0,Wang H,Body measurement,initial,2019-08-14,GCST009123,Hip circumference
12191,European,197261.0,31453325.0,Wang H,Other measurement,initial,2019-08-14,GCST009115,Heel bone mineral density variance
9105,European,6898.0,31413261.0,Deelen J,Other measurement,replication,2019-08-14,GCST008599,Longevity (age >99th survival percentile)
4487,Asian,38683.0,31417091.0,Kou I,Other disease,initial,2019-08-15,GCST008788,Adolescent idiopathic scoliosis
4545,Asian,79211.0,31417091.0,Kou I,Other disease,initial,2019-08-15,GCST008789,Adolescent idiopathic scoliosis
12166,European,187204.0,31420334.0,Lindstrom S,Cardiovascular disease,initial,2019-08-16,GCST009029,Venous thromboembolism
12167,European,187204.0,31420334.0,Lindstrom S,Cardiovascular disease,initial,2019-08-16,GCST009030,Venous thromboembolism
1475,African American or Afro-Caribbean,15152.0,31420334.0,Lindstrom S,Cardiovascular disease,initial,2019-08-16,GCST009031,Venous thromboembolism
1474,African American or Afro-Caribbean,15152.0,31420334.0,Lindstrom S,Cardiovascular disease,initial,2019-08-16,GCST009030,Venous thromboembolism
6453,European,1254.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",initial,2019-08-19,GCST008735,Response to beta blocker use in hypertension (diastolic blood pressure)
6454,European,1254.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",initial,2019-08-19,GCST008736,Response to beta blocker use in hypertension (systolic blood pressure)
630,African American or Afro-Caribbean,315.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",replication,2019-08-19,GCST008736,Response to beta blocker use in hypertension (systolic blood pressure)
629,African American or Afro-Caribbean,315.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",replication,2019-08-19,GCST008735,Response to beta blocker use in hypertension (diastolic blood pressure)
6700,European,1552.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",replication,2019-08-19,GCST008735,Response to beta blocker use in hypertension (diastolic blood pressure)
6701,European,1552.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",replication,2019-08-19,GCST008736,Response to beta blocker use in hypertension (systolic blood pressure)
7414,European,2466.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008877,Lobar intracerebral hemorrhage (MTAG)
7589,European,2716.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008873,Non-lobar intracerebral hemorrhage
8030,European,3519.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008878,Intracerebral hemorrhage
7590,European,2716.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008876,Non-lobar intracerebral hemorrhage (MTAG)
7413,European,2466.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008874,Lobar intracerebral hemorrhage
8029,European,3519.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008875,Intracerebral hemorrhage (MTAG)
4629,Asian,165726.0,31451708.0,Hellwege JN,Other measurement,replication,2019-08-26,GCST008747,Estimated glomerular filtration rate
13288,Hispanic or Latin American,4961.0,31451708.0,Hellwege JN,Other measurement,replication,2019-08-26,GCST008747,Estimated glomerular filtration rate
12662,European,567401.0,31451708.0,Hellwege JN,Other measurement,replication,2019-08-26,GCST008747,Estimated glomerular filtration rate
12258,European,223386.0,31451708.0,Hellwege JN,Other measurement,initial,2019-08-26,GCST008747,Estimated glomerular filtration rate
12052,European,152624.0,31451708.0,Hellwege JN,Other measurement,initial,2019-08-26,GCST008745,Estimated glomerular filtration rate in non-diabetics
1562,African American or Afro-Caribbean,36369.0,31451708.0,Hellwege JN,Other measurement,initial,2019-08-26,GCST008745,Estimated glomerular filtration rate in non-diabetics
4240,Asian,13359.0,31451708.0,Hellwege JN,Other measurement,replication,2019-08-26,GCST008747,Estimated glomerular filtration rate
1515,African American or Afro-Caribbean,20967.0,31451708.0,Hellwege JN,"Other measurement, Metabolic disorder",initial,2019-08-26,GCST008746,Estimated glomerular filtration rate in diabetes
1470,African American or Afro-Caribbean,13842.0,31451708.0,Hellwege JN,Other measurement,replication,2019-08-26,GCST008747,Estimated glomerular filtration rate
11509,European,70762.0,31451708.0,Hellwege JN,"Other measurement, Metabolic disorder",initial,2019-08-26,GCST008746,Estimated glomerular filtration rate in diabetes
1572,African American or Afro-Caribbean,57336.0,31451708.0,Hellwege JN,Other measurement,initial,2019-08-26,GCST008747,Estimated glomerular filtration rate
3426,Asian,3858.0,31462767.0,Sun Y,Neurological disorder,replication,2019-08-28,GCST008645,Alcohol dependence or heroin dependence or methamphetamine dependence
12130,European,171516.0,31482140.0,Meng W,Other trait,initial,2019-08-28,GCST008672,Knee pain
6674,European,1534.0,31455332.0,Zhang Y,Response to drug,initial,2019-08-28,GCST008755,Phenylephrine infusion rate during anesthesia
3761,Asian,6155.0,31462767.0,Sun Y,Neurological disorder,initial,2019-08-28,GCST008645,Alcohol dependence or heroin dependence or methamphetamine dependence
540,African American or Afro-Caribbean,156.0,31466081.0,Luo A,"Biological process, Other measurement",initial,2019-08-29,GCST008748,Epigenetic age acceleration in alcohol use disorder
83,African,291.0,31482010.0,Liu C,Metabolic disorder,initial,2019-08-29,GCST008668,Proliferative diabetic retinopathy
468,African American or Afro-Caribbean,69.0,31482010.0,Liu C,Metabolic disorder,replication,2019-08-29,GCST008668,Proliferative diabetic retinopathy
4813,European,154.0,31466081.0,Luo A,"Biological process, Other measurement",initial,2019-08-29,GCST008748,Epigenetic age acceleration in alcohol use disorder
230,African,1772.0,31469419.0,Manichaikul A,Cancer,initial,2019-08-30,GCST009007,High-grade serous ovarian cancer
143,African,815.0,31469255.0,Lule SA,Other measurement,initial,2019-08-30,GCST008749,Systolic blood pressure
144,African,815.0,31469255.0,Lule SA,Other measurement,initial,2019-08-30,GCST008750,Diastolic blood pressure
231,African,1990.0,31469419.0,Manichaikul A,Cancer,initial,2019-08-30,GCST009008,Epithelial ovarian cancer
7884,European,3275.0,31497858.0,Dumitrescu L,Other measurement,initial,2019-09-01,GCST008830,Neurofibrillary tangles
7583,European,2701.0,31497858.0,Dumitrescu L,Other measurement,initial,2019-09-01,GCST008822,Neuritic plaque
7582,European,2701.0,31497858.0,Dumitrescu L,Other measurement,initial,2019-09-01,GCST008821,Neurofibrillary tangles
8880,European,5976.0,31497858.0,Dumitrescu L,Other measurement,initial,2019-09-01,GCST008829,Neuritic plaque
8951,European,6296.0,31477735.0,Liu X,Other measurement,replication,2019-09-02,GCST008752,Post-term birth
6115,European,972.0,31477735.0,Liu X,Other trait,replication,2019-09-02,GCST008753,Early spontaneous preterm birth
11624,European,84689.0,31477735.0,Liu X,Other measurement,initial,2019-09-02,GCST008751,Gestational age at birth (child effect)
2325,Asian,719.0,31476763.0,Otsuka I,Other measurement,initial,2019-09-02,GCST008771,Age at suicide
11477,European,68036.0,31477735.0,Liu X,Other measurement,initial,2019-09-02,GCST008752,Post-term birth
9616,European,9291.0,31477735.0,Liu X,Other measurement,replication,2019-09-02,GCST008751,Gestational age at birth (child effect)
4279,Asian,14795.0,31476763.0,Otsuka I,Biological process,initial,2019-09-02,GCST008772,Suicide
11444,European,64923.0,31477735.0,Liu X,"Other measurement, Other trait",initial,2019-09-02,GCST008754,Spontaneous preterm birth (preterm birth)
11410,European,61287.0,31477735.0,Liu X,Other trait,initial,2019-09-02,GCST008753,Early spontaneous preterm birth
11285,European,51564.0,31508503.0,Warrier V,Other measurement,initial,2019-09-03,GCST008887,Systemising
10745,European,25501.0,31508503.0,Warrier V,Other measurement,initial,2019-09-03,GCST008889,Systemising
10755,European,26063.0,31508503.0,Warrier V,Other measurement,initial,2019-09-03,GCST008888,Systemising
8736,European,5421.0,31508503.0,Warrier V,Other measurement,initial,2019-09-03,GCST008890,Autistic traits score (Social and Communication Disorders Checklist)
12553,European,401198.0,31504236.0,Wiberg A,Other trait,initial,2019-09-05,GCST008820,Handedness (non-right-handed vs right-handed)
12550,European,394889.0,31504236.0,Wiberg A,Other trait,initial,2019-09-05,GCST008819,Handedness (left-handed vs. right-handed)
12552,European,401198.0,31504236.0,Wiberg A,Other trait,initial,2019-09-05,GCST008818,Handedness (Left-handed vs. non-left-handed)
12079,European,161168.0,31501611.0,Karlsson T,Other measurement,initial,2019-09-09,GCST008742,Predicted visceral adipose tissue
8497,European,4822.0,31498392.0,Kusic DM,"Body measurement, Other measurement",initial,2019-09-09,GCST008823,Body mass index
13913,Other/Mixed,429.0,31498392.0,Kusic DM,"Body measurement, Other measurement",initial,2019-09-09,GCST008823,Body mass index
12085,European,163984.0,31501611.0,Karlsson T,Other measurement,initial,2019-09-09,GCST008743,Predicted visceral adipose tissue
12435,European,325153.0,31501611.0,Karlsson T,Other measurement,initial,2019-09-09,GCST008744,Predicted visceral adipose tissue
14281,Other/Mixed,51541.0,31511532.0,Teumer A,"Other measurement, Metabolic disorder",initial,2019-09-11,GCST008792,Urinary albumin-to-creatinine ratio in diabetes
14298,Other/Mixed,348954.0,31511532.0,Teumer A,Other trait,initial,2019-09-11,GCST008791,Microalbuminuria
3779,Asian,6324.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008790,Urinary albumin-to-creatinine ratio
12657,European,547361.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008790,Urinary albumin-to-creatinine ratio
12658,European,547361.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008794,Urinary albumin-to-creatinine ratio
3129,Asian,2335.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008790,Urinary albumin-to-creatinine ratio
1331,African American or Afro-Caribbean,6795.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008793,Urinary albumin-to-creatinine ratio
1330,African American or Afro-Caribbean,6795.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008790,Urinary albumin-to-creatinine ratio
13066,Hispanic or Latin American,1442.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008790,Urinary albumin-to-creatinine ratio
4034,Asian,8842.0,31513605.0,Jeon S,Other measurement,initial,2019-09-12,GCST008824,Subscapular skin fold thickness
4033,Asian,8842.0,31513605.0,Jeon S,Metabolic disorder,initial,2019-09-12,GCST008827,Type 2 diabetes
4032,Asian,8842.0,31513605.0,Jeon S,Cardiovascular disease,initial,2019-09-12,GCST008828,Hypertension
4031,Asian,8842.0,31513605.0,Jeon S,"Body measurement, Other measurement",initial,2019-09-12,GCST008825,Body mass index
4030,Asian,8842.0,31513605.0,Jeon S,Body measurement,initial,2019-09-12,GCST008826,Waist circumference
5944,European,858.0,31519223.0,Scepanovic P,Other measurement,initial,2019-09-13,GCST008902,Gut microbiota (bacterial taxa)
5945,European,858.0,31519223.0,Scepanovic P,Other measurement,initial,2019-09-13,GCST008903,Gut microbiota relative abundance (bacterial taxa)
5943,European,858.0,31519223.0,Scepanovic P,Other measurement,initial,2019-09-13,GCST008901,Gut microbiota (beta diversity)
5942,European,858.0,31519223.0,Scepanovic P,Other measurement,initial,2019-09-13,GCST008900,Gut microbiota (alpha diversity)
5355,European,483.0,31530798.0,Alliey-Rodriguez N,Other measurement,initial,2019-09-17,GCST009206,Cerebral white matter volume
601,African American or Afro-Caribbean,250.0,31530798.0,Alliey-Rodriguez N,Other measurement,initial,2019-09-17,GCST009177,Entorhinal cortical volume
5356,European,483.0,31530798.0,Alliey-Rodriguez N,Other measurement,initial,2019-09-17,GCST009207,Lateral ventricle volume
602,African American or Afro-Caribbean,250.0,31530798.0,Alliey-Rodriguez N,Other measurement,initial,2019-09-17,GCST009201,Sub-cortical grey matter volume
5353,European,483.0,31530798.0,Alliey-Rodriguez N,Other measurement,initial,2019-09-17,GCST009201,Sub-cortical grey matter volume
5352,European,483.0,31530798.0,Alliey-Rodriguez N,Other measurement,initial,2019-09-17,GCST009177,Entorhinal cortical volume
603,African American or Afro-Caribbean,250.0,31530798.0,Alliey-Rodriguez N,Other measurement,initial,2019-09-17,GCST009204,Total intracranial volume
605,African American or Afro-Caribbean,250.0,31530798.0,Alliey-Rodriguez N,Other measurement,initial,2019-09-17,GCST009207,Lateral ventricle volume
5354,European,483.0,31530798.0,Alliey-Rodriguez N,Other measurement,initial,2019-09-17,GCST009204,Total intracranial volume
604,African American or Afro-Caribbean,250.0,31530798.0,Alliey-Rodriguez N,Other measurement,initial,2019-09-17,GCST009206,Cerebral white matter volume
12027,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008847,Depressive symptom (suicidal ideation) (binary trait)
12022,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008842,Depressive symptom (fatigue) (binary trait)
12023,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008843,Depressive symptom (appetite changes) (binary trait)
12028,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008848,Depressive symptoms (sum-score)
12024,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008844,Depressive symptom (low self-esteem) (binary trait)
12030,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008850,Depressive symptom (sleep problems) (ordinal trait)
12029,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008849,Depressive symptoms (binary sum-score)
12020,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008840,Depressive symptom (depressed mood) (binary trait)
12026,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008846,Depressive symptom (psychomotor changes) (binary trait)
12031,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008851,Depressive symptom (fatigue) (ordinal trait)
12032,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008852,Depressive symptom (appetite changes) (ordinal trait)
12033,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008853,Depressive symptom (low self-esteem) (ordinal trait)
12034,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008854,Depressive symptom (concentration problems) (ordinal trait)
12035,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008855,Depressive symptom (psychomotor changes) (ordinal trait)
12036,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008856,Depressive symptom (suicidal ideation) (ordinal trait)
12037,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008857,Depressive symptom (anhedonia) (ordinal trait)
12038,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008858,Depressive symptom (depressed mood) (ordinal trait)
12039,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008859,Depressive symptom (anhedonia) (binary trait)
12021,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008841,Depressive symptom (sleep problems) (binary trait)
12025,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008845,Depressive symptom (concentration problems) (binary trait)
8929,European,6197.0,31545351.0,Irvin MR,Cardiovascular disease,initial,2019-09-23,GCST009103,Resistance to antihypertensive treatment in hypertension
7587,European,2708.0,31545351.0,Irvin MR,Cardiovascular disease,initial,2019-09-23,GCST009099,Resistance to antihypertensive treatment in hypertension
1004,African American or Afro-Caribbean,2045.0,31545351.0,Irvin MR,Cardiovascular disease,initial,2019-09-23,GCST009103,Resistance to antihypertensive treatment in hypertension
10194,European,15141.0,31545351.0,Irvin MR,Cardiovascular disease,initial,2019-09-23,GCST009102,Resistant hypertension
11343,European,54612.0,31545351.0,Irvin MR,Cardiovascular disease,replication,2019-09-23,GCST009101,Resistance to antihypertensive treatment in hypertension
1077,African American or Afro-Caribbean,2708.0,31545351.0,Irvin MR,Cardiovascular disease,initial,2019-09-23,GCST009098,Resistant hypertension
1078,African American or Afro-Caribbean,2708.0,31545351.0,Irvin MR,Cardiovascular disease,initial,2019-09-23,GCST009100,Resistant hypertension
10192,European,15141.0,31545351.0,Irvin MR,Cardiovascular disease,initial,2019-09-23,GCST009098,Resistant hypertension
10193,European,15141.0,31545351.0,Irvin MR,Cardiovascular disease,initial,2019-09-23,GCST009101,Resistance to antihypertensive treatment in hypertension
1487,African American or Afro-Caribbean,16152.0,31545351.0,Irvin MR,Cardiovascular disease,replication,2019-09-23,GCST009099,Resistance to antihypertensive treatment in hypertension
7095,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008937,Triglyceride levels
7096,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008938,Total cholesterol levels
7086,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008928,Phosphatidylcholine-ether levels
7094,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008936,High density lipoprotein cholesterol levels
7093,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008935,Low density lipoprotein cholesterol levels
7088,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008930,Phosphatidylethanolamine-ether levels
7091,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008933,Sphingomyelin levels
7087,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008929,Phosphatidylethanolamine levels
7085,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008927,Phosphatidylcholine levels
7084,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008926,Lysophosphatidylethanolamine levels
7083,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008925,Lysophosphatidylcholine levels
7092,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008934,Sterol levels
7082,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008924,Diacylglyceride levels
7089,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008931,Phosphatidylinositol levels
7080,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008922,Triacylglyceride levels
7090,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008932,Cholesteryl ester levels
7081,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008923,Ceramide levels
11900,European,124716.0,31553412.0,Legge SE,Other trait,initial,2019-09-25,GCST008897,Psychotic experience (multiple occurrences)
11893,European,123522.0,31553412.0,Legge SE,Other trait,initial,2019-09-25,GCST008896,Psychotic experience (distressing)
11914,European,127502.0,31553412.0,Legge SE,Other trait,initial,2019-09-25,GCST008895,Psychotic experience
1573,African American or Afro-Caribbean,68155.0,31564439.0,Fang H,"Other measurement, Body measurement",initial,2019-09-26,GCST008904,Height
12313,European,253918.0,31564434.0,Wells HRR,Neurological disorder,initial,2019-09-26,GCST008898,Adult hearing aid use
12302,European,250389.0,31564434.0,Wells HRR,Neurological disorder,initial,2019-09-26,GCST008899,Adult hearing difficulty
1035,African American or Afro-Caribbean,2256.0,31579629.0,Fiorica PN,Neurological disorder,initial,2019-09-26,GCST008906,Schizophrenia
830,African American or Afro-Caribbean,1019.0,31579629.0,Fiorica PN,Neurological disorder,initial,2019-09-26,GCST008905,Bipolar disorder
13587,Hispanic or Latin American,25847.0,31564439.0,Fang H,"Other measurement, Body measurement",initial,2019-09-26,GCST008904,Height
12295,European,248507.0,31564439.0,Fang H,"Other measurement, Body measurement",initial,2019-09-26,GCST008904,Height
3318,Asian,3054.0,31564439.0,Fang H,"Other measurement, Body measurement",initial,2019-09-26,GCST008904,Height
11009,European,35004.0,31564434.0,Wells HRR,Neurological disorder,replication,2019-09-26,GCST008898,Adult hearing aid use
10874,European,30765.0,31564434.0,Wells HRR,Neurological disorder,replication,2019-09-26,GCST008899,Adult hearing difficulty
4449,Asian,32692.0,31562340.0,Akiyama M,"Other measurement, Body measurement",replication,2019-09-27,GCST008839,Height
4544,Asian,78079.0,31562322.0,Takata R,Cancer,replication,2019-09-27,GCST008860,Prostate cancer
4626,Asian,159095.0,31562340.0,Akiyama M,"Other measurement, Body measurement",initial,2019-09-27,GCST008839,Height
4295,Asian,15770.0,31562322.0,Takata R,Cancer,initial,2019-09-27,GCST008860,Prostate cancer
315,African,7526.0,31675503.0,Gurdasani D,"Hematological measurement, Inflammatory measurement",initial,2019-10-01,GCST009061,White blood cell count
299,African,6407.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009035,Mean platelet volume
307,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009037,Lymphocyte counts
304,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009033,Hematocrit
305,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009034,Hemoglobin levels
317,African,7526.0,31675503.0,Gurdasani D,"Other measurement, Hematological measurement",initial,2019-10-01,GCST009054,Hemoglobin A1c levels
316,African,7526.0,31675503.0,Gurdasani D,Inflammatory measurement,initial,2019-10-01,GCST009039,Basophil count
314,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009065,Mean corpuscular volume
313,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009064,Mean corpuscular hemoglobin concentration
312,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009063,Mean corpuscular hemoglobin
311,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009062,Red blood cell count
310,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009041,Eosinophil counts
309,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009040,Neutrophil count
308,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009038,Monocyte count
358,African,14126.0,31675503.0,Gurdasani D,"Other measurement, Body measurement",initial,2019-10-01,GCST009060,Waist-hip ratio
357,African,14126.0,31675503.0,Gurdasani D,"Other measurement, Body measurement",initial,2019-10-01,GCST009055,Height
303,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009032,Red cell distribution width
355,African,14126.0,31675503.0,Gurdasani D,Other measurement,initial,2019-10-01,GCST009052,Diastolic blood pressure
327,African,9004.0,31675503.0,Gurdasani D,Liver enzyme measurement,initial,2019-10-01,GCST009050,Gamma glutamyl transferase levels
326,African,9004.0,31675503.0,Gurdasani D,Liver enzyme measurement,initial,2019-10-01,GCST009046,Aspartate aminotransferase levels
343,African,14126.0,31675503.0,Gurdasani D,Body measurement,initial,2019-10-01,GCST009056,Weight
344,African,14126.0,31675503.0,Gurdasani D,Body measurement,initial,2019-10-01,GCST009058,Waist circumference
345,African,14126.0,31675503.0,Gurdasani D,Body measurement,initial,2019-10-01,GCST009059,Hip circumference
356,African,14126.0,31675503.0,Gurdasani D,Other measurement,initial,2019-10-01,GCST009053,Systolic blood pressure
346,African,14126.0,31675503.0,Gurdasani D,"Body measurement, Other measurement",initial,2019-10-01,GCST009057,Body mass index
347,African,14126.0,31675503.0,Gurdasani D,Lipid or lipoprotein measurement,initial,2019-10-01,GCST009042,Total cholesterol levels
348,African,14126.0,31675503.0,Gurdasani D,Lipid or lipoprotein measurement,initial,2019-10-01,GCST009043,LDL cholesterol levels
306,African,7526.0,31675503.0,Gurdasani D,Hematological measurement,initial,2019-10-01,GCST009036,Platelet count
350,African,14126.0,31675503.0,Gurdasani D,Lipid or lipoprotein measurement,initial,2019-10-01,GCST009045,Triglyceride levels
354,African,14126.0,31675503.0,Gurdasani D,Other measurement,initial,2019-10-01,GCST009051,Bilirubin levels
349,African,14126.0,31675503.0,Gurdasani D,Lipid or lipoprotein measurement,initial,2019-10-01,GCST009044,HDL cholesterol levels
352,African,14126.0,31675503.0,Gurdasani D,Liver enzyme measurement,initial,2019-10-01,GCST009049,Serum alkaline phosphatase levels
351,African,14126.0,31675503.0,Gurdasani D,Liver enzyme measurement,initial,2019-10-01,GCST009047,Alanine aminotransferase levels
353,African,14126.0,31675503.0,Gurdasani D,Other measurement,initial,2019-10-01,GCST009048,Serum albumin level
1561,African American or Afro-Caribbean,33671.0,31578528.0,Tin A,"Metabolic disorder, Other measurement",initial,2019-10-02,GCST008972,Urate levels
12925,Hispanic or Latin American,608.0,31578528.0,Tin A,"Metabolic disorder, Other measurement",initial,2019-10-02,GCST008972,Urate levels
12685,European,753994.0,31578528.0,Tin A,Metabolic disorder,initial,2019-10-02,GCST008970,Gout
14297,Other/Mixed,346213.0,31578528.0,Tin A,"Metabolic disorder, Other measurement",initial,2019-10-02,GCST008973,Urate levels
12363,European,288649.0,31578528.0,Tin A,"Metabolic disorder, Other measurement",initial,2019-10-02,GCST008972,Urate levels
12362,European,288649.0,31578528.0,Tin A,"Metabolic disorder, Other measurement",initial,2019-10-02,GCST008971,Urate levels
4042,Asian,9037.0,31578528.0,Tin A,"Metabolic disorder, Other measurement",initial,2019-10-02,GCST008972,Urate levels
4586,Asian,125725.0,31578528.0,Tin A,"Metabolic disorder, Other measurement",initial,2019-10-02,GCST008972,Urate levels
5209,European,407.0,31587654.0,Torres-Aguila NP,"Hematological measurement, Other trait",replication,2019-10-07,GCST008915,Leukocyte count in ischemic stroke
2022,Asian,346.0,31591379.0,Sun Y,"Other measurement, Neurological disorder",initial,2019-10-07,GCST008966,Alcohol dependence
7112,European,2064.0,31587654.0,Torres-Aguila NP,"Hematological measurement, Other trait",initial,2019-10-07,GCST008915,Leukocyte count in ischemic stroke
3354,Asian,3381.0,31591379.0,Sun Y,"Other measurement, Neurological disorder",initial,2019-10-07,GCST008966,Alcohol dependence
7460,European,2527.0,31596875.0,Traylor M,"Immune system disorder, Other measurement",initial,2019-10-09,GCST008992,Joint damage in rheumatoid arthritis
7461,European,2527.0,31596875.0,Traylor M,"Immune system disorder, Other measurement",initial,2019-10-09,GCST008993,Joint damage in rheumatoid arthritis
58,African,196.0,31596875.0,Traylor M,"Immune system disorder, Other measurement",initial,2019-10-09,GCST008992,Joint damage in rheumatoid arthritis
11111,European,39456.0,31600170.0,Teumer A,Cardiovascular measurement,initial,2019-10-10,GCST008991,Early cardiac repolarization
8749,European,5452.0,31626034.0,Thomsen H,Cancer,initial,2019-10-11,GCST009077,Uveal melanoma with chromosome 3 loss
8750,European,5454.0,31626034.0,Thomsen H,Cancer,initial,2019-10-11,GCST009073,Uveal melanoma (TNM stage 3 or 4)
5558,European,585.0,31626034.0,Thomsen H,Other measurement,initial,2019-10-11,GCST009072,Disease severity in uveal melanoma (TNM stage 3 or 4 vs TNM stage 1 or 2)
8763,European,5484.0,31626034.0,Thomsen H,Cancer,initial,2019-10-11,GCST009076,Uveal melanoma with epithelioid cells
8771,European,5529.0,31626034.0,Thomsen H,Cancer,initial,2019-10-11,GCST009074,Uveal melanoma (TNM stage 1 or 2)
8786,European,5616.0,31626034.0,Thomsen H,Cancer,initial,2019-10-11,GCST009079,Uveal melanoma with any chromosomal aberration
5526,European,571.0,31626034.0,Thomsen H,Cancer,initial,2019-10-11,GCST009075,Presence of epithelioid cells in uveal melanoma
8792,European,5637.0,31626034.0,Thomsen H,Cancer,initial,2019-10-11,GCST009078,Choroidal melanoma
8829,European,5789.0,31626034.0,Thomsen H,Cancer,initial,2019-10-11,GCST009071,Uveal melanoma
12732,Hispanic or Latin American,12.0,31615970.0,Rodas G,Other disease,initial,2019-10-14,GCST009002,Tendinopathy
11288,European,51574.0,31607149.0,Ramirez J,Cardiovascular measurement,initial,2019-10-14,GCST009068,T wave morphology restitution during exercise (MTAG)
11289,European,51574.0,31607149.0,Ramirez J,Cardiovascular measurement,initial,2019-10-14,GCST009069,T wave morphology restitution during recovery from exercise
1594,Asian,3.0,31615970.0,Rodas G,Other disease,initial,2019-10-14,GCST009002,Tendinopathy
11286,European,51574.0,31607149.0,Ramirez J,Cardiovascular measurement,initial,2019-10-14,GCST009016,T wave morphology restitution during exercise
11287,European,51574.0,31607149.0,Ramirez J,Cardiovascular measurement,initial,2019-10-14,GCST009017,T wave morphology restitution during recovery from exercise (MTAG)
5082,European,327.0,31615970.0,Rodas G,Other disease,initial,2019-10-14,GCST009002,Tendinopathy
426,African American or Afro-Caribbean,21.0,31615970.0,Rodas G,Other disease,initial,2019-10-14,GCST009002,Tendinopathy
12495,European,357157.0,31619474.0,Zhu Z,"Other disease, Other measurement",initial,2019-10-17,GCST008917,Asthma (childhood onset)
12569,European,411593.0,31619474.0,Zhu Z,"Other disease, Neurological disorder",initial,2019-10-17,GCST008920,Asthma and anxiety disorder
12605,European,447576.0,31619474.0,Zhu Z,"Neurological disorder, Other disease",initial,2019-10-17,GCST008919,Asthma and attention deficit hyperactivity disorder
4552,Asian,95380.0,31624269.0,Terao C,Other measurement,initial,2019-10-17,GCST009066,Mosaic loss of chromosome Y
12661,European,567288.0,31619474.0,Zhu Z,"Other disease, Neurological disorder",initial,2019-10-17,GCST008921,Asthma and major depressive disorder
12510,European,369777.0,31619474.0,Zhu Z,Other disease,initial,2019-10-17,GCST008918,Asthma (adult onset)
12548,European,394283.0,31619474.0,Zhu Z,Other disease,initial,2019-10-17,GCST008916,Asthma
12255,European,220759.0,31649266.0,Gallagher CS,Other trait,initial,2019-10-24,GCST009157,Heavy menstrual bleeding
11387,European,58655.0,31649266.0,Gallagher CS,Cancer,initial,2019-10-24,GCST009158,Uterine fibroids
12287,European,244324.0,31649266.0,Gallagher CS,Cancer,initial,2019-10-24,GCST009158,Uterine fibroids
12204,European,202580.0,31649266.0,Gallagher CS,"Cancer, Other trait",initial,2019-10-24,GCST009156,Uterine fibroids and heavy menstrual bleeding
10773,European,26679.0,31672989.0,Lopez-Isac E,Neurological disorder,initial,2019-10-31,GCST009131,Systemic sclerosis
1565,African American or Afro-Caribbean,51661.0,31676865.0,Klarin D,Cardiovascular disease,initial,2019-11-01,GCST009097,Venous thromboembolism
12665,European,576590.0,31676865.0,Klarin D,Cardiovascular disease,initial,2019-11-01,GCST009097,Venous thromboembolism
13572,Hispanic or Latin American,21868.0,31676865.0,Klarin D,Cardiovascular disease,initial,2019-11-01,GCST009097,Venous thromboembolism
12645,European,462690.0,31689377.0,Wootton RE,Other measurement,initial,2019-11-06,GCST009096,Lifetime smoking index
11452,European,65534.0,31712607.0,Nudel R,Other measurement,initial,2019-11-11,GCST009130,Hospital contact for infections
